<SEC-DOCUMENT>0001193125-26-098507.txt : 20260309
<SEC-HEADER>0001193125-26-098507.hdr.sgml : 20260309
<ACCEPTANCE-DATETIME>20260309161130
ACCESSION NUMBER:		0001193125-26-098507
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260309
DATE AS OF CHANGE:		20260309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Septerna, Inc.
		CENTRAL INDEX KEY:			0001984086
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				843891440
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42382
		FILM NUMBER:		26735053

	BUSINESS ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE, SUITE 65
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-338-3533

	MAIL ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE, SUITE 65
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sepn-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-09T15:15:01.8126+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:sepn="http://www.septerna.com/20251231" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8f9ea807-794c-4777-9a46-3a60232a5cd5" name="dei:AmendmentFlag" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b">false</ix:nonNumeric><ix:nonNumeric id="F_87dcc3df-b443-4e09-9eab-dd08d07551fe" name="dei:DocumentFiscalPeriodFocus" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b">FY</ix:nonNumeric><ix:nonNumeric id="F_b85ac4cb-e129-4694-8025-6f87e7e2d8a2" name="dei:EntityCentralIndexKey" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b">0001984086</ix:nonNumeric><ix:nonFraction id="F_b8ad14a0-c1e3-48c5-855b-31addb820eb6" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b4a2dcb4-49e4-4ea1-b88c-386a51c040ce" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1edf648f-796a-4d0b-aa2e-b021bcd9a7ee" name="us-gaap:PreferredStockValue" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1db7472e-771e-4c85-b753-944c6e60f5ad" name="us-gaap:PreferredStockValue" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</ix:nonNumeric><ix:nonNumeric id="F_faecfa98-652d-4cca-94de-7a02c3297ab7" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member</ix:nonNumeric><ix:nonNumeric id="F_b8efe224-c188-42df-a41c-9d6bf32284b2" name="us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b">http://xbrl.sec.gov/country/2025#US</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sepn-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8115a838-2092-4741-a82f-c5a56ba848ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8213da3e-71aa-4154-b70b-40d696bee78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84234d5b-13da-4f60-8e97-1e3d68e04f15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84474bd9-0ca3-4043-a28f-246196964124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_855097d9-96a1-4e02-94d5-4334f3801f9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:OriginalLeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87cdb1d5-fac7-4ece-beec-6c0efa23647c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_885615b0-7d7a-4feb-b3a7-220a271f5de4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_886793f1-e018-4e02-b853-202065e4572b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sepn:UnvestedRestrictedStockSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88ac2057-9216-425c-b13e-16df574b3054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sepn:VertexResearchServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a386e2d-47cd-42af-a8e3-db3089a6f1be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a5f118b-d06e-4890-a43e-997cc3e53337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sepn:InterimChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a9deb64-57ac-4f0b-acec-1f6759eaac45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c6cd37e-c9c8-4880-a575-854c05609cbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_909026b5-982c-4acc-89af-ef9bf4949a1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_925590ce-df4f-4dd8-8abe-e9865066e1a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93212ce3-a90a-4a57-a707-34c5cc5ff182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93730b11-03a0-4363-ac76-9b4b4706269a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_975ebf25-328e-4bac-b245-59af615c9971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_976a0a52-eca0-4d4d-ae45-b70fef55d6e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9888954c-fbaf-4612-8b15-1d1088548ab8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99f18d25-7a69-4282-995c-9eebff9e8b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aa30191-c34b-4a93-8ee6-eeca325c6cba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:AdditionalLeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bf04a86-29ff-485b-98ad-fd0cfacc548a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneAndTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c2248bf-d680-4e4c-9956-051672a0ad00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c372061-ee03-484f-8e37-ab25c25fbca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sepn:FourZeroOne401KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cc53a78-1854-48cf-b102-67dba4fd3597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeAndNon-EmployeeStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d256ca5-ca4e-416a-9cfc-3811d06616cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sepn:FourZeroOne401KPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9db2cf60-a723-488b-983c-bd979235ca35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dd7f8d2-59e4-40bc-9f16-2e9328a32206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e8af7b3-5a45-498e-98e0-2a164d3ce69b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a022d47a-da08-4672-8253-3308b645d9aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a07cba62-15fb-408e-9eca-ccd2f26f2784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:MaterialRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a16a30b4-7855-443e-8e8c-93eee3c5898a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a706c6c6-3f56-4dc2-a361-8d8d19beee7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9403ba1-557a-40df-a781-80b2faef2036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9816031-a377-48f3-a65a-63d6a0198c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aae82e13-ba71-4eff-a125-de3c3ef90394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab94e00d-ea2a-4055-a162-0c519f4d3c16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:ResearchDevelopmentProgramsAndManufacturingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3d53d15-29ec-421d-989c-75e94a00a664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5c224dc-4113-4169-a143-5596c3204f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:OriginalLeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb23122e-3c2b-4030-8ff0-177914816c06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:LizBhattMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bec2c5bd-26fb-45e2-b7fd-c7e78e0c918b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c30be0fc-4d13-491e-b258-067754619704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:OriginalLeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:InitialTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3cf3248-6c46-426f-8551-507bf07f1e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c800dc65-a3df-4be9-b13c-6170777fad6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:SamiraShaikhlyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8ea85e2-1da3-448c-b148-4c967f416f46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca4c5acf-d189-48eb-b452-a7a26d138b38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cebc2669-0a16-4e56-bad3-816ef82b4bab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2961116-d112-4899-9e01-f6d82d75041d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sepn:VertexAssetPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3c78d76-dd2e-4cd2-a4ec-26c17d567446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4bd1786-5f2f-4271-a5d8-e93f78bac79d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5287ebc-ed11-4be9-a9a2-49a7065ae6fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d86b0a04-264c-4ec6-a98a-514c21b6fcd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da673621-a76d-4b43-ba2e-10ba33dfce9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db2dcbd2-97a4-4ddf-ba1c-ede279cbcae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e20810db-824c-4b6e-aef6-6aad0885a137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2f01c6e-2c71-481c-920d-0563fd77c7f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e34ee022-7881-4415-9223-49c1cc144b97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5502035-9c62-4bfa-b75f-04b8934fb13b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5529578-cb7f-423b-ae3c-3d4cbfedbb24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:LizBhattMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7f2b074-5874-4a74-ac56-9ee225b000cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-18</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e999414c-e45b-4680-8108-7315ee154945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea277975-b2f2-4b8a-b194-b83995f01006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:InitialTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edbd8258-cfdd-447f-8899-e8bf5ca401c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef8945b7-cd7c-40a3-87d4-443fa84b4251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f01b0a9e-0bec-4e73-87b2-511f0f3402f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4c23b37-5cfc-40da-a0d2-d57dcfb5120d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:RaCapitalManagementLPServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f57fea07-b224-42ba-828d-12e6d48e58e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneAndTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f65b9339-0f3a-4b2a-8936-a9b7e8f4f353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8051df8-6f74-4da2-9664-e548022686e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fab764e8-30d4-4a5a-8352-b6d7d8e5c87b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb785e0f-2bdc-4e89-ac3b-e5d3f8322c6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04565b03-4afb-406b-9060-3d79c752b374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04ddd023-f899-4392-8195-43ee327ecc9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneAndTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07465302-3c57-4c51-8649-8a24eb806c09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:CombinedLicenseAndResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0baed1d2-4492-4d81-b9ab-a87043b82d59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d155a10-3368-4e21-9ede-8d1675cae5c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fbb9c90-762c-43f1-b17f-96b2e4b4c262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_124207ea-9553-4036-b32d-b292d0dd4f7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12930a8d-66c5-4c50-9202-0f635796fbca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12bf748d-8c8f-43c8-986f-7e62abb1f3b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:SamsaraBiocapitalLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13a6815f-57a4-459f-b517-409e1abf0033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14b12819-68bb-4fc2-a4a0-9759c3528569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_155d82b1-0c77-4ae4-bb15-deffd6d81ad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15ee37b0-5f7b-4d77-b60f-a12687d07532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_188353cf-4494-4271-90fa-2b494b9ce37b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:ResearchDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1966a14f-61e2-41d4-a6ff-47aa4fad01b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a5a03ec-3b78-4b4f-984f-9c02f37f3f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:SamsaraBiocapitalLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c50a455-abd2-40af-bc2f-471cb232f201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20efa5c4-f0f4-4871-a51a-f97b96ba7528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26b3acdc-a041-414e-a35d-958f1caf4710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29cc3ec0-ed7a-4862-b908-992644953c81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ca0b610-feb1-4fc4-9fb6-285c278593cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f1fe350-b8c7-4223-a96e-9534890d1439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31980d7f-00b5-4148-b37d-689b558648c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_319a9d87-f6e6-4839-a984-753a05d06533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31b3e28f-bc58-4c85-9b5a-81f738157245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_322b3bab-f26e-4ef7-b671-7788690ea969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_322e150f-75d2-4c33-a81b-00ef3a3995d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32ee6c26-363c-447f-b284-d18487b21d59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36e0e89a-7c81-4296-9fff-19f854f1ce13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38782ba4-4fa6-40c7-934f-d3a079936095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_388d86f8-b34d-4f0d-9ce6-8aae94db4af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_398ed5f7-f194-4e12-ab54-8894f63345b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39947422-5330-41f2-b716-f2d784c2e0cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b25f05e-0de5-4de6-9e95-c302e515b95c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cba6681-4177-41a6-98a7-0683daf19bf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cfa7cb5-0ba6-432f-9236-d31d63d2d6b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3dd767cf-b320-4070-b5e9-d4aef8502c4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f36de4b-8700-4f6c-bc71-ae1a9dc8ff7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4012e7ef-84ff-438a-9d21-608b4581ba16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeAndNon-EmployeeStockOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43471eb0-1ae4-4188-8890-d5649bb442c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43f43b58-1c3c-4c77-a255-d8e27eb71c5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_451917b5-3692-415a-a8fc-e2773e3c5ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4586a8d6-90a1-4f22-a91e-ed46c95e215d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45f515bf-1005-4082-bc32-9ade4315528d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4856f235-0b67-45f9-87be-48a2c2e0e5a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ce5aad8-c86e-421c-9386-a0a475a3e0cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d8fbc94-ff88-4825-9417-f0e8f0e8e33a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:RaCapitalManagementLPServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dd9f47b-1fb7-4754-a5f2-2c832537c007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4eecc548-826c-47a9-80f2-d64a0e8b8074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fac1b78-8311-432d-aff9-c804f3132070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50876280-ce05-4b2f-a74c-aab5ab966a93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53a67097-47c1-490a-8b40-0541279b1af4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sepn:VertexResearchServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55101ae3-0a3e-4d43-a901-c61588a76992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_572956ed-3133-4ecc-8cc8-1ffe3b8330b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bc6c479-79c8-4152-9bfc-76c56f1b6c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e52f314-36a4-4891-b35b-86b9cc4844f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60266656-e390-427d-9798-309361aca6dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_605171e8-8b01-43d7-a003-6089b7762a8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61651a61-4b9e-4a51-a5f6-c5b66b40d36c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62168868-0203-4750-a338-01cfd04ab7de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62d33bbc-a9d1-4e0d-b374-febca2f135b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6336c77b-4ec0-4b5a-bb48-f2f824e6b90e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6351b22f-2be8-4ebf-a536-1da1776a2f78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sepn:InterimChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6646c47e-b885-4673-91f4-70ca9e64299e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66e5c4ac-4b2d-4683-bb29-b0c9430f9075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6779c8bc-bf3a-4123-b629-4da74d3cadda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69798fd2-c3f2-4367-9df7-974806f034ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6babc3f6-8967-4f07-bbd1-1345bb333060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c210c25-1bfe-4528-904c-2b7a7741e679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d0ae500-5d31-4464-8a21-1873d26e4998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">sepn:AccountingStandardsUpdate202507Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ec0577b-0a29-403d-97f4-adea4205df16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sepn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchase2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_718c5e70-92f5-4610-80c7-d02725f7db49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_718c7a03-3168-40d9-845c-81b6ea2dc196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71f726e5-b69b-43a5-9553-9360762a27cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76244c83-b690-42fd-93b3-51188d2e836f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7629b057-ea4b-4ebf-80e6-83afecdacd5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76c0e442-ab86-41b5-ab70-7fb7e89c9db2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:SamiraShaikhlyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79b1f183-8e7f-4be0-a70d-a466859c1d3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ab5629f-2853-4b6b-ba19-5748e1822866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bbf537c-2701-4b45-969a-1f72cf64e583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sepn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchase2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f97baf0-9093-442d-82b0-a802ec9a04a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001984086</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Position"><xbrli:measure>sepn:Position</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f1953c39-e551-4940-8c04-a300b368e702" fromRefs="F_7008d5d3-9bdd-490b-96e6-88078f8933a4"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_9ae89f8a-23fd-4c50-a308-c16f6583e5df" fromRefs="F_39fd5ca1-4334-4c7d-a6eb-c996d69d21c0"/></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:37.733%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:37.731%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98796e35-84d1-4118-beeb-8699391f3ba9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="margin-left:37.733%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:37.731%;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5.2%;box-sizing:content-box;"/>
     <td style="width:94.8%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'MS Gothic',sans-serif;"><ix:nonNumeric id="F_88b5bbf2-a487-4712-b248-6ddb8819e78e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
    <tr style="height:2.9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">For the Fiscal Year Ended </span><span style="font-size:8pt;"><ix:nonNumeric id="F_fef408f8-6738-45f6-abc3-6341ac68949f" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span><ix:nonNumeric id="F_1c19b9eb-7b89-418a-b96e-7a8755fa1e1c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_cb143847-e506-43b9-9244-97520ed6bcdb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">OR</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'MS Gothic',sans-serif;"><ix:nonNumeric id="F_c8920cf7-5d20-4361-b6c7-bd8c55b8532b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
    <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Transition Period From __________to__________</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24bc474f-96a8-4576-a230-efa1079313cb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-42382</span></ix:nonNumeric></span></p><p style="margin-left:37.733%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:37.731%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d937af30-3e04-49e4-bc70-b7eb00f98fcb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Septerna, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:37.733%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:37.731%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2db3c003-eb5a-4c67-bea5-ce85b4fe61c8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_928dca82-5da2-4805-936c-2dee784fca68" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-3891440</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b8dbd03f-454c-4d82-9c22-f6fff6017efc" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">250 East Grand Avenue</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5b6b1859-1b90-4721-854e-cf943eebfb13" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_6d727ef5-7296-4282-bb4b-a233128593a5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_28bd6a5a-5262-4386-8ea3-8861a56e738a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd874455-ab68-4a59-96ac-76ebb755f360" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38174ef4-c12f-4f3f-a078-f383794608fd" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">338-3533</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_011b4661-b8aa-487d-bf40-1e5343032f25" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7b3b0a3e-6916-4758-ad55-d0a873f00286" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SEPN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bc73c716-290f-46e7-9353-cad053852bc5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d7146a9-5f94-45f3-8755-51c573624fcf" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e9bdedd-173b-4b1c-91d5-8b95dcd20507" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_659789c5-cc28-4802-a8a3-007000bc7ec2" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e90fb55-209b-4a6d-85ff-44ae9d7cd46a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:63.36%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:34.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large Accelerated Filer </span><span style="color:#000000;white-space:pre-wrap;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated Filer </span><span style="color:#000000;white-space:pre-wrap;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_2beb7a86-a635-4ae0-92b3-0b5e16c50cac" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated Filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Smaller Reporting Company </span><span style="font-size:8pt;font-family:'MS Gothic',sans-serif;"><ix:nonNumeric id="F_c391a931-48c4-4147-b057-90c502760f47" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging Growth Company </span><span style="font-family:'MS Gothic',sans-serif;"><ix:nonNumeric id="F_ab0de347-68cf-4fc4-b364-7283bebe505d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_09bf6857-2192-42a5-ba20-1e855580c4e8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.    </span><span style="font-size:8pt;font-family:'MS Gothic',sans-serif;"><ix:nonNumeric id="F_8b32b639-fd4a-4b2a-bbb6-1fef77dc659b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.    </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_22fa8b98-66f3-49a1-bccd-615d4a775629" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).    </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="font-size:8pt;font-family:'MS Gothic',sans-serif;"><ix:nonNumeric id="F_0f9bee74-0a81-4fcd-afaf-b20ef9b7ec46" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'MS Gothic',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_bef0b64d-4c03-435d-8f70-ba73c24f8645" contextRef="C_a16a30b4-7855-443e-8e8c-93eee3c5898a" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">363.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $10.57 per share </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as of such date. In determining the market value of non-affiliate common stock, shares of the registrant&#8217;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 2, 2026, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29661fb4-0b26-4041-b893-c122bf888c5e" contextRef="C_925590ce-df4f-4dd8-8abe-e9865066e1a9" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,906,374</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.001 par value per share, outstanding.</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0a1ade7-c6fd-4109-a29f-3b32653ba419" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p></ix:nonNumeric></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.1%;box-sizing:content-box;"/>
     <td style="width:82.82%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_regarding_forward"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">i</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factor_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factor Summary</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">iv</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own various U.S. federal trademark filings, including a registered trademark, and possess proprietary trademark rights in our name and logo that we use in connection with the operation of our business. This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) includes our trademarks and trade names which are protected under applicable intellectual property laws and are our property. This Annual Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the &#174;, &#153; or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may use our website, our X (formerly known as Twitter) account at Septerna_Inc and our LinkedIn account at https://www.linkedin.com/company/septernainc/ to distribute material information about us and for complying with our disclosure obligations under Regulation FD. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.Septerna.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our social media are not incorporated into, and does not form a part of, this Annual Report.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="special_note_regarding_forward"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These statements are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, progress, results and costs of conducting our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our current and future programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential therapeutic benefits of our product candidates, including our SEP-479 and SEP-631 programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate, and the timing of, preclinical proof-of-concept </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for multiple programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to replicate positive results achieved in our preclinical studies or clinical trials in current or future clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval for our current and future product candidates and research and development programs, including our SEP-479 and SEP-631 programs, and to advance any product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug (&#8220;IND&#8221;) applications or comparable foreign applications, and final U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, scope or likelihood of foreign regulatory filings and approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our business model, and strategic plans for our business, product candidates, and technology; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to leverage programs within our initial target indications and to progress additional programs to further develop our pipeline;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the partnership with Novo Nordisk A/S (&#8220;Novo&#8221;) and the intended and potential benefits thereof, including the receipt of potential milestone payments and royalty payments from commercial product sales, along with tiered royalties based on global net sales, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novo's ability to develop and commercialize potential oral small molecule therapies for metabolic-related diseases and the potential of G protein-coupled receptors, including the GLP-1, GIP, and glucagon receptors, to address the unmet medical need for treating obesity, type 2 diabetes and other related conditions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing collaborations and strategic partnerships, to identify and enter into future license agreements and collaborations, and to realize the intended and potential benefits of such agreements and collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to rely on third-party manufacturers and successfully manufacture product candidates for preclinical use, clinical trials and on a larger scale for commercial use, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to realize the benefits of collaborations for the development and commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to commercialize any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments related to our proprietary Native Complex Platform&#174;;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments in the U.S. and foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth potential of the markets for our product candidates and our ability to serve those markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire, and retain additional qualified professionals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the period over which we expect our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our anticipated use of our existing resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance and estimates of our future expenses, capital requirements, and our needs for additional financing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of macroeconomic and geopolitical developments (such as the ongoing conflict in Ukraine, and new conflicts in Iran and the Middle East) on our business, including rising inflation and capital market disruptions, changes in or disruptions of U.S. governmental agencies, whether from a future U.S. federal government shutdown or reduced resources, new or increased international tariffs and retaliatory tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks and uncertainties, including those listed under the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;contemplate,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; or the negative of these terms or other comparable terminology, and similar expressions, although not all forward-looking statements contain these identifying words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements in this Annual Report represent our views as of the date of this Annual Report. We do not undertake any obligation to publicly update any forward-looking statement except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. All of the market data used in this Annual Report involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Annual Report. Unless the context otherwise requires, reference in this Annual Report to the terms &#8220;Septerna,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar designations refer to Septerna, Inc.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="risk_factor_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY OF MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties and are subject to change based on various factors, including those highlighted in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. These risks include, but are not limited to, the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history and have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial additional funding in order to finance our operations. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts. We have not successfully completed any advanced clinical trials, and as a result it will be years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future therapeutic candidates on a timely basis or at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance obligations, which is costly and time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and prospects.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary Native Complex Platform&#174; is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to expand our development portfolio of product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing, sales or distribution capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receive marketing approval, such product candidate may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers, clinical research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and suppliers to supply, develop and test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The material and other risks summarized above should be read together with the text of the full risk factors and in the other information set forth in this Annual Report, including our financial statements and the related notes, as well as in other documents that we file with the SEC. If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">v</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T I</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1. Bu</span><span id="item_1_business"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">siness.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (&#8220;GPCR&#8221;) oral small molecule drug discovery powered by our proprietary Native Complex Platform&#174;. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all FDA-approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged. For certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary Native Complex Platform&#174; replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex Platform&#174; is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists (which activate GPCR signaling), antagonists (which inhibit GPCR signaling), and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands) to affect GPCR signaling in different ways to achieve desired therapeutic effects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women&#8217;s health, cardiovascular, and respiratory disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GPCRs as Therapeutic Targets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GPCRs regulate physiological processes in nearly every organ system of the human body and are the most targeted drug class due to their significant role in human diseases and their pharmacological tractability. Nearly one-third of all FDA-approved drugs in the United States, representing approximately 500 products, target GPCR-associated pathways. In fact, GPCR-related drugs comprise approximately 27% of global pharmaceutical sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GPCRs are proteins that span the cell membrane seven times, and their primary function is to recognize extracellular substances, or ligands, and transmit signals across the cell membrane to the inside of the cell. Ligand binding induces conformational changes in GPCRs, forming complexes with signal transducers, including G proteins. These transducers interact with second messengers, modulating various cellular processes. Certain GPCR ligands are capable of activating multiple pathways through different transducers, leading to diverse physiological and pathological effects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GPCRs constitute the largest and most diverse family of cell membrane receptors, with around 800 identified members. GPCRs are key therapeutic targets due to their vital roles in a variety of physiologic processes including immune regulation, nervous system transmission, mood and behavior regulation, sensory transmission, and maintaining cardiovascular and gastrointestinal homeostasis. Despite the pharmacological and commercial success of GPCR-targeted agents, a majority of GPCR therapeutic targets remain undrugged. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, drug discovery has been highly concentrated on a small number of GPCRs. More than 70% of current GPCR-related drugs target only six subfamilies of GPCRs. There are about 400 known non-olfactory GPCRs, each represented as a branch on the phylogenetic tree in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_0.jpg" alt="img170310032_0.jpg" style="width:319px;height:222px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 1. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GPCR phylogenetic tree highlighting the number of FDA-approved drugs for each GPCR as of February 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Today, approximately 75% of potential GPCR therapeutic targets remain undrugged, representing significant opportunity to address a vast range of therapeutic areas and diseases. And, even for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Native Complex Platform&#174;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past decade, drug discovery across various target classes has been revolutionized by state-of-the-art tools and technologies, including structure-based drug design, computational docking, and DNA-encoded libraries (&#8220;DELs&#8221;). However, the utilization of these technologies has been limited for discovering oral small molecules targeting GPCRs due to the inability to isolate functional native GPCR proteins outside of a cellular context.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With our proprietary Native Complex Platform&#174;, we can purify GPCRs outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous or synthetic), all housed within a well-defined lipid bilayer environment. These Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we are advancing a new approach to GPCR drug discovery, designed to expand the landscape of druggable GPCR targets with novel oral small molecule medicines for patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Native Complex Platform&#174; is powered by a suite of tools and technologies that we have optimized and integrated into a proprietary and industrialized workflow, forming an efficient and iterative discovery process for identification and optimization of novel small molecule product candidates targeting high-value GPCRs, including:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Native Complex biochemistry and structural biology:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Native Complexes reconstitute native GPCR function in a purified biochemical format, enabling efficient high-resolution, three-dimensional structure determination using cryogenic electron microscopy (&#8220;cryo-EM&#8221;). This reveals receptor binding pockets that we can target with a range of pharmacologies (e.g., agonists, antagonists, and allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Native Complex-driven hit identification and optimization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We virtually screen our GPCR structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to screen billions of candidate molecules simultaneously and have developed proprietary technologies to discover and optimize compounds with a variety of modes of action. Additionally, we use our proprietary Native Complex biochemical screens in our hit identification and optimization processes.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advanced cellular and in vivo pharmacology models:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We efficiently evaluate hits and lead compounds through the integration of advanced cellular and in vivo pharmacology models. Prioritized compounds with desired pharmacologies are </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">either advanced as potential drug candidates or fed back into the process for additional Native Complex-driven compound optimization.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our oral small molecule drug discovery process, powered by our proprietary Native Complex Platform&#174;, is depicted in the figure below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_1.jpg" alt="img170310032_1.jpg" style="width:505px;height:267px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industrial-scale Native Complex Platform&#174; is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies to achieve desired therapeutic effects. Our platform has led to the discovery and development of a pipeline of novel, highly potent and selective oral small molecules, and for our most advanced programs, optimized them into clinical development candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to develop life-changing GPCR-targeted medicines for patients with significant unmet medical needs. We plan to achieve this goal by efficiently advancing our portfolio of GPCR-targeted programs, continuing to expand our differentiated GPCR-targeted pipeline focused on indications with significant unmet needs, maximizing the potential of our Native Complex Platform&#174; through continued innovation and investment, and evaluating potential value-creating strategic partnerships.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portfolio Opportunities Targeting the Full Breadth of GPCRs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are significant unmet medical needs across numerous GPCR-driven diseases. Our portfolio is focused initially on three therapeutic areas with the potential to expand to additional therapeutic areas in the future:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Endocrinology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The endocrine system involves glands that secrete hormones into the bloodstream that have effects on other tissues. Central to this system are GPCRs, which serve as primary receptors for many circulating hormones. GPCR biology is at the center of endocrine diseases, such as hypoparathyroidism and Graves&#8217; disease, highlighting the urgency for therapeutic interventions targeting GPCR-mediated endocrine disorders. Other endocrine disorders, like osteoporosis, impacts more than 10 million older adults in the United States and could benefit from a small molecule GPCR-directed therapy to help rebuild bone mass.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Immunology &amp; inflammation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> GPCRs serve as key signaling molecules in various cellular processes, including involvement in the regulation of immune responses and the activation of immune cells such as macrophages, T cells, and dendritic cells. Upon activation by extracellular ligands, GPCRs initiate intracellular signaling cascades that modulate cytokine production, leukocyte trafficking, and inflammatory mediator release. Dysregulation of GPCR signaling pathways is implicated in numerous inflammatory and autoimmune diseases, such as chronic spontaneous urticaria (&#8220;CSU&#8221;), making them attractive targets for therapeutic intervention.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Metabolic diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> GPCRs are known to regulate various physiological processes such as energy metabolism, glucose homeostasis, and lipid metabolism. These receptors are involved in sensing nutrients, hormones, and other signaling molecules, thereby influencing appetite, insulin secretion, and lipid storage. Dysregulation of GPCR signaling pathways is associated with metabolic disorders, such as obesity and type-2 diabetes (&#8220;T2D&#8221;). For instance, GPCRs like adrenergic </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receptors regulate lipolysis and thermogenesis, while receptors such as the GLP-1 receptor modulate insulin secretion and satiety. Targeting GPCRs is a clinically and commercially validated approach for the development of therapeutics that manage metabolic disorders, offering the potential to manage glucose levels, promote weight loss, and improve metabolic health.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond our initial therapeutic areas of focus, we intend to evaluate opportunities in additional therapeutic areas where GPCRs are directly connected to disease pathology, including in areas of neurology, women&#8217;s health, cardiovascular disease, and respiratory disease.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing a deep portfolio of highly potent and selective oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is focused initially on three therapeutic areas &#8211; endocrinology, immunology and inflammation, and metabolic diseases &#8211; and is summarized in the figure below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_2.jpg" alt="img170310032_2.jpg" style="width:720px;height:345px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our target selection process considers the validation level of the GPCR and existing preclinical and/or clinical data demonstrating desired biological outcomes upon target modulation for a variety of different indications. We have prioritized indications with well-defined biomarkers to streamline the path to clinical proof-of-concept data, high unmet medical need and significant market opportunities. When analogous molecules exist that are approved or in clinical development, we explore differentiation opportunities and leverage our Native Complex Platform&#174; to address known limitations. We also leverage regulatory insights from established precedents to guide each program&#8217;s development strategy. As we expand our portfolio of GPCR-targeted programs, we will continue to focus on targets and indications with well-understood biology, predictive biomarkers for early proof-of-concept, efficient clinical development pathways, and high unmet medical need. We are building a deep portfolio comprised of programs that we can independently develop and commercialize upon regulatory approval, alongside select programs that may benefit from the development and commercial expertise, infrastructure and financial support of a strategic partner.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PTH1R Program: Oral Small Molecule PTH1R Agonist for Hypoparathyroidism</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing novel, oral small molecule Parathyroid Hormone 1 Receptor (&#8220;PTH1R&#8221;) agonists for the treatment of hypoparathyroidism. While there are PTH peptide products approved and in development for hypoparathyroidism that target PTH1R, to our knowledge, we have the most advanced and comprehensive oral small molecule PTH1R agonist program. We believe our PTH1R agonists offer potent and selective activation of PTH1R, a GPCR highly involved in blood calcium control, with the potential to achieve sustained normalization of serum calcium and phosphate upon once-daily or twice-daily oral dosing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the third quarter of 2024, we initiated a Phase 1 single- and multiple-ascending dose (&#8220;SAD/MAD&#8221;) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule PTH1R agonist product candidate that was being developed for the treatment of hypoparathyroidism. On February 18, 2025, we announced our decision to discontinue the development of SEP-786 and advance a next-generation oral small molecule PTH1R agonist. This decision followed the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial, both of which were without elevations in alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase liver enzyme levels. Dosing was discontinued for both study participants, and the bilirubin elevations were reversible. There were no events of liver injury, cholestasis, or hemolysis across all participants, and there were no serious adverse events (&#8220;SAEs&#8221;) in the Phase 1 trial. In completed 28-day preclinical toxicology studies in rats and dogs, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation. We observed early signals of on-target pharmacology in the MAD portion of the trial including initial increases in serum calcium and decreases in endogenous parathyroid hormone levels.  In September 2025, we announced the findings from our post-discontinuation investigation that SEP-786 was a potent UGT1A1 inhibitor, which is a mechanism known to be associated with increases in unconjugated bilirubin. In a follow-up cynomolgus monkey study of SEP-786, conducted after clinical discontinuation, we also observed elevated unconjugated bilirubin levels.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We announced in September 2025 that we had selected a new PTH1R development candidate, SEP-479.  We presented preclinical data for SEP-479 from a translational rat thyroparathyroidectomy model demonstrating that SEP-479 achieved sustained normalization of serum calcium and phosphate levels over a 28-day dosing period. We also conducted a seven-day pharmacokinetic (&#8220;PK&#8221;) / pharmacodynamic (&#8220;PD&#8221;) study of SEP-479 in healthy cynomolgus monkeys, which showed robust, dose-dependent increases in serum calcium and decreases in endogenous parathyroid hormone levels across multiple dose levels of SEP-479.  We observed no significant inhibition of UGT1A1 or other transporters for SEP-479 and no hyperbilirubinemia in any of the non-clinical studies to date for SEP-479, including the 7-day and 28-day GLP toxicology studies in healthy cynomolgus monkeys. SEP-479 was generally well-tolerated in 28-day GLP toxicology studies in rats, dogs and cynomolgus monkeys. In the first half of 2026, we plan to initiate a placebo-controlled, SAD and MAD Phase 1 clinical trial in Australia, pending the successful completion of regulatory submissions. We anticipate announcing topline data from this Phase 1 clinical trial around the end of 2026 or early 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Hypoparathyroidism</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disease Background and Role of PTH1R</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of parathyroid hormone (&#8220;PTH&#8221;) that affects approximately 70,000 patients in the United States and 140,000 patients in Europe. PTH is a critical hormone for calcium and phosphate homeostasis and functions through activation of PTH1R. Under normal physiological conditions, PTH is released from the parathyroid glands when circulating calcium levels are reduced and will act on PTH1R expressed on bone and kidney cells to increase calcium levels. Most patients with hypoparathyroidism develop the condition following damage to or loss of the parathyroid glands during thyroid surgery, while other etiologies include autoimmune and genetic disorders. Patients with hypoparathyroidism are at risk of both short-term and long-term complications and comorbidities, such as tingling, muscle cramps and weakness, fatigue, cataracts, and in severe cases can lead to life-threatening complications including abnormal heart rhythms and seizures. Chronic hypoparathyroidism is associated with cognitive and emotional symptoms, such as mental lethargy, inability to concentrate, memory loss or forgetfulness, anxiety, and depression. Many patients experience persistent symptoms that negatively impact quality of life and reduce work productivity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Treatment Options and Their Limitations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The standard treatment for hypoparathyroidism includes high-dose calcium supplements several times a day and activated vitamin D (calcitriol) which aim to correct serum calcium levels; however, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis, and they can lead to long-term complications, including soft-tissue calcifications and impaired renal function.  Hormone replacement therapy with injectable PTH peptides is designed to sustain PTH in the normal physiological range, thereby more fully addressing the underlying condition. An injectable PTH peptide, palopegteriparatide (marketed as Yorvipath by Ascendis Pharma), was approved in Europe in 2023 and in the United States in 2024; however, it will require life-long daily injections.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: Oral Small Molecule PTH1R Agonist</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Program Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe there is an unmet need for an oral small molecule PTH1R agonist that offers hypoparathyroidism patients a convenient, more physiological treatment option. Since conventional therapies, such as calcium and vitamin D, have limitations and do not restore other actions of PTH, such as release of bone calcium or renal calcium reabsorption, we believe an oral option that can increase serum calcium and replace the other functions of PTH is needed for patients. Our potent and selective PTH1R agonists are designed to address all patients with hypoparathyroidism. This includes the most severe patients, who may start injectable PTH peptide therapy, as well as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mild-to-moderate patients who are currently on high doses of calcium and vitamin D and may be less interested in an injectable PTH peptide treatment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our Native Complex Platform&#174; affords us the opportunity to continuously discover and optimize oral small molecule PTH1R agonists in addition to the lead compounds we have already identified. We may develop additional molecules for hypoparathyroidism or for other indications where PTH1R agonists can address disease pathology, such as osteoporosis.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discovery and Preclinical Activity of Small Molecule PTH1R Agonists</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Native Complex Platform&#174; was applied to PTH1R and yielded multiple tractable chemical series of small molecule PTH1R agonists with distinct binding sites. Iterative structure-based design has led to multiple lead compounds from different chemical series. In September 2025, we announced that we had selected SEP-479 as the lead compound that we plan to advance into clinical development in the first half of 2026, pending the successful completion of drug product manufacturing and regulatory submissions. SEP-479 was generated from a chemical series that is unrelated to the chemical series from which we generated SEP-786.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have assessed SEP-479&#8217;s potency and selective activation of PTH1R in human, dog, and rat receptor cell-based assays. In vivo, we have demonstrated that SEP-479 showed activity in a translational rat thyroparathyroidectomy (&#8220;TPTx&#8221;) model of hypoparathyroidism (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2.A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). In this model, surgical removal of the parathyroid glands replicates the human disease of hypoparathyroidism with a reduction in serum calcium below the normal range and an increase in serum phosphate levels above the normal range. To assess the activity of SEP-479, we dosed the TPTx rats with SEP-479 once-daily and analyzed the dose-dependent increases in serum calcium and decreases in serum phosphate allowing for an assessment of compound activity and PK/PD relationships.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a 28-day repeat dose study (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2.B and C</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), SEP-479 was dosed at 0.15 mg/kg orally once-daily which led to sustained increases in serum calcium to within the normal range and normalized serum phosphate levels over the entire 28-day dosing period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_3.jpg" alt="img170310032_3.jpg" style="width:562px;height:401px;"/></p><p style="margin-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (A) Rat hypoparathyroidism disease model (thyroid-parathyroidectomy model, TPTx). (B) Repeat once-daily oral dosing of SEP-479 in the TPTx model showed sustained calcium and phosphate control over 28 days of dosing. PO = oral; QD = once-daily.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a 7-day repeat-dose healthy cynomolgus monkey PD study (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), SEP-479 was dosed orally once-daily at 0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 3 mg/kg which led to decreases in serum PTH levels and dose-dependence increases in serum calcium.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img170310032_4.jpg" alt="img170310032_4.jpg" style="width:677px;height:195px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Preclinical pharmacodynamic study of multiple doses of SEP-479 in healthy cynomolgus monkey. (QD) = QD = once-daily.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PK profile of SEP-479 across multiple species was determined to support human PK projections based upon allometric scaling of the nonclinical PK parameters, in addition to in vitro-in vivo extrapolation (IVIVE) of intrinsic clearance in human hepatocytes. These human PK models projected that SEP-479 will have a human half-life in approximately the range of 43-87 hours following oral dosing. We believe that the totality of preclinical data for SEP-479 supports a projection that once-daily oral dosing of SEP-479 could lead to control of serum calcium within the normal range in patients with hypoparathyroidism.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan and Status</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the first half of 2026, we plan to initiate a placebo-controlled, SAD and MAD Phase 1 clinical trial in Australia, pending the successful completion of regulatory submissions. This Phase 1 clinical trial in healthy adult participants is designed to assess preliminary safety, tolerability, PK, and PD of oral doses of SEP-479.  In the MAD portion of the trial, we plan to evaluate oral dosing of SEP-479 to evaluate safety and determine the optimal dosing regimen for serum calcium control. Secondary endpoints include PK, serum calcium, serum PTH, and other biomarkers.  We anticipate announcing topline data from this Phase 1 clinical trial around the end of 2026 or early 2027.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEP-631: Oral Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell- Driven Diseases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing SEP-631, a selective, oral small molecule MRGPRX2 negative allosteric modulator (&#8220;NAM&#8221;), initially for the treatment of CSU. In preclinical studies, SEP-631 demonstrated potent and long-lasting inhibition of MRGPRX2, which is a highly and uniquely expressed receptor on mast cells and when activated is a key driver of CSU and other prevalent mast cell- driven diseases. In August 2025, we announced the dosing of the first participants in our Phase 1 clinical trial of SEP-631. The Phase 1 SAD and MAD clinical trial evaluated the safety, tolerability, PK and PD of SEP-631 in healthy adult volunteers. On March 1, 2026, we presented positive results from our Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma &amp; Immunology (AAAAI) Annual Meeting.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of CSU</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disease Background and Role of MRGPRX2</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CSU is a systemic inflammatory skin disease characterized by the spontaneous and recurrent appearance of itchy, painful hives, known as wheals, on the skin and angioedema, or swelling, that affects approximately 2-3 million patients in the United States. These chronic symptoms, which typically last between two and five years, can interfere with daily living, including the ability to work, and are frequently associated with psychiatric comorbidities, including depression and anxiety. Some patients with CSU report associated systemic symptoms including headache and fatigue, wheezing, flushing, palpitations, and gastrointestinal symptoms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While there is no known trigger, the activation and degranulation of mast cells and release of histamine and other inflammatory mediators lead to the debilitating symptoms of CSU. Two canonical pathways represent the primary mechanisms for activation and degranulation of mast cells: activation of the IgE pathway via receptor cross-linking by antibodies targeting the high-affinity IgE receptor</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Fc&#949;RI) or IgE itself, and activation of an IgE-independent pathway via MRGPRX2. Upon activation, mast cells release a plethora of mediators leading to the hallmark symptoms of itching, redness, and swelling.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MRGPRX2 is highly expressed on the surface of mast cells and plays a critical role in mast cell activation and degranulation. This receptor is activated by a variety of stimuli, including neuropeptides, antimicrobial peptides, immune mediators, and certain drugs. Upon activation, MRGPRX2 triggers a signaling cascade that leads to the rapid release of pre-stored inflammatory mediators such as histamine, proteases, and cytokines from mast cell granules. This degranulation process contributes to immediate hypersensitivity reactions and various inflammatory conditions. The unique ability of MRGPRX2 to respond to a broad range of ligands highlights its importance in host defense mechanisms and its potential as a therapeutic target for treating allergic and inflammatory diseases.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Treatment Options and Their Limitations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patients suffering from CSU are treated initially with antihistamines to control symptoms; however, approximately 37% of patients are inadequately controlled in this first-line setting.</span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant proportion of patients have persistent symptoms with antihistamines, highlighting substantial need for additional treatment options. In 2025, the FDA approved two new treatment options for CSU patients:  dupilumab, an injectable biologic that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), and remibrutinib, a twice-daily oral Bruton&#8217;s tyrosine kinase inhibitor.  With the expanding knowledge of the pathogenesis of CSU and the role of mast cells, novel therapeutic agents targeting distinct drivers of CSU are in development. We are aware of several new mechanisms, and programs are being explored in clinical trials, such as anti-KIT antibodies barzolvolimab and briquilimab, an oral KIT inhibitor SAR449028, an MRGPRX2 inhibitor EVO756, and a long-acting anti-IgE antibody, ozureprubart.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: Oral Small Molecule MRGPRX2 NAM</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Program Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe an oral small molecule that targets MRGPRX2 could provide a differentiated treatment option for patients with CSU. Our MRGPRX2 NAM program is designed to selectively inhibit mast cells, minimizing the risk of broad immunosuppression, which might be observed with other mechanistic approaches that either eradicate mast cells or inhibit multiple immune cell types. We believe selective mast cell inhibitors have the potential to be safer treatment alternatives and could be used for both monotherapy and combination therapy. With our NAM, we believe that we may be able to universally block all endogenous MRGPRX2 agonists and prevent MRGPRX2 activation even in the presence of high concentrations of MRGPRX2 agonists. We believe that with this combination of features, our NAM could have the potential to control patient symptoms and protect against disease flares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing SEP-631 initially for the treatment of CSU, as we believe this may provide an efficient path to clinical proof-of-concept. There remains a significant unmet need in CSU, since antihistamine-refractory patients have few oral treatment alternatives. Because multiple diseases are driven by activated mast cells, we believe there is an opportunity to expand into indications across several therapeutic areas, such as atopic dermatitis, interstitial cystitis, migraine, prurigo nodularis, and asthma.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Activity of SEP-631</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEP-631 has been demonstrated to potently block the activation of intracellular signaling in HEK293 cells with overexpressed human MRGPRX2 stimulated by cortistatin-14 (IC50 = 1.6 nM). Experiments using a matrix of different concentrations of SEP-631 versus different concentrations of cortistatin-14 showed strong suppression of maximal agonist effects (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which we believe demonstrates SEP-631 has the potential to be a NAM which, when bound to MRGPRX2, cannot be outcompeted by excess amounts of an MRGPRX2 agonist.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_5.jpg" alt="img170310032_5.jpg" style="width:380px;height:221px;"/></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 4. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEP-631 shows strong negative allosteric modulation of cortistatin-14 activation of MRGPRX2 in HEK293 cells expressing MRGPRX2.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEP-631 can block IP1 accumulation in HEK293 cells expressing MRGPRX2 in response to activation by several clinically relevant endogenous MRGPRX2 agonists (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), demonstrating that its inhibitory effect is independent of the activating agonist (i.e., the inhibitor does not show probe dependence).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_6.jpg" alt="img170310032_6.jpg" style="width:376px;height:209px;"/></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 5. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEP-631 potently inhibits the activation of MRGPRX2 by a range of endogenous MRGPRX2 agonists.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In different in vitro cellular models of mast cell degranulation, SEP-631 was shown to be a potent inhibitor of activation and degranulation in LAD2 cells (IC50 = 2.3 nM) and primary human cord blood-derived mast cells (IC50 = 0.72 nM). In typical experiments on primary human skin mast cells, SEP-631 fully and potently inhibited tryptase release triggered by an EC90 concentration of Substance P (IC50 = 12 nM) (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_7.jpg" alt="img170310032_7.jpg" style="width:274px;height:206px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 6.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In typical experiments on human skin mast cells, SEP-631 potently inhibited Substance P- stimulated tryptase release from primary human skin mast cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key feature of SEP-631 compared to other MRGPRX2 inhibitors is its long target residence time or slow off-rate of inhibition, meaning it takes a long time for the receptor-ligand complex to dissociate and for the receptor to become activatable again. Two experimental approaches were taken to determine the half-life of the receptor-ligand complex: radioligand binding experiments and a surface plasmon resonance study demonstrated long half-lives of 124 minutes (with a standard deviation of 20 minutes) and 50 minutes, respectively. Long target residence times of receptor ligands are recognized as being potentially advantageous for prolonged drug action in vivo, which have been shown to translate to enhanced clinical activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For characterization of SEP-631 in vivo, we developed a transgenic knock-in (&#8220;KI&#8221;) mouse model in which the coding region of the endogenous mouse MRGPRB2 receptor was replaced with the human MRGPRX2 receptor, due to the low sequence homology shared between the mouse and human orthologs. In this model, MRGPRX2 agonist ligands such as cortistatin-14 or icatibant stimulate robust plasma extravasation, or edema, when injected into the skin. Extravasation can be quantitated by following the redistribution of Evans Blue dye from the circulation into skin tissue (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 7.A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). In the MRGPRX2 KI mouse model, SEP-631 robustly inhibited skin extravasation when dosed orally prior to the cortistatin-14 and icatibant skin challenge, demonstrating complete blockade of skin mast cell degranulation at an oral dose of 3 mg/kg (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 7.B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_8.jpg" alt="img170310032_8.jpg" style="width:720px;height:322px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 7. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) Human MRGPRX2 KI mouse model of plasma extravasation into skin. (B) SEP-631 potently inhibited cortistatin-14 and icatibant mediated plasma extravasation into skin in a human MRGPRX2 KI mouse model. PO = oral.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies to Support Clinical Advancement of SEP-631</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preclinical drug metabolism and PK profile of SEP-631 across multiple species was determined to support human PK projections. SEP-631 has the potential to be highly orally bioavailable with low clearance and a projected half-life consistent with once-daily oral dosing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In vitro and in vivo safety studies explored to date support that SEP-631 has a favorable tolerability profile. In 28-day repeat oral dose GLP toxicology studies in rats and dogs, SEP-631 was generally well tolerated with wide safety margins over projected maximal exposures at human efficacious doses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Study Supports Clinical Advancement of SEP-631 to Phase 2</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2025, we announced the dosing of the first participants in our Phase 1 clinical trial of SEP-631. The Phase 1, double-blind, randomized, placebo-controlled, SAD and MAD clinical trial evaluated the safety, tolerability, PK, PD and food effects of SEP-631 dosed orally once-daily (&#8220;QD&#8221;) in healthy adult volunteers. On March 1, 2026, we presented positive results from our Phase 1 clinical trial of SEP-631 at the AAAAI Annual Meeting. In the SAD and MAD cohorts the adverse event profile for SEP-631 was comparable to placebo.  No severe or serious events were reported in the study.  In the SAD cohorts, two adverse events of mild transaminase elevations (&lt;1.5x the upper limit of normal) in subjects receiving SEP-631, both of which were not related to dose, and at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rates similar to placebo with one mild transaminase elevation observed in a subject receiving placebo.  In the MAD cohorts, one mild transaminase elevation (&lt;1.5x the upper limit of normal) was observed in a subject receiving SEP-631 and one was observed with a subject receiving placebo. The observed elimination half-life of SEP-631 was approximately 24 hours which we believe will support QD dosing in future clinical studies of SEP-631.  In a food effects evaluation cohort, we observed subjects on a high-fat, high-calorie meal resulted in similar exposure of SEP-631 to subjects in fasted conditions as assessed by the maximum plasma concentration and area under the curve.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 study included a PD assessment of SEP-631 in the MAD cohorts using an icatibant skin challenge.  The skin challenge agents that were injected into the forearm of healthy adult subjects included saline (injection negative control), histamine (wheal positive control), and icatibant at 10 ug/mL and 100ug/mL. Icatibant is an MRGPRX2 agonist that is known to cause wheal formations on the skin at the injection site.  The skin challenge was performed at baseline (Day &#8211;1) and at steady-state (Day 9) following once-daily dosing of SEP-631 or placebo.  The size of the wheals in the skin challenge was assessed using a precision image-based technology called AllergyScope detector, which utilizes short-wave infrared spectrum to image the skin wheals.  Those images were then transmitted for central lab analysis and adjudication performed by two independent and blinded adjudicators at Johns Hopkins University. SEP-631 substantially inhibited icatibant 10 &#956;g/mL-induced wheals at 10 mg QD, the lowest dose of  SEP-631 that was evaluated in the study (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 8.A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). SEP-631 inhibited icatibant 100 &#956;g/mL-induced wheals in a dose-dependent manner up to complete inhibition at 200 mg QD (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 8.B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img170310032_9.jpg" alt="img170310032_9.jpg" style="width:720px;height:244px;"/></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 8. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) Icatibant 10 ug/mL. (B) Icatibant 100 ug/mL.  Note that nominal p-values comparing each SEP-631 dose level to placebo for change from baseline are based on an ANCOVA model including a fixed effect for treatment group and baseline wheal response as a covariate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan and Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting long-term GLP toxicology studies for SEP-631 in rats and dogs which we expect to be completed summer 2026.  Subject to successful completion of these toxicology studies, we plan to initiate a Phase 2b global, randomized, double-blind, placebo-controlled study to evaluate safety and exploratory efficacy of SEP-631 in CSU in the second half of 2026. In addition to CSU, we are exploring other high potential indications where tissue mast cells express MRGPRX2 including atopic dermatitis, interstitial cystitis / bladder pain syndrome, migraine, and asthma where we believe SEP-631 could offer a novel oral treatment option for these patient populations.  We plan to explore these indications as potential future clinical development opportunities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TSHR Program: Oral Small Molecule TSHR NAM for Graves&#8217; Disease and TED</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a novel, oral small molecule TSHR NAM for the treatment of Graves&#8217; disease and thyroid eye disease (&#8220;TED&#8221;). We believe our TSHR NAM could offer a disease-modifying treatment that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#8217; autoantibodies. We are advancing several lead compounds towards selection of a development candidate for IND-enabling studies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Graves&#8217; Disease and TED</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disease Background and Role of TSHR</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Graves&#8217; disease is one of the most prevalent autoimmune conditions affecting over 2 million patients in the United States and is the leading cause of hyperthyroidism. In Graves&#8217; disease, the body produces autoantibodies that bind to and activate TSHR on thyroid cells. These autoantibodies stimulate the thyroid gland to produce excess thyroid hormone, resulting in hyperthyroidism. Thyroid hormones affect many body systems, so symptoms of Graves&#8217; disease can be wide-ranging. Common symptoms of Graves&#8217; disease include anxiety and irritability, tremors, heat sensitivity, weight loss, rapid or irregular heartbeat, and sleep disturbance. Although Graves&#8217; disease may affect anyone, it is more common among women and people younger than age 40.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TED is a related, yet distinct, vision-threatening autoimmune condition that develops in approximately 50% of Graves&#8217; disease patients. In TED, autoantibodies bind to and activate TSHR on orbital fibroblasts located behind the eyes, thereby resulting in inflammation, orbital fat expansion, and fibrosis. TED is a progressive disease and early diagnosis and treatment are important to prevent worsening and serious eye damage, including proptosis (eye bulging), strabismus (misalignment of the eyes), and diplopia (blurred or double vision).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Treatment Options and Their Limitations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most common treatments for Graves&#8217; disease have remained largely unchanged over the past 70 years and include antithyroid drugs, such as methimazole and propylthiouracil, designed to lower the amount of hormone the thyroid makes or block the effects of thyroid hormone on the body, radioactive iodine therapies that aim to destroy overactive thyroid cells, and thyroidectomy surgery to remove all or part of the thyroid. For many patients, there is a high rate of disease recurrence after treatment with antithyroid drugs, and lifelong hypothyroidism develops after ablation and thyroidectomy. In addition, these treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current treatments for TED depend on disease severity and are designed to help manage symptoms and slow disease progression. For patients with mild TED, lifestyle changes and over-the-counter remedies, such as artificial tear drops and selenium supplements, may help with dry eye relief. For severe TED, steroids and/or eye surgery, such as orbital decompression, may be considered. Historically, patients have had to live with TED until the inflammation subsides, after which they are often left with permanent and vision-impairing consequences and may require multiple surgeries that do not completely return the patient to their pre-disease state.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: Oral Small Molecule TSHR NAM</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Program Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe there is a significant unmet need for a disease-modifying approach that directly addresses the pathobiology of both Graves&#8217; disease and TED. Our highly selective, oral small molecule TSHR NAM program is designed to block the activation of TSHR by autoantibodies and could lead to a universal treatment option for all Graves&#8217; disease and TED patients. Our NAMs are designed to prevent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the activation of TSHR even in the presence of excess amounts of TSHR activating autoantibodies, thus potentially providing protection for patients with high serum antibody levels and for patients with polyclonal activating antibodies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With few innovative, non-surgical or ablative treatments, we believe that there is a significant unmet need in Graves&#8217; disease. While treatments exist for TED, they are focused on the most severe patients, so an oral small molecule TSHR NAM could provide a new option for all TED patients. Because over-stimulation of TSHR is at the center of Graves&#8217; disease and TED, we believe that if we can treat Graves&#8217; disease patients early in their disease course with our oral small molecule TSHR NAM, our treatment may be able to prevent the progression to other manifestations of the disease, such as TED or Graves&#8217; dermopathy.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discovery and Preclinical Activity of Oral TSHR NAMs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have used our Native Complex Platform&#174; to identify multiple tractable chemical series of oral small molecule TSHR NAMs. Molecular pharmacology studies with TSHR NAMs have demonstrated multiple compound series with high potencies and desired drug-like properties. In cells expressing human TSHR, cAMP signaling activated by an autoantibody isolated from a Graves&#8217; disease patient was significantly inhibited with several of our lead compounds. In addition, our compounds exhibited high selectivity for inhibition of TSHR over a broad set of other GPCRs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An effective treatment for both Graves&#8217; disease and TED will require broad inhibition of patient autoantibodies, which are typically high affinity and present at high titers during active disease. Furthermore, these autoantibodies may bind to different sites on the large extracellular domain of TSHR. We believe a TSHR NAM can have an optimized pharmacologic profile to fully block the activity of all patient autoantibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To demonstrate that our TSHR NAM can fully inhibit multiple patient autoantibodies, we assessed the activity of one of our small molecule TSHR NAMs (SP-1351) against Graves&#8217; disease patient-derived polyclonal sera applied to TED patients&#8217; orbital fibroblasts. Fibroblast activation by the sera is measured by quantifying hyaluronic acid production by the cells. SP-1351 was able to inhibit the activity of 10 out of 10 polyclonal sera samples, each from a different Graves&#8217; disease patient (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). This result suggests broad inhibitory activity of our TSHR NAMs against the diverse range of polyclonal autoantibodies found in Graves&#8217; disease patients.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_10.jpg" alt="img170310032_10.jpg" style="width:458px;height:182px;"/></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 9. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SP-1351 inhibits activation of primary orbital fibroblasts by all 10 polyclonal serum samples collected from Graves&#8217; disease patients. mAb = monoclonal antibody.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To characterize the effects of these oral TSHR NAMs on disease manifestations in vivo, we developed a translational mouse model of hyperthyroidism (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 10.A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). Mice chronically treated with a Graves&#8217; disease patient-derived TSHR-activating antibody developed multiple manifestations similar to Graves&#8217; disease patients, including increased plasma thyroid hormone T4 levels (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 10.B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), increased thyroid weight (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 10.C</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), and proptosis (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 10.D</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). After one week of SP-1351 treatment with repeat oral dosing, several of these manifestations showed signs of reversal including normalization of thyroid hormone T4 levels, reduction in thyroid weight, and reduction of proptosis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_11.jpg" alt="img170310032_11.jpg" style="width:522px;height:316px;"/></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 10. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) Translational in vivo mouse model of Graves&#8217; disease.(B, C, D) SP-1351 demonstrates reversal of the hyperthyroid state and proptosis in mice chronically treated with a monoclonal TSHR autoantibody. mAb = monoclonal antibody.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the same mouse model, effects on thyroid tissue were assessed. Thyroid glands of Graves&#8217; disease patients are characterized by follicular hyperplasia and/or hypertrophy, intracellular colloid droplets, follicular colloid reduction and scalloping, increased vascularity and lymphocyte infiltration, all of which manifest in our mouse disease model. After oral treatment with SP-1351, we observed significant reduction in follicular hypertrophy and colloid droplets.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Next Steps</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are continuing to optimize multiple early-stage oral small molecule TSHR NAMs, with the goal of advancing lead compounds towards selection of a development candidate for IND-enabling studies. In our preclinical studies, we have identified multiple TSHR NAMs that demonstrated the ability to reverse hyperthyroidism and proptosis in a novel mouse model of Graves&#8217; disease and inhibit multiple Graves&#8217; disease patient TSHR autoantibodies in cell-based assays using primary human cells. We intend to pursue future clinical development of our TSHR NAM program for the treatment of Graves&#8217; disease and TED.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Metabolic Diseases: Collaboration with Novo Nordisk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 13, 2025, we and Novo Nordisk A/S (&#8220;Novo&#8221;) entered into a global Collaboration and License Agreement (the &#8220;Collaboration Agreement&#8221;). Under the Collaboration Agreement, we are exclusively collaborating with Novo to leverage the Company&#8217;s proprietary Native Complex Platform&#174; to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The collaboration objective is to discover and develop several novel mono-, dual-, or triple-acting oral small molecule drug candidates directed across five GPCRs, including the GLP-1, GIP, and glucagon receptors (the &#8220;Collaboration Targets&#8221;). The collaboration included our most advanced preclinical metabolic program focused on developing an oral small molecule agonist to the GIP receptor.</span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the Collaboration Agreement became effective on July 1, 2025, we and Novo commenced four simultaneous research and development programs (each an &#8220;R&amp;D Program&#8221;) with each pursuing one or more Collaboration Targets from discovery through development candidate selection. Beginning with investigational new drug-enabling activities, Novo will then be responsible for all further global development and commercialization for each product candidate at its sole cost and expense. Subject to certain limitations, Novo has the right to modify the research plans and explore additional combinations of the existing Collaboration Targets for one or more of such R&amp;D Programs provided that no more than four R&amp;D Programs will be pursued simultaneously. Novo reimburses us for 100% of the costs arising from all research and development activities undertaken by us under the Collaboration Agreement. Novo is also responsible for all commercialization costs subject to our profit and loss share option described below for up to one program under the collaboration.</span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Collaboration Agreement, we will provide Novo with exclusive licenses to enable Novo to develop and commercialize products directed at the Collaboration Targets. We retain all other rights to our Native Complex Platform&#174; and all of our other research and development programs.</span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, Novo paid us a one-time, non-refundable upfront payment of $195.0 million. For each R&amp;D Program, we are also eligible to receive up to approximately $498.0 million in research, development, regulatory, and commercial milestone payments. In addition, we are entitled to escalating, tiered royalties ranging from mid-to-high single-digits based on global product sales on a country-by-country and product-by-product basis with respect to a R&amp;D Program until the later of ten years after the date of first commercial sale of the first product in such R&amp;D Program in such country, expiration of specified patent rights covering such product in such country or the expiration of specified regulatory exclusivity for the first product in such R&amp;D Program in such country. The royalty payments are subject to certain step-down provisions including reductions due to valid patent claim expiration, generic product market share on a country-by-country basis, payments made under certain licenses for third party intellectual property and application of Inflation Reduction Act maximum fair price provisions (with such cumulative reductions in most cases subject to a royalty reduction floor). Subject to certain terms, conditions and limitations, we hold an option to elect a profit and loss sharing arrangement (in lieu of milestones and royalties) for one product candidate under the Collaboration Agreement, which must be exercised by the Company within a specified time period following completion of either IND-enabling studies or the first Phase 1 clinical trial for such product.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary and novel products and product candidates. While we believe our product candidates, platform, knowledge, experience, and scientific personnel provide us with several key competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Our future success will depend in part on our ability to maintain a competitive position with our structure-based drug discovery platform. If we fail to stay at the forefront of technological change in utilizing our platform to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our approach obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and platform. Several other companies also focus on GPCRs and have platform technologies that are distinct from our Native Complex Platform&#174;.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any product candidates that we successfully develop and commercialize, including those from our PTH1R program and SEP-631, may compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for our product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial, technical, manufacturing, marketing, sales, and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other applicable regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate manufacturing facilities for the production of our product candidates and currently have no immediate plans to build our own clinical or commercial scale manufacturing capabilities. We have engaged, and expect to continue to rely on, third-party CMOs to supply our product candidates for use in our preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we intend to rely on third-party manufacturers for later-stage development and commercial manufacturing if our product candidates receive marketing approval. As our product candidates advance through clinical development, we expect to enter into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the number of manufacturers is limited. In the event it is necessary or advisable to acquire supplies from an alternative supplier, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. If we need to change manufacturers during the clinical or development stage for product candidates or after commercialization for our product candidates, if approved, the FDA, European Medicines Agency (&#8220;EMA&#8221;), and other comparable foreign regulatory authorities must approve these new manufacturers in advance, which will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. Reliance on third-party manufacturers and CMOs may expose us to different risks than if we were to manufacture and develop product candidates ourselves. Should any of these manufacturers become unavailable to us for any reason, we  believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have personnel with extensive technical, manufacturing, analytical, and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our intellectual property is critical to our business and we strive to protect it, including by pursuing and, once obtained, by maintaining patent protection in the United States and in selected foreign jurisdictions for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. We also rely on the skills, knowledge, and experience of our scientific and technical personnel, as well as that of our advisors, consultants, contractors, and collaborators. To help protect our proprietary know-how that we elect not to patent, such as our proprietary Native Complex Platform&#174;, processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents, we rely on confidentiality and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other agreements to protect our interests. We generally require our employees, consultants, scientific advisors and contractors to enter into confidentiality agreements prohibiting the disclosure of our confidential information and requiring disclosure and assignment to us of their ideas, developments, discoveries and inventions important to our business. In addition, we also plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See the subsection section titled &#8220;&#8212;Government Regulation&#8221; for additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we may file in the future, nor can we ensure that any of our patents or future patents will be commercially useful in protecting our product candidates and methods of using or manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates, if they obtain required regulatory approvals, will be protectable or remain protected by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will also depend in part on our ability to operate without infringing the proprietary intellectual property rights of third parties, and in part on our ability to prevent others from infringing our proprietary rights. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our future drugs or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. See &#8220;Risk Factors&#8212;Risks Related to Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Filings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We generally file patent applications directed to our product candidates in an effort to secure our intellectual property positions vis-&#224;-vis these programs. For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and therapeutic methods of use. Throughout the development of our product candidates, we will seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including by protecting inventions related to additional methods of use, processes of making, formulations and dosing regimens. As of March 1, 2026, we owned 2 issued patents and 135 pending patent applications in the United States, Europe, Japan, China and other territories, covering our product candidates and our research efforts.  Assuming the timely payment of all applicable maintenance fees, our issued patents are projected to expire between 2044 and 2045, and our pending applications, if issued, are projected to expire between 2043 and 2046.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 1, 2026, for our programs directed to small molecule agonists of PTH1R, small molecule inhibitors of MRGPRX2, and small molecule inhibitors of TSHR, and methods of using each of the foregoing, we own a total of 12 patent families. Assuming the timely payment of all applicable maintenance fees, the patents that may ultimately issue from families are projected to expire between 2043 and 2046.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Extensions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If one or more of our pending United States patent applications are issued as United States patents covering our products or their therapeutic use it is possible that the patents may be entitled to patent term extensions. If a therapeutic use of a drug candidate or the drug candidate itself receives FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any other jurisdictions where available. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted and even if granted, the length of such extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trade Secrets &amp; Know-how</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we also rely on trade secrets, trademarks, proprietary information, confidential know-how, and continuing technological innovation to develop and maintain our competitive position. Our trade secrets, proprietary information, and confidential know-how includes our Native Complex Platform&#174;. However, trade secrets, proprietary information, and confidential know-how can be difficult to protect. We seek to protect our trade secrets, proprietary information, and confidential know-how, in part,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">using confidentiality agreements with any collaborators, scientific advisors, employees, and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide adequate protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets, proprietary information, and confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop substantially the same or similar proprietary information and techniques or may otherwise gain access to our proprietary information. As a result, we may not be able to meaningfully protect our trade secrets, proprietary information, and confidential know-how. For more information regarding the risks related to our intellectual property, see the section titled &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union (the &#8220;EU&#8221;), extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review and Approval of Drugs in the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the U.S. Department of Justice or other governmental entities. In addition, an applicant may need to recall a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND which must take effect before human clinical trials may begin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an institutional review board (&#8220;IRB&#8221;) representing each clinical site before each clinical trial may be initiated at that site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCPs&#8221;) to establish the safety and efficacy of the proposed drug product for each indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation and submission to the FDA of an NDA and payment of user fees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review of the product by an FDA advisory committee, where appropriate or if applicable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with any post-approval requirements, including risk evaluation and mitigation strategies (&#8220;REMS&#8221;) and post-approval studies required by the FDA.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before an applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient (&#8220;API&#8221;) and the formulated drug or drug product, as well as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term preclinical testing, such as animal tests of reproductive adverse effects and carcinogenicity, may continue after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The IND and IRB Processes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments. In addition, an applicant submits the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. The FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold) may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with GCP, including review and approval by an independent ethics committee (&#8220;IEC&#8221;) and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an on-site inspection if necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review of the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ClinicalTrials.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> website.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Human Clinical Trials in Support of an NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1. The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine maximal dosage.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2. The drug is administered to a limited patient population to identify possible adverse effects (&#8220;AEs&#8221;) and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3. The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product. Post-approval studies, often referred to as Phase 4 studies, may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review of an NDA by the FDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain exceptions and waivers are available for some of these fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of an NDA within 60 days of its receipt, before accepting the NDA for filing, to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10 months from the date of filing, and applications for &#8220;priority review&#8221; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During its review of an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">use (&#8220;ETASU&#8221;). ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track, Breakthrough Therapy, and Priority Review</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third, the FDA may designate an NDA review for a priority review if it is for a product that treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from 10 months to six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval Pathway</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), the FDA is permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s Decision on an NDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued, the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have been addressed to the FDA&#8217;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety or effectiveness after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain marketed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or voluntary product recalls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning or untitled letters or holds on post-approval clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidances, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hatch-Waxman Amendments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug (&#8220;RLD&#8221;). ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#8217;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Patent Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity (&#8220;NCE&#8221;). For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, which states the proposed generic drug will not infringe one or more of the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the original product approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDCA also provides for a period of three years of exclusivity for non-NCE drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or for the applicant and are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication, but it generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A drug product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection and patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hatch-Waxman Patent Certification and the 30-Month Stay</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Upon submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no patent information on the drug product that is the subject of the application has been submitted to the FDA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such patent has expired; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the date on which such patent expires; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the 30-month stay is extended so that it expires seven and a half years after approval of the innovator drug, unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Restoration and Extension</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question and within 60 days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review and Approval of Medicinal Products in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows similar lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires a submission to the relevant competent authorities of a marketing authorization application (&#8220;MAA&#8221;) and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, an applicant for authorization of a clinical trial must obtain prior approval from the national competent authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the relevant independent ethics committee has issued a favorable opinion. In April 2014, the Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted in the EU. The Clinical Trials Regulation is directly applicable in all the EU Member States and repealed the Clinical Trials Directive 2001/20/EC, as of January 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, known as the &#8220;Clinical Trials Information System&#8221;; a single set of documents to be prepared and submitted for the application, as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by an elected Reference Member State, with support of the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (the Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national laws of the concerned EU Member State, however overall related timelines are defined by the Clinical Trials Regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain a marketing authorization for a product in the EU, an applicant must submit an MAA either under a centralized procedure administered by the European Medicines Agency (&#8220;EMA&#8221;) or one of the procedures administered by competent authorities in the EU Member States (national, decentralized or mutual recognition procedure) for obtaining a marketing authorization in one or more EU Member States. A marketing authorization may be granted only to an applicant established in the European Economic Area (&#8220;EEA&#8221;) (which is comprised of the EU Member States plus Norway, Iceland and Liechtenstein).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for other products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure, the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) established at the EMA is responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from a public health perspective and in particular from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP opinion, the European Commission will adopt its final decision on the MAA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decentralized marketing authorization procedure allows an applicant to apply for simultaneous authorization in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within the mandatory scope of the centralized procedure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of another EU Member State. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan (&#8220;PIP&#8221;) covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver or (3) a deferral for one or more of the measures included in the PIP. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which a marketing authorization is being sought. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (&#8220;SPC&#8221;), provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data and Market Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. Data exclusivity prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar (abbreviated) marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the EU. During an additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall 10-year period will be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained a marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2) either (i) such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate sufficient return to justify the necessary investment in its development and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product would be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An orphan designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product leads to a ten-year period of market exclusivity being granted. During this market exclusivity period, the European Commission or the competent authorities of the EU Member States may only grant a marketing authorization to a &#8220;similar medicinal product&#8221; to the authorized orphan product for the same therapeutic indication if: (i) a second applicant can establish that its product, although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized orphan product consents to a second medicinal product application; or (iii) the marketing authorization holder for the authorized orphan product cannot supply enough orphan medicinal product. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is established that the product no longer meets the criteria for orphan designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before submitting an application for marketing authorization. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Periods of Authorization and Renewals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A marketing authorization has an initial validity of five years. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA (for a centrally authorized product) or by the competent authority of the relevant EU Member State (for a nationally authorized product). To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authorities of the relevant Member States decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for centrally-authorized products) or on the market of the authorizing EU Member State (for nationally-authorized products) within three years after authorization is granted, ceases to be valid (the so-called sunset clause).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Requirements after a Marketing Authorization has been Obtained</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive (EU) 2017/1572, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and APIs, including the manufacture of APIs outside of the EU with the intention to import the APIs into the EU.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the EU notably under Directive 2001/83/EC, as amended, and EU Member State laws and industry codes of conduct.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reform of the Regulatory Framework in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. On December 11, 2025, the European Parliament and the European Council reached agreement on the EU Pharma Law Package, also known as the General Pharmaceutical Legislation. While he adopted acts of the new pharmaceutical legislation are expected to enter into force in 2026, the following two years, until 2028, will serve as a transition period. In this time interval, EU member states are expected to update their national laws to align with the new rules, after which the new legislation becomes applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK ceased being a Member State of the EU on January 31, 2020. Following the end of the Brexit transition period on January 1, 2021, the UK is not generally subject to EU laws in respect of medicines. The EU laws that have been transposed into UK law through secondary legislation remain applicable in the UK, however, new legislation such as the EU Clinical Trials Regulation is not applicable in the UK. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) became the UK's standalone medicines and medical devices regulator. On January 1, 2025, a new arrangement called the &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the MHRA with respect to medicinal products. The Windsor Framework removes EU licensing processes and EU labeling and serialization requirements relation to Northern Ireland and introduces a UK-wide licensing process for medicines. A single UK-wide marketing authorization may be granted by the MHRA for medicinal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">products intended to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review and Approval of Medicinal Products in Australia</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Therapeutic Goods Administration (&#8220;TGA&#8221;) and the National Health and Medical Research Council (&#8220;NHMRC&#8221;) set the GCP requirements for clinical research in Australia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the regulations, standards and codes set by the TGA and NHMRC is mandatory. Under the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutic Goods Act 1989</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Cth) and the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutic Goods Regulations 1990</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Cth), it is a condition (amongst other conditions) of all clinical trials involving investigational medicinal products to comply with the National Statement on Ethical Conduct in Research Involving Humans, published by the NHMRC (the National Statement), and the Guideline for Good Clinical Practice published by the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;ICH Guidelines&#8221;). The ICH Guidelines have been adopted in Australia, and must be complied with across all fields of clinical research involving therapeutic goods, including those related to pharmaceutical quality, nonclinical and clinical data requirements and trial designs. The basic requirements for preclinical data to support a first-in-human trial under ICH Guidelines are applicable in Australia. Requirements related to adverse event reporting in Australia are generally similar to those required in other major jurisdictions (and there is alignment with the European Union&#8217;s Clinical Trial Regulations: Regulation EU No 536/2014), although reporting timeframes may differ to other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials conducted using &#8220;unapproved therapeutic goods&#8221; in Australia, being those which have not yet been evaluated by the TGA for quality, safety and efficacy (and including unapproved indications of therapeutic goods which have otherwise been approved for use in Australia) must occur pursuant to either the Clinical Trial Notification Scheme (&#8220;CTN Scheme&#8221;) or the Clinical Trial Approval Scheme (&#8220;CTA Scheme&#8221;). In each case, the trial is supervised by a Human Research Ethics Committee (&#8220;HREC&#8221;), an independent review committee constituted in accordance with the National Statement that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. A HREC reviews, approves and provides continuing oversight of trial protocols (including any amendments), methods and materials intended to be used in obtaining and documenting informed consent of the clinical trial subjects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTN Scheme broadly involves:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the investigator or sponsor of the Australian clinical trial submitting a &#8216;Notification of Intent to Conduct a Clinical Trial&#8217; form (&#8220;CTN Form&#8221;) to the TGA and payment of the relevant fee (for unapproved medicines, this was AUD 429 at 1 July 2024: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutic Goods Regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 1990, clause 3, Schedule 9, item 14(a));</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the TGA may request further specific information relating to the &#8216;unapproved therapeutic goods&#8217; that are the subject of the clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to a HREC, of all material relating to the proposed clinical trial, including the trial protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the HREC reviews the scientific validity of the trial design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol. The HREC is also responsible for monitoring the conduct of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the institution or organization at which the trial will be conducted, referred to as the &#8220;Approving Authority,&#8221; giving final approval for the conduct of the trial at the site, in terms no less restrictive to those advised by the HREC; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensuring that the CTN form is signed by the sponsor, the principal investigator, the chairman of the HREC and a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial, however CTN trials cannot commence until the trial has been notified to the TGA. It is the responsibility of the sponsor to ensure that all relevant approvals are in place before supplying the &#8216;unapproved&#8217; therapeutic goods in the clinical trial in Australia.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the CTA Scheme:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment, which includes payment of the relevant fees (for unapproved medicines, this was AUD 2,046 for a 30-day evaluation and AUD 25,426 for a 50-day evaluation, as at 1 July 2024: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Therapeutic Goods Regulations </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1990, clause 3, Schedule 9, items 1(a) and (b) respectively). The TGA encourages all sponsors to request a pre-submission meeting with the TGA in order to clarify any questions about existing studies or the proposed data package for the CTA application, and obtain specific advice from the TGA relating to the CTA application process, including the best ways to submit the application and dossier;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the TGA will undertake a preliminary assessment to ensure that there is sufficient data to begin evaluation. If critical data is missing, the TGA may request further information;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sponsor must forward any comments made by the TGA Delegate to the HREC(s) at the sites where the trial will be conducted;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor cannot commence a trial under the CTA Scheme until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval for inclusion in the Australian Register of Therapeutic Goods (&#8220;ARTG&#8221;), is required before a therapeutic good (including pharmaceutical product) may be marketed (or supplied, imported, exported or manufactured) in Australia. Exceptions apply to therapeutic goods/pharmaceutical products that are supplied, imported, and exported to and from Australia for the purposes of a clinical trial, on the basis that certain conditions are met (e.g., the trial is conducted in accordance with the CTN or CTA scheme).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a sponsor decides to register a therapeutic good/pharmaceutical product in Australia, in order to obtain registration of the product on the ARTG, it is required that (amongst others):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sponsor submits appropriate documentation, including the outcomes of clinical trials and studies, to allow the TGA to assess the quality, safety and efficacy of the therapeutic product/pharmaceutical product; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sponsor submits evidence which demonstrates that the manufacture of the therapeutic product/pharmaceutical product complies with the applicable GMP requirements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The TGA has the ultimate discretion to decide whether to include the therapeutic product/pharmaceutical product in the ARTG.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect our ability to operate include, but are not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil and criminal false claims laws, including the False Claims Act (&#8220;FCA&#8221;), which can be enforced through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating these statutes without actual knowledge of the statutes or specific intent to violate them in order to have committed a violation;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Department of Health and Human Services (&#8220;HHS&#8221;) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals (i.e., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. Factors payors consider in determining coverage and reimbursement are based on whether the product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective and medically necessary; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost- effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (&#8220;ASP&#8221;) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Even if we do receive a favorable coverage determination for approved products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and Future U.S. Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required collection of rebates for drugs paid by Medicaid managed care organizations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required manufacturers to participate in a coverage gap discount program, under which they were required to offer 50 percent point-of-sale discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (later increased to 70% and then later replaced altogether under the Inflation Reduction Act with the Medicare Part D manufacturer discount program); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, and, due to subsequent legislative amendments to the statute, will remain in effect until 2032.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) included several other provisions that may impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries and impose new manufacturer financial liability on all drugs in Medicare Part D.  Further, the IRA among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.  The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.  HHS has completed the first and second rounds of price negotiations and has announced the first and second sets of &#8220;maximum fair prices,&#8221; covering a total of 25 drugs.  The Medicare drug price negotiation program is currently subject to legal challenges.  It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The One Big Beautiful Bill Act of 2025 (&#8220;OBBBA&#8221;) imposed significant reductions in Medicaid funding, additional work requirements for Medicaid recipients, and more frequent reenrollment requirements, which are expected to place substantial pressure on state Medicaid budgets, reduce enrollment, and limit covered services, which could decrease utilization of, and reimbursement for, our products, if approved.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. The Trump Administration has issued executive orders and supported proposed regulatory initiatives in 2025 that could have a significant impact on the prices that we, or any collaborators, may receive for any approved products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 12, 2025, President Trump signed an executive order directing the Secretary of HHS to set and communicate most-favored-nation (&#8220;MFN&#8221;) price targets to manufacturers and propose a rulemaking plan to impose MFN pricing if &#8220;significant progress&#8221; is not made, and also directing the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets. The executive order further states that the Administration will take additional action (for example, examining whether marketing approvals should be modified or rescinded or considering individual drug importation waiver authorities) should manufacturers fail to offer American consumers the MFN lowest price. In July 2025, President Trump sent letters to certain pharmaceutical companies demanding that these companies extend MFN pricing to Medicaid and newly launched drugs as well as move to direct-to-consumer models priced at MFN pricing, and soliciting binding commitments by September 29, 2025. Since this time, multiple drug manufacturers have announced plans to, for certain of their drugs, lower prices to reflect similar pricing around the world, and to sell these reduced-price drugs on a direct-to-consumer purchasing platform developed by the federal government; however, it is not known what results will occur to the extent the recipients of these letters do not reduce their U.S. prices.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (&#8220;GLOBE&#8221;) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs (&#8220;GUARD&#8221;) model for Medicare Part D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five year performance period on October 1, 2026 and GUARD would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November 2025, CMS introduced the GENErating cost Reductions fOr U.S. Medicaid (&#8220;GENEROUS&#8221;) Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effect of these healthcare reform initiatives on our business and the pharmaceutical industry in general is not yet known, but could be substantial and materially adverse to our ability to successfully commercialize our product candidates at profitable price points.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states have also been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Protection, Privacy, and Security</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, transmit, store, use, disclose, transfer, maintain and otherwise process sensitive information, including personal data. Accordingly, we are, or may be become, subject to numerous data protection, privacy, and security obligations, including global, federal, state, and local laws, rules, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations related to data protection, privacy, and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These data protection, privacy, and security obligations are evolving and may impose potentially conflicting obligations. Such obligations may include, without limitation, federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., the Federal Trade Commission Act). In addition, in the past few years, numerous U.S. states have passed, or are in the process of enacting, comprehensive privacy laws, rules, and regulations that impose certain obligations on covered businesses, and similar laws are being considered in several other states, as well as at the federal level. While these laws exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing, as more fully discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, to the extent we collect personal data from individuals outside of the United States, through clinical trials or otherwise, we are, or may become, subject to foreign data protection, privacy, and security laws, such as the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;) and the EU GDPR as incorporated into laws of the U.K. (&#8220;UK GDPR&#8221;). Such foreign data protection, privacy, and security laws impose significant and complex compliance obligations on entities that are subject to those laws, as more fully discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and Human Capital Resources</span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 130 full-time employees, 67 of whom have M.D. or Ph.D. degrees. Within our workforce, 98 employees are engaged in research and development and 32 are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California 94080, and our telephone number is (650) 338-3533.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our website address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.septerna.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information that is contained in and can be accessed through our website is not incorporated into, and does not form a part of, this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Exchange Act, are available through our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our filings with the SEC may also be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at www.sec.gov. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors &amp; Media,&#8221; as a source of information about us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A. Risk Factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report, including our financial statements and the related notes appearing at the end of this Annual Report and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our common stock. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Limited Operating History, Financial Position and Capital Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biotechnology company with a limited operating history, which may make it difficult to evaluate the success of our business to date and assess our future viability. Since our inception in December 2019, we have focused primarily on organizing and staffing our company, business planning, establishing our intellectual property portfolio, raising capital, developing our proprietary and structure-based drug discovery platform, identifying and developing our product candidates, conducting research and preclinical studies, including IND-enabling studies, initiating and conducting clinical trials, and providing general and administrative support for these operations. Our approach to the discovery and development of product candidates based on our Native Complex Platform&#174; is unproven, and we do not know whether we will be able to develop any product candidates that succeed in clinical development or commercially. Other than SEP-631, all of our current product candidates and development programs are in preclinical development or in the drug discovery stages. Accordingly, we have not yet successfully completed any advanced clinical trials, demonstrated an ability to successfully obtain regulatory approvals, manufactured commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred significant losses since our inception, with the exception of the year ended December 31, 2023, and negative cash flows from operating activities and capital expenditures and expect to continue to incur significant and increasing operating losses for at least the next several years. If our product candidates are not successfully developed and approved, we may never generate any significant revenue. For the year ended December 31, 2025, our net loss was $48.9 million. As of December 31, 2025, we had an accumulated deficit of $167.3 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive marketing approvals and begin generating revenue from product sales. We expect to continue to incur significant losses for the foreseeable future, and we expect that our expenses will increase substantially as we continue our development of, seek marketing approval for and potentially commercialize any of our product candidates, recruit and maintain key personnel and seek to identify, assess, acquire, in-license or develop additional product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we succeed in developing and obtaining marketing approval for one or more of our product candidates, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable could decrease the value of our common stock and impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional funding in order to finance our operations. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development of pharmaceutical product candidates, including conducting preclinical studies and clinical trials, is a very time-consuming, capital-intensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate and conduct clinical trials of, and seek regulatory approval for any product candidates we may identify. In addition, if we obtain regulatory approval for any product candidates we may identify, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility of a collaborator. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reasonably estimate the actual amount of capital necessary to successfully complete the development and commercialization of our product candidates. Other unanticipated costs may also arise. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce, or eliminate our research and product development programs, future commercialization efforts or other operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had $548.7 million in cash, cash equivalents and marketable securities. We expect that our cash, cash equivalents, and marketable securities will enable us to fund our operating expenses and capital expenditure requirements at least into 2029. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and progress of research and development, preclinical and clinical development activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number, scope and duration of clinical trials required for regulatory approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of any of our product candidates in any jurisdictions in which we or our current or any future collaborators may seek approval for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing clinical and commercial supplies of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents and other intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing clinical and commercial supplies of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents and other intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaboration and license agreements on favorable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product liability or other lawsuits related to our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our implementation of various computerized informational systems and efforts to enhance operational systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred to attract, hire and retain skilled personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or invest in businesses, products, and technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of global economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the factors discussed above.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate preclinical studies and clinical trials of, and seek marketing approval for, product candidates, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly other restrictions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. We have no committed sources of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Without sufficient funding, our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Additionally, if we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates we develop, or we may have to grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never generated revenue from product sales and may never be profitable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, obtain the regulatory approvals necessary to commercialize and eventually commercialize, product candidates we may identify for development. We may not generate revenues from product sales for many years, if ever. Our ability to generate future revenues from product sales depends heavily on our or our collaborators&#8217; ability to successfully:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify product candidates and successfully complete research and development of any product candidates we may identify;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance our product candidates through preclinical and clinical development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek and obtain regulatory approvals for any product candidates for which we successfully complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launch and commercialize any product candidates for which we may obtain regulatory approval by establishing a sales force, marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which we may obtain regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for the product candidates we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">address competing technological and market developments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receive coverage and adequate reimbursement by healthcare payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary rights, including patents, trade secrets and know-how;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defend against third-party intellectual property claims of infringement, misappropriation or other violation; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain qualified personnel. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses could increase beyond expectations if we are required by the FDA, EMA, the competent authorities of individual EU Member States, or other comparable foreign regulatory authorities to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Even if one or more of the product candidates we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations. Our failure to become and remain profitable may have an adverse effect on the value of our company and depress the market price of our common stock and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidate pipeline, achieve our strategic objectives or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Discovery, Development and Regulatory Approval of Product Candidates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts, and as a result it will be years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates. We are early in our development efforts and discontinued our first Phase 1 study of our prior lead candidate, SEP-786, in 2025. Other than SEP-631, for which we presented data from the Phase 1 clinical trial at the AAAAI annual meeting on March 1, 2026, our product candidates and development programs are in preclinical development or in the drug discovery stages. We have invested substantially all of our research efforts to date in developing our Native Complex Platform&#174;, identifying potential product candidates and conducting preclinical and clinical studies. As an organization, we have limited experience in conducting and managing clinical trials necessary to obtain regulatory approvals, and we may be unable to do so for our product candidates. While we plan to continue to advance SEP-631 in clinical development, and we are also planning to advance multiple lead compounds towards selection of a next-generation oral small molecule PTH1R agonist development candidate, we have not successfully completed any advanced clinical trials to date. Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery or preclinical development and may never proceed to advanced clinical-stage development. If we are able to advance these other targets and programs into advanced clinical development, we do not have experience managing multiple clinical trials simultaneously, working with global clinical trials, or working in multiple different disease indications. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. Before obtaining regulatory approval for the commercial distribution of our product candidates, we must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have the financial resources to continue development of, or the ability to enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical study results may show the product candidate to be less effective than desired or to have harmful or problematic side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product-related side effects experienced by patients in our clinical trials or by individuals using product similar to our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party manufacturers&#8217; inability to successfully manufacture our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and those of our collaborators to supply the needs of clinical trials or commercial sales;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in submitting INDs or other comparable foreign applications or delays or failures in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical studies conducted outside of the United States may be affected by tariffs (including tariffs that have been or may in the future be imposed by the United States or other countries), sanctions, trade protection measures or import/export restrictions imposed by the United States or other foreign governments (including further legislation or actions taken by the United States or other countries that restrict trade);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions imposed by the FDA, EMA or other comparable foreign regulatory authorities regarding the scope or design of our clinical trials;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in enrolling patients in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">high drop-out rates of our clinical trial patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to obtain alternative sources of supply for which we have a single source for product candidate components or materials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater than anticipated costs of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that no longer make a product candidate economically feasible;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to demonstrate a benefit-risk profile acceptable to the FDA, EMA, or other comparable foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable FDA, EMA, or other comparable foreign regulatory authority inspection and review of any of the clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">varying interpretations of our data by the FDA, EMA, and similar foreign regulatory authorities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to complete development of, or commercialize our product candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future therapeutic candidates on a timely basis or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful development of pharmaceutical products involves a lengthy and expensive process, is highly uncertain, and is dependent on numerous factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial results may show the product candidates to be less effective than expected (for example, a clinical trial could fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things, may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to follow-up, length of time to achieve trial endpoints, additional time requirements for data analysis or New Drug Application (&#8220;NDA&#8221;) or similar foreign application preparation, discussions with the FDA, EMA or other comparable foreign regulatory authorities, including FDA, EMA or other comparable foreign regulatory authorities requesting additional preclinical or clinical data (such as long-term toxicology studies), or encountering unexpected safety or manufacturing issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical study results may show the product candidate to be less effective than desired or to have harmful on-target or off-target side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of extensive post-marketing approval requirements; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proprietary rights of others and their competing products and technologies that may prevent our product candidates from being commercialized.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the length of time necessary to complete clinical trials and submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict. Even if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced. Even if we are able to obtain coverage and adequate reimbursement for our products once approved, there may be features or characteristics of our products, such as dose preparation requirements, that prevent our products from achieving market acceptance by the healthcare or patient communities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with cGMPs and GCPs for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with a product post-approval, such as AEs of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of failure in developing product candidates is high. It is impossible to predict when or if any product candidate would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development, submit an IND or comparable foreign application to permit initiation of clinical studies, and then conduct extensive clinical trials to demonstrate the safety and efficacy of product candidates in humans.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our INDs and other regulatory filings. We cannot be certain of the timely identification of a product candidate or the successful completion or outcome of our preclinical testing and studies and cannot predict whether the FDA, EMA or other comparable foreign regulatory authorities will accept our proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of any product candidates. Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. As a result, we cannot be sure that we will be able to submit INDs or other comparable foreign regulatory submissions for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs will result in the FDA, EMA, or other comparable foreign regulatory authority allowing clinical trials to begin.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other events that may prevent successful enrollment, initiation or timely completion of clinical development include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to generate sufficient preclinical, toxicology or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> data to support the initiation of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with applicable regulatory authorities on trial design or implementation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining regulatory authorization to commence a clinical trial;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs, other vendors, or clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different vendors and trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining approval from one or more IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional participants, or withdrawing their approval of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting suitable patients to participate in our ongoing and planned clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to the clinical trial protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing sufficient quantities of our product candidates for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having our product candidates being shipped on time, clearing customs and arriving at clinical trial sites intact;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">participants choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of adequate funding to continue a clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of AEs or SAEs associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of SAEs in clinical trials of the same class of agents conducted by other companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">selection of clinical trial end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials producing negative or inconclusive results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or contamination or cross-contaminations of product candidates in the manufacturing process;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol or other regulatory requirements or committing fraud; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements, guidance, or feedback from regulatory agencies that require amending or submitting new clinical protocols or otherwise modifying the design of our clinical trials.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs overseeing the conduct of such trials, by a Data Safety Monitoring Board for such trial or by the FDA, EMA, or other comparable foreign regulatory authorities. Such regulatory authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other comparable regulatory foreign authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination and approval, which may impact the costs, timing or successful completion of a clinical trial.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we have done and may continue to do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory requirements, as well as political, currency exchange and other economic risks relevant to such foreign countries. Investigators and patients may not be able to comply with clinical trial protocols if quarantines or other constraints impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff which in turn could adversely impact our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with public health concerns. We may face delays in meeting our anticipated timelines for our ongoing and planned clinical trials, which could adversely affect our business, financial condition, results of operations and growth prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not completed the evaluation of any product candidates in advanced human clinical trials. It is impossible to predict when or if any product candidates we may develop will ultimately prove safe in humans. As is the case with pharmaceuticals generally, it is likely that there may be side effects and AEs associated with our product candidates&#8217; use. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials with a broader group of patients, or as use of these product candidates becomes more widespread if they receive marketing approval, illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants. Many times, side effects are only detectable after investigational product candidates are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has received marketing approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition. In particular, because we are developing our product candidates for chronic indications, the FDA, EMA, and other comparable foreign regulatory authorities will likely require that our product candidates demonstrate a higher level of safety over a longer period of time than would be the case for product candidates intended for short-term use. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial value for the product candidate if approved. We may also be required to modify our trial plans based on findings after we commence our clinical trials. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. For example, we discontinued development of our previous lead candidate, SEP-786, following the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our product candidates receive marketing approval, the FDA could require us to include a boxed warning in our label or adopt a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. For example, the FDA required that the product label for NATPARA, an approved, injectable parathyroid hormone product targeting PTH1R for the management of hypoparathyroidism include a boxed warning related to the risk of osteosarcoma based on rodent carcinogenicity studies and also implemented a REMS program to ensure patients and prescribers were appropriately counseled on the benefits and risks of the drug. Similarly, the FDA initially included boxed warnings for FORTEO and TYMLOS, injectable PTH peptides approved for osteoporosis due to the risk of osteosarcoma. While we have not yet conducted carcinogenicity studies for any of our product candidates that target PTH1R, it is possible that absent compelling data to the contrary, the FDA, EMA, and other comparable foreign regulatory authorities will similarly require a boxed warning if any product candidates we may advance to clinical development that target PTH1R are approved for marketing. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several other potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may need to conduct a recall;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive, and our reputation may suffer.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, prospects, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance obligations, which is costly and time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, clinical development, testing, quality control, safety, effectiveness, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, marketing, import, export, distribution, post-approval monitoring, and post-approval reporting of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, neither we nor any current or future collaborators are permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, new relevant statutes or regulations may be enacted, and the FDA, EMA and other comparable foreign regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA and other comparable foreign regulatory authorities, which could require us to delay or abandon clinical development plans. In addition, regulatory authorities may require us to conduct further preclinical studies before evaluating our product candidate in a clinical trial. Once we initiate clinical trials, the FDA, EMA, or other comparable foreign regulatory authorities may require additional clinical trials or suggest changes to our planned clinical trials, prior to and in support of the approval of a NDA or equivalent foreign marketing application. Changes to data requirements by the FDA, EMA, or other comparable foreign regulatory authorities during the development of our product candidates may cause the applicable regulatory authorities to require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or regulatory authorities may object to elements of our clinical development program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA, EMA or other comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with the design or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA, EMA or other comparable foreign regulatory authorities for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to demonstrate that a product candidate is safe and effective, and that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with our interpretation or analysis of data from preclinical studies or clinical trials; such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval may be granted only for indications that are significantly more limited than what has been applied for and/or with other significant restrictions on distribution and use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our current or future collaborators&#8217; clinical data insufficient for approval.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our current or future collaborators from commercializing our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA, or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment and retention in clinical trials is a significant factor in the timing of clinical trials and depends on many factors, including the size and nature of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data with respect to the study drug, the number, nature and duration of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical trial sites and the eligibility criteria for the clinical trial. As our programs progress, we or our collaborators may not be able to initiate or continue clinical trials for any product candidates we identify or develop if sufficient numbers of eligible patients are unable to be located and enrolled to participate in these trials as required by the FDA, EMA, or other comparable foreign authorities, or as needed to provide appropriate statistical power for a given trial. For certain of our product candidates, the conditions which we may evaluate include rare diseases with limited patient pools from which to draw. In some cases, patient populations for rare diseases are located at specific academic sites focused on such indications, often with multiple competing clinical trials. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We or our collaborators also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for the planned clinical trials and monitoring such patients adequately during and after treatment. As noted above, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates, which may make it more difficult to fully enroll patients in clinical trials for our product candidates. In addition, the process of finding and diagnosing patients may prove costly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The eligibility criteria of clinical trials for our product candidates, once established, may further limit the pool of available trial participants. If the actual number of patients with these diseases is smaller than anticipated, clinical trials for our product candidates may encounter difficulties in enrolling patients, thereby delaying or preventing development and approval of our product candidates. Even once a sufficient number of patients have been enrolled in a clinical trial for our product candidate, the inability to retain patients through to the study&#8217;s completion may cause a failure of the study to meet its objectives and/or clinical endpoints.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on the ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in our clinical trials for a variety of reasons. Patient enrollment and retention in clinical trials depends on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population, in particular for rare diseases such as the diseases on which we are focused initially, and process for identifying patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the existing body of safety and efficacy data for the product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility and exclusion criteria for the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the complexity of the trial, including number of office visits, lab tests, patient evaluations, and dosing regimens;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to adequately monitor patients during a trial, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that enrolled patients will drop out of a trial before completing all site visits; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in clinical trials for our product candidates. In addition, any negative results we or our collaborators may report in clinical trials of a given product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. Further, if patients drop out of clinical trials for our product candidates, miss scheduled doses or follow-up visits, or otherwise fail to follow clinical trial protocols, the integrity of data from clinical trials for our product candidates may be compromised or not accepted by the FDA, EMA, or other comparable foreign regulatory authorities, which would represent a significant setback for the applicable program. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance. Such delays or failures could adversely affect our business, operating results and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, EMA and other comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or other comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary product recalls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or withdrawal of approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, under the FDORA, sponsors of approved drugs and biologics must provide six months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA issuing a publicly available non-compliance letter to the sponsor. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The policies of the FDA, EMA and other comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. As a result of the U.S. Supreme Court&#8217;s decision, the FDA and other agencies may be less inclined to engage in formal regulation and may rely to a greater degree on informal guidance, which may not always be susceptible to immediate challenge. We cannot predict the likelihood, nature or extent of government regulation or guidance that may arise from future court decisions, legislation, or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or guidance or the adoption of new requirements, guidance, or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our therapeutics may be delayed and, as a result, our stock price may decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial or the initiation of other clinical programs. All of these milestones are and will be based on numerous assumptions, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our available capital resources or capital constraints we experience;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate of progress, costs and results of clinical trials for our drug candidates and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our or our collaborators&#8217; ability to identify and enroll patients who meet clinical trial eligibility criteria;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our or our collaborators&#8217; receipt of approvals by the FDA, EMA, and other comparable foreign regulatory authorities and the timing thereof;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other actions, decisions or rules issued by regulators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our or our collaborators&#8217; ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts of our collaborators with respect to the commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securing product reimbursement</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If these milestones are not met as publicly announced, or at all, the commercialization of our product candidates may be delayed or never achieved and, as a result, our stock price may decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results of preclinical studies and early clinical trials on any of our product candidates may not be predictive of results of future clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported AEs. In addition, while the animal models used in preclinical studies are designed to be representative of disease states in humans, these preclinical models may not be able to accurately predict the way a product candidate will affect patients in clinical trials. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, product formulation and other clinical trial protocols and the rate of dropout among clinical trial patients. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited financial and managerial resources, and to date, we have focused on research programs and product candidates within the endocrinology, immunology and inflammation, neurology and metabolic therapeutic areas.  In September 2025, we selected a new PTH1R development candidate, SEP-479, and we plan to initiate a placebo-controlled, SAD and MAD Phase 1 clinical trial in Australia, pending the successful completion of regulatory submissions in the first half of 2026. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued by leveraging our Native Complex Platform&#174;. As a result, we may forgo or delay pursuit of opportunities with other product candidates or in other therapeutic areas that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. We must continually assess the potential commercial viability of our research programs and product candidates, and we may decide to pause or discontinue development of any of our product candidates based upon such assessments, even if we obtain positive data from our product candidates in preclinical studies and clinical trials.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our proprietary Native Complex Platform&#174; is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to expand our development portfolio of product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key element of our strategy is to use our proprietary Native Complex Platform&#174; to overcome the historical limitations of GPCR drug development, including the isolation, purification and stabilization of GPCRs in their native forms, in order to build a robust and diverse portfolio of potentially first-in-class and best-in-class oral small molecule therapies that address both well-validated and novel GPCR targets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scientific research that forms the basis of our efforts to develop product candidates with our platform is still ongoing. We are not aware of any FDA approved therapeutics utilizing the technology underlying our platform. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our platform is both preliminary and limited. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates. For example, we have only generated limited clinical data on our prior lead candidate, SEP-786, which led us to discontinue the program, and we have generated only limited early clinical data for SEP-631, our selective, oral small molecule MRGPRX2 NAM. Our current data on our development pipeline is limited to animal models and preclinical cell lines, the results of which may not translate into humans. Further, relevant animal models and assays may not accurately predict the safety and efficacy of our product candidates in humans, and we may encounter significant challenges creating appropriate models and assays for demonstrating the safety and purity of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the novelty of our technology, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory authorities may lack experience in evaluating the safety and efficacy of product candidates like those developed using our platform, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our research and development efforts to date have resulted in a development portfolio of potential programs and product candidates, we may not be able to discover or identify novel chemical matter to new GPCR targets and thus not be able to develop product candidates to expand our development portfolio. We may also pursue opportunities to acquire or in-license additional businesses, technologies or products, form strategic alliances or create joint ventures with third parties to complement or augment our existing business. However, we may not be able to identify any product candidates through such acquisition or in-license.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in continuing to build and expand our development portfolio, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will be successful in clinical trials or receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary, topline and interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously made public. As a result, topline and preliminary data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between topline, preliminary or interim data and final data could significantly harm our business prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may develop our product candidates in combination with other therapies, which would expose us to additional risks.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may develop our product candidates in combination with one or more currently approved therapies or therapies in development. Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also evaluate our product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA, EMA or other comparable foreign regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we cannot be certain that we will be able to obtain a steady supply of such therapies for use in developing combinations with our product candidates on commercially reasonable terms or at all. Any failure to obtain such therapies for use in clinical development and the expense of purchasing therapies in the market may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies. If the FDA, EMA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain approval of or successfully market any one or all of the product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization, Marketing and Competition</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing, sales or distribution capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no internal sales, marketing or distribution capabilities, nor have we as a company commercialized a product. If any of our product candidates ultimately receives marketing approval, we will be required to build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in the markets that we target, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Furthermore, we are currently developing products for multiple indications in different medical specialties, which will require us to build different sales and marketing capabilities that are tailored to a given product or medical specialty. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receive marketing approval, such product candidate may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product, and even if any of our product candidates are approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Historically, several injectable PTH peptides have been approved by the FDA and other regulatory authorities for treatment of hypoparathyroidism and osteoporosis. However, our lead product candidate is an oral small molecule agonist; to date, no such oral small molecule in this indication has been approved by the FDA or any other regulatory agency. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt new oral treatments for hypoparathyroidism or osteoporosis, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications and patient populations for which the product candidate is approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety, efficacy and potential advantages compared to alternative treatments and therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of the product as well as competitive products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectiveness of sales and marketing efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of our or our collaborators&#8217; relationships with patient communities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to offer such product for sale at competitive prices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments and therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings, including distribution or use of restrictions contained in the product&#8217;s approved labeling;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inclusion of any REMS program or other restrictions included by the regulators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of the product together with other medications. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. Because we expect sales of our product candidates, if approved, to form the basis for substantially all of our revenues for the foreseeable future, the failure of our product candidates, if approved, to find market acceptance would harm our business and could require us to seek additional financing.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we are able to commercialize any product candidate, the third-party payor coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors in the United States are essential for most patients to be able to afford treatments such as our products or product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for drug treatments by governmental authorities, private health insurers and other organizations will have an effect on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize our products, and potentially attract additional collaboration partners to invest in the development of our product candidates. We cannot be sure that adequate coverage and reimbursement in the United States, the EU, Australia or elsewhere will be available for our products or any products that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. For more information, see the section titled &#8220;Business&#8211;Government Regulation&#8211;Coverage and Reimbursement.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products, medical devices and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug is available. It is possible that a third-party payor may consider our products or product candidates, if approved, and a generic drug as substitutable and only offer to reimburse patients for the generic drug. Even if we show improved efficacy or safety or improved convenience of administration with our products or product candidates, if approved, pricing of an established drug for the same or similar indication may limit the amount we will be able to charge for such product. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products or product candidates, and may not be able to obtain a satisfactory financial return on products that we may develop.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs, biologics and medical devices will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs, biologics and medical devices. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products or product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our products and product candidates, if approved, and on drugs related to our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Many countries, including the EU Member States, established complex and lengthy procedures to obtain price approvals, coverage and reimbursement. These procedures vary from country to country but are commonly initiated after grant of the related marketing authorization. More particularly, in the EU, potential reductions in prices and changes in reimbursement levels could be the result of different factors, including reference pricing systems. It could also result from the application of external reference pricing mechanisms, which consist of arbitrage between low-priced and high-priced countries. Reductions in the pricing of our medicinal products in one EU Member State could affect the price in other EU Member States and, thus, have a negative impact on our financial results. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products or product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. As an example, many EU Member States review periodically their decisions concerning the pricing and reimbursement of medicinal products. The outcome of these reviews cannot be predicted and could have adverse effects on the pricing and reimbursement of our medicinal products in the EU Member States.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or product candidates. We expect to experience pricing pressures in connection with the sale of our products and product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary and novel products and product candidates. While we believe our product candidates, platform, knowledge, experience and scientific personnel provide us with several key competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our future success will depend in part on our ability to maintain a competitive position with our structure-based drug discovery platform. If we fail to stay at the forefront of technological change in utilizing our platform to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our approach obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discovery process that we believe we derive from our research approach and platform. Several other companies also focus on GPCRs and have platform technologies that are distinct from the Native Complex Platform&#174;, including Nxera Pharma Co., Ltd. (formerly Sosei Heptares), Structure Therapeutics Inc., Tectonic Therapeutics, Inc., and Confo Therapeutics.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we face competition with respect to our product candidates and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several pharmaceutical companies that have commenced clinical trials of product candidates or have successfully commercialized products addressing areas that we are targeting. Takeda Pharmaceuticals owns the rights to parathyroid hormone product (brand name NATPARA) for the treatment of hypoparathyroidism. NATPARA was voluntarily recalled due to manufacturing issues in September 2019 in the United States and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer. In October 2022, Takeda Pharmaceuticals announced manufacturing of all strengths of NATPARA will be discontinued globally by the end of 2024. Ascendis Pharma received regulatory approval for a proprietary once-daily injectable PTH peptide, palopegteriparatide (brand name YORVIPATH), in Europe and the United States. In March 2024, AstraZeneca acquired Amolyt Pharma, who was developing eneboparatide, a proprietary, once-daily injectable PTH peptide, for hypoparathyroidism, currently in Phase 3 studies. In addition, we are aware of several academic groups and companies working on making longer-acting agonists of the PTH1R. Other companies and groups are developing or commercializing therapies for hypoparathyroidism, including Calcilytix Therapeutics, Inc. (a BridgeBio Pharma, Inc. company), Entera Bio Ltd, Extend Biosciences, Inc., and MBX Biosciences, Inc. Several companies are developing clinical-stage small molecule MRGPRX2 inhibitors, including Escient Pharmaceuticals (acquired by Incyte Pharmaceuticals in April 2024), Evommune, Inc. and BioArdis LLC. Further there are several other companies pursuing therapies for chronic spontaneous urticaria addressing other receptors of interest, such a Genentech, Inc., Sanofi, Celldex Therapeutics, Inc., Jasper Therapeutics, Inc., Novartis AG, Third Harmonic Bio, Inc., and Blueprint Medicines (a Sanofi company). For TSHR, we are aware that Byondis BV and Crinetics Pharmaceuticals are also working on research stage compounds, but they have not yet entered clinical development. In addition, several companies are working on other mechanisms to address Graves&#8217; disease, such as Immunovant, Inc., and TED, including Amgen, Inc., Viridian Therapeutics, argenx SE, Roche Holding AG, Lassen Therapeutics, Inc., Tourmaline Bio, Inc. (acquired by Novartis in October 2025), Sling Therapeutics, Inc., and Acelyrin, Inc. (merged with Alumis, Inc. in May 2025). There are also several currently approved injectable products targeting incretin receptors for the treatment of obesity or type 2 diabetes (&#8220;T2D&#8221;). These include, but are not limited to, products such as Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk A/S) for T2D and obesity, respectively, Trulicity (dulaglutide, marketed by Eli Lilly and Company) for T2D, and Mounjaro and Zepbound (tirzepatide, each marketed by Eli Lilly and Company) for T2D and obesity, respectively. There are also several injectable peptide products in development pursuing similar indications with similar mechanism of actions along with combination products, including those being developed by Amgen, Inc., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk A/S, Roche Holding AG, and Viking Therapeutics, Inc., among others. In addition, there are oral products such as Rybelsus (semaglutide, marketed by Novo Nordisk A/S) approved for patients with T2D and other oral products in development for treating obesity or T2D, including those being developed by AstraZeneca, Eli Lilly and Company, Pfizer Inc., Roche Holding AG, Structure Therapeutics Inc., and Terns Pharmaceuticals, Inc. Based on our continuing evaluations of the competitive landscape, we may decide to reallocate resources and reprioritize our development programs if we determine that a particular product candidate or target indication is no longer commercially viable or advantageous.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Any failure to compete effectively could harm our business, financial condition and operating results.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU Member States.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions, including the EU. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to reward improper performance is typically governed by the national anti-bribery laws of EU Member States and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the United Kingdom despite its departure from the EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in some foreign countries, including some countries in the EU, the proposed pricing for a product must be approved before it may be lawfully marketed. The requirements governing product pricing and reimbursement vary widely from country to country. For example, some EU Member States have the option to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining marketing approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining marketing approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, it does not mean that comparable foreign regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining marketing approval in one jurisdiction may negatively impact the marketing approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price to be charged for a product candidate is also subject to approval.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining foreign marketing approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or our collaborators fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, which would adversely affect our business, prospects, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future growth may depend, in part, on our ability to commercialize products in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, manufacturing, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for approval of drugs in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the existence of additional third-party patent rights of potential relevance to our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from pandemics or similar public health crises. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for any of our product candidates are smaller than we estimate, even assuming approval of a product candidate, our revenue may be adversely affected, and our business may suffer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Business Operation and Industry</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, degree of success and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our product candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with third-party manufacturers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies or other assets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be difficult to predict;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to adequately support future growth;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and success or failure of preclinical studies or clinical trials or regulatory approval for our product candidates or any competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions and departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effects of macro events, such as inflation, tariffs, armed conflicts, geopolitical conflicts, pandemics, natural disasters and supply chain issues, on our business and operations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the changing and volatile global economic and political environment.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, from time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 130 full-time employees. As we advance our research and development programs, we may need to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, biology, chemistry, manufacturing, general and administrative matters related to being a public company, regulatory affairs and, if any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our general and administrative functions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, recruit, integrate, maintain and motivate additional qualified personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and build a marketing and commercial organization; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improve our operational, financial and management controls, reporting systems and procedures.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities, to managing these growth activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent on the services of our senior management team and if we are not able to retain these members of our management team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on our senior management team. In particular, we are highly dependent on the development and management expertise of Jeffrey Finer, M.D., Ph.D., our Chief Executive Officer, and the other principal members of our management, scientific and clinical team. The employment agreements we have with these officers do not prevent such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. In addition, we will need to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on terms acceptable to us, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer operating history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop product candidates and our business will be limited and we may experience constraints on our development objectives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. For example, employment of our key employees is at-will, which means that any of our employees could leave our employment at any time, with or without notice. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future marketing approvals, sales of our product candidates and our results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i) FDA, the national competent authorities of individual EU Member States, or comparable foreign regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, EMA, or other comparable foreign regulatory authorities; (ii) manufacturing standards; (iii) U.S. federal and state fraud and abuse and other healthcare laws and regulations, including foreign requirements; or (iv) laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials or falsification of clinical trial data, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal or non U.S. healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies, including imposing several rounds of tariffs and export control and sanctions restrictions affecting certain products manufactured in China. Both China and the United States have each imposed tariffs indicating the potential for further trade barriers, including the U.S. Commerce Department adding numerous Chinese entities to its Unverified List, which requires U.S. exporters to go through more procedures before exporting goods to such entities. It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry. For example, in December 2025, the National Defense Authorization Act (&#8220;NDAA&#8221;) for Fiscal Year 2026 was enacted, which includes Section 851, commonly referred to as the &#8220;BIOSECURE Act.&#8221; The BIOSECURE Act restricts U.S. government agencies from procuring certain biotechnology equipment or services from, or entering into contracts with, entities that use biotechnology equipment or services from designated &#8220;biotechnology companies of concern,&#8221; which include WuXi AppTec and WuXi Biologics, or collectively WuXi, and from expending certain federal loan or grant funds for such equipment or services. While the BIOSECURE Act is primarily directed at U.S. government procurement and funding and has not yet been fully implemented through final regulations, there remains a continued policy interest in limiting U.S. companies&#8217; relationships with biotechnology providers with relationships with foreign adversaries. The potential downstream adverse impacts on entities having only commercial relationships with any impacted biotechnology providers is unknown but may include supply chain disruptions or delays. Sustained uncertainty about or further escalating trade and political tensions between the U.S. and China may prevent or hinder the export of materials or technical information among us, our contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other relevant third parties, such as pharmaceutical partners, or could result in trade or retaliatory restrictions that may hinder or potentially inhibit our ability to rely on CDMOs and other service providers that operate in China. Further, regulatory or legislative action taken by the U.S. to impose restrictions on transactions with China, like the restrictions described above, could have the potential to severely restrict the ability of companies like ours to contract with Chinese biotechnology companies of concern, which could have adverse effects on the development of our product candidates and our business operations. See the risk factor titled &#8220;Risks Related to Government Regulatory and Legal Requirements&#8212;We rely on third-party manufacturers, CROs, CMOs, and suppliers to supply, develop and test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any unfavorable government policies on international trade, such as export controls, economic, sanctions, capital controls or tariffs, may increase the cost of manufacturing our product candidates and platform materials, affect our ability to commercialize our product candidates if approved, the competitive position of our product candidates, and import or export of raw materials and finished product candidate used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including pursuant to our service arrangements with WuXi. If any new tariffs, export controls, sanctions, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if either the U.S. or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chinese government takes retaliatory trade actions due to the recent trade tensions, such changes could have an adverse effect on our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of any product candidates we may develop.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of clinical trial and product liability exposure related to the testing of any product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have not completed the evaluation of any product candidates in human clinical trials or that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any product candidates that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant time and costs to defend any related litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of our management&#8217;s time and our resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exhaustion of any available insurance and our capital resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of investigations by regulators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any product candidates that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decline in price of our common stock.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we continue to commence clinical trials or if we commence commercialization of any product candidates, we may seek to increase our insurance coverage. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If and when coverage is secured, our insurance policies may also have various exclusions and we may be subject to a product liability claim for which we have no coverage. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred losses and we may never achieve profitability. As of December 31, 2025, we had $45.8 million of federal net operating loss (&#8220;NOL&#8221;) carryforwards and $77.9 million of state NOL carryforwards, available to reduce future taxable income. To the extent that we continue to generate taxable losses, under current law, our unused U.S. NOLs may be carried forward to offset a portion of future taxable income, if any. Additionally, we continue to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a portion of future taxable income, if any, subject to expiration of such credit carryforwards. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as one or more stockholders or groups of stockholders who own at least 5% of the corporation&#8217;s equity increasing their equity ownership in the aggregate by more than 50 percentage points (by value) over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws. Our prior equity offerings and other changes in our stock ownership may have resulted in such ownership changes in the past. In addition, we may experience ownership changes in the future due to shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOLs or other pre-change tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us and could require us to pay U.S. federal income taxes earlier than would be required if such limitations were not in effect. There is a risk that due to changes under the tax law, regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, under Senate Bill 167 enacted by California in June 2024, generally, there is a suspension of the NOL deduction for tax years beginning on or after January 1, 2024, and before January 1, 2027 for individual and corporate taxpayers with net business income or modified adjusted gross income of $1 million or more, and a limit of $5 million of business credits on the aggregate use of otherwise allowable business tax credits that any individual or corporate taxpayer could claim for tax years beginning on or after January 1, 2024, and before January 1, 2027. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have and may in the future engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have and in the future, we may consider strategic transactions, such as acquisitions of companies, asset purchases, and in-licensing or out-licensing of products, product candidates or technologies from time to time. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our senior management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure to unknown liabilities, including potential indemnification claims from a potential spin-off or out-license of certain of our intellectual property rights;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption of our business and diversion of our management&#8217;s time and attention to develop acquired products, product candidates or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher than expected costs in risk-sharing collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher-than-expected acquisition and integration costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lower-than-expected benefits, from out-licensing or selling our technology or intellectual property or from in-licensing intellectual property or purchasing assets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">write-downs of assets or goodwill or impairment charges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty and cost in combining or separating the operations and personnel of any acquired or sold businesses with our existing operations and personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may disagree with our strategic partners about decisions affecting the business, which could result in litigation or arbitration that increases our expenses, distracts our officers and directors and disrupts the day-to-day operations of the strategic venture, including by delaying important decisions until the dispute is resolved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our strategic partners may take actions that we oppose;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our strategic partners might experience financial distress or become bankrupt;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of relationships with key suppliers or customers of any acquired or sold businesses due to changes in our senior management and ownership; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to retain key employees of any acquired businesses.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to the extent we enter into a strategic transaction that includes ongoing operations or shared ownership and management, our strategic partners may take actions that we oppose or we may disagree with our strategic partners about decisions affecting the business, which could result in litigation or arbitration, distract our officers and directors and otherwise disrupt the day-to-day operations of our business and the business of the strategic partner or entity. Furthermore, to the extent that our directors and officers serve on the boards of our strategic partners, such directors may be required to abstain from board decision-making in the event of a conflict of interest.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, although we cannot be certain that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks, and could harm our business, results of operations, financial condition and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have conducted and may continue to conduct, clinical trials for our product candidates outside of the United States, and we may do so for our other product candidates. However, conducting trials outside of the United States exposes us to additional risks, which could materially harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted, and may in the future conduct, certain of our clinical trials at centers outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or another comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. For example, in cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trial conducted outside for the United States or the applicable jurisdiction, and the FDA has discussed proposals to increase user fees for marketing applications containing certain foreign clinical data. If the FDA, the EMA, the U.K. Medicines and Healthcare products Regulatory Agency, or other foreign regulatory authorities do not accept any data generated from other jurisdictions, we would likely be required to conduct additional clinical trials, which would be costly and time consuming, and delay aspects of our development plan, which could harm our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conducting trials outside the United States also exposes us to additional risks, including risks associated with:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional foreign regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign exchange fluctuations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural differences in medical practice and clinical research;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished protection of intellectual property in some countries; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information systems or data, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences from such compromises, such as damage to our reputation, significant financial and legal exposure, or other adverse effects to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on information technology systems that we or third parties with whom</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we work, operate to process, transmit and store electronic information, including sensitive information, in our day-to-day operations. For example, in connection with our product development efforts, we may collect and process a variety of personal data, proprietary information, trade secrets, and clinical trial information. As a result, we and the third parties with whom</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we work, face a variety of evolving threats that could cause cybersecurity incidents, data breaches, or other adverse security events.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities could result in the theft or destruction of intellectual property, personal data, or other misappropriation of assets, or otherwise threaten to compromise our confidential or proprietary information and disrupt our operations. Attempts to disrupt or gain unauthorized access to our and our third-party vendors&#8217; information systems from malicious third parties or insider threats may incorporate widely varying and frequently changing tactics, which may be enhanced or facilitated by artificial intelligence (&#8220;AI&#8221;). Such threats are increasing in their frequency, sophistication, and intensity, have become increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, intentional or inadvertent wrongful conduct by personnel and vendors (such as through human error, theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities, wrongful conduct by hostile foreign governments and industrial espionage. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties with whom</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we work are subject to a variety of evolving threats, including but not limited to the deployment of harmful malware (including as a result of advanced persistent threat intrusions), ransomware, denial-of-service, credential stuffing, credential harvesting, social engineering fraud (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by evolving technologies, such as AI, telecommunications failures, earthquakes, fires, floods, and other similar threats.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, there can be no assurance that our efforts will prevent information cybersecurity incidents or data breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues or other constraints not found during due diligence of such acquired or integrated entities, creating additional challenges to integrate said information systems into our information technology environment and security program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Like other companies in our industry, we, and our third party vendors, have experienced threats and cybersecurity incidents relating to our information technology systems and infrastructure. While we have implemented security measures designed to protect against cybersecurity incidents and data breaches, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate known vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect and remediate all such vulnerabilities on a timely basis for various reasons including but not limited to the impact on the functional operations of affected information systems or the availability of a solution for the impacted technology. While remedial measures and/or patches designed to address identified vulnerabilities are being developed and/or implemented, these vulnerabilities could be exploited and result in a cybersecurity incident or data breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of cybersecurity incidents and data breaches. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. Additionally, laws in all 50 states require businesses to provide notice to customers whose personal data has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread cybersecurity incident or data breach is difficult and may be costly. We also may be contractually required to notify patients or other counterparties of a cybersecurity incident or data breach. Although we may have contractual protections with our service providers, any actual or perceived cybersecurity incident or data breach could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived cybersecurity incident or data breach. Any contractual protections we may have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards. Determining whether personal data has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. Any failure, or perceived failure, to prevent or mitigate cybersecurity incidents, data breaches or other improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state (e.g., state breach notification laws), federal (e.g., Health Insurance Portability and Accountability Act of 1996), and foreign (e.g., the GDPR) laws, and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business, results of operations and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we maintain insurance coverage, we cannot assure that such coverage will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse effects arising out of our data protection, privacy, and security practices, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our reliance on the computer systems of various third parties with whom we work, including our CROs and other contractors, introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on our third-party partners to implement effective security measures and identify and correct for any such failures, deficiencies, cybersecurity incidents or data breaches. However, our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. Any failure by such third parties to prevent or mitigate cybersecurity incidents, data breaches or other improper access to or disclosure of such information could have similarly adverse consequences for us. While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or that of the third parties with whom we work have not been compromised.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a cybersecurity incident or data breach, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats could cause a cybersecurity incident, data breach, or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">access to our sensitive data or our information technology systems, or those of the third parties with whom we work. A cybersecurity incident, data breach, or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulatory and Legal Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, SEC and other U.S. government agencies caused reduction in staffing, by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of business may relay, which could negatively impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal agencies in the U.S., including the FDA, the SEC and other comparable regulatory authorities, operate pursuant to annual appropriations and other political and budgetary processes, and may from time to time be subject to continuing resolutions, funding lapses, or other fiscal constraints. Currently, although the FDA and many other federal agencies have funding sufficient to continue their activities through September 30, 2026, the timing and amount of future funding is unpredictable. Without appropriation of sufficient funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted. The ability of the FDA, EMA, and other comparable regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s or other comparable regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and other comparable regulatory authorities have fluctuated in recent years and may continue to fluctuate as a result of these factors. In addition, government funding of the SEC and other U.S. government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, including executive and congressional priorities, which is inherently fluid and unpredictable. For example, the Trump Administration has issued executive orders seeking to greatly reduce the size of the federal workforce, including through layoffs and severance packages offered to employees of federal agencies within the executive branch and independent agencies, including the FDA. Any such reduction in personnel may result in longer review times by the FDA and other agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, the SEC and other agencies, including as a result of substantial leadership changes, personnel cuts, policy changes or otherwise, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Changes and cuts in FDA staffing have been reported by some in the pharmaceutical industry as creating delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Over the last several years, including from October 1, 2025 to November 12, 2025, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and cease critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs again, or a widespread freeze on federal funding occurs in the future or if global health concerns or staffing changes prevent the FDA, SEC, EMA, or other comparable foreign regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, including formal and informal interactions with product developers, it could significantly impact the ability of the FDA, SEC, EMA, or other such comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns and/or substantial leadership, personnel, and policy changes at the SEC could impact our business by delaying review of our public filings, which in turn could delay or frustrate our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations or delay the review or effectiveness of required regulatory or securities filings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain orphan drug designation or exclusivity for our product candidates for which we seek such a designation or exclusivity, and even if we do, that designation may not provide an expedited development or regulatory review or approval process and any orphan drug exclusivity we may receive for approved products may not prevent the FDA or the EMA from approving other competing products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition. A similar regulatory scheme governs the designation of orphan product candidates by the EMA in the EU. Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA (as applicable) from approving another marketing authorization application for another similar product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the EU (which can be extended to 12 years if the sponsor complies with an agreed-upon pediatric investigation plan). The exclusivity period in the EU can be reduced to six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years if at the end of the fifth year it is determined that a product no longer meets the criteria for orphan designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. Hypoparathyroidism is a disease that affects approximately 70,000 individuals in the United States, and accordingly, any product candidate we advance forward in development for hypoparathyroidism may qualify for orphan drug designation. However, the FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. In the EU, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same product candidate for the same condition if the FDA or EMA (as applicable) concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">While we may in the future seek designations for our product candidates with the FDA, EMA and other comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA, EMA, and other comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we may seek a Fast Track Designation for one or more of our product candidates. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and a Fast Track Designation does not make approval more likely to occur. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, we may seek to participate in the PRIority MEdicines (&#8220;PRIME&#8221;) scheme for our potential product candidates. The PRIME scheme is intended to encourage development of product candidates in areas of unmet medical need and provides accelerated assessment of product candidates representing substantial innovation, where the marketing authorization application will be made through the centralized procedure in the EU. Eligible products must target conditions for which there is an unmet medical need (i.e. no treatment option exists in the EU or the applicable product candidate can offer a major therapeutic advantage over existing treatments). Many benefits accrue to sponsors of product candidates with access to the PRIME scheme, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and the possibility of accelerated assessment of a marketing authorization application once a dossier has been submitted. There is no guarantee, however, that our potential product candidate would be deemed eligible for the PRIME scheme and even if we do participate in the PRIME scheme, where during the course of development a product no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Breakthrough Therapy Designation for one or more of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval and priority review.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at the time of submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Where appropriate, we may secure approval from the FDA, EMA, or other comparable foreign regulatory authorities through the use of expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA, or other comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA, or other comparable foreign regulatory authorities may seek to withdraw the accelerated approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for our one or more of our product candidates from the FDA, EMA, or other comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA, or other comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA, or other comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA, or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, rules, regulations, policies, industry standards, contractual requirements, and other obligations related to data protection, privacy, and security. Our actual or perceived failure to comply with such obligations could adversely affect our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to various data protection, privacy, and security laws, rules, regulations, policies, industry standards, contractual requirements, and other obligations that apply to our collection, transmission, storage, use, disclosure, transfer, maintenance and other processing of sensitive information, including personal data. The legislative and regulatory landscape for data protection, privacy, and security continues to evolve across jurisdictions worldwide. For example, in the United States, federal, state, and local governments have enacted numerous data protection, privacy, and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the federal level, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, and implementing regulations, establish stringent privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Further, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission (&#8220;FTC&#8221;) Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulators and legislators in the U.S. are also increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries. For example, the Department of Justice&#8217;s January 8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; prohibits data brokerage and data sharing transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements, employment agreements and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions, and may result in exclusion from participation in federal and state programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data protection, privacy, and security obligations remain an evolving landscape at both the domestic and foreign level, with new laws, rules and regulations coming into effect, posing continued legal and compliance challenges. For example, as of January 2026, twenty U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to conduct our operations. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, in California, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, &#8220;CCPA&#8221;), provides for fines of up to $7,500 per intentional violation and allows privacy litigants affected by certain data breaches to recover significant statutory damages. The CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties with whom we work.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The existence of comprehensive privacy laws in different states adds additional complexity, variation in requirements, processing restrictions and potential legal risk, requiring additional investment of resources in our compliance programs.  These laws may also impact our business strategies, result in increased compliance costs and/or changes to our business practices and policies and increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several states are also specifically regulating consumer health information. For example, Washington has enacted a consumer health privacy law, the My Health My Data Act (&#8220;WMHMDA&#8221;), which went into effect on March 31, 2024 and regulates the collection and sharing of consumer health information. WMHMDA places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states, including Illinois and Texas, have passed laws that regulate biometric data specifically. These various privacy and security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there have been discussions in the U.S. Congress of new comprehensive federal data privacy laws to which we could become subject to, if enacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards govern data protection, privacy, and security. For example, if we conduct clinical trials in the European Economic Area (&#8220;EEA&#8221;) and/or the United Kingdom (&#8220;U.K.&#8221;), we may become subject to additional privacy laws in those jurisdictions, such as the EU General Data Protection Regulation (&#8220;EU GDPR&#8221;) and the EU GDPR as incorporated into the laws of the U.K (&#8220;U.K. GDPR&#8221; and, together with the EU GDPR, &#8220;GDPR&#8221;), both of which impose strict requirements for processing personal data. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to having a legal basis or condition for processing personal data, stricter requirements relating to the processing of sensitive data (such as health data), where required by the GDPR obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, requiring data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the GDPR, data protection authorities may impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million GBP) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Non-compliance could also result in the imposition of orders to stop data processing activities, which could have a material adverse effect on our business, financial position, and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to transfer personal data from the EEA, U.K., and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Although there are various mechanisms that may be used in some cases to lawfully transfer personal data to the U.S. or other countries, these mechanisms are subject to legal challenges and may not always be available to us. For example, the GDPR requires certain adequate safeguards to enable the transfer of personal data outside of the EEA or the U.K., in particular to the U.S., such as the EU standard contractual clauses, U.K. International Data Transfer Addendum/Agreement, and the EU-U.S. Data Privacy Framework (&#8220;Framework&#8221;) and the U.K. extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework). However, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the U.K. or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the U.K. is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the U.K. as providing adequate protection under the EU GDPR, or the Adequacy Decision, and, therefore, transfers of personal data originating in the EEA to the U.K. remain unrestricted. In December 2025, the European Commission adopted a decision to extend the validity of the U.K. Adequacy Decision for six years until December 2031, determining that the U.K. continues to offer a level of data protection that is &#8220;essentially equivalent&#8221; to the EU standards. This follows the U.K.&#8217;s adoption of the Data (Use and Access) Act 2025 (the &#8220;DUAA&#8221;) on June 19, 2025. The U.K. government has confirmed that personal data transfers from the U.K. to the EEA remain free flowing. The respective provisions and enforcement of the EU GDPR and U.K. GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. This lack of clarity on future U.K. laws and regulations and their interaction with EU laws and regulations could add legal risk, complexity and cost to our handling of personal data and our privacy and data security compliance programs and could require us to implement different compliance measures for the U.K. and the EEA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, the NIS 2 Directive (&#8220;NIS 2&#8221;) is replacing the cybersecurity legal framework under the current NIS framework, aiming to ensure a high level of cybersecurity in the region. NIS 2 brings new medium and large organizations providing services in the EEA within scope of the legal framework. It extends to additional sectors and expands the list of in-scope healthcare organizations, including to certain providers engaged in research and development of medicinal products. The new regime imposes direct obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on management in respect of an in-scope organization's compliance with NIS 2, requires covered organizations to put in place certain cyber risk management measures, strengthens incident reporting requirements and provides supervisory authorities with a greater oversight. The majority of obligations will come into force when national legislation implementing NIS 2 becomes effective in the relevant EU Member State. EU Member States had until October 17, 2024 to transpose NIS 2 into national legislation, although many countries have still not completed the transposition. As such, the cybersecurity regulatory landscape in the EU is currently fragmented and uncertain. To the extent we are subject to NIS 2,  we will require additional investment of our resources in compliance programs. Under NIS 2 companies may be subject to administrative fines of up to the higher amount of &#8364;10 million or 2% of worldwide turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if we fail, or are perceived to have failed, to comply with applicable data protection, privacy, and security laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties. For example, HHS has the discretion to impose significant penalties, and such enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the data protection, privacy, or security of the personal data of state residents. We cannot be sure how these laws, rules and regulations will be interpreted, enforced, or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws, rules and regulations at the international, federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we rely on certain third-party vendors to process certain confidential, sensitive, or personal data on our behalf. Failure by us or our third-party vendors to comply with any of these laws, rules, regulations, contractual requirements, industry standards, or other obligations could result in notification obligations, enforcement actions, regulatory investigations or inquiries, significant fines, imprisonment of company officials and public censure, litigation and claims for damages by affected individuals, customers or business partners, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees and personnel use generative artificial intelligence technologies to perform their work, and the disclosure and use of personal data in generative artificial intelligence technologies is subject to various privacy laws and other privacy obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our use of new and evolving technologies, such as artificial intelligence, may present risks and challenges that can impact our business, including by posing cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, and our third-party vendors, may use and integrate AI into our business processes both in our own development and implementation of AI as well as through the adoption of commercially available tools. Use of this technology could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, reputational and other risks and challenges that could affect our business. Specifically, risks related to accuracy, bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks (including model poisoning or data poisoning), surveillance, data leakage, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies. If we enable or use solutions that draw controversy due to perceived or actual negative societal impact, we may also experience brand or reputational harm, competitive harm or legal liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A growing number of legislators and regulators are adopting laws and regulations and have focused enforcement efforts on the adoption of AI, and use of such technologies in compliance with ethical standards and societal expectations. These developments may increase our compliance burden and costs in connection with use of AI and lead to legal liability if we fail to meet evolving legal standards or if use of such technologies results in harms or other causes of action we did not predict. For example, Europe began implementing its EU Artificial Intelligence Act (&#8220;AI Act&#8221;) on August 1, 2024, with a significant part of the law scheduled to come into effect in August 2026. As currently enacted, the AI Act, which may be amended as part of the EU&#8217;s Digital Omnibus, imposes significant obligations on providers and deployers of AI systems, and encourages providers and deployers of AI systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on legal and risk determinations that rely on novel legal provisions that have not yet been interpreted by courts or regulators, and non-compliance can lead to significant fines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the AI regulatory environment is complex and uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the Trump Administration has endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued guidance on the use of AI in medical devices, requiring detailed risk management and review processes to obtain approvals. If we develop or use AI systems governed by these laws or regulations, we will need to meet higher standards of data quality, transparency, monitoring and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements, with the potential for significant enforcement or litigation in the event of any perceived non-compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary intellectual property, or by undermining our ability to assert or defend ownership rights in intellectual property created with the assistance of AI tools.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our vendors may in turn incorporate AI tools into their offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. In addition, the use of generative AI models in our internal or third-party systems may create new attack surfaces or methods for adversaries, which could impact us and our vendors. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of these compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. Our efforts to comply with the evolving data protection, privacy, AI and security laws, rules, regulations, and other obligations may be unsuccessful. We may need to devote significant resources to understanding and complying with this changing landscape. In addition, such requirements may require us to modify our data processing practices and policies, utilize management&#8217;s time and/or divert resources from other initiatives and projects. Any actual or perceived failure by us or our third-party partners to comply with such laws, rules, regulations, and other obligations regarding data protection, privacy, AI and security could result in significant government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity. Further, any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the hardware, software, data and cloud computing platforms that we rely on may not continue to be available at reasonable prices, on commercially reasonable terms or at all. Any loss of the right to use any of these hardware, software, data or cloud computing platforms could significantly increase our expenses and disrupt or otherwise result in delays in the provisioning of our services until equivalent technology is either developed by us, or, if available, is identified, obtained through purchase or license and integrated into our services, and no assurance can be provided that such equivalent technology would be developed or obtained in a timely manner or at all. Moreover, as a result of the increasing use and deployment of AI technologies, infrastructure capacity requirements, including network capacity and, computing power and energy requirements, may increase which could lead to an increase in serve interruptions we experience.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. For more information, see the section titled &#8220;Business&#8211;Government Regulation&#8211;Current and Future U.S. Healthcare Reform.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to set a price that we believe is fair for any of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenues and achieve or maintain profitability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical and biologic products. In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. The IRA includes several provisions that may impact our business, depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay until January 1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, other healthcare laws and regulations and health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, as well as our proposed sales and marketing programs. In addition, we may be subject to health information privacy and security laws by the federal government, the states and other jurisdictions in which we may conduct our business. For more information, see the section titled &#8220;Business&#8211;Government Regulation&#8211;Other Healthcare Laws.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the limited statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legislation or other changes in U.S. tax law may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. For example, the One Big Beautiful Bill Act (&#8220;H.R.1&#8221;) was signed into law on July 4, 2025 and made significant changes to U.S. federal tax law. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. For example, under Section 174 of the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development performed outside the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. H.R.1 provides that for taxable years beginning after December 31, 2024, expenses that are incurred for research and development performed in the U.S. may, at the taxpayer&#8217;s election, be immediately deducted or capitalized and amortized. In addition, H.R.1 provides that for taxable years beginning after December 31, 2021 and before January 1, 2025, certain eligible taxpayers generally may elect to retroactively deduct expenses for research and development performed in the U.S. in such taxable years by filing amended tax returns for such taxable years, and all other taxpayers that are not eligible to make such an election and that amortized expenses for research and development performed in the U.S. in such taxable years generally may elect to accelerate and deduct the remaining unamortized amounts of such research and development expenses (i) in the first taxable year beginning after December 31, 2024, or (ii) ratably over the two-taxable year period beginning with the first taxable year beginning after December 31, 2024. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A decline in the federal budget, changes in spending or budgetary priorities of the U.S. government, a prolonged U.S. government shutdown or delays in contract awards may significantly and adversely affect our future revenues, cash flow and financial results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, U.S. government appropriations have been affected by larger U.S. government budgetary issues and related legislation. As a result, the Department of Defense funding levels have fluctuated and have been difficult to predict. Future spending levels are subject to a wide range of factors, including Congressional action. In addition, in the past, U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the U.S. Although U.S. lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the U.S. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, government spending levels are difficult to predict beyond the near term due to numerous factors, including the external threat environment, future government priorities and the state of government finances. Significant changes in government spending or changes in U.S. government priorities, policies and requirements could have a material adverse effect on our results of operations, financial condition or liquidity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business</span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the start of the Trump Administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the U.S. Congress and the current administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could hinder our ability to compete in certain markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations are subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. Anti-corruption laws generally prohibit us and our employees, officers, CROs, consultants, contractors and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">partners and agents from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to U.S. and foreign export controls, trade sanctions, and import laws and regulations. Such laws may prevent or prohibit the export or provision of certain products and services to countries, governments, and persons targeted by sanctions. Violations of these above laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, breach of contract and fraud litigation, reputational harm and other consequences.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Third Party Relationships</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently rely on, and may continue to depend on, collaborations with third parties for the discovery, development and commercialization of our product candidates. If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a third-party collaborator for research, development and commercialization of some of our product candidates, and we may seek third-party collaborators in the future. Pharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. If we fail to maintain our existing collaborations or fail to enter into future collaborations on commercially reasonable terms, or at all, or if such collaborations are not successful, we may not be able to execute our strategy to develop certain targets, product candidates or disease areas that we believe could benefit from the resources of either larger pharmaceutical companies or those specialized in a particular area of relevance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in May 2025, we entered into the Collaboration Agreement with Novo. Under the Novo Collaboration Agreement, we and Novo are exclusively collaborating to leverage our proprietary Native Complex Platform&#174; to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The collaboration objective is to discover and develop several novel mono-, dual-, or triple-acting oral small molecule drug candidates directed across five Collaboration Targets. The collaboration includes our most advanced preclinical metabolic program focused on developing an oral small molecule agonist to the GIP receptor. We and Novo have initially commenced four simultaneous research and development programs, with each pursuing one or more Collaboration Targets from discovery through development candidate selection. Failure by Novo to meet its obligations under the Novo Collaboration Agreement, to apply sufficient efforts at developing and commercializing licensed products, or to comply with applicable legal or regulatory requirements, may materially adversely affect our business and our results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our collaboration agreements, we have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations involving our product candidates may pose the following risks to us:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the foregoing, our existing collaboration or any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a current or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to any current or future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, to the extent that any of our current or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers, CROs, CMOs, and suppliers to supply, develop and test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely, and may continue to rely, on third-party contract manufacturers, including in China, to manufacture and test bulk drug substances, drug products, raw materials, samples, components, or other materials and reports. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, terminated or of satisfactory quality or continue to be available at acceptable prices. In addition, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for a product candidate is subject to FDA, EMA and foreign regulatory authority review. In some cases, we, and our suppliers and manufacturers, some of which may be our sole source of supply, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA, EMA, and other comparable foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA, and other comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the FDA and foreign regulatory authorities, including for continued compliance with cGMP requirements, quality control, quality assurance and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements, comply with cGMPs or maintain a compliance status acceptable to the FDA or foreign regulatory authorities could adversely affect our business in a number of ways, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in the progress on certain research programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to initiate or continue clinical trials of product candidates under development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of the cooperation of existing or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our therapeutics.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we currently rely on foreign CROs and CMOs, including WuXi AppTec (Hong Kong) Limited, for manufacturing and development activities and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be subject to U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the BIOSECURE Act passed in December 2025 prohibits U.S. federal agencies from entering into or renewing a contract with any company that uses biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; in the performance of that contract. It also prohibits loans or grant funding from U.S. federal agencies to entities that use any biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; in the performance of the government grant or loan. As the BIOSECURE Act is recently enacted, the full effects on our industry is unknown; however, it could have the downstream effect of restricting the ability of pharmaceutical companies that enter into contracts with or receive funding from U.S. federal agencies from purchasing services or equipment from certain Chinese biotechnology companies, including those that are specifically named in the proposed BIOSECURE Act, as well as supply chain disruptions or delays. As passed in December 2025, the BIOSECURE Act does not currently name WuXi Biologics or WuXi AppTec as &#8220;biotechnology companies of concern,&#8221; but treats any company on the Department of Defense &#8220;1260H list&#8221; (named after Section 1260H of the NDAA for Fiscal Year 2021) of &#8220;Chinese military companies&#8221; as a &#8220;biotechnology company of concern.&#8221; By December 18, 2026, the Director of the Office of Management and Budget (&#8220;OMB&#8221;) will publish a full list of &#8220;biotechnology companies of concern&#8221; based on recommendations from key federal Secretaries and Directors, including Defense, Justice, HHS, Commerce, National Intelligence, Homeland Security, State, and National Cyber. The Director of OMB will thereafter review and update that list at least annually, based on recommendations from those key federal Secretaries and Directors. To the extent WuXi Biologics, WuXi AppTec or other contractors we use are named as &#8220;biotechnology companies of concern&#8221; or if we have an existing contract with a company subsequently added to the &#8220;biotechnology companies of concern,&#8221; a grandfathering provision contained within the BIOSECURE Act may allow us adequate time to identify and execute agreements with alternative contractors if necessary (although there is no guarantee the terms under which we would engaged an alternative contractor would be favorable or how the government implements the BIOSECURE Act). Depending on how the BIOSECURE Act is interpreted by U.S. federal agencies, and whether the BIOSECURE Act is subsequently amended, we could be potentially restricted from pursuing U.S. federal government business or government reimbursement for our products in the future if we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to use WuXi Biologics, WuXi AppTec or other suppliers or partners identified as &#8220;biotechnology companies of concern&#8221; beyond this grandfathering period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the BIOSECURE Act, any additional executive action, legislative action, or potential sanctions with China could materially impact our work with WuXi STA. U.S. executive agencies have the ability to designate entities and individuals on various governmental prohibited and restricted parties lists. Depending on the designation, potential consequences can range from a comprehensive prohibition on all transactions or dealings with designated parties, or a limited prohibition on certain types of activities, such as exports and financing activities, with designated parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the pharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting pharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the U.S. and the United Kingdom, or U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs. Any of the foregoing factors could have a material adverse effect on our business, results of operations, or financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, as product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have entered into a collaboration agreement, and may in the future enter into additional collaboration agreements and strategic alliances to maximize the potential of our structure-based drug discovery platform and product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part of our business strategy is to explore additional collaborations with third parties to further utilize our platform capabilities on additional novel GPCR targets and to leverage partners additional disease biology understanding, development and commercial expertise, regional insights or other complementary capabilities to existing or future Septerna programs. We have therefore entered into the Novo Collaboration Agreement and may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our structure-based drug discovery platform or our product candidates that we may develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to enter into the arrangement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development collaborations are subject to numerous risks, which may include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources causing delays or termination of the research;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of our structure-based drug discovery platform or collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for collaboration product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could develop or acquire products outside of the collaboration that compete directly or indirectly with our products or product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel to pursue further development or commercialization of our structure-based drug discovery platform or the applicable product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we could face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming, expensive, and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our structure-based drug discovery platform or product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate their desired safety and efficacy profile. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into additional agreements on certain terms or at all with other potential collaborators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these risks, we may not be able to realize the benefit of any future collaborations or licensing agreements we may enter into. In addition, we may face regulatory obstacles in completing such transactions. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our structure-based drug discovery platform or product candidates or bring them to market and generate revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. If collaborations occur, these institutions often provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our products require specific constituents to work effectively and efficiently, and rights to those constituents are, and in the future may be, held by others. We may also seek to in-license third-party technologies to enhance our Native Complex Platform&#174;. We may be unable to in-license any rights from constituents, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which could harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology in order to establish or maintain our competitive position in the market. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates or our structure-based drug discovery platform could delay the development and commercialization of our product candidates in certain geographies or limit our ability to discover and develop new product candidates, which could harm our business prospects, financial condition, and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacturing of our product candidates is complex, and our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide patients supply of our products, if approved, could be delayed or stopped.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of manufacturing pharmaceuticals is complex, time-consuming, highly regulated and subject to multiple risks. Our contract manufacturers must comply with legal requirements, cGMPs and guidelines for the manufacturing of pharmaceuticals used in clinical trials and, if approved, marketed products. Our contract manufacturers may have limited experience in the manufacturing of cGMP batches.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing pharmaceuticals is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at our third-party manufacturers&#8217; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if we or our future collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scaling up a pharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not have the necessary capabilities to complete the implementation, manufacturing and development process. If we are unable to adequately validate or scale-up the manufacturing process at our current manufacturers&#8217; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure that any stability or other issues relating to the manufacture of any of our product candidates will not occur in the future. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial condition and results of operations. Regional or single-source dependencies may in some cases accentuate these risks. For example, the pharmaceutical industry generally, and in some instances our Company, our collaborators or other third parties on which we rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities. Our ability or the ability of our collaborators or such other third parties to continue to engage these China-based suppliers or service providers for certain preclinical research programs and clinical development programs could be restricted due to geopolitical development between the United States and China, including as a result of the escalation of tariffs or other trade restrictions, the BIOSECURE Act or the enactment of new laws that limit our ability to freely contract for goods or services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our process development efforts, we also may make changes to the manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our clinical trials. In some circumstances, changes in the manufacturing process may require us to perform </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have the ability to independently conduct preclinical studies or clinical trials required to develop our product candidates. We intend to rely on CROs, clinical trial sites and other third parties to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs and others for the execution of future nonclinical studies and to monitor, manage and report data for our clinical trials. We expect to control only certain aspects of our CROs&#8217; and others&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs and others does not relieve us of our regulatory responsibilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, our CROs and other third parties we might engage will be required to comply with good laboratory practices (&#8220;GLPs&#8221;) and GCPs, which are regulations and guidelines enforced by the FDA, EMA, and other comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs and others to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs and others does not relieve us of our regulatory responsibilities. If we, our CROs and other third parties we engage fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA, or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs or others fail to comply with these regulations or fail to recruit a sufficient number of participants, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we will have agreements governing their activities, our CROs and other third parties we engage will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future nonclinical and clinical programs. These CROs and others may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and others, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. In addition, certain of our agreements with CROs and other third parties currently or will provide for monetary and other limitations on their liability. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for any other reasons, our preclinical or clinical programs may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed, decreased or eliminated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our relationship with these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently depend and in the future may continue to depend on single- or limited-source suppliers for some of the components and materials used in the product candidates we may develop.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently depend and in the future may continue to depend on single- or limited-source suppliers for some of the components and materials used in any product candidates we may develop. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly or at all. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our therapeutics, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will file additional patent applications both in the United States and in other jurisdictions, as appropriate. However, we cannot predict:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and when any patents will issue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the degree and scope of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the patent applications that we own, or may in-license, will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in foreign jurisdictions.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely, and may in the future rely, upon a combination of patent, trade secret and trademark protection for our current and any future product candidates and proprietary technologies to prevent third parties from exploiting our achievements, thus eroding our competitive position in our market. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain, expand, enforce, and defend the scope, ownership or control, validity and enforceability of our intellectual property protection in the United States and other countries with respect to our current and any future product candidates and other proprietary technologies we may develop. Our commercial success depends in large part on our ability to obtain and maintain patent protection in the United States and other jurisdictions with respect to our current and any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner, including as a result of factors impacting our, our licensors&#8217; or governmental patent offices&#8217; operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or in foreign jurisdictions. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been or will be found, which unknown prior art can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do issue and even if such patents cover our current or any future product candidates, third parties may challenge their scope, validity, or enforceability, which may result in such patents being</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patent applications we hold or have in-licensed with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for current or any future product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drug products. Any such outcome could have a negative effect on our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Composition of matter patents for pharmaceutical products provide intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of any of our product candidates will be considered patentable by the USPTO, or by patent offices in foreign jurisdictions, or that the claims in any of our patents that may issue will be considered valid and enforceable by courts in the United States or foreign jurisdictions. Method of use patents protect the use of a product for the specified method. We cannot be certain, however, that the claims in our pending patent applications covering methods of use of our product candidates will be considered patentable by the USPTO, or by patent offices in foreign jurisdictions, or that the claims in any of our patents that may issue will be considered valid and enforceable by courts in the United States or foreign jurisdictions. Further, this type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, once approved for therapeutic use by FDA. or counterpart foreign regulatory authorities, physicians may prescribe these products &#8220;off-label&#8221; for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or enforce against.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign jurisdictions may not protect our rights to the same extent as the laws of the United States. Patent applications in the United States and certain other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to file for patent protection. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies or products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patents or narrow the scope of our patent protection. These changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a negative effect on our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or another patent office or become involved in opposition, derivation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review (&#8220;IPR&#8221;), post-grant review (&#8220;PGR&#8221;) or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights or obtaining a costly license from a third party. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology, products or methods, or limit the duration of the patent protection of our technology, products or methods.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years from the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. For instance, a patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not necessarily extend to all claims, but instead only to claims that read on the product as approved. Laws governing analogous patent term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. In addition, although upon issuance in the United States a patent&#8217;s term can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Without patent protection for our product candidates, including once the patent life has expired even if patents covering our product candidates are obtained, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent term has expired for a product, we may be open to competition from generic medications. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we have or obtain patents covering our products or methods, we may still be barred from making, using and selling such products or methods because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop our technology or to successfully commercialize any approved products alone or with collaborators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent applications in the United States and elsewhere are generally published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our methods and product candidates could have been filed by others without our knowledge. Additionally, pending claims in patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies or related products. These patent applications may have priority over patent applications filed by us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor, co-inventor, owner or co-owner. For example, we or our licensors may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. In the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by one or more of our product candidates. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to challenge the enforceability or validity of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex parte</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> re-examination, IPR or PGR proceeding. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office (&#8220;EPO&#8221;), or other foreign patent office. The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office, then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop non-infringing technology, which may not be possible on a cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our technology licensed from various third parties may be subject to retained rights.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act (&#8220;Bayh-Dole Act&#8221;). The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. We sometimes collaborate with academic institutions to accelerate our preclinical research or development, creating a risk that federal funds may be commingled. Therefore, we cannot be sure that any intellectual property co-developed from a collaboration with an academic institution will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration date of a third-party patent, which might adversely affect our ability to develop and market our products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product candidates. Thus, we cannot guarantee that our product candidates, or our commercialization thereof, do not and will not infringe any third party&#8217;s intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that any patent searches or analyses that are performed, including the identification of relevant patents, the scope of patent claims or the expiration dates of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our future products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our future products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The landscape of intellectual property related to our product candidates and future products is constantly changing. Therefore, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and certain other jurisdictions are confidential for typically a period of at least 18 months after their priority date, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents. Should we fail to win an interference challenge, a third party may obtain rights to intellectual property related to our product candidates and future products.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because our programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our future licensors or collaboration partners. If any of our future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology platform or product candidates in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce, and defend such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are subject of such licensed rights could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our future licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that we may be unable to obtain necessary licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us (which could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects). In the event we are unable to obtain necessary licenses at a reasonable cost or on reasonable terms, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patents and other rights to third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to transfer or assign the license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be required to license technologies relating to our programs from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or our current or future collaborators were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including but not limited to lack of novelty, obviousness, or insufficient written description or enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, PGR, IPR, derivation proceedings, interference proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in loss of rights to, the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our technology or platform, or any product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a patent claim. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other intellectual property that we may develop. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened or questioned,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it could dissuade companies from collaborating with us to license, develop or commercialize our product candidates. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that we or our employees have misappropriated the intellectual property, including confidential information, know-how or trade secrets, of a third-party, or claiming ownership of what we regard as our own intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or these employees, consultants or contractors have used or disclosed such third-party intellectual property, including know-how, trade secrets or other proprietary information, to us. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, it may a have negative impact on our business and our ability to develop product candidates or commercialize our technology. In addition to paying substantial monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could incur substantial costs and be a distraction to management and scientific personnel.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may license intellectual property rights from third parties. Such licenses may be subject to early termination if we fail to comply with our obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become a party to licenses that give us rights to third-party intellectual property or technology that is necessary or useful for our business, and we may enter into additional licenses in the future. Under these license agreements, we are or may become obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. These fees may be significant, which could make it difficult for us to achieve or maintain profitability. In addition, under certain of such agreements, we are or may become required to diligently pursue the development of products using the licensed technology. If we fail to comply with these obligations, including due to our use of the intellectual property licensed to us in an unauthorized manner, and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business, harming our ability to develop, manufacture and/or commercialize our platform, products or product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the agreements under which we license intellectual property or technology to or from third-parties can be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. The failure to obtain or in-license any compositions, methods of use, processes or other third-party intellectual property rights at a reasonable cost or on reasonable terms, could harm our business. If we fail to obtain licenses to necessary third-party intellectual property rights, we may need to cease use of the compositions or methods covered by such third-party intellectual property rights. Furthermore, we may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel, patent annuity service providers, or our licensing partners to pay these fees to the applicable government patent agencies. If these fees are not paid when due, our rights to such patents or patent applications may be irrevocably abandoned or otherwise materially impaired.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various non-U.S. government patent agencies require compliance with numerous procedural, documentary, and other similar provisions during the patent application process. For example, many jurisdictions, including the U.S. and China, require a foreign filing license before seeking patent protection in a jurisdiction outside of the jurisdiction of which the inventor is a citizen or in which the invention was made. Each jurisdiction&#8217;s laws regarding foreign filing licenses vary and may even conflict. We employ reputable law firms in foreign jurisdictions and other professionals to help us comply and we are also dependent on any licensors to take the necessary action to comply with these requirements with respect to our intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, maintaining, enforcing, and defending patent applications and patents covering our current and any future product candidates worldwide is prohibitively expensive, so we will pursue patents in a limited number of jurisdictions. Moreover, our intellectual property rights in some jurisdictions outside the United States can have a different scope and strength than do those in the United States. Consequently, we will not be able to prevent third parties from practicing our inventions in all jurisdictions, or from selling or importing in and into various jurisdictions products made using our inventions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and, further, may export otherwise infringing product candidates to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. Further, these product candidates may compete with our product candidates in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems protecting and defending intellectual property rights in jurisdictions outside the United States. The legal systems of certain jurisdictions do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to pharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, including the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patents and other intellectual property rights in jurisdictions outside the United States could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in intellectual property laws in the United States and around the world. For example, in Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Certain jurisdictions, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties under certain circumstances. In those jurisdictions, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop and our technology, one or more U.S. patents that we license or may own in the future may be eligible for limited patent term extension under the Hatch-Waxman Amendments. Under certain circumstances the Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought and within 60 days of FDA approval. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable patent term extension or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, we may be open earlier than projected to competition from competitive products, including generics or biosimilars following our patent expiration, and our revenue could be reduced earlier than projected. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of our trade secrets and other proprietary information. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary information and confidential know-how that we elect not to patent, including processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery, development processes and drug discovery platform that involve proprietary know-how, information, or technology that is not covered by patents. In particular, our trade secrets, confidential know-how and other proprietary information includes our proprietary Native Complex Platform&#174; drug discovery platform, which we do not plan to patent. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Such risk of disclosure can be increased by our use of AI technologies and can result in misappropriation and other security incidents. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets, confidential know-how and proprietary information, however, may be difficult to protect. We seek to protect our trade secrets, confidential know-how and proprietary information, including our proprietary processes and drug discovery platform, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Although we use reasonable efforts to protect our trade secrets, we cannot provide any assurances that all such agreements have been duly executed, and notwithstanding the existence of a confidentiality agreement our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information, including to competitors. In addition, competitors or other third parties may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign jurisdictions do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.  Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or data breach.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our intellectual property rights do not necessarily protect against all potential threats to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. These risks and uncertainties include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to file patent applications covering certain of our product candidates or inventions we own or control;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending patent applications that we own or control may not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or control may be held invalid or unenforceable as a result of legal challenges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other jurisdictions that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in jurisdictions where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, opposed, infringed, circumvented, invalidated, cancelled, declared generic, determined to be not entitled to registration, or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many other jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Trademark litigation could be expensive. In addition, we could be found liable for significant monetary damages, including treble damages, disgorgement of profits and attorneys&#8217; fees, if we are found to have willfully infringed a trademark. We may not be able to protect our exclusive right to trademarks or trade names or may be forced to stop using these names,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which we need for name recognition by potential collaborators or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks or trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks or trade names to third parties, such as distributors. Though these agreements may provide guidelines for how our trademarks or trade names may be used, a breach of these agreements or misuse of our trademarks or tradenames by third parties may jeopardize our rights in or diminish the goodwill associated with our trademarks or trade names.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or equivalent body. Furthermore, in many jurisdictions, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Furthermore, assertions of potential trademark infringement or possible market confusion may lead to coexistence agreements in order to avoid costly disputes related to our trademarks. As a consequence, we may be forced to amend the list of goods and services covered by our trademarks more narrowly than as originally filed and intended, which could adversely affect our ability to establish name recognition. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights to improvements to our product candidates may be held by third parties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the course of testing our product candidates, we may enter into agreements with third parties to conduct clinical testing, which may provide that improvements to our product candidates may be owned solely by a third party or jointly between the parties. If we determine that rights to such improvements owned solely by a third party are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing the product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby giving our competitors and other third parties access to the same technologies licensed to us. Failure to obtain a license on commercially reasonable terms or at all, or to obtain an exclusive license, could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. If we determine that rights to improvements jointly owned between us and a third party are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such improvements, such co-owners may be able to license their rights to other parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our intellectual property in order to enforce such intellectual property against other parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not know whether a market will be sustained for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for you to sell your shares of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our common stock is listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;), an active trading market for our common stock may not be sustained. If a market for our common stock is not sustained or if trading volume in our common stock is low, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, some of which may include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of existing or new competitive product candidates or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment, completion and results of preclinical studies and clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to commercialize our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure or discontinuation of any of our development and research programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commencement or termination of collaborations for our product development and research programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts, if any, that cover our stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us, our insiders or other stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of market stand-off or lock-up agreements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage our growth;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in quarterly operating results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash position;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting practices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ineffectiveness of our internal controls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, industry and market conditions; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales, or the perception of future sales, of our common stock in the public market by existing stockholders could cause our stock price to fall.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. The possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 44,806,272 shares of our common stock outstanding. Shares of unvested restricted stock that were issued and outstanding will become available for sale immediately upon the vesting of such shares, as applicable, and the expiration of any applicable market stand-off or lock-up agreements. Shares issued upon the exercise of stock options pursuant to future awards that may be granted under our equity incentive or inducement plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market stand-off and lock-up agreements and Rule 144 and Rule 701 under the Securities Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain holders of our common stock have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have registered the offer and sale of all shares of common stock that we may issue under our equity compensation plans, and those shares are available for sale in the open market, unless such shares are subject to vesting restrictions with us or any applicable lock-up restrictions. Once we register the offer and sale of shares for the holders of registration rights, they can be freely sold in the public market upon issuance, subject to any applicable lock-up agreements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, in the future, we may issue additional shares of our common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2022 (&#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the completion of our initial public offering (&#8220;IPO&#8221;), although circumstances could cause us to lose that status earlier, including if we are deemed to be a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30, or if we have total annual gross revenue of $1.235 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31, or if we issue more than $1.0 billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on the financial statements.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore, while we are an emerging growth company, we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.  As a result of this election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act, and we may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. We may continue to be a smaller reporting company even after we are no longer an emerging growth company, which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this Annual Report and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred and will continue to incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (&#8220;Dodd-Frank Act&#8221;) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to the fifth anniversary of our IPO. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the beneficial ownership of our common stock as of December 31, 2025, our directors and executive officers, holders of 5% or more of our capital stock and their respective affiliates beneficially own a significant percentage of our outstanding common stock. These stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on shares of our common stock and do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP"). As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, beginning with our second Annual Report on Form 10-K after we become a public company, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we may be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We are engaged in the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy or consequent inability to produce accurate financial statements on a timely basis could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis cause investors to lose confidence in the accuracy and completeness of our financial reports and could cause the market price of our common stock to decline significantly.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future discover material weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create a classified board of directors whose members serve staggered three-year terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that special meetings of our stockholders can be called only by our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholder action by written consent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that our directors may be removed only for cause;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated bylaws; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv) any action asserting a claim that is governed by the internal affairs doctrine (&#8220;Delaware Forum Provision&#8221;). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (&#8220;Federal Forum Provision&#8221;). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">political instability and geopolitical events could adversely affect our business, financial condition, stock price, and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions, including as a result of an economic downturn and geopolitical events, such as changes in or disruptions of U.S. governmental agencies, whether from a prolonged U.S. federal government shutdown or reduced resources, disruptions in capital markets, the potential for significant changes in U.S. federal policies or regulatory environment or other factors that affect the geopolitical landscape. The global credit and financial markets have also generally experienced extreme volatility and disruptions (including as a result of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, changes in interest rates, uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our product candidates and in our ability to raise additional capital when needed on acceptable terms, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflicts, such as the ongoing conflicts between Russia and Ukraine, and Israel and Hamas, terrorism, or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Additionally, changes to policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. For example, the implementation of tariffs by the U.S. government has led to increased trade and political tensions, between not only the U.S. and China, but also between the U.S. and other countries in the international community. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. For example, the BIOSECURE Act signed into law as part of the recently-enacted NDAA may restrict the ability of United States pharmaceutical companies to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the United States government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect our Company, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential or actual breach of statutory, regulatory or contractual obligations, including obligations that require us to maintain letters of credit or other credit support arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, investor concerns regarding the United States or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity, our current and/or planned business operations, and our current or projected financial condition and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or planned business operations and our current or projected results of operations and financial condition. For example, a customer may fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as a customer. In addition, a customer or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on the Company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any customer, collaborator or supplier bankruptcy or insolvency, or the failure of any customer or collaborator to make payments when due, or any breach or default by a customer, collaborator or supplier, or the loss of any significant supplier or collaborator relationships, could result in material losses to the Company and may have a material adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock or publishes inaccurate or unfavorable research bout our business, the price of our stock could decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in litigation and investigations that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time we may be subject to litigation claims and investigations from the SEC and other government agencies through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, government-issued subpoenas, contractual relations with collaborators and licensors and intellectual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">property rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, the announcement of negative events, such as negative results from clinical trials, or periods of volatility in the market price of a company&#8217;s securities. These events may also result in or be concurrent with investigations by the SEC (which may not be publicly disclosed by the SEC or by us, particularly where the SEC or investigating body has made it clear that no wrongdoing has been alleged). In addition, we may be exposed to litigation or investigation even if no wrongdoing has occurred. Responding to litigations and investigations is usually expensive, and our insurance coverage many not be sufficient to cover the legal costs for doing so, as well as any damages for which we are ultimately held responsible. In addition, responding to a litigation or an investigation diverts management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we maintain commercial insurance at a level we believe is appropriate against certain risks commonly insured in the industry in which we operate, there is no guarantee that our insurer will cover costs or that we will be able to obtain the desired level of coverage on acceptable terms in the future. Some of the policies we currently maintain include property, general liability, crime insurance, workers&#8217; compensation, and directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance, clinical trial insurance, transportation insurance and umbrella insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Changes in the market conditions and our business operations may necessitate the addition of new insurance policies or change of our existing insurance policies. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond our control, which could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our facilities are located in California. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity, pandemics or other regional or global disasters and generally do not have a recovery plan for such events. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Increased attention to, and evolving expectations for, environmental, social, and governance initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies across industries are facing increasing scrutiny from a variety of stakeholders related to their environmental, climate change, social, and governance (&#8220;ESG&#8221;) and sustainability practices. Investor advocacy groups, certain institutional investors, investment funds, and other influential investors have increasingly focused on ESG practices and have placed increasing importance on the non-financial impacts of their investments. Expectations regarding voluntary ESG initiatives and disclosures may result in increased costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) to improve the ESG profile of the Company, such initiatives may be costly and may not have the desired effect. Moreover, we may not be able to successfully complete such initiatives due to factors that are within or outside of our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntary.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain market participants, including major institutional investors and capital providers, use third-party benchmarks and scores to assess companies&#8217; ESG profiles in making investment or voting decisions. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us, which could negatively impact our share price as well as our access to and cost of capital. In addition, in recent years &#8220;anti-ESG&#8221; sentiment has gained momentum across the United States, with several states and Congress having proposed or enacted &#8220;anti-ESG&#8221; policies, legislation, or initiatives or issued related legal opinions, and the President having issued an executive order opposing diversity equity and inclusion (&#8220;DEI&#8221;) initiatives in the private sector. Such anti-ESG and anti-DEI-related policies, legislation, initiatives, litigation, legal opinions, and scrutiny could result in us facing additional compliance obligations, becoming the subject of investigations and enforcement actions, or sustaining reputational harm. Therefore, to the extent we take actions that are seen as positive to some investors, other investors may take issue with such actions or face regulatory pressure to refrain from investing in, or divest from, our business. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees, which may adversely impact our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we expect there will likely be increasing levels of regulation, disclosure-related and otherwise, with respect to ESG matters. For example, the SEC has issued rules that require companies to provide significantly expanded climate-related disclosures in their periodic reporting. The new climate disclosure rules were the subject of multiple legal challenges, and the SEC voluntarily stayed the climate disclosure rules pending the completion of judicial review. Therefore, it is unknown whether the new rules will go into effect and if they do, whether there will be significant changes. If the new rules go into effect and are not substantially different than the rules adopted by the SEC, we may be required to incur significant additional costs to comply, including the implementation of significant additional internal controls processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors. Even if the SEC rules are not adopted, states or ex-U.S. jurisdictions in which we currently or may in the future operate may also have or adopt ESG or climate-related disclosure rules requiring similar or broader disclosure obligations. These and other changes in stakeholder expectations will likely lead to increased costs as well as scrutiny that could heighten all of the risks identified in this risk factor. Additionally, our business partners may be subject to similar expectations, which may augment or create additional risks, including risks that may not be known to us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of social media platforms presents risks and challenges.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates, operations, or business may cause us to be found in violation of applicable legal or contractual requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, collaboration partners, and others, and which could have an adverse effect on our business, financial conditions and results of operations. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image and goodwill.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, it is possible for individuals or groups to target companies with disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide access to our product candidates under an expanded access policy, our reputation may be negatively affected and our business may be harmed.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ed Staff Comments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p><div><ix:nonNumeric id="F_059e3ba8-cf14-487e-8c88-78e40a1e95e6" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_059e3ba8-cf14-487e-8c88-78e40a1e95e6_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented a cybersecurity risk management program in accordance with our risk profile and business size that is informed by recognized industry standards, including elements of the National Institute of Standards and Technology Cybersecurity Framework and International Organization for Standardization 27001 Framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is comprised of a number of components, including but not limited to written information security policies, external cybersecurity risk assessments, and system monitoring. We also have an employee privacy and data security training awareness program that includes cybersecurity risk awareness trainings and phishing campaigns. We maintain an incident response plan to help guide our response to cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We leverage the cybersecurity services of third-party vendors, including a third-party managed services provider and IT consultants, to support our cybersecurity risk management program and assist us in conducting external cybersecurity risk assessments. As part of our cybersecurity risk management program, we take a risk-based approach to the evaluation of third-party vendors. As part of our vendor diligence process we require vendors with access to our information technology systems and infrastructure to complete information security program questionnaires.</span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e39c6c2-d064-4334-88d1-d80aa6036ca9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dccd0c2e-f8f4-4ac3-a42d-b57cf5457f8e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, like other companies in our industry, we and our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87e1c4ae-8069-4aa8-b884-e8eaaa4d352c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vendors have from time to time experienced threats relating to our and our third-party vendors&#8217; information systems and infrastructure.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For more information, please see &#8220;Item 1A, Risk Factors.&#8221;</span></p><div><ix:nonNumeric id="F_ea59504a-cf36-43f9-b13e-2aed18356821" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true" continuedAt="F_ea59504a-cf36-43f9-b13e-2aed18356821_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_059e3ba8-cf14-487e-8c88-78e40a1e95e6_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ea59504a-cf36-43f9-b13e-2aed18356821_1"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45cd0564-8214-4fa1-96bb-5ae51c20129a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4db0f61d-2099-482e-9620-145195999ea1" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#8217;s general risk oversight function.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9f44453-916c-4646-8449-3a6da8360567" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60ab5640-9dd8-49bd-9f84-3928625f043d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#8220;IT&#8221;), and is responsible for the strategic leadership of our cybersecurity risk management program.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f96e871-6d2a-415b-8781-d7adbb0b5ca4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2f8b022-8114-415d-9ea9-3cdaa9dfd2e5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Head of IT relies on both internal and external cybersecurity resources to manage and remain appraised of overall cybersecurity risks to our business and our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_2ef30887-4bf6-4db8-a9b8-4853c1d76ca6" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c26337c2-6791-4f00-b070-ab1430a86c79" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.</span></p></ix:nonNumeric></div></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in South San Francisco, California, where we lease and occupy approximately 44,819 square feet of combined office, research and laboratory space at 250 East Grand Avenue, South San Francisco, California 94080. The current term of our lease expires in July 2032.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our existing facilities are adequate for our current needs and for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Le</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gal Proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in or be subject to legal proceedings, claims and litigation arising from the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">afety Disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registra</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nt&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;SEPN&#8221; on October 25, 2024. Prior to this date, there was no public trading market for our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Holders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 2, 2026, we had approximately 60 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in &#8220;street name&#8221; or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not declared or paid cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Part III, Item 12 of this Annual Report on Form 10-K (this &#8220;Annual Report&#8221;).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds from our IPO</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 24, 2024, our Registration Statement on Form S-1 (File No. 333-282469), as amended, relating to our IPO was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) (the &#8220;Registration Statement&#8221;). Pursuant to the Registration Statement, we registered the offer and sale of 18,400,000 shares of our common stock. On October 28, 2024, we closed our IPO, pursuant to which we issued and sold 18.4 million shares of common stock at the public offering price of $18.00 per share, which included 2.4 million shares of our common stock issued and sold on October 30, 2024 to the underwriters pursuant to the full exercise of their option to purchase additional shares of our common stock, at the public offering price of $18.00 per share. Pursuant to the IPO, we received gross proceeds of $331.2 million, which resulted in net proceeds to us of $302.8 million, after deducting underwriting discounts and commissions and other offering costs payable by us of $28.4 million. J.P. Morgan Securities LLC, TD Securities (USA) LLC, Cantor Fitzgerald &amp; Co. and Wells Fargo Securities, LLC acted as joint book-running managers for the IPO.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds from our IPO have been invested according to our approved investment policy in a mix of money market funds and high-quality, fixed income securities. Our planned use of the net proceeds from the IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) on October 25, 2024 has changed due to the discontinuation of the development of our prior lead product candidate, SEP-786. As a result, we currently expect to use our cash, cash equivalents and marketable securities, which include the net proceeds from the IPO, to advance SEP-479 and SEP-631 in clinical development, continue to advance the other programs in our pipeline, and the remainder to fund working capital and other general corporate purposes.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Series B Convertible Preferred Stock Financing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we sold an aggregate of 60,828,732 shares of our Series B convertible preferred stock, at a purchase price of $1.23297 per share, for an aggregate amount of $75 million. We incurred $0.1 million in issuance costs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No underwriters were involved in the foregoing sale of securities. The sale of securities described above were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, as transactions by an issuer not involving a public offering. All of the purchasers in these transactions represented to us, in connection with their purchase, that they were acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. [</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved]</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included elsewhere in this Annual Report. This discussion and other parts of this Annual Report contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors including, but not limited to, those set forth under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and you should carefully read the section titled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovered powered by our proprietary Native Complex Platform&#174;.  Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of drug candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary Native Complex Platform&#174; replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex Platform&#174; is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists (which activate GPCR signaling), antagonists (which inhibit GPCR signaling), and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands), to affect GPCR signaling in different ways to achieve desired therapeutic effects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is summarized in the figure below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img170310032_12.jpg" alt="img170310032_12.jpg" style="width:720px;height:345px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, we changed our name to Septerna, Inc. We are headquartered in South San Francisco, California.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since our inception, except for the year ended December 31, 2023. Our revenue to date has been generated solely from research services. Since our founding, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, developing our proprietary and structure-based drug discovery platform, identifying and discovering our product candidates, establishing our intellectual property portfolio, conducting research and preclinical studies, including investigational new drug(&#8220;IND&#8221;)-enabling studies, initiating and conducting clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and related raw materials, and providing general and administrative support for these operations. We have not had any products approved for sale and have not generated any revenue from product sales. Further, we do not expect to generate revenue from commercial product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one or more of our product candidates. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net loss was $48.9 million for the year ended December 31, 2025 compared to net loss of $71.8 million for the year ended December 31, 2024. As of December 31, 2025, we had an accumulated deficit of $167.3 million. We have incurred net losses in each year since inception, except for the year ended December 31, 2023. We expect to continue to incur net losses for the foreseeable future. Our net losses may fluctuate significantly from period to period, depending on the timing and expenditures of our operational activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur significant and increasing net operating losses for the next several years as we:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to advance our product candidates through preclinical studies and into clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain additional personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to operate as a public company, including expenses related to compliance with the rules and regulations of the SEC and those of any national securities exchange on which our securities are traded, legal, auditing, insurance expenses, investor relations activities, and other administrative and professional services;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research and development efforts and expand our pipeline of product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire, discover, validate, and develop additional product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture supplies for our preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain, maintain, expand, and protect our intellectual property portfolio;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implement operational, financial and information management systems;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make royalty, milestone or other payments under any future, license or collaboration agreements; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially seek to identify, assess, acquire, or in-license or develop new technologies or additional product candidates;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially experience any delays, challenges, or other issues associated with the clinical development of our product candidates, including with respect to our regulatory strategies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursue regulatory approval of product candidates that successfully complete clinical trials; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval and related commercial manufacturing build-out.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net losses may fluctuate significantly from period to period, depending upon the timing of our expenditures on research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses and other current liabilities, which includes accrued research and development, in the statements of cash flows in our audited financial statements included elsewhere in this Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we will require substantial additional funding to further develop our product candidates and support our continuing operations. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. See the section titled &#8220;Liquidity and Capital Resources - Future Funding Requirements&#8221; below for additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We historically financed our operations primarily through the issuances of convertible promissory notes and convertible preferred stock, an initial public offering (&#8220;IPO&#8221;), and collaborations with other companies. In October 2024, we completed our IPO, pursuant to which we issued and sold an aggregate of 18.4 million shares of our common stock (inclusive of an additional 2.4 million shares of our common stock issued and sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares in full). The aggregate net proceeds received by us from the IPO was $302.8 million, net of total offering costs of $28.4 million. In July 2025, upon the effectiveness of our Novo Collaboration Agreement, we received a one-time, non-refundable upfront payment of $195.0 million (see &#8220;Novo Collaboration Agreement&#8221;). In August 2025, we received a $12.5 million milestone payment from Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;) (see &#8220;Vertex Asset Purchase Agreement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our cash, cash equivalents, and marketable securities of $548.7 million as of December 31, 2025 will be sufficient to fund our operations and capital expenditure requirements at least into 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use contract research and development organizations to conduct our preclinical works and clinical trials. Additionally, we utilize third-party contract manufacturing organizations (&#8220;CMOs&#8221;), to manufacture and supply our preclinical and clinical materials during the development of our product candidates. We expect to use similar contract resources for the commercialization of our products, at least until our resources and operations are at a scale that justifies investment in internal manufacturing capabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct research and manufacturing work outside of the U.S., including China, that may be affected by tariffs, including tariffs that have been or may in the future be imposed by the U.S. or other countries through reciprocal tariffs. While we do not currently believe tariffs will have a material impact on our business or results of operations, we will continue to carefully monitor the situation. Additionally, we continue to actively monitor macroeconomic conditions and market volatility resulting from global and national economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships, changes in or the disruptions of U.S. governmental agencies, whether from a continued U.S. federal government shutdown or reduced resources, new laws and regulations or amendments to existing laws and regulations in the U.S. and foreign countries, and military conflicts. While we believe such factors have had no significant impact on our business or financial results during the periods presented, future developments and potential impacts on our business are uncertain and cannot be predicted with confidence.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration, Research Services, and Asset Purchase Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, we entered into the Collaboration Agreement with Novo. Under the Novo Collaboration Agreement, we and Novo are exclusively collaborating to leverage our proprietary Native Complex Platform&#174; to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The collaboration objective is to discover and develop several novel mono-, dual-, or triple-acting oral small molecule drug candidates directed across five Collaboration Targets. The collaboration includes our most advanced preclinical metabolic program focused on developing an oral small molecule agonist to the GIP receptor. We and Novo have initially commenced four simultaneous research and development programs (each an &#8220;R&amp;D Program&#8221;) with each pursuing one or more Collaboration Targets from discovery through development candidate selection.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the Novo Collaboration Agreement became effective and, subsequently, we received a one-time, non-refundable upfront payment of $195.0 million, which was recorded as deferred revenue in our balance sheet. For each R&amp;D Program, we are also eligible to receive up to approximately $498.0 million in research, development, regulatory, and commercial milestone payments. In addition, we are entitled to escalating, tiered royalties ranging from mid-to-high single-digits based on global product sales on a country-by-country and product-by-product basis with respect to a R&amp;D Program until the later of ten years after the date of first commercial sale of the first product in such R&amp;D Program in such country, expiration of specified patent rights covering such product in such country or the expiration of specified regulatory exclusivity for the first product in such R&amp;D Program in such country. See Note 4 to the financial statements included elsewhere in this Annual Report for additional information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Asset Purchase and Research Service Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Asset Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we entered into an asset purchase agreement with Vertex for a total of $47.6 million under which Vertex acquired all of our IPR&amp;D asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (&#8220;Vertex Asset Purchase Agreement&#8221;). Additionally, as part of the agreement, Vertex assumed all claims, counterclaims and credits associated with the program, and we gave up all rights to the intellectual property. The transfer of the IPR&amp;D asset to Vertex was completed in November 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Vertex Asset Purchase Agreement also provided for a potential milestone payment payable to us contingent upon achievement of a certain research milestone. In July 2025, this milestone event was determined to have been achieved and, as a result, we received a payment of $12.5 million in August 2025, which was recorded as a gain on sale of the non-financial asset within total operating expenses in our statement of operations and comprehensive loss for the year ended December 31, 2025. Subsequently, there are no additional payments related to this IPR&amp;D asset.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Research Service Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the Vertex purchase agreement, we also entered into a research service agreement with Vertex (&#8220;Vertex Research Service Agreement&#8221;) under which we agreed to perform certain exploratory research activities for Vertex.  We recognized revenue associated with the Vertex Research Service Agreement over the performance period of the research services as the services were provided. The Vertex Research Service Agreement expired in September 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not generated any revenue from product sales and do not expect to do so in the foreseeable future. Our ability to generate product revenue, if ever, will depend on the successful development and eventual commercialization of any product candidates that we identify. If we fail to complete the development of any future product candidates in a timely manner or to obtain regulatory approval for such product candidates, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected. Our revenues to date have been exclusively related to license and research and development (&#8220;R&amp;D&#8221;) services. Our license and research service revenue consists of amounts recognized from the portions of the non-refundable upfront payment and R&amp;D services performed by us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses account for the largest component of our total operating expenses. Research and development expenses consist primarily of direct and unallocated costs incurred for the research and development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses consist of:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Direct costs, including:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical program costs, which include external costs to conduct clinical trials, including costs paid to contract research organizations (&#8220;CROs&#8221;), the production of clinical materials and fees paid to contract manufacturers, costs incurred in connection with clinical laboratory operations, materials and supplies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preclinical and research program costs, which include external research and development costs related to (i) the production of preclinical materials, including fees and milestones paid to contract manufacturers and (ii) agreements with contract development organizations, consultants and other third-party contract organizations to conduct our preclinical studies and other research and development activities on our behalf, costs incurred in connection with laboratory operations, materials and supplies, and other preclinical studies; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unallocated costs, including:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payroll-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">external research and development costs, including contract research and development and professional service fees for consulting and related services;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facility-related and office costs, including lease/rent, building-related expenses, facility-related overhead, and depreciation expense; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#9642;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other costs, including expenses related to our funded, sponsored research activities and technology licenses, laboratory operations, information technology (&#8220;IT&#8221;)-related expenses</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant portion of our research and development costs have been external costs, which we track by stage of development. However, we do not track our unallocated costs on a program specific basis because these costs are deployed across multiple projects and, as such, are not separately classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect that our research and development expenses will increase substantially in absolute dollars for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct new clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, and as we incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing product candidates, many of which are outside of our control, including the uncertainty of:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing and progress of preclinical and clinical development activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our current research and development programs and to establish new ones;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing an appropriate safety profile with IND-enabling studies;&#149;the number of sites and patients included in the clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of sites and patients included in the clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the countries in which the clinical trials are conducted;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to replicate positive results from a completed clinical study in a future clinical study;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per patient trial costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in, and the initiation of, clinical trials, as well as drop out or discontinuation rates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to FDA, EMA, or any other comparable foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or disruptions in review, approval, inspection, or other actions by the FDA or other applicable U.S. or foreign government regulatory authorities that could impact the timing, initiation, conduct, or completion of our clinical trials or marketing applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of trials required for regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and terms of any regulatory approvals from applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing collaborations and strategic relationships, to identify and establish any future collaboration arrangements on favorable terms, if at all, and to realize the intended and potential benefits of such agreements and collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the performance of any current or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the performance of any current or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation and regulatory guidance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations or to those of the third parties with whom we work;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of the product candidates following regulatory approval.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any changes in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our product candidates. For example, if the FDA, EMA or any other comparable foreign regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. We may never obtain regulatory approval for any of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, costs related to maintenance and filing of intellectual property, legal fees related to corporate matters, professional fees paid for accounting, auditing, consulting, tax and investor relations services, insurance costs, general corporate expenses, and IT-related and facility-related costs not otherwise included in research and development expenses. Personnel-related costs include salaries, benefits, and stock-based compensation for our personnel in executive, legal, finance and accounting, human resources, and other administrative functions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will increase substantially in absolute dollars for the foreseeable future as we continue to increase our headcount to support our business growth  and to advance our research and development programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income consists of interest earned on our cash, cash equivalents and marketable securities during the period.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net consists primarily of changes in the fair value of our cash equivalents held in money market funds, loss on disposal of our fixed assets and foreign currency transaction gain or loss.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benefit (Provision) for Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to corporate U. S. federal and state income taxation. Our benefit for income taxes is recorded in accordance with Accounting Standard Codification 740, Accounting for Income Taxes, which provides for deferred taxes using an asset and liability approach. We establish a valuation allowance against all of our net deferred tax assets. We consider all available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings (losses), future taxable income (loss), and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;H.R.1&#8221;) was signed into law, which introduced significant changes to the U.S. federal income tax code. Among other changes, H.R.1 makes permanent key elements of the Tax Cuts and Jobs Act, including restoring 100% bonus depreciation, eliminating the capitalization requirement for domestic research and development expenses, and modifying the business interest expense limitation, which now allows depreciation and amortization to be included in the limitation calculation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our results of operations for the years ended December 31, 2025 and 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.477%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,951</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,075</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,876</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,584</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,337</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,247</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,164</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,561</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,603</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,248</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,898</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,350</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(68,297</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,823</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,526</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,530</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,617</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,913</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(90</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,430</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,527</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,903</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before provision (benefit) for income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,867</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(72,296</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,429</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(498</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(510</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,879</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(71,798</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,919</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenue was generated from research activities performed for Novo in connection with the Novo Collaboration Agreement and Vertex in connection with the Vertex Research Service Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$45.4 million of our total revenue for the year ended December 31, 2025 was generated from research activities performed for Novo in connection with the Novo Collaboration Agreement, of which $26.8 million was recognized from deferred revenue associated with our upfront payment, while the remainder was generated from research activities performed for Vertex in connection with the Vertex service agreement.  All of our revenue for the year ended December 31, 2024 was generated from research activities performed for Vertex in connection with the Vertex service agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the periods indicated by direct and unallocated costs (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.477%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct costs:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PTH1R</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,895</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,719</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,176</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MRGPRX2</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,994</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,866</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,128</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,526</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,222</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,304</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated costs:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll-related expenses, including stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,833</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,924</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,909</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,486</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,287</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,801</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facility-related and office costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,365</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,390</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,975</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,485</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,929</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,444</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,584</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,337</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,247</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense was $97.6 million and $65.3 million for the years ended December 31, 2025 and 2024, respectively. The increase of $32.2 million was primarily due to (i) $22.3 million of higher direct costs attributable to increased spending with our other programs, (ii) $10.1 million of higher direct costs associated with our MRGPRX2 program, including an increase of $6.9 million in external clinical development expenses, (iii) $9.9 million of higher employee-related costs as a result of increased headcount as we grow our business, (iv) $2.0 million of  higher facility-related and office costs as we expanded our office space to accommodate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher occupancy and larger operational activities and (v) $1.2 million of increased direct costs associated with our PTH1R program. This was partially offset by a decrease of (i) $11.8 million in unallocated external research and development costs and (ii) $1.4 million in unallocated other costs. We expect to continue to incur increased research and development expenses as we advance SEP-631, SEP-479, and our other programs in our pipeline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $29.2 million and $16.6 million for the years ended December 31, 2025 and 2024, respectively. The increase of $12.6 million was primarily due to (i) $6.1 million of higher employee-related costs as a result of increased headcount to support our growing operations, (ii) $2.5 million of higher legal fees, (iii) $2.0 million of higher IT operation expenses, and (iv) $2.0 million of higher facility costs, consulting and other expenses, primarily attributable to our operational growth and operating as a public company.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain on Sale of Non-Financial Asset</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset of $12.5 million during the year ended December 31, 2025 was attributable to a milestone payment under the Vertex Asset Purchase Agreement. No gain on sale of non-financial asset was recorded during the year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income was $19.5 million and $8.6 million for the years ended December 31, 2025 and 2024, respectively. The increase in interest income was due to higher average balances of invested cash in cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provision (Benefit) for Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our income tax was not material for the year ended December 31, 2025. For the year ended  December 31, 2024, we recorded a benefit for income taxes of $0.5 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net loss was $48.9 million for the year ended December 31, 2025 compared to $71.8 million of net loss for the year ended December 31, 2024. As of December 31, 2025, we had an accumulated deficit of $167.3 million. We have incurred net losses in each year since inception, except for the year ended December 31, 2023. We expect to continue to incur net losses for the foreseeable future. Our net losses may fluctuate significantly from period to period, depending on the timing and expenditures of our operational activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We historically financed our operations primarily through the issuances of convertible promissory notes and convertible preferred stock, an IPO, and strategic collaborations with other companies. In October 2024, we completed our IPO, pursuant to which we issued and sold an aggregate of 18.4 million shares of common stock (inclusive of 2.4 million shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares). The aggregate net proceeds received by us from the IPO was $302.8 million, after deducting underwriting discounts and commissions, and other offering costs payable by us of $28.4 million. In July 2025, upon the effectiveness of the Novo Collaboration Agreement, we received a one-time, non-refundable upfront payment of $195.0 million. In August 2025, we received a $12.5 million milestone payment from the Vertex Asset Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had $548.7 million in cash, cash equivalents, and marketable securities, which we believe will be sufficient to fund our operations and capital expenditure requirements at least into 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any off-balance sheet arrangements other than our indemnification agreements as described in Note 7 to our audited financial statements included elsewhere in this Annual Report.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,189</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,470</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(229,352</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(160,598</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,689</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,781</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(117,474</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149,713</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by (Used in) Operating Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by operating activities was $110.2 million for the years ended December 31, 2025. The net cash provided by operating activities for the year ended December 31, 2025 was due to $162.8 million of net change in operating assets and liabilities, primarily resulting from the upfront payment from the Novo Collaboration Agreement and $8.8 million of non-cash charges for depreciation and amortization, stock-based compensation, non-cash operating lease expense, accretion of premiums (discounts) on marketable securities, and other adjustments, which was partially offset by net loss of $48.9 million and gain on sale of non-financial asset of $12.5 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $67.5 million for the years ended December 31, 2024. Net cash used in operating activities for the year ended December 31, 2024 was due to our net loss of $71.8 million, which was partially offset by (i) $4.1 million of non-cash charges for depreciation and amortization, stock-based compensation, non-cash operating lease expense, deferred income tax and accretion of premiums (discounts) on marketable securities and other adjustments, and (ii) $0.2 million of net change in operating assets and liabilities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities of $229.4 million for the year ended December 31, 2025 was due to $451.0 million of purchases of marketable securities and $0.5 million of purchases of property and equipment, partially offset by the maturity of $209.6 million of marketable securities and the receipt of the $12.5 million milestone payment related to the Vertex Asset Purchase Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities of $160.6 million for the year ended December 31, 2024 was due to $213.4 million of purchases of marketable securities and $2.1 million of purchases of property and equipment, partially offset by the receipt of the remaining $22.6 million from the sale of non-financial asset in 2023 and the maturity of $32.3 million of marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by Financing Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $1.7 million for the year ended December 31, 2025 was primarily attributable to the proceeds from the exercise of stock options and employee stock purchase plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities was $377.8 million for the year ended December 31, 2024. Net cash provided by financing activities for the year ended December 31, 2024 was primarily due to $302.8 million of net proceeds from the issuance of our common stock in our IPO and $74.9 million of net proceeds from the sale and issuance of our Series B Convertible Preferred Stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary use of cash, cash equivalents, and marketable securities is to fund our operations, primarily research and development expenditures. Cash, cash equivalents, and marketable securities used for operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop, obtain regulatory and marketing approvals of our product candidates for the expected indications and patient populations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing collaborations or strategic relationships and the extent to which we identify and enter into future collaborations or other arrangements with additional third parties in order to further develop our product candidates, as well as our ability to realize the intended and potential benefits of such agreements and collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish additional collaborations on favorable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. However, the trading prices for our common stock and for other biopharmaceutical companies have been highly volatile. As a result, we may face difficulties raising capital through sales of our common stock, and such sales may be on unfavorable terms. Similarly, adverse macroeconomic conditions and market volatility resulting from global and national economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships, changes in or the disruptions of U.S. governmental agencies, whether from a continued U.S. federal government shutdown or reduced resources, global health crises, or other factors could materially and adversely affect our ability to consummate an equity or debt financing on favorable terms or at all. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect existing stockholders&#8217; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We historically financed our operations primarily through the issuances of convertible promissory notes and convertible preferred stock, through an IPO, and strategic collaborations with other companies. In October 2024, we completed our IPO, which resulted in net proceeds of $302.8 million, net of total offering costs of $28.4 million. In July 2025, upon the effectiveness of the Novo Collaboration Agreement, we received a one-time, non-refundable upfront payment of $195.0 million. In August 2025, we received a $12.5 million milestone payment from the Vertex Asset Purchase Agreement. Since our inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business and scientific planning, conducting discovery and research and development activities, establishing, maintaining, and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and component materials, engaging in collaboration activities, and providing general and administrative support for these operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for revenue in accordance with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Under ASC 606, we recognize revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following four steps: (i) confirm we have a contract with a customer that creates enforceable rights and obligations; (ii) identify promised products or services to be transferred to a customer; (iii) determine the transaction price, or the amount it expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable and allocated to the performance obligations; and (iv) recognize revenue when or as performance obligations are satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. For arrangements that include multiple performance obligations, we allocate the transaction price to the identified performance obligations based on the standalone selling price of each distinct performance obligation. In instances where standalone selling price is not directly observable, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract using a cost plus margin approach, which is an estimation method used when standalone selling price is not directly observable. Key assumptions used within this estimation method may include full-time equivalent personnel effort and estimated external costs associated with the performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided our performance, (ii) our performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date. If we do not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues are primarily derived through our license and research and development service arrangements. Payments to us under these arrangements typically include one or more of the following: one-time, non-refundable upfront payment, research and development service funding, milestone and other contingent payments to us for the achievement of defined collaboration objectives and certain collaboration, research and development and commercial milestones, as well as royalties based on net sales of approved drugs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration received prior to revenue recognition is recorded as deferred revenue in the balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current. Contract assets represent research and development services which have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performed but have not yet been billed and are reduced when they are subsequently billed. Such contract assets include accounts receivable when our right to consideration is unconditional. For our current contracts, we recognize revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and, if over time, revenue recognized is based on the use of an input method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of us, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of our collaborative arrangements include one or more of the following</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the license to our IP is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For a license that is determined not to be distinct, it is combined with other promises and we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. We generally recognize revenue using the cost incurred to date as compared to the total estimated cost of each performance obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - We evaluate the customer options for material rights or options to acquire additional goods or services at no incremental consideration or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised and performance obligations are satisfied. If an option is not exercised before the option right expires, we will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under our collaboration agreement include research and development services to be performed by us for or on behalf of the customer. Payments or reimbursements resulting from our research and development efforts are recognized as the services are performed and presented on a gross basis because we are the principal for such efforts. Reimbursements are recognized in revenue in our statements of operations and comprehensive loss. Expenses incurred as part of our efforts to perform the research and development services are recognized in research and development expense in our statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under our collaboration agreement include manufacturing services to be performed by us. Payments or reimbursements resulting from our manufacturing services are recognized as the services are performed and presented on a gross basis because we are the principal for such efforts. Reimbursements are recognized in revenue in our statements of operations and comprehensive loss. Expenses incurred to perform the manufacturing services are recognized in research and development expense in our statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- At the inception of each arrangement that includes development or regulatory milestone payments, we evaluate the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore, consideration included in the transaction price is constrained. We applied the variable consideration allocation exception under ASC 606 whereby variable milestone payments are not estimated and included in the transaction price at inception. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial milestone payments and royalties </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied)</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation is measured based on the estimated grant date fair value of the award and is recognized as expense on a straight-line basis over the requisite service period (usually the vesting period). Forfeitures are accounted for in the period in which they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of the options granted and Employee Stock Purchase Plan (&#8220;ESPP&#8221;) shares, we use the Black-Scholes option pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The expected term represents the period that our stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). We have very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. We will continue to apply this process until a sufficient amount of historical information regarding employee exercise patterns and post-vesting employment termination behavior becomes available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; Due to our limited operating history and lack of company-specific historical volatility as a public company due to our recent IPO in October 2024, or implied volatility as a private company, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies and clinical trials, contract manufacturing for the production of clinical and preclinical materials, information technology-related costs, allocated overhead costs including facility-related expenses, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on our behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into agreements with outsourced contract manufacturing and development and clinical research vendors. We estimate accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. We periodically confirm the accuracy of its estimates with internal management personnel and external service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to our audited financial statements included elsewhere in this Annual Report for more information.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We qualify as &#8220;emerging growth company&#8221; under the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;), which permits us to take advantage of an extended transition period to comply with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">companies that comply with new or revised accounting pronouncements as of public company effective dates. We could be an emerging growth company until the earliest to occur: (i) the last day of the fiscal year in which we have more than $1.235 billion in annual gross revenue; (ii) the date we qualify as a &#8220;large accelerated filers&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), with at least $700.0 million of equity securities held by non-affiliates; (iii) the issuance, in any three-year period, by us of more than $1.0 billion in non-convertible debt securities; or (iv) the last day of the fiscal year ending after the fifth anniversary of our IPO. Even after we no longer qualify as an emerging growth company, we may continue to qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Quantitative and Qualitative Disclosures About Market Risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inancial Statements and Supplementary Data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is presented at the end of this Annual Report beginning on page F-1. An index of those financial statements is found in Part IV, Item 15, Exhibits, Financial Statement Schedules, of this Annual Report.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Chang</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Con</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trols and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. As required by Rule 13a-15(b) or Rule 15d-15(b) promulgated by the SEC under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report at the reasonable assurance level.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive officer and principal financial officer, or persons performing similar functions, and effected by a company&#8217;s board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles ("GAAP") and includes those policies and procedures that:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that the Company's receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision of and with the participation of our principal executive officer and principal financial officer,  management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#8212;Integrated Framework (2013 framework). Based on this evaluation, management has concluded that the Company maintained effective internal control over financial reporting as of December 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Limitations on Effectiveness of Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, the effectiveness of any internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Information.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b6aaa43-d18d-43b7-a9ab-515fd9a00197" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6ca7103-79c4-4a0d-b893-8ab1ed9285d9" contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 20, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9414c45b-5fb1-4044-bbb0-d1569fcca814" contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liz Bhatt</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, M.S., M.B.A., our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0be01cad-2ce6-4726-886d-de4af0b04d26" contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President and Chief Operating Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d819fc81-922f-41fa-9f2f-d2e91f2e193b" contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0958cc2e-79c6-432c-a696-09e45d2ff5f6" contextRef="C_e5529578-cb7f-423b-ae3c-3d4cbfedbb24" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">41,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Ms. Bhatt), which plan expires at the earlier of January 15, 2027, and the date upon which all authorized transactions thereunder are completed. Ms. Bhatt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77334444-0a0b-4da4-aa8d-a1b5f4332db1" contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e6cf68d-6d7c-4927-b838-be61e9265ca5" contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Samira Shaikhly</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ea7dd9a-c213-4a94-9d55-e78482520c25" contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief People Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1b9fdb6-22d3-4bc6-bfa2-5b5d2adcd519" contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6705a7b4-96a1-4b01-beed-597cc4cc7676" contextRef="C_76c0e442-ab86-41b5-ab70-7fb7e89c9db2" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">109,206</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Ms. Shaikhly), which plan expires at the earlier of October 30, 2026, and the date upon which all authorized transactions thereunder are completed.  Ms. Shaikhly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2025, no other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3aa8bd89-dcbe-495e-a09f-fd03a16a1706" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a8596a05-6da5-4a4d-bd37-2abb564f9e14" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0874ef4-216c-4d37-a089-94e358695568" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="sepn:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_bc93741e-e7e0-4a68-b416-95c4f425fdf5" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="sepn:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_baa97e75-f638-4cca-a6c5-59059342872a" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_bddcdd08-7f4e-491e-bfa3-513e5974df62" contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement&#8221; as each term is defined in Item 408 of Regulation S-K.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T III</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Dir</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ectors, Executive Officers and Corporate Governance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in our definitive proxy statement relating to our 2026 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), which we will file with the Securities and Exchange Commission (the &#8220;SEC&#8221;) not later than 120 days after the end of our fiscal year ended December 31, 2025 and is incorporated in this Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) by reference.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of business conduct and ethics (the &#8220;Ethics Code&#8221;), that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer, or persons performing similar functions. The full text of the Ethics Code is available on our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.septerna.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If we ever were to amend or waive any provision of our Ethics Code that applies to the Company&#8217;s principal executive officer, principal financial officer, principal accounting officer, or any person performing similar functions, we intend to satisfy our disclosure obligations, if any, with respect to any such waiver or amendment by posting such information on our website set forth above rather than by filing a Current Report on Form 8-K. Information contained in, or that can be accessed through, our website is not incorporated by reference herein, and you should not consider information on our website to be part of this Annual Report.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Exec</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utive Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item (excluding information under the subheading &#8220;Pay Versus Performance&#8221;) will be included in the Proxy Statement and is incorporated in this Annual Report by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Securit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated in this Annual Report by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Cert</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ain Relationships and Related Transactions, and Director Independence.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated in this Annual Report by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_14_principal_accounting_fees_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Accounting Fees and Services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be included in the Proxy Statement and is incorporated in this Annual Report by reference.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T IV</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits and Financial </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement Schedules.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of Septerna, Inc. and the report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm, are included in a separate section of this Annual Report on Form 10-K beginning on page F-1. All financial statement schedules are omitted because the information is inapplicable or the information required is presented in our financial statements and notes thereto.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The following is a list of exhibits filed as part of this Annual Report on Form 10-K:</span></div></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8.982%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:41.588%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:6.741%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:12.362%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:6.741%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:17.984%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524245578/d851611dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-42382</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 28, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524245578/d851611dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-42382</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 28, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524231178/d762905dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, by and among the Registrant and certain of its stockholders, dated as of June 28, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 24, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Common Stock Certificate</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 24, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sepn-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524231178/d762905dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2024 Stock Option and Incentive Plan and forms of award agreements thereunder</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2024 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non-Employee Director Indemnification Agreement, by and between the Registrant and each of its non-employee directors</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Employee Director / Officer Indemnification Agreement, by and between the Registrant and each of its executive officers</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Jeffrey Finer, dated as of September 9, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Ran Xiao, dated as of January 18, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Liz Bhatt, dated as of May 20, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Jae B. Kim, dated as of September 4, 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Samira Shaikhly, dated as of December 22, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Uwe Klein, dated as of February 17, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12#&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Daniel Long, dated as of September 27, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-42382</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 10, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Senior Executive Cash Incentive Bonus Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312525001834/d753888dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter, by and between the Company and Gil M. Labrucherie, dated as of December 6, 2024.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-42382</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 6, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Severance Plan of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8.982%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:41.588%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:6.741%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:12.362%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:6.741%;box-sizing:content-box;"/>
     <td style="width:1.12%;box-sizing:content-box;"/>
     <td style="width:17.984%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524231178/d762905dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement, by and between the Registrant and Britannia Pointe Grant Limited Partnership, dated as of April 20, 2021, as amended by the First Amendment to Lease Agreement dated as of September 14, 2022, Second Amendment to Lease Agreement dated as of September 23, 2022, Third Amendment to Lease Agreement dated as of December 22, 2022, and Fourth Amendment to Lease Agreement dated as of December 12, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524231178/d762905dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Service Agreement, by and between the Registrant and Third Rock Ventures, LLC, dated as of August 25, 2021</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19**</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000095017025106551/sepn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Novo Collaboration Agreement, between the Registrant and Novo Nordisk A/S, dated as of May 13, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-42382</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 11, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sepn-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, by and between the Registrant and Mark Wilson, dated as of January 6, 2026</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000095017025045745/sepn-ex19_1.htm"><span><ix:nonNumeric id="F_7946e69d-df28-4622-bc7b-199a5001c0d5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-42382</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 27, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524231178/d762905dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sepn-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sepn-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sepn-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sepn-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524239994/d762905dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Compensation Recovery Policy of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-282469</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 21, 2024</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page formatted as Inline XBRL and contained in Exhibit 101</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC because the Registrant has determined that information is both not material and is the type that the registrant treats as private or confidential.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Annual Report and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 16. Form 10-K Summary</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIG</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:48%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Septerna, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 9, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey Finer, M.D., Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Finer, M.D., Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY AND SIGNATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Jeffrey Finer and Gil M. Labrucherie, as such person&#8217;s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following person in the capacities and on the date indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:26.92%;box-sizing:content-box;"/>
     <td style="width:2.88%;box-sizing:content-box;"/>
     <td style="width:40.34%;box-sizing:content-box;"/>
     <td style="width:1.42%;box-sizing:content-box;"/>
     <td style="width:28.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey Finer, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Finer, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(principal executive officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gil M. Labrucherie, CFA, J.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gil M. Labrucherie, CFA, J.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(principal financial officer and principal accounting officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey Tong, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman and Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Tong, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Abraham Bassan, M.S.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Abraham Bassan, M.S.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Bernard Coulie, M.D., Ph.D., M.B.A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bernard Coulie, M.D., Ph.D., M.B.A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alan Ezekowitz, M.D., D.Phil.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alan Ezekowitz, M.D., D.Phil.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Shalini Sharp, M.B.A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shalini Sharp, M.B.A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jake Simson, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jake Simson, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Keith Gottesdiener, M.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Keith Gottesdiener, M.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPTERNA, INC.</span></h1><h1 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index to Financial Statements</span></h1><h1 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements as of and for the Years Ended December 2025 and 2024</span></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span>&#160;</h1>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:94.061%;box-sizing:content-box;"/>
     <td style="width:1.01%;box-sizing:content-box;"/>
     <td style="width:4.929%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PCAOB ID:</span><span><ix:nonNumeric id="F_660bfb59-64ce-4d3d-9250-4527b2f8394b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Statements</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_comprehens_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
   </table><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span>&#160;</h1></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Regi</span><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Septerna, Inc.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f09b134c-3d81-4200-b54e-986498a72370" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Septerna, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0f66161-0801-4bfa-a1d6-5716b9b7b915" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b0e0d24-d1ef-4c78-a6bf-7e2c72c0306f" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPTERNA, INC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except for share and per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acf4930c-ca83-4eca-9553-deddc08d7447" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c33a08d-7ac7-4557-9143-52ff84da6bc6" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_803383c6-132e-4d87-9d1e-2a29b13e409e" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,367</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba95a5e9-e45f-4c21-8c09-99a739d8d292" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_020b32e2-bdc3-483e-b100-4c6063d29320" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,356</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43c3154f-b0f5-4a15-a438-996fdc03fe92" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_970cc211-3caf-4987-9d35-3e1270cf0f35" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,519</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68e5f615-352c-441d-a280-0ed58fb3ad0f" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,730</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fa3ad85-2174-468d-9d71-ce97a60c3791" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410,964</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d581683-3261-48db-bf21-3637b88221cf" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">356,824</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10b0b6c9-f777-4717-ab2e-eb7ab9ddc795" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,569</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73c85c6d-ca82-4087-8014-5b72f37e5098" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,866</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b7e8a2b-c5d6-4f70-9caf-56a8644e656a" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,434</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b115ceb9-b47b-4a71-9f3e-7ac8bbf66617" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,090</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6475836-2ca9-4bf1-aad3-b5e018884b04" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,499</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa8c6e7f-5f84-446d-9e7b-1b54aca36463" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,602</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44b41123-67c7-47db-8a3d-0f35136618ee" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93bfb6d4-0811-40d3-822d-b1fb207866d2" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed568a99-ab9c-4438-8709-4c403abccf0d" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1b27dd2-02cf-4f2d-9258-93a2dbee11e3" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94d7f6f9-612d-48a3-b159-52102bad45b7" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6b1de0-69b6-4a54-bf7c-54bbf29ba067" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">456,554</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders' Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a09f0e0-b6ca-4763-b977-4638edc5494c" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,283</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a47b5f28-93ef-43f3-92d5-3c8354b4e83f" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,200</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0003953d-4cc9-48dd-adb9-c2a736d74cf4" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,167</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f902761-7206-4ece-8bf7-4aff6e505b84" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue, current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_741c1dfd-7aad-4097-9f8d-0c48fc8506e9" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a56bd882-8043-43cf-a435-1beb427a365c" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93861c93-92eb-42d4-a05e-9c3cd79e343f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,212</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9eaba3a-b43e-4ca9-904c-ffc00bfc79f0" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c3cd91-f131-4ad2-9ce9-c2611a14404b" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,931</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ad7a51-7136-4775-83ed-384b55b1d7e4" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,849</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue, non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99f1eff6-b36e-4d2b-a860-0563ddae30c4" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,917</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f8b2dee-01d2-4bd3-975d-69154b49b7b5" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4f15690-b52b-49a9-9d23-4f72cbd5b148" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47769dbf-fa49-4a58-a3a4-5b05d70fad8c" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,625</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e59bf442-9b10-4e44-804f-b47673321989" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfbd177b-a215-4a0f-b506-4b5e6aab3fc3" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54fb2b0b-8aaf-48b6-8e2d-b3b7f329ac80" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,261</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b405203-fe41-4cfd-a40a-22b8f3b16479" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,507</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b8ad14a0-c1e3-48c5-855b-31addb820eb6;"><span style="-sec-ix-hidden:F_b4a2dcb4-49e4-4ea1-b88c-386a51c040ce;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Note 7)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e847c6c-4fc9-458a-8f45-12139e20dcba" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2e56a17d-5c29-4bf9-8c27-d2944911b81e" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a9bbb8c-ae80-41b0-b7e2-d2d2796fb8e7" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a2502d80-7943-4c50-8e8f-412dda0d5df1" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of December 31, <br/>&#160;&#160;&#160;2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8629a021-7243-4a0f-aef9-0e87416da2a5" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c483f94a-dde5-46b7-8cd6-d92e8ab41274" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6993f7c5-aa47-4e91-a559-5fcf200b944e" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8652078a-736b-47f3-8995-239194bf6c7c" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of December 31,  <br/>&#160;&#160;&#160;2025 and December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1edf648f-796a-4d0b-aa2e-b021bcd9a7ee;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1db7472e-771e-4c85-b753-944c6e60f5ad;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76af0a0e-66da-4521-89a5-9f14e18aa816" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3a2fdb13-6c04-4a28-98f7-41b3505014d3" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1771f1d8-c878-4105-bc6d-1686dd281d48" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_02304057-5e80-4dcd-a943-b5cf1c15563b" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares <br/>&#160;&#160;&#160;authorized at December 31, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_735762cc-2505-4997-a0a5-a350b5c92cf6" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_123235ac-6527-475b-876f-3ae07e1abff4" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">44,806,272</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57a4f1bb-d55c-4d97-ae21-cf440607a4bf" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_17cb09c7-1559-47bb-ac8f-5aca38940e9d" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">44,422,505</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2025 and December 31, <br/>&#160;&#160;&#160;2024 respectively; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baedc257-8ffd-48cd-9c36-401706a0c03b" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:RestrictedStockOptionsSubjectToRepurchase" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">131,224</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5654125-5499-4d59-98f5-c2db44db70be" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:RestrictedStockOptionsSubjectToRepurchase" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">576,829</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares subject to repurchase as of <br/>&#160;&#160;&#160;December 31, 2025 and December 31, 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c889f7f-0a2d-4383-b0b8-97fe43683739" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6a8fee0-b52a-41ab-ad6e-9db04ff47e31" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37fc9ef8-f656-497d-82d3-7efd09d2e665" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">548,517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22c8996a-c057-4aa5-8d43-24371b8e4a82" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">538,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d8a215e-c9ac-48a1-a147-0833fe6085b6" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1dbe982-0055-48b9-8c71-518458e0098f" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6a730cf-3943-42c4-9b38-84a9f7dfc6f5" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00c0cb93-96d9-40a9-93e1-af62582a3c73" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a739cdce-2cfa-4af3-bce2-6e8d6815253f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">381,926</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320e6421-5cc4-4965-b5c7-00df6e43c0d3" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">420,047</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1401aa07-7540-469e-9523-833550252cc1" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e3e758-e7b7-4e53-9223-93a48d25562b" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">456,554</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPTERNA, INC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_comprehens_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Operations an</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except for share and per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:70.434%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.942%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.942%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30789f73-4870-4e8c-a5ec-32eb8b630ca8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92583c8d-040d-47c1-9d9d-ec6e8732baa1" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,075</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16621812-e1a4-4b98-aaa3-da40b05aceb4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,584</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada3a216-1f5e-4489-8273-2047dd78ec67" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,337</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3e8ef15-85d2-4dde-92c1-00e7df543122" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,164</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22bb0fcd-1b90-40da-b751-04b01b55100e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,561</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8b50311-dab3-497c-a00d-ec284f7285ae" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e352f7c-744a-40ad-bdae-5cd9ca20af61" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f85bca6-cda6-4cd2-b28a-37b573ca59dc" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,248</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c6d2c16-a9b8-444c-b15a-0b0c179efee5" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,898</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc4cbc55-efa3-47b8-863f-54e8877f3d69" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,297</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fafe3ae-2b35-4072-accb-17642d78ed21" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,823</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b827d23c-1560-4d48-a0c2-fa0b8363a244" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,530</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27561eca-73dd-40f6-a08c-936d6dc12cf1" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9a71ff3-51da-49c5-b67a-5cab83e6c1b0" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c29cb9a-79fc-474d-b1e7-1d37a121ccd2" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de8df4e2-fa67-4180-8b4d-59db7d7f97f8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,430</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390fd8f9-82ab-4568-9777-987bd1a790b9" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,527</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before provision (benefit) for income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba35d45b-dbc1-446f-88ad-b5a205315855" contextRef="C_6336c77b-4ec0-4b5a-bb48-f2f824e6b90e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fa87c4f-d90e-4876-aa42-d6417dc3b50f" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72,296</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f098a3-c274-4d15-a38e-67bbf813c5d5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d7be666-ee9f-4a2e-904c-9aa06a66bb10" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">498</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9389cdca-8c4c-4854-851b-1bbdac393278" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9796c77a-2ec6-4c90-8edc-be86ac89d654" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a960ca-292b-4634-9ad9-874290efd535" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9f820c81-7b9d-43f4-b896-4c21b77312c4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.10</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2d0f1d6-4baa-4081-ac71-519a46610a60" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_66f67dbb-fa03-4e76-b517-f37311a0a0d7" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">7.26</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4ead10c-abac-4a74-8172-c085009defd0" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a1adea1b-f354-4e4d-9b51-528964dc3f39" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">44,258,338</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697190e6-7e80-4358-9040-6167d0128b20" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_823fe17c-8f0a-42df-b5eb-f10e7f82d83f" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,891,126</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49be5273-1aff-473f-a094-fa0dc96b2dca" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdc702c1-f7f8-465f-b2e5-b1e27ecc1015" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized gain on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a85641-24e1-4c05-b894-6a4a000a4d2f" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c6e4bcd-e938-4c3b-a706-1ffce953e367" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c69ba1ba-1425-43e6-ae0b-3a6c12918f45" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1a9c46c-9600-4bf7-80f0-7e25aaaaa2ee" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dc07d8f-5d9d-46e2-9682-65af4a3cd06e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,318</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24abbbf3-a407-493d-9329-51b266d8c40a" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,742</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPTERNA, INC.</span></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Convertible Prefer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">red Stock and Stockholders&#8217; Equity</span></h1><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span>&#160;</h1>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:16.957%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.759%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.599%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.759%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.039%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.759%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.919%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.439%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.459%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.439%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.879%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="41" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands, except for share data)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Series A</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Series B</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34afe894-fed7-4e50-9bf5-d42a078b8258" contextRef="C_d4bd1786-5f2f-4271-a5d8-e93f78bac79d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba509a06-840f-452c-a438-05f4a592a573" contextRef="C_d4bd1786-5f2f-4271-a5d8-e93f78bac79d" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,694</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d08cc37-035d-433c-8363-575bbbf071b3" contextRef="C_a706c6c6-3f56-4dc2-a361-8d8d19beee7f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,828,720</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60803c4b-0948-41d7-a7ff-9ca3522aeb73" contextRef="C_a706c6c6-3f56-4dc2-a361-8d8d19beee7f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,521</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02f3e3b9-983c-4741-861c-0811cbdc70e0" contextRef="C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,168,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82412867-2ed1-4c61-9edc-a37fdba56162" contextRef="C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a468f743-2b10-4394-ae24-167706eb2005" contextRef="C_718c5e70-92f5-4610-80c7-d02725f7db49" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,199</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17eb239c-bb88-4b5d-9f12-7c3f7c5577a6" contextRef="C_e20810db-824c-4b6e-aef6-6aad0885a137" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,576</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c69a19b-941d-4505-ab2d-c086499a7260" contextRef="C_e5502035-9c62-4bfa-b75f-04b8934fb13b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">Issuance of Series B Convertible<br/>&#160;&#160;&#160;Preferred Stock, net of issuance<br/>&#160;&#160;&#160;costs of $</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4dcc26f-42e4-493c-94d9-48ba362d5ebb" contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f" name="sepn:StockIssuanceCostsOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe358f37-df2d-444d-b22d-076d8fb30dc2" contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f" name="sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,828,732</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be3da2b-3e92-49db-82d8-6970a4cf1d72" contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,942</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in <br/>&#160;&#160;&#160;connection with initial public<br/>&#160;&#160;&#160;offering, net of issuance costs <br/>&#160;&#160;&#160;of $</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a191bb0b-1d16-468a-8586-cbc031d8077e" contextRef="C_bec2c5bd-26fb-45e2-b7fd-c7e78e0c918b" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,431</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c526744-e7fe-406a-ab92-8673b7184139" contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,400,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a816e1c2-18e4-48eb-a0ff-131ad5059374" contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15dcfc19-f89e-430d-a280-3c5a21d39854" contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,749</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd022d9f-1b47-4c10-9acc-3fc50d368692" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,767</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of convertible<br/>&#160;&#160;&#160;preferred stock to common<br/>&#160;&#160;&#160;stock upon initial public offering</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb456c17-2242-40b6-8ed2-e5741c05b9a3" contextRef="C_d5287ebc-ed11-4be9-a9a2-49a7065ae6fa" name="sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_373a4261-d1da-4f6a-9c49-7f320581c57e" contextRef="C_d5287ebc-ed11-4be9-a9a2-49a7065ae6fa" name="sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,694</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6282d11e-23a0-441b-9dca-17ee13b4248d" contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f" name="sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">121,657,452</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5db28503-09ae-4ddb-a6d7-3cda96b0b877" contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f" name="sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149,463</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a59132-c704-479c-a7b3-c0fdc84cfb6c" contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,839,774</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8fbaeb5-2715-46b6-9e4b-3015c1e3e4fe" contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6fba5e3-d309-48bf-8c8f-e66250a88765" contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ada6e7f-f82a-429d-a4b6-ac7f3089cfc6" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,157</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock <br/>&#160;&#160;&#160;upon exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4164e9e-e534-411e-bca1-0e03eb702e3c" contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,896</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deccab53-5119-44e7-8c37-cbcb59225dba" contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b01373dd-1a95-4a69-8043-d71150bd2d1a" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted common <br/>&#160;&#160;&#160;stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5252e96-7f7a-4a65-a5de-f100bde373b3" contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6" name="sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_184ec5ac-a063-4c52-9356-b91292b93e8b" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchases of unvested restricted<br/>&#160;&#160;&#160;common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01a11ae5-e9c1-49e8-901d-c260c82b8c60" contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,299</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41d27d2e-4f9c-4a9e-8cff-5121aea8b38c" contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854ad16f-1b38-4bbc-8f51-c0bd54f29a64" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized gain on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5443f7ad-b997-4902-9d63-8d7c1a02e818" contextRef="C_3cfa7cb5-0ba6-432f-9236-d31d63d2d6b4" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33915922-2f95-4dd7-b007-adfe6c6cbd09" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5dba921-bf71-4aed-b013-24e86d340e52" contextRef="C_04565b03-4afb-406b-9060-3d79c752b374" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ce23ae-3d59-46f9-8445-b6c37f964fb4" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ba27b92-da0c-4734-95d9-25985cf8e307" contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">44,422,505</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de992ec3-27eb-44a0-85ae-94e6ce4568cf" contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f0eb2a9-db44-45e1-b1ef-a6927d09b847" contextRef="C_909026b5-982c-4acc-89af-ef9bf4949a1b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">538,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3584f71-d14e-490e-a9fd-bc25eca600a5" contextRef="C_451917b5-3692-415a-a8fc-e2773e3c5ae4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a84c8abd-201e-40a5-a52a-36c205f585c8" contextRef="C_4eecc548-826c-47a9-80f2-d64a0e8b8074" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7201fd8d-0a67-4614-90e6-500cd41399bc" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">420,047</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock <br/>&#160;&#160;&#160;upon exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_553b952d-aad7-43ec-8020-486c8041b922" contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">268,188</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6056667-97ab-4f05-89fa-831ba0f7201c" contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e77ad29-8dd7-4e73-a26c-057eed7aba73" contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">981</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_148da0e0-35bc-48e5-ac4d-0f7fb8d8d8ac" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c9e8322-86fa-4faf-9362-2fbc30b701a9" contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">118,191</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12b9e3ba-a195-48fc-b089-19991e1eab8e" contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03ea6125-f599-455e-bfde-388e0d37ecb5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted common <br/>&#160;&#160;&#160;stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd51cc63-b14d-4f2b-91da-77634a329fc6" contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4" name="sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96291cdc-4a79-46e0-a80c-231cbac6ebc9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchases of unvested restricted<br/>&#160;&#160;&#160;common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71035690-5732-45fc-b162-62d0528ea670" contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,612</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a91e74-3013-4160-95f9-86abac150f2b" contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d10b529-bfbf-4fdb-bde9-c833a6841426" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68e5fe4d-4bcc-4c82-95a4-0163b30e5cd7" contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,476</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dba09ea2-6af9-4e52-826c-99743b7a1da3" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,476</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized gain on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fd60ca5-2775-484a-a2f1-34e319d5138a" contextRef="C_155d82b1-0c77-4ae4-bb15-deffd6d81ad9" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e93dd72-4a9e-4250-9f45-18437126ca78" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.747%;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcab7922-280d-4b9d-8671-aadf9d0cf336" contextRef="C_8a9deb64-57ac-4f0b-acec-1f6759eaac45" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_657c3999-c36c-41a3-9b6f-ff494d65b1ec" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eb40e8e-3797-4549-b5cd-84900068ad92" contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,806,272</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd7055ca-cd16-42ea-a8c4-86b67a8e50ec" contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae267966-6c6e-4a4e-aa4b-43c43534742c" contextRef="C_124207ea-9553-4036-b32d-b292d0dd4f7d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">548,517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7171a0cf-d504-4da9-b829-f9673883392e" contextRef="C_975ebf25-328e-4bac-b245-59af615c9971" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9878c414-faed-432d-8a83-0188b517e649" contextRef="C_4856f235-0b67-45f9-87be-48a2c2e0e5a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:6pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e85172-e387-4553-81af-84e04a246747" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">381,926</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span>&#160;</h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPTERNA, INC.</span></h1><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.12%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42d5dc6c-8dbc-4c99-91a6-84147298c0e8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf24dfb-325c-4ba9-9289-d749a4e99add" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05eefdbc-5c5e-4551-95c8-01b0da2ba342" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,604</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4880d0ca-88e8-4bc9-8542-737ba83626a3" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,401</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_963e61a5-e778-4d01-9308-93f01348f3d7" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:GainOnSaleOfNonFinancialAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d8e8910-c7e7-45ea-8466-b44289800052" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:GainOnSaleOfNonFinancialAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b33e889-9759-406b-a881-a2e88c4d2cf9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c02735e-f834-43ca-834a-7bc15ec673b4" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,383</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15b2ea4a-e855-4012-b243-f81c3411dd55" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,476</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f00bc78-8390-4880-801b-551efead9257" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discounts, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_defa2793-aba5-4f43-b5ce-bcd5ff275372" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,448</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38af88fe-0825-4552-9e71-c29d44eb4086" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,410</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_492a6149-3495-4042-9eaf-c0ba51a5c0fa" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6437abb5-95b3-4fa9-8f06-a803774503f5" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b966fd9e-6d30-40c9-811e-0f0bc7a8eb2c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3b16ece-5759-42f7-9465-ec458b1ff7a5" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c0721dd-d1f7-4742-b75e-653868ab1a7e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85cf5d6a-3765-403b-a45e-4b0ce1ba23e1" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,297</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df322d3f-49a6-4570-957a-d31530bbb4e5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,185</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4d47af5-c30e-400b-8c7e-6aabb6db75d3" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a925f57-3713-4e3b-bc78-56f081d86e34" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">554</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b29a886-2468-455f-9ee8-f5eb63ed1ffc" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e21606d-b831-4f96-965d-1dfbb5f86b26" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,603</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6caf7157-8813-4c4c-a662-1ab278e59310" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fc072e-75bd-4772-8b7d-f640432f81cd" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6168eded-dfdd-48fc-857b-937748714007" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,564</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2dd59cc-92c0-43d7-83b1-1d345cd6faeb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c0a26ef-97bd-46de-a0b5-63cf3da39299" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating leases, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d93a574-42d3-4cf1-8e4a-b0125d32705e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3875423-015d-4482-a37f-08bc8a5fca2b" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62c2693e-bf20-4ff7-ab38-b8c8f696cd08" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,189</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37d7f642-e011-4ddf-afa2-5acdeca8a05f" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_155abb43-1e3e-43ec-b03b-d7924aa9880b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">518</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d5a4c50-2f7f-4c73-8d6f-e7be35fc864d" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,103</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of non-financial asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ba28f75-599a-492e-a13a-7dda28430690" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:ProceedsFromSaleOfNonFinancialAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33bbd77a-4cf8-4781-8cf1-2ac8bc318d95" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:ProceedsFromSaleOfNonFinancialAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,625</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of available-for-sale marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0f2d9e7-f0e5-45c9-ad4a-31ce571b4984" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450,950</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc891813-1560-492a-8d74-f92ea7a05b70" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,390</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of available-for-sale marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_528c3b15-5f9f-4cc7-ab7a-4050703d2975" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209,616</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0cda50d-6393-4588-b15c-fa74655f9e74" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4fa0195-691e-48fc-9cd7-d4f2c0005fec" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">229,352</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db308cc1-0cb1-4650-8cef-77e1996ed654" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,598</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from Initial Public Offering, net of offering costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a2fe528-e15d-4ffa-a656-05ce1dc172a9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be8c213-1ff2-42bd-b663-271e5691930d" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of Series B Convertible Preferred Stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69bddcf4-e25e-49eb-8dad-5b37b754db59" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4a4e822-7442-499f-b4c9-a3756f062ec4" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,942</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchases of unvested restricted common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8c8784d-38c5-4b7d-b292-dc9694ced6ad" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:RepurchasesOfUnvestedRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2238336-65d9-4366-a009-3afb9c3def3b" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:RepurchasesOfUnvestedRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_712ec8f7-e46a-4954-98ca-864c970262a9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f72fa704-9f29-458a-aeab-08769de9ab38" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89c119d0-6199-46e5-88c8-cc84784dc5d8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df04974-d9db-4376-8253-288319cf9b77" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcc11a6e-6368-4554-badb-c0cee7188421" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33fcd8ce-427e-481a-9a39-b64cb003e8ac" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377,781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81f4f965-fc9a-463b-a29b-6e9b990de5ca" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4e90265-b111-45d4-b47c-809272260087" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149,713</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d6429e0-d62b-416b-a12d-9cc12953fcbd" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32b632f9-f8a3-4133-8520-d92911952f87" contextRef="C_e5502035-9c62-4bfa-b75f-04b8934fb13b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,388</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82e708b6-ae46-47bf-bd88-6494bad62de4" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,627</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_560bf814-1b04-4751-8314-90060d8ab6fc" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37b0531d-60fd-4af2-8cbe-f0972a58c6b5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6944952-9ffd-4ed2-bf5c-08ad9d7e29be" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure for noncash investing and financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment included in accounts payable and accrued expenses and other <br/>&#160;&#160;&#160;current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d0ad69c-c185-4a02-b541-d4f810525693" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07bcdb4f-baf4-4a5c-a7bc-27e62467db98" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use asset recognized in exchange for operating lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab6e6de-ec1f-4604-9e12-999d7316f0bb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21e3e429-28f0-4d83-b6f8-1288226b565a" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,462</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of convertible preferred stock to common stock upon initial public offering</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5234c76c-2160-445b-a868-81465b94ff11" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0f00f11-be2e-4ef2-9d82-71a2bb68977e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,157</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unpaid offering costs included in accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d27a0b1-3917-4e75-adbd-910fe3a3f0d1" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:UnpaidOfferingCostsIncludedInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b03692b-c7e0-44ed-9331-65d1a2c6d256" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:UnpaidOfferingCostsIncludedInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa1a5024-1fb5-4921-a4e7-a1fab7a55045" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff037c1-a511-427e-b057-38e4d5370663" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf0967b-026a-4af1-9969-c935891b9512" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_424fed75-6151-4978-b594-94d4bb9e0ece" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash at end of year</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0be09a-09e9-4c4a-bc93-6ac1a3c4d64f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,627</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23f8d142-c508-4182-8c05-d02189a90bd7" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEPTERNA, INC.</span></h1><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statements</span></p><div><ix:nonNumeric id="F_26b7185e-1b57-4b7a-8109-564d97ff4c24" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:OrganizationDisclosureTextBlock" escape="true" continuedAt="F_26b7185e-1b57-4b7a-8109-564d97ff4c24_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Septerna, Inc. (&#8220;Septerna&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company with a world-class team of G protein-coupled receptor (&#8220;GPCR&#8221;) experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The Company&#8217;s proprietary Native Complex Platform&#174; is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. The Company is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s proprietary Native Complex Platform&#174; replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale. The Company&#8217;s foundational technologies enable it to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. The Company then applies state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging its platform, the Company has transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable GPCR targets with novel oral small molecule medicines for patients. The Company&#8217;s Native Complex Platform&#174; is designed to enable it to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was incorporated in Delaware in December 2019, under the name GPCR NewCo, Inc. In June 2021, the Company changed its name to Septerna, Inc. The Company is headquartered in South San Francisco, California.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 18, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_941c5c4e-0714-4e43-98f2-021e923d4785" contextRef="C_e7f2b074-5874-4a74-ac56-9ee225b000cb" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-8.6103</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding shares of common stock. Upon the effectiveness of the reverse stock split, (i) all shares of outstanding common stock were adjusted; (ii) the conversion ratio of the convertible preferred stock was adjusted; (iii) the number of shares of common stock for which each outstanding option to purchase common stock is exercisable were adjusted; and (iv) the exercise price of each outstanding option to purchase common stock was adjusted. All of the outstanding common stock (including shares of common stock subject to the Company&#8217;s options and as converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. The number of authorized shares did not change.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company completed its initial public offering (&#8220;IPO&#8221;), pursuant to which it issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5d713a-de47-4d97-a682-1286f41de02c" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">18.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at the IPO price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_025e7a00-2e64-4cf3-a986-3120308918de" contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cead4b27-aa26-4181-b312-4b592c4a46ee" contextRef="C_da673621-a76d-4b43-ba2e-10ba33dfce9a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares that were issued to the underwriters pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_352252f7-aa06-460f-af26-e08a05146855" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">302.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d27f892-8199-4375-b620-442b34b2a7cf" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="sepn:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and other offering expenses payable by the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_786f60ce-3fe7-4a61-8a9e-87bbe0019792" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="sepn:UnderwritingOtherOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Immediately prior to the closing of the IPO, the Company&#8217;s then outstanding convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f00668ff-26f8-466d-a192-b5cd41200007" contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,839,774</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the closing of the IPO, no shares of convertible preferred stock were authorized or outstanding. In connection with the completion of the IPO, on October 28, 2024, the Company&#8217;s certificate of incorporation was amended and restated to (i) authorize </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a16ce7ff-fb11-44bc-ba64-4bd26621f215" contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d482291-ac9d-40ba-9fe4-c55f97efe42f" contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which eliminates all references to the previously existing series of convertible preferred stock; and (ii) authorize </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2e0b373-40f7-4b42-9120-0710ffa90948" contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036" name="sepn:UndesignatedPreferredStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of undesignated preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1845d00f-068f-4dfd-b950-82471b101546" contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036" name="sepn:UndesignatedCommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share,  that may be issued from time to time by the Company&#8217;s board of directors in one or more series.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_26b7185e-1b57-4b7a-8109-564d97ff4c24_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which assumes that the Company will realize its assets and satisfies its liabilities in the normal course of business. The Company is subject to risks inherent in operating an early-stage biotechnology business. These risks include, but are not limited to, dependence on the development of marketable products, the ability to attract, retain, and motivate qualified personnel, rapid technological changes and the rapidly evolving nature of the biotechnology industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant losses and cumulative negative cash flows from operations since its inception and expects to incur losses as a result of its continued research and development activities. To date, none of the Company&#8217;s product candidates have been approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for commercial sale and, therefore, the Company has not generated any revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a742416-5202-4731-9928-619dbf17a914" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">48.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41786137-04dd-4c89-966e-f34fa8d9edac" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">167.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 31, 2025. The Company believes its cash, cash equivalents, and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_317b09e0-41d6-4b43-9bce-08eb2ac4707c" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">548.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 31, 2025 will be sufficient to fund its operations for, at least, 12 months from the date of issuance of the financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company historically financed its operations primarily through the issuance of convertible promissory notes, convertible preferred stock, the sale of its common stock in an IPO, and most recently, through a one-time, non-refundable upfront payment  upon commencement of its collaboration agreement with Novo Nordisk A/S (&#8220;Novo&#8221;) and achievement of a milestone event pursuant to its agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to continue to generate operating losses for the foreseeable future. The Company will need additional financing to support its continuing operations and pursue its growth strategy. It expects to finance its operations through equity offerings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. Any failure to raise capital as and when needed would compromise the Company&#8217;s ability to execute on its business plan and may cause the Company to significantly delay, scale back or discontinue the research and development of some of its programs or curtail any efforts to expand its product pipelines and will materially harm its business, financial position and results of operations.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_56367a61-8e12-4e22-abf2-5a22324efe3d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40eef4f3-10d6-4427-8108-c157b04d055b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), stated in U.S. dollars and include all adjustments necessary for the fair presentation of the Company&#8217;s financial statements as of December 31, 2025 and 2024, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASUs</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of the Financial Accounting Standards Board </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FASB</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11a997a5-7de8-41bb-b8be-8eecf0d19d3c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in determining the fair value of assets and liabilities, the useful lives of property and equipment, the rate used in determining the present value of lease payments, fair value of assets and liabilities, research and development accruals, the estimated fair value of common stock prior to the Company's IPO and assumptions used in stock-based compensation, the initial allocation and continued evaluation of a revenue contract&#8217;s transaction price to each distinct performance obligation on a relative standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, tariffs, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_1" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fc264d0-6d4a-4fe0-bad6-1ffbade4a05d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84d19030-cff0-4ed6-9ea8-75b48f3b53e1" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:RisksAndUncertaintyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company limits its credit risk by placing its cash, cash equivalents, and marketable securities with banks and institutions that are highly creditworthy. Such cash may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits, and the Company's cash equivalents and marketable securities are not insured by the FDIC. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities to the extent recorded in the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary focus of the Company&#8217;s investment strategy is to preserve capital and meet liquidity requirements. Management believes that the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash, cash equivalents and marketable securities since inception. The Company has no significant off-balance sheet concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, efficacy of product candidates, intense competition, and dependence upon the availability of liquidity to sustain operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f76725b-155a-40da-a3e7-2b2509575182" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company holds marketable securities that consist of highly liquid, investment grade debt securities. The Company's cash and marketable securities are held or issued by financial institutions that management believes are of high credit quality. Marketable securities are classified and accounted for as available-for-sale. Marketable securities with original maturities of 90 days or less are classified as cash equivalents. Marketable securities with original maturities over 90 days and remaining maturities of less than 12 months are classified as current. Marketable securities with remaining maturities of more than 12 months for which the Company has the intent and ability to hold the security for more than 12 months are classified as non-current. The Company&#8217;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported in stockholders&#8217; equity as accumulated other comprehensive income. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. The Company does not generally intend to sell the investments and it is less likely that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, the Company recognizes a loss in its statement of operations and comprehensive loss, whereas if the decline in fair value is not due to credit-related factors, the Company records the loss in accumulated other comprehensive income on its balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of marketable securities for purposes of identifying and measuring an impairment. Accrued interest receivable on marketable securities is recorded within prepaid expenses and other current assets on the balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_38e130e8-62e1-4b9e-97e9-d3276556b1d8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true" continuedAt="F_38e130e8-62e1-4b9e-97e9-d3276556b1d8_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#8217;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to its landlord. The collateral account is classified as restricted cash on the Company&#8217;s balance sheets. As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_2" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_38e130e8-62e1-4b9e-97e9-d3276556b1d8_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining term of the leases is greater than one year and the related restricted cash is classified as non-current on the Company's balance sheet.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d3f14b0-a804-4a17-be0e-93a71e46cb4a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:DeferredRevenuePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Revenue</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue consists of amounts received prior to satisfying revenue recognition criteria (see Note 4).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7ca7e5f-2dfa-4a5a-9f24-5f89ca0bdad6" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of assets, or at the time services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_533c5980-e98e-416e-8b6d-3b61f433a9c0" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_949707ce-c420-45d4-95f9-f88a2544dcde" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s accounts receivable was entirely attributable to Novo. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s accounts receivable was entirely attributed to Vertex.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f9586aee-b7c4-4fb6-b4f9-c956c9a55993" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation and amortization. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6241d8f-36f9-45c6-9b47-9dc7acc9ea03" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" escape="true" continuedAt="F_a6241d8f-36f9-45c6-9b47-9dc7acc9ea03_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a6241d8f-36f9-45c6-9b47-9dc7acc9ea03_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:57.54%;box-sizing:content-box;"/>
           <td style="width:1.94%;box-sizing:content-box;"/>
           <td style="width:40.52%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cb2dca2a-9e66-43f0-8aef-d5972d6691b4" contextRef="C_0d155a10-3368-4e21-9ede-8d1675cae5c8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b981ec88-7fa3-405e-be6e-6d54b2677f0d" contextRef="C_31980d7f-00b5-4148-b37d-689b558648c6" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_474f63fc-a746-4391-a726-2028fd05e384" contextRef="C_db2dcbd2-97a4-4ddf-ba1c-ede279cbcae5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer Equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5d7a153b-6386-46fa-ad48-d1e7c631a372" contextRef="C_f65b9339-0f3a-4b2a-8936-a9b7e8f4f353" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
          </tr>
         </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation or amortization is removed from the balance sheet and the resulting gain or loss is recognized within other income, net in the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee621192-198d-4bc6-bd34-0934bf692952" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be91ce25-4a89-4f3e-a27a-731e20cfb142" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c22542b7-a6b3-47b0-bdd0-5f3efacd0cd5" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairments of the Company&#8217;s long-lived assets for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_92e01aba-0dd8-4d72-ab66-2164baaf03a2" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_92e01aba-0dd8-4d72-ab66-2164baaf03a2_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its leases in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 842&#8221;). The Company adopted ASC 842 on January 1, 2021, prior to entering into the lease agreement for its office and research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is reasonably certain that the Company will exercise that option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_3" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_92e01aba-0dd8-4d72-ab66-2164baaf03a2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments if the Company&#8217;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Right-of-use assets represent the Company</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s right to use underlying assets for the lease term and operating lease liabilities represent the Company</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s obligation to make lease payments under the lease. Right-of-use assets also include any lease payments made prior to the commencement date and exclude lease incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company elected to apply the practical expedient of combining lease and non-lease components for the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company elected the short-term lease practical expedient that allows the lessee to not record a lease liability and right-of-use asset for all leases with a term of 12 months or less. See Note 6 for additional information on the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_3a8fa56e-8423-4c38-bf1f-5ab07e70b202" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_3a8fa56e-8423-4c38-bf1f-5ab07e70b202_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for revenue in accordance with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following four steps: (i) confirm it has a contract with a customer that creates enforceable rights and obligations; (ii) identify promised products or services to be transferred to a customer; (iii) determine the transaction price, or the amount it expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable and allocated to the performance obligations; and (iv) recognize revenue when or as performance obligations are satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price of each distinct performance obligation. In instances where standalone selling price is not directly observable, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract using a cost plus margin approach, which is an estimation method used when standalone selling price is not directly observable. Key assumptions used within this estimation method may include full-time equivalent personnel effort and estimated external costs associated with the performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the Company's performance, (ii) the Company's  performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the Company does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues are primarily derived through its license and research and development service arrangements. Payments to the Company under these arrangements typically include one or more of the following: one-time, non-refundable upfront payment, research and development service funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain collaboration, research and development and commercial milestones, as well as royalties based on net sales of approved drugs.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_4" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_5"><div><ix:continuation id="F_3a8fa56e-8423-4c38-bf1f-5ab07e70b202_1" continuedAt="F_3a8fa56e-8423-4c38-bf1f-5ab07e70b202_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration received prior to revenue recognition is recorded as deferred revenue in the balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current. Contract assets represent research and development services which have been performed but have not yet been billed and are reduced when they are subsequently billed. Such contract assets include accounts receivable when the Company&#8217;s right to consideration is unconditional. For its current contracts, the Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and, if over time, revenue recognized is based on the use of an input method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s collaborative arrangements include one or more of the following</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For a license that is determined not to be distinct, it is combined with other promises and the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost of each performance obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - The Company evaluates the customer options for material rights or options to acquire additional goods or services at no incremental consideration or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised and performance obligations are satisfied. If an option is not exercised before the option right expires, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under the Company's collaboration agreement include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#8217;s statements of operations and comprehensive loss. Expenses incurred as part of the Company&#8217;s efforts to perform the research and development services are recognized in research and development expense in the Company&#8217;s statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under the Company's collaboration agreement include manufacturing services to be provided by the Company. Payments or reimbursements resulting from the Company's manufacturing services are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#8217;s statements of operations and comprehensive loss. Expenses incurred to perform the manufacturing services are recognized in research and development expense in the Company&#8217;s statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore, consideration included in the transaction price is constrained. The Company applied the variable consideration allocation exception under ASC 606 whereby variable milestone payments are not estimated and included in the transaction price at inception. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if </span></div></div></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_5" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3a8fa56e-8423-4c38-bf1f-5ab07e70b202_2"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial milestone payments and royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied)</span></div></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_958e5903-d7e7-4c94-8727-8981db70c47d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:SaleOfNonFinancialAssetsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of Non-Financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of non-financial assets that are outside the scope of the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary activities are accounted for under ASC 610-20, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income - Gains and Losses from the Derecognition of Non-financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 610-20&#8221;). Pursuant to ASC 610-20, the Company applies the guidance in ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 606</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to determine if a contract exists, identify the distinct non-financial assets, and determine when control transfers and, therefore, when to derecognize the non-financial asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation of the gain or loss for the non-financial asset.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1deb197-d9d9-4400-a4fa-d2d6e201c437" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies and clinical trials, contract manufacturing for the production of clinical and preclinical materials, information technology-related costs, allocated overhead costs including facility-related expenses, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into agreements with outsourced contract manufacturing and development and clinical research vendors. The Company estimates accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e92b6a4-0479-4275-b699-456032e02806" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:PatentExpensesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs to secure and maintain patents covering the Company&#8217;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6887664-429e-44d8-bb72-f5a71014b3bf" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_6" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb9a4ee1-0400-47b3-8408-58dba1922339" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The carrying values of the Company&#8217;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33ac6381-63ef-4091-8226-c3c881d81b44" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is recognized based on the grant-date fair value of the awards. The fair value of stock options and employee stock purchase plan ("ESPP") is determined using the Black-Scholes option pricing model on the date of grant. The fair value of restricted stock awards is determined using the estimated fair value of the Company&#8217;s common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the IPO, the Company utilized estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to the Company&#8217;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award of four years. For stock-based awards with vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based compensation expense on an accelerated basis over the vesting period when achievement of the performance criteria becomes probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is recorded within research and development and general and administrative expenses in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d3364ac-52be-41a4-b665-4667792daf5d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the asset and liability approach to account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa326d61-c978-4da1-9773-ad914f28b61e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. The Company&#8217;s other comprehensive income (loss) is comprised solely of unrealized gains or losses on marketable securities. The Company has not recorded any reclassifications from other comprehensive gains or losses to net loss during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_a73542b2-0a9d-4d50-b255-e873483ef097" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_a73542b2-0a9d-4d50-b255-e873483ef097_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_7" continuedAt="F_56367a61-8e12-4e22-abf2-5a22324efe3d_8"><div><ix:continuation id="F_a73542b2-0a9d-4d50-b255-e873483ef097_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of basic net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock, and ESPP shares. The dilutive effect of stock options, unvested restricted stock, and ESPP shares is computed using the treasury stock method. For all periods presented in a net loss position, diluted net loss per share is the same as basic net loss per share since the effect of including potential dilutive securities is anti-dilutive.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d127591-af58-4eaa-ba9c-c5a9b7ef6d3f" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU No. 2025-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expand the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. In addition, ASU 2025-07 is expected to reduce diversity in the accounting for share-based non-cash consideration from a customer for the transfer of goods or services, as well as provide investors with more comparable information and reduce accounting complexity and related reporting costs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adoption of the amendment allows for either the prospective or modified retrospective application and is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company early </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_098c6036-dc51-49c4-b08c-51fe1a611401" contextRef="C_6d0ae500-5d31-4464-8a21-1873d26e4998" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this standard using the prospective method for the derivative scope refinement with the effective date of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51161d8f-8b45-451a-b7fd-afcc6507eac0" contextRef="C_6d0ae500-5d31-4464-8a21-1873d26e4998" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Prior to adoption, the Company did not have contracts that incl</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ude are subject to derivative accounting and the adoption of the ASU did </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_093ad106-e1df-4ccb-be4b-5034b791030d" contextRef="C_6d0ae500-5d31-4464-8a21-1873d26e4998" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a material impact on its financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_faecfa98-652d-4cca-94de-7a02c3297ab7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU No. 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years beginning after December 15, 2024, on a prospective basis. Early adoption and retrospective reporting are permitted. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company follows the provisions set forth in ASU No. 2023-09 on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a044b4b-39e8-4452-8f1f-43894671186c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the FASB issued ASU No. 2025-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset in developing reasonable and supportable forecasts during the application of the current expected credit loss model for current accounts receivable and current contract assets arising from transactions under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-05.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires the Company to disclose more detailed information about the types of expenses (including employee compensation, depreciation, and amortization) included in each relevant income statement expense caption. The ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4a013d9d-bee6-4a17-a210-2b776242b667" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" escape="true" continuedAt="F_4a013d9d-bee6-4a17-a210-2b776242b667_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status and Smaller Reporting Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_56367a61-8e12-4e22-abf2-5a22324efe3d_8"><div><ix:continuation id="F_4a013d9d-bee6-4a17-a210-2b776242b667_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.</span></p></ix:continuation></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54048a5a-3abc-4a7f-8e9d-34aecaca4d01" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Balance Sheet Components</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b432b3e-36b5-4f7b-97d6-1474e2402e7c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e67e8d2d-6913-4179-b0e9-592926a06f5a" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,622</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c38d22-3318-4146-8437-e056a0ef2647" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32fdf685-044b-425a-a4e7-1a8c8abf4a39" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,384</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6c94aac-d1aa-4450-a840-eaf424ff9f42" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">953</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid bonus</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44ee81b9-5052-48d8-b32d-b708e57bba50" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:PrepaidBonusCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">361</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4721d006-0ca5-4796-9933-97da9afe5d4f" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:PrepaidBonusCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cfa22ee-8971-4bb5-89df-fddd2cf5fee8" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,152</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8f8cbe3-5eeb-428c-9558-77fa8eeb5946" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432580e9-0b83-4770-bc56-bdf6afe64f90" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,519</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a436cfd-79af-4aa3-a6fb-8781b9a0f2a1" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,730</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4df8aa7f-5477-4ca2-aa35-4d490493a018" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f54e573-c6cc-4cec-80c7-467cd8a8607a" contextRef="C_0d155a10-3368-4e21-9ede-8d1675cae5c8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,339</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96871689-9083-4ea2-bd16-9037e3fc5a92" contextRef="C_5bc6c479-79c8-4152-9bfc-76c56f1b6c0b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,679</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture, fixtures, and office equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3a2738-8de0-4170-8ff1-68decbe1e2ef" contextRef="C_4586a8d6-90a1-4f22-a91e-ed46c95e215d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea87df9a-131c-485c-b248-dfd8a41effc7" contextRef="C_0fbb9c90-762c-43f1-b17f-96b2e4b4c262" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08a1c09d-9dbc-4ba7-a677-bcbb455485cc" contextRef="C_62d33bbc-a9d1-4e0d-b374-febca2f135b7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d24659c4-c1fe-4189-a7f3-45ab2b25fcfe" contextRef="C_398ed5f7-f194-4e12-ab54-8894f63345b1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24796e13-63d7-4c31-bb70-8651b2fd001c" contextRef="C_f65b9339-0f3a-4b2a-8936-a9b7e8f4f353" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4014319c-77dd-42b3-956c-201493433ebb" contextRef="C_d86b0a04-264c-4ec6-a98a-514c21b6fcd1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">401</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46ec1082-b9f8-420b-905d-ba05148362d9" contextRef="C_9db2cf60-a723-488b-983c-bd979235ca35" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7664446b-b1c6-4b7b-b57b-768d7dca1bfb" contextRef="C_87cdb1d5-fac7-4ece-beec-6c0efa23647c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e8b6e81-406a-4578-af52-baa8789dad62" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_217f54cb-8431-4331-8496-7aca899ebc57" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,019</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1b600b-0485-43bc-a884-e278c51cbc71" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,352</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f03d95-4fef-41dc-b06c-de32375ba82b" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,929</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_122ca3ff-174b-41e7-89c6-8f0d8c18c6ec" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,434</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4bae600-66a1-46c7-bc6e-e331bf08d025" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,090</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00728c62-98fd-4414-9eaa-4f97cd16b625" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da24e3ad-925c-4eca-bb6e-8153dbc6914a" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b60dae5-c56d-4498-acdf-191ac75f3784" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da3b73c0-bfed-428c-bebf-1ea4fc55da4f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,606</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d9bd324-2c78-4981-b4f4-2e475f826509" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7ce355f-d8eb-4b42-9063-8fb2c399f269" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,179</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0de2f492-2f56-45ae-b6a1-22aefa43d4fa" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,888</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f06771fc-b9ab-4a9b-b63b-f0ad404280d6" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:AccruedGeneralAndAdministrativeExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">915</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7c90415-8dc2-45ae-b815-7a7bbd2dde9d" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:AccruedGeneralAndAdministrativeExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">703</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaba6153-fd1e-4bd1-b696-1bce8ac0d705" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77637712-d8d9-4d3b-bdf0-1c50e1647fe4" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec2acb8-bc84-4698-a45f-719b468f78e8" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_798a2afd-424b-4793-8788-77380fb1e400" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6de28f-c2d7-4c6e-8652-8f3f6245c5ec" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e2c71aa-4481-4d1f-a65e-1f8da5423d99" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,798</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_3da3738f-f5ae-43a1-9703-173c35c9f823" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_3da3738f-f5ae-43a1-9703-173c35c9f823_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Collaboration and Research Service Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, the Company's revenue is comprised solely of arrangements with Novo and Vertex. For the year ended December 31, 2024, the Company's revenue was solely comprised of the arrangement with Vertex.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 13, 2025, the Company entered into a Collaboration and License Agreement with Novo (the &#8220;Novo Collaboration Agreement&#8221;). Under the Novo Collaboration Agreement, the Company and Novo are exclusively collaborating to leverage the Company&#8217;s proprietary Native Complex Platform&#153; to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon effectiveness of the Novo Collaboration Agreement on July 1, 2025, the Company and Novo have commenced four simultaneous research and development programs (each an &#8220;R&amp;D Program&#8221;), each pursuing one or more Collaboration Targets (as defined in the Novo Collaboration Agreement) from discovery through development candidate selection. Subject to certain limitations, Novo also has a right to modify the research plan with the option to commence additional R&amp;D Programs. Novo will reimburse the Company for 100% of the fully burdened costs arising from all research and development activities undertaken by the Company under the Novo Collaboration Agreement. After development candidate selection, beginning with investigational new drug-enabling activities, Novo will be responsible for all further global development and commercialization for each product candidate at its sole cost and expense unless the profit share option described below is exercised. Novo is also responsible for all commercialization costs subject to the Company&#8217;s profit share option for up to one program under the Novo Collaboration Agreement. Pursuant to the terms of the Novo Collaboration Agreement, the Company will provide Novo with exclusive licenses to enable Novo to develop and commercialize products directed at the Collaboration Targets. The Company retains all other rights to its Native Complex Platform&#153; and all of the Company&#8217;s other research and development programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon effectiveness of the Novo Collaboration Agreement, the Company received a one-time, non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ed4bb3-5cc8-4861-b81f-68e5f8897801" contextRef="C_e2f01c6e-2c71-481c-920d-0563fd77c7f5" name="sepn:NonRefundableOneTimeUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">195.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in July 2025, which was recorded as deferred revenue in its balance sheet. The Company is also eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_065a5eb1-ef56-48fa-8935-82c9da866185" contextRef="C_7f97baf0-9093-442d-82b0-a802ec9a04a8" name="sepn:MilestonePaymentsReceivableFromCollaborationAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">498.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in research, development, regulatory, and commercial milestone payments for each R&amp;D Program. In addition, the Company is entitled to escalating, tiered royalties ranging from mid to high single-digits based on global product sales on a country-by-country and product-by-product basis with respect to a R&amp;D Program until the later of ten years after the date of first commercial sale of the first product in such R&amp;D Program in such country, expiration of specified patent rights covering such product in such country or the expiration of specified regulatory exclusivity for the first product in such R&amp;D Program in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Novo Collaboration Agreement, the Company has a one-time option to share in the global development costs and operating profits or losses (in lieu of milestones and royalties) with respect to one licensed product (the "Profit Share Option"), subject to certain terms, conditions and limitations. In the event that the Company chooses to exercise the Profit Share Option, it will be required to repay Novo all previously reimbursed developmental costs pertaining to that program at a predetermined multiple and reimburse Novo for a portion of the continued R&amp;D costs incurred under the selected licensed product and will share in the profits resulting from the commercialization of the licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the term of the Novo Collaboration Agreement continues until expiration of the last royalty term for the applicable product in the applicable country. The Novo Collaboration Agreement is subject to customary termination provisions, including termination by a party for the other party&#8217;s uncured, material breach. The Novo Collaboration Agreement also includes customary representations and warranties, covenants and indemnification obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded the Agreement is not within the scope of Accounting Standards Codification 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as the Company does not share equally in the exposure to significant risk. Accordingly, the Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Novo, is a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At commencement, the Company identified the several performance obligations within the Novo Collaboration Agreement, including research and development services on research targets, option rights held by Novo, license to use the Company&#8217;s intellectual property to conduct research and development activities, and participation on the joint steering committee (&#8220;JSC&#8221;). At inception of the Novo Collaboration Agreement, the Company identified the following performance obligations:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Four combined performance obligations comprised of the license, related research services, and participation of the JSC for the four R&amp;D Programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing services related to one of the R&amp;D Programs; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material R&amp;D Program modification right held by Novo.</span></div></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_3da3738f-f5ae-43a1-9703-173c35c9f823_1" continuedAt="F_3da3738f-f5ae-43a1-9703-173c35c9f823_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the license granted at contract inception is not distinct from the research services as the research services significantly modify the intellectual property underlying the license.  As a result, for each R&amp;D Program, the license has been combined with the research services and JSC participation into a single performance obligation, which is the combined performance obligation comprised of the license, related research services, and JSC participation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In assessing whether the various options under the Novo Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material right identified above, the Company concluded the option provided Novo with a discount that it otherwise would not have received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue related to the combined license and research services performance obligation and the manufacturing performance obligation over time using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of actual cost incurred to date to the total estimated cost at completion of the performance obligations, which the Company believes best measures its progress towards satisfying the performance obligations. A cost-based input method of revenue recognition requires management to make estimates of cost to complete the performance obligation. Judgment is required to evaluate assumptions related to cost estimates. The estimated standalone selling price for the material right was determined based on the estimated discount provided to Novo and the probability that Novo would exercise the option.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aee86c79-307d-4e53-84e9-6922a2b1a969" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue recognized, unrecognized transaction price, and estimated revenue expected to be recognized in the future as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.385%;box-sizing:content-box;"/>
         <td style="width:2.759%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:21.855999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transaction Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Combined license, research and manufacturing services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2d35a1b-cbcf-4e46-9b56-e460c20dcbb6" contextRef="C_07465302-3c57-4c51-8649-8a24eb806c09" name="sepn:TransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,846</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material right</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebc5b7d7-0805-4aef-932e-f214645a02f9" contextRef="C_a07cba62-15fb-408e-9eca-ccd2f26f2784" name="sepn:TransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,190</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total transaction price</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7008d5d3-9bdd-490b-96e6-88078f8933a4" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="sepn:TransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,036</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39fd5ca1-4334-4c7d-a6eb-c996d69d21c0" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized transaction price as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a37898f8-01ab-4e49-93da-d805cfbada43" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="sepn:UnrecognizedTransactionPrice" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243,659</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_f1953c39-e551-4940-8c04-a300b368e702" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of the allocation of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_534b6776-65ba-4792-886d-390937883e2c" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="sepn:NonRefundableOneTimeUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">195.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million one-time, non-refundable upfront payment, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e58275c8-400c-4fdb-8bda-097e15a9d5a9" contextRef="C_ab94e00d-ea2a-4055-a162-0c519f4d3c16" name="sepn:NonRefundableOneTimeUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">153.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the four R&amp;D programs and manufacturing services and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b283a79-51b4-4a62-a6af-f73e156c5dec" contextRef="C_a07cba62-15fb-408e-9eca-ccd2f26f2784" name="sepn:NonRefundableOneTimeUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the material right and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95603b85-e76d-40b6-acc1-2a65180f9cbf" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="sepn:VariableConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">94.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of variable consideration related to estimated research and manufacturing services for the four R&amp;D Programs.</span></ix:footnote></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><ix:footnote id="FNT_9ae89f8a-23fd-4c50-a308-c16f6583e5df" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded within revenue in the statement of operations and comprehensive loss for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aae6384-35b2-4cd6-9703-97d4d95e0e15" contextRef="C_188353cf-4494-4271-90fa-2b494b9ce37b" name="sepn:NonRefundableOneTimeUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized of the one-time, non-refundable upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6511bd0b-fc2a-4dec-a8cd-8c367e2d8f68" contextRef="C_188353cf-4494-4271-90fa-2b494b9ce37b" name="sepn:VariableConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million variable considerations related to estimated research services for the four R&amp;D Programs.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the Novo Collaboration Agreement are recorded as accounts receivable in the Company&#8217;s balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s balance sheets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e0a35c1-ffb9-46c1-9671-d4eec5cb8e9d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:SummaryOfChangesInDeferredRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes in deferred revenue for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.385%;box-sizing:content-box;"/>
         <td style="width:2.759%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:21.855999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e528a9f-e92e-43de-8138-e0be80e29a5f" contextRef="C_9c2248bf-d680-4e4c-9956-051672a0ad00" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f91d546d-e2f1-4f9f-80d7-158f408dbd8c" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="sepn:ChangeInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a8182f3-8f47-49c6-9796-3c0df53ff2fc" contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,814</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee90e8fb-797b-40bb-a12e-27c3b5986690" contextRef="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168,186</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea62926-c73d-48a5-b4f6-11e04cd97fbf" contextRef="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred revenue, current and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f844565e-1ada-4cdc-9142-1137924b9455" contextRef="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred revenue, non-current, which is expected to be recognized over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24c11777-abf0-410f-bd5a-acbd3436d95b" contextRef="C_12930a8d-66c5-4c50-9202-0f635796fbca" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all of the Company's performance obligations are outstanding.</span></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically assesses the probability of receiving payments from achieving the research and development, collaboration target, and regulatory milestones and includes the payment in the transaction price when they are deemed probable. Royalties and commercial sale milestones will be recognized when the subsequent sales occur based on the sales or usage-based royalty exception.  The Company also periodically reassesses the probability of exercising Profit Share Option. As of December 31, 2025, none of the milestones were deemed probable and no royalty revenue has been recognized, and the Profit Share Option was deemed improbable with no amount recognized for repayment of reimbursements to Novo.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3da3738f-f5ae-43a1-9703-173c35c9f823_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Asset Purchase and Research Service Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Asset Purchase Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company entered into an asset purchase agreement with Vertex, under which Vertex acquired an in-process research and development ("IPR&amp;D") asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (the &#8220;Vertex Asset Purchase Agreement&#8221;). The Vertex Asset Purchase Agreement also provided for a potential milestone payment payable to the Company contingent upon the achievement of a milestone event.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, this milestone event was determined achieved and, as a result, the Company received a payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92cdb64d-ad4d-42ca-9941-6a00d4fd4d46" contextRef="C_d2961116-d112-4899-9e01-f6d82d75041d" name="sepn:MilestonePaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in August 2025, which was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recorded as a gain on sale of non-financial asset within total operating expenses in the Company&#8217;s statements of operations and comprehensive loss for the year ended December 31, 2025. The Company will not receive any other payments related to this IPR&amp;D asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Research Service Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the Vertex Asset Purchase Agreement in September 2023, the Company entered into research service agreement with Vertex under which the Company agreed to perform certain exploratory research activities for Vertex (the "Vertex Research Service Agreement"). The Company recognized service revenue associated with the Vertex Research Service Agreement over the performance period of the research services as the services were provided in accordance with ASC 606. The Vertex Research Service Agreement expired in September 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5a5217-469a-46c6-a47d-0a4db8dbddd7" contextRef="C_88ac2057-9216-425c-b13e-16df574b3054" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to research activities performed in connection with the Vertex Research Service Agreement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company recorded revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_540ef838-fc58-4d80-bb49-3b455dbd7d85" contextRef="C_53a67097-47c1-490a-8b40-0541279b1af4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to research activities performed in connection with the Vertex Research Service Agreement.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span><span><ix:nonNumeric id="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:MarketableSecuritiesAndFairValueMeasurementsTextBlock" escape="true" continuedAt="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Marketable Securities and Fair Value Measurements</span></ix:nonNumeric></span></p><div><ix:continuation id="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191_1" continuedAt="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records marketable securities and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_974d35b5-0221-4b32-9702-40e93a0ca038" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true" continuedAt="F_974d35b5-0221-4b32-9702-40e93a0ca038_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.53%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_866241fd-d267-4449-a95a-dcd13cba6547" contextRef="C_9dd7f8d2-59e4-40bc-9f16-2e9328a32206" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,736</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cd14179-ff1f-4b13-8a15-bdaaf68e576f" contextRef="C_322e150f-75d2-4c33-a81b-00ef3a3995d8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,736</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8106e33b-b35d-4b54-80a9-eda7570e154a" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e115698b-c129-4dc6-adb8-de21b50b46c6" contextRef="C_fab764e8-30d4-4a5a-8352-b6d7d8e5c87b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d541711e-c5a8-4147-8cb1-279e6a6dacb0" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,190</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_732d4d51-f611-4b40-87ad-03b96246557e" contextRef="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,190</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c1262a-c534-4bf0-945b-6a5f21453c55" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f945a11-1c79-4f8e-be9d-5d7fd9c292e8" contextRef="C_c8ea85e2-1da3-448c-b148-4c967f416f46" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_907401fb-87da-40de-a02e-1157c2b3de35" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,784</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0723cb20-9f29-4748-9af5-6fb038314ab5" contextRef="C_fab764e8-30d4-4a5a-8352-b6d7d8e5c87b" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,784</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85556068-5818-4d8b-9fb6-47a7310fd5ba" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,573</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b5aff61-4889-4168-911c-e1ed92536d24" contextRef="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,573</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d69701e-cd5e-4b2c-ab77-9883855a9663" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,026</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ddcd1b1-34ea-48dc-b1b6-c541f6dc5c2f" contextRef="C_84474bd9-0ca3-4043-a28f-246196964124" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,026</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_438fe1e7-abba-4743-a61e-1f6b9f3167a0" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,632</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_977d258b-bf02-4613-bcdd-9c29ee05c00f" contextRef="C_c8ea85e2-1da3-448c-b148-4c967f416f46" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,632</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b52c5f7b-ae35-432d-adfe-5e203402d607" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,713</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0560858c-21d6-41a7-9feb-38becea10448" contextRef="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,713</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49ac7d26-9780-4fb1-afb7-ca59c3d5e50e" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f54bde0-1ba7-4adc-809b-0eec2bbd14c9" contextRef="C_84474bd9-0ca3-4043-a28f-246196964124" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a491f840-eb5d-4193-9e35-84d10765e180" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">544,025</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88cbc855-3ea9-46d0-b3c1-e3f0293bd0d8" contextRef="C_93212ce3-a90a-4a57-a707-34c5cc5ff182" name="sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,736</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c17a7c7-dd98-4e28-9e32-0d48cb1302c8" contextRef="C_3f36de4b-8700-4f6c-bc71-ae1a9dc8ff7d" name="sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480,289</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191_2" continuedAt="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_974d35b5-0221-4b32-9702-40e93a0ca038_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.53%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df897add-a938-45f1-b6e9-1d5f9c86b14a" contextRef="C_2f1fe350-b8c7-4223-a96e-9534890d1439" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,779</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6b15554-71b4-44c7-9c03-ca6fca933d89" contextRef="C_f01b0a9e-0bec-4e73-87b2-511f0f3402f1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,779</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_049d6095-3b58-4d68-949c-ba19119fda39" contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,527</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce613127-fbbe-4cb2-9e5c-a1187db7d53f" contextRef="C_6779c8bc-bf3a-4123-b629-4da74d3cadda" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,527</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84da8f71-625a-4397-8a29-fbd16cb27f65" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a01d6536-c59f-452c-92d0-fe1576d72b78" contextRef="C_99f18d25-7a69-4282-995c-9eebff9e8b6a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd6e4f9-a979-41a2-ad28-212623bf990d" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,555</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e04d5794-670b-4abb-81f0-6e033c687fc9" contextRef="C_fb785e0f-2bdc-4e89-ac3b-e5d3f8322c6c" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,555</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce8373dd-d125-4c27-9725-78f9427e8ef8" contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e05b4d5-c0cf-414c-a26d-b0a02b92010d" contextRef="C_6779c8bc-bf3a-4123-b629-4da74d3cadda" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dfee6fb-462e-4da9-b013-0f93e16e425a" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,193</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4b4ae97-08a8-4a75-9bdf-91147c352103" contextRef="C_99f18d25-7a69-4282-995c-9eebff9e8b6a" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,193</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb5d092-1f37-48c5-bc15-9dc37bbfb1ab" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecbccfb2-d22e-4fd4-b96a-923a97b751be" contextRef="C_62168868-0203-4750-a338-01cfd04ab7de" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a297b1f-e7af-4200-98f7-aa478477e469" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34a36456-23d3-4a33-9a8d-57830927c882" contextRef="C_fb785e0f-2bdc-4e89-ac3b-e5d3f8322c6c" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fada2b7f-d64f-4494-bdd6-beb8624609ff" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,514</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dad3501-5bfc-4cd9-874d-94304201328f" contextRef="C_99f18d25-7a69-4282-995c-9eebff9e8b6a" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,514</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a0e95bf-d040-4f25-bbf3-749a058e62dc" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cc23fc7-7b58-4444-8a7e-21a10fae0ca4" contextRef="C_62168868-0203-4750-a338-01cfd04ab7de" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a8e33a8-4e4f-42be-8be2-46822d883660" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">414,958</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37a63c0b-ab13-4960-af72-1a40435e03fa" contextRef="C_38782ba4-4fa6-40c7-934f-d3a079936095" name="sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,779</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea608e92-3068-43c7-9824-7dc2d235e138" contextRef="C_3dd767cf-b320-4070-b5e9-d4aef8502c4f" name="sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,179</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s marketable securities consist of debt securities, including U.S. treasury and agency securities, corporate debt securities and commercial paper. These marketable securities are carried at fair value and are included in the tables above. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these marketable securities and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met at December 31, 2025. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and the Company's expectation is that those payments will continue to be received timely. Based on this evaluation, as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company determined that unrealized losses of its marketable securities were primarily attributable to changes in interest rates and non-credit related factors. As such, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ecff618-3310-44da-a7ff-dc8ba1f727c8" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowances for credit losses were recorded at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aafdf896-77b5-434c-ae03-70ddba0ce5d9" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:MarketableSecurities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t hold marketable securities at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest receivable as of December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41d005b7-1741-41f9-b8e6-d036a9ac2b16" contextRef="C_b3d53d15-29ec-421d-989c-75e94a00a664" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddaf9b06-5160-421f-abf8-bced75dafb05" contextRef="C_43f43b58-1c3c-4c77-a255-d8e27eb71c5c" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and is recorded as a component of prepaid expenses and other current assets on the Company&#8217;s balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, all marketable securities in an unrealized loss position had been in an unrealized loss position for less than 12 months. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e887b2d3-5e3f-4853-a4fe-ed97879920aa" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Position" decimals="INF" format="ixt:num-dot-decimal">44</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> marketable securities had been in an unrealized loss position for a period of less than 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div><ix:nonNumeric id="F_a5757424-cb6e-4f8a-b640-174493f64e06" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true" continuedAt="F_a5757424-cb6e-4f8a-b640-174493f64e06_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.42%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:15.36%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.440000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.440000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.440000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining<br/>Contractual<br/>Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Estimated Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a10d9284-f7f4-4efb-8df6-25825daefa2f" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,939</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f97c91b-b7af-4fcd-abf7-49c6e8b13e42" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad0ca3b8-7a04-466e-b041-781c846f1db7" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7602c5fa-5591-4c85-a948-83336e9c416d" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,947</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d976a60-367c-492c-b8aa-6b2176f8db14" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,688</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69cd85eb-1b8b-4574-add8-b50eb125e7bd" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6a8b47a-03ab-48cd-902c-19bbab818ec6" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b9d26e2-4130-448c-aa35-630d46ebd0cb" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f74abead-9de9-4996-85b8-0fb73810898a" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,755</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b09049e5-bb1d-490d-8722-79e43b29c1e2" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8ec1f0e-8652-40ee-ad69-7f7ae6d05ab8" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b00889e5-8bb7-43e5-b139-6f053d0029bc" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,763</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96e8de3e-e674-4ba6-8d99-cc21027a6f2a" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,992</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a0a5ee2-d75f-4065-ab03-02bb77b3a788" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f710121-cfda-4181-b86f-9af3d701b8e8" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f29ca788-eb88-482e-8dc1-e57da88e412e" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,026</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_019ba459-de37-4576-b56a-c08dec61083f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">322,374</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad1ecd1a-d702-480b-9f1c-5fdae6390b57" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">361</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ddc2cab-e242-4ade-93d0-069376ccef26" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11e6800b-2a36-46c6-908b-2dd9429a7d91" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">322,720</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca95d410-f606-4ce8-b258-3749c07276be" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,376</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_687390da-46c5-4afe-ab9c-244b9ebaf186" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dfcbd08-1ecb-4efc-8f2d-7b6d3bffa3ad" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da206d0b-355d-44b7-bd6b-324972a666e9" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,632</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a3b218e-955d-41dc-9cae-4b6411ea46c4" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,699</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dee7a23-7fc6-49b3-b56d-0cbe8ec86aa4" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2395504c-43f9-4adc-963b-809712dfa3d2" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df3c9a58-f95c-4d36-9d8d-ceb9e53ea765" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,713</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d65db3c4-4c2e-41e7-a127-ffc79b3671d0" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,223</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f1ef592-bd00-480a-8259-7981163e1392" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78ed053-21d2-44b1-805f-6a9382990001" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32fc4352-66e1-4a0d-8b44-f562c0aff8ae" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5d2f42d-21c5-41cf-8224-34c8db41ad79" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">479,672</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b3481a-e442-4640-9b82-39c833c5a28c" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_527fff61-d8aa-4d2a-acd4-8db43cf94efd" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adc0319f-4ff0-4258-94cb-c81441f92463" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">480,289</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a5757424-cb6e-4f8a-b640-174493f64e06_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.42%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:15.36%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.440000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.440000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.440000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining<br/>Contractual<br/>Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Estimated Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b1b68a7-bdc0-4272-97fa-972ea8e07ff9" contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,017</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e95e0fbb-4af0-459c-ac83-2d79708c46f2" contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5929441e-c456-4e09-b9f3-95b63912adf9" contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eec8c874-5ebe-4d7d-8aa6-ac57bb4e6e10" contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,014</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b9a3b3-ecb7-45e1-a75c-b89c104f7b60" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,511</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c743dfa-236c-488c-9805-f21c31c2d6ef" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5402750-0b2b-4146-8bd3-e175f7cf53dc" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57bd5281-2e93-4008-8de0-9b3d30744629" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,555</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6837d6cc-73f5-4df6-8be3-5e98286a0945" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,245</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_467baa86-5d8d-4c9a-8124-6bad64119672" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_032ebcdc-1b3e-4baf-bdb2-eb45730eaf29" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb31c94a-df71-4b19-baf2-1a345b386cd5" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,252</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3dbb90d-cbec-4a58-a637-b88ff3b08fdc" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c4cc00f-69d2-4cf7-888a-4b112ef69b13" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c2ba136-caf8-464c-8717-6dcbd53b41f9" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12b5de6-1254-458c-8e23-da468b3250d6" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38f8c8a6-06cb-4908-9952-21a9ac71e073" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203,264</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b89e8bcc-003a-4c95-a01a-82b4769b9fe4" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6d1a0ed-e11a-4658-b223-43ae79cd1fb9" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8533fc9b-4085-4c38-af35-afd606a76ba5" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203,313</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc5e22a0-bf0d-4730-8198-5067f6adc222" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,427</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f1f1da-ee46-497c-aa20-2213fddbf4e2" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c39fa0ab-b088-4bac-900c-28fd56608ae0" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_346382a5-8602-4c72-ace1-727b27847322" contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57c338ca-c06e-4117-8c79-c4e933bbe884" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c550919d-e2f2-4726-82eb-521df1c64b75" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15c53f9b-0fb8-45ef-9117-9e17da47ed4b" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30d50ae9-3152-4776-ba31-9b0436bd5828" contextRef="C_e999414c-e45b-4680-8108-7315ee154945" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,514</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc7cb5b5-4dfb-47e5-9e53-a063021318c9" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,940</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf24e0ee-8bc5-46f1-aebb-32a52277d8ff" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d7f2386-eb70-4913-bfe7-8598f7524fd9" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a798d3a2-b13c-47d7-90b4-65bdb336e66b" contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2103f87e-c2ca-4562-88eb-2df51544cc0a" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,123</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71572632-781f-4d07-8c13-d102d6ca0979" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09090e3d-9c08-48fb-9fcf-c3187a3221ae" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3102b94-2bda-457c-ba9b-3bae7ba07c0d" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,179</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a16ffcd-d264-4fc3-83f5-ca3e617d53f3" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the following table summarizes marketable securities in an unrealized loss position (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.649%;box-sizing:content-box;"/>
         <td style="width:12.503%;box-sizing:content-box;"/>
         <td style="width:2.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.224%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.224%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Contractual Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fecf850-2e18-49cf-a39b-7f40123ed818" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,503</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e1a2ee7-8192-4727-9cf0-2cf6346e4818" contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31c020cb-e1c6-440d-b425-cd01787cbbea" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,064</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3a0e12-a510-4ccc-9370-675f139312cf" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fdaa94c-7272-405b-93b3-21ada17b6ab5" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0c7044e-52aa-4535-9421-574e056ea03b" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_362c3b75-bf64-4edc-a4d0-0b511b882f29" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,484</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb138e3f-b5ba-4f86-8eeb-7af9c9efa3b2" contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b592bd7b-3040-4c2e-8801-083c098b3878" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,009</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4b6c7c3-8ed2-49c5-9720-c552254e6961" contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d9a038d-ad3f-4101-b1b5-109c72397c0b" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,389</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3fab707-5b0d-4170-a7b5-d6b42b069d1f" contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcee41e2-6a40-49a2-9e05-b93ccaa67018" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,449</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fad00663-bee7-4867-aa0a-9dc5f318c7e6" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span><ix:nonNumeric id="F_ce0763ef-c1e4-4932-9b72-38d8070116c5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_ce0763ef-c1e4-4932-9b72-38d8070116c5_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leases</span></ix:nonNumeric></span></p><div><ix:continuation id="F_ce0763ef-c1e4-4932-9b72-38d8070116c5_1" continuedAt="F_ce0763ef-c1e4-4932-9b72-38d8070116c5_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and research and development space at the Company&#8217;s headquarters in South San Francisco, California under an operating lease. In April 2021, the Company entered into a lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da33746b-4912-4d6e-b4d8-14db164e6928" contextRef="C_c3cf3248-6c46-426f-8551-507bf07f1e44" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">12,560</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet, set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fca862ea-e7e8-449f-98a1-9479982b8041" contextRef="C_29cc3ec0-ed7a-4862-b908-992644953c81" name="sepn:LesseeOperatingLeaseExpirationYearAndMonth" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In September 2022, the lease was amended to add </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3903fba3-899e-4eba-9239-49157002026d" contextRef="C_322b3bab-f26e-4ef7-b671-7788690ea969" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">9,348</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet, totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b18de93-7b40-4ff7-8002-315c99fd963c" contextRef="C_855097d9-96a1-4e02-94d5-4334f3801f9b" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">21,908</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet (the &#8220;Original Leased Space&#8221;), also expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd27e090-9529-4da4-aefb-59bd02829ad6" contextRef="C_b5c224dc-4113-4169-a143-5596c3204f77" name="sepn:LesseeOperatingLeaseExpirationYearAndMonth" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In December 2022, the Company entered into another lease amendment to extend the term of the Original Leased Space and added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58883eed-8925-4768-9eae-89196f091e89" contextRef="C_9aa30191-c34b-4a93-8ee6-eeca325c6cba" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">22,911</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet (the &#8220;Additional Leased Space&#8221;). The Company took control of the Additional Leased Space in November 2023, at which point the Company vacated the Original Leased Space to allow the landlord to renovate it.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Renovation of the Original Leased Space was completed in July 2024. Upon completion of the renovation of the Original Leased Space, the lease of the Original Leased Space commenced, resulting in the total leased premises increasing to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2412be08-7816-4002-8f6f-c8e9479fb069" contextRef="C_7629b057-ea4b-4ebf-80e6-83afecdacd5f" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">44,819</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet (the &#8220;Leased Space&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term for the Leased Space expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5ae684b-e85c-4971-9f84-ea0b463e4af4" contextRef="C_cebc2669-0a16-4e56-bad3-816ef82b4bab" name="sepn:LesseeOperatingLeaseExpirationYearAndMonth" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02bb35b3-fd78-45a7-8d83-6b3d5becc031" contextRef="C_cebc2669-0a16-4e56-bad3-816ef82b4bab" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9048f7c0-02a1-4a73-b5b0-0221a7cabb52" contextRef="C_cebc2669-0a16-4e56-bad3-816ef82b4bab" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for eight additional years (the &#8220;Extension Option&#8221;)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, it was not probable that the Company would exercise the Extension Option, therefore, it was excluded from the right-of-use asset and lease liability calculations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company recorded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9e9f198-e2c6-4a84-8717-8d8dcb0650df" contextRef="C_c30be0fc-4d13-491e-b258-067754619704" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5c38c817-7370-4424-9f02-83c9cc8d2d26" contextRef="C_c30be0fc-4d13-491e-b258-067754619704" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million operating lease right-of-use asset and operating lease liability upon completion of the renovations of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_346c39b6-4ce4-4edf-905b-faf06d5d7834" contextRef="C_c30be0fc-4d13-491e-b258-067754619704" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">21,908</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square foot office and research and development space (the "Original Leased Space") as the Company occupied the property. These amounts are disclosed in the supplemental information of noncash activities on the statements of cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ce0763ef-c1e4-4932-9b72-38d8070116c5_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay base rent plus its proportionate share of operating expenses, as defined in the applicable lease agreement on all of its leases. Variable lease payments related to operating expenses including utilities, maintenance costs and real estate taxes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6bdd67-6069-4aeb-9506-8ba676d225e9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d14ada56-9005-439b-992f-e84acccd02e4" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024,  respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease expenses, excluding variable lease payments, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7681ff8d-f14e-4c72-a30e-68c59d234df4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bba6324-451d-43d7-b7ef-fc616410cb89" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively. Short-term lease expense was not material for the periods presented.  As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the weighted average remaining lease term of the Leased Space was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ac7a2df-e60c-4e4d-b866-93faeed05321" contextRef="C_4fac1b78-8311-432d-aff9-c804f3132070" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1842b56d-41d8-4cf7-bf00-a0585ebefb8d" contextRef="C_976a0a52-eca0-4d4d-ae45-b70fef55d6e0" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. The weighted average incremental borrowing rate used for the calculation of the present value of lease payments over the lease term was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_366c9dfe-7c2f-461a-a9aa-0db45211d958" contextRef="C_4fac1b78-8311-432d-aff9-c804f3132070" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dd52d86b-f21c-4cda-81e4-0cb1d806708d" contextRef="C_976a0a52-eca0-4d4d-ae45-b70fef55d6e0" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">11.34</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for both the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b56e44d-789b-445d-a0f6-8944b92b8989" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c21a148c-302c-4ce2-96b2-992f8b8a2139" contextRef="C_13a6815f-57a4-459f-b517-409e1abf0033" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,469</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afd1a016-ddba-4016-a764-5cbd51872c40" contextRef="C_15ee37b0-5f7b-4d77-b60f-a12687d07532" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,631</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_562222a9-0de1-41d6-8d8f-735bcc603afe" contextRef="C_13a6815f-57a4-459f-b517-409e1abf0033" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,721</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf55776b-ca17-44b8-adaf-1044343df531" contextRef="C_15ee37b0-5f7b-4d77-b60f-a12687d07532" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,462</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4be565eb-64e9-4b07-a323-2f59fc69422e" contextRef="C_13a6815f-57a4-459f-b517-409e1abf0033" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a41d067-7d5a-4557-990e-a570f283c6d2" contextRef="C_15ee37b0-5f7b-4d77-b60f-a12687d07532" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ef2694f-9679-4f28-9c24-9f10ed12c408" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, future minimum rental payments for operating leases were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.823%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future<br/>Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cc48c19-0cce-4431-8108-7652a1eba29b" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,612</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdb50233-33f5-4ba0-9c19-8b5662f64235" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,760</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e35c38a9-9649-4735-843d-49d1c919b115" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,912</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_986e310e-745d-4de0-b260-286882f15e4f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,070</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe1ee44-c4a1-4c0d-abe2-77e1c5131d0d" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,234</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ab7f7b0-a902-46a8-83ba-01cacf4e7646" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,616</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1faf7b3-1932-4dff-bc4d-534743ee1d8f" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_314e0a84-bd45-48f0-a055-c7b9c41455b6" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,579</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total present value of operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71bf2655-2c4a-4f32-9f80-1d268d5ef175" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b627b5d8-f335-4609-852e-4f986d546632" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,212</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef01cb34-ed3b-4655-aad6-4813c404ff96" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9028fe1-922a-44cb-bf8f-996cc6bebe23" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did not have any finance leases.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_1c8988e2-9cf2-44ab-bf0f-16e9758b69d3" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_1c8988e2-9cf2-44ab-bf0f-16e9758b69d3_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation, as the Company operates in an industry susceptible to patent or other legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company was not subject to any material legal proceedings as of December 31, 2025 and 2024, and the Company is not currently a party to any legal proceeding that, if determined adversely to the Company, in management&#8217;s opinion, is currently expected to individually or in the aggregate have a material adverse effect on the Company&#8217;s business, financial condition or results of operations taken as a whole.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1c8988e2-9cf2-44ab-bf0f-16e9758b69d3_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and may enable it to recover a portion of any future amounts paid. The Company is not currently aware of any indemnification claims. In addition, the Company believes that the fair value of any potential indemnification obligations is minimal. Accordingly, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81b65ada-2118-4464-819d-ac43aa93e1fc" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_131e1feb-1c48-421e-a4a6-c1887e3a5a87" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record any liabilities associated with these indemnification rights and agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abe732cc-6df7-49c1-a5bd-868873051bed" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:ConvertiblePreferredStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the closing of the Company's IPO in October 2024, the Company&#8217;s outstanding convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db009339-2c66-4d97-bc7e-7d0228e86025" contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,839,774</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of common stock. Converted preferred stock outstanding as of the date of the IPO consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47fabfba-fe54-4596-87fa-74643a28ac5f" contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">196,657,452</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. Each share of outstanding convertible preferred stock was converted into common stock at a ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74449b94-56a7-45e8-bcea-d40db0035886" contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.6103</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible preferred shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17d758a1-cc1c-4968-afb9-355b0fcc2576" contextRef="C_31b3e28f-bc58-4c85-9b5a-81f738157245" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common share. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65734d6a-52c9-41da-9387-bae2b81b1aa9" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f02b615c-1326-4311-b82f-f06b378da9d3" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_196d191a-8f5b-4e8e-844d-6c18ffa1ebc4" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_031d4f12-6157-47bd-93e8-546a5b82d756" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2e36db69-bab1-44ec-8cf2-7554fbfdf9ef" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9da6d97a-888a-4cd5-8f16-94c89da3b4a4" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of convertible preferred stock were authorized, issued or outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, the Company executed a Series A Convertible Preferred Stock financing arrangement that would provide financing of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88e58021-0748-4919-b60a-77a6e763faae" contextRef="C_ea277975-b2f2-4b8a-b194-b83995f01006" name="sepn:TemporaryEquityStockFinancingArrangementFinancingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million over an initial tranche and subsequent callable tranches through the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_985233a9-f00a-46d6-b145-d64a1d3155c5" contextRef="C_45f515bf-1005-4082-bc32-9ade4315528d" name="sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock at an issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c9a2ee1-1a32-4530-8b26-0987a7581a7a" contextRef="C_1966a14f-61e2-41d4-a6ff-47aa4fad01b8" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. In the initial tranche, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97593be6-d7e8-4f3d-b733-273ed2491542" contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102" name="sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">45.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a229a4f2-d23a-4718-83e5-1ca4cef73a14" contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">44.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_665a08a3-aa98-4e43-b2bc-638168610639" contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102" name="sepn:CashProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was received in cash, net of issuance costs, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27a4065b-1769-49a9-a761-126883371239" contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102" name="sepn:NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. The Series A Convertible Preferred Stock financing arrangement represented an equity financing, per the terms of the outstanding convertible promissory notes, and as such the unpaid principal and accrued interest outstanding of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae9d1864-6665-48a4-8f2d-b2db9453d634" contextRef="C_ca4c5acf-d189-48eb-b452-a7a26d138b38" name="sepn:ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fac38477-c548-41db-b9ec-95d36bd318c8" contextRef="C_ca4c5acf-d189-48eb-b452-a7a26d138b38" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock. Additionally, in November 2022, the Company executed the second tranche and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fc4926f-96a1-4e7e-bc93-40867e263467" contextRef="C_60266656-e390-427d-9798-309361aca6dd" name="sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock and received net cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c95b481-2f7c-4006-a53c-6e0b44ea222c" contextRef="C_60266656-e390-427d-9798-309361aca6dd" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the Company entered into a Series B Convertible Preferred Stock financing arrangement in which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_036cbecd-94dd-4a46-af85-7e1878db3912" contextRef="C_9bf04a86-29ff-485b-98ad-fd0cfacc548a" name="sepn:TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">121,657,452</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series B Convertible Preferred Stock were authorized to be issued at an issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18e9246f-732a-402c-a0c3-06e1442ee714" contextRef="C_04ddd023-f899-4392-8195-43ee327ecc9a" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.23297</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share over two tranches, for total proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dcf7394-a3d0-4b65-a2b1-675fd93dce0f" contextRef="C_f57fea07-b224-42ba-828d-12e6d48e58e5" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In June 2023 and July 2023, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fc85858-bbb7-4fad-8d04-82ec5850d552" contextRef="C_61651a61-4b9e-4a51-a5f6-c5b66b40d36c" name="sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series B Convertible Preferred Stock at an issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1964966e-74e9-4174-a503-e0afc59f23c6" contextRef="C_572956ed-3133-4ecc-8cc8-1ffe3b8330b1" name="us-gaap:PreferredStockConvertibleConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.23297</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_333086c1-1c7d-4d8c-85c9-eda168f291e1" contextRef="C_61651a61-4b9e-4a51-a5f6-c5b66b40d36c" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">74.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the first tranche, with a potential second tranche of additional funding for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c06312be-5966-4b5a-b7ec-dbd72f6e6ce0" contextRef="C_79b1f183-8e7f-4be0-a70d-a466859c1d3f" name="sepn:TemporaryEquityStockAdditionalFundingBasedOnApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on approval of the Board of Directors and consent of the majority of the holders of the then-outstanding Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock Purchase Agreement provides that, upon the fulfillment of certain conditions, each investor will purchase its pro rata portion of the shares to be issued in additional Series B Convertible Preferred Stock closings. Further, the Company agreed to sell, and issue said shares of Series B Convertible Preferred Stock on the same terms as the first tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were not freestanding from the associated shares of convertible preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51001d22-3a9c-43fc-8e9f-049bf57b1773" contextRef="C_0baed1d2-4492-4d81-b9ab-a87043b82d59" name="sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series B Convertible Preferred Stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6707a7e-bed2-4e74-84ae-459319132daa" contextRef="C_0baed1d2-4492-4d81-b9ab-a87043b82d59" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">74.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_0a0eeb76-ec24-4e18-916f-f2b68c069e8f" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:CommonStockTextBlock" escape="true" continuedAt="F_0a0eeb76-ec24-4e18-916f-f2b68c069e8f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company was authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17a50f98-5761-4268-8039-275cdb3ea55d" contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6a03237d-51a6-4575-ba3a-0dcf1f6b281c" contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4ceab65-931f-47c8-b9fc-036891c956a4" contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_71fd5c02-0f2d-4405-aeea-a365c3018031" contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company amended and restated its certificate of incorporation, which was filed immediately prior to the closing of its IPO and among other things, increased the number of shares of common stock authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f799e56-6196-4258-9cbb-b9897993282d" contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company completed its IPO of its common stock. In connection with the Company's IPO, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc7e368a-b615-420a-85ca-e4bde02bcd8e" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock, which included an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64523752-98a4-4bd6-bfa1-2cda8fd027c9" contextRef="C_da673621-a76d-4b43-ba2e-10ba33dfce9a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock that were issued to the underwriters pursuant to the full exercise of their option to purchase additional shares of common stock, at the public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1917de6-ce62-4b63-b3b1-76acadce2965" contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As a result, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0010126f-546e-4583-9a9e-88eba16d37fc" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">302.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions and other offering costs payable by the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c10b5a72-ddcc-4457-87d3-bb5dea95f53e" contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866" name="sepn:UnderwritingDiscountsCommissionsAndOtherOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of common stock are entitled to dividends when and if declared by the board of directors. The board of directors has not declared any dividends and the Company has not paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_0a0eeb76-ec24-4e18-916f-f2b68c069e8f_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e815310a-3b45-48cc-ab0b-1cacc03af9c7" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock, on an as-converted basis, for future issuance:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f085ea9e-f4bb-4d37-8bab-a8e53c3980f9" contextRef="C_20efa5c4-f0f4-4871-a51a-f97b96ba7528" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,378,484</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908c2689-f8f3-4fe5-995c-c031ea9f65cb" contextRef="C_319a9d87-f6e6-4839-a984-753a05d06533" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,938,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future grants under 2024 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0e7627-7dbd-4be2-be9c-731256b0d599" contextRef="C_69798fd2-c3f2-4367-9df7-974806f034ff" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,257,640</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80266da5-6b33-4fbe-bfcf-37f94004e998" contextRef="C_93730b11-03a0-4363-ac76-9b4b4706269a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,743,915</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for 2024 ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a58ce5d1-1f8e-470e-9878-25ae5cc80577" contextRef="C_7bbf537c-2701-4b45-969a-1f72cf64e583" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">251,211</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4b35ff8-4f28-4053-b910-6709d02e828a" contextRef="C_6ec0577b-0a29-403d-97f4-adea4205df16" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">369,402</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_069adc29-bdf3-45d5-9aa2-8bb64e5e8e7a" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,887,335</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1ba1c00-2848-4739-b1bf-bd72edc51b9c" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,052,299</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_222b5ae5-c413-4482-8567-cc97393aec15" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_222b5ae5-c413-4482-8567-cc97393aec15_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company's board of directors adopted, and its stockholders approved, the 2024 Stock Option and Incentive Plan (the &#8220;2024 Plan&#8221;) which became effective on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_275fba1b-0062-4ecf-90eb-0be32e137197" contextRef="C_84234d5b-13da-4f60-8e97-1e3d68e04f15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 25, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The 2024 Plan allows for the issuance of equity-based incentive awards to the Company's officers, employees, directors and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034 by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03e5ab04-124a-4f49-900d-9bcb896f3ec5" contextRef="C_9e8af7b3-5a45-498e-98e0-2a164d3ce69b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company's compensation committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 Plan replaced the Septerna, Inc. 2021 Stock Option and Grant Plan (the &#8220;2021 Plan&#8221;) as the Company&#8217;s board of directors determined not to make additional awards under the 2021 Plan following the completion of the IPO. However, the 2021 Plan will continue to govern outstanding equity awards granted thereunder. The shares of common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added to the shares of the Company's common stock available for issuance under the 2024 Plan. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b325c16d-9d73-4277-9b84-6c195aea5adc" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03f4626f-b3a2-4de6-8769-601ac345fbd6" contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares remained available for future issuance under the 2024 Plan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options are governed by stock option agreements between the Company and recipients of stock options. Incentive stock options and nonqualified stock options may be granted under the 2024 Plan at an exercise price of not less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3324023a-518e-43e4-adb6-4d233a3ee325" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the board of directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of the stock options may not exceed ten years from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Stock Option and Grant Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2021, the Company adopted the 2021 Plan, which authorizes the Company to grant incentive stock options, non-qualified stock options, restricted stock awards, unrestricted stock awards and restricted stock units, to officers, employees, directors, consultants, or other key persons of the Company. The terms of the stock option and restricted stock agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2021 Plan. Stock option awards expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc98810d-7993-43e5-96a0-52996fbd0ec5" contextRef="C_3b25f05e-0de5-4de6-9e95-c302e515b95c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date, or as otherwise determined by the Board of Directors, or in the case of incentive stock options granted to 10% stockholders, the term is no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c9194c6-206f-455b-affc-f5ae69825b61" contextRef="C_ef8945b7-cd7c-40a3-87d4-443fa84b4251" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date. Additionally, the Company granted and issued restricted stock awards and allowed the recipients to purchase the unvested restricted stock awards at par value per share. The shares issued for unvested restricted stock awards under the 2021 Plan are subject to repurchase by the Company at the original issuance price in the event of the holder&#8217;s termination of its relationship with the Company. Consideration received for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#8217; equity as the related awards vest over the requisite service period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4742bb25-c80f-43c2-a257-f4a4823db67a" contextRef="C_6babc3f6-8967-4f07-bbd1-1345bb333060" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2b1ab7fd-59e9-4f73-bec6-1161a4e2f696" contextRef="C_aae82e13-ba71-4eff-a125-de3c3ef90394" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mained available for future issuance under the 2021 Plan as of December 31, 2025 and 2024 as the 2021 Plan was replaced by the 2024 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company granted restricted stock awards from the 2021 Plan and from outside of its stock plans, under the terms of restricted stock purchase agreements and subscription agreements. Unvested shares are subject to repurchase by the Company upon the holder&#8217;s termination of its relationship with the Company at the original purchase price. Consideration received for shares associated with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_222b5ae5-c413-4482-8567-cc97393aec15_1" continuedAt="F_222b5ae5-c413-4482-8567-cc97393aec15_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#8217; equity as the related awards vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f73a2776-6459-4fb0-a9bc-4204d876730b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes restricted stock award activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a877dcf1-62f0-41a0-961c-d0105b464b40" contextRef="C_885615b0-7d7a-4feb-b3a7-220a271f5de4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">576,829</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cb02752-2306-47f7-a873-6435ca59e001" contextRef="C_885615b0-7d7a-4feb-b3a7-220a271f5de4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.62</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock awards vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd1b0f3f-7b9e-4639-af0b-07941c713905" contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">442,993</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0720e725-3f28-4602-bceb-141b6d29e684" contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock awards repurchased</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6279aac7-9bea-448e-9452-59ffa456f53f" contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679" name="sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,612</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d74723fc-bf87-4187-9c7f-6ba336b25d09" contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679" name="sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.30</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e2498d3-011e-4c35-9e31-8a3cecc50526" contextRef="C_6646c47e-b885-4673-91f4-70ca9e64299e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">131,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c693ab7-ff10-438a-b10e-0fcf24c209d2" contextRef="C_6646c47e-b885-4673-91f4-70ca9e64299e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.81</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The restricted stock awards generally include a service condition for vesting and vest over four years with a one-year cliff vesting and pro-rata monthly vesting thereafter, but some awards vest over different time periods. In addition, some restricted stock awards include vesting criteria subject to the achievement of performance-based conditions in addition to service conditions (&#8220;performance RSAs&#8221;). As of December 31, 2025, none of the outstanding and unvested performance RSAs were subject to achievement of performance-based criteria for vesting. The aggregate grant date fair value of shares vested during the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17014c4-e993-4f13-8648-0fff1c77bf3c" contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The remaining liability related to restricted stock awards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 was not material and was recorded in accrued expenses and other current liabilities on the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70d154be-d27c-4919-8c42-a02ce0a58981" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes stock option activity under the 2024 Plan:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.11%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.662%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.942%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.662%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.182%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Options<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_495cd3eb-f09f-47fd-bf1a-ee90e8c150b5" contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,938,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_111a53ac-5577-4322-9fe1-22f2514226ad" contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.64</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1f99cf87-715c-4869-9b1d-234ed0784e88" contextRef="C_36e0e89a-7c81-4296-9fff-19f854f1ce13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.11</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1a6d772-d351-47a3-9c2a-92db708bf4f5" contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,706</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bece00b-5390-4eb4-8fb2-05560499bbac" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,914,914</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f45813f-3087-4aff-a6f8-48453f58f6ed" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.44</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2b2572b-63a6-4f99-9e50-077051bfb8e7" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">268,188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e13f2fff-5988-4d75-9002-61460ccd4ba6" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.66</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c9f603c-7462-4d53-a854-2c1fb79513d6" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">207,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b7d5433-8382-4f12-8354-e9c9fa211663" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.70</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e9bb596-edec-4220-ba06-9cb5bd1615fc" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,378,484</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8132464e-48eb-4455-ad20-b4041799938b" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.97</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_df8f3904-f3a5-4f99-925b-343432c5b6e6" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.79</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61627bc3-f9aa-479d-a6d6-022beb3ba001" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,194</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93206a6d-99f6-4d27-952b-09820a4bcb27" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,096,087</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb658692-95f1-43cb-a735-63c01fcbfe4a" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.60</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5451532e-fdad-4045-833b-003b6a9dcfb2" contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.19</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_409cc626-54f5-463e-8a95-69cfe363a0b4" contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,516</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options include a service condition for vesting and generally vest over four years. The aggregate intrinsic values of options outstanding and exercisable were calculated as the difference between the exercise price of the options and the closing market price of the Company&#8217;s common stock as of December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate grant date fair value of options that vested for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a10672b-6d6a-4f27-9a2c-239b09cdd2d9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The options granted in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> had a weighted-average per share grant-date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6dd91c1-f91d-4646-8d00-ec28d3c497a7" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.58</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08af04ef-cb74-4098-a723-cc5ffc73a453" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and a total grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f586d490-8495-4fd6-a31d-47938d745b50" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37413059-43ed-4ecb-bd42-d510347f674e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The total intrinsic value of stock options exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a28169-4954-41e3-a955-c80d527375b9" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company's board of directors adopted, and its stockholders approved, the 2024 ESPP. The 2024 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2026 and each January 1 thereafter through January 1, 2034, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a222287-f1d7-489a-bf56-d2832a5515dc" contextRef="C_8c6cd37e-c9c8-4880-a575-854c05609cbb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5db1c626-6566-472c-8579-a9f99c27f4da" contextRef="C_66e5c4ac-4b2d-4683-bb29-b0c9430f9075" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the outstanding number of shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_222b5ae5-c413-4482-8567-cc97393aec15_2" continuedAt="F_222b5ae5-c413-4482-8567-cc97393aec15_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the administrator of the 2024 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d018352-3b91-4581-a5a1-809e83ff21b5" contextRef="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offering periods begin on May 1 and November 1, will be twenty-four (24) months in duration and include four (4) purchase periods, each purchase period lasting six (6) months.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The purchase price will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dec4f4b1-cc1c-4696-b112-fa9078b9ba13" contextRef="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f" name="sepn:PurchasePricePercentageOfFairMarketValuePerShareOnOffering" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value per share of the Company's common stock on either the offering date, which is the first trading day of the offering period, or the purchase date, which is the last trading day of the purchase period, whichever is less.  If the fair market value of a share of the Company's common stock on any purchase date within a particular offering period is less than the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2546b6a-3504-4163-93db-3b27ff5974fa" contextRef="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,191</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares at a weighted average share price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f799150-1616-407e-91cb-86ce4be05321" contextRef="C_e34ee022-7881-4415-9223-49c1cc144b97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70a34857-9fb8-4a28-b82f-21b39da1dd4b" contextRef="C_e34ee022-7881-4415-9223-49c1cc144b97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares available for issuance under the 2024 ESPP.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option and ESPP Valuation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of the stock options and ESPP granted, the Company uses the Black-Scholes option pricing model and assumptions discussed below. This model utilizes inputs that are subjective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term represents the period that the Company&#8217;s stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The Company will continue to apply this process until a sufficient amount of historical information regarding employee exercise patterns and post-vesting employment termination behavior becomes available.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the Company&#8217;s limited operating history and lack of company-specific historical volatility as a public company, due to the Company's IPO in October 2024, or implied volatility as a private company, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free Interest Rate &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the near future. Therefore, the Company used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75b23b9e-d296-43b2-848e-151aa1919a39" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used to value employee and non-employee stock option awards granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.2%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="9" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2422f48-57fd-4ef2-8775-d155fe8f8d7c" contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f1c34b4-9c4c-4903-af8f-a6dacbe92556" contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.83</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bead90b9-b46a-436c-a3d2-d294c0fdc113" contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">92.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb232003-0efc-4017-874d-d06567b3fecc" contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">91.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_206530c4-f315-4dd8-b101-24d188cf12b0" contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.97</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8ddf9f42-7b4e-4fc0-bc8c-d44f6dfc1d25" contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6017a525-b52d-429a-9e3a-9168b19414d8" contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_234d0c84-082a-45bb-885c-ef9e507a6542" contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used to value employee stock purchase plan shares granted during the year ended December 31, 2025, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:64.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.75%;box-sizing:content-box;"/>
         <td style="width:1.562%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:4.688%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a5a917-515e-44ac-8141-5c9aea0489b3" contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.82</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d63f224b-38fa-430c-9064-70fab294143d" contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">86.53</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_850bd51b-334c-481e-b2d6-4dd45be63b4e" contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.22</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da472cfb-b42f-4849-ab64-fdcd72025f06" contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_222b5ae5-c413-4482-8567-cc97393aec15_3"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29eeaf90-b2ab-4526-8d3b-ab4faf818608" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for restricted stock awards, stock options, and ESPP recognized in the Company&#8217;s statements of operations and comprehensive loss is presented as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a261a29-6fb0-4fb0-8cd4-a39b2f94d93a" contextRef="C_3cba6681-4177-41a6-98a7-0683daf19bf3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,087</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e60093-c685-4e81-a4cf-94d1396d472f" contextRef="C_4dd9f47b-1fb7-4754-a5f2-2c832537c007" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,619</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c50a772-0fa1-4a1b-8613-170cb4c479aa" contextRef="C_bb23122e-3c2b-4030-8ff0-177914816c06" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,389</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_985a2a9a-5103-4d28-b6ff-997b02482e00" contextRef="C_39947422-5330-41f2-b716-f2d784c2e0cc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,533</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f53b4a-88c9-4916-83b4-ad7bee94b62c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,476</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ef76a8e-2ae7-4f92-8861-0ad2a8a781ea" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,152</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized stock-based compensation expense related to unvested restricted stock awards, stock options, and ESPP was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70c57a5a-499a-46c5-9a01-06a404633062" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b456bcd-0d2b-416a-945c-d51c53edbb74" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div><ix:nonNumeric id="F_003ccfd2-5240-48c9-8615-e31fc337ae09" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_003ccfd2-5240-48c9-8615-e31fc337ae09_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71c5ab32-345f-460b-a5eb-bef439869b4f" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the provision (benefit) for income taxes were as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.08%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbafc55b-dfc3-4ff3-8c76-d7d052d3fd19" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94a5af08-ce0d-4c27-9709-d04011f0d487" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb47ed6c-a9cf-4c08-b1dd-67035a9d5a9d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34735712-9eb0-471d-88e7-f6e194b9ac30" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ed8eb1e-d28e-4374-815a-0fd1bddfa0f4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b5d8827-6b2f-4772-94bf-ba308b56e913" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85efae01-538f-48fe-848f-0bc5deced04e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b606fd47-2129-4b87-a302-1935fd08457e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bdbda1c-8e52-4b1d-8a8a-e823c0828bc4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58a60ec7-51ea-4b4c-9c24-8708c95b6d42" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4203683a-da93-4dc1-93e7-c6fa60fab12c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f74448b7-8826-4ad6-877e-a75e85b4e3ac" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fa1680e-8e27-4656-8c36-2ea27b0542ac" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bfacaa6-b3ad-49e0-956e-89d4c3a75b5e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 2, we adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. For the year ended December 31, 2025, the tax provision expense was not material. For the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded income tax benefit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7916679f-305a-4d2c-8d53-63f1e94fd17e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div><ix:nonNumeric id="F_eea6df1a-1d03-4e5a-a47b-400e37c670b0" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_eea6df1a-1d03-4e5a-a47b-400e37c670b0_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate to the statutory U.S. federal rate is as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.807%;box-sizing:content-box;"/>
         <td style="width:1.205%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.278%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.205%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.073%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.434%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2025</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b8efe224-c188-42df-a41c-9d6bf32284b2;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;federal taxes at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1090205a-a771-478f-8473-9d0bdc357945" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,262</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_450134bb-3eb6-4e68-a504-4a0e9e9b7100" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acb829bd-62a3-49ca-bfa9-a0b5d5de8766" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_741577d5-7c6d-4594-b866-ce6cb3f3be87" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f995fd7-8ff1-4e71-9aaa-5d9e7b3fd58a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,195</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_267ec387-6225-4f82-84ab-8b304cea4195" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4b3ef5-84e9-4663-a15a-26927ea61a30" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,972</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3d3e8de-a290-43e0-b509-df74d6890d8a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">20.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e97ba6-a000-4483-83b1-4ecaac43cbdb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,081</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ea7269-df6c-488a-8776-79dc76ba4c44" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1922472e-d2ba-46e4-8b39-12b74d6b0e85" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16b15f43-236c-4f89-8246-86f13cae191c" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_435c1c5f-8b94-4ee4-9fbe-ca4b01fb8961" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f67e271-e5b8-4bfd-8534-e11bf91da47a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c450d89-17ee-4be3-ac26-86f63f91abef" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationTaxContingencies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1adc672b-c75c-4168-87ee-9e12424eb196" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fb96a9c-956c-4a6c-b9d6-8f2f6726d661" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbdbb1ba-9601-4501-bbbd-b42a5714d6b1" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4bac637-4c31-4815-a5b9-4acd24f12215" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb97566f-6e64-43a7-b8cf-78ef1a9e2adb" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_003ccfd2-5240-48c9-8615-e31fc337ae09_1" continuedAt="F_003ccfd2-5240-48c9-8615-e31fc337ae09_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_eea6df1a-1d03-4e5a-a47b-400e37c670b0_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:74.32%;box-sizing:content-box;"/>
         <td style="width:1.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal taxes at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_247b49bb-e370-472b-8828-3f4057e3a102" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b1024ba-8ed8-4c59-8c66-1565c0a9a1b7" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4d4ffbb-efef-4daa-82a0-1104e1efee0d" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b852214c-6e32-451b-bc73-8f48d62aa211" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a517eff-706c-491a-ac46-bde7e81065e9" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">29.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e03bbd02-c76b-4802-b71c-479d392e3711" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total effective income tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b0925f-2806-4d1c-9c69-671fa80a0d58" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><ix:nonNumeric id="F_3af38355-6a33-4c24-b210-2c2a76b00411" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_3af38355-6a33-4c24-b210-2c2a76b00411_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The types of temporary differences that give rise to significant portions of the Company&#8217;s deferred income tax assets and liabilities are set out below (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3af38355-6a33-4c24-b210-2c2a76b00411_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90e57dfd-7c9f-49fb-829d-3fa169afd2b3" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,149</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd34e9a9-6f3b-4062-a112-e576f6275819" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,122</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0800c25-7a1c-4c38-bd74-3dbeb6f564e0" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,318</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76aa8bfb-0ff9-4c4c-a5b9-c08425ecdf03" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3845c132-5ba7-4482-a3fa-05b1e43fddf0" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,620</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_742fe482-2bc2-4029-aa83-3b6e8a73d1d4" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c43a3e0-a694-43fe-9f11-afc37d36dc81" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_699f16fa-634d-4a75-92d6-f2e3eab0374e" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_539f12d0-cb76-4ece-a0a3-491ff881bf63" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d07df18b-f43a-43cd-be2e-1acf9bb02b47" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 174 capitalized research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e6dc719-76e2-48a1-851a-878e0cd3f302" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,932</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e9f3402-c267-4166-917c-c971250ca2fb" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,855</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d2b1aec-0696-45cc-8c52-8bc69d5697cf" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,812</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee8701f8-93ea-4970-b4e4-50dec22133f1" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,432</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe94b3ef-3a4d-4b95-8280-1e4dedd43d83" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,015</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd5f235f-d9ed-4fcc-b1ff-1985daffb8d9" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,061</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d67f089-b052-458d-8643-c0a5523852c3" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,797</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e30e30d-3835-470d-90a6-35d91fbf5435" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,371</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfe9f8df-de93-475d-ba1e-3a6546299f51" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">683</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1abd7d52-4366-405b-b4f2-e1828862744c" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">766</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_480e70ff-c43b-4f23-b319-a423a5b8cb31" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="sepn:DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,114</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a293dbb1-0f11-4efe-99ad-86adffcbdd28" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="sepn:DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,605</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5855f46d-9c86-412f-a943-b1794cdc8a51" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,797</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dc74dc2-177a-4e49-98f1-8cf837c39bda" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,371</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b66c429-94b6-48ac-8961-8997f4bfab04" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9daddc26-68d6-4647-afbb-095554e3b2a4" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established a valuation allowance for the amount of deferred tax assets that are not more likely than not to be realized. Management considered all available evidence, both positive and negative, including but not limited to the Company&#8217;s historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in the total valuation allowance for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was an increase of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43acd0d0-f218-4b13-aab9-ea3d936f9c66" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a905d0d6-c4cf-4b15-9766-1e7b043d826b" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d80a6bd-3208-4cee-b2d2-5afafb66b3cf" contextRef="C_32ee6c26-363c-447f-b284-d18487b21d59" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal net operating loss carryforwards and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2869cc8f-8dd3-49cf-a841-092585823ae1" contextRef="C_edbd8258-cfdd-447f-8899-e8bf5ca401c7" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">77.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state net operating loss carryforwards, available to reduce future taxable income. The federal net operating loss carryforwards will carryforward indefinitely. The state net operating loss carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a66cca3-7fe3-4955-b201-77b13dce445f" contextRef="C_76244c83-b690-42fd-93b3-51188d2e836f" name="sepn:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2041</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if not utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal research and development tax credits carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_443f0503-ae26-4e09-a044-0940456210dc" contextRef="C_55101ae3-0a3e-4d43-a901-c61588a76992" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and state research and development tax credits carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ed1a552-4c35-462e-8af0-029dad1fd69c" contextRef="C_26b3acdc-a041-414e-a35d-958f1caf4710" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, available to reduce future income taxes. The federal research and development tax credits will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68f1d6d1-09fc-4e1d-8c6b-3fa5675c5ab5" contextRef="C_43471eb0-1ae4-4188-8890-d5649bb442c2" name="sepn:TaxCreditCarryforwardExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if not utilized. The state research and development tax credits have no expiration date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Revenue Code section 382 (&#8220;IRC Section 382&#8221;) places a limitation (the &#8220;Section 382 Limitation&#8221;) on the amount of taxable income that can be offset by net operating loss (&#8220;NOL&#8221;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules. When an ownership change occurs, IRC Section 382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax attributes in one year but the identified ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. The Company performed a Section 382 analysis through the year ended December 31, 2024 and determined there were ownership changes in 2021 and 2023. The ownership changes did not result in a reduction of its net operating loss or in its research and development credit carryforwards expiring unused.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_003ccfd2-5240-48c9-8615-e31fc337ae09_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79945723-a476-428f-908d-e16d8313efc1" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e04d017-dd8c-4f8f-943c-0bea8a90186a" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4cc549-e633-4ad5-82b1-e59e3fc1d2ed" contextRef="C_e5502035-9c62-4bfa-b75f-04b8934fb13b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f166d3e7-ab50-42b7-86f4-cb26646b0f4a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c35427c-05e8-412b-86ba-eec965f21830" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">998</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment based on tax positions related to prior years</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ebf5435-cf6b-4bae-b0e6-6251371915a4" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6784753c-3c33-4984-944d-14d6b4de33f2" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of the year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d917316a-e572-444a-a040-22bcd8fc21dc" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,145</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a67bba-707d-4dfa-a03c-38d30455b9e1" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reversal of the uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. During the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0daaddc5-7697-4ed7-83cf-a833afedc2d4" contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2228e0cf-94cb-416f-b7e4-a7829bb69920" contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize accrued interest and penalties related to unrecognized tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income taxes in the U.S. federal jurisdiction, the state of California and various other U.S. states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All income tax returns will remain open for examination by the federal, state and foreign authorities for three or four years, from the date of utilization of any NOLs or credits.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_4af4c4d0-275a-4f4f-9698-a235b7429a22" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" continuedAt="F_4af4c4d0-275a-4f4f-9698-a235b7429a22_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Related Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third Rock Ventures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48e4f2dc-8cfe-4aac-94a5-8ae053164eae" contextRef="C_2ca0b610-feb1-4fc4-9fb6-285c278593cf" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its Series B Convertible Preferred Stock to Third Rock Ventures VI, L.P., a holder of more than 5% of the Company&#8217;s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49702887-f5fe-4928-8e2c-e645e4c23348" contextRef="C_2ca0b610-feb1-4fc4-9fb6-285c278593cf" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18489e8e-0662-41c8-a00a-94053e993601" contextRef="C_4ce5aad8-c86e-421c-9386-a0a475a3e0cf" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2021, the Company entered into a service agreement with Third Rock Ventures, LLC (&#8220;TRV&#8221;), a holder of more than 5% of the Company&#8217;s outstanding capital stock, (the &#8220;TRV service agreement&#8221;) under which TRV provides consulting services to the Company. For the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91f7db92-11e1-4a79-8578-96dceeb173cc" contextRef="C_d3c78d76-dd2e-4cd2-a4ec-26c17d567446" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for such services as general and administrative expenses in the Company&#8217;s statements of operations and comprehensive loss. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb36c901-5c4b-47f7-8b98-e8629b0c6c09" contextRef="C_a9816031-a377-48f3-a65a-63d6a0198c1e" name="sepn:AccruedExpenseAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of expense related to TRV was recorded in accrued expenses and other current liabilities. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76eb8565-5951-4084-92e8-1c24ebf5fc86" contextRef="C_1c50a455-abd2-40af-bc2f-471cb232f201" name="sepn:AccruedExpenseAndOtherCurrentLiabilities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expense recorded in accrued expenses and other current liabilities and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99fff109-9eb1-473b-9743-45ab09a66a82" contextRef="C_1c50a455-abd2-40af-bc2f-471cb232f201" name="us-gaap:AccountsPayableCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding accounts payable to TRV at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's former interim Chief Medical Officer, and also a current member of the Company's board of directors, was designated to the Company's board of directors by TRV and is affiliated with TRV. He did not receive any cash compensation from the Company for his service as its interim Chief Medical Officer as his services were provided to the Company through the TRV service agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the total fees the Company incurred under the TRV service agreement for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5afbd66d-31bc-4f40-959b-1472452bacca" contextRef="C_6351b22f-2be8-4ebf-a536-1da1776a2f78" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was attributed to consulting services provided by the board member. Additionally, as compensation for his services as the Company's interim Chief Medical Officer, the Company granted him options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91a12df6-09a9-4fc9-97f0-3583d216b11c" contextRef="C_8a5f118b-d06e-4890-a43e-997cc3e53337" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,227</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares during the year ended December 31, 2024 at the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d8c152d-ba77-4737-aec4-4f5935cdf895" contextRef="C_8a5f118b-d06e-4890-a43e-997cc3e53337" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The board member ceased serving as interim Chief Medical Officer in September 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a separate consulting agreement with the board member, under which he may provide up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4ef091a-3cda-4097-9abd-c12c76d67d01" contextRef="C_8a386e2d-47cd-42af-a8e3-db3089a6f1be" name="us-gaap:ProfessionalFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of consulting services per month, which are also provided to the Company through the TRV service agreement. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f415dcb9-a712-451c-9e19-a2d8452a2acd" contextRef="C_50876280-ce05-4b2f-a74c-aab5ab966a93" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for such consulting services. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, there was a minimal expense recorded in accrued expenses and other current liabilities and a minimal outstanding accounts payable to the board member.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RA Capital</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5811967-fcab-4f58-a999-dba874737465" contextRef="C_f4c23b37-5cfc-40da-a0d2-d57dcfb5120d" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its Series B Convertible Preferred Stock to entities affiliated with RA Capital Management, L.P. (collectively, &#8220;RA Capital&#8221;), which held more than 5% of the Company&#8217;s outstanding capital stock, during the second tranche closing in May 2024, for total cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c73e15a4-cdd2-4dd5-bf46-d69b2e35c6d7" contextRef="C_f4c23b37-5cfc-40da-a0d2-d57dcfb5120d" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These shares were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4af4c4d0-275a-4f4f-9698-a235b7429a22_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">converted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to shares of the Company's common stock upon the consummation of its IPO in October 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c258376f-5878-4369-8cc4-4476aaacd5c9" contextRef="C_4d8fbc94-ff88-4825-9417-f0e8f0e8e33a" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Samsara BioCapital</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43f87130-4ba3-4613-b4ac-551529382eec" contextRef="C_12bf748d-8c8f-43c8-986f-7e62abb1f3b2" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its Series B Convertible Preferred Stock to Samsara BioCapital, L.P. (&#8220;Samsara BioCapital&#8221;), a holder of more than 5% of the Company&#8217;s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ac5ae7-9c5e-434f-ac21-415509c5fedb" contextRef="C_12bf748d-8c8f-43c8-986f-7e62abb1f3b2" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05987e37-3815-47e5-83f0-b4d1ee9401ae" contextRef="C_1a5a03ec-3b78-4b4f-984f-9c02f37f3f79" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32f93eca-88f4-47ea-8404-15a47fd8b951" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89fc8877-ee06-4468-9d06-35cefd18ca6e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,554,420</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of potentially dilutive securities, comprised of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb08eb9-6131-4fa4-a885-81ccd5216459" contextRef="C_388d86f8-b34d-4f0d-9ce6-8aae94db4af3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,378,484</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding stock options, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee13ba28-af77-41c8-8bc6-19bb276ebdb1" contextRef="C_886793f1-e018-4e02-b853-202065e4572b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">131,224</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unvested restricted stock awards subject to repurchase, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a31113a0-258f-4fcf-8f4f-4cb768d5cd16" contextRef="C_f8051df8-6f74-4da2-9664-e548022686e5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,712</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable under the ESPP, not included in the calculation of diluted net loss per share for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025  because to do so would be anti-dilutive.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a49f3a35-c126-4e69-ba0d-150484379159" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Employee Retirement Benefit Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a 401(k) retirement savings plan (the &#8220;401(k) Plan&#8221;) for its employees. The 401(k) Plan allows eligible employees to make contributions up to the maximum allowable by the Internal Revenue Service (&#8220;IRS&#8221;). For the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made matching contributions of and recorded contribution expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e9fa86a-664e-4d3f-8762-30777e34d14d" contextRef="C_9d256ca5-ca4e-416a-9cfc-3811d06616cf" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_744eed61-3851-4bfb-82c2-3c5c3b29f343" contextRef="C_9c372061-ee03-484f-8e37-ab25c25fbca6" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1f41741-4cc8-456b-9eb9-dfe62d99b6c8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company&#8217;s operating segment and decides how to allocate resources based on the Company&#8217;s available cash resources. Total operating expenses and net loss of the Company&#8217;s operating segment are used to monitor budget versus actual results. The measure of segment assets is reported as total assets on the Company&#8217;s balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86a46e5c-76ee-48cc-b1d7-b5a79a6d4b9b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM is regularly provided with the following significant segment expenses:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5c7d069-c49e-49f4-bc89-9a648f6bdd1a" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,951</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28377e25-2202-4d9e-b1bd-594d350cc814" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,075</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cdcfd57-b101-499f-9655-2c87f23a1e8d" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,468</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae206dbb-d0db-43c3-9662-5227f311070e" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,233</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85527a3c-bc12-43ba-bcac-47bee3c80282" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,476</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6b2395-81ce-461c-a393-732a29a3b9e5" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,152</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2d0ae6d-9ea5-4332-ab17-745a60a896a7" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:ExternalResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,519</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f7c048d-3064-4039-8e6b-bc0b94cf1c81" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:ExternalResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_100ee1c6-642f-4d44-8bd3-61d470768cef" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="sepn:ExternalGeneralAndAdministrativeExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,856</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3ff6dd6-046c-431c-bd25-4c5de461443c" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="sepn:ExternalGeneralAndAdministrativeExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,511</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b15dbf73-7935-462c-9911-b16eb668a629" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66d43db9-5794-47ab-80b6-c5dc0877930f" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses*</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97e771ac-d2d0-4c5b-94fc-844d48538fa8" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,429</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aca3999-5999-4461-8f21-16793f35440f" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,216</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1c15270-4116-48fd-87ab-6a544cb6579b" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,248</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff99c5c-5061-45bc-aa15-59c512ce4c05" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,898</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0a1a4ee-d6f9-433e-955c-c2c412cc3510" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,297</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81759b9d-b40f-40c2-84fb-0e0710772746" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1fb3497-e99b-4ba5-988a-342e45d56f87" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,430</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d8bbde8-ddf5-42a4-afbe-f73a4a9229f3" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,527</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ab61134-98e4-4d6d-8135-3289e0ccc5e5" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,867</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba6a9d87-ab31-4410-a351-51cee11c30a9" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5a1259f-05ee-481d-842e-f5bda2526c67" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acef9cfb-5979-4efb-b8a7-12460b85235f" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4280da-52ab-4283-817f-985a5dda9489" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,879</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc673cca-1a43-4a35-9203-6aee313dfe9a" contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,798</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Other segment expenses include facility related and office costs, information technology costs, general laboratory costs, and other operating expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, all of the Company&#8217;s property and equipment was maintained in the U.S. For each of the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s revenue was generated from providing research services and was earned in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc2353db-b260-4ea2-b9e8-697135966b5e" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2026, the Company appointed Mark A. Wilson as Chief Legal Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>sepn-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-09T15:14:59.8293+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of the Registrant&#x2019;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following summary of the general terms and provisions of the registered securities of Septerna, Inc. (&#x201c;Septerna,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our amended and restated certificate of incorporation (&#x201c;certificate of incorporation&#x201d;), our amended and restated bylaws (&#x201c;bylaws&#x201d;), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part, and applicable provisions of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;). We encourage you to read our certificate of incorporation and bylaws, and the applicable provisions of the DGCL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our common stock, par value $0.001 per share is registered pursuant to Section 12(b) of the Securities and Exchange Act of 1934 and trades on The Nasdaq Global Market under the symbol SEPN. The summaries below do not purport to be complete statements of the relevant provisions of the certificate of incorporation, the bylaws or the DGCL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.001 per share (&#x201c;common stock&#x201d;), and 10,000,000 shares of preferred stock, par value $0.001 per share (&#x201c;preferred stock&#x201d;), all of which shares of preferred stock are undesignated.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All of our outstanding shares of common stock are validly issued, fully paid and non-assessable.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesignated Preferred Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting, or the designation of, such series, any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. We have no shares of preferred stock outstanding, and we have no present plan to issue any shares of preferred stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain holders of our common stock are entitled to rights with respect to the registration of these securities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). These shares are referred to as registrable securities. These rights are provided under the terms of our amended and restated investors&#x2019; rights agreement, dated June 28, 2023 (&#x201c;investors&#x2019; rights agreement&#x201d;), and are described in additional detail below. The investors&#x2019; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us. All selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Demand Registration Rights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain holders of our common stock are entitled to demand registration rights. Under the terms of the investors&#x2019; rights agreement,  upon the written request of stockholders holding at least 25% of the securities eligible for registration then outstanding to file a registration statement with respect to at least 25% of the securities eligible for registration then outstanding, having an anticipated aggregate offering price, net of related fees and expenses, of at least $5.0 million, we will be required to file a registration statement within 60 days of such request covering all securities eligible for registration that our stockholders request to be included in such registration. We are not required to effect any registration pursuant to this provision of the investor rights agreement (a) during the period that is estimated to be 60 days before and 180 days after the effective date of a registration statement that we initiate, (b) if we have already effected two registrations pursuant to such requests for registration on Form S-1 or (c) if the initiating holders propose to register securities that may be immediately registered on Form S-3. The right to have such shares registered on Form S-1 is further subject to other specified conditions and limitations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short-form registration rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain holders of our common stock are entitled to short-form registration rights. Pursuant to the investor rights agreement, if we are eligible to file a registration statement on Form S-3, upon the written request of stockholders holding at least 10% of the securities eligible for registration then outstanding to file a registration statement with respect to securities having an anticipated aggregate offering price, net of related fees and expenses, of at least $1.0 million, we will be required to file a Form S-3 registration statement within 45 days of such request covering all securities eligible for registration that our stockholders request to be included in such registration. We are not required to effect any registration pursuant to this provision of the investor rights agreement (a) during the period that is estimated to be 30 days before and 90 days after the effective date of a registration statement that we initiate or (b) if we have already effected two registrations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to such requests for registration on Form S-3 within the twelve month period immediately preceding the date of such request. The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Piggyback registration rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain holders of our common stock are entitled to piggyback registration rights. Pursuant to the investor rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of our common stock, including common stock issuable upon the conversion of our preferred stock, are entitled to include their shares in the registration. Subject to certain exceptions contained in the investor rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investors&#x2019; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expiration of registration rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The demand registration rights and short-form registration rights granted under the investors&#x2019; rights agreement will terminate on the earliest to occur of (i) the closing of certain liquidation events, (ii) the fifth anniversary of the completion of our initial public offering or (iii) at such time after this offering when the holders&#x2019; shares may be sold without restriction pursuant to Rule 144 under the Securities Act or another similar exemption under the Securities Act within a three month period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ordinarily, other than underwriting discounts and commissions, we are generally required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel and reasonable fees and disbursements of a counsel for the selling security holders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-takeover effects of our certificate of incorporation and bylaws and Delaware law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some provisions of Delaware law, our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board Composition and Filling Vacancies</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Written Consent of Stockholders</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Meetings of Stockholders</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advance Notice Requirements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&#x2019; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Incorporation and Bylaws</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Undesignated Preferred Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest, or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Forum</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law (&#x201c;DGCL&#x201d;) or our certificate of incorporation or bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) any action asserting a claim governed by the internal affairs doctrine.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Consequently, this choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction. Moreover, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit, and may be enforced by, us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our bylaws provide that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 203 of the Delaware General Corporation Law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 203 defines a business combination to include:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder; </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial benefits provided by or through the corporation.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq Global Market Listing</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is currently listed on The Nasdaq Global Market under the trading symbol &#x201c;SEPN.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer Agent and Registrar</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>sepn-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-09T15:14:59.8348+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.20</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 6, 2026</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mark A. Wilson, JD</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1613 Ray Drive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Burlingame, CA 94010</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Re: 	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Offer of Employment by Septerna, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Mark:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On behalf of Septerna, Inc. (the &#x201c;Company&#x201d;), I am pleased to confirm our offer to employ you as our Chief Legal Officer. The initial terms and conditions of your employment, should you accept this offer, are set forth below in this letter agreement (the &#x201c;Agreement&#x201d;):</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As Chief Legal Officer of the Company, you will report to Jeff Finer, Chief Executive Officer. This is a full-time, exempt employment position. It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time), except as expressly authorized in writing by the Company&#x2019;s Chief Executive Officer (the &#x201c;CEO&#x201d;). Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not interfere or conflict with your obligations to the Company. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Your employment with the Company will begin on January 5, 2026, unless another date is agreed to by you and the Company. The actual first day of your employment with the Company shall be referred to herein as the &#x201c;Start Date.&#x201d; </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Compensation and Related Matters.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company will pay you an initial base salary at the rate of $450,000.00 per year, payable in accordance with the Company&#x2019;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and adjustments at the Company&#x2019;s discretion. Your base salary in effect at any given time is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Bonus. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will initially be eligible to receive an annual performance bonus of up to 40% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; The actual bonus amount is discretionary. To earn an annual performance bonus, you must be employed by the Company as of the payment date of such bonus. Any annual performance bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates. Employees who commence employment with the Company on or after November 1 will not be eligible to receive a prorated annual bonus, annual merit increase, or annual equity award for that calendar year. You will be eligible for the Company&#x2019;s annual compensation review cycle for your subsequent calendar year of service subject to the terms and conditions of the Company&#x2019;s compensation plans, policies, and practices (as such may be amended from time to time). </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits/Flexible Time Off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You will be eligible, subject to the terms of the</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable plans and programs, to participate in the employee benefits and insurance programs</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">generally made available to the Company&#x2019;s full-time employees. Details of such benefits </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will be made available to you as and when such benefit(s) become available. You will be entitled to flexible time off consistent with the terms of the Company&#x2019;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, amend or cancel any of its benefits plans or programs at any time. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">            (d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will promptly reimburse you for all reasonable expenses</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incurred by you in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executives. The Company will reimburse you for professional license annual maintenance fee costs actually incurred by you upon presentation of reasonable documentation for such costs.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. 	Equity Grant.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Subject to approval by the Company&#x2019;s board of directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensation committee thereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you will be granted an option to purchase 165,000 shares of the Company&#x2019;s common stock (the &#x201c;Stock Option Grant&#x201d;). The per share exercise price for the Stock Option Grant will be equal to the closing market price on the Nasdaq Global Market of one share of the Company&#x2019;s common stock on the date of grant (i.e., the fifth trading day of the month following the later of (i) the Start Date or (ii) the date on which such grant is approved by the Board or the Compensation Committee. The Stock Option Grant will be governed by the terms and conditions of the Company&#x2019;s 2024 Stock Option and Incentive Plan, as amended from time to time, along with the applicable stock option agreement for the Stock Option Grant (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). You will be required to execute/accept the Equity Documents as a condition for receiving the Stock Option Grant. The Stock Option Grant will vest according to the following schedule: 25% of the underlying shares will vest on the first anniversary of your Start Date, with an additional 2.08334% of the underlying shares vesting monthly over the subsequent thirty-six months, subject in each case to your continued employment with the Company on each applicable vesting date, resulting in full vesting of the Stock Option Grant on the fourth anniversary of your Start Date.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. 	Location.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Your primary work location will be at the Company&#x2019;s office which is currently</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in South San Francisco, California, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that you may be required to travel for business from</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">time to time, consistent with the Company&#x2019;s business needs.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. 	Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You will be entitled to enter into the Form of Employee Director/Officer Indemnification Agreement with the Company in substantially the form set forth on Exhibit 10.5 to Amendment No. 1 to the Form S-1 Registration Statement filed by the Company on October 21, 2024.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. 	Termination Benefits.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> You will be eligible to participate in the Company&#x2019;s Executive</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Plan, as amended from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Severance Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as a &#x201c;Tier 2</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x201d; (as defined in the Executive Severance Plan). Your participation in the Executive</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Plan is contingent upon your execution and delivery to the Company of a participation</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agreement thereunder. All matters relating to the termination of your employment with theCompany, including eligibility for any severance payments in connection with such termination </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of employment, shall be governed by the terms and conditions set forth in the Executive Severance Plan.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	At-Will Employment; Date of Termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  At all times your employment is &#x201c;at will,&#x201d; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#x2019;s benefit plans and personnel policies and procedures, may change from time to time, the &#x201c;at will&#x201d; nature of your employment may only be changed in an express written agreement signed by you and the CEO. Your last day of employment for any reason is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; In the event that you elect to end your employment, the Company requires you to provide at least 30 days&#x2019; advance written notice to the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company for purposes of this Agreement or the Executive Severance Plan.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.	Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. 	Continuing Obligations.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">             (a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenants Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As a condition of your employment, you are required to enter into the Employee Confidentiality, Assignment, and Nonsolicitation Agreement enclosed with this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenants Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For purposes of this Agreement, the obligations in this Section 10 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continuing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">             (b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Agreements and Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which restricts in any way your use or disclosure of information, other than confidentiality restrictions (if any) or your engagement in any business. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation and Regulatory Cooperation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> During and after your employment, you shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relate to events or occurrences that transpired while you were employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section 10(c).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relief.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. 	Section 409A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), the Company determines that you are a &#x201c;specified employee&#x201d; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six months and one day after your separation from service, or (ii) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and to the extent that such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#x201c;separation from service.&#x201d; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.	Withholding; Tax Effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.	Interpretation and Enforcement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Agreement, collectively with the Restrictive Covenants Agreement, the Executive Severance Plan and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. Except as expressly otherwise provided in the Executive Severance Plan, the Equity Documents or the Restrictive Covenants Agreement, the terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) will be governed by California law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in California in connection with any Dispute or any claim related to any Dispute.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14.	Assignment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Severance Plan solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15.	Waiver; Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company (other than yourself).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16.	Enforceability.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17.	Conditions.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This offer is contingent on the completion of successful reference and background checks, and proof of full COVID vaccination including all eligible booster / annual vaccinations, and if the Company makes future vaccinations mandatory at its discretion, your continued employment may be contingent upon keeping up with vaccinations that you are eligible for. As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18.	Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature page follows.]</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:0.75in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To accept this offer of employment, please sign and return this letter of agreement and the Restrictive Covenants Agreement by January 6, 2026. We look forward to your joining the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Very truly yours,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">       /s/ Samira Shaikhly</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: _________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Samira Shaikhly</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Chief People Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enclosure (Employee Confidentiality, Assignment and Nonsolicitation Agreement)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">I have read and accept this employment offer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Mark Wilson</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_______________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mark Wilson</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: 1/6/2026</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>sepn-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-09T15:14:59.7610+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:sepn="http://www.septerna.com/20251231" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>EX-23.1</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="sepn-20251231.xsd"/></ix:references><ix:resources></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-282837) pertaining to the 2021 Stock Option and Grant Plan, 2024 Stock Option and Incentive Plan and 2024 Employee Stock Purchase Plan of Septerna, Inc., and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No.333-286152) pertaining to the 2024 Stock Option and Incentive Plan of Septerna, Inc.;</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our report dated March 9, 2026, with respect to the financial statements of Septerna, Inc. included in this Annual Report (Form 10-K) of Septerna, Inc. for the year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e920429a-9797-4ed3-91e2-2293fa07ba84" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9eae183-1cc1-4c27-990a-db5da3ce3579" contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 9, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sepn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-09T15:14:59.7733+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Jeffrey Finer, certify that:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Septerna, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.3%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:64.68%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 9, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey Finer, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Finer, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:19.45pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sepn-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-09T15:14:59.7708+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:7.467%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Gil M. Labrucherie, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Septerna, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.294837131453586%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div></div><p style="margin-left:11.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.3%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:64.68%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 9, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gil M. Labrucherie, CFA, J.D.</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gil M. Labrucherie, CFA, J.D.</font></p></td>
    </tr>
    <tr style="height:19.45pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sepn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-09T15:14:59.7758+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                              </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Septerna, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-5.678%;padding-left:5.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.3%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:64.68%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 9, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey Finer, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Finer, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:19.45pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.3%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:64.68%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 9, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gil M. Labrucherie, CFA, J.D.</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:7.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gil M. Labrucherie, CFA, J.D.</font></p></td>
    </tr>
    <tr style="height:19.45pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img170310032_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_0.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 8\# 2(  A$! Q$!_\0
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M^6_PH\Q?4_\ ?+?X477=?U_PZ^\!]%,\Q?4_]\M_A1YB^I_[Y;_"BZ[K^O\
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M=:G=SQZ]_93:3';PZK$=5+RWBW$U]^C'[3?[4'[-6I:OX;\07?[6/BSX0R_
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M&98VG26(GB_J].&'IQGB,1RTXQE4J3]AA\3RM:3E^Z2339QX_%1P>$Q&(?\
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M::^>T@DN+;4K6YEU&!8-HA3N-'^+'[3GQ&\&_##26_:LU+P3X9UWPA)IVB>
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MEBI588/V%2;A&,5S58MSA!.--R=J\54NHN*C)6I\]*DZG*?FOXK^*'Q&\?\
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M\=5NO#MJD6B:/H9C\1Z;>+&;C]6?&::A\7O!?_"&Q:C:70_:O^ .E6>K>*O
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MN[_5K>X^P)O@K^R%^W]^S1X6_9-\*_M0^./BCXL^$NHZQXZTGXIZO=ZEK_C
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MJ+JRG:.5"C-#=V5W XEM=0TZ\B9;FPU&SF"S6E[:R17%O*H>-U-?-UGK6M_
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MX(BE&WX4\:_\$I/A;XH\.WGA&^_9Z^(5SI-]J>GZB=;\-?&:P\'^*-+%E?\
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M/*E^XHS6399**35-2JYTI1=ZE&E)<DOP4^#WQ3\>?L1_MD>.?%7[5GAOP9\
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M2K:WNY,/=ZUJ<^K7_BB\CT/P_;,VIZI(CK)-% EA"QN[V '*^%VE>&=+\?\
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ME^84JV'QN"PF,P^(<7B*.)P]&O2K2@H*$JD*D)1J2IJ*4)23E"R46DE;\J/
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M)2[:&$67NK6FUB:]5N%)02I3Q52<82OB+*7/67LY)UYSJ.-!.<FXJ7+U%O\
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M)-7UB"]@T&QL=7N'\9>'M'TO7)(O#MS9ZSI$5IXI%Y87]EJ>LZ;8_;/M,O\
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MRUO=8$'B_P 2^'HTCLI%OM/VJT5=W^S/^S?X2^$?Q2^+WB5K[6/B'\1[W1O
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M98>)/#O@B_MO"6N7^M)-?+?:(UG(VKQ:E<65ZZ78A>!X[C]\T%LT/S3\=/\
M@FKX!^,R_ 2Q^$/[;NK^"+;X0>)K+5;NTU3Q2_BK4GEM_#'@/PTVO>&_L_BK
M1;K0?%B+X&.II->076EOJGB76[Q+>U+RPWOZ-D_'V1YC6HX;,.-LJI2Q%&JZ
ME:*J4Z^&K*A*K3C5_L7%X7%8Z-:M3C0JJO"M%PJSJRY91YGY=7*LIBHSP+IR
MFITY?5WB,/B*<X2E&,E"&8+$PP[A&3G3>'C2;E",;\LK'Y2>#/\ @G=^V=\
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MUHRYXQE>*J,N9:Q:MW5K^BWWOOTL%%%%<)04444 %%%% !1110 5XEJ7Q_\
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M5XYH)9(W5@RL5()TZ?R:\FFFO)IV:?DT,**** "BBB@ HHHH **** "BBB@
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MNH6=CK&&VJUUK%X8QU ]DKPJ^E9/')\<#)L=)\16?P\FD'"G3=1M%CO)QNX
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M,D[1<IV7+)HGE6F^COHVM;WU\GU6EW9]+ /\_A_G\:***XTK*U[^;*"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img170310032_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_1.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $+ ?@# 2(  A$! Q$!_\0
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MG[S#_@O-\=L#_BS/PNSCD'5/$N<^G$I&<^]'_#^7X\=O@O\ "_\ \&GB4?\
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M(1H5ZU>$,3DZJT)X:%6K5H5*<\JA4I5?94G*$<3'#OVTXX.JJ6*C4I0^SO\
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MK^93_3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<KRCC;ZIE6!P65X:&%P\HT,#AZ6$HIRPF$G)QI45"FG*<W*3Y;N3;W9,&;<
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M#*5],/Q O_-?S'S/ZE****_F0_TR"BBB@ HHHH **** "BBB@ HHHH ****
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MG3E*CA:5?*<;A*,L142Y*7M,55HX>"DTY59^S2YE)+^DJBBBOYJ/]*0HHHH
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M]9P__/\ H_\ @R%NE[.]GO\ \,?LI17XV?\ #_\ _P""3'_1V&C?^$)\3/\
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MDUZ#\-OA9XT^*OB&W\->!]%NM8U*XDC23RH76WLH9F*++=W&)$B8D-MCQYI
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M]OJ-W9VL]S%:3K=;7N49FENWBC>X6W6/XN\+?M._MG_LC:3?_!7XU? WP_\
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M\:7=F6+MI?A2T*S[G0Q7.L76DV.?](<Q_P"=1K^LZSXGUS6?$OB'4[W6=?\
M$.JZAK>MZQJ-Q)=7^JZMJEU)>:AJ%_<REI;B[NKJ:6::9SO9W.ZOVWPF\/:>
M>S_UDSNC[7+,-5]GEV$K1?L\=B*+2G6JQO:>$PLOW:IZ0KXF#C43A1E&I\#Q
M=Q.LNFLKP511Q=2*GB:L'>6&ISM*,$W=QKUE[SG\4*<[Q:E.$H\_JM_JNL:A
M>ZOK6HWVKZOJ5U/?:EJNJ7EQJ&IZE>W,AFN;R^O;IY;J[N[B5VEFN+B62:5V
M+.['FJ5O//975M?6CM!=V5S!>6TJDJT=S;2)-!*".04D1&!QG(X]:OO'G/'.
M#P3QCVXXYS[?EBJS1X((QD^IZ]CR <C) R> <9Y(K^GG!<O(TDK6LDDK6V2M
M9+R5K6\CX&ABU)>\U+FW4M;Z:WONG?6^Z=FM6W_HI?\ !(O]J7P]\=?@-X8@
MBU&%-1U#1[774L3,K-;ZS#;6]CXST-$+%EETO6X9;A$.&EL[J.X163+U^ODA
M,@*QL,C.0>1@JR\C*DX;&1GKC-?P9?\ !'/X3?MQ^&?%$GB_P#X,UFS^$6MO
M#J[+JZWVFZI)JL$>;+Q'X/MGBW$30*;;4!J"PZ;K%@X$;3/#$]?U[?#[]K_2
MH73PY\9M*O/ OB>V*V]Q>O9W;Z/<NI5//,:Q/=6)?YI)$V7$,9SB<+M1?XVX
M[X?P]'B+,EDF*P^9053VF(PN$JQK8C"U'I*#A!MU'%Q:K1I<TJ532I"'/&*^
M@X4X@APG@</D/$RJ99EL*DX\.Y]BU*GEV*R^I.52AE^,Q<E[/!8W!*:P]%XJ
M5*GC,+&E4P]2<X5$O'/&O[-G[2'[6/AGXN?"K]IOQF?A?X#/Q+T[6OAGJ'P6
MUG31K.L^'_#'B*+6_#USJ\FH:?=XTV:WLK.+5]"U>S_TN^FO"\;10VLC^&1_
M!3]O?XY:EKWPX\0?&KPY\)?"/[,/QTTU_AUJVDZ+;^*I_COX.\/:''>^"K'Q
MTUKK&CWFBW:Z=J.@:CJ]]+;W,<?BR.ZEAT6\M;. 5^K(^.'P=N+1KU/B;X'$
M!0@G_A)-,6X &&P;9KE;M64$'8T 92?[PX_.OP9XT^"W[)TOQ;F^%OCGQS\9
M=;^*7C?5O&;1>+-4AO-%\-W6K7E[?OI=CJT.GV5WJ>G6=YJ-S':&1;_4VT^.
MRL'U&6*TCE;\TPF29SAZF&PN!P6*Q6'J8S%U<PQ698JNJF#I5E6KQE"IB*<H
M2I1Q+I8>-&=6C3P^%?-%R]DJ<OI<5Q7D&0TL)%YY@L=AJU?%3K5)YM#,<UDJ
MRJ5L-1P&"PT<1BLPYZ\HX:E1HI2I4N5J-1\TUZ#^W/\ M(VGP8_9:OM6^)Z6
M7A+Q'?>#VU_QSHUIJL.I0Z/8Z%:Q7NN6MG?1K$E]#?:G%%H^BMY:/?O=JJQ%
MQ(H_SD-5\<ZIXS\6>*_'FJ!H]3\:>)-7\37D1<MY$FKW\]ZML&)RPMXI8X%R
M2-B+@D8K^F#_ (*J_LZ_\%%_VO\ PLGC3P3X*OO$OPBTQV\0>+?#NC17<7CC
MQ;=6)$^G"QT5@([CPSH< :73O#VGL=2N;EC<S0W$D=M&G\MUQ!>Z3>7.E:I9
M76F:CI]Q)9WNGW]M-8WEG<0L4EMKNTN4BGMKB!PT<L,\4<D<BE60,#G^T/ +
M#Y1E>$QN)IYAA,=BJC=#$PP]12E2FYP4N:FW&=.F_9J-*3A&%:,%.+=VE\=.
MCFF.S#&\0YI@\1EM;-*.%PV6X"M%*OEV2X&52K0ABG"4XQQV.Q.)JXW%4$V\
M+&5#"RDZE&3/4=.U_.W+%6!&<GC/KR.N!QQC/.00#7]('_!)+_@L!K7P9UGP
M_P#L]?M'^(KS7?A!J<MIHW@CQOK%_)<W_P -+F1Q!9Z5J-W=&66Y\&R%T@A,
MDBR:$50Q%M/'DP?R[17!#?+Z<'<,GM_0\Y]CQ7166LR0X#89!@$9['C!'IU&
M#P<G(&37[KQ5PAD''.35\KS&C&K3JQ<\/5CRK%8'$<MJ>)PE3XJ=6#>L4_9U
M8N5*K&=*4HOT<#F>)R^M&I)OECI)KFY9P6CC-6U36J=FXO5:JY_K#7UIH?BW
M1C;7,.GZYHNJ6Z2&.5(;RRO+:0!XI4#"2&5#\LL4BDCA9(V/RFK.BZ+IN@6$
M6FZ38VNGV4 Q%;6D20PH.Y"(H&2<L2<DDDDY.!_,]_P02_X*.R_$GP[-^R)\
M6M>%UXN\&V(N_A7K.I7F;O6_"-LBI<>'IGG;=/?^'R(_LA5@TVDR1@H#8RL_
M].JDD9(Q]#D'@$$' R.>U?YR<6\,9EP=G^.X?S2/[_!U%*E6C%QI8O"U$IX?
M%T4W*T*U-IN/,W3J1G2F^>E)+].P6+HX[#PQ-%IQFK26EXSC92A*V[A)-)]G
MV8M<SXQ\8>&? 7A?7?&?C'6K#P_X8\-Z;=:MK6LZE<);65C8649DGFEE<XR
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MU^D=N:_M^7H/H/Y5_)WC;_R6D'_U)L!_Z>QG^9I#_/\ ]M%HHHK\@- HHHH
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MWKO?!7[(_P 'O!UU#J T5];U"$AH[G5YGNBK+@A@K';G(R, 8YQQ6[>?M/\
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M3WIZ?BO\Q7P#6Z;O9VNM-GZ[W1[2U2=WJET[I>7]:_+^'/\ X.U<CQA^S0"
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MIS3C)R_>+F;FFW&5I63EHKIM7;U33MK>$?\ @D'\+/#=A;:)>_$[Q-K^B1^
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M'WK]HGPWXA\2> ?)\+:5+K.MVFKV$]M81,5:2)S)!<2$@'Y8HY/,?I\JGD$
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M-?QVXR1VX&,\9X XK^C^#?\ DGLO_P"O%/\ ](B?FF6/WLW[+B'/5_YD)O\
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MANV\/6U[?)(\PNL(5,YC.3IT>#Z<)8:GAI8?VOL<-4C@Y9E6O+!>VA"M*O\
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MI(TO]B<#_H)?&(Y_[<O!HQ_GZ8K^*#(R21GOUQCGUK^U_P#X.[?^07^Q.?\
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M:=;V;<7/V4Y\3580F^5\LITJD8NS<)*Z<NG9&G6(((/V6'(/;$2#^8/':KE
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MI[F/3+18U62_D2=Y]0N%_>2) (X$_H?AABMXHX((TBAB18XXXU"HB*,*JJH
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MT_\ P@RKR_Z@/+\7W!4UZ_-^7GY?CZW_ )5_^'%WQ@_Z*#HO_@M/_P ET?\
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MV7]?F>\MEYI?E]WW:!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MX4;U]?T/^%?R;'_@X$_:0_Z(G\%1_P!MO'']=?--_P"(@7]I'M\$_@I_W_\
M&X_]SQK]1_X@;XB?]"_+_P#PZX3_ .2?G^';7Y__ %KR=?\ +ZK\L/6\O[OK
M^!_67O7U_0_X4;U]?T/^%?R:_P#$0+^TA_T13X*_]_\ QO\ _+ZC_B(%_:0_
MZ(I\%?\ O_XW_P#E_3_X@;XB?]"_+O\ PZX3R_O>N_Z:O_6O)]/W]7_PGJKM
MY>OX']96]?7]#_A1O7U_0_X5_)K_ ,1 O[2'_1%/@K_W^\;_ /R_I?\ B(%_
M:/\ ^B)_!;_O_P"-_P#Y?4O^(&^(G_0OR_\ \.N$\K_;]?TO;5?ZUY/>WMJO
MK]6K)?9Z\MNKZ]/)G]6^JZ7I>M6<UAJMC:ZA9SHT<MM=V\=Q%(C @JR2HR\@
MGG&1U!!YK\I_VEO^"5_PP^)HO_$GPH:#X=>+I5EG-I;Q9\/ZC=$%_P#2K!?W
M<1D;Y6EMO+<Y!=7(Y_)__B(%_:0_Z(I\%?\ O_XW_P#E_1_Q$"?M(?\ 1%/@
ML/I/XW_KKQ_E6^'\%?$K"U%4HX3!4Y+?DS;"I27:2<K23[/377;7"MQ%D.(A
MR5I2FMTY8:HW&7NW<7RWB]]8V>BU6AXC\2OV0?C[\+?%B^$O$'@74;RXN96C
ML-5TF*2]T6_4.0)H[X*HA! 5F2X2*1"0BJ1M)^[?V:O^"6WBWQF;'Q#\4Y1I
M.DL(IQI;>:A=<JP1\H))CM)!V[8N,<KQ7SA>_P#!?#X_:CY7V_X#? N\,+B2
M/[0?&DFUAT9=VNG:PZAASGI@'%7E_P"#@+]HQ %C^"'P3C4 *%6;QN%4#LH&
MO  ?A7IXCPJ\4*]-4UE^74=+3G2S3"1E+;[3J-TU96?L^5[<KCJC@H9APU1J
M.;K5JMG>*JX>M*,=NGL_>:>W.Y+NI/5?TJ_"3]G;X6?!O2[:P\*>&M.AGACC
M1[V6UB>=FC4#>AV8C).2=H!YY/ KW8,HX' & ..,>@ ]/PK^3;_B(%_:0_Z(
MI\%?^_\ XW_^7]!_X.!?VD>WP3^"GXS^-Q_[GC7C/P.\16VW@,ODV[MO-<*V
M[VNVW.[>[;;;N]==_57%.3+_ )>U4DK:8:K9)**LDHZ):I):+3R/ZRMZ^OZ'
M_"C>OK^A_P *_DU_XB!?VD/^B*?!7_O_ .-__E]1_P 1 O[2'_1%/@K_ -__
M !O_ /+^E_Q WQ$T_P"$_+__  ZX3R_O^O\ 2UI<5Y/_ ,_ZO_A/5UV\M.O]
M;_UE;U]?T/\ A1O7U_0_X5_)K_Q$"_M(?]$4^"O_ '_\;_\ R_I?^(@3]H_O
M\%/@K_W^\;G_ -SXI_\ $#/$3_H7Y=_X=<)Y?WOZ^3%_K7D^G[ZKT_YAZOEY
M>OW+Y_UD[U'4_P _\*4,#C!ZC(X/(]O7\*_DT_XB!/VD#T^"GP5_[_>-_P#Y
M?5^H7_!-'_@I#X\_;4\0?$70?B'X&\'^$KOPJOAV31'\'R:TT-Y#JL6MOJ!U
M$:Q?7Q#P/I]J+40>4&6:<N6P@'C9_P"%?&7#.58G.LVP>#I8#".@J]2EC\-7
MG%XC$4<+2M2A/GES5J].+Y4^5-R?PV?5@^(,NQU>&&P]6<JM12<8NC4@K0@Y
MS;E)65HQD[/>UC]BJ***_.CVPHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K\I?^"SS'_A@/XEXX_XJ;X=C\!XOTS'X\FOU:K\I/\
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M)N8 V%:2$NB$JC$/D5^CGPP\=>#="_X*,_M.:M>^+]#\.7/C/7?VH_#GPO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\I/\ @L__ ,F!_$O_ +&?X=_^I?I=?JW7S'^UW^S7H_[6/P+\3_!/
M7-?U7PU8Z_>:+J2ZMHR6<E[#=:#J5OJMK$%OX+BV,,\ULL4Y:/>(F.QE<AA[
M_"N88;*N)^'\SQLI0PF SC+L9B9PA*I*%##8JE5JRC"*<IN,(MJ,4Y2>B3./
M,*-3$8+%T:23J5<-7I03=DYU(.,4V]$F]V]%N]#_ #XZ*_I9/_! .TRVWXPZ
M\5W$+OL=(!QV)VV0_(9[\]*3_AP);?\ 18-<Z?\ /EI)Y[?\N8XK^P_^(Y>'
MG_0QQ_\ X:L;_P#*_/\ /LS\V_U5SC3]S1UV_?T_)7W\T?S49Z<#C'3_ #U_
M*G;NN<D?W2%QSC@X ].<8W8!X.37]*G_  X#MO\ HL&N_P#@%I'Y?\>7]:4?
M\$ [8_\ -8-<'_;GI'Y<V8I/QQ\//^AACMO^A5C>MG_SZOVVZKRT2X6SA_\
M+FBMO^8BGKMOK;JM'?9==#^:DD$GJ,@C"@#:"", ]<$$@\C*ML/R@ F5.>,#
M@8&!D#H#@ D8"C'3 Z=!7]*O_#@.W_Z+#KO_ (!:1_\ (7]!^-'_  X#MO\
MHL.N_P#@'H__ ,A4O^(X>'?_ $,<?O?_ )%>._NZ_P /KWW7O:K4?^J^<O\
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MM^!_PN'7?J++1_3WL3_^OZTO_#@.V_Z+#KI_[<M'_I8BC_B.'AW>_P#:&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img170310032_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %L O<# 2(  A$! Q$!_\0
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M _X)8?\ 1P6N_P#AE_C/_P#,)1_Q$ ?\$L/^C@M=_P##+_&?_P"82OXAM/\
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M_P#YA*_SHJ*T_P")3O#7_H:<9?\ ASR?R_ZD'D_O\A?ZPXW_ )]X7_P"K_\
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M5%'_ !*=X:_]#3C+_P .>3^7_4@\G]_D'^L.-_Y]X7_P"K_\N_J[\K?Z+O\
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M_P .>3^7_4@\G]_D'^L.-_Y]X7_P"K_\N_J[\K?Z+O\ Q$ ?\$L/^C@M=_\
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MO\9__F$H_P"(@#_@EA_T<%KO_AE_C/\ _,)7\%R_LD?M'GP+H_Q-;X2^)8O
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M6F7-K?\ C3QGKGC37;?Q<T$MRKOX3CNO%%LVK:?*ZZM=O;7;)$YEB8_VF_\
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MN[;^Q/\ XA[/^"7_ /T2'QM_X=_XB?\ R\H_XA[/^"7_ /T2'QM_X=_XB?\
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ME3_Y5_5GY7_SNZ*_T1/^(>S_ ()?_P#1(?&W_AW_ (B?_+RC_B'L_P""7_\
MT2'QM_X=_P"(G_R\H_XFN\,O^@'C#_PTY7_\_?7^GH?ZOX[^?#?^#*G_ ,J_
MJS\K_P"=W17^B)_Q#V?\$O\ _HD/C;_P[_Q$_P#EY1_Q#V?\$O\ _HD/C;_P
M[_Q$_P#EY1_Q-=X9?] /&'_AIRO_ .?OK_3T/]7\=_/AO_!E3_Y5_5GY7_SN
MZ*_T1/\ B'L_X)?_ /1(?&W_ (=_XB?_ "\H_P"(>S_@E_\ ]$A\;?\ AW_B
M)_\ +RC_ (FN\,O^@'C#_P -.5__ #]]?Z>A_J_COY\-_P"#*G_RK^K/RO\
MYW=%?Z(G_$/9_P $O_\ HD/C;_P[_P 1/_EY1_Q#V?\ !+__ *)#XV_\._\
M$3_Y>4?\37>&7_0#QA_X:<K_ /G[Z_T]#_5_'?SX;_P94_\ E7]6?E?_ #NZ
M*_T1/^(>S_@E_P#]$A\;?^'?^(G_ ,O*/^(>S_@E_P#]$A\;?^'?^(G_ ,O*
M/^)KO#+_ * >,/\ PTY7_P#/WU_IZ'^K^._GPW_@RI_\J_JS\K_YW=%?Z(G_
M !#V?\$O_P#HD/C;_P ._P#$3_Y>4?\ $/9_P2__ .B0^-O_  [_ ,1/_EY1
M_P 37>&7_0#QA_X:<K_^?OK_ $]#_5_'?SX;_P &5/\ Y5_5GY7_ ,[NBO\
M1$_XA[/^"7__ $2'QM_X=_XB?_+RC_B'L_X)?_\ 1(?&W_AW_B)_\O*/^)KO
M#+_H!XP_\-.5_P#S]]?Z>A_J_COY\-_X,J?_ "K^K/RO_G=T5_HB?\0]G_!+
M_P#Z)#XV_P##O_$3_P"7E'_$/9_P2_\ ^B0^-O\ P[_Q$_\ EY1_Q-=X9?\
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M,Z5TFXJZ6Z36TFG_ "/^&_\ @HKX-\*?$+PM<7'@SQY\3?A1X.^$NH^%=/\
M#_C&T^&W@J_OOB7IGQ$L/C-\-O&<7@WX>V4?@KPMH7A+XG>'O#TFHZ5I^HZU
MJNL>'KKQ83J,=WK8LHL?3/\ @HE;3?"?PAIWB/3O'T7QB\!?!WXG_"*QU+PU
MI7PL_P"$2\:'XAWWQ"OX_&/B7QKK^D7_ ,4_"]U;O\2]>A\6>%_#!OM,\<0V
MT:?VIX:.L:N[?U\?\0]G_!+_ /Z)#XV_\._\1/\ Y>4?\0]G_!+_ /Z)#XV_
M\._\1/\ Y>5Q/QQ\"W9O(N+W+GI59/\ L[+N6=2$,93J3=+^W?80EB:>/Q,,
M0Z5*FYQ6'<?9RPN%E0O^RLU_Y^X;9I>_/1-P=K^RN^5P35V_M;J3O_(3KW[<
M/P.^(UWX=M_B1\//B]9Z%\.?BY\*?CAX!_X036/!\6M:MXI\"?!WX<_"WQ%X
M5\83:Q=PVVE:%K=Q\--&U?PYXNT ZGX@\+P7FK0C0[Z6_P#]']"^)/[7_P '
MX-)^ /Q[NK'Q'X@_:)N?@_\ M0F+P9X0\1>$KCX2^$-9_: ^*_QDDN=+\>6T
MUS)XR\.W7AVP\;ZAJ]IX>MM,F_X2[3+C0);R?1H4DNKW^K3_ (A[/^"7_P#T
M2'QM_P"'?^(G_P O*/\ B'L_X)??]$A\;?\ AW_B)_\ +RHEXY>"M\'&G@..
MZ5#">TA]7CA<%*G4PM? 8K 8K">]Q Y0HXR&*G4Q;B_:5:D8M3@VG$_LK,_>
MO/"-R2]YRE=2C.$XR_@V;CRV5U9*^_7^*SXG_M=>%_'NE_M4Z?9^$O%-D?V@
M_"O['OAO1'O]0TJ5- _X9F\-^'=%UE]=6"=S=VWB"[T-KSP[#8"4V"R6YOEB
MFC8CZTU#_@J/X'UWQ GB&]\%?$WPQ<>"?C7\0/C!\-U\):;\']1U+7%\=1>%
M;[^P/&'B?QGI>LZS\/M7T?Q'X4M[FV\<?#L:U?3:-=FQ?14O]-T_4E_J?_XA
M[/\ @E__ -$A\;?^'?\ B)_\O*/^(>S_ ()?_P#1(?&W_AW_ (B?_+RM<1XZ
M>!V*I4*5?)>,YQPT>6AS8' R]FGE>69+.RGG\H2<\LRG"85RG&4DE4K0<,14
M=6(LJS2+<E5PMY.[]Z?_ #\G5Z4NDZDG\K:JR?\ %AK/[8F@ZV-<FN_"7B-K
MS6OV&='_ &49&:]TLP1^+++Q!I'B"_\ %:IYV4\)W-S8W;0V"#^U%GNA+);Y
M,A'G?QI^.OPU^(_[7&M_M%6/PZU3Q)X&\6^.=(^('B[X5?$2ZM+%=6N;B*U/
MC'P@-8\):A/*N@W,L5S!H&O1RVNLI$]M>WVG07$+VS_W)_\ $/9_P2__ .B0
M^-O_  [_ ,1/_EY7->+?^#?_ /X)D:1HKWMI\(_&RS"_TBW!/Q>^(+?N[S5;
M.TF&'UIUYBF<9VY!.00<$>CAOI$^#F#JNMALLXVI3>#Q6!?)@\%&^'QGU/VT
M8N/$$94YWP.'=.K3E"I2E!RA*+G)F<LFS*:M*IA7[T9:RE\4>:U_W+O\<KII
MI]=D?RI1_M^_!'P/;_"_1?AQX7_:C\>>&_!_[0GPS^-<UG^TI\4?!WCR]^&^
MA_#R;7))/ GP0NM)TZ*:P?Q)%K[VFN:]K=UIMI?V6AZ);-X=MW#W5O3\$_MP
M_LT?#GP/XB\+>%?A+\11?ZU\&?VEO@Q+K.H>%?@U<^(M7C^.-I\3;+0O'FI?
M$34[K7/'OAW^Q+/QQI=GK7PA\%ZAI7@)I]+U'7;'5;R_U*ZM;[^M[_B'L_X)
M??\ 1(?&P_[J_P#$3^NN4?\ $/9_P2__ .B0^-O_  [_ ,1/_EY7DR\</!&5
M.5.66\>RC5J1JXARHX23Q-2$:\(3KWX@<92IPQ-91E&,'SR]M)NO^]6O]EYK
M=/VF$T5HZR]U>[=*U'2[BF_1I:63_C]UK]LG]GKQK:^)=+\:> _C5!I7BQ_V
M1O&VJ)X8N_ 27EM\2/V7?!OB3P!<^'[&;4M1$,OP^\=^'M>^U)XBGBB\5>'-
M61E7PWJUI$C3=;K/_!0CX0^*(?C+_P )=\-/'_BW2?'?Q!_:8\:>%_AAXMT[
MX6^*O!=C)\=/$GB'Q'X:U2R\<ZI OQ/^#'B#P;>:U:7OB&W^%6H:AHWC74M)
M2:X73XM1U(7/]:O_ !#V?\$O_P#HD/C;_P ._P#$3_Y>4?\ $/9_P2__ .B0
M^-O_  [_ ,1/_EY5R\<_!&7(I99QTU2]DZ*>&P;]@Z6%PV"C*@_[?O1J?5<)
MAZ*KTW&O!TH5J56GB;UA+*LT6U3"+>[O+6\G+WOW6JYI2=MG=IIQ=G_G<1JR
MHBLV]E159\8W,  6P.FX\X[9I]?Z(G_$/9_P2_\ ^B0^-O\ P[_Q$_\ EY1_
MQ#V?\$O_ /HD/C;_ ,._\1/_ )>5]E_Q-=X9?] /%_\ X:<K_P#G[Z_AWTY?
M]7\=_/AO_!E3_P"5?U9^5_\ .[HK_1$_XA[/^"7_ /T2'QM_X=_XB?\ R\H_
MXA[/^"7_ /T2'QM_X=_XB?\ R\H_XFN\,O\ H!XP_P##3E?_ ,_?7^GH?ZOX
M[^?#?^#*G_RK^K/RO_G=T5_HB?\ $/9_P2__ .B0^-O_  [_ ,1/_EY7,^,/
M^" '_!,C1M!FO[/X1^-5G34-"MP3\7OB$W[J^U[3+&X #ZTZY:WN94!*DJ6W
M+A@K!?\ $UWAE_T \8?^&G*__G[Z_AWT/]7\=_/AO_!E3_Y5_5GY7_SX:*_T
M1/\ B'L_X)??]$A\;?\ AW_B)_\ +RC_ (A[/^"7_P#T2'QM_P"'?^(G_P O
M*?\ Q-=X9?\ 0#QA_P"&G*__ )^^O]/0_P!7\=_/AO\ P94_^5?U9^5_\[NB
MO]$3_B'L_P""7_\ T2'QM_X=_P"(G_R\H_XA[/\ @E__ -$A\;?^'?\ B)_\
MO*/^)KO#+_H!XP_\-.5__/WU_IZ'^K^._GPW_@RI_P#*OZL_*_\ G=T5_HB?
M\0]G_!+_ /Z)#XV_\._\1/\ Y>4?\0]G_!+_ /Z)#XV_\._\1/\ Y>4?\37>
M&7_0#QA_X:<K_P#G[Z_T]#_5_'?SX;_P94_^5?U9^5_\[NBO]$3_ (A[/^"7
M_P#T2'QM_P"'?^(G_P O*/\ B'L_X)?_ /1(?&W_ (=_XB?_ "\H_P")KO#+
M_H!XP_\ #3E?_P _?7^GH?ZOX[^?#?\ @RI_\J_JS\K_ .=W17^B)_Q#V?\
M!+__ *)#XV_\._\ $3_Y>5RWC;_@@#_P3)T3PKK>JV/PD\:)=V5H)8';XN_$
M)U5_.B3)5];96^5B,,I'/K@A?\37>&7_ $ \8?\ AIRO_P"?OK^'?0_U?QW\
M^&_\&5/_ )5_5GY7_P ^2BO]$0_\&]G_  2^R?\ BT/C8>P^+_Q$P/;G7"?S
M)/O1_P 0]G_!+_\ Z)#XV_\ #O\ Q$_^7E/_ (FN\,O^@'C#_P -.5__ #]]
M?Z>A_J_COY\-_P"#*G_RK^K/RO\ YW=%?Z(G_$/9_P $O_\ HD/C;_P[_P 1
M/_EY1_Q#V?\ !+__ *)#XV_\._\ $3_Y>4?\37>&7_0#QA_X:<K_ /G[Z_T]
M#_5_'?SX;_P94_\ E7]6?E?_ #NZ*_T1/^(>S_@E_P#]$A\;?^'?^(G_ ,O*
M/^(>S_@E_P#]$A\;?^'?^(G_ ,O*/^)KO#+_ * >,/\ PTY7_P#/WU_IZ'^K
M^._GPW_@RI_\J_JS\K_YW=%?Z(G_ !#V?\$O_P#HD/C;_P ._P#$3_Y>4?\
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M+]G>P^%%G\19?VIO"_ASQ%I'QEM_B3))\2?V-_BI8?"3XT:/<Z,GPY\&_9_
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M_#UC8RZG=ZU!$MPTUSID&G0RWKWEO'+!]FC:8.4&: .MHKP7Q=^TO\(?!?\
MPC;ZIJWB?4[7Q7X/D^(.E:EX-^&WQ)^(&CP^!HFL5D\6:YK'@;PEXATSPSH*
M+J-K,VH^([K2[=;9IKDN+>UN98?5H_&7A&5+N2/Q3X==-/LK+4K]AK>FD6.G
MZC"MSI]]>_Z3_HEI?6[+/:7-QY<-S$PDA=T.: .DHKD]9\=>$- \.ZAXKU/Q
M#IL?A_3-._M:[U&UG&HH-/:S?4([BWATX75Q>">QC>[M8[.&>6Z@4R6R2KS6
M9JGQ5^&VB6HO-5\<>&;&'^V_#'AN03:O9B>VU[QGJEGHOAC2;VT65KJQOM8U
M*_M;:V@O(8&7>\TWE003RQ@'?T5R]EXT\+7T=J\>N6%K->:3+KT-AJDO]CZL
MNBP-(D^J7&CZJ+/5+6Q@:*19[FYM(8H2C>8RXK9TS5=+UJT34-'U*PU:PD>6
M..]TR\M[^TDD@D:&9$N;626%GAE1XI55RT<B,C@,I  +]%%% !1110 4444
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MWPWXI^*7C*ZU#Q-X'\'Q6VK:5IWC7_@H0U[XDUW2M6UOPUK-O;'5?@C>:AK
MNKJVNK.'PG<OXDAM@8XKU/%_VDOC9^UA\$?"7Q5\,?$?XW?M:^$=.^&'@?\
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M_P!#1X(_\(/7O_GCT?8?B1_T-'@C_P (/7O_ )X] ';T5Q'V'XD?]#1X(_\
M"#U[_P">/1]A^)'_ $-'@C_P@]>_^>/0!V]%<1]A^)'_ $-'@C_P@]>_^>/1
M]A^)'_0T>"/_  @]>_\ GCT =O17$?8?B1_T-'@C_P (/7O_ )X]'V'XD?\
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M .CV$4OPT-S-KOA>^ATW7[=H+;PWJYT/Q%\//$B:Y:2P_P!DZEX<U/0M2=2
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M9_M/[CS/-^6@#O" >H!Y!Y]1T/U':BN6_P"$/TG_ )^_$O\ X6/BW_Y=4?\
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ML/'WB6[?3[J]TO3]<L[>\6#7I#;S76C:MI>JV\<NUIM.U"RO(PUO<PR/J?\
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M_$O_ (6/BW_Y=4?\(?I/_/WXE_\ "Q\6_P#RZH ZFBN6_P"$/TG_ )^_$O\
MX6/BW_Y=4?\ "'Z3_P _?B7_ ,+'Q;_\NJ .IHKEO^$/TG_G[\2_^%CXM_\
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MBO#H/Q8\<137UMHK>SZ#\%?VS_ _B6YU_3/B7^V3XH/@OQ7^P%X@\)Z3XO\
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M_F?H_P"&POV<!_S4RS_\)_Q=_P#,_7\_;_=/X?S%0U_9?_$L'!'_ $.^*O\
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M^1;\:=?P\-U&?VV/V7UZ_%6R'_<M>-/_ )FZ_G.DZ-]?ZU1DZM]/Z5O'Z*O
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MWC_7_/\ GGMI_0E\,9I-\1\>:M;8_A_K;_JFWW/1I\:9E.U\-@=>U/$=+?\
M40^_RW/["#_P4N_8?7D_'C2Q]?!WQ(_^8ZHS_P %,_V&QG/QZTOCK_Q1OQ)_
M^8VOXYIN_P!!_.LV;O\ 4?R/^?\ "NN/T'O"YQO_ *R\?;7_ .1AP]WM_P!$
MR>A2XIQ\U=T,(M.D*WEWKON?V4'_ (*;_L,+G/Q\TH8_ZDWXD_T\&TP_\%._
MV%AU^/ND_P#A&_$G_P"8ROXRY?XOP_I6>_\ %_P+^M=4/H+^%DK7XF\0-[:9
MAP[Y?]4P=U//\7-*]+#*_P#=J]D_^?WK_6_]H)_X*?\ ["8Z_'_2A]?!GQ+_
M /F+IA_X*A_L'@X/[0&E<?\ 4E_$P_J/!6*_BUD[?C_2JC=3]3_.MU]!+PJT
M_P",F\0=79_\*/#GE_U2_F=,<ZQ+=G3H;=(U/+_IXS^URT_X*=_L)WMW:V4/
M[0>A)/>7,%K"UWX6^(5A:I+<2+%&UU?7WA"VL;*W5G!GO+VXM[2VB#37,\4*
M/(OW;;7-O>6]O>6=Q#=6EU#%<VMU;2QSV]S;SHLL%Q;SQ,\4T,T3+)%+&S1R
M(RNC%2"?\ZZ3JWT_I7[??\$R/^"FEW\(;K0_V?OCUJMS>_"J]GBT[P1XTNY)
M;F[^'%U/((X-)U)F+S3^!YY&"Q%-\OAF5M\,;Z.\L6G_ )3XP_0JI\-\,U,_
M\,,QX@XAQF61JXC-LASF> Q6/QN!C%2E7R2>79=ERJ8K"*,ZE3+ZM*M5QM)O
MZG46)HT\+C.[#9DZDU&O&$%.RC*":2D^DN:3T?\ -I9[JSNOZF:*9%+'/''-
M#(DT,R)+%+$ZR1RQR*'CDCD0E71U(9'4E64@@D$&GU_GVTTVFK-:-/=/LSUP
MHHHH **** "BBB@ HHHH **** "L?6/$.@^'O[,.O:SI>C#6M6LM T@ZI?6U
MB-3US42XT_2+ W,D8NM2O3%(+2RAWW%P4811N5(K8KY3_:Q^$*_&WP_\*_!E
MYHNHZOH:?&?PIK7B"YTF4VVI>&M.TS1_$K6_BW3[]?WFFZCX>UB72]0TS48@
M\EGJ4=I*(Y$#QL ?3=IJ^EW]WJ=A8ZC97=]HL\%KJ]I;7,4UQIES<VL5[;P7
MT,;M):S3V<\-U%',J.\$L<J@HZL=&OQEUOP/^V9;W'C!];TWQ596LWQ;?3_B
M!XD^&@U^/6?B;I'AOX2>&?#GPW^)&@6W@7QGX(\9V>B:UK%E=7/BK0='\0I_
M8GBNY@M=;LM5\(:7J%T(=1\<?%OP]\2OA]X,\?>/?BOK7QD@^(O[*^CZ=8^%
MO'>E>'_#3>"]0\/>';WXCZ%\1OA_H/BR]T:7Q1K?B"#Q3J^NWMSI?B&6;P[/
MH4^C:\_AS3?$T*@'[+W=[9V$0N+Z[MK* S6]N)KN>*VB-Q=SQVMK ))G1#-<
MW,T5O;Q!M\T\L<,:M(ZJ8]/U*PU6V-YIEY;7]J+B]M#<6DJ3P_:M.O)]/O[?
MS(RR^;9WUK<V=RF=T5Q!+$X#HP'XHV_@+]I?QL/$?_"PO!GQ[_X0B6W^$7C>
M^\,OXU^(MUK4?CWP/\>=!U/Q=!H=[+X_EOY[^P\"W=RZ0^ K#P3X!\50:5'J
M'A7PS=76F)=+]*V/@S]JMX[/2=&U;QI9)XQU_P",/B74M6U[Q+=I'X-NOAW\
M4/BKK'PNTEC<WLMU#H7Q8T_Q!\+-+NM+TZ-K67P9X9\1&_$4DMM#, ?I-7*G
MQSX+6+Q;.?%GAWR? +2IXXE_MG3RGA!H-+BUN9?$C"X(T4Q://#J<@U#[.4L
M9%N6Q$=U?"W[)EI^T/X2T_XC:_\ %,?%#7Q9^!M%NY?"7BVUU6:\U3XJZ;;Z
MM=>*D\'ZAXA^('C:YN(=686&GI'X2M]!^&$D[6EQX4LT4WL=O\_7?[/W[2?@
MOP)\5[B_T;3/&^H_M/?LZ_&_1?B+HO@O0+RSUO2?BWKVC^-?'O@N[\4W-_KE
M[::O,-0\8>(OAG;7>GVFGP6T<FAV:Q?8+:Q2V /V#T[6-*U@7K:5J-EJ2Z;J
M-YH^H&RN8;D66JZ>XBOM.NC"[B"]LY"$N;:3;-"Y"R(IXJM;:?X?\,V^L7UM
M;:7H5I>7M[XAUVZ1;?3[6:^FBC.HZQJ,Q\J$3RQ6T;WE[.P9UB$DTAVEJ_+K
MQ=X$^/.CZG\1O[/\._&M/#VO>,?VDM9^']M\'_$0\,:DOQ>\1^)/#MQ\*_%O
MC.2#7=$%]X(GTN'4VL)-??4_ =I.FI-XUT>X2ZT<C*\<?#O]IGQ/XA^.GA#7
MM-^*/C73?B!\*O'.EZI<+XF\4^$?"FB7K_#G27T.R^'$FD>/SX'U?3]:\;V-
MSIFD6NE^%_!_Q(TY=6U6?QCJESHL=O!?6JDXQG",YQA4Y?:04FHSY7S1YXIV
MERRUCS)V>JLP/UR1TE1)(W62.15>.1&#HZ. R.C*2K*RD,K*2&!!!(-5(]2T
M^;4+O28KRVDU.QM+*^O+!)4:[M;/4I;Z'3[J> '?'!>2Z;J$=M(P"RO97*H2
M87Q^2.F^%_VM!X^OI]+NOC!HFBVVB3GP-83)XHO-!7X5+\#TLM$\/:_+KGQ)
M&B6/C^U\??)J%SJ7@[4?BZGC."VU!-9O/!DU[+!UM[X ^._AJS\/6%W)^T-X
MA^'D'@#]FB;XGQ^'OB#XLU'XJ:UJGD_'N\^*<?AW7Y_%%MXHBU2'Q;J_PWG\
M8V7A36=+U/\ X1Z+3-.T51H^FMIRP!^F>H^)?#ND:IH>B:KKND:;K'B::\M_
M#FEW^HVEIJ&O7&GVWVR^M]'M)Y8Y]2GL[3_2KF&T2:2&W!FD58P6#M-\1:!K
M%_K>EZ3K>E:GJ7AJ\@T[Q%8:?J%K>7FA:A=64&I6UCJ]O;RR2Z=>3Z?=6U]%
M:W:0SO:7$%PJ&&:-V_/3XU?#CXH^*M'_ &8?&VF^!_&E[XR^#'A_QI\0H=-U
MW6-)\5>,;3Q/H.D^'+O1O#.N^(;".TTO4_%GC31[+6/##7$&+*XUK466YO)H
M4EO9?,]"^%/QF\(ZIXD\1>(O"GQ73PS\1/B7X-^(OQRL/A'K=]HWQ"US4/$7
MP9UFXN['0M9\/ZYH7B34/#G@7XF7^A^$M5B\-ZS::W-I&@Z&SBZT"RUJW< _
M6#4]6TS1;5;W5]0L],LVO-.T];J^N(K6!K[5]0M=)TJS$LS(AN=1U2]L]/LH
M0?,N;RZ@MX5>65%*:KJ^E:'9_P!H:SJ-EI5C]JT^Q^V:A<Q6EM]LU;4+72=+
MM?.G=(_M&H:G>V>GV<6[?<7EU!;Q*TLJ*?R1U#P#^TWK8^'FG?%O1?C9XI\1
M0>(_V3]6\-2^'?$MG/X T/PWX0^,7AOQ#\4?^%QZ5I&LVWAG7/'>G:58:?J&
MM:I-I&M7%[=V-M=> [Z&SM/$<M:%UHG[2OC/2_!/@KQ'X+^+MP/!&@^$['QM
M>^*+R*]\/^*_'/A_]L3X#^*[?6],N?[<U#_A(SI/PTT#Q+K-GXEG@2./09;Z
MQL[EKN#5["S /UEO+VRTZVDO-0N[6PM(=@ENKRXBM;:(RR)#&))YW2)/,EDC
MB3<PWR.B+EF ,.K:3INNZ;?:-K-C;:GI6I6TMGJ&GWD2SVE[:3*4FMKF!P4F
M@E0E)8G!21"58%20?Q:\6_#_ /:?^(]Y\6=-\2>#/CA%X(\1>"O&-SJ_AE_'
M/CB=[GQMX3^.WPS\2>$+;PSJ#>/(=/COQ\-[/QA)HES\,/#W@3PEK%K-::/.
M=>\3V6^Q]5\3>'_VH;R7QHOA6+]H#3O&EW<?&^77=<N_%=W_ ,*_N_A;JFB^
M(D^ >F?#71[K7;JWTGXE:->3^ FOKK3-&T[Q5;WND^/7\?:A?1ZEH@NZA.=.
M<*E.<J=2G*,X3A)QG"<6I1G"46I1E&23C)---)IIH#]78XXX8XX88TBBB1(X
MHHT5(XXT4*D<:* J(B@*B* JJ    !3ZYCP7H,?A?PIX?T"*ZUN]&F:7:V[W
M?B/7=8\2ZY<3E!)<2ZGKNO7NHZOJ-T]Q)*7EO+V9D&V&+RX(HHDZ>I;;;;=V
M]6WNWW8!1110 4444 %%%% 'C7QJ\ >(?'&D^#M1\'W&BIXQ^&_Q T+XC>&+
M+Q--?6WAK6K[2K'6-#OM#UR]TVTU&_TVVU+0/$6LPV6KVNF:K+HNL_V9JYTG
M4TL7L+CP;XA?"?X_?$ZPTO6_&&@?!O4-3TOQ??ZKI7P]TCXA_$3P9/X5TB?P
MK;Z%:7_AO]HGPQX&L_'$'BK^U5OM3U;9\.+/0]6T'4$\)7-JT5B-7O/H7XO?
M$/4_ &D>&;?PYH]GKOC/Q_XSTKX?^"M.U6]FTS0_[>U/3]7UJXO]>U&VMKRZ
MMM(T;P]X?UW6;B.TM9KO49+"'2;7R;C4([F'Y,^)'[7_ ,3/@Y=ZWX&\8?"[
M2_%'Q$\.Z#JWBJ]UCP/JB0^!)O"LGPT^*'C7PQXAGM?$FJV/B33?M.N_"OQ)
MX:UO0[3_ (2'4+."S35[&:\34K2VC );G]GW]HRR\+>+O#<7B#X=^/-0^,7P
M5TOX3_$3Q9XO\3^)]&U;PC?6G_"<Z6?$.A0:=X'UM?B-'9>%O&5GIL,&M77@
M+4-6U7PX-7U'48?[=GMM,^OK3P':WGA/6_!6L6$>E:3?-:Z;)J'A37]3TC6_
M$NF6NC:+8/K.K:IH]GX?U70M=OOL,NEW":7JNH74.E65C);^(5DG^R:=\S:C
M^WK\*?#?AZRO_%_AOQ]X>\5/=7D.I> ]0L?"NG>)++3=*\*>&_&FJ^*T&J^,
M;+1KGP_'X=\6^'=1LM/M]:F\:WTFL66B6WA*7Q*9]%A]@\/?M(>#?$^E_%KQ
M)I.@^,Y?!WP?M9+C6/&+Z=HZ:+XEEM_!^F>.KJS\&VPU]O$&J7%KX>UG2YY)
M;_0])L)+J\6QM[V>[ANHH #.\2_ (S>!]!\+:%XCUOQ%?Z+\6_A1X^MM<^)O
MB"^\3ZQINA>"?BCX$\9:UH&DZU-9W.H0PR:%X2FLM)M9,_;-1DA?6-28SW%^
MG!?M$_ CQM\9[_3KNS\$_!R34[;1/&?@S1/'7B/Q+XN3QQ\*+?6]=\.:CHWQ
M/^'EQIWA*XL9_%UG'H,&J/X7=?#TMGKVG:,MM\2+C2!JEI?3Z5^VW\.K^XU&
MWU+P#\8/# TJR\03WL^O^%=%6%-2T+X?:%\5XO#L0T?Q5J\USK>M_#CQ+HOB
MS2TMX9--M[2]73=?U+1-?CETB/-T?]O3X/ZXGA6.PT+QR^J^)O&?B+P/+H['
MX?-+H6J>%AX8DU6:\UJ'X@S>$O$$9MO&/A^\T[3/ 'B/QGXEU>TNKJ;3-!NA
MI.KBQ /);_\ 80O)[^_U^UT_X7#Q5=Q>,;\>)9[*<:RWBC6_VFK#XO:+X@DU
M-/#LEZFIZ;X%AO\ P^FIHYO[#4;ZXTRPE.D7=S>L_P (_L(W7A2\\#:U8Z9\
M+++Q'X9'[-EY?:]86-Q%JTNL_"_XKS^,_B;JEEJ8\.QWHO?%OA>YGT.UO6D@
MNM860Z3K<EII(#CZ:\+?M'6M[\)_&OQ6\9>"O$OA6S\)?$#QGX&M/#\8T76=
M?\33>'O&T_@G0FT*VTC7+^UFO/%&IK:VUG:W][IIMKN=_MWV2PA:^//^*/VS
M?A?X'U3P?H7C;0O'7A#7_$UG'J6M:%XAL/#&GZK\/],G\57/@NVU'Q7:/XL9
MM5M+O7K2X6R;X='QY)>Z.B^)[2.;PS+%K#@'UQ17Q]\"_P!J5/B#\)/BI\6_
MB'I6F^#M#^%=V)=9?29K[4T30K3X._#_ .*6KW[I)&;B6XM'\7:C8PP6ZN9[
M;3[5U'GSR*.(_P"&X].T75OB"WCWX?>,O!6F^"]1O["W\,ZII.D)XXNO(\-_
M [4K8ZM=?\)@?!6AF?6/B^EJ+Z[\0?\ "-Q:5;P:EJWB+1/LE_&X!]\45\?:
MI^VY\&]$U3P'I&KQ>(["[\;Z3H&MW/F/X.FC\':;XI\17?A/P]<Z^]IXPN#K
M4>JZ]8W-M _PY7QXD=BD6O7+0>'KFUU:;#OOV^/@UI]UX_T^YT7QTFJ> KC0
M87T^2#P5;OX@C\1^,YO 6G7=I>W?CBWTGPC;+XC@D@O3\5M1^'<UA9F'4;N&
M*QN+>>4 ^W:*^1[[]M3X-Z9XM\%^#K__ (2*VU+QAIG@?4)IGB\.O!X6F^)5
MU<6'@;2M=M(?$LFM:EJ&OZA;-:1R>"=)\7Z7I_VC3[S6-2T[3=4TV]NO2/@5
M\?/"/[0/A[4O$_@[2_$&FZ787T5I&WB ^&C/?0W,'VFUO(XO#?B3Q(-,>2+/
MVK0?$+Z+XMT:8?9M?\/:3=%82 >X4444 %%%% !1110 4444 %%%% !1110
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M!_\ "/\ #W_RNI/^%2_"O_HFG@#_ ,([P]_\KJT7TK<H33_U/S+2W_,UPO\
M\RF\/H^9G&U^)<"]4_\ D7XC?3_J(/Y:9$?YOE;K_=/K]*HR(_S?(W0]CZ5_
M5&?A)\*CU^&?P_/U\&^'3_/3J0_"+X4'K\,?AZ?KX,\.?_*VMH_2RR>+N^#<
MS?\ W5L+MI_U">OX&\/ +,HN[XCP+_[D,1Y?]1'>_P"!_*;,K8'RD_@>/PQ_
M]?\ *LN56Y^5L;CS@^_MC]:_K$/P?^$IZ_"_X>'Z^"_#9_\ <;3?^%.?"/\
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M -TT\&?_ "EK=?3XX<5O^-<YWH[_ /(^P'E_U+_(Z(Y)-.[Q$-K?PWY?WC^
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M]'_",>&O^A>T/_P4V'_R/0 ?\)/X;_Z&#1?_  :67_Q^C_A)_#?_ $,&B_\
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M*;#_ .1Z #_A)_#?_0P:+_X-++_X_1_PD_AO_H8-%_\ !I9?_'Z/^$8\-?\
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M]H?_ (*;#_Y'H /^$G\-_P#0P:+_ .#2R_\ C]'_  D_AO\ Z&#1?_!I9?\
MQ^C_ (1CPU_T+VA_^"FP_P#D>C_A&/#7_0O:'_X*;#_Y'H /^$G\-_\ 0P:+
M_P"#2R_^/T?\)/X;_P"A@T7_ ,&EE_\ 'Z/^$8\-?]"]H?\ X*;#_P"1Z/\
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MV\0V>F0^)-'EO[K04BDG;6K>T2\:>;21!#-.=0C1K3R8I9O-\N-V !^*>O\
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M6SO+G3[MK6>*=;:_LY#%=V<YB9A%=6LH,=Q ^V6%P5D56&* +E%>,_$KX\>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,^(-7\:ZSJNGZ5%:>&(18:#K\.I:_%K>J:S%;7.J:7XHN]3TT ^^O$_[4GP
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MN6NDVSZCJ*73>$O#EC]CTF)+FW@US4H;F*.TX+4?V!3H_@T:+\//'VJ6FO\
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MOX<?6-<M/#MF-5TV+4!/9#^UKV*UF-R(A ZRK)B2-DKM#\8OA,-4UW1#\3/
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M"TLYK>\DTG6-!\0ZWI<MQ9RB\TR>[MM7M(Y[FPBMY?GGPQ^S!XWNO'VE>/\
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MZ5X1;5A;C5'L-=\%ZQ)J.L7^6UN2\TK2M1T6^TNT&KP:M^K] !1110 4444
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M+/"S+\L<7#-<95Y;?'1H1O:UOA?D?QO_  $_X)R_M%?'/XFZ;X3\3?#[QO\
M"GP=$PO_ !1XU\;>$=:T&UT_1TE1)X='AUJTL%UO7;K=Y-AIUL[*CL;J^>WL
MX99*_K(^"GP3^'7[/OP[T+X8_##0H=#\-:'"!GY9=1U?4)%07NN:Y?!$DU'6
M-1D02W=W(%'W(+>.WM(+>WB]8HK\E\8?'WC'QBE@,+FL,/DV09:E5P_#^65:
M\L%5Q[C*,\RQM2M)U,9BU"3I8?VB5+!T7..'IPJ5\35K_H.6Y70RVGR4Y2J3
M:LZDTE+E5K126D5HF[:M[NR211117X8>D%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5YN?B5;@D?\ "%_$@X)''@O4R./0C@CT(X->D44 >;?\++M_^A+^)/\
MX16J?X4?\++M_P#H2_B3_P"$5JG^%>DT4 >;?\++M_\ H2_B3_X16J?X4?\
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M_P *])HH \V_X67;_P#0E_$G_P (K5/\*/\ A9=O_P!"7\2?_"*U3_"O2:*
M/-O^%EV__0E_$G_PBM4_PH_X67;_ /0E_$G_ ,(K5/\ "O2:* /-O^%EV_\
MT)?Q)_\ "*U3_"C_ (67;_\ 0E_$G_PBM4_PKTFB@#S;_A9=O_T)?Q)_\(K5
M/\*/^%EV_P#T)?Q)_P#"*U3_  KTFB@#S;_A9=O_ -"7\2?_  BM4_PH_P"%
MEV__ $)?Q)_\(K5/\*])HH \V_X67;_]"7\2?_"*U3_"C_A9=O\ ]"7\2?\
MPBM4_P *])HH \V_X67;_P#0E_$G_P (K5/\*/\ A9=O_P!"7\2?_"*U3_"O
M2:* /-O^%EV__0E_$G_PBM4_PH_X67;_ /0E_$G_ ,(K5/\ "O2:* /-O^%E
MV_\ T)?Q)_\ "*U3_"C_ (67;_\ 0E_$G_PBM4_PKTFB@#S;_A9=O_T)?Q)_
M\(K5/\*/^%EV_P#T)?Q)_P#"*U3_  KTFB@#S;_A9=O_ -"7\2?_  BM4_PH
M_P"%EV__ $)?Q)_\(K5/\*])HH \V_X67;_]"7\2?_"*U3_"C_A9=O\ ]"7\
M2?\ PBM4_P *])HH \V_X67;_P#0E_$G_P (K5/\*/\ A9=O_P!"7\2?_"*U
M3_"O2:* /-O^%EV__0E_$G_PBM4_PH_X67;_ /0E_$G_ ,(K5/\ "O2:* /-
MO^%EV_\ T)?Q)_\ "*U3_"C_ (67;_\ 0E_$G_PBM4_PKTFB@#S;_A9=O_T)
M?Q)_\(K5/\*/^%EV_P#T)?Q)_P#"*U3_  KTFB@#S;_A9=O_ -"7\2?_  BM
M4_PH_P"%EV__ $)?Q)_\(K5/\*])HH \V_X67;_]"7\2?_"*U3_"C_A9=O\
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M4DY*JU>4=$VIM)7C=^Z]XO356Y?W&HHHK_/<^G"BBB@ HHHH **** "BBB@
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MC25DG)**LK:))*]V[MW"BBBOR\[@HHHH **** "BBB@ HHHH **** "BBB@
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M'WO1W6EK?T__ /$4_P"%_P#HT;7/_#H6/_S*4?\ $4_X7_Z-&US_ ,.A8_\
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MSFHQ2O*RU]V][NUW:W[T?\13_A?_ *-&US_PZ%C_ /,I1_Q%/^%_^C1M<_\
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M'11_Q+7X0_\ 1/8S_P /V>?_ #?Y?GW8?VYF/_/Z'_@JG_\ (_U=^5O['/\
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MH_XBG_"__1HVN?\ AT+'_P"92OY?/V4/@KX/^.GQ'\3>&_'NO^-/#WA3P?\
M"/XD_%75KGX>>&].\6^,M0A\ :7:Z@NB:%H6K:IH]C=7>IM<B(/-?Q>4J%E5
MR<5[E\4?V'XI/"_P7\?_ +.^I?$/Q%X7^+NF?%J_N]&^/WASPG\$/$W@2S^#
M5_X=M/$WB_Q'JVJ^+I? \'PYU&/Q1IR:-XLNO$-C;RZM::IHS1M>P1++PXOP
M1\"<!F4,JQF3XW#8B<8R56MG'$,,%%RPV+QD85,=+&?5:4WA<OQ=:U2K%<M)
MIM3J4XSJ.:YM.#J1J0E%=%3I.3M*$+J"CS-<TXK1=7VT_H1_XBG_  O_ -&C
M:Y_X="Q_^92C_B*?\+_]&C:Y_P"'0L?_ )E*_F4M_P!B']I)[_Q=9W_@[P[H
M%IX$N? -OXG\1^)?B=\+_#W@^V3XHZ0WB'X>WFD^+]7\8V?AOQ39>,= CEU?
MPY<^%]4UB+5[.&9K-I&AE5/3/'G_  3>_:/\.?$WXA^ /!^F>$_B#IO@?XJ7
MGP?T[Q98_$GX6Z-9>,O'$.EP:W8^%O#EEJOC>&?4O&6I:5<PSP>"].>^\1QW
M#G3IK%-01[95/P6^CW3JQHSA@XSEAWBDWQ=F7LU04<'-3E5_M3V4/:4\?@ZM
M*,YQE6I5X5:49TW*2%FF<-7]YI24?]WA?FUTMR7?P23LK)W3L[(_H?\ ^(I_
MPO\ ]&C:Y_X="Q_^92C_ (BG_"__ $:-KG_AT+'_ .92OY9;7]ECX\7G@%_B
M1#X&">'E\/:WXPBTZZ\3>$;'QU>^#?#6H7.E>(?&>F?#.]UV#XB:KX0T34+'
M4+?4_$NG>&+G2+7^SM1GDNQ;6%W-#SGQ?^ _Q/\ @/J6C:+\4]%TKPYK>N:7
M::U:Z';>+_!_B/6[+3K_ $_3]5T^;Q!I'AG7=7U#PQ+J.F:KI^HZ?:>(K?3+
MN]LKE+FV@DA#,O?2\ O ROB%A*& IUL4YUZ:PU+BK-*E=U,+R_68*C#,W4<\
M/S0]O'EO2YESJ/-K+S?-5'F<FHVB^9X>"5I6Y7=P2M+IWUMY?U>_\13_ (7_
M .C1M<_\.A8__,I1_P 13_A?_HT;7/\ PZ%C_P#,I7\<=%>C_P 2U^$/_1/8
MS_P_9Y_\W^7Y]V9_VYF/_/Z'_@JG_P#(_P!7?E;^QS_B*?\ "_\ T:-KG_AT
M+'_YE*/^(I_PO_T:-KG_ (="Q_\ F4K^..BC_B6OPA_Z)[&?^'[//_F_R_/N
MP_MS,?\ G]#_ ,%4_P#Y'^KORM_8Y_Q%/^%_^C1M<_\ #H6/_P RE'_$4_X7
M_P"C1M<_\.A8_P#S*5_''11_Q+7X0_\ 1/8S_P /V>?_ #?Y?GW8?VYF/_/Z
M'_@JG_\ (_U=^5O['/\ B*?\+_\ 1HVN?^'0L?\ YE*/^(I_PO\ ]&C:Y_X=
M"Q_^92OXXZ*/^):_"'_HGL9_X?L\_P#F_P OS[L/[<S'_G]#_P %4_\ Y'^K
MORM_8Y_Q%/\ A?\ Z-&US_PZ%C_\RE'_ !%/^%_^C1M<_P##H6/_ ,RE?QQT
M4?\ $M?A#_T3V,_\/V>?_-_E^?=A_;F8_P#/Z'_@JG_\C_5WY6_L<_XBG_"_
M_1HVN?\ AT+'_P"92C_B*?\ "_\ T:-KG_AT+'_YE*_CCHH_XEK\(?\ HGL9
M_P"'[//_ )O\OS[L/[<S'_G]#_P53_\ D?ZN_*W]CG_$4_X7_P"C1M<_\.A8
M_P#S*4?\13_A?_HT;7/_  Z%C_\ ,I7\<=%'_$M?A#_T3V,_\/V>?_-_E^?=
MA_;F8_\ /Z'_ (*I_P#R/]7?E;^QS_B*?\+_ /1HVN?^'0L?_F4H_P"(I_PO
M_P!&C:Y_X="Q_P#F4K^..BC_ (EK\(?^B>QG_A^SS_YO\OS[L/[<S'_G]#_P
M53_^1_J[\K?V.?\ $4_X7_Z-&US_ ,.A8_\ S*4?\13_ (7_ .C1M<_\.A8_
M_,I7\<=%'_$M?A#_ -$]C/\ P_9Y_P#-_E^?=A_;F8_\_H?^"J?_ ,C_ %=^
M5O['/^(I_P +_P#1HVN?^'0L?_F4H_XBG_"__1HVN?\ AT+'_P"92OXXZ*/^
M):_"'_HGL9_X?L\_^;_+\^[#^W,Q_P"?T/\ P53_ /D?ZN_*W]CG_$4_X7_Z
M-&US_P .A8__ #*4?\13_A?_ *-&US_PZ%C_ /,I7\<=%'_$M?A#_P!$]C/_
M  _9Y_\ -_E^?=A_;F8_\_H?^"J?_P C_5WY6_L<_P"(I_PO_P!&C:Y_X="Q
M_P#F4H_XBG_"_P#T:-KG_AT+'_YE*_CCHH_XEK\(?^B>QG_A^SS_ .;_ "_/
MNP_MS,?^?T/_  53_P#D?ZN_*W]CG_$4_P"%_P#HT;7/_#H6/_S*4?\ $4_X
M7_Z-&US_ ,.A8_\ S*5_''11_P 2U^$/_1/8S_P_9Y_\W^7Y]V']N9C_ ,_H
M?^"J?_R/]7?E;^QS_B*?\+_]&C:Y_P"'0L?_ )E*/^(I_P +_P#1HVN?^'0L
M?_F4K^..BC_B6OPA_P"B>QG_ (?L\_\ F_R_/NP_MS,?^?T/_!5/_P"1_J[\
MK?V.?\13_A?_ *-&US_PZ%C_ /,I1_Q%/^%_^C1M<_\ #H6/_P RE?QQT4?\
M2U^$/_1/8S_P_9Y_\W^7Y]V']N9C_P _H?\ @JG_ /(_U=^5O['/^(I_PO\
M]&C:Y_X="Q_^92C_ (BG_"__ $:-KG_AT+'_ .92OXXZ*/\ B6OPA_Z)[&?^
M'[//_F_R_/NP_MS,?^?T/_!5/_Y'^KORM_8Y_P 13_A?_HT;7/\ PZ%C_P#,
MI73>"O\ @Y\\,^,?&7A+PC'^R?K=F_BGQ-H/AQ;QOB98RBT.MZK:::+DQ?\
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MV;HD26EM:NP^PZ?I&F_;M2FMY-6U3^RM'T?2?[3OKO\ LS2=/LO)M8_[#O\
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M-?&7_P )OP=_A1_Q"U?LY_\ 1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\
MROS_ #[,/[#S'_GW3_\ !L/\_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP
M=_A1_P 0M7[.?_1S7QE_\)OP=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_
M )]T_P#P;#_/^K/RO_$M17]M/_$+5^SG_P!'-?&7_P )OP=_A1_Q"U?LY_\
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M-?&7_P )OP=_A1_Q"U?LY_\ 1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\
MROS_ #[,/[#S'_GW3_\ !L/\_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP
M=_A1_P 0M7[.?_1S7QE_\)OP=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_
M )]T_P#P;#_/^K/RO_$M17]M/_$+5^SG_P!'-?&7_P )OP=_A1_Q"U?LY_\
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M_P#/NG_X-A_G_5GY7_B6HK^VG_B%J_9S_P"CFOC+_P"$WX._PH_XA:OV<_\
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MP=I5YJ4J/+'I]I>Z]?6,%U>-%')-]F@>280QR2E!&C, #U"BL3PUXF\.>,]
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M=GI=)]$!^G@T^P#P2"QLQ):R32VSBVAWV\MP<SR0-LS#).>9GC*M*?OEJ?\
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M\$_$_0OC!8^)]/T_6K?3+?QYJ7A?QAJVEZOX>TB\E7=T+]EC]N'Q/=^!-?\
MC5XO^/=S\0HOBY^Q7X8^(E[X&^,VL:#X-O?A.OP'T?0/VK)[#2/#^O:9H[:5
MK_C5M2B\6:S9Z=;^(I-6MH=8\)3Z=,$NI/Z!J* /YG/%GP._X*>#4OAEH&G^
M+?C=HWA?POH/BKPI\'=3TS0[_P"*WBWPGXWT3]IGXJMHGBGXEZVW[4OP/T(Z
M?J/P#D^$D6B>(?BYI/Q>\/ZEH.E^(](UG2[+6=2EM=9Y;XY_L]_MK^#?AO\
M%[X4_LW?!WX_:'XBOOBK^WG\2/!7CG2?'_C34-'O_BYXX\3^&O%OP*UW1M.T
MCXV_#>VT[3+S1KBYN]!\=^-]=UKP5X9U[3_$GAC4_A7KNI:L9)?ZC** /YQ]
M+^!W[<ME\2?C;J?P;\(_'SX:_&_QU\=?B]\1E^)7BWQUI5M^SEK/PD\3?LIZ
M+X;T_3(?"$?B:^T:#XA:I\=;+P_+HL<O@NWUO1O$FAS>,=1UH^#;2[L+O/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:)_M!M!#]G,_G 3>:8_,\T"3=O -:<<4<,:Q0QI%$@VI'&BQQHOHJ* JCV
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M^)K9H[I+*XGT)Y39ZO<03_:W_"!Z5_T&/&W_ (7WC+_Y=T?\('I7_08\;?\
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M@>E?]!CQM_X7WC+_ .7= ';45Q/_  @>E?\ 08\;?^%]XR_^7='_  @>E?\
M08\;?^%]XR_^7= ';45Q/_"!Z5_T&/&W_A?>,O\ Y=T?\('I7_08\;?^%]XR
M_P#EW0!VU%<3_P ('I7_ $&/&W_A?>,O_EW1_P ('I7_ $&/&W_A?>,O_EW0
M!VU%<3_P@>E?]!CQM_X7WC+_ .7='_"!Z5_T&/&W_A?>,O\ Y=T =M17$_\
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MC+]Y1G4HU(3=*K&%6"DE.$7H.,HR5XM-7:NMKIV>O74****\T84444 %%%%
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MDM%9QIMWE4=OV)HHHK\K/DPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGW]I?
MX=>+/B1\.;*U\"+I5QXS\'>/?A]\2O#FF:W>2Z=I6N7_ (!\5:=XA?0+O4HH
M+IM-&M65I=Z=;Z@UK<PV5W<6]Q<0O!'(*^@J*]'*<SQ&39G@,VPBI2Q.78JC
MBZ,*\'4H5)T9J?LJ].,H2G1JI.G5C&<)2IRDHSA)J24HJ2<7LTT_F?GGXO\
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MX,>#/"'@VW\2Z_K&LPZE;S>)M6\8ZOXIUFYN)KJ^U2ZTJRTVQLK2RDK]+Z*
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M<1%]QC#LS!<!B3DU)117 9A1110 4444 %%%% !1110 4444 %%%% !1110
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BQ^*=#=Y)'8*B(BWQ9W=B%55!9F( !) KLZ* "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img170310032_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &1 C(# 2(  A$! Q$!_\0
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M,US3+S3)KG2YX-8TZRM;]GTRYN--,LTAL9Y;7RG/U+0 4444 %%%% !1110
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MP=29AK/AU0S!6GU/<H8A6QILQ&X X;!Y&0<'D<UO5@:E_P AKPW_ -=]3_\
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M,W=K&H"MF2294&!N*Y /UQH5S%>Z9!>02B:"Z>>X@E!)$D$T\DD3@GG#1LK
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M@7^SK97G@C3?AQYDMC%=_![3Y_%.K^,-<\1>"4OKJUM=;MU^U>(?#GQ"MO\
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M<*O XKRS0_$+9_L_^.__ %J-G^S_ ..__6K]H?\ AG_X)?\ 1+/!'_@@L/\
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M-I6FRZW;6MEK$EE;/JEI8SO=6=M?M"ANH;6X=(WF@CF+K%(R*S( 3D\GP#X
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M>"".6ZG9_P F?$_[6W[0\GC?XH^(O",'C"R\)_"WXN^$O &C^ M0\/?!JQ\
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M+\;FF%PF'=3#XS,:4?91K9*O2MI3>U_=C&S5N9V<N6Z6^JBW:Z1^G.D_L]_
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M:='XNF^"GQ_T35KG2[KP_<V>L_\ "-Z)XUT"UUUHO"^M>(M"TV\UJRT^WO\
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MXW:[\;OB!X#U/X<^"?A1KWC.U^$WP[U/0?!O@+1-$L_BI<^'O#%X/%SW%_\
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MV^K*22T2LNR/#O$7[,O[._B[Q-J/C/Q1\$/A9X@\6ZO=VVH:IXEU?P/X>O\
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M59[:&ZO[N2".YO)O)$QBC*Q*B+[/7CWPF_Y"/QB_[+#KG_J+>#J]AH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *_FJ_;L^*?C7]E'XS>)-<T;P;XO\ @E=_$/Q5XKUWP?JF
MG_ME^&_B3H_Q7L[&:TN/$/Q"N/V4OB1\ ?C]'X*\.V\EY:_\))>>%[/P=IFA
MRW=G%>^)+.XOH%E_I5K\3OV_=2_:%T?]L#X:W'[$FG>.9?VF+_\ 9M\26?CJ
MX;0_@-K/PQN/@7!\2;)M+3R_C9\3/A;='XAZ/X\N[J\L6\&:UJ5G;Z3?*?'6
MB7EK=>&FC /TF_9&\7^*_B!^S/\ !7QQXWU;P3KWB?Q9X#TCQ!J6M?#C4- U
M;P-J@U19+NPOO#6J>%9[CPYJ.G7&FRV<BWNBR+IUS*TLUM!;1N+:+\]O@#^R
MU\;_  !^V*WC'PU\+O%OP$^';>/?VL/&/Q\\51_M)Z_\4?AI^TG!\8O$5YKO
MPJNO!'PMU_Q'JT_@/Q9I&OZC_P )UX@N[GP5X*A\#W5EJ_@GP]J/C#0/$2W$
M/WI^Q;\,+GX-?LM?!?X;7_A_Q-X6U?PYX3SX@T3QEK_@SQ/XHMO$VLZKJ/B#
MQ/<:UK7PZ)\!75YJ?B#5=2U1H?!PC\-Z?'>IINCPPV-I!"GU!0!\ZQ:-KO@;
MXK?#72X?B)X^\2:3XITWQ[%JVE>*]3TC4[)WT?3M(OM.NH/LVA6%S;W5M-),
M!)%<JDD4\L<T<@*;/HJO&/&G_)8_@E_UZ?%#_P!,6C5[/0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Q'Q(\&3_$/P+XF\$VOC7QO\.;CQ'IKZ=%XX^&^IZ;HWCKPTSR1R#4
MO#.J:OH_B#3++4D$9C2:\T;481')(#;L6#+_ #'?#+2?&FO?'O\ 9F_:7^)?
MQ'\8?%OX#S_MCP_ OX1Z/\3?VD/AMXZ_:A\/^.-'^(GB7X;:%XF\9_#P?LJZ
M!INGZ8WB[PQ<:SXV^'_@GXI:9XT\#>")V\0:EJFHOH>O:9%_517\O?[&GA2R
M^)/[8>F?M4ZQX+_:EOOBQXE_:'^+NA:M\8OAG^PS^RSH?[,/B?P[HGQ%\9>!
M+2]TKXZ:C\,(OCZ/AYJ?A71-.TK7_'6H>);?QUJU]!J0N-3ELIXO, /ZA***
M* /'OA-_R$?C%_V6'7/_ %%O!U>PUX]\)O\ D(_&+_LL.N?^HMX.KV&@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K^=O_@K9X4\+ZQ^UM\#M;U#X3_"#]J'6]._9[\:Z>/@
M/\4/@-^U#^T+=^#=(OOB'HLP^+WAO1/V>? GC6P\!IK-[:GP7K.O>*X(;KQ4
MMAIVE:0\4>@WWG_T25^%7[:G@_XA_&S]KKP9\1O@+I'[0/QH\'?#;X/>/?@S
M\1(/V*OVM/A+^SG\1/AU\4#\0]&UN;0/BO<^(/'7A#Q-XLTF\TJQ5M)\+ZC=
M1Z;X1U.RGUNTL+N[\32W5D ?I]^QO;P6O[+GP/M[7X>:!\)[>'P%I20_#?PM
MX+\;_#OP]X-0&;;HFD>!_B3H_A_QYX9LK7K'I7BG1=-U:#>3/:QAES]+U\Q_
MLI^-/#FJ_"_P]\/XM=\23_$3X:>&_#VF_$SP5\1OBYX9^-?QD\ :QJL=[/8:
M/\7?'?A3Q!XHTS5O%]U!:7%Q)=_VS=/=P1K*KM&%8_3/F1B01&1/-*-((MR^
M88U95:0)G<45F568#:&903D@$ \;\:?\EC^"7_7I\4/_ $Q:-7L]>,>-/^2Q
M_!+_ *]/BA_Z8M&KT";QEX9@NVL)M5B2\4R@VYANC+^XD2&9E40'<D<LD<;R
M+E%:1 6^=<@'3T4F1MW<D8SP"21C/  ))] !D] ,USEOXLT>ZOCIT*ZQ]L'V
M??%+X;\16ZQ+=/(EO)/-/I4<,$,C0R@332)$!&[,X52: .DHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OY.?V/-9^&FM?ME:1?Z-^TA\&?A-KDO[8'Q?M]6_9.TCXM_M[^*O$<'BRR
M^+'C6RUK1A+!^T1!^S)X@U[Q=?6\GBR_:T^%US\.1>:Q/9KI-XUH\[_U*_$'
M6/%_A[P9X@UOP%X-A^(7B[2[$WFB^"9O$EGX0_X26:&:)I]+MO$>HV=]INF7
M\]G]H.FR:G%%IL^H+:VNH7^EV<\^IV?X&? [6?CA\$/&6G^%/AAI'_!6NY\-
M:=\2?&?C*R_93\2?LK_LF:!\&K >-O%VN^,]6\ G]I'4M @T#3OAU;Z[X@OC
M9ZOH/QLU+5[+30JZ7/<%8[)@#^B2BO$O']Y\<-2^"-S=> U^'WPY^.&K:#H'
ME)XQGU?Q]X)\$:WJ-UIB^)$4:':^'-1\>7>@6$VK)X;LX8O#MKXHUZVTNVNY
M]+TZ\GEB^7?V'_VK?&'Q:^"?C7Q%\:[779?&OPY^/WQ0^"NHP:;\'_&_ASX@
MR:?X2OX;[PAK'Q,^#6CV_B[5?AEXI\0^#]2T?Q!-I7VR\T2[T;5?#WB&PN[2
M#Q+:Z7: 'U=\)O\ D(_&+_LL.N?^HMX.KV&O"?@7K-GKX^+>JV$6J0VMQ\8O
M$(CCUG1-:\.:BIA\-^$(7\_1_$%AIFK6N71C']JLH?-CVS1;X9$=O=J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXH"T3PIIOB"RNA=_V-H/S7#ZOJE_"UL(1,"D:)+YAB(?:'4^]W'_ ".&E?\
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M1_8Q^ &A2>']9\,7</@ZXO\ 4](\1^,_!'Q \1#6=<\0:UKFMZEK_BKX:_\
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M7C'P;J^KV'B_P3J\EWJ&F:?K>EI<7&EO>IINI:9^5O[$_P"WMX>\!_%SQ_\
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MB;_GT3_O]#_\<H X:BNY_P"%>>)O^?1/^_T/_P <H_X5YXF_Y]$_[_0__'*
M.&HKN?\ A7GB;_GT3_O]#_\ '*/^%>>)O^?1/^_T/_QR@#YB_:!^,.A? 7X/
M>.OBGK[Q-#X:T:<Z58RR+&VL^([Y39>'M&A)()?4-4FMTEVY:*T6YN,;86KY
M?_8O^.?CW]J#X):)J]MXH\)>"[[P@T7@KQK_ &#I!UWQ=-K&G6T4D6IVMMK+
M+X:\-V>M:?)#=6'F:9XF 9;E0$DA*1_H[XE^$GB/6].%E)X:\+:]&9TE:R\5
MQP7FF*4CE5;A(6M-17[7$S@0N8!M1Y2)%) ;$\ _ _Q)X/TB+2U\,>"M(,-G
MI]M+<>$K:&P;4Y;.%H3<:D@L;#>Z@DP%GN73S)5WJ"2WZ-E>>\*X#P]S;*Y\
M.T\3QIB>(LOS' \1XK&8/%8?!Y7A</6PU3+%D&*P->E7A4>)Q5:M7JUI.=:I
M@ZD*2C@9.>4H3=6,N>U-0DG!)ZRNG=R3TV2V6EU?4^*OVDOV//A_\:O ,UIX
ML\7?$DW7AQ=3\4/K!\21ZIJ>LWNGZ3=FSL[T:Q8WNEZ;I4$IDG_L_P .:7HL
M$D[H\BL(+=8^P^%?PAU[]E[P1I7A/P-KWC#XK?#;13<M)X4\3/I-UXV\,V5S
M.UU-/X"O=-L-(M]8L;>66XN+GP;J:?:K@2/)X=U&*Z"Z1>_8VM_!W5_$-J]E
MJ,6HK:RP7%K<0:=K]]I*75O=QF*>&Z_LV^M6N$>,L@$I8H&?85+$U;T[X5^(
M-,A:"%+ZX5G\S?J>M7.JSJ=H4*EQJ%W<31Q *"(D<1ABS!=S$G.IXC<1XGA7
M!\)9CF^)S;(,+F6(S'_5_,,+AJF70JU8JG"MA<5&4<=@\32A/$QHUL)*A.A2
MK?5J4OJJE1D>Q@IN<5RR:2YHMIZ6T:V:=E=.Z=K[ZGC(^(6DW>D6'B'0++4_
M%&@Z@]M!#JFAG2C'%>W.H1Z7_9MY:ZIJNEZA9:E:7TT=OJ5C=6<5SITI>*\C
MAFBEC3LK*XENK=)I[&[TZ5BX:SO3:-<Q;6*@N;&ZO;8AP Z>7<R'8PWA&RH_
M.C_@H[!\;OA5!X,/[/W@3XBW/CCQIXATOQ%X\U3P'X?U36?#%WIWA36--N/#
ML'B>'3[&\L/^$FUKQ!!9:?#>V\MEK%]H5M>:9J4M[97-E%'^COPMM/%/Q+^'
M?@WQY/X5UCPI>>)]!L=3U+PQXCLKC1];\/ZK)'LU32+_ $[44MKR"2QU".XA
MB>6%!<6ZQ7$>8Y5-:<1<$5<JX(X6XWPSPTLIXIS'.,'AZ,\7&IG67_V9["%*
M&:86G6]E&&-JK,G@<73P]!8W#8".*EAL!]8AAFH5>:K.D[W@HN]O==]^5^5U
M=7=FVKNUR2BNY_X5YXF_Y]$_[_0__'*/^%>>)O\ GT3_ +_0_P#QROSDV/SN
M^*?[7?P\^&O[4_PR^"&LQ7UW?Z[X0US^U-0TFVN=4N=&U_Q1=:)-X)T$Z58Q
M375W=Z_'HET3'$AE@%_I,@1DN2:^B3\6_#(^_HGQ*CQUW_"OQ_\ ^R: _P#^
MOCK7F/CC]CO]F[Q+\9+;QIXL\$>"]0\;ZBVM:[KFOWGBO5X-2'B;0[WPE'HU
MU+)!XC@CL+W3D$J:?;P);I$D+B*';;C9]KKX!\3G;*MNKY D5Q<0ONZ,&!\P
MAMW!SSNSGG-?IO%57P^IY1P1'(\EXMAF%+AM4.):^:XC!9=A<=G$<?BJ];&Y
M4J:S><L-.>)K8>%.HL+[/!X7+ZKISKXG$N.,%5YJO/*%N>\%%-M1M&RE?EUL
MKWUUD^B1^>O@K]L'X7^,?VI_%_P/LKVYL-3T_P !Z*EGJ>OQW/A\:GXJT[5-
M2O->\'IINM16-[#JVFZ;J^GW$4,L0FO9(]3A@B;[(K2?9LYFBBE,4(FG2-S'
M;O)]G$LJJ2D33,DGDAVPID,;^6#NV-C:?D73?V"O@&?BS<>.9/@/XDGURZO;
M?7DU[68_B+?07/B_4]8U>76M0U-=4U2>QN(KF.YMY+O[? ^G"*3*(JA]OT\/
M@9\5?!@\SX=ZG%JNBP\_\*^\=ZK<7NGQ0KUM_"_C4M?^(?#V!Q;66L1>)]%B
M^6"WM],M\-'OQS@_#W$XW)5P34XARKEX=R>CF.&XQPN$H4,;G.&PM.CC*^$S
M'+<RQ\:$,;)4I>RQ>'P6%PU9XA5,7A:,*<14G52E[3DE[\N5T[Z1;NDTTKVU
MU3DVK:-W*.D:_K>HZE?V%SX:@L(M+NXK.^NQXBAO-DDVG6^HQO;VR:7 UPAC
MNH8F#2P,LGF$!E0;^MKY%_94_:2\/?M'_%O]H+X=>'M.&D:]X \0V%Q9VEUJ
MNG7LGB#1["PLO"VO:E97%E-)8W,.E^)]-GMEFL;BX@NM-OM+OT91/)'']Y_\
M*\\3?\^B?]_H?_CE?)\8<-9OPEG4LESS)Y9'F-++\HQE7!2G5J>YF>5X3,:=
M95*F)Q<9JI#%)?NJSA3E&5&2C6IU4M*<XSCS1DI*\E=?W6TULNW](X:J=]J.
MG:7!]JU._LM-MC(L0N+^[@LX#*X8I$)KF2.,R.%8JF[<P5B <''HO_"O/$W_
M #Z)_P!_H?\ XY7%?$>-?A3X"\7_ !)\9O!I_A?P1H&I>(]:NI)[?(M--MWG
M\B!6DQ)=WDHCL[.(?-+=3Q1C[U>!@\-6QF+PN#P^'K8O$8O$4<-A\+AE?$8F
MOB*D:5'#T$H5'*M6JSC3I14)N4Y12BV[%-I)MM))-MO9):MOR1CZ9KFB:T9!
MHVLZ3JYB5'E&EZC9ZAY:2,5C:3[)--L61E949L!RI"DD&OBK]M7XT^+M%^#_
M (]\%_ WPIXU^('Q%UNTN?"6H:OX$T&^UO2OAS;7UNS:]>ZWK5D&MK+7H-$^
MUQV.G0//>6%U<0W>HI8K'$)NH_9(\6>*?VR?@MH'BK0&A\!>#-,GO/"_C'1]
M UN.7QQJNOZ?()KS1SJD*V\O@[PU-8WEG,MY8E_$^M0W$@M;S0($\RZ^N=?^
M&][X/\$W?AO0?"UU:V#:#K.FZ/H_A;0[W4(())+"=4C:'1K:Y%N]S/,&:YO"
MC7=P\DLTTLQE<_IF&RW#^&W'^'PW$&2K.LZX:XBIQK\+8K$)X&G7RW%QFEG6
M,PE-QQL)NE'$/+\O<L-/#S@L7F'N8C U,6W6I-PERQG!VFEJU)?93VW:O+6^
MRV9\P?LB_%/Q3\0?@_X1TOXH:#KW@[XO^&- L]-\7^'/%6DWFAZSJMIIQ&FZ
M;XWL;2_CB?4-(U^"&&2YO[3S8+?6#=VEPT,IB63Z=GOK&U94NKZRM79=RI<W
M=O;LRYQN59I$++D8R 1GC.>*JZA\(-6^(6CZ9=6D&M^%_%'A@QR>&O%%QI-W
MI6L:!J;VD2SK'::U!9#6=!U! +/7M%F$NE:O;!H)6BO(+6ZM>&UBWO-0TK6O
M#?Q$T3PYX=^('AR?PI)J5G?O8R:7J^DWOC#0]/M/%/@W4]34/?\ AG4KZ>.T
MEMS(;_0M4N!HFLQ+<R6MQ?\ B9MAL'Q)GV89KEF72R>EC\VJUL?P[@XRKO(?
M[1QO[N67QJJ%3$Y+&IB(4Z#DE7P%Z>#Q3E&>#QN-J+<(QBW=J*49/3FLE\5K
MVEOWONKNZ7N_P^G@N?$6FS6T\-S$TC 2V\L<\1*D!@)(F="5/# -D'@XKZ>K
MPWPAX$U/0=9LY_[.M;*Q@E=O+LTM884W-N+"&W*(N[!+,J99NN2<U[E7PTN7
MF?)S<EWR\]N;EZ<UM+VWMI<U]0HHHI %?RY?"7XD?![]JK]J+X2_\)-\0_\
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M:VVC^=9'3U.H;;N.4Q'RY?L;9F!C+[CW_P#PH?X(?]$>^&'_ (0?A?\ ^5=
M'J]%?-2?LY?#(?%*YUUOA%\-?^$4?X?V.CPQ_P#"(>%C"/$$7B34;ZX<:;_9
M^5F.GS6P-_Y(+H!;>:1'L'??\*'^"'_1'OAA_P"$'X7_ /E70!ZO17E'_"A_
M@A_T1[X8?^$'X7_^5='_  H?X(?]$>^&'_A!^%__ )5T >KT5\U> _V<OAEI
M4GCD^(/A%\-735/B#KVL:#YOA#PM>[/#]Y:Z4EBD0&GR?8H5FM[K98?NQ 2S
M")/-RW?CX$?!$$$?!_X89!!'_%!^%SR.1P=+(/T/% 'JU%?-'PM_9Q^&>A>
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M\5^%)]4\/^+%\.^U?MF_MHZ5^R_X?\06FD:#>^(_'FB_#+5OC!J$EQI-W?\
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M02VSRQ1R/;3&(S6[NBLT$Q@DFA,L1)CD,,LL1=3Y<CIAC+110 4444 %%%%
M!3)'\N-Y-KOL1GV1C=(^U2VU%) 9VQA1D98@9%/HH \9/QCE!(_X5+\9C@D9
M'@ZS(."1D'^W>0<9![C!I/\ A<<O_1)/C/\ ^$;9_P#R]KV>OYW_ -L/XSR>
M&OC[_P %!F7]K;XL?#'XZ_"/P#^SSJG[%WP3\*?&'6;.P\>_$K7OAQK>KZ5X
M3TK]G0WUQX>^+]G\2OB3!I/A;Q5!=^$]:E%E?3JNHZ+);)?VH!^W/_"XY?\
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MV5'09"Y./_PN.7_HDGQG_P#"-L__ )>U[/7XL?M7?'']H7PQ\5_V[?$O@O\
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M VO^(-,VS%P(AJ&FVLUL;B/RR9H-_F1!D+@;USSW_"[-)_Z$+XQ?^&K\7?\
MR!7LU?G?_P %$O'&L>$M"_98T*T^-GB/X >&?BA^UUX)^''Q%^(?A;Q)X9\'
M:O;^"+WX5_&;Q//I,?BGQ;I6KZ1HL6I^(O"GAQ)KDVJW4XB%C;3QO=G< ?57
M_"[-)_Z$+XQ?^&K\7?\ R!1_PNS2?^A"^,7_ (:OQ=_\@5^!FO\ _!5[XH?L
MU>%OBAHVD^,_"/[4/A/X2?$OXP:EX0^*7CJ6V;Q7\7/V??A]JGP=T62[M_&/
M@Q? /PMN;CPYX\\>^/?A:?BA8'Q%J&O:]X#T^SM_A?XBO)]=UVV_5?\ 9;_:
M^\=?M _&/XN_!W5_A]HOA;5OV<8?$/A3XYWMM>ZO<0Z3\6;SXBZ]9_"_P]X=
M6\MX$OM$\6_!'1=)^,M[=S2R7-KI?Q$\$6<!8R7TE 'TY_PNS2?^A"^,7_AJ
M_%W_ ,@5=TWXO:9J>HV.FQ^"OBK:27]W!:)=:C\-O%%AI]NT\BQK-?7UQ9)!
M:6L9;=/<S,L4,89W8*":^;/V'/%WQD\0S?M:>'_C=\3+;XI^)?AM^UMXT\$Z
M)KFF^$['P1HND>$7^&WPH\7Z/X4T+PY9W^L7%GI'A^7Q9>V=K/K&NZ]KFH'S
M+_4]5GGN3'#]V4 %<GXM\7VOA"VM+FZT3Q7K:WD[VZQ>%/#6J>);F!DC,IDN
MX-+@GDMH& V)-*%1I"(P=Q KK** /&?^%V:3_P!"%\8O_#5^+O\ Y H_X79I
M/_0A?&+_ ,-7XN_^0*\H_;W^+OCWX$?L@_'/XL_"[4-+TGX@>#_"UG<>%=5U
MG2(M?TS3=4U/Q'HNAQW]WHLT]M#J:6<6IRW"6<T\44TL<:2ML+ _$/C3]N+X
MU?LA_%GXC_ 7XN:UX-_:B\00>&?@IXU^&/B:QL]/^"6NJ_Q4N_C=I^K_  _\
M9^'_  O:?$2Z\0Z[ID/P5N/$WA0?#GP-JGB+5=#UZXDUGPY9Z/X=U#Q4H!^F
MO_"[-)_Z$+XQ?^&K\7?_ "!1_P +LTG_ *$+XQ?^&K\7?_(%?%G[.'_!3?P1
M^TEXF^$'@?PY\+/&/A_QM\7M(\)?$+3O#>M:GI;W.B_ KQ7\#;'XL0?&C4I;
M:$J_ANT\8WO_  H^2QB07<GQ%@GB\V*SC=EX+XZ?M9?M2?#[XV_M'?"Z(?"?
MPWHL(_83\,? '6K/3];\57_A%/VJ_P!HWQE\!_%'Q,^*)U,^']/U74='BTF#
M7O#W@G2TCT&QN+33-/U3Q%K+:I?M;@'Z('XV:2 3_P (%\8N/3X5^+L_^D%>
MMV%VNH6-G?I#=6R7MK!=);WUM+9WL"W$2RK#=VDZK-:W,8<)/;RJLD,JM&X#
M*17RM^QQ\5_'?Q3^'GCZU^)6H:7X@\9?"+X]?&GX%:GXST;2(_#VG^.X?A9X
MVO\ 0-+\7?\ "/P7-Y::)J6I:4ME#X@TS3[N?3K;Q'9ZNNGBVLS#9VWUI0 C
M-M5FPQVJ6PH+,<#.%4<LQZ #DG@5XVWQJTE693X#^,)*LRDK\+/%K*2K%<JP
ML"&4XRK D,""#@U[+10!XS_PNS2?^A"^,7_AJ_%W_P @4?\ "[-)_P"A"^,7
M_AJ_%W_R!7Y+:!^V3^TWX#\/^!?VE/B1\5O OC3X1^/OVSOCU^S9J_P/D^'G
MAKP1J/A;P9X&^(WQQ\)>&O%_A#XH2>*;,W6K^%M)^$MIXB\:_P#";6S>'[GP
MU+XIU:?4/#<6CQ7@W_"G_!:'P-=Z?XMU'Q]\$O$GA"S\+QWEK!JND>*AXDT+
MQ%XJUKX+O\:_A)X'T#4=3\)>$+G5?$/Q8TG2O%GA;P]>Z;IU[X4G\6>'8[70
M_$?B73M:T_4: /U*_P"%V:3_ -"%\8O_  U?B[_Y H_X79I/_0A?&+_PU?B[
M_P"0*^?/VE_C9\??AOKG[&UQX.T+P!X?\&_%KX__  U^&_QPA\57>JZYXUTJ
MS\=:9JCP^%/ UGIME::!]K@U2TD.M>,-5U7%K9Z<+/2?#E[/JYU'1_FK]AK]
MLC]H#XM?M#ZC\&OC?87J:AKOP/\ &GQGU/1Y_@[XB^&VE?!SQ3X/^-EK\-&^
M%_A+QKJDL^D_'+PIJ/AW7](UJP^)&@7>K:=?WFD7]_::P;77(= \.@'ZC>$O
M'EGXPGO8+7P[XVT0V444SR>*_".L^&H+@3.Z!+.75+>!+J5"A:6.$LT2,C.
M&&>XHHH Y'Q;XQM?!\%E/=:'XLUM;V:2!(_"GAG5?$L]N8HQ(9+R'2X)WM87
M!VQRS!4DDRBDL"*X?_A=FD_]"%\8O_#5^+O_ ) KV:OB+]MSXB_%[P79_LS>
M$O@SXZT[X;>(?CE^U-X/^#FN>-+[P=I7CJ?1O">I_#7XM>-=2DTG0-;N;;2G
MU2XOO NE6D5U>&:.VM9[ME@>5D9 #W?_ (79I/\ T(7QB_\ #5^+O_D"C_A=
MFD_]"%\8O_#5^+O_ ) K\B-:_P""L'B[]FVQ^*'@?XW>&- ^.WBSX#?%[XD^
M"O&?Q#^'E_!X$G\5_#;P/8_"'6CXWTKX6V%IX_U&+Q3HUO\ %MO#'C.*YO?#
M/POL?%/@37+:3QWH.H:M9>';/[Y^!_[9]O\ M">-?B%\+O!G@"^\/>/OA5X8
M\<GXHKXHUBSNM#^&/Q)T+XH^,/ACX-\ ^)Y-(C-[>3>.H/ OB#XDZ;>Z?'$$
M^'7]A:P(G/B;2\@'OW_"[-)_Z$+XQ?\ AJ_%W_R!2'XVZ2 3_P (%\8S@$X'
MPK\7$G'8#[!R?05^(GBO]N#]MW2M*C\/?#OQEI7Q]'C#XD)X5^'OQ6^$_P #
M?#L&L?$76O 'P/\ BWX^_:#TKX#>#/''COPWX(\?_!GX;_$/PQ\,/#*?%KQ'
MXKTZZU32?$OC?0_"=QX\\5>'['4:_;G]F_XG3_&K]GSX(?%V[N= O-0^)?PH
M\ >-]4G\*G43X:;6/$OA?3-5UA- &L0VVKKI$.IW5W#8)JD$.HQVT<:7L:W*
MR  'L%E=+?6=I>I#<VZW=M!=+;WMO):7D"SQ+*L-W:S!9;:YC#A)X)562&4-
M&X#*15FBB@ HHHH **** "BBB@ K+ET/19M2BUF;1]+EU>!0D&JRZ?:2:E"@
M5E"17SPFZC4*S*%250%9AC!-:E% 'DWQ1^!_PU^,7@KQ9\/_ !MH#R>&O':P
M0>,H?#VIZIX0U/Q+81W-I/>:5J^O>%KS2-;N])UJWM%TCQ#ILE^;77M!GO=#
MU2.ZTN]N;63TV#3["VL(=*M[*UATRWM(K"#3XK>)+*&QAA6WALXK54$"6L4"
MK#' J")8E$:J% %7**        #  X  Z #L!1110 4444 >+?%G]F_]GSX]
MW/AZ\^-_P/\ A-\7[KPG'J<7ABX^)GP^\*^-Y= AUIK!]8M](?Q)I>HM86^K
M/I>FMJ=O;&.&_.GV9NHY?LT.S(U_]EG]GO7O$L/CX_!SX8:;\3M,TG1]+\+?
M$^R^'7@>?QSX,D\+V,EAX,U7POJVJ^'M1CT_4_!$#HGA29[6XATFWACT^*W;
M3#)9/] 44 >.? 'X'>"OV</A+X4^#O@#^TIO#WA8:S=2:IK<EC/X@\2>(O%/
MB#5?%WC'Q=XCN-,T_2=.N?$7B_Q;KNM^)==GL-+TZRDU35+HV=A9VODVT4&J
M?LV_L]ZV_P /)-7^!_PGU)OA)J$^J_"XWO@#PO<#X>ZC<W\6JW%YX.633&7P
M]//JL%OJTKZ6+;?JMK:ZDP-]:V\\?M5% !1110 5R/CSP!X&^*7A'7/ 'Q+\
M'>&/'_@;Q-:I9>(O!WC+0]-\2^&==LX[F&\CM=7T/6+:[TW4(([NVM[J.*ZM
MI42X@AF4"2)&7KJ* /FY/V.?V3(_!FG?#J']F?X$0> M(\3R>-=-\'6_PI\$
M6_ANS\7SV1TRY\3Q:/#HL=B-=O-+9M+OM4:%KR^TMFTZ\EGLF,!D^%_[+OPO
M^$OQ3\;?%OPM:W$6O^*O GP^^$^@:0+'PSI7A;X7?"+X9C5[GPM\+OAKHOAK
MP]H:Z+X.@UWQ#KWB.>SU&?6;QM4U,PV][;:38:9IME]&T4 >;>,/@W\)?B%9
M^,-/\=?#/P)XPLOB#I&A:!XZM_$GA71-8C\7Z+X7O;S4_#&F>(_MUE.=7LO#
M>I:A?:EX?@OC,FBZA=W%]IHM;J5Y3TWA'P?X3\ >&=%\%^!?#6A>#O"'ANPB
MTOP_X8\,:58Z'H&BZ=!GRK+2])TV"VL;&V0LS"&W@C3>SN07=F/1T4 %%%%
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MU '\V?Q=_P""B/[6/PW/Q4^!5Q^T#I=Q\6_@E\1/VL(1X^TCX,? SPW?>/\
MX>_!/P!\#/&GAOQ'XWU+XS_%GX??!CP5H?A_5OC/_P (WXRT;P1:^)/B7XTM
M;30[WPEHN@"+7=2G^E/V$_VDOB%X^^$/_!13]IR;5_!>C>.]7\(_L_?&W36\
M77GB$?"/PAXNUW_@FG^SC\0[@ZA#9RZIK>E?#NQ\5WMUJ&M0:4+G4XM)-],K
M7.HEYI?V:U_X2?"KQ7<V5YXH^&7P^\27>F>('\6:;=:_X,\.:Q<Z?XJEMK:R
MD\364^HZ;<RVGB"2SLK.T?68&CU%[:TMH&N3%!$B='H_A7POX=MKBR\/^&]
MT*SO([6*[M-'T?3M,MKJ*RT^WTFSCN(+*W@BGCM-*M+73+5)49;?3[:WLX@E
MM#'&H!_+KI'_  5,_;"ETGP1\'IO&W]H_%+QG\8_ /A[QS\2X?"G[)26GPV\
M*^,OV?O'/Q9T"Q^&WQ13X]0_LE_$.#XK^)O 5_9?#:[\;ZWX0\?:#X46^TWQ
M#X#\1^+-3\+W]SN_\/'_ -O7Q!\-?B/\9#\3O@SX.T#]G7]E;X*_&#Q?HGAC
MP'X1^(NA?%G5O'O[3GQW^"^M^-[CQ[I'C;Q!X?\ "GA"V^''PLTOQY?V'@O6
M/$NE:3XDDUN*T\7:AX6L8Y;K^C.#X"_ RV\':M\.[;X,?">W^'^OZBVL:[X%
M@^'7A"+P=K6K/+#,^J:MX9CT==$U+46FM[>5KZ\L9KEI8(9#*6B0KV$/@?P5
M;V5SIMOX/\+P:=>^';3PA>:?#X?TF*RN_"=A#=VUCX7N;5+18)_#ME;W]]!:
M:)+&^FVT-[=Q0VR)<S*X!^&WC+]N3]H7XU_M=^*_V<?V:?V@/A7X7\!)^T+X
M@^&5A\5/#_@/PU\7I])\/>%/V$O#W[1&K:=H\T^O+X8U7Q(/B7J+6-Y?Z@-0
MM--T6:]T>33FU&VAGM_3/^"<?[5O[4_QC^(7PDT_X_\ Q \"^.M'_:'_ &"O
M!?[7>F:/X2^&D'@&#X7>*;GQ_IW@K5/">B7T>OZYJ7B3PYK&EZW8:K/+XEGN
M]5L=>LKTZ?>Q:-?6^EV'ZT^&/A7\,/!5KIMCX-^''@/PE9:,93H]GX8\(>'M
M!M=*,]BVF3'3;?2M.M(;$S::[Z?+]E2+S+%VM'S QC._IOA;PSHLEC+H_AW0
MM)ETS1T\/:;)IND:?82:?H$4R7$>AV+VMO$UIH\=Q''.FF0&.R2:-)5@#JK
M _F\^&H_8KUWP;\3_C5^V?\ $SQ'H7[?_AK]M[X@^%-0U'PC\0=>@_:O\"^*
M-._:2U+P_P#LZ?"3X'?#S3[S4/$#_#?Q/\)S\/8M'\#^&O!NI^#?B!X#\0Z]
MXCUJPU0ZCK>JP2>$OV__ -K7X[?M(Z/\&?A)\2/A5XST?]I'3?VT] ^$EK\8
M/AG\,_#'PX\(>)OV>=:EM? WB;1O"'A/XH^._P!I+4-%T"[T?4--\877QN\&
M>%[;QEXBM4U+PEHOAO3/)LU_H@N_A7\,+_QQ8_$Z_P#AQX#O?B3IEI]@TWXA
M7?@_P]<^.-.L?+DA^Q6/BR;3GUZTM/*EEB^SV^H1P^7)(FS:[ LT?X3_  L\
M.^(=2\7>'_AI\/\ 0O%FLZK/KFL>)]'\&^'=,\0ZMK=U:W%E<ZQJ6M66FP:E
M?:K<6=W=6D^H75S+=S6MS<6\DS132(P!^=_PJ_X)USI=_LX_$'XJ^.?&GASX
MI_ SQ]\3/B'XGB^&?QJ^)&J^'/C'XP^)%MKD>N^./'EW/9_#V"X\4>)+_6Y+
M[Q)!9^#[;1GT.WM/AW96B>";*RT^W\C_ &U/VN?V@O@Y\>_VE'\.?&SP=\*/
M@;^R[^QO\,/CGJNE:E\#A\6M;\:?$/XR>.?C1\,M!MKZXC\8>$KZR\.:%J?A
M#PYJZ:?8ZEH27VJB%->\5^'_  K_ &Y=C]JZP-2\*>%]8_MD:OX;T#51XCT8
M>'?$(U+1].OO[=\/K]L"Z%K/VJVE_M31E&HZ@!IE]Y]D/M]YB#_2I]X!_-O\
M&OV[_P!N+XQ_':Q_9'TWXV^'/">NW7[4:?#+4/B_XD^&OP"\=?$G1/ .H?L5
M^-/VB;C2+SPY\%/B7XU^!,7C/3/&O@X:=I=S#K>K'2]"U.6P\6:+J6KZ?OG\
MX\0?\%5?VM)_@7XT^)6M_M%? ;X$>.?@C\%?A)K>A^"_%/PRT6ZB_;#\:>+O
MCA\1_A%XW\4^%K'7O%UOKNBZ/ILG@.ST/1O#GP]?5)?#_C_5-1N/%5UJ'AXZ
M1I!_IP\,?"CX6^"H]-B\&_#7P!X2BT4(-'C\,>#O#N@QZ2([2^L(QIJ:5IUH
MMB(['5-3LD^RB+9::C?6ZXAN[A)/DCX\_P#!.OX&_M#>,]*\1^-=:^(NF^$[
M>P\.:7XA^#WAC5_#5A\+?%NG^&/%<_C*UMKG2]0\):MXD\%KKFL7!B\<R?"C
MQ1\/9_B'I,-MI'C>77K&WCB4 _.S]E__ (*$_M9?%S]LGPSX1\60^$-*^&WC
MO]HW]JWX':O\&=8U/X$Z1XC^&WAGX"3?$&T\*>(_#=EHWQ3U;]HS6?'MPW@C
M0-7^(EI\1?A=X?\ !5QH'C^VU3PI_8EC:^'[KQ/_ $$5Q=C\-_AWIGC+5?B-
MIO@+P7I_Q"UVRATS7/'=CX6T.T\9:SIMN(EM]/U7Q1!8QZWJ-E L$ AM+R^F
M@B$,02-1&FWM* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)_
MJY/]QO\ T$U\IK_R'Q_V%1_Z55]7,-RLO3<",_48KRX?#.$7POO[4;<+H7)0
M6IVY\WS"H)N,X[ G/K@]* /4J_#+]LWXY_M(_!/_ (*/>'/B/\-/$?B[Q7\"
M_@7^Q5I'Q/\ VB?V<-*2XU6U\=_"[Q/\?=?\)?$#XG^#-#C<;_BW\&=!TO3_
M !WH4%LGVOQ?X5T+Q3X&B<7NM:9M_<VN1;P#X);QO/\ $EO"NA-X_N?",?@&
MX\8-IMLWB"?P3#J]QKT7A674FC-R^A)K5W<ZHNFLYMA>SRW'E^8Y) /YQ/V<
M/^"E/[1>L?LV>,O%WPC\2?!KXF>'?@)\#_C]^V?XZ\?_ !U\2^,-4U7XW?"S
M5?VN/VKM$^'/@?X3ZYHNJ6,'AO2].^&WP8GLK;X@Z];>+=+TJ^U3P/X8A\)?
M95N[I/??#_\ P4,_;A^*WB7P:?AGX-_9D\+^#?CA^V7\1OV3?A)'\0=)^*NH
M^+_"&F?#7X3_ !1^*FL_$GXE6VC^*M)T_5]3GC\$67ARV\ Z%_88BO([_4+K
MQ0D5]!9:7^F>J_L#?L5:WI/P\T'5/V7?@G=:%\*#JZ_#O1?^$"T*'2/"MKK_
M (HE\;ZWI6GZ;;VL5DVA:IXQFD\4WV@7<%QHEQX@;^UY+ WRK./9;/X'?!W3
M[_2=4L?AIX+M-1T'XC^)_B_HM[;Z!817.E_%'QKINM:-XM\?6,J0A[?Q5XCT
MGQ'KVG:OK,96\OK/5]0@GE:.YD5@#\+O"_\ P5?_ &I[3X=^!O'/Q1\+?LQ>
M'9/CY\ O$'Q"^#5CHMK\<-:_X1_XA^"_VD?A7^SI?>%=>TSP_9^*?%WQ4O?B
M)<_$ZW\4_#CP7X#\-:!K\FMV-O\ #[4=9EAO9O'ECV/[*/[<'QT_:2_;1^#_
M (&^(JW/@Z?X9^(?V[?A#X\\/Z%H'C#X9Z!\1KKX?^#?V/?'?@3QAXE^$OC'
M7_$NO^#O$.C:;\6M1TU-!U_7]:O-,N'O[ZWN+1-6>PM_UC\0_L>?LM>*_"6F
M>!/$7P#^%VK>$-$\+ZMX+T30;GPGIGV'1/"^N^+-"\=ZKHVBK'#')I%M=^-?
M#'AWQ8S:=);3Q>(=$TO5X)8KZRMYTO?#+]E#]FKX,:G8ZW\*?@?\-O .M:=<
M^)+ZSUCPSX7T[3=5CU#QCIGA;1O%VIOJ,47VRXU3Q3IG@GPC:>(]3N)I;_6X
M_#NDMJ=Q=26<3@ _(3XZ?\%;/C9^SE\1?VE;KXE?"[P/%\+_ (;6O[0]K\$=
M$M- ^(EW??&G4_@QX6.MZ"WA7]H#PO=^,_@WJOB;4KFRUV?XI?!SQ#I7PY^(
MOPJ\/Z+K-];Q^,;OP_?6=V:#_P %'/VZ=>\6^"_@1'\)/A#X?^+GQ#^-WPJ^
M'WASXD?$GX??%CX<> 8O"WQ&^"GQV^+&OW,_P@U7QS>_$Z?6/ MS\#[S3])U
M>;Q%IOACXDZ5XCTN]TJ;1+NQUNVT[]:E_8X_95'Q)\7_ !?;]G_X52_$CQ]9
M>(]/\9^*KGPAI-U>^([?QCHZ>'O&+:I;W,$NGW%YXOT&--$\5ZC]C&H>)-(!
MT[6KJ^LV:%F?#']C7]E7X,QZ3'\+?@%\,?!+:%XPB\?Z/=:+X7L8M0T[QE;>
M%=6\"V/B&UU*9)M0CO\ 3/!>NZSX3TEA<^7I/AS4[W1M-CM=/N)+<@'Y/_%#
M_@KC\8/ ?[,7P>^,FE_#/X4ZSX^^(OPF_;C\<ZGX6N]7\26.AVNN_LI_$S0_
MAWX9L[22*\N=7M-$\3W&J2-XCN;I+RZTZY$<5D R-#)V>F?MU_MN>#OCUJ?P
MV^+7AO\ 9=UCP?\ #G]L[]G;]DSX@:E\/;#XI:7XB\5#]J3X=^$?'GA;Q=X/
MC\1>(]3T_P ,'X97'C;2-$UW3M:C\1_\)];VFI:K82^"9?LNFR_H7%^P/^Q9
M#XC\;>+D_9@^"_\ PDOQ&_X2H>-M7?P+HLMUX@C\=7UMJGC6WNS);O'':^+M
M6L[;5_$MI:1V]KK>KPKJFI0W.H%KD^RW_P #O@]JNLZIXBU+X:>#+[7=<\>^
M#/BEK&KW.@V$U_J7Q'^'6F:9HW@3QO>W+PF6X\2^$=)T72=.T#5I&:[TRSTZ
MS@MI(T@C  /S-_:T_;O_ &B/@A\6_P!J.W\!>'?@/?\ PA_8X^!7P&^/7Q$T
MKQK=^+T^*_Q0TSXK>*/B5I&M^#O ,VDZM;:#X9U&QTGX>SR>&=>U?1O$=MJG
MB[4=)\,7.DI#J3ZI8?$'A/\ X*1_M4?LM?"GQ-\5_BCIG@7XT_!OQ3\=/^"H
M&B?#O2KO4_&UO\;-%O?V>/&OQT\>> K?Q;XNU._U#PDG@-],\"WG@:XT32_#
M$%SX \*V6CZU!K&N):WNBVW[$^(?V /V=?'?[4WBS]K#XG^"O#_Q.\=ZSX5^
M"_AKPM8>,_#NDZKIWP^F^"VM>/\ Q!H^L^'99HFGGN]6UCQS!J=Y;:HMU966
MJ>%?#VJ:=#!J%HMPGN[_ +._P(EL],TZ;X0_#RXT[1M>^)/BC2]/N?"ND7-A
M9^(?C%:^)K+XK:O%9W%K);&]^(EGXS\66OC&5XF.OV_B/6(=1$\=_<*X!^0'
MQ3_X*"?MQ?"/QIK_ .S]>^ /@-\4OC)IL/P(\?3>-_@9X8\?>/=*TCX3_&/1
M/C3<:HND_L\O\1M.^*7Q6\9^#O$7P>9!8?#_ ,93:GK?PW\1M\2H/"4$/AK5
M-#GYK2?^"K7[0GBGPYX_^,WA#2?V7O%'P4^ 7PU_8]\>_$^RT*Z^+/\ PG'Q
M/N_VB=8U+PQXYT'X5MXHM_"5YX,OO!VMZ/J5GX3T_P"('@:\UO7O%EM/\/M7
MTO3-0M9]='ZA6G_!/;]B/3_ -]\+[']F'X0V?@;4O%&E>-;K1;;PK:P,?%F@
M:=-HV@:_;ZK&5UJRU+0=$N+G0]#N++4;<Z/H5S<Z+IHM=+N9[23@_"'_  3,
M_9*\*?'S7OCZ?A1X'U?5QHWP.T3X7^&;WP;X?B\._!6S^ VD:YIOA1? %M:V
ML:VZO=ZRFO1QWL4Z:1K^G66KZ2+;44^U  _+#X)?\%"_VIOV?O@UX2\0?'#7
MO@?XP^'7Q(TS_@H[K'PQ\9>/=;^*=EXS\,:_^S3\:O%J>!HOB]XJLK;QJ_B+
MPWXNTZ_M?"FG^&_ 7@-?$GAU]/\ #F@Z+)XFGO\ %ID:M_P4N_;(UOXL> O"
M&M1^&?!(^!W[4^DQ?%RRC^#?Q2^%.L?&GX0:]^PS\?/VBH/!7_"K/B'XMU?Q
MIX.UVTO_ (;ZE;Z/<ZQJ877]6'@C6[C1--LK35M'U+]Z]:_95_9L\2>%M.\$
M:_\  WX8:SX0TC3_ (D:5I?AO4O"&CWFCZ?IWQ@GN;KXHVEG8SVSP6\7CRZN
M[FZ\3")%.J74K7%P6F"N.(T/]@[]C;PW81:=HG[-OPFT^"+QEX)^(GG1^%;*
M34I_'OPW35(O OC.]UB<2ZM?^)_#%MK>KV.EZW?7MQJ,.FZC=Z8UP]A*UL0#
MXP_X)W_M_?M!_M4>.=!T/XP?!S3_  AX4^*'[-V@_M+?#[Q-H_@_QEX$@\.V
M6N:SX?M%^'%Z/'_B'4KSXM0_V/XKTG4M,^+_ ('TG0/">I76G:W8W6@Z2T^B
M&\\$N/\ @I'^V)?^$M%\36FG?LV:-??%OXN_M5^$?@MX#T'X9?M$?&CXIMX!
M_9*^(/C;X<>*_%6O>"_ VKZ;8:O#XAUO2/"UYXA\3W?BGX>>$/A3I6LVXO;O
MQGJNN6&GZ?\ K]\'/V4_V;?V>]:\4>(_@C\$OAS\+]=\9I'!XDU7P=X:L-'O
M-0L8;^\U2#2$FMXP;#0;?4]0OM2M_#^F_8]$M]0O+J\AL([F>25LKQA^QO\
MLK^/]!\*>&/&/P$^&6O>'_ WB3QEXN\(Z5>>&;%;70/$'Q&U:^UWXA7^GK;I
M"T2^.]7U*^U#QE9,S:?XGN;F1];M;[Y0H!^//@C_ (*Q?M3?$GP/9?'?0/AA
M\!M%^#_@KP#_ ,$YO&OQ1\*:M=>/=2^(WB.X_;AN?#^C^*=%\!:Y9:G9^'?#
MJ?#6\UQ=8T'4-?T;Q"WBBW1-#O;/29E?63@_$'_@L1^TA\*_AUX)_:$\0?#3
MX#>*?A1\<OA9^U'\2/A5\,_#%_XZMOC/X)G^"/BOPSX)\&:#\2[VXU'4M$UH
M:IJOBJQN_B;J&@>'=$D\$WMEJOA:QL-5NH(-7G_;K0OV4_V:_#'A74/ WAWX
M&?##1?!VK6?P[T[4O#&F>$-'L]#O-/\ A'>0W_PNL9M-AMDM6L_A_>6UO<>$
M;7RQ!H+P0_V<D"Q(%^)/A9_P2>^$7@[]H;Q1\??B)KGA_P"+USK.@?'#PQ;>
M'=5^"OPK\(2Z]I'[0>KV%[\0V^,NO^%-'M)/C+J,VCZ?%X6L)]8TO1-/DTNZ
MU34M?TK7_%.IW7B!@#T_]A3]IWXY_';5OCIX$^/?PZM_"7BCX.ZOX!&F>*[#
MP/XK^%%GXUT7X@>'+W65BF^%7Q!\2^*?'?A'4O#&H:7?:>]]JNJ7&D>+-)NM
M&UW0WA,VHZ?8?H97C/P4_9W^!W[..@ZIX9^!?PN\'?"_1=<U1=:URU\*:3#8
M2:WJL=G;Z;;W^LWQ\S4-5N+/3+2TTRP:_NK@:?IEK;:=9"WLK>*!/9J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img170310032_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ## J4# 2(  A$! Q$!_\0
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M_:'^(/Q!^&OP_O\ Q1X!TWX7)_9L&H:CXG\:_&GQ]<^ /AE\./#6F6$]]?\
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MU9%ZR@ HHHH **** "BBB@#S?XO:_P"-O"_PU\7:_P##GPV_B[QIIFF"?0]
MBB2ZGO)3=6\5W-;:>]_I0U>[T[3Y+O5+30UU72Y-=N;*+1XM2L);Y+N'Y2T3
M]L#2] MKRP\4>(]+\5^(K[QE;>%- T'6_#>H_L_^*] NH_"VK>(]9A^)6F?%
M2[T_2M$L8HM"O6\,^(M-O;O3_%7VNSL],AN&CEOY/L_QCX2T?QUX;U/PMKW]
MHKIFJ+;&672-6U+0M5M;BQO+?4=/OM.U?2+JSU'3[VPU"TM;RVN+:YC*S0(L
M@DA:2)_)Y_V;_ %U<#6;J_\ &=QXVCU:QUBV^([^*KZ/QY97&G:-K'AZTM;3
M6[=88X=*CT/Q!KFG/I/V)M/N(]4N;FYMYK]8+N'[WAG,N#*&4XG!\2Y=B<5B
M9XNM6P]7!T:,*LDZ6"6%I8O&S<\5' 4ZU'$SKT\ME@,5"%:HI3S+ZS1CE><U
M4<DX-)62:=^[O9;7M:U[K_#]KS'P]^V=X6\5W-I+H?@;Q7/X=FOO@=I5SK]S
M=Z!:_9-5^/.MVNA>&['^S/[1FNK@Z)=RW3>(YXF\B**T1M+?5%NHV7'\1?MQ
M>'M$O/$MO9_##QSKMMX.GU1/$=Y97WA2V%M;Z=\;-8^!$,ME;ZAK=M+?W&H^
M+-)%_:VJ^0$T2X^T7,\%W"UD_L<?[,GPHM],UG3+.QU^T_MJ3X9W<NI1^*=<
MGUFSU3X07,=[X"UJPU6^O+N[CU?2;^)+ZXO)Y+AM5N=S:JMXDDD;XEG^R'\%
MK/3M:TXZ;XDO4\16PMM;N]2\7Z_?ZCJ)_P"%I7OQEEN;B^N+Q[AKRX\?ZC>:
MK/<!E>2WF.F\6"I OO4L?X/JO*K4R3/Y4(XW+84\+*K6E.>7?5<"LUK5ZU/.
M*/\ MOUEYB\)&BJ="26&E.%.'/2<VKVMS1O9Z]G=V27*]+6O>_5=B'6?VDX;
M/X(?%?XIVOA2ZM/$'PMUWQ1X)U7PEJM];SP1>-=!U:UT.WAFUC23=0S:!<W6
MIZ7J,NI6R":'2;B5YK>WNH)H8['B;X@?$7X):;JWB/XGZSX+\<^%Y+708=,N
MM'M;7X<:II7B74];MM'O+?5V\2>)M1T%?!<,-];:B-?EU6'5=.\BYL)-.UJY
MNM/+^GV/PA\ 66@?$+PNVB+?^'_BEK_BCQ)XWTO4[JZOK;5]2\8P06VO@":4
MO:6MW#;QK';6CPI:$>9:^5)AQYW=_LM?#/4Y4U'6[WQWX@\36;^&&T'QIKWC
M?7-6\7>%8_!^JQZYH5OX;U>\GE.G11ZK&+W5&:&>?Q%-M;Q%-JIAM_)\C!YA
MP*JM2E6P6*HY?/-9XBO2EE]/&XK$Y95AE+P^ PN-J9A3QF4K 8FAF\IXG#XF
MMB,7A<90IUUC)T4HMJK;1IOE5M6DI:W;7*^:Z:LG9)K2USQ[0/VC]>^*WB'P
M1K_PIN?%9MI1XPA\3?#;7/"MI9>&+R?P;<^.?"][HMMX]F\.7%R?%NL^+](T
MV[T:>#Q#INBZ5X5TJ>Z\1:5'J6OZ187/JWBGXL?$CP_\%OAUXZUKPAI_@OQU
MXF\;_!#PWXF\)ZE<?VW!HL/Q"^)'A#PEXCMHY[.XM"+V'3-<OGL/-ED;3KT0
M"]BNS;S0R^K_  T^&?A7X1>&9O"WA/\ M5-)GU[Q#XFN9-=UO4->U"XUOQ7J
M]UKVOWUQJFK3W%[-)J.LWUYJ$HEF94GNI1$(XMD:3_$+P#X=^*/AO_A%_$$N
MIQV,6N>&?$=K=Z%JDNEZG8:YX/\ $.F>*O#U_:7ULQ>*6RUK2+"Z\MUDAN$B
M:"XBEAD=&G&YYPA5S[+Z>"X?AA^&L#G&%DL3B(1JYSB,DHX_%U9X?%TL/+"X
M+$SJX3%4Z=5XF&*QTOJ6'A+-*D74<Q1J*-W*\W'5+X>9J.JNFUL]K+WG[IY!
M\6_VIO ?P@\9Q^"]<A-U>V7AS1O&'B:1=;\/Z9<Z1X;U_7[SP]I=SH^C:MJ-
MIK'C34I+C2M<OKG1?"]G?W]KIFD3.R/?W^CZ=J/$ZK^VWX!TBSM6NO#FN0:J
MQU'3=9TN^U/PYI47A3Q7!\4_^%1Z1X:\4ZQJFJVFEZ*^O>(K77=2L]5O)TT^
M+PYX<U74YGWBUM;GU2^_9U\$ZM?QZKK&M?$+4]4FTZUT/7=1E\;:K977B[PW
MIVKRZ[I7AKQ4^D/IRZKHNDZI=ZC-I\&R"XB@UC6=/>ZDT[5;ZTGCN?V8_@_<
M:G\2=<B\/W^G:[\4_%7A+QQXEUK2]<U.PU*U\7>!A&_A?7_#MQ!=*/#U[IM\
MLNK,--2*VO\ 5;S4;W4K>\DU&]\_MP6*\*Z.&P%+'Y;G^+Q6'C0EC<30KRIT
M<?45?"T<53E2>*HRPM%T*^8X[#U,/%U/]ARO!5(J>*Q^*@FJUY-.*3V3Z:=[
M:N]D[Z:R:V2/GN;]N*P3Q,UW;Z"+SP5'X5T^WODCN]-\O0?'3_%/7? &I:EK
M?C^'4[GPE!\.(;?2[:[M?%<"W&G7*ZCILWVJ.2^-G:_;_@SQ-!XS\*>'O%=M
M;"T@\0:59ZI%;)J>C:U'"MU$LFR+6/#NH:MH6JP D^1J.D:E>Z?>0[+BVN'B
MD4UY5!^SIX$LKL:OIFI_$#2O$S:4-)G\6V'CSQ#%XCOH7\3ZEXOO)]2OGO98
MM2EU#6M7OY+NWOK:XTW[&]MI]O86]GIVF0V?I?@+P-X:^&?A#0O O@[3FTSP
MYX=M&M--M&GENI0)9YKNZN+BYN)))[B[O;VYN;V[GD<M+<W$LF%#!1YG%6-X
M%Q>"HKAC+<=E^-I8N$)2Q+E.-; +#U5)3E]9E3C5IUU0=.HZ-7$8N-2L\14P
MSPT/KK@JJ?OR333VW3NK=-K7OK9:6O?3L**3)]#^G^-&3Z']/\:^#-1:*3)]
M#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C2_@1]<?T)H ****
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M9U.6YOS',8+NZ@NPDZB5)!]7UP/Q(_Y%_3/^Q^^%G_JS/"5 '?4444 %%%%
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M+XB^'5OM%U*.QO?"6@?!;PUX.\-Z;=K>Z;=^!+W7O"WBNT\16.LW@>]^Q?\
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M:SK7B">VT33M'U.[$2:M/J,C6PTY;E#;W19;6;X-^&_P"^.EG^QCX@\&^'-
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M&TM(%:XM)&6&WMTCAB5I'=V"(H+LS'+,2?7Z\K^%GW?B)_V53QE_Z-LJ]4H
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MV/&TGQ(&IBU'VL>.YO"!\ R^*1)N_P"0N_@TGPXUSC)TL^1M_BH [ZBO(!\
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MK1/@G<_"'PWXQ\%:A)HR7^C7_P .+K4+SQ_\/-:CAM-4T[QX$\07$2P3SZ*
M#[C\$?M5?L__ !&^)VI?!OP7\1M/UOXD:79^*+^Y\.1Z1XDLC<6W@;5M'\/^
M.'TK5]2T6ST+7)?!7B'7](\.>,+?1=4U"Y\+^(KQ= UV*PU>*>RB^A*_+W]G
M#]C#XT?"C]J"Z^)GC'XC:?JOP>\#Z%^T/I/PJ\'6FLIJUU<ZM^TE\5?!/Q4\
M:>*M1T\_#SPM=>%;ZXUKPG?ZAJNEW'C3XAZ=)K'B:\M_"8\)>&-/LM&?]0J
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MR8F2%69F5 68GK:S:LVNQ:=TGM=7[_Y?D%%%%(84444 %%%% !1110 4444
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M>+XM4T_4OB#\09[/PQ:>)+2;_A%+N_O-)US41<ZM]OTZ;3;31-5U#V3]K/\
M:K\.?LE^#/#OC3Q-X>M/$-CXA\1MX=2&]^+7P*^$$%FZ:1J&KO>-KOQ\^)OP
MO\-Z@J0Z?(CZ=I&KW^L*CM>-IXT^VN[J#R']AO\ :/\ %?[4/BG]I'XBSSZ1
M9?#*U\5?#GPY\-?!^G_%[X#_ !>O/"TVG^ +2Y\;'5-2^ GC[XCZ'H<NN:W?
M6^I6NE:_XA769K0QZA'86VGW5LTH!^A-?.OP;_:8\&?&CQ9XR\$:5X6^)/@K
MQ/X-T'POXQ?2/B7X0E\(7VO> O&VK>+]#\(^.=$LIKV[O8M#U_4_ GB>"TLO
M$-MH'B>!-/2XU'P]96][92S_ $2P)5@IVL00K8SM)'!QD9P><9&>F:^+_P!G
MK]D2X^$=O\4HOBC\3%_:,O/BMXJ@\9>)/$7C[X=>%=-\5ZGKEO=:B]HWB#6=
M,DGCUK3=!TNYTWPYX,T&&PTG0/!6@:+:V'A_2[1;F]>< ][^%CH!\0@74%OB
MKXS"@L,L5DLV8*,Y)"@L0.0 2>*]1\^'&[SHMNP2[O,3'EDX$F<XV$\!_ND\
M U\Y?"7X6?#:UE\0W-IX&\+VL_A#XR?$W5O"\EMHUE = U/Q)IRZ#K]_I0BB
M5;.ZUC1KZ\TS4)80C7-G<S029C<BNT_X4!\$_P"Q?^$<_P"%6^"/[!_X0'2?
MA9_9)T"P^P?\*XT&^EU/1?!/V?RO+_X1O2]1GFO;+2\?9K>YD>6- [$T =SJ
MWC'PMH5U%8ZQKVFZ=>3E5AMKJY2.:5WCEF6.-#R\K0PRS")<R&*-Y-NQ2PWT
MN;>2-)8YXGCDC,J.)%*M$N-T@.>47<-S=%) 8@FOR!_;Y_:G\"_LK_&3X!>&
M?#7PFT#Q7XG\=_%K3_C3\5]1/A_4KC^QK&P\+W'PGT+QW?7VB:=J-TGB:"T>
M-+2_^R7=ZGAOP3>6$<)2>!D^S]*_97\"Z_I^FGQG'X>O]#3PSXN\.6'A#X?>
M'X? O@Q/"/Q.U&W\0^/?#DD]I<WOB_6=!\;:M!::GXFT^Z\2VVC>(;J!+C4-
M#PWDIT3P\H4J-6?N0K1DX-WDY<DN5\L5&R:T?ORBFFFF<\:\9U:M*'OSHN*F
MEHH\\5*-Y-N][M/EC)IIII/?W'Q)\5? WAB__L6\UI=2\2LJM%X2\-VMWXF\
M5R^8NZ$GP_H<-]J-M#-D!+R^AM+!<[I;J.,,XYW^W/BWXM.S0]!T3X9Z5*9$
M35O&\\/B;Q:ZA,M):^#?#FHQZ+8R(,E'U3QA=3P-C[;H7R/ \FE_L]_ S0X[
MZ+1OA+X TI-4O_ .J:H-.\,:59G4M3^%EY'J'PYU'47M[:-[Z_\ !=]#%=^'
MKRZ:6XTZX1989%<9K:@^#WPLMK^UU6W\ >%8=1L=>\;^*;.]CT>T6YMO$?Q*
MCN(?'^M0RB/<FH^,(KNZC\070/FZFD\JW+.'.<N:"^&-W_-/7[H+W5Z2<T:\
MLG\4K+^6&GR<G[S]8\C,6#X0>%;V6+4?'NJZM\4-2B9+N*7QQ?6UYH-J[E?+
MFT[P9I]OIW@NR&]!Y%VNA2ZA\JAM0F*AJPOB!\&O!/C3Q9X?U_5/@_\ "#Q=
M/HK+:OJGBS3-%N-8FM8M,OX++28FNO!^L21VVF3WBWUG;F]\J/#RPP0N0QZ2
M3X"?!:;2?[!E^%_@J31O^$'\+_#3^S'T&Q:R_P"%?^"M1FU?PEX/\@Q;/^$?
M\.ZI<3W^D:;C[/974KS0HKL37YJ?M7_M*^'O@3^TG\-/AMX4^ 4'Q'U?XE^.
MK'XD:3K'@N_\(W>I'XN_V'+\.M1UR[TS_A$]?UVP\:Z1X0-C:SZFTEQ<W?@_
MSK6T@C6WG*?5\'<(\1<<YO+)N&Z%'$YA3P&/S%TZ^-PV7TH8/ 8>6)QDU7Q5
M:A0BZ6'A.JX<\7[.G.=E"G*48J*E"%YJT7*-WR\S<K^[=M2;UZO[]3]?TE@6
M-,/"BK$7 21"BQQ85RI&!Y41PI? 5> =O2GF6($@R1@AD4@NH(:3_5J1G[SY
M&P=6S\H-?)\7P]\*ZII*Z!X/_9@\-VN@MX*\7?#<S>/XM$\':*W@7QYJMOK/
MC3PO#H6GVOB7Q,_A_P 3ZM;0:IK6EZAH6CQ:C=PQS2AI%R-6;]G2#Q)>7&I^
M++GP?HUQJ&K^!_$-_;_#SP)H^G7<VN_#,0_\*\U*Y\3^*AXHU*[U'P2;:U_X
M1S4[*QT*XTS[/&UC':. 5\?^R94M<;C\MP7]R>)^N5VU\4)4,LACJE"I'9PQ
M:PRYO=<DS3F[)OY6_%V3WZ'TC?:IIFEVLM]J>HV&G6,"N\]Y?7=O:6L*1';(
MTMQ<21PQK&>'9W 0\,0:\T?XT>";MGA\*/K'Q!N4*@IX#T:\\0V +E@GF^)(
MT@\)VN]E*I]LUZWWG[@89(YG0/V6_@'X>63R/AKH6K3S:EXNUJXNO%/VOQ;<
M3:SX_O;G4O'&K9\27.IQ6]]XLU"]N[W79;.*V6^N;F:21!OQ73'X#_!@Z4="
M_P"%8>"AHQ\(^!O /]EC0+!;'_A"OAGJ,VK_  ^\+"V$(B&A^#M3N)[_ ,/:
M<%%OIES*\MLB,Q-'-DE#X89AF,]TZDJ&64(M?9G2IO,:V(@W=N4<3@IV=DHO
M4/>\E][?KTMZ6?Z'YV?&_P"&?[9OQ$_:^^"VO_#_ .)GCKX-_!;Q!;W[>,O#
M\GB30]?C\/7?@FVAU&\230]%E\BUC^(-E+INDMIUEXHOI$GM=5U&:XL%<0R?
MH?'\*/#^I.EYX^US5_B5<KBY6#Q5>6P\+V_EM\SVG@O2HM/\*F*-R EQJ6FZ
MI?Q@*C:@_.ZC?? ;P)=>,-.\:VNE:3INLZ3XXU/XF6,MMX=T"22+X@ZWX13P
M%K'C,W5QI\UV_B/4/!BOX:EU0S_:1I$TEDKB$A1=_P"% _!0:-_PCP^%O@G^
MP_\ A ]?^%W]D_V!8_8?^%=>*;^#5?$?@O[/Y7E_\(YK>I6UO?:EI>/LUU<P
MQRRHS*#7U/$''>99MEW"^ PU')<HI\/Y(\IA+(,KAEV/JKZ]BL1[;,<UE2_M
M+&8F6%JX7!U*CQ]6G4IX.+G%U)U:M>(TU%S;<I<TN;WG=;):):+5-K32^G9>
ME3:?I\FGC2HF;3[2-8((HM)NI-)>V1"C00VTFGR6\ELA"JJQ0LBO&3'M*,0:
MF@Z+I?AVR33]-N+QK1%$<$5_K%_JI@CM4$1BMY-2N[J6*.( "1$<*&&7&[FN
M$\3?#7X96<.M>*[KP%X'N+\:YX2\?:MJ>M1V&DVYU[X:VEI!X3\5ZIK,]K<)
M;7G@G2]-MSI&ISQDZ7;6,2QRP1Q[T\S^%=O^SW\1_ 'AWXH:%X6^$X\':G%\
M0]0\->(-'U/0]9TAT^+6I2W_ ,5FCU6*UL[2WN?&.N)</XP@5Y'U*_CE-^3*
MK*/BX_79X6JXRK2PDL1359*;=.6)G&<J7/#F]^K*,*C@W%RM&I9V4CNA@L35
MP\\93HRGAZ=>EAIU8V:C7KQJ3HTK)\W/5A1JRA%1O*-*HU=0E;ZB\Z'&?-CP
M%1B=ZXVRG;&V<_=D/"'HYX7)KQ7XB?!S3/B!KFE>*VU]]'\9>%H-1M_ OB.U
MT?P]<ZIX2N[^?1]0NA87ESI[ZC);7EQH-DFKZ:UZD.IZ5+J&F70-K>/MX+4/
M^&0;:"71&M/A9JZS>'_A_P"#I="\.:;:>+;V7PW\*=6EUWX;>'VT?PQ;:O?/
MIO@?6;B;4_#5G]E,>E7LLD]JL<A)K\\/B'^UG\-?"'_!07X+_ K3?V8OB*=*
M\=^*-0^(2?$*YTOQ/X.O;KXL^-M*M_!L?Q/\(^%M8&EK?:5IWAR+5?"/CKQ#
M=#3KVXLM;OK6.RNDM(X]5]OA[!<01QE7$9/2K4,3A<#C<3.K.E0C'ZI2H2^N
M0MC.6E5C5P\ITJM"*FZ]&I.C.G.E4J(]W)>#\^S^KBZ.#R[$/ZGEF.S:M*M"
M&&A]4RVC]8Q$H3Q=7#0JSC35X4Z,JE:4K<M-Q4I1_7KP#XU;Q3IEY!K,%MI'
MB_PU<?V5XQT2.??#8:E'$DT>H:?)(1)<^'=<M'BU?P_J+#%SIUS'%/Y6H6U]
M;6_>F6($@R1@AE0@NH(=P"B$9SN<$%5ZL"" 0:^7?B!^S[\.]+T"PO?"/PM\
M*W^F>'/ >I?"_7?AU;:#IYTSQG\$M6N4OM?^',%@8A"WV6ZB&O>&[!BMK/JD
M5SI$OE6VNW<\7IFF?#_X.>,8[;QSIWA'PEK(\2>(/"'Q)BUY=)MGGU#Q3X0T
M:TT7P;XHEEDB6<:[X:T:RM-)TVXG5+W2K>T2QQ"T!C7SLPP]&=.GF6"@H8/%
M3<*M"+E)9?C5'GJX.3DY3]A-7KY?4J2DZN&YJ+JUL3@\8X?+IO9[K9]UW]>C
M\];)-'JOG1<?O8^?,Q\Z\^4<2XY_Y9GB3^X>&P:\,21/A'XQ\M75/A?\0]:1
MHMK*;;P%\0]>N3L3 (%IX4^(=^[& _ZC3?'5P\:YB\6(+#IT^"?PCCAMK>/X
M<^$$@L[3XC6-K"NB60CM[/XO:DFL?%"VB7RL)#X\U1$O_%$8&W5[I1+="1AF
ML_5_V?\ X*:]HFL^&]6^&/@^\T3Q#X?\">%M9T]]'MDAOO#WPOOY-4^'.E2M
M$L<JVW@;4YI-1\+")XWT2^875@\$ZJX\V$DFTU>,E:2ZVO>Z_O1>JZ='>+:9
M*-TFM)1UB_/JGOI):/39W7O)-=TWC/PHFKKH+:_I@UIIC;KIAN4^V-,)$B:,
M0??)622-'P,(SJ&(W#/0^?#MW>=%M\OS=WF)M\KIYF<X\O/\?W?>OSC\ ^,O
M@IX3_:\TC]EOQ1I/A^\^,OA_PYX\^,_@_P 6_8M*>X\07GC)+71M2U[4YHBM
MW9?%O6?!']L67B^62WC;Q%H>FW&OQ2BVU<V-K]@G]G[X(G1O^$=/PK\#G0O^
M%?P_"G^R3X?L#8?\*VM[XZG!X(^S>5Y?_"-1:B3>II6W[,MR3*$W\U56G*DX
MJ2:YX*<6]IPE?EG'1/EE;2^JU3U3)IU%44FI)\DW"22LXS23E&6K]Y75^G5:
M-'KIEC!VF1 P<1D%U!\QE#JF,YWLI#!?O%2"!CFD\Z+&?-CQM=L[UQMB.V1L
MY^[&Q"N>B$X8@UP-S\)_AI>:K<:Y=>!O#-QK%WXVT7XD76IRZ3:O>3^/?#F@
MV_A?0?%TL[1EWU_2/#MI;:+I^HD_:+;3H([:-UC4"LY/@?\ !^*S@T^/X;>#
MDL;;0OB!X8M[1=#LA!#X=^*VJQZY\2M%CC$6U=.\<:Q%'J7B6U \K5;Q%GNE
M=QFLC0]/\V+G]['QY>?G7CS3B+//'F'B/^^>%R:X/XE_$33OACX0O?%U[H/B
M[Q:+?4-'T>R\-> /#]QXH\5ZUK.OZQ9:%I>FZ9I=O)!"C2:A?P?;=1U2]TS1
M=&L5N=5UO5--TRSNKR&B_P %?A+(+D2?#KPBXO!\.A=!M%LB+@?"*_\ [4^&
M E!CPX\!ZB!>^%\_\@BX_>6OEMS7GGQJ_9]G^('P<^(7PK^$OCW4/V=-2^)7
MB"7Q#XD\>_#[0M/GUZYN=;U^SU?QXX62XT^6#4?']C#>Z'K?B/3M0T[Q)8VN
MJW6HZ'JNFZU#9:A; "Z1^UK^S_>?"'PK\<?$?Q(\.?#/P!XNU#6="TZ_^*NK
M:5X!N+?Q/X:U77=#\2^%+V/7;Z"W_M_P_J_A?Q'9ZC:65U>P%-$U#4+*ZN]*
MA%^]F7]KC]EB'2=-UZ7]HWX(QZ'K/B34_!VDZP_Q/\&KIFH^*=&2RDU70;.^
M.L?9KC4M/CU32I+JVCD9X8]6TF1P$U2P-QY=KO[%OASQ9\*O@7\,?$7B2PMK
M?X&67CNQT:7P7X"\/>$/#MY!XU^#/Q,^"20V7@Y9M6T_P_;Z%X:^)5U>V,5C
M>3O<:CI4#74SQ7MXC?#7Q]_X)C_$-VGL?V=_$^D*OQ-\!Z?\'OB5KGC6;P[;
M6/A[P%IO@K]FCP%'_9OA&3P/KL6H2W>G?L]V_B"YU31=6T/7K?6=2_L:WAFT
M^73]:\)@'WYXV_;L_9K^'MXND^*O'4&G>(KKXEWWPLT3PF?L;>+?$^O:5KS^
M%M7U7PWX<-^NJZKX5TKQ+::QH5]X@BMEM(M2\/>((%$@TJX<?2'PZ\=:!\4?
MA]X%^)GA5[N3PO\ $3P=X8\=>&Y+^U>QOI- \7:)8^(-'>]LI&9[.[;3M0MV
MN;5V9[>8O$S$H37YZ:__ ,$T=!U;5M%N['XQ^(]*TJZG^&6L_$[3Y/!WA?5]
M1^(/BSX5>-/B/X]T'Q'9:_J1DN_!,FL>(/BIXKN/%5GI,-X-44V!L;G29?[7
MEUGZP_9A^#'CSX!?##PY\*_%WQ=7XMZ-X%\+^#O!/@2^D^'^D>!+_1O"_@SP
M[9^'+&TU3^Q]6U.#7=0NK:PM)[G46BT\"99!%:)'(%0 ^C**** "BBB@ IKM
MM1V+*@56;<_"+@$[G.1A5ZMR. >1UIU(P#*RG@$$'Z$8- 'XX>'OVR?CM\:?
MC[\)--\!:]X8\&?"G3/%6A^%_B-JFFZ/KWBGX=_$&ZUK58]0TVXT?Q'J_P '
MW\7V%MX^\&?N?AF^L7GP9\/R>(93J^D>.?C%HD3Z5%^R%?E5\-_ .N> ?$&H
M_#?X"?MC_L=>#O!_C7Q/>7MU%X-^!7PXC_: U;5YG9)81J'A?XLZ3\+]?\6V
M]I"+&WUR]^"-Q'!% INO"EZ\4OG?J99P/:VEK:R75Q?26UM!!)>W?DF[O'AB
M6-KJZ^S0V]O]HN&4RS>1;P0^8[>5#$FU% ,Z7PWX=GCU2&?0=%FAUR:*YUJ*
M72[&2/6+B 1""XU1'@*ZA-"((!%+=B:2,0Q!& C3'-_$C_D7],_['[X6?^K,
M\)5WU<#\2/\ D7],_P"Q^^%G_JS/"5 '?5\%_"!Q\+?VT?VB?A:^;?0_C%HG
MACX^^$HG)6/^VUMU\*>/HK=>$,M[J%G;ZDX0%BD$A/\ JV)^]*^!/VO-WPY^
M*W[,?[0ENIBM_"WCF\^&_B^X3@OX4\?6A1OM)R,P6)LM2GAW?(MW<0KD&7)^
MHX7_ -IJYKDTM5G.48JC13?NK'8%PS7!2\ISJX%X6+6ML5./PRD>SD7[W&SR
M]_#G&&K94H[<V)KN%7*X\WV8_P!L8?+I5'M[*,T]&S[[HI%96564AE8!E8$$
M,I&001P00<@C@BEKY<\8**** "BBB@ HHHH ***^;/B-\6O"_A/XF^&_!6I_
M&"R\*:GX@^RF/PW-H4-\D"W/[C3S?:J4,6FC6+Q'BMC?30 D[EQ$4<]N!P&)
MS&M*AA:56M4A1JUY1I4*^(DJ=&//4DX8>E6FHQBFW)Q4%HI25U?TLJRG&YSB
M*F%P%"MB*U/#8C%SA0PN+Q<U0PT/:5ING@L/B:L80@FY5)05..BE.+E&_P!)
MURGCG5K#0_!_B;5=4N([/3K+0=7N+Z^G>.&TL;6'3KF6>\O;F9XX+2SMXT:2
MXNIY(X84!>1U4$US/C;XR?#[P']FMM6UR&^UO4))(-)\,:$8]7\1ZI<1(LCQ
MV^GV\H6UBC1E:?4=5GT[2;1&$E[?V\9WU^?/[=<TGQG_ &;O&?A_X@:AJGA3
MPEK=QHUOI7A/X>WUS<^(I=:%ZMUH5]\0/&S6K^%1X>LKZVBNM7\$Z/:ZG!K+
MI!II\42B4-'Z>1Y#B\TS'+</*E7HX?&8W#T/;JC*4G&I6C"4J-.3@JKC=^\Y
M0HQDK5:U-:KW^%>$LPSW.<DPE6ABL+@LRS+!X58KZM*<Y0K8F%*<\)1E*E]8
M<+R]]U*>%A-<M?$T5J?ICX,U6QUOPIX=U33)TN]/O=%TNXLKR%TEMKVUFL;>
M6"\L[B)GANK.YB=);>Y@D>&>)EDC=E(-=-7Y>_L#:M8?!3]FOP=X;LH/$6O?
M"CP]=:O87WB2_OI]<\4^!=9DOY+W6)O$6EP-(K_#N[O;J:[T'4O#=C:0^$M.
M;^SM:T9[.QO/%,OZ<V=[9ZC:6NH:?=VU_87MO%=6=[9SQ75I=VMQ&LL%S:W,
M#O#<6\T3+)%-$[QR1LKHS*03AGV55,GS7'X&7/*GAL;B,-"K*,8N?L:CC:I&
M$ZD:=7EY9RI<\FE*,XN5.<)RX^+<@J\.9_F^6/VE2A@LSQN"HXB<(PE46&K2
M@E6IPJ5HT,1R<E2IAW5FXQG"I"52C4I5:EFO _B?XKU"+6=.TCPY%!?>(X;R
M/1_"5A<*TEG<>/M<T^XEAU348T!9]$\ >%?[1\5Z_@J6AN["WMW&I362/['X
MBURR\,Z%JNOZBZ1V>DV,][,7D2)6$2$I%YDA$:--*4A1G(0/(I8@9->(_!/0
M;W6VG^+/B)&-]X@MKN#P=;S1O&UAX8U.[BU+4M=,,H5X;[QUJ,%KJ2AQYUKX
M1TOP9I$JPW&GWB/E@81HT:^/JQ4H4_\ 9Z$);5<15BW*-NL(TKJLKQ:IU>:$
ME444\,JIT\-AL7F^(BI4Z"^J86G+;$XRO!\U.R?O4X8=R^LJ\&J-9SIU(UE2
M4NMT_P"'&H^'=&\*:'X:UC38K?P[?OK=]?:YI5YJ>J^(_$5Y'JC:UK>IW5MK
M.G(;O6[_ %>[U2](B8B[D9(F2V\N&+UA X1!(5:0*HD9%*(SX&XHC,[*I;)5
M6=RHP"S$9+J*X*E:I6=ZC4I7E)RY8J4G.3E)RDDG)N3;U;M?0\G$8JMBGS5Y
M*<^:I-SY(*<I59NI.4Y1BG-N;E+WF[.3M9:%2^OK;3K66\NVD2WA"F1HK>XN
MI '=47;!:Q33O\S#.R-MHRS84$CD/AO>P77A#18(DNHI;"QMK6ZANM/OM.DA
MF$88Q^3?6MJYVJ0"8T9 ?EW9!%=O)+'"C232)%&N-TDCJB+D@#<S$*,D@#)Y
M) ZFF0W%O<AFMYX9U4[6:&5)0K8SM8HS '!!P><'-)22IRARN\IPES<RLN12
M5N7EN[\[N^9=-.\*I!4)TG&3G.I3J*?.E%*G&<4G3Y&VW[67O>T5O=TWO-7+
M0^&)(O$,WB'_ (2+7Y99X8K633I!H7]FFS@GO+FWM L>AQWRQ0RWLQ607_VE
MP$6:XE52&ZFOGC2OVF/A7J_Q;NO@Q9?$#X7W7CFTO;O3Y/"]G\0(+KQ@-0L!
MJ,M_IA\+#1H[I-5TVUTY[W4K)[L"TM)!.9WC3<WH9=E6:YE#'SRS 8G&T\OP
M=3&YC+#T'6CA,#3:]IB:[49>RHP=G*H[*-KMI)M1&LZ7,E**]K'V<N:,)<R;
M3Y5S1=G=)IQL[I-/0]J\3>(]*\(Z!JWB76YV@TO1K.2\NFCC::XE"X6&TL[=
M/WEW?WMP\5GI]E"&GO;V>WM8$>:9%/CVEZ9-HNAWWC#QU<6.F^.O'OB#PAJ>
MK6EU?6P70-'T_P 1Z6-!\&V,KR+'+:>%K"YD.HSV^8+WQ#?Z[K"E(]12./48
M-\3/B!M(9_ 7PMU8,<C%OXH^)UJ,J.05N=)^'L<F\]8I?&MPA!2\\($/PO[3
MO[57P0_99TKPKKGQO.MVNC^*M0O])T;4M-\(WWB>SBU*SMHKV:QO9K.&9=.G
MN[3S)[1;CRUO$L[HQLQMG TR7)<WS_,L)DF0Y;C<XS?,)2CALMR[#U,5C<2Z
M5*>(E2P]"E&52K.-*E.M.,(R?+#IRR.>4DU*;DHPC=1D]KOW92>VU^6.JO[V
MK337T_#-#<Q1SV\T4\$JAXIH9$EBE1N5>.1"R.I'(920>QJ6N9\%^(]+\7^$
M?#7BO1+2_L-&\2:'IFN:3::IITFD:A!INJ6D5[8K>:7,%FT^<VTT;26DRK+
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M%'BA-;T^#5=.NHI]3N9[:2YE>.9$F24R4 ?7]%%% !1110 4R1@B.YR0B,Q
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M1IGAF?1-5\1RV>J']M: /QLM/V!/CYX<\?>$OB+HFK_!W7+WX$^*/&EU\*]
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MB:>NE:0^IW*^-1)=-ING(MG9^83Y$ V)@$YW_P#AK+PE_P!$^^*G_@I\(_\
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MPE_T3[XJ?^"GPC_\VU?)]'^?\_F* /K#_AK+PE_T3[XJ?^"GPC_\VU;WA?\
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M"@>-?!1Z>,_!YY(X\4:">0<$?\A#J""#Z$8HYI?TO3^OGZ!_Q%?CG_G]AO\
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M>>40P1K%$)9Y=0:6>41HOF32LTLK[I)&9V8D ^K?^&K/%7_1(+3_ ,.39_\
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M?#J;PUXD\*?\(A;>-3XT\-:SK-D/ U]9^.+CX>6WA#4_$]YK6D3>*FTF&#]
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MVBB[N(%20S(YE9$B)E9 ??J\A^/WAGQ1XQ^"GQ2\,^!=(\*:WX[UCP-XCL_
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M_I>L+9Z,NL^)M4UCQ-K.KZM>_9% !1110 4444 %%%% !1110 4444 %%%%
M'S3^V-K?CSPW^S#\:?$'PRT>77O&NC>#+O4M(TNWB\#SW4\-I=6DVLRV5O\
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M74[C3_[1T2;4K);NRAU*V6>W^TF5%DBD9$65 ?7?^$0\)_\ 0K^'?_!)IO\
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M[N.VF@MYII#"&H ^C:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?$6_TOP)XI^'/Q-U32O$VDZ3K=YXG^+G@G]H/7_VE/%GCZQDM[W1?"'A6_\
MC)X^\1WMO\0X[7P/?W5MHEGHFE>"-5\'Z?I]Q:Z@ ?IOX*^+?PS^(\T%OX"\
M<>'/%TUSX)\&?$B!-!U*#4?,\"?$1-6D\#>*0UN64:1XJCT+6)-%N68"]CTZ
M[>)2D3&O1*^#_P!@7]E_5?V;? 'Q'N/%FFP:+XO^*_Q:\:>.(_"T.OP>*X?A
M?\,SJ]Y9_"#X+:5XEM]/TR#4?#WPT\'"*VTV&VLUM+"_UC6;>TGO8=M[<?>%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img170310032_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= 7P# 2(  A$! Q$!_\0
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M4VY4ZL(5(-QE%N$XJ46XS49Q;BTW&45);22::"BBBLRPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Y;QS;R7?@GQA:PFR$USX6\06\1U*Y-EIPD
MFTF[CC-_>":W-I9!F'VJY%Q 8(/,E$T13>O4UR_C@: ?!7B\>*XY)O"Q\+^(
M!XEBAAN+F670#I-V-9CBM[-)+N>1].^TJD-K')<2L0D"-*RJ>+,N5Y=CU*<*
M<7@L5S3J35.G"/L*EYSJ23C"$5[TIM-1BG)II'9ETI0S# SC&<Y1QF&E&-.#
MJU)2C6@U&G34X.I.35H04X.<FHJ<6[K^:/\ X)Z>/?!'Q!_:]_9ZNO'G_!5'
MP=^V;\=]#TSXEZ/HW[-_P<\6^,=-^!'P,T:U^'/C!=7E\$V&IVOB[5/C=>:;
M;/'X>C^)7Q6\86/BK^R7%S8:SJB"/2;O^H2OYJ?V!K[X;>(?VO\ X$>)_A]\
M,_\ @KCX1LF\'?%"S'C7]I']F'P%\&/V:/B;::YX9U35O#7BCQ+XB\+>%O#4
M"ZG;^"=+\.>%?!&D^']&\/Z=XEM?"W@O6M6T]];T>_O]6_I6KVL7S.G@^:,H
M2]CB>>$X.$HS_M/'\\I1J.IB.:M*^(G+&8G%XV<ZTI8O$.NYTZ?E4(QC4Q,(
MRA*,)X>$94YQJ4W".!PJ@J4J<*%#V5.*5*BL+A,#AE2IP]CA:<?>G^=VC?L8
M?%OP7\=OV\/V@?AW^T/X4\,^-?VQ?"?PGT'P>VH? N^\0P?!#6?A'X,U/P7H
M?B6=)/C-IUO\399[75KC5'TN>T\$VD>J069EDN[".XL;KB_A=^Q)^TIX&^"V
M@_!'Q]^T7^SG\>O"/_"3>)/^$XT+XA_L3PV?A'Q/\/?$>CP+<Z'#X<T_]H&[
MNW\<WGC*?Q)XY\7_ !$\7>(/&5[X[U+Q'/#J^EVEQ;/JE[^HM%><J5/V4J$H
M*=&>$PF!G2J_O:<L+@ISJ4*3C4YTG[\X5JRM7Q%&3H8BK5HV@NUU:CJ1JJ3A
M5A6GB(U*=J4U6G@Z. YN:FHMJGAJ%)8>#;IX:M%XK#PIXF<ZTOE#0OV)OV:8
M?V<?A!^RS\1/A!\./CE\(O@KHGA72_!OACXW> _"?Q0T>SU'PCH%[X;TOQ+!
MHOC32=<TJRUVWTG5=9T^TO[2VCN=/TS5]0TNSGCL;J>&3Y[_ &9/@7\$OV??
MV_\ ]KWP9\!?@[\*_@CX/U/]CS]@+Q/J7A3X1?#WPE\-O#>H>)+WXU?\%(]*
MO/$-]H7@S2-%TN[UR[TO1='TVYU:>UDOY[#2=,LY;A[>PM8XOTSKX@\ _P#*
M2/\ :O\ ^S(/^"?/_J^?^"FM=%6K4KU:E:K-U*M:I.K5J2UE.I4DYSG)]7*3
M;?FS*G"-*FJ5.*A3IPC"$(Z1C"'+&,4NBBDDO)(^WZ***S&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)_M(_'C
MPE^S!\!OBQ^T+X\T_P 0ZMX/^#_@G6O'/B'3/"EA%J?B*_T[1;8SRVNE6=S=
M6-HUS,VQ/.OKZQT^SC+WFH7MI903W$?ME>,?&GP-\1_'FF^%M.^'_C7P9X7L
M;+Q)=77Q!\/^/OAW/\2/"_Q0\":AX3\3>'-3^'>K:9;>+_!\NE6FHWNN:=K3
M:TMSJZ0SZ#!:7.A:G97EU <,3[9T*L<,XQQ$H.%&<DI0I5)^Y"M4CJY4J,I*
MK5C"-2I*G"2ITJM1QIRWPSHJO2EB(NI0A-5*U*,G"=>G3]^>'ISLU"KB%%T:
M4YN%*%2I"56I2I*=2/R-XS_X*$K\/_#7PAUWQ+\$->,OQX^-GPL^"OPD.A?$
M#P1KOASQ]-\5? DGQ$L_B+X8\66MPEA??#7PAX?@O/\ A-=?GMK.ZTZYTG6#
MI.F:W8VUE>ZC#\9?^"C&D? ^U^$W_"5_!SQ#?ZI\7=.^/7BK0++P_P"/OA[J
M&FI\-/V?O ,_Q)\1_%4>)YM6M- F\"^(O#260\+ZC+>V=U/J>NZ!9ZI9Z7%?
MSW=E\V>"?^"0.M^!+3]E?0]/^//P\\2^ _V6;W]ICQ-X5^$WQ)_9WUOQW\,I
MO&'[1EWJ\=O'INA-^T%H5SH_P^^$7AG6M0\*?#WP5=7VMW<-G>W][=^)Q/<P
M0V7TMHG_  3]_MS]H;X9?''X_P#CCX9_'/1?A3^S W[/OA/X57_[/FD:!X0T
M7Q%J_B[0_%?BOXEZ!9ZAX]\8:+HJ:A#X;T'PKX?\++X:O+_PYX6T?3[2X\::
M_J/]H:IJ'1.*JRJQI3^JQQ&(Q<J%2M#V[R_"QRC$/"4L12IR2QF(EG66X>$Z
ME&O"E7PG$;;6 EETI87&FU25)U5]:>'P]*%=4F\.\QQ3S2="K7P\JBG]3P_]
MDX^GCHTJU.56CB<CJ86^,6-B\3ZYJ/[=7P%\/?LA>!OVU?&.H>(?!/PE^(O@
MSX?^+?"NE>*-'CL/'NHWGQ0ATW_A"?!4/AQ+Z>"7QCK=_JUEID%I!JDNDQR/
M+J4^LQ:!;7.L0V_&G[6FG^"->_9L\.7/P]UKQ+J_[1WB/1=$T_3? OBKP-XM
MU?P?I6OZ=J&J0^--5T?3M>_M'7O _ANTLX)O'GC'PM!JWA7PS;WL-U::YKMN
MT$EQX]\;/^"=/A;XD7OA_P 1^$_BQ\5M(\5^&OC;;?';2+;XM?$KXO\ Q_\
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M\.)\6AXHET$6Y72H_BVEZUD%\7J"/'>+2P^*Q'LY-8;AS <0*,7?VWUW'X/
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M*,[2H*FHI.BXQ<.9*O&EC%BL+ABH?L]OY0@\B'R%*E8?*3RE*.)$(CV[ 5D
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MV6ZN1"4$\N[L=7T71O$%C)IFO:3IFMZ;*\4DNGZO86NI6,DD$BRP226EY%-
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MPZ\=:UHDMK?7)D\.Z[XAU#1;^XMM'U;5=.O-;T;2[^R\*_9D^#OA+X(_M_\
M[7OA3P9J_P 5-:TO4/V//V O$,]U\7?CI\;?V@O$D=_=_&K_ (*1Z;+;V/C/
MX]?$+XD^,-,T-+?2;62V\,:;KMIX;LK^74]5L])@U36M8O+_ +\4J,<3B(X>
M7/AXUZRH2LX\U%5)*E+E<ZCC>'*[.I4:O9SD_>?)AG5>'I.O95W0I.LHZQ]J
MXP]I:3A2;7/S6?LJ=U_R[A\*_3.BBBL#0**** "BBB@ HHHH **** "BBB@
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MA2****X3I"OB#P#_ ,I(_P!J_P#[,@_X)\_^KY_X*:U]OU\0> ?^4D?[5_\
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M:ZG9>,]*ET>\%]X7N-/OHIK.\CURWWZ:8+F*2&0W(5U(S7=5\K?M?? >Z_:
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MI8&,CR)#)_.3X&_X*+?M;Z;8_"OX&^,?BM\?M/\ V@?$OQ8_:;T?XW_\-!?
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M^1W[3W_!9S]E[]D_XY>-_@!\1? ?Q[UKQEX!_P"$:_MC4_!7A?X>:CX9N?\
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MVT6BFTMX]3'BN?PQ-*^IV)T:'5DCU)]/](\8>)CX0T*XUP>'?$_BDP36L/\
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M%2J>SK5$FU%.-"E.M-7=E=PIR44VKRM&^I^BU?$'@'_E)'^U?_V9!_P3Y_\
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M5'VE6,H+]]Z*\&B_:H_9@GD2*']H_P" TTLAVI%%\7_A[)(['HJ(GB(LQ/H
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M%O;6$/XD?\%5O^"K7[0G[#?[0_@_X2?"3P?\%_$?AW7O@UX=^(6H7GQ#\/\
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MYQ=7DY5.GF>$G3<54IU8.LIQBZ"E3=ZZII.+:DNS W]M-)57?!Y@FJ7/S-/
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M>&?A?X>U/XCMILVF7'PVBD\)W6I:E:S6EI_877XA?M<_LP?%3]L/]K+]M/\
M9_\ !/Q9^%GPJ\%?$+]@+]A#1?B%?^/?@=XY^+_B8W<?[0__  45UGP%XD^'
M.H^#_P!I#X!V7@W7O OB+1I?$/\ Q5&E_$G1/$6HIH4%_HMOH^F:QI?B?7%4
M\)FD<;3S?#4\QCCJ>*4Y8K]XH8S$1GR8ZI!QG[>="M/V[IR2]K).+E&]S[KP
MEXSAX8^('!/&-/!U<5@N%.(,AS3$9=A<5BL%5Q66Y7F6#Q6)P.'K87%89*=;
M#8:5"E3Q;Q&7U'*,,=A,5AG4HR_D:\ >.OMGC_X00W/@&^^*T</CKP?+K_PP
MTJ6^T[5_B8(?$FG(? FA:IHFGZAKFBZMXQMTDT:PU7PW8SZUIM[J]O/H\$E]
M;Q0O^Q\OQ$^'\()F_P""$W[246.OF_M%_M;1_P#H?PU4 ^H/(KUCX%?\&VWQ
MM^ GQ>^!_P 9=$_X*0^'O&>N_ CQ3IGC+P_X?\>_L<Z[=^%O%?B'0K@WGA^]
M\?0>%?VPO"6OZ_\ V)?Q6&I64=KXATM9M0TRTNM1-\TE\+S]W/\ A ?^"D?_
M $=?^Q!_XKY^//\ ],UKR>%^"N .#\'6RZ/#V XAHUL36QE/$5(3P$\/+$U:
ME6IAG&="O*K3I.:I4).7[O#TZ5)7Y+G]+_2$^E]5\9LVX;S3ASA;,^$:639=
MC\OQ>#S'BC/_ &F*J5<=[:CBJ4^$L^R'"NG*C%-+&4*^)BIJ//2M*FOY0OVG
M_B#X$U7X(^-+31?^"4/Q<_9OUE7\-RZ?\:O&OQE^/7COP]X%D3Q7H?VB2]\+
M?$/P+I_A+4'\1V1NO!]H^JWENUE=^(8+ZP,FI6UI#)^?GPH^)FN6'QD^">O:
M?X2UOQSJ'AGXC?#[5H/!/A34-2\/>,/&NL:7XLTN\B\/>#O%7AFRN_%GA+Q)
MXEDM[?2=!U[PC%_PD6B:M=V^HZ)&^I6MFM?V>?M6?L7?MV?M?_L^?$S]F_XC
M_MD_LI>&_!OQ1TG3]*U?Q!\//V#OC/H?C?1'TG7M)\2Z7JWAC5]8_P""C?B+
M3+#5M/UC1-/NK:XO=#U.!3$0]J^05_+']G/_ (-P/C?^SI\<?AG\=[/_ (*-
M>$_BKK?PHU:T\0>%_!_Q3_8PUH^!)O$6DSP:AX<U[7+#X9_MA?#3Q#JVI^&=
M<LM.U[2I)_$RPS7]A':ZU!JVBW>J:3?K.."> \ZS/ 9U3R3+LIGE%-QPV6_5
M'CEBZDW4>)G/%>SH0HJO1E"C"$Z-54ITE6BXN5U]=X*_38P7AIX8\5\#\0<(
MYSGV;Y]FF>8[!9M@N(LSJ87!T<TX?RG*,/2K5.(<VS7.8RP^*P%;$S6!Q^'H
MJG6@\-3HXIUJ]7BO#GQ2_P"$<C^'47A;_@AS^U_HT'P@7Q@GPBA\/?M'_MAZ
M-%\+$^(1F/CY/ATNB?#&Q'@T>.#<7)\8'P_]A?Q,;B?^VFO?-?=\D?MO_$?Q
M WP2M]$LO^"='[0O[&6E>)/V@(OBKXB\>_%3XJ?'WQ[X*\>_$O5O"7BRRU:Y
MO/"WQ:\%Z#X+N_BMXFM1%JUQ\1 ]WX_N-(\*:AI[75SIM[JDD?\ 5]_P@/\
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M.?#;P;HG_"JS\0O/_P"$^/PX_LS1;7_A!SXX^U7/_"8?\(Q_9?\ PDOVB?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img170310032_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #1 7@# 2(  A$! Q$!_\0
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M]YE&95,JQL4W95/9XNFUS4?:05.=&<Y0]M24_?J*\0^#7[3?[-O[1G_"2?\
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M.7EY?K/]K1_LKV=WS<O]F>T_AVC[/V/UG_:_:GEO@'_E)'^U?_V9!_P3Y_\
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M  E?_"5?VE;26U[%KH^%8T<>'1I0NXKC27\.'4FU0VUY'K:VJRV#?KGA7GG
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MM-,_2Z-15:5.HG%\T4Y.#O%2M[R5]?=E=-.TDU:23304445F:A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^+/_  6'O;^\T;X&>"O!7AOQ.GQ4\17WC[4_#'Q-\/?MXO\ \$^U\%>'/#L?
M@\>+]#N/BI U[<^-+CQB^K:";3X<CP[K4%Q#H%]XIEDTY_#4<TO[35^*O_!9
M#X$W_P :/#7P0L--T/\ 93U#5]<UW7_@YX5\2_M87'P/N?"?PU\6?&#6_A[8
M6GQ!\*>#?C5X*\31_$CQUI.A>'O$-CX/\#>#=5T76]8\5ZGH*ZAIGBK14O--
MM^3%0G4E@J=.+E*>.PT(*+A%NK-RCAJ?M*D)PI+$8IT,-*I+V=.,:S]M7P]!
MU*]/KP4Z=.K5G5FJ=.&$QLJE22J25.G'"5G5JN%&2JU?94U.K[*G&K4J\GLZ
M>'Q-24</4^J/^"='QB^$7CC]GKP)X*\$RZ;X:\;^$]/\50^._AC>_M Z/^TI
MX[T37-&\>:YX>\4>*_$OQ:L=>U[4OB):>,O%4%_XATGX@ZO+:S^*[/5H+U+*
MQ82Z=9?H%7YW_P#!//\ 8[^!_P"S3\,+'6_ /P>\ >!?B!J\/B3PEXC\>>'/
M!'P&\'^-/B!X1T#QQK:>$+KXB3_LV:3HGPIUG7$TVVLKJ3^P['&DW,]W8S^7
MJK:RUS]I_%'Q'XR\(_#OQCXE^'?@)OBCX\T?0;Z[\'?#L>(K7PA'XR\2+'LT
M?P_<^++[3]6L_#%CJ%\\$-_XANM+U*#1;(W&HR6%VEL;>3T\?6I<]3$<SJ2M
M7K8AT*=>I2<O;UYP6#I2]KC)P>%]A:E44\1[=U:<5-*#EYV#I5/X'*H+V[I4
M/;U*,)\MXP<L373AA;NO[5_68RC1J4/9XB<H.<U'O:*_#WQG_P %;_B=\(/@
M]XQ\;?'_ /9O^ _P-^(FB_M.67[,OA3P?XY_;=M+?X9>+-?@^'EG\0O%NMW?
MQQ3]G5=,\.P^%H;^+PW/9GP=K%G+XEM]1T_4M;T/[!+(?V3^'VNZYXH\">#/
M$OB;2=!T'Q#XA\+:#K>MZ)X7\5KX[\-:3JFJZ9:WU[IV@>-ET7PXGB[1[2XG
M>#3O$D>@:-'K5HD6HQZ;9I<+ F,8N=*=>#A.C#ZC>K"<)PDLRRW#YO@G3E&3
M56-;+L7AL2Y4G.-*->G"LZ=62IFLW[.I3I34H5*JQDH4YQE&=L!CJN6XOGBT
MG3=+'4*V'Y:BA*I*E.5)3IQ<SY/\ _\ *2/]J_\ [,@_X)\_^KY_X*:U]OU\
M0> ?^4D?[5__ &9!_P $^?\ U?/_  4UK[?J2GO\H_D@HHHH$%%%% !1110
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MHN*E=/1ZGO-%?)'@[]K7PE=Z?X8NOB,/#7A__A96J^*_^%,:S\+/$7B3X\>
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M,9_A1\7OA5\2]8\)_#:Y^*%Q8_#W7?BC!\6[KQ;K3^$]4L_!EIXM\-:5JS^
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MXA>./A9\2_V7/!?PZT7P[K'PC\8? SXG?";Q)\//BG-=^%;'X5Z7J7A/X?\
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MS(/^"?/_ *OG_@IK7V_4%2W^4?R04444""BBB@ HHHH **** "BBB@ HHHH
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MQAX?\/ZDNIZ?X?\ %O@C5/W=AJ]Q<6]Q!X@MDM[B&.2>&YAWQ-]?UX3^TK\
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MS9>)9K1HY;G3Y/&^L_LXZKH_AV0V(NIK:^U:T&EFYAA@U"\TVTFFU&TX.).
MLZR+B+$9#A\)F./A"M0I8;'U<NE@*.*590BJSY\1B,/A\/[:4XQK5L6H.C&.
M(J.E"=H]6'Q=#$TE6I5:4XMR3=*K&JE*+LX\T-Y+K%*Z>EKGW%17XJ?L:?\
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M:LU:G!<M-6A%M139111699\0> ?^4D?[5_\ V9!_P3Y_]7S_ ,%-:^WZ^(/
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MS3A3J).IAYU*?M*5*52C4I5^11K1;****_'#]#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /RQ\4?"?QY\3_^"D?[1G_"$?M-_'#]G/\
ML/\ 8@_80_M/_A36@?LVZY_PF/\ :?QY_P""D/V+_A)/^&A/V?/CO]E_X1[^
MS[O^Q_\ A$?^$5\_^W-4_M_^W/)T7^Q_;_\ AE#X\_\ 237]M_\ \('_ ()N
M?_2^:MZ+^U/\#-2^-W[6'A?PG\-_'6K_ !L_9S\'_!?1_BU?:+\+H(/&'C[1
M_%1\?^(_@_X"\(ZI=36&O^-;+2M0U[QI?Z%#JYTWP1X>OO'NLZO8:S;VNM^)
M]3A] _94_:D\!_M=_"^\^)W@/P[\0/!:Z'X[\<?##QCX$^*?AZT\,?$#P+\0
M?AUKMQX>\6^%?%&DZ9K'B'2(]1TV_@!\W1]?UC3YH)X6BO6D\Z*(I_O>;V?O
M\N%IXUI;_5*M6G1AB4MY4/:U\/3G4C>-.>)PL:CB\5AU4JHW2M[1*%\1'"+F
M2=L4\(\;&A)Z\M6IA(U,12A)IU*5*O*FI*A6Y/-/^&4/CS_TDU_;?_\ "!_X
M)N?_ $OFC_AE#X\_])-?VW__  @?^";G_P!+YK[?HH%=^7W+_(^(/^&4/CS_
M -)-?VW_ /P@?^";G_TOFC_AE#X\_P#237]M_P#\('_@FY_]+YK[?HH"[\ON
M7^1\0?\ #*'QY_Z2:_MO_P#A _\ !-S_ .E\U\Z>&?A;^T[K7[6WQN^ MU_P
M4H_;#C\'_#;]G3]EOXNZ%J5O\./^"=:>)+OQ)\;OB9^V#X,\5V.K7DG[!<NE
MSZ'I^E_L^^#)_#UM9Z/87]I?ZGXGEU+4]6M[W2K71?UJ)P">>!G@$GCT R2?
M8 D]J_._2_V]/V5))_C/\3]/\,^)M/\ &7@S]H[X>_L%>)+Z]^'VE^&_B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img170310032_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #. 1(# 2(  A$! Q$!_\0
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M+FE)W;B"Y8N-W)VNY-).4G)-MV22NVWRQ2BKVC%))+[?HHHK( HHHH ****
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ML'%PI0I2K6]^MELITJ,9/GO@JD:/-3IY;&#SYXJIR<RO)-\M]4_3M+5^JO\
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M7,$]M(TRQW$,D$C6]Q/:3JDJ-&S075K)#<VTP5B8[BVFBGA?;)#(DBJP^%_
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M2Y$J;E&'*J<*LH<LJT*:A"-.G6<X0C"$8Q48Q2"0 23@#DD] /4UXM9_M'?
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M97_!2/\ ^A0K(=GV?W,^WZ*^(/\ AX-\!O\ H0?VW_\ Q65_P4C_ /H4*/\
MAX-\!O\ H0?VW_\ Q65_P4C_ /H4* L^S^YGV_17Q!_P\&^ W_0@_MO_ /BL
MK_@I'_\ 0H4?\/!O@-_T(/[;_P#XK*_X*1__ $*% 6?9_<S[?HKX$\,?\%+?
MV8O&WAOP]XS\&:%^V'XN\'^+M#TGQ/X4\5^&/^"<'_!137O#?B?PWKUA;ZKH
M7B'P]KNE?LKW>EZUH>M:7=VNI:3JVFW5S8:C87-O>6=Q-;S1R-N?\/!O@-_T
M(/[;_P#XK*_X*1__ $*% 6?9_<S[?HKX@_X>#? ;_H0?VW__ !65_P %(_\
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M-_A[QEXNUS7=#\=^./C!XKU[2=3\?ZAIFI6L4]U9Z1?B_P#$\<MSKD-S4/\
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BVOL[2<'4F4445S&X4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img170310032_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (J!-4# 2(  A$! Q$!_\0
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M '^F717\6_\ P=*_\%"_CYI?P:_81^%W[!/QJ^+GPQ\4?'?PG\7/VTM<\;_
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M/'>E-?\ @34DT^UNM1\>P?M7^&YH++69G1[E(OA_J#Z9%N"PZL?D;T_X#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!_:!\6O^"??[(?QS_:B^"'[:'Q3^$G_"4?M+?LXZ<NE?!GXD_P#">_$[1/\
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MT?B)_P %#/#GPB_L[]L'XK^#K+P!X_\ B]_PGWQ/O/[>\):=X=\#>%+/2?\
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M3P[XUT>\T'Q7#*_@TZ)J46IZ[I>H7D-_XBMK^'Q%)/.U\NJK?JETH!_G\_\
M!#K_ ((O?MD?MW?\$]O#GQ:^%_\ P67_ &IOV/?@QXD^)'Q+\*:E^S+\+].^
M*=[X!8:%KD%EX@U55\/?M1?#7PH][XNW&XOO/^'<WESA'O7U?:=W[1?MR?\
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M]I32/!?CB_UI;E'&G?">;X>:CXD@\,);K#XKU^\T*VUB_'ABRU_0/$G[$_\
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M32/ /B'%]XCUF?S?%7A;7)C]L\LR&&WM8X #V3]I#^T_^&>/CU_8OV_^V?\
MA2_Q1_LG^R_M']I_VG_P@^N_8/[.^R?Z5]O^U>5]D^S?Z1]H\OR?WFVOY5_^
M#9O^PO\ B'A^/G]D^9]O_P"$E_;+_P"$HW_:-O\ ;O\ PKC3/L_E>=^[\O\
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M*"R_;+ZUU[2?#WB37[N+4/']O:0_T=?L;_L0_LO_ /!/_P"$4_P(_9'^&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/C)'X77PN_A$Z-,EMJ'AR/1TO='B /ZF:*_CK_X-=/\ @I[_ ,%$OV^_BO\
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MPQ2-#)+I7B+P[?:EH^HQ1RH\3R6=Y,J2(R,0RD  [*BOFU_VR_V0(OBX_P
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MXD\-ZK8:YH&MZ7>1B6TU+2-8TN>ZT[4K"ZB99+>\LKF:WGC(>*1E(-?S#?\
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M98>6^N/V#?\ @F5_P3F^+O\ P;._%']IGXI?"3X9^/OCYX]_9\_:[^/'C_\
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MY+#Q3XPTI[YM,\4:Q:70!_-S^R'_ ,K6W_!;G_LP#QY_Z2?L)U\7_P#!M_\
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MFXTZZ_9S^#7[7'[0\_Q9^!GP#ET6XBN=$A^&GPYL?"?A.RM-+T=K6P6Q\/\
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M?B+;V(OXK64Z<UNDMK. ?IA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX];_ &@/!7QX_8^\-_%;XB_&W_@I5^RE^W;H_P &OA5^U1XBUCP>^L?LW_\
M!2CX.^"M#\&?"[6_&.G> T\$^+I_B-]L\-_L^>(/$-OX[^';:1X[D^(.NZ=^
MX/\ P;>?&_\ :P^)6@?M@^"/CK\2;OXK_!OP'XM^$&M?L]:_XX_X*0_LI_\
M!3WXY>&)?&GASQ9%\6?!7Q7_ &A?V9]>B>[TT>)/"^C^+/AI8>-/AUX*ETS0
M_$NL>&-'NO$<'A>YU-OWF\"?LA?LF_"[X7^-_@A\,OV7_P!G?X=?!;XF_P!L
M_P#"R/A#X$^"GPU\(_"_X@_\)%HEKX:\0?\ ";^ /#_AG3_"GBO^W?#EC9:!
MK/\ ;VDW_P#:>B6=KI5[Y]C;Q0)V/P;^ _P._9U\(O\ #_\ 9]^#/PH^!7@*
M75[WQ!)X(^#?P[\(?#'PC)KVI0VEOJ.MOX:\$Z/H>C/J]_!86,%[J361O;J&
MRM(IYI$MH50 ]7HJI?&_6W9M-2UENE966&\DEA@F4'YXS<0QS/;LR\I+]GN%
M5@ T1#%E\JUFV^,'B6;[!92^'_ .CEG6[U&WNYO$&OS1YPHT]A:V5I;K(F3(
M76VNH3M,%T&!)B<^2UH3FY.R4(WU_O2=HQ7G)I&E.G[3F]^G!15Y2J34=+V]
MV.LYORA&36[LM3L?%'CKPSX01!K.H!;N;8+;3+.*6^U2Y,LBPQ&.RMEDECAD
MF=(A=7(@LTD95DN$S7'P?&/34>1]<\'?$#POIRA676-;\,RKIS*S!5W&PN+Z
M[C8Y#%3:G:FZ1F"*S#I?"'P[\/>#D,UI'<:EK$P+7WB'69VO]9O9G55EFDNI
M<^29@JB46ZQ><$C-PT\B"0]U6:CB)/F<Z=-75J:@YV5[M2FY1NVM/=C%1>SE
MUU<L-%.*IU*KL[U)5%3UMHX4XQERI/?GG-R72#VY.#QYX+N8/M-MXIT*XC*[
M@(=2M99CD$[%MDD:X:7 /[D1&4$$%,C%?/\ XW_:'DL-0CLO"]K!)!YI@-S>
M)ONKJ1CLC>V@\S$$8D/(GAD=DPS>2Q:)?H/Q9J/A_P /:+?:YK=I9RVUE$\@
MCEM[:2:YG*DQVUN)EPT\[+M'. H:1R(XV8?G%X@NY?%.L7?B:=;'3KB_N0PT
M_382EA;6,14VR0,50DE(T\Y]B-+*9)WC1I"J],.5NSMS--I7W47%2:CNTG*-
MW>RYDFM480LVUNUK:_W76_?R/H6T_:$\31&&*[TS3W=6_P!(:6WN&8KZC[++
M;I$1R=SQE3[<9[C3_C]82.5U#3;>), B:&_=>>X\IK6521SC]^.>#C!-?'ZN
M"I D5SWVMGC)Z^V2/QJ%XV9N,;1CC/'OQTY_6M.6/;]/R-.6/;\S[XL?C)X/
MO 2SWMK@$DRQ6[IP<?*8+J5F)X( 3.#D@<X+_P",?A2T3-NFH:C(0"(K6.UW
M<G WK)=I*H[Y$3<= 3Q7P<.!@<#T' _+I4D=Q-"WR9VYS]['/.>/RZXI<D?/
MT_K7\1<B\_Z^1]JR?''1(P7.F79C ))5KC>/0;6L%3/][]Y@=BU>!?%GXU3^
M*[)K'PC:3)=64+RI9ZBZQ17-RWFH7B9'VRR>442..5 ZJTP"[)G#<59WYN8V
M-R[++M( 4DY&#GE2!TZ]^.O2N)U+3/M,KS03B"ZC??!(0K#=U 8-')CGJ<UC
M6ISG"K3IN4)5*?+3J1>M.5_BNUH[::WMO9:FV'=.C6I5I0C6C2FI5,/55Z=6
M*M:+V;OKS+F2V.;\.?%Z2VD:P\26]Q8W;N]O>07".EFZ2;E<[YV7;;J^8% 6
M0&38$(X8=//HVG:@D>J:=J$L:7">8T:G9 "R(X\LD'>N"0"I  P#S7**;V^F
M6VU#3+#5B9-LDNI6S$KY3[RT<FPJ%W(&7Y<'@  D&NYBABP$54B0*H2&-5$4
M>!@B-0B87IV_+I7)E^'S/"IT<=BL/C*#;^KU8T6L5HDVL3._NI+2-TN9V2U9
MZN;8C)L6J%7+<OJY9B+/ZYAI55B<,]/=EAZJTCKK*+;TT:)M.\177@73=5U5
MO%4>BZ19Z?>ZEK=_<W:VL&G:78V[WVJW\UZ[QFWM[6TMI;F9FF6.**$A H 6
MO,_V3_\ @H=\#?VL-&\7^)?V<OC3>_$JP\!^)CX3\6"6U\46$^BZO);"^L1/
MHWB&.QN&L=4L7%_I.I"VDLM2M298F!C>,=_JFBZ9K&FZCHNKV=MJ6E:SI]]I
M6IZ;>1K+9ZCIVHVLME?6%W'D"2UO+6>6WN8\@O#(Z@@G-?,7[.?[)7[.G[%7
MAGQ/X7_9K^%NE?#;2?'&O)XD\5+9ZCJ^K7^KZG9VBZ?IPO=1UR_U&\^QZ58D
MVFDV$4XL["W>2.!%#D#O:J*I"RI>P:?.Y->TYKKX;_9M;IK)N[2N>+RKLOZM
M_7_#L_4W0?CO<F>&SU*UMKX,J#[0-]A<'KO>4^4UL6Z;8XK=%QG=*,9KUOX<
M?%+P5\5](U'6?!&L1:M:Z/K5_P"'=654>.;3M:TQD6\LIXW RR>8C)-&7AF1
M@8Y&(=5_.31]5@NWE65F:Y7!>$EXVD,F5"13)DX(X9TPT0)8@8S7V]\!_A='
MX$M_%?BB=+RSUGXD7VD:UK6ERRNMI;W&EZ;_ &;;WD=BWRV6H7]KY?\ :(4(
MTD=M8+<0Q74,ZGGK?6%B*'L(TI827M%7E.35>#Y&Z;A!-IKVB47=?#)RO=)/
MJH++)8+'/$U,3#,84<-+ 0HPC+"U*SQU2.)A7FXWC&.7.C5A*,[_ %F,H-24
MI./O]%%%:GGA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!^,?[17QW_:?\(:]^WA\0?!/
MQTNO#V@_LN?%G]ESP]\,OA?/\._AGK?@C7;#XD>#?@'K'Q TGXF7U_X47XD:
MYH>I3>.]6GT3_A#?B)\/_$FBWFI:JS^);_3T\/Z;H'DW[86H?$K4_ W[37[-
M/Q/^+?BWXLZ#X(^+_P#P3HU+P]XZU[1?A]X.\?65O\9OBY:V7BG2EN?A5X,\
M!>&_LNFZAX._M;PQ?#PV-<TV35[BVOM6U5+.REB_7_Q3^S1\$O&ME\7M.\3>
M"O[3L_CQK_@OQ/\ %>'_ (2/Q;9_\)5KGP\TSPCH_@^^\S3]>M)=#_L?3O G
MA6V^S>&WT>SU#^RO.U2WO9[[4I;R+QG^S%\#OB#JWC+7?%_@C^U]5^(&I?"+
M5_%UU_PDOB^P_M?4?@1KEWXD^%-QY&EZ_96UA_PBNM7UU>^3ID-E!KGF_9O$
M<6L6B1P( ?CI^U5\5O&7QL^ _P -/A_J^J:A;^(?V>+SX6^(OVEX8+B25-0^
M,/AK]K7P/^S+X/T?6C;WLK-I'B_6/#WQR^*>CV^L2W=K>1>%_ _B'1_[?_T;
MQ!I&CXI?X%^%OBW_ ,%)/BA\:_V"]0_:GT+P3\:-$O\ 5_B-IGPV_9T\?7/@
MKP[;_L\?!N2[TF4?$KX@>'_BA8Z?I37$_B35[_PCX5U?0_#VE7E[XCN;^ V.
ML-9?KCJG[*G[/^LO\7)+[X<V._X[^+? /CKXL-9:QXFTO_A+O%GPPNM OO!.
ML3?V7K5F-*FTF_\ #&CZA<V^@C2[/7+^.^OO$%MJEUK.LS7_ *'X7^%G@'P;
MK'Q)U[P[X>BLM3^+WB6'Q?\ $6:>^U74X?$OB"#POHG@R.]FL=5OKZPT^+_A
M&?#FC:7)I^D6VGZ;,EH;F:S>]NKRYN #\J?AMX UG68?^"?_ .R7^T#K^B^-
M?A;J7P)^+/Q>U?1[+Q3=^.?AQ\:O$O@C7_A]/\'OA#J'B*66.+XG^!OAA\.?
M'E_XG73=:N=?\+?$(^"_#WB'4M'U&VT"QO:R?BEI_P '_A?IO[:_PO\ A]^S
M]\6OV8]3\9_L%_M->.?^$#MC\!](_9N\=Z3\.M(LO!ES\3O#W@CX2?$;QK>>
M&OB-<_\ "8:!I27][H7@BX\0^$MR^*M+N=9T;2_L?Z+V?[('[/&G_"C1?@G9
M^ [J#X<>%?%<?CCP/I*^./B$=8^&_BVWN[F]L-=^%GC1_%;>-_A9?:1+>ZA%
MH3_#SQ'X930+'5-6TW14L-.U74;6YBT?]CK]GG1X?B)YG@S6O$^K?%;P!J_P
MI\=^,?B+\2_BI\4OB/JWPRUZUEM=7\ 6GQ/^)/C7Q7\1/#W@^]\YKR3P]X:\
M3Z1I::LL6MPVT>L007T8!^?_ ,)O@+_;K?LA:]\$/V'8/V5]<\'>(_AGX]^(
MW[0;V?[,?@B?Q9\.]-\%7=MXQ\&P+\"?B5XX^(OCA/BO'JR6<V@>.=#T/P]%
MYL?BK7;BV\1Z!H]J?B/2=#^#<7[%^A:=J?[#MKIOQ9^,OQ#^)/PM^&7[:^M:
M%^S_ .%?"GA+XN^*_C9X\TWX>_$_Q7\9_#/Q O\ ]H/P%IGP_P!7AT^>'6-1
M\#:?J>LZAX;M/!>@0ZB^N:+#J'],>B:-IOAS1=(\/:-;?8]'T'2]/T;2;/SK
MBX^R:;I=I%8V-M]HNY9[J?R+6"*+SKF>:XEV;YI9)&9SY.G[.?P67X*:Q^SK
M)X$L;OX,Z]IGBG2-6\$:CJ.N:I;75EXSUC5?$/B #5M1U2Z\06]U<:YK.H:K
M8:A:ZM!J&A7[VUSH-UILFGZ>UJ ?F?KWP8U+XB_MP?M%6.L_LY?LL_M8ZQX5
M^ /[']IJVN?M+ZE;^#O[$U*[/Q\AOM6\%:9:?L[_ +0%K!_PFEUI<MYXCL;9
M_"MOIO\ 8^@V\+:_&RG1\'X8:-^SQ:_LG_ ;7_VL/#_B7XI:S\"M>^.?[.7A
M?]EWQ#IVE?&71?%GQ\T;XH>(/!\GA'X:> =5TJ[A^)WB#PC9>"KOP!\#M;U7
M69?#7P[^$]]J5SK]_P"&HX/%/B32/T1N_P!C'X%76MKXEMQ\:-"\1/X0\'>!
M-0UWPA^U)^U#X(UC7_#'P_BU:'P;9>+-2\'_ !BT.\\87F@IKNM?9-;\4S:Q
MKK/JNH27&I327<SO7U;]B']F_54^%:P^%/&7A9_@GX:USPE\+[KX<_&SXY?"
MR_\ "NC>*9K:Y\6F'4?AM\2/"E_J6L>,;JSMKSQEXEUJYU+Q)XNO85O/$FK:
MI=9E(!4_9M^&_CWX1?L;^#_AU\3;CS/&GAOX<^)X=3TX>(+KQ5%X5L]0N-?U
M;P_X!MO$EX6GUNR^'/AR_P!)\!V.I;Y(+JS\.026LLMJ89&_(C]C/4IOCEH7
M[#_PA_:S\%:UX,_9P7X ^"9/V9/ ?B,:+J'P]_:;^+OP_P!)6+Q5JWQ<2&\N
M2K:'80VWB?X(?"CQ#9R:)XWT*+4?'VIR7&JV.F^&+7^@#POX"T#PCX-M_ 6G
M3^*M4\/V]MJEGYOC7QYXZ^(WB:ZMM8N[V\OH]3\<_$'Q'XG\;ZO^\U"X@LGU
M3Q#>2:7IZVFE:8UGIEA86EMYKJ7[+_P-U7X-^"O@%=^"I$^&'PW/@F7X>Z58
M>*O&FD^(O ]_\.+NROO ^M^$OB'I7B*R^(OA[Q+X;N;"W:P\4:5XKM?$7E&Y
MMY]4FMKZ^BN #X\^ GP/^#O[5L?[0WQ&_:6^&O@_XP?$<_M$_'3X126WQ'TR
MS\83?"'P1\,?&NM>#_ '@;X<1:HMQ;_#56\%+HWC2^UOP#!X:U7Q?K_B?_A/
M=2O[_4KO3=0@]O\ V"_&'BGQA\"M27Q'XHUGQ_IW@SXR_'/X:> ?B/XBN-0U
M#7OB#\-?AY\4_$_A7P5XEU?6]3FN+SQ+J TG34T2Z\37$]Q>:_+HS:IJ5W?:
MK<W]]<]YXZ_9&^!/Q#\0>(?%6N:#XSTG7O&6CZ7H/CS4/A[\9/C1\)F^)&F:
M)ILNB:1'\3[?X6?$'P;:?$RYT[0II- M-1\>0>(M2AT C0TNQI*)9K[YX=\.
M>'O!^@Z1X6\):#HWA?PQX?T^UTG0?#GAW2['1-!T32K&)8++3-(TC3(+73]-
MT^S@1(;6RLK>&VMXD6.*)$4  &S1110 5!=75O96MS>W<R6]K:0375S/(=L<
M-O;QM+--(>R1QHSL>RJ34]?"7QT^&_[2WCHW^GZ?X@L9_#U_=6>GP:#I$_\
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M=K&HTC3[A7#I.LLEO#=ZA=1LH>*6=8((G((M9)88;D?1U%%29!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !17\7W_  <9>,OVNO%G_!4'_@E1^QY^S;^V
MW^T=^QMHW[4]IJ7@#Q-XD^!_Q-^)OA;3+34_$/Q.T;P_9>+]=\$> _B+\.;7
MQK?Z':W3K:V^H:YIUP]N7M(M5LXY"P^(O^"FO[,?_!67_@A7\'O ?[:V@_\
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MARVO/&GA3X'>%5\86^EWNG1>,_$\U_JW@_P0]_IVF^(?%.H7<D&FWNN7+?U
M^%_VX_V4_&?[($W[>WAGXQ:+JG[)-O\ #/Q5\7Y_C"FC^*[?3X? /@E-8/BK
M4I/"]YH%OX[35M&N= UC2KGPB?"X\8OKUC+X=M] FUUHM.D /J^BOGS]EO\
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M?BIXP;0?"?AZPTU;E-/U*R\->'M*TRSNKG3M-@L(QZM^W)\4_A;XR_X*+_\
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MVX] );N7'3M@_A4D/[/'PIB21'T"[N/-&'>77=;20@=!OMK^W8XZ#)/& <@
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M8_\ !%_]@3_@B9^P9^TAXSUK_@GY_P %(/#_ .T[\;OC%\,=1^'UQ\,=5_;
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M[K?CC4OB;:_V[>ZWJ<_VJR\9VU[IGVGR]'N=/AAMXXO'?&7_  1F_P"";'Q
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MN&VGLI;33M)@L #^6S]FW_A@#_B$&^*.W_A2/V/_ (96^.__  G/]H_\(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/INI:6VA0ZG<Z\FK_;;*/0[?0K?4;O7+B^LK;2;>]N+RVBE_!CXH>-M=\(?
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M\(:W\/=3U'Q!H\GB9[P _;RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_(S_@L%K'[0_@W]GN3QC\(/'-YH_P[O+76OAS\=/"$7A[PIJT.
MK^#?B%9-X?M]8_M+6=$U#6=)2*>[F\-WSZ)?6=P1XCL+R&2VET]KFOUSKEO&
M_@OPQ\1_"'B7P'XUTBWU[PGXNT:_T#Q#H]RTT<.H:5J5N]M=VYFMY(;FW=HW
M+0W-K-#=6LRQW%M-%/%'(OVOASQ3A."N-^&N*,?E."SW+\HS3#XG,,JQ^"PF
M/HXO N3IXN-*ACH5,/''4Z$YULMQ,TI83,*>&Q,)PG24EG6@ZE*<%)P<HM*2
M;33W6J:=KZ-=5=;,^./^"=.N_M%^-_V<- ^)_P"TIXZO/&'BOXEW4GBGPM97
M7AOPEX;_ .$>\!30Q0>'5:#PMX?T-+NX\1113>)EN;PW6-*U32(84M98[P3?
M>%5;&QL],LK/3=.M;>QT_3[6WL;&RM(DM[6SL[2)(+6UMH(E6.&WMX(TAABC
M54CC1410J@5:KRN*\[H\2<2YYGN&RK+<BPN:9EBL7A,FRC!X; 9;E>$J5']5
MP&$PN#HT,/3IX7#JG1<X4HRKSA*O5YJM6<I.G%PA&+DYN,4G*3;E)I:MMW>K
MU_ P-#\*>%_#$WB"X\->&] \/7'BS7[CQ7XIGT/1].TF;Q+XHN['3M+NO$GB
M"6PMK=]9U^YTS2-)TZXUC46N=1FL=+TZTDN6M[*VCBY;P?\ !OX0?#W4(M5\
M ?"KX;^!]4ATG4-!AU+P?X&\,>&=0AT/5]?G\5ZKHT5YHNEV5Q'I.I^*;JY\
M2ZAIR2"SO=?N)]8N89=1FDN6](HKY\L\[\6_"'X3>/\ 4AK/COX7_#OQKJZZ
M+_PC8U7Q;X*\->(]2'AW^V=/\1_V +[6-,O+H:+_ ,)#I.EZ]_98E^P_VSIN
MGZIY'VZSMIX]/4?AW\/]8D\9S:MX%\':I+\1_#MKX0^(<NH^&-$OI/'GA.QM
M=:L;+POXS>YL96\4>';.R\2>(K.UT37#?:;;VNO:U;PVR1:I?)/V-% '-ZOX
M/\+Z[X0U/P!J>AZ?/X+UCPW>^#]0\-10"STJ;POJ&ERZ+=Z'';61MUM=/DTF
M:2P2"T, @MB(X#$%3;XIX6_9K\%W'P,\ ? WX[Z3X%_:.T7X=6]I8:1=?$KX
M:^&M5L+JS\.#4]&\#:C?^&M?/BC23XOT/P3=6GA[5_%%H;5]>U%=:URUT[0+
M;7I-!LOH^B@#QZ3]GCX 3?#J#X/R_ SX.R_"6UOVU2U^%TGPR\%/\.K;4VO9
MM2;48/!+:(?#4-^VHW-Q?M=QZ8MP;V>:Z,GGRO(W.>%_V2/V4O ^J-KG@O\
M9D_9[\(:VVGZKI#:QX7^"_PWT#5&TK7=.N=(UO3&U#2?#5I=G3]8TF\N]+U6
MR,WV;4-.NKFRNXIK:>6)OH2B@#,T71='\-Z/I/AWP[I.F:#X?T'3+#1="T+1
M;"UTO1]%T?2[6*QTS2=)TRQB@LM.TS3K*""SL+"S@AM;.UABM[>*.&-$%F^L
M;+4[*\TW4K.UU#3M0M;BQO["^MXKNROK*[B>"ZL[RUG22"YM;F"22&XMYHWB
MFB=XY$9&93:HH \R^'OP4^#?PDTO5]#^%/PE^&7PRT3Q!,+G7]'^'O@/PKX+
MTO6[A;<V:SZOI_AO2M-M-2F%HS6HEO89G%N3 &\HE:;\-?@E\&/@Q#J]O\'O
MA%\,/A1;^()+*;7H/AKX!\*>!8=;FTY;E-/EU>+POI.EIJ4E@EY>)927BS-:
MK=W*P&,3RA_3Z* .0F\(:9ITWC7Q!X+TCPAX9^('C2QMUU/QC-X4M[Z;6=8T
M72)=*\)7_C6/2K[PWK?C&Q\.0M%;6^FW'B73KI=(272M,U?1TF6YAY+X$?"+
M2?@1\)?!GPKTC4[O78_#-E?2ZKXCU""WM=0\5>*_$6L:CXH\:^+]0M+3%I:7
M_BWQAK6N>)+VTM +6UNM4EM[;]Q''7KE% 'E>D? KX(Z!\0-2^+.@_!SX5Z)
M\5-:-\VL?$S2/A[X1TWX@:LVIJB:D=2\9V>D0^([\Z@D4:WQNM2E-VL:+/Y@
M10.U\,^%/"_@K1X?#O@WPWH'A+P_;W>JW]OH?AG1].T'1X+[7=6OM>UR]ATS
M2K:TLHKO6==U/4M:U6Y2!9M1U;4+[4;MYKR[GFDWZ* .9N?!7@V\\6:9X]O/
M"7AF[\=:+I%_X?T;QI<Z#I4_BS2=!U6>&YU/1-,\1RVCZQ8:1J5S;6]Q?Z;:
MWD5E>3P0RW$,DD2,O%:M\ ?@1KWQ"LOBWKOP4^$FM?%;3;C3;O3OB;JWPX\'
M:C\0K"ZT:*.#1[FR\9WFC3>([6XTJ&**'39H-2CDL8HXX[5HD10/6Z* ."NO
MA5\+[[0_%7AB]^&_@*\\->.M=N/%'C?P]=>#_#UQH?C'Q+>3V%U=^(O%6DRZ
M<]AXAUVZN=*TRXN-6U>WO+^>?3K":6X:2SMVC@U/X0_";6])\;Z#K/PO^'>K
MZ'\3-1CUCXD:-J?@KPU?Z3\0=6A@TVUAU3QOIUUIDMGXKU&*UT?2+:.^UZ&_
MN4@TK385E$=C:K%Z)10!Y;X4^!OP4\!P>%[7P/\ !_X6^#+7P/J.NZOX*MO"
MGP_\)^'8/"&K>*+"32O$VI^%X=(TBSC\/ZCXBTR:;3==O=)6TN=7L)9+/4);
MBW=HS6T'X _ CPKX]U3XJ>%_@I\)/#?Q/URXU>[UKXCZ#\./!VC^/=8NO$$[
M7.O7.J>,-.T:W\0ZA<:W<NUQJ\UWJ,TFI3LTMXTTC%CZW10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !117AO[3WB+7/!_P"S5^T-XM\,
MZE<Z-XD\+? WXM>(O#^L6;*EYI6N:)X!U_4])U*U9U=5N;&_M;>Z@9D91+$I
M*L 0>_*\!4S7,\NRNC.%.MF6/P> I5*O-[.G4QF(IX>G.IR*4N2,JBE/EC*7
M*G9-V0I/EC*3VBF_N5SW*BBBN 84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?S\?\%@/VA?VE/%/[
M6/\ P3H_X)4?LN_&;Q%^S+K?[?>M?'76_C7^T7X&ALU^*7@;X'? [X=W'C#Q
M-X9^$6K7T4P\*>.?&^D0>*O[.\?:5)IWB;P3K/AWPU=:%>,-4U%(P#^@>BOQ
M'_9,_P"";W[9_P"Q1^V'9^,_#7_!4#]I/]I3]@O7_A)K8^,7P@_;V\>7O[27
MQP/QDT:YO8/ VJ_"CXHW6D>#M,^%W@5-+UV[USQ9=:>F^\N/"D?AO7_!_CC_
M (2[P[XX^"7QGJW_  <>^-+KPO\ %#]K?X7_ /!,7X[?%C_@E+\'OBS?_"WQ
M?^WEH7QG^&.C^+M4M]!O="\.^(_B)X _92UO3+?QGXS^&]OXNU^RL=(\80^/
MM.T.;1?M=[XJO_!?BK0O%O@;PV ?U"45_/3^T'_P6]^,OA_]N32/V&_V(_\
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M7X->$?#2ZWX:\%:GXO\ %EKI_A#Q7XS\5^%=>\9?#8VOQ2T[P);O_;G@OPZ
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M_P##OP7XXTE/^%^>.H?!L.IWVF>!M#\5^$O$_BKQ#HFM^&/#NFWLFD:IJ5F
M?O=17\LGQ"_X*F_$?_@I%_P2>_8_^(7P7T3QS^Q_\7O^"D/[>?PB_8Z\+P_"
M[XSZ[JWQ%^&/A70OCYJNH_&/QQX<^*WA;PW\+_$>G0'X-?!OQU+K6K:5H.F7
M6B:;XADTJTN[G4[C3KFXA^,'_!QY\:O 6L_\%"KCX=?\$LO'/Q@^%G_!-3]H
MS6_@W^T5\9++]JKX>>"?"FF^![3QAK7@GP_X_P!(T7Q/\.%\8^(_&&N:MX?U
M"YU/X6^"M \76O@S1YM(U7Q/\0[*UUFQ:0 _JAHK^?G]G+_@N?XD^,O[;'[+
M_P"S1\3_ -@7XQ_LW_!G]O7X6>,_BK^PU^T+X^^*?PW\2^(_C+H/@_P58_$3
M[7X]^!W@F/5[KX+Z7K?A"/6[[39=5^)'BCQ(EQ-X$^V^$K;2/&5]K?A/\6O@
M;^U-^VDO_!MU>?M\:3^TM\??&7[0W['G[<VI?&LZUXR^-7Q+UZZ^+7PU\$_'
MO1/ _B?X)_%;4-2U_4;[QO\ "*]\#>,M5GN?!'B"2^T*VDT33+NPMK2[T^TF
MC /[JZ*X;X8?$#0OBS\-/AY\4_"[O+X9^)?@;PE\0/#LDGWY-"\9:!I_B/2'
M?A?G?3]2MV;Y5Y)X'2NYH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***_EOT']NWQ!^SK_P6Z_X+9^(OC[\:/B]J'[)G[)W[#OP#^,]
MA\)&\9>)_$G@CP=/#\,?A'KGB*Y^&/POU/7X?!ND>-?&>HW][9Q2:9;:)+KV
MOZ\RZIJ<0U"[NP ?U(45^%/[$O\ P5I_:V_:;^*GP$T[XR_\$C_VB_V<?V:/
MVL?!?B3QQ^SI^U1HGQ(T#]HKPO<:-8Z3I'BSP9?_ +1'@[X;>!['4/V7='^(
M_@_5[2?PKJOQ'UV9=4\4WECH.BVVMZ%#XD\9>&?E/Q__ ,'&GCSX/?M2_"#X
M2_&S_@FS\1/@M\"/CQ^T+HOP-^%OQ(^*W[1WPU^'W[57B'0?$_BK7_ GAGXW
M77_!.WQ?X4T3]HCP]\(=8\6>&M4@@\<^(KG2_"#:7% +;Q-=^+M1T?P7J0!_
M4%17\55A_P %*/\ @I!XD_X*6?\ !<;X5_%;X.?%ZW_9R_9\_9)^)MA/I7PW
M_:[^&/PVU;]C'X>^!?V</B]\4?A=\7_AC?Z!X$UF3Q=\7OVI?$"Z#?Z/XZT[
MPQXL^(O[/]SXY\,VOC=_$_AOX26?AB'D/BG^W]^TCX)TG_@UR^)'P N?VV_C
M!!^T%X8_:OD\3_LX7_[4=WX^^*/[47B%/#WP2T7X8^'?VC/BU?Z;\'/AY\2K
M7P[XG\43ZOKOQ4^)7@72?#GPS\)S^*/&TVC06NDZ@EX ?W"45^%?[,7_  6?
M\6_%"V_;F^&W[1O[ OQ[_9[_ &T/V%?">B_$/Q9^QQ\-]=T_]K#QW\7? WC+
M0H;_ ,!WGP2\2_#/PUH5CXZUW7M:EMM#U*QT[17\,:%!KOAC7?\ A--3T^Y\
M4+X/\3_8R_X+Y>/?CW^V#K/[$W[2O["EE^RK\:$^!GCCXSZ#HGAC]LOX-_M0
M:EIMWX TN77==^'/QM\._#CPQX?U_P#9\\=IH]O<3MX0^(%BOC_3+I([;Q#X
M'T:&ZM;R8 _I HK^0[0/^#H;XV7_ .R;\,/V_M=_X)#?%;1?V'M3^(VG?#/X
MW?'^S_:K^%^K'X=Z[<?$V[\&ZC/\+_AO<?#_ $;Q[\9](L/#S:-/;^(]<TGX
M.>$K[XJ7>L?".3Q)8C1(O&^K=TG_  4"_P""BFM?\'*\7[*^D?!KQ1XH_9<T
M#]F!)M+^&-I^T'\./"?@W2?A!X_^(OPO_P"$A_;TUS1ET*TOO'7B#1FTZW\)
M>'?@=XFFU;XE>&['5?$-QX-U#0-/\3^*+?5@#^K>BOP<_P""^G[0OQH^'GP/
M_90_9<_9T^(?B[X0_&+_ (*$_MN_ 7]DVS^+?P^\3W/@OQ_\,/A_XHU_^UOB
M!XO\#>*;&:*^T7Q,8=/T/PQ%>VNR:WT;Q-K5S:W,.I0:?'<?$7_!S?\ 'G_@
MIS\!_P!C_P")-_\ LKZ_IO[-'[*?PJT3X!S^-OVE= ^,7C.W_:O^+OC;QQ\5
M;3PKIGPM^#^H^%KZ/Q1\,/#WP\_LG1O$/QI^(/C#Q';>)?BI8^,_#GA/PEJ=
M[HT7Q:T[4@#^L"BOYJ/^"G_Q'_:!^/7[?G_!*K_@EW\._P!IGX[?LI?"O]J/
MX?\ QT^,_P"T#\7?V:O&B_#O]H+6[+X.?#.]\5>"_"W@SXG'3]6U'PI;7>O>
M'-13Q,8K:6WUNTUJ)M4@U*'2UTN]]R_X()_M%?&WXG?"O]M?]FOX_P#Q5\5_
M';QI_P $^OV_/V@OV.?#GQH\?W;:K\1?B/\ "[X8ZK9V'@C7?B-X@>&*?Q/X
MV$L>NVFI^)+TR:KJUC!I<^KRW6IBZO[T _>6BOR6^'W_  5'_P"$[_:]_P""
MI'[*G_"C/[*_X=K?#?X7_$'_ (3S_A9OV[_A='_"R/A)?_%/^R/^$7_X5]9_
M\*Y_L;[#_87V_P#X2+QW_:/F_P!I_8K'9_9[_ ND?\'#GBOXG?L^_P#!._Q#
M^S=^P!XL_:!_;(_X*)67QG\5^!OV0_#W[0?ACPGHGP^^&OP.\;>._!/BKQOX
MQ_:%\8?#?3="MXM1N_!OVW0;?4?A_H6CR6\7BJ+5_$VCS^']%7QB ?TQT5_.
MS\+_ /@NOKGQ.^''_!9#4_B%^R9XM_9.\<?\$H?A/X?UO7O#_P 1?B+H'CCQ
M)XQ^)_BSX>_&+58?"ATK0?"]CX1L+#3_ !_\+;?P[X*\5:#XW\?^$?BQH'BG
MP_XVT;4]*T#4+5;KYW^$O_!47]L3]CC4?V+?^"6N@_L8?&7_ (*+?MI>)/\
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M-_M+^S?[2T[[?]C\[[']OLOM'E_:H/,^ OAQ\0/VL/BC^U-X'^&WQ0\:ZO\
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MJ/BO1[#Q#KOA'1IO$JZ#X=O[CQ%=;?URHH _#G]EK]F/_@L]XU_:_L?VC?\
M@HS^UU^S3X/^#O@3X3ZS\,_#?['7[ NG_%6Z^"GQBO?'$^HW'B?QO\:;W]H7
M1(_%&B>)O"\FG>#SX2U3PE>ZWKTL,%]IGA_7_AAH-W\0]'^,GYF6'_!#7_@J
M=\.?V</BM_P2?^#G[6O['MA_P2G^*WQ0U[7(OB5XO\!?%B\_;L^''P>\<Z]H
MOCGQ=\'_  OX;L(W^!^OV<?B:QU;2AXD\2^*F\2^(;;Q%K_B>/6/!UO>Z)\/
MO"O]?-% 'XD?L\_\$N/'/[/'_!6D?MC^$M?^'T?[*WAC_@EM\/?V OAYX,FU
M_P 27?QGL==^''Q!^%FM:'JFMZ4/ UAX);PHG@_X?364NKV7C-M9FUJ6U1?"
ML%E--=6GPU\8/^".7_!023]H[_@LWJ?P.^(G[&=S^S'_ ,%</@\^@Z]%\4-0
M^..D?'7X?_$KPS\%?B#X2^'D.DIX7\(>(O .F^#'^(OQ$UB[\=ZU=S^,M9U'
MPC%8S>&_#.@:K:S:;>_U.44 ?S.?'7_@DM^W;JO['O\ P3;^#/PLUC_@FO\
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M^RU^T_XZ_;,^!'[/G_""_M)_$J?X@W/C;XD?\+8^.'B?^VI_BIX@3Q3X\?\
MX0_QC\2O$/@+3O[=UZ-+_;I/A:P32\?9=&73K,FW/SI\-/\ @F1\4]+_ ."D
MG_!7+]J?QYX^\+Z7\#/^"B7P/^ OP>\ I\,/%/B.Q^._@3_A7_P$T3X0>-]?
MU1=9\ Q^$/"^L1ZA9W^K^ M5T7Q#XWVE--O]7TRRG6;3%_:^B@#^.#XN_P#!
MJEKVD?$O]@NP_9:_X*&?MNZ7\ /V<?'OC35/&EE\7?VL[VR^)?P'\*Z_-X:O
M[34?V"[;X=_L[Q>"OA?X]UK5+;Q!>>-+O5DT/3M1F@\-7$4DUQ%>NO[?_P#!
M;3]E#Q-^V#_P2:_;*_9W\#V]YX@\>:A\(K3QEX%T]XFU'7?%/C#X(>)O#7QB
M\/\ ANP9/):3Q%XXU#X?Q>%+*<M!!)?Z^OVQELI+E3^L%% '\QWB#]FSX\?\
M%"?@S_P1U_X*V?\ !.'XI? /PC^U?^SO^SVEOHOA3]H_3?'E[^S]X[\-?&/X
M4:?\/?B[\/O'M[\,SJ?CO1]:^&.NIXVT738]#AU"*YUY]0CDUC3YM.TS6T^C
M_P!C[]@3]O[]@S]D3XFQ?!7X@?L@_%#]OW]JO]LKQ7^UW^U9XN^--C\9K#]G
M!=4^,&I6D_Q2\-_"J+P)#:?$BX;0+#2[%? 6H^)K#3;?5=7O=;U+7]+TNUNK
M33++]XJ* /R,_:!_8&^+_P =_P#@KI^PO^VYK?B+X:WO[,_[&'P3^-^G:#\/
M]8UGQ3+\14_:!^,MEJ_A>^\8:+X43P=<>")= M_"47@]SK6H>-[;7+?7?#]G
M<6?AX2Z1IFIM^N=%% '^;C^P+_P3D_X*H_\ !23_ ((M>,OV7_V?OC;^QAX6
M_9#^('[3'Q"^(K6/QET_XRZ'\=+/XH>!?BMI-MJ/PQB\3^"/#_CGP-#\$+FW
MT2S^+5EXE?PE??$>;XD37G@>>UL_!+P:[!]-?MJ?M>>+_P#@DU_P60_;CT?P
M#\=?"_[)G@#]MGX(? GQ!\=O'O[7/[*OQF^+GA_Q!XA\ _#Q/"&D>-/V!KWX
M"WGB:3XH^)-(@\6^-4C3X]P_"SX1:1\1[?QAX+\:_P!KP>'-!9/[]** /X_?
M^""'_!.K]I*;]FC_ ((S_&3XS:-I?PW^%G[)FC?M[?&2+X5^,QXIT?XK^(_B
MI^T[XNU7P?\ !CQC>>";[PK_ &'!X1T;X.:IXR\5^']5U/Q+I^N+<>.=$U*R
M\/7L$UIJFF?26L?\$7?VH]0_9H_X+O\ P:A\>_ )?$__  5 _:>\;_&KX!7\
MOBGXB+H/A#PMXE\80>(+&P^,%TGPL?4- \0164317=KX+TOX@:='=$)#JL\6
M9A_3A10!_/Y!_P $IOVAXOVF/^"#?QF;QE\&#X7_ ."7?[,OC+X,?'^P'B+Q
MP=?\7^*/$/[-?AOX.65_\'K4_#H:=X@T"+Q/H]U?75UXTU3X?:BF@R0746E3
MZ@TFEQ?EK^T'^Q?\>O\ @G!_P;N>-O\ @G#XTU3X:_$O]J;]LS]J_3?@7\$M
M&^$6K^+/$/A[Q5XC_:%^.7A_QA;:3:7'BCP+X0U]K_2/ASX4\8ZEKLO_  C2
MZ?I+V/VA-2GA03'^TVB@#R_X(?#.S^"WP6^$/P<TZ[DO]/\ A-\+_ 'PSL+Z
M4DRWMGX$\*:3X6M;N0L QDN(-*29RP!+.<@'BO4*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OY6/C+^P?\-_BQ_P4'_X*_?$3XZ?
MM%_#/P3\!?\ @H!^REX,_96MCH,WCO\ X6A\"/&'PS\)>"/"-SXK^-=MXB\
M:%\-?ASI&L>*/A]=:S\(CXC^(OV3XT:4FGCPJUW:ZO&]?U3UG3:/I%Q]M^T:
M5IL_]I26LNH^=8VLOV^6Q\K[%)>[XF^U26?DP_97G\QK?RHO)*>6N.;$QQDH
MQ^IUL-1DFW-XG#U,1&4;72BJ>)PSBVU9R;FK2;4;Q2?N9'6X;HU:[XDR[.\Q
MH2IQ6&CDF<8')ZM*JY6G.M/'9'G<*\%3DYPIPIX>3J4U3E54*KG2_EC_ &)+
MO_@IQ\+]6_9D^!W[1G_!1+]B_P"%'[%O[+/POU'X;2+\!O@/\4=._:&^+7A[
MP;X8TGP'\%?#_P"V'>?M*_#>W\(_LE32Z)HB>(_#FN^%-6\%Z[\1+ZSN_"GA
M6'QJ?$VD^/?"7XL^"?\ @B[\=/#/A;X2>$=9^.G_  2VBU?]GW]LWPY^U78?
MM'>*O@_^TUX&_;'^-,6E_$?Q#K^H:#^W?^T#X^\ :YJG[-.FZYX<N+>^^%?P
MIN]&U7PQ\5/%MOIUQ:>(O$.L:-:>._$?^B%-H^D7'VW[1I6FS_VE):RZCYUC
M:R_;Y;'ROL4E[OB;[5)9^3#]E>?S&M_*B\DIY:X)M'TBX^V_:-*TV?\ M*2U
MEU'SK&UE^WRV/E?8I+W?$WVJ2S\F'[*\_F-;^5%Y)3RUQQ>RSO\ Z#LK?_=+
MQ2O;_NK.U^77>WM':_LX\_TGU_PN?_-+<>1OO;CK()<M][7\/H\_L_:2M?D]
MI]5IW]G]<J?5/Y#_ (U_LQ_&*Z_;[_X*9?'SX%?M#_L=Z%^SC_P5&_9.U3X)
M?&;P]^T3HG[2?@+XU?L_^+= _9-\6?!;P ?$5Q:>!KCP/\(M,\:?%.W\->*[
M36_C-)97_CKP1J_B+1OACX'U/6M$T&]\4^0>._V%_CMI_P *?^"$<7P&_:Y_
M91^%OQU_X)->$OCW/\2]<^-WA[X]P?#9O%WB^S^&D_@?PGX^TJZ^%OA7Q%\/
M/ OQ6?X<ZSX)U2[^*M]\%O&&L>$_%4_B#X,#Q?XDM-+M9?[3YM'TBX^V_:-*
MTV?^TI+674?.L;67[?+8^5]BDO=\3?:I+/R8?LKS^8UOY47DE/+7!-H^D7'V
MW[1I6FS_ -I26LNH^=8VLOV^6Q\K[%)>[XF^U26?DP_97G\QK?RHO)*>6N#V
M6=_]!V5O_NEXI7M_W5G:_+KO;VCM?V<><^O^%S_YI;CR-][<=9!+EOO:_A]'
MG]G[25K\GM/JM._L_KE3ZI_%MK?[!?QO_:0^%_\ P5;^*?[6_P"W/^SM\-/V
M[?\ @HG\)/AY\%?#DWP2\%?'GX=_LY?L\?"_X*WWA3Q#HW@+X[ZI\4/"^@?$
MWX56'[2I\'#X7W9^)VCW6I7'@2ZUK7? TWQMG\5+X(L>2_8C_P""=OCOX _M
MF?LS_M3?$+QQ_P $P/@?X<^''[+7QM_9=^*?PH_9=^#7[07P"M/!NF:A\-_$
MWAWX4?%GXW>*_BG\/[WQ1KOQL^*_B/4;2W\4>(?VD=4^%E[XI\/:):ZE\,KS
MXG:W?R6U]_;M-H^D7'VW[1I6FS_VE):RZCYUC:R_;Y;'ROL4E[OB;[5)9^3#
M]E>?S&M_*B\DIY:X)M'TBX^V_:-*TV?^TI+674?.L;67[?+8^5]BDO=\3?:I
M+/R8?LKS^8UOY47DE/+7![+._P#H.RM_]TO%*]O^ZL[7Y==[>T=K^SCSGU_P
MN?\ S2W'D;[VXZR"7+?>U_#Z//[/VDK7Y/:?5:=_9_7*GU3^+R]_X)\>(+G_
M (-UO#__  2)D_:-_9TT+]HRT\<7_BO7?'7C2?XX^"_@IX$L$_:GU?XX:?:?
M%C7]?^!]KXZ^$.J^)_"<YT_P1:?$GX=^&8_'GB*,VG@VYUS39[75Y_LGQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)OVN/VFO^"DG[67P=_:6OI_&GBB_NO&GPOMQ^VK%XE^&'B7P?=:U-H-KX/\
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M(]7US45T#PKX7T/1_#OAK1S9Z1I=BD%KYLOZT4 %%%% !1110 4444 %%%%
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MB?P]XADLUB>[31-9T[57M4G+K"]RMC<3F!9FBD$32!1(8W"$E&QT= !1110
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MU&X,T]BEQ80S32R>N_\ #-7@3_H:OCC_ .)#?&[_ .;RC_AFKP)_T-7QQ_\
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M/1?%OX8_"S3H[3P@VKV.OZ7I%L/$&M7.KG0+2UTC3M5U:^N)KK4=/ENKB_H
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M !17 WO@/[;>75Y_PF7CJT^U7$MQ]EL]<@AM+?S7+^3;0G3G,4$>=D49=BJ
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MB7_PD^L:3?\ P/A\-II_Q2\.^'9_&WA[4;, ]P^!_P $/^%-:Q\?M5_X2?\
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M\+:SIGB.[T.T[K]F;]BK_AG7Q'\+/$'_  LO_A,?^%:?LG^'?V8/LG_"&_\
M"/?VU_8'CV]\;_\ "<?:/^$KUS^S?M?VO^S/^$:\F_\ (\O[;_PD$V_[(OI7
MPJ_;+_9T^-6N^#O#WP[\;:SJ5Y\1?#.I^+OAU?Z[\,_BKX&\,_$31=#M]+N]
M?'@#QCX[\$^&O"/C;6?#MOK%K+XD\,>%];U7Q-X>6VUC^VM(L3X>UX:;Z?\
M&/XAZW\,? M_XE\+?#/QM\8?%DMYINB>%/AWX#M[-=5\0^(=:NX['3H]3U_6
M;BP\,^"O"UD\C:CXH\:^*M2L-$\/:):7ER#J.JMI>B:H >>? 7]F[1O@_P#L
MT:#^S3XCUI?B+X>T_P .>,/"NO:H^E7'A9/$>C>--9\1:CJEH^FVFN:K=:8K
M6/B*?2VDMM<EN&$1NX9[:218X?$K;]D3XX-\']6_9VU;]J:PO/@G:_!'XE?
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M/_:2TGXR6GQSMOVI[#QU\'S\:C\>/&GPJ\>^(8_!]Y^S_P##V]_9YTS2=?\
M@SX-\ >"VM=!^$<^E:-XFMKGPO:>+3\0[/QE?^(KW5EU#3=2N0#]O**** "B
MBB@ HHHH S-:_P"0-JW_ &#+_P#])9:\J_9O_P"3=_@+_P!D7^%O_J#Z%7JN
MM?\ (&U;_L&7_P#Z2RUY5^S?_P F[_ 7_LB_PM_]0?0J /:**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)\7]7L_$>D3W^C>.;[5O'-_H5KX<?LM_M(6/A/\ 9A\'ZS\']7T2X^!/A_\
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MM\--6U+0?%^L>+6U_3K7Q7X4NOA%XDT#XIZ9JWA:&\\.WL]K'J>GW@!\#_\
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M_)N_P%_[(O\ "W_U!]"H ]HHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<.DZ5#XIUN]?2;K5_P"RM2TOU*@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@SH-Y8VG[,%QX(\->)]/\0ZKX"7PYJT?CFR\9:1\2+?XM?$JWUJ*30O /\
M@M1\>_@Q;?$O]FCX;^'OVOOV-_A)^U%\-]9^,FN>%_ G[5'Q2G\#^$_A]JGQ
M)_9]\7>$/"?[1.IW^D:'XMD\+?$#X.IX@D\7_!E/%6BZ18>.=3NM;\.>&?%.
MA^)I]/U"#V7_ ()$_L@?M*_ ZY/Q+_:,^#?P]_9PUS3/V/OV2_V0S\/? _CK
MP_\ $'Q%\6=8_9GT;Q3I]]^T#\6-=\&V-MX1BUO4;+Q#I_@GX?Z3;:IXK\0Z
M7X(T-K;Q!KT$(T;1-,C_ ."FOASQ!X7\8_"!_#/CG]HSQ_\ M"_&3XT^*W_9
MQ\"_ 3]GS]B#Q_\ $+P;X0\._ \6_P 4/"FF^,/VI/">G^#?#7PSL[33-0\;
M^(/$WBWQ<_C"Y\1>+H?">BWMUH=Q9Z): '"_\$5?#7[,_A+XJ?M@^$/V4_B#
M\ /&GPK^&7PT_8C^#NC3_LUZA'XH\(>+;7X<?#[XG:='\;_BOXWT+1-,\#:I
M^TC\7;Z\U1OB5X>T#4_%>N^&O#7A3X>W'C/Q5J^I>(+-++^@.ORX_P""9&E_
MM-:/H/Q>L_VC-(_:IT4G6/"$W@RS_:;\(_L(^$':*2QUY=?G\$6G[#E_>Z3=
M0O*FDIXAG^(JPZDLT>D)X=\RT_M79^H] !1110 4444 >!_LT?\ )*C_ -E.
M^/7_ *OCXDU[Y7@?[-'_ "2H_P#93OCU_P"KX^)->^4 %%%% '\*O[>?_)Y?
M[2W_ &6+QS_Z?;RODFOK;]O/_D\O]I;_ ++%XY_]/MY7R37_ $)\ ?\ )!\$
M_P#9(<,_^J7 GR=;^+5_Z^3_ /2F%%%%?6F84444 %%%% ']Q_\ P3L_Y,F_
M9S_[$"'_ -.VJ5]HU\7?\$[/^3)OV<_^Q A_].VJ5]HU_P ^_B=_R<GQ"_[+
MCBS_ -7V8'U=#^!1_P"O5/\ ](B%%%%?#FH4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?BY_P5[@^)FFR?LR^.?A#\:/"O['OC'P
MEXS\3)=_MO?%7XY^'OAU\$O@SX2U=O"2^(?AU\0/@UXGGGT7]J#4OC7'86^G
M>#/AO?:=I*>'M6\*S^,X/B/X#NM,A&O^B_\ !)/P=XR\%?"3XQ:3\7+74O%?
MQZ@^-WB'3OCA^T:WQXL?V@/"G[3OC[0--TSP_?\ Q'\#ZU9?V3_PK#0M$&F'
MP)-^S]+X"^':_!?4O#=YX3M] U2")/%GB'RC_@LC^Q/\?OVIO"?A_P 4_L__
M  S^%'QV\3:%\!?VJ_@*OPJ^+GBBS\'1^&=3_:7\+>"M!T3]H+X6Z_K.A:]X
M:L_BE\*9O!MSI4-OK*Z#<:EX*\<^+K/0O%V@ZB3!J_TE_P $\/@#\9OA?+^T
MW\9/CG\/OAS\#_&O[5'QAT'XH3? 'X5>)X_&OAKX<Q>&?A;X)^&<VM>)/&%E
MH/AC1/$_Q7^)EYX2N?&?Q&UCP]HJZ3)<W>D6?]K>(-1LM0UJ\ /QT_X*[?$[
M]DWXX_M=Z;\%9/V\?V+OA5K[?LZ?$7]FG]HZV^.?Q/?PSXP_9_\ A/X_^,GP
MHO\ XW7WP;N[73-5\/K\=OBO\,M(USX1:W\/_%&M_#W6+WP/K=AXH@U^Z\-:
M5KFEWWZ5?\$;M1^$_B#X:?M=>+/@GJOP3F^'/B?]M[XF7?AWPS^S+%<W'[.G
M@;3=)^&/P:\,Z1H/PJ\2KX;\)Z!XT_M70M#TGQK\1_$?@S0K3PDGQ<\5^/?#
M^G2ZC=:#?ZOJ/SA^W?X:^)OAK]HGX9_#KX+^-OVR_C#^U%XH\ _'+XFZN_[/
M?P6_X)NMKFB?L^:G\6O#<NA:'X\^(_[5G@?P[H5GX6\%>(-0T7P+\.=!\/:Q
M>^+_ !/::-<ZWXS&M:AIG]N-^DG_  3NT_X]:9\!+^R_:)LOVAM/\;P_$/Q%
M_9UG^TM;?LFV?CV'PN^F>'WTX:;;?L9NWPCB\)M?MJKZ:MV$\8G46UA]97["
MVCLP!]WT444 %%%% &9K7_(&U;_L&7__ *2RUY5^S?\ \F[_  %_[(O\+?\
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MXRMA<LP]2,*BH5L9#$U8>PH5I1F3:5E\3=H^KZ^D5=ONE;=H]:^$^E^.=*\
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MB+\/_!_B?P%\-])\06L+ZMIM_P"//$GAVUGT#R_$0E&A2Q:B_P">'[0O[/\
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M0<E%MJS^*.DGW=D[^DDT_*]MT%%%?G3_ ,%-X_$4WP(\#Q6NJV>A_#9_CO\
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MA7XXL-6U'X*^'-!\.>%M3T_Q?XN5_$VDO+'X<TVZN[73)K.WDEC:-UE220N
M5O\ @E;K/QA\.?&']H[X&_M.#]K7PO\ M >$?A_\%/B5_P (#^T)^UGX&_:Y
M\"2?"?XDZI\3=+\+>+OAKXV\$_"_X71Z)XD'BCP)XQ\)_$GP_J.D7"6]YH6A
M76BZEK&D7EOJ4GRQJ/Q?_8C^&'_!0G_@HEXP_;Q^ _C_ .)WQ3N_BS\*_!'P
M'\5:Y^Q-\<_VF/#^A?LU:!^S1\&]0M?#_P -/$GA?X/?$7P=X5T6]^+VO_%G
M5/%>GZ%?Z;J6M^)+FXN_$,-W]ETUH/U'_9+_ &)OBG\#?CQ\7/VC?CG^U[XK
M_:P^)OQ.^%GPR^#$>I>(/A/\-OA1:>$_!GPM\5_$CQEI-A9Z;\-HK:PU&ZNM
M:^*'B":ZNM0MA>)']GA\YXDC2/Y4LO@RW_!0_P#:\_;>T3X^?M"?M&>#/ /[
M)OQ;\#? WX6?LS? 3X^?$;]G+38=#U?X%_##XM7/QX^)>K?!_7_!OQ!\>ZU\
M1O$7Q UG2?!(U/Q*O@KP_P"'? QMM.T:\UR;6K] "K_P28USX/ZM^TE_P46D
M_92^'GC?X6?LAZWJW[,'CSX=^"=<^"'Q+_9\\#Z?\8O$_@GXBZ/\>[WX<_#3
MXD>#/ DNAVVKOX0^'6H>*H_#/A^U\/W?B.:XU=!)J&JWL\_[F5^4_P"P#?\
MC7X9?M%?ML?L87GQL^(?[1'PI_9Q'[//C#X7>/OB[XG;X@?%7P$WQU\,>.M5
M\4? +QU\2KA(]6\>W'@-O!6A>./#&K^*FOO&UIX.^*FAZ3XEU?5UL=+U*[_5
MB@ HHHH **** / _V:/^25'_ +*=\>O_ %?'Q)KWRO _V:/^25'_ +*=\>O_
M %?'Q)KWR@ HHHH _A5_;S_Y/+_:6_[+%XY_]/MY7R37UM^WG_R>7^TM_P!E
MB\<_^GV\KY)K_H3X _Y(/@G_ +)#AG_U2X$^3K?Q:O\ U\G_ .E,****^M,P
MHHHH **** /[C_\ @G9_R9-^SG_V($/_ *=M4K[1KXN_X)V?\F3?LY_]B!#_
M .G;5*^T:_Y]_$[_ ).3XA?]EQQ9_P"K[,#ZNA_ H_\ 7JG_ .D1"BBBOAS4
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y//VL_
MC'K,GQ_^.FK?"R;_ (*[>+/"^I?M86?['O@?Q5\)?VVOA'\(_@-K7[:?BK^P
M?L'P/T#P9K>EZK\0OAK\(=%O];.AZK\8=1\,ZUX4T/6]+UC2X+74G6RFO?UB
M_P""3WB/Q?+X*_:,^%_Q;G_:)L?C[\#_ (\1> OC)X0_:#_:+T[]J1O#FJ:K
M\+OA[\0?!U_\*_BYIG@GX>)K'PT\7> O&?AWQ%96FH>$M#UK3/$-UX@L-5TV
MVGM@9?#/BA_P1R^*WC'QSXWUSP%_P45^+OPE\ ^)OVQ;G]N7PU\+M)^!?P)\
M5:9X(^/3ZY!XDL=;L/$_BK0KWQ/K6G:=JULERFB:U>W.C7"AHKC3G@S'7W7^
MQ3^Q_P"*/V7;K]H'Q=\1/VC?%G[3_P 3OVD/B9X=^)/COXC^+/!'@/X?7'VS
MPE\,/!?PDT+2+'PY\.+'3?#4%I8>&/ FCQM-!8P7%Q<B:6Y\V9WE< _%/]G'
MXZ?L#?"?7?VN)OVS_P!EKXM_$#]I_P"(W[9W[7%_\2O&_B?_ ()U_M$?M W/
MB;X<V/QT\;^&/@5HND_$C3_@5XX\/ZC\-]'^!NB^ M.\'^&O#FO3>&=,TU9'
MAL8;^^U*2X_0[_@C _AV/X-?M3:9\+_!?C[X=_LXZ9^W'\9Y/V6_ _C[X;^/
MOA&WA?X*>)/!_P *O&AT?P;\.OB3H/ACQ-X3^']M\4/$WQ,_X1?0VT+3=*TJ
MW>;3=%M+?3+2V@C\4_9[_9ET/_@I"WQ]_:%_:<_:+_:I_P"$NT3]J/\ :5^"
M7@_X'_!?]J+XQ_LY^!OV7O#/P&^,'BSX6^#="B\)_!/Q?X%FUWXF>(?#?AK1
M_BAXH\:?$27Q'=ZI+XUT]-$L].\+V^FVT_V'_P $QO'GC[7/ O[2OPC\:_%?
MQ#\?M)_96_:X^)G[.?PU^._B^XT_4O&GQ*^'WA?PI\._%]A#XZ\0:39Z=I?B
MWQW\,=<\<^(/@SXN\76>GV3^(M9^'5SJ6K0)X@FU@4 ?I?1110 4444 9FM?
M\@;5O^P9?_\ I++7E7[-_P#R;O\  7_LB_PM_P#4'T*O5=:_Y VK?]@R_P#_
M $EEKRK]F_\ Y-W^ O\ V1?X6_\ J#Z%0![11110 5_GF>/O^1X\7_\ 8RZW
M_P"G&XK_ $,Z_P \SQ]_R/'B_P#[&76__3C<5_HM^S]_WWQ4_P"P7@W_ -/<
M3'D9MM0]:GY0.2HHHK_2H\8**** "BBB@"2'_6Q?]=$_]"%?Z"?P:_Y(_P#"
MG_LFW@;_ -1?2Z_S[(?];%_UT3_T(5_H)_!K_DC_ ,*?^R;>!O\ U%]+K_//
M]H#_ ,B7PP_[&G%?_J)D)ZV5?'6_PP_.1Z31117^99[04444 %%%% !1110
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MXRU7PSJMUJ6JQV?A;2;!+&R@ /VLHHHH **** "BBB@ HHHH **** "BBB@
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M):Z1%J]O>:8;NSN.%_8T^(7QF\+?M3?MB?L7?%_XO^)/V@;/X&>%?V</C/\
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M&?%?C33M&URTBM9KC3[B"_>6**\A6XMG9H+26+$L+K(N)"0#\V#Q7YF>'/\
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M;]G/_L0(?_3MJE?:-?%W_!.S_DR;]G/_ +$"'_T[:I7VC7_/OXG?\G)\0O\
MLN.+/_5]F!]70_@4?^O5/_TB(4445\.:A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!^&_P#P63?]IKPXWP?\>? SQ(-#TUOAC^TU
M\'M%U6^_:*\%_L^^#_A5^T)\=?#7@GP)\)OVCOB4GC?QUX'L/BAX-^"_@2?X
MU:C:^$--'C#7]+\8:QX:\1Z)X)U34[*TU70>\_X(_P#@#1OAQX<_:H\-?"[Q
M1-JG[-VD?'C2?#?P%T/5/CYIG[0FOC3_  A\*? OACXA?%*^\16'C[XE7'@[
M3/CU\0]+USXIZ!X UCQ+!K-A9:W)XGU+PSX6NO%DNCV_CG_!95_!7PW^+G[%
M_P"TA\1_#W[!?Q!\&?#W3/VB?AW??#C_ (*#?'CPC\&/AMJ6H?$ZR^%.I:?X
MH^&8\9?#OXEZ9J7Q1\.IX N[2355\.7+Z9X+UOQ%I;/:?V^E_:_4'_!*/XX_
M"GXY_"7XH:U\)?A=^PY\+-(\/_$X:%JVF?L'_%WPG\9OAMJ>K_\ "*:!J#7_
M (M\2^#/A)\(](LO&T5I=VUG/H[Z9K-Y;Z-!I-Q/J<:W45C;@'PO^UA^RK;W
M'QU^('Q.^-O_  35_:/^*5_XXU9TU/X[_P#!,#]K+Q=\(9_C%X8L7GL/"EE^
MT;\$+3]H/]G#7[OQQI?A>/3] U37;6/XIVEQ:6<<=MXZM-.-KH6F?H+^Q!-\
M9](TSP'\,_AY^P;H_P"P;^QO\.=#U.RT3P?\3_&W@O4_C9XBGO(KZXL%T'X;
M_!_7_B%X6\*6]QXANIO$?C/QA\2/BEJ/COQ%J$]X;KPC<ZCK5WXHM/TRHH *
M_.#]O;XI?%FQ\??L3_LO_!SXBZM\&M>_:_\ C_XI\%>,/B_X:TCPOK?C3P/\
M*_A1\#?B;\;_ !K#X M/&^A^)_"%IXV\7R^!M#\':9KGB+PSXCL?#^FZUK.K
MPZ'?:C:V+0?H_7R#^US^RYJO[1EG\&?%/@#XE#X-?'/]G'XM6OQD^"GQ+N?"
M$/Q!T'2]?F\(>+/AUXM\,^-? TFO^$YO%?@;QW\/?'/BCPUK^F:=XL\+ZQ;R
MW6G:UI.NV5]I,*S 'E'_  3P^+?Q8\8VG[6/P0^-/CJZ^*WC3]C_ /:P\5_
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M?XYUC3/#VFB2S\.Z-?\ B"?2/#\-U?C1K&Q.HWYN<+_AF+X'?VQ_;W_"$?\
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M2Z_SS_: _P#(E\,/^QIQ7_ZB9">ME7QUO\,/SD>DT445_F6>T%%%% !1110
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M*=6I-I)7E)VBE%6BDE48QBE&*48I622227DEH%%%%< PHHHH **** "BBB@
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M_J#Z%7JNM?\ (&U;_L&7_P#Z2RUY5^S?_P F[_ 7_LB_PM_]0?0J /:****
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M?FV-Y;7<8)4M;S)*%93AE<(Q*,IX96 8'@@5<H **** "BBB@ HHHH ****
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MH **** /[C_^"=G_ "9-^SG_ -B!#_Z=M4K[1KXN_P""=G_)DW[.?_8@0_\
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MM;J2%'N+=95U!ED6"5GB$BLP<*&!(.:_"6B@#]Y?^&O?A'_T6?0/_#6^.?\
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MTF@A3(1)K9HK@JH+DLS9]:BBB@CCA@CCAAB18XHHD6..-%&%2.- %1%  55
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MBU?Q)=S)ITLJSV=I/;1%2BJ[>Y4?\3,>.W_1R,\_\%99_P#,'E^?=A]2PO\
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MAV_U"VL;D:IKMW/#IL\B36MI)#&%**K'W>@#\>_^'7GCO_HY'PC_ .(_ZO\
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MQ\6:]:VECKGBBST73;;Q%K-E8 +8V>JZW#;)J6HVMD !:6]Y<S0VP $*( *
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MEC?Z"H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?L>_\FD?LM?]FY_!'_U6?ABOHROI.,O^2OXJ_P"RDSS_ -6F*(I?PZ?^"/\
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MKN0OM.U<@X%:U%6TG:Z3MJKK9]T8\TDN52?*]U=V?RV"BBBF(**** "BBB@
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?B9\=?V_OVG[O\ ;.^-W[)?
M[-C?L5^"/$GP"\+?#/7;+PK^US\3_&G@WXC_ +3]_P#$;PA_PF:#X(Z-X8TM
MH-)\!:(63P'J'Q%ND\:>5\0+?6M,N?"MI::.MSJ&%\2_^"@_[9^I_M$_"SX
M_#CP#^RI^SEXD\1?L-?#3]K'XEZ%^VE\1/%FDZOX,\9>.?B3XP^'FM?"32M3
M^&=MJ^AZY>>$+SPOON]6BD6"_2875NJ13)''>_;0_9O_ &I/BC\2_BWX=^('
M[#7['O\ P4S_ &=OB!-I6I_ 6/XW>*_ _P (_B%^R[<S^$M'T#Q=X'U+5=6^
M$OBK5=9\%ZAXITRZ\?Z#\1/ ?B!?B;H\NOZOH,FCW<6FZ#>I\?1_\$P/VG?A
M)\2/V9_$OCW]E/\ 9A_X*DV?PO\ ^"=7PS_94\3W?[2'Q!\-:>OACXI>$/C+
M\1_B'J6M^#Y?C%\+/BMJVN:#:>&/%NC>!]&\0ZC!I?BG5-&T*TN->D-Y)<VZ
M@'V;\0?VPO\ @H%H7C7]BKX ^"K?]@OQ7\;/VG= _:S\;^(O'T'C/XQ7G[/^
ME>%?V>KSX5QZ%8^$M6TS0I_%6I>(=9A^(MQ;Z\+VP73K/4=(FBM)V4$-]0?L
M)_M<?%KX]^-_VK_@/\?O!?PP\/\ QI_9!^(_@/P/XQ\3_ OQEKGCCX->.K'X
MF_#71OB=X:O_  SJ7B?P_P"&_$FA>)=&T[5GT;QOX,UJPN+G0=1@LKJ'5+^Q
MUBU>/XFU;_@FU)^U1\3?V"]8_:)_88_9L^!W[/\ ^S5X:_;5\/\ BK]F'P+X
MQT#Q7\/]!U/XP2?!2\^%_BGP?:>"/!'PUT-KC5]3\,^/]2\165GH=@='OKI+
MVYFU*ZU5YHOO'Q#_ ,$U?V:3\+O"7P;^#*_$S]D/X?\ A'Q5K?C1-&_8U^)/
MB']FZ3Q/XC\0V=O8ZKJ7CR_^'DFGWOC>ZN(K6V<W7B.>_O/-M[=FN6$$*Q@'
MQGH/_!5#XD?$G]JZ?X8_"BR_9&U+X=Z;^T_X@_9LM?A!XQ_:-TGP=^V9\3-"
M^''C:X^&OQJ_:$^&WP[UF*S\*W'@CX<>--*\8/H_@2\U:?Q?\2?"7P^\3Z[H
M%W8ZG<Z#X=U+TBR_;M_:F\)?M<_ KX._&OX,?!7PEX-_:>^+_P 6/AG\-_A+
MX8^*=[XK_:U\ ^ _A[X>^)'B/PS^T?\ %#PCINE7/@:7X5^-K+X;K)KL'A[7
MVE^&P^('@2SU+6_$&MW.KZ/IGQW)_P $OOC_ .&_^%A?LG^#?@[\%Y/@E\2O
M^"CWA[]O>U_;=N?'=K;_ !B\#Z%;?'SPM^T1KWA>[\%2>%)_&6L?'C3=1\/Z
MO\(/!7C:P\2GPE<_#GQ%!JFN:MI-S:ZIX6U'W+Q;^RS^VY\>/VD/V<=6^,/P
M;_9P\'>(OV:_VJ+;XP7W_!0+X:>)+;2/B/\ %/\ 9X\'ZOXWO?!_[/\ H/P[
MMM!?XB:!<^/?#/BS3/ /QE\-^+O'5[\+8;+3?$7B;09_%6IZGH=CI0!]4_ 3
M]N[QQ\;_ -O/X[?LJW_[/OCCX2_#CX5? [PW\3_!/C[XHV;^&O&'Q?N-1^+W
MQ ^%>M>)?#W@:6>35-"^%XU#P)=Q^#M:\46NDZUXTB2?Q)INE)X4O-"U35_6
MOC+^U:GP]_:4^%_P T:WT9H1\(/BU^T_^T)XJUA=2N8_AI^SS\+X+7PU8WNF
M:?IF+B_\6^._B5XATJQT&%_/MXO"_@SXC7_V*]O[#3;6>GIGP!\>VG_!2'QM
M^U)*-'_X5?K_ .Q'\+_@%8,NH9U__A/?"7QV^+OQ$U83:5Y/[O1_^$>\:Z*;
M;4/M!\Z]^U6WDKY&]ODC]IWX=^(['_@H7K]^$@32OVV_^":'Q4_9%^&VM7\C
MP:58?'GX1^*O'GQ4T3P;?W_EO'IDOC[P!\5_&GB33MP)N[7X1^(Y%222R1"
M>B6/_!:7_@G3JT$4VB_&CQ3KTFI^$;7X@>#M.T'X#_'[6=9^*'@&5;EK_P <
M?!W1--^&5SJWQ>\'^&5L[H^-?$GPXL_$VC^"A;RGQ5>:0%R?0?B#_P %6?V#
M/AGI/@[Q!XB^.MMJ'ASQK\&?#_[1-IXD\%>!_B-\1?#WAOX$^+4F;PM\6OB/
MK?@/PEXBTWX7> _$<EM=VNB>(OB'<^&M/U.]L-1M+266XTV_CMO%?V>OV(_B
M[\,/B?\ \$YO%FOVOA"+1_V6O^"6/C']D#XA#3M52>XM?BSKC?LD"SC\-PBS
MC^W>&FC^"_C))M71[8(HTQ3;,+W]U^$6M0?$+_@EG\#/VB?V==7\8?LI:U\6
M_BY_P2O^ GP[^*W@3XR?%[Q#\-O$'@?QM\,/A+\:/@]X?N_@KI-Y\-=:M/VL
M/!?CZVU!]+TWP)\+M3'BS1/BK$/#GB&PTNR^(5AK%J ?NG^TW_P4QUSX>?$/
MX*6/P'\-^#_B/\+_ !QH'[&7BKQEXOUV37].N;70/VY_VM?AE\ O@K<:!#&+
M62TNK_P+)\:_'LMCKE@MTUSX6\-VLT5E!<W^_P"E?$?_  4L_8S\.>%_^$O/
MQ6O?$VD7GQB\3? /PM#\/OAW\3/B1KGQ(^*O@FSN[_QOX:^$GAKP)X0\0^(/
MBU%X*M]/U0>+]?\ ASIOB;PYX:N-'UFTUG5K*[TG48;;\EM'_P""7GQL^.7[
M",OPW^*/AZ/P_P"-/BQ\6O\ @EZOB+PW)XXU/PGXA\/_ +*7[&NB?LUZ9X@\
M,+XF\/2P:[X5\<7A\,?'CQC9V&DWMAK&D>(_'?V.VOM.U)#<Q<1XR\ _%;_@
MFCXS_8BE\8>,OV?;_P ,_LD^-?VIOV>/V.+?XU_$ZX^"OA?XQ_LD?&;X?> ?
M$^B>'O%WQAG\":Y\//A7^TE^STWP\TGP+I:^-8]*L?V@/A[H?B'5M$UG_A,;
MS5[%0#^A?]G/]IGX(?M9_#@?%O\ 9]\=6GQ$^'Q\2^)O!_\ PD5EINM:3$OB
M7P=JDNB^)M)>SU_3=*U&.YT?58)K"[WVBHMS#+&KLT;X^%?VD?VI/VSHOVZ=
M/_8Y_90\/_LMQ1V7[)FD_M,^)_%_[1VO?$W2EF?5OC#XE^%L7AOP_!\/='U<
M.85T2WU2:>_CB/[^5$+!5 ^:?^"0WQ<^-B?#/P-+J/PA\,Z[X4_;"_;1_P""
MF?QK\4_$SX=Z_P"()?A[X(\*?\+D\3>*?A[XT\!OJ7@C3CXZ^&GQ3U>\?2O"
MOC#5I_!=QK5E?:#XHTK2-6M-=FCT_P"A?C__ ,$ROAO^U;_P48M_VA_VD?A#
M\-_B_P# ;0_V)]$^"OAC2O%\]S=ZMI/Q:M?CMXJ\=:G?6^BV[VNS39_!VLVM
MM_:;W4@DN3+9_9U"L[ '@W@/_@J[^T'\8-+\&?L^_##X%?"+4?V[?%/[27[4
MG[.NIQR_$[Q%J/[*/AO0?V/D\'7'Q@_:,@\?6/@^'Q]XF^'F/B/\//#?AGP7
M:>$=.\5W_P 1?$MSX-U/4-'A\.ZOKT?N_AO]K?\ ;7\(_%/XA_L>_'/X:? *
M;]JG6OV;_B!^T7^R/X]^%^M^.&^!'Q\M_AMJVA>'/&?PW\4Z#XK@L_&_PR\<
M^%O$7B_P''J"0:QXQT;4/#'C2U\3Z9J4MSHFK>'DU/CS^PYXC^$?BK]D3X[?
M\$\/A?\ !/PMXG_8WTCXQ_#JP_9HNVC^$'PN^*'P+^/R>%-0^)/A#0O$OACP
MWKEGX!^(5EXT\ >#O'WA?Q)?^&=1TG7-:M=<TWQ=/;Q^(9==L.4\.^%_CJ_[
M0'B+_@IQ^WKX5^'_ .SAX#_94_9>^+O@'X0_!/PC\01\7/$6B:%XWU3PEX_^
M./Q:^)OCC3=!\/>&O[>U73?A1X-\*> _ GA"/Q%!:Z?%K-_J.OS:MK%II=D
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M:.U\;_#B.R2T@?6;E/.]2_X+1_\ !/[18?%CZW\0_BCHMQX @TW6_'^EZO\
MLT_M':;K?@+X=ZU;6EYHWQJ\;:)>_"V#5?"GP&U>TOK>XTWXU:[:6/PVO4,P
MM_$;O:7:0?'/[4/[,7Q$^*7Q6_X*^_LF>'!HEIXP_P""@/PB_9K_ &@?@)J_
MBRYN=/\ #&OP_"KP[X'^ 7QH\*7>K165\8[GP!<?#_X>:_J%C';7+II_Q<T&
M7RO*N)Y$^FOVG?V%OC)\7O%?_!5W6_"MQX+BM_VTO^"=7PV_97^$3:IJ]U:W
M%M\1O">A?M::=J<GBT1:7<?V1X9:Y^-GA!K;4+5]1FE2/6':QC-I$+D ]O\
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M@_X'?&SQGXEO/@_X,U2+2/$/QPUCPCX7\ :KXH\+_!"WN;BUGL?BUXFTC2?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@\0:5\3=.\=Z5X4^'=V;=]<_X0#1+WX6?$&/4[G0[,:YJ^EP>("^A_27Q_\
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M[*_BV;P"E]XRT'QM\/\ 3?%VL-\)O"_BR?Q7XO\ B/??%?Q'I7PF\%>%=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img170310032_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_9.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $; T$# 2(  A$! Q$!_\0
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M+Q/\'M2U'X9^(+6\\0>(K3QPL[>"-, /U<HHHH **** "BBB@ HHHH ****
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M,-!\:_!KQ?X1\3?'_P 8^ /C!XR\#V'@'1K'XT? &_@U+PU\2M/\$32_%E?
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M/ G[$_[=GPBN?V=OB1X!LOV3]5^*GAO_ ()Q>$/^">_Q4\->*?C#\7;3P+X
MN?AYXG35/"_Q\^'/BS3/V=+S7/C6E]:2W-YK?P4\4^"O@"(KN&WTBR^,TD$\
MNMP?N710!_-[\?\ _@EO^W;-\*_@Q^RI\"_B)\,?B'^RW^SA\+/V&_#?P.T?
MXF?M/_%C]FB;2/'G[)?B[P;XE\;^*/BU\.?@K^R?\6E_:!F^,MIX TK2=-MO
MB%\8Q\*?A5<ZS'XN\-? *^\>>!M#\5:QJZE^P=_P4KO/#7[0T$O@7]AJ^\3?
M%G_@K)^RK_P4=T-H_P!JWX^:)H3>'/@!-^S;J/B/X>:L&_8<\0ZAX?UOQ-J'
M[*'A*'1+VS/BZQTRS^+/B*2_N+R?X4Z9'\6?Z+:* /@K]CS]G?XS?L]_%']M
M(^+KGX8WOPB^.7[4'C+]H_X7ZEX<U[Q5JWQ'N[KXH>&_!%AXET+Q]H.I^$/#
M/ACP/!X,U+P;<6VACP]XD^)DGCBQU^'4[^]\!W'AY]'\1\E<? K]J%_^"IVF
M?M31>$_@(?V:+3]E35?V:;C59/C;\0T^.8FU+Q?IGQ>7QE#\)E_9RD\ 21Q>
M.-(@\ '07^/,+/X4O)?B,-875[1/AG=_I%10!^0?@3]@KXU>'_%/P@^!>LZE
M\)W_ &*/V>/VJ_B+^V3\/?%5EXL\:W_[0GC/Q9XF^(7Q%^+?PY^!/BGX;7'P
M_P!*^'7@WP'\(?B3\7M9U6S^*NF?%GQOKWC#PM\+/AYX3G^%GAC5?$?B/QMH
MWN_[:/[/_P >/B#\6OV+/VA_V==-^$?B_P >_LF?%?XJ^*=0^&?QJ^(_C+X/
M>$/'7A#XN_L^?$KX-ZF++XG>!OA!\>M9\.>)/#.L^*O#GB&PLY_A;K>F:_IE
MIK>F7&I:#=/8WX_06B@#^1#XS?#3XY?L/^&/V+_A1\9OVR?V-?V?_C]X6U?_
M (*3_%#PO\?'^/"_L#>&X/AS^T-\=_ 7B[4?A!X.^/'[4G[+O[?/PH^)^K:Y
M>^.[SQK\1/AA%\$/"OCS0;GPW\'-9\+^-=%M_A#J/C/X^_M5^PKX.U:R_9S^
M'/CWX1_#3X'Z9X=^%_[*>E? +]D#X<^%?C]XY^(?P?O='\":OXGT\>(=(_:7
MO_@EH_B7Q-\(/C_9^"?@+J5E\9X/@;XGUS7O#7A:#XF:3H7C:SUO3%U_]1:*
M /YT_P!EC]@/_@HO^SC_ ,.O?M?@7]BKQ9_P[V_8N_:>_9SU[[/^UE\<]'_X
M6;XW^,W_  JK_A$M4TCS/V%=1_X1OPK9_P#"@O!/_"1WU[_:VKV'_"R/%/\
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M>ZG/X6\)Z,U]X<\*#X:^'I/$FBZ%JUE;Z=I*^*O#7C#][J** "BBB@ HHHH
M**** "BBB@ HHHH **** /C'_@H=\(?C/^T/^Q+^T]^SM\!=*^&&H_$/]H;X
M'?%7X#VE[\7?B#XK^&_@SPMIGQ?^'_B3X?ZIXTN-8\&?"GXQ:YJU_P"$X/$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP5X@UK7[.QL-1U.#3O"'B*P\4);Z;::K:WVE33W>H:5902QZE97=I):M/'+
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M+&A"@<5ZE2&%%%% !5=KNT2XCM'N;=+J52T5LTT:W$JJ"6:.$L)'50"254@
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M&D"R.LW+^%H_B.?$?_"1#0C!#M4&W)E6R:Z$IM/MH\X(3QY>TU]Q"[^,\?\
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MXBM;W3K(V4#:#?[KN1M1N+=943))BA+S, 0J$D4 =AX'_P"1+\(?]BOX?_\
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MB(1\.NX_I /&_C:[^2P^%7B&V<C*RZWJ_AJSM2#]TL;#5M3N5]6!M]R\Y&0
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M&/MJB@#X/E_:6^/7BOX9?#3QY\,?V9-=\7Z)\0OAKIGB?Q#J5SXYTWX?^)/
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MO"]I"EG_ ,)O+-'<FZ"WI$0\(^7YGBK /V%)49/.W&JTG[2&J1Z;=ZC_ ,*
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M(DU3P3:S:6MWJ7P_^,T(VW&G>(K#3I]2GT&XM[>Q(DB6O@CQ)^W-^TYX'B^
M=G\/;CXQ_L^MX(T/]G&SM_V<]5N)KGPE?>$O%>N:KIWBNYTS0;SP]K'C?XE>
M';S25L]5_M[7]3\-?\(;87FFV31W)1]O]0_A/XY7G_".^%=+E^"7Q9NHH8O!
M&B)?'PW:RV#KJ7P^M/%)UV*1[PYTG39L>'KR["!XM>(M50J?,K2M_P!H?4+F
M&PO&^ 7QHAEO;/PA,4G\*VJW-F/%>LW.ES6MUF])BE\-+;C5/$,88K:6$\$Z
M>:S;0 ?S$?LR:W^T[+XU^$_P/^'WCGXC_!#PUX_\<> _#/B[Q?X1\(06?BFV
M\*:]\5?VD-3\26]IK^K:#=?9+B06^FS65Y??:8-*,L$T< CN5$FSXW_;6_X*
M%^&[7PCX9U#XK^)O#%EX(L_C'HOP^^(/B+2[JUU?XZ_$#P+^T!XK\#:%HWBS
M1M,\+:@_C?45\$:5HS-X;TY- _X2*2_DUJTO$CC\L_TO7G[1NJ6EC=7J_ /X
MV7+6VB>,M96TMO"]L]U/)X2\26GA^#28$-\ VI^*(KIM<\.0[@MYHUM<7#O$
MZ",Z-S\>;Z/5WTL_ _XNW"VWB3Q%H2:FGAJV?3RF@>!QXRCUV&8WF[^R-;N&
M/A+2+H*'N/$X-BR(G[V@#V[PI?:IJ?A?PYJ.N6@L=9O]#TJ\U:R59$6UU*YL
M8)KVW6.4"5!%<O(@20"1 H5P&!K?KYLL?VA=3O)-.C;X%_&>U&H#X<EGN?#5
MNB67_"?V]W/<B\87Q$1\$&U$7C'&?[.EN(%C\_>2*J_M':HU@U]_PH3XVJRZ
M+%K'V-O#%L+LO)XP3PH=+$?V[!U*.%SXED@W8'AY6O Q?$= 'T[17S5>?M#Z
MI:+J;+\"OC1<_P!G-\3E46_AJW<W_P#PKFVAN+4V0^W#S!X],OD>"=VW^U)H
MY%D\C;DVXOC[J4M]!9GX)?&&-9O$/AG03=R>'+=;6&/Q%X1;Q5+K4T@O25TC
M09@/#>M7 !:U\0,+14=#YM 'T517S'!^T;JLUA87Q^ GQMB:]T;POJ[6<OAB
MV%W:/XDUZ?1)=+NHQ?D)J6@1PC5]<A#%;72I8[A7D+;*=>?M&:I:PWLR_ ;X
MUW)L].\8:@(;?PS;O+=-X4UF#28;&V4WP\R\\2I,=3\/1<"\TZ*69VC*A2 ?
M35%?.[_'O4DU>32A\%/B^Z1^(=7T$:DOAR Z>\6E^"(O&2:TDOVW<=(U*>0^
M%-/N"H:7Q-')8LB(/..?8?M$ZI>M8*WP(^--H+V/X72,UUX:MD%I_P +)>_6
M[2Z(OCL?P!]A5O'"C/\ 9:WEH8O/\PX /IBN1\>75K;^#_$ZW%S;P&3P_K C
M$TT<1<_8)QA1(R[N2!QGK7B!_:.U46$M\?@)\;MT>CZIJPL_^$8MOM<CZ;XS
MC\(IID<?V_#:CJ$$G_"46,)8"7PXCWA97'E&IK_QI@O5OQJO[.OQ4UY=,?XA
MPPK/X,T[4!=IX)TFVU*)K%;FY</'XU:X_L[PK]T:E?030RB)5W'2E*,*M.<^
M;EA.,FHVN^5IV5VEK8VP\X4Z]*I4Y^2G.,VH).3Y&I))2:6K5GKHM?(^E='N
M;:YTVR-O<07 2SM5<P2QRA6^SQG#&-F .#G!YQS6G7S)I7QH73;RWTS2_@!\
M4])@OO$?A#0Y;BT\)6%G90IXH\(W'B:77+HV]T@&D^&I+9?#6OW6UFM-=E@L
MT21&\P1Q?M(:K+IUGJ!^ 7QOC:[\/^%M=:R?PQ;"\M9/$OBI_#,NC7,?V_$>
MK>'XD_X2'7+?)2UT)ENEDD8^74RY7)N-^5NZYDD_G9M?B14<'.3AS<C;:YTE
M+775)M;WV>J[;'T_17S1>?M$ZI:"^*_ CXTW/V*/QM(HM_#-NYN_^$.O8K.!
M+7_3AYC^*Q*;KPR"1]MMHY'<Q%=IO1_'S4GU,::?@G\8$0Z[=Z+]O;P[;BR\
MNU\)#Q0-6\W[;G^R[F8_\(Y;S[=S^( ;0H$_>5)!]$T5\SV'[1.J7J6+M\"/
MC5:&]A^&,K1W7AFVC>S/Q&N;FWNH[H"^81R> A;B?QLH)_LR&>!HOM!<@5V_
M:1U5=-N=1_X4%\;RUOH?BK6A8CPO;?;)W\,^-!X0ATF&/[?AM4\0P'_A*="@
M)"W7AH&]9XW_ '5 'U!37=(U9Y&5$0%F=V"JJCDLS,0  .220!7SG=_M :E:
MS7T(^"'QCN19ZEXPT]9;?PY;/'=IX3T"SUR"^MB;X&2R\3279T?P[+@&\U6V
MN(&6-4#F-?CU>W]Q9:9<? KXOFWU76/".ASR7?AFT:QMH/%OAB\\17&I7^^]
M91I/AN2U&@>(Y=K_ &36KFWM525',@%:^NW6V]AJUU>]KJ]M[=;7TOV/4O#6
MH6$GBGQTL=]9NTFIZ*(U2Z@9G(\/V((15<EL8/0'H:] KY LOC-IMO;V6L6G
M[+WQ3LKN?0/#/B(1Q> M(M]1M+C7O&<G@Y]'F:*X5HM9T&WC_P"$GUB!7(MO
M#3I>*[L3$.KN_P!H?4[5[Y%^!?QHN?L1^(H5H/#5NRW?_" RVT5M]E)O@9/^
M$V%P9/"&0/[1C@G,GDE0#M6G"<DX<]E3IP?.DG>G3C3NK-Z/EO\ .W2YOB:E
M*I4C*E[2RI4:;]HHIWHT84KKEE)6ER<VNJO;6USZ4HKYS3X_:F]^+$_!'XPH
MAU:'2_MK>'+<6@27PL_B4ZB7^VY%A%*G_"/R3;<KKC+:[2I\RJMG^T1J=W#9
MS-\"OC1;&[B^'LIBN/#-NDEL?'FI2Z?<QW"B].R3P6D?V_Q<!G^S[)TDC,Y.
MT8G.?2U4KW3--U.(P:CI]E?P$$&&]M8+J(@]<QSQR)SWXKYJN?VDM5M]*O-3
M'P ^.$SVGA_QIKHTZ'PO;M?W,OA#Q6GAB#1K:+[<%?5O%$+GQ'X<MRP6\T!6
MNW>)AY=;%U\?=2MKZ[LA\$OC!.MKK_B?0UNX?#MNUK<Q^&_"UOXEBUF!S>@O
MI.OS3GP]H=Q@-=:[#+:LD:KYE--IIIM-:IIV:?=-;#C*46I1;C):IQ;33[IK
M5'HU_P#"3X9ZBFR?P1X>AZG?IMA%H\V3GG[1I/V*?/)Y\S/OTKGC\"_!EKEO
M#M[XO\(3')-QX=\5ZNDNX_Q8U:;5H@WTC"^U<I:_M!:G<SZ; WP.^,EN-0NO
M!%L\T_AN!(K$>,M&GU>>XO6^VDQV_A1X1I?B=P&^PZC+%"@E#;A07]I#56LH
M[O\ X4%\;PS^'=$U\VI\+VPN4DUCQK/X/DT5T^WX&L:5!"/%6IVV=L'AJ6.]
M#LY,0Z(XS%P7+'$U^7^1U9R@_6$FX/T<6=T,TS*FN6./Q?)UIRQ%2=)_XJ4Y
M2IR_[>BS\Z_V_P#]C?\ :4^(WBWX1ZA\+OB[XL\2^'8O%&G:9;Z1XIUV*&Z\
M&:_.9)T\61WMC;6"W\*0VTK,7@^TVC1+#%E9RS?I9X1T+]HGP;X7T#0M0\1^
M OB/?:7I5E9ZAK^NIK/A_5=1N+:!$EF>/3K6^M)II64CSY6A\PXDD4,S"N"\
M<_M!ZE!>:!"/@;\9IQI_C;QRJ26_ANV=+_\ X5S9SBT-B3?#SO\ A/?MC'P2
M#M_M,6ER9# $&>WC_: U.2_-E_PI#XQHHUC1M)^V/X<MQ:E-7\)-XIDU,2?;
M2?[.TN9?^$;U*;&8?$#+:*KJ3(/:QO$&,QF697@,11P-2A@/K/LI?4Z4*LW5
MJ1;=2I34).UDO<<.=^]5]I.TE]3FO&F:9GD/#V38W"Y16PF3QQSP\O[,PU+$
M5'B*]Y.M7H1I5&XJ*3]DZ7M7^\Q'MJJ4UU7_  GOQ%T__D-?"'5Y(8L"XO\
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M)QE)89$EC8>JNA96'T)KY,\1^/?#&NZO-;>(/V8?''B&6#Q+XB\/)JU_\/\
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MU+9^\NYV6BZ+I7AS2=.T+0["VTO1])M(;#3=.LXEAM;.TMT$<,$$2@*B(H
MZDY)))).G52RO8-0MH[NV,IAE!*&:":VDP#@[H;B.*9.>SHIJW7A59595:DJ
M\JDJTJDY5I57)U9592;J2J.=YNI*3;FY-R<FW+6YHK6TVZ6VL%%%%9@%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEVA5 &""<FOI>O'_ !3_ ,EF^$G_ &+OQ0_]%>#Z]@H **** "BBB@ HHHH
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M3;;QO%':P^7IUIXJATK4=7LEURSTX6MM?[-2NY?.B87$S3B3'UW110 4444
M%'3K17C_ .T!X>\+>+/@G\4/#?C;X@ZI\*/"6M>#-:L/$/Q*T7Q/%X+U;P1I
M<]JRW7B/3O%<\L,.@7>F)^_AU*65([=E#.2I((!_(E^V#'XS\<_MZ?&/PCXI
M^%?BJX^)2^.'\:?!7X9Z5^S/;>)OA]KWC7PIXQ\ 6OP]\4:M\0K?PI<6_B"R
M^(7@:7Q99>._$^K>(88-$TVU%L;>SN;2%YO[0[ W!L;,W4,5O=&TMS<P0MNA
M@N#"GG0Q,50M%')N2-BJY10=JYP/XFO!'PR\+^%?C%X5\-?LQ_%_]K+_ (*I
M>'(O%^D6VJ^+-/\ VF?VD/A)?^#=-76(&N]5U#XRW'C_ ,/_  /\=Z3I<(:X
MGT7PKH-[/J<,#6CM)]H(;^VBU4K;6ZE70K!"I220S2(1&HVO,23*ZXPTA)+D
M%B3F@">BBB@#Y\UJ_P#$<W[0/PVM-0T.TLM$M_#?Q..F:K%JINKB_8Q^#PRS
M6'V.(6FT8(/VF;=D\#%?0=>/^*?^2S?"3_L7?BA_Z*\'U[!0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %(3@$G. "3@9/'/ ')/L.M+10!\E_M _M5Z1\%?AQXK\8V
MO@WQKK^HZ(CVUE:?\(OK-GI;7TCM!;W&H:K<6D=K;:7'+M>:Y#ONCPL09F%>
M7_LC_MMCX]_#M]:\6^"/$VE^)=(O3INJW?AWPUK.J^&=2FY9)],N[6WN3#(L
M>T75E,Y>"0\2,C#'WGJVDZ9KVF7VC:S86NIZ5J=M+9W^GWL,=Q:W=K.ACEAG
MAE5DDC="00P/J.0*Q?!7@?PE\.O#EAX2\$Z#IWAOP[IB,EEI>F6Z6]M%O8O)
M(54;I)I7)>6:0M)(Y+.Q-?H&'SS@2GP=C,IK\'8VMQ36S?"XK#<0+/)1C0RZ
MG0E"OA/8K">S7/5;?L_8353VJJRKPEAJ5.>#A7]K&:K15-0:=/V>\KIWOS=E
MO?3:VMUT=G=1WMK;W<2S)'<PQS(EQ#);SJLBA@LL$JI+%( </'(JNIR& (K\
M/O%/B3]N+XR_M(?\% ;'X-_M5V_PFT+]E6_^'UK\./AWJ?PP\+^*_"?B&ZU/
MX0Z=\0;^#Q7J=U+IVOI9ZKJDTEA-+9ZG%)9VTOG19,>T_N37Y:_%/_@F5-\0
M/B]\?/B7X8_:]_:,^$/AW]IIO#?_  N'X8_#O_A7%GX?\0IX<\)VW@H1V7B/
M4_!6H>.-"_M/P_;+:7TFD>([20%Y)+9H7((^ =FVXII-NR;NTKZ)NRNTM+V5
M][(W/D6S_P""[/A/PM\*_@+X^^)?P4UNVM_'O@KX5ZS\0]<L?&7@?0[/3];^
M(FN0>%9(?AOX9\1Z[9^)_B%;:1K$HN]532K)38V4C10RWLT#;ON?P1_P4B^'
M'CKQKX"^%^E>"?%D?Q/\:?M!?$+X#WO@:=]/&K^%A\-=%C\3^(OB!K4:S,8_
M"+>&KJQU;3[I4#WBW7V>/]]$XKYK^(O_  0X_9Y\7WGB"P\(?$[XG_"OX?>+
M/"WPC\+>(?A_X6L/ .KV\]I\%ETT>$&TGQ;XO\*Z]XS\-VTTFEV]UK^DZ%K=
MCI6N7S2WE]:23R%Z]*_9F_8FUWP]_P % OVD/VU/'O@NU\&_VWX&\$?!SX6Z
M./$\/B)]=A\,6'V7Q1\9+K3[*TLM.\->(_&5LMMHUU!!%+=W6G1.+N7Y8U"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT/\ \M*/^%N0?]$]^*'_ (2T/_RTKURB@#R/_A;D'_1/?BA_X2T/_P M*/\
MA;D'_1/?BA_X2T/_ ,M*]<HH \C_ .%N0?\ 1/?BA_X2T/\ \M*/^%N0?]$]
M^*'_ (2T/_RTKURB@#R/_A;D'_1/?BA_X2T/_P M*RM4^.^BZ-)I,6I>!_B;
M;2:YJUOH>EJ_A6+_ $K5+J"YN(+5"-4(#R0VEPX+87$9YSBO<:XWQ=X3'BF?
MP?.;PVG_  BGC'3_ !6%$8?[6;#3]5L?LA)^X)/[3\S>.1Y6.] '*_\ "W(/
M^B>_%#_PEH?_ ):4?\+<@_Z)[\4/_"6A_P#EI7KE% 'D?_"W(/\ HGOQ0_\
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MQ-N?AUJIUOP+=_$KP=:QFR\57/A;4A'<:5+/+!L^SVT<XGCMXU'VT
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M)TQM/\(^&M4UG6M*T>UL_ _A/PG8W%R^J:_J=_JNM:A;W>JZK<S*]Q<!(DC
M!^$7Q&^)OP;M_@Q^U[^T9^TI^TMXN^%_[?OA7X__ !J\)_!#PY>?%;Q)X0O?
M".K?#[Q.R?!?X:^"?AA#JEMX>UOP[XSTB/1[2>_U#0M23Q+8ZK/<I?1NA<4;
MZ?X<^)/A?^WI^T=\4OC%XH\!?MC^ OB!H.J_"M-'^./BW3M<TGQRW@/P?JVE
M^"_#WPLM_%<F@ZII&K>*[NXTJ72H_"MS%/%=3*)%V&0?TT_$']EO]FOXL:Y<
M>*/B;\!/A!X]\3W5B=-F\3>*_AWX5USQ&UD8O)2%==U#2Y]5B\F, 6TD5VDM
MJ55[9XG16%>W_90_9AMO%-EXYB_9Y^"I\<:<;%K/QK-\,O!USXPAETV"*VL+
MC_A)[C1Y=<DNK2""&*&ZEOWN$6-,2Y4&@#O_ (2:KXEU[X5?#+7/&ELUEXQU
MGX?>#-5\66;1&!K3Q+J/AS3;S7;9H#S"T&J3741B/,90IVKT&BB@#^43]L+X
MG_M'_"S]L;QMXB^&3Z[X^^*TG[6?A#PYX.\7>&?CCI4VA>%/@?JGPW\/CQ1\
M'=7_ &>HM9DUC^W-+@?6_%UYKDOAJ:![>\M=7AUJ/[/) /K'_@F?KMI;?'OX
M+)\/?BMXI^)-G\9?V(+3XM_M.6VM>/=6\<6^D_'<>*] MM,U.\L=1O[^'P-K
MNJ_VGXTTVZ\.V4>E1)!H,,1TU&M#(_[B'X/?"8^/S\5C\,_ 1^)S6;:<WQ#_
M .$2T+_A-6L'@:U:S;Q-]A_MEK=K5FMFB-X4-NS0D>62I;X$^#OPE^%UYXCU
M'X:_#+P%X O_ !A?_P!J>*[WP;X2T+PU=^)-1WRR?;M<N-'L;.75+KS)YY/.
MO'F?S)II,[Y7+ 'X4WG[8_\ P4'\8?&ZS\*^"?B-\#?#'@?XA?M4_M/?LZ>%
M+?5OAK=:QK7@O1O@9'KVK:1XQN;H:O#'XCU?5(_#\VAW^C3I9V4<-VFJQW/V
MF(V]>):S_P %;OVK/$'P[TOXI:-XJ^!_PJ7PCX2_9*O]1^'/B_PY+JFN_'Z\
M^/?BSPQH'C+6_A]=RZG:S:3I?A@ZU?:?8PV%OJ:#4],O%U"6$1QA_P"E6'X:
M_#NVN[6^M_ G@^"]LM:UCQ)9WD/AO1XKFU\0^(5F37]=MYTLUEAUC6UN+A=7
MU*-EO-16>47DTPD?/PC\;_\ @E]^S_\ '7XG>"O'VO7WB+P]X?\ !I\$B#X7
M>%M*\ V'@F:+X>^(K/Q5X9L]->X\&W?B3PIIHUS3[&[UC3/"FNZ18ZN+6-)X
M$,EP\X!X-_P4)UW3?$W[2_[&7PB^/?CG7_AO^R!XZ\+_ !A\6_$C4]'\5:O\
M/]$\9_$GP?H.CZEX,\$^+O'.B7NF7^BZ2EG/JNJVFFPZMI[:_<++:"5S %'Y
M0Z/X\^"_Q?\ C;X*^!VE?'S5_B'^P#H/[:<OA_X<^+I_CCXJTC2;FPU'X*7>
MO>,?AVWQ)L?%.B:_K'AKP/XPAM[?28M6URY>&2=X3/<'YJ_K&\>?#;X>?%/P
M[-X0^)?@;PC\0/"EQ)%+/X;\9^'=)\3:'++!GR)7TO6+2\LC+#D^5)Y.^/)V
M,M>-+^Q=^R(NDWOAX_LR_ F7PYJ&HV6L7/AFX^%O@RY\,_VOI]F;"UU:#P[<
M:/+HMIJ:6;&W?4+2Q@NYX\">:4@$ 'QI_P $Q]6AM/&/[:'PN^'OCKQ!\2/V
M;OA5\9/#.D? OQ/KOB;4/'$=G_;'A-]2^(/@_0_&NJ7-]>^(M$\+:\EE#9S2
MZCJ!M6O98/M<G./UEKE?!G@7P5\.?#]GX4^'WA'PSX'\+Z>7-AX<\(Z%IGAS
M0[,R$&0VNE:1;6EC 9" 7,4"ER,MDUU5 '\Z?[2WB71M?_;=\1Z)^S'\9O$6
MK_M%_#+Q,_Q!^-'BC7OBHVG> _AGX-L_ LD>B_LT>$/AU)KD&E^+O%_CZ]BA
MU5K*UT34-6T87,VI7E[ 7M+9_AI_B=KW@GX3_#_5_@]\<?'_ (@B^/O[*OP(
M\9_MI:__ ,+(UOQ)?^"/&'C7]HGX/^$?B%XHG^TZA>GX8:U_PA7BOXHV>HV&
MF)HJZ/8Z(;@6=NVFF>OZF9_V6?V9[KQX?BE<_L]_!2X^)AU:+7F^(4WPN\%2
M^-6UN#9Y.L-XH?16UIM3A\M/*OC>FYCV+ME&T8V]#_9_^!7AFT\;V'AWX-?"
M[0K'XEO<O\1+/2/ ?AC3[7QTUYYQNSXMM[73(HO$/VDW%PTXU5+H2M/,[AFE
M<L ?F#^Q_P"-Y/A1\/?^"DFG_"/QA?\ C[X+_L]^/-4O/V=];\1>*M2^(.GP
MPQ?L]>#/'GB?0K+Q9J=_J-]XBT+2OB-?ZW"[OJEU]EEDN],29?LVR/XWT[]O
M7_@HKI&CZKXS\4_$'X#ZEHGA']GS]GK]J'7-$TWX9W=I>:MH_P 9_BF/AQ?_
M  LL[]]9<6D6DP6UWJ]IXQ*/?3W,MO9O8")7D']$_A+X6_#3P%X._P"%>>"/
MA_X,\(> O(O+4^#/#?AG1]%\+M;ZB)%U"%]"T^SM]-DCOA+(+Q7MF%R)'$V_
M<<LD^%'POEM[BSE^'/@:2TN]#TKPS=6S^%-":"Y\.:%?'4]$T"XB:Q,<VC:1
MJ3-J&F:9(K6=A>LUU:PQ3DN0#\/?@S_P43_:/^(7[3OP#T76O&WP=L/ ?QS^
M.WQP^%6J?L]P^'B/BS\+M%^%6F_:]%UC5M?_ +2-Y=7NOY2?4%O=)M+&*.2/
M^RYKE2Q2+]HG5?@'XU_;:_:MT_\ X* ?&O7?@_\ "/X)?"SX2ZC^S_IEQ\4O
M$_PH\'QZ7XPTR^_X3/XI6&I>'-7T7_A)O%FE>*UL]-2UNI-4CT<+$)-.=)#G
M[U\#?\$V/@QX)_:B?]J?_A)/&?B#Q59:UXM\1>%_#>L6_@F+1?#6L^-;6&QU
M>X35M(\(:9XQUV"RLH$M/#UIXB\2:I#HUNSI%YI*L/KSXD_ KX*?&1]*?XM_
M"/X:?$]]#=I-&?Q_X(\-^+VTIG8._P!@;7M-OS:K(P#2)"421@"ZL0* /Y=?
MV8=6^&?[5GC[P3>_MK?&C78_"^@_L8>(=4^'/C34/CIXG^&$^O:9H/QQ\2>&
MO"/Q-6W\/>+?#ECK/BJ_\"Z=I=R\US9ZA/>!$NY;=VNF5OW=_P""7?C;X@?$
M']B7X1^(_B-K6M>*-5^T^/=&\/\ B[Q&DBZ]XP^'OA[X@^)]"^''BK5C+%#+
M/>:[X)T_0[][R2-7U!)4OSG[3FO:I_V,/V1[NTT.QU']F?X%ZO:^&$N(O#46
MN?"_P=K@\.V]U=M?36>A/J^D7LFCV!O':X2PT]K:SBE8O% A-?1MA86.E6-I
MIFF65KIVG:?;0V=C86-O%:65E:6\:Q6]K:VL"1PV]O!$JQQ0Q(D<:*J(H4 4
M 6Z*** "BBB@ HHHH **** "BBB@ K^1;]G+]GW]IGXR6VO?&#X<>#/&'P_O
MO"O[9'[3/B3Q?^UCK/[3OB?6QXH^&7@+XV_$6#5?ASIWP/D\5ZG:0V^K:%IP
M\%V2W/A_3+728!%J%K/$((V/]=-<_HOA+PMX;TJYT+P]X;T'0M$O+K5;Z[TC
M1](L--TRZO=<NKB^UJ[N+"SMX;6:YU>]N[J\U.>2)I;ZZN9Y[II99I&8 _D_
M\/?\%2?VA/@G\+/V:M&\$>-O#WBW1/!?@']E^V^)WAWQ)X4O-5UK6'^+7BJ;
M1]8N?$OQ.\4ZU8S)JDVE/!/H4'@^U\1W$<Z22ZXUK&\>?KWQ3_P4U_:1\'_#
MGXS?'RX\4_ [5/[*\0_'#P5X*_9'_L?4H_C'X:E^&?Q$L_ FC>,]2U:RN;BX
MU*R6RED\5^+;;6M/TG2K329K5M*O[H&0K^U^I_LP?LVZSJ.D:OJ_P!^#6J:I
MX?TZUTC0M0O_ (:>#KN[T?2[&1I;'3]-GGT>1[*SL97>2SM[<QQ6CR2-;K&7
M?=T$?P+^"L/B/Q'XPB^$?PUC\6>,-,FT7Q9XE3P1X:77?$ND7"JMQIFO:J--
M%[JUA<*B+/:WTT\,PCC$B,$3 !_,P_[=7[5WQA^,/[-GA?Q/\7?A=\$/$_AS
MXU^,?#MO\5M<FT4>#-;T#Q#\#-)\90VOC+P+HWBEO#3Z[IFJ74MII%A>ZX\4
MVF-!JN8-0E:"O9M._P""J_[4WB+P!_PL"_G^$/PN?X5_ [P3\5-=\->)M(FN
M)_VHK[Q#\0]1\'747PEDN;^UO=&T:\T_3A/I#:?;:MJ;:Y<BUFMEL-EQ7[JS
M_LG_ ++UUX7M_!%S^SK\$;CP=::G/K=KX6F^%W@J70+;6;D1K<:M!I3Z*UE%
MJ4Z11)-?)"MS*D:(\K*J@=/KOP$^!WB>X\'W?B3X/?#'7[KX>I;1^ [C6/ O
MAG4I_!D5FXDM(O"\MWIDSZ%%;2 26\>F&V2&0!XU5@#0!WGA?67\1^&?#OB&
M2RGTU]=T+2-9?3KD%;FP?5-/M[YK*X4@%9[4SF"4$ B2-@0*W:  !@# '  Z
M >E% '+>.-$UOQ+X/\2^'_#?BF[\$:]K.C7^FZ3XPT^PM=3OO#=]=P/#!K-G
M87K):75U8NXGMXKEA"944OE00?YJ/AW=7>I?L\?L:?!GX\?&WXA7GP<\5_MB
M_MD>"OC#\4/$?Q&U7POKOC _#^^^,=SX"T?Q7X\T_4=,NM(@OM=T:QO+>SL]
M0TZVGNM/M=)ME$#);G^H"O+O$?P0^#7B_P (7'P_\5?"CX<^(_ MUJMQKMSX
M.UKP7X=U+PQ-K=W?2ZG=:Q)H=WITNFMJESJ,\]_/J!MOM<UY-+<R2M-([D _
M(7P3^TG\>/A?_P $E/#/Q9\&>(K'Q#\2['XBZ1\,?AMXO^),%SX@M-:\!ZY^
MTW;?"7P%XEUUS);W>MF]^'.H:5J46I-*9M0D>&^9YC(2WSEXD_X**_M[_ JQ
M\?\ C'X@:C\)OC)I'PW^/?Q7_9SM?!'@[P!>>&M?^(&L^%_V??%GQR\-^,3>
MQZG>MHUS]KT.#PK>>&].AO8KNT#:E%<+=2^0O]%TW@7P3<^&;#P7<>$/#$_@
M_2DTB/3/"LVA:7)X=TZ/0+BVN]"2QT5[4Z=:KHUU96=SI:P6R"PN+6WFM?*D
MAC9>3\7?!+X8^,?#WB'P_?>#] T\>(Y]8U.XUC1]$T>QUZP\2ZUH%WX9NO&6
ME:F+"22R\7QZ+>W%A;^(55]1CMG-LTKVS/"P!^9'_!/G]KSXZ_&K]H;XN_"'
MXH?%SX+_ !GT'PU^SK\"?C9X?U[X1^'ET/\ X1_7?BQJ?C2+6?!>NO%J>HQ7
M;Z#%H5C:VLC&&\D599[Z""XE>"/\I_&?Q4^$6D_L[?'']IGX[?M+^+?A]_P4
M<L_V@_B=X=^%OAK4/BMXC\,ZKH/B;P-\1K+3O!/P?\,?"0:M#X<U+PAK'AZY
MTZP-SJ'AVY_MZPU.748=3W19C_?G]C_]@'X3_L<:[\0?%G@S7O$WBWQ;\1K'
M0-$UC7_$MAX+TF2V\-^%YM1N=$T6TT[P+X5\)Z4WEWFJZCJ%_J5W9W.I:CJ%
MY/<3W&&"#W#Q[^RK^S/\4M>O?%7Q'^ 'P=\;^*M0LQ8W?BCQ-\.O"FK^)9;5
M0HC3^W[S2Y=7C>#:C6\T5XDULZ(\$D;HK  _FS\6K\,==\)_\%$?V@/BA\8/
M$_P]_:X^''Q*TJ_^$D6C?'#Q=IFMZ'XS3P)X4U72?!GAOX6P>*Y-"U;2=2\5
MW4VDR::GA2ZBN8KF0"1=N\?U!?![5O$^O_"3X6Z[XVMFL_&>M?#GP1JWBZS>
M(P/:>)]2\,Z9>:_;- 0#"T&JS7<31$ QE"F.*XG_ (95_9E/BVU\?2?L^?!B
MX\>61L'MO'%W\-/!]YXR2;3+>&UT^Y;Q1=:/-KLMW:6\$,4-W+?O<JL:?O<@
M&O?* "OYO?VK?&-Y\,OVX?AO\5?@5\3==\<ZQK'Q8^)OP^^*NA:9\3-;UCQS
MHWBY_@9KB^$OA:OP3N+B'P[9?"C1[U-%\:WWBFSTJ36K/4F^TF_FLY)53^D*
MO-D^#?PDC^($WQ8C^&/@!/BA<VIL;CXB+X1T%?&T]F;?[(;:7Q.+ :S)";3_
M $4QO>%3;8@(,0"4 ?AO_P $SO$%M!\>?@9_P@'Q8\5?$F+XU?L1#XM?M26F
MM>/-6\;6^D?'2/Q;H%MI&J7NG:C?W\'@37=5;4_&VEW/AVQCTF);?088SIRF
MT,K5K_\ ;%_X*#>+_CG;^$? WQ&^!WACP-X__:S_ &F/V:O"=OJWPUNM9UOP
M9HWP1BUS5M(\:7-T-7AC\1:QJ*Z!-H=[HLZ6MBL%VNJ)<_:8C!7[I>!?@Y\)
M?A??>)-3^&WPR\ ^ =2\8WW]I^++_P &^$M"\-7GB74=\LGVW7+G1[&SEU2Z
M\R>:037KS.))II =\LC-IP_#;X>6UY;:A;^!/!\%]9:YJ_B>TO(?#>CQ75KX
MD\0+,FO:_;SI9K+#K.M)<3KJNIQLM[J"S2B[FE$C@@'\T^M?\%;OVKM?^&]A
M\4M&\5_ _P"%7_"%^"_V6-3U'X>^+_#<VJ:U^T#J/QP\9^'_  WXQUCX?74N
MIVLVD:9X9_M2]L+*'3X-24:GI]VM_)"L<>_[R_X*$Z[I_B?]H_\ 8N^$?QX\
M<:_\-_V0O'WA[XN^*OB9JNC^*=7\ :+XQ^(_A#P[I6J>"O!'BWQSHMYIFH:)
MI!MYM3U2UTZ+5=/;7;F-[03.8@H]W^.?_!+W]G[X\?$KP7XZU^^\1>'/#W@]
M?!T<?PO\*Z5X!L/!-Q!X#\16OBOP[9Z:]SX-O/$?A/3SKEC9W6L:=X3US1[+
M5Q;(L\"-)<23?>'CSX;_  ]^*7AR?PA\2O WA'X@>%+F2&6?PWXS\.Z3XET*
M66WSY$KZ5K%I>632P9/DR&'?%D[&7- '\G&E^//@O\7/C7X/^!FC?'O5_B%_
MP3_T+]M>TT#X=^+I/CAXJTG2)[+5?@IJNN^-_AN?B58^*=%\0:OX9\$>+;>S
MATJ'5==N7@EN)(?M%P>1^RO_  3*U:VLO''[:?PL^'7CK7_B/^S9\*OB]X2T
MKX&^)-;\3ZCXYAL)=:\)3:E\1/!NA^-=5N;^]\0Z)X7UR/3TM99=1U$VCZA-
M;_:Y. /LQ/V+?V1$TF^\/']F3X$R>'-1U"QU>Z\,W'PM\&7/ADZOIMH]A9ZM
M#X=N-'ET6TU2.S=K=]0M;&&\GC.)YI< CV_P7X$\$_#?P_:>$_A[X0\,^!O"
M]@7-CX<\(:%IGAS0[,RD-(;;2M(M;2Q@,C %S' I<C+$F@#JZ_*'_@JX_B%/
M!G[/JP74VL> IOC1<Q?$OX4Z5\7-,^!_B;XLZ$/AUXTETS0] \?:MK/A^TAD
MT'7H]/\ %=_HHUC3Y]6T_1YXX)9)8E@D_5ZN*\>_#;X>?%30F\+_ !,\#>$O
MB#X;:YAO3H/C/P]I7B;2#>6Q8V]W_9VL6EY:BY@+-Y,XB$L>YMC#)H _CM^'
M/QA^*7Q'^!WQ#\9_M ?%'Q]X!^,'P&^ ?A;Q3^Q?X=/Q4U2SN/$.LC]H#XE^
M'?"6HVS:9?VME\8M1U[0M#\#^$M0GNH-=MK[2;F.\6+.I+>']Y?VU?VA?VI/
M .H_LM^ ?@5XG\!^"O$WQ5^&/QM\<^.]?\=^$7\6"UF^$GP]\)>*;>RTS2EO
M=/1)M1U;6+FQOVDDQ!:RM-&IFMXXW_0G6/@+\#_$-_X(U37O@_\ #+6=2^&D
M=M#\.[_5/ WAJ^N_ T-GY?V.'PE<7.FR2^'H;7R83;1:4UK' T431*K1H1W.
MK^$O"WB"]T_4M=\-Z#K6HZ3;:K9:7?ZKI-AJ%YIUGKL$5KK5I8W-W!+-:VVK
MVT$%OJ<$#I%?0PQ172RI&J@ _G#T[_@II^VGH?A+P7:^.=7^#2^)/CW\*OV<
MOB?X?\<6?A*\L_!7[.VE_&;XC>-O 'B"_P#%D=QJ&[Q?H?AUO!T%S::CJ,ND
M1R7^OVUI=O'#%O;Z[^#'[6O[3'Q2_87_ &[/'%KXD\$?%#XU_ #QK^T=\,/A
MKXW^%6@&QT'Q@?AK82Q^'_%.D:(MUJ,=QJ81WODL[>>XM[F_M4MX/-1QN_0'
MXY_LD?";XX?#'5?AG+I=M\/H+_1=&\.VGB+P)X?\(6>L:;X?\/ZG+K&E>&EM
M]8\.ZQHM_P"$X-1N+FXD\+:GI=WHKR75Q,EI%<N+A9OV4/V5?AY^R#\*YOA7
M\/+K5]5L=4\7>)_'GB37-?CT6+4]?\6^,+Q;[7M3GM/#VDZ'H=A;S2I''::;
MIFEVEE96T:00Q8!+ '\Y]Q\1?V??A#H/[%6L_LP_M/>*?&O[7GQMT_0KGX_>
M#M4^,7B3Q7K_ ,0O WCKX<:KJ'Q9\4>,/!6L:Q>:;X1N_A_K"WE]I":/IV@W
M.@7]L+(12"):ZW]F:'X:_#/0O^"7GQ&_9\^+?B?6_P!HOXV?$WPYX:^/'@J#
MXT^+?B;'XW^&^NG6C\2=:\:>#]<\4^);7P\WA6QABU>TU**UT465S!'"H8'R
MJ_H0/[('[*H\2CQG!^SK\%['QA_;*^(7\5:9\./"FE^(Y=84RE[Z?6].TNUU
M.XDN?.F6]2:YDBOTED2]CG1V4]%\/_V;/V>/A/KESXG^%WP*^#_PY\1WD<T5
MWK_@;X;^#_"FLW,5RQ>XCGU+0]'L;R5)V8M,CS%96)+AB: /:Z_-/_@J!XV^
M!?@;X,>$-2^/'C3QI8:-=>/;?3?"/PE\ >,9_!'B'X_^.]2T;5;#PS\-WUVQ
MU/1]0L])&H7,>OZG=PZGI]KI\.E"^U*[2RMY4?\ 2RO,OB9\%O@]\:+#3]+^
M,'PK^'?Q3TS2+IK[2M/^(G@SP[XSLM-O7C,+WEA:^(M.U&"SNFB8Q-<6Z1RF
M,E"^TD4 ?RN^(9OB)X;\(_$73/CQ^T3JTWQB_9[_ &3?@_\ $O\ 9.M?!WQC
MU"31;[XE^+/BO\1OM&B:7J&D:P++XR:SH@TWP?\ #+7/MO\ ;R/:VHFEMHY-
M1\]O?_@]\0/%&J_M(_![XI:E\3O%\O[4_BS_ (*/_%3X#?%#X73>-M6>PM?V
M7]"\(?$"?1H+KX9->'2=)T"PM="\%Z]8>+$T6&>YO=14?VC,+T1G]_8?V8?V
M;K9/ \5M\ O@W;Q?#.XGNOAU%!\-?!\,?@6YNKK[=<S^$8X]'5/#TD]]_ILS
M:4MJ9+O%RV9@'KJ[7X.?"6Q^(5]\6[+X9> ;3XI:G8KIFH_$:W\):%#XWOM/
M5406=WXHCL5UJ>V"1QQ^5+>,ACCC0@HB@ 'XT_MO_MG_ +9OPM^-WQZT7X'^
M)/A'HW@'X$Z/^SA-_8?C/P==ZWJWBW5OCMXNTKP9>QW.M0:A;MH]EX?;6K?6
MK-[:VGEO9+>2PE5(G$M>2^*_^"A?[8.A^)/%_P !=5^*/P0\!>,_A7XJ_:4M
M==_:%\6^!TMO!7CT?!;POIWB;PWX&TKPC<ZW!8Z-XBU];]TU.1-6N;Q+"*&?
M2[2ZNGDAK^@75?AQ\/M=N=6O=;\#>$-8O-?&D#7+K4_#FD7]QK \/W$5YH(U
M2:ZLY9+\:+=P0W6E?:FE_L^XABGM/)EC5A\D?M7?L _"/]JW3M*L=8U76?AS
M)9ZQXAUG6+GP+H7P_F7Q5=^*],31];OO$%GXO\'>)[.?7WL5VZ?XHMH;77]/
MF/F)?2*L:( ?"_[17[1WQ8^*7_!,/]EGXO:UXHO/A_9?'WQK^S_IG[2'Q#^&
M@O-,G\%?"?QUXD%EX_UOP]/%YM]HFFRVWV>TEUI)$FTBPNWNS+$077\U_P!J
M_P"(7P/^&^N_M"? 7]BSX_ZQXI^!4G[/VAZE^T%HNC_'#Q5XKM?A-\2]*^-_
MP\\/:3J=CXWO_$EYX@\.ZQXQ\*:[KT>NV>G>(([2XMQ_::+;>4%']5/@;X-?
M#WP!\(?#'P,TKP_9:C\-?"O@_3? UGX>\06UKK5I?^']-LH[%;;6+:[MVL]1
M-W'&9+U9K403RR2-Y*JP0>;Z=^Q=^R-HZW\6D?LS_ W2;75]+N]$UK3],^&'
M@^PTO7=(OKB.[NM.U[2[328M.UNTDN8HIUAU6UNTBEC1X@A48 /SA_9:T_X;
M_"+_ (*&Q_!S]E'XBZUXU^!7B7]EO6/'?QC\)K\3O$'Q;\(?#_XF:5XT\-:9
MX U/3?$FOZYXGGTC6?%NB:CXIBOM$CUIEN8-)2\^R0FW)/[;UYG\-?@O\'_@
MU97VF_"+X6?#OX7:=J<T=QJ5C\/?!GAWP=:7\\2LL4U[;^'].T^*ZEC5F6-Y
MD=D5B%(!->F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >4_$/X=^)_&MUI]QH'Q?\??#6*SAEBGM/!]MX-G@U%Y
M'5EGO#XG\+Z_,LD0!2,6TMNA#$NK'!'G/_"A?B/_ -'6?'#_ ,%_PE_^=O7T
MY10!\Q_\*%^(_P#T=9\</_!?\)?_ )V]'_"A?B/_ -'6?'#_ ,%_PE_^=O7T
MY10!\Q_\*%^(_P#T=9\</_!?\)?_ )V]'_"A?B/_ -'6?'#_ ,%_PE_^=O7T
MY10!\Q_\*%^(_P#T=9\</_!?\)?_ )V]'_"A?B/_ -'6?'#_ ,%_PE_^=O7T
MY10!\Q_\*%^(_P#T=9\</_!?\)?_ )V]'_"A?B/_ -'6?'#_ ,%_PE_^=O7T
MU(ZQH\C9VQHSM@9.U06. .IP.!WK\C?@A_P5+U7XY>,M"N_#'[+?Q$N_@!XI
M^*.O_"/2?C-H'B;P_P"*M7T+Q)HD^K6R:I\1OAAH\,GB/P'X7O[C1KN"/5]2
MNIVM))+7[?;6ZW",0#[8_P"%"_$?_HZSXX?^"_X2_P#SMZ/^%"_$?_HZSXX?
M^"_X2_\ SMZ^,OV?/^"B7QY_:.MM+\8^"OV,;J#X1:EXO\3>'!X\U#XX^$8]
M0BT_PKK-]H^I:W_PB7]@KJ+KYEC)/%8BX$SH0/,!YKA?AS_P5L\4^)-#^#OQ
M3\??LC^,O 7[//QQ^+-M\'_!7Q;L_B+X7\57$7B+6/$^L^%/#=UK7@JUL-/U
MNTT[6-3T6X5WM9+R:Q1T>:)D!>@#]!_^%"_$?_HZSXX?^"_X2_\ SMZ/^%"_
M$?\ Z.L^.'_@O^$O_P [>O*/VP_VZ-#_ &5O$7P[^'VF> [OXG?$WXDV'B+Q
M!I/A>/Q9X=\#:;I_A3PI%&VKZWJOB?Q/*FG027-U-#I.A:9&DMWK&L31647E
M;_,'C?QN_P""H$'P2T#PCX[US]FGXO?\*WN/"O@#Q5\2O%^LR:-X83P'_P +
M"U2/2-.\,:18:G*6^(/C'3KMI)=4T+PY<B2&RC6YCFE,\$<@!]=_\*%^(_\
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M ,[>C_A0OQ'_ .CK/CA_X+_A+_\ .WKZ<HH ^8_^%"_$?_HZSXX?^"_X2_\
MSMZZSP5\)_&?A;7[?6-8^/GQ1\=6,$4T<GAWQ-9_#Z'2;EI5 269]!\%Z/J0
M> @M&(KZ-"2=ZN,"O<** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L;Q#I=YK6BZEI5AKFI>&KR^M9+>WUW1TL)
M-3TN1QA;NR34[._L&GC/*"ZL[B'/WHFK9HH ^8_^%"_$?_HZSXX?^"_X2_\
MSMA1_P *%^(__1UGQP_\%_PE_P#G;U].44 ?,?\ PH7XC_\ 1UGQP_\ !?\
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MX/\ B6)G\"Z_>>+M+6P\1PVLPM[ZZL769V^QZ=<,(-3NYEBMM.F_=WLL#@@
M&C_PH7XC_P#1UGQP_P#!?\)?_G;T?\*%^(__ $=9\</_  7_  E_^=O7TC87
M]CJMC9:IIEY:ZAINI6EM?Z?J%E/%=6=]8WD*7%I>6ES"SPW%K<V\D<UO/$[Q
M31.DD;,C FW0!\Q_\*%^(_\ T=9\</\ P7_"7_YV]'_"A?B/_P!'6?'#_P %
M_P )?_G;U].44 ?,?_"A?B/_ -'6?'#_ ,%_PE_^=O1_PH7XC_\ 1UGQP_\
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M&>*/#^KQZKXJTJVCN=!^'/B_PUX@T-]*TJ+39;VW>:V<2_U244 ?S@_L!_\
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img170310032_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_10.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "V <H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HK^6W]N__ (+'_MM?L]_MI_M'
M?L^_"'1OV6$^'GP<\1_#?P_X>NOB1\(_BWXQ\::E_P )=\ OA#\6-6N]9UOP
MQ^T?\.M#D\K7/B+J6GZ=;V/A2Q^SZ58V*7,][>&XNY4_81_X+(?MM_M!_MI_
MLX?L^_%W1OV6'^'GQD\2?$?P]XANOAQ\(_BWX.\::;_PB7P"^+WQ8TF[T;6_
M$_[2'Q%T.+S-<^'6F:?J-O?>%+[[1I5]?);365Y]GNX@-+VNKVO;7JK]K;>9
M_4G17R-^T1^T3XD^!7B"UT\>'=(UFQ\<_#W7[;X2B5[VWNM?_:"LO$&@:)X3
M^&.IW"W!M_LOCU?%^FW6D-:007MC;>%?&5[=3SVZ6XM/G6'_ (*0#7Y_!EOX
M%^!OQ6\1MJ/C-]&U.XU/PO8>#;#QKX3@^''QW\47'BKX8ZMXL\7:3H)*:W\%
MI+A]+\0:R;Z#PKKFF,T$NM7TEMI>;JTXTG6G-4Z<8UIRE-\O)'#UZE#$2J)Z
MTE14(8FI[50_V&OA\='FPE3VRT5&HVU"#FHV3E%IQYI4*%:G%2;2<JKKO#4D
MKJ6,HU\+=5H*,OU#HK\VI/\ @H1IFK>%/BIK/@3X?>*?%MSX"\':AX[EU6[M
MO!OA/PWX6T'6M,UD_#;_ (2B+7?BA'KGB2;7-;T'4K+4H_!5I/JD=O;MY>B6
MMY<:9!J7KGP-_;+\*?'#Q1XF\(:/\/OBCIEQX6TCQC>'Q9J?@ZZL_ OBG4?A
MMXFMO!'CS3/"NM_:;@3W>G^+)WL](M+T07.M6$%S?V@9+2Z2+6:=*-251.G[
M+"+&U(S34X8=82ICJDG"W,_98:C4J3Y5)346Z+JQ]XRDU%TU>_M<5B,%!Q]Y
M/$X>IA*<J<K:PE/Z[AYPC-1FJ<^>I&FD?9-%?F'I?[;WQ'\+Z)\$?B#\1O"G
MA3QKX4_::^'^F>./AMX#^#UE/9?$/P+?^(/%OPG\->'O"GBC7_''CU/"/CRU
MN9/C!H5CKGC>&U^%6G^'->TU]/.@ZK#K=K<:=N:7_P %$?#*Z[KZ>)_A]XMT
M71"-/\->$M/CAT&[\3WOQ?2^^(&BWOPDU"2U\4W>@W/B7Q-K_P /M=TWX?W6
MDWDFA:HVEW;:CJ]F;S3EEJ=.=-RC./+.%6>'J4VUS4\33J3I5,.[-QG4IU(.
M$O92J0;E2<)SC7HRJ-:W<?>A9RC47P2IJ$*GM;NSA3<)J5ZJINT:K<5[*IR_
MI!12*25!(*D@$J2"5)'()!()'0D$CT)%+4 G=7[ZZII_-/5>CU"BBB@ HHHH
M **** "BBB@ HHHH ^1?VX_&?BCX:_LX>/OB5X;^(WC'X;0^ K%/$&N:I\.[
M'X2MX[U;31-'I\.A>&_$/QUT/Q5\)?!DU]J5_8M?>*?&WA76-(TW38KIYI=%
M4MK=A\A_\$U?VK?$/QK\<?&SX4^*/&WQI\6ZK\,+;2;LK\8_$'[)?Q&N[<3Z
MWK6@7C^'_B;^R1IWA?POJVEB]TB2,V7B?PQ>ZC)<F<:=XOOIM+U[0M"^L_V\
M/&,GA?\ 9C^)>E:1\2/ GPQ\<>/-$N?!/P]UCXA^,/ /@30M6\3:LA>3PS!X
MF^)^D>(O VG:MKFA6^L6>G3:]X<\2V\$S&\7PYKC6O\ 9T_D7_!-N\\":-\+
M-7^&NF>)/"&H>/?"6J33:WX:T7XU? _XXZ_X7\(WTGG^&+75?$'P)^''PK\,
MZ'HEQJ5SXBN] \.WOA"UO(;BYUN_CO+T7LQ@6!UQF9.3]K0A@%:C*S?UR;Y.
M>A4GS*,L+0=/$8C"QIU'*A4^L1>"DYXC$5C=,#@8Q2I5ZF8+]^NF$IRI5)0K
MTH\KE#%U(UL+0Q,ITTJZ="7UJ,(X>E^D%?G_ /$__@I9^S1\*+/]H>]\1W'C
MF2#]F;Q;\)? OC^5?"T>@6FJ>+/C+XAOO"_A;3/!FK>.M5\(Z+K]G8ZQIM_;
M^(?$SZE8>$=-^Q7_ ).OWKZ;J4=I^@%?(WQ&_8]\)^/?$?Q?\::;\2OBE\//
M&?QC_P"%,/JOB/P>_P -M0?PW-\#)/$C>%9/#>B?$'X;>.?#-PFK1>*=4MO%
M%IXOT7Q79WL7V632;?1+RV2Z.-?VZBG149/FHW@VHMQ^MX9UVJDN:,;X*.+I
MQ_=R<:]2C7M4C0EAL1I1]CS/VMUI)IW?(VJ550A-0BYI.NZ$ISB[JC"K3C%3
MJPK4/H_P-XLL_'O@OPGXXTZQU#3=/\8>'-%\36.GZL=-.IV=GKFG6^I6MM?G
M1]1U?26NXH+E$G;3-5U*P:0,UI?74!29^JK\@/VM/V,?V9?A)\!/V4]1\/\
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M+>$I0<9.GI*I%WO3J5*4KIJ\J<W!M7W3:TO9KX9*,U******D HHHH ****
M/#_VE/'L'PN^ _Q3^(5U\/&^*]OX2\)7^L3?#[[/+<6WB6. QJ]MJ:V^@^*K
MN'1+4.=0UZ\LO"WB6^T_1;._OK'P]K5W;PZ;<^'_ /!/GX]^'OVC?V>M/^(G
MA3X)Z3\"M ;79M*L?"_AF&9?!VJR)X?\.:MJ6M>$;RY\"_#>XU32;35M8O\
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MZGK.H_8;&?[%I6G7VHW/E6=I<31_EK\6OA+^UCX3_:Q_;'\6>$_V-_C+\8?
M7QA^,GP[^(?@3QW\._B)^R1I6BZEHNE?LD_LT?"35[6ZTGXN?M,_"WQMINJ:
M;XU^%WBNQG@OO"<-I<6D-EJ&GWU[:WL<BGPF^$O[6/BS]K#]CCQ7XK_8W^,O
MP>\!_![XR_$/XB>._'?Q$^(G[)&JZ)INB:I^R5^TQ\)=)M;72?A)^TS\4?&V
MI:IJ7C7XH^$[&""Q\)S6EO:37NH:A>V5K922-C[2I[3D]B^2]O:<VEN]N7]3
MQ?[2S'^T?J?]BUOJGM>3^T?K4/9\G+S>U]C["]K^[R^UO?KT/VS\<?%'X?\
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M-?XW?\$^9_B1XT^+7Q'\!?%/0_AOXP\<^./V;_B7X.2[^%?_  D_A?PKXT^
M$_Q"DO+WQ5HFF>/O!=UX\L?B%%\1]9;5(;35_!FI:5J21ZL=6UBX=XQAB)5X
M13H4XU9.IAH.+:BXTYXW"0Q-:\IP4U0P#QE6-*\95:\:*4TE*G5THQHR<E6F
MX6A6E!J_+.<,/7E1HMQIU94_;8I8>$JRIU%2I.K/V<Y**.K_ &W?%'AWQO\
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MK\'_ (<?%IWC\(67[-_Q$BTN#2XOB'#H2LWBO4)+^32Y=1,5BMTEE G[%/\
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MW;W_ .\WK_5LK_*3_P";4O\ NWO_ -YO7Z7X<;\2?]B:I^<S^?\ QVW\/O\
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M .">/[$/B'Q#XI\<>-_$_C?]ECX&?$CQ?XO^)'CWQI\3/&GB3QI\3/AUX?\
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MC?L7_P#I_P#VQZ_K1K^2[_@V5_Y*7_P4 _[$;]B__P!/_P"V/7]:->MXK?\
M)Q.+?^QK/_TS1.?(/^1-EW_8-#\V>5^/OCI\$OA1XD^'?@SXI?&+X5_#;QA\
M7]<;PQ\)O"GC[XA>$O!WB3XH>)$O]#TIO#WP[T+Q%J^G:IXVUQ=4\3^&]-;2
M?#5KJ=^+_P 0Z'9FW%QJUA'<>J5_$=_P5A_;N_;3\(?\%)?BWX!\!_M'^)/
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MVC3P:SH.GRRRZ>]S;)/8SVMU/_E]?\VI?]V]_P#O-Z_OU_X(3?\ *,#X%?\
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MQ_IAU_.I_P '+/\ R:+^R_\ ]GO^&?\ UEO]K*OZ*Z_G4_X.6?\ DT7]E_\
M[/?\,_\ K+?[65?E/ ?_ "7'!G_95\._^K?!GO9K_P BO,_^Q=CO_46J?+/_
M  ;*_P#)2_\ @H!_V(W[%_\ Z?\ ]L>OZT:_C:_X-\_CI\$OV??$W[>?C/X]
M?&+X5_!'P?J>A?L3>&--\5_%WXA>$OAMX;U#Q)>ZA^VSJMGX>L==\9ZOHNEW
M>N7>EZ+K&I6VDP74E_/8:3J=Y%;O;V%U)%_83X8\3^&_&WAOP]XS\&>(=#\7
M>#_%VAZ3XG\*>*_#&K6&O>&_$_AO7K"WU70O$/A[7=*N+O2]:T/6M+N[74M)
MU;3;JYL-1L+FWO+.XFMYHY&];Q6_Y.)Q;_V-9_\ IFB<^0?\B;+O^P:'YL_S
M_O\ @K[_ ,I4OVY?^QY^!?\ ZQK^S/7]GW_!,K_E&Y_P3Y_[,@_90_\ 5#>
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M>SH6=?\ (YX9_P"PC'_^F\*?Z#M?R7?\'-7_ "4O_@G_ /\ 8C?MH?\ I_\
MV.*_I]^$7QT^"7[07AN^\9_ 7XQ?"OXW>#],URY\,:EXK^$7Q"\)?$GPWI_B
M2RL-,U6\\/7VN^#-7UK2[37+32]:T?4KG29[J._@L-6TR\EMTM[^UDE_F"_X
M.:O^2E_\$_\ _L1OVT/_ $__ +'%?*>%?_)Q.$O^QM2_]-U3OS__ )$V8_\
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M_P#)T.&/^ZU_ZSV;'?Q3_P B',/3"_\ J;AC]2O^#:;_ )-&_:A_[/>\2_\
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M3O\ E)_^W7_V4?X(?^L7?LO5_7Q_P4&_Y(-X!_[/?_X)E?\ KR3]E"OY!_\
M@J=_RD__ &Z_^RC_  0_]8N_9>H"7\.7]?:@?TP?\$)O^48'P*_[*/\ M??^
MMH_M"U_ 5_S:E_W;W_[S>O[]?^"$W_*,#X%?]E'_ &OO_6T?VA:_@*_YM2_[
MM[_]YO7Z7X<;\2?]B:I^<S\ \=M_#[_LK:'YT#^Q_P"-7_'O\"O^SW_^"=W_
M *WK^S?71?\ !RS_ ,FB_LO_ /9[_AG_ -9;_:RKG?C5_P >_P "O^SW_P#@
MG=_ZWK^S?71?\'+/_)HO[+__ &>_X9_]9;_:RKY/PV_Y+/@[_LK^'O\ U:X
M^[X8_P"22SO_ !9K_P"JO#G\Y_\ P3A_Y/ '_9MGQ@_]6A^SI7]3'_!,/_D\
M#]M3_LVS]A'_ -6A_P % Z_EG_X)P_\ )X _[-L^,'_JT/V=*_J8_P""8?\
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MG3+&*"RT[3=.LH(+.QL+."&UM+6&*WMXHXHT0?S+?\$I?^24?'O_ +.3OO\
MU0GP K^GO_@D=_R9'HG_ &<I^WS_ .M\_M,UP>+-*E#&XVI"E3C4J<5\3\\X
MPC&<_P#A5QOQR24I?-LZLDE)X'!IMM++\OLFVTO]EI[+H?I91117XT>R%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PS_P %&?#_
M (&U#]DWXF>*_&W@?X9>.O\ A6FGQ^-?#EG\8=6GT7X=Z+KL4JZ(/$WB:\A\
M7^ A)IVAZ7K6I7T^G2>,?#@U=8SI46M:7<WD-];^;?\ !*.+Q?'^R[</XO\
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M*_P7^.NH>&/"7C#XH_ SXG^#[OXNV/B*R\>^#[\VGP[^"_B'PEXKL?C#X/\
M"=[K'P=U7XS^#]6M+J;XD? ;XS77B3P%X-^)?@#PY\1KO2_T7_8N_8:\&_LI
M^';+6/$&H67Q4^/USHFH^%_$/QRUFSU^_P#%Q\$76O'7=*^&.A>(_'GBKX@?
M$&'X>>&'BL(-)T;7?'.MHCV%LMBFCZ!8>'?"_AP*MRZM:O9/\W_DSZ$_9[\3
M_%+Q9\)/#.H?&[PM:>$/BUIMSXE\)>/]/TJVOK3PWJ_B'P-XKUOP;=>./!=O
MJ4L^H0^ OB0FA1?$'P'!?W-WJ-MX0\3Z+:ZE<S:C!=.?@W_@H5^WYH_[-'B3
M2_@-JDGQ>^$&L?%+X9#QKX!_:E\%> _!/Q;\+>!_%6G_ !0\)>!+/0-6^#]_
MJMS\1OB79OXF\4^!=%\<:#\.? _B7Q$?#_Q)T:VT6?0]4U)?$_AOZP_:&^-G
MB_2O@W\>;O\ 97L_"'QL^/WPHTJ*"X^&.D>(]'U?Q'X<U>_$,\CZCX2M]3M+
MG4O%&F>'7U#Q5X7^'&L:QX*D^)-[I5MX3M?%GAHZRFO6/P#^Q7^QQ\0/''BC
MX5_M0?M"?%'QO\0[SP+XS\4_%[X2MXINO%>I6GBSQ#\2? &J>'K3XV^#]#^*
M%]>?$/\ 9N\,?$/X9?$>70OBA^Q_?V#>$_ WQ<^&GA?Q1\,;OPMX?TVXM/&8
M"MJW\E^5K^O6]UT>IZA_P3!UG]KCQCX>\8?$'X_>)_$7B3X>^-?"_P .M4\(
MWOC#Q!X/\3C7_BJLGB\?%;XB_ ^]\)>&_#&H:+^RU\2-#D^&OB7X3>#/B+IU
MEX_\(:E-XMT34=$T*UM(8[[]3=0OH-,L+W4KKSOLVGVES?7/V:VN+RX\BTA>
M>;R+2TCFNKJ;RXV\JVMH9;B=]L4,<DC*IRO%?BSPOX$\-ZWXQ\:^(=%\)^%/
M#6EW^M^(/$GB'4K32-$T71]+M)K[4=2U/4KZ6"TL[*QL[>>ZN;B>5(X8(I)'
M8*A(_&S]M;]N3Q9XP^*.O?L:_LUV/Q:M?'OA#X@^#]$^,7BGX<ZA\-?#7CG7
M=#NOAWI?QGUCX7_L_>*/%'C*]G\,?'36OAGJ3_$#X??\+ ^&*^#/B[X4^&_Q
MM\(^#/%^BZ_X7N?$^C OB>R7X)=+_P"9]"^-?CE\=?C+HGP'_;)_8$\9^"?C
MY^S%IWA'XDWOQ ^"T%FVD^*OVC;2Z\6^$M#MYOA7XE\3Z9H:^#OB%\,K?PG\
M1)O#-MXEU73_  UXTUZ[D\#^(;;2;?6++QUX5_2BVE:XM[>=[>:T>:&*5[6Y
M\G[1;-(BNUO<?9YKBW\Z$L8Y?(GGA\Q6\J:1-KM\=_L@?LHV?[-^B>(]9UJ]
MTW4OBS\1+E+GXJ:UX&?Q5X+^%OC76M%O]3LM+^).F_ ?_A)]5^%OPQ^)?CKP
MZ=&U;XQ7WPWT/1K'Q7XZ&HW[2W=A'IWE_5'B/Q=X5\'P:;=>*_$>B>&[?6-<
MT3PQI,VMZG9Z9'J?B+Q)JEKHN@:'I[7DT(O-5UG5KZST[3K"W\RYN[NYBAAC
M9W H!^7]?UWM?\E@_%7XH^!/@G\.O&'Q9^)VNQ^%OAYX T6Y\2>,O$L]EJ-_
M:^'O#UCM;4M;O[?2K2^OAINEV[->ZG=16LJ6.GP7-]<^7:V\TJ?F-\6?C;^T
M3\-OVBO@'\<_ OB;XE?M'_L^?M2^)G\#_"?X!_"/P5X9;PY:^ -:_9TT'Q[X
M*\<>)O$?B/0M"U3POXLNOBKHWCGQ7K7Q!\4?$'3/!.F_!;48-$N?#/\ PDNA
M0?;_  ?XO_M=_$_]MOXWZ9^S[^RSJ/Q1^'?@?P;XS^*?A#X@^+=&TCX07^NZ
MYXK\ >--.^%4GCUO#/B3QKXGL/B;^SU\'OB!K&A:;^U9^S[XJ\/?##XK+X%^
M+GPG\<V-S=:;JLV@)^L_[+_[/'A+]FGX86G@;PGI4'AXZI=KXK\3>&/#_BGQ
M_K?PS\->,=7TS3D\3:-\&O#?CWQ)XB;X8_"BWU2TG?P=\-_#!TCPSX<L)=EE
MI%O<SW<DH.UM]^W^?;Y:^A]%5\I_&#XMZ/XN\8^+?V/OA5\;+'X6?M7:O\)=
M(^+6B&?PK/K>K^'?A1J7CP>"]<^(GAR+7-#O_!6K:EI\MAK6BZ4NH#7++0_%
M5WX=O?$GA[4-+N([#4>=_:D_;D^$/[+_ (+?Q)?0:W\5?$3_ !6T/X'V?PY^
M%-WX,U;QM+\5O$GPXU+XMZ#X(GM?%/C'P;H=CXHU_P"'^G)J_A'PSJ?B'3M?
M\>:IKG@WPAX*L-<\6>-_"ND:I^?W[)/[/OQ6_:SU[1_VB/VI?$^J>+=-T[Q9
MK?C/P/K&CZU/X/ETOQ'_ &O::UX"\7_LC?%7X0>+=#^(7A;]FGQW\)/%M[\,
M?C7^SO\ %36O&5I+XT\'7,8\2>.XKO7O&OBP!+2[VZ;7;\D]TNNQ]N_L*?$;
M]HCQ5H7Q0\ ?'^QU;Q'<_!;Q?9?#_P ,?'?6/ 'C?X6WGQL6ST^0>(KZZ\(>
M.?A[\,VU._\ ">J01Z5>_$SP'X8MOA1\2S>0ZUX%6U2WU73[3[ ^(OC_ ,*?
M"CX?^./BCX[U*31O!'PX\(^(_'?C'6(M/U+5I-*\+>$M'O->U_4UTO1K34-6
MU V&E6%W=&STVQO+ZX$1BM;::9DC;0\3^+O"O@K38M8\8>(]$\+Z3/JWA_08
M=2U_4[/2;&36O%?B'2O"7AG2DNKZ:&%K_7_$^NZ+X?TFU#^=?ZQJNGZ?;K)<
MW<$;_B)^T9^V-\0?VJOC3;?LK_LOW7Q?\"Z+X$^,7CCX;?&KQSX*MOA"OC;Q
M#K'A+4-2^'%_=?#RT\8>+_$FGZYX2^!?Q$GTCQ[^T+\&_B7X"\#:_P#$;X(Z
MIX-\9>%O$D_@CQ9HF@?%L!+F?9=>B\_2_IIZ(]?_ &B_CQ^V2_QS_9+^-W["
M/A;4_P!J7]F[XR?!GQ-J/BOP)8Q>&]#^&FI:$FI^$_$N@_%"+XH^*=5\+R>"
M?&^J>%O$XD^&VF7<FKZ9\2+?2-9\,76BZ,)_^$\\)?K]7S!^RE^S;H'[-OP]
M?1+"RTO2?%'BZXMO%?Q&T?P1K?C]?@WIWQ U&W^U^,7^"OPV\9^*?$FF_!_P
M!K?BJ\UWQ-;^!O"$>E:1!J6N7]W/;SW4IE%[]HC]JSX0?LT_#_XC^._'7B"R
MO9?AAX=\%>)O$G@_2-;\+6GBBVTCXC^.G^&G@75=0_X2C7_#F@^&/#6O>-X+
M_19/&OC+7/#O@G0H]'U_5?$7B'2M(T#5[VS!;V2]-K-^NMOZU-[XG_'7X<>
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MMOQE\6OC#>_L>_LU0?&'1]7\%_$^V\)?&SQ7\-;OX5^'_B+XHLHO 4WCB_\
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ME^#]%U_68-%L;B]AN-;UMM/_ +)\/:4EWKFO7NFZ+I]_?VW\^_QA^(7[3?\
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MN&PCKX:-.ICI>-:)H'_!,[5O#,GB:]_; _:%\*)IOP_\$_$WQ7H?C#_@KO\
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img170310032_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_11.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &\ MT# 2(  A$! Q$!_\0
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MCADC2;8\J*[9V1-(N_ X)5"=Y&>_/)Q4N5FE9N[2OT5UN^J[;6OI>^@:?/\
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M.I=T7.>F,XZ=_P#]9JXTYV2W>UW;6WX;?UM=<K[?KV[>J/HN2145BS!<8Y)
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MQ$U[X;>&?#]CH^F?#/1?B-%\3O&!O(!-J=UKMM;7%M%'I\RLK0;EE5F8HRD
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M'7P3UWX52SW.E>+$B2V_M&WM+8LUO-)-#(I,[L'7:H_=CK7ZR/&&?<#C/4$
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M?'-KX%M/#\EQ)XJ\"W>B:I_8]K>:^!<3(IF0//*\2#86YP<5^K?P]^"?P/\
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M!^U[\-[KQYXN\'77A?Q=\.]7UO2_#'@ZYE8Z9''K9M[>'7()9YA]N6(#S&C
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M*JBYXM2BVU%VLU%Z:ZI-)O=;7&PH(XU15"*H"JHR      >@ X [ 8HDZ#D
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MACJ"BBB@ HHHH **** "O%_BQ^SY\)?C:^BS?$CP=I7B.YT"Y2XTRYO( \\
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M-&K#!'&<X_S]/I[4XJ-NT<#&..PI:*GECHK:+;\P_K^OO$4!0 .@I:**H!"
MPP>E(B! <=SD_6G44K*][*_< HHHI@%(RAA@C(R#^5+12:3WU 0 *, 8%+11
M0DEH@&>6F<[1GU[]<]>O6GT44));(!NQ?3^=*JA1@<"EHHLM[=W]^X!1113
M**** "D(!ZBEHH C>))/O#..F?\ /^!IHA4=>?J/7]/TJ:BE9=E\_P"O(/\
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M 44A8#J<4!@W0YQ1=7:OJM6NJ7=@+1110 4444 %%%% !1110 4444 %%%%
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MA-X@^+_P4M/AGK7@Z?3-#TNXU]M(\27^H6ES:S2:1:P7<Q62&VG4W MBJ>:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ9K6GZEIZQ-<VM]92,SV\T7G*KHQW!@00*^M:8PHHHH **** "BBB@ HHHH
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MWNK[6^_R]-7_ %.QOO0-_G/?]:?7XU_'S_@L-X,_9_\ B;XV^&VJ_LQ?M/\
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M<^LYI65W=+1M+F7N;)[OS>NFGZ'C_@X&^)F<'X#:?[D:_98'&<<I_G]*</\
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M\?KWQUXX\?W/AB_UG5/A[X5\7:K?ZIIG@F_UW4GU:]GTV>]O;J60B\EE:%9
M%A1_+C"H !^O-%/6][N^UWJ[62MJM-EM9KI85M&KNV^CZ]_4\G^+FBZ9+\,_
MB7<S:9ISSMX#\7%IGLK>21F_L#4#N9FC))!  ).<8K\L?^"":@?\$_O!6  /
M^$C\2\    :G<8  Z"OUE^+7_)*_B5_V(7B__P!1_4*_)O\ X(*?\H_O!/\
MV,?B;_TYW%)=K[/2_;EBOT7_  +@DKRZ:)^KN_TU]3]I:***8PHHHH ****
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MXQ\*Z+8W+W.M:>]TJN2OVFW#9 )X4N#G@\\C&..F?YUOVE?^"N,VLZG?^'O
MZW*Z3!<30+=6;/$TBKN4-YB\%>.".,]QBOB)/VUO$VO2K)=7VJR7]RQ@M(&O
M';S/M'R!F0 9(#9'<$=!V^(Q5;%SJ7]G+EN^1M==&FTDWUN[_CN?H. X5G45
MZN(I4Y)I.FI.4HQ?+NW97>EDK]D[[_TO6OQ(M_B3XX31-/OR8-+E^TW*Q.LW
MF)"0RY\K<%&%.=P!.<CCBOJ*-+4Z?>W")N6:V6!I55@2$0+@C'M@G'4'CU_'
M7_@FK:>(-6UCQ3XKO+J[,E]!%#/%J<<I02E'&VWDEVK@DD':3CC)K]M= L +
M21;Q%6$!BR+C8V>IP1R&ZXYZY S7-!SM)3=W97<5IS-WZ[?EZO0X\UPM/#U8
M4:<KQIIV?5V4;K?2[NEK>ZUVN9^DRYC:T12RCRV);H,1KA03P3CGK@=\5BV]
MM>6WB"_U%4W(TRZ>D0.5$*[9?-QNP&Y(/L.GKT6F6-^T^K&1%6U$ZM8L@(;8
M$52"03GN.0,CVQ6C8VD,,TA(9H_,>:X=QD;]A *'&.H''L>M&MDF^:UK;^7=
M]]W^!XTFE=+2^]M?DK;:]$WKML3ZLJP:7-,S;L"-E7C)#'D,.YQWZ#.>*X+5
M@9[/:\ $'V1I.2/ERO#+DY![]/\ &MW6I;AX"\<RS12L-L?5BC$ $#)X!XST
M!]QFN9E%[<V,D5U'Y;RB2WC &,0Q$HI)[$KUZ$\&DGS>6OKI_P /OIL_F0]$
M]>U]O*]EMKOZL\?-DL/F6Y\Q[*?S)XYW(P)<DA%(P3@L1C/8?CX9XKU^#2KN
M^54WI;2CS$!!;'EC+ $].1GCUXKZ5UF%;?2[:R09?SF",03GYB6'(SUSCZ$]
M^/C7XK+_ &>OBR[<C[7%;,T,6,EF$ (? Z*HX)[UUT%:+LM$VK*VK=G?=>1I
MAHJ=2TFG9):O9;]-WKZ]TC"C\4:=J4<JVT@E61F8YY*<X*YQP<@YY_'T\S\9
M@3V-VJ0^9'M.(P 6VKU8%N,XRP[=L&OD[X.?'?1;[5M<T/6-1@M[BSOIH$+R
MJFY%E/!W,#P3V_#FOJZ?6-)U:S;^S[R&Z\U"I\N1&^4KR?E)]>.G4&O3P]9P
M<8.RU36FKC[NSOMWMK=:Z!C\).E&4N5RB]7*TFEL]79^:?E;N?*?F)#?3K:L
MJA7(EA;'."?E9>I8=. %)[5Z-X;U*.&8-:.()& )A+$!3CYF'.,$Y/7(XSBO
M)O']J^BZN9 6MV>0M&Z@A'W,<+,O\0Z8)P%'/:L73_&>FPJ8M4O5TRY(*PWT
MC[;8L<[0TA(3:3]X;NG4]J^MPBE.$:L6W&+5[K5V:=K;Z*^N]OQ^;J0T:;N]
M6MM$_P!%UOO]Q_:E_P $+-=;6?@]\0DDYDM/$=K&3US_ *)G.>_;I^-?O!7\
MT_\ P;B>(=;UKX0_&>'55AD@LO&=G'I]];.DL%W;/IZNLB21LZ$9." >HYZ5
M_2Q73.2G)R6SLU]R]#&W+IV27X!0>01ZT4'H<=>U2 @ '3_]?UK^-7_@K/X&
MU?\ :'_;F\<^&OV;_P!GWQ3K'Q ^%'@L:E\;_&VE_%[5_A59>*O#=NUK?7.D
M26=C;/#KN^T>!/M#NQ(C^SD8!Q_7[XQUG6M%\,ZWJV@:3_;>L:=I]Q<Z?I 9
MU;4;J)"T=HIC^?=*1M7;DDD 5_%K^U]K7[.'QI_:,\;?%/\ :5\/?MP_LO?%
MG6],G\+:OX=\"^'=8LM"\1Z5#(D:O:7-IK5H=1ANQ;Q$22Q LK;1\F!2LW*+
ML[1NV]E>VB=]&F^G6VOF].63OKHDNKNXMZ6;^'[71VUNS]L?^"/?PD_97\7?
M"CPA^U1\&/A+?_"OQ9JGA"'X>ZOX9U74I]2?0TTB\DN;A+*YN8HWO/,NY')O
M@B&8.P/"U^X$(4#KEAD$^O3O_P#7K^8[_@B!\"M+^'7Q"\9:U\+_  W^TSHG
MP4;PS!:^&KWXY6FJ:/I.HW!OC*]SHVG7&J7UK-))&Y9I_+60KDEL 5_35')L
M5F"C X')Y'!&!USDG\CWJI:6:=HN*TVY;;ZM:IR=TFWJW;1$;MO5>]U5VU9*
M/I[MD^JLB]151+DN"0O !['.1CY<=CU![ CKZ.$Y./E^4XRV>!G''X=*FZZ:
M_P!7_K_@,=_Z^=OZ_ LUQOQ%_P"2?>.?^Q/\2_\ IFO:ZDW#!L;  3\K$\'\
M?6N5^(G/P^\<G_J3O$O_ *9;VI;3M9WU6J]=4W^F^UT,_'W_ ((0_P#)J?Q(
M_P"SA_B5_P"C;"OVUK\2O^"$/_)J?Q(_[.'^)7_HVPK]M:I.ZN@"BBBF 444
M4 %%<UXE\7^&O!]H+_Q-K6GZ'9LZQK<ZA,(8F=NBAB#EB> *X8?'SX-9(/Q)
M\*$J5# :BA92WW01C*YXQD<T?\-_7^>PMW9)^MM+Z:>NJ_ ]>HJE8:A::I:P
M7VG7$5W8W,:RV]U"V^*:-AE7C;C*GC!QT.>]7: 33V] HHHH&%%%% !1110
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M..5/<YP0>0.0:]W\)?&_]FOXN^-_&WAK]EKP??\ @/X6^&;+39=%T;5-1O\
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M%[PO+]F\;ZN)3)YNE7(2(DOY<AMP% Y(SP> !C/UK[8U,6UF@DEFPGF ,A
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M\<1\#/"OAVW>]_X2[0=0.FZE?KKUSN46[(7TJ6';Y\@"SY,8;!'[5_M(?\%
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MW_TQBCS<;_RY_P ,O_;2T_0?7^AK[Q_X)?\ _)]?P&_[&:V_]">O@Y^@^O\
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MCI\&/VE?%/@_X2>$_B=X;\'?%_X"^.)M0O/!'QTM;/PS\,O%R3:3/:(T&O\
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M_$^=_B#IGGQ6Y8;LJ=V 3GY<X/!X!YP<8/3V\&N-(FL0DT>2CRY?.2 ,@],
M^O7/<=Z^OO$EC%+.D6S<&1L+@8Y5AR".,$D^QKRG4=%=H9;9H%(5R58 8\O/
M!SCZ]:Z:<ES13>C5FM/+I;^ET9:E))N+LW9JZ[6[^G];GPW\1O LVIR3WBHS
MVS'S J1,60G)R,#A<]3VXYKY#\6^!K:\@>TU&T5GAE+V\FSY@0>,-U[YZYS^
M%?KO/HBR1W-JL<;M+;/&J,BG'RG'4'GD\=L\"OF'Q%\/IKV>=XK'>T,A5T,0
MP#N[#;Z#(]A]!7J1ITVHW;333T6FMM'YK>^]CHAB:L&KS?*K7L^7333KN]=G
M\SX:T'19[/[+"B,ZVK;$DZ?NB&8[B>  Q(QTKUNW#QP$X;/EYX4[7 R>,<>O
M(_G7N5E\+(K>^\_[.1;7:K'+:2 <$A<M$Q&1R"< >O)[:NI_"RYM[:06Z>9$
MIW0+L"NL9Z*>"2RY)ZYQ@8)%=4)1BU[RLK=+-;6O9VTNNWYHX,5S57.::LVI
M7T?-:R6K>]EVN^O1K]W_  M9_:_V8/V:)!&<+X: 8$$')TV#_P"M_ABJ4\0M
MX\E%'RC"XP1SW)P![_EZUW'AJT;3OV9OV=[>;Y6A\/;"&X/RZ?",= /Y<?G7
MGVH73.2#R@) QGGGV.<#GMZ$<\'CQ]3FKSU3BE3<>FU.#Z]?+370B@DJ4+K1
M76G5J6B?>^WFE;UBC99MSL<D?P@@G!YZCT_H?:N)\1>'K76&#7$3$AQM08"8
MSU<8.1ST&.HSZUT_VI4'E!<?[0STSD'C'TY/_P!=T2HIR[&0NV1N&?EQ^6,'
MZ\5X]::YKW<HZ)?)+Y?+KMLCK@WIHX_RV>FMMU:_3:S^6IR]AX.LX61&6-8U
M"E8HUV@\]P0>/Q]>:U=8C62-;2-0L42+%&H'R!FRH/'=>#],9%=+"!%;RW3%
M,C(4R #Y"=@"Y[[L=,GL.M<Q>2A%C>?:-TS$*&!9\;?F*Y)VY! ]N!6*3<7H
MDVTT[=OO_'??74I/WDW=I+\7;6SZZ?JB3RHM/TZVLPQ?S"%)!&&D)7=GKT/
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M_8Q^)?\ TYW%+[7R=O\ R7]28JRMU6_]>EC]I:*:S;1G&><8Z?SH#@C.1T)
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MDX)^4#'<=#SG%=A#X/\ %)C#+X8USE0 3I\V1TZC:><=P>_UK\4Q_P %3?\
M@H P\M/CW=._0(G@SP<[<XQA4T,MR/;)';O2C_@J;_P4"49_X7Y>A(Q\S_\
M"&>$1&AR,JS?V'A&&>58J?48S6*^C#QFW9YMP\K6LOK&*6CM9_[C?7[-]V_0
MK^W*>ZH5/7FTTY=O>>J=M%^"1^V$WA3QA<&"U_X1;7#%&2Q)T^4*, G!^7'O
M]<&N7U_P-X[N5B$7A36D\R11O&GRY6WC8$L!MX+)G K\=5_X*H?\% @OF_\
M"_[PQ$X:0>#?"'EJ0/N^:-$VACQP6[]Q4A_X*G_\% RBN_Q]O5C( C9_!W@\
M(<#^%FT,!@!S\I(YSR*/^)8>,[-+->'D[?\ /_%[W2<5? [WO==K:ZC>=Q5K
MX>I;5IW6MK>:LG=:WLWI>Z9^NESX&\:3O#;IX9UXP6ZB1Y'T^8C8HW/U4Y.!
MC'J,]ZP(-%\>2Z)JFJ)X0U\!FN;6PC.G3AI7MY6A5L;>$(3.1U!! Z5^4_\
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MF!XY_P"$-\%YP#G _P"))Q37T7>-$U_PK9 [;?O\7H]-5_L/>[_I72SNDG_
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M_H:^\?\ @E__ ,GU_ ;_ +&:V_\ 0GK]AX^_Y(GBG_L2XW_TV<E'_>*'^/\
MR/\ 0%G_ -1-_P!<I/\ T!J_SE_^"B Q^V_^TS[_ !#O#_Y*VM?Z-$_^HF_Z
MY2?^@-7^<M_P42;/[;_[3 '7_A85Y^EM: __ %O\BOY"\*O^2BK_ /8NJ_\
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MRMYDTJ-]E 5I&PS-CDCI@5EZC^S/^U/J]W-J.K?"3Q_J.H3G,UW=Z7J$]Q(
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M/\:.?[X_(?XU[B?V6_VD$/[WX.^+X@3\I?3+Q V> %+6_)SVZGIUJC+^S?\
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M+Q-]BCN)8[BYL;6UUF;7;BRT^3;Y%KJ6HW %Q-?1X;S#-F0J5)/( _7@@'J
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M,OW&&7_3B@O_ "E#4\ ^HOV(O^3S_P!F3_LJ.E_^DE[7^BK:_P"IB_ZXP_\
MHM:_SJ/V(/\ D\W]F+_LJ&E?^D=[7^BO:_ZF+_KC#_Z+6OY%^D+_ ,E7E/\
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M_P N?\,O_;2T_0?7^AK[Q_X)?_\ )]?P&_[&:V_]">O@Y^@^O]#7WC_P2_\
M^3Z_@-_V,UM_Z$]?L''W_)$\4_\ 8EQO_ILY*/\ O%#_ !_Y'^@+/_J)O^N4
MG_H#5_G*?\%#_P#D^+]IG_LH5Y_Z36E?Z-<_^HF_ZY2?^@-7^<O_ ,%$@/\
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M%$KOB 9U&<H&8?,V?N_*P/.>YKYB^&]_<^('N-:ED,Z[F=+EN$<$_,(5^[M
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MRXD*G )-?K76CVCO\$;WM?NUHEHGIKKH2MFKW2;MU\[]DWN[:)A1114C//\
MXL<?"_XC8P,^!?%V??\ XD&H5^37_!!3_E']X)_[&/Q+_P"G.XK]9?BSG_A5
MOQ(('3P'XN(Y[_V!J'X?YZ5^37_!!3_E']X)_P"QC\2_^G.XJ)_DG^<1+K;O
MZ=$?'/\ P<$C-Q\#/^NVNG\K>&OYN!U;ZCW[#_.>OY5_2+_P<%$BX^!>.\VN
M _\ @-#7\W9X(]SS[\'%7TC_ (8_^DK_ ",I::]>:7X6^X&Q@_0_K7]-_P#P
M;[?\B9\=?^QJM/\ TVVU?S''@G()!'Y8_P ]<C]*_IQ_X-]O^1,^.O\ V-5I
M_P"FVVJX=?6-_O(ZKT?YQ/U@_P""C'_)E7QW_P"Q3'_I?95_GN6?_'M%_OM_
MZ&U?Z$?_  48_P"3*OCO_P!BF/\ TOLJ_P ]RS_X]HO]]O\ T-J_J?Z.W_(O
MXI_[#LN_],8HYL;_ ,N?\,O_ &TM/T'U_H:^\?\ @E__ ,GU_ ;_ +&:V_\
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MOV,_^38/@M_V(7AW_P!-=K7T[7\:5OXU;_K]5_\ 3DC_ &1P7^YX3_L&H?\
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M^IZSJ?B1]0LF3QAH+WMIXY\$72K]GUC3;=FBN[BPAF^69+J-?-N%WO/O<"
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M08P1C@DYP />OS'^)/[*/A>Z\13^*-.TB6PDCF^U*ECO,,I!RRLN0@.XG@#
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M4K);N6FVUWV[Z:_CTO8E0/;F1  =S<GVP<].>#[9Z_7S#Q%,'&YV;*L58@$
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M/^>G-4=*^$^LK?/-?>/?A@JECM/_  G_ (4PJX.,?\3<D8/U]?IQRP&8)JV
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MQDFFKN]FGMOL<-249SE*,HRBW=2B[Q:LM4[*X4445TD!1110 4444 %%%(2
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MHH&%%%% !1110 4444 %%!X!/I4?FKG!R.O)'&!GGJ>.* &23A"!@DDD=/\
M"OG[]H_X[1_L_?#74OB7/X,UKQK8Z1/:KJ6G:")/MEI82W$<5SJ4K)!<^7;6
M4+O<SED \J%OG7.:]6\:^(=.\->&/$&NZIKFF>&K+3=+O9FU[6KB&TTG3)O)
MD%O>7UQ.RPQVT4YB:0R,%(!![U_'U\3?VX_V\_C/\8[O]F:^^/?PE\ K9-J>
MM_"GXCV&FZ+K7PR_:<C N1+\.XM7\ZWTVVU&;3HGWVT#7\N9!^ZR]2FVW&]V
MG>^EK6ORM+KV2]YZK>UA6>KUB].5Z-Z]'YKO9*ZU5[KZ>_;7_P""@VE_$C]H
M7X7^'&^,EEX)_8^U?X>_\)9JNIV5B^JZ1\4M:BTR2]U[X5ZOK-M<K8Z;>E4C
MTZ2WO3)(\EYL\G<<'KO^"=7[ /PX^-VHZW\9M6\"Z9_PR'XOUW7=8\!?L^?$
MO16US4_!WB*WOGEM/$7A36+A;6"QT#5I9#>)806+*UN(4$[!-QU?^"<G_!/>
M\\8:IJGQ2^,7PBM_!'@+6]2O8?&W[-WQ)\,1ZYHEE\1[%O,U3QU\/+C6(8DT
MO0-=OGBGLXM,L([4P0!(Y&7D?T:Z#X=T?PKI5AHGA_2[+1M%TJVAL]/TS3X(
M[:SL[2!5CB@M[>)5CB1$55"H  !P#T-/39WDU:-W9<K<7.ZNU>R279+35,2D
MDK+W4FK[MW3:23MNW\35]GOH.T7PYI/AO2-.T+0;"TTG1](M8;/3M.L85@M+
M2UMXUCA@AB0!41(T5!@= ,YQS9O]1EL=/O[R.SFNI+&TN+F.TA!,UTT$3R+!
M%@,3+*4V( K'<1P:T#/'@YR!@DG P  2<\]AU[5_-Y_P5'_X* _M+_L[?$35
M].^!OQ&^'?BCX5Z[HL7A?Q4_ADZ;XB\>_L_ZW=7ULK>/_$^B6S&\?0+:WS:R
M/>R6EO'/=Q9D#!<RY:KWM)67->]KM<LK7V:NNVMV]!I=(]-;6NGJE9M:IZIK
MR3/0_P!MW_@J)X@'[.GQ MO@QINH?#GXU>'/$FG:#XUT'6+>35?%_@7P=>:S
M9Z=>>-X=#@BL]0GLTAGN'$T<")"L;2-*5C)'Y]_!WX$^"OVT_CKIC?LV?$)M
M7\>?#OPQX3OOC'\>=4TZ;6/AS\?-!UZ:2VUWPEXH\-))&LVL:=;I>&*6]U*6
M2VNKM9##E<-D_"#]DW]IK]H[XX>$=6\9^+-/\=:_!;:5XF\%?MF>"M @N_AO
M\7_AC?W*KJ/P]^(NA6,C:+?:E%;OJ>'U#4;N:*=H7$68U-?U<_"3X#_"3X%Z
M/-H_PJ^'GA+P';7A274[?PMHMCH\%Y>$*9IY8K*&)#NE!< YP6.#R35I\GO6
M;ES-\OPKF48J/O7NHMVDUU:<7>,D%TEI?WHJ[3NEK>[C9KFLE%;/E<7;F3,W
MX!?L[?"/]G'PFOA'X3> _"_@6QNI&OM9M_#&EQ:9:ZAJDV9+FY:.($[3,\C1
M1EF$:L0"3R?<;N>"VMIKBZFCM[>)"\T\KB..) 1EWD8A44=R2 .],\Y(5>69
MECB16=Y&(5(U7)9W9B-J@#)8\5\\_M*,?&_[.WQ;TKP=XGTFQO\ 5?!^L:99
M:^VKQ6%CI=Y*@B%Q/JBOML_LY#%I"058#)'6LWL[)WWLGJ[67NWZ;)7TU2TN
MA15^5.2BFTE*5W9.RN]FWNW^I^;O_!2W]MO]JOX&Z]X?\)_LI_"NT\?PVW@N
M7XC>-/%%[I[ZUHEWX<MM8BT2^\,Z28L1OK4Z70N(O+FDD\M)%$+<FOPNN?@S
M^SY^T[J7QA^,/P=^#/Q.^)?Q-^(*1P^*/V7S=7GP[?X,?%*[^SQ3?%-!JNG2
MB^M#,88$>&VA!5.)S7W5^R/K'[7W['=_X?\ V4OC?J=]^T%\'_CK%J]C\&OV
MC_#FD'QLOP^UK5+N[O/['\27L;3I>Z;9W NI%N+N]C1##%&(Q\IK]9?V$?\
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M<\02VFIV\301[4G@6TD"L<Y'S'C![@5\P)_P2!^*3J67XZ_ WCU\4W'3_P
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M,$W+1))/1'//_P $S=:BCF9OVC_V?_+@#>:?^$G?Y<?>P#8C.>O7O[8KE_\
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MZTNNNMOZ -,_9M_83_X*?:-X0_:]N?#!\9WNM:8D.@ZG>N!J?A'4+(PQWMG
MA"-9ZIIUY"8)RR*5FC<!17ZHZ!I%KX=T?2]!L6<V6DV%IIMF)&#2"WL[=+:$
M2$_><1QJ&(QG'>OG3]CS]EGP-^R!\%O#WP9\#RWEY9V,^IZWK&IWTPGN-4\2
M:[=/J6NWY<(A6.?49IY88R"8T<*6;&:^IWA0+N PR]&SCJ>Y].?\:IV5XQ;]
MFN7ENDDDHJ]K*S2ES6EO;KN9).23:O)<W5K2ZY59ZI\J3?2_2UB$J"Q3AMY.
M/4%?F[$\<#IWSS3%N )UMVEBC=B&CA>5%G=026*Q,1(RX[A3BOS!_: _;B_9
MV^(&K_&+]C[X>?M1>$OA#^U%HMB=-TV[U[4X-%_L3Q-!+!=6]I'=WEW9Q74M
MQM2"2WAF$IBG)(P<5_,AXG^.G[9>C?$K7](^.WQZ^,NA?MQ?#7Q-H-A\#O!_
M@6+7;WX.?'7P/_;4<$NI06&GQW-E>W%YIHFEOKE-1F6&&19I@$ZRI)ZWT]UZ
M*[?,TM$F[VU<NJBFUMKHHM676[25K62BG>3M9+2R;VVUN?ICX5^'G_!22+_@
MJ%>^,M7@^+:_L3R?$;Q#'IFA3>(='::'53JB^7J\J!,-X.E<B:RL5B^VQV64
MDF+\U_3/=>%?#&K:I:ZWJ7A[1K_6--WI8ZG>:;9W-[:K(0S"WNI87FC&54_(
MXP0,8KD?@UJ?BSQ+\)OASKWQ"TQ=(\<ZMX.T"_\ %NE*JJ-/\07.G02ZI:$8
MR#!=/)'CJN,=:]02-8\[01G&<G/2GJN6+2?(FN9/=W5FM$[6O:^U]$+?F;^T
MUI96MY]+WMJK7LO.ZA$4Y"@'&.../3Z#L.@[4ZBB@84444 %%%% !1110 44
M44 %%%% !1110 =:;M7I@'ZC/\Z=10 @ '0 ?0"N7\8>)['P9X;U[Q3J@N/[
M+\/:7=ZM>BUADGN&MK*W>YF$$42.\DFR-MJHK,6( !X%=$9&5\,."?EQR2.2
M>@[#WZ^M?RV_\%6_V^/V\?V.?VV/"%AX.U_X>VO[._C#P0)O#OA_Q;H$DT/C
M'Q!9_;+K4O#MMJLVI6]DNL3V,/EQ(T,KRO)&BQ,6 ,O5QBDN:5U&32LFE?5W
M];)7;>R'%7O9/2S=K)RNTG;I?75NWX'VCX^_X+P?LMZ FGWG@/P7\1?B[I5I
M*I^(VH>$;,QM\*K -MN-1\66%W:->QP6@69YD2)9%$,F0.*]A3]AS]B;]M;Q
M'X5_;.MK"X\8>(/%,7A;Q;X,\;Q3Q?:M'ATR!;BPAT\O&'M5DCEC%[#(OF;D
M4'85(K\ _@W\(_BU^WI\5-2^)?[.7PB\>_L.^)_B[X<72OVG_#OBGPUJ9^'?
MQ+\$Z_!-;7FM>'2+#2+"#7KF"YU"Y$@N;V2.22!C'G&[^MO]F/\ 9[\&_LN_
M!;P+\$O 3ZA/X=\':5!8P7&I7 N+JZF$,:W5R[^6A59I8S(L9&Z-2 22,U5N
M6*=O?TLY.[U:4VDGHK6^+6]TR;VT326[MM9VLG=;W;O:RV:ULSV[3X(]/L;2
MP#/*MC:V]JDDA!DD2WC6-"S8PS%$&XC@MVYJZQS@J"<#("#)8#'RD 'L>^:D
MDC@BCDEE/R1H\CECD(J*69N<8P 3U[5^4'Q\_;.^%WQZ\-?%[X#_ +*'[5'P
MW\%?M/>"=\.G:;KNL6-I<-KEF\,XTF*VGU*QEOVN<&W9+=F.9#D?*14R=MTY
M.S;:2U>G,E'=)/M[NNO0$I733C%74;R;Y8W?NW>UWMYVT/U)UF29]+U&.".9
MIFTN]V6UNZI=.QMY0GD$@JDK. L3L-H<C/H?YG_V.OAK_P %*])_X*+:AXQ^
M.*?%.?\ 90OO%GC^/X9:-?>(=(G30<6TI2Z\61QKF[TRZA:!-&AM$AEAF1S*
MS@@#\S+7]KG]N6V^+L7B7QG\9?BUH_[;WA/XPZ+X8O/V6K'2?$.H_"SQM\++
MO4]-TRXU[0=/ME-B;-8+B_OQJ:7%S;*86R?W;&O[E- ENK[1],N=3M!9:A<6
M%I/>V@*L+>YD@C>:$,J@-LD9AD'MBK2<;R3NM(M.VJ=I<R>TH_9ERZW23:82
M4DW%KWG=M.ZLHI0=TG>[<DX[Z:]RL?"_ABYUI=?N/#VBSZ[%%Y<>L2Z;9RZB
MD7 ")>-$TZA0  !)QCMBND$: Y"@'U[TBQ(AW*N#Z]_\]/RJ2I6UGMLNNE[K
M?\NZ'N[[O1ZZV=EL_5:!1113 **** "BBB@ HHHH *1NA^A_E2TULXX/&#G\
MN.U3)M1;6C74#^:O_@I'\4-#^%'Q/^(GBKQ%<B#3=,@@N9%1E1V2*QA8J"<@
M$X].N.>X_G+^'7_!8[P!\2/BH_@NST&^L=(%_+90:M/*FR0I(T9;H,@D'''T
MK[M_X.3?B/=>$-1\=Z5!*Z'65MK?Y2=[;[*(%1MYZ*<XX.#U%?Q)>#==D\*Z
MO87EDC/JJW8EL;>W;SI999'W#]U&"ZDEB68XP,DGI6W-4<H1]HG%6YK=KIM7
M=V]&]-?4<'%.\=7M?732-EWT:UMJ_NM_H*>$O%=GXIT^RU33IUDAOH4DB<?,
M L@#*25Z$\>W3UKU2VB%A'$OW[B8;F?(VQC&6+9R.>BC)/Y8K\MO^"8WC3QA
MXY^%*S>,6B2ZT](U2VBD6>6UA^14%U*A(23!P8G574GG -?7G[1?Q]\$? 7P
M==^*?'.MP:='&"--T[[9'%<ZA*?NJL3$NZ@D9&WH>3FOG>(<9&$Y0I[))^[N
M[J.FF^J>B[Z;7/7R[!XC'XBG1HTG.M4ERQ2:NTK.[;:24;IN3>B6I]&_VK%:
M)*K7<$>XY:XN/DA7 YRY*J.3QS^/6OE3XN_&ZPTWQ/H7A&SDM]1N]2NE@,UG
M<P,D49#%I&!D8D J%P#NR>@ZU^ ?QR_X*IZYXTO+G3M%N=0LM'625((-,F>T
M\R,,4C\Q]K"0LN-Q&.OUKPSX/?M*^(/%WQ4\.S+)J5S*^IVRQBZN6N&MQ(P4
MLS[0 ,MDC QG)KXV4L1)N4J<E!I6<]WM;?5:O\6NES]*P7"+A2G/%8BE*M&#
MFZ5&7,XO3XNE]-;-[WN?T^+XFTY9-/M=/L+B[U;6K]+*=E=&2"W$0E,C@#/+
M)@$>O(ZUV=Q&MSKUW!! 6DM+>*VW+TC+$+GC/ +'./Z"L;P!X=LM)AT35[N-
MY+N^BMI5^8,?-FM48L"5. -Q'7(P1D]*]QL/#L=O>O>Q1Y:^0R2L<$]V )P,
M8(X^G2IC&TG9MVT5]];-[>K];]#Y.O.TG2TM=I^34K)7MLNMDW>_30\LA2YT
M/4H[.0^;F(RR2#) #C(C.3P?Y$UYWIMVA\2W916(EOL* ,[3O.0#C@9/X>W2
MO<CI<E_J6I)(C9A5CNZ\?-M*\=NN/TKS_P &Z&C76I&15>9=2D$<SCYE(E<
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M292O:SM!QM=WOJDI-KETD^R;23>ET=[X9T8Z'X>T70!/%(ND:59:<KV]NMK
M_P!C@2 216Z96)"%!6,'"=,G@UT  @0L[9QDY/J>Y^O^>V(H%\IF&#ACG RV
M&/H3C QC@<#C'%?/MO\ M5? '6_B5K'P-TGXK>#C\9--A8MX N-4AC\0!V1C
M%*-/),KP[L%F P%()X-)OHK.33LM.9VLVD]7I>_X]1\O>]E9];)::O6WI?I9
M',_M7?MB_!W]D3P-%XP^+5SJLUKJ<WV&QT#PWITFM^(M2$RNLCVFD0.MQ<0Q
MJK^:Z A<$$]Z_C(^+W[)OPE_:O\ ^"@/A$?LV:SIOASX2?MBZR/'MK\</"EI
M';>,_ OB*PC:QO/"ZW5E*EWI>H&2PN;B6V^UQ2J^_,>037TO^TA\)/VD?BC^
MWEXUTOXU^(=9\$?M6Z/K^G^)/V1=0NOM.I? ;X@^#-.B6VN/!UW8WA&C?VI=
MF>W2[G33IKB.X@F&YR6S_17^QC^P5\-?@#!)\2W^'FE>%_BAXV^RZ_XM\/V=
MW)JGAGPSXL-LEOJ5YX/@NHDAT:.]E6:Y9-/M[50]U)@$$[B,/AG)WLG:+M:4
M7;1V6K=KM:6DDEI+6KI<T;.[:5TO@=XM25[7LNU[IRL]%:S^QQ_P3N\'_LRQ
M6GB#QCXINOC=\4]'SI_AOXJ^,[1KKQCI7AH0B.+0VU6]EN[V>**5IY1(9D&9
M<!!C)_1N./8#EBQ)/)]\?X4Z,,$4-]['-/HWLWNET7*NE]%:R;5[6]1=_/>^
MK^]ZA1113 **** "BBB@ HHHH **** "HWX.[.!@C'KP?;H,^HJ2F,,Y(Z@<
MY].?\_UI/\-]-[K56)ETM:]U:_KJ^NRO_FC^0#_@M7^QU;?M6_%/Q;HL^K3:
M6;1+=X)(PS,9OL46T@!DQC<1UXR>G2OYP/#'_!&WQ9X-D:[M-8CU/61<E;6]
MO$W-\[A%*F1V,7E1DN6R0VTJ<9S7]H/[9,._X]>+RBER7L]V[C'^A6_;^73V
M]:^2A9(ER97C'R D+CC<0>1VX'Z=>F*UQ5:E0HJK=W]FE)645S:*[MHFKV_4
M*5&3EHU9K2VMWRQ>COWTL]O,^=OV6_@5I_[/?PMTOP5;W4%UKLL*:AXKU<(J
MM>ZBX5K@+@DB*,J"BAF4')&,U_+#_P %0/VD==^,'[0WBOPQ]KE/AGX?W]SH
M-C9;V$$MS92R6US.R@[2TC1JP&"5/<G./Z_]4NYE%ZEO&0[PS[VP!\IC;8 ,
M>I/..GM7\-W[87A[4-#_ &B?BHVI6,\7]H^+M:OK=W#;9EN+Z63>A(P3CDXR
M,$\\FOA74]KBWSZV;E!MK5OHK[V3;Z;Z/8_2N$*/)#&8B-E5C3HQ3=VX1=^9
MI:\JE)14KJUDM5<\&U#2K"TTO0+Z+5GN-4U,W!U+2C;^6NDQQ2A+5Q,9&$OV
MF(^:,HF,;0<<U^HW[ 7P-_X2'Q7I^IL!=H9X;O[1_=AB*EP!@]&YR#SCWQ7Y
ML?#[P;J_C[Q%8:;!;RRI)+#'/*J$+Y*%51&8 XP#C/L<C@@_U'?LE?"?3O@Q
M\-)_%5_IXAOH]-2*T@8$/(I5"T@7&0"RDYQ_%V[>?F6)C%4L/[2TFVY)):*Z
M:6U]%V6U[IZH^ZG56'PM>NDHU:WLZ&'O)J;YE&-6;C)RNI/5M;2E[O+9H_57
MP996EU8Z7&I9O[,MHHE#9W QQA,X/OWP3@Y]Z]DTUXDV>9N4F+"J?4%CP.N/
M;_ZU>%_ [5O[?T2RUR2U:T@NK=F5'S\Q$I4,"1R#@]_IG(KZ"2S:2YM'490@
M@[1PH*L >WX>_P"&>6FT[>5E>RU=DDW9V\_,_*L?"4,1.',N;GDY.-FI:W<5
MV[=];;W,N'3TC6ZN-BAKB1@6!_A!; _$'TZ?B:\WT&T$6LW]B(0$DN7F5^F&
M9B<CN>2>^#SUZCV2ZM7AMYH4)!5PV.2Q.<]QG!_H?I7%);K:W+7:H!.)E)QG
M[AZGW[=36C7OQLTNC5EZK5[>7D<=.7.E:]KM==&MF_+R=EIKU'>*[$-9(-N6
M9"IQ@L<#'7!QGKQTZ9SUX;PY8K'::AIURCHERC@'!.>0>1SUQC.>/I7=:O>2
MW,3)$,L&51D=R,G&<]\XQ_6H],T^;<'DC<J% <!<'G&21CIS],=*33;CTTUL
MM]-K=+::^>I3=M.6W,M=?ZMUZ=UMH_A7XXZ9IPT>:<QGS-.N)X68@!B"A5<-
MU&YFP.*_"[]L7X<2WNC)XE6V)4P/"^Q2Q577;"9".<98$L?J><U_1)\?O"HN
M]*U:&UB91/+',"!D,PF1G(SCD@<^P/:OR\^/.B:9=^$=;\,SP+<WMUID;VH3
MYI(IHE=R43')! R"<D#J!6D&HRYDF[-+SWU_"RVVV[GOY)B%1K)I\M[0G=*4
M5";5F]&TXO7W6FUU/YA?'/A:;P5K=OI,NLZ=J\NHV=M>Q+I5Q'=O";N(2K8R
M^425NH]PB:-AN#JP('('VW^P5^S'9_%'XI2CXB_&*V_9O?2-$NO$_A7Q!KUJ
MD@UZ_L#&T&D/97-YIX"WD;.5E\R085?W9W8KU_\ :R^(G[+/A;X+?"C2O@G\
M,;O0/VA_"IU&Q\=^+]?@^V6&L?VA+&9+BWL;KS+8RV9C;R"%!4G@J#BOR>O_
M !/XHU[5!?ZCK6H7.HR,5BF2YFB59&8#9;0QOL@4D_ZJ(! ,#&,5]30='DC-
MVJ*5.+<5[L;VB]7W5]UM;1VU.W%RQ564Z5-3PB=6<83E:55PY_BC'6/).%FN
M9MVE9QNG;^C#7-8T?QQX3M-6TK4DUFRBGNK&'58XA"+QM,N9M/ENXH@[[$N7
MMGG50Y!#@Y-<5X<NGLYXXY&$D9D5(G'49)^_C.&'N>WTK"_9U\/WMK^S]H6D
M3,/MZ6<EU"KY+@R/)*>O4G>2QZDDD\D&J]C=".],,Z-;W<4Y$RMD(S+U*@X
M! [=#7KY9.]-:W]]JUV[);)6^?F?GV9T8T<=6IQOR1K*W_;W(Y+3;6]DM-4[
M:6/W)_X*5_$=_A]_P2]^"UU#-)%-J/@F:RBEB8H09M(A0$%3GJX'I]!G/\$/
MA9KFSUJ/69)/*E;59-4:<<2-,\QF+E@<Y9B69CSGGIP?] ?]LG]G'5/VHO\
M@GI^S5X%TV\-E)/X7+B;DA6.F6Y7KUY7 R??J:_FH\$?\$5OC)9^(+Z3Q5?A
MM TFZ+:=;%2C:IL<F))I%7='$P #%-W#<@UZ"YK\_+>SERV5V[R;=]--6]MM
M>IYR;YVK[-)7M;7D;_#==[GZV?\ !*_X[Z]XJ^"WB'Q)XH29]"\ 6#3I?S!O
M+G^S0L8H(6;*RDA1O8'Y6&#DDU^*W[<_[6'C_P"-_P 6O$Q;4Y;&RN]6ETGP
M_9_:&C@BMD/E";&0JJVQ@1C[QY-?O]9_!67]FC]BCQ3X?M+6.TU35+61KV.V
M4(6C2"55154*-J@J"^,R$;FR6Y_D%^*%WJMQXYUR[U$R17":G(T$84@Q!9"1
ML Z9^\>F2<9KY/,,3+&9E*,^7V=&G'EAHWS*UVUIKMO9I:7[?HW"V&IX?+L3
MC(QBZE:I[)36CIPBXO2?O2BY.ZT5WHT]"QX^^&'B+X7OH#>(+O3[B3Q1IJ:O
M9FQNTGN%BF=\?;%0[HI&96!5LD_+CK7ZL?\ !-'P)J"^,/"OB1XI4FGU:+R6
M*$2"$O&68/UQM)).,8[\<?F/:3W7Q9U_P9HUM%=W=W:K;VFH75P9)"(8GR5C
M5BXCC&.BD GMP*_J6_X)\?"72K,6NKSVT<%IX:L(+>$R )&TVSRWE)(Y(X8'
M!.0.3P:\C,L0E"G2=E4E=M65[+X;>MXVZ]EN?6KDP^&Q=:-1NG*')3C?F4G.
MGS33DU&_)JE[J=W:ZW/W6\,.S:?;[3O:&V56)]0H'))Y/ R?7KZ#JEDFU5[>
M%,A4<!EQD'!.<]L'M_3DUSWA&*W;3A# 2ZR@L)0<AD(SPW0C!!'KQ[5Z%I%A
MY%P(XP2R+OW$Y&>H' ZD=!^58PC:G3\XJ3>C3>FVGIY_,_,9UKU)<RWE>[T=
MO=N]UM;73=:]S3T[1;:T:YF8*6$8()4# P!MZDGGGMWJ9;>.YM67C)?>JGCG
M(_J,9/:K4WF^3*QS\P)(Q_"/IWSQC/Z9KAM-U:YENKB%V*K%*50$8RH /'8\
MG'M]*;:ZV^=B[I05E[K2?7K:WIHW:UK&A>VK0L3@[%P)"#GGIZ'J.W>L1D\I
M)PP812(SIQGYNN?3C^?UKH4ODN998)\ @CC'49_B]^",^HSZ50UJW(1%B)9<
M'"J,@ @9!..@)_I1:[BK7>NF^EO^&W,^5]=.NK]--.OE^'?YH\4LMQ=R7<T@
MB6T+JQ;&& [_ (@?KU-?C!^UE\!WU?5?%7B6PLA-HVLQ2?:90-RB7R@I;:!@
M\C()/_UOVO\ &VFFYT_5+=8V#S0R;64$,' P#D8QC.#_ #YY^*3KN@^(I-1^
M'.H64KS1Q307;2%B2[L2KC=GG:1R.W<CBN6HU:[^SJMUU2UM9NU[)7\CZ/(\
M7+"U)2C'FC[O-9IM)-.ROWTV5VKIZ.S_ ) _&G[+OQ8M+C5/$^E^%=0E\!CQ
M#<:'+XOFAEBT33KU8Q=.E]>&-H+=$@<."\@RQ [BOI#]E/\ ;.\._L.+XZ\*
M>'O!?ASXPZEX]\.W^AZMXBURPM9K3PWJ=_:SV\$WAUKB.Y!DL;B9)5O;=XV<
MH/N[0:_3+]KCQQ\9OAS\(_'/[-'AR73+;X3^,[R74[VVFT"PFOY[XB/$T&LO
M$;RVDVPQJWDN"R J3ACG^;R^\*:UI.K?V+-;M',MVBQR;<!@9!APQ .#VY/M
MC%>YA<91G27(VJBIN-3G4;+2S<5>2M;J[/5I'T=3#5<;S5:D8O"5*ZG0A1DY
M.2O"25=-0<)<SE:$7*+7QO=']1O[)_Q-N/'GPYT35M2N -6BC2&_.<"3"@;@
M<\9Y&.QP.M>G_%+2]2C$6K:?$EY:R$-=6C@/E/[ZDYVG' ..=W![5\)_L8IJ
M?A[X?1V]RYD+&WRISDAAR5/7(Y'!]/Q_2K1;VRU#3_LM^=T;1E4=N=I88VL2
M<\9XSV%;97BU#D:;Y'/WIZ?S1L]=;:OU2/@N(<+&..Q"II+F;;IVY8I12UC;
MSLG;N[]S^@#_ ((;745U\&_';QQM$P\0VX>)A@H1:CCGDC/3MCCCI7[J5^*'
M_!&#0TT7X8?$%(B##/XCADB8="IMA@#MQDC XX]<U^U]?4\ZJ>^G=2L[_(^6
M::=I;I*]O1!1110(**** "C('4XHJO.&;"@G!Z@'!/;\N>M#_P M_7^K>8?U
M_P 'Y=221EVGYL?3D_I^?X5^(_\ P4$_;;UC]G7XQ>']7^&_CNW^(-IX2\,:
MM%\4OV>?#LMM-XOFTN_> _\ "7:;%)Y9EGT:W('D?:@3YQ)B)&1Z5^W'_P %
M,O#/[,WB35/A!X1^'WCOXH?$"U\,7GB+Q8G@(VK7O@'PX+43/K]REW')O,%N
MYN8TB621O*.$8D ?@#^S-^S)K/[6GC36;+Q3;^*=4\;_ !,UN_\ BU\ /VW]
M!:;^U=+M=-O'74OAYX]CNUD@9].N=372S:QZ9 CI8,?FV[JF/ONZ;C&VK=UI
M>S5]%%[N\FE))Q338W:/,I1YFK65KZO?3=Z;6U5[NRN<#\"/V*_CY\6OC!X4
M^(W[+WQA\=?$?PI\2O&<WC2^^*<:6K^$_"VBWFH33:QX9\>W+B/4I-9L));C
M2%TYX+BR\B'<06537]FGP=_9[^$GP/@UB7X:> /#G@_4_$SPW_BN\T'3H+)M
M;U?R($NKNX$*(N)9(C+L4"/>2X4$Y.!^S;^SMX"_9H\ VO@GP%X;T?1+B[%M
M>^++S18Y(8=?\0I;K'>ZQ+'+(RQS7LYDGD2)8D,DKG8"17TK$#L&1@GL?3 J
MNBBFW%=6M97BE>[U<;))7WM>Y&LKR;5VUHG>RTNKZJ^FJ3T>R2*JM\OS#;R
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MK:7W5EIKUM\[=CX^<U4DVMK;K7U5_*VJZ?,S]:O#8V,LCR#:4*CH#R<]N<]
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MLK:=+)+YJXELO))?=^CW7DPHHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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MK7M=WW;>KMHK_=ML):I-I7>NFUWZ_F]?,****904444 %%%% !1110 4444
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M_P"")XK$O_E[MLN6/EV2['XNZ;_P2+T?1;Q[K2OB?J-FK-GRDTZ+R^H/W?M
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:!0@N6,=E=O\ %MLS;E)MR=Y/=V2O\EH?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img170310032_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img170310032_12.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %L O<# 2(  A$! Q$!_\0
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M _X)8?\ 1P6N_P#AE_C/_P#,)1_Q$ ?\$L/^C@M=_P##+_&?_P"82OXAM/\
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M_P#YA*_SHJ*T_P")3O#7_H:<9?\ ASR?R_ZD'D_O\A?ZPXW_ )]X7_P"K_\
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M5%'_ !*=X:_]#3C+_P .>3^7_4@\G]_D'^L.-_Y]X7_P"K_\N_J[\K?Z+O\
MQ$ ?\$L/^C@M=_\ #+_&?_YA*/\ B( _X)8?]'!:[_X9?XS_ /S"5_G144?\
M2G>&O_0TXR_\.>3^7_4@\G]_D'^L.-_Y]X7_ , J_P#R[^KORM_HN_\ $0!_
MP2P_Z."UW_PR_P 9_P#YA*/^(@#_ ()8?]'!:[_X9?XS_P#S"5_G144?\2G>
M&O\ T-.,O_#GD_E_U(/)_?Y!_K#C?^?>%_\  *O_ ,N_J[\K?Z+O_$0!_P $
ML/\ HX+7?_#+_&?_ .82C_B( _X)8?\ 1P6N_P#AE_C/_P#,)7^=%11_Q*=X
M:_\ 0TXR_P##GD_E_P!2#R?W^0?ZPXW_ )]X7_P"K_\ +OZN_*W^B[_Q$ ?\
M$L/^C@M=_P##+_&?_P"82C_B( _X)8?]'!:[_P"&7^,__P PE?YT5%'_ !*=
MX:_]#3C+_P .>3^7_4@\G]_D'^L.-_Y]X7_P"K_\N_J[\K?Z+O\ Q$ ?\$L/
M^C@M=_\ #+_&?_YA*/\ B( _X)8?]'!:[_X9?XS_ /S"5_G144?\2G>&O_0T
MXR_\.>3^7_4@\G]_D'^L.-_Y]X7_ , J_P#R[^KORM_HN_\ $0!_P2P_Z."U
MW_PR_P 9_P#YA*/^(@#_ ()8?]'!:[_X9?XS_P#S"5_G144?\2G>&O\ T-.,
MO_#GD_E_U(/)_?Y!_K#C?^?>%_\  *O_ ,N_J[\K?Z+O_$0!_P $L/\ HX+7
M?_#+_&?_ .82C_B( _X)8?\ 1P6N_P#AE_C/_P#,)7^=%11_Q*=X:_\ 0TXR
M_P##GD_E_P!2#R?W^0?ZPXW_ )]X7_P"K_\ +OZN_*W^B[_Q$ ?\$L/^C@M=
M_P##+_&?_P"82C_B( _X)8?]'!:[_P"&7^,__P PE?YT5%'_ !*=X:_]#3C+
M_P .>3^7_4@\G]_D'^L.-_Y]X7_P"K_\N_J[\K?Z+O\ Q$ ?\$L/^C@M=_\
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MO\9__F$H_P"(@#_@EA_T<%KO_AE_C/\ _,)7\%R_LD?M'GP+H_Q-;X2^)8O
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M6F7-K?\ C3QGKGC37;?Q<T$MRKOX3CNO%%LVK:?*ZZM=O;7;)$YEB8_VF_\
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MN[;^Q/\ XA[/^"7_ /T2'QM_X=_XB?\ R\H_XA[/^"7_ /T2'QM_X=_XB?\
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ME3_Y5_5GY7_SNZ*_T1/^(>S_ ()?_P#1(?&W_AW_ (B?_+RC_B'L_P""7_\
MT2'QM_X=_P"(G_R\H_XFN\,O^@'C#_PTY7_\_?7^GH?ZOX[^?#?^#*G_ ,J_
MJS\K_P"=W17^B)_Q#V?\$O\ _HD/C;_P[_Q$_P#EY1_Q#V?\$O\ _HD/C;_P
M[_Q$_P#EY1_Q-=X9?] /&'_AIRO_ .?OK_3T/]7\=_/AO_!E3_Y5_5GY7_SN
MZ*_T1/\ B'L_X)?_ /1(?&W_ (=_XB?_ "\H_P"(>S_@E_\ ]$A\;?\ AW_B
M)_\ +RC_ (FN\,O^@'C#_P -.5__ #]]?Z>A_J_COY\-_P"#*G_RK^K/RO\
MYW=%?Z(G_$/9_P $O_\ HD/C;_P[_P 1/_EY1_Q#V?\ !+__ *)#XV_\._\
M$3_Y>4?\37>&7_0#QA_X:<K_ /G[Z_T]#_5_'?SX;_P94_\ E7]6?E?_ #NZ
M*_T1/^(>S_@E_P#]$A\;?^'?^(G_ ,O*/^(>S_@E_P#]$A\;?^'?^(G_ ,O*
M/^)KO#+_ * >,/\ PTY7_P#/WU_IZ'^K^._GPW_@RI_\J_JS\K_YW=%?Z(G_
M !#V?\$O_P#HD/C;_P ._P#$3_Y>4?\ $/9_P2__ .B0^-O_  [_ ,1/_EY1
M_P 37>&7_0#QA_X:<K_^?OK_ $]#_5_'?SX;_P &5/\ Y5_5GY7_ ,[NBO\
M1$_XA[/^"7__ $2'QM_X=_XB?_+RC_B'L_X)?_\ 1(?&W_AW_B)_\O*/^)KO
M#+_H!XP_\-.5_P#S]]?Z>A_J_COY\-_X,J?_ "K^K/RO_G=T5_HB?\0]G_!+
M_P#Z)#XV_P##O_$3_P"7E'_$/9_P2_\ ^B0^-O\ P[_Q$_\ EY1_Q-=X9?\
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M,Z5TFXJZ6Z36TFG_ "/^&_\ @HKX-\*?$+PM<7'@SQY\3?A1X.^$NH^%=/\
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M_H!XP_\ #3E?_P _?7^GH?ZOX[^?#?\ @RI_\J_JS\K_ .=W17^B)_Q#V?\
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M^._GPW_@RI_\J_JS\K_YW=%?Z(G_ !#V?\$O_P#HD/C;_P ._P#$3_Y>4?\
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M+]G>P^%%G\19?VIO"_ASQ%I'QEM_B3))\2?V-_BI8?"3XT:/<Z,GPY\&_9_
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M_#UC8RZG=ZU!$MPTUSID&G0RWKWEO'+!]FC:8.4&: .MHKP7Q=^TO\(?!?\
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M..]TR\M[^TDD@D:&9$N;626%GAE1XI55RT<B,C@,I  +]%%% !1110 4444
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MWPWXI^*7C*ZU#Q-X'\'Q6VK:5IWC7_@H0U[XDUW2M6UOPUK-O;'5?@C>:AK
MNKJVNK.'PG<OXDAM@8XKU/%_VDOC9^UA\$?"7Q5\,?$?XW?M:^$=.^&'@?\
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M_P!#1X(_\(/7O_GCT?8?B1_T-'@C_P (/7O_ )X] ';T5Q'V'XD?]#1X(_\
M"#U[_P">/1]A^)'_ $-'@C_P@]>_^>/0!V]%<1]A^)'_ $-'@C_P@]>_^>/1
M]A^)'_0T>"/_  @]>_\ GCT =O17$?8?B1_T-'@C_P (/7O_ )X]'V'XD?\
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M .CV$4OPT-S-KOA>^ATW7[=H+;PWJYT/Q%\//$B:Y:2P_P!DZEX<U/0M2=2
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M9_M/[CS/-^6@#O" >H!Y!Y]1T/U':BN6_P"$/TG_ )^_$O\ X6/BW_Y=4?\
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ML/'WB6[?3[J]TO3]<L[>\6#7I#;S76C:MI>JV\<NUIM.U"RO(PUO<PR/J?\
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M_$O_ (6/BW_Y=4?\(?I/_/WXE_\ "Q\6_P#RZH ZFBN6_P"$/TG_ )^_$O\
MX6/BW_Y=4?\ "'Z3_P _?B7_ ,+'Q;_\NJ .IHKEO^$/TG_G[\2_^%CXM_\
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MBO#H/Q8\<137UMHK>SZ#\%?VS_ _B6YU_3/B7^V3XH/@OQ7^P%X@\)Z3XO\
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M_F?H_P"&POV<!_S4RS_\)_Q=_P#,_7\_;_=/X?S%0U_9?_$L'!'_ $.^*O\
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M^1;\:=?P\-U&?VV/V7UZ_%6R'_<M>-/_ )FZ_G.DZ-]?ZU1DZM]/Z5O'Z*O
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MWC_7_/\ GGMI_0E\,9I-\1\>:M;8_A_K;_JFWW/1I\:9E.U\-@=>U/$=+?\
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MVK0?$+Z+XMT:8?9M?\/:3=%82 >X4444 %%%% !1110 4444 %%%% !1110
M5\Q_MD?\FV_$K_KCX7_]3;PW7TY5'4]+TS6K&?3-8TZQU;3;H1BYT_4K2"^L
MK@12I/$)[6ZCE@E$<T4<R"2-MDL:2+AT4CV.'LSADG$&1YS4I2KT\HSC+,SG
M0A)0G6A@,;0Q<J4)R3C"52-)PC)IJ+DFTTK'E9]ETLXR/.<HA5C0GFF59CET
M*TXN<:,L=A*V&C5E!.+G&FZJFXIIR2:33=S^75T?:?E;M_"?4>U0['_NM_WR
M?\*_IB_X59\,?^B=>!?_  DM _\ E?2?\*K^&'_1.? G_A(Z!_\ *^OZU_XF
MERGKPCF/_ASPWE_U#>OX'\QQ^CCFB5O]:,!O?_D78CR_ZB3^9W!]#^1J#8_]
MUO\ OD_X5_33_P *K^&'_1.? G_A(Z!_\KZ3_A5/PO\ ^B<> _\ PD?#_P#\
MKZ:^E-E"_P":1S'=/_D9X;I_W*^;_#OII'Z.F9Q_YJ? :V_YEV(_^:?7\#^9
M1E;:>#^1]:J,K9)VMCUP?3Z5_3M_PJGX7?\ 1-_ ?_A(>'__ )7TG_"I_A;_
M -$V\!?^$?X?_P#E?6B^E5E*L_\ 5#,=+?\ ,TPWE_U"^OX%KZ.V9II_ZS8#
M3_J7XCR_ZB/7^GI_,#*C$'"L>/0^I_E51U;!&UL\<8.>HK^HC_A4WPL_Z)KX
M!_\ "/\ #W_RNI/^%2_"O_HFG@#_ ,([P]_\KJT7TK<H33_U/S+2W_,UPO\
M\RF\/H^9G&U^)<"]4_\ D7XC?3_J(/Y:9$?YOE;K_=/K]*HR(_S?(W0]CZ5_
M5&?A)\*CU^&?P_/U\&^'3_/3J0_"+X4'K\,?AZ?KX,\.?_*VMH_2RR>+N^#<
MS?\ W5L+MI_U">OX&\/ +,HN[XCP+_[D,1Y?]1'>_P"!_*;,K8'RD_@>/PQ_
M]?\ *LN56Y^5L;CS@^_MC]:_K$/P?^$IZ_"_X>'Z^"_#9_\ <;3?^%.?"/\
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M -TT\&?_ "EK=?3XX<5O^-<YWH[_ /(^P'E_U+_(Z(Y)-.[Q$-K?PWY?WC^
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M]'_",>&O^A>T/_P4V'_R/0 ?\)/X;_Z&#1?_  :67_Q^C_A)_#?_ $,&B_\
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M*;#_ .1Z #_A)_#?_0P:+_X-++_X_1_PD_AO_H8-%_\ !I9?_'Z/^$8\-?\
M0O:'_P""FP_^1Z/^$8\-?]"]H?\ X*;#_P"1Z #_ (2?PW_T,&B_^#2R_P#C
M]'_"3^&_^A@T7_P:67_Q^C_A&/#7_0O:'_X*;#_Y'H_X1CPU_P!"]H?_ (*;
M#_Y'H /^$G\-_P#0P:+_ .#2R_\ C]'_  D_AO\ Z&#1?_!I9?\ Q^C_ (1C
MPU_T+VA_^"FP_P#D>C_A&/#7_0O:'_X*;#_Y'H /^$G\-_\ 0P:+_P"#2R_^
M/T?\)/X;_P"A@T7_ ,&EE_\ 'Z/^$8\-?]"]H?\ X*;#_P"1Z/\ A&/#7_0O
M:'_X*;#_ .1Z #_A)_#?_0P:+_X-++_X_1_PD_AO_H8-%_\ !I9?_'Z/^$8\
M-?\ 0O:'_P""FP_^1Z/^$8\-?]"]H?\ X*;#_P"1Z #_ (2?PW_T,&B_^#2R
M_P#C]'_"3^&_^A@T7_P:67_Q^C_A&/#7_0O:'_X*;#_Y'H_X1CPU_P!"]H?_
M (*;#_Y'H /^$G\-_P#0P:+_ .#2R_\ C]'_  D_AO\ Z&#1?_!I9?\ Q^C_
M (1CPU_T+VA_^"FP_P#D>C_A&/#7_0O:'_X*;#_Y'H /^$G\-_\ 0P:+_P"#
M2R_^/T?\)/X;_P"A@T7_ ,&EE_\ 'Z/^$8\-?]"]H?\ X*;#_P"1Z/\ A&/#
M7_0O:'_X*;#_ .1Z #_A)_#?_0P:+_X-++_X_1_PD_AO_H8-%_\ !I9?_'Z/
M^$8\-?\ 0O:'_P""FP_^1Z/^$8\-?]"]H?\ X*;#_P"1Z #_ (2?PW_T,&B_
M^#2R_P#C]'_"3^&_^A@T7_P:67_Q^C_A&/#7_0O:'_X*;#_Y'H_X1CPU_P!"
M]H?_ (*;#_Y'H /^$G\-_P#0P:+_ .#2R_\ C]'_  D_AO\ Z&#1?_!I9?\
MQ^C_ (1CPU_T+VA_^"FP_P#D>C_A&/#7_0O:'_X*;#_Y'H /^$G\-_\ 0P:+
M_P"#2R_^/T?\)/X;_P"A@T7_ ,&EE_\ 'Z/^$8\-?]"]H?\ X*;#_P"1Z/\
MA&/#7_0O:'_X*;#_ .1Z #_A)_#?_0P:+_X-++_X_1_PD_AO_H8-%_\ !I9?
M_'Z/^$8\-?\ 0O:'_P""FP_^1Z/^$8\-?]"]H?\ X*;#_P"1Z #_ (2?PW_T
M,&B_^#2R_P#C]'_"3^&_^A@T7_P:67_Q^C_A&/#7_0O:'_X*;#_Y'H_X1CPU
M_P!"]H?_ (*;#_Y'H /^$G\-_P#0P:+_ .#2R_\ C]*OB7PZ[*BZ]HS,[!55
M=3LBS,Q 55 FR2Q(  Y).!2?\(QX:_Z%[0__  4V'_R/2KX:\.*RLOA_1%92
M&5ETJP#*RG*LI$ (((!!'((R.: -NBBB@ KS/XJ:9\2=1\.*?ACXXT/P'K-A
M<37]]J.O>#/^$VM;[38-/O"=-BT_^W_#WV.>2\:TG_M 75QY<5O)!]D?S_,C
M],JK?6[7=E>6JL$:YM;BW5V!*HTT+QAB!@D*6R0""0,"NO 8J6"QF&Q488:H
MZ-6,N3&83#8[#27PR5;"8RCB,-7CRMODK4:D;I24>9)I-75G?7LVG]Z::^3/
MSS\"?%W]IF+]D^Z_:/U?6?"_Q.UWQ'\.= \3^&/ 7A[X::AI!\-7FIZG;0ZM
MJU])I7B;6-7\86&@:/<SZS<:-IEAIFHW\&E3VUE*+BYC*L\'_M#?$2X\'?&'
MQ-H'QI^#/[0/A[PC\'/'WC>R\1^%M"7P1XK\$>.O#&F7-WI7ASQ1\/I?$NMW
M][X?U40R2Q7]Q%I-]97-C/97AN1<P21^\>&_@1XR\+?LP^#O@?X;^)=SX3\<
M>"O#?AG3M(^(>@64AMEU?POJ5IJ<)N]'GN(I+_P]K'V,Z5KVDO=P27VCWM[;
MQW5O-)'-'Y3JW[,/Q5^)'B'Q;XT^)OB#X2:'XHOO@A\4/@WH)^%OA37=.@U4
M_$G38+*77_'>IZWJ-QJFJVFC2VL5SI'ARUQ!83W%]<KJ,\TPQ^X4,UX!QV(X
MEGCH\+X7!SXIS6IE\Z&34:%2>18>I@(Y%AJ&78;(Z-6GAZ\*-94\9EN;9?B*
M=2KC:_$V7YO0E@Z9S\M5*%N=ODCS7E?W]>9M\S3?=-..W(XZWP;O]NSP+K7@
M[X P> OB-X%U_P")WQ$\=?!#PYXM\-6@FN9[>R\9W.FQ>.%L[-C%]FFT])[L
M0R&:7[&R ,LA&#YEJO[6'Q"@L?C9XC;]I#X%>%==^'7Q-^+'A+PK\$_$/@8:
MQXG\26O@76;NP\-:4SZ1X[L/%ESJ/BQ((;>VETSPY-*)[B.2V@O0K)7V-XJ^
M %UXA^&'P.\!V^KZ39:A\)O%WP2\2ZAJQTZ0Q:Q%\*9],EOK6TC1EGMY-72Q
MDCM'GD=;;S5\X2!65N-7]D+1]3^&/Q2\$>(M4L1XD\7_ !>^(GQ?\#>/M"TT
M6?B/X=^)?$GB:?Q-X/UC2;^?S+I-9\*W9MTN98)H[;4[9;FPDC^PW<T+:99G
M7A+@Z*G_ &<Z4:N>RI5Z>,P^5YYCX975S-2GB:<\;PU'"0P"P:BH8>AA8YK0
MIJ:H8QSFZ;3C7?VOL)JUXKFMJFE/FO?SY7U74[#XR?%[QIX,_9-\3_&FRTBW
M\(^/-/\ A9I_C$Z'XB@^W6WA?7[[3]/N;S3=7@\ZU^TKHES=SV]TC36^\VS;
MWB^8KX-X>_:4\7^$?B3X$\-Z_P#&CX/_ +0?A?Q;X=\>:_XL?X7>'8-+\3_#
M'3?!'A2;Q.WB34H]$\;^,+"\\/7LMLV@-'J%OI=X^K7VGBQGF_TB!?I'XE?"
MGQI\6?V;=?\ A%XN\1>'CXZ\6>!;;PUXA\46&F7<?ANZUH+:#4=6M]'EE>[@
ML;^2WEG&G--(;?[0;<2R1QAV[#4_A-X87X?^,?!_A/0/"WA.\\5^#=;\,2:C
MHWA_3]+B\_5=$N=*CN[N/3+>VEN(899UF:-G+E$VJP;!KY3*\WX,P&38C 9C
MEN!QV+Q_$/$F&JO"T*$XX+*L1E^4X7)L?0S;'9=B,XIX;+<;4S#,,!1P-?#5
M\;/"RHYI&5&NHRT<:CDFFTE&#U>\KMR3BG:[5DVU97O'5:>3:1^V#\/?$.B>
M%-7T#P=\7-7N?'J7VH>!?#EM\/M03Q-XL\+Z7IFBZIJ/CC3-+N9X#%X.M(_$
M&F67]M:E-8I<ZI<)IUG%<7,D22,N_P!L[X/+IB:OH=MX^\965IX.G\>>*SX1
M\$:QK%U\/_#EM>ZMIEQ)XZL=L%[H.J0:GH.N64V@R03:U$^D:C/)8K9VS7)J
M2_ 7XB>$A\$/$WPO\3^#E\=_"GX-K\%-:M?&FEZQ/X2\6>&YK7PA)+>0-HUW
M!JVBZCI^N^#[/4;%XUNH[JRNKK3[Q$)@N8?C+QK\.?%W[-:_%'1/"GB36M3\
M;?'3X7:[-XUU";X+>*_%^@_$'XD^(-<\>ZCY?PKF\(ZS/!X8UZWO?&,^DS^&
M_&Q72H-%ET37([Z\-OJRU]'DO"_AIG]>6'R_$8N>,J5D\!ESS''RJUJ4<WQV
M'QRQ\Z60U)8;#X/(X9=F>$QF'A5>(Q=>M'$4(86&*I95$IUH_$E;K*RM?EBU
M9<RNW)RC:^B6[=N;[GT_]KKX7:QKEYHNC:7\0]932/ NB?$;Q%K6E>!=8U#0
M_#?A;Q+X/N_&WAZXU:]M$F<7^M:59RVVGZ396]YJ4^JO#8"V#3(YS;[]LSX6
M:%!J[>+]!^)W@O4=*LO!FK)H'B3P%JEMX@U;1/'OBB'P9X<U;1M+M'O9KZ"?
MQ)<6^EW=HI35+&XGA2XL%,BBN(^'O[,?CW0OA9\3M'MO'3>"/&7Q4^#OP<\'
MV.K:1%<_VGX%\0> ?AA;>#[^:2\M+NUEN1+J'G,EQI-W8W4%NTKV5S!=B&X7
MS#1/V$/$]KXST[QB^I?"SPG&O_"GQJV@>#-$\57']HS?"[XS>&?BK=ZOJGB?
MQ-JVI:_XDUGQ'%HUUI!N=7D5=-5K$)]I NYI<\/DO@X\5CJ>+SO&4,-@Y931
MHRIXO$5J^.FJ&58G-ZL*T<L]C0A.MB<VP&'=/#8VG&.6PJSG1E4PU3,CFQ%E
M:*;?-=M6MJU&ZYK]$WMO;O;Z#A_;.^&#7UWI]]X8^*^BSZ'XPT'P/XU?6/A]
MJEG:_#_6_%=UI]IX6'B^[$DMM96?B"35M.DL;JQEU&..WNX[B^^QP_/7UQ7R
M)XP_9KU?Q/8_'ZSB\4:;:M\9/BA\+?']@\MC=2+HMI\/K;X<6]UIMX%E!NI]
M1/@>Y:":$I'"M_")%/E/GZ[K\[XGI<)QP^65>&I8B->IS+,<-7Q-3%*ES91D
M&,4H5*F#PME3S;&Y[ED8IU&Z&5X>I-RG-XG$ZP]I>2G:WV6DE?62V3>\5&73
M636RLBBBBOD#0**** "BBB@ HHHH **** "BBB@#\]?^"E7@7XD>.O@;\.Q\
M+=,^(6H^(O!G[3G[.GQ'OI_A3HOAWQ)\0M#\,^!_B1I>M^(_$?A;P_XK630-
M:U31=,@FO(=.U&"YAN=A3[-,V$/SG>?#+XQ_M&WG[.WAKQ7K'[:MQ\//#WQ'
M^.5W\7]7^(LUI^S1XRU/2-2^!6H67PYTZ['P)U3P:^L>$;#QY<VMUHT\9%_'
MXKC26^E>SLHD/ZQ^/?'_ (9^&WAZ3Q+XJN[F"Q^VZ?I5C::=IU_K6M:UK>KW
M4=CI&A:!H>E6]WJFM:UJEY*EO8Z;I]K/<S,6?8L,4LL?(>&OCM\//$-A?7M_
M?:GX"GTW6[3P[>Z1\4-%U'X=:S'J^HVD5_IEM;V'BJ#36U$:G9S)-83:6][!
M<[9H4D^T6]Q#$ ?@9I_P%_;M\8+^S3/\:/!?[0'B_P".6E>*/V ?&FF?$&7X
MAP2_!+X<>&?AYX'\#M\<;/XN^!(?&-IH^M>/=-^,MGXC\4>*)(_!>O\ B/Q'
M/=Z5K/A?7[;0M,U.SM.GT#X-?MQ1>#XH#X4_:ML-#T_P;\!;3]M'P]KWQJ;5
M_'G[07Q)T/XP:-JOQ]UK]F#6K7XCRS^'+#7/AQ!K\=Q=>"=7^%VC^+?#.H:7
MX-\(Z7H_BNUFN+3]_=)^(?@'7[VYTW0O&WA+6=0L]2_L:[L=*\1:1J%W:ZMY
M5Y.-,N+>TNY98;\PZ=J$HM)$6<I87K!"+6?RT@^(WP^N=2MM'M_'/A"?5KW1
MV\0V>F0^)-'EO[K04BDG;6K>T2\:>;21!#-.=0C1K3R8I9O-\N-V !^*>O\
MP$_:C\3:%XK\5:#X;_:6\"WGAW]F+X6>&O@=X&\0_M%>)/%FN:)XHD_:!\<W
M/B67Q9J.F^(M/TWQ%\2&^#3^%!KMQXB;Q'/X>TZZ7PW'XCU_4M*EUN[Y[Q/^
MS;^W'H.GZEXJ^$^M?'@?$GXE7/[9EI\2DU?XS:O>V4G@N7XU>'?$?P8\/^"K
M'Q7XDO?!WPY\2W_POMO%OAKX2^)-!L-%D\/7NNVC>(=4AL[>.>R_<31OB7X)
M\2WFC6WA?7K'Q5;ZX-<%GK'AB>+7] BG\/+I[ZE9W^MZ5)=:=87RIJ=H]O:7
M4\4]TK.T*.$8USB?'?X5W'C*[\":?XMTO5O$.FQV,FKQZ1=6VI66BM?W6N6<
M<&L:A:S26FFWEO-X>U/[;974D=W9Q1Q37$*13(Y /P\U[]G[]L_76N_$'P,\
M(?&GP!X8TC4_V@I?V;="^,OC^'7/BY\,-$\5?L^>!_#&LVU]XL\5^*_&>K^'
M)_B#\0[#QPGPT3Q/XHUBZ\+7^HV>KWD^C:2]HEKYI\8=;\9_!(:/JWQ9N?VD
M?A'^Q9XG\:>-?^%?_!3Q_P#M(/X0_:'?Q[HOP)MI+/Q7)\0M>^+=OKW_  KK
M3OB9:Z[K47@+5/BK=W=QKMS8^-HO"^H^"+2328?Z*U^+/PM;0[?Q.OQ(\"'P
MY=ZH-$M=>'BW0?['N-98,PTF'4OM_P!DDU+8CR&Q68W(C1Y#$$5F#=<\2?"G
M6-0O?!_B77?A_JNJ:-:#Q#J/AC7-1\/7U]I=C:0+=C6[S1K^:6>RMK6VE2Z_
MM":WCC@@E2?S4CD5V /Q1_8=U7XY>*OBK^RU\-]7^(GCGQ!X5M_V9_@O^UG\
M<8O$'Q$U/7/'7@[XK1?"!?@[I/PT^(:R:A<7MOI/Q2L-9\,_%^W\/:A';:;X
MBU_P?XH\9PVD\NHO=R?OC7FEM\1?@_:V5EXIM/&_PYMM/\7W\&CV'B&W\0^&
MX;7Q+J=@GV2VTRWU2*[6/5KZPC_T:*S2>>>S3]R(XE^6N_L]0L-06X:PO;6]
M6SO+G3[MK6>*=;:_LY#%=V<YB9A%=6LH,=Q ^V6%P5D56&* +E%>,_$KX\>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,^(-7\:ZSJNGZ5%:>&(18:#K\.I:_%K>J:S%;7.J:7XHN]3TT ^^O$_[4GP
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MN6NDVSZCJ*73>$O#EC]CTF)+FW@US4H;F*.TX+4?V!3H_@T:+\//'VJ6FO\
MB/X%_%3X*?$B_P#&FO>+?%&D>([;XE>&[Z;^VM'TF]U.[M?#DNF?$FX_X2I;
M33+>V@DL;_5+(J9'A- 'UO9_M!?"DPZI/K_B[1/!,>G?$?Q+\+;<^-=8T?P[
M_;?BGPM=0VFHPZ']NOT&H0/)<0F QE9RDB&:"$N@:7QO^T'\&?A]:>/IO$GQ
M%\)V]]\,O#%[XP\:>'X-?TF?Q)HF@V,$=Q+>7>B"]2]@$BSVR0_:$A1Y;NU5
MG03QLWR[XH_8_P#'%WK'Q UOPYXL\!2W/Q+B^/'A+6[3QIX9U/7=.T3P1\;]
M=T+69M6T"WMKZSW>+="_L8VUYIEV4T7Q1!-917=_IXTF%[FA=?L5>,$\1>/8
MM!^(&DZ%X*\6>"?%^@3VT:>*=1OO%FK>)?A]8>";+4_&GA[5-8O/"MGK6FWF
MF6&O:QXV\(Q:5KGB[[#9Z5J&GV=LEU->@'V3IGQH^$VKWNG:59?$;P5)K.J^
M%+?QQ9Z(?$VBKK$GA.YTU-8CU_\ LX7IN1I8TN1;^2]"&V2SS=&7[./-K%M_
MVA/@U<:?K7B%?B5X"7P7H>D^']6NO'/_  F_A*3PNT7B+5_$NAV4?VZ'69)+
M<G4O"VI6L5S>P6UEJ%RDUKI5S?W.G:M#8?&J?L+^++SQ?KGB'6O%OARYM_$M
MY>^.;H#5OB7++H'Q!U+X0K\,+K3-"T:/Q)IWA.[\.6TQFOM.\1:KHCZU%X<N
M+GPG<Z%<K)#K%KWFH?LE>++'4_!_BGPGXA\$_P!O?#OP5^SUH7AG0?$6C:E+
MX-U+5O@YH_QCT#6&UJWT^2*[L[+5++XK+>^';VPCN+W1M2T=GFM)XKI@ #Z%
M\:_M _#_ ,#>)_@MX9U":_U-?CQK-[HG@CQ!H$5KJOAQ;FVTN'5;2YU34X;P
M+;Z;JZ7-M:Z7?VL=[!<7ES;QNT4<JRUE:-^T_P#"#4[[XMPZEXDM?!^E?!KQ
MO8^ /$OBCQI>:5X=\,:CX@OM*M]2">']6O-1$.HV]O/)=:-.\@MIAK&E:I:)
M ZVC2MYK\1_V8_%?COPI\+=.;QCX9M_%/PT\&^,[6RUFT\*1>']$7Q[J=IH5
M[X/US2?#6BN+72/#_AWQ-H%E+<:1!,;JYT,262WC74\UPW$Z5^Q]XS\&ZIHG
MC#PGXM\':SXN\+>(/"GB>QM/&NC:I-X:\4:Y'\(=9^&WC[6?$B:9.MY8:]X@
MUWQ%J_CC3-8TU+MK.\NK_2Y[1K?5[BXM@#Z<\=_M!?"?X?\ _",V^K>,= O=
M9\9:AX(L_"WAO2M;T:Z\0^(+/Q[XPT'P7H^NZ/I;:A%<:GH<6H^(;2[O-0LE
MFB738;NY@\\P^6UOQ?\ '+X<>$?#VG>(F\1:;X@MM8N_"\.D6GAK4M,U:_U6
MQ\4_$/PK\,H-<TZWBO5%YHFE^*?&6B6NL:C;O)!9"X$;%KEX;>7XVT?]A[QE
MX1M= \.^'?&_@;5O#D_B#]G;Q9XQO_$OA+4!XCLM7^ OQ!L?&G]F?#L6FI7%
MAH'AK7X$O=.TC3KQ[B3P= T]I:2:I%K%S<6#]._8Q^)Z_P#"-:3JWC_P-+X;
M^'^@:9X2\&G3="UVVUF]TC3?VDOA/\<_[4\2/<WUU9IJMQI'PZE\,FQTU?L<
M.H2PZJ+N:"]ELM, /JGQK^U!\!/ 6B^-]<UOXI^"I8?AQ+I</C:PTOQ+H>H:
MOX<?6-<M/#MF-5TV+4!/9#^UKV*UF-R(A ZRK)B2-DKM#\8OA,-4UW1#\3/
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M"TLYK>\DTG6-!\0ZWI<MQ9RB\TR>[MM7M(Y[FPBMY?GGPQ^S!XWNO'VE>/\
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MZ5X1;5A;C5'L-=\%ZQ)J.L7^6UN2\TK2M1T6^TNT&KP:M^K] !1110 4444
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M+/"S+\L<7#-<95Y;?'1H1O:UOA?D?QO_  $_X)R_M%?'/XFZ;X3\3?#[QO\
M"GP=$PO_ !1XU\;>$=:T&UT_1TE1)X='AUJTL%UO7;K=Y-AIUL[*CL;J^>WL
MX99*_K(^"GP3^'7[/OP[T+X8_##0H=#\-:'"!GY9=1U?4)%07NN:Y?!$DU'6
M-1D02W=W(%'W(+>.WM(+>WB]8HK\E\8?'WC'QBE@,+FL,/DV09:E5P_#^65:
M\L%5Q[C*,\RQM2M)U,9BU"3I8?VB5+!T7..'IPJ5\35K_H.6Y70RVGR4Y2J3
M:LZDTE+E5K126D5HF[:M[NR211117X8>D%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5YN?B5;@D?\ "%_$@X)''@O4R./0C@CT(X->D44 >;?\++M_^A+^)/\
MX16J?X4?\++M_P#H2_B3_P"$5JG^%>DT4 >;?\++M_\ H2_B3_X16J?X4?\
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M_P *])HH \V_X67;_P#0E_$G_P (K5/\*/\ A9=O_P!"7\2?_"*U3_"O2:*
M/-O^%EV__0E_$G_PBM4_PH_X67;_ /0E_$G_ ,(K5/\ "O2:* /-O^%EV_\
MT)?Q)_\ "*U3_"C_ (67;_\ 0E_$G_PBM4_PKTFB@#S;_A9=O_T)?Q)_\(K5
M/\*/^%EV_P#T)?Q)_P#"*U3_  KTFB@#S;_A9=O_ -"7\2?_  BM4_PH_P"%
MEV__ $)?Q)_\(K5/\*])HH \V_X67;_]"7\2?_"*U3_"C_A9=O\ ]"7\2?\
MPBM4_P *])HH \V_X67;_P#0E_$G_P (K5/\*/\ A9=O_P!"7\2?_"*U3_"O
M2:* /-O^%EV__0E_$G_PBM4_PH_X67;_ /0E_$G_ ,(K5/\ "O2:* /-O^%E
MV_\ T)?Q)_\ "*U3_"C_ (67;_\ 0E_$G_PBM4_PKTFB@#S;_A9=O_T)?Q)_
M\(K5/\*/^%EV_P#T)?Q)_P#"*U3_  KTFB@#S;_A9=O_ -"7\2?_  BM4_PH
M_P"%EV__ $)?Q)_\(K5/\*])HH \V_X67;_]"7\2?_"*U3_"C_A9=O\ ]"7\
M2?\ PBM4_P *])HH \V_X67;_P#0E_$G_P (K5/\*/\ A9=O_P!"7\2?_"*U
M3_"O2:* /-O^%EV__0E_$G_PBM4_PH_X67;_ /0E_$G_ ,(K5/\ "O2:* /-
MO^%EV_\ T)?Q)_\ "*U3_"C_ (67;_\ 0E_$G_PBM4_PKTFB@#S;_A9=O_T)
M?Q)_\(K5/\*/^%EV_P#T)?Q)_P#"*U3_  KTFB@#S;_A9=O_ -"7\2?_  BM
M4_PH_P"%EV__ $)?Q)_\(K5/\*])HH \V_X67;_]"7\2?_"*U3_"C_A9=O\
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M4DY*JU>4=$VIM)7C=^Z]XO356Y?W&HHHK_/<^G"BBB@ HHHH **** "BBB@
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MC25DG)**LK:))*]V[MW"BBBOR\[@HHHH **** "BBB@ HHHH **** "BBB@
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M'WO1W6EK?T__ /$4_P"%_P#HT;7/_#H6/_S*4?\ $4_X7_Z-&US_ ,.A8_\
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MSFHQ2O*RU]V][NUW:W[T?\13_A?_ *-&US_PZ%C_ /,I1_Q%/^%_^C1M<_\
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M'11_Q+7X0_\ 1/8S_P /V>?_ #?Y?GW8?VYF/_/Z'_@JG_\ (_U=^5O['/\
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MH_XBG_"__1HVN?\ AT+'_P"92OY?/V4/@KX/^.GQ'\3>&_'NO^-/#WA3P?\
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M2U^$/_1/8S_P_9Y_\W^7Y]V']N9C_P _H?\ @JG_ /(_U=^5O['/^(I_PO\
M]&C:Y_X="Q_^92C_ (BG_"__ $:-KG_AT+'_ .92OXXZ*/\ B6OPA_Z)[&?^
M'[//_F_R_/NP_MS,?^?T/_!5/_Y'^KORM_8Y_P 13_A?_HT;7/\ PZ%C_P#,
MI73>"O\ @Y\\,^,?&7A+PC'^R?K=F_BGQ-H/AQ;QOB98RBT.MZK:::+DQ?\
M"+Q^;Y'VGS?+\Q ^S:70'</XO:]2^!W_ "6KX0?]E0\ _P#J5:57/B_HW^$=
M+"XFK#A_%J=/#UJD&\]SMVE"G*47:6/L[.*=GH];Z-E1SO,7**=:-FTG^ZI]
MU_=_J[\K?ZTU%%%?YG'W 5_DM_ OXD1?!SXU?"7XMSZ3)K\'PR^(OA'QW-H<
M-VFGRZQ'X8UJTU9]-BOY+>Z2SDO%MC ET]K<+ SB0PR!=I_UI*_EQ/\ P:U_
MLY9./VFOC*!GC_BF_!W]% _(#Z"OZ2^C]XC<&\"8?CC"\88C%T*'$5'(\/AX
M87!XK%>VI86&>T\=&<L*G*C:&84%&3<92YI.#O!M>)G&"Q.+EA)8:,6Z+JRD
MY2C&SDZ+A;FWU@V_3S1_*Q9_MF?%#Q1\:? GQ%_:$\3?$/\ :-\ ^"?B%<^-
M8?A/\3?B1XDUS0I+>ZN;MS8V/]KRZMIUA>6UO<Q);74FCWEI(UI%;WVGW>FR
MW%E+]$?$C_@H=X8\8> [#P'H_P ,/%%K#H_P9_:.^$%GK>M>)/ =O=7L'Q]\
M0?"CQ"FMW6A_#WX9> /"^G+X8F^'%SIHTC2])4:E8:G;2W&I-=V]S)<_T/?\
M0M7[.?\ T<U\9?\ PF_!W^%'_$+5^SG_ -'-?&7_ ,)OP=_A7[QB/&OP$Q-?
M 8B=3,:<LMCRX&GA\HS;"X?#WAB:<I1PN']EA^><,;B%5FZ;E6YXRK.<J%%T
MO)CEF;Q4HI0?/\3E4IRD]8/XI7=ER1MKI9I:2=_Y>M=_:V\-:M\"9OA=;_#_
M %ZT\5:I^S'\/_V;=;\12^*M.N/#LEC\-/B[I7Q+\/\ B?3=#C\/6^I6T]_9
M6M_HVLZ9=ZS?0M=36-_97%M%;3VMS](V?_!3^SG9[36?A[XWTS1]$\<>"?B'
MX/7P)XR\ Z7K3ZIX=^#_ ,+OAAK_ (>\5:OXR^$_CJ7^P]<O?A7H_B/2M8\&
MKX5\5>'#>WUC%J5^XL;RP_?3_B%J_9S_ .CFOC+_ .$WX._PH_XA:OV<_P#H
MYKXR_P#A-^#O\*QK^,O@#B8RA7JYM54L1BL5[^79W)QK8WZDL1*#<KP4H8#"
MTHQC:-*E"5.FH1J5>9QRW.(VY536D8Z3I6:CS-7MO9SDWW>NNE_YL/"W_!0/
M5M ^)/PC^(-WX*N]1?P=\'/CC\&?'L)\16DVJ^)])^._COXF^,/$6O\ AO5=
M<\/:_9Z)XAT=?B% NF3Z_HOBBROM2T,3ZS8WMAJ-S8+I^-/VZ?!/Q+\,:M\(
M/B+X$^*_BKX+7OASP7!9-)\2O!.D?$ZR\:>"O&GB?QG;^)+6]T+X4:9\-]+T
M/5W\6:GHNI^$=(\ 6<1ACM]?.JS^(9+V[N?Z//\ B%J_9S_Z.:^,O_A-^#O\
M*/\ B%J_9S_Z.:^,O_A-^#O\*J7C-X RKT\2JN:T\11Y71K4LMSNE5HSIXVO
MF%*I2J4Y1G3J4<7BZ]2G*+7+&?LW>G3IP@O[-S>SC:FT]TYTFFG&$&FG=6<8
MQ3]&]WK_ "WZO^UMI-Y^WCHW[9&F_#^^TS1=$^+'@#XCV/PW?Q.M]J$-AX%T
MWPYIT&@GQ;)I4(GN)X] 7;JTNCALRB26U>16W9OA#]MKXVI\<_A3\7OC%\1_
MBM\;=+^%7C.[\7:/X2\:_$GQ#K$,$MW8ZC8R1:3/KD^JV>E731WJ(]]#8-*T
M,/E8", O]47_ !"U?LY_]'-?&7_PF_!W^%'_ !"U?LY_]'-?&7_PF_!W^%=G
M_$=/ ITH495LPJ1I9/2R&E.KDN:5:]'*Z5&MAX8>CB*D95Z4W1Q-6%7$4ZD<
M154DZM6;IQ<5_96;7<DH)NJZS2JTTG4;C*[BG9I.*:BTXJSLM=?YB_@]^U]X
M&\ Z!\#Y_&?PI\1>+O'_ .R]XY^('CSX'ZOH?CZS\,>%[F^\=:GI_B6/2_B;
MH4_A/6M2URP\/^+M,M]9M[CPWKGAO4-5L7N-"OYTMVANX/K?Q#\9O@<?@E\7
M/C/XD\5>$==^.?QB_9+^"GP=\CP?\3EGAU'Q5X/\6_"J2\TN7X,7/@/2_$W@
MK6]-\+?#C[-XOU74_%6J^"5U"T&H>#_M$&NVT%K^WO\ Q"U?LY_]'-?&7_PF
M_!W^%'_$+5^SEG/_  TS\9<^O_"->#L_GBO,QOC+X(8O%4L72SCB#!UEBX8F
MNZ.6YQ)5Z2S)9Q5P:C4<HT,-B,R<L5B*5**I5:E2;J4Y2A0E0N&6YK&+@Z=*
M2Y>6-YTO=?(J:D[?$XP]U-W:4=&M>;^<GPG^WEX!T?XK_M$?%G6?@GJ%UXB^
M,?QPTSXR^&]7TO7_  1/XA\,:?I]WXAO;KX::C?>._AIX\TT^']<N=7TZZU#
MQ)X6T?P[XNMI=%B@LM12UNC';V=>_P""A>CZO\;?!OQ:@^%FJVUIX5^,G[7_
M ,67T";Q?:SSW9_:GO\ 5M1CT>+4%T*.*!_!TNJF*6_:S?\ MJ&!-L%@S$+_
M $6_\0M7[.?_ $<U\9?_  F_!W^%'_$+5^SG_P!'-?&7_P )OP=_A6C\8_ &
M55UI5LY=26#> O+ Y\TL(\L>4.C&+J.,8_4)2HII*492E6BU6;F"R[.$K*-)
M+FY_BH_%[15+[?SZOO:VJM?^:'X+_MNZ=\,/!7PM\$77AKXAV,?P^^%7C+X;
M7GB/P!XZ\/:5?:O_ ,)3\6KCXF^;?^%/&G@;QQ\/_%'AV:WN'T'5/#7C+PUK
M0$ZP:]HNHZ5>0/#<?)_QX^(V@?%SXO>.OB1X6\ :+\+] \6:P-0TWP-X?^S?
MV;HD26EM:NP^PZ?I&F_;M2FMY-6U3^RM'T?2?[3OKO\ LS2=/LO)M8_[#O\
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M-?&7_P )OP=_A1_Q"U?LY_\ 1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\
MROS_ #[,/[#S'_GW3_\ !L/\_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP
M=_A1_P 0M7[.?_1S7QE_\)OP=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_
M )]T_P#P;#_/^K/RO_$M17]M/_$+5^SG_P!'-?&7_P )OP=_A1_Q"U?LY_\
M1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\ ROS_ #[,/[#S'_GW3_\ !L/\
M_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP=_A1_P 0M7[.?_1S7QE_\)OP
M=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_ )]T_P#P;#_/^K/RO_$M17]M
M/_$+5^SG_P!'-?&7_P )OP=_A1_Q"U?LY_\ 1S7QE_\ ";\'?X4?\3-^$W_0
MUS7_ ,,>8?\ ROS_ #[,/[#S'_GW3_\ !L/\_P"K/RO_ !+45_;3_P 0M7[.
M?_1S7QE_\)OP=_A1_P 0M7[.?_1S7QE_\)OP=_A1_P 3-^$W_0US7_PQYA_\
MK\_S[,/[#S'_ )]T_P#P;#_/^K/RO_$M17]M/_$+5^SG_P!'-?&7_P )OP=_
MA1_Q"U?LY_\ 1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\ ROS_ #[,/[#S
M'_GW3_\ !L/\_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP=_A1_P 0M7[.
M?_1S7QE_\)OP=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_ )]T_P#P;#_/
M^K/RO_$M17]M/_$+5^SG_P!'-?&7_P )OP=_A1_Q"U?LY_\ 1S7QE_\ ";\'
M?X4?\3-^$W_0US7_ ,,>8?\ ROS_ #[,/[#S'_GW3_\ !L/\_P"K/RO_ !+4
M5_;3_P 0M7[.?_1S7QE_\)OP=_A1_P 0M7[.?_1S7QE_\)OP=_A1_P 3-^$W
M_0US7_PQYA_\K\_S[,/[#S'_ )]T_P#P;#_/^K/RO_$M17]M/_$+5^SG_P!'
M-?&7_P )OP=_A1_Q"U?LY_\ 1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\
MROS_ #[,/[#S'_GW3_\ !L/\_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP
M=_A1_P 0M7[.?_1S7QE_\)OP=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_
M )]T_P#P;#_/^K/RO_$M17]M/_$+5^SG_P!'-?&7_P )OP=_A1_Q"U?LY_\
M1S7QE_\ ";\'?X4?\3-^$W_0US7_ ,,>8?\ ROS_ #[,/[#S'_GW3_\ !L/\
M_P"K/RO_ !+45_;3_P 0M7[.?_1S7QE_\)OP=_A1_P 0M7[.?_1S7QE_\)OP
M=_A1_P 3-^$W_0US7_PQYA_\K\_S[,/[#S'_ )]T_P#P;#_/^K/RO_$M7T]^
MR=_R/GQ(_P"S7?VL_P#UG;XC?Y_2OZR_^(6K]G/_ *.:^,O_ (3?@[_"O0?A
MM_P;7? 7X9ZQKVLZ5^T7\5M0G\0?#SXD_#FXBU#PWX5\J#3/B;X'USP)JM_!
M]GDA?[?I^GZ]<7FG^8SP?;(8?M$4L/F1MY^;?22\*L7EF/PM'-,T=7$82O2I
MJ62X^*<ZE-QBG)TTDFVM79+6]K.VE+),PC4A)TX6C)-_O8/1->?]6]+_ ,;?
M[-'[0.N_LU^-?&'C[PLVNVGB?7?@_P#$GX:^'==\-:_/X:UOPGK'CO3+73[/
MQ7I^JVL4EU'-HIMVE$%J]K<3B3;'>0$$MZ3\)_VO==T[XD^)/B'^T9+X\_:(
MUC6/AMJ7@#P[XF\7^,++Q1XP^'=W=:IIFIVGB3PH?BCH/Q#\)7$]K%97^F'2
M];\-7U@EOKE_?VBVNK16UXG]37_$+5^SG_T<U\9?_";\'?X4?\0M7[.?_1S7
MQE_\)OP=_A7-B_'OP/QU7&5\3B,QGB<=AZ6$Q&*629E3Q+PU%N5.A#$0A&K2
MI<TY.I3ISC"JI2C6C.+E$<<IS6"@HQ@E"3E%>UIVN[7;5[-Z:/=6;BT['\U/
M[3G[=6F?M >&/$/A_2OAMJGA1M<UC]E_5DN-3\4Z5K7DG]F_X:^//ATD=U#H
MOA/PII\TOBN+Q;8ZM(VFZ7HUCI,]C?6MEIJVMU:QVFUXZ_;S\*>(_B5X+\?Z
M#\+?$NEPZ#^V;:?MB:YH^K^-=+U1K[6KC1O#%GKW@_2+RR\*Z4ECI\NHZ#<3
MZ-J5Y:7MW9V%W#:WJ7T\#W,W]'G_ !"U?LY_]'-?&7_PF_!W^%'_ !"U?LY_
M]'-?&7_PF_!W^%>=2\9_ .A1PU"E7SB%'"4J]&A#^S\]:C3Q.$P>!JQDW-NI
M?"X'"TXRJ.4J?LY3@XSG4E+1Y;F[;;5-N3BVW.EO&3DO3WI2;MH]?(_G>U;_
M (*0W.L_#2'PY)X4\;:1XPT?X2^-_@IH4WASQ?X*TGP->>%/%5UXG@L-;\46
M[?#"[^)ESX@TKPSXJO\ P_JFFZ)\2]'\,>*#;6EY?:=:02ZCI][\0?M$_%F'
MXZ_&CQM\6(-%F\.Q>+O^$6":+<7Z:G-8KX;\$>&?!^'OTMK-9Q<MX?:]0+;1
M"!+E;?YS"9'_ + /^(6K]G/_ *.:^,O_ (3?@[_"C_B%J_9S_P"CFOC+_P"$
MWX._PKKROQT\"LEQ,\7EN(S/#8BI#%4ISCE&;33IXROA\37ARU%*-I5\-1G'
M2].TH4W&$I1(J95FU6*C4C"23B]:E/>*:3;3O>TG?O\ =?\ B6HK^VG_ (A:
MOV<_^CFOC+_X3?@[_"C_ (A:OV<_^CFOC+_X3?@[_"O?_P")F_";_H:YK_X8
M\P_^5^?Y]F8_V'F/_/NG_P"#8?Y_U9^5_P"):BO[:?\ B%J_9S_Z.:^,O_A-
M^#O\*/\ B%J_9S_Z.:^,O_A-^#O\*/\ B9OPF_Z&N:_^&/,/_E?G^?9A_8>8
M_P#/NG_X-A_G_5GY7_B6HK^VG_B%J_9S_P"CFOC+_P"$WX._PH_XA:OV<_\
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MP=I5YJ4J/+'I]I>Z]?6,%U>-%')-]F@>280QR2E!&C, #U"BL3PUXF\.>,]
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M=GI=)]$!^G@T^P#P2"QLQ):R32VSBVAWV\MP<SR0-LS#).>9GC*M*?OEJ?\
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M\$_$_0OC!8^)]/T_6K?3+?QYJ7A?QAJVEZOX>TB\E7=T+]EC]N'Q/=^!-?\
MC5XO^/=S\0HOBY^Q7X8^(E[X&^,VL:#X-O?A.OP'T?0/VK)[#2/#^O:9H[:5
MK_C5M2B\6:S9Z=;^(I-6MH=8\)3Z=,$NI/Z!J* /YG/%GP._X*>#4OAEH&G^
M+?C=HWA?POH/BKPI\'=3TS0[_P"*WBWPGXWT3]IGXJMHGBGXEZVW[4OP/T(Z
M?J/P#D^$D6B>(?BYI/Q>\/ZEH.E^(](UG2[+6=2EM=9Y;XY_L]_MK^#?AO\
M%[X4_LW?!WX_:'XBOOBK^WG\2/!7CG2?'_C34-'O_BYXX\3^&O%OP*UW1M.T
MCXV_#>VT[3+S1KBYN]!\=^-]=UKP5X9U[3_$GAC4_A7KNI:L9)?ZC** /YQ]
M+^!W[<ME\2?C;J?P;\(_'SX:_&_QU\=?B]\1E^)7BWQUI5M^SEK/PD\3?LIZ
M+X;T_3(?"$?B:^T:#XA:I\=;+P_+HL<O@NWUO1O$FAS>,=1UH^#;2[L+O/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:)_M!M!#]G,_G 3>:8_,\T"3=O -:<<4<,:Q0QI%$@VI'&BQQHOHJ* JCV
MKC/^$#TK_H,>-O\ POO&7_R[H_X0/2O^@QXV_P#"^\9?_+N@#MJ*XG_A ]*_
MZ#'C;_POO&7_ ,NZ/^$#TK_H,>-O_"^\9?\ R[H [:BN)_X0/2O^@QXV_P#"
M^\9?_+NC_A ]*_Z#'C;_ ,+[QE_\NZ .VHKB?^$#TK_H,>-O_"^\9?\ R[H_
MX0/2O^@QXV_\+[QE_P#+N@#MJ*XG_A ]*_Z#'C;_ ,+[QE_\NZ/^$#TK_H,>
M-O\ POO&7_R[H [:BN)_X0/2O^@QXV_\+[QE_P#+NC_A ]*_Z#'C;_POO&7_
M ,NZ .VHKB?^$#TK_H,>-O\ POO&7_R[H_X0/2O^@QXV_P#"^\9?_+N@#MJ*
MXG_A ]*_Z#'C;_POO&7_ ,NZ/^$#TK_H,>-O_"^\9?\ R[H [:BN)_X0/2O^
M@QXV_P#"^\9?_+NC_A ]*_Z#'C;_ ,+[QE_\NZ .VHKB?^$#TK_H,>-O_"^\
M9?\ R[H_X0/2O^@QXV_\+[QE_P#+N@#MJ*XG_A ]*_Z#'C;_ ,+[QE_\NZ/^
M$#TK_H,>-O\ POO&7_R[H [:BN)_X0/2O^@QXV_\+[QE_P#+NC_A ]*_Z#'C
M;_POO&7_ ,NZ .VHKB?^$#TK_H,>-O\ POO&7_R[H_X0/2O^@QXV_P#"^\9?
M_+N@#MJ*XG_A ]*_Z#'C;_POO&7_ ,NZ/^$#TK_H,>-O_"^\9?\ R[H [:BN
M)_X0/2O^@QXV_P#"^\9?_+NC_A ]*_Z#'C;_ ,+[QE_\NZ .VHKB?^$#TK_H
M,>-O_"^\9?\ R[H_X0/2O^@QXV_\+[QE_P#+N@#MJ_//]L+]G7XI?&?QC!XA
M\%);3IX7^"GB#3? 4]QXHDT2Y\,_&6Z^+GPG\2Z5XFT55EB.DZLG@SPOXFT\
M^)K9H[I+*XGT)Y39ZO<03_:W_"!Z5_T&/&W_ (7WC+_Y=T?\('I7_08\;?\
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M@>E?]!CQM_X7WC+_ .7= ';45Q/_  @>E?\ 08\;?^%]XR_^7='_  @>E?\
M08\;?^%]XR_^7= ';45Q/_"!Z5_T&/&W_A?>,O\ Y=T?\('I7_08\;?^%]XR
M_P#EW0!VU%<3_P ('I7_ $&/&W_A?>,O_EW1_P ('I7_ $&/&W_A?>,O_EW0
M!VU%<3_P@>E?]!CQM_X7WC+_ .7='_"!Z5_T&/&W_A?>,O\ Y=T =M17$_\
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MC+]Y1G4HU(3=*K&%6"DE.$7H.,HR5XM-7:NMKIV>O74****\T84444 %%%%
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MDM%9QIMWE4=OV)HHHK\K/DPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGW]I?
MX=>+/B1\.;*U\"+I5QXS\'>/?A]\2O#FF:W>2Z=I6N7_ (!\5:=XA?0+O4HH
M+IM-&M65I=Z=;Z@UK<PV5W<6]Q<0O!'(*^@J*]'*<SQ&39G@,VPBI2Q.78JC
MBZ,*\'4H5)T9J?LJ].,H2G1JI.G5C&<)2IRDHSA)J24HJ2<7LTT_F?GGXO\
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MX,>#/"'@VW\2Z_K&LPZE;S>)M6\8ZOXIUFYN)KJ^U2ZTJRTVQLK2RDK]+Z*
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M<1%]QC#LS!<!B3DU)117 9A1110 4444 %%%% !1110 4444 %%%% !1110
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BQ^*=#=Y)'8*B(BWQ9W=B%55!9F( !) KLZ* "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>sepn-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-09T15:15:02.6230+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.septerna.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:sepn="http://www.septerna.com/20251231" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets" id="StatementStatementOfBalanceSheets">
        <link:definition>75010 - Statement - Statement of Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical" id="StatementStatementOfBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Statement of Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3" id="StatementStatementsOfOperationsAndComprehensiveLoss3">
        <link:definition>75030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2" id="StatementStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>75040 - Statement - Statements of Operations and Comprehensive Loss 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1">
        <link:definition>75050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical">
        <link:definition>75060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>75070 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows2" id="StatementStatementsOfCashFlows2">
        <link:definition>75080 - Statement - Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995420 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganization1" id="DisclosureOrganization1">
        <link:definition>995455 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1" id="DisclosureBalanceSheetComponents1">
        <link:definition>995475 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAsset" id="DisclosureGainOnSaleOfNonfinancialAsset">
        <link:definition>995485 - Disclosure - Gain on Sale of Non-Financial Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1" id="DisclosureCollaborationAndResearchServiceAgreements1">
        <link:definition>995495 - Disclosure - Collaboration and Research Service Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" id="DisclosureMarketableSecuritiesAndFairValueMeasurements">
        <link:definition>995505 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995515 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995525 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>995535 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>995545 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation" id="DisclosureStockbasedCompensation">
        <link:definition>995555 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995565 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>995575 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3" id="DisclosureNetLossIncomePerShare3">
        <link:definition>995585 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlan" id="DisclosureEmployeeRetirementBenefitPlan">
        <link:definition>995595 - Disclosure - Employee Retirement Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995605 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995615 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995625 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995635 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995645 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables" id="DisclosureCollaborationAndResearchServiceAgreementsTables">
        <link:definition>995655 - Disclosure - Collaboration and Research Service Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsTables">
        <link:definition>995665 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>995675 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995685 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995695 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockTables" id="DisclosureConvertiblePreferredStockTables">
        <link:definition>995705 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995715 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995725 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareTables" id="DisclosureNetLossIncomePerShareTables">
        <link:definition>995735 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995745 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" id="DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>995765 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails" id="DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails">
        <link:definition>995785 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>995795 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995815 - Disclosure - Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails" id="DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - Gain on Sale of Non-Financial Asset - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Collaboration and Research Service Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec" id="DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec">
        <link:definition>995845 - Disclosure - Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1" id="DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1">
        <link:definition>995855 - Disclosure - Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails" id="DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails">
        <link:definition>995865 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails" id="DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails">
        <link:definition>995875 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetailsDefault" id="DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetailsDefault">
        <link:definition>995875 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details) [Default]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>995885 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995895 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails">
        <link:definition>995905 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Major Type of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails">
        <link:definition>995915 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Values and Continuous Unrealized Loss Positions of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails" id="DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails">
        <link:definition>995935 - Disclosure - Leases - Summary of Expenses Recognized and Cash Paid for Leased Space (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" id="DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
        <link:definition>995945 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2" id="DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2">
        <link:definition>995955 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3" id="DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3">
        <link:definition>995965 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995975 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails">
        <link:definition>995985 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>996005 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails" id="DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails">
        <link:definition>996015 - Disclosure - Common Stock - Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails" id="DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails">
        <link:definition>996025 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" id="DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails">
        <link:definition>996035 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails" id="DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails">
        <link:definition>996045 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions used for Grants Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>996055 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails" id="DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails">
        <link:definition>996065 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails">
        <link:definition>996075 - Disclosure - Income Taxes - Schedule of Components of Provision (Benefit) for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996085 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails">
        <link:definition>996095 - Disclosure - Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
        <link:definition>996105 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>996115 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" id="DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>996125 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>996135 - Disclosure - Net Loss Per Share (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails" id="DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails">
        <link:definition>996145 - Disclosure - Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2" id="DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2">
        <link:definition>996155 - Disclosure - Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails" id="DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails">
        <link:definition>996165 - Disclosure - Net (Loss) Income Per Share - Summary of Potentially Dilutive Securities not Included in Calculation of Diluted Net (Loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails" id="DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails">
        <link:definition>996175 - Disclosure - Employee Retirement Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails" id="DisclosureSegmentInformationSummaryOfReportableSegmentDetails">
        <link:definition>996185 - Disclosure - Segment Information - Summary of Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996195 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets" xlink:href="sepn-20251231.xsd#StatementStatementOfBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2" xlink:href="sepn-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2" xlink:href="sepn-20251231.xsd#DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows2" xlink:href="sepn-20251231.xsd#StatementStatementsOfCashFlows2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2" xlink:href="sepn-20251231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3" xlink:href="sepn-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3" xlink:href="sepn-20251231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="sepn-20251231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails" xlink:href="sepn-20251231.xsd#DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="sepn-20251231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="sepn-20251231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails" xlink:href="sepn-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="sepn-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails" xlink:href="sepn-20251231.xsd#DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="sepn-20251231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical" xlink:href="sepn-20251231.xsd#StatementStatementOfBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1" xlink:href="sepn-20251231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:href="sepn-20251231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="sepn-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganization1" xlink:href="sepn-20251231.xsd#DisclosureOrganization1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="sepn-20251231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1" xlink:href="sepn-20251231.xsd#DisclosureBalanceSheetComponents1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAsset" xlink:href="sepn-20251231.xsd#DisclosureGainOnSaleOfNonfinancialAsset" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:href="sepn-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases" xlink:href="sepn-20251231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="sepn-20251231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="sepn-20251231.xsd#DisclosureConvertiblePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock" xlink:href="sepn-20251231.xsd#DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedParties" xlink:href="sepn-20251231.xsd#DisclosureRelatedParties" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3" xlink:href="sepn-20251231.xsd#DisclosureNetLossIncomePerShare3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlan" xlink:href="sepn-20251231.xsd#DisclosureEmployeeRetirementBenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:href="sepn-20251231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="sepn-20251231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sepn-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="sepn-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="sepn-20251231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:href="sepn-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockTables" xlink:href="sepn-20251231.xsd#DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:href="sepn-20251231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="sepn-20251231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:href="sepn-20251231.xsd#DisclosureConvertiblePreferredStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareTables" xlink:href="sepn-20251231.xsd#DisclosureNetLossIncomePerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="sepn-20251231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="sepn-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="sepn-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails" xlink:href="sepn-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails" xlink:href="sepn-20251231.xsd#DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:href="sepn-20251231.xsd#DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails" xlink:href="sepn-20251231.xsd#DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails" xlink:href="sepn-20251231.xsd#DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="sepn-20251231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails" xlink:href="sepn-20251231.xsd#DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails" xlink:href="sepn-20251231.xsd#DisclosureSegmentInformationSummaryOfReportableSegmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="sepn-20251231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetailsDefault" xlink:href="sepn-20251231.xsd#DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetailsDefault" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CombinedLicenseAndResearchServicesMember" xlink:label="sepn_CombinedLicenseAndResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRule10B51ArrModifiedFlag" xlink:label="sepn_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAsset" xlink:label="sepn_GainOnSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202309Member" xlink:label="us-gaap_AccountingStandardsUpdate202309Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidTaxesCurrent" xlink:label="sepn_PrepaidTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_FourZeroOne401KPlanMember" xlink:label="sepn_FourZeroOne401KPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanLiability" xlink:label="sepn_EmployeeStockPurchasePlanLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExternalGeneralAndAdministrativeExpenses" xlink:label="sepn_ExternalGeneralAndAdministrativeExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlan2024Member" xlink:label="sepn_EmployeeStockPurchasePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccountingStandardsUpdate202507Member" xlink:label="sepn_AccountingStandardsUpdate202507Member"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" xlink:label="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" xlink:label="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TaxCreditCarryforwardExpirationYear" xlink:label="sepn_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MaterialRightMember" xlink:label="sepn_MaterialRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheTwoMember" xlink:label="sepn_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidClinicalTrialCostsCurrent" xlink:label="sepn_PrepaidClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanMember" xlink:label="sepn_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RestrictedStockOptionsSubjectToRepurchase" xlink:label="sepn_RestrictedStockOptionsSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" xlink:label="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" xlink:label="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRefundableOneTimeUpfrontPaymentReceived" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TransactionPrice" xlink:label="sepn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UndesignatedPreferredStockSharesAuthorized" xlink:label="sepn_UndesignatedPreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" xlink:label="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RepurchasesOfUnvestedRestrictedCommonStock" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" xlink:label="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RequiredPriorNoticeDurationToTerminateAgreement" xlink:label="sepn_RequiredPriorNoticeDurationToTerminateAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockLineItems" xlink:label="sepn_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MilestonePaymentsReceivableFromCollaborationAgreement" xlink:label="sepn_MilestonePaymentsReceivableFromCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InitialPublicOfferingStockOptions" xlink:label="sepn_InitialPublicOfferingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ChangeInDeferredRevenue" xlink:label="sepn_ChangeInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExternalResearchAndDevelopmentExpenses" xlink:label="sepn_ExternalResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockFinancingArrangementFinancingValue" xlink:label="sepn_TemporaryEquityStockFinancingArrangementFinancingValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneMember" xlink:label="sepn_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeaseCommencementPeriod" xlink:label="sepn_LeaseCommencementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="sepn_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsLeaseLiability" xlink:label="sepn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RisksAndUncertaintyPolicyTextBlock" xlink:label="sepn_RisksAndUncertaintyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" xlink:label="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" xlink:label="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" xlink:label="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="sepn_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" xlink:label="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchase2024PlanMember" xlink:label="sepn_EmployeeStockPurchase2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeMember" xlink:label="sepn_EmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PercentageOfChangeInOwnership" xlink:label="sepn_PercentageOfChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" xlink:label="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_FurnitureFixturesAndOfficeEquipmentMember" xlink:label="sepn_FurnitureFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncreaseInSharesReservedForFutureIssuanceInShares" xlink:label="sepn_IncreaseInSharesReservedForFutureIssuanceInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OperatingLossCarryforwardsExpirationYear" xlink:label="sepn_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InitialTrancheMember" xlink:label="sepn_InitialTrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexResearchServiceAgreementMember" xlink:label="sepn_VertexResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" xlink:label="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStock" xlink:label="sepn_UnvestedRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnrecognizedTransactionPrice" xlink:label="sepn_UnrecognizedTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ProceedsFromSaleOfNonFinancialAsset" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OrganizationDisclosureTextBlock" xlink:label="sepn_OrganizationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LesseeOperatingLeaseExpirationYearAndMonth" xlink:label="sepn_LesseeOperatingLeaseExpirationYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockTextBlock" xlink:label="sepn_CommonStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OriginalLeasedSpaceMember" xlink:label="sepn_OriginalLeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" xlink:label="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsAndCommissions" xlink:label="sepn_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LizBhattMember" xlink:label="sepn_LizBhattMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SamsaraBiocapitalLPMember" xlink:label="sepn_SamsaraBiocapitalLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InterimChiefMedicalOfficerMember" xlink:label="sepn_InterimChiefMedicalOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EquityIncentivePlan2024Member" xlink:label="sepn_EquityIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidBonusCurrent" xlink:label="sepn_PrepaidBonusCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PerformanceConditionsMember" xlink:label="sepn_PerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VariableConsideration" xlink:label="sepn_VariableConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Rule10B51ArrModifiedFlag" xlink:label="sepn_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockTable" xlink:label="sepn_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation" xlink:label="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingOtherOfferingExpenses" xlink:label="sepn_UnderwritingOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:label="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" xlink:label="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeasedSpaceMember" xlink:label="sepn_LeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ThirdRockVenturesViLPServiceAgreementMember" xlink:label="sepn_ThirdRockVenturesViLPServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" xlink:label="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockOptions" xlink:label="sepn_CommonStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredRevenuePolicyTextBlock" xlink:label="sepn_DeferredRevenuePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnconditionalRightOnNonFinancialAsset" xlink:label="sepn_UnconditionalRightOnNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" xlink:label="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:label="sepn_AccruedGeneralAndAdministrativeExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ResearchDevelopmentProgramsMember" xlink:label="sepn_ResearchDevelopmentProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PatentExpensesPolicyPolicyTextBlock" xlink:label="sepn_PatentExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" xlink:label="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TermOfResearchServiceAgreement" xlink:label="sepn_TermOfResearchServiceAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" xlink:label="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" xlink:label="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SamiraShaikhlyMember" xlink:label="sepn_SamiraShaikhlyMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" xlink:label="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" xlink:label="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AdditionalLeasedSpaceMember" xlink:label="sepn_AdditionalLeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnpaidOfferingCostsIncludedInAccountsPayable" xlink:label="sepn_UnpaidOfferingCostsIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RaCapitalManagementLPServiceAgreementMember" xlink:label="sepn_RaCapitalManagementLPServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAssetTextBlock" xlink:label="sepn_GainOnSaleOfNonFinancialAssetTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfInProgressResearchAndDevelopment" xlink:label="sepn_GainOnSaleOfInProgressResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ServiceAgreementExpirationYear" xlink:label="sepn_ServiceAgreementExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneAndTrancheTwoMember" xlink:label="sepn_TrancheOneAndTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockIssuanceCostsOfConvertibleSecurities" xlink:label="sepn_StockIssuanceCostsOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AgreementDescription" xlink:label="sepn_AgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfChangesInDeferredRevenueTableTextBlock" xlink:label="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UndesignatedCommonStockParOrStatedValuePerShare" xlink:label="sepn_UndesignatedCommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncentiveStockOptionsMember" xlink:label="sepn_IncentiveStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PaymentReceivedOnSaleOfNonFinancialAsset" xlink:label="sepn_PaymentReceivedOnSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MilestonePaymentReceived" xlink:label="sepn_MilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedExpenseAndOtherCurrentLiabilities" xlink:label="sepn_AccruedExpenseAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncomeTaxesLineItems" xlink:label="sepn_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock" xlink:label="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OptionAndIncentivePlan2024Member" xlink:label="sepn_OptionAndIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" xlink:label="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexAssetPurchaseMember" xlink:label="sepn_VertexAssetPurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockTextBlock" xlink:label="sepn_ConvertiblePreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncomeTaxesTable" xlink:label="sepn_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards vested, Weighted Average Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CombinedLicenseAndResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined License And Research Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CombinedLicenseAndResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined license and research services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CombinedLicenseAndResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined License and Research Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, continuous unrealized loss position, Less than one year to two years, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10b5 1 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10b5 1 Arr Modified Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain on sale of non-financial asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain On Sale Of Non Financial Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Gain on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Proceeds From Issuance Of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202309Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-09 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202309Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-09</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Beginning Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of earnings to participating preferred stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Allocation of earnings to participating preferred stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Taxes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Taxes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_FourZeroOne401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Four Zero One 401 K Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_FourZeroOne401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Four zero one 401 K plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_FourZeroOne401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than option repurchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock awards repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary equity, Conversion of convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, Conversion of convertible preferred stock to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents and Marketable Securities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and marketable securities, fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset recognized in exchange for operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset recognized in exchange for operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average per share grant-date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B Convertible Preferred Stock, issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercisable as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, net change in total valuation allowance increase during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal taxes at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlanLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlanLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlanLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator, basic:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExternalGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExternalGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External General And Administrative Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExternalGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External general and administrative expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of marketable debt securities, contractual maturity, one year to five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost of marketable debt securities, contractual maturity, one year to five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards, subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option awards granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Options outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan 2024.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net (Loss) Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccountingStandardsUpdate202507Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2025-07</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccountingStandardsUpdate202507Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 202507 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccountingStandardsUpdate202507Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Standards Update 202507.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">liabilities associated with indemnification rights and agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Associated with Indemnification Rights and Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities associated with indemnification rights and agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Marketable Securities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Retirement Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Total Options outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Total Options outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities by Major Type of Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Lease Cost and Cash Paid for Operating Lease Liability [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of lease cost and cash paid for operating lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Expenses Recognized and Cash Paid for Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Features of Convertible Preferred Stock [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Material Right [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Material right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of available-for-sale marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Estimated useful Lives of Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of estimated useful lives of property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Useful Lives of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Options Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total Options Outstanding, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Initial Public Offering, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Trial Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical trial costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal taxes at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RestrictedStockOptionsSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Options Subject To Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RestrictedStockOptionsSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock options subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RestrictedStockOptionsSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock options subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Assumptions used for Grants Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income per share attributable to common stockholders:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock 2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2021PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock 2021 plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, marketable securities current and non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Marketable Securities Current and Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents, marketable securities current and non-current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, continuous unrealized loss position, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets before valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer And Director Equity Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive officer and director equity awards .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time non-refundable upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable One Time Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable one time upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of available-for-sale marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Financial Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UndesignatedPreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated preferred stock authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UndesignatedPreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UndesignatedPreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock, shares authorized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research &amp; Development Programs and Manufacturing Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research &amp; development programs and manufacturing services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Programs and Manufacturing Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total antidilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of unvested restricted common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of unvested restricted common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of unvested restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchases of Unvested Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchases of unvested restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Additional Funding Based on Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Additional Funding Based on Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock additional funding based on approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total Options outstanding, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Options outstanding, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RequiredPriorNoticeDurationToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Required Prior Notice Duration to Terminate Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RequiredPriorNoticeDurationToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Required prior notice duration to terminate agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RequiredPriorNoticeDurationToTerminateAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required prior notice duration to terminate agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MilestonePaymentsReceivableFromCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Receivable From Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MilestonePaymentsReceivableFromCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments receivable from collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MilestonePaymentsReceivableFromCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments receivable from collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InitialPublicOfferingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InitialPublicOfferingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InitialPublicOfferingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ChangeInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ChangeInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ChangeInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted convertible preferred stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Income Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash proceeds on shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance of Series B Convertible Preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockFinancingArrangementFinancingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Financing Arrangement Financing Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockFinancingArrangementFinancingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Financing Arrangement Financing Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockFinancingArrangementFinancingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock financing arrangement financing value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Stock-Based Compensation Adjustment, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, stock-based compensation adjustment, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Options Outstanding, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total Options Outstanding, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant date fair value of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock 2024 plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock 2024 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Stock2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock 2024 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LeaseCommencementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LeaseCommencementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LeaseCommencementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchases of unvested restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrealized Loss Positions of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value Per Share, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value Per Share, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RisksAndUncertaintyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks And Uncertainty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RisksAndUncertaintyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainty [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RisksAndUncertaintyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total present value of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Values Restricted Stock Award Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period values restricted stock award vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Research And Ddevelopment In-Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain Loss on sale of research and development in-progress.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain on sale of research and development in-progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds After Deducting Underwriting Discounts And Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds after deducting underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds after deducting underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares (denominator), Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-sale - Matures After One Year Through Five Years, Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sale - matures after one year through five years, gross unrealized gains.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains of marketable debt securities, contractual maturity, one year to five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards repurchased ,Weighted Average Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Repurchased In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than option repurchased in period weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of common stock shares reserved for future issuance on convertible basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Sale of Non Financial Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities sale of non-financial asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchase2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase 2024 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchase2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase 2024 plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeStockPurchase2024PlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase 2024 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Financing Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Financing Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Change in Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of change in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of change in ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure for noncash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right-Of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_FurnitureFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture, fixtures, and office equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_FurnitureFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture Fixtures and Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_FurnitureFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture fixtures and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncreaseInSharesReservedForFutureIssuanceInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares reserved for future issuance, in shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncreaseInSharesReservedForFutureIssuanceInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Shares Reserved for Future Issuance, in Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncreaseInSharesReservedForFutureIssuanceInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in shares reserved for future issuance, in shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before provision (benefit) for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InitialTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InitialTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InitialTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of earnings to participating preferred stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Allocation of earnings to participating preferred stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VertexResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Research Service Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VertexResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Research Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VertexResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex research service agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee and Non-employee Stock Option Awards Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee and non-employee stock option awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee and Non-Employee Stock Option Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred income tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred income tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards repurchased ,Weighted Average Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnrecognizedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized transaction price as of September 30, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnrecognizedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnrecognizedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received cash on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OrganizationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OrganizationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization disclosure text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OrganizationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LesseeOperatingLeaseExpirationYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Expiration Year and Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LesseeOperatingLeaseExpirationYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, expiration year and month.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LesseeOperatingLeaseExpirationYearAndMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses of marketble debt securities, contractual maturity, less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses of marketble debt securities, contractual maturity, less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities within one year gross unrealized loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-Sale Marketable Securities and Fair Value Measurements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sale marketable securities and fair value measurements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares (denominator), Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares outstanding used to compute net (loss) income per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OriginalLeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OriginalLeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Original Leased Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OriginalLeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Original leased space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding number of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Subject To Repurchase [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock Awards Subject to Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of revenue recognized, unrecognized transaction price and estimated revenue expected to be recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Jurisdiction of Domicile [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Differences, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, nondeductible expense, permanent differences, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains of marketable debt securites, contractual maturity, less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities within one year gross unrealized gains.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LizBhattMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liz Bhatt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LizBhattMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liz Bhatt Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LizBhattMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liz Bhatt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SamsaraBiocapitalLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Samsara BioCapital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SamsaraBiocapitalLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Samsara BioCapital L P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SamsaraBiocapitalLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Samsara BioCapital L P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InterimChiefMedicalOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interim Chief Medical Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InterimChiefMedicalOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interim Chief Medical Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_InterimChiefMedicalOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interim Chief Medical Officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EquityIncentivePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EquityIncentivePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EquityIncentivePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plan 2024.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Stock Award Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Gain on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B Convertible Preferred Stock( in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidBonusCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidBonusCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Bonus Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PrepaidBonusCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid bonus current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Conditions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PerformanceConditionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision (Benefit) for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with initial public offering, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b5 1Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b5 1Arr Modified Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (Loss) Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Stock-Based Compensation Adjustment, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, stock-based compensation adjustment, amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair market value of the common stock exercise price percentge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Exercise Price Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value exercise price percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease expenses, excluding variable lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding convertible preferred stock conversion in to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Expenses Excluding Stock Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee related expenses, excluding stock based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee-related expenses, excluding stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Other Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting other offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities And Fair Value Measurements [TextBlock]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities and fair value measurements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities and Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue remaining performance obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant date fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status and smaller reporting company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status and Smaller Reporting Company Status, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status and Smaller Reporting Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leased Space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leased Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_LeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ThirdRockVenturesViLPServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Rock Ventures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ThirdRockVenturesViLPServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Rock Ventures VI L P Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ThirdRockVenturesViLPServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third Rock Ventures VI L P Service Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Proceeds Conversion Of Outstanding Convertible Promissory Notes Plus Accrued Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Conversion Of Outstanding Convertible Promissory Notes Plus Accrued Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds conversion of outstanding convertible promissory notes plus accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_CommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income applicable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B Convertible Preferred Stock, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property and equipment included in accounts payable and accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment included in accounts payable and accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowances for credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredRevenuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredRevenuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredRevenuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnconditionalRightOnNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unconditional right on non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnconditionalRightOnNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unconditional right on non-financial asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnconditionalRightOnNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconditional right on amount of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Preferred Stock Remaining Unissued Shares Agreement To Cancel</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Remaining Unissued Shares Agreement To Cancel</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock remaining unissued shares agreement to cancel</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedGeneralAndAdministrativeExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General and Administrative Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedGeneralAndAdministrativeExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedGeneralAndAdministrativeExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock awards repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options repurchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards Update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ResearchDevelopmentProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ResearchDevelopmentProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research &amp; Development Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ResearchDevelopmentProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research &amp; development programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost of marketable debt securities, contractual maturity, less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of marketable debt securities, contractual maturity, less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PatentExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PatentExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PatentExpensesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Promissory Notes, Unpaid Principal and Accrued Interest Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Notes, Unpaid Principal and Accrued Interest Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes such as unpaid principal and accrued interest outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sec 174 capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Matures After One Year Through Five Years Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale matures after one year through five years gross unrealized loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses of marketable debt securities, contractual maturity, one year to five years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TermOfResearchServiceAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term of Research Service Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TermOfResearchServiceAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of research service agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TermOfResearchServiceAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of research service agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Equity Awards Options Grants Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation equity awards options grants fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other receivable related to sale of non-financial asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivable Related To Sale Of Non Financial Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivable related to sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering (IPO)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivable related to sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Other Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SamiraShaikhlyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Samira Shaikhly [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SamiraShaikhlyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Samira Shaikhly Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SamiraShaikhlyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Samira Shaikhly</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock authorised to be issued during period shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Authorised To Be Issued During Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock shares authorized to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Share Issue Price Divided By Conversion Price In Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of share issue price divided by conversion price in effect.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of share issue price divided by conversion price in effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value per share, 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 44,806,272 and 44,422,505 shares issued and outstanding at December 31, 2025 and December 31, 2024 respectively; 131,224 and 576,829 shares subject to repurchase as of December 31, 2025 and December 31, 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (loss) income applicable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AdditionalLeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AdditionalLeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Leased Space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AdditionalLeasedSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Leased Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnpaidOfferingCostsIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid offering costs included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnpaidOfferingCostsIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Offering Costs Included In Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnpaidOfferingCostsIncludedInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid Offering Costs Included In Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RaCapitalManagementLPServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RA Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RaCapitalManagementLPServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RA Capital Management L P Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_RaCapitalManagementLPServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">RA Capital Management L P Service Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable securities, continuous unrealized loss position, Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Marketable securities, continuous unrealized loss position, Gross Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAssetTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain on Sale of Non-Financial Asset [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAssetTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain on sale of non-financial asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfNonFinancialAssetTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on Sale of Non-Financial Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfInProgressResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain on Sale of In Progress Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfInProgressResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain on sale of in-progress research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_GainOnSaleOfInProgressResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of in-progress research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and Research Service Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties related to unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of unpaid principal and accrued interest outstanding into shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ServiceAgreementExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Agreement Expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ServiceAgreementExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service agreement expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ServiceAgreementExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service agreement expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Benefit) provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision (benefit) for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision (benefit) for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting pronouncements not yet adopted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneAndTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche One and Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneAndTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One and Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TrancheOneAndTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One and Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockIssuanceCostsOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockIssuanceCostsOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs Of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockIssuanceCostsOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance costs of convertible securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Life, Exercisable as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Adjustment based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with initial public offering, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock awards vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net (loss) income per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reportable Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Changes in Deferred Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of changes in deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UndesignatedCommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UndesignatedCommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Common Stock Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UndesignatedCommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated common stock par or stated value per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NovoCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novo Collaboration Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NovoCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novo Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_NovoCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novo Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PaymentReceivedOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment received on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PaymentReceivedOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment received on sale of non-financial asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PaymentReceivedOnSaleOfNonFinancialAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment received on sale of non-financial asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedExpenseAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedExpenseAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expense And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_AccruedExpenseAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Expense And Other Current Liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockPlan2024And2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2024 and 2021 Stock Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockPlan2024And2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Plan 2024 and 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_StockPlan2024And2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 and 2021 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts commissions and other offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts, Commissions and Other Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts, commissions and other offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of present value of lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of non-financial assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Non-Financial Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Non-Financial Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OptionAndIncentivePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option and Incentive Plan 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OptionAndIncentivePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option and incentive plan 2024.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_OptionAndIncentivePlan2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Option and Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Net (Loss) Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary equity, Conversion of convertible preferred stock to common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, Conversion of convertible preferred stock to common stock shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Temporary equity, Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted preferred stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Differences, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, nondeductible expense, permanent differences, amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discounts, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Percentage Of Fair Market Value Per Share on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Price Percentage Of Fair Market Value Per Share on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price percentage of fair market value per share on offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of marketable securities in unrealized loss positions less than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate estimated fair value of marketable debt securities, contractual maturities, one year to five year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator, diluted:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net (loss) income per share attributable to common stockholders:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VertexAssetPurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Asset Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VertexAssetPurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Asset Purchase [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_VertexAssetPurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex Asset Purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator, basic:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Total net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_ConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sepn_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period for recognition of expenses related to non-vested share-based compensation arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator, diluted:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CombinedLicenseAndResearchServicesMember" xlink:to="sepn_CombinedLicenseAndResearchServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_NonRule10B51ArrModifiedFlag" xlink:to="sepn_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_GainOnSaleOfNonFinancialAsset" xlink:to="sepn_GainOnSaleOfNonFinancialAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202309Member" xlink:to="us-gaap_AccountingStandardsUpdate202309Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PrepaidTaxesCurrent" xlink:to="sepn_PrepaidTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_FourZeroOne401KPlanMember" xlink:to="sepn_FourZeroOne401KPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" xlink:to="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:to="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:to="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeStockPurchasePlanLiability" xlink:to="sepn_EmployeeStockPurchasePlanLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ExternalGeneralAndAdministrativeExpenses" xlink:to="sepn_ExternalGeneralAndAdministrativeExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeStockPurchasePlan2024Member" xlink:to="sepn_EmployeeStockPurchasePlan2024Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AccountingStandardsUpdate202507Member" xlink:to="sepn_AccountingStandardsUpdate202507Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" xlink:to="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" xlink:to="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TaxCreditCarryforwardExpirationYear" xlink:to="sepn_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_MaterialRightMember" xlink:to="sepn_MaterialRightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TrancheTwoMember" xlink:to="sepn_TrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PrepaidClinicalTrialCostsCurrent" xlink:to="sepn_PrepaidClinicalTrialCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeStockPurchasePlanMember" xlink:to="sepn_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_RestrictedStockOptionsSubjectToRepurchase" xlink:to="sepn_RestrictedStockOptionsSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_Stock2021PlanMember" xlink:to="sepn_Stock2021PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" xlink:to="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" xlink:to="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_NonRefundableOneTimeUpfrontPaymentReceived" xlink:to="sepn_NonRefundableOneTimeUpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TransactionPrice" xlink:to="sepn_TransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UndesignatedPreferredStockSharesAuthorized" xlink:to="sepn_UndesignatedPreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" xlink:to="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_RepurchasesOfUnvestedRestrictedCommonStock" xlink:to="sepn_RepurchasesOfUnvestedRestrictedCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" xlink:to="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_RequiredPriorNoticeDurationToTerminateAgreement" xlink:to="sepn_RequiredPriorNoticeDurationToTerminateAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CommonStockLineItems" xlink:to="sepn_CommonStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_MilestonePaymentsReceivableFromCollaborationAgreement" xlink:to="sepn_MilestonePaymentsReceivableFromCollaborationAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_InitialPublicOfferingStockOptions" xlink:to="sepn_InitialPublicOfferingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ChangeInDeferredRevenue" xlink:to="sepn_ChangeInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ExternalResearchAndDevelopmentExpenses" xlink:to="sepn_ExternalResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TemporaryEquityStockFinancingArrangementFinancingValue" xlink:to="sepn_TemporaryEquityStockFinancingArrangementFinancingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TrancheOneMember" xlink:to="sepn_TrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_Stock2024PlanMember" xlink:to="sepn_Stock2024PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_LeaseCommencementPeriod" xlink:to="sepn_LeaseCommencementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="sepn_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_DeferredTaxAssetsLeaseLiability" xlink:to="sepn_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_RisksAndUncertaintyPolicyTextBlock" xlink:to="sepn_RisksAndUncertaintyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" xlink:to="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" xlink:to="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:to="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" xlink:to="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="sepn_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" xlink:to="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeStockPurchase2024PlanMember" xlink:to="sepn_EmployeeStockPurchase2024PlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeMember" xlink:to="sepn_EmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PercentageOfChangeInOwnership" xlink:to="sepn_PercentageOfChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" xlink:to="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_FurnitureFixturesAndOfficeEquipmentMember" xlink:to="sepn_FurnitureFixturesAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_IncreaseInSharesReservedForFutureIssuanceInShares" xlink:to="sepn_IncreaseInSharesReservedForFutureIssuanceInShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_OperatingLossCarryforwardsExpirationYear" xlink:to="sepn_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_InitialTrancheMember" xlink:to="sepn_InitialTrancheMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_VertexResearchServiceAgreementMember" xlink:to="sepn_VertexResearchServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" xlink:to="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnvestedRestrictedStock" xlink:to="sepn_UnvestedRestrictedStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnrecognizedTransactionPrice" xlink:to="sepn_UnrecognizedTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ProceedsFromSaleOfNonFinancialAsset" xlink:to="sepn_ProceedsFromSaleOfNonFinancialAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_OrganizationDisclosureTextBlock" xlink:to="sepn_OrganizationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_LesseeOperatingLeaseExpirationYearAndMonth" xlink:to="sepn_LesseeOperatingLeaseExpirationYearAndMonth_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CommonStockTextBlock" xlink:to="sepn_CommonStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_OriginalLeasedSpaceMember" xlink:to="sepn_OriginalLeasedSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" xlink:to="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" xlink:to="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnderwritingDiscountsAndCommissions" xlink:to="sepn_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_LizBhattMember" xlink:to="sepn_LizBhattMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SamsaraBiocapitalLPMember" xlink:to="sepn_SamsaraBiocapitalLPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_InterimChiefMedicalOfficerMember" xlink:to="sepn_InterimChiefMedicalOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EquityIncentivePlan2024Member" xlink:to="sepn_EquityIncentivePlan2024Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PrepaidBonusCurrent" xlink:to="sepn_PrepaidBonusCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PerformanceConditionsMember" xlink:to="sepn_PerformanceConditionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_VariableConsideration" xlink:to="sepn_VariableConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_Rule10B51ArrModifiedFlag" xlink:to="sepn_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CommonStockTable" xlink:to="sepn_CommonStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation" xlink:to="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnderwritingOtherOfferingExpenses" xlink:to="sepn_UnderwritingOtherOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:to="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" xlink:to="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_LeasedSpaceMember" xlink:to="sepn_LeasedSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SeriesAConvertiblePreferredStockMember" xlink:to="sepn_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ThirdRockVenturesViLPServiceAgreementMember" xlink:to="sepn_ThirdRockVenturesViLPServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" xlink:to="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_CommonStockOptions" xlink:to="sepn_CommonStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:to="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_DeferredRevenuePolicyTextBlock" xlink:to="sepn_DeferredRevenuePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnconditionalRightOnNonFinancialAsset" xlink:to="sepn_UnconditionalRightOnNonFinancialAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" xlink:to="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:to="sepn_AccruedGeneralAndAdministrativeExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SeriesBConvertiblePreferredStockMember" xlink:to="sepn_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ResearchDevelopmentProgramsMember" xlink:to="sepn_ResearchDevelopmentProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PatentExpensesPolicyPolicyTextBlock" xlink:to="sepn_PatentExpensesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" xlink:to="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TermOfResearchServiceAgreement" xlink:to="sepn_TermOfResearchServiceAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" xlink:to="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" xlink:to="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SamiraShaikhlyMember" xlink:to="sepn_SamiraShaikhlyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" xlink:to="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" xlink:to="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AdditionalLeasedSpaceMember" xlink:to="sepn_AdditionalLeasedSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnpaidOfferingCostsIncludedInAccountsPayable" xlink:to="sepn_UnpaidOfferingCostsIncludedInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_RaCapitalManagementLPServiceAgreementMember" xlink:to="sepn_RaCapitalManagementLPServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_GainOnSaleOfNonFinancialAssetTextBlock" xlink:to="sepn_GainOnSaleOfNonFinancialAssetTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_GainOnSaleOfInProgressResearchAndDevelopment" xlink:to="sepn_GainOnSaleOfInProgressResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ServiceAgreementExpirationYear" xlink:to="sepn_ServiceAgreementExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TrancheOneAndTrancheTwoMember" xlink:to="sepn_TrancheOneAndTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_StockIssuanceCostsOfConvertibleSecurities" xlink:to="sepn_StockIssuanceCostsOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AgreementDescription" xlink:to="sepn_AgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock" xlink:to="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UndesignatedCommonStockParOrStatedValuePerShare" xlink:to="sepn_UndesignatedCommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_IncentiveStockOptionsMember" xlink:to="sepn_IncentiveStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_NovoCollaborationAgreementMember" xlink:to="sepn_NovoCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PaymentReceivedOnSaleOfNonFinancialAsset" xlink:to="sepn_PaymentReceivedOnSaleOfNonFinancialAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_MilestonePaymentReceived" xlink:to="sepn_MilestonePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_AccruedExpenseAndOtherCurrentLiabilities" xlink:to="sepn_AccruedExpenseAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_StockPlan2024And2021Member" xlink:to="sepn_StockPlan2024And2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" xlink:to="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock" xlink:to="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_OptionAndIncentivePlan2024Member" xlink:to="sepn_OptionAndIncentivePlan2024Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" xlink:to="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" xlink:to="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_VertexAssetPurchaseMember" xlink:to="sepn_VertexAssetPurchaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_ConvertiblePreferredStockTextBlock" xlink:to="sepn_ConvertiblePreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sepn_IncomeTaxesTable" xlink:to="sepn_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RestrictedStockOptionsSubjectToRepurchase" xlink:label="sepn_RestrictedStockOptionsSubjectToRepurchase"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_RestrictedStockOptionsSubjectToRepurchase" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" xlink:label="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_25"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockIssuanceCostsOfConvertibleSecurities" xlink:label="sepn_StockIssuanceCostsOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_StockIssuanceCostsOfConvertibleSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAsset" xlink:label="sepn_GainOnSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" xlink:label="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ProceedsFromSaleOfNonFinancialAsset" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RepurchasesOfUnvestedRestrictedCommonStock" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnpaidOfferingCostsIncludedInAccountsPayable" xlink:label="sepn_UnpaidOfferingCostsIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sepn_GainOnSaleOfNonFinancialAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="sepn_ProceedsFromSaleOfNonFinancialAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sepn_RepurchasesOfUnvestedRestrictedCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_UnpaidOfferingCostsIncludedInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LizBhattMember" xlink:label="sepn_LizBhattMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SamiraShaikhlyMember" xlink:label="sepn_SamiraShaikhlyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Rule10B51ArrModifiedFlag" xlink:label="sepn_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRule10B51ArrModifiedFlag" xlink:label="sepn_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sepn_LizBhattMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="sepn_SamiraShaikhlyMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="sepn_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="sepn_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganization1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OrganizationDisclosureTextBlock" xlink:label="sepn_OrganizationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sepn_OrganizationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAsset" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAssetTextBlock" xlink:label="sepn_GainOnSaleOfNonFinancialAssetTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sepn_GainOnSaleOfNonFinancialAssetTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:label="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockTextBlock" xlink:label="sepn_ConvertiblePreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="sepn_ConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockTextBlock" xlink:label="sepn_CommonStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="sepn_CommonStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RisksAndUncertaintyPolicyTextBlock" xlink:label="sepn_RisksAndUncertaintyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredRevenuePolicyTextBlock" xlink:label="sepn_DeferredRevenuePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock" xlink:label="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PatentExpensesPolicyPolicyTextBlock" xlink:label="sepn_PatentExpensesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" xlink:label="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_RisksAndUncertaintyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_DeferredRevenuePolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_PatentExpensesPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" xlink:label="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfChangesInDeferredRevenueTableTextBlock" xlink:label="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" xlink:label="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" xlink:label="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_StockPlan2024And2021Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneMember" xlink:label="sepn_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexResearchServiceAgreementMember" xlink:label="sepn_VertexResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheTwoMember" xlink:label="sepn_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsAndCommissions" xlink:label="sepn_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingOtherOfferingExpenses" xlink:label="sepn_UnderwritingOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UndesignatedPreferredStockSharesAuthorized" xlink:label="sepn_UndesignatedPreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UndesignatedCommonStockParOrStatedValuePerShare" xlink:label="sepn_UndesignatedCommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" xlink:label="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfInProgressResearchAndDevelopment" xlink:label="sepn_GainOnSaleOfInProgressResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" xlink:label="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sepn_VertexResearchServiceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_VestingAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UnderwritingDiscountsAndCommissions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UnderwritingOtherOfferingExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UndesignatedPreferredStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UndesignatedCommonStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_GainOnSaleOfInProgressResearchAndDevelopment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccountingStandardsUpdate202507Member" xlink:label="sepn_AccountingStandardsUpdate202507Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202309Member" xlink:label="us-gaap_AccountingStandardsUpdate202309Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="sepn_AccountingStandardsUpdate202507Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202309Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidClinicalTrialCostsCurrent" xlink:label="sepn_PrepaidClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidBonusCurrent" xlink:label="sepn_PrepaidBonusCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidTaxesCurrent" xlink:label="sepn_PrepaidTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="sepn_PrepaidClinicalTrialCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="sepn_PrepaidBonusCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="sepn_PrepaidTaxesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_FurnitureFixturesAndOfficeEquipmentMember" xlink:label="sepn_FurnitureFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_FurnitureFixturesAndOfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="sepn_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:label="sepn_AccruedGeneralAndAdministrativeExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanLiability" xlink:label="sepn_EmployeeStockPurchasePlanLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="sepn_AccruedResearchAndDevelopmentExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="sepn_AccruedGeneralAndAdministrativeExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="sepn_EmployeeStockPurchasePlanLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAsset" xlink:label="sepn_GainOnSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ProceedsFromSaleOfNonFinancialAsset" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnconditionalRightOnNonFinancialAsset" xlink:label="sepn_UnconditionalRightOnNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PaymentReceivedOnSaleOfNonFinancialAsset" xlink:label="sepn_PaymentReceivedOnSaleOfNonFinancialAsset"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sepn_GainOnSaleOfNonFinancialAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sepn_ProceedsFromSaleOfNonFinancialAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sepn_UnconditionalRightOnNonFinancialAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sepn_PaymentReceivedOnSaleOfNonFinancialAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexResearchServiceAgreementMember" xlink:label="sepn_VertexResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexAssetPurchaseMember" xlink:label="sepn_VertexAssetPurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRefundableOneTimeUpfrontPaymentReceived" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MilestonePaymentsReceivableFromCollaborationAgreement" xlink:label="sepn_MilestonePaymentsReceivableFromCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MilestonePaymentReceived" xlink:label="sepn_MilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AgreementDescription" xlink:label="sepn_AgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TermOfResearchServiceAgreement" xlink:label="sepn_TermOfResearchServiceAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RequiredPriorNoticeDurationToTerminateAgreement" xlink:label="sepn_RequiredPriorNoticeDurationToTerminateAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ServiceAgreementExpirationYear" xlink:label="sepn_ServiceAgreementExpirationYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sepn_VertexResearchServiceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sepn_VertexAssetPurchaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_NonRefundableOneTimeUpfrontPaymentReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_MilestonePaymentsReceivableFromCollaborationAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_MilestonePaymentReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_AgreementDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_TermOfResearchServiceAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_RequiredPriorNoticeDurationToTerminateAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_ServiceAgreementExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CombinedLicenseAndResearchServicesMember" xlink:label="sepn_CombinedLicenseAndResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TransactionPrice" xlink:label="sepn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MaterialRightMember" xlink:label="sepn_MaterialRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnrecognizedTransactionPrice" xlink:label="sepn_UnrecognizedTransactionPrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_CombinedLicenseAndResearchServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_TransactionPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_MaterialRightMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_UnrecognizedTransactionPrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" xlink:label="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRefundableOneTimeUpfrontPaymentReceived" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MaterialRightMember" xlink:label="sepn_MaterialRightMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VariableConsideration" xlink:label="sepn_VariableConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ResearchDevelopmentProgramsMember" xlink:label="sepn_ResearchDevelopmentProgramsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_NonRefundableOneTimeUpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_MaterialRightMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_VariableConsideration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_ResearchDevelopmentProgramsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ChangeInDeferredRevenue" xlink:label="sepn_ChangeInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_ChangeInDeferredRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:label="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OriginalLeasedSpaceMember" xlink:label="sepn_OriginalLeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LesseeOperatingLeaseExpirationYearAndMonth" xlink:label="sepn_LesseeOperatingLeaseExpirationYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AdditionalLeasedSpaceMember" xlink:label="sepn_AdditionalLeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeasedSpaceMember" xlink:label="sepn_LeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeaseCommencementPeriod" xlink:label="sepn_LeaseCommencementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_OriginalLeasedSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sepn_LesseeOperatingLeaseExpirationYearAndMonth" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_AdditionalLeasedSpaceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_LeasedSpaceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sepn_LeaseCommencementPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeasedSpaceMember" xlink:label="sepn_LeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_LeasedSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" xlink:label="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InitialTrancheMember" xlink:label="sepn_InitialTrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneMember" xlink:label="sepn_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" xlink:label="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheTwoMember" xlink:label="sepn_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneAndTrancheTwoMember" xlink:label="sepn_TrancheOneAndTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" xlink:label="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" xlink:label="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockFinancingArrangementFinancingValue" xlink:label="sepn_TemporaryEquityStockFinancingArrangementFinancingValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" xlink:label="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" xlink:label="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" xlink:label="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_InitialTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheOneAndTrancheTwoMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_VestingAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockFinancingArrangementFinancingValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockLineItems" xlink:label="sepn_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockTable" xlink:label="sepn_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncreaseInSharesReservedForFutureIssuanceInShares" xlink:label="sepn_IncreaseInSharesReservedForFutureIssuanceInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="sepn_CommonStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="sepn_IncreaseInSharesReservedForFutureIssuanceInShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockTable" xlink:to="sepn_CommonStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_CommonStockLineItems" xlink:to="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchase2024PlanMember" xlink:label="sepn_EmployeeStockPurchase2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanMember" xlink:label="sepn_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchase2024PlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_StockPlan2024And2021Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_StockPlan2024And2021Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" xlink:label="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanMember" xlink:label="sepn_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" xlink:label="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeMember" xlink:label="sepn_EmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncentiveStockOptionsMember" xlink:label="sepn_IncentiveStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PerformanceConditionsMember" xlink:label="sepn_PerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OptionAndIncentivePlan2024Member" xlink:label="sepn_OptionAndIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlan2024Member" xlink:label="sepn_EmployeeStockPurchasePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" xlink:label="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InitialPublicOfferingStockOptions" xlink:label="sepn_InitialPublicOfferingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" xlink:label="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sepn_EmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_IncentiveStockOptionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sepn_PerformanceConditionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_OptionAndIncentivePlan2024Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlan2024Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_InitialPublicOfferingStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncomeTaxesTable" xlink:label="sepn_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncomeTaxesLineItems" xlink:label="sepn_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OperatingLossCarryforwardsExpirationYear" xlink:label="sepn_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TaxCreditCarryforwardExpirationYear" xlink:label="sepn_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PercentageOfChangeInOwnership" xlink:label="sepn_PercentageOfChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sepn_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesTable" xlink:to="sepn_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_PercentageOfChangeInOwnership" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" xlink:label="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="sepn_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsLeaseLiability" xlink:label="sepn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" xlink:label="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" xlink:label="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sepn_DeferredTaxAssetsOperatingLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sepn_DeferredTaxAssetsLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ThirdRockVenturesViLPServiceAgreementMember" xlink:label="sepn_ThirdRockVenturesViLPServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InterimChiefMedicalOfficerMember" xlink:label="sepn_InterimChiefMedicalOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RaCapitalManagementLPServiceAgreementMember" xlink:label="sepn_RaCapitalManagementLPServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SamsaraBiocapitalLPMember" xlink:label="sepn_SamsaraBiocapitalLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedExpenseAndOtherCurrentLiabilities" xlink:label="sepn_AccruedExpenseAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sepn_ThirdRockVenturesViLPServiceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sepn_InterimChiefMedicalOfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sepn_RaCapitalManagementLPServiceAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sepn_SamsaraBiocapitalLPMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sepn_AccruedExpenseAndOtherCurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockOptions" xlink:label="sepn_CommonStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStock" xlink:label="sepn_UnvestedRestrictedStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="sepn_CommonStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="sepn_UnvestedRestrictedStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_FourZeroOne401KPlanMember" xlink:label="sepn_FourZeroOne401KPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="sepn_FourZeroOne401KPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation" xlink:label="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExternalResearchAndDevelopmentExpenses" xlink:label="sepn_ExternalResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExternalGeneralAndAdministrativeExpenses" xlink:label="sepn_ExternalGeneralAndAdministrativeExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="sepn_ExternalResearchAndDevelopmentExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="sepn_ExternalGeneralAndAdministrativeExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_OperatingExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NetIncomeLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EquityIncentivePlan2024Member" xlink:label="sepn_EquityIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OptionAndIncentivePlan2024Member" xlink:label="sepn_OptionAndIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlan2024Member" xlink:label="sepn_EmployeeStockPurchasePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EquityIncentivePlan2024Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_OptionAndIncentivePlan2024Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlan2024Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RestrictedStockOptionsSubjectToRepurchase" xlink:label="sepn_RestrictedStockOptionsSubjectToRepurchase"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_RestrictedStockOptionsSubjectToRepurchase" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" xlink:label="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" xlink:label="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockIssuanceCostsOfConvertibleSecurities" xlink:label="sepn_StockIssuanceCostsOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sepn_StockIssuanceCostsOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAsset" xlink:label="sepn_GainOnSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" xlink:label="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ProceedsFromSaleOfNonFinancialAsset" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:label="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RepurchasesOfUnvestedRestrictedCommonStock" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnpaidOfferingCostsIncludedInAccountsPayable" xlink:label="sepn_UnpaidOfferingCostsIncludedInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sepn_GainOnSaleOfNonFinancialAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="sepn_ProceedsFromSaleOfNonFinancialAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sepn_RepurchasesOfUnvestedRestrictedCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_UnpaidOfferingCostsIncludedInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LizBhattMember" xlink:label="sepn_LizBhattMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SamiraShaikhlyMember" xlink:label="sepn_SamiraShaikhlyMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sepn_LizBhattMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="sepn_SamiraShaikhlyMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_StockPlan2024And2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneMember" xlink:label="sepn_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexResearchServiceAgreementMember" xlink:label="sepn_VertexResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheTwoMember" xlink:label="sepn_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsAndCommissions" xlink:label="sepn_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingOtherOfferingExpenses" xlink:label="sepn_UnderwritingOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UndesignatedPreferredStockSharesAuthorized" xlink:label="sepn_UndesignatedPreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UndesignatedCommonStockParOrStatedValuePerShare" xlink:label="sepn_UndesignatedCommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" xlink:label="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfInProgressResearchAndDevelopment" xlink:label="sepn_GainOnSaleOfInProgressResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" xlink:label="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sepn_VertexResearchServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UnderwritingOtherOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UndesignatedPreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_UndesignatedCommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_GainOnSaleOfInProgressResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccountingStandardsUpdate202507Member" xlink:label="sepn_AccountingStandardsUpdate202507Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202309Member" xlink:label="us-gaap_AccountingStandardsUpdate202309Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="sepn_AccountingStandardsUpdate202507Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202309Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_FurnitureFixturesAndOfficeEquipmentMember" xlink:label="sepn_FurnitureFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_FurnitureFixturesAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexResearchServiceAgreementMember" xlink:label="sepn_VertexResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VertexAssetPurchaseMember" xlink:label="sepn_VertexAssetPurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRefundableOneTimeUpfrontPaymentReceived" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MilestonePaymentsReceivableFromCollaborationAgreement" xlink:label="sepn_MilestonePaymentsReceivableFromCollaborationAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MilestonePaymentReceived" xlink:label="sepn_MilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AgreementDescription" xlink:label="sepn_AgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TermOfResearchServiceAgreement" xlink:label="sepn_TermOfResearchServiceAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RequiredPriorNoticeDurationToTerminateAgreement" xlink:label="sepn_RequiredPriorNoticeDurationToTerminateAgreement"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ServiceAgreementExpirationYear" xlink:label="sepn_ServiceAgreementExpirationYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sepn_VertexResearchServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sepn_VertexAssetPurchaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_NonRefundableOneTimeUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_MilestonePaymentsReceivableFromCollaborationAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_MilestonePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_AgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_TermOfResearchServiceAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_RequiredPriorNoticeDurationToTerminateAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_ServiceAgreementExpirationYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CombinedLicenseAndResearchServicesMember" xlink:label="sepn_CombinedLicenseAndResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TransactionPrice" xlink:label="sepn_TransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MaterialRightMember" xlink:label="sepn_MaterialRightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnrecognizedTransactionPrice" xlink:label="sepn_UnrecognizedTransactionPrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_CombinedLicenseAndResearchServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_TransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_MaterialRightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_UnrecognizedTransactionPrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" xlink:label="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NonRefundableOneTimeUpfrontPaymentReceived" xlink:label="sepn_NonRefundableOneTimeUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_MaterialRightMember" xlink:label="sepn_MaterialRightMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_VariableConsideration" xlink:label="sepn_VariableConsideration"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ResearchDevelopmentProgramsMember" xlink:label="sepn_ResearchDevelopmentProgramsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_NonRefundableOneTimeUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_MaterialRightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_VariableConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sepn_ResearchDevelopmentProgramsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ChangeInDeferredRevenue" xlink:label="sepn_ChangeInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sepn_ChangeInDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetailsDefault">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NovoCollaborationAgreementMember" xlink:label="sepn_NovoCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sepn_NovoCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" xlink:label="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OriginalLeasedSpaceMember" xlink:label="sepn_OriginalLeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LesseeOperatingLeaseExpirationYearAndMonth" xlink:label="sepn_LesseeOperatingLeaseExpirationYearAndMonth"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AdditionalLeasedSpaceMember" xlink:label="sepn_AdditionalLeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeasedSpaceMember" xlink:label="sepn_LeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeaseCommencementPeriod" xlink:label="sepn_LeaseCommencementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_OriginalLeasedSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sepn_LesseeOperatingLeaseExpirationYearAndMonth" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_AdditionalLeasedSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_LeasedSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sepn_LeaseCommencementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_LeasedSpaceMember" xlink:label="sepn_LeasedSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sepn_LeasedSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InitialTrancheMember" xlink:label="sepn_InitialTrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneMember" xlink:label="sepn_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" xlink:label="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheTwoMember" xlink:label="sepn_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TrancheOneAndTrancheTwoMember" xlink:label="sepn_TrancheOneAndTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" xlink:label="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" xlink:label="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockFinancingArrangementFinancingValue" xlink:label="sepn_TemporaryEquityStockFinancingArrangementFinancingValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" xlink:label="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" xlink:label="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" xlink:label="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_InitialTrancheMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="sepn_TrancheOneAndTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockFinancingArrangementFinancingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockLineItems" xlink:label="sepn_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockTable" xlink:label="sepn_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncreaseInSharesReservedForFutureIssuanceInShares" xlink:label="sepn_IncreaseInSharesReservedForFutureIssuanceInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" xlink:label="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sepn_CommonStockLineItems" xlink:to="sepn_CommonStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="sepn_IncreaseInSharesReservedForFutureIssuanceInShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_CommonStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_CommonStockLineItems" xlink:to="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesAConvertiblePreferredStockMember" xlink:label="sepn_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SeriesBConvertiblePreferredStockMember" xlink:label="sepn_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanMember" xlink:label="sepn_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchase2024PlanMember" xlink:label="sepn_EmployeeStockPurchase2024PlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sepn_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchase2024PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_StockPlan2024And2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_StockPlan2024And2021Member" xlink:label="sepn_StockPlan2024And2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_StockPlan2024And2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" xlink:label="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanMember" xlink:label="sepn_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" xlink:label="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeMember" xlink:label="sepn_EmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PerformanceConditionsMember" xlink:label="sepn_PerformanceConditionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2021PlanMember" xlink:label="sepn_Stock2021PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncentiveStockOptionsMember" xlink:label="sepn_IncentiveStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_Stock2024PlanMember" xlink:label="sepn_Stock2024PlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OptionAndIncentivePlan2024Member" xlink:label="sepn_OptionAndIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlan2024Member" xlink:label="sepn_EmployeeStockPurchasePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" xlink:label="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InitialPublicOfferingStockOptions" xlink:label="sepn_InitialPublicOfferingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" xlink:label="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" xlink:label="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sepn_EmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sepn_PerformanceConditionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2021PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_IncentiveStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_Stock2024PlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_OptionAndIncentivePlan2024Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlan2024Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_InitialPublicOfferingStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncomeTaxesLineItems" xlink:label="sepn_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_IncomeTaxesTable" xlink:label="sepn_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OperatingLossCarryforwardsExpirationYear" xlink:label="sepn_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_TaxCreditCarryforwardExpirationYear" xlink:label="sepn_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PercentageOfChangeInOwnership" xlink:label="sepn_PercentageOfChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sepn_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="sepn_PercentageOfChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sepn_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ThirdRockVenturesViLPServiceAgreementMember" xlink:label="sepn_ThirdRockVenturesViLPServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_InterimChiefMedicalOfficerMember" xlink:label="sepn_InterimChiefMedicalOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RaCapitalManagementLPServiceAgreementMember" xlink:label="sepn_RaCapitalManagementLPServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_SamsaraBiocapitalLPMember" xlink:label="sepn_SamsaraBiocapitalLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedExpenseAndOtherCurrentLiabilities" xlink:label="sepn_AccruedExpenseAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sepn_ThirdRockVenturesViLPServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sepn_InterimChiefMedicalOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sepn_RaCapitalManagementLPServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sepn_SamsaraBiocapitalLPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sepn_AccruedExpenseAndOtherCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" xlink:label="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_FourZeroOne401KPlanMember" xlink:label="sepn_FourZeroOne401KPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="sepn_FourZeroOne401KPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EquityIncentivePlan2024Member" xlink:label="sepn_EquityIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_OptionAndIncentivePlan2024Member" xlink:label="sepn_OptionAndIncentivePlan2024Member"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlan2024Member" xlink:label="sepn_EmployeeStockPurchasePlan2024Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EquityIncentivePlan2024Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_OptionAndIncentivePlan2024Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sepn_EmployeeStockPurchasePlan2024Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202309Member" xlink:label="us-gaap_AccountingStandardsUpdate202309Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="sepn_ProceedsFromSaleOfNonFinancialAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sepn_RepurchasesOfUnvestedRestrictedCommonStock" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sepn_GainOnSaleOfNonFinancialAsset" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="9" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="15" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_ProceedsFromSaleOfNonFinancialAsset" xlink:label="sepn_ProceedsFromSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_RepurchasesOfUnvestedRestrictedCommonStock" xlink:label="sepn_RepurchasesOfUnvestedRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_GainOnSaleOfNonFinancialAsset" xlink:label="sepn_GainOnSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="sepn_PrepaidClinicalTrialCostsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="sepn_PrepaidBonusCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="sepn_PrepaidTaxesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidClinicalTrialCostsCurrent" xlink:label="sepn_PrepaidClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidBonusCurrent" xlink:label="sepn_PrepaidBonusCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_PrepaidTaxesCurrent" xlink:label="sepn_PrepaidTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sepn_EmployeeStockPurchasePlanLiability" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sepn_AccruedGeneralAndAdministrativeExpenseCurrent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sepn_AccruedResearchAndDevelopmentExpenseCurrent" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EmployeeStockPurchasePlanLiability" xlink:label="sepn_EmployeeStockPurchasePlanLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:label="sepn_AccruedGeneralAndAdministrativeExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="sepn_AccruedResearchAndDevelopmentExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" xlink:label="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" xlink:label="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sepn_DeferredTaxAssetsOperatingLeaseLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sepn_DeferredTaxAssetsLeaseLiability" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" xlink:label="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="sepn_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" xlink:label="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsLeaseLiability" xlink:label="sepn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="sepn_CommonStockOptions" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="sepn_UnvestedRestrictedStock" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_CommonStockOptions" xlink:label="sepn_CommonStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
          <link:loc xlink:type="locator" xlink:href="sepn-20251231.xsd#sepn_UnvestedRestrictedStock" xlink:label="sepn_UnvestedRestrictedStock"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sepn_PrepaidTaxesCurrent" name="PrepaidTaxesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" name="TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_MaterialRightMember" name="MaterialRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset" name="OtherReceivableRelatedToSaleOfNonFinancialAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_EmployeeStockPurchasePlanLiability" name="EmployeeStockPurchasePlanLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" name="ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_LeasedSpaceMember" name="LeasedSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ServiceAgreementExpirationYear" name="ServiceAgreementExpirationYear" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sepn_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_TrancheOneMember" name="TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_AccruedGeneralAndAdministrativeExpenseCurrent" name="AccruedGeneralAndAdministrativeExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_UnconditionalRightOnNonFinancialAsset" name="UnconditionalRightOnNonFinancialAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_RisksAndUncertaintyPolicyTextBlock" name="RisksAndUncertaintyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_EquityIncentivePlan2024Member" name="EquityIncentivePlan2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_VertexAssetPurchaseMember" name="VertexAssetPurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_UnvestedRestrictedStock" name="UnvestedRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_OrganizationDisclosureTextBlock" name="OrganizationDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_OptionAndIncentivePlan2024Member" name="OptionAndIncentivePlan2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_InitialPublicOfferingStockOptions" name="InitialPublicOfferingStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock" name="SaleOfNonFinancialAssetsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_EmployeeStockPurchase2024PlanMember" name="EmployeeStockPurchase2024PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" name="GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashEquivalentsAndMarketableSecuritiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" name="SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" name="AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_StockPlan2024And2021Member" name="StockPlan2024And2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_AccountingStandardsUpdate202507Member" name="AccountingStandardsUpdate202507Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_TemporaryEquityStockFinancingArrangementFinancingValue" name="TemporaryEquityStockFinancingArrangementFinancingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_LesseeOperatingLeaseExpirationYearAndMonth" name="LesseeOperatingLeaseExpirationYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_OriginalLeasedSpaceMember" name="OriginalLeasedSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ConvertiblePreferredStockTextBlock" name="ConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" name="EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering" name="PurchasePricePercentageOfFairMarketValuePerShareOnOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_CommonStockTable" name="CommonStockTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval" name="TemporaryEquityStockAdditionalFundingBasedOnApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember" name="EmployeeAndNon-EmployeeStockOptionAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_CombinedLicenseAndResearchServicesMember" name="CombinedLicenseAndResearchServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" name="CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_Stock2024PlanMember" name="Stock2024PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" name="NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" name="ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation" name="EmployeeRelatedExpensesExcludingStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_FourZeroOne401KPlanMember" name="FourZeroOne401KPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_IncentiveStockOptionsMember" name="IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember" name="ResearchDevelopmentProgramsAndManufacturingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_UndesignatedCommonStockParOrStatedValuePerShare" name="UndesignatedCommonStockParOrStatedValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sepn_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" name="SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_CommonStockLineItems" name="CommonStockLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_TermOfResearchServiceAgreement" name="TermOfResearchServiceAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_AgreementDescription" name="AgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_RequiredPriorNoticeDurationToTerminateAgreement" name="RequiredPriorNoticeDurationToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" name="EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" name="ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_PrepaidClinicalTrialCostsCurrent" name="PrepaidClinicalTrialCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_EmployeeMember" name="EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" name="CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_ThirdRockVenturesViLPServiceAgreementMember" name="ThirdRockVenturesViLPServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_DeferredRevenuePolicyTextBlock" name="DeferredRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_PatentExpensesPolicyPolicyTextBlock" name="PatentExpensesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect" name="PercentageOfShareIssuePriceDividedByConversionPriceInEffect" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" name="LiabilitiesAssociatedWithIndemnificationRightsAndAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_UnderwritingOtherOfferingExpenses" name="UnderwritingOtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_PaymentReceivedOnSaleOfNonFinancialAsset" name="PaymentReceivedOnSaleOfNonFinancialAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_SamiraShaikhlyMember" name="SamiraShaikhlyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_PerformanceConditionsMember" name="PerformanceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" name="AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested" name="StockIssuedDuringPeriodValuesRestrictedStockAwardVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_FurnitureFixturesAndOfficeEquipmentMember" name="FurnitureFixturesAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_NovoCollaborationAgreementMember" name="NovoCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ProceedsFromSaleOfNonFinancialAsset" name="ProceedsFromSaleOfNonFinancialAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_RepurchasesOfUnvestedRestrictedCommonStock" name="RepurchasesOfUnvestedRestrictedCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" name="AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_LeaseCommencementPeriod" name="LeaseCommencementPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_GainOnSaleOfNonFinancialAsset" name="GainOnSaleOfNonFinancialAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock" name="CashProceedsFromIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" name="EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" name="TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_GainOnSaleOfInProgressResearchAndDevelopment" name="GainOnSaleOfInProgressResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_GainOnSaleOfNonFinancialAssetTextBlock" name="GainOnSaleOfNonFinancialAssetTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts" name="UnderwritingDiscountsCommissionsAndOtherOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_MilestonePaymentsReceivableFromCollaborationAgreement" name="MilestonePaymentsReceivableFromCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_PercentageOfChangeInOwnership" name="PercentageOfChangeInOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_CommonStockOptions" name="CommonStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_ChangeInDeferredRevenue" name="ChangeInDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_NonRefundableOneTimeUpfrontPaymentReceived" name="NonRefundableOneTimeUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_VertexResearchServiceAgreementMember" name="VertexResearchServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_CommonStockTextBlock" name="CommonStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" name="SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_UnrecognizedTransactionPrice" name="UnrecognizedTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress" name="GainLossOnSaleOfResearchAndDdevelopmentInProgress" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" name="ShareBasedCompensationEquityAwardsOptionsGrantsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_LizBhattMember" name="LizBhattMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_EmployeeStockPurchasePlan2024Member" name="EmployeeStockPurchasePlan2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset" name="DeferredTaxLiabilitiesSaleOfNonFinancialAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_UndesignatedPreferredStockSharesAuthorized" name="UndesignatedPreferredStockSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sepn_StockIssuanceCostsOfConvertibleSecurities" name="StockIssuanceCostsOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" name="MarketableSecuritiesAndFairValueMeasurementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_UnpaidOfferingCostsIncludedInAccountsPayable" name="UnpaidOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_InitialTrancheMember" name="InitialTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_TrancheOneAndTrancheTwoMember" name="TrancheOneAndTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_AccruedExpenseAndOtherCurrentLiabilities" name="AccruedExpenseAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_InterimChiefMedicalOfficerMember" name="InterimChiefMedicalOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_AdditionalLeasedSpaceMember" name="AdditionalLeasedSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ExecutiveOfficerAndDirectorEquityAwardsMember" name="ExecutiveOfficerAndDirectorEquityAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_TrancheTwoMember" name="TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" name="TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_SamsaraBiocapitalLPMember" name="SamsaraBiocapitalLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_IncreaseInSharesReservedForFutureIssuanceInShares" name="IncreaseInSharesReservedForFutureIssuanceInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_PrepaidBonusCurrent" name="PrepaidBonusCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_UnvestedRestrictedStockSubjectToRepurchaseMember" name="UnvestedRestrictedStockSubjectToRepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_ResearchDevelopmentProgramsMember" name="ResearchDevelopmentProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_TransactionPrice" name="TransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_ExternalResearchAndDevelopmentExpenses" name="ExternalResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_ConvertiblePreferredStockPolicyPolicyTextBlock" name="ConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_VariableConsideration" name="VariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_Stock2021PlanMember" name="Stock2021PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_ExternalGeneralAndAdministrativeExpenses" name="ExternalGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_RaCapitalManagementLPServiceAgreementMember" name="RaCapitalManagementLPServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" name="PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sepn_SummaryOfChangesInDeferredRevenueTableTextBlock" name="SummaryOfChangesInDeferredRevenueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sepn_RestrictedStockOptionsSubjectToRepurchase" name="RestrictedStockOptionsSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sepn_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 02, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Septerna, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001984086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-3891440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SEPN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">250 East Grand Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">338-3533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text"> Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,906,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Septerna, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 120,722<span></span>
</td>
<td class="nump">$ 238,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">270,367<span></span>
</td>
<td class="nump">112,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">10,356<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,519<span></span>
</td>
<td class="nump">5,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">410,964<span></span>
</td>
<td class="nump">356,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">157,569<span></span>
</td>
<td class="nump">69,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">21,499<span></span>
</td>
<td class="nump">23,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">596,187<span></span>
</td>
<td class="nump">456,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,283<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,167<span></span>
</td>
<td class="nump">7,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">62,269<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,212<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">86,931<span></span>
</td>
<td class="nump">12,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">105,917<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">21,413<span></span>
</td>
<td class="nump">23,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">214,261<span></span>
</td>
<td class="nump">36,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share, 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 44,806,272 and 44,422,505 shares issued and outstanding at December 31, 2025 and December 31, 2024 respectively; 131,224 and 576,829 shares subject to repurchase as of December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">548,517<span></span>
</td>
<td class="nump">538,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(167,253)<span></span>
</td>
<td class="num">(118,374)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">381,926<span></span>
</td>
<td class="nump">420,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 596,187<span></span>
</td>
<td class="nump">$ 456,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">44,806,272<span></span>
</td>
<td class="nump">44,422,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">44,806,272<span></span>
</td>
<td class="nump">44,422,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_RestrictedStockOptionsSubjectToRepurchase', window );">Restricted stock options subject to repurchase</a></td>
<td class="nump">131,224<span></span>
</td>
<td class="nump">576,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_RestrictedStockOptionsSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock options subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_RestrictedStockOptionsSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 45,951<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">97,584<span></span>
</td>
<td class="nump">65,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,164<span></span>
</td>
<td class="nump">16,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of non-financial asset</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">114,248<span></span>
</td>
<td class="nump">81,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(68,297)<span></span>
</td>
<td class="num">(80,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">19,530<span></span>
</td>
<td class="nump">8,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">19,430<span></span>
</td>
<td class="nump">8,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision (benefit) for income taxes</a></td>
<td class="num">(48,867)<span></span>
</td>
<td class="num">(72,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="num">$ (7.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="num">$ (7.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding used in computing net (loss) income per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">44,258,338<span></span>
</td>
<td class="nump">9,891,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">44,258,338<span></span>
</td>
<td class="nump">9,891,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (48,318)<span></span>
</td>
<td class="num">$ (71,742)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,168,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="num">$ (38,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 8,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46,576)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Beginning Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">60,828,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Beginning Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,694<span></span>
</td>
<td class="nump">$ 74,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B Convertible Preferred Stock, issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,828,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B Convertible Preferred Stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with initial public offering, net of issuance costs</a></td>
<td class="nump">302,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">302,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares', window );">Temporary equity, Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000,000)<span></span>
</td>
<td class="num">(121,657,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock', window );">Temporary equity, Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (74,694)<span></span>
</td>
<td class="num">$ (149,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,839,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">224,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">224,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested', window );">Vesting of restricted common stock</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of unvested restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(71,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,798)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,422,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 420,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">538,321<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(118,374)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested', window );">Vesting of restricted common stock</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of unvested restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of unvested restricted common stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(48,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,879)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,806,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 381,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 548,517<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="num">$ (167,253)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending Balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period values restricted stock award vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, Conversion of convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, Conversion of convertible preferred stock to common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with initial public offering, issuance costs</a></td>
<td class="nump">$ 302,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">28,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_StockIssuanceCostsOfConvertibleSecurities', window );">Issuance costs</a></td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_StockIssuanceCostsOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_StockIssuanceCostsOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_GainOnSaleOfNonFinancialAsset', window );">Gain on sale of non-financial asset</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,476<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts, net</a></td>
<td class="num">(3,448)<span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,781)<span></span>
</td>
<td class="num">(4,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(10,185)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non-current assets</a></td>
<td class="num">(554)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,603<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (Decrease) in Contract with Customer, Liability</a></td>
<td class="nump">168,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating leases, net</a></td>
<td class="num">(1,851)<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">110,189<span></span>
</td>
<td class="num">(67,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(518)<span></span>
</td>
<td class="num">(2,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ProceedsFromSaleOfNonFinancialAsset', window );">Proceeds from sale of non-financial asset</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">22,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale marketable securities</a></td>
<td class="num">(450,950)<span></span>
</td>
<td class="num">(213,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of available-for-sale marketable securities</a></td>
<td class="nump">209,616<span></span>
</td>
<td class="nump">32,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(229,352)<span></span>
</td>
<td class="num">(160,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">302,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series B Convertible Preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_RepurchasesOfUnvestedRestrictedCommonStock', window );">Repurchases of unvested restricted common stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">377,781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(117,474)<span></span>
</td>
<td class="nump">149,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">239,101<span></span>
</td>
<td class="nump">89,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">121,627<span></span>
</td>
<td class="nump">239,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure for noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized in exchange for operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">224,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UnpaidOfferingCostsIncludedInAccountsPayable', window );">Unpaid offering costs included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities', window );">Property and equipment included in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents and Restricted Cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">120,722<span></span>
</td>
<td class="nump">238,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">$ 121,627<span></span>
</td>
<td class="nump">$ 239,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock upon initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_GainOnSaleOfNonFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_GainOnSaleOfNonFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ProceedsFromSaleOfNonFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of non-financial asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ProceedsFromSaleOfNonFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment included in accounts payable and accrued expenses and other current liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_RepurchasesOfUnvestedRestrictedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchases of unvested restricted common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_RepurchasesOfUnvestedRestrictedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UnpaidOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid Offering Costs Included In Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UnpaidOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented a cybersecurity risk management program in accordance with our risk profile and business size that is informed by recognized industry standards, including elements of the National Institute of Standards and Technology Cybersecurity Framework and International Organization for Standardization 27001 Framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is comprised of a number of components, including but not limited to written information security policies, external cybersecurity risk assessments, and system monitoring. We also have an employee privacy and data security training awareness program that includes cybersecurity risk awareness trainings and phishing campaigns. We maintain an incident response plan to help guide our response to cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We leverage the cybersecurity services of third-party vendors, including a third-party managed services provider and IT consultants, to support our cybersecurity risk management program and assist us in conducting external cybersecurity risk assessments. As part of our cybersecurity risk management program, we take a risk-based approach to the evaluation of third-party vendors. As part of our vendor diligence process we require vendors with access to our information technology systems and infrastructure to complete information security program questionnaires.</span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, like other companies in our industry, we and our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vendors have from time to time experienced threats relating to our and our third-party vendors&#8217; information systems and infrastructure.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> For more information, please see &#8220;Item 1A, Risk Factors.&#8221;</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#8217;s general risk oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#8220;IT&#8221;), and is responsible for the strategic leadership of our cybersecurity risk management program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Head of IT relies on both internal and external cybersecurity resources to manage and remain appraised of overall cybersecurity risks to our business and our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#8217;s general risk oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#8217;s general risk oversight function.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p><p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#8217;s general risk oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#8220;IT&#8221;), and is responsible for the strategic leadership of our cybersecurity risk management program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Head of IT relies on both internal and external cybersecurity resources to manage and remain appraised of overall cybersecurity risks to our business and our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#8220;IT&#8221;), and is responsible for the strategic leadership of our cybersecurity risk management program.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 20, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liz Bhatt</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, M.S., M.B.A., our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President and Chief Operating Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Ms. Bhatt), which plan expires at the earlier of January 15, 2027, and the date upon which all authorized transactions thereunder are completed. Ms. Bhatt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Samira Shaikhly</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief People Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,206</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Ms. Shaikhly), which plan expires at the earlier of October 30, 2026, and the date upon which all authorized transactions thereunder are completed.  Ms. Shaikhly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2025, no other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement&#8221; as each term is defined in Item 408 of Regulation S-K.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_Rule10B51ArrModifiedFlag', window );">Rule 10b5 1Arr Modified Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NonRule10B51ArrModifiedFlag', window );">Non Rule 10b5 1 Arr Modified Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sepn_LizBhattMember', window );">Liz Bhatt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Liz Bhatt<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Operating Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 20, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sepn_SamiraShaikhlyMember', window );">Samira Shaikhly</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Samira Shaikhly<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief People Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 31, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">109,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b5 1 Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b5 1Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sepn_LizBhattMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sepn_LizBhattMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sepn_SamiraShaikhlyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sepn_SamiraShaikhlyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_OrganizationDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Septerna, Inc. (&#8220;Septerna&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company with a world-class team of G protein-coupled receptor (&#8220;GPCR&#8221;) experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The Company&#8217;s proprietary Native Complex Platform&#174; is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. The Company is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s proprietary Native Complex Platform&#174; replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale. The Company&#8217;s foundational technologies enable it to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. The Company then applies state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging its platform, the Company has transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable GPCR targets with novel oral small molecule medicines for patients. The Company&#8217;s Native Complex Platform&#174; is designed to enable it to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was incorporated in Delaware in December 2019, under the name GPCR NewCo, Inc. In June 2021, the Company changed its name to Septerna, Inc. The Company is headquartered in South San Francisco, California.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 18, 2024, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-8.6103</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding shares of common stock. Upon the effectiveness of the reverse stock split, (i) all shares of outstanding common stock were adjusted; (ii) the conversion ratio of the convertible preferred stock was adjusted; (iii) the number of shares of common stock for which each outstanding option to purchase common stock is exercisable were adjusted; and (iv) the exercise price of each outstanding option to purchase common stock was adjusted. All of the outstanding common stock (including shares of common stock subject to the Company&#8217;s options and as converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. The number of authorized shares did not change.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company completed its initial public offering (&#8220;IPO&#8221;), pursuant to which it issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at the IPO price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares that were issued to the underwriters pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">302.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and other offering expenses payable by the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Immediately prior to the closing of the IPO, the Company&#8217;s then outstanding convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,839,774</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the closing of the IPO, no shares of convertible preferred stock were authorized or outstanding. In connection with the completion of the IPO, on October 28, 2024, the Company&#8217;s certificate of incorporation was amended and restated to (i) authorize </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which eliminates all references to the previously existing series of convertible preferred stock; and (ii) authorize </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of undesignated preferred stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share,  that may be issued from time to time by the Company&#8217;s board of directors in one or more series.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which assumes that the Company will realize its assets and satisfies its liabilities in the normal course of business. The Company is subject to risks inherent in operating an early-stage biotechnology business. These risks include, but are not limited to, dependence on the development of marketable products, the ability to attract, retain, and motivate qualified personnel, rapid technological changes and the rapidly evolving nature of the biotechnology industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred significant losses and cumulative negative cash flows from operations since its inception and expects to incur losses as a result of its continued research and development activities. To date, none of the Company&#8217;s product candidates have been approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for commercial sale and, therefore, the Company has not generated any revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 31, 2025. The Company believes its cash, cash equivalents, and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">548.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of December 31, 2025 will be sufficient to fund its operations for, at least, 12 months from the date of issuance of the financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company historically financed its operations primarily through the issuance of convertible promissory notes, convertible preferred stock, the sale of its common stock in an IPO, and most recently, through a one-time, non-refundable upfront payment  upon commencement of its collaboration agreement with Novo Nordisk A/S (&#8220;Novo&#8221;) and achievement of a milestone event pursuant to its agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects to continue to generate operating losses for the foreseeable future. The Company will need additional financing to support its continuing operations and pursue its growth strategy. It expects to finance its operations through equity offerings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. Any failure to raise capital as and when needed would compromise the Company&#8217;s ability to execute on its business plan and may cause the Company to significantly delay, scale back or discontinue the research and development of some of its programs or curtail any efforts to expand its product pipelines and will materially harm its business, financial position and results of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_OrganizationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_OrganizationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), stated in U.S. dollars and include all adjustments necessary for the fair presentation of the Company&#8217;s financial statements as of December 31, 2025 and 2024, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASUs</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of the Financial Accounting Standards Board </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FASB</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in determining the fair value of assets and liabilities, the useful lives of property and equipment, the rate used in determining the present value of lease payments, fair value of assets and liabilities, research and development accruals, the estimated fair value of common stock prior to the Company's IPO and assumptions used in stock-based compensation, the initial allocation and continued evaluation of a revenue contract&#8217;s transaction price to each distinct performance obligation on a relative standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, tariffs, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company limits its credit risk by placing its cash, cash equivalents, and marketable securities with banks and institutions that are highly creditworthy. Such cash may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits, and the Company's cash equivalents and marketable securities are not insured by the FDIC. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities to the extent recorded in the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary focus of the Company&#8217;s investment strategy is to preserve capital and meet liquidity requirements. Management believes that the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash, cash equivalents and marketable securities since inception. The Company has no significant off-balance sheet concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, efficacy of product candidates, intense competition, and dependence upon the availability of liquidity to sustain operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company holds marketable securities that consist of highly liquid, investment grade debt securities. The Company's cash and marketable securities are held or issued by financial institutions that management believes are of high credit quality. Marketable securities are classified and accounted for as available-for-sale. Marketable securities with original maturities of 90 days or less are classified as cash equivalents. Marketable securities with original maturities over 90 days and remaining maturities of less than 12 months are classified as current. Marketable securities with remaining maturities of more than 12 months for which the Company has the intent and ability to hold the security for more than 12 months are classified as non-current. The Company&#8217;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported in stockholders&#8217; equity as accumulated other comprehensive income. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. The Company does not generally intend to sell the investments and it is less likely that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, the Company recognizes a loss in its statement of operations and comprehensive loss, whereas if the decline in fair value is not due to credit-related factors, the Company records the loss in accumulated other comprehensive income on its balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of marketable securities for purposes of identifying and measuring an impairment. Accrued interest receivable on marketable securities is recorded within prepaid expenses and other current assets on the balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#8217;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to its landlord. The collateral account is classified as restricted cash on the Company&#8217;s balance sheets. As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining term of the leases is greater than one year and the related restricted cash is classified as non-current on the Company's balance sheet.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Revenue</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue consists of amounts received prior to satisfying revenue recognition criteria (see Note 4).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of assets, or at the time services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s accounts receivable was entirely attributable to Novo. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s accounts receivable was entirely attributed to Vertex.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation and amortization. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:57.54%;box-sizing:content-box;"></td>
           <td style="width:1.94%;box-sizing:content-box;"></td>
           <td style="width:40.52%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer Equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
          </tr>
         </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation or amortization is removed from the balance sheet and the resulting gain or loss is recognized within other income, net in the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairments of the Company&#8217;s long-lived assets for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its leases in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 842&#8221;). The Company adopted ASC 842 on January 1, 2021, prior to entering into the lease agreement for its office and research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is reasonably certain that the Company will exercise that option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments if the Company&#8217;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Right-of-use assets represent the Company</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s right to use underlying assets for the lease term and operating lease liabilities represent the Company</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s obligation to make lease payments under the lease. Right-of-use assets also include any lease payments made prior to the commencement date and exclude lease incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company elected to apply the practical expedient of combining lease and non-lease components for the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company elected the short-term lease practical expedient that allows the lessee to not record a lease liability and right-of-use asset for all leases with a term of 12 months or less. See Note 6 for additional information on the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for revenue in accordance with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following four steps: (i) confirm it has a contract with a customer that creates enforceable rights and obligations; (ii) identify promised products or services to be transferred to a customer; (iii) determine the transaction price, or the amount it expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable and allocated to the performance obligations; and (iv) recognize revenue when or as performance obligations are satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price of each distinct performance obligation. In instances where standalone selling price is not directly observable, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract using a cost plus margin approach, which is an estimation method used when standalone selling price is not directly observable. Key assumptions used within this estimation method may include full-time equivalent personnel effort and estimated external costs associated with the performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the Company's performance, (ii) the Company's  performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the Company does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues are primarily derived through its license and research and development service arrangements. Payments to the Company under these arrangements typically include one or more of the following: one-time, non-refundable upfront payment, research and development service funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain collaboration, research and development and commercial milestones, as well as royalties based on net sales of approved drugs.</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration received prior to revenue recognition is recorded as deferred revenue in the balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current. Contract assets represent research and development services which have been performed but have not yet been billed and are reduced when they are subsequently billed. Such contract assets include accounts receivable when the Company&#8217;s right to consideration is unconditional. For its current contracts, the Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and, if over time, revenue recognized is based on the use of an input method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s collaborative arrangements include one or more of the following</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For a license that is determined not to be distinct, it is combined with other promises and the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost of each performance obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - The Company evaluates the customer options for material rights or options to acquire additional goods or services at no incremental consideration or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised and performance obligations are satisfied. If an option is not exercised before the option right expires, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under the Company's collaboration agreement include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#8217;s statements of operations and comprehensive loss. Expenses incurred as part of the Company&#8217;s efforts to perform the research and development services are recognized in research and development expense in the Company&#8217;s statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under the Company's collaboration agreement include manufacturing services to be provided by the Company. Payments or reimbursements resulting from the Company's manufacturing services are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#8217;s statements of operations and comprehensive loss. Expenses incurred to perform the manufacturing services are recognized in research and development expense in the Company&#8217;s statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore, consideration included in the transaction price is constrained. The Company applied the variable consideration allocation exception under ASC 606 whereby variable milestone payments are not estimated and included in the transaction price at inception. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial milestone payments and royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied)</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of Non-Financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of non-financial assets that are outside the scope of the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary activities are accounted for under ASC 610-20, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income - Gains and Losses from the Derecognition of Non-financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 610-20&#8221;). Pursuant to ASC 610-20, the Company applies the guidance in ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 606</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to determine if a contract exists, identify the distinct non-financial assets, and determine when control transfers and, therefore, when to derecognize the non-financial asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation of the gain or loss for the non-financial asset.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies and clinical trials, contract manufacturing for the production of clinical and preclinical materials, information technology-related costs, allocated overhead costs including facility-related expenses, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into agreements with outsourced contract manufacturing and development and clinical research vendors. The Company estimates accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs to secure and maintain patents covering the Company&#8217;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The carrying values of the Company&#8217;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is recognized based on the grant-date fair value of the awards. The fair value of stock options and employee stock purchase plan ("ESPP") is determined using the Black-Scholes option pricing model on the date of grant. The fair value of restricted stock awards is determined using the estimated fair value of the Company&#8217;s common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the IPO, the Company utilized estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to the Company&#8217;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award of four years. For stock-based awards with vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based compensation expense on an accelerated basis over the vesting period when achievement of the performance criteria becomes probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is recorded within research and development and general and administrative expenses in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the asset and liability approach to account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. The Company&#8217;s other comprehensive income (loss) is comprised solely of unrealized gains or losses on marketable securities. The Company has not recorded any reclassifications from other comprehensive gains or losses to net loss during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of basic net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock, and ESPP shares. The dilutive effect of stock options, unvested restricted stock, and ESPP shares is computed using the treasury stock method. For all periods presented in a net loss position, diluted net loss per share is the same as basic net loss per share since the effect of including potential dilutive securities is anti-dilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU No. 2025-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expand the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. In addition, ASU 2025-07 is expected to reduce diversity in the accounting for share-based non-cash consideration from a customer for the transfer of goods or services, as well as provide investors with more comparable information and reduce accounting complexity and related reporting costs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adoption of the amendment allows for either the prospective or modified retrospective application and is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company early </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this standard using the prospective method for the derivative scope refinement with the effective date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Prior to adoption, the Company did not have contracts that incl</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ude are subject to derivative accounting and the adoption of the ASU did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a material impact on its financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_faecfa98-652d-4cca-94de-7a02c3297ab7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU No. 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years beginning after December 15, 2024, on a prospective basis. Early adoption and retrospective reporting are permitted. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company follows the provisions set forth in ASU No. 2023-09 on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the FASB issued ASU No. 2025-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset in developing reasonable and supportable forecasts during the application of the current expected credit loss model for current accounts receivable and current contract assets arising from transactions under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-05.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires the Company to disclose more detailed information about the types of expenses (including employee compensation, depreciation, and amortization) included in each relevant income statement expense caption. The ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status and Smaller Reporting Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Balance Sheet Components</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,622</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,384</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">953</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid bonus</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,730</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,339</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,679</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture, fixtures, and office equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">401</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">401</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,019</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,929</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,090</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025 and 2024, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,606</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,888</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,798</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Collaboration and Research Service Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Collaboration and Research Service Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, the Company's revenue is comprised solely of arrangements with Novo and Vertex. For the year ended December 31, 2024, the Company's revenue was solely comprised of the arrangement with Vertex.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 13, 2025, the Company entered into a Collaboration and License Agreement with Novo (the &#8220;Novo Collaboration Agreement&#8221;). Under the Novo Collaboration Agreement, the Company and Novo are exclusively collaborating to leverage the Company&#8217;s proprietary Native Complex Platform&#153; to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon effectiveness of the Novo Collaboration Agreement on July 1, 2025, the Company and Novo have commenced four simultaneous research and development programs (each an &#8220;R&amp;D Program&#8221;), each pursuing one or more Collaboration Targets (as defined in the Novo Collaboration Agreement) from discovery through development candidate selection. Subject to certain limitations, Novo also has a right to modify the research plan with the option to commence additional R&amp;D Programs. Novo will reimburse the Company for 100% of the fully burdened costs arising from all research and development activities undertaken by the Company under the Novo Collaboration Agreement. After development candidate selection, beginning with investigational new drug-enabling activities, Novo will be responsible for all further global development and commercialization for each product candidate at its sole cost and expense unless the profit share option described below is exercised. Novo is also responsible for all commercialization costs subject to the Company&#8217;s profit share option for up to one program under the Novo Collaboration Agreement. Pursuant to the terms of the Novo Collaboration Agreement, the Company will provide Novo with exclusive licenses to enable Novo to develop and commercialize products directed at the Collaboration Targets. The Company retains all other rights to its Native Complex Platform&#153; and all of the Company&#8217;s other research and development programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon effectiveness of the Novo Collaboration Agreement, the Company received a one-time, non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in July 2025, which was recorded as deferred revenue in its balance sheet. The Company is also eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">498.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in research, development, regulatory, and commercial milestone payments for each R&amp;D Program. In addition, the Company is entitled to escalating, tiered royalties ranging from mid to high single-digits based on global product sales on a country-by-country and product-by-product basis with respect to a R&amp;D Program until the later of ten years after the date of first commercial sale of the first product in such R&amp;D Program in such country, expiration of specified patent rights covering such product in such country or the expiration of specified regulatory exclusivity for the first product in such R&amp;D Program in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Novo Collaboration Agreement, the Company has a one-time option to share in the global development costs and operating profits or losses (in lieu of milestones and royalties) with respect to one licensed product (the "Profit Share Option"), subject to certain terms, conditions and limitations. In the event that the Company chooses to exercise the Profit Share Option, it will be required to repay Novo all previously reimbursed developmental costs pertaining to that program at a predetermined multiple and reimburse Novo for a portion of the continued R&amp;D costs incurred under the selected licensed product and will share in the profits resulting from the commercialization of the licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the term of the Novo Collaboration Agreement continues until expiration of the last royalty term for the applicable product in the applicable country. The Novo Collaboration Agreement is subject to customary termination provisions, including termination by a party for the other party&#8217;s uncured, material breach. The Novo Collaboration Agreement also includes customary representations and warranties, covenants and indemnification obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded the Agreement is not within the scope of Accounting Standards Codification 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as the Company does not share equally in the exposure to significant risk. Accordingly, the Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Novo, is a customer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At commencement, the Company identified the several performance obligations within the Novo Collaboration Agreement, including research and development services on research targets, option rights held by Novo, license to use the Company&#8217;s intellectual property to conduct research and development activities, and participation on the joint steering committee (&#8220;JSC&#8221;). At inception of the Novo Collaboration Agreement, the Company identified the following performance obligations:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Four combined performance obligations comprised of the license, related research services, and participation of the JSC for the four R&amp;D Programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing services related to one of the R&amp;D Programs; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material R&amp;D Program modification right held by Novo.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company concluded that the license granted at contract inception is not distinct from the research services as the research services significantly modify the intellectual property underlying the license.  As a result, for each R&amp;D Program, the license has been combined with the research services and JSC participation into a single performance obligation, which is the combined performance obligation comprised of the license, related research services, and JSC participation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In assessing whether the various options under the Novo Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material right identified above, the Company concluded the option provided Novo with a discount that it otherwise would not have received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes revenue related to the combined license and research services performance obligation and the manufacturing performance obligation over time using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of actual cost incurred to date to the total estimated cost at completion of the performance obligations, which the Company believes best measures its progress towards satisfying the performance obligations. A cost-based input method of revenue recognition requires management to make estimates of cost to complete the performance obligation. Judgment is required to evaluate assumptions related to cost estimates. The estimated standalone selling price for the material right was determined based on the estimated discount provided to Novo and the probability that Novo would exercise the option.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue recognized, unrecognized transaction price, and estimated revenue expected to be recognized in the future as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.385%;box-sizing:content-box;"></td>
         <td style="width:2.759%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:21.855999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transaction Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Combined license, research and manufacturing services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material right</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total transaction price</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,036</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized transaction price as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of the allocation of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million one-time, non-refundable upfront payment, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the four R&amp;D programs and manufacturing services and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the material right and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of variable consideration related to estimated research and manufacturing services for the four R&amp;D Programs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded within revenue in the statement of operations and comprehensive loss for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized of the one-time, non-refundable upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million variable considerations related to estimated research services for the four R&amp;D Programs.</span></div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the Novo Collaboration Agreement are recorded as accounts receivable in the Company&#8217;s balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s balance sheets.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes in deferred revenue for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.385%;box-sizing:content-box;"></td>
         <td style="width:2.759%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:21.855999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,814</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,186</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred revenue, current and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred revenue, non-current, which is expected to be recognized over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all of the Company's performance obligations are outstanding.</span></div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically assesses the probability of receiving payments from achieving the research and development, collaboration target, and regulatory milestones and includes the payment in the transaction price when they are deemed probable. Royalties and commercial sale milestones will be recognized when the subsequent sales occur based on the sales or usage-based royalty exception.  The Company also periodically reassesses the probability of exercising Profit Share Option. As of December 31, 2025, none of the milestones were deemed probable and no royalty revenue has been recognized, and the Profit Share Option was deemed improbable with no amount recognized for repayment of reimbursements to Novo.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Asset Purchase and Research Service Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Asset Purchase Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company entered into an asset purchase agreement with Vertex, under which Vertex acquired an in-process research and development ("IPR&amp;D") asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (the &#8220;Vertex Asset Purchase Agreement&#8221;). The Vertex Asset Purchase Agreement also provided for a potential milestone payment payable to the Company contingent upon the achievement of a milestone event.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, this milestone event was determined achieved and, as a result, the Company received a payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in August 2025, which was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recorded as a gain on sale of non-financial asset within total operating expenses in the Company&#8217;s statements of operations and comprehensive loss for the year ended December 31, 2025. The Company will not receive any other payments related to this IPR&amp;D asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Vertex Research Service Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the Vertex Asset Purchase Agreement in September 2023, the Company entered into research service agreement with Vertex under which the Company agreed to perform certain exploratory research activities for Vertex (the "Vertex Research Service Agreement"). The Company recognized service revenue associated with the Vertex Research Service Agreement over the performance period of the research services as the services were provided in accordance with ASC 606. The Vertex Research Service Agreement expired in September 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to research activities performed in connection with the Vertex Research Service Agreement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, the Company recorded revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to research activities performed in connection with the Vertex Research Service Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Available-for-Sale Marketable Securities and Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Marketable Securities and Fair Value Measurements</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records marketable securities and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.53%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,736</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,736</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">544,025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,736</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480,289</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.53%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,779</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,779</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,527</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,527</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,059</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,059</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,193</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,193</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">414,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,779</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s marketable securities consist of debt securities, including U.S. treasury and agency securities, corporate debt securities and commercial paper. These marketable securities are carried at fair value and are included in the tables above. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these marketable securities and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met at December 31, 2025. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and the Company's expectation is that those payments will continue to be received timely. Based on this evaluation, as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company determined that unrealized losses of its marketable securities were primarily attributable to changes in interest rates and non-credit related factors. As such, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowances for credit losses were recorded at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t hold marketable securities at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest receivable as of December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and is recorded as a component of prepaid expenses and other current assets on the Company&#8217;s balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, all marketable securities in an unrealized loss position had been in an unrealized loss position for less than 12 months. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> marketable securities had been in an unrealized loss position for a period of less than 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.42%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:15.36%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining<br/>Contractual<br/>Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Estimated Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,939</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,755</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,763</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,992</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">322,374</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">322,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,699</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">479,672</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480,289</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.42%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:15.36%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining<br/>Contractual<br/>Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Estimated Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,017</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,014</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,252</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,264</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,313</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,427</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,940</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,123</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the following table summarizes marketable securities in an unrealized loss position (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.649%;box-sizing:content-box;"></td>
         <td style="width:12.503%;box-sizing:content-box;"></td>
         <td style="width:2.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.224%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.224%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Contractual Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,503</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,064</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,389</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,449</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leases</span><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and research and development space at the Company&#8217;s headquarters in South San Francisco, California under an operating lease. In April 2021, the Company entered into a lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,560</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet, set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In September 2022, the lease was amended to add </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,348</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet, totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,908</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet (the &#8220;Original Leased Space&#8221;), also expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In December 2022, the Company entered into another lease amendment to extend the term of the Original Leased Space and added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,911</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet (the &#8220;Additional Leased Space&#8221;). The Company took control of the Additional Leased Space in November 2023, at which point the Company vacated the Original Leased Space to allow the landlord to renovate it.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Renovation of the Original Leased Space was completed in July 2024. Upon completion of the renovation of the Original Leased Space, the lease of the Original Leased Space commenced, resulting in the total leased premises increasing to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,819</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet (the &#8220;Leased Space&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease term for the Leased Space expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease for eight additional years (the &#8220;Extension Option&#8221;)</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, it was not probable that the Company would exercise the Extension Option, therefore, it was excluded from the right-of-use asset and lease liability calculations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, the Company recorded a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million operating lease right-of-use asset and operating lease liability upon completion of the renovations of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,908</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square foot office and research and development space (the "Original Leased Space") as the Company occupied the property. These amounts are disclosed in the supplemental information of noncash activities on the statements of cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay base rent plus its proportionate share of operating expenses, as defined in the applicable lease agreement on all of its leases. Variable lease payments related to operating expenses including utilities, maintenance costs and real estate taxes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024,  respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease expenses, excluding variable lease payments, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively. Short-term lease expense was not material for the periods presented.  As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the weighted average remaining lease term of the Leased Space was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. The weighted average incremental borrowing rate used for the calculation of the present value of lease payments over the lease term was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for both the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,469</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,721</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,462</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,035</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, future minimum rental payments for operating leases were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future<br/>Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,912</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,070</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,234</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,579</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total present value of operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,212</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did not have any finance leases.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation, as the Company operates in an industry susceptible to patent or other legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company was not subject to any material legal proceedings as of December 31, 2025 and 2024, and the Company is not currently a party to any legal proceeding that, if determined adversely to the Company, in management&#8217;s opinion, is currently expected to individually or in the aggregate have a material adverse effect on the Company&#8217;s business, financial condition or results of operations taken as a whole.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and may enable it to recover a portion of any future amounts paid. The Company is not currently aware of any indemnification claims. In addition, the Company believes that the fair value of any potential indemnification obligations is minimal. Accordingly, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record any liabilities associated with these indemnification rights and agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ConvertiblePreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the closing of the Company's IPO in October 2024, the Company&#8217;s outstanding convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,839,774</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of common stock. Converted preferred stock outstanding as of the date of the IPO consisted of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196,657,452</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. Each share of outstanding convertible preferred stock was converted into common stock at a ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6103</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible preferred shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common share. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of convertible preferred stock were authorized, issued or outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, the Company executed a Series A Convertible Preferred Stock financing arrangement that would provide financing of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million over an initial tranche and subsequent callable tranches through the issuance of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock at an issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. In the initial tranche, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was received in cash, net of issuance costs, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. The Series A Convertible Preferred Stock financing arrangement represented an equity financing, per the terms of the outstanding convertible promissory notes, and as such the unpaid principal and accrued interest outstanding of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock. Additionally, in November 2022, the Company executed the second tranche and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series A Convertible Preferred Stock and received net cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the Company entered into a Series B Convertible Preferred Stock financing arrangement in which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,657,452</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series B Convertible Preferred Stock were authorized to be issued at an issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.23297</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share over two tranches, for total proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In June 2023 and July 2023, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series B Convertible Preferred Stock at an issuance price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.23297</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the first tranche, with a potential second tranche of additional funding for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on approval of the Board of Directors and consent of the majority of the holders of the then-outstanding Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock Purchase Agreement provides that, upon the fulfillment of certain conditions, each investor will purchase its pro rata portion of the shares to be issued in additional Series B Convertible Preferred Stock closings. Further, the Company agreed to sell, and issue said shares of Series B Convertible Preferred Stock on the same terms as the first tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were not freestanding from the associated shares of convertible preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of Series B Convertible Preferred Stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company was authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company amended and restated its certificate of incorporation, which was filed immediately prior to the closing of its IPO and among other things, increased the number of shares of common stock authorized for issuance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company completed its IPO of its common stock. In connection with the Company's IPO, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock, which included an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock that were issued to the underwriters pursuant to the full exercise of their option to purchase additional shares of common stock, at the public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As a result, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">302.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions and other offering costs payable by the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of common stock are entitled to dividends when and if declared by the board of directors. The board of directors has not declared any dividends and the Company has not paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock, on an as-converted basis, for future issuance:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,378,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,938,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future grants under 2024 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,257,640</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,743,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for 2024 ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,211</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369,402</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,887,335</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,052,299</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company's board of directors adopted, and its stockholders approved, the 2024 Stock Option and Incentive Plan (the &#8220;2024 Plan&#8221;) which became effective on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 25, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The 2024 Plan allows for the issuance of equity-based incentive awards to the Company's officers, employees, directors and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034 by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company's compensation committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 Plan replaced the Septerna, Inc. 2021 Stock Option and Grant Plan (the &#8220;2021 Plan&#8221;) as the Company&#8217;s board of directors determined not to make additional awards under the 2021 Plan following the completion of the IPO. However, the 2021 Plan will continue to govern outstanding equity awards granted thereunder. The shares of common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added to the shares of the Company's common stock available for issuance under the 2024 Plan. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares remained available for future issuance under the 2024 Plan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options are governed by stock option agreements between the Company and recipients of stock options. Incentive stock options and nonqualified stock options may be granted under the 2024 Plan at an exercise price of not less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the board of directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of the stock options may not exceed ten years from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Stock Option and Grant Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2021, the Company adopted the 2021 Plan, which authorizes the Company to grant incentive stock options, non-qualified stock options, restricted stock awards, unrestricted stock awards and restricted stock units, to officers, employees, directors, consultants, or other key persons of the Company. The terms of the stock option and restricted stock agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2021 Plan. Stock option awards expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date, or as otherwise determined by the Board of Directors, or in the case of incentive stock options granted to 10% stockholders, the term is no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date. Additionally, the Company granted and issued restricted stock awards and allowed the recipients to purchase the unvested restricted stock awards at par value per share. The shares issued for unvested restricted stock awards under the 2021 Plan are subject to repurchase by the Company at the original issuance price in the event of the holder&#8217;s termination of its relationship with the Company. Consideration received for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#8217; equity as the related awards vest over the requisite service period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares re</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mained available for future issuance under the 2021 Plan as of December 31, 2025 and 2024 as the 2021 Plan was replaced by the 2024 Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company granted restricted stock awards from the 2021 Plan and from outside of its stock plans, under the terms of restricted stock purchase agreements and subscription agreements. Unvested shares are subject to repurchase by the Company upon the holder&#8217;s termination of its relationship with the Company at the original purchase price. Consideration received for shares associated with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#8217; equity as the related awards vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes restricted stock award activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">576,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock awards vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">442,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock awards repurchased</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.30</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The restricted stock awards generally include a service condition for vesting and vest over four years with a one-year cliff vesting and pro-rata monthly vesting thereafter, but some awards vest over different time periods. In addition, some restricted stock awards include vesting criteria subject to the achievement of performance-based conditions in addition to service conditions (&#8220;performance RSAs&#8221;). As of December 31, 2025, none of the outstanding and unvested performance RSAs were subject to achievement of performance-based criteria for vesting. The aggregate grant date fair value of shares vested during the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The remaining liability related to restricted stock awards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 was not material and was recorded in accrued expenses and other current liabilities on the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes stock option activity under the 2024 Plan:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.11%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.662%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.942%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.662%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Options<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,938,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.11</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,706</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,914,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.70</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,378,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.97</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.79</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,194</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,096,087</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.19</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options include a service condition for vesting and generally vest over four years. The aggregate intrinsic values of options outstanding and exercisable were calculated as the difference between the exercise price of the options and the closing market price of the Company&#8217;s common stock as of December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate grant date fair value of options that vested for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The options granted in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> had a weighted-average per share grant-date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.58</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and a total grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The total intrinsic value of stock options exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company's board of directors adopted, and its stockholders approved, the 2024 ESPP. The 2024 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2026 and each January 1 thereafter through January 1, 2034, by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the outstanding number of shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the administrator of the 2024 ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offering periods begin on May 1 and November 1, will be twenty-four (24) months in duration and include four (4) purchase periods, each purchase period lasting six (6) months.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The purchase price will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value per share of the Company's common stock on either the offering date, which is the first trading day of the offering period, or the purchase date, which is the last trading day of the purchase period, whichever is less.  If the fair market value of a share of the Company's common stock on any purchase date within a particular offering period is less than the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,191</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares at a weighted average share price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares available for issuance under the 2024 ESPP.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option and ESPP Valuation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining the fair value of the stock options and ESPP granted, the Company uses the Black-Scholes option pricing model and assumptions discussed below. This model utilizes inputs that are subjective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Term &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term represents the period that the Company&#8217;s stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The Company will continue to apply this process until a sufficient amount of historical information regarding employee exercise patterns and post-vesting employment termination behavior becomes available.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Volatility &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the Company&#8217;s limited operating history and lack of company-specific historical volatility as a public company, due to the Company's IPO in October 2024, or implied volatility as a private company, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free Interest Rate &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected Dividend &#8212; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the near future. Therefore, the Company used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used to value employee and non-employee stock option awards granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.2%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="9" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.97</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used to value employee stock purchase plan shares granted during the year ended December 31, 2025, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:64.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.75%;box-sizing:content-box;"></td>
         <td style="width:1.562%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:4.688%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.22</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for restricted stock awards, stock options, and ESPP recognized in the Company&#8217;s statements of operations and comprehensive loss is presented as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,087</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,619</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,389</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,533</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,476</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized stock-based compensation expense related to unvested restricted stock awards, stock options, and ESPP was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the provision (benefit) for income taxes were as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.08%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 2, we adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. For the year ended December 31, 2025, the tax provision expense was not material. For the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded income tax benefit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate to the statutory U.S. federal rate is as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.807%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.278%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.073%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.434%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2025</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b8efe224-c188-42df-a41c-9d6bf32284b2;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;federal taxes at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,195</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,972</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:74.32%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal taxes at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total effective income tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The types of temporary differences that give rise to significant portions of the Company&#8217;s deferred income tax assets and liabilities are set out below (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,149</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,318</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 174 capitalized research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,932</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,855</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,812</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,432</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,015</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">683</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">766</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,114</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,605</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established a valuation allowance for the amount of deferred tax assets that are not more likely than not to be realized. Management considered all available evidence, both positive and negative, including but not limited to the Company&#8217;s historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in the total valuation allowance for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was an increase of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal net operating loss carryforwards and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of state net operating loss carryforwards, available to reduce future taxable income. The federal net operating loss carryforwards will carryforward indefinitely. The state net operating loss carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2041</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if not utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal research and development tax credits carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and state research and development tax credits carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, available to reduce future income taxes. The federal research and development tax credits will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if not utilized. The state research and development tax credits have no expiration date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Revenue Code section 382 (&#8220;IRC Section 382&#8221;) places a limitation (the &#8220;Section 382 Limitation&#8221;) on the amount of taxable income that can be offset by net operating loss (&#8220;NOL&#8221;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules. When an ownership change occurs, IRC Section 382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax attributes in one year but the identified ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. The Company performed a Section 382 analysis through the year ended December 31, 2024 and determined there were ownership changes in 2021 and 2023. The ownership changes did not result in a reduction of its net operating loss or in its research and development credit carryforwards expiring unused.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">998</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment based on tax positions related to prior years</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of the year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reversal of the uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. During the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize accrued interest and penalties related to unrecognized tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income taxes in the U.S. federal jurisdiction, the state of California and various other U.S. states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All income tax returns will remain open for examination by the federal, state and foreign authorities for three or four years, from the date of utilization of any NOLs or credits.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Related Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third Rock Ventures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its Series B Convertible Preferred Stock to Third Rock Ventures VI, L.P., a holder of more than 5% of the Company&#8217;s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2021, the Company entered into a service agreement with Third Rock Ventures, LLC (&#8220;TRV&#8221;), a holder of more than 5% of the Company&#8217;s outstanding capital stock, (the &#8220;TRV service agreement&#8221;) under which TRV provides consulting services to the Company. For the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for such services as general and administrative expenses in the Company&#8217;s statements of operations and comprehensive loss. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of expense related to TRV was recorded in accrued expenses and other current liabilities. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expense recorded in accrued expenses and other current liabilities and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding accounts payable to TRV at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's former interim Chief Medical Officer, and also a current member of the Company's board of directors, was designated to the Company's board of directors by TRV and is affiliated with TRV. He did not receive any cash compensation from the Company for his service as its interim Chief Medical Officer as his services were provided to the Company through the TRV service agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the total fees the Company incurred under the TRV service agreement for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was attributed to consulting services provided by the board member. Additionally, as compensation for his services as the Company's interim Chief Medical Officer, the Company granted him options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,227</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares during the year ended December 31, 2024 at the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.76</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The board member ceased serving as interim Chief Medical Officer in September 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a separate consulting agreement with the board member, under which he may provide up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of consulting services per month, which are also provided to the Company through the TRV service agreement. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for such consulting services. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, there was a minimal expense recorded in accrued expenses and other current liabilities and a minimal outstanding accounts payable to the board member.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RA Capital</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its Series B Convertible Preferred Stock to entities affiliated with RA Capital Management, L.P. (collectively, &#8220;RA Capital&#8221;), which held more than 5% of the Company&#8217;s outstanding capital stock, during the second tranche closing in May 2024, for total cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These shares were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">converted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to shares of the Company's common stock upon the consummation of its IPO in October 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Samsara BioCapital</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its Series B Convertible Preferred Stock to Samsara BioCapital, L.P. (&#8220;Samsara BioCapital&#8221;), a holder of more than 5% of the Company&#8217;s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,554,420</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of potentially dilutive securities, comprised of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,378,484</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding stock options, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,224</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unvested restricted stock awards subject to repurchase, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,712</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable under the ESPP, not included in the calculation of diluted net loss per share for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025  because to do so would be anti-dilutive.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Retirement Benefit Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Employee Retirement Benefit Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a 401(k) retirement savings plan (the &#8220;401(k) Plan&#8221;) for its employees. The 401(k) Plan allows eligible employees to make contributions up to the maximum allowable by the Internal Revenue Service (&#8220;IRS&#8221;). For the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company made matching contributions of and recorded contribution expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance for the Company&#8217;s operating segment and decides how to allocate resources based on the Company&#8217;s available cash resources. Total operating expenses and net loss of the Company&#8217;s operating segment are used to monitor budget versus actual results. The measure of segment assets is reported as total assets on the Company&#8217;s balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM is regularly provided with the following significant segment expenses:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,951</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,233</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,476</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses*</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,429</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,248</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,898</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,297</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,430</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,527</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,867</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,879</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,798</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Other segment expenses include facility related and office costs, information technology costs, general laboratory costs, and other operating expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, all of the Company&#8217;s property and equipment was maintained in the U.S. For each of the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s revenue was generated from providing research services and was earned in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2026, the Company appointed Mark A. Wilson as Chief Legal Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), stated in U.S. dollars and include all adjustments necessary for the fair presentation of the Company&#8217;s financial statements as of December 31, 2025 and 2024, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASUs</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of the Financial Accounting Standards Board </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FASB</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in determining the fair value of assets and liabilities, the useful lives of property and equipment, the rate used in determining the present value of lease payments, fair value of assets and liabilities, research and development accruals, the estimated fair value of common stock prior to the Company's IPO and assumptions used in stock-based compensation, the initial allocation and continued evaluation of a revenue contract&#8217;s transaction price to each distinct performance obligation on a relative standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, tariffs, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_RisksAndUncertaintyPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company limits its credit risk by placing its cash, cash equivalents, and marketable securities with banks and institutions that are highly creditworthy. Such cash may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits, and the Company's cash equivalents and marketable securities are not insured by the FDIC. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities to the extent recorded in the balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary focus of the Company&#8217;s investment strategy is to preserve capital and meet liquidity requirements. Management believes that the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash, cash equivalents and marketable securities since inception. The Company has no significant off-balance sheet concentrations of credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, efficacy of product candidates, intense competition, and dependence upon the availability of liquidity to sustain operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company holds marketable securities that consist of highly liquid, investment grade debt securities. The Company's cash and marketable securities are held or issued by financial institutions that management believes are of high credit quality. Marketable securities are classified and accounted for as available-for-sale. Marketable securities with original maturities of 90 days or less are classified as cash equivalents. Marketable securities with original maturities over 90 days and remaining maturities of less than 12 months are classified as current. Marketable securities with remaining maturities of more than 12 months for which the Company has the intent and ability to hold the security for more than 12 months are classified as non-current. The Company&#8217;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported in stockholders&#8217; equity as accumulated other comprehensive income. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. The Company does not generally intend to sell the investments and it is less likely that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, the Company recognizes a loss in its statement of operations and comprehensive loss, whereas if the decline in fair value is not due to credit-related factors, the Company records the loss in accumulated other comprehensive income on its balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of marketable securities for purposes of identifying and measuring an impairment. Accrued interest receivable on marketable securities is recorded within prepaid expenses and other current assets on the balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#8217;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to its landlord. The collateral account is classified as restricted cash on the Company&#8217;s balance sheets. As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining term of the leases is greater than one year and the related restricted cash is classified as non-current on the Company's balance sheet.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_DeferredRevenuePolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Revenue</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred revenue consists of amounts received prior to satisfying revenue recognition criteria (see Note 4).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of assets, or at the time services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance for credit losses was recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s accounts receivable was entirely attributable to Novo. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s accounts receivable was entirely attributed to Vertex.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation and amortization. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:57.54%;box-sizing:content-box;"></td>
           <td style="width:1.94%;box-sizing:content-box;"></td>
           <td style="width:40.52%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer Equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
          </tr>
         </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation or amortization is removed from the balance sheet and the resulting gain or loss is recognized within other income, net in the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairments of the Company&#8217;s long-lived assets for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for its leases in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 842&#8221;). The Company adopted ASC 842 on January 1, 2021, prior to entering into the lease agreement for its office and research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is reasonably certain that the Company will exercise that option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments if the Company&#8217;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Right-of-use assets represent the Company</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s right to use underlying assets for the lease term and operating lease liabilities represent the Company</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s obligation to make lease payments under the lease. Right-of-use assets also include any lease payments made prior to the commencement date and exclude lease incentives received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company elected to apply the practical expedient of combining lease and non-lease components for the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company elected the short-term lease practical expedient that allows the lessee to not record a lease liability and right-of-use asset for all leases with a term of 12 months or less. See Note 6 for additional information on the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for revenue in accordance with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following four steps: (i) confirm it has a contract with a customer that creates enforceable rights and obligations; (ii) identify promised products or services to be transferred to a customer; (iii) determine the transaction price, or the amount it expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable and allocated to the performance obligations; and (iv) recognize revenue when or as performance obligations are satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price of each distinct performance obligation. In instances where standalone selling price is not directly observable, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract using a cost plus margin approach, which is an estimation method used when standalone selling price is not directly observable. Key assumptions used within this estimation method may include full-time equivalent personnel effort and estimated external costs associated with the performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the Company's performance, (ii) the Company's  performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the Company does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s revenues are primarily derived through its license and research and development service arrangements. Payments to the Company under these arrangements typically include one or more of the following: one-time, non-refundable upfront payment, research and development service funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain collaboration, research and development and commercial milestones, as well as royalties based on net sales of approved drugs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration received prior to revenue recognition is recorded as deferred revenue in the balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current. Contract assets represent research and development services which have been performed but have not yet been billed and are reduced when they are subsequently billed. Such contract assets include accounts receivable when the Company&#8217;s right to consideration is unconditional. For its current contracts, the Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and, if over time, revenue recognized is based on the use of an input method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s collaborative arrangements include one or more of the following</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of intellectual property, or IP - </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For a license that is determined not to be distinct, it is combined with other promises and the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost of each performance obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - The Company evaluates the customer options for material rights or options to acquire additional goods or services at no incremental consideration or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised and performance obligations are satisfied. If an option is not exercised before the option right expires, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under the Company's collaboration agreement include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#8217;s statements of operations and comprehensive loss. Expenses incurred as part of the Company&#8217;s efforts to perform the research and development services are recognized in research and development expense in the Company&#8217;s statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing services </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- The promises under the Company's collaboration agreement include manufacturing services to be provided by the Company. Payments or reimbursements resulting from the Company's manufacturing services are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#8217;s statements of operations and comprehensive loss. Expenses incurred to perform the manufacturing services are recognized in research and development expense in the Company&#8217;s statements of operations and comprehensive loss.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone payments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore, consideration included in the transaction price is constrained. The Company applied the variable consideration allocation exception under ASC 606 whereby variable milestone payments are not estimated and included in the transaction price at inception. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commercial milestone payments and royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied)</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock', window );">Sale of Non-Financial Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale of Non-Financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale of non-financial assets that are outside the scope of the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary activities are accounted for under ASC 610-20, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income - Gains and Losses from the Derecognition of Non-financial Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;ASC 610-20&#8221;). Pursuant to ASC 610-20, the Company applies the guidance in ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 606</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to determine if a contract exists, identify the distinct non-financial assets, and determine when control transfers and, therefore, when to derecognize the non-financial asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation of the gain or loss for the non-financial asset.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies and clinical trials, contract manufacturing for the production of clinical and preclinical materials, information technology-related costs, allocated overhead costs including facility-related expenses, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on the Company&#8217;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into agreements with outsourced contract manufacturing and development and clinical research vendors. The Company estimates accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_PatentExpensesPolicyPolicyTextBlock', window );">Patent Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs to secure and maintain patents covering the Company&#8217;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The carrying values of the Company&#8217;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is recognized based on the grant-date fair value of the awards. The fair value of stock options and employee stock purchase plan ("ESPP") is determined using the Black-Scholes option pricing model on the date of grant. The fair value of restricted stock awards is determined using the estimated fair value of the Company&#8217;s common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the IPO, the Company utilized estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to the Company&#8217;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award of four years. For stock-based awards with vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based compensation expense on an accelerated basis over the vesting period when achievement of the performance criteria becomes probable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is recorded within research and development and general and administrative expenses in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes the asset and liability approach to account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. The Company&#8217;s other comprehensive income (loss) is comprised solely of unrealized gains or losses on marketable securities. The Company has not recorded any reclassifications from other comprehensive gains or losses to net loss during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of basic net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock, and ESPP shares. The dilutive effect of stock options, unvested restricted stock, and ESPP shares is computed using the treasury stock method. For all periods presented in a net loss position, diluted net loss per share is the same as basic net loss per share since the effect of including potential dilutive securities is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU No. 2025-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expand the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. In addition, ASU 2025-07 is expected to reduce diversity in the accounting for share-based non-cash consideration from a customer for the transfer of goods or services, as well as provide investors with more comparable information and reduce accounting complexity and related reporting costs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adoption of the amendment allows for either the prospective or modified retrospective application and is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company early </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this standard using the prospective method for the derivative scope refinement with the effective date of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Prior to adoption, the Company did not have contracts that incl</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ude are subject to derivative accounting and the adoption of the ASU did </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a material impact on its financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_faecfa98-652d-4cca-94de-7a02c3297ab7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU No. 2023-09</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years beginning after December 15, 2024, on a prospective basis. Early adoption and retrospective reporting are permitted. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company follows the provisions set forth in ASU No. 2023-09 on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the FASB issued ASU No. 2025-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset in developing reasonable and supportable forecasts during the application of the current expected credit loss model for current accounts receivable and current contract assets arising from transactions under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-05.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires the Company to disclose more detailed information about the types of expenses (including employee compensation, depreciation, and amortization) included in each relevant income statement expense caption. The ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock', window );">Emerging Growth Company Status and Smaller Reporting Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status and Smaller Reporting Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_DeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_DeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status and smaller reporting company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_PatentExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_PatentExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_RisksAndUncertaintyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Uncertainty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_RisksAndUncertaintyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of non-financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:57.54%;box-sizing:content-box;"></td>
           <td style="width:1.94%;box-sizing:content-box;"></td>
           <td style="width:40.52%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer Equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or estimated useful life</span></span></span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of estimated useful lives of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,622</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,384</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">953</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid bonus</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,730</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,339</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,679</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture, fixtures, and office equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,222</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">401</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">401</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,019</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,929</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,434</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,090</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,606</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,888</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued general and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">703</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,798</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock', window );">Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents revenue recognized, unrecognized transaction price, and estimated revenue expected to be recognized in the future as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.385%;box-sizing:content-box;"></td>
         <td style="width:2.759%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:21.855999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transaction Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Combined license, research and manufacturing services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">247,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material right</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total transaction price</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,036</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue recognized</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized transaction price as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of the allocation of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million one-time, non-refundable upfront payment, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the four R&amp;D programs and manufacturing services and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the material right and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of variable consideration related to estimated research and manufacturing services for the four R&amp;D Programs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded within revenue in the statement of operations and comprehensive loss for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized of the one-time, non-refundable upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million variable considerations related to estimated research services for the four R&amp;D Programs.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_SummaryOfChangesInDeferredRevenueTableTextBlock', window );">Summary of Changes in Deferred Revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes in deferred revenue for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:73.385%;box-sizing:content-box;"></td>
         <td style="width:2.759%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:21.855999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognized revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,814</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,186</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred revenue, current and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of deferred revenue, non-current, which is expected to be recognized over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all of the Company's performance obligations are outstanding.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_SummaryOfChangesInDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of changes in deferred revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_SummaryOfChangesInDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of revenue recognized, unrecognized transaction price and estimated revenue expected to be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Available-for-Sale Marketable Securities and Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.53%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,736</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,736</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,190</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">544,025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,736</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480,289</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.53%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,779</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,779</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,527</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,527</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,059</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,059</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,193</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,193</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">414,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,779</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Securities by Major Type of Security</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.42%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:15.36%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining<br/>Contractual<br/>Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Estimated Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,939</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,755</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,763</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,992</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">322,374</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">322,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,699</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">479,672</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480,289</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.42%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:15.36%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.440000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining<br/>Contractual<br/>Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Estimated Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,017</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106,014</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,252</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,264</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,313</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,427</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,514</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,940</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,123</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Unrealized Loss Positions of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the following table summarizes marketable securities in an unrealized loss position (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.649%;box-sizing:content-box;"></td>
         <td style="width:12.503%;box-sizing:content-box;"></td>
         <td style="width:2.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.224%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.224%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining Contractual Maturity (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,503</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,064</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total maturity less than 1 year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 to 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,389</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,449</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock', window );">Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reserved the following shares of common stock, on an as-converted basis, for future issuance:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,378,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,938,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for future grants under 2024 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,257,640</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,743,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for 2024 ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,211</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369,402</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,887,335</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,052,299</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock shares reserved for future issuance on convertible basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock', window );">Summary of Expenses Recognized and Cash Paid for Leased Space</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,469</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,721</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,462</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,035</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, future minimum rental payments for operating leases were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future<br/>Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,912</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,070</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,234</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,579</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total present value of operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,212</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of lease cost and cash paid for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Award Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes restricted stock award activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.98%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>Per Share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">576,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock awards vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">442,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock awards repurchased</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.30</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions used for Grants Awards</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used to value employee and non-employee stock option awards granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.2%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="9" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.83</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.97</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.03</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used to value employee stock purchase plan shares granted during the year ended December 31, 2025, using the Black-Scholes option pricing model, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:64.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.75%;box-sizing:content-box;"></td>
         <td style="width:1.562%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:4.688%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.22</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for restricted stock awards, stock options, and ESPP recognized in the Company&#8217;s statements of operations and comprehensive loss is presented as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,087</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,619</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,389</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,533</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,476</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember', window );">2024 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following summarizes stock option activity under the 2024 Plan:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.11%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.662%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.942%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.662%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Options<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,938,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.11</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,706</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,914,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.70</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,378,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.97</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.79</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,194</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,096,087</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.19</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_Stock2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision (Benefit) for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the provision (benefit) for income taxes were as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.08%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company&#8217;s effective tax rate to the statutory U.S. federal rate is as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.807%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.278%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.073%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.434%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2025</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_b8efe224-c188-42df-a41c-9d6bf32284b2;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;federal taxes at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,195</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,972</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:74.32%;box-sizing:content-box;"></td>
         <td style="width:1.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal taxes at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total effective income tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The types of temporary differences that give rise to significant portions of the Company&#8217;s deferred income tax assets and liabilities are set out below (in thousands):</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,149</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,318</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 174 capitalized research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,932</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,855</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,812</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,432</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,015</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">683</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">766</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,114</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,605</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">998</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment based on tax positions related to prior years</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of the year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Reportable Segment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM is regularly provided with the following significant segment expenses:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,951</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,075</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,233</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,476</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,152</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on sale of non-financial asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses*</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,429</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,248</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,898</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,297</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,430</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,527</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,867</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,879</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,798</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(*) Other segment expenses include facility related and office costs, information technology costs, general laboratory costs, and other operating expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 18, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse Stock Split description</a></td>
<td class="text">1-for-8.6103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 302,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Converted convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,951<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,253)<span></span>
</td>
<td class="num">(118,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent', window );">Cash, cash equivalents, marketable securities current and non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts', window );">Underwriting discounts commissions and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UnderwritingOtherOfferingExpenses', window );">Underwriting other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Converted convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,839,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UndesignatedPreferredStockSharesAuthorized', window );">Undesignated preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UndesignatedCommonStockParOrStatedValuePerShare', window );">Undesignated common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexResearchServiceAgreementMember', window );">Vertex Research Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents, marketable securities current and non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts, commissions and other offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UnderwritingOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UnderwritingOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UndesignatedCommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undesignated common stock par or stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UndesignatedCommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UndesignatedPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undesignated preferred stock, shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UndesignatedPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexResearchServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexResearchServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Leasehold improvements<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">ASU 2023-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=sepn_AccountingStandardsUpdate202507Member', window );">ASU 2025-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards Update, adoption date</a></td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph c<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph a<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph a<br> -Subparagraph (3)<br> -Publisher SEC<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=sepn_AccountingStandardsUpdate202507Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=sepn_AccountingStandardsUpdate202507Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 4,622<span></span>
</td>
<td class="nump">$ 4,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">3,384<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_PrepaidBonusCurrent', window );">Prepaid bonus</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 9,519<span></span>
</td>
<td class="nump">$ 5,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_PrepaidBonusCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid bonus current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_PrepaidBonusCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 8,786<span></span>
</td>
<td class="nump">$ 8,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(4,352)<span></span>
</td>
<td class="num">(2,929)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">5,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_FurnitureFixturesAndOfficeEquipmentMember', window );">Furniture, fixtures, and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_FurnitureFixturesAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_FurnitureFixturesAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation expense</a></td>
<td class="nump">$ 5,606<span></span>
</td>
<td class="nump">$ 4,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expense</a></td>
<td class="nump">5,179<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AccruedGeneralAndAdministrativeExpenseCurrent', window );">Accrued general and administrative expense</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee stock purchase plan liability</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 12,167<span></span>
</td>
<td class="nump">$ 7,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AccruedGeneralAndAdministrativeExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AccruedGeneralAndAdministrativeExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Gain on Sale of Non-Financial Asset - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_GainOnSaleOfNonFinancialAsset', window );">Gain on sale of non-financial asset</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ProceedsFromSaleOfNonFinancialAsset', window );">Received cash on sale of non-financial asset</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 22,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_GainOnSaleOfNonFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_GainOnSaleOfNonFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ProceedsFromSaleOfNonFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of non-financial asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ProceedsFromSaleOfNonFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Service revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,951<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Service revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived', window );">One-time non-refundable upfront payment received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_MilestonePaymentsReceivableFromCollaborationAgreement', window );">Milestone payments receivable from collaboration agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexResearchServiceAgreementMember', window );">Vertex Research Service Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Service revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexAssetPurchaseMember', window );">Vertex Asset Purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_MilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded within revenue in the statement of operations and comprehensive loss for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized of the one-time, non-refundable upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million variable considerations related to estimated research services for the four R&amp;D Programs.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_MilestonePaymentsReceivableFromCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable from collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_MilestonePaymentsReceivableFromCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable one time upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_NonRefundableOneTimeUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexResearchServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexResearchServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexAssetPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sepn_VertexAssetPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (45,951)<span></span>
</td>
<td class="num">$ (1,075)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TransactionPrice', window );">Total transaction price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">289,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(45,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UnrecognizedTransactionPrice', window );">Unrecognized transaction price as of September 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement | Combined License and Research Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TransactionPrice', window );">Total transaction price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">247,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement | Material Right</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TransactionPrice', window );">Total transaction price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 41,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of the allocation of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million one-time, non-refundable upfront payment, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the four R&amp;D programs and manufacturing services and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the material right and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of variable consideration related to estimated research and manufacturing services for the four R&amp;D Programs.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded within revenue in the statement of operations and comprehensive loss for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized of the one-time, non-refundable upfront payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million variable considerations related to estimated research services for the four R&amp;D Programs.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UnrecognizedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UnrecognizedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sepn_CombinedLicenseAndResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sepn_CombinedLicenseAndResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sepn_MaterialRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sepn_MaterialRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Parenthetical) (Details) - Novo Collaboration Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived', window );">One-time non-refundable upfront payment received</a></td>
<td class="nump">$ 195.0<span></span>
</td>
<td class="nump">$ 195.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_VariableConsideration', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">R&amp;D Programs and Manufacturing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived', window );">One-time non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Material Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived', window );">One-time non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">R&amp;D Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived', window );">One-time non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_VariableConsideration', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_NonRefundableOneTimeUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable one time upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_NonRefundableOneTimeUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_VariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_VariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sepn_MaterialRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sepn_MaterialRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sepn_ResearchDevelopmentProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sepn_ResearchDevelopmentProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Details) - Novo Collaboration Agreement<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at January 1, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ChangeInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">195,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized revenue</a></td>
<td class="num">(26,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2025</a></td>
<td class="nump">$ 168,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ChangeInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in deferred revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ChangeInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">$ 62,269<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">105,917<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">62,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">$ 105,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember', window );">Novo Collaboration Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue remaining performance obligation</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sepn_NovoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">$ 270,367<span></span>
</td>
<td class="nump">$ 112,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">157,569<span></span>
</td>
<td class="nump">69,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure', window );">Total measured at fair value</a></td>
<td class="nump">544,025<span></span>
</td>
<td class="nump">414,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure', window );">Total measured at fair value</a></td>
<td class="nump">63,736<span></span>
</td>
<td class="nump">141,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure', window );">Total measured at fair value</a></td>
<td class="nump">480,289<span></span>
</td>
<td class="nump">273,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">141,984<span></span>
</td>
<td class="nump">73,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">117,632<span></span>
</td>
<td class="nump">65,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">141,984<span></span>
</td>
<td class="nump">73,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">117,632<span></span>
</td>
<td class="nump">65,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">28,026<span></span>
</td>
<td class="nump">14,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">28,026<span></span>
</td>
<td class="nump">14,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">32,573<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">35,713<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">32,573<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">35,713<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">63,736<span></span>
</td>
<td class="nump">141,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">63,736<span></span>
</td>
<td class="nump">141,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">50,163<span></span>
</td>
<td class="nump">82,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">67,784<span></span>
</td>
<td class="nump">23,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">50,163<span></span>
</td>
<td class="nump">82,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">$ 67,784<span></span>
</td>
<td class="nump">$ 23,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities, fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Position</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">$ 3,384,000<span></span>
</td>
<td class="nump">$ 953,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowances for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of marketable securities in unrealized loss positions less than 12 months | Position</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Major Type of Security (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Amortized cost of marketable debt securities, contractual maturity, less than one year</a></td>
<td class="nump">$ 322,374<span></span>
</td>
<td class="nump">$ 203,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains', window );">Unrealized gains of marketable debt securites, contractual maturity, less than one year</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss', window );">Unrealized losses of marketble debt securities, contractual maturity, less than one year</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year</a></td>
<td class="nump">322,720<span></span>
</td>
<td class="nump">203,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">479,672<span></span>
</td>
<td class="nump">273,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Estimated Fair Value</a></td>
<td class="nump">480,289<span></span>
</td>
<td class="nump">273,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Amortized cost of marketable debt securities, contractual maturity, less than one year</a></td>
<td class="nump">141,688<span></span>
</td>
<td class="nump">73,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains', window );">Unrealized gains of marketable debt securites, contractual maturity, less than one year</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss', window );">Unrealized losses of marketble debt securities, contractual maturity, less than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year</a></td>
<td class="nump">141,984<span></span>
</td>
<td class="nump">73,555<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Amortized cost of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="nump">117,376<span></span>
</td>
<td class="nump">65,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains', window );">Unrealized gains of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss', window );">Unrealized losses of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, one year to five year</a></td>
<td class="nump">117,632<span></span>
</td>
<td class="nump">65,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Amortized cost of marketable debt securities, contractual maturity, less than one year</a></td>
<td class="nump">27,992<span></span>
</td>
<td class="nump">22,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains', window );">Unrealized gains of marketable debt securites, contractual maturity, less than one year</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss', window );">Unrealized losses of marketble debt securities, contractual maturity, less than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year</a></td>
<td class="nump">28,026<span></span>
</td>
<td class="nump">22,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Amortized cost of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="nump">4,223<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains', window );">Unrealized gains of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss', window );">Unrealized losses of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, one year to five year</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Amortized cost of marketable debt securities, contractual maturity, less than one year</a></td>
<td class="nump">34,755<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains', window );">Unrealized gains of marketable debt securites, contractual maturity, less than one year</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss', window );">Unrealized losses of marketble debt securities, contractual maturity, less than one year</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year</a></td>
<td class="nump">34,763<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Amortized cost of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="nump">35,699<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains', window );">Unrealized gains of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss', window );">Unrealized losses of marketable debt securities, contractual maturity, one year to five years</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, one year to five year</a></td>
<td class="nump">35,713<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Amortized cost of marketable debt securities, contractual maturity, less than one year</a></td>
<td class="nump">117,939<span></span>
</td>
<td class="nump">106,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains', window );">Unrealized gains of marketable debt securites, contractual maturity, less than one year</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss', window );">Unrealized losses of marketble debt securities, contractual maturity, less than one year</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year</a></td>
<td class="nump">$ 117,947<span></span>
</td>
<td class="nump">$ 106,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale - matures after one year through five years, gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale matures after one year through five years gross unrealized loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities within one year gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities within one year gross unrealized loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Fair Values and Continuous Unrealized Loss Positions of Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 67,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Marketable securities, continuous unrealized loss position, Fair value</a></td>
<td class="nump">92,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Gross Unrealized Loss</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value</a></td>
<td class="nump">10,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Marketable securities, continuous unrealized loss position, Less than one year to two years, Fair Value</a></td>
<td class="nump">17,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Marketable securities, continuous unrealized loss position, Less than one year to two years, Fair Value</a></td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Marketable securities, continuous unrealized loss position, Less than one year to two years, Fair Value</a></td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract', window );"><strong>Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value</a></td>
<td class="nump">57,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,348<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_LesseeOperatingLeaseExpirationYearAndMonth', window );">Lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,499<span></span>
</td>
<td class="nump">$ 23,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,413<span></span>
</td>
<td class="nump">23,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses, excluding variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_OriginalLeasedSpaceMember', window );">Original Leased Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_LesseeOperatingLeaseExpirationYearAndMonth', window );">Lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_AdditionalLeasedSpaceMember', window );">Additional Leased Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_LeasedSpaceMember', window );">Leased Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of lease | ft&#178;</a></td>
<td class="nump">44,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_LesseeOperatingLeaseExpirationYearAndMonth', window );">Lease expiration period</a></td>
<td class="text">2032-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend description</a></td>
<td class="text">option to extend the lease for eight additional years (the &#8220;Extension Option&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses, excluding variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,721<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Percentage of present value of lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.34%<span></span>
</td>
<td class="nump">11.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_LesseeOperatingLeaseExpirationYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, expiration year and month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_LesseeOperatingLeaseExpirationYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_OriginalLeasedSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_OriginalLeasedSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_AdditionalLeasedSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_AdditionalLeasedSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_LeasedSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_LeasedSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Expenses Recognized and Cash Paid for Leased Space (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_LeasedSpaceMember', window );">Leased Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">4,469<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">4,721<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">$ 1,035<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_LeasedSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sepn_LeasedSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 4,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">4,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">4,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">5,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">33,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of operating lease liabilities</a></td>
<td class="nump">23,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,212<span></span>
</td>
<td class="nump">$ 1,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">$ 21,413<span></span>
</td>
<td class="nump">$ 23,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements', window );">liabilities associated with indemnification rights and agreements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities associated with indemnification rights and agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,828,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Outstanding convertible preferred stock conversion in to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 74,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of unpaid principal and accrued interest outstanding into shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding', window );">Convertible promissory notes such as unpaid principal and accrued interest outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Initial Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock', window );">Cash proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest', window );">Net proceeds conversion of outstanding convertible promissory notes plus accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Maximum [Member] | Initial Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockFinancingArrangementFinancingValue', window );">Convertible preferred stock financing arrangement financing value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,828,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,828,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, shares</a></td>
<td class="nump">60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</a></td>
<td class="nump">$ 74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Tranche One and Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares', window );">Convertible preferred stock shares authorized to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,657,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Maximum [Member] | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval', window );">Convertible preferred stock additional funding based on approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Maximum [Member] | Tranche One and Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Convertible Preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Outstanding convertible preferred stock conversion in to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,839,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Converted preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,657,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds from issuance of convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Promissory Notes, Unpaid Principal and Accrued Interest Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds Conversion Of Outstanding Convertible Promissory Notes Plus Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Additional Funding Based on Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock authorised to be issued during period shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityStockFinancingArrangementFinancingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Financing Arrangement Financing Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityStockFinancingArrangementFinancingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sepn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sepn_InitialTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sepn_InitialTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sepn_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sepn_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sepn_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sepn_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sepn_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sepn_TrancheOneAndTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sepn_TrancheOneAndTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 302,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering (IPO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="nump">$ 302,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts', window );">Underwriting discounts commissions and other offering costs</a></td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts, commissions and other offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">8,887,335<span></span>
</td>
<td class="nump">7,052,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">4,378,484<span></span>
</td>
<td class="nump">2,938,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember', window );">Stock 2024 Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">4,257,640<span></span>
</td>
<td class="nump">3,743,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchase2024PlanMember', window );">Employee Stock Purchase 2024 Plan [Member] | Common Stock [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">251,211<span></span>
</td>
<td class="nump">369,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_Stock2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchase2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_EmployeeStockPurchase2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sepn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sepn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Beginning Balance | shares</a></td>
<td class="nump">576,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested | shares</a></td>
<td class="num">(442,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased', window );">Restricted stock awards repurchased | shares</a></td>
<td class="num">(2,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Ending Balance | shares</a></td>
<td class="nump">131,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 2.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock awards vested, Weighted Average Fair Value | $ / shares</a></td>
<td class="nump">2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock awards repurchased ,Weighted Average Fair Value | $ / shares</a></td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 1.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option repurchased in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Options Activity (Details) - 2024 Plan [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Options outstanding, Beginning balance</a></td>
<td class="nump">2,938,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Total Options outstanding, Granted</a></td>
<td class="nump">1,914,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Total Options outstanding, Exercised</a></td>
<td class="num">(268,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Total Options Outstanding, Cancelled</a></td>
<td class="num">(207,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Options outstanding, Ending Balance</a></td>
<td class="nump">4,378,484<span></span>
</td>
<td class="nump">2,938,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December 31, 2025</a></td>
<td class="nump">1,096,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">12.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">7.97<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable as of December 31, 2025</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">9 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, Exercisable as of December 31, 2025</a></td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 87,194<span></span>
</td>
<td class="nump">$ 53,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable as of December 31, 2025</a></td>
<td class="nump">$ 25,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_Stock2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted-Average Assumptions used for Grants Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember', window );">Employee and Non-Employee Stock Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.98%<span></span>
</td>
<td class="nump">3.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.10%<span></span>
</td>
<td class="nump">91.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
<td class="text">6 years 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">1 year 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,887,335<span></span>
</td>
<td class="nump">7,052,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue', window );">Total grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition of expenses related to non-vested share-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average per share grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.58<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_Stock2021PlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_Stock2021PlanMember', window );">2021 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember', window );">2024 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 25,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding number of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage', window );">Fair market value of the common stock exercise price percentge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,914,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlan2024Member', window );">2024 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The offering periods begin on May 1 and November 1, will be twenty-four (24) months in duration and include four (4) purchase periods, each purchase period lasting six (6) months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering', window );">Purchase price percentage of fair market value per share on offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlan2024Member', window );">2024 Employee Stock Purchase Plan | Maximum [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding number of shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate grant date fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Percentage Of Fair Market Value Per Share on Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value exercise price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation equity awards options grants fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_Stock2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_Stock2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_Stock2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_Stock2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sepn_EmployeeStockPurchasePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,476<span></span>
</td>
<td class="nump">$ 3,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="nump">$ 1,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision (Benefit) for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (498)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (12,000)<span></span>
</td>
<td class="nump">$ 498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset, net change in total valuation allowance increase during period</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">20,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 45,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forwards</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 77,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forwards</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal taxes at statutory rate</a></td>
<td class="num">$ (10,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration', window );">Tax Jurisdiction of Domicile [Extensible Enumeration]</a></td>
<td class="text">country:US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(1,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">9,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount', window );">Permanent differences</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percentage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal taxes at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.40%)<span></span>
</td>
<td class="num">(29.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, nondeductible expense, permanent differences, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, nondeductible expense, permanent differences, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates tax jurisdiction of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 14,149<span></span>
</td>
<td class="nump">$ 7,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">5,318<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">5,620<span></span>
</td>
<td class="nump">7,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Sec 174 capitalized research and development costs</a></td>
<td class="nump">22,932<span></span>
</td>
<td class="nump">20,855<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">49,812<span></span>
</td>
<td class="nump">40,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(44,015)<span></span>
</td>
<td class="num">(33,061)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,797<span></span>
</td>
<td class="nump">7,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(683)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(5,114)<span></span>
</td>
<td class="num">(6,605)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(5,797)<span></span>
</td>
<td class="num">(7,371)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 3,567<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Adjustment based on tax positions related to prior years</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Adjustment based on tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 4,145<span></span>
</td>
<td class="nump">$ 3,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Cash proceeds on shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 74,942,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sepn_ThirdRockVenturesViLPServiceAgreementMember', window );">Third Rock Ventures | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series B Convertible Preferred Stock( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Cash proceeds on shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sepn_ThirdRockVenturesViLPServiceAgreementMember', window );">Third Rock Ventures | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Outstanding accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting services</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_AccruedExpenseAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sepn_ThirdRockVenturesViLPServiceAgreementMember', window );">Third Rock Ventures | Interim Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Total fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options to purchase</a></td>
<td class="nump">23,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sepn_RaCapitalManagementLPServiceAgreementMember', window );">RA Capital | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series B Convertible Preferred Stock( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Cash proceeds on shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sepn_SamsaraBiocapitalLPMember', window );">Samsara BioCapital | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series B Convertible Preferred Stock( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Cash proceeds on shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_AccruedExpenseAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expense And Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_AccruedExpenseAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sepn_ThirdRockVenturesViLPServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sepn_ThirdRockVenturesViLPServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sepn_InterimChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sepn_InterimChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sepn_RaCapitalManagementLPServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sepn_RaCapitalManagementLPServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sepn_SamsaraBiocapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sepn_SamsaraBiocapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,554,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,378,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sepn_UnvestedRestrictedStockSubjectToRepurchaseMember', window );">Unvested Restricted Stock Awards Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">131,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">44,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sepn_UnvestedRestrictedStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sepn_UnvestedRestrictedStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator, basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator, basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">44,258,338<span></span>
</td>
<td class="nump">9,891,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator, diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used to compute net (loss) income per common share, diluted</a></td>
<td class="nump">44,258,338<span></span>
</td>
<td class="nump">9,891,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic</a></td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="num">$ (7.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted</a></td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="num">$ (7.26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Summary of Potentially Dilutive Securities not Included in Calculation of Diluted Net (Loss) Income Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">4,554,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">4,378,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sepn_UnvestedRestrictedStockSubjectToRepurchaseMember', window );">Unvested Restricted Stock Awards Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">131,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sepn_UnvestedRestrictedStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sepn_UnvestedRestrictedStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Benefit Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=sepn_FourZeroOne401KPlanMember', window );">401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution expenses</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=sepn_FourZeroOne401KPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=sepn_FourZeroOne401KPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 45,951<span></span>
</td>
<td class="nump">$ 1,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation', window );">Employee-related expenses, excluding stock-based compensation</a></td>
<td class="nump">33,468<span></span>
</td>
<td class="nump">22,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,476<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ExternalResearchAndDevelopmentExpenses', window );">External research and development expenses</a></td>
<td class="nump">53,519<span></span>
</td>
<td class="nump">32,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sepn_ExternalGeneralAndAdministrativeExpenses', window );">External general and administrative expenses</a></td>
<td class="nump">8,856<span></span>
</td>
<td class="nump">6,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of non-financial asset</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">22,429<span></span>
</td>
<td class="nump">17,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">114,248<span></span>
</td>
<td class="nump">81,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(68,297)<span></span>
</td>
<td class="num">(80,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">19,430<span></span>
</td>
<td class="nump">8,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision (benefit) for income taxes</a></td>
<td class="num">(48,867)<span></span>
</td>
<td class="num">(72,296)<span></span>
</td>
<td class="num">$ (48,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,879)<span></span>
</td>
<td class="num">$ (71,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related expenses, excluding stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ExternalGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>External general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ExternalGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sepn_ExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>External research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sepn_ExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sepn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>175</ContextCount>
  <ElementCount>433</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Statement of Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets</Role>
      <ShortName>Statement of Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Statement of Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical</Role>
      <ShortName>Statement of Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75070 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995420 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganization1</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Collaboration and Research Service Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1</Role>
      <ShortName>Collaboration and Research Service Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Employee Retirement Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlan</Role>
      <ShortName>Employee Retirement Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Collaboration and Research Service Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables</Role>
      <ShortName>Collaboration and Research Service Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Gain on Sale of Non-Financial Asset - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails</Role>
      <ShortName>Gain on Sale of Non-Financial Asset - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Collaboration and Research Service Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and Research Service Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec</Role>
      <ShortName>Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1</Role>
      <ShortName>Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails</Role>
      <ShortName>Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Major Type of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Major Type of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Values and Continuous Unrealized Loss Positions of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Fair Values and Continuous Unrealized Loss Positions of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Leases - Summary of Expenses Recognized and Cash Paid for Leased Space (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails</Role>
      <ShortName>Leases - Summary of Expenses Recognized and Cash Paid for Leased Space (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Common Stock - Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails</Role>
      <ShortName>Common Stock - Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions used for Grants Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted-Average Assumptions used for Grants Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Income Taxes - Schedule of Components of Provision (Benefit) for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision (Benefit) for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Net Loss Per Share (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996165 - Disclosure - Net (Loss) Income Per Share - Summary of Potentially Dilutive Securities not Included in Calculation of Diluted Net (Loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Summary of Potentially Dilutive Securities not Included in Calculation of Diluted Net (Loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996175 - Disclosure - Employee Retirement Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Retirement Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sepn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996185 - Disclosure - Segment Information - Summary of Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails</Role>
      <ShortName>Segment Information - Summary of Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sepn-20251231.htm">sepn-20251231.htm</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sepn-ex23_1.htm">sepn-ex23_1.htm</File>
    <File>sepn-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img170310032_0.jpg</File>
    <File>img170310032_1.jpg</File>
    <File>img170310032_10.jpg</File>
    <File>img170310032_11.jpg</File>
    <File>img170310032_12.jpg</File>
    <File>img170310032_2.jpg</File>
    <File>img170310032_3.jpg</File>
    <File>img170310032_4.jpg</File>
    <File>img170310032_5.jpg</File>
    <File>img170310032_6.jpg</File>
    <File>img170310032_7.jpg</File>
    <File>img170310032_8.jpg</File>
    <File>img170310032_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="697">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sepn-20251231.htm sepn-ex23_1.htm": {
   "nsprefix": "sepn",
   "nsuri": "http://www.septerna.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "sepn-20251231.htm",
      "sepn-ex23_1.htm"
     ]
    },
    "schema": {
     "local": [
      "sepn-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 358,
   "keyCustom": 75,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 32,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2025": 7,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 175,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 806,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 697,
    "http://xbrl.sec.gov/dei/2025": 42,
    "http://xbrl.sec.gov/ecd/2025": 16,
    "http://xbrl.sec.gov/cyd/2025": 13
   },
   "report": {
    "R1": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
     "longName": "75010 - Statement - Statement of Balance Sheets",
     "shortName": "Statement of Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Statement of Balance Sheets (Parenthetical)",
     "shortName": "Statement of Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3",
     "longName": "75030 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
     "longName": "75050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical",
     "longName": "75060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_71f726e5-b69b-43a5-9553-9360762a27cd",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bec2c5bd-26fb-45e2-b7fd-c7e78e0c918b",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
     "longName": "75070 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995420 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_82ed9a58-9067-49d5-bf77-47a022e4ad30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_82ed9a58-9067-49d5-bf77-47a022e4ad30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganization1",
     "longName": "995455 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:OrganizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:OrganizationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1",
     "longName": "995475 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1",
     "longName": "995495 - Disclosure - Collaboration and Research Service Agreements",
     "shortName": "Collaboration and Research Service Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements",
     "longName": "995505 - Disclosure - Marketable Securities and Fair Value Measurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:MarketableSecuritiesAndFairValueMeasurementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:MarketableSecuritiesAndFairValueMeasurementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases",
     "longName": "995515 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995525 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStock",
     "longName": "995535 - Disclosure - Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:ConvertiblePreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:ConvertiblePreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock",
     "longName": "995545 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation",
     "longName": "995555 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995565 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedParties",
     "longName": "995575 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3",
     "longName": "995585 - Disclosure - Net (Loss) Income Per Share",
     "shortName": "Net (Loss) Income Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlan",
     "longName": "995595 - Disclosure - Employee Retirement Benefit Plan",
     "shortName": "Employee Retirement Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995605 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995615 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995645 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables",
     "longName": "995655 - Disclosure - Collaboration and Research Service Agreements (Tables)",
     "shortName": "Collaboration and Research Service Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables",
     "longName": "995665 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockTables",
     "longName": "995675 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995685 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995715 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995725 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995745 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Organization - Additional Information (Details)",
     "shortName": "Organization - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_e7f2b074-5874-4a74-ac56-9ee225b000cb",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "sepn:OrganizationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e7f2b074-5874-4a74-ac56-9ee225b000cb",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "sepn:OrganizationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "995765 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_0d155a10-3368-4e21-9ede-8d1675cae5c8",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0d155a10-3368-4e21-9ede-8d1675cae5c8",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails",
     "longName": "995785 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Assets (Details)",
     "shortName": "Balance Sheet Components - Summary of Prepaid Expenses and Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
     "longName": "995795 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995815 - Disclosure - Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Balance Sheet Components - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails",
     "longName": "995825 - Disclosure - Gain on Sale of Non-Financial Asset - Additional Information (Details)",
     "shortName": "Gain on Sale of Non-Financial Asset - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:GainOnSaleOfNonFinancialAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Collaboration and Research Service Agreements - Additional Information (Details)",
     "shortName": "Collaboration and Research Service Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7f97baf0-9093-442d-82b0-a802ec9a04a8",
      "name": "sepn:MilestonePaymentsReceivableFromCollaborationAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
     "longName": "995845 - Disclosure - Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Details)",
     "shortName": "Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6ea5876e-4f38-4f62-bb26-1a536fd2018e",
      "name": "sepn:TransactionPrice",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1",
     "longName": "995855 - Disclosure - Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Parenthetical) (Details)",
     "shortName": "Collaboration and Research Service Agreements - Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_e2f01c6e-2c71-481c-920d-0563fd77c7f5",
      "name": "sepn:NonRefundableOneTimeUpfrontPaymentReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6ea5876e-4f38-4f62-bb26-1a536fd2018e",
      "name": "sepn:VariableConsideration",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails",
     "longName": "995865 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Details)",
     "shortName": "Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_9c2248bf-d680-4e4c-9956-051672a0ad00",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfChangesInDeferredRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9c2248bf-d680-4e4c-9956-051672a0ad00",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfChangesInDeferredRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
     "longName": "995875 - Disclosure - Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details)",
     "shortName": "Collaboration and Research Service Agreements - Summary of Changes in Deferred Revenue (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "div",
       "sepn:SummaryOfChangesInDeferredRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
     "longName": "995885 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995895 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails",
     "longName": "995905 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Major Type of Security (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Major Type of Security (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
     "longName": "995915 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Values and Continuous Unrealized Loss Positions of Marketable Securities (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Fair Values and Continuous Unrealized Loss Positions of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_322b3bab-f26e-4ef7-b671-7788690ea969",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_322b3bab-f26e-4ef7-b671-7788690ea969",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails",
     "longName": "995935 - Disclosure - Leases - Summary of Expenses Recognized and Cash Paid for Leased Space (Details)",
     "shortName": "Leases - Summary of Expenses Recognized and Cash Paid for Leased Space (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_13a6815f-57a4-459f-b517-409e1abf0033",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
     "longName": "995945 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995975 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
     "longName": "995985 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)",
     "shortName": "Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "us-gaap:TemporaryEquitySharesOutstanding",
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "p",
       "sepn:ConvertiblePreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Convertible Preferred Stock - Additional Information (Details)",
     "shortName": "Convertible Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_31b3e28f-bc58-4c85-9b5a-81f738157245",
      "name": "us-gaap:PreferredStockConvertibleSharesIssuable",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "sepn:ConvertiblePreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_31b3e28f-bc58-4c85-9b5a-81f738157245",
      "name": "us-gaap:PreferredStockConvertibleSharesIssuable",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "sepn:ConvertiblePreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "longName": "996005 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_55584b29-8759-4aa6-8eef-4c5377a2f3a5",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "sepn:CommonStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
     "longName": "996015 - Disclosure - Common Stock - Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis (Details)",
     "shortName": "Common Stock - Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20efa5c4-f0f4-4871-a51a-f97b96ba7528",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
     "longName": "996025 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_885615b0-7d7a-4feb-b3a7-220a271f5de4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_885615b0-7d7a-4feb-b3a7-220a271f5de4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
     "longName": "996035 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_a8105ecc-3402-4d93-af5f-2dce7689dfe9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails",
     "longName": "996045 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions used for Grants Awards (Details)",
     "shortName": "Stock-Based Compensation - Summary of Weighted-Average Assumptions used for Grants Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_4012e7ef-84ff-438a-9d21-608b4581ba16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4012e7ef-84ff-438a-9d21-608b4581ba16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "996055 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails",
     "longName": "996065 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails",
     "longName": "996075 - Disclosure - Income Taxes - Schedule of Components of Provision (Benefit) for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Provision (Benefit) for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996085 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails",
     "longName": "996095 - Disclosure - Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails",
     "longName": "996105 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "996115 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_c9ed796e-c245-49e4-a05c-5a3905d6aa43",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e5502035-9c62-4bfa-b75f-04b8934fb13b",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
     "longName": "996125 - Disclosure - Related Parties - Additional Information (Details)",
     "shortName": "Related Parties - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4ce5aad8-c86e-421c-9386-a0a475a3e0cf",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "996135 - Disclosure - Net Loss Per Share (Additional Information) (Details)",
     "shortName": "Net Loss Per Share (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8051df8-6f74-4da2-9664-e548022686e5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
     "longName": "996145 - Disclosure - Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details)",
     "shortName": "Net (Loss) Income Per Share - Computation of Basic and Diluted Net (Loss) Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
     "longName": "996165 - Disclosure - Net (Loss) Income Per Share - Summary of Potentially Dilutive Securities not Included in Calculation of Diluted Net (Loss) Income Per Share (Details)",
     "shortName": "Net (Loss) Income Per Share - Summary of Potentially Dilutive Securities not Included in Calculation of Diluted Net (Loss) Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails",
     "longName": "996175 - Disclosure - Employee Retirement Benefit Plan - Additional Information (Details)",
     "shortName": "Employee Retirement Benefit Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_9d256ca5-ca4e-416a-9cfc-3811d06616cf",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9d256ca5-ca4e-416a-9cfc-3811d06616cf",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
     "longName": "996185 - Disclosure - Segment Information - Summary of Reportable Segment (Details)",
     "shortName": "Segment Information - Summary of Reportable Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b",
      "name": "sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sepn-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting pronouncements not yet adopted.",
        "label": "Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202309Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202309Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-09 [Member]",
        "terseLabel": "ASU 2023-09",
        "documentation": "Accounting Standards Update 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r540"
     ]
    },
    "sepn_AccountingStandardsUpdate202507Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AccountingStandardsUpdate202507Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2025-07",
        "label": "Accounting Standards Update 202507 [Member]",
        "documentation": "Accounting Standards Update 202507."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r167",
      "r168",
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r265",
      "r266",
      "r300",
      "r302",
      "r303",
      "r325",
      "r326",
      "r329",
      "r350",
      "r351",
      "r352",
      "r353",
      "r483",
      "r484",
      "r485",
      "r486",
      "r537",
      "r538",
      "r539",
      "r540",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r589",
      "r590",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r628",
      "r629",
      "r646",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivable related to sale of non-financial asset",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r953"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Total",
        "terseLabel": "Outstanding accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r1352"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "totalLabel": "Total accounts receivable, net",
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable Net Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discounts, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee stock purchase plan liability",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "sepn_AccruedExpenseAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AccruedExpenseAndOtherCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Expense And Other Current Liabilities",
        "documentation": "Accrued Expense And Other Current Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_AccruedGeneralAndAdministrativeExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AccruedGeneralAndAdministrativeExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued General and Administrative Expense Current",
        "documentation": "Accrued general and administrative expense current.",
        "terseLabel": "Accrued general and administrative expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "sepn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research and Development Expense Current",
        "documentation": "Accrued research and development expense current.",
        "terseLabel": "Accrued research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation expense",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r881"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r140",
      "r740"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r65",
      "r146",
      "r735",
      "r769",
      "r773",
      "r1320"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r17",
      "r593",
      "r596",
      "r672",
      "r764",
      "r765",
      "r1114",
      "r1115",
      "r1116",
      "r1172",
      "r1173",
      "r1174",
      "r1176"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "sepn_AdditionalLeasedSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AdditionalLeasedSpaceMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Leased Space",
        "documentation": "Additional Leased Space.",
        "label": "Additional Leased Space [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid In Capital Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid In Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1172",
      "r1173",
      "r1174",
      "r1176",
      "r1321",
      "r1390"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r167",
      "r168",
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r204",
      "r265",
      "r266",
      "r300",
      "r302",
      "r303",
      "r304",
      "r325",
      "r326",
      "r329",
      "r350",
      "r351",
      "r352",
      "r353",
      "r483",
      "r484",
      "r485",
      "r486",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r628",
      "r629",
      "r646",
      "r647",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1006",
      "r1016",
      "r1049"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1009",
      "r1019",
      "r1052"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "sepn_AgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AgreementDescription",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Description",
        "documentation": "Agreement description",
        "terseLabel": "Agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1044",
      "r1053",
      "r1057",
      "r1065"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r487",
      "r497"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total antidilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Area of lease",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r102",
      "r142",
      "r178",
      "r179",
      "r180",
      "r225",
      "r237",
      "r254",
      "r257",
      "r299",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r566",
      "r570",
      "r635",
      "r721",
      "r722",
      "r729",
      "r823",
      "r899",
      "r900",
      "r909",
      "r953",
      "r959",
      "r960",
      "r973",
      "r1208",
      "r1209",
      "r1339"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r150",
      "r178",
      "r179",
      "r180",
      "r299",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r566",
      "r570",
      "r635",
      "r953",
      "r1208",
      "r1209",
      "r1339"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r1002"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r1002"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r1002"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r313",
      "r728"
     ]
    },
    "sepn_AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AvailableForSaleMarketableSecuritiesAndFairValueMeasurementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Marketable Securities and Fair Value Measurements [Abstract]",
        "documentation": "Available-for-sale marketable securities and fair value measurements."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale - Matures After One Year Through Five Years, Gross Unrealized Gains",
        "documentation": "Available-for-sale - matures after one year through five years, gross unrealized gains.",
        "terseLabel": "Unrealized gains of marketable debt securities, contractual maturity, one year to five years"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Matures After One Year Through Five Years Gross Unrealized Loss",
        "documentation": "Available for sale matures after one year through five years gross unrealized loss.",
        "negatedLabel": "Unrealized losses of marketable debt securities, contractual maturity, one year to five years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r906"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "terseLabel": "Amortized cost of marketable debt securities, contractual maturity, one year to five years",
        "totalLabel": "Amortized cost of marketable debt securities, contractual maturity, one year to five years",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Aggregate estimated fair value of marketable debt securities, contractual maturities, one year to five year",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost of marketable debt securities, contractual maturity, less than one year",
        "terseLabel": "Amortized cost of marketable debt securities, contractual maturity, less than one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate estimated fair value of marketable debt securities, contractual maturities, less than one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r724"
     ]
    },
    "sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains of marketable debt securites, contractual maturity, less than one year",
        "label": "Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Gains",
        "documentation": "Available for sale securities debt maturities within one year gross unrealized gains."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses of marketble debt securities, contractual maturity, less than one year",
        "terseLabel": "Unrealized losses of marketble debt securities, contractual maturity, less than one year",
        "label": "Available For Sale Securities Debt Maturities Within One Year Gross Unrealized Loss",
        "documentation": "Available for sale securities debt maturities within one year gross unrealized loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "terseLabel": "Aggregate Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r313",
      "r616",
      "r630",
      "r631",
      "r632",
      "r633",
      "r718",
      "r877",
      "r940",
      "r944",
      "r951",
      "r1190",
      "r1325",
      "r1326",
      "r1327"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r634",
      "r937",
      "r938",
      "r1095",
      "r1355"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r634",
      "r937",
      "r938",
      "r1095",
      "r1355"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "sepn_CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total measured at fair value",
        "terseLabel": "Total measured at fair value",
        "label": "Cash and Cash Equivalents and Marketable Securities, Fair Value Disclosure",
        "documentation": "Cash and cash equivalents and marketable securities, fair value disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r138",
      "r879"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r1323",
      "r1324"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r90"
     ]
    },
    "sepn_CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, marketable securities current and non-current",
        "label": "Cash, Cash Equivalents, Marketable Securities Current and Non-current",
        "documentation": "Cash, cash equivalents, marketable securities current and non-current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash at end of year",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r175"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r72"
     ]
    },
    "sepn_CashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash Equivalents and Marketable Securities [Policy Text Block]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_CashProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CashProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash proceeds from issuance of convertible preferred stock",
        "label": "Cash Proceeds From Issuance Of Convertible Preferred Stock",
        "terseLabel": "Cash proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r132",
      "r167",
      "r188",
      "r265",
      "r325",
      "r329",
      "r350",
      "r483",
      "r538",
      "r547",
      "r548",
      "r556",
      "r557",
      "r559",
      "r589",
      "r604",
      "r605",
      "r628",
      "r629",
      "r646",
      "r667",
      "r668",
      "r762",
      "r763"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards Update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r167",
      "r265",
      "r325",
      "r329",
      "r350",
      "r351",
      "r483",
      "r484",
      "r538",
      "r547",
      "r548",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r589",
      "r590",
      "r604",
      "r605",
      "r606",
      "r609",
      "r628",
      "r629",
      "r646",
      "r667",
      "r668",
      "r762",
      "r763",
      "r1105",
      "r1175"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r189",
      "r203",
      "r301"
     ]
    },
    "sepn_ChangeInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ChangeInDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Change in Deferred Revenue",
        "documentation": "Change in deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer"
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r143",
      "r144",
      "r145",
      "r178",
      "r180",
      "r209",
      "r210",
      "r217",
      "r219",
      "r227",
      "r228",
      "r299",
      "r338",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r354",
      "r355",
      "r357",
      "r358",
      "r360",
      "r364",
      "r366",
      "r367",
      "r370",
      "r371",
      "r374",
      "r635",
      "r778",
      "r779",
      "r780",
      "r781",
      "r788",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r811",
      "r831",
      "r853",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r1090",
      "r1166",
      "r1167",
      "r1177"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r227",
      "r357",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r588",
      "r778",
      "r779",
      "r780",
      "r781",
      "r910",
      "r1090",
      "r1164",
      "r1166"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r182",
      "r375"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "sepn_CombinedLicenseAndResearchServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CombinedLicenseAndResearchServicesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined License And Research Services [Member]",
        "documentation": "Combined license and research services.",
        "terseLabel": "Combined License and Research Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r337",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r94",
      "r731",
      "r810"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r331",
      "r332",
      "r873",
      "r1203",
      "r1205"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "sepn_CommonStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CommonStockLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Line Items]",
        "documentation": "Common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r1172",
      "r1173",
      "r1176",
      "r1321",
      "r1386",
      "r1390"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_CommonStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CommonStockOptions",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock options",
        "documentation": "Common stock options",
        "terseLabel": "Common stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock Par Or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r811"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r811",
      "r829",
      "r1390",
      "r1391"
     ]
    },
    "sepn_CommonStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CommonStockTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Table]",
        "documentation": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_CommonStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "CommonStockTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Text Block]",
        "documentation": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value per share, 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 44,806,272 and 44,422,505 shares issued and outstanding at December 31, 2025 and December 31, 2024 respectively; 131,224 and 576,829 shares subject to repurchase as of December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r355",
      "r363",
      "r733",
      "r953"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r156",
      "r158",
      "r163",
      "r719",
      "r747",
      "r748"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2025",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "periodStartLabel": "Balance at January 1, 2025",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r380",
      "r391"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r380",
      "r391"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r380",
      "r391"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "sepn_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering",
        "documentation": "Conversion of convertible preferred stock to common stock upon initial public offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of unpaid principal and accrued interest outstanding into shares",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "sepn_ConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock.",
        "label": "Convertible Preferred Stock, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ConvertiblePreferredStockRemainingUnissuedSharesAgreementToCancel",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock Remaining Unissued Shares Agreement To Cancel",
        "label": "Convertible Preferred Stock Remaining Unissued Shares Agreement To Cancel",
        "terseLabel": "Convertible preferred stock remaining unissued shares agreement to cancel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted preferred stock outstanding",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r36",
      "r58",
      "r82",
      "r372"
     ]
    },
    "sepn_ConvertiblePreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ConvertiblePreferredStockTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Text Block]",
        "documentation": "Convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Notes, Unpaid Principal and Accrued Interest Outstanding",
        "label": "Convertible Promissory Notes, Unpaid Principal and Accrued Interest Outstanding",
        "terseLabel": "Convertible promissory notes such as unpaid principal and accrued interest outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r923",
      "r940",
      "r954",
      "r961",
      "r1383"
     ]
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Securities",
        "label": "Corporate Note Securities [Member]",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1164",
      "r1169",
      "r1317"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r1164",
      "r1169"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1164",
      "r1169",
      "r1317"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1076"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1076"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1078"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1078"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1080"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1078"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1071"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1072"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1072"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1070"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1070"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1070"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1073"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1075"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1075"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1076"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1079"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1077"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1074"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "terseLabel": "Allowances for credit losses",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r313",
      "r321",
      "r322"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, continuous unrealized loss position, Less than one year to two years, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r318",
      "r906"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss",
        "negatedLabel": "Marketable securities, continuous unrealized loss position, Less than one year to two years, Gross Unrealized Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r318"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r318",
      "r906"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r318"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of marketable securities in unrealized loss positions less than 12 months",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1200"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable securities, continuous unrealized loss position, Fair value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r316",
      "r906"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable securities, continuous unrealized loss position, Gross Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Marketable securities, continuous unrealized loss position, Gross Unrealized Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r317"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r906"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss Positions of Marketable Securities",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r906",
      "r1199"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1169",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax",
        "label": "Deferred Income Tax",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r115",
      "r1164",
      "r1169"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r92",
      "r526"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "sepn_DeferredRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "DeferredRevenuePolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue",
        "label": "Deferred Revenue Policy [Text Block]",
        "documentation": "Deferred revenue policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1169",
      "r1316",
      "r1317"
     ]
    },
    "sepn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Capitalized Research And Development Costs",
        "documentation": "Deferred tax assets capitalized research and development costs.",
        "terseLabel": "Sec 174 capitalized research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "sepn_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability.",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "sepn_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "documentation": "Deferred tax assets operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Net deferred income tax liabilities",
        "negatedTotalLabel": "Net deferred income tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "sepn_DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Operating Lease Right-Of-Use Assets",
        "documentation": "Deferred tax liabilities operating lease right of use assets.",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "sepn_DeferredTaxLiabilitiesSaleOfNonFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "DeferredTaxLiabilitiesSaleOfNonFinancialAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Sale of Non Financial Asset",
        "documentation": "Deferred tax liabilities sale of non-financial asset.",
        "negatedLabel": "Sale of non-financial asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contribution expenses",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation And Amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r166",
      "r225",
      "r241",
      "r257",
      "r882",
      "r899",
      "r900"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r447",
      "r478",
      "r479",
      "r482",
      "r925"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r1002"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r1002",
      "r1045"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net (loss) income per share attributable to common stockholders:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share Basic",
        "verboseLabel": "Net (loss) income per share, basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r164",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r206",
      "r209",
      "r217",
      "r218",
      "r219",
      "r224",
      "r353",
      "r485",
      "r554",
      "r563",
      "r613",
      "r614",
      "r720",
      "r749",
      "r890"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share Diluted",
        "verboseLabel": "Net (loss) income per share, diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r164",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r209",
      "r217",
      "r218",
      "r219",
      "r224",
      "r353",
      "r485",
      "r554",
      "r563",
      "r613",
      "r614",
      "r720",
      "r749",
      "r890"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r221"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShare3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r220",
      "r222",
      "r223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal taxes at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r508",
      "r541",
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r929",
      "r1164",
      "r1170",
      "r1309"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1164",
      "r1170",
      "r1309",
      "r1311"
     ]
    },
    "sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Differences, Amount",
        "documentation": "Effective income tax rate reconciliation, nondeductible expense, permanent differences, amount."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Permanent Differences, Percent",
        "documentation": "Effective income tax rate reconciliation, nondeductible expense, permanent differences, percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1164",
      "r1170",
      "r1309",
      "r1311"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1164",
      "r1170",
      "r1309",
      "r1310"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r929",
      "r1164",
      "r1170",
      "r1309"
     ]
    },
    "sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Stock-Based Compensation Adjustment, Amount",
        "documentation": "Effective income tax rate reconciliation, stock-based compensation adjustment, amount.",
        "terseLabel": "Stock-based compensation adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationStock-BasedCompensationAdjustmentPercent",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Stock-Based Compensation Adjustment, Percent",
        "documentation": "Effective income tax rate reconciliation, stock-based compensation adjustment, percent.",
        "terseLabel": "Stock-based compensation adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total",
        "terseLabel": "Changes in unrecognized tax benefits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r929",
      "r1164",
      "r1170",
      "r1309"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "terseLabel": "Tax credits",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r514",
      "r1164",
      "r1170",
      "r1309"
     ]
    },
    "sepn_EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status and smaller reporting company status.",
        "label": "Emerging Growth Company Status and Smaller Reporting Company Status, Policy [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status and Smaller Reporting Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EmployeeAndNon-EmployeeStockOptionAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeAndNon-EmployeeStockOptionAwardsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee and Non-employee Stock Option Awards Member",
        "documentation": "Employee and non-employee stock option awards.",
        "terseLabel": "Employee and Non-Employee Stock Option Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees [Member]",
        "label": "Employee [Member]",
        "documentation": "Employee."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EmployeeRelatedExpensesExcludingStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeRelatedExpensesExcludingStockBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Related Expenses Excluding Stock Based Compensation",
        "documentation": "Employee related expenses, excluding stock based compensation.",
        "terseLabel": "Employee-related expenses, excluding stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1305"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period for recognition of expenses related to non-vested share-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1306"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "sepn_EmployeeStockPurchase2024PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeStockPurchase2024PlanMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase 2024 Plan [Member]",
        "documentation": "Employee stock purchase 2024 plan.",
        "terseLabel": "Employee Stock Purchase 2024 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EmployeeStockPurchasePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeStockPurchasePlan2024Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan 2024 [Member]",
        "documentation": "Employee stock purchase plan 2024."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EmployeeStockPurchasePlanLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeStockPurchasePlanLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan liability",
        "label": "Employee Stock Purchase Plan Liability",
        "documentation": "Employee stock purchase plan liability."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r124",
      "r131",
      "r132",
      "r160",
      "r161",
      "r162",
      "r185",
      "r186",
      "r187",
      "r190",
      "r198",
      "r200",
      "r202",
      "r226",
      "r300",
      "r304",
      "r326",
      "r352",
      "r376",
      "r485",
      "r536",
      "r537",
      "r550",
      "r551",
      "r552",
      "r555",
      "r562",
      "r563",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r612",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r672",
      "r745",
      "r764",
      "r765",
      "r766",
      "r788",
      "r853"
     ]
    },
    "sepn_EquityIncentivePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "EquityIncentivePlan2024Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Equity Incentive Plan",
        "label": "Equity Incentive Plan 2024 [Member]",
        "documentation": "Equity incentive plan 2024."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1006",
      "r1016",
      "r1049"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1003",
      "r1013",
      "r1046"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "sepn_ExecutiveOfficerAndDirectorEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ExecutiveOfficerAndDirectorEquityAwardsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer And Director Equity Awards [Member]",
        "documentation": "Executive officer and director equity awards ."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ExternalGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ExternalGeneralAndAdministrativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External general and administrative expenses",
        "label": "External General And Administrative Expenses",
        "documentation": "External general and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ExternalResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ExternalResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External research and development expenses",
        "label": "External Research And Development Expenses",
        "documentation": "External research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r624",
      "r940"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r624",
      "r940"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurements on Cash Equivalents and Marketable Securities",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1323",
      "r1324",
      "r1329"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r413",
      "r414",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r624",
      "r626",
      "r631",
      "r687",
      "r688",
      "r689",
      "r877",
      "r907",
      "r908",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r940",
      "r944",
      "r951"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r397",
      "r402",
      "r413",
      "r617",
      "r624",
      "r631",
      "r687",
      "r877",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r940",
      "r951"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r397",
      "r402",
      "r413",
      "r415",
      "r617",
      "r618",
      "r624",
      "r631",
      "r688",
      "r877",
      "r907",
      "r908",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r940",
      "r951"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r413",
      "r414",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r623",
      "r624",
      "r626",
      "r631",
      "r687",
      "r688",
      "r689",
      "r877",
      "r907",
      "r908",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r940",
      "r944",
      "r951"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Features of Convertible Preferred Stock [Abstract]",
        "terseLabel": "Convertible Preferred Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r306",
      "r307",
      "r310",
      "r311",
      "r312",
      "r314",
      "r319",
      "r320",
      "r349",
      "r373",
      "r588",
      "r603",
      "r627",
      "r634",
      "r637",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r727",
      "r746",
      "r906",
      "r940",
      "r942",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r954",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1322",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1330",
      "r1332",
      "r1333"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Financing Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Financing Receivable, Allowance for Credit Loss, Beginning Balance",
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r119",
      "r120",
      "r121",
      "r147",
      "r305",
      "r308",
      "r309",
      "r1349"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1053"
     ]
    },
    "sepn_FourZeroOne401KPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "FourZeroOne401KPlanMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Zero One 401 K Plan [Member]",
        "documentation": "Four zero one 401 K plan member.",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_FurnitureFixturesAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "FurnitureFixturesAndOfficeEquipmentMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures, and office equipment",
        "label": "Furniture Fixtures and Office Equipment [Member]",
        "documentation": "Furniture fixtures and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "terseLabel": "Gain on sale of non-financial asset",
        "negatedLabel": "Gain on sale of non-financial asset",
        "negatedTerseLabel": "Gain on sale of non-financial asset",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "sepn_GainLossOnSaleOfResearchAndDdevelopmentInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "GainLossOnSaleOfResearchAndDdevelopmentInProgress",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Loss On Sale Of Research And Ddevelopment In-Progress",
        "documentation": "Gain Loss on sale of research and development in-progress.",
        "verboseLabel": "Gain on sale of research and development in-progress"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_GainOnSaleOfInProgressResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "GainOnSaleOfInProgressResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on Sale of In Progress Research and Development",
        "documentation": "Gain on sale of in-progress research and development.",
        "terseLabel": "Gain on sale of in-progress research and development"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_GainOnSaleOfNonFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "GainOnSaleOfNonFinancialAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial asset.",
        "label": "Gain On Sale Of Non Financial Asset",
        "negatedTerseLabel": "Gain on sale of non-financial asset",
        "terseLabel": "Gain on sale of non-financial asset"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_GainOnSaleOfNonFinancialAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "GainOnSaleOfNonFinancialAssetTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on Sale of Non-Financial Asset [Text Block]",
        "documentation": "Gain on sale of non-financial asset.",
        "terseLabel": "Gain on Sale of Non-Financial Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative costs",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r833"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "sepn_GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "GrossProceedsAfterDeductingUnderwritingDiscountsAndCommissions",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds After Deducting Underwriting Discounts And Commissions",
        "documentation": "Gross proceeds after deducting underwriting discounts and commissions.",
        "verboseLabel": "Gross proceeds after deducting underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IPO Stock Options [Member]",
        "terseLabel": "Initial Public Offering (IPO)",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r1002"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r76",
      "r941"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "sepn_IncentiveStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "IncentiveStockOptionsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "terseLabel": "(Loss) income before provision for income taxes",
        "totalLabel": "Loss before provision (benefit) for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r97",
      "r101",
      "r721",
      "r723",
      "r742",
      "r884",
      "r886",
      "r887",
      "r893",
      "r899",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r330",
      "r573",
      "r578",
      "r579",
      "r587",
      "r621",
      "r622",
      "r625",
      "r636",
      "r637",
      "r638",
      "r759",
      "r761",
      "r838",
      "r876",
      "r877",
      "r930",
      "r931",
      "r938",
      "r939",
      "r943",
      "r951",
      "r1318",
      "r1319",
      "r1356"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r330",
      "r573",
      "r578",
      "r579",
      "r587",
      "r621",
      "r622",
      "r625",
      "r636",
      "r637",
      "r638",
      "r759",
      "r761",
      "r838",
      "r876",
      "r877",
      "r930",
      "r931",
      "r938",
      "r939",
      "r943",
      "r951",
      "r1318",
      "r1319",
      "r1356"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r1313"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r1313"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r503",
      "r508",
      "r515",
      "r516",
      "r517",
      "r523",
      "r530",
      "r542",
      "r544",
      "r545",
      "r546",
      "r726",
      "r775",
      "r783",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionBenefitForIncomeTaxesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "negatedLabel": "(Benefit) provision for income taxes",
        "verboseLabel": "Provision (benefit) for income taxes",
        "totalLabel": "Provision (benefit) for income taxes",
        "negatedTerseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r116",
      "r178",
      "r201",
      "r202",
      "r225",
      "r242",
      "r257",
      "r507",
      "r508",
      "r543",
      "r750",
      "r884",
      "r886",
      "r887",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r505",
      "r506",
      "r523",
      "r524",
      "r529",
      "r534",
      "r777"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r929",
      "r1309"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal taxes at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1309",
      "r1311"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1309",
      "r1311"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1309",
      "r1310"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1309",
      "r1310"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r929",
      "r1309"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total",
        "terseLabel": "Changes in unrecognized tax benefits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r929",
      "r1309"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total",
        "terseLabel": "Tax credits",
        "negatedLabel": "Tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r514",
      "r1309"
     ]
    },
    "sepn_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Taxes Paid, Net, Total",
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r174",
      "r531",
      "r532"
     ]
    },
    "sepn_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase Decrease In Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase Decrease In Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r1160"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase Decrease In Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating leases, net",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1160"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "label": "Increase Decrease In Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sepn_IncreaseInSharesReservedForFutureIssuanceInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "IncreaseInSharesReservedForFutureIssuanceInShares",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in shares reserved for future issuance, in shares",
        "label": "Increase in Shares Reserved for Future Issuance, in Shares",
        "documentation": "Increase in shares reserved for future issuance, in shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1044",
      "r1053",
      "r1057",
      "r1065"
     ]
    },
    "sepn_InitialPublicOfferingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "InitialPublicOfferingStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering stock options",
        "label": "Initial Public Offering Stock Options",
        "documentation": "Initial public offering stock options."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_InitialTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "InitialTrancheMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Tranche [Member]",
        "label": "Initial Tranche [Member]",
        "terseLabel": "Initial Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "sepn_InterimChiefMedicalOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "InterimChiefMedicalOfficerMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interim Chief Medical Officer",
        "label": "Interim Chief Medical Officer [Member]",
        "documentation": "Interim Chief Medical Officer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r240",
      "r257",
      "r899",
      "r1117"
     ]
    },
    "sepn_LeaseCommencementPeriod": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "LeaseCommencementPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commencement Period",
        "documentation": "Lease commencement period.",
        "terseLabel": "Lease commencement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease payments",
        "label": "Lease, Cost",
        "totalLabel": "Lease, Cost, Total",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r952"
     ]
    },
    "sepn_LeasedSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "LeasedSpaceMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased Space.",
        "label": "Leased Space [Member]",
        "terseLabel": "Leased Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r665"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r666"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r666"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease liability term",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "sepn_LesseeOperatingLeaseExpirationYearAndMonth": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "LesseeOperatingLeaseExpirationYearAndMonth",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Expiration Year and Month",
        "documentation": "Lessee, operating lease, expiration year and month.",
        "terseLabel": "Lease expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1165",
      "r1171",
      "r1350"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease option to extend description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r56",
      "r178",
      "r179",
      "r180",
      "r299",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r567",
      "r570",
      "r571",
      "r635",
      "r809",
      "r892",
      "r909",
      "r973",
      "r1208",
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r95",
      "r737",
      "r953",
      "r959",
      "r960",
      "r1164",
      "r1168",
      "r1198",
      "r1334"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_LiabilitiesAssociatedWithIndemnificationRightsAndAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "LiabilitiesAssociatedWithIndemnificationRightsAndAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "liabilities associated with indemnification rights and agreements",
        "label": "Liabilities Associated with Indemnification Rights and Agreements",
        "documentation": "Liabilities associated with indemnification rights and agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r137",
      "r178",
      "r179",
      "r180",
      "r299",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r567",
      "r570",
      "r571",
      "r635",
      "r953",
      "r1208",
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_LizBhattMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "LizBhattMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liz Bhatt [Member]",
        "documentation": "Liz Bhatt Member.",
        "terseLabel": "Liz Bhatt"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities",
        "totalLabel": "Marketable Securities, Total",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r1109"
     ]
    },
    "sepn_MarketableSecuritiesAndFairValueMeasurementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "MarketableSecuritiesAndFairValueMeasurementsTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities And Fair Value Measurements [TextBlock]",
        "documentation": "Marketable securities and fair value measurements.",
        "terseLabel": "Marketable Securities and Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities, current",
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities, non-current",
        "terseLabel": "Marketable securities, non-current",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "sepn_MaterialRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "MaterialRightMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Right [Member]",
        "documentation": "Material right.",
        "terseLabel": "Material Right"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r333",
      "r334",
      "r335",
      "r336",
      "r437",
      "r473",
      "r474",
      "r475",
      "r499",
      "r620",
      "r715",
      "r758",
      "r760",
      "r774",
      "r801",
      "r802",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r869",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r905",
      "r910",
      "r924",
      "r930",
      "r932",
      "r933",
      "r944",
      "r945",
      "r949",
      "r950",
      "r956",
      "r1210",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "sepn_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Received",
        "documentation": "Milestone payment received.",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_MilestonePaymentsReceivableFromCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "MilestonePaymentsReceivableFromCollaborationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments Receivable From Collaboration Agreement",
        "documentation": "Milestone payments receivable from collaboration agreement.",
        "terseLabel": "Milestone payments receivable from collaboration agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r333",
      "r334",
      "r335",
      "r336",
      "r437",
      "r473",
      "r474",
      "r475",
      "r499",
      "r620",
      "r715",
      "r758",
      "r760",
      "r774",
      "r801",
      "r802",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r869",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r905",
      "r910",
      "r924",
      "r930",
      "r932",
      "r933",
      "r944",
      "r945",
      "r949",
      "r956",
      "r1210",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1239",
      "r1267"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided By Used In Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net (loss) income",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r74",
      "r98",
      "r132",
      "r135",
      "r154",
      "r157",
      "r162",
      "r178",
      "r179",
      "r180",
      "r184",
      "r189",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r215",
      "r299",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r353",
      "r356",
      "r359",
      "r365",
      "r485",
      "r554",
      "r563",
      "r614",
      "r635",
      "r744",
      "r830",
      "r851",
      "r852",
      "r884",
      "r886",
      "r887",
      "r971",
      "r1208"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net (loss) income applicable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r165",
      "r194",
      "r195",
      "r196",
      "r197",
      "r206",
      "r207",
      "r216",
      "r219",
      "r356",
      "r359",
      "r365",
      "r563"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator, basic:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net (loss) income applicable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r219"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator, diluted:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Proceeds Conversion Of Outstanding Convertible Promissory Notes Plus Accrued Interest",
        "label": "Net Proceeds Conversion Of Outstanding Convertible Promissory Notes Plus Accrued Interest",
        "terseLabel": "Net proceeds conversion of outstanding convertible promissory notes plus accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1010",
      "r1020",
      "r1044",
      "r1053"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "sepn_NonRefundableOneTimeUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "NonRefundableOneTimeUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time non-refundable upfront payment received",
        "label": "Non Refundable One Time Upfront Payment Received",
        "documentation": "Non-refundable one time upfront payment received."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5 1 Arr Modified Flag",
        "documentation": "Non Rule 10b5 1 Arr Modified Flag."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure for noncash investing and financing activities:",
        "label": "Noncash Investing And Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income Expense",
        "terseLabel": "Other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net:",
        "label": "Nonoperating Income Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_NovoCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "NovoCollaborationAgreementMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novo Collaboration Agreement Member",
        "documentation": "Novo Collaboration Agreement.",
        "terseLabel": "Novo Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r884",
      "r887",
      "r893",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs",
        "verboseLabel": "Operating lease expenses, excluding variable lease payments",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Noncurrent",
        "verboseLabel": "Operating lease liability",
        "terseLabel": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r660"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of present value of lease payments",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r952"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "sepn_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "documentation": "Operating loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_OptionAndIncentivePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "OptionAndIncentivePlan2024Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option and Incentive Plan 2024 [Member]",
        "documentation": "Option and incentive plan 2024.",
        "terseLabel": "2024 Option and Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_OrganizationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "OrganizationDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganization1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Disclosure [Text Block]",
        "documentation": "Organization disclosure text block.",
        "verboseLabel": "Organization"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_OriginalLeasedSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "OriginalLeasedSpaceMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original Leased Space",
        "label": "Original Leased Space [Member]",
        "documentation": "Original leased space."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r953"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Net unrealized gain on marketable securities",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r89"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain on marketable securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r745"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r89",
      "r155",
      "r158",
      "r198"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "terseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Noncurrent Assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r936"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "sepn_OtherReceivableRelatedToSaleOfNonFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "OtherReceivableRelatedToSaleOfNonFinancialAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivable related to sale of non-financial asset.",
        "label": "Other Receivable Related To Sale Of Non Financial Asset",
        "terseLabel": "Other receivable related to sale of non-financial asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r997",
      "r1008",
      "r1018",
      "r1051"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1011",
      "r1021",
      "r1054"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1011",
      "r1021",
      "r1054"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of earnings to participating preferred stockholders",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "negatedTerseLabel": "Allocation of earnings to participating preferred stockholders",
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r1089"
     ]
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted",
        "terseLabel": "Allocation of earnings to participating preferred stockholders",
        "negatedTerseLabel": "Allocation of earnings to participating preferred stockholders",
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sepn_PatentExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PatentExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent expenses.",
        "label": "Patent Expenses, Policy [Policy Text Block]",
        "terseLabel": "Patent Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "sepn_PaymentReceivedOnSaleOfNonFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PaymentReceivedOnSaleOfNonFinancialAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment received on sale of non-financial asset",
        "documentation": "Payment received on sale of non-financial asset.",
        "terseLabel": "Payment received on sale of non-financial asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "terseLabel": "Purchases of available-for-sale marketable securities",
        "negatedLabel": "Purchases of available-for-sale marketable securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r170",
      "r268"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Retirement Benefit Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r431",
      "r432",
      "r433",
      "r923"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "sepn_PercentageOfChangeInOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PercentageOfChangeInOwnership",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Change in Ownership",
        "documentation": "Percentage of change in ownership.",
        "terseLabel": "Percentage of change in ownership"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_PercentageOfShareIssuePriceDividedByConversionPriceInEffect": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PercentageOfShareIssuePriceDividedByConversionPriceInEffect",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Share Issue Price Divided By Conversion Price In Effect",
        "documentation": "Percentage of share issue price divided by conversion price in effect.",
        "verboseLabel": "Percentage of share issue price divided by conversion price in effect"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_PerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PerformanceConditionsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Conditions [Member]",
        "documentation": "Performance conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Conditions [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding convertible preferred stock conversion in to common stock",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Convertible preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r366"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Convertible preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r811"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Convertible preferred stock, shares issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r366"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted convertible preferred stock outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r811",
      "r829",
      "r1390",
      "r1391"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r355",
      "r362",
      "r732",
      "r953"
     ]
    },
    "sepn_PrepaidBonusCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PrepaidBonusCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid bonus",
        "label": "Prepaid Bonus Current",
        "documentation": "Prepaid bonus current."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_PrepaidClinicalTrialCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PrepaidClinicalTrialCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical trial costs",
        "label": "Prepaid Clinical Trial Costs Current",
        "documentation": "Prepaid clinical trial costs current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense And Other Assets Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid Expense, Current, Total",
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r323",
      "r324",
      "r880"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_PrepaidTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PrepaidTaxesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid taxes",
        "label": "Prepaid Taxes Current",
        "documentation": "Prepaid Taxes Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from Initial Public Offering, net of offering costs",
        "verboseLabel": "Net proceeds from initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash proceeds on shares issued",
        "terseLabel": "Proceeds from issuance of Convertible Preferred stock, net of issuance costs",
        "label": "Proceeds from issuance of Series B Convertible Preferred stock, net of issuance costs",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "terseLabel": "Maturities of available-for-sale marketable securities",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r1191"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ProceedsFromSaleOfNonFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ProceedsFromSaleOfNonFinancialAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of non-financial asset",
        "documentation": "Proceeds from sale of non-financial asset",
        "terseLabel": "Received cash on sale of non-financial asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r717",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r878",
      "r883",
      "r886",
      "r887",
      "r911",
      "r912",
      "r955",
      "r956",
      "r957",
      "r958",
      "r962",
      "r1094",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1206",
      "r1207",
      "r1354",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1384",
      "r1385"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r717",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r878",
      "r883",
      "r886",
      "r887",
      "r911",
      "r912",
      "r955",
      "r956",
      "r957",
      "r958",
      "r962",
      "r1094",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1206",
      "r1207",
      "r1354",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1384",
      "r1385"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Consulting services",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r899",
      "r971",
      "r1388",
      "r1389"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Profit Loss",
        "terseLabel": "Net (loss) income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135",
      "r154",
      "r157",
      "r172",
      "r178",
      "r179",
      "r180",
      "r184",
      "r189",
      "r198",
      "r201",
      "r202",
      "r299",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r353",
      "r485",
      "r554",
      "r563",
      "r565",
      "r568",
      "r569",
      "r614",
      "r635",
      "r721",
      "r723",
      "r743",
      "r787",
      "r830",
      "r851",
      "r852",
      "r934",
      "r935",
      "r972",
      "r1116",
      "r1208"
     ]
    },
    "sepn_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in accounts payable and accrued expenses and other current liabilities",
        "documentation": "Property and equipment included in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Total property and equipment",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r139",
      "r741"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property Plant And Equipment Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r665",
      "r725",
      "r741",
      "r953"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r112",
      "r114",
      "r739"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "sepn_PurchasePricePercentageOfFairMarketValuePerShareOnOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "PurchasePricePercentageOfFairMarketValuePerShareOnOffering",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price Percentage Of Fair Market Value Per Share on Offering",
        "documentation": "Purchase Price Percentage Of Fair Market Value Per Share on Offering",
        "terseLabel": "Purchase price percentage of fair market value per share on offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "sepn_RaCapitalManagementLPServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "RaCapitalManagementLPServiceAgreementMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RA Capital",
        "label": "RA Capital Management L P Service Agreement [Member]",
        "documentation": "RA Capital Management L P Service Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r333",
      "r334",
      "r335",
      "r336",
      "r395",
      "r437",
      "r473",
      "r474",
      "r475",
      "r482",
      "r499",
      "r620",
      "r690",
      "r699",
      "r715",
      "r758",
      "r760",
      "r774",
      "r801",
      "r802",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r869",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r905",
      "r910",
      "r924",
      "r930",
      "r932",
      "r933",
      "r944",
      "r945",
      "r949",
      "r950",
      "r956",
      "r965",
      "r1204",
      "r1210",
      "r1326",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r333",
      "r334",
      "r335",
      "r336",
      "r395",
      "r437",
      "r473",
      "r474",
      "r475",
      "r482",
      "r499",
      "r620",
      "r690",
      "r699",
      "r715",
      "r758",
      "r760",
      "r774",
      "r801",
      "r802",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r869",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r905",
      "r910",
      "r924",
      "r930",
      "r932",
      "r933",
      "r944",
      "r945",
      "r949",
      "r950",
      "r956",
      "r965",
      "r1204",
      "r1210",
      "r1326",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1003",
      "r1013",
      "r1046"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r267",
      "r404",
      "r427",
      "r676",
      "r677",
      "r730",
      "r738",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r828",
      "r858",
      "r1387"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r676",
      "r677",
      "r678",
      "r679",
      "r730",
      "r738",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r828",
      "r858"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fees",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r676",
      "r677",
      "r1338"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r1338"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r267",
      "r676",
      "r677",
      "r679",
      "r834",
      "r835",
      "r838"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party Transactions By Related Party [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r267",
      "r404",
      "r427",
      "r676",
      "r677",
      "r730",
      "r738",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r828",
      "r858",
      "r1338",
      "r1387"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r677",
      "r680",
      "r784",
      "r785",
      "r786",
      "r836",
      "r837",
      "r838",
      "r856",
      "r857"
     ]
    },
    "sepn_RepurchasesOfUnvestedRestrictedCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "RepurchasesOfUnvestedRestrictedCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchases of unvested restricted common stock",
        "label": "Repurchases of Unvested Restricted Common Stock",
        "documentation": "Repurchases of unvested restricted common stock."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_RequiredPriorNoticeDurationToTerminateAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "RequiredPriorNoticeDurationToTerminateAgreement",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Required Prior Notice Duration to Terminate Agreement",
        "documentation": "Required prior notice duration to terminate agreement.",
        "terseLabel": "Required prior notice duration to terminate agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r1308"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r1308"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Total research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r876",
      "r884",
      "r885",
      "r899",
      "r1347"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "sepn_ResearchDevelopmentProgramsAndManufacturingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ResearchDevelopmentProgramsAndManufacturingServicesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; Development Programs and Manufacturing Services [Member]",
        "documentation": "Research &amp; development programs and manufacturing services.",
        "terseLabel": "R&amp;D Programs and Manufacturing Services"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ResearchDevelopmentProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ResearchDevelopmentProgramsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Programs",
        "label": "Research &amp; Development Programs [Member]",
        "documentation": "Research &amp; development programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r993",
      "r1004",
      "r1014",
      "r1047"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1005",
      "r1015",
      "r1048"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1012",
      "r1022",
      "r1055"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1107",
      "r1162",
      "r1348",
      "r1353"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r1108",
      "r1162"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Awards [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "sepn_RestrictedStockOptionsSubjectToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "RestrictedStockOptionsSubjectToRepurchase",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Options Subject To Repurchase",
        "documentation": "Restricted stock options subject to repurchase.",
        "terseLabel": "Restricted stock options subject to repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings Accumulated Deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r84",
      "r736",
      "r768",
      "r773",
      "r782",
      "r812",
      "r953"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r131",
      "r132",
      "r185",
      "r186",
      "r187",
      "r190",
      "r198",
      "r200",
      "r202",
      "r300",
      "r304",
      "r326",
      "r352",
      "r485",
      "r536",
      "r537",
      "r550",
      "r551",
      "r552",
      "r555",
      "r562",
      "r563",
      "r591",
      "r594",
      "r595",
      "r598",
      "r612",
      "r646",
      "r649",
      "r764",
      "r766",
      "r788",
      "r1390"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r924",
      "r1093",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r924",
      "r1093",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total net revenue",
        "terseLabel": "Revenue",
        "label": "Revenue recognized",
        "negatedLabel": "Revenue recognized",
        "verboseLabel": "Service revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r225",
      "r238",
      "r239",
      "r253",
      "r257",
      "r261",
      "r263",
      "r264",
      "r388",
      "r389",
      "r390",
      "r717",
      "r884",
      "r887"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Collaboration and Research Service Agreements",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r393"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue remaining performance obligation",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized in exchange for operating lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "negatedLabel": "Right-of-use asset recognized in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r952"
     ]
    },
    "sepn_RisksAndUncertaintyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "RisksAndUncertaintyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Uncertainty.",
        "label": "Risks And Uncertainty [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5 1Arr Modified Flag",
        "documentation": "Rule 10b5 1Arr Modified Flag."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "sepn_SaleOfNonFinancialAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SaleOfNonFinancialAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of non-financial assets.",
        "label": "Sale of Non-Financial Assets, Policy [Policy Text Block]",
        "terseLabel": "Sale of Non-Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SamiraShaikhlyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SamiraShaikhlyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Samira Shaikhly [Member]",
        "documentation": "Samira Shaikhly Member.",
        "terseLabel": "Samira Shaikhly"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SamsaraBiocapitalLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SamsaraBiocapitalLPMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Samsara BioCapital",
        "label": "Samsara BioCapital L P [Member]",
        "documentation": "Samsara BioCapital L P."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r204",
      "r442",
      "r1091"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Net (Loss) Income Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Marketable Securities by Major Type of Security",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Provision (Benefit) for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Income Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureEmployeeRetirementBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r42",
      "r43",
      "r44",
      "r410",
      "r411",
      "r412",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net (Loss) Income Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r929",
      "r1309"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense For Restricted Stock Awards, Stock Options and ESPP",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r665"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183",
      "r184",
      "r676",
      "r677",
      "r679",
      "r834",
      "r835",
      "r838"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Reportable Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockBasedCompensationExpenseForRestrictedStockAwardsStockOptionsAndEsppDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r482"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r86"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Assumptions used for Grants Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Award Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r81",
      "r83",
      "r84",
      "r143",
      "r144",
      "r145",
      "r227",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r588",
      "r778",
      "r779",
      "r780",
      "r781",
      "r910",
      "r1090",
      "r1164",
      "r1166"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r928"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Security12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r225",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r243",
      "r244",
      "r245",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r264",
      "r894",
      "r897",
      "r898",
      "r899",
      "r901",
      "r903",
      "r904"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment expenses",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r244",
      "r245",
      "r257",
      "r899"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r260",
      "r263",
      "r895",
      "r896",
      "r902"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "terseLabel": "General and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r883",
      "r884",
      "r885",
      "r887",
      "r1155"
     ]
    },
    "sepn_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1111",
      "r1212",
      "r1216"
     ]
    },
    "sepn_ServiceAgreementExpirationYear": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ServiceAgreementExpirationYear",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Agreement Expiration year",
        "documentation": "Service agreement expiration year",
        "terseLabel": "Service agreement expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSegmentInformationSummaryOfReportableSegmentDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation",
        "label": "Share Based Compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Repurchased",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option repurchased.",
        "negatedLabel": "Restricted stock awards repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards repurchased ,Weighted Average Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Repurchased In Period Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option repurchased in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, Beginning Balance",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461"
     ]
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock awards repurchased",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriodWeightedAverageGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period Weighted Average Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchased in period weighted average grant date fair value.",
        "terseLabel": "Restricted stock awards repurchased ,Weighted Average Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSubjectToRepurchase",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards, subject to repurchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, subject to repurchase",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, subject to repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock awards vested",
        "terseLabel": "Restricted stock awards vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate grant date fair value of shares vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards vested, Weighted Average Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "terseLabel": "Effective date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value of the common stock exercise price percentge",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Exercise Price Percentage",
        "documentation": "Share based compensation arrangement by share based payment award fair value exercise price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonStock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Common Stock",
        "documentation": "Share based compensation arrangement by share based payment award fair value of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares reserved for issuance",
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable as of December 31, 2025",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercisable as of December 31, 2025",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total Intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Options Outstanding, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Total Options Outstanding, Cancelled",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Options Outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Total Options Outstanding, Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock option awards granted",
        "terseLabel": "Total Options outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average per share grant-date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total Options outstanding, Beginning balance",
        "periodEndLabel": "Total Options outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Beginning balance",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average share price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest as of December 31, 2024",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest as of December 31, 2024",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest as of December 31, 2024",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding number of shares of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "sepn_ShareBasedCompensationEquityAwardsOptionsGrantsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ShareBasedCompensationEquityAwardsOptionsGrantsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant date fair value",
        "label": "Share Based Compensation Equity Awards Options Grants Fair Value",
        "documentation": "Share based compensation equity awards options grants fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r451",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable as of December 31, 2025",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, Exercisable as of December 31, 2025",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate grant date fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Shares Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesSummaryOfExpensesRecognizedAndCashPaidForLeasedSpaceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r952"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r143",
      "r144",
      "r145",
      "r178",
      "r180",
      "r209",
      "r210",
      "r217",
      "r219",
      "r227",
      "r228",
      "r299",
      "r338",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r354",
      "r355",
      "r357",
      "r358",
      "r360",
      "r364",
      "r366",
      "r367",
      "r370",
      "r371",
      "r374",
      "r635",
      "r778",
      "r779",
      "r780",
      "r781",
      "r788",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r811",
      "r831",
      "r853",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r1090",
      "r1166",
      "r1167",
      "r1177"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Statement Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r62",
      "r63",
      "r124",
      "r131",
      "r132",
      "r160",
      "r161",
      "r162",
      "r185",
      "r186",
      "r187",
      "r190",
      "r198",
      "r200",
      "r202",
      "r226",
      "r300",
      "r304",
      "r326",
      "r352",
      "r376",
      "r485",
      "r536",
      "r537",
      "r550",
      "r551",
      "r552",
      "r555",
      "r562",
      "r563",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r612",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r672",
      "r745",
      "r764",
      "r765",
      "r766",
      "r788",
      "r853"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r226",
      "r354",
      "r355",
      "r357",
      "r360",
      "r649",
      "r717",
      "r776",
      "r789",
      "r800",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r811",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r833",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r853",
      "r886",
      "r887",
      "r966",
      "r1387"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r204",
      "r442",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r226",
      "r267",
      "r354",
      "r355",
      "r357",
      "r360",
      "r649",
      "r717",
      "r776",
      "r789",
      "r800",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r811",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r833",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r853",
      "r886",
      "r887",
      "r966",
      "r1387"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1007",
      "r1017",
      "r1050"
     ]
    },
    "sepn_Stock2021PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "Stock2021PlanMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedForGrantsAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan [Member]",
        "label": "Stock 2021 Plan [Member]",
        "documentation": "Stock 2021 plan."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_Stock2024PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "Stock2024PlanMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Plan [Member]",
        "documentation": "Stock 2024 plan.",
        "label": "Stock 2024 Plan [Member]",
        "verboseLabel": "Stock 2024 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "sepn_StockIssuanceCostsOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "StockIssuanceCostsOfConvertibleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Stock Issuance Costs Of Convertible Securities",
        "documentation": "Stock issuance costs of convertible securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B Convertible Preferred Stock( in shares)",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r36",
      "r59",
      "r62",
      "r84",
      "r348"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock in connection with initial public offering, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84",
      "r778",
      "r853",
      "r865"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total Options outstanding, Exercised",
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "terseLabel": "Total Options outstanding, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84",
      "r457"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r62",
      "r63",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "negatedLabel": "Proceeds from employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with initial public offering, net of issuance costs",
        "verboseLabel": "Issuance of common stock in connection with initial public offering, issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84",
      "r788",
      "r853",
      "r865",
      "r972"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r62",
      "r63",
      "r84"
     ]
    },
    "sepn_StockIssuedDuringPeriodValuesRestrictedStockAwardVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "StockIssuedDuringPeriodValuesRestrictedStockAwardVested",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted common stock",
        "label": "Stock Issued During Period Values Restricted Stock Award Vested",
        "documentation": "Stock issued during period values restricted stock award vested."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_StockPlan2024And2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "StockPlan2024And2021Member",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedStockAwardActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2024 and 2021 Stock Plan.",
        "label": "Stock Plan 2024 and 2021 [Member]",
        "terseLabel": "2024 and 2021 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of unvested restricted common stock (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Repurchases of unvested restricted common stock (in shares)",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchases of unvested restricted common stock",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r59",
      "r84"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Stockholders Equity",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r75",
      "r813",
      "r829",
      "r854",
      "r855",
      "r953",
      "r973",
      "r1164",
      "r1167",
      "r1168",
      "r1198",
      "r1334",
      "r1390"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split description",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r682"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r682"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r682"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r682"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r682"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SummaryOfChangesInDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SummaryOfChangesInDeferredRevenueTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Deferred Revenue",
        "label": "Summary of Changes in Deferred Revenue [Table Text Block]",
        "documentation": "Summary of changes in deferred revenue"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis",
        "label": "Summary of Common Stock Shares Reserved for Future Issuance on Convertible Basis [Table Text Block]",
        "documentation": "Summary of common stock shares reserved for future issuance on convertible basis."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Estimated useful Lives of Property, Plant and Equipment [Table Text Block]",
        "documentation": "Summary of estimated useful lives of property, plant and equipment.",
        "terseLabel": "Summary of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Lease Cost and Cash Paid for Operating Lease Liability [Table Text Block]",
        "documentation": "Summary of lease cost and cash paid for operating lease liability.",
        "terseLabel": "Summary of Expenses Recognized and Cash Paid for Leased Space"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized [Table Text Block]",
        "documentation": "Summary of revenue recognized, unrecognized transaction price and estimated revenue expected to be recognized.",
        "terseLabel": "Summary of Revenue Recognized, Unrecognized Transaction Price and Estimated Revenue Expected to be Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry forwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "sepn_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Expiration Year",
        "documentation": "Tax credit carryforward expiration year.",
        "terseLabel": "Tax credit carryforward, expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]",
        "documentation": "Indicates tax jurisdiction of domicile."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r929"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Taxes Payable, Current, Total",
        "terseLabel": "Accrued income taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r355",
      "r357",
      "r358",
      "r364"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheets",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible preferred stock",
        "terseLabel": "Convertible preferred stock, carrying value",
        "periodStartLabel": "Temporary Equity, Beginning Balance",
        "periodEndLabel": "Temporary Equity, Ending Balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r354",
      "r355",
      "r357",
      "r361",
      "r496",
      "r498",
      "r734"
     ]
    },
    "sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, Conversion of convertible preferred stock to common stock",
        "documentation": "Temporary equity, Conversion of convertible preferred stock to common stock.",
        "negatedLabel": "Temporary equity, Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, Conversion of convertible preferred stock to common stock shares",
        "documentation": "Temporary equity, Conversion of convertible preferred stock to common stock shares.",
        "negatedLabel": "Temporary equity, Conversion of convertible preferred stock to common stock upon initial public offering (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r357",
      "r358",
      "r360",
      "r364"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, liquidation preference",
        "label": "Temporary Equity, Liquidation Preference",
        "verboseLabel": "Preferred stock, liquidation preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r357"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r357"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "periodStartLabel": "Temporary Equity, Beginning Balance (in shares)",
        "periodEndLabel": "Temporary Equity, Ending Balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r357"
     ]
    },
    "sepn_TemporaryEquityStockAdditionalFundingBasedOnApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TemporaryEquityStockAdditionalFundingBasedOnApproval",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Stock Additional Funding Based on Approval",
        "label": "Temporary Equity Stock Additional Funding Based on Approval",
        "terseLabel": "Convertible preferred stock additional funding based on approval"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock authorised to be issued during period shares",
        "label": "Temporary Equity Stock Authorised To Be Issued During Period Shares",
        "terseLabel": "Convertible preferred stock shares authorized to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TemporaryEquityStockFinancingArrangementFinancingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TemporaryEquityStockFinancingArrangementFinancingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Stock Financing Arrangement Financing Value",
        "label": "Temporary Equity Stock Financing Arrangement Financing Value",
        "terseLabel": "Convertible preferred stock financing arrangement financing value"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B Convertible Preferred Stock, issuance costs (in shares)",
        "terseLabel": "Issuance of convertible preferred stock, shares",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "documentation": "Temporary equity stock issued during period shares new issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B Convertible Preferred Stock, issuance costs",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of convertible preferred stock, value",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": [
      "r1211",
      "r1213",
      "r1214",
      "r1215"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Convertible Preferred Stock",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215"
     ]
    },
    "sepn_TermOfResearchServiceAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TermOfResearchServiceAgreement",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of Research Service Agreement",
        "documentation": "Term of research service agreement.",
        "terseLabel": "Term of research service agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_ThirdRockVenturesViLPServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "ThirdRockVenturesViLPServiceAgreementMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Rock Ventures",
        "label": "Third Rock Ventures VI L P Service Agreement [Member]",
        "documentation": "Third Rock Ventures VI L P Service Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1185",
      "r1337"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TrancheOneAndTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TrancheOneAndTrancheTwoMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One and Tranche Two [Member]",
        "label": "Tranche One and Tranche Two [Member]",
        "terseLabel": "Tranche One and Two"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tranche One [Member]",
        "terseLabel": "Tranche One",
        "label": "Tranche One [Member]",
        "documentation": "Tranche One."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tranche Two [Member]",
        "terseLabel": "Tranche Two",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_TransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "TransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Price",
        "documentation": "Transaction price",
        "terseLabel": "Total transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r349",
      "r373",
      "r588",
      "r603",
      "r627",
      "r634",
      "r637",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r727",
      "r746",
      "r940",
      "r942",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r954",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1322",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1330",
      "r1332",
      "r1333"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementOfBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Common stock, shares repurchase",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r167",
      "r168",
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r204",
      "r265",
      "r266",
      "r300",
      "r302",
      "r303",
      "r304",
      "r325",
      "r326",
      "r329",
      "r350",
      "r351",
      "r352",
      "r353",
      "r483",
      "r484",
      "r485",
      "r486",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r628",
      "r629",
      "r646",
      "r647",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfChangesInDeferredRevenueParentheticalDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Government Agency Securities",
        "terseLabel": "U.S. Government Agency Securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueMeasurementsOnCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValuesAndContinuousUnrealizedLossPositionsOfMarketableSecuritiesDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesByMajorTypeOfSecurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Treasury Securities",
        "terseLabel": "U.S. Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r889",
      "r919",
      "r921",
      "r923",
      "r940",
      "r1351"
     ]
    },
    "sepn_UnconditionalRightOnNonFinancialAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnconditionalRightOnNonFinancialAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureGainOnSaleOfNonfinancialAssetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unconditional right on non-financial asset",
        "documentation": "Unconditional right on non-financial asset.",
        "terseLabel": "Unconditional right on amount of non-financial asset"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Discounts And Commissions",
        "documentation": "Underwriting discounts and commissions.",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UnderwritingDiscountsCommissionsAndOtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnderwritingDiscountsCommissionsAndOtherOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts commissions and other offering costs",
        "label": "Underwriting Discounts, Commissions and Other Offering Costs",
        "documentation": "Underwriting discounts, commissions and other offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UnderwritingOtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnderwritingOtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Other Offering Expenses",
        "documentation": "Underwriting other offering expenses.",
        "terseLabel": "Underwriting other offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UndesignatedCommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UndesignatedCommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated common stock, par value",
        "label": "Undesignated Common Stock Par or Stated Value Per Share",
        "documentation": "Undesignated common stock par or stated value per share."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UndesignatedPreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UndesignatedPreferredStockSharesAuthorized",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock authorized",
        "label": "Undesignated Preferred Stock, Shares Authorized",
        "documentation": "Undesignated preferred stock, shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "sepn_UnpaidOfferingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnpaidOfferingCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid offering costs included in accounts payable",
        "label": "Unpaid Offering Costs Included In Accounts Payable",
        "documentation": "Unpaid Offering Costs Included In Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Balance at the beginning of the year",
        "periodEndLabel": "Balance at end of the year",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r520",
      "r928"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Adjustment based on tax positions related to prior years",
        "negatedTerseLabel": "Adjustment based on tax positions related to prior years",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r928"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r928"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r928"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Adjustment based on tax positions related to prior years",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r928"
     ]
    },
    "sepn_UnrecognizedTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnrecognizedTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized transaction price as of September 30, 2025",
        "label": "Unrecognized Transaction Price",
        "documentation": "Unrecognized transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UnvestedRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnvestedRestrictedStock",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested restricted stock",
        "documentation": "Unvested restricted stock",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_UnvestedRestrictedStockSubjectToRepurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "UnvestedRestrictedStockSubjectToRepurchaseMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareSummaryOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock Subject To Repurchase [Member]",
        "documentation": "Unvested restricted stock subject to repurchase.",
        "verboseLabel": "Unvested Restricted Stock Awards Subject to Repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r229",
      "r230",
      "r231",
      "r232",
      "r721",
      "r723",
      "r891"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Deferred tax asset, net change in total valuation allowance increase during period",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "sepn_VariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "VariableConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsSummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRec1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Consideration",
        "documentation": "Variable consideration.",
        "terseLabel": "Variable consideration"
       }
      }
     },
     "auth_ref": []
    },
    "sepn_VertexAssetPurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "VertexAssetPurchaseMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vertex Asset Purchase",
        "label": "Vertex Asset Purchase [Member]",
        "documentation": "Vertex Asset Purchase."
       }
      }
     },
     "auth_ref": []
    },
    "sepn_VertexResearchServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.septerna.com/20251231",
     "localname": "VertexResearchServiceAgreementMember",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureCollaborationAndResearchServiceAgreementsAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vertex Research Service Agreement",
        "label": "Vertex Research Service Agreement [Member]",
        "documentation": "Vertex research service agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average common shares (denominator), Diluted",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "totalLabel": "Weighted-average shares outstanding used to compute net (loss) income per common share, diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r219"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator, diluted:",
        "verboseLabel": "Weighted-average shares outstanding used in computing net (loss) income per share attributable to common stockholders:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails",
      "http://www.septerna.com/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average common shares (denominator), Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r219"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.septerna.com/20251231/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfBasicAndDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator, basic:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001193125-26-098507-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-098507-xbrl.zip
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MJ75BUXXDHQ>!J;XONZN/?@4P*CYZV!X#D*TLZ] YE =C[;]JF=:XMG\,2/)
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M]@&WEFS3]<[*O-8I6;C-0H^91W_/T[%9C]\/\[?G;MV;P+41O)@> V'!"XB
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M[4./S*^\2K1<G;DI=U%5KNH%18S"3_S6YH^9 S^D,=.#:"#>*Z7,6.BW%$#
M')F6N^L9@Q6++'^\ ?>!"4[8S+?2;03Y27/="O(,3+_I>G&#D-P/=B62OJ:
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M50M0U)R\MRF7[&IK/MQ.=WR7&]%=D7Q(/G+L66Q:P*T,' ,28V08K3]Z&<>
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MD829/>$"A:U'7IU3F]UCG$VQ(CX_B4_/6]I2%Y+?LH+=)@AWN')G7#+1H93
M99,6O=OK^O>I12AN;9G+/CK6')V$A+-R.IGC[&'AC/F7U;_EE+2M2,5E:BR
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M=&+C27<SPFOS2!Z1M5MRF*0O6+76(PR"HI(\3G:)+XJ''A9SA2&7\0:I-$$
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M$\+6NW3#F7LB _[Q\YA/@\C6MC0HCR?ZU;QX9*5E[Z:8^?MO=9@[B_6JW3J
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M&@*OV+B[J?1=C,!?,[JO)8'AHVLW3GI#U,DB/$#*MGP;&+NIP?(#BI2.@)W
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M'^Q=\_98,Q6?T?4HC85D+1'#S =[O-W:@E27*+IY0?L [KRHDY)5A&=CK;%
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M4Q&WN0(MOJS:>2HTLL>0++C6QZW+W?EN:&MPD4P3W/CZ>5^7I3[!\EEF>1)
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M*H-*!;)X3@E0N'2G8TS;!0]O\-]H,2Q'-1<NKHN4JABL/G(F6R*#+_G@#76
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M2Q?\A"YU!BDY?M565]MA1N-2C?,O\.^@.HM$X1WGJ^LMY_K[GHM+U4]J*U8
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M3K]&7QS?>L+PH15,(TP9Q?(Z"P"(QTT:OBGZ)DWC)=ZP>D@"I3WU"N<>O;)
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M!KK+T2Y==_PFS?9!KQY!YKGHHGWO1MXVG3'Q(*Z?BK1*!ZN?GJ=)I]\:)TS
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M\5\J;=$97^[Q0(RI'W\H.%JH_38E5[T%P,DN"$FML=(RTV^3:<Z6TP,X ?M
M],"V]G.\(\!<9^"#I[YYK[3 ^'[5;;M4O?DB_F/#]ZYK!T6B.!>U(3ZN=1'>
MZ=M_$QK&_\X:0QFJEFBSFI@UE^5TW4Y2OC^)(@<//\)7H;21<<<!0?X5,V"
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M<BECL/-J]-@94R.RVX"\U'O&Q*-K>N3!\'<@(NRI!CQPR*!18Q-]I:06!/*
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MLE2(F#V5$6!]H\+1ZRL8LEM>2M;[KBV:C&U_ Z-:"0WXT":;@[\*"KMB.U6
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M<#"=[OD;M.^22@#Y#H]#-KV0C.OF0ECG,Z8?=.L0CHV6GS EK5*7;0F2A"]
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MNOI7:\!4M$?;9ZWN=;N@0LWAARZ.SFS695GU(W)!F8AAGZ2$/GO75/H>-WB
M@S.EM')\.;4AN:"(-WI _Z<!N5!NXA9:IN]NJEUR''MWE\R\  .UY'^UBH>(
M,+_8W*-XA9M+N'9S"E4&_T14&<FYT19?F-Z00*X-J?'@[W^HEXF7.W2RN5%\
M@S5?6+K'"<DA]?HYQHH$X]7YUK?%9", $;3ZT&(@M[I;$-.BO\3%ZU80:,[_
MVZ$@HYY90.!"K(<TFYIUNF=L<D!)XM"NX%N9;]4GIGQ)U4EH.;"D:/6)-WQ
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MWH.&=]B!3#$7S#/[(:XGT+_&$4]DIOC-B2]BL#+G@ ';C!5K(*$ ]GQV 8C
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MOZS<0XS\<I__KVB^I7W=/S8[#;87[U4TZ3N:34\[F0J2@VW1LACXCRQ204Q
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MHMU=ZQ2EX^<ZA)DD>1WH/KES]?9$VZD1F4>.ISM8Q )"-W <K<\>.\J^K?[
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MQLB\D_CQ5H96*>R=;:IBP<N2$;/SMZ*K2-)#+M2UD6P3Z@9=YN1)'S-GF>Q
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MY8G2$WSG4'@,TA?P[*'<[7>#R_.OVZP8?NVK^ #J#Z3>-->4^JOD4]Q5/M]
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MMU"-D=;#_0%SR1R$G8S;&$)N)BRMKQ"AR+;VCY).$*[GA480B/_1@[W8V^U
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MHGO_;U/_PIVYLX XQ)8#W?QV=>:9T?6Z,X0@>(\K7@S5?_G?>+$/?Q\6+!5
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MY**B&@#3R!6)1<9F F=)5Q4?+"V_MVK]XC1[I5*""K#I_O&HS"# TL#"12*
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MIXC=OJW/NSO%\S=W_/\NR8.H5OFO)(],..(77*!7TV&*<&\1&9$7=H!::[]
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MNNGY#3O0Y O*CB?)_9-GVW7"7G^6:0XL]TK#[5XN7<H;S# K,?C5AB$+P^A
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M"QKX38T+</BU=RP]R$T:O2R]QS1#_XT\^FP+4)'/;PXQW/2ED@T0P51S)&]
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M0J,T_()1H?ZGKWBYNGOQ!7JK>]]_\GR"+V4FP^2FT?TC\-^SWRSD-D+H"ID
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M98J?3%_>MSO3*1S7>J-0]B8-8?JMZH3&A//"Y5/&:KA L_-+[WJ&3JM\P&?
M>OW_K0\5_Q<;E#O\'U!+ P04    " !K@6E<FY,:@ V[   ^Q@  $P   &EM
M9S$W,#,Q,# S,E\Q,"YJ<&>LNPE4$VD7]QEW 3$"L@M1 1$0X@*BB$DK#30@
M1'8!(6W3R"9&%"1"2+IE":MTR]:"$&4QLAD58A1"(B2!5VAE#Q*$D$1%0*2B
M$$JR37QGSC=GEG-FSGQ3.<\Y=5)/W:I;SWWN__YJ4;Y5SD!V>+IYN$'6K5\'
M^57U@R@G(2Z0=?^3RP\C_[,VUBE?0K2V0IZMZ]NP;B]DO=:Z#5KKE&P(# )9
MM^E_[0#YWY9UZS=LW+1YRU8U=0U5!^H.R/IU&S:LW[AATZ:-&U5;TU7;(1NU
M-FGO.71JLX[OA2U[$W<>_O/O^UO-3C_ITO4; LR/_';UIIJZGKZ!H9'%/LO]
M5M;V#D<=CQUW<OG9U<W]%P]/_X# H.!S(:&1OT==C(Z)C;N6E'P]!7LC-2,S
M*YN8DYMWN[BDM*S\GSL5-;5U]0_(#QL:G[:V49_1GK]H[V:Q.3V]_WG5-SPR
M.L8=?SO!$PA%[S]\G/TT-R_^^FUY1;(*?E_[X=<ZR(;_X?K_K5]:*K_6;]RX
M8>.6'WZM6Y_RHX/6QDU[#FW6/N6[Y4*BSM[#?V[=>?KO^T^ZU,R.^ &ZOUT=
M4M<SMQ=8B'^X]E_/_M\Y=O/_DV?_P['_W2\>9-N&=:K!VZ %04(4BOTU>9#_
MWQKE TVRI(3<[%5,HEOYBV2I.WZ N34),W$!88K;)8:Q"% P=4'HWHW,QQ\2
M/ZA70M127L(SD7H.\9W184#O(@Q8<"GN&T?LG0_%5V$B!5ZPUKF@HU;73BX*
MGG>4(B_ P /$19KTE()':"5^EHI3W.1E,,%L#TH;YPZLYEQF[,*9@;29):-8
M)I"+6P]VBB,].H:H3!W%,$PKZ1C]]34!]PYY_NCJ]$Z&U*TT'5<V$A*17OUE
MMWWG(TK\9$2CO(5V1^XQA#;##\':4+F(3=B;XRA3DV&'2M@NV<GQ189V;H1D
M>@$MO]=,/W4OIEH'C&QX9]M%D\*+@CEK"=R_N'^=2HM,$* -(Z90)]O#\E%5
M%U07Y"]-/&%S&*@_@^%@M)[5BAR'J"<*4=T24\W'8DKF#)@HYG/T3:W!R"9L
M*X?G<],SGK"I[GDZG&WTBI'1W?[QG]<;V\>6RW@1EUN.#2>3'7SN1H9>+>'#
MS:^LS)]E>]:D#@<$[,EM6 Q OHT7B(<^=@=(^EW=:A-.;X\[ZN,;VUL1L#^(
MK+MO^&KC MW!_%%]02U:(SE4_;#<I89YM$YU@IFQ%;0LA'4\8B.8+B3IO0,U
MNGC$6Q_&+B_2C05(33#L%+?M]>^RHTI(9HUMBC S=39WW[A#YQ:_IZ.U0&#=
M6MUUR>*'3V6T<J/?C<H?X33E3V568A;'=!^0701(A;?N) H2S'H<B9P*4L:C
M9IF&L,I=0,MMH6N)7A_I;N?S+F]<327D6Z:=W#N\?.I:R[E3UP@QAK9VMVTO
M5NT?+?UY3GI@;\]HP8A_MLD%Z\A&C^YW Q,7'HXV( (M'/0^M3]9+:@;#7=(
MDYX/,MNT!7;#V<?T@?;=ACY>M__:%],K!:,7&P:JZV+KTHM=\1?F",]6V02-
M3Z2-^-TR-X"<Y1PO0/'B!8H[HJ+LZ0W@R:B3Y6SD>CZ8P6&JR1P$2^K86K2X
MM\B_&^%,?5$LVIP5^0@[;8S."B40'18=EK_=FW^\<)UF=/UCN1*R20OH6VA?
MPY($J_E)X3L*D:P([1$1\52'^.029YD!_EDS+3,?-:>*O:<SK@G1.O%*")0Z
MY2B0<XMO[,MJ/%I^G7>+<A%C_Z&,[)/TKO;8US>ZT<0&;^IKE(Y/W5P J\/1
M<)3LMUU;XM>P^8-'][7"U,,/N;3$U?O1^T?1&QL>GB93.UJS'-4:(AH?+!JU
M<-*L[S+K=OI969S:W;!;N^YFP-__,==6,U';6'3:U?8GRV3\VGP%P7XEHNAL
M3=Y^R/^I;7B/GBSJP>\'XZ7'L%)A<+;"#-LK:$.L?X+:$5]!9G7 ,EM$G6'>
M.NYDUGTLAHTT24+JXBR W\=YI?)\-);<,ZW+M2]T],Z;^UCNZL>;(OZ' 'BC
M>30VTDB6*&X5H/*<$\1D3CN%I9&P[S.E![D#_XJ@]6B1O39-O1>!)"KV*5X9
MI63)X$VQOZW^<OM(E)"P+6+^\/D[/55"Z5Q;9]KI04:KG.X<:9FEA%Q$YJ8&
M_2TV>TG:ADL4O=:>[4)"DXMR\ <!Z)_VMF%LWE/]8M9!;*40_[<0OB&6]^S%
M_; %O=0DWBK1V0NS\5^,/JM"%*J$1*/>HP'OCH'U,7P-!T)V>W2N\YZ'V-7N
MT+J1>+S1$-X!!P5%%!#=[3A\0V% '<.= BP%O=W,;9]2+7KJKPEM.C>P:(P=
M5'JV<#:,>>OK<L2_OYXS2;Q37"QIV_-'4*V-X\HKAD^JKN6_M0=LMZ"T<KI[
MJMRM=1%/]&\65YMIG9LZ>,R 8QTX?U%C=>%'% >4V P7V90<2C8+TW#1L1KQ
M;$^R6'G8?2P57:?[70D1(Q7J(5)[W/Y6^?TEG'NBZ,YN^1UZ&%#^DH$LQ=F:
M_AG;B&T5P7,P=+@@X4A7!>T6%;WU4[N\ZM:3!_Q)D,@>:#B'=?>6ZBHAQ91I
M1F6#>^S:.K09SDU>A+,4\;5D:/&#2K&-L)PU8"B+5$*R#JY1<F2F2H@F=0OP
MCK_!7&R&#4)I?B+MP!MC9UF.:DVNPBJ_28Y>-7P(%QR=IC_Q^W#"LE?_[^W'
MQB7S5D.^Q1]KL4=KWN%IV<F\!KN8'G"_<*YW]6HBQ:\P+:!0[<(3(U^)\P!O
M*G9?%=\LKC1PJ_=INUBG+YGD8QV-!YM\#ODWJ8\BB@#'_ .RM!FF&BCR>3)J
M/X7L,=TUA/..),_W>CM5556_((?-!ST;GW4?34ZW>"2\^4'[^HA#N&=7W39N
M^?C9G7?6&F5_R%N0D;")<H'E2]0$RA=00KJ8Q/9>-G2"+_E+E1//R4Q!;W$M
M9UH=*,IA.&+]7X;"93OADMC!$9=AA=54C(?PM76?HI?-L KW\AE<6FXQ)8">
M=(]MH0F=#UK3$N +\NO"]#QV\+F+TR9!39]W%?LEW?CP^6X)U9M5VK:"2O<)
M18R\'4HFY,VQ>'.Z4LY6J;>9E6O:ZSE#^_:CS=UY-FRDX($JL/G@>24$> ,#
M!@D;E!#!?27D4P:A^RT D]D1ONLB!2>4D-OA<J9*37ME.:J(""'\!ZIP18$/
MF>^U%'?.59CR77>>7?=_:+HLV2]@)3 Y,WMSA:3:1Q^_!PL3H%D#VPG1A&X7
M$3_7], @#CK3N46*#GPRF$1:).T$JY40K\%EYJ+WM8 1^X03B^.#Z;3 T4M)
M"YBC7[],&T).Y-D055+F**#U(#=]XFLIM'"G 20'1:PV4PRIE".ME[G=.>0>
M*.I*796X-:7?F^>_G;8".(J&^_.DB=2/Y0V?>$5O,62I7A,9'3N."/Q0SSZT
MNA/BZ_K_V-9][Q#W*M3V2-?CA_AZL@3QB'"IBZ\7S]^),#O_2;_:7KP]0^JB
M&(%!+ZWT,[=A75B,]4-V=0"3552 T 8*JUZ3,NF6@BG#V9$VF^.8O<."%XRT
MRCD[NP>(+80N<^2OJ(E>(?\FP@FW%SPN?*TA)+(JJU)7N_![QIDQ1;Q(H6XU
M\8:0L!6;_S)TZAU>'RP2YW,86O07=* \W]FUUGSM5M8-V[NA=>-';1/233I'
MD7U+,EV*A 8^ ;XIU*.D%T!MV*2+:+4;"<5&<F";%E5Y5 GI)E"7>E"9IGJ#
MR^'^D@!P@_ $=Y"N)8#G*O0&+R6LH'3C(\RY<,J!MIQ)7RYEQ:NC8;;CQC^6
M,NTPR7.P5:SQP[0)J(WY89HS ,76<M"&B[APE6D.Z8?I_&F]<?MPN,JT7'AB
MWSA.2\C/55@-8EJ6F;HQ#&/N@<M+2;G&/MQF^XZ.D)F.6WH4LA(2^ 3]EC^)
MYAU'/EYC<A$-*^TD](>/ON\EL.#WDH:.Y]*PL$48B<!VZV?^."<I-(]!6QEX
MJ(3$$J(&%9Q921R9NK8T+J>,M<2TDX*81^^6C2KFJ'QU;!A'^],1L)P5NB6'
M##SJ3!"2MGD_^L2[3H$3G5%1\6F1T<*3F[U/\P3+Z:G#_7ZCEQ:IZ<Z3\SM"
M^=.3G"M_A_O<3G1"O:3<=-K>U!C?;MFUE-6.H+4LZ(#$$*[]  3KU^L_EBQM
M@FG%EH=.WR<DU'&24YK.STT?%"<7]MQWIJ0XD//H7I@#+7J=C2W\5\QGA%QF
MG 9!1X;,D%P#"(4.3;"L($>D"6+/4>(-NZPH\7H8=$'/Z'HQX/<FK<7I8W_/
M.-X!Z,.Y%9\%RNXXS5<$T3# M^#G1[M7SSA&;(J51BN&VY40=AI??2[UP'4G
MB]?C.10'4;S4#H<16^8PH*"7)]@I)*S[Q'MWU(B0BQ@1MWM'_S)D;V-["33S
M:$6O \O/<Y/A.B&L*$&G%\LINL__2O.<K^_YM[SO608CY>8!#8+';^IQ;GL/
M)R;%_(9\*@ZXX$>/]'G:-]=?'=#X:Q5J*,YJB!Q*KQL]V'9P;-](R8,JSR%)
M0$R/>@2O32\JJP4%=>W7L;IXN'"7<V-:F*)H&O\&W3I];^WW<OYZQO8(1*ZN
MS.A$..XP<'[6*R/P:9'WJ&!$-J7%Z-U>2V;I%GX.4H2&A[KJTN?%;CE.:$W9
M/C!DAJ^]4'T$(+(PZ[#!'(7E31NT-I;,JMX!*'*%)GC>%H^]-&YRE2/JV6CR
M?K/;Q]Z?H]CM.V6>R)CZ3R8^EM*+FF2='YP9DYT"_GG[-CZ4EDEW5FP;1&C)
MP@?IJ-HVDCI^&^[T&#U&836"PZX5.#DS',1;BF0[U]1&$GK*]Y5;9J\4IOB-
MR9"4+L*0;#,X)CTO.PVR@+YQ(85(=Q>@U'A8HK"'*!34J)CAO@"U#LSZ #AF
M4YD;R#)SA+,4GOLY83G!9YQS134E72@@JENQ*R%P4682U02R@J3[7CQ,LG#P
M.^07A]FRRQ^_?'Z_,-+M$-E^--J(>B&B(-JEM$\=W]=.]M.U8EG&#DMNC=QL
M,*C'OCXN=?J'['!1T*]VX>-4L 4T?NMH9KUW=Y.TXQ=P V#)6BOK:/Z$W,30
M^=3.S%VQ,8ED5SPH!1:ZC?#W*?.\Z)Q?Q=<K&Q8<RRJ<@XU*Y<1\VQ:9?U3*
M#?-Q/89Y]LGK:CJ!IZX?21Z8$ D0+YJQJ"!3[2'[ (!\JUEA80)G,4P!1A$9
M6][3_G/[BA)"3.;K>F#N$^+F4_#&XS+4([#)/<;AA G#<O01-4T)H7D?R./K
M4'I)D]=^$NM1A"AMU:0( Z_=!V^^61-UF^Z45S&L4*(65+<^WUAQ&'?BQ4B2
M]V_07?,_9B*<1=B$U1>&H:)GOE<&8/0FWK2GEQ.I+:9NW[\,""T7Y<"7R6Y>
M--O64G@K7VC,SU7IW?-'..]Z&1PLEY[%NO5W*R%:^ VXZ/(0\$A3#$EM[]"*
MP3)F@RQ1E<J( F"ZZ&%<K!*RE?NW"+Z.;?%<3^\;9\"G.9W(W4LVPJH/2LZ>
M+:9XF60V9; 'R1DLCE-ITU!&0V&]\WK*?B_X[?K4;]T]CU:LO(-;LDON6PEC
M'2(N!]]':Q:R? K1F)"I8X%DM%HF9=?IS)U'MOI3]G_]S6I$_JJ&$2:.SD'&
M-7TB7)Q"O8S8#!*B5(DC-IC9YE,H+-(-CUVMUAZ!XTT75BMNE=;*2:R*)4FF
M4W0A[)?6L$ZGQ>003,)GVXIWGU+:N0UD<&D1FB;UP*8)\?<%A"PC=!$N4#"0
M'^J8[1S]("[T_%I=*(S5$CE3+J'D.!-FFHIT>IB_ U&TWBGK7@'_#_KQ2W8M
M%N7!7.<;0IN-:?GAIP-&M!2OCW?7U\T)$PUBG;P#\];J3$+!K/V.AA<BW70;
M_5OTX<WM$;T:1BOSOF1_:XV%0V3K!'AL)DLH?##F>,D[VJW:I,%!,69X]0U5
M\Y/?W;BQQ ?D_?@,7W0!0P\4J&AGL_@\#U:$P<$VERFV \&<3A=_X!D)@(LD
MI!KLVD<>9B+??]C9XH8 8W)JQC;:7=R<4L'G).AWFYH_0>_D>=3.5;P[JE?Q
MIK86K!#29L%>Z:]Q%9KC6=% 49',[&&7$+G5Y=ZG5.3+I<*U+TPA4AV9O^SM
MCQ97K?::>+''V[=D_JRC&=P='+&%>RD9O<-+T'^<&D7-9ZTI*A]^H@;9%5AY
M)CCZ&>3=+5D*]:PV3:Y]O<D#->GTI-9J. L:ZW=%/I_/@C<?(UL$V26VY[T/
M;C#TB_-K,K+3*0Q4\R^)VO_"NE'O8P!S&GX*WSF$WJ'H@1D@8U'Y08CCS^4U
M"%B,8EW'<'GWM5BCRZ29@3S&]HX1AZH(S<MH/1#Q!96CV#6T/* ?!GIZ>>L9
M(PVP,/_Q-MN0%>/'\-!CE[[8,:9K?!,_=.1_S'+*[?&]FZ"ZP&XC&2467UZE
M#9;<MQ58G>KQJ;[=H)\VTN!7\JB"WO"ZBYH^$N\U0<GV/.*7M[\F[R_U_35_
M_&C.2$F)^#-,@[%!Y@]F)0-BALTDZ-4=O,;F0QD#MAQ:;N0?/92$AA9&AK#I
M>9+7V=FSXY0#=%MAV"+2M97)> )(J"F8[9775(,*H$A%>%-Y+2&Z!2FTS$*H
MS2'7MVT>OSC<C(,+_KF(WA+WU)(H.]X4%SJ>B;'#:0#3HH#A!(>$WU2YT;$B
M W3W<1=#LZC/;>OH5%KV?$2M1/P"^$#^3!3S1)S4I4+Z\1IR1HE7$\YII"T!
MW7,(C6BM[ZT-G3-"Y:P0H"#&W^A!VQJ^].&<PDR\^4_!PI2U9&WR_+A]NIU7
MI]OD!PIH5B';7R3QYR8HH+#\1# .FL=[-7I)8>\.]$WVE$WO;0?@K/Y%3XF$
M)4 6*<S!BV^^<;3"0\ !CF:*<#_=M1'[C5UM.^ZP"/NE<Y3WQN&F_"/<B7SR
M@HM%UV\QKB''N#<XNQP\F1VK\^YOQR37)$MO?4L](][HM*"K"W\KM].WO6M?
M=8:O=;J)ZS&DZ&L)/5B.?.'I0SWVIK*N*FXH*^KXZ5+34&93FZ_K850.<N8>
M_^LINJINCU85Z!O[E)#QV_@^78D<=^K'_%%5[IHS,.E))03<%ZR@%TO.4FB?
M8*[S2LC^+(*ND1(BVW52O.4\6 N0)/\J(=DP(.$1$6!)(N3W9&:J?.<H<WA&
M0[0\BD6:R%REAW&!BDG%6U4_W^R!,Z,XFVCI<25$!6T7THO./ANWPT5**(MR
M4SCT1NBLA(+^8*F$'*U70JZO*B'T:<9(QE?GS4G?2F\5AJ1[V97M(SY].,=K
MO-I:6OSQ5OY4]'O%_L3L:]V83"7DJ64V4=)#\++KD?]VDX*SEU?<)M]PGWC=
MT,\/CO>"S4^X[@SFD)JR=OK^M$GW:^\B2HIZI^BO@&8XHQP_2\4L$9XH@N["
M6@KH-/YF"F/=I"IT;$2H/*0V'B;;"P;78F]/BM"]Z S'VZHM;) H-CL%2(H>
M@J%\-B\H0Y+N'R1>7,U8/I$6[K,ZG[I^*NV_A]H9S$;2R(MS0*M";0%H[4+J
M(0Y@+87DHK8B&"Y@!*$5XP3MMCWR<HV4NR77 ;D!5$*$VU+&AV2GQ$H(*WTS
MWX4VB#=>F+MVM5TVKH1@*L_0:"-V9L^KT[RO@*E@X_*5YZ$.B<?N>H=B<0@8
MU">Y:9P2FDAV*S2R%UF7QHTU[.^N.N;F?_>#08^=]][H8]V'5:NGM4IFC[]R
MVY'I7T(^[O&PYU#>U9*ZX3SO9[=U%&JEJG%^IT)-G!(R\1>^#[9VG[X!C1D7
M$F4[I!(!>$WJB>\G07\@X#80*B3?5.Q6L FM\,^%P(BP:J"H&;<!FBWS:)K&
MG1B7;=G< "SY 6@VTCABOL*0J]# /G,KYQBA,QT"'[\8G'5"5=Y(P9 5XV-"
MX!_ZYGW/H"99[%^?8&](G<#SX4;_X+S5ZBJSXG1KU=L^%J/*$O-;?7B9<?Y-
MNGZEOP22D:FZ5F^.9 HEB7?#"HJ_5)Y2#?'Q4_\7KE2UB#W2T_@AI 8A:B";
M1^+P"V@1QX85IC'(A$HV?@_@W@W+YQNH,%9WN*US2ZCXZ!-AD7XL<C-=0R2_
MUHW?,KB,A,Z7\Y20(F?W!['X;8.X#J^$R(BG'6/V'6D#&$H.8>8!Z6LA']P/
ME]^!+J*5D$98;YMFW'!Z**(;Z,VYY!PNH$"Q%$_:N*T]4^=3*BHG:1*M T:R
M&6IB"VHV]0*F(602)'95'QE.@AI@O<YG3W\\MH+9!E).#^$\[O%;>DH?Q3I=
M;XA-CM[^8>\R[)2L(6;'#\3\VLLNFJR56(#'1=[1@E[.TJ2^Y!P8+(:R2!-\
MX"]00^B^N 4H?JFP'V12EYM,4CP4$P S5Q9>OU"!ECP@-L:VOZF2+!@@)NOC
MCCH5TBJC4S#V1-8/F^9@K\C;6-#;#?^OS08QE$W@(8$BK(:@=U$-*.XUM1]G
M/K5O6DP)4O0 S&SG\,;X"K(D@E@_G_JF5F)LJ.#4QX[S"@=*HV,3[0EE3#V&
MMH*+T)$W$RX1]+ HB2/8+R:^1!O@58492)Q!F<A.@+E2\]A0N_J:.?13U.<A
MH#B8VCZ,M\./(#5P"0_F*S"%>'WLHQXLG&ZI6<^I.QJ:34I/BT_;E8?;!WI)
MSX&MDL?R6\[!0N9;O@C>M;1.9JHZ!E1H>4N6(M816G[^N_%3Q>7<1OPK=%MO
M=_@^[K@'Z"$](_,5/ZMOC(MP &L%)PQV/P'N<LLDQ1'S1EF+I2TEMX\BALEM
M[R7PVQ+)75Y8YPN"/T<Q_"^A#4^6YX?-5X\72]T7SDIP=^G3XV^E&CS%$IS:
MN;:,O"1+%+NKM(L53]D8@IWE&*5D?V&8@0/>8-K,/Q1.3[(28ABO-TX+O4B\
MQ 7._'4^HO="XBZ=:2JU.-PX7N<J'-/<\L5R&'<"X'<[4?*3%S5. ^[9#@,[
MIEP:P*60X:376US'DOO?FL&B1YW#'DYT)=QHF'+1G/EZ>2677''L2_:K]0/?
M9)-2+\5_CC+;>CH2FA;X.K*P&9!^")"&J4I45CYZ:X_D,(@2;J<*3:#L)K&C
M_PO%B!:V1O3S*-UP)D1V0O#]4EO=2-00E9A^<<[YY\$YIBZ(DFP R2VX<#$\
M1Q:\I;M3QP=X\X02M^:>Z^RKXJGI_8_!R185NZP6(/:\0G),MKB G,1FG!O
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MCI*$< Y2&ULL^7-(YBXZT;*AVU3_!7>1OD'J(4.#*8([=O;(=6!:=[5V:_5
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MB1YR\RF-L/-3V"*OFVUM*'"_?M?)J]Y!YNWMPR*JN)-,;+--"QV61<?/%!F
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M^!8.0P$*\7[6.!2.W0K=\.I_JO^C)?#8<%USLY>=S5#=>&6>S/&VF<EOO=S
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M5O"+$VDGM+/(F\C@7LNO^")!\1W&V8F-&IK030YA,S$J2)5#2:(;0Y2VR5]
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MT#ZL#=X%+?(7.2%,7;:,=%[SA*;3<FN#:33]1?'\7_Z-'EF;!"MOE5N2>GW
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MO$]+G/(->5BK$F +8E>,*)^U4+I&)4)_8-Z)Y$D=8*\@V"^>1H(^^A9C/R,
MMV)&'<<CE"7H1XSU&&HDE#*^(_)2V-D'"]>3JYB,;[\3D:LOP8UPQ>&S_(,A
M*ZJARN(T!#[+39+$J#6ES/BDQ*C#BA%/^N]*N<.--SO5)R4Z(BY#?BI!;20*
MVPI40$;L$J &+0H]VV#LNSJ&/!1Y6BC%$X-%IZOA]^\-*STGC)9Y'MG9!47^
M@CQ_<D^T?U"D;'?B;[=Q]00(Z[9VN$$<8D[VVN;0\"LQI1+J$]\&/H)KED<8
M91<P?Y@42LWBIQ_(25"+W&%E>[#G:N*;@S:=CA'[RSMM)@P&_$N>#*>RS8-\
M1W<Y]#@S#89GQSPH0RR1O"HGIQV((]3C%YHYB\A-T#0Y/OM?-"2'/Y<?\/T8
M'QUG@)'ZLAS5T85DB,.=TZXO!LPMSI6ZX\OQ%TO]!6&$[G43=H$^OL'?ZER?
M_48^"K2V,[[=P<H@^; (T21#H-#;;2%'I("&\5*"022'"A0C.?R2']#ZKT#0
M^)\:BF^T)QZEI*U<WMNV/S;49"QUI]+V#J#R>D'R 1O-C[?93'NZ6J?1>'"!
M[$)S(SP>-]?W@#'U@( @^TL@F8Z"/G$QR9A?8#G1"1:24?FIIFWK.PLNMP,;
MH/8S=>\78"G2%GIC?U ];NN7L32>RF7EIO3"ZS*QSL5/W-Q8.9ODNR/,&$N(
MS/XEXGTX($MN):/YRPEU^<9'WAE@QJ0%\^_#+=!6S^K[?T2K6B.N$XQ IU/7
MR?[P_(.=VOOJ%HP=:FY)FZE*']Y97U<?KWN#6)1L<$34#;3N!3YFD6X@"Y")
M:(&A3?R?&:4,:'>DZ+Y&$N*H>X5(O,Z3X '#5FZ/SJG.Z8"CV8<'RSM(^+[#
M;0<>(#'OI@J^UMQ+&C>ML;&9NN+?T-_]3;AGW$Y\MZ"[<-7=2M%MVKI&T=$*
M]>]\2(<01;2#+T'=K$>/&G-]DT5!4T"\MZD$%>=?VC5-D'47G1LJ?4]6_]+$
M<WJ::&[/#7Q%(DSMW)-?.!LU7!QMF:^52CIL&)$ZZQCHX=7ST7@81A+A7XI2
M.D"XNQ'-1<9AR)(5NT-!+6;FER;?MI M\[ R!' M=G^95$X&E*#S:'F$Y5EE
M\U'VGQ-_8QE4F76\)[:IZW;DDM/\J7Y-%@79T?ZAUX>!5GM+0RAO"L_+!Z4Z
M+7>P++?YR3=D/VVO^" Z+D8@.)2%#?<R:UM=3JR74>6@4[K:"*E7YH%MAF5U
M!!Y5AN@ZW1YUE=T:63;1RI4Y^+5MXO$W"J09\C(D!D##RO,X);+2%\9&DAX
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M6&7C^<P"O2&J>;Y,Q+HG[ \KUVJZ"8YMUV'TSNNUG4[,P568L$\34WDT:R7
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M]:4#4Z.,] +I.GY",KP-9EMJ@I_3#-"IA)\BS"QT0D;;.;CX@:/O%^C&(DM
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M#<B[DQSF8'_4?O?"#C,M$83,60?X6 P/_)T=]TA02'K\6'<U&8$O))M_A16
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ME4/*[2P+T7_2=^^)4V9B?FH%PB++QHG'F*MZ3XO#C(K6#U!B@*E"0N-,AM"
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MA+K='=R8)V</[^^=:N.MZU9^AH/D9+.)0FO84VXI=*(;(D<>"O>/V0\DZ*"
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MGTDGV^RB6= &AOF"L*UR<68D6+TPQI9)TJT+<@UNSW5E%F]DGN^>0<RK8D*
M1FLQL]3ED=M[9U1;$,VV!7)@-)BXR#U-?(HT%?@KQ#3\2YW>DX@*NF/IYH!.
M.9G7XV^IZ&MHZT?A?6>A>KXY]P2H"( YC^ M-\CKX8[6)MO<;#<=1RW\)T:[
M%OQ0+K?U)$.?*VJI[@([H^>#V& %W6C"NGQ\?CI/C4/.:JKGE&A5IJ8"(%92
M.;Y]W. :N.O-0GMN#5'Z/8&OLX>QP[&D'R#Z= X4)#-@)N S21::0B )S&OC
M\%?3W)8J=)B[L:U"" JBP?EV[ G%J]JY&6OX^?+ZYI&R0<I;K]ZI%ZJ9:4?(
M1I4)G4V'O-^@T=.)E+6?$ LHI4"XJ+<:2!)CERGHZ1R6C447\1XU>V%*8'<0
MO@%V-GCJV'/RGD\I"3D%HC.<>>L!@ON]*=**T-.<@00U\3EN"ZS+))81#@TK
MY+EWYQQ=*<N! V!N)I*DL+WHC \8>-K+=98YVWTC#<ZY]<[&^GJ?[3?)>' A
M*>'R[(C-^ZE;:[/%P]%_;HU#F<'- IY1WT4Q]H+<RTRP<&J!PYC=D.A,#ZSK
MO7Q)S V2VSH)2%:]]R<7HB[$:NBBA:],F69[/[Z(7AW31&-=>7E^M-5&NX76
MPVIT%Z&'JQ2^G&FV&C,*D$$7II1XAW0 CH.J.G!&C?!AWGYHS0N9LW< ?)6>
M"/[;UVZ'@;:S:JD$*5ET8C;73MO-7ZFUAXW?#"_JB2BW/<I3@0@991U1FFL1
M56C0]GS=YY0"$K.K5UN8O'5P42^*GXMN)"#QFOM:=YH 9Z'S+#'DH6:%0RO+
M+ ;G!-K?(=ET:ZUC0M;%T,P@EU3H,"8;YS@ 8!QN Y1*:JA(3LP8COA4R/L3
MVB(Y+@;V)#[Y(J##1*S]@H:\F_:.7'?EEGH_XI6R3O">T OXRZ>8.MU]K =9
M6P-K:"83$E,W&WH#W*8U0O9#K&S@1!F"!E=RY%6=22*Q=B68EGSVMY6EM>31
M+HI7?YG_#5W"5>%,:9UXU-(^W@[2II<M!3(& S"74]91\<?%B'.TG!FW58Z_
MRY*5WTH,\]:NRZ$+"U$96#<V=<Q88T&TAM^?!V=N)^R83:&?@2PS$VJV_C@P
M<[F5<JEE?QVM:62A?PQF08.RCIM((M@GI>D0Z!1(;,</F_G!.='@SHX@4%M7
M$P+GDN"4QQ/#G$S@0=W=D1/-3> _&9P+<BO$ZUGL@KVJH21XLB^ZSR8%<[KY
M.<Q4Z4/ERN82*O^\AH6/4=N@-[Z7HAG^5*;.*EM=QEI!-X[?164W#3)).I*C
M"_J@L8+'R&X8*J?."(?_5^S5?0DVE,T8P>$J6E_].&PC3UE)4*(/B]WP#W#K
MJ$X*-++^ACSI#F\3$+&HE]9Q M;C[:_C=>/0U/LF^P2_40T$9T/.!^&,>[76
M4Y(U0!1MG[:3Q2F?5D.Q@K4QY/7 A<? $<@R%;@JH]BT@X3'YX\^A@UD_!F_
M!V4?OUCC'I8,N;V+'G9Y&%D6LK^D@CS)84:4A_K$7J$TI) FYT_WUQXQ??RZ
M/Y$PTJQ^F_1I;/3\^1.[:O7[_%JN]2R,S!!FOD0'_6]&F:[V 4[##\"1LP/\
MG_$6D]J#$'FZ0TT<H3JHJD#W6X@[/0FR].U!W,NI+,)@O1/:*#9D=4A'[F.0
MG5V+F$-.(K()HO^,2FE'6_$L)]P+44)V9@AVS*7G:T,^[1,:]/<UDXUGU//3
MR75E+1=J@4OP*,CZ2:</^,S&3JED+6(#KKEUHY)$C=>%4V$\PK*)]OAG/OWB
MP&5,?7.7.=5&L.26;:<L2=8#V$BI)C&QRUC'3;;TZ3-J^Y@Q*W&U;M%(F KY
M#TC(@&MZ ZB@2D3[ON W3 .6U1-UHWPA:[@>V %Y<5HIPS[M:$.$R*9.G82#
MH,!S8,O7NG(80\[P^0,N]/4^W[+R00/=7D)YP*\AUN C<C-9ZVE.@ 'HD$O;
M!Z_E;02.B9=ZK3!#P:%N(%!F_^I%#Q NM]47VNU.;:5YW-5)D'6#<O>TV1:4
MW)9U$_N?U':>?@-T"F<*Q>(S$\).C)3!$]"(S&=Z .P@PYU0<YN8IP^'RT+Y
M:T*H>6WS*H\&;=%C3C9"+('QQU[WYQU[WL]V3OB>J+E!:.#V/VVTL+YDB:)7
MG _Y&/KI?-MH+,D%9&?,H59'XS;IM,:3F&*W06(&=G/Y9%-14?IX%O=8DT6+
M//YQU-G!?3XN%55TP4$=]L3>%G3^\MJ#E%Y%ROS;PA*#EAZK4_LCH3I^^@/P
M \MNJ7>_E?-7 BN8K0N= PWL.]P]X,,V' KB9\U$6 ]F(+'J(PB.U3ZVFY[%
M?XG)22":P'52?!;@^.@3X KW@*&*:NWF7H @ZPQLU]HY@O?6!=$(0;WO&^:^
M1VDCO\P(=9; 7<91TJLGR>MPFZ@=BJ#6KF&*(&0(/ S?:$VR=M=IZB%6&'RB
M=BI9<@NQ6SCZUT+GY[N+>A9:<_C=OXHVO!DVK/H\FZG=#NRS=J7(8FTI,OZM
M73R$;0>O!?%O^'5\89B9C"S,Q!Z*E#D;UJ()?8"W@K41UM1'N5@!.0:'!WB;
M8*9H^.N?,ML?Q)XI-@+:AE1_7QMAR(J<C+S2X)'0T'2<B3I0.THWU!D&RJJA
MF*E8-G >^N4U=!%URP-]D[;NK92_EMJ@=28A[OU:IX^P2QQ>I/4 [7(Q3 S7
MK%Q808U_PP+SAJC"#NM\CBQW#370ES> ];GXD\EH 8*?TR0Y:)[@=L?8N1;(
M^=-%:G?@;#>P51TU(3%::C=[%/S\FD)_&A8*[&Z!QO(>Q^(V]W)]*ZEF[=H-
MO>.0R5^XS:!/!A*BM8(&.*E(](WPFLGBU="*QJSK)9^^CR-F/@H?)09B2,^G
MJHI! R;638'1YZ=A]U$4&&O8H1UM A"AE?\2EU$I9Z&;$.HV$BLE,Y*<Y?AE
M\+M%O6 0DXF]NF2Y6T&.?'MYB:^<PJBAE'9=+8N6.&K;)76<-M0P)0BD* ^J
M ZA5 5#5Q' =<!A.DL>A1>YV-DWUD)?R*W.I 4.?Z@S\&J2+BJV@2Y(7[NVY
MZ<4[^J:Y86HW((*R-L>AO7BM>B4[26&FJ6-/\NMQ.R%*.F+R:-+.$6)EUI.-
MJ)23.?;]#3.FDV<+C^6%;[S_=$_#@&;V>:CWY\YMOXKL?KR4?R1'WW/GO2LC
MSF'SBWH.S?RYE+=<@MP6(\!MA RRY]ZZZ/S1GB<QO,T#G^M?M/1_?=([&VHX
MYWR8$.?NRVGN3S3.5#J715V^['R%<N5_QBMJN'UO-\;!Y>JSM%Y)X[&*ZV"S
MZK4F%?%;U-O(CPB+%=B9M(#$VXB)[#@2)EO48VH=&R$?T4,B&O9L'UZQU-G+
M#(A]42 O_5V'D Z@CUR2!ER0SF30C9#@<FJJ"&_MS+B%&3G34J!JUC0B$5"L
MPF1F^H;:[1#$\!E +"'<B(!L@PT"Q3,R,D.[!7[R#K/,5\%<J@/7I=T"49AS
M3WMP#G#0R3^ 4)PI7 IRCO?@#B".<#A$/@H&,:<MO+;/MY$?HU]BIAO*M)TT
M\\%?N'G'"N1D$:$Y+E+>-BC\CD3*Z*F\31"-E5C%S-U(U9=>J9$7);VAKVR@
MH/>7XIFT;='\-?6C6X0BTL&!Q+# @(=G]T3/[]&K,4_Z1>([JT%+)D:F[IW0
MNW?ZGF'@G=L^WO4/_OOEU^-=AWW<O@TJ\>KCL+<J #[CWC:S$8[OH.T$E>5,
M+$IV8]1)QLFHQ8;+_WL1RLU.Z$*=GQ+S-CR_%[,@+I(1;*:ZUL>*0TQJ*]AO
M'W]9R.J930G07*@KZ.;M0@) 1BLQ8VP_7*-XG^.',J3J"Q;FF7/?'G])YF0U
M=.BHZNE8;#);Y<-PM?'4Q 9S&;[/FYLLDA-__[9J4Z'<W[S>K,OR'\ET(.2M
M^@TN4A\%_.!;94*Y&>@N9R";>;NA<@'Q+LF+*_[*6QX=,I_:X)4DHXC(']5R
M=Z$2TT$VH&$!:WA^?2\)9OW(:,.M'^!MH/*/#+I^=ZM2>]HZ")\9NK18*O[1
M7'<>WK.H=X&82VZTS,)'&4L,$/]^;BS$EXZ+,&N 0_"M<H1$9B2O)R]/"-N)
M-XT.Z6HEVFH_2- X.RI!IZ=1P'60H7 7TLU"HP?I*[EQE;'\>DL!V0XF_/2Z
M?XZ\GNKDSQ*MU78'64DQ#-)R.%C6(T-G:$W!^5M<EZ:N+.R/Q78@KR"Z) J*
M)>V&UI3KG%*,Z81JCW?L\H6NS(:BP"#NO^%'8IN'_EQK6HF)_-$]Z27IUM'U
M/VU::G#T_W9]6]3+Y%O@-@";>B^[2;+YIEPK4'%T(-&XQN'4 $!9:MWD02NI
M'*+2ST,1XC_#DZK#A@\E/1/*6*MA9ECL#CM"7NF7PB*YZ$)=T3W]T+;B@R#Y
M9DT"4V(#UPF+3>L@@ZP$],JH()*].$&S3G(.2LIF*WH1-UG.WKAC\C%/Y0UR
M?^E=H4]O7"%!>4PI'NLUC-@<^\U;$7E':T:3#%.8--V<%CN Y2)BEJ1N)M/M
M(! ./E08I-$VP>%2?H<D@[?S.10IF,G"&S=TF<:24-H/$%XW_1O>-%4GHW6"
MD-%(\W@!NHMRC6&#MG^#8SU6YR^0L[1><)\Z !Y1J<7V\&;0^PT-#8_(CFO1
M"*4>8K1Z><H-A*,.,DE;G,^9@034&F05/"+'KP=.<I;*+$;KT-X%<M9Q_5;U
M$9U-5L[<HD?3;Y%M$S1[;>CZU.S)CC?)9:4+ONKMVE9Z'7\:\Q3.;2-MX$%K
MJN0C4W0K"=PGE^@&9S,Y_$ Q@=LZJ.0&R@D3ES$-3A3&V)HF\590ISS'X0(Y
M?14U7!!$-YNCKXP:<X-S7#ARSS/]%XV&$C]/-!97T2=,M4+R2W(&;SGLBT14
M1]'-%?!CN?-68;%)(CPG)S-X'G"J[F$REN"AQ/:+#H!P&Z+''&%*16RQE=@5
MLPPFMP]K\Q[#XO&@?AU0O1<N<"WQZ]PBQ99JLR.=FD9^;&>\]+R*MP)VK@$\
M(8[2($F*7P^_]],4N>WX^I6WD]HG/-R[8$RV!O;W*>=R<*CUD]H?PHS;:*YY
M4N17M 40 <ZG 6=*8,O3O6YQ/WP.S770B97?Z:V'W2A#= '-$TX!2X2#01)S
M8NM6:*5"'O:A5'8 V ,&>L-Y57"!#"T@9Z^CA@:G$$42B[C+6G>AK&A?V[#!
M3<!&<9!K+@L[17TO"O&KM0<';W/CQ\G/%_6F"574.A'=%!]-'%Z&7*_6_6YS
M)![\)L??HFT$?H9\WN1FCVT6=P@IJP%'L=80^15BW^49>#^#5U*R[7Z 4G+;
MO&QD@W=Q5O!]FZX-@#Z$%BKUY6E-->.,7;-A&XP3"\@MRH4XCF] 5/O2^1-:
M)[W^0P6$;Z,WL#K89K'X-=PP>0<XFL^I@"V)X->;^,LLHXF%-75QLAE3;;>=
MM7C6T.P,!S1IF&$42#M$]#6(L^8W+88N\+K*IIIUT(U=^283'IY3_&J)+>X@
M<%#S%\\J=JG]M^/DMPF<>7=IK^L76=^T2V(.743:!KF\")=UK8(]!84FV2>>
M45/;QG9#^RM*X7AAB/V=N*O/)A=RJ@]FF^V"DI57R6NU&V$S^?Q-)!@4RI/2
M$\@; 3PD9M!E? N8*-H?G5(RU>12:ICQ]=V_H^"O[X[<.W\8"@O^U&'RSU]@
M6.OJGMM7OLZ\C1ZBO]%6TW'X1GX'_HZ$$U;PAK@<V0B[0<9^\!DYGID\D][0
M8C0NH&WJY4>Q&?1ZAU9ZIIT]' OAQLB98^MT^ +JRWAU8$9?4#>6(AO=*K<H
M41!OT^N)-W^&9Z1T2UC26B(\:TW/YOOA+U(^&@OP+WF,LLFQ_04R?EMNCH?'
ME#4^G>8XP3>8Q1A,HHUI-C&UD1Q8AQ;GQ(ED.^"G;JWI%_<DZYH.!G:S')VE
MW?$2_*>Q[KJ,;US.0-9&/*(&'EOP5)$U+ "OW@6L 7W>8%;!C# (DX;;V%$S
M05O+@YQYJ6LXD;+8KK63"^VW'L>XX^QZ74-3KNB<)*DD[LDG:GE@PRL(SXQ\
M42 :VZ7#]74Q364E\3/U^LG!<;21[]]I]-^^\956ZE.POBI:MQ#3Y]#F$[Q=
M4 &3MQDN LS *IF[L,C]E%@GAP.AVQ,>!9E79M$K)T+$=;*6%7Z_R6HL0R 7
M?NU2"7<;D,VH=][^[:=!-R4.7Y>UJ+<2'VVHW4=O]>7AM5W[:2M MZ>LNL%<
MW.H1(!"V451U9?#7(>PUR"Y8)GUFV9;,[V@>)9SKIIGKO$)^2RT5?1J.@)I5
M5QL@AYM:>YAX!&*\H3#YR[2;X+SVW9,%8Y::&4VY3D/C4_F-!JUT2\  _D?V
M!W)"2K<8^6%;>F\?&>0UQ[RTM6S'H<2K PF/=, _N->FQN%TQD'3C%=]<S9Q
MWC[\_OJ1+C\X7N:9NPS!Z:SIU[DAQ#]1*C& 8P6#./NF7E<TZA/U-AWU19Q\
MJNGO851ZPBA:Z+&M\.&PFPX?[7H31LW\]MEXN;2+WVWX^<?HD;@YR>PW;4-+
M09?D)6/Z-REKB-&J^NVU;GY%Z)S"VIR(IT" I@2#0\.!0KPY#]/QE+@7IB*'
M(-QOL>Y97))V8\^B7MVLK>=IB),%!,MKCO6=;!S ^LO)IM2[4P%B"NXRO%2G
M&]V-X?I"6Z7TZ4$9VX+:IUB3$POACX))(D+7LE%JN;2L 3*0GA_;P-,\TKTL
M!(VB/B1"Y2*R+C:KL%9RXYI?\ 9#T3QK,"@'2"H/1;:FRMNSY%,Y 5Z6<]8\
MW^Y%O?#<-)ZII@;Q5H=3[8806PBMXYX;70RZ14*+#0&<5UF*/OL2A05:6RCC
MM?/8;U=K)G NW34)RTHD,32K@80+"E]' !^GH#;(I"Q#VQWF8LX@9VZD3VN$
M+!V-6ZHS<0!+A/YCZZ!*TSRZ[*J#FH-0YWC._Z#QZ9&E@R<<TBZ0T3YR8U'/
M-.?DN]EHB4U$'AF<F59>E=\X@-L!;(-/0)ZR4SH(Q1G"<VX/^6DL\]FN-!)&
MVP:AOP:U\^^BC?"76!EC9DT#]9YS=3JI;X1L@MU AHS!F'V+G%%T6<<TUH50
M,;(@P8PAL\5@J4/?Z/:OA'.41 R*&BC$;>QIL(TEBUU1J[\T991&SIZACG=(
M;M*-Z-&2--YNV!ZJ$N07[X9O*&)7U TDO!T+#1UQ:KY>PNW%'I)I0@:>] /X
MI8)NOX9,X6P@B[RK<95?DMN*RDHNQ)N(5O6O^#J@4FH2O[U&%O5H_5IGN$,7
M66>X5.T8A3?!;1P]JO9$?%[TXS8!>Z#M)>!(>P!<]::@\-I]W91W9='<)PN2
M?U_4TT,BI6$&[18T%_@JE*H*A?:_*/-6Z)XT3"6T+>H9X79-C>V'RF_'8=W4
MCFH[;;N=D28?V%KJ6\%)YVU#KN4)]Q>OAPJ4AE=!]8_=M&UPE= C/J3(H-6:
M<>=22I(<GXE82IN=3)R$O+7D++PI;A/<I5W;A8*OH<WAKK807GZ3B/\C8@9'
MHEMST]"K>6M;Y38SYB/ /M ] S".E'L1CX,?;M&K/L+D$PT]U5>^)I!UFL$.
MK"W8&A(L8%WL3O#=YW?KIVT6+V[&3\SJY\6,N$C&-4#N3=X!>NN/6FMD#\QQ
MF(9DNARNDENVVQ01A6C4HEY]PJB'.>P-3BF"VG*-IW3.VP <4;C?4?!3DH1)
M$G._[,@T&"_ >32#K(ROEY$@12S>Y(MU;=:S&'*NY.7\- &2J%IAF4ZR9\'"
M%(?6?J;B;-4%R/H$S9C*.@G.=.1@3O6Z(!@YV@3&RS#M$M.Q\XA+#^ K&T++
M),H]4HGI!-YN42^2G=-8$$+. K8L!+7G+H_![>VAQ^.V+=7@,*1MUCF]Y?18
MJO(I6-Z!OBT9"?&@-GOW(I[Q5Q5=>K$\.VA-UE4IVLJ%\S3F=JR)Q[C(/82=
M@?B4TG^!WPO:QT76/@SNH?(HVE[H%U:5)N+'F;BF&@KE]?5D+:,PJLE @!F2
MR"XW)674HY<!&^"#8(>P2=RP_4^9<JLWZ'Y39XMR=CK-F,*,0.MK#^+*HPJW
M%\2B5?D-5>>?FAYM82<:ET=?*CR+'-?HU F%;DKKY]=AVE$&VK_1J[CDE$<-
M+&$G2M[":$>EH=?/>45V+)WWCV8ZU>R3X>_@+*E).F]7#1S3X5L&;M?$K_##
MTXV0JB2\'/&%PR-D:IN'DK3&P@XF%E-Y3KNH]WY]O,^V?<?N"W=B ]IV[OKM
M_<;L,XK?-I@G)-J';3"/V&9Z: LO4%. #^]*Q[] 6%:N_-OW.F5=#(DE;ANG
M[0#.^E 93!L1DE'<HW29QN$PM*(@E;W+]2'1E"YPJRQ:)YCQ!3\W5TU9!Z5N
MRL:CJ%LD0JUYXXMNY;+M#92@$C*M7(1_7H"887QA7\H3X$=8LX8!H7]*!QP4
MZ RZ(6T'< !.DBLIJA2H]L]'\+7VP;8^*C(&"X3^FD?3]35H D@6T9GT51?A
M,!F=J92R5R''(,N;':+_SK',)R6QV@%)8Y* -63FTUT+7'T*CW?@=D%^#Q44
M4VJDC"%H01\?U&Z:(JV%+SQ"F2,!4/U9TB8(E8[U*M-E6$?&J61^=N)HDJC0
MM]+K<][C:/PP;\=@O8EQX,(P+TC#UF&R3GVC&\L%H;GI.AAN^.:J\1MIPZ.0
MN/ +)6-PB8R5ZRJZ%Z7=#?YW,$$3>/QUOGE^'/X\J'I='D.SA HR9A(IAC#'
M9P#QK)JT!J2DKS/CFJU@GX(O8 T[:(V\U)="OM _%E)2<;;1+,-R**EUYDXC
M&H7;'0H'"?%&7$H\I1:VF))G#2#^X/A1F%])G3G4U(V](/7RD1%S:&9 BJ8
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MC$#R".%Z^/7H%7-C?WH-E+;5>SRX/=2B*MH%<OTEP64ET<^BE4E1TR[.8JU
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MEGN]A&@*)3A=+-8W=+0/N%V3*]3X;<CN?P3^831E=@ ;YN:W]_6_!R^NWWF
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M^=(_M+LA1B;6398['*EZ*:Y'&TL:\E]# 5U:HS[UKW1!>?UQFF4LWI+-ED&
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MC!K^IDE'SCG>LHZ,>DV0K#T7[#O=EV!\G;M,-X /OST9FVBRS<UD"9N2[M8
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M63-KS7H_O&OFW+4_G7///L_>Y^S][%O._YPO 6[H:^MI Z@N40%\+R[ ^2Q
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M 49>1!^J0^-+3+<^JCT>D@"P&6G];PI(,J1,=(51=\N =KL'H!SIE"E ZW^
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MX?K#CLKYA5\B$W)FV3PR4VE@M@%"]X+-&].7[#J*E3;OH)T3;]DHR*01AO2
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M1I_<DM$@)MZH?QQE;CRY^V1L JPG?[@_E0XFG .,+@A4-JG=O)J$F^0IX.%
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M%MX?H$[P7G2-;&5UO4.H?QFG-W)W-BOG^EMZZ913_]3WE0L31OEU(]GBXK<
ML6&_W%]9AG5CJJ..Q!O-'.TG,E0TXW-X^.4AWXLM,C[PJ^B$SIKI!* \-.1
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MGEEC=G;P&' \][<OM'0W?=0-95]T8*,6AWZE"_0N\(2W+SH9E-G<7)1WB1&
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MTH(@R: Y'PMD^R5@.F\Q>UL0F_UY[@$!@3- +6;!%]8/!ZFT?J&GU?=X+G)
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MS1FGV0UU?8\!: 9)T[TFR]+UHYHLU;^*EO\GYK^T(MVRW6J@_O)$NKON.R&
M^XC\DM" $Z:XLO!RB7YZ]$3.OQ]E'@.F0(=;0!G=Q=0$9R*!,@=LCUA$:TXG
M$8QPE4>)PD$AJIHSRU2&F^4Q0)WJ9VOS.0-A91=V#/C"3HD%+IC?)PIT:,2<
M9"XTC77BX__,$JU TLL-,/%SS<IN GL?)N_?KVZU)3AB,K&V7:Y-[-(,HP1
M2EI_T"E^#)"Y?:1<C'^,AU"W<6'W=T$R01O9L"+G$BW!@S#$0RH7\#^RJ_(A
MLALM,HK/JS/>)2T;G.@$N+,=L?26L'96!8B;<'@[6348PEZR8C<4:\J2<$G;
M4SNL)G\GV.2<MX72@Y4$GP_LH4G$HLU11-MGU#$@WSNL%@T^W*[\8VFWNV,9
MU#W#13N_NPUM-MIB9; UTH*@&#1[E#JL:GWV3'Q;@";G!&RO*^X\!9E"DD!=
M$7%ZK<6Q*76%-35A3Y$*M1M,H@MN-,*%Z,[,)73Q=%;6$XQXYXM8P6*^KF6M
M298O)[S.N=6?KESM7<*F-^FA<X.:]8!>MEFW78Y'?##FY.8,9LJR?,#$(A+I
M8Y'N-2M73Q(NB5;L3SJ+?;$F<B/>*+=6S4#;/*(/NI.)MJK_:I:B$C#WZQ<;
M0.@<78J$W( < TX;4\H#D">H%D_SL:#SH'XD&8^[T:\0)SNHO/5?"<$V6?K^
MY4H%903_ ^->X5JKHEWUUL+;8@L8&!P$S<J/UA2B]-O^V:KM%S;7_8-$5KBC
MZC)]O\F\3/+UMA,,':S[-=V[[$CZXX3Y:/3?[O1F8%CC.I@[T,DC*?][WPM7
MI09&["SL(*EKH#D-.T/H*C*JCI"(OJ5ICW;^U$0RSJM&9>M.:=093EK.8, 2
M(PONO=C^&5CY+@A[E&)D94N>75E?H7.NGY@[%+@3R&X-M>/0E L$D:,HU]3O
M3%'T%TQCT:/TU]C*M XM+T@%X:[C^Y9<@4)(2K]"A4VT-F@+B,TF/R4:;3K.
MRYZG&/4H9]35V7*3\F/HT)+F=QVY^AT-N2VE3LBZ1WW\FP474SI8(HI;E(\!
M$3=#9?+G=38DYH"7; )'VQ&7W67\+NJ8YW?"SZ:L&;';#'S377GLEK>CLN(R
M_BF\WEN;K1<YJ2#V-NV<=Z!PCQ!YW5RAJH*\'#"U*_-"6F!&<1+ZPH6-/*Q&
MP*0?A"DS8$._MK&R##8@L9^<0"F'DE@[$9SJ8<6!P?NAZBT*E !(.;YW'L$G
M&_VAIZ1HN0!_UNU/]ZY8^P3/;M/(2+0D*#.5<;:(IM1!PFE34%]=!?Y%S1LH
MFQ%78K=:N*9ZKQ'SBA:,V" ]>G_\XB.AR32:&K_,M:EE[M1!_P^\;<BI,DFW
MO?'RX* @CV+:S/?5#*VB%K/)EBSH'[HO!7$,8+$_RF4(,\;\@;7IR67K(VV?
M*9ETV#PB>G=(/M#\'BGDOC22/%YX9NG+)ZMIZ^[+K9>#?GME'3VBI!80:@*Y
M>I2Y( VAN\> =L&%>X[I([.Z@<-(N4R1.SV?A8,OC:_N=].UC@$I88OY-"ZZ
M_C&@&(HU0TNY;Z34-=":ZG"D/2NV\KK9K8.-[2H\8G:H)XER=8?EZ"-#;-Z4
MZ>@+0RSJW*DW7Z%")QZ.?S/NJ![9B:1<8Z=GY7<FT500[^RH2NT8F&LT]S,M
MP/]?TUZUB+@D1TU@H'8R-F-HHH&LY#Z*;@"QH&=WYJ]5KK[!I((-PM#)P.C>
MI$)\5.,H"L2K*^JA=/ZCKG^&Z>OPQU=SPNRUI#>VZR;V,2O?I&7=6W)/0(%]
MFOZ!<A)%+$D4$Z+)_(FA56>?MP-2)@1SP3T(8AZEI]-K[8H9%9F$XFU)I^K#
MW"VV.L)R"_,<SPJ/FSW@T=$K)UHQV)B( ?/ S8N.).I!CZT*Z6@H6G8_UV1^
M.RK4I@R_EN4<X;$_H[L/G=J;VO9P+_H0W^OH8G:/EQLA<_L; (A4,)DX:&R9
M#&Y\ 7*MG8(Y-5B8#9<W>A2LX\=V$/%9,IFR'>!W ?*0+)_!66:2%R2O;U:7
M'_-=D;D^LT#LPSU :LYKC!1B+L*5E<Y%:[, G  O7;\5 #A3XO4&L K:SUB8
MI*=@WMF1KP5BC@'/CAY@;AP#YB+R=Y*V68X!?WL6/(Y4IXUMD#4C1_6O,2?C
M?6HNI:G!);^\\4AQ'PQQ^=]4+?Y'*PG(ES'IYN7WZ1%=\D L22Z;YGM<W='[
MCI5+/-+V-D*.%DE(<$\';$+KJFIM/4J6! F'AU J<&63YCDDA$!A>E@_-*23
MGET-,KE\'_U$*/:7Z"IT&8&ZA]_Y0UUZZ.D9!AZGD8] >TF,<[HG.BE*+&G#
M4&Z6)#( $'P-/CI4Y_3[K8PCU()5/&^'04C)E*'3S]S<U]-?%UDEF(5!&\"8
MEKL4D\7<2_WF=10K(F%VC:_8 1TSX()]/!XG]WZ*S=A0VTAO.^N+K6&9'W<1
M1 \TA;[BD..7TIQ+X\-:UGW]FH7:PNM4IEC.$"I;=HG0S0_.@CCP?GMH\.X.
M_,3#:S(%L0F^53)Z^BJ_3H>^2T7<9<2]H[A_9B(FM7KKYG#"@(G!P&S"^NC;
MN*\C@:<+KX,C6YB&_'B]A1;?XMX2?O4L6NBOE<D$5*7,>(_2#_?VW2?#ZKPB
MEV&O8%)X-<O"O/[^<H)#>LEN!_GO_:MJRAJ/Y!<ET'*):1+8+\> O*3>(6I\
M0I+'/J(/\^7$$47!$WB-(N',*=H>,]=?Z-GD[/#$O!H#(MKK_J$HD)(7V0-&
M\T9OKCNUQC$[R\Z^2C/*^."UYBF7,YEM+M\/45..A[ENZB7F'UIM;?F.MBY(
MBDW6M&2%8#?=LS61C>/ 03!VGM#\G56L WR"BFM48\%&GXF'HV^7C!(1FWD^
M>?D/[?Z<^5(>R-7KXTS,:-6_"I]([/L<<>^76.K;7XO"VA<]"&!BA.T#I&P[
MF*FVC2>?UWLN@7H)L$C8^_<]/2BMJY#11*75?H/4'0-:&G9:T+B:8<>?:3"(
MS6%_DY]_S?K.J($,G"D0W)V5%!ZJ51)8<*^9IEE>W*A8L0F3CY1]OU3^J,\;
MP"^:")J1/@9 \?&\(GS-Q,KH&N'<JH**H:H9ZRZ' /T0+_6,.RH)N-,Z=_0H
MR9Z+JBQ.&(@6NB,%63//^J:Z*6'J-^M58IBJ$+S)+U$#/+^6@VDW8CKC(,6-
MU3,-_+6=D(S;(QCO;A1/?/3:5(3>?>[?Y(Y)K,A%V<&[I#!</%M]63N&^K[(
MD+61E@Q+OW5$=R_&#1DW8D/PL5KCY?6RJ/6QQ5H2O'0\*FVTW,F]?J62EC?S
M?*,RF?6$F]=K$%C&8,\\O@,80]7,_M:<%-GDRE CZ<U8#EPPI^;DNYB-[I$$
MOBNQ#G)NGN?;?3[/:D)%!,F^D4X3 [.IG^[UO++AO?R)DXDUL76_Q_;NZ_J+
MT$[XA9JWH4 V]5-"#5]+_A:J2K6%#3T<&E4GNC!F^Q 9 I,-E1N>M%)MNY-T
M4)@"-[-]+W7F%FI[Q,!VH ^VSG,%2H!(N$],V=@P? /7R01*\@)02'_!Z%PO
M:U2MUJ2L7[_-F>ZNS_KQV>NG1ZL<QOBEDXM3K/RP3XJ&'ER"MJ/L$EONC#&N
MXT*?9C_=:3)R=)_POU-96Y5>5\3/R:(=\\I4^ZJ<L>%]%45JZ@(X5D1@1*NO
MBXB9WS"^%YYLD/.&_G?U[$K*XU91C/5D/Q7=TVS8OA:R2#P&M/88)J[B!%\5
M(WOKZT0=NG+?Y#7^M#72&^&?,#L,LD\RD'&931>9U!4OZY0@TO>&U5BJZ28&
M]4^7T[/NQM<$W\2%N6\'M*R\>0$_F3O<E8KG-7058_-";OK%OGZA,'R=#S7U
MJ"&E 54.8LN]?RW\6>)I?2C-,M0U_NGD=E6HX[>UVY2X"1"H&?PT,:12DP\V
MHE)I.3CBDG?^Q=4XL43E")5/,I[:053)8P Y/,_F.C1>-D:$!9WVY)J#/F#@
M;!OG9:7;CAG;7&\WM(*<XXX!$ ^.U70OZXXY_"GM0&_MK+.O$G*G8K]=G+X0
M$BQ2%A1]IL:,^H]\\.T/Q =KC-ZF-EMMY38M%%_A,%K,50NI#!E70%4*[E0E
M.6TTX$WZX3<8PW URH^"A_/;G#:XGI(;Y6?0?CR)V60/]-I$W>OV\[0"#QA'
MBLOFL^L7.HF?R9711V5P\5S6=NH=_%\IQF44ZONHXI?"1]B?HY7BG%VO#XI'
M-S6?O6[K_9BAX_#R^:;J0W(K:2B;7$A,>E/TXU/2ON5K]=OH!S]W+C0.WM$5
M#!(N;QG%0#6@OW:W0B_.Z3Z_038;+6#ZWO2]TYY9:.Z#IYIY@5Z>2$F'U /S
M!%2)UHON:21E<,+&_-^@N4!RJJ'O;"+HQ:9$76FSXEXCWCZ?Q+X)(:EU*I\;
M0CB_<JNSK*R!D 6L_<G(&XVN;OM0=!S(8E'YRH<<]2C]%18EG4L([-!"#IE<
M-QE<A,):6 7:XHQV?><L!T*![K!:Y=BCU)BZ^)^B_IJO'P_ IRRF0F^/PUGI
M/*09Y(DT5?U8%!;?VB__ I&E6B_TW0IV=GFZ80%[RJX9\=T,") \=0PX%\IR
M3_IGMJI\^*J.>IC:PI<*=;<,M-Y%E*MOEJZ?$19I4PNK?/;,U"8K1S5MFV3C
MVE094N1A8!:SR!J%<$7$,G@R.N]8V4W-GO#7P[*NJCYT@^L3*<5?UU/X%-5D
ME8890^I0J9]R;KW>/5F[&$&Z%<FY4UJ^@VH7A](>NTH<"WA&2( MF;^3V;[1
M\I&?]_) YLJ'A!_8VZQ\/5LT ^+2\DN*ZMP+'#!D(Q4V*S>6HC*D0<)720):
M3L<9*2$B9P&"X:9H*UT+I.U?]02.B+"PBTYEKSS<W;3P,E6YLC7]'H?!C>*H
M5,NT#:B:]IT8\R:T?S,^KW)F:V-H!6=*DBFH['(\@RR;7>. I$=TMZLE^UW'
M3GUQLK W,V-Z7B^IL3[*10ZGQ&(N^GI$#@?&N= %Y[<OLW-#_$]A[Y&I9?HL
MI#[QVX=1]NFS$HEWEB\C^PI4D=-'2CVM&5*#QX"S32P_[-6Q>F=45?C!^7L5
M-!PRYKS\BZE0(>*U9-T7$E:WXD"72E."$W.\)K,6*[,<QZY(Z]H+#(?4KKJ.
M&FEM5NWKTILV:J//->6.E7853>8-4C4L&VUJ:;;.BX,8FAW=C,2=93V)'0DK
M>#(BN_=*><HF:POW+.I5 R3M<UO \U]NG(5+0CO>KTZFA"0.,A%L@XYMB@]A
M97=Y72WYI[IN^:;63TDC]<2@MO6L(_]QU'8,]2YO$T5GCKM?4AOS.D/F]SU3
MYBK=.0?[Z7.-17:4,_^P0>Z:W'2PN07\#_.+7^JU5^^4AT]'"R5..Q=Y(=R7
MI6OG$U,:C@$9*NY6755FV[$-K@?;(9"BP?R-:;?G'L8IP][KIC>RWW]M[E?(
M=V\.8>BL@5&8SL;^*45!_0'YQXWYCPU$UL*4==!U66NG\T"ITIVD%SIB->K#
MH Q_I_5!.6MDERQ6M,>.3TI*X1C YPKREA:C/:HIO%,^,UT!?YSG:,'MW&<Q
M%IX<-2AOA_(_!A C%9/S%N=UWIQ]^L)2[9;^;2G_;R(_>VRG",;B^(Z,^HAA
M^&7*1=P&03U!:FGZ_&,3Z(65DEVAL2%P'P1+[&GL=?TV7Y&%RAT/DYK.@M\_
MRHY''14)NAVM9=%EL-U4G"FJ,JP*H1ZQQGP,D,[6(''3\SUFJ)X^?XYNTDPQ
M=+)7OD7)H@BF<?O$AO>OM@#O54K2KQ,Y.T6G(Z?Z=[X+O=VZ?7>O2N+91"@7
MY-P3. ?E(D?OJ6?VUPAX%M\>Y#&@(O3AQV/ C9='MUX= RR/_'8M71[TRTG;
MZ$6,;&V%0(J'&&P43O=-4F<*5P[[C%'O,0 3=I/V_(+_88K/,>")L_K;'*\K
MZG[4R<UE3 (=Y'7QWU 4G"FV0SZV"'H+<*@/^)R<],G^LSH#HT+I6(AY1W^G
M$\,0H?".+(#>7?X^&G[TUQ]W\-6]]&U>H/IBI;7/=)GKFFIT1@/9 KY>=XT<
M#/TCFK;@=!A$[-VN*).H]@BDHW3^%=@\[!8.9\V?MO8]Z8\]TMK'0/GI5ILS
M2[#54.HH(S,GA",/105ZD) V\?H6R!8@1<CU$2SD;?'1!#.2 [8H#&]!+<W>
M.BJD>\W/;:ESS;V[[A:[DJ2?$,7\(>BMD-?D=X+-1WFAED8]N>X;5+W<TWZ^
MM<< %P3\/?[?;N6;3F-8GZ\MMFM@SXH6A]W&?/VQ8Y?/P3=+&0J4D>\.9JR7
M%#-M&EQYNL.L(IW\F^M-B? NWV(.7.0OTN?'T0^Z\X6YV4#9UDFSWZUL!:.B
MA\K.T:<X(MC:")3)^D [\J>&"<Y;CD1P!RT*@>&"S%L),S9>OATEX(J"N1F5
MRBY]#1[0[A3SEG>,_?W]YD0=0R_SC!K_W;3]:ESZ$;@X"8N@*(]H(6* _+_$
MDBCZ;O=NJ%[F5%C=C5B[H]&%T.8Y9#\Q<Q](&N@X.%]@.P-X:=46Z%79BN1]
MQQ2M:C05+6![Q6?.TS!P<01C*PFM7=,T%?L(Z1Y!'6&]DJ9@4.@6A'LA)0VY
M' (MP_>N_^..^4(5L&1_F-A<SI'#GI3:OA.HU@E:_/8RO]VHV$8&<['36]^=
M^N*IC%G@PM'B-4,^68DZ5AZZ(?P/\#3\5""07$>I661_@_^!;T=B>^:!79CS
MLR[P\Z.^LOPNM@*-%(^%D-YKZ&R:OCY)-G;#X\;.-N<_6A@*(SD?X,X'GC8L
M*290QZ,F,LNLVA#%^&[R9'J '-NU^HC[[ZZERW>(1MQGC9 ?K40( =&3;YKL
M%Q#8R47S5N34%7( 17E^4VW>*,I=W68!(0#1O$;<[D#P6]F)\1ZDGD6BU#K3
MEX*4S_BFWZS+/-6MZ<8LJ9167PEW2D.E5#=X%*5M4#7\_D+">D$M<0,W#\:;
M!?1-_;[B#HX!##9^FCI=^R@3_#H_^AAP@7'S[RI5]EUE0?XS#W87]*FUH8ZZ
M@(%_.,(I@KO,UY\AIK_N/%1/_BX*%3(G=-]?];'K+Z%?;B0?409(O+ K9 =*
MOX.?K\@%HRN!H&YE3<EJDB%:,0FW5?MO%-4?KYUBW0YS=$AW?&^1=GX"\TW-
M\_/E2UY_]U>$@S0SZ5#=6<*4I:[>W48LO5$Q3 !J<[#VR):PE0_"F8VDYY4B
M[W1Q/S-^:BY(NL+0/4A$;!B19!F92&AUE?*"+#UU6^C$_.8OV!W)VXX$U[8@
M_&KI <RD7<;9AR>244(290P"%\P9[[\C<99TO6- Q.5C0&\I_?$QH":&DG8,
M*' #D2<B*U(V$;__QU+=_]VB4^N#V%"K>0\V7"4^3EWW,\5[O*9NT69\0^&3
ME;"_;ICZV<Z #B]+$]XS!M5,.?22U%\O3\VMJ+:IK)"0RT.,\\S$@C;@N5#8
MO.P[O!"*':M,3LI89$W M]NQMYP)O4TJVDHK<9%1./1 XRBN%\'/LBC5.#T!
MBZ=,S>%"QC!04&U: [I:P!RCK]6_E-48EF)X "X!7PK$M<W>CAV:!_,$!G1^
MEXR&^ I##<>3GY,RE)2YHO@74R?C"#OL#]@7[=I9-]IH]T//43QHS^B:Q)5(
MNBC-'MX7\"<0;T#<?E>[?86"M!Y3YY&>&1]O4FIPCE6_ZZLF*XFE+@1N?F[X
MF:5B"3%G^6"&:5C%B^O=_>Z85-IV]>ME'9/=,RP']%+L<#SV0!<RK-52B9LU
M<Y^<\:NMFTAOP;EM86=Q( ]"B,#S9UK,ZL> A58@L;Q%3.0D+X4'_H0#_PI$
MP0T0;:?!R\!9MF/ CZ1.#-7G)W+"+AZXHP\70_R-6=@^NNW*<ZAXH@G<QX"/
MB$ )1C>8\QA &%PH"C5:.;RG'Q3,B#TJ^AHG^3^+4!;!+<U?75RKH5F#&856
MO]I>A1F2L;UBGDS71/X]'A_2X$ZYI/+O?3 (L]X;-8(WS!]'T=[W@6+L8H\!
M['\CC80"];0O:#XGG?DXD).,/N_;XZ7!/9^DPLI7-7B+TS<Q,-<A^M&+Z[XO
M>Z_?C38W,WX(NG7ZL=CEP ,-7_%>"<=*K#FALODNF, YK,7-_;]6OWB,'3N<
MUZ:#+^P@F!G!I@V5:C?5?'9Y5+83'[.N;T[&&1S-V)!1^8M0,.A=>2TMR(XA
M.$G2.7SY7R5?X!C0M6G/.)=*PK5A+E5*5'_7K06CU^[Z(EYS9@PKH*5#2J?#
MW<K*_BY8_#)E_J:X?X7.&;^@="(]/J&:).6X M(E3(ED9F5%%N3:]U_6A9,^
M_-+;8OV7#0H3ZMU5SK2LG<R-5G@;7(8R27,Z852G;.1 "1;*"4FY7T!PF-()
M)1+,/(&;0='+/V,_BG7BSE\LY(@C;?\M)PLBIMK)",[ &.,KV.6_6&FI75CA
M5/']4X+:,A<*V?.TO-DE^!2'SXX;*I449EOCQ+ U"!\""OG'H.N%C;(CK.$;
MKFH3BT?X[!MB7\A\E;H?H0A62+DMTYDC])(:=C?O4[F7\&]29[M* 4O3UIV3
M"'%^\WC.7Z.FMV(U?H9%ZL)3IE_,+B]9D9Y>0]9+227*BW9\$%O./]NH9COC
M'R,*TG=FS1N:&]-58 OM'[A\$^-&ZEFN#FYV N3;2+M2SSV)OO.@>K'<K. I
M*J'!PWS8W?_5[=W*FVW:)N[0]-LMFX5?ZYJRJ^-:<,+/)F$5-](?Z3JG/?_H
M:SSXNUF)7OB^\^6%"Y<8><(D^X7$RH+5T;6 $[=5>X%;!U3VNXMB)FGX8&XQ
M32A/[1P]G7*BNZ<?UA#)!9IIQ%V3T=^WU7^$-6?*%"87B$DE1SK>K.RU_<G7
MI@'=C>\"U@5TY<<)--FYDJ(VQPL/OBNDETK%IA0\*1.UB$]Y[ES,;N2N>=TB
M+DU"'+*#)M6.61J$2@<8Z6_"*N!1X?/6'M5^Y=VWK1/AO7V:P^).5:DC.+U;
M:AXE1FN"K0+CC%+G$MT [NKSWR:V(_SYEEXSJ>X-JET(9K(SA-0-8W$=UY?8
MR*0$&&N.0]+]48V0/.@R^U3M^A5-9J)3T;?/#38/.]*K>V^QU!K5P@F-;W>B
MATI7$EDG&T*]#8H?BEX3L=HY^]+KCQ=.=:BD61P>GXFS"JT;12)2-1$\NL85
M8^;U _W0W1==A:-A?C:-UW95I"72FVYVV(\YK]-[ZJ :_S[>CS&ICVT;XE.W
M%_-K(_P-<4)_B7JERUT.5' 0XM154>FQV\U"?IN2U[J "("*HEDEO"/*A^I7
MPO$_>3A3UX4K<'@;X50T774P"V=66X,V]6C\NC^SYI75,NHD+@EX%ZW-UL,J
M416R@EX?BG'-,/>H4'MR;Y3;(UYU*(?ODF?@5C!S*])O_&J:U09"GE7H)BN+
M<X379G+^LR'FO"N=#'8UYG9KC]C&)>$O0\L)7D.4X=]9(YLJ:R/88P!8:;:E
M<L]8=_V_KX!;TNT2R9/[FB\FW#?WC^QMHZE&,Q85<!,9."SEPJG'W3K"5-]%
MQ9W\1'5]CU>%4&5ED1=U,<:-D2>NB7974W50%92'H(Z3P?'J=]05B_#XN^%^
MW]0PG_Y.U=HG=3*'XQ+3#F5IEJ'WZHBR;_;'$7EA>@]>/5K>]:0Y9MV^T^.B
M%BV?]V:A\?:.B>^>^Y;<L-JZ8S$F!%XQ^QX,$]=/*U7;/X#Q",_6[>AM'N8=
MS7OP0;"):1?B[\0[/$V^F]MNX7#U8ZI@M2A04N3V)?F<K'^:5ZV:LJ2VN2K(
MTID<U T^"<"E0 D^1N#* F9J<L&T&/-UBO#=E2C=:S&Y<>"#S):]UY>^M7X]
MS^O7"K(HK ?J0:8I?\\5=$M.7M;TU+1VO,\<+<:1L+]N.RA0G7#H4/'E1IV^
MH0/:QG=SHD<$?%$%I+"096;6D-[7BW)OAL&QTX<":C@<:/A&FN_SGAN$2HLD
MF9=,I^^YG\7EW;FDPP-,:+F.LPBT,L^,)]S-\1\Y--9)"Q<'U?*_5DW1LD]Y
MI*.>Z)-LKAY08'3B7PW<$9ZZ=UI;0PNYV@#VK#DB!:6K/M:LL0HVX.Z&YU3-
MLA$MJ5@ST.HEX2!Q_=NLZG,B.7Z+)7]-])Z:O*WV';'U,$"MHO0FQ]?2DIAV
M;VDZI*/'$:!$FA_=HP%/=:6$D.Y,&ORWSZ_]+]2 WA1*V*K]NO_/!,6F.ULC
ME=,\NK%^@RHS20]M8UY]@Z"_=_@)M]9?8IKO*+WX]_12ZN3H7_/=W1.Q4*7T
M+("G&N<\Z%S]'521HC IGT"A*X\E7.Q_7E[UKQ)9CNF_JJ&79Z1(#M@0ICV<
MIEL0B[-EBM0-?&&+L\S13,/<EZ]H^$RV:!;(&;)U&ZR+C>HV6WJ;6_G6X&TC
MC$-[L2376WLV@G7OJ8=XL[2AL8G&% ?'" X/SE.7[DT;.0GO&#UAI$GGR%5G
M%A^F*[%$ ]40#6QK06MGYQ+E+4J#Q#O$O(HW3C0B(W$%V+^>]8O4DTB7)TZV
M9^7'JYN46DUA(;=UO=0SN'K.<<8]?A]0O92<R*2^DF0G*M\59GM.NEMZM0)E
M]<(N  '.Q+]M'^LRB[PUZN.=(9E@U81T?[^:EHLWDK;<E)5)2)9G%8#E/#RR
M_V[V,6\I[VU.WI%/XK3_ET7@N=4Z95F?2LBV;]D2$@OK<#@5:#RW\G9(E&^Q
M&)'K@35GG%M4JBG%4T):U[T;GESANH<V<R,IQ#5^5/[4Q+,8H3+D%4=Y!X9Y
M<$%'*C+,L149!U(O:\.1PDU#M:'AF0#^JTHZGCKW<0MRIC]\2A'.,E8MVI,V
M C QO%4C0RW_\YR*F1_/VL(MDQ3(75=#XP0[F<TI&X(#<DIM^TC6DOX834E=
MC!Q6H.V\'%FF&?1UKBM_^O"A/Q_D^2Q*=9I)]==B'#5. 74W;+/]QG+6U$N(
MJ04GQZFYA)"7.7ZL278]=I0;E26QBC#[+DU04T/C';O[W/)=I3VW[M_2$80M
M9;C.I=S'&JKT(G$VIUK/Z_*2>%XQQ5]?M'<N;1.*7D\,7KHPJ2"T*:X<X!C
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MD/@RQ9;U<L)R&;]SF@F5*(@WTJI<X["((DLZ;T(QAY+RNB=ZGA)3;6W^]OW
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MZ-4[Q9Q)U>#A"(F0!W<DDWBR$_HD"T)7-\ "X>P8^10,] ()V:/Z^RGDW'!
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M"-XWWB?DC?A-7]$<,.Y/965[$OCWXI^LFX"!]3/'8[VHIH1:GY:#[&_D+),
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M<2P2-O8R$X)TB*.T)#J39I J^%#K_UXK"=*'#E"G483_[S<RMV T/Q8]7DL
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MG"L!":#LCP;,=W00KZ1:C&0^G144YHQ/MTX43[]AI(-H*S<?<_Z4._71@F_
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MT]ZU;%]E_,PV-6S!V1@T;SI7"N?W?4K!48I!TG) L\8Z+O"O2T9LCTJOA'G
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M@6WG&0!7L23(WFH ^!N4#Z'#3S7<V T_WUO"'/DWWA=E=OS_.V\K-.PPO<D
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M5,&?[Y/Y/EEF?IYUC[76.EMHH%-X!F3N5$*5)G8VMH42@$G<[]4,NTV@X=F
MA+@?G:N"V-W>Z!2FD$8TN-L)7>)*A"J7$NQYFQ#&4L3??_/RUY.XYM15F."7
M1"J?Q,'^PW4=3<.E77$0&TF.T/ZA<>V>-"4[GI0>64$3#I^^T.'QQFQP'.+0
M6^GKAH\/;1SU%4VQ N);?.W'H>U/LF+-VW/FURG^';38LD2,0H;?IQT(AIVH
M5/^H2.W6??)<D8[O#X'1H/TUZ=\D=^(YA !^GYLU/-<Q*J'&6;EBJB14ZX)O
M:TVG2!Y9'=)E#O<W[.<@XM[P)#1UQ7)8_MYE ,1O@$0"H,;,O/CX/5I[Z<D2
M;$_6<QTKT5,$MY?O16]4?LJ5*WBF,2J2WL!,L.<063.*F+U"^(J,0%,3>'-_
M @*]'3'!^R,FS<1E9+S%& <VK<8_*9KWV#.J#M?M:5Q@[6#'$4D0FRP?.;Y<
MS\NU;X<XCGAORW[AE[Z#?M4E18"=[R!XI/YR>428;#SK_DKVJBS[,_U;-$-J
M2ZPL ] ] 41_<K%+H0NQ6E[W _"H);1)I403FQ[])O)_%A#?U%QD9<IM3H,O
MNT \.6O59ZLPW.P/7=G5A:ZSJ_=CV55&'=?&$ V?5W;-Q)(/SR7W/"XM\43(
MM:+/1P^!\QV]C4<N\0NTJ @[3:Y$'<W)C[=,+?AXQW8XAH,0_DI:10)$P M#
M?6RY:?;SV >*L\%:JWQ_==$, ._[;H57*B-6 #.HJH%9B=?JQ:[M?5@OT\J/
MFS(==-R-'21V#@F_G80>9=<,2GUDJ2O7?S!PL74\@R3M3^7ET(=@8EU>I$:/
M,@ G/5[<\PR\^6WA;[B^X+)=Q;[ \...5*TG<T6^W8.3M13$=4^\!QT;$SM\
MZ/\;AA^,^LJG'5&/?.<?L5Y8#WYN@'\QSTM\V?4<1>?Q?=8K*&N$7#YU@Z.+
M'+"]WU4-!A/4TK=L+O&_5"G=E31O\]I9]L4^-&%I>CY0<(H: B9))U)Y3RHP
M\U%..J''3.@.>N%DA/?MHP[/,=576L\<X0$68B1I")67J[B5&M-NUW],%<(>
MKG6IDW[!E^L$(&@G2V/T<@8I5U2ISD0%LX1G,+U?U)P47_29PW:4C\^7^3 ^
M'\RZHTWA9&-37FV8P_PP+NIS;(L321B1W::*PQ2&=_D5&V3ND5__+0G:M\R.
M3XU,/?QV4ADL:E+LG5<<K@MFR5N9_*E4;B9DVY3SR08Q?_;%B,&#.ZQEL4Q7
MU8V$HS\>N[E @,OWF+YA.K<7:C]%'45V+H VM=,R6JQ4HP(*K/X=8&5,ZT@F
MFQ!W8N)J3FH)HVL$))>3XXM9<C4DL9)9H$8P46;6<X&:%AYEDS,1#=8+S:.D
M'SI0*7\A,V]E?WS?E]^KRS>%43F7<8VY!NO5, (#T%?GE7N/9.NHQC,#>W\"
MJDA;*C745]UGJ>D7RU7*9'\>_?AQ\B\2L(=G5'U.LMRL\+9U5_=9X.OG)V*B
M L#O&0#"'FR&%K= /,#$];%WS7.MGV!W/J_UT%6+>)^9=8!G" 4,P,^C]Z(:
M_SK5%=&IT<D,XU*\J+&PM/-@0M4;3=\CJDN&J>T1=Q0<YRR[E07I+,P=RIN<
M'JB?"=TF[].N0#%-Z>>M37!:5Q99.,#7+PL]+1>^0XZ?MEL%%GE=(7!G8,8_
M9RF<]$'G_UCJ.PA>U.5^;XQ=DLI$L&#C-(9C_: D:0,\)9(:]9[BT=7!J8[[
M??'\Q0H@9FVA:9ZIYYQ;T9&0G\+H6B6$&=,S4R OF0-]K@N1RP!DEG/O,0#O
M2!T;D /AD#!D.S/3'H3L+L:H9I&W& "QSJ,3HYC#'LXIF(T_*^FCRD"KG@?2
M+\ZIO\MQ:U]\2W MTC9O0XQ=1[QVZD,TSV*$9%US2 2DMEH0&M0JI3[ 8B@"
M1;2=A70]@/L_"]31[#]SLI\ ?IZX\YN\'CFN1F72P\'>HT32^G!V=FN7"X?&
M]@+3MVT<)3?3!$CC-Y;IR'X=F;G'BE[3 \%=<C&WY(SI\Y]A3[68DW)E<J:5
M[,P V.*IK@3PHMQLF$T-%4AT1JRUK76-^]G;W+ZC+AP%$YU"!)H&W KKXD[R
M<>5-P(PF8<.N>)B7.#WGT^=D^1ZH'S"SK#S)] /0V'FW53H_=#C53X>#8"(2
M)K;#BB/]<:6?"CF*. ,5000:,0#)8ET"JW\]']H0*,K$;Q:-'F^J5!JE^)<9
M@ <Z<.0$ ^ W[D-2X87!50<':5&5VTM;:5]T.**-FY+UP"SAI96I%?2^YGYV
M=8$I%#QTOW^E&6^+!O4,?,@#)=*O^[>_$M(;D,@>^,F]2O-Q@G29P?TO(;'O
MQ0XE2!(P9I_[N:E8XI<9^JFPHS "C-CN*+XJRD[0-]Z3848&^=CV".R)AO(]
M/VRXD=&3B#-)JO2&Y#EE_/;#<S$AOO!A=TN-$F7RER&;=[T=7R?QE% D>.V0
M?C((/<H3KHD!]CCZGUUS*$I4Z4N2*Q)HT#22<\^Y,*:_; ^0_4C,1(2K:]EN
M-<3R0KK.PKVXTZ#U!MW09"$8 B0 2X$%@\X[V.."Y--*UA:GITWX,K$[>RDR
MZDM#!5N9]JW'%,$M^^21D,Q%DH\RPBT<][LB>6A=6L7C5<&JOBE"R>QFX2V+
MV,V)[>/;+BB''VF&$\:EMK)NV2;._*,4W.<NO?_8/WT'$3!_8Q+6IH2!GO6A
MQ&:'5"UX"3G/E_B43+WE=TAM'&M+\GHZCF&KXZD)>Z1[]C3DJI@0!+T,3790
M+<06LG>!:Z1Z%$Z3L)WSTJ:<UHE]D;E)KIP(!6S#N6F[AOVJ?72K+:ANR#/[
MKI#;F3XV[G76@SQ2_"+W2RA+AW3T/0)JRGV2>@5-L[1'7M@!WOH[9X^ B14*
MN"L(LFT]&,KNE%*A!H3GTT\=9P#8?M&:8@6I.L1$?!@A'WLA_^AVN+]3UJ$+
M$=H%?U&DW-@T4?Y[OV)^!M3\ITKYM-FH!?)B5=5*IFMFBN&'W1,GRSRD?"KE
M'>=:MTNF6N5MH*;6\Q_?6OBA5N >8\H-8_:MVW-V]"Z(FW]:AR+M(YT]'+B8
MF$[G]UE@IQHLRNG,K^]VN4CDC<<8=PZQ!6YGF5R_$E=:-F20*"FO!#9I]17L
MTCJ@G(>.=WC2,AD 3R" C@2R14L133!E[U[+:EVJL)N9]@J=O_I[GYO;>^!T
M3MNS3\U(%4U'DV8C/8OH?GZY5M:&& EYDX\CO(3NFH%.FI+IE$R9.]%A1FK;
M8=3#5VCMX$*%3SN^!.[HK-K@;#WY49YE+2W#*366B>X;%DE_"A[N26DWCT#D
M]TD?CLR9?&37 '\.;YC,/Y*BJI)T/8AB/<+*7M0[D# LB)ODAGOF<PT&:&B8
M6'WE>]?Y^=U+#><,AP6L!57ZUN$$!U\E4Q(3GDZ>BQ:;D"3I?2*A?@(YHX.(
M]]8;'\]T+_!H.9>!*J:]C@WY3TLUQLNJG"QK>:W,\E'P#;_@V]FWX-VG]2@W
M6%2KAG)U3O5X.S[2J]JMH19D#3,H:YEJ>@)K'9,X?.EG_OH4QVCYHP*W]-.!
M"SP1I!AL-@-@ 4F"[ U'@9/$N.#HAB(^4OS1 Y('1@O"&>*LB49ET,6;?HZR
M1+O%W)WZ%@(73C')Q[C*O;X3=+SUCFM$4MET?HDY/&=T,ZQ73#A<S80 2E?&
M6_;."R%A3$(Y0Q1]NKT_?'-\S6_,_]164]'R5:<M)_<3@8J3A?G)D3Z#>W S
MF\-]4./7GB8/CY"5S;9Z<GE'2_2[907JV42Z*6C1@%8 [('1A!^!&QM(:4RE
MO)BK 7?G?CW>?=GD//TW_)R#QN.0K.M\9=\O83.-[,\>N$N*(N!^7@88,' X
M]5IQ\L=3Y(P#A"^\CA^A^QRRF(B*Y&( AM[N[RU']QZY>M %4[!7QYC#<%*G
MM8_V _1_+*>*EI/'/&[.%GUH?HM%JG\V&8LM(5=I0:J:1ZE4(]KUK%?BOH*K
ME Q_ FROE9/*I4 +[V8 <%_$=&* _Z_2ID+0)C-"2.4?*:[2DU^]8P!*PQKH
MR9/P=2;A5-]@ -8:8$O@4@5J3@2(EG0=LN[N^C^7/A6D?AM)U3=TUQF\<QH:
MTPHW"X<M2]$Y@4>GJ*=K2/&$RH-/A.VN*+%4!^=W/:L=M$]M4ABXJ*-GA_RD
M,F@SZDN/*NX+*7FP2\ Y7^-T4\YJ=%E/5 1L?=XD9I.*#7]H%]!]3+&O9@.E
M0AV =#UB #R@"?.\HFP$T(L][J1Y+1+FR#C:.1?[TT6LEC@/Q0R?X#ZKD+AE
MO=K:,B%G,ZP\T5"733LY4OWD4O=!A6^%/FIE)>/JNT"_V8'JRACECL+S/WBS
M<O8R9#JF9<J'PQJ:VDN18W+#8-*E[>Z+-[NQ0#PG,1%CT"4#CQ,#1#\JM\-U
M\#(9B6K_:-&?;_BK([CTT*$@I6SC5F%[V;?O;[[">!5^<'_AH\DGI7"]>*PQ
MT"_0!_FT#UM!T4^F8&+.H_MZ1M/$6+0"T*,"X?S8PU=[41<=>R)C*[!R"@A1
M$?COZA 6OK*5=U<S>9J^YZS:<'/5M77Q<YW @&%BC0P /AZS_;<;?4B53;/5
M^T&T:?CF,VWP@BJ!T;R>Q3D<U>.POQ09F^_!FR53K(\*TJ\U['XLX_?XD_<*
M?L#KNKSAE_6YF=#87=]VY\:UW+5S?A8V]07Y7O*.FE*-^97&]#"=$7[/@*[C
M[[^PI7_,"YL^<?MO!*Y_)$9Q>V:_-S8ZMDNL*>P5 ^ +>467)2IWG(>3PK#@
M5QWB[82%'N#Q]4"YX<GX+_:C(6?T>@PS0;R($<Q8,5>955"_RHI8'9,.#3!B
M>(,C+ZHE+9/.CQ/JG8F^3D!\JEJGW_PCZU>_(3PT=W-K$+&%0 CW7XZ8%,XO
M3UM-*LT(OK?D9N4]ESW1ES?3ESLPIUR]W=AHNW_7H4(%)E/G;#E5'E8)OQ>;
M1K6)6>#4D>@XR=H9*Z^N#:):4A*7P=E@PIU$#J;U4@DF9PW_K3;VE*0O$)6:
MEXX@&66QI50GHD*B7(=@M$E],_%,TO%QTOG>P8/=]<8;LQ)-B=N$*J[L;\EF
M^BP/S/39C:FUS#2'JY"9.X'@K&^EU^>O$"])BKS2_3*;^?SF20TVT?>KRE=G
M4AK3CZIS02Z5MLO(?K.-_"@<TK%Q<CY))K9\'EJ_BJ\@\!^89MP&"E+-YD7!
MYY4'2O'UK2UJIX_)] /''N;[33R+V "_@_)"T)7P.NW]CH9O).Z##T1YZ)>8
MG)'LC[IESC&OG:Y=<CUA*M"(>LKZ(?SB21C'OW..D4I4KDM6BUB'G]]'%'W8
M[U/.:$8Q50_K(;EYFX-5^-:A!C4]<K]*(Z+1P0OBK-F1L20EF3>)C]3YBL-]
M1N$FG.BUL<*0+ENX^]PU3PH\#>(%/^>->CQYX4^]<)KT\K>70Y?K*][7NT?+
M;(EMA(ON4Q*/E.A30":3^FBK@2=TN,*3J'I>F/R>[Q,%T[/3^5&)2>Y6,R&\
M]Z?T+7<24'E,7E(ZE0J5O\'^@%^C3_=WX*U#Z@8E@"EZC 28I*MSJR@_VMK[
M-D*X4'6A2'.5*%$N8M&8X6\+^>$#'S(K7G56*#<8S,(7VT*D@EOW:$^8DY%:
MN% #[GO5)4CX_"PR=6$*1<9/,7FE'KS=1'\U07\!)IA#R#=AZ33(DN7%2.85
M6B&D" ^E1NG1CR!KON ),0,PF3\ 2'NU#*>X\C[#AI71!2'XLO+_2XD=^_]]
MG9^6F %?2EJ$'IW#0O:F!@QHBXDD9L;) -RV9P#^,$'9J90!^"T$'P'33XDK
M'OG3D3H,P-EM;KKQ-(JB#*(7_^\5_\ %@OG543S\Z#X+BGZ!;Q7GZ\G- #A2
MD^EW"95TXW]'V,E7,@#EA%4TW#@%TJ/9-;=!_X[>;&4 ZEP5RC\1OZPR ##3
M-+M1/Z6!(M71AWRO(.?416*5/RZQWO,KCHJ%*W\M6;=[*'8?M7=:GU;HLI4#
MIEW:VS<I7X% _UX1JWZ(# 4[_JQ>V.4Q6:E: "G1I("N-PPVNPAVY_^%*^Y$
M[OLAXU5G@%PH9,.NV*:G;NPOX/'7&F*$.-+36 FC>O9]6+D,:;J)6 E!K<,I
M3AD'NNQTW L&X+L3D/[A);/7Q<DR$A^EJ_I]L\Z&GQW*W-@!BF7@2!-?*Y\M
MR,9QK5P'2!SU.@%B@*.\94W#L9Z@?7 1/)X> 6S"BI&>*J0_3/M(*E6%X%]$
M!U^,8@ H&TMFD [@);H*Q?PH-'887'_FQY$=U6UB#_2B0W8BN,JDY^[*('W(
MM*VYZ4="_YT5 \D'-S,+TH4%V=6W=SQI.7"O( 9 &82@1JY-QP$SFT[ ?XM>
M&-VY]FSRCEEU2,[/,JU\N1>XT9L_?SXHN/'657WPYK<R07V37',O]7JD(?&B
MQCPHRV8EM*4QUS2V/1;[,X).HB:2QD8/^Y: B/8_]$%X?1\@FI?8S,RSDE0_
MAC, G8^5S("U4+P\8+0++/P\TD/_#SONX/X!+(3(SRVW^ZO<!_<!HP7',0#O
MVYEPG.6 +R^$PTCL+X)H1#(WL02ZG=$/28N"46\VX>5/@+I PKZ=JT>BS'D'
M[FWOT;P@&&:G_."$,BT?I!:.'YL!WN=%\3S;K;/?,H?13&\4@9G0^DN[$+0<
M-;,Z\X=0]!_CI^PA\HZ-BZ XVD2FWD*U, #=,O3QDFR"(R)9VRPSEGWU(/H!
MT-U_VB[.@/G$LY&N!G\T*)"2'6V*.;WFV2&-.S"CR"MA9QL\"NY[ G2W)%\Y
MA#BCYL-MB&L0$+%4,O5--XPU@0X9V';9A+B#IUU3H\\3FU>AI*QU;2!!8+QI
ML^+()!AX/-I_1(/>!Y]!0<G!6%25R:*9J./J#UWDYHH=4'[B< ,&?7A@+=\^
M$#-\@%_O,(A3#.$R<'IIONZ$9]4VF!=;LL7#NA;BX"=A$#<DH;)G>C7^6X<\
MU8F )+7^?*=6Z]$C9%;B'U-K<BFX-M^.KW[#Z+/5^\3'W<\-V7<OP=V!TXYQ
ML9SA"Y)I'W'\5/222$Q^P=DSSPP1AHOUH$WLD<T5?-$G!N 4?%$<7@.61VS:
MKU^.LL+5GKB '3(MK3AUP^I-!(Q3&[%$[N52D56[L!P!^=[3?>&K^:\;EF\W
M'ICG"BF!SL&,K&TK3SL;SO/;/FT1V5N6DC;SS_'$RAC+#_KHT1VNUK=Z+.1Y
M;-H3( \(.<L-^"+8Y\8D#(S#NPEX-NL0I,H__:IJ\=I>X=UYPR9E(D(NR?-B
MB=ZYEG>//Z[*P=T5XIMT+G%6VKF00&:$S2+-AF2$LZU1%N2BU_SY&B5<RRQ(
MI/9>6@7^9B-6J -?\_%I,M'79?L ]Z=#&/@3%\OCG?<D03NG.O^+=Z[#A3*?
MJG4;&Z6JN7I;5.T)(ZZP4U<$TIZ1)41.D>D, !J%MWQV,/J59-G'?:6PIKY.
MK>Y^QO%OKR7"SQJ=.YLEU3\ULBPP"DMX5>D0N["A%9!CWNX]F%R6_^ K[2W.
M\H6WXX9BJKM&A1'2V[RT$'?-2*EL1,B1T\)ET[%-MCXKT'3F7H?DN&^[PL*V
MCP+3M:,U?DR4C4O]0$8K+%[D['X7EO< /@XU?UG4J;WNJ%E7;"+1ZB::F# *
MUJ^C?8@]1;JD([E^(5;X=[21*X1POH<"?_G1\<BM+<.^M@6);LHL+L*)K!L+
MW;U[M<]?L<3BV^E8ESL$L0.HN##X&&DBSOKO(Y]$%HE.]J77:2E]OTY,C/XZ
M[C-$\#B 9WEN?R:$]23)7_C[MR]X<>]EW=,33;:J=/";&:N;>Y)<;[PK'W2/
MYBIB9]N17OK?O)\H:WR5]LNH"WRKZ&T&:37/,9#W.(%,">1O3'; N.4]\RKS
M,59K(2E\ YO-/(U<W?Q$"$.OIK=)59(2%H/5E%R&B$(;79,7GLU/.<8D#P>G
MI%GB;U8-/;]K(M"TRSY0<,;,![=]+'88R)+8 V*A&C2T(/<4$N=/YEN]Z[O0
M<;FCKFB:-&TWVY&C_-NQ_\D[O -TZN$;??CZ7[0"6VSP3.PHI'ZBN"T4<J;-
MW2_C&>JF 5L83^7<S=J&+O.3<TK'K)I%7O692:]2E0[QUG+UDU(85 _'4S]^
MFO3PHX[P*X)<;/UO C_%:4@)LLZF;T83[-K,I*M$U3LQ%8NNTL:I05QRA@_*
M+++++*?NVN4<M[YK9K5Z9>O/@^R.+X-O)]01Y[H'ZLGY 5Y3@W+7C:2"2^2"
M6[UF'!?V8^BGHZ\UDY*(8(2J$/?+Z" ,**F(G=#84+RF(]I>6_]\R*XU;\?7
M9NB^X]%;G[!&7;%S-[32&\B51&X,J O.Y)WZ@R1TC*MS1R/))XS[E4K,8Q/!
M*H^6,;^&U[F+1[>+/,=-0ITUAAQ&+"4%=H1_K"@OQ(DUGGG[YB(347IE3G[J
M;U3-=2C63Q#;Z:2]?=[>Y92N+H#+C#J2I_]QR)E%H1@ ]@[Q>1>GFH@M/^5"
M?:.R-UDN!J$- Z&/C;2"D'P:X#\W*1/.+JI#&V-%' _1)>\??;)6MRC3Y79Q
M^OOU;8E#FK11RYOG(5+7C6WK+7[\.7ACGL:A-O)5F<X?(75M0]3]PK9[>[W?
M05,,47X7[?\3-NW3W0+_J;&E94\XU)]03FDW&[*U6V[,4WVEW!S/YB7@.57V
MY-E,QZ,WMV'CPM"I/O3C]05"PNR&J% 1<K&LMZE7CN/ACT:YJVERSZ>=PP-*
MSYUG2:<MO;]K#-RZ,W 1<A6(>0OW2N@B26&+>[AJQAK./6,7=/5!G$2OPOQR
MFL0VB4?.72&/(J%<.E>K#MX_EU/=]*)\RNJZ^=<D[.@Z3U]6K,OMD6?75W@&
M:ZP(,MR(<&F^[^\-7E:]KOSP<'VB=[#PZR,?JX >O;ME(@;*RRH7ELT"DR>N
M?N8K<#=O4S)_^_;3<0Z'ZPC%P@.7/<M0D[ 8R=BDZ6@A6D&T(GI4,%S! EFU
M/Z/MT6>;FYMQ>OFM+>7X[]JF&5X+T\N0CSU6AM#H;;E=4;W  W"=P<^4T=,S
M1DK0"T[AQ@R 7>.XEJ#O%]RS^?!DR7AKHUS;)"6_CX8F_XNW]XQJZOO61H,H
MJ#01$9 N(-*E=V(#! 2D-R$J("4"TGNB(M)!0$ 1R(_>B2 D2 N]"DB-A-X-
M+0DU0,K%<_[O/>>\Y]S[Y;WC?LB'/9+LO?9<<\WU/',\:T[],N_=U$RB*71J
M^;#^1XK-#H2#]#C';0T<LY;282HEU<8IWPOIO]9K?D$J\2[?_JGQ60 Z;*G^
M$;O;L8CJG ;W,G[@CI8\8!5^:5*C0[]5#Y(-\M$5TCBLLC"@9Q=E5AL@5VR(
MU_C^O#,D5U+:G?K=ND[<_?61N'G1LNEDRM'$@'5T'?2Y4J9>.3"RKZ]<9;8'
MW.6>ZA5N-4^Y3(9!K@6A%W$=.,:@".-O^*<C0:E+S'5:2:7N-_PPA1U3#@\T
M/\3X:Q;L"B(\G\4$XC 0@@9ZO6?;#K_9!F70DG6'<."9%G_\&NTP;'1EZ!'X
MUO2C.C:TW!HC6]N9VKO).2!7]J9'M1Q\J@5!E_OR+I&4B-F']2[I&Q))WS8<
MW)_VSSF-YH=_NN#&S3B8^ C[UB8D:6OXU&SCR-==#=ENS+^A]GY=WGX6&_+^
MZ"K@CC)RZIZZCHZQ5W\S(YPM8T%VKW-R60/.&EG*^"!(9IM1KJC\A3=S3:9O
MYWA6EJ.T@YM!YLD<1JQ4QNV"X9/,3^;F+K>1>=[-F4]+U6TD1#V1-5J0]=/E
MW6O_#G?@?E3 !RMRH3DCB9U0\H?.+XYB_)CV$&+\[:@8VB%.&251 5VI!!0]
M/448DT3/U4,*/>%!CT,KGJI3 0^V8%0 \V>@S ET#?Y[S;Q,,U>F_G\!GG_=
M/P!8@]R6E(6]RU'B4N$:P9V<;32:@N0T*L#-)(MTG9"W7+5]\^]A;!$J8'A=
M]Z2K [6OU7?& [$15, J!0K[%]KA8_]WS)?X[W!T1_30CEQPA7*T@(M;.D\J
MW!_H9,H!F$Z2L@XW0OS+Y"B#5 #?S8\=,AWVGF+C;PYW)40Z7^G<[[ND[?>2
MYTW_I?-\'S).>CK0-<-RZ?/DQ_BO;G#"(=I;S4)R_OM71(-VLP)FP'X?=Y2C
M^E\>NPT^E:7\VG7I)QHNQ;Q9J%4*O'K[E8N;ZZ( SY771J]]8T'$ET",X&O^
M1=&8#J=X;HDWOMB(*^O?./NZ@ =Q40C*;+_,]*G9I<GY,Y X?/+]:K%)T?&M
MBFV<-OPG0>OL&6=6N!&9^+IU_SS;1TAVLS<:YNNP 7W)CQ%V!%XD/6%@+"-_
MV/3FRPVK2'X$.^/,V]<6SA/O+74+7&E3."U:YVUO-?)M&QX;?U(?%[63.>P3
MM4HNC$C#;=I7 A=8IHP-VBWG#?8G*>ZS^[;\H[HD[AH]HADAXU=0>R<SX P1
MOPK^(WN2 S[1AJ^/42[RXWN61#N\(N>O2S5!%WFMVC-N1,56K-=$F2/3YPRB
M+=M8"[33%5289<=XV_Y(G## %^?9P".=!#2K5<=D872N&1>76:5.@?AH5GBD
M2)#Y^\)+4GS5 =A\S3#-B<MZY8H7BQ!NTV6X<3'NW&4-O\*\%L;?>S*Q(!8_
M>.P<@.#5D1U<'*=-^)#DG[=Q:XKT@](7E.O$^DC.\1D=+< ;"Q(/NTWD.N6G
M]**82<IX7Y,6HEWA])^ (Q]K9"*.I,G<&,S4-8Z^.BCDGJ+M+2?Y7>WX[:,_
M!2O>1]WT3WTW05V!I.LRA\[-$T"P<3P_>\OMH!0ID#&(01J%_]Z^O+13M[#Y
M=5#L9NV8"+ZN*JJHO^3(H_1+G:QX;O920L;.53?ELM@QF"X8[.'?$&B': 2%
M1W)B7TXCRK"V1WI^8^&*!P&ZA_+X4W,\7>7B'VG(C3FB)Q70WA8?X$LT!8OM
MOX)+(G;=5BL3Y>2_+1>_LK+S&?J@9/+QHE1W$/V84)93$A[>)T.\21_59+"(
M(HH>M7^580N/58]QK/]175<W^1+M*5E[K'1\O2$]__6%3O3(8E.'DI.X>6HO
M[<'"FY WD*:QE+KT!I_FP"FE;%S9=%_E;S!8.;"L@9(^+W3L<,:R4RB=_+7*
M7?.8J$X.%!/4A0EH-]DB-$\4:V(YU<4Z2-2-^!M_V,RM(&QDW"A,L=73;(W9
M60CU3]^847G[SD657P.+PC\&3CNVMZ@WD#/J0/33Q+'%]22(?)@4<6*)!4-3
M1Q2X7ATDTZ&6GKK$)+=NX+H:++-SP/2\Z)UE@Y5S9'\NXR-*'U[-,4E?3-MG
MM_)&8K^>>FB_ 6)0QC)M)RVV,1 ;ONT?V+]<!?>;F]Q%5)ZM:"K@'&KA"S^"
M_HSJNLZ_FZ<)TUM@TAI; +6",-?^%AV*'+[>^.HL>J1@8PHW,"&NZ2?WN_DD
M4.I6.I)(Z5,!W^_T25/#F#W*)3<\\/ M&B) <B2 $K2DL1#!!OR'VEVW%B["
M7&Z^:^A6[9>5^*JOYU^*7,BU)[ZPT3,-9C^9>NK2^02X""*N++A0KE !5_>2
M3B(<QCP*4D,D)(335O/6()Y]2G4BFZ+2E8J-4XBMNA'[8U0]Z3D5$ %54#=F
MH'1K2>$'WR/9?KOR\VH)N%F:S>F[-*5C1BJ$$G:*7RF,)1^M/N-*NH7R Q,D
M_B>-L=XLJ)D*4'X>><WD\;D69_(W*F!E2DN6"OB=5$4%8!D/]B?^IL"7_Z;
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M=?#B\C69W\,4PX@%)#G:@??,5/:5X>J@[CI4@AT%97%VG0*<8N0XS6&CM)5
ML247KIG89 M:.)E:1W2?D:6<)L>Q7$TUVASQ"6T!7CV!9_LG?*ALT3)*[=XQ
MM&V7[<\D=E::8HQVQ"\?%A-P\;5>"7-2WT;#["K= I(U2V+G)D\>"49_M;9Y
MU\U,IR><HRHTV1( BH4 &0U(=PG"VR0MA\I;-,)LK9JZ>UL2>XX4!B\JX +]
M&/ E#)/1Y<!N?,4MTY]P(ZP&H_"Q>;]_,J#-5(5_3?)TG*E85< J ]('17S(
M)^0PR8W9XY.BPP25*E\B3S378Q1^U/ZN:SSWB/)KK"#[_HS=#]UI8:>(B%J"
M_:=C<0EQ:4\Q7_TG'HTV2I-5)RC_YA"M]YCI7<QF52E&QOZJ+0X.>W PVR(9
MIJU#GD]H,DF1:ZS3&[G4P\/'PG6DNE361P M?=IB#?-:,NDVR#9])</O( N#
M0T/V$L3/7'6\,F5C[ ERW"HX5J^RR"8_T4\H3.5I68.3D_]:K?.M!Z?1*YIT
M %4-?P&^-\L:Z\W.:F*JJJ;O@Z&9/ CC-&1E=E.MY?R#1XJ5#?M&@YC^#?2T
MH<:A6CY!:,D.T;8\?%VU;\%][,*0\3^J/.%W<;9[)&UBLH>KT]>>%A&KAS-E
M_FZ)='+*C'[8<4+/:-/0VEJXFAPKVU"J:#ICW]NW'X-Y7/Y9IL4TG:U,MLHP
M^9IY,Q1"S\4_:<!M##K8:RK_\6+/^(+?6HN!?)=9L<G8^W^._?6ET<VPAG2X
M<2J)K''K>J7+(*>1E6U/6E'%9*/P&(YH?53?(AWVN/%+Y'!2V.-JR:\/3392
M!02RZ)955_8WYS4EZJN):01VQ'O"<"S+IQ_G-U*5YE;8?E$!&KX@A2!?LWJ"
M>69X]U>7PW Q(3-O_]=*=>,]0(W+K1^2SC\KY66^$"J24#"96SDN+Y'5N\#V
M,:A7.(5^;+XN2!XNIE7:^ HSIEV&2&H@A6@=,1NTM6FWO5HN<T?/'<Y1HO)%
M.V$Q')?UB;C.1<" [,2M"V]XJ[%#LED$$W@G%1!=8:E &(ZY*"=>EJ!O*9)(
M(WWOC['CL!#<,X3!E#79R$!B@64G*U%E<QO]>U+K'YTOM%^]XS[PWUI,$19@
MUTBD"][&/IG);L;*P$AJ.$3&LQ]V1+/FVE5;C_!PC08_7;,RD@EAG]XW:+/S
M])-:M;WE\U76Y%J:7RD  !_)!94([$3%6S5DG/'?2^@X@;&E=#WN&W6MON?.
M=7@:^0S1.Z:I=*L6G%L+34L,<'.:79N1YQ$T];F?F'55Y5"S7+W3U\#1Q9N<
M03L<'))W,9_KIO!Y]=[\Y EK/]J<[)($/>U9Y<*&>5TLHNP([&4>IR\6)NLV
MO560MEV&],!5?<UQ(4@LZW8. HW5"M>3PMR3 N7;"K"3)\V_7%Z<DQ@JSUK(
MGHZF7=WL 7Z=YVIZ0$ NG6_P'PBS)&84#.=MI$M!/0J)92>_YVQ$VH.C+279
MWEOV+ZRPP:#E6F*;L!<_$!]>H$.RK--OS[!Y.,6E^RJ+6"#*'5_CLM #B!SY
M,4]8IUEO%;K#KCK]$HT48W+E@ER%T\(UOUXA3@&*7:G2IWS1O(9F7"7"RB$
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MRU>>VC-R_$(E3Y^A!=W*L U#V8JS:>/>\\',%MOMNH+.II:B2%/:>F#P])K
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M0;E2GN9[9M 0+):SKT^[8&LR02FG00F!JPGT!MM/D'\W\S</<M1-;#5XC4C
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M9DK&M3?B<PJATH["%Z=5F,NB$AI]Y#1U0[H3G VNS@1; %UW<NO2JS0]P(W
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MQ>LSN(&#M<@8.7Q-#-%B=FB$';;M\XN<O^UR$J,C>T'T17",R9]9Q>_D/W
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M?:U$NB(Q.M[SFN@]Z8*<C&]U)^)'-53,G5!LPH[#9 > C4],)LQ;#?<:>P9
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M,I-[U_)/R,WAWAG(R*OQTCB)D7=R15>+^/UEX)10<D"_%D1QLN2G<:;;6N@
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MB4/HG #SE?)#^JV1ZSO\AOQ7WI5[">M;R.FLSK?.O]9DH-125=>33Q6AC[S
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MA<I"@=KS77M=MGO$$R#S7^(-;(_47]QIQ9=8[?*8OSB7RLF&RK^'/+85W ^
M$(.<0"&>^VL)]LFW7V[$*^6?ALYC%>W#<,GRA&/L2YI>=FRBH;D57$5V\L+F
MO[_\A1%^A#OA#A>LO&!=FH[43I< V<\>>.+V40%D&N*WVNU;SSCC%"OC[4VI
MUG38F],NOA)[&F[.H\"J(!>WVTUIVX<*9S%2,MEVMQRQOQ@,K];9*6_P">&3
MC2+1]AF6AO :U16@$(= 7N )7+?Y>.(")HQ:'$;1MJXOHUN;ZUDN >V:8@.[
MV956\[BAX1[2+7J<B/J?_TZKH>#\;,<W]R+S&R6WG[G[CM(Q?$Q[9"'-)6Y*
MO?OUZK4VS:F0C]?:CI<WM9HT\ \E/0>U7U?SWKX$,+%0W4.I._6R?G 7CV$B
M]*6T@0&SQRWW&,"NKKNP1B/]S8Z-GD6R3_:/NT1'=/1KS69A8PIJ)Z-.!^WV
M!"Z%J,7/"3[_8-?:+/BHB5R:V-*,I$O V]U!ZI%TFZMRE>":=TPA]AC*!>&X
M_<D\0H57RA^R_)0K>N%(.W>Q?]S\H[F3)X+J*W?DY[@'$ABA#&*7[Q!YEHR#
M9D><',2[Z-:2Z'!CKT"Z)7 \PHE4HC.;/*?FP?;ST?(E('2^>R"OU&)? 8;G
M\9!I/!XEW6H\$R"\8SQL8>^:VWQV^+5KWJ*Q H%*T5P>ODHEG>"OOPQDER5G
M>&_U>8ZWCO'V*P=22#^UFD?6V-@5QZEZO4M=UB9< K L#WE*J,,+3_OO71M(
M81(Y>>^J8:1DN\DKW,M9I3C%.-GY!73B'YDEM^?PR<2V5C(ZU]Y:3X&K)C1R
M.+;>W4=[<,9,_!+PB"&JR;YP_S<[X0/%=.Z11\L9V9D008[]-,X4GJMRKOMR
M]#UJ_6Q4+<N G6H&UL8M^Q@\TV\CUC/ONRE,$\;];JDTFN,Q:YMJW! YVX4W
M+Q-JX0>);\2N7/$BUX=\VDB!E 1Q8 ]?C]9[)'IJ$?RAZBY=>$=)K(+T HU)
MSJ.NV3ST'6 \Q8H0WRLQ[ET:*!GYR7),QZ:QRQ(KM5K=Z)II3'UN2F_2]03R
MNE<4Z['E?[8'EW6:(,M*Y]&UUR>4==M&[09X-UV\$09&UGN1OXXLL-]%N&.7
MEKDL\ZJ_=HO:%/XM#ZW=ZU?)1ZIX!2W!)\66Q,*A.WM>D',#(BOZ2V6['BND
M1^QD>#KR^^?W M#5FYU>C;Z4+%8 ':HK3YMIN_H^UF?8!/#FVVTDD>N5&?6,
MZ9]HIV[)(YGM9C3;75"'[C_AVZ-ZO7RZ^-;?28\$4YFN+S-!"R5ZY :<2/=P
MWHEIG_QWPVI]F=W5%M??29L(3'US(Y\!L+IO.8 U<!&19HS=F88-&;0>FJTC
MD5\QKI^4N/8AVX>2O-Y,3=Q=$TF&\BHQG>/%?U9U:MW2M,L%M'*9E/-P:KFV
MMU^J]K^/![UW&KKJF(&)G&A+>PP0#SM8N+N635":7^V9:Q7ED-A&HVIY4RX!
MP=<0YU]^7_UF762-[''>>Y+0];&"(>;X2UFSHC1-0%;2WLFWS;3FC&&!H5=K
M4P'2CO??3'>X;/ED&Q#Z>S05%DOG=^89)FOS\SHXH\R6>#5,)YRC!NK-3Y7!
M W3O5\(>OFME%(?K4B^A&2=63?3:G?0EGG^VGMUF;G2<3RW-@WOO>@^]0@Z7
MMDM">RY,.C&B*MD2 ]_C&V!']#GV#9#WGH^OVMH=E;J*W!4Z!^9FW#?I$M#N
M92)GK[P/*@ 9>[AL\ ,74A_M3HQ"SN5)0X>4AGMLS[_I*Y%Q7)"OQ_W9\'3N
M/3"Y"3E4HB5O">B29.F3CL#?%KR^'&IQLS+0&<#[^9Z"YOR&R9V9J9(W>(9[
M@0#5C,XEH%X 6<:]G_'?EV6VT85+NG2J1LO6'_:?-]'3341 I9MAQMQ'3MAD
M06-FN)6%6_J:?:H-ZEP[:S_W$B!0LDZZ68DK0'\</FZ,B9R_/OH1O<#P2+6?
M$*^>HAZH[]7YK(?R13 GNT]]"3MV/2;BB2M[-.QZZQ]Q$SK5UD&MF".^P\TS
M9_BT_?TXP=:A*9+E_L\'2=+7\#>#;RAR%V]OHZ.]D@J186_S>';<[BOU2&R/
M95!% P4DN9= ])> ?W;,2BYMZAA^ZZ/Q*;AN(XML=!;MQOR])5JE[GG,5)Z&
M!B$IF3=MR$A@(EFY']3W[JI%' EU]*DD<:][SW_&,G<>QGZC%A?5V_",/I4=
M!RX.S=.5#Z5> NX,+;SW;*!9LO%E;=1;WG+8@ASK>$ZXWH8G]\RP.U-_7$[8
M3%#/,WWKK\XT%:JU)686>=]I%*567V$[]]S!2!R4PA!D;YEUV[]!54HX%V)D
MH@O_6W?!TL39Q%GG1L/ Q$5-T!OPGC-/L 4]G#%*/ZFHL5K5O 2T/95])LB/
MFUYPL__A7K <[SY$_,[VG=A<J=E_E;@W(<^/?)ZEA>+4,2B6;$DI6L7,3JF2
M._X6D%1M4H9OH$O1F'[3RYC@[HK)R_O$OI3P[YB,A6PZ;1S'6EY&DY]Q_>5U
M3H@@"_(MD?1C.9K"'=%DNBP)^2A_NU=JGD(5B00C)\[ M>FL8Z0HMOO*:J<W
MN(P'BM9.X]4F$+MA4]-@HN[$>7;LP'\'8A,*I%.9EU-:XV&K:3&T*@='K8R5
M6YZDK.#_SJ^5]C*(=T1AFUHHPNC=Z-FX$N_GF9N7Q\I(].X 'UV\JZ],,F!V
MJ7_!=)MJQ:FY,CZ#33=@B+''&%(Q>G3LSZA-OW)P&F_%WB0A,3>S4+PC1392
M=PE8$L950^4KKN5#X,6:#8CRJB-2<@,\5RS0H&B%,9^Y%+X;.3)B4RKFI:*:
M7RB0K*/C"N1:N\I%G&A<&SH#PO4L&+Z,I!8A:G^C=OHW=;(CY13MH%=]57$.
M'TZ#$A5@S[P?#6]MI^!2J6]^V +UD0"!<>4!>@ZEC^BW;(F?F]B<[1S=IWGQ
M.?]!/1DC(SE;5ET%N^'P:DM2=I]\<!=Z!W=]VK%.UNSS@<-!)"Z.<#6<.B'+
M+KR>AG<VYL<V&Z'K=OM@K^APV%5]*&WA<^;N/VIVKP:J5Y?UR/3)R5S_:&WA
M&M<\D=:S9T*SQ]X)=[Z@K,HC[$<=;B?Q1NSA6C^9K[?G^L@O=JRR/<NKSF'2
MU?@.S:CJGL<FJ\E9 ,6!&X9FXJW;NR;YDFOI4$Z=ZJ&O[5L'#$BEM^N6ZA7>
M 3=ZU%J2(B@[7(:),@XT\4H5W*X-81FKOPZC3VYUOWF\3/8O*PG2'2V>!-<5
MM#U#!(3(EWN[HJ!?B5$,PVYM(3F]#JJ-@J?,EJS\4&^43[//X6$!.X'++8HK
M#6R-LK;WC5>YP_,WH,N)&!A9U%H]9/<Z8'ML_+]-!B#W(]$A@C6[[W05X--2
M_8EYI*_"9 CC>J$76]+Q.YO?!#"XKJE>XY^M0YD%2\+YJKJ_]G3\]86$#*?!
M6P- 59Q:D(/-]R<9WCF#KL'R5$H?5WR7)?XPKEN?@F1*2]A>XM*4AFA\025Z
MDMY?<[?SKSAF(4YS [E I$UT9#$<+V>V/ T^LREXNK^/V38?2K0#+B3*RM88
MC9+^L5_G8.3/)B@7#@(XET7?^:+>G:6M",(6TC&9 3N-%P4^@.E*\0[WJJ\)
M&U-5C#U%*]3=+<<P&@/0USG=%#<(SYIJ)'L_Y2J7FIOKRMDQBSFQ&>?6=G]K
M8G2+C;W>NF)9/EF\9];TU;2BM#_@[# :4AL2X65DH*1"'^"O(O];*WUBNK#A
M]/0$20'*!09J333)1-I !]+7/GF+UG*9(.:)8NEZ5]TI+#( XH6>*Y&&#I)6
MK+I&O69BE6,JOP3+9L= _\ 6DK+$8FN',-0+*@)T*X02T\* UBN2Z_98<!UP
M+[QR/V76)^N@B4\!<@*BHD=AX;1W[#68*=GJ>CE8T)@Y2IR7V,1OQCTF,JH:
M-;F(J\%SAP7%M)#A"C>6Y<1]':E]?9?SU&[B=E#:"5C7IK2P5*70:)#^R!$;
MSR_2@1A5U@&)#@AD9I5[V\#[?0KW0$0:,SP81[DS@%U>DD^M<)]ORQ*QO^\>
MC<$SPREM!8LPTYRN$0PIPE%T'PR3R*G8[LGMP>Q+#^"D6U9NK/,=)G2OBC0:
M.C_[*ET"DF74?% KNEOY7JXVT9UK>D1Y*:;G_0]"TS)MWO+0)-:;,1=U]QIQ
MY2ALZPN ?!>)I63QJ\Y&5(W\OU@$[D66:)5LJ@>=/M[23MQ20_L<Y4W??I[3
M=#CVWP64_QOW?>5O,A[M;BO24'Z@6_IVZXBII,!J-HC,MG).B470F))2G.1L
M/.]_/EG6R"$%'H-5.L^JZ+BOI=T5'81,?0EB6HV7LDZSH151[\IST2@"<'.Z
M#/+B>)> 1 8KO!MV=1P?A44ONG6Q1\WQ8R=RE\#V[ 1@^_VN+W#" Q VO[VC
M!"+9G%QL6PTRU1Q(HZY^;V"]9/\<17](27QHCV^\J(>97T', G>$SSVB(C;;
MGT3F'J&"HWHTC#,)V3N.NG$),!EQ'G9L$/W%:1"55#5K>RBM8_ YJ4H@3[V8
MUP*TCNX W21Z_K?)AVB!W>_:#T3=\'(ZI_'YAYE+%4C"<2_E)T=X4[=? B+G
MJ?=IG[M >OGYR[[^C/E4_WO^6=JAK5-#<W]LM),RC6:CAU'=%#A-M+9BL\OI
MZSZ<=Q-"G^=FLY'F".6';DPKS6VK5#1,GP%&@9;SDR#2;>]<]W?XYGIL&RYS
M#U' *7FOT&/!UH=FC"]2:&ZJ-9!#?RO-9>79K?ZG26EBUS[X%&T\^@ /<?86
ME*NT$C50#2I(M^3\/'+'4\JY-E 1-.? 8LL8:<6ZO0Z:/,3K8\5V_+#@COD;
M7M3\JZN9D6=9R#);M]%;>R(@6@@25 Q!KK8_T5L?L\S2,WO\8[@]^:ME2Z&[
MNL#"R_[AZNC"^J-UHFUFTO+#B[35U08ESAPXA%<X?\#&WJXQE7,EP?; <-9@
M9#M)?RN;1_4(I:(76,2G&3RG)B-GDEXI_4W2;4BXJ^ZZ"]+&-&HR.)HAZ:&;
MNI)II1#MJ^4ZS7!BV\5/H)W@U/32#3@N B]+^'[^R5UED7KW0\YDIIAJ(QHA
M+FRR WH@Q\>@@X^;G3.:ZG+A[Q[S5W&WI/U1R!G)HGOX9 D6G5UK'(7C-1F1
ME?+R(/3_\IDQN>NE^G/2ZQX6YF>*MO>YY^6"!>+'OJD4RWTI['&R\'3X7A"6
MWU*O*F\1S/30QE>M*B\+.3KKP8O\.S+\;!]JV%!4,('9R!E/ =<DE9OG9*[L
MFM=4V4,1]6=FBR8AV5@-1=1"D6[+J_$%0BVJ4CJ;IND=6^HOU256UH(0;<F<
M4X^FH@=W%S8-P\K*= 1K>RP2XTV)Z*,AET43*EM,?@6RV-U3'C4A/+MI5CQG
M4^LF5EOZA*I];DO/V+I;&_1GF9S*M)X]P" [0EH%F[XXV(R[\]&(HT<2&5!S
MYQ+P<%.Y)!>$HQC,)&_(_\7XYZ61=-QRR3(K9(Q6)$9*CJG;T6DDJS29G_M/
MVAK(S<6R1FVB&8XX>CN?BJJ92-9!9JO,84J-^P>W:.A6GE,R+D?+R ;\WI#2
M+/K_[V;X?X/2P&Y\T]<G%SB8^0'P&. ,\ 94F'2S<5=BK8*/]^FV_)?/!3LP
M1G/E'OQ?XCV#:ZN0GJF!-.^C#Y2J1#%%95VA #8*9WEYW8Y[MTX=>CGB/>YU
MS,/+8?PHK#9J>AF/NXB&06-NZKE+F1 \(>=2A(ZVZ_;W"+"N!O*$=\OL]_4O
MJK8UL+NUI:+Y]N8-G?B7IPX<[WC[#N0C'CP$](]WOQ"P,9)7Y7V6=.QV7*4+
MW0FA]YR2X9LMRZ@8<=WT=K&;]\/'Q* 6FMBKYGS3O-=]B0PXAJ6])!N>[%!,
M2.#7OU!L2:OH=)1"5S*#:Y0GRT,_R^]Q3_7IWCU[L]0<!/PR-)F.G\"Q!\&^
M;D/NQ#"Z!W0)N8.[6JAP39I=^'(VUE<4=;]#0(*,GMKQ$F8,O_^T6*ZHN](_
M10%(=XD<!,2YAY?66 L7:=#D9I/G^3U"]M)^"(/R12%1:BG[KJW5XGPGBGP;
MJPK]7N[N'''W:?M=C[4[F6]7% 7LS:.5'INQ.32>35_\N 18H6Z0^E$437>P
M*JV@(M#B/*6-NEZ;0['AG8C2XD"A\O%^5'*0CHW9*SYSNRA%\OC7VG9ZA?8P
M%0FI9@--&^X<1 N_O7-O<XTJ5V/MA&N5&WBV$=-OB:B6:03YR\AVC[2^[JL5
MK<47<P8R<:JX3PCS378(O6<.74#:V6ZS+!1QDSU^W/M9Z"#VVH[G6EZ\^--H
M)0L@I_6!A%EL>+A^>H89X $:X:/NY751W<+@Y8%%=^W[7@*J0G8_8>?;3&I.
M_-TZ"FT:]BK-;+YA5M,[Q$=,:[,U*I,O*KY!I_BGHLTEV%_0OW*=E9 2Q:CH
M%K[Z-,MY[MFP_8\V:51-2/=34_IJU'RC&V)NSO7?A=*$>>I1L[PX1VH!5.#$
M M%88B3%_/WM=W+_8E[Q.P]^8U@BS]C78'A) N020,$[ EO(P81$^H@7=DE<
M BSN[#]T)P&##41.0IW#1N6Z:O(%FO19(.G-K[8>^@E;0VF9OJ2R] W>)#M\
MA<;77]1#6P2ZEDR8B!8$1"YI>NX!H2.'8'J(-Z@<\7I71.3#(=O[FT&JHP(B
MNY2@6DW3KQ-W(LYQQ?E= U4_P-PG7R'GB?^X&EJ&C_HSU?[IVS(\?)@PA[E>
MQK]G[B^6=K_OIV@O4[#<;GA-ACWG7DV$&J;0QHF[)A=OT5\^HEI JZ':!?\^
M6[-7EI/(.N+6Z*@FM0EWK,2B@@5<\M%[TC(Y0Q5=#"ELE0+I5@(Y<=^N<RV_
M'RU2!P"4NJ5,&^0>D<7^9#<^BJ!],E,:L#U//"*6*"<ALJ8%&HRW8?T-;'OG
MS6P-4U-?+W3\/M!I G+"G_\_D6<7L@%+XA>ICJ9FE"#6[6H^&P,;B(Q1K\%)
MMQ5P[]X1/N& 2]SA31\<'X\Z_WE<'_<IB36>EU&OB/OQ@QBUNO4ZDB.)%=9F
MUG0-Q[&42Q 8DFNI'*$@UJK;CO:E<[[@D ?__,/)XG $;X0MK,R'GAC?'_-R
MRY?C_36A@YE?Y?:TKPJE9_Z^42B^L'!,3U1R%S-*:&]H#EJ-?[U5ZLI5B43:
M2^I;Q)U0S\K?*>8*LQ1O[>7.APY\ZJ/!AW6!TV8KTG7=[.6/T&/?'-1PX[O>
MSB.B1D<0L"UI&_;S"O%TK98R9?NU1@OUG[0$<8;U_+W^A^P%E\>#'B3(X%C%
M.BC007"^[H>=U9]IQFZ]6D>)C5Q.DAZ\WY[P3"Q*^LMR=A"O6*0!9\/HB(B*
M=9[^*B)D18M!X]<3SK:VL'$CI74 &IU=8](S3^Y%@769#_=R*F\K5&#D4!UM
MF6+1E0PLW"OI[&PLXC2';GR7@&<NL9A_D7B;U<N]M[>76Y"^E171DFYX?+##
MQL$>6B@?Q2TYSM5/E]:H/+A;&_^IP4YU([EP&(6I-. L07]3J%NM$)!5U"7+
MJ.?)3>@!QAB<:B[M=V_?%>L\8PC\NH(<LSOFS?<=L'(BX_P4VY7WV=ST#0\#
M8*]W0Q*]P-XC2.#)JE]6Z<^4^E _QE?C$J_E?_>55<TA!Y4&4 C_.[9JV8%Q
M^QA.19 Y5R8$=,W32TN]ZBTV[#O+K.H6J#!8+.^,I*N6_0?H-X^DLGK6(JK1
MJ52OG)'X2,=I=A=Z;(#JJD@!*K=]BPAZ,40?FL\S')">+V\X* B*R#^:&-CW
MS!Y=(J2KZ0N?&\FV+^WK3,!'^EQUY17Y.]]J<OB^[G]VC:TI&C$U(X^4/)ZY
M_\9 1<6]'"FHV'^_?EGZ>H\XR;^RZ=KB-/\SU@>ZC5$KC2WA&.W3 '91B)9I
M:Y(XF0.KXTMYD/(),_6]'GN/DTJ%Y)9WG&7?0*Z #*K/T;*9/&;,2E-(*/W)
MQ,#NUH7]OU/)PYI,?G[7[ 2-*MW:_O($-Y0J-5^0@+.,LI0$=?J/R"K%5V_N
MO>*0D&9?4?T^E^X:THFTH ]-/K\-&!QM6B&+O@%:W!UI_K/I:+)E$*\8]4,[
M>J_):UH9-UT!5#Z\!-S8L$8;Q,5IKQDIR[$,REH\U050'?5\=/"_)HM(S!?1
M3):<_2"VVFB'<?,$'JP[!$1F7JQ:H<&G\["1"]7T4M?;(U75BB]-SC<RW#9G
M[KE+>X9WHL:<-_;8%9X0^^N2%DU?L_D8=8B32;-_/ \_,C(#>5H7N#'9/ 6P
M?+X/:&-B\W7;3ACXWM3P,47R_9F_PMJL?B-](E63M=[U:V3B'0ZMK+PYV8U<
M4XW;I>B^>7BI1&*-7;\:>)/D.37?/T8XZ=$UD\-9-EK8<H"]Y:?=_W!E+3L]
M9"2G7B#SRY+8@!RBN]EI3!;W.Z>=0W2U L!&R#3GLGY;\S<&.K<GM5UFE"2.
MMM,NJ DH*$5PM451@W#U /15P+CVQ LFI>4BNV;<_.CI]@7"!6HA^P1L.#W@
M1OO!SB(SMJ&+N:'V$L#GYX>JG_%TVYQ7G2TJYMQIEK2I2#FOK9:9@5/?/N8:
M*-.BJ]?9E7@^:W#6Q9U#= 5:"U.'2CXKMF#!VJJ7E?WDU#G,BS;O>5);#=4Y
M O[5(+1/]'3//6I!UH=]:0Z>G>-X3A&F_O:WQ8['PLJU:/$!F%3V/9AUN7T;
MP^^&F3GE2K5XH7C76/K!'4F:/K.B?2(*[$/F,S9'0T#>MKF!9P;1\'&Q#<_*
M-2W;_?GGJQ<_4S0#$Y#A8[6MX9'7B(SW*DW]FI4,-1E=;]X9])KFS.#0J&5/
M;IBP8T$6,VYZJEA9-"+%C$.'L'O%2X(4VZ_!;0CHG+QNE%YSS5:9SX&_HCCK
MC9L<<7$FI@3F[NVBGCL&?G>W8N8Q,]\X[2*ATZNW?SK^ZETO--3]0Q(>6<?N
MM1SLPRIMJ2QC^#M?T;K'</CM2)"?ZRHM\EMTQ@FFG<M+W W^T[M:-R0W9*B+
M^6(DF7A:D)@W/FUD%Z_6#Y6$C+Y;++%=]*RH1<OG)31L7P*H"PJ/K<H-E5S.
M97V&Q"@BGY-8*8C=F@'XF_*OQ$U!3$S;$TU!7(?@K_QKY-Q.- 3<3"0ID[IB
M#;G$S_'A(@%F!:-Q#S_<P4!# K/V5E<2.2$L'H9J1A&?62BX*>>W32*_77EV
M,Y259W;$@1?OB,#' 5;<" KAUQ6"2=:\\SS;*E&YQ9$\<#WM1UY!SHFC+6:V
MX-15N=^(C[275_YP0E5@HB7-9-?Y (.9N8@Y"/Q4K;Q!=K?M#7/C9[;"NG4R
MUD.URL[(>)H@S?,J8'.&>=:;(=F<)G1[EN@HT:P L]6@A9N=-N%T;,?]*6,U
M<@KZ$CNUS#YF6=TBZ.6 !;::W+H$V! *U6L>!>*DIC?CK^2(:IDO/ZYJ.&=9
M*O6; M/QX:'-IW9-.YL71F#=4E?$1/8Z*L%;G(>^,BE7+=!P;:5YLK2F/I?!
MNZ9Q7GOF#/;QA6V+^8$">Q: ;_V:^I<(H4$ XZ#C*T]T( '5XV$'7VZDOF7M
M5FDX0$6"'G8NQC__^23;L7@VGC[X.SE^"96UCV$@W6XLM15KJ(A:I&8"ZRLD
M(_6<QQW_">Q0, @I:C[VRO/SVQS3 >W<.M<G1'0!:]3"OI1M5=MNP_EB04["
MD>??HM45=_3L^MTDAL@?$0SJB@?+RM74(_/B$^OC5X?KY<^YFX]=M^;F8: @
MG/#+)"$1"TI)K541Y30UPU[>=KO]D7.(TYE;RLZH(2:43K''.O(WQV=RKT[V
M?1>F06#*YQ&N&E,Z'5,SJ7E>!)A0V5/AO9T\_%E,C.&!*MMU_\^?Y6\"DBP6
ML-X*RY.ZW_A-0T#?*^2>M&D-\6>PX"*7I?%$*9$;:;7HEM)JW?-9#%K+:]O&
M0$#4P\BZWC@:W8#611HQK9T@[_>*C/?5ZE!8+S_V.\Q@>[WGT$/0-J'>1&N
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M;679Q^'"%Z*LTBE9<]8CJV#.+Z!CF?^YH?ZU+(M/OQ5H3 3^D!"P;!+F]?*
M.H0D0$B2GGN,$PS@L_3['-^A,HYX85>1@Q2B%OP*H@T\=3W4RZZDWKFS:!]$
MLVG")LOE3O9F&&C]WW>^ET.XIT,=:$=#=PX2K;/]$Z+<+^MRJD>NJ45&4Q\
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MPT2_IR?^^%WB+6?6NAUC3T*XF[3N@L]A[ZO0G B(HD#Y5!([4(@VB>H62T#
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M_?S;?\M <M? 'Y_N*+,9T/WQ)P A[ZH5JPF%275N566P!_/-@)M<QK=2YTX
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M ZG]M:$)374;J$>T92$+?6.^,$RXB1J.SOH[6X-,_:FPPNR$I\IW,OI6QZ.
MNX6T8,@PLEV3C-G/:<UT)&E_:701!WATI[J+YYS=(21H'>'V_&N\46%'X(%I
MX<[K:*-+K/H.<7>*4EF@Z.S?F46A5/1C*DO@@H&P(ZE$ KLQ)G0-M&XWP&&J
MX*:)C! +3$5V<)S9Z[7D[B:6:]WG>1U8) UYCD9%V:O5YTWL8;+UU\2')/)L
M:Q^%/<R19NNI6-!$P@45VT(BUSR\:@X]:-<8/PVVTU/T/$\ EJP/1BODI:"M
M+3F.HD\YLU$!/U=S))/IQ:U4QYI9JD0SA\22BT]NIH,D_U4=TW:K#P!-3<LN
M+:W5URY=<_"X2/4"U[86GC-,LE,2/^+MK#M9/[-\9ZF+(GGG;@_YLIOP?+E]
MX7;O;0$F00$6S=75H8 NMFL3^SG"E>I;H03'L+#&+:Q;N0H1Z!)0P\DG52=J
MZY[3G.RHN!'ILL*]O=*9%6[0Z: 8>Z,D>E]]C>/7918#E88YIJY;+I'I*G\B
MQZ4Z<FO['WN<OY7U=Y=DK*E++C7L>?*?V TPQT^\9H<H/9:EM.N=B4#"\I-/
M;,6M-U=35W8.1ASVW$1-*\L:';U'=4IUM+2;BHT)*]D%8/M:]+^64()_&VZ\
M(MDW*3FK-51S6&4U-70S4I2R,B/A+?&DX"J/!7DW,]>N[Z%>S.&176_MYP@;
M'9:S+#-XR(NY[7"F6-S?H()=T$7?BW]+I3!;@K:9G<(7OG6N:*T<:U5"W/]F
MH:U<VC8Q0I*E\Y"-L9;($!H.9,'[>ZW9T7M+](F,5DS<\\613ZO9?S9_=E(6
M@USBO073SSW[V%@U!A"[!7IH@@QG>3U2%Y'QQE_V6R,01$$N?DF40LM$")#"
MQ3(@\N-#X[S>QHYWVE\PYY<SE#5M_IE*[9(B:1:R?DGX89H&RJ\4'LPO4A"S
M$4/'564,#&% =U?$DG<&PV!_RXRK3*<)3YGT'Z4><87[81[*DV>)]/%<L0MU
M,NGJ)5IU?X2\'CVLMEF&![XK9]+UPF.>,JY.]TH4$\4C"!-\7'<O6&+[@K8R
M_%C%3DF:T*/G"'G?_KKVD<"S"]7?V-Y?M6-W\USDG&(27-"S\!\,IZ$W]Z<K
M5T-0(*K(!\%*VPI&SU$M$KO1XN#OU98QD($WGTM((K*J@7B?= P[5Q00I0R7
M[<TD/!5O<^PP]0N309?#5?8CF'JN7,:KZ43]>= ?<K77D#6Z@]QKR#'\@S]!
MTT\[F5Y#3LA0S>7-K[N*QF[-77M9FW'3WTD4YGM-;)I%1'X7T<H2,K^59*2P
MC'YMT9Y?,19@[][<=E[$+2\ #YY5A#@5/3TG6"=QXW[5/)O:Y>G9Z;%]_%!P
MI$89\M_1YR=':N+S+K>*G\A5MQ5$JAY5%=?5;B*]9F?8D"EFHZHII@^OXF]_
MU8UADF-FBM<<D=3_<"R?0&8DY+;$D>RHC]\?CC&S2'Q8$#XS<I<Z>0*(5=,*
MT50(XNW]HXZRYM=Y^NWM!<%8H5>9CV_JW>PJF"%7?LJV4M&->N.+=(T+O:DI
MT"':38MT+SAZT%A6?MW:TJ'GFLS6EKSSU#[!ZL?*2G[7^P:UZU U%_?LC8'L
M'8PYJA9S]^@Y-;+68#V&IH1^%4IU410($9OZ^I_6BGCPWO%N8B#,*+@SV5C\
M4?O3IV&!KW-ZSP7HA D<[8EQX=7H[PP\>4P/HV]B%$VD5I%SBR\U&3&L_,P2
M CE2X-YUQ5N966<.I()'ZC7ACH))^ZK81X'@=@L*Z72+G"W'Y%MFU\BW\2]$
MG0 (=2< X&:X0=\()SX\;[XT65='^[+OD.C2C5=.;P(O_S3=8_9J.":#ND?Z
M0'$M0[ANO9<*FA%-^C5JS5^-TS[(I W$NV:T6$=W]0L?!8*F-5(W1'>F1G](
M?V_Z?MG/T DN][8P7?EQ:I%HT";++AOM4;A8M[9&W]L]#-L_(,](-0GDZ1@.
M+KF'1G_/_G69^VKMU>[<]<[B?.,E0LG$-C7Q;;HTL.(0IKG3O >T\[,X9!12
M#.[/1[N(I@M=?-T]L+=$VUNH35DVSVL\7J=S<] S##S,3P ;U?XE>/.ZNP>>
M1*.4Z,#BCO?,<)8LO0A2@/R1*16\_<.?-9R'4V:*LVZF3&)6&"J5FK4A^*PU
MM]?*13N0,&#@8?7&8BZ-V^)*3JH8'NA]'G4CDU>IB%2)<A>.[Q=39!&@P+%Z
M++=1!>9VCFI063<MC][)%,[?>YSI!I(XIEAL-[!ZS=;2RGWC2XA+6.-:V+)@
MN_<UI=KYC2M\AP[6H2X[9M-^,RF.[6W#71T.JBV@Q+U"SF'WN,FSF8M2Z)NI
M_LQ%V:^WLBEPMZ:W!$"]:>:X^GJPP,+XSDWM@_JHVV_-0[YWF-HP,0&46)A6
M>P-/8VA]U?(1ZZ9](?<5&;[%B^^T8V,[#*R62GJ:@??J*@_L''PG9W5"]?6#
M;*7P>$)=C.UQW>?5715*;9>;VXT,<?S#ZG_<LGK?1V['&$@Z61:]L_(,8>W?
MM6](?Y,5N%%RTTH$G9Y4!SH!^#K5H75,V'G<)77NG">GE[P6'%:^95YIP4[H
M%WX:P7K_D^Y_AK298I43 (Z8/>DH"]8@C/CK. R!R-./X^* $U(YM(K<-0NE
MSY3V!#UZ=^Z5SP/#H>8"8AEZ+:*O2J!UOH:?373Z.+X?_A34U.4EI)O<_5.2
M,[SV0LFM>/2U[AGDNY>W_VD)[S&\V@+-JD>8".;"J30G><J"-Y/ 0>=R4X@T
M2S!VS6]SU1]<!T9]4XMR''1$ZU3053<.)*O)X%3S(-JG[P)G.N:3Q&ZZ;O6)
MT7VH7KUBY]6$Q)* HK?&%CB\:WY(M"9(Z7S*O/,QT_C6P$>IDI=1(?!V?^:P
MW-_#0M&IY2]YBS_NOM-<T<W8M]*J]USK8D0V?;7;M ',!6+A^MV4.KU$A!/>
M,10U,X1$C>Y/.= *'G4/)RJG+-G8@2.D6E;#9AEG#OW)A'FU$T!:L..0]JYE
M\G&_OT13R_/8DFN"EG^_@JKT#E=QAR3JQ'9UM";9IH?8IO#:T:G)H7^I,<\6
MW*7PB@NPP*)_V -]RI#[O8@</+QV]:>@_?W73:]3@WNY5'"Q6WTKJ%[X5/DI
M(+ZT_"VQ^\AG6NG#D'<(GZL,PE/W@KWQG*:L^,J:?6]JCG$.L?U2;KI917&+
M7@ZEK9 "V;0M;A53TTYK4>0@^D%VO&?['?;-VZ8.432]-3L40Z Y1E&D6A>N
MK&]H^"K,[?4:#EM2U;Z[W5@Q*GCF5O_.)1/FZC/&3[R$D4%]=1KS8>OII=QN
M)<,Z)FU8^Q1"ZUW>#;W^^3# F4ZFS#ZU/5MXUYK8.M93P3/A,$Q*^<4?_4>V
MS/DNI@(SAHN+Z5-;GRP?5GT:E.5'Q1 II*/#PWWR[HL'\KCBY^8%RI-'2BG!
M"+^!$P"D;8IV.E;FT//Z?-3?ZM!%/:[1/JNF$\ --YCP$6X]!V)T NB4#K;?
MLTK05T)^Z\RF^0DWQO$1"8#4H]@CX%IE3"C;+(>Y<:EBS1ZNDM*PRP]-4LIC
M9,4ER]67WRQ+EF/*(L/2CJ6W:??RNB%J9)F,>6=VO&GYMPG$T!V<14/22N:S
M>)?E3=.R\SLMG^,ZL@(G,1K0N0H0<@9&TXQFW=YZJ\\_5$F*S.BI\\-UZHM0
MW^-NSE U.E':Z_M'T:+B$_ZNF> "#N-6<X1U!-O5JTQ!O2/'_"/[SPOW:^B)
M^C>/=;";(5%@ORYS)-DE.=BQ?WUSI;0K[!WI(#3B]4KV1FBHC6-WN;1'CA-3
M*G!7XM06.'JFP0L0@6-^>A,Q7_KV?]>,-3[0%V_8]D_5/Q/]_#LT"9CX9%1Q
M0M<V\),S">L _7$M0J0Y=H]BSB;55.P6?*/_89Z&&K956%JJL+E\2 CFBPC9
MG/:IF$Q?L##)]1O2D*NMI4V.X6M/ "K_QGP.U" 71\AN^_'TQBT(5_0]>I7J
M"2 >B@CI2U2,UE/JA9Y-4H/&@\3:A7TN5+9X[Z_!_DX;@8E1G)HFS/\MV.:/
M$2E-?J;R(%S>>@U-@VJR_XBJ,X]Y7<*=%;6F(&I>.WW7!BV'TTYO^CR,*VC;
MQ>16< RNRA3;,%<_99,M..ZB?X#.I;0S485HIJL8080!7]^7<(T.D$_>O.PK
M\88=C^VES3+R8$A8+8GH?:[I!H\C0>C._F^!F_/ZA_!I+3=;8,A\^X$LH.C@
M>%O>Q.]QV69I-]);-KPJ-_D@.VM4'8L@M+:!U&8&'Z,KBK/;DR?3-^PK_LR?
M=[[#%;&%J[?2\UW>PEOM?Z;*TV2IAM%!9%@O/NQ-LZ#B7".*]F"T;7QW1#70
M9-'^'.^@L$?7X-5KIF5V8>+7U [73@!G]4\ <;G'MO37NE[;2L;;T(Y#?;GG
M4'ZUWE$_BM*&W9AK<VNZ$+KJ:[*-6W"CBUYE[0B?8<[?\V=%?,FR^Q_H#;J2
MITHN4;NVUXCP3B6./]2U7@SGL4H]U9&HL?Z:7,"Z%R5R1Q+FPQE13X58^,@F
M'#QJI)EKELR:>T-&7M2UGLGD#'(8N??7Y>@EGN8;7L>?6S3@Z//(S+[-]GVY
M;Q1-3[=P9E7VLPD3>7 _BYI$7B'"^L0N$J)!5$P$F8=&G,FOA R7GF_5\*U=
M$SO;?CWZ BZ$^F*69BPOKY.FO; 1*9R=DJOQ#TGN;S>RY:??8G1@OB;&03U!
M3*3&NYRTJ6,3?^[PY87Y=B09],^ L]7YALW,6F@[+RJ<SSL7#@UK-N)%3B#>
M^@V\!J6< +8-H<S'YDAJ*5D;:[\=7%#:J:<@/J$K+9L<K7P*;SBB;<(" ]1
M3*= X_+;P9BRYZLBK>H[WJO^@"34#=,*("7##^U@W#DH^O(E%]<Y R?:A+1
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M-C+;*'# '@GBYB_8L6S4PB6?>7@KY98$(6KQ^CX[*C(%/^<QB"B6.JS!K!R
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MCBW'U^2N)3D!K9SK9'/13U S,$+2+1&A>F.,(DDQZDD$Y@MT )^R=>KJ^TI
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MQ]>4[>',#'<)GFR,T<V@"IS[$E,>$LO?16:6HG(EW%0"0^'B/GE2%#=T*^R
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M7%^_K76+*\J:J'?8&\>\8A=>\,0CP\6^FO&UWBLYR;=C=QG]7'K(H7/L OF
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M1P3=! J6T:4H> \'-WE.8D(9+ >F$#2TI;^NA1C.>*RLTGYN>&)[JWQPZS<
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M;YG:RU$<32X*\O+@H&EBL2N6F?)9GT58X;)<D19LS)@ZCQAOI,*&BN!LF0&
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M/&4G6)Q$5B&Y%L@AD4DU!C3!0&1!]"892&"GT.&@^9UU<3I<+2SUR.C%=TA
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M$U]^^S2N(/[3YI!#&U=7>HCJXF$$G* -2&"7ZD'+N?PQ4JSX%&3^7YO0%G_
MJ>(SFBDJ]^@L/D+=FZM&(SURH;>,5\?5;>1_N,?E?1]! I@FZWH9Y]C&*F-!
M+K!N0P.'>\/"8TP@6<&P<?;+L9D..6(/XJM, [LQG!KGIQ5-\B%!=QZNWYPQ
MGJ?P3O)-5,$B"8SU6V'CA<X0N9M??<;XN5[6;S&>1.)AVOWJ!68RXS!>F=<A
MU- >P^WQ)B*R6HG:G83=/&OL5-,(%-6".MP[IY^L8=E=TFG6/MZ\4ETU<\I\
MCX7G1H.^[W]B-3[I$4+ L$;*SF6J+#X(E^KZ@5-W)V1+9S!Y)Q[7C#K*S.9<
MHERNZJ6K%I/@4S5)F<0,]\"2J=]O3!LUC7PY$W SJ>U#PROX1+4@$6*M6POU
M(-*8+S). MO#].5N],IT:J0DJ^N)4H)).PG6[SJ97JYZLT)GRGE )@[M,Z,$
M'B)J@XI1>%T_90M IZ/E&KCSKS:M.!W3WY\2?#)8?KBWS H)+!YU9D8"H^-:
M23 \N45\1"KCX ,=YKW+D:KVE!8]GVUC%'EQ3Y 7>C>-N0G_[L9P7<6T!+9!
M UA(K-/AS<C9N:>RU)7!L-A29T=EFL=Z3\O(=D@5A+L"K85CW&V$(V!'?-WN
M$G-T5 A<>1*U"S2LY<%WW6AGC 3L&/8US*B)C5V.G]<?[OR8;^4=<;Q?]<_*
MP0DS"6S'$,$0$*Z5,J-> :CX(#Y5W@=UL'\4^.RR,PL=)\25G%43EY;YE'O[
M[LADQQM87\^I[PTQH;_O0]Y,,,EZ/IZLV""S&#^ZCH..6B83;HU%ZHU=%E6B
M]D%&?!M*PQ&"5401Q&4/_D@P/3QF0AKBC":36XZ:(LN@1RQ;@!FE&\P<2+6'
M8K7B[D!J//@.PHY^H9KB^'PB/)ZJWW[AYY"EX GDN>[#%1Z 1$! <SAIC@EN
MY%VC/B*-OB+)D3QK23'9ASE"*W!/B]BH;UG;!#TPC4AQ^[4O) "R(AX2ZC*@
MH"(H]SR070JJK#1+2;^A=PQLKJE.9/_A'[O48@$C&A&'2+(2F%>RVQA/B0Z8
M7X2R\O LE@3VCLU>B.G"<WAY0<Y0<:,T2>]@XR"M/,&@_Y,BM@)W@'&X'B ]
M%!^:S@S6,]=K<^>9A3K?S)0]R@]X1C03LQ&JP@=C 7LGUR;(ZU9"!X#:J.8N
MF.Z6P#SK<:VX740-?-7$(@NQ2P*[PQU@705TTHO?<F>HR&9?$PDL:6VE%;<#
MNC#62AGBQ(N>!_).^W.M@9'GWIXB1-=OB'9,0OX_YU /"0/2$;'$S:*WI@=Y
M+[59B+T,59\/H%$RG;F%(N=,_#CX#;TEA+H5;R]KIC7*^*,FMJ5]SX5>4^T2
MO)$E"&]%[H02@$FTDFF@ J=_4#L"%04X"3H =+Q_B.@4'S>7RH\:92J*&]P.
M -FI_'^VQ3P.&L4N#W7$Z03D$@=^-+M8",E^?"[\;'ZCHKAT5!0PEPV''(IT
M6HN!(7/ =7AN-E6\(FWPEWOH7R0P_R5 ;8(A@2E(O^XS]36:C03-^2\RK857
MP-\?X099C5R5JP0U8%;%_GU,*QQR4HD6OWP 5-I@T1N%EIVCE7VH@U!0B\L(
MQ;?8LHW@UDD*6$A"[T<=Q=L1-J]?FZ3(,0[@W04TJ<3YI1L3A]O% ](+>>O,
M@;'F( *<"7@PTI"/&7L@^8YF,;KKN+_P(%5XO"J#CR('426P)F4PE:^PUI]7
M<U*</OD*_L/S//!CSN[UY*#;RQ(O1+7ZR_53+C/9LO38"Y -::P=(8BK_M#-
MO(D>L+P(16R>&V\M=0== C9-<=6ET3Q)25W_HH$5;15U:(A&DF_G/MSC:#?)
MW$'8+(%MWDANS=X.E8(.+3B:N="\2^I_B*^YC2._ K84?ELK="H0(+N)7C#V
M71?WA$_D "MG_R08]_\-1;V!,L=:U8]45-;TU.F,26#P:64FO"S81/6EP[KG
M2LR_>7/I!1B66&<RBH'[H+1!M[Q,R]BEM"H_<[N(B-K\*FQ;6R3JZU_'_>;+
MOB\&Z,[Q?ME[Z-B='3QWIY#)F7]]YRD@IN+3/LYN0(R)?^F"OS=D\JGBL\6E
MG;NIMC%H1&Q3W\M]5Z,O^91X]STK^M!3M%G_1<Z1$22;O[^IRNY/S^=5Z@IO
M;^M]IISZ?,2A)/_8J=)'C4[-W='7FX(GIBX%OWY[Y.KC%UB[%ZYY!1)83)/H
M!7JRP%D"XZ'Y"V+/R?\NDA'VMJ&%6D)7">RSB(0.6,'PA"WFN $2>'S_;@G,
MG'%,.HPO<B6P%S]^/B8^V7^[3P*KP'N2UC:WFS*G Z9)9Q' 5TIEF$AA2&JF
M#O>/F?\J^5T"R\SRE,J"E40);)5"_3%2W(=\+8%M9*Z^!-VF2/4>:J3YY.]B
M"4PGF-RMG'28!%WBE>I(8"<^%$I@9AV3I\5?);#*F]^%MI72)D2T(H0=#B1>
M!?-NC@1F@.J0P+9Q]TI@BR:XCD11#T0Z>96[@&"M;N^*5#Z]CY8=UA(^)5Y.
ME?[@65?D :B>QJQX'^"8L5[ER16WLI=T2?>X R]"H%R/?TY&2R*MOBR@#)D+
M/&1D^,D4\1[B*0ELXCXS^VB$!%8K1O]8[3-:+P3$M^DXB^S-?EK9@?Y4\:.?
M)/%]519[7B>-F@9,"'KDGJ^2>OLH72=%=/3=PS.@[><@\JJ2T)L# ,,72'[D
M@<APX;4*Q(H.OD<">UXC#LJ;Y.)FKMZ9YF*FL.S)X@:_@1\O7*M%F[^/X)8U
MC&^-L14_#HP33)GS.+WY#)$<?!(0#U$J1F= M^90">Q)0"M3V-YK*1@3I7%2
MP;O-<!QT@1 @,CV%:__,#1.N);1E,-?9:YSSJ'CA!JVRB%95G?+GR#L2V*3%
M1*@Y>^>1-&KZ]VVHKP0V4Y0D'>HUQX"A7('#C1_\X3AI7"XP#90.9OMY;C5I
M]L6'CI:9#4D_Q$=):OO=IWA!N,_?AK&3I-([WT+0YL+H$(>U0U"D"1<U=G@J
M^:/4,<PGPKK C/ACV"S=O_OFZ#M(:2N?<9$F#R@].:)Z:7R.G@%C&J3P*-8]
MD,)#/T\*X [L#A?>Z6&+/HU(1=^$"S,COL:H5P)S^9C%)))RQ*[:592NC:P/
M>2.DU@2!B_M]E%1SOB5]7O*"Z,V*1@UW9NK?C$7@RLPHO;6DQK-H]^_KW'U+
M/ GL?B&9_!/(>8,5;]^WOI\Z O45PM>?B0^0,-LX/XL">T7PGXK):!*D%MJS
MI@H%&*;RU8WZM I,#L[X"TW7L],0>RIKTAFRQYRJ>LLC_;A[URE]JU*BB!>W
M^JXP#+U9,SQ$'$[X\:J6>+O!NC(2EZ+B)8%]L.3O$[OMIGZO"*@51UJXWP@1
MDEIK;RWI MU61LTW@LHRW7_N%#"%J63,](\BZ^8=(_X=LNFE?OG'G3((V'F2
MJXQX^]EU!:K,6/I?Z/DK4!S)CK?CJG1V;#XBBE=>((3TR 2L[A%K(,9'%W%_
M7Q6I4OTI9]?<J1"_?'R:-(+F""6P[ AOT3;"R4P;$*'NT_]5C)@)6"O@!G45
MMCY_-D<PE''K!=6D%NW@S+:@]:UHP'[A:^0#M+I^^3(0UDP6N[^53H+-IT0Q
MK4'@C/4856C'E">M)E/',OTEL+/"&4/IAYV0+,5B^PRY,Z+IAZH$5E(729?
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M4%>1P'(BS*4C:B.M0Z/KO^IA_I^J0?.T *YHAPI2+'><"8D00!+>5QP]!Y?
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MX>L\(;/<5,K!<U"M39=^Q+;9B>XRVKJ9TQ<K/G@XAA$B0O%=T2T8*E:GYJP
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MCI7U\^ ^[0(3KWY*R!+,Y%?:'BO;F.,S]OJ-31G_9EW\=N@!+_K4Q %NC]/
MK,L5CNF<!3Q-[U5M0_W%^*U_O.2W[3]V*/,7^7WR7P] CHU#3KJ7_P^G;/_$
MG91:#DF)Q7BW&996([D(WRN<R%S,3HU3;.96&YO0D0A:"6:E,P.1*U)P.%N]
M<'@@,E..;3&6"^MX]N+;%=+\B'M#5DS^CNK//R98T'JYS'EZ; E^'2(R3*6?
M)>2@E:NEH:0MM"%ZC)BL$.1N1E*2U,0;% DKF:G-I,+(LNGFSC+1I GE5L,:
MTJ[/=/6<W%4:Y];%3OMLJHSCN[N?$ @@138U%/^H6./,\77(7GR*]>KVHBI,
M;B/IP(#4\B4C-Q8;]L+78XS:T3"@GGSP>.? $P/#R"N$2SEQEN!Y,7G7*,&(
M%XE3PCM<!>U6#8CMY\>[NQ4$:E-CQX?BCDEQ$G*"U"<FL@*?/N'"'#")6+/T
M"KDS/6'W<.37F!ZDG5;FV_Z0+YSY/X_CO9>W@]7"N>-=&CG$/58ZA80+@U(-
M8,$.B+J_V"&IJ8D0Z! 0DL#[D1U@?&3)C+GX:M\!;H- .Y@;^$:VJV& ;O[B
M5!<V<+GR:* 2#[6Z&4;.7E*TN\@$/LFVY75=D776\J36DNN]S\TR  Q"Q1.\
M =T&XCID4 !1*.S.]XY@M PN_#JC$/(2V[A9?J*I?M!H'&!VFO#M.F4'@#N9
M<JEE_8<&XH[.,.6L;C3Z*@-"I@27AE"4'@<31#CMX#M1%IT/[OH+5Z&II%,#
MTI/^(59W!C:BH3U^$5<_YF-_#%"'-J"[?+Q&6-_SKI:L0Q2\KR7BL>P5:H;4
MXC7 !^5$G66 6&Q6*%**?XL+Q/E'WB9ITOLBY&V2J^'?,XTNSOE7S;B[8"V(
MCS<M\V990& G<SM!O@:TZT3H<Y8\<)&==&#^Z0N?Z>@J7=7^Y*3B*?3P'=EQ
MB6(),\/J?/-\NVCYO9C]+;B9] 0#K_FKN;,(Z[\UX^M2]BQ,'-B,C?6^#EZ-
M\#%GY04FF'ZJ!WBICKST11\CZ?6;0W$'C#16KM":&55DU1NTH=\&EBSO!"VN
M7<"&W)1?.I+7S5C[VXHHAL7\LE9BY1TBACF(;U:6H<'0#8>6E_0E?AVRH[61
M6F4-N+1'%W0E-XP:# A0G /I(QVXV.<?$4\PV,9Y^1"JP6M>"-6R.QL"H.=<
M5R]U "QW\$'5*&8,1AV(S-X:]!#3F&?[Q*#8*ESBSHH[!*R1[U$WZ./9DN')
M1H0<6(UDC=SA_&X^=J)_ECKG<%G2L_2Q\<YWW@$=X\+5;=(K0W3##?MRE] V
M- ]H!T>EFC6;WZLAH"7N**#S@1"7BM  :E*B]I/. JT+R;+#8/VO R9TX^]>
M 649"U2XA3'S)7A'[!F9@1JLIF"AKY#WE] ZP1:?N]+H<B\G41AQ@?&.I;<R
M@UZ#ZN?XEO%FZ:EZX$NM<$1IKP?&K79RY4E)TH9,JEIR(.\',U#:2U 5@Q)_
M[.&"E#9!)K3!H'KU2C!408J++?4)RM-9AZ01S"F3419Q3_S*#1*$E)T>/O@H
M$2D_H'C2OI*_ 9&63;Y;.9,Y7MGMX^9HPM*Z4U 9=+HCZI.N*=@B0;F 4R&*
MO(R%&KB.$GL=LL?JW%W@.=[LB^ RH)O@MWI5N@W(_I-:.7KY_8Y2";PK2Z9-
M!J_>JHG4KIS)"*M!=PLY?G[;AE[\&1'-G%63F+ MY))O2:W%%"4PV4=7*75L
M?S8K.C<C[B@F3S=>J*2;O=-A3Y>(N!6--]\(L,K4V$.K+/Y]BF%6,;; _2HO
MZ\G=ZKO-U[6JNR8C!$H-S#UX<R? )"NBP,096/O,SJG[X.$[<[*K:DI]X,(M
M U[-KF7>=XN"#_?.+D4\G)\_6O/+*1]?Y0!<=^):)3/H#%U1=*1$LHO&SRQC
MDQ4F9<=!,J88-&"UD7<OZH1V=]:->4UIO:\0!AD1+,/5J<\G+6S>ITAP;?R4
M-"O-[96;)+N+7O:*'+46'(?7(<E5:R]R11IMH\>6OU_A?!G4$&8]$:-V0N4O
M\Q&M.''O;JQ%$B^KH=NTSU@:4XY1S^TN?,/_G%,QGKUK2FM@FJ0JZY$85^C?
MS]JT%)B%V$RP6PV,)^@#WZ\!8Y6 R\76GW?O.W55P$HQ,5WWD 2907?<78^)
M*2HM$[5>$'=8E):,"W9[>W9%EH%F7U9XCLPA\:ML%TS$.:NIJ#$_Y.S)L .,
MYA17P%2K8RS?*FRZ6]@4-[J[-GSU5S0AFNSF_>;%['5$RAV&]NFJ%Y^"Y2?2
MMJ5Z5$Z,$/F<Y21<LA86F6:8(Y7:4OND&,F?4[Y;&H&4E-^:P? *? [/M@_>
MG;V3)9S!8A>T/#J$JYDFG3*%!@DE>0_>2J7:QUY\SM^1&[(.N<S0PN=WZ>J#
M.%W:W?))BY2.XX)M(,IEB*[YQU=,W#Z >'\))3?%3^2;/K)^89)AM!AK[?1L
MVBBRVV'MYAA7?$O91JLK^$^H&=YNV0"ARJ6K57NB\0;\A?:<#?K_[+:/!SYL
MCC)OC-B-%6C T6H?V_#E]78F&7.,0U,YM9>_:J*6;=X,CN%)PRZ+>QCZX)<X
MTQGT5JK#.D3#D@#G24^+F2FG2FCM1/6>*CY^K!T)!7WYW^9X/)D:![YVFA55
M.WKZ;;%GK]_+ZS:XR) J'X>2M_K4B62I$\A:=0SB\]BCWBRRLAOK8E_ 6FF-
M%"DL!'B_#.9H(^-U]_59>0N]]5Y^](:OC8#O9+&H7[BA&XJ_,R$,!TT1<ZS.
MWUR9>R,W':#VXWRY-&2M;'9BB'"%="YS,1]/B!&MHN2SD_,._HF1[5@KA<6I
M3OFJA'AX9SK-P@7;9O8$6W3(O+T??KL\0-517W5HT*)KT:;7('N=;/Y34_M&
MF_-[,:-[:(W,.!C$W_ZD?"::^@FQ7SWOYJ. \/)I#5LE#3!NV@\7$+B7=_KO
MZL*\NUN=3EZZ\="V7>_$BD'ZXM<K[^\:A#\.-*VXT'J]Z/2;FQ&3UQ[=/X[:
ME%&2GG3TG?EC/^=KC_6/3#\*";X[W.FS2WRTYU0>U="6A,GUOSW]I*+DZ$"R
MN:*[HL5?]UMY9VPK'U]K"#F\B,P;EFV5!A\0"\W9"5VXK>!?*^N0P1.2[,XF
MF,.X4I>FPEVBG,S@]=E5TC:)=5AO:<X?T6$_HMT7UR$VQ"O.*ZYAVPPCVY]:
M<I?QL[B(Q8:(#])3*?W?# OU]=EGGU6'Z&HHA&AA S_+ K^Z4^+>HZ%?E#X3
M5,%:0W03L-I1==9PO_%#NQ]+%-4-(1G0RW>^\07Z)WK?Y_?CNXB*A-_'28)P
MV[/KD'-IE+G-Z2M&&IS3::]@M__PM7%^/Y-_XE]U&NK%5T27$5!OTKW_^NGK
M ;[>A(@@VV4J0^,347L=L@DY_HS9X-Z%3&O&)4H=@=7.=<A.@HZJPD^RQ.L<
M4^$V:/L@[>R=#%/L4KP:7OG@?)I'/WW <-^_R^J<_C$W*\RY+*M#[-P8<>0J
M0FK9Q]@G/=%7V">%%[9OC_.,U$'_^N!7WYF\S\#%1TY<N*:R0U34 :?O!VA9
M8P,*,?C6&^G2W$XH%-_5>?2W$TU5)WZ8G<\I<5=B_0CP^MKFVO7ZW>E_:ZG'
M[0<[;PP>GO);>W'M5<1U<4K9SB<2.%:6D/,YXA2?\/CSL4?![XL'G#^[-3A[
MV03E-U;/SSZTV>N$3M;]Z__N$OO_3G//)Z>YC3_8B/)H=L(].UV%P7_$?5D[
M%O42?!_80.[2I$8MQ)4]LL/K$*':2V(2%*B;6X=,.H"/-GRC6X5,;<KT5[E\
M8GLW;1U2:")"R52\RD"G#8)D+) E,M.0H$TP6>C[Z+^0_K^!5/U_(I4CGT0[
M[MTD'%/B6NF/Z^P4L'Q509P$>KE_;MZ$HBZ0J2"5!;WP^;*[B,)RW[%IBR<=
M7THV/OA>=SS7\7EMM.??&A!S^=BQI?\.>_E_'N"[GP,\_M\'Z&XB\D&W(TX\
M8GW%/Q(RV9DN,A6<LB=8=C$9O1.?K.T=$G,U"S\+5\BPQ/X-@QO4F>]!8;>7
M*7ZN;A6UQ>Y5N(L-L?(5_\>D*C<FQ?B?)O6?>V_\C][/$47I@QM4-AOT=%N'
M+.H3[#>^'+^VX0D6\XYLZ6$* [S7(7U/?J;KW%'M\O.F=-*3C:!YP9U-EAZB
MH@"*_8L_K49DZC[,-7GB'B*0/H3\B77G)Y;T/V&-;&#E_E^Q<G$;6.C_POHO
MK/_"^O\3UE$)P8Z6XR'2503O)]OO.?$5-'?).CS6%O7/7+MMT\=YO.M6TI/)
MP?](>H8VC!M&JTJM@7PA(D.$W UVR93EX=!T\B["T2JP-<(2JM)=".+8LJ,-
M TO=W;%Z3K6#U37S>]ZYJQRM(]GX-Q\>V\OCPC\)-&3J71+T)2#KB4'=R@&
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MQMYNN?D9/;LU,F(;/GI^P]M< )' B"V#WI(EF_YV!;@9'Q 9%K6[I0Q\(1]
M&NL\BYZ5'1Z(Z(D>UKQ_9Z4CL[%HLUW4GG<0Q 'PZ>HU@D?6URY7E!*>R(J3
M Q92B4$"!6R:<"$URE&LM!?,&*?-KDFLV7PN*:+5^LWRS'-\'%H-C+,4*.*3
MM5?G0KGG+.T&J<3=YW7+EL^L:3*Q%*TJ<D@_0R.(WYOX23)?">"L,?08/.+
M-%-E$9E,8RH?SEEH[P<1#D?HIPFFW04&VI/PU8+P6UR27OZ%;+L"ODD%3K:=
ML&^(X/@2Y#B#KH!LM8/_F518AD48- $Y:69-+SVF^7!>2J2W]YKC;.;G00M2
M?$QD4?!1TQJ3B+=Y[R9Z:#LSB@*!;&$H60P',_R!F38W$L);GY/;Z2;3&C@H
M.36L_W J8_.,?1!MNNC*14Z4/*O@K#J[ENJD# $?B<SG)F*%%,5@QBD@*GY#
M1J&4/$? "9\!9 /=6^00XL^6[0$Q99-WQDYR(UI/MX]!)"D?0JH)X9$BU+;S
M53/?IA#[O,F[SBVN]#DZ<_DP1>_E*3HP7RL>IML!(HX-0(H?#R%VD+:]IDO4
M&R+)J;QHI7N+@GV.I5-Y2;2$T#A=#WLMW^O\&:_(A2P7-DF+6DMV&VPP:/0\
ME#WC&#ANV*:DX@%&7>$Q5*1GN!&"':R8$&$FT@4(C8\)>#X2[/QC):DQ%QOF
M=UC]#H^VKZF9EJ2N.7_AX[M,BZI[6%0\<_NMR%7!7C[A&!@KE[H$4Y.>+<=B
MA#I*JU=7S^=>R;B8;]_28F:+S=#.U-H1D9%_UW-@XDJZI3P[I[P6HK0/VA"8
M0;!\B8G3!..%2(@G_B'6),.<SY0>1*MJ=T3K%FBPR-LFXTQ?V1LO$$X*UYP[
M%SQKN?=\/\QXV>:'E[:%YA4T3[MI_'$9$=6P5B_%EDTQ]#?X^X/G,S3&\75(
MXG'V1F1!,$6*<3NDR.?7I5L!)INR9WBRK&ULBX282OV<X,S]C49V(E^H[5\4
MS.U86(IU<4SV=G"@- J6P\ M)LFFO=L< +3P/FE//S6?HH+QU7[4AM"-U4;Q
M*,]CO$=O<-NJ%.E>F9^+LS%1=\H-FJBX^BL+.W883S,AC!W8G#L6<=0-XWE?
M[5]Z'?/=*Y)4-+ZV\RO_7<AQ.RH@>\;M^^CQ=O]Q3*&GYR30F:[G<VJ _T\A
M+?G,X)9_9%OB^DGZX%<KNRI/4,\!H-U;)&^2GI.HU92%B3(R'=BTG[>B4_*4
MLCE7M(Q\H31.(:?!(22@JF0(ZG5:<-UFZU]3#^P.CZ'>([0D71N_7(<H(K80
MG)M!BGA!9QJJ$;&PMT.,W@J6N0^$5D\TT,!8,5+37J2TO1OW@D44.F0K^.#C
M>O3S/@JFUB'#WV4^2\\>ZC>\73DKI&P!S=L::>H(5: Q0=AB66XZXYWOH^I0
MSPF9:.Q?_& :<FSL4LC!=+,$QX&0D(:1?>FSU-I[VAZN!S-__6-,;8TDVX;7
MG7%A ,1V:(JO5BLW8LW:?LC$%+=C,L?<O=EW8U/FW>(I>Q:7LIR,.U?ZSM":
M#]^5,+9#$-:HD;S5]D=HY'V9;J9)FY==^Z+$-[[Z(SX#S;6RDVSQX,CV#DOM
M&/VF#MW0+6_'[W"+4L<^"# 6"_<CD*H=B@5=J;_WV3Q8A2.OKC5*B6'"'RX>
MH&4)Z-+Y?>P ,)22M,A4P<K.- Y([8K [/:X@Q*_%H[I*CI9@ZQ,A3G8)[!Z
ML3&["\;O+I[]C>YX&ZG<5>(Y]E9CV$VP-6ZW)_@7OI,GQ/UY0/)K?RZ+Q3X)
M.EC[H%=5(LBSFTKR%VKO?NE=59 =SI2_75WTJ-3L5MJ?(IM5L[C>OX+0P'UK
M "6\Y:NC-<=,Z\R QDLM\OZ0*)94<<V:WU!]K"Z:S,T:AYJ"QIL7,E"O26T[
M^8Z'C39])=];AX2N67>XH^668AV$U=F)#!WI90 93S\?(^I!L7T/#"F2TZ5A
MQJT!F/$0$YG*.F1+L)=-XZMFTI/2X4D)N.H.["<=#;F];>"0JA=*(8I8GSL7
M5B/%-;>^EFBT%]@)OR<M*:4@ 2I=6W3NPCK$*8N[#FE_L3+67[5$ 2]%*"G:
M[:[6:9U[(J4Q='/9"*UD)(W_<<;MN_H?&0O/YQ";I2JOAJ0FE _2PV!X8#7>
MX+T !2178,?GMBL(=GT8[HV*] \L[%5+9^2'E'U$^_:660??R$;ES'^>Y6XG
M7>"/J8(V .5-%.G H)4J,-&FJ]HJ\;;$Y\RP&/OZ%].6!*>\TT;A]D:WQK'_
M^(KFIX7/_VXP$$U_"8?F6]6,0^7 J.5%25E:Z$*$HHG0/3&4[ECN"&R>:+M/
MLI1$YB;!';7%O9GT\^,CEID.U[D,]2FO!/,4[U_RKX4XL"PT4A>5E$>NIA5-
MWWI9W_U(HK?\%J14$4S  MPX<QO>I9UD"H:/,U/=!2KP#:87Y=0FG'-H6X=H
M6&& /T8)IU;=X[.E!G&AU>.Q*%\:XF!"NW*&=\_I2T]XKJ2+&?.]BK+>C?^#
MH"5Y*T0FHG<3X(?=O6QF;P?%*?4U-*G/L%;N-S/BD4\# Q1R^Y;.EK3VO[UA
MVO0IJE8Y],!;BG0KJ">BU!+;'8%<H2!U=W[YS$IK/-?J8.$T++ "K'1ODLBE
MX>;X\^_<LF9\>#7SD:W. 0<7X'<_#9::X G3D!_DY0I)8+:I()6\TQ2ZJTM2
M[]X?2I>7N'3$'0($;ZJCVE;D[L/M"29*2:1V\7M)TO+3D/)B!>+=;:79_G@3
M'*YF_-+<ES<*(IGV6J/L$.CPAJEHA!1N'628S9A#Y8M CDB@\D'0O?P/0@>+
M."NQ2[$Z6>)(%&8K3/^L16/\M 0,G1=T/IIQ]U4&&LF4X:Z \)==9B^^JPO*
MZX.\8)W593.<*3=5;+1CP3RY-'C JWTE*2FKF-M;[N7E4Z=9/;?@]:Z_IC!M
MR,"L3W/+/HYN9 5A8U&JS/Y:^2F4O/+Q1/<AZMPN 8B\T")[RX7/.47VX'[E
M2%<UMU5W5E?;Z5+*&PZZ?;N6?OS'T/R++%?(#RB;V?A3 ,%B).D\=S#P^50X
M:"#P?@V&E<SHGN!5&<L.>P<AX( @80'N(?V%L;4)4&,\T,:G'U]#KZIV, [R
MK(Z]54MN*>P*TV<-#TDH<VEBZ%8!6,=CHY5,WUKA )HM^ ^_,46(2Z712%MX
M"U)#(3&!8=2G L=NJ$Q,\_V': ^"?6-]"[;GT,"W]N\Y[E]A6;78E\-7F [X
MU>7KX'%QCV'7,FH<N1-/] #SMZJ33DM\4X2QFY54L(W8&HS6<F%@A<"^[!_>
M<O,H-^/WO$'S&]<&'YK&U!KUM1V.+<A^LY#@=3-;*:5A(8D$>=57+>3-"?MG
MI88OO#']+%%%Q ^Z@W)]\ML#PQ3[$DQ(Y>9$-/'F!UC7WXTYHA-*#PF>JS?P
M"RRHJBDYB0-JOS%O)I6);$#_F,H@7;@DISK@N?1*\\\'K)=H#I5O91K#^)C5
M[=SISG.'OK2+?5(ZF3?RSMU![6S;NLQU$4K-UU[)CES'0]N\!!E2Q?%1+\$%
M8!TR*PB4I/B^DI2L);=&BLA\!0>@XTLV$5AMFQM_/;M4;8+*Z,B#<5^9+&4K
M;6]%'!QH.$)Q9U'."?C?D=L0RK[X]ZA4&G&7E5RX>!AGM*1IY8],BO D7.8G
M)64O!Q2L0Y:[AZD@(^%*9Q[M1M@?$4O>Z@^J76_L-5V'_(G<TE" :N>_?PJD
M"%NSJL=3MU$2J);H[9/* OR-X=#0A4.TOIJ';,=2ZY"H<O1'SXX@B?YC'NVV
MEQ$L_.0?2D\;H/QU2&=XD.Z6(;H+T,5:L?G>Z:V 02AAO-PS*4NXN='?P55K
M($200C\?BTQ<G(R(M3UGSLY#9]Q8W1M=Y5@\,G//[OR+T8_N#I+M'+;L!+@D
M;MV,O(] @)CG>+WQW&0"NN3G2S,O)U?B,C UP1;?[]^@\PC6@2^GM.YK=513
M&S-_#ZRG/[0T:+@7]-$D;\#D]9A4 Z@6I#,T9IRZMI.%"XF*5<&^.P"S@N*@
MY;SM3T4%WI<&I6<8^O9Z]:L1+E-C.CSJFAD+U4@2H.PC/2,U#^8L\]]?@N%Y
MX^@V<IK69W):W $"#(!FPM<0[\Y9]+I+D,FF!<$KB@CM7'IZ6^ @+/!F7=:T
MO;'ZT/=?]!]\M&OZ\)=2TB)YQ%#D2KY71;#68.5(HM)-%K,3OB/T5+%>'[UT
MGV!$Y)0\03H5K38E4P$HB01O\5;.WU._=D=BA*-0MNT^^!$J=LK(=/5"P)SI
MPLB+&5\PS?\%B!7>9QP$ [$O03F6["B86QJ\TK7LDU4H[I6;0IAD> Z8P)7D
MI\;VOP88#[#5GC9&>=]3K2Q%.LYJKUM?]6VVVW\Z-E;T,XSND.)P41BQ4C)I
MNP1.77K_X&[4;IHP4\\I*Z9Z\[L0\XNO(YL:'GWGNQ6$A95]N/0:B]7\TI!:
M3:^S[<'=(\N1V7DF][6%.-8W$64WIM'++%ZD!%Z,.%@9Q'?+O\F/RR^;HKU@
M.P9B2C]8?ICJ>_-/CGKH<N.]?3I%!Z *&#2M*S,RGZCI-07=ODA4QB=< 6CM
M9&WP*H]%@DDBOY"KP$!1U'TX6<'^#P&?N&O1)X9MCM"F]8?"7S%W-T USXLJ
M+]P /M(NG PSR"E<C0VFE./C1MH$\L5@?*#_N$ !SQ2%5@@+[#K(PRM0Z6&$
MB43IWD($<;=/L&SS0)%%=@H<MQ,KF1:+E,'8_1I<?]O'+'RO$=';*ZX'6O^>
M7!+<K)/=II1T)QK1$H()K,(TCFT#/JGG%922R]<AV*G&[Z^ZREZB=C]]22R;
M"OMGYU0NFE&K/G_:JWXC3AV\/:8<DYV(5OR"2P%*F/=VD78!JS]M&*<V/O@B
MX<+H;[8%NZ+_TGH6YCU[<3!E^5XY?6T)$CWT/Z2((,^I;4@=$:J-HH4W9*EX
M]];,A 5E^*F-_GOGSCQ75[^?:L_./26;M_(:OMK=LG#FVOY7E%LO6KY6=:D\
M^O(T%)=X;>SXL:[Q;_M/56M8F*C$LUW8_:Y^FA=<2J>=TY_YGSEK.W49-OK'
ME[NQNWBP?T_17<I?#>?(:>2*=(X><;UV\O$QOQF+\,>!^P:O3=NW7]WC]"3_
M_L-ZZ;'\Y>UKA067?(ZSSNI!OY[^$ /<)M=@GS'7(?>BXP8TM.FM>NU=!Y8D
MOJ36\^+YZ._(M>@U\ 437[*8+]%Z1/]#>FJ)V9KC#[VV<A-+$_6^Q>!5VDQ_
M+]DY/#=438C3G)UO?&-<]BVM<AW29HH,MNQI5]1H/[Q_;6$?IE+*.7MV@91@
M0*_TV.C-*8Z76W)?2^/>W:V$,7/.WJ_G1&?6(8A.9L7.XR/ML<;T:VT-4WYX
M^Z_#-80B'5CK:?PR(G^3L&SWYX\4)9=3A$9: [L_ASOV(6@9#71]\URU)+;M
M1QBB"5<Y5"3_XJ0%BA6B]LBYI5]J+CH3&>+>D7OR\BX+S;RWJJN&J+\S5YY\
M_]O8L2[?6]]S8M6G;/'N\R MPZ2&C76)TQZH,CVWQ;JVD6.:";W2F-Z+XC2L
MGLG1QCHX!+D>2M[G[WKMHA/'T,C>8M'],\, ;.L<,Q+_X<$PZNR+.,4WSD$_
M"6@(_NWKL\-E.%Q:26(!X6))!OMKASN;6^E65;C#.;'0]MG1KKD39^.T34IF
M7TV[W:%/PX]EZO_^[&%Z76/:8<J=^='V]".4[O?C_Z\\-ON4+3OT'*#AAC6N
MKT-8A?[KD'^?4V9N,]_&C"-9&;C[:&V&"D&?/A385XTP(-@!Q/C0R!9OCX6:
MB%0K5/7PU*EILV471YS:1V[:[9M98_9">Y_-IN7R?FNPQ6C@^SU0K-1UAG'J
MC5OGK\)I35T]18LS'UD[@,7:$[TOQ<7B/RF773\6YO:%W1^RMQNF.AHZ7_;5
M#;O?X1>0F*45EE$UW7G9*;%&-%F.-9V3O#4O79FM7KNQ#F&[R#36(46V/"0P
MZ?&SRIJ=U 8I)*Z8AH2O0W8G9:]#3CT!#XJ)'QZ]T3T$;OA!+5D/GSFG2,$_
M>L/4E&X!;LZTD;7C5"9]?R8D7O  'T2)0BPO(!4)YPO!>A].9*Q7^W?6Z8\S
MT;HOC+XT]%$.<OF?88=RZ#M-/J0L/VKB-5"4/H"G67GY,[X*$AK[G"5;RZX#
MF61!B]<'B"Q'%*I?=@BK2KC(H6/"QV-, ;.BEU, _N7 =S2-T?]P_GA&R^^-
M?C#B+WZ$?< 6M9T/\?+C$[;%4T.%3\-V1^;>P+PC:9%.A5X[^31)*TM!P7E?
MBO.Q:VNY5L^84:YV_^0$YG>4_%L6D1<QR7GFA<O%VU1^,]0.FE\>@G("_]-"
M/";^I]5"O\_-8(Z3B#H11P@ZABFA"%U\?R0EGF_2A=XWK87N("<V,O:#X<+6
MP YQ6S#!1I1/T3&(UWVJ7A]5Y.6-3UO:85I]4_SKWT%?QUAEOHX:^1N:NM9]
MSJ0<.W84^ >,W)Y?#=IU<!D09KU$(Y,!!?TBR?L%4^IQ!S@$Z'@,11DL<ZP'
M4T2.+N<'&UJQ5P8(BF$BA<HU$_?^!=C#2Y&Q\!IJT3BY?Z7UK&N)PTZAXV77
M_:]IITNG.M7\;)TKM)X^"]P18\])?RPJ,L$ZE@YYG#7,"Y0O_E$S^^05$!7B
M<WA0*Z1X-)<<@BQ#@^G$]G7(8A!_0J:C )4%'%F'I)9)3=8AMIDU1&%?[3KD
MBS/S;QV39;.U(FJFTAO$@7J0N-E3>I6H#-WF&:Q["C!^(%)TZVHWEQWC6/E1
M1O'^;A)8;FK$!F4U^]Z&.)+2(8/Q&D;-67&:6M<>SGB5/'89L7JK-!N^>J&W
MQF<R;7Q-/F16>KP8')7Z(]GDY#N"7<:$HQ1L%$*S'YYI+FKMRA"#82\[*L&\
M=ZNLO,B: E%,Y4PU$35H&D%=C<W\J#PO50 4SW;TM5<X1^HY(4S^52T[YEJ2
M7*%9EC=FO"\]O!!^_ PW<0K>JVEC,G=+X!A072WKT0E]G/MA!AK3/XK!$E'K
M$,G>=4C2.F2RG]HKM5!'_C?VWBRLB>QK'XTC*D)4)@4AK8+(& <&14P:;4!
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M^>WEX&CCUX5@/'GI[\#X#S3";QLBMR*JHHOD2W0?C#=NNF1M:-\?:&622\)
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M8AE>)()]0_=S4ED57?^(*I*-Q.8X/! CC)OW%B(JNX2$;_SU%\)/[RA32VC
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M<\^RN%G#\! [<6MAG%B"/U/1UW#L-(2;Z-2#*.ZU_4MS9>=:LN6[^:=Y<[A
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M9A33\O,NX:N=*HT_M,O242G/ASRU7-\8^Z84GRXM!NF\+854XQ,2381(E#3
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M=8KMJQJWT;,<MLH^$!%[O;+ZN+MYKH\K,P],L$;-NMPSFM5DE$V*13#SF7?
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M=/.$]Y\_A7\):*5M8HT71MA#UY[BA#K0:"X1V[P&CV_0 ((=>O5.BV#Q8SH
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M03\MH:E?GW=8"Y*!E:5>+EEY3F0 5M;-L_>OK)$0G:UL C6,<S)>7F:7C&P
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M[SE?07N3\NND1E_!A\:.J>"M4\Q%)"%U M$46 ;2 +O"3<X%>JW'XZ5 ):Z
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MVW*!27^$?UN+D2_?Y0:\)?WC\YQY[B8H<8D$]LU1@7:VU!U5/T CBTFFT/?
MHK #9YN+H;B30&<ZW9R:!%N%^[A43GFRG,#@Y(N+1JH1YJA#'25V449%V513
MR*(5.8A?0O=6FV@W47GS*?ZKH5:A&Q3,@1$UX.@='F4CU.Y=7P?1>0D7OK7"
MNWI(6_D9)JW:JP,%"EC6<FY*QF*"'4LI%+?)US&-TZ:^TO#-IVU,^W"AM.\>
MA4V9;9HX:?FUXBHZ$TGFH'.[($6TE[FE 5O5X,-@49&0BXLX#VTM="*F\#%4
M@6/F]:&#]&?I*+D9.D]LTC+$2$2;'"SF&]CDN/6+K!^?U3K'?4O2D2#64OI(
MH4]G8%5 @O@RPYNE<)3#N!4-%&35O +I*M4=2+FY@!JB\3M3,4J3%OYZ(/P8
M"#[6'>T7]V:%DTR((6P>%EE60:PQ:_<3=_5)JJ!)JW*%G5XWMP+U105 +24
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MW'!@L=7<\#[(UO"#OIV*-H22:2^R82U@=TOD]*2>(S"1F\J:]LG/Z"3\I74
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MX*I-Q##'XPD["9XW@!2>Z#LAB$O"2Q7PCP!I14! *W5GWU8PRXS/*1WHKEE
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MT$]2/,O0<[96.CF ,8*SIRBT/IT$%[<+09A;ZSUM_14J;VV/\QJ?Q3X7T9^
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M7D7L\7#,CS@TH'XK[N!)\X/>TLI)!W?=,-U7!@)MLW'X1HRB>6.39+NX>=>
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M"K"(J]M<B/USU*3;&;LW SIR%,N:&I2O2L1YK<4[-0V1P^PFF(ATWE< _^E
M:>; QU.OVVQSSR1OU[W[HR*,I);(L*=?IX=>'MM'\K67?.::"3N[5X9WL#C8
M.E-[]?Y]OZZ"-U:-#]1F5HV$(/O-4DJ>",Z$,T;AJ4VD)/*E.<@H)=%:WCQP
M=]Y AE8 T"\TU]>_J562XU%3%_.I13+Y&)7<HJ+QHIP?+[HP][@=G@'2'8$"
M!:"+Y[.T86+-HWW_1@9$6M>QT;ID25<@?IZC_Y!_L6!#XVK8-?'S@<W[?V#^
MZ"JIP.P,\/V)*92K/XIF-P=,K#&UT&SB@@8;&0W9#]/#(=G0.(&(ZXR[$F#+
M\VH[,#]VI)]Z8F3^V+>O0/#^HDFPI#N -$VAE^MEARJNQ9("YT?-W RLM#_U
M.2'\U<KQ9[GN<<6U-"+@LHK9+.1+<!2Q[+H$O"$D%G8,-S#-4#J8'$K>_]'F
M$UK<G%,7K\6I[X.22-^_:]_JL61JYN\<J/WYT?S[KQC1N\9BY0I(T9CW\QY>
M2:G/3MS1/=FET2($W?IZ*'8LL>D/XF:>RSSNQ4!A*:7M@VZ^)K0NN[5!<MJV
MY&O:O2NC=B_R=#+FLJUT,OGK/S(:0K8@AZ]BL$TO3!97UTX#\3VYB^PNYH)Y
MRSH\RBA8+0$OQ<D^I N'5"BW=*-9>G&EXL&6M0,__#"^-ES'D7:OX*#M2)4F
MWQYR-UQ:<.(+7[MG>2^\2A<AC<ML"U>MY@9'X%4*+#TP);@8AD.&<W3)9\J6
M/Z*+9YWO9!?,&E122#YK2T65.46S@V=?9R%5Q[#96Q6=/*31*E $_+E*&QPY
M(*4<H+]3DN:Z%^=*\(@,LC20V4J5XK5ELC="O>JKN#EMU4'LO\@Z"J7:'CU7
M[0=E6*ZQJ:@-)?6BPWGMT*%)CGT5AEO.<#_+\TJ HS :[&EF+-^6 ]V9)/I.
M(#H Q4N5X_098U(#WP-#D:+.@#V=D3H\BC:X7Q3P"JU?E>1B5=>G _PX>RJ"
M );.P*&?^P>>>A .%4WW_$O,'F,B$8/5358PS)%_'OG>VS.=]Z#6ZUJ_6DSK
MS26C^_"X>X?U5'/UGKWIC\HQ^!)C,7!]K7+X6_4:%A+S_$.WV[#%12NGT<;"
MYC[!9Z63V?1U*900!!*HCO#_&#2RYH#W;>4+\7L-[CG%7ZS8V<?[*) #(WR3
MM]F" [_PBJ$>NJ7<Z5@25C6!H5^G;/6Z=@-37"2=HL_I&K9D(R,%.V9IBKH*
MX(,=6)(Y1P,#>3<0<FEP3+N))_*8#%T>/SCSTY0H.FK0TTO/9+F_#")+=N*,
M#+V(SK6%T&_QZ!OU/Q'; 4*[8 <7'+>L:#*!2*(0'N5)"-2 V85PF5GJL12!
M#*)U/'J-M3]!Z9%X<B:6HW!#WB&VR8V(B[%NXHZE<QI#4W;/9JWF*;Y\F[(P
M,%![#+C .P__DQ8G!.TCL&5I"8P&6@Q,;79<W&B;?V@Q$I= 'Q,;6.FTF7RG
M)#:@BRM.N48=U!G=%ZH1.I_1].QX(Z82NZA6F_'3;Y".WVLNFZD9> JZRS;I
MC:NXTP0N-4J.<\^HK1@E]BG=2[/#(,-M,\$]8WO&2<E\Z,UHHH/$?I6/I5._
M[JOM>S9G.)PE^&3E+A^@[:);^.!MVOWJT>&G]VJ$()-;3RP/WGM48R%_>=N1
M"8/H%N7(Q)59I"R0N3K$148'02(A*&[EVP V-ADNV>0R =F'H[)^OIO-6,=&
M!;E!_]A*_Y/7'_U=GT+/:J.4U#BCB]V6_SXV(*K@,N\)=T;+!ZT6L#$.%E5O
M#<*+PM@;"P:?N)(DC[  HB4&>T_NS+MA5X,K^[Y&/'=]X? M(Y/KX (,<6-6
M3W$'GN<C4$7 5E)LRXNBPOH2ALWP.W@0!!#V"B?3@P9RD93B?!1/K76MFH'Y
M\_ED??727^U2;8M+[I"O32=2<!^QTI8"J;M PY<KO>NC5X^U]I2VNGH\9\^W
MWBVU&F#V=9Y)K#TDKVUW@G/R8O'^(OG4-FO3_F>3GN"XPM5F(>C!-:A58$W.
MAO=B :P+2-FP!AS8@VU6LA/,3Y$5/NM3Y=R.=H)499#A7DS:M9Y (6@GRB&$
MMFHUG;W1M:#EQVI=J)"^6_(T[H61YX>[6="%(([U*_QI7EU*^#8<N04B3CTQ
MY[Z[1P<I3Y^$[P**=,K'XV1E]-SWAX7^T8O56FFTU-KB$C95-6\;*+7-!NAK
M*DU11^R?X!>)?"7@%V?3_)T0)&/T8$(C&QJ;J]U-\/["#RAJ#RUVTW^\\ TX
M6XP_!=QD_ZK<G7_\+).CT?G[,(W[\SYK$L-(@+IJ.'OT"[[10.W[<Q)?DTO\
M7LV#T\=DME(-6 *O6\,5IS$6(\:@/&HUIW$/:_I:KR:9CYK J#'"C^71U_49
MX*CU%@S2-+GM\O)\LZH6XAKE,G;W\P?8M6< LI6_7U3KG<?I!^[ZY\LCDT44
MW#.P#E((B5QVN7_0X<!3CM_U" \[SI0Y5M@CGTW\_#@,B>R\]\"F_.%'C<_)
M4G+V%/S;>3V6C75S/R?MND^:%5'VA-.5:]96EF;D((]YQ>#51)[N='R3%YL<
M.;X3[\2+'V>W%;-$DOBF-SF(O8"A:0WODE[&X!KU(/?[F#JU+I.QOIJ)#O;3
M-:V-[[U2U91E#,,XNL6]BE%PWBS'^AT'C#VXO1/CB7Q")?XF-R_1".G!7C"_
M\5F@-">0>\W5G8HI!B*Z&-=Q;QP](FVK^U;^]E4:V.L)UI%\CU%A5IL;/D#C
M0CFRK8;(1+CH#X$<__?^0#R:I\\D'.2+\$0GH'&!6YICXS'EYAQCR];P8XU4
M'C@F"+E_+L2]664EU>?N)OER7Q-<ZR5JH3 ^U/\]#K$:#'1P%B7#/ZY!#E$@
M<;5I@$L+L@;!5U%2[X:I^^@)H-Q?/$(B7[D$;\ EQC9A7B*_S#F/SN'LN[]3
ME+T'G7T'&RR?J_J+-])RHMECVPNN'6KRO2>2P3YQZULD27-)(:Y]>CESE]?Y
MG,-W;F9. )'B-M)'\VZ>TE'+_)/6/P>(F88XP8XY92A++ZC;YK@,!8RR!'-7
M($WQ*'WP5^P8?G;XN?K0.$N;YHM2?EW;0X+MQU&HFFIMQI")W#INN2U/)&IY
M>$&6L;X6 14<G96/X]T(#A;(]^DH6K8.J H^K0_,?[R3]G=]'27K3%(_"E(3
M$^\7E*>(DW('Y#B+8+X]ETA_&ZXV ]NII,K-H( 98'&3DO<%[R'1?*NB<<OB
MX7D(JXH4,9O59Q"89,RLCA.O2?&7S<2[;J;RC08@N_ J$VZBS#66SGA-<39/
MF4.+2VL3'$UK6[.?GX#(>_<"!<Z\SK$Z2#PQ:^S!LJ+2[NH^9[2+3$1;SYZ*
MQV5GFQ2X'6V$-X,,0I)S2B3L$$"<O).P%:3FG)08=V@3#[*ZQM 0)UQ]:WD>
MMAO(9L*T!Y#78> TFZ8$)DRR/^%REEM.>RR)<J'$S='14@^KQ>V"I+_]6G]5
ML]KWVKYBPVV94SB^O9L]]61T\.,6.SH"XA(_MD.SQ1)\V.],KE-2*R? XO;J
MB[/K?WUIETSV*=U8^%F<AE*[/1DZ='%AM"BP9VI,SS@%L4F&*0").&W$3J?Y
M\#,Q#-C.09@:4#-K3UZE12OMYJZ0YI"C0(?5D-8F+4Z-)QTU^#B0+.+BTE$Y
M%_(M^O63BUHU"6\C?Q] @I:OS%>-JN1+\VB13185?'V>"!/Q/]A[TZBFDK9M
M-+8#*F(4&12$:*.@(D2101F25D1$A @H"!&B(C()-#)%"$DK,@]I1: %)2*3
MR!"!!)0A 0*D%9&9" @A09"9O07"!C*<]/NN;ZWOO,]SOG76.C_/\V.O9-7*
MOJOJJKONZ[JS=U7%JJB7%T'WYV?81!6@9^IHT=2<B!Q)("#Y7V/J<\\ \U4)
M8W/3E'MZ0\.6\&B"(>0$%@JN@[;4L2'DCH_@*V%X3PA527B_4ZCL_<JK.EL%
M^N'A633C8K#R6&YHBN')*KV_;:@AU65:6;EZS3;?.Q^?\Y+CU'_3-DH0U"?T
M#1E#[!9B1:_$2D);H+"Y'M.8F>HC1H+7,J)+4,I"7>#"\Z"=E4@6::-N!K_4
M_:J2]2'OHAF&1N\]$HW@_&;*\PHC_5-WCW6/7^%)7LH.UJW*)'\;<YT./8+N
M]L<5GSW7VH]Z?DCQ<&086,MACB03*DKW&\HH7RJ0W1=/35^_P=9J&O]:4BD3
MP_;\O<5.PYC\Q#I3+V#D1O:T8\I/&MU[V'E0S\^*KHH(P"-;!A%DH0:/JHKW
MF76#2"WAFB^I4\J_^>E]]0DM'VZ<T,1DZ!UZ=(9_Z*\"RV2&AT&/TV=<>=F3
MHDEN)8YUFHYU+KG;.R>TYB=J;^ME&U)R\.Q6H@;H&5-R*.[M7RIMK,'^C'LW
M#^PUI6IMO*L]-2C,B'NW]UYQW*EO5!EG_HGG_D'/1T_0QX]\NO;NJZD?P6S[
MERNT0]/VA?L^6!RIUF9;JS9^.*<S/Z;$R;)Z]SI!N_7(_WKZ"-4*!@%<4ITW
MC_)'.:3%JF'&T>$[B'VX377>19K)/BL.DVO*L09F]C_LP,WLC$6LL[?%:'K$
M.\L_7??NNJCQTP.U53PRB&"-\7WA4GU3)2@=FT%\'6M [#W0M8R+)^HPZ0S1
M.QHNL?J=*SY\YMQ=I8JO;<!P;G>=)>!V.A?RY*L=? UN^<"375!JD8D;$T>9
M^HZ19(6F@*@C7HA[JYN6._3M^L VQ_Z5*W5UO2'6?P?/(2]U+Y7J#2Y>[5OV
MLQ5/R)J96/<<GU]8\/>X6#KWW?WAN(S@%60:C#>XODS:C0D+Y)MPM\&W82$X
M6UD='=OLXI\L$V\@9SC3< 6*%&)]^HEJ-73.1 W%*H6UKC+?8Y<R;8VM]3X,
M$Z;W$7\1?W4[!M:Y%!2!#H*>;GTF C\D6*D&R[)X'0GB4T!_]&N\-6N/8?GZ
MX4&\"\?J?954"FT?"*G%^YN>+,';+"7[LHT)/7BGUO",>.%!(Z'&C"4&9 L5
M]C:.PF6@C$823<1.$;J"JH+3H+B>7Z]Q(9W3$ YGC:V;33E2U&@VOM=Z%DIG
MZZ1I(O ^>,Z>VS*R(>:3G%6(G^W0=16<0*/]3>.Z>:$P$,*^G40= E'/^;78
M89DFU-9R*)$Z?<*%^]>2-!/W,0ZEOAWRN=\L* J4(B;C:&3\>^SZI4_\U@CM
MMHO(W:_44PNF,XE47\7YK!"YX;KRQ@/X%R?/!OENGCVJYTF0KR]MKQ-??OLT
MKB#^T^:00QM75WJ(ZN)A!)R@#4A@E^I!R[G\,5*L^!1D_E^;T!9_P*GB,YHI
M*O?H+#Y"W9NK1B,]<J&WC%?'U6WD?[C'Y7T?00*8)NMZ&>?8QBIC02ZP;D,#
MAWO#PF-,(%G!L''VR[&9#CEB#^*K3 .[,9P:YZ<53?(A07<>KM^<,9ZG\$[R
M353!(@F,]5MAXX7.$+F;7WW&^+E>UF\QGD3B8=K]Z@5F,N,P7IG7(=30'L/M
M\28BLEJ)VIV$W3QK[%33"!35@CK<.Z>?K&'97=)IUC[>O%)=-7/*?(^%YT:#
MON]_8C4^Z1%"P+!&RLYEJBP^")?J^H%3=R=D2V<P>2<>UXPZRLSF7*)<KNJE
MJQ:3X%,U29G$#/? DJG?;TP;-8U\.1-P,ZGM0\,K^$2U(!%BK5L+]2#2F"\R
M3@+;P_3E;O3*=&JD)*OKB5*"23L)UN\ZF5ZN>K-"9\IY0"8.[3.C!!XB:H.*
M47A=/V4+0*>CY1JX\Z\VK3@=T]^?$GPR6'ZXM\P*"2P>=69& J/C6DDP/+E%
M?$0JX^ #'>:]RY&J]I06/9]M8Q1Y<4^0%WHWC;D)_^[&<%W%M 2V00-82*S3
MX<W(V;FGLM25P;#84F='99K'>D_+R'9(%82[ JV%8]QMA"-@1WS=[A)S=%0(
M7'D2M0LTK.7!=]UH9XP$[!CV-<RHB8U=CI_7'^[\F&_E'7&\7_7/RL$),PEL
MQQ#!$!"NE3*C7@&H^" ^5=X'=;!_%/CLLC,+'2?$E9Q5$Y>6^91[^^[(9,<;
M6%_/J>\-,:&_[T/>3##)>CZ>K-@@LQ@_NHZ#CEHF$VZ-1>J-7195HO9!1GP;
M2L,1@E5$$<1E#_Y(,#T\9D(:XHPFDUN.FB++H$<L6X 9I1O,'$BUAV*UXNY
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M26#G/T[:\U\0^H9W_-J3I_T@K&R=,G!6BER6F"7[0DCHCD%/VT"I(E/5RVC
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M)V"!E69J[,@.<(5,U)[![3L ):YK3ZZ%D*/KPO+Q));-:+TY:T2M'B+G$"Y
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MQQV[ZL=G9_?U'SS4K99?_'.F9603M)@[3=K-K!2:@*6F9E0\6_"TGX@8(B#
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MR;X[OW]^=6&/N)U9K1Y5..UV#,*4$O (>>+A&^*!=(I\JA/47CPR8#7Z@6B
ME\K>+:;HT6*$(O1TI9&[DV!- AA#+0P5R)IOLX5ED<KBU,SEXF.OQGP9.3/+
M#-0/B"=N W4FDJ6R(9S=XK@VRMF<7<Z+YW.6MA8"/Z<6BIRY,^%7,UQ"HG\6
M%'H)!!D.+6;=E;0CO+V<TQ0UL>(W_*>%ADQ28G ]MMGX7JB>#SBE[#B8EI[
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MG-Q5&N?6Q4[[;*J,X[N[GQ (($4V-13_J%CCS/%UR%Y\BO7J]J(J3&XCZ<"
MU/(E(S<6&_;"UV.,VM$PH)Y\\'CGP!,#P\@KA$LY<9;@>3%YURC!B!>)4\([
M7 7M5@V([>?'N[L5!&I38\>'XHY)<1)R@M0G)K("GS[APAPPB5BS] JY,SUA
M]W#DUY@>I)U6YMO^D"^<^3^/X[V7MX/5PKGC71HYQ#U6.H6$"X-2#6#!#HBZ
MO]@AJ:F)$.@0$)+ ^Y$=8'QDR8RY^&K? 6Z#0#N8&_A&MJMA@&[^XE07-G"Y
M\FB@$@^UNAE&SEY2M+O(!#[)MN5U79%UUO*DUI+KO<_-,@ ,0L43O '=!N(Z
M9%  42CLSO>.8+0,+OPZHQ#R$MNX67ZBJ7[0:!Q@=IKP[3IE!X [F7*I9?V'
M!N*.SC#EK&XT^BH#0J8$EX90E!X'$T0X[> [41:=#^[Z"U>AJ:13 ]*3_B%6
M=P8VHJ$]?A%7/^9C?PQ0AS:@NWR\1EC?\ZZ6K$,4O*\EXK'L%6J&U.(UP ?E
M1)UE@%AL5BA2BG^+"\3Y1]XF:=+[(N1MDJOAWS.-+L[Y5\VXNV MB(\W+?-F
M64!@)W,[0;X&M.M$Z'.6/'"1G71@_ND+G^GH*EW5_N2DXBGT\!W9<8EB"3/#
MZGSS?+MH^;V8_2VXF?0$ Z_YJ[FS".N_->/K4O8L3!S8C(WUO@Y>C? Q9^4%
M)IA^J@=XJ8Z\]$4?(^GUFT-Q!XPT5J[0FAE59-4;M*'?!I8L[P0MKEW AMR4
M7SJ2U\U8^]N**(;%_+)68N4=(H8YB&]6EJ'!T V'EI?T)7X=LJ.UD5IE#;BT
M1Q=T)3>,&@P(4)P#Z2,=N-CG'Q%/,-C&>?D0JL%K7@C5LCL; J#G7%<O=0 L
M=_!!U2AF#$8=B,S>&O00TYAG^\2@V"I<XLZ*.P2LD>]1-^CCV9+AR4:$'%B-
M9(W<X?QN/G:B?Y8ZYW!9TK/TL?'.=]X!'>/"U6W2*T-TPPW[<I?0-C0/: ='
MI9HUF]^K(: E[BB@\X$0EXK0 &I2HO:3S@*M"\FRPV#]KP,F=./O7@%E&0M4
MN(4Q\R5X1^P9F8$:K*9@H:^0]Y?0.L$6G[O2Z'(O)U$8<8'QCJ6W,H->@^KG
M^);Q9NFI>N!+K7!$::\'QJUV<N5)2=*&3*I:<B#O!S-0VDM0%8,2?^SA@I0V
M02:TP:!Z]4HP5$&*BRWU"<K368>D$<PIDU$6<4_\R@T2A)2='C[X*!$I/Z!X
MTKZ2OP&1EDV^6SF3.5[9[>/F:,+2NE-0&72Z(^J3KBG8(D&Y@%,ABKR,A1JX
MCA)[';+'ZMQ=X#G>[(O@,J";X+=Z5;H-R/Z36CEZ^?V.4@F\*TNF30:OWJJ)
MU*Z<R0BK07<+.7Y^VX9>_!D1S9Q5DYBP+>22;TFMQ10E,-E'5REU;'\V*SHW
M(^XH)D\W7JBDF[W384^7B+@5C3??"+#*U-A#JRS^?8IA5C&VP/TJ+^O)W>J[
MS=>UJKLF(P1*#<P]>',GP"0KHL#$&5C[S,ZI^^#A.W.RJVI*?>#"+0->S:YE
MWG>+@@_WSBY%/)R?/UKSRRD?7^4 7'?B6B4SZ Q=472D1+*+QL\L8Y,5)F7'
M03*F&#1@M9%W+^J$=G?6C7E-:;VO$ 89$2S#U:G/)RULWJ=(<&W\E#0KS>V5
MFR2[BU[VBARU%AR'UR')56LO<D4:;:/'EK]?X7P9U!!F/1&C=D+E+_,1K3AQ
M[VZL11(OJZ';M,]8&E..4<_M+GS#_YQ3,9Z]:TIK8)JD*NN1&%?HW\_:M!28
MA=A,L%L-C"?H ]^O 6.5@,O%UI]W[SMU5<!*,3%=]Y $F4%WW%V/B2DJ+1.U
M7A!W6)26C MV>WMV19:!9E]6>([,(?&K;!=,Q#FKJ:@Q/^3LR; #C.845\!4
MJV,LWRILNEO8%#>ZNS9\]5<T(9KLYOWFQ>QU1,H=AO;IJA>?@N4GTK:E>E1.
MC!#YG.4D7+(6%IEFF".5VE+[I!C)GU.^6QJ!E)3?FL'P"GP.S[8/WIV]DR6<
MP6(7M#PZA*N9)ITRA08))7D/WDJEVL=>?,[?D1NR#KG,T,+G=^GJ@SA=VMWR
M28N4CN.";2#*98BN^<=73-P^@'A_"24WQ4_DFSZR?F&28;08:^WT;-HHLMMA
M[>885WQ+V4:K*_A/J!G>;MD H<JEJU5[HO$&_(7VG WZ_^RVCP<^;(XR;XS8
MC15HP-%J']OPY?5V)AESC$-3.;67OVJBEFW>#([A2<,NBWL8^N"7.-,9]%:J
MPSI$PY( YTE/BYDIITIH[43UGBH^?JP="05]^=_F>#R9&@>^=IH553MZ^FVQ
M9Z_?R^LVN,B0*A^'DK?ZU(EDJ1/(6G4,XO/8H]XLLK(;ZV)?P%IIC10I+ 1X
MOPSF:"/C=??U67D+O?5>?O2&KXV [V2QJ%^XH1N*OS,A# =-$7.LSM]<F7LC
M-QV@]N-\N31DK6QV8HAPA70N<S$?3X@1K:+DLY/S#OZ)D>U8*X7%J4[YJH1X
M>&<ZS<(%VV;V!%MTR+R]'WZ[/$#545]U:-"B:]&FUR![G6S^4U/[1IOS>S&C
M>VB-S#@8Q-_^I'PFFOH)L5\][^:C@/#R:0U;)0TP;MH/%Q"XEW?Z[^K"O+M;
MG4Y>NO'0MEWOQ(I!^N+7*^_O&H0_#C2MN-!ZO>CTFYL1D]<>W3^.VI11DIYT
M])WY8S_G:X_UCTP_"@F^.]SILTM\M.=4'M70EH3)];\]_:2BY.A LKFBNZ+%
M7_=;>6=L*Q]?:P@YO(C,&Y9ME08?$ O-V0E=N*W@7ROKD,$3DNS.)IC#N%*7
MIL)=HIS,X/795=(VB758;VG.']%A/Z+=%]<A-L0KSBNN8=L,(]N?6G*7\;.X
MB,6&B _24RG]WPP+]?799Y]5A^AJ*(1H80,_RP*_NE/BWJ.A7Y0^$U3!6D-T
M$[#:4776<+_Q0[L?2Q35#2$9T,MWOO$%^B=ZW^?WX[N(BH3?QTF"<-NSZY!S
M:92YS>DK1AJ<TVFO8+?_\+5Q?C^3?^)?=1KJQ5=$EQ%0;]*]__KIZP&^WH2(
M(-ME*D/C$U%[';().?Z,V>#>A4QKQB5*'8'5SG7(3H*.JL)/LL3K'%/A-FC[
M(.WLG0Q3[%*\&E[YX'R:1S]]P'#?O\OJG/XQ-RO,N2RK0^S<&''D*D)JV<?8
M)SW15]@GA1>V;X_SC-1!__K@5]^9O,_ Q4=.7+BFLD-4U &G[P=H66,#"C'X
MUAOITMQ.*!3?U7GTMQ--52=^F)W/*7%78OT(\/K:YMKU^MWI?VNIQ^T'.V\,
M'I[R6WMQ[57$=7%*V<XG$CA6EI#S.>(4G_#X\[%'P>^+!YP_NS4X>]D$Y3=6
MS\\^M-GKA$[6_>O_[A+[_TYSSR>GN8T_V(CR:';"/3M=A<%_Q'U9.Q;U$GP?
MV$#NTJ1&+<25/;+#ZQ"AVDMB$A2HFUN'3#J CS9\HUN%3&W*]%>Y?&)[-VT=
M4F@B0LE4O,I IPV"9"R0)3+3D*!-,%GH^^B_D/Z_@53]?R*5(Y]$.^[=)!Q3
MXEKIC^OL%+!\54&<!'JY?V[>A*(ND*D@E06]\/FRNXC"<M^Q:8LG'5]*-C[X
M7G<\U_%Y;;3GWQH0<_G8L:7_#GOY?Q[@NY\#//[?!^AN(O)!MR-./&)]Q3\2
M,MF9+C(5G+(G6'8Q&;T3GZSM'1)S-0L_"U?(L,3^#8,;U)GO06&WERE^KFX5
MM<7N5;B+#;'R%?_'I"HW)L7XGR;UGWMO_(_>SQ%%Z8,;5#8;]'1;ARSJ$^PW
MOAR_MN$)%O..;.EA"@.\UR%]3WZFZ]Q1[?+SIG32DXV@><&=398>HJ( BOV+
M/ZU&9.H^S#5YXAXBD#Z$_(EUYR>6]#]AC6Q@Y?Y?L7)Q&UCH_\+Z+ZS_POK_
M$]91"<&.EN,ATE4$[R?;[SGQ%31WR3H\UA;USUR[;=/'>;SK5M*3R<'_2'J&
M-HP;1JM*K8%\(2)#A-P-=LF4Y>'0=/(NPM$JL#7"$JK270CBV+*C#0-+W=VQ
M>DZU@]4U\WO>N:L<K2/9^#<?'MO+X\(_"31DZET2]"4@ZXE!W<H!@,)F;B+8
M> Z\Q67.@-J^"=<=CQ1=YZ=J. 5M:_%)?CRR_93"7<EG\@OA?E_7>-&M;$V2
M<QGZ2/N7,]$_DK0&CXHPKBP7,OQR.&NH78QQO3_P^8_*A [GJ+4ON@UG*]X9
M% OU=0YSZENK5K!E7PB!0,KRH\%\D7F&%S+S&^$NJ#K.3)(=EQ#9@E3W=8@B
MC*ZVL5CU';K[FP9"&YA*ZQ L1NMJ2ME,+ND@L-9)+7<0KD-F1S*]VF'&"IRP
M_1IAUN:QAG,3P(+#0.0YAPY?98E[T@1.WA,4MUL$C%6/G[L\T3&FPY3(I4A/
M;^W96+C1"ZQV<VYT67J$)KS;1-,G*.'BP,+[LKO(1X&$QK$G$KGEW_OH86*F
M&OZE8MS"+WVR(]*3$J5VP7V92EU=YBSC (;&W</'H]F5$<9^LBY)=J)BSVAU
M34,(7+4B* I5Y/O+H7OO8XA&?4C_7M7)98V_#-G$E!6SHL#Q$90</NI7 /U&
M:1MX!W;Y"-SQT,JJ,YCO'UZ!A0+/=&)0_1S6RI=,OTAAB/K,A@S43^:.??W"
MQYH,CIUN-Q+V=]U467GB*:S#N[YY>::JKA49>-3H=K5W\NOH+ >KZ[7'JDZ>
MJ3*VV^E:IS3[[@/!"G_O[K,*_V!)OV7QYYJ'#&[=LX\/&]^^D_*8+?Y]\^N0
MX!X-6P#&3*<[ .N03ETH;PFEZT4X _0FU"S0#Y[&L]C1R:1F:@$O21J $YD!
M9B7"A%*%RA;!'O-4V&R#8';T*E]R@T[UOAOT(8Z[<K6ET"%<F)T\=HI'=RW!
M5WH"N R"R?;J\1@?9)M79THQAC_;*T*F:O@>04':RJ:;?2FE'\$;7WCHYGRV
MP6=1'?7;K<C#==\RB!]0#FC%8+,%$73[!_"!['@047U1T= .],-IM.$49RS,
MDW\',L<>88'L:Q)$Y2Z^>WI#1JLM;F\SF#/P=<:C)<.54\JY61NO&8J\$>L6
MP]PU4X?G"*ECE&(LXR071S<LERH-",;_(:IY@#%77[WNC]/"^!KUTPMP[>IC
MT&O]D;TJ8 *;%Y[IXN;PY%+-@X.=^Y#;F7<W#+.BYT88W-_BP]4C2;I!XZ/7
MS7;O"]Y3[7;7:F9DYS3J1$F^G2;A8BUNT[:=GR5:,:U[^MM:AT9"NY\&+V;#
M&NISRM!"XDA@&\ELT$H_4(B&X-<AUZA<J4Z4>!VBAMU-VE<_@- &[6PD*:E2
M!5&!>X=[/9AH%_Y_I!=*)< JV2$$RS5J6.7PB$-,4<FG2^<_Q1V1<4G&T$UQ
M!M+S0"[KY[M[GVD@JD+J 'J+LU4GF[=7%^(3'!I><QZ.85L<+9VYN:SHGK72
M(ESYE*Z.)+(UZ4M9V;\#+,VFQN:&A"I0;U4;@Y8W6EHS=)&4=-UOR%;>$->R
M?6/>4"4/\+9MO]1: A49LA5&'FM%?N2J<P)%.E\>YG#=U!L?Z">:FTDN/%2X
MA)E&UN6R47L()X80RF"]>*BS:+R2F,0C*UCI!Y3@=<_IVM0^;2B/6(?L ;\C
MCC 2.L;T^B.J#RF>OAIK#)6?^B<T4N&'$4DTY:RHAY1[1;<MB<_18CCD3@R[
M7KIQ^E(8//IIEN.N ,)5XX@_L-LLU+"=)]O':SVN=\M9*[EOFM/9Y]K!+;AN
M28U2Q/TK6LRXUU#UA-)*PU28QW43,2!&\@ZJ"W+82"4J!;)A%K2,!O2N25^+
MN@&K&\U;'V)).R0&1948"]\6C$E*9.MMA>.I2SKJ7WO=^I;.PN ^QN-O'K(.
M/,A#'ENKB3LAO0!8Z>X"S-L*7"YR9(9@#E(-/T6^GH%JKD-MDAKWKT-HD6L6
M'B9OLQ0HVEASA Z@^RCJ\X^_4)11M%=S=VE]UX*R]-2E./-@I":Q4:=X$*$V
MR=R5%;\,5V'G(3.H"VJ*OP5#@XP7_N +Z\QN#KG!&U4S4D[]S4GDKD-N$C?A
MQ2)>.N,HP6E@42E-SQGH2J+KC0L4\44LK[BB4E#U4M_$4*2.3P./$=,61A3%
M^KNNAA;=@<UI'GC%F1WZ_9*6W0^C(IVV?<8&K(DSSXST'X]_O;QO8=8PD7WS
M-0&E@I*WV_EUR>%4Y0Y>FS!L:"*/EX747+IE"]WF+;=S2=\W27/$=?]^W,)9
M>&^D>F&,8-3+K'4H(((?C0V-GEBN!=9ZF&\DXY3-8)?(MD(RT3:PX96;B4G:
MO]P[9WF!4]1GP)M?6K-F:[W/#B@U2%.G9]RNN_SMW%P]Y@$;5YILT+/AE^8*
M@04VPF @XH,I=(^UT$0-G\+6W0.@LM7%+*\D<CK=3O@/%6-L%"(]6C+#8UAR
M0I9R^J@>5K#8EV H%Q;WA7_FX*7##$[2:';B.J0N,Z6=J#T9+7LBXH0+3>0V
MHO/,*P 9WYF@4T))VG#TCSIT524$DD;]H*KS8\03H8\W:R4=([^\8W@67H@Y
M>!_3W]KU;)+X:C!Z\\\,7\7@!"L:>B]B2AH6)ERS9C'EZ:=+"0$_2X U=_O2
M.+>6T!FGT+ZH&-SX:L_=)=BAU:O <G:-P+$4<S(XNJI_Y+IV[XLD);G?:S\0
M:V[X[_.K57WS18T;H[5$,M1A.Q?)]Q4F5U[(\<_]+0AH.#J O_MY:/I&?0E:
MU9,.(VSU961UQSI_:DS7\6XM'G6DNF5E>"]&;=B<4B+A5#,+ORKD94EW+8]!
M!AEZDV86)0OWX(KN7GV+!2ZL9INEK,K22<9Q9OX;_E(U+WW1GF*Z#M$RR]Z6
M^9CW:$QPWN!I[%;=M^/9F5ZT3*N3Y3-_2?4E/3DE)6#V^;[/_6[?V_C5C65^
M-=<Q;707(5-M*NYPT\\JE,BB#X*WY=@]F)7Z8+<B5&NMCX6W) 07]DTIA>GG
M&'ZA%1BC^$OLVF1:0W1]0, 6[(X8R=Y"4.N/N 2G2E3QH5BF*GX.3E;%Y\QT
M-G=6FB>'')+HE%9$-_L6^<6\')E:7K$96NLL-*R5ZJWE+_V4:V-6K4#O?<)!
MX6B,2"Z-KE,UK86[Q] F[R:<_OF83[%GE]<0+46Z"9D1&?&*9Q58DC\3BV4K
M5/V96_]AK*U4I52_E3T!HN4+<P;O[O9/JLA[^<&SS;6HH[9MR.%T24K%>9=J
M%/^W5P_?N5YA:?J(PJ^[7K]6DO*F:XO6-;_T S/?8J:^#D\76%+N3$VU?.G'
M["NYN5")]G*R40/?]OVOCO'^GS0U,;E!+GN)G"380?<3,Y6L_1"US[N*X(^]
MGJE>]V@)UCTT8/J4T;]+P^S1&>^8'T_-KMNZ_7K?X<B1L2[T2=DP\FO(S^H/
M,]E)S"4S8"C6<+OPQ >9B?#Z[E/W3^Z[$KCG=_P5-]T7K1;@+5M,4I%OIDTD
MWK7D[(7+TY)'[@ABQLDS]S5V2HQ/R[M%G/2X"GT?=B9X<?2E$_O7[EIXT% "
MEU/FK/+,IR#/;N)W)N"$S"R7]]$0+O_RS_NT*A(2*-[/0\:L0[89@C,A!7E0
M5HY8ST*]D9B;QI,>%WEG-\>1!U>A4TLUIUT[M3E;L[L0*:36]W%/9%E^A(/
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MZP''1##:![$>O"B"_4#,+K[E?)SZ1S/2KBQ+^4\N?J3X7T=_7T- FC01[)#
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M D?/CIVN5UK7>GZ)6UM5S\C02L#Q[L3[7+4X=-UI,^?IQO@C_W5(G^"I)QZ
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M%7=!+D/IS!X3/SSQ,FO0& FP6E![@^73!YS/6DG=61DM6]11MQC6^M-CF:E
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MS%7&P)(57,+BJ<>EZ=VXP73YU6#),%W[.];5#U]:UUR[,U^O]:9>1W=D]K6
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M\PCSA050!W<JBJ$L(U;G"Y(@XC<(H[X@401Q>*U":@[$QC1\X +,!Z#,KU#
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M,UVS4.&N8-:A1L/3;\<W0GK:O,CJ>?(5:I&OZI.<&XN"3Y="+SV.O_F3-&[
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MZYDN%7V;1FD_+3]N^\>M4\9QW]7>7__FH_F=>'XGBG>:>Y*=%N4!/ITK4^C
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M:]00J9'/!K*<O<Q-K+)$JTIY-+LM&<FY5<2XXC]SED9+W*0T)05[W\EXFXE
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M+]-,Z&-ZP@J+?=B!#W3OG\"TP!9G-C_:!4&=&KG=*0S_M>36DT,FC$,<@2W
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M+<7^0!\%$SV"3;:;_WGB%6,(R8=> /QX.33?"N&@(D?V=FHG26LGGG"'HSC
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MO,[&%"H\-=8"7."/L-2D4MM@TH-W3^S!W$/@\/>+@&])9?&'SAHKGL/5'VV
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MU -_&2]AB7Z=[/GZ:@37Q\*Q>3#OT-W? VX,&VS<N1*BQ%CY;?LJVCJ:2Y;
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MU33IZZ@2<5T,P)@P^8MR?G</\?4:!IH@7M<W_<Z9^S-[Y&Q2%I^(K(U6>?C
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MA(\D:8[)+NB%,HIW3H#"9%;0P2M604SZ.H4:54+I'4B>EF/P)K7+>6)K7M8
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M.U6MXDS)6957[.L<#T80V3=B6A>XPCPI\+6"101,V-<XMX% YG7.K:&Z)J)
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MD'[.E._ B:F;\M$V8UAPBD#T5O42F+^N#6;9W#JN[,V5=.PJ1YK(D_&'I&Y
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M@I#U5;@(*M>Y7,8#.J$VM0OR7'+>VX?!NZ#G5S#,P+_![*, >2ZF<SU*=99
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M1=\C-;>"W -/PCT#CVVO);D<>.EP0_8)6<%XJ-6GLNK>?&M/M[,DEQ?3V0W
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MSS;()/LM?:(YNALU@7;VW'H1"G@ !BPU8%^>$6W'G2SV&-#>"QK+88C!'.P
M^CKSQ'C@P FD_7Q#&9*K "!W0:*L+<1$8)CQEN-8)5IX&.5Z?51#,45@H=;4
MI:A#D9,VBTL BZ&E=D$'>1EBD>OA$*!D3O4#B0KNG*E3PHK0F@%X.4<SDY[9
M"1/V"-IS92 :*LG0:V+BR#F(V9*(1V@WVCH81>CAGAL-6 <#\3+(L.,Y= _O
M57Q[[=Z$4<!)-BUSQ9Q]#1 SKPU3^46>$?#VCHZ<YF&"R1?0JDB_,B\MEK3
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MRS?W$'93TQ\="YZ*Q_<?^6'5^;;ES/7'?/L_G!;@<2;[TZ84^NZWO?@%']X
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M1=4!VYM#VE;8&[E<#Z^J0O+W*2<LZ3Q@<?K9?YY5\77%KR"\"\K.CD)O)PV
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M.9C'G"U"I4MX4''G0L;P=2(EF\D%]"$,MQ8K)7:N&Z)*F>S%B=Y;F0.W&>*
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M//S(/ ^?[/?US;*?N,YLUB?$W&))T,(K/NVV *O+N3S8>GA510DY4?CS8K]
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MC3RW>HA$(Y5!Z&'U,:BH?OQ3'-\_QB!(WH<V!%U@G\1XQ+QZ# K#<V)^DY,
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MOP4:<J/=XKE$Z+7(>_/0MT;$0INY8)!X0V "MHG-8VX)+>&38JT>R,R0M1?
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M"31EF=/%3?XQB2[SJ%44\_$6L@%B!1;?*>6S+!G;>J(YB^$LL16N*SIM'K6
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M3S^X^\#/[/#+'Q?['6H\<V+IUKWK;OWHN>B"\ 0<,8MA+($/0!=&U"(Q5W\
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MH, FS^".@]W6X!17\XII2I?/H_9T?T_JI0C&-3-[4^$SBG<(^K9S.^%+O-N
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M[<J"[("[%OS6_O+?_+P<"=YSB:R+-#D:\!%EC#/.\Q2(\PO9T1Q:,7QM8Z?
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MV#2"H206O/E@Y>S:\#R3+E8H.GD>]5(OF>G848I@LQNUR^GD*0 .5I-,X&_
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M-*(-=$2;=!IG L>Q%EA"YD_@YV8R#4M(YU@(3;SW :LP3D<MI[10RSZ!HJZ
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M@#1.77<!$C]0&8ZC=(1: ]&=$8Y+U^R&PJ28&R@+\.-=<'_B7>)."2*_QA[
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M_> LNC'V/93)$4Q]+/2I>7,_09B0R 2"D-D9K>-7W:;0O0PG8*849:Q"0%Y
MLQC9:[ +#B>SPH#E4Y"+-"F8%QY'2?4Y*@]X=7G<._;)O&=-!6@=\,:4@.>2
M;$?=;!"APS/M7;?'/XV9K8$&E <T/&H+/AN-$^94"HM"SP"4!:72/5(S/*)"
M 6F\7BUP\WJ^(+D-']L =3X[,0G>8P7O?5$[*TB;KG]ZDO3#?&AHS8:V5Y3N
M:4NLT2P78T2YSW!?A?6@G5$[$E=AIF[H7'*K/4\X4>8/34IL'+AD"Y4/\/M7
MUBE_.C1_;/!BIZ-WHI@6TVMK,]9*63O?L0K+6^QW. +6ME6D71(/F MPERW3
M5[Y+O(2B(S^UFJWY[Y*8#.WB-XLRLP)/0.G*$"(&\A?+-VLGQ =(E*#S-&8$
M4S&J)(8>C]#MM,P2&5B> NH:I/"-!#D'8;B4%,S.R'V+G?KDN3CN+KA';\ M
MNR^SMIQ;1N=JU\?,%@:MPL1XTT^53OFY)$/- +79-E_I3H0!4TWWTZR?.KKU
MQQT>[\RDS7GU10I\S]5#>N+VW)8T9N7<*NS4JQ<@BG9YKJ(<CQ3<_G_]9T%/
M3XK,J]D 2@7_0O7L-L^IZ6K\)=WJG0L53\HEHL;2W"3GI.6C7WC6 ?<8EAO]
M2,&J;S4'H@E2<87,IE%U":1RL1L)RD-@[DR!-9<$6X7E:''N;*VBNN%NW;#,
MM?]09^*5G8^@"Q]<P4<^_WC<9,?$*PZ[!K YRCTCM%.:L>&^!<WP<^&;Y(&V
M"/G4O:3)C\E3->[2@](M]$XQU?3 2,[^QN4=?Z44GGLY;==7<_:N>/[<;W_.
M+&TYWO@A<$VH]>&NR&?)M+BH\3[[G";0[%.HHF8<?O2WMZFXT=L[=T_U?'5P
M;QV1!-0ZT7!1X?-/*\3X#824GG"L IG;\L0URS&R/UWAE5YS3#-RJ?E=15IO
M<T!'4.%-9KS@AW5$<V4LJ0]KKD$1ZKC2XT#]0@/8)[ZA,=2P*L1(&4;L%&8'
M94KCT_3_&Y%4L.$%->N!=UU2?2?_L!$DK85B EV(J7-L$,M,3WU[7^6J7S<:
M(E_\M0C*&&OX=>\HO:#A3%?&RY2&\-: LPUG?D^_/?=3U>V9/3Z1CR?QEQ-N
MA>^,G4#DE N!P%58<<UF,*N-^0P*5AQ0T\]K@Y.DKF$88R1T@? $^&$55N(J
M2Q>]NR,--$@,'OKLJ-HCY269<O83GHWT1?F'O>;S)P^_L.)H:%D?A0%+Z6PY
M9 ]G!?E+!KC"$FP+EHW.(9NHSH%H"9I-1Q 2WCK8X$.U?<YV4ED">''<=7C^
MR3*Z4U-)P_M9ABMPM)4&901.F9QQ;>C?/<4Q6-Q_2&\VR?Q/Q#VF-N^*[C',
MH&<K=5UU1++ZB<I-\K\.J) .1<5!(T\@=H\ 443,%#NEL/;WQXHQA9[VE!:J
MX:P5J4QB$''\>1N06YJ?5H?S;'J05!]YI#]Y$ OY*;= [.YVZO.2^AN:[6SI
M*LQ0PT/H=$:(<:%A7^WYQ$,@M=?6'$B_NDBVQLD3'^.L?AGTWB8B,'80L.P7
MT1/LQK#9FCTO3%K'%M+'AS6Y0S\B;MM^IXWCC'D!5I8D9I8R=K=#_H\(&#&3
M0[W!W*S:KFUC"5TT-$]R CTX4=;1P-2]#!X;;9KH(=Q(,H_$=6"*6DO\>0(M
MT?B]8D)=DGD?N]Z,+GJ^1T)&EM '#%6X@7I<2A&Y!<_"FLZ&# !R"586H-Q!
M>G\IL5*=]]H^S_N<B)H?CKWJO07T$I\:6SQ%.R=1;F$8'THY%^<CJT+=E0;9
M:EP4\?AIH>*[(ICJ"RA?,!<QU\^2-ZD"E;:$%'%]#[)(J*M!1A+/ ](Y@6U]
MIC:_%F34M8I\,L7I-X@N(&KYY.LR3D4(:3M@62!W[?+J'8R<RV#FT!?55@H6
M2\/ER_T9^2SA>BT^(C>IPD /F:_T#3YGVAGJDW*@;<!VMGCF*I+X$Q..LM0,
M6"%[LWRQ4&&3KT1H,O%):QAO$*^D>D?0":V?Y=Y>]W'[X'"(S':W.O%YO*/\
MP8J]'XR4JAG#OJ1SA854(]3W!)Z(4DRRBK]$3%?_26?&HHMF05MA+SU%3-Z$
M+B">;8@7&G?J(?(ORL^!>H6I)6B)?6G+?T0[>K]8[1#\JHJ]7-_;MJ<^.AR[
M@N=@)I9Y3&/F>68I\Z6ZJ5Y$^VZDEZG?RLS&ZBYQRK!=2KWL.BBM%@KU'65L
M=RR_^7I<Q \-*3M5S'XQ\,O*81Q%QWK668IY&7\?WD<7!"OV0'20USN]>] 1
M+:Z2H;82CZW"<C?L:@>19X"=2_DR!/ 6DQW]_4AKWU<1Q7@V/*B?6?)YR7_X
M05EW1WLAT5\<IMD\YUE#2TE*DD1XY&-L!F1AVM"M4F2#H5R*T:SM=B#OCF7O
MP/L82?K"H\<\^OL$RW2KN )5EJ2/;,2A"]U:._^:WERJ__.YT22G8NS I4V.
M?W@>S2'EG?X144AM07=C"M'-JS"9J5@NF.D)Z9,4@Q*A;OR*7GX+.4>;Y%"[
M(.R/0RWRB3<14("D@6D;+]SH*L/R!#934_U-MU$(0A6KQAQTRFT(3!-CS'@/
M9J=W6+VC?A#J:'=M)<(4Y:SAH;8"_KR9895U ^'+LN)B53205$:@=@ODN0QC
MHCND;;!4XPF<WT_X?=:-O@9B<BM684;>@3:T\K*F((^\"5=]@\#0B/Z]TK\T
MUW;?AW^L4MQ64]$)R.LUZZ$[0"C+TQ%MU>D/9BKV(EXB\](:,%>91IUGQ;*X
M[ND-8'MOOY>HMK7NM2AS ]%:A"[B:PP@K01:.&JV(=81]V727 *@!V*Y>500
MKHEP$O$>7L)L'N<X94:I[S'V$\U ^'57:@FUF5$LD6\4?**:;.?70NE2H8[J
M!"#/:R';0*'A8T2/=0,%W@>?^#V%T*R:'<! 48O,(3+"6KUA ?FMRJ2 ,Y@M
MJ]RM XS[JPO0^ 9ZX272(--(E:C\@="G*!AB>*KV0A6Q#>'_$OT!)JLK43S
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M*W4[XWLH^-0HT0[4B\Y6T %DD:M<$'A&Z_ 79H$R43J['_7U%*BC\@#1K!1
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M8QZ?V>)#[[$Q&?D1*DS/ NN#H7WB&-HG)S%6H,-:)KE 'L^@JC.O7X['0;5
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M<LVG\O]9^>?_9P]Z=>+_ E!+ P04    " !K@6E<$[684O?<  !WY   $@
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MQ:^?=T4Q$2F--\ \HQRD=/A9@:=3E\USBR;33>(7'#>VT!7(-RZ$E> 83%(
M5L">A7N5@S$Y ^86[A6?)\W-!Z[[_2'S.=C9!K;S_[,X8WMRM\Z>!U&11PX_
M"E?ZM&0JY<:6D^8X'F<2U)R2=1"A\K>V<$AJ5OD.+I+PTW_<VI=],BJEL21$
M_ _$:Y+(5*QR\J"--U9427+>K'XR9GPJF)YPIZ"I\Z$WKVTV[$1OVJDZL*"U
M$'75L^R+P!1G:F\V>^E\S^P:3&A0U<\*Y.[&9^TFV)NMP79"5]H<)'=_S":_
M[^G_>-Q8[V'/D-SE])_?\.VU+EM2=9.GY[Y^J:FK"3DA^-RY/P5]$.<?&GIE
MCVK@?RB@P;B\R=(K$!U%/LFP!_N7!MYL/-TC.4BB>4-AI6)3\$K2+50T1UF/
M'9([C96EZ-M%%$-P44PV,BDGR>%\]XXUF&/?*T'(YK[6S)SAJ5G\C=\@+'++
MVSV1BG\J;H(SR!+4%6)TRK"6 :8*A"<B3+9IZU;UD#5$8SMG_/8 ;;$BD/ P
M+P]/_Y3J\?N(S] [X\>ET\O6]P5^G]MSIKR?CL0D+$=P[JG](+G"^;LL;^=I
MZS6*#I^_X92MON.-$$CY</" 2VM3Z?6:%T&,4_*=[E6J(<>O]X+*YW5<8OSO
M>]YY]E?[\:+ZFZ;IW-F\NA&C!708@1 0SCS<1;W*D&FN^Q[+T<V&X"Y]8@QC
M)DW=]R,]%ZIO].Z/S_V$@?0FVIBE(Z1*^WZ38 <6S;Z\ES7#.(I._>Y6"4K?
M3STZE&B0(>\RJ[O*0I@9PN5L:<#Z!ECFYH&W^-AM9!MAIMDUL?5E0EN+=;@/
M($GR+Q[Y/'U1+D!@''QPCIT1)]_K].E]A5?B8-<P_>\N:L 8;)*RMQN!,6M+
M%#N((C;,.]65#R!\1:NWFL-*ZVC17X"KJ6$&A;[6I?U.DSLZB"J\P5[KD9:/
M1<$#EID=+5]>/+RWLE>L <PQA0U7>@9:PCS\Y)';$YN<IBF'!X@_R,?S(46/
M?C/FULETWR<#?J<M;1^',X/\?%GQAFE.]CO5!)_SV#6TJ5%4DYUELJ3E8[:Z
MYU^F1:Y)/FZ>%V_)N!Y=GCW>FTJPS4-P_[CMT&1ONZOZW+$:]VLE25XV)5/S
M=F&A/3W(V:QAL0?&M\0KT!'P6'HJH!R>'J(\0BB*L)L[RTA'W<"VV#%,0Q<Q
MS:4'836QFRPCTGT<[&N[6'JE I1]<Q6Q^JX$YW%]K+7_IV'_8Q*6CZ;Q=DGV
M^I <@Y.P9P?,X#O$3E#&.%49HO"%'O&&K/E8OQU :SDH8RM !$O,ZON&3_;Y
M]\PA+(2/P_,ZKZMAZP;T!8;23S_%-2[&WI/(B*VAL*) [^KHA9D9AS$%DH,O
M<.[);\NJ;/(CB-I,,42K3U?UV(4@XA$_9\"\9H^;,3614DMG,@GOSLX@MHYC
M%<3'@!]^*@"CH24_2:%(I'7EF#'3F/@5,[^3%.4*(E^OP0+KDNTYM>P(O^7
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MV_/P 6\J22C^@(6=&ZB:6#3CK9J!3)P8"?. ;HD48^@[Q=@\?HY)%'NFW==
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M\>H?&8 Z2A-R:--6A>Q>0LI+!=T+#K2=8M0:+#)![ +A1%:M4!NP+N,:N?N
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M"5J]+SZ5.TBV1R<A-PQ<11A1"_1B15M8)MN#TAD9)$$3<L\ 89&^M5$M5G_
M1(PJADSX7"->+\=-V([A*9S,)>%;9#SZ"")@J:)J#SQI]%@_1X<A/L<#8AN9
M4I)!/ZW51)9)'+VBJ@@,;T+J ;&S(0&%I!2OQ#;L3D,Q<8(6DWXEWX1B/*TM
MG<8G".51$SO3I:K+ZT&SZIAK9K.[@@ H9FEB%C[8Y@0]%:(2Z)6+^7%K,#76
M6(R?Y6K>NBA9=VJ'@-B6%;HFM2F(7MX,WQ2\/CXUU!:_0(L3.$S,R!N<7,T6
M'[VDR,?0X#E0P2D GD1&"1=75)^7#7^",Z_QQK/AL%*)82!*X9J9EP>?<@B(
M>2ZB;R-[.&1LY:B(#!AA=I"_"*Y(POX9J1$+:K-%)CL"Z;LHVD'JF^EY@;\K
MIW$B#=(X[8,&IE^B3NF&5WJT\N*S]@"_^>AU+&NE*XNE7P8Y3U_A.S:HM]#N
M&W/<3&(7'1H4?7@]LW_WB^$1$RA9QU>?I[-V]X:8*([-C&J$7PJQ_O;(_?/&
MR>D#.7=EUP-IN0Z!=V>T5=:![0<1G/$#\Y\73G.UN\DZA.+/=GE0]3E 932#
M6@#%VM1U<<Z2<253VOMZ."8!0JT[1D=;+%.K"R%B<[\E)3-WY+,O*:#9*7>R
M>FS=[S4>$*ODDCR$:<WX9Y1#8@M((')@;H>P)_L1$<#,4@+@,2LG-YFE"C0[
MD=#\.XQY_ECD&FPCY_"ZQ31PM)7@?;51<M.69<5FF*0PUP%C^=F&I[2:]?N>
M+.5@U=Y88ULHNZ![\+NEX@,F/*&N00!XR;F/XUA *FY%RTQE[0(8M"9L(F_S
M(AKZ*X2Z8^:.45KTHA:FF98_9<D"L!OS?&S3^^E"%'!6Z\Z*"W0#U$</B&U$
M(^B6C9Z 6F+9 G;W._#<=X\NEHD62?%<'VM[-4\9:4WI<KBU28"9L?1_"PPD
ML#K,M?!_]DVDG'E.><<(>@DOZ775O7+F2_ I@WU6AD$G<+O//TI PVJE3B(V
MW&:^78-!^M39VR!SX@-JNS'ED%TAB=G\$U(4AK7(83= UZC18:%8A=AF167R
MN2XSU(;V(HA$NC;?5/<[YAIBI^FJAY#77-^I3!H[$_57HE\MF%\0)M)8@\E#
M/AL7/R9\$<-%;Q'8@C$_N_R@.V:M::73WIOS\H.:VF=3TQ\^/=1R/<;1\K=3
M19:^HN;K#F+(OKIC\N5]C^^\_^_\]2]JXCH>)'%,@(&6]3]\NCPOD8/+QT5&
M*)Y(V%^7]=,UA*CRN7\H?&SJE$>]@/6/\:*#HWR(K[%CZ+?W1MI&9YLP7^IC
MOQHI+[WI69##MRON)-$<0&P<D^-/$#IN/-DOMBB4=$H,NHQS@2J&R/H*/-X[
MH,6A 76VV_!BXI\-Q&U0HF-#O4#LME1O97U$(^8AYA]D)TB[SZ)JD8BN0%7#
M:D[=E<*J5J_@)(Q+%QN#2=1HC[!#<P7LB'W3G<Z"^:MF<NO AD_$/WO?L<$P
M\HSW&?J[[ZL98JF0ZV89)6NPW9])0];>;9Y5T$/)(2ZM+=5#/32IE'2GIU^
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M2HXVG9<:^P\G=O_;<-&FKU/U88<S=R@&XA:8T?K[V7(&EGP"ML/^&$S!?C\
MTW+TQU5YJSRHBPI<2G=\,<3XD5Y6/'15-?3GM/>#\I-$\[Q"C?-VG(9DC?#
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MH3@Q;A*W)Z? 1Y[?RTJW;;8-K0YG'8+^_F\K1RZCG8&F;*]$(H!XDLT6I2?
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M'Q1K"YLR;YD#R&*?+1@;XOBPL=KTG/>.6DO'B*_(WIY=AGU$0'&?/W_>Y]
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MAYY;FE=Y7_'87>-->DER=5*RCR7QR[E2GY&R^)T/R=2&7)-GA=7=8>4\DL0
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M[M\*#7O=_&5IP?/.YA8+&3K3>8?UUYQ2=,&% ZP*:L*_1\0T?D/[)H D%D"
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M/Y7WQ?@5M9$W&I>NO-47ZOM)=:"T4DJ/N^G_'>4\<<+67[*N.T5R6-*\5LU
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MJ;P('KII@LBW:J;R=O[-0]"L?[>"7(_%#R*2WA*L(/V@D5F.HCOSZ'\76'E
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MT%/ZU#62/5W[*5Z&3NYT%GZ*XBIP!!"=[F+OQ1['%BQ_'II8WKEG(ON[X.3
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M8!V4F]YEE7^BZ1C7ZUYS4\$JH[4/HQ5"I?L6JEUSOH'Z&(B[=SKC1%4.3>$
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M+! L,>C- U"A'\/X  2""!^ OGT#TX=VC?<%_!.@P*&Y=M9#1'=Y=<NL)W
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MO]>[Q_P30G4?F57.$*N %&+/I$36BUDWX..UE@\,0O;<WTC1*L.YE_05WE-
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MZHX^B"[;6,:49\"Z/J-XZ-H=E]IJ4U &E ^:^]INPWAEC-93#YGD^:RX01?
M><6GH4V72H75?<]M42ZX-WQ-XOKUHE$,Y2TDA*TU6),#$#&3XP"D)D@9U[]
M)V!IX(0LY]AXO$[9C '#DN2%,-N/,'G?&F=R,HWQ-^N/=N"MW,%8M\_:\MQJ
MQV7] ?-_BY !]CF47C[8_O>NH>]HY4C&2G^(MZ)[B(Q">F:&-;[X1UYFVL<A
M)Y4LEB_5\C1REJ=+=$PL7R'/V?'!@'A,B>[W"PY5"I?#-XO,\AL-Y4<"RXX;
MYY@WI2U%P)@:'"GM2^G+4.#1VP/0PO54P(=7$C,D-XRASU\[ 'V-1KYFU#Z+
M4:=9<B2]X0:*KOV<>\,+O'H4P-GS5J.=GH-49<5"CV,H5@68WYWO%[+GR>3-
M?32O,.M<N\0!:."7-DM<'O-;C@U=XE7D*BM>/YT--P5>UGUV^8]YPAC?YT?+
M'8!.VH*9GQT2,)WPN?9=">99MK<U8E.P[P1',NIT.'*@8S'M,L/H61C'$<QG
M@_(S44M&%Q:RM]J@M=BWF"X'&O;OO__,(GJJLFYLL]78U]Q]W+F!/CWP#"+J
M1]6[?JSU'7V[IUM92O+Q[L2-DAJEAC"(6FOR".B:ON>SR9L]Z:K?]IJG<- U
M3AK"QZNE!7 HG'*9ZB+_<'5%630]XT+R<:="-LTHT@DBUIK>8?<]D_G,ZH\>
M&9\']\">IC-M@7HJ1@@92A7^Q,L+)Z@,'8"\/RA'2ONVDFJ*&%$4KSKZ^9X9
M-<:7$7V)29GG.3?2@==,0X^2_?<;I%VEQT*,E9@_IF.X=?YA?_&/^[D'(!^N
M#UNO*/LX/%?)IU;OQ&#$OM JK:S+7]CGHFI<I(1//M_(]D@L#-F(X4.X*S+,
M8^II ^]7<MI2HNGK&UW:SNZO2X#.7C6NA<=MVV0+ATBL,GYL9VM[&?F2%"(_
MG%%??52T]XVG==ZM4O[ ]!+1WDO!-&4[8UVMM(4V;:L2L0P[RQ_7& >@G@>'
M8,\G;8[=7C'N*K]Y__S9C-3CIVQ3#+B?Z1Q+9XD=[H%MF6QAF3JW,9MG86PC
M)Q+)%3F8+TJ?-*;3:-T%#$5[AL,.J;2HA&T0&K3C(3H(MM1(KN2TDQ2Q)YD6
MZ4X$X&DQS&<7_&R+EQ_)=;V>'AE]FG6Z/;NSV\V#N/=@J^HO!I::##G-"6;C
M[-J[FS\@E@6@[^L<4]WJXR+@:\.Q\HJ^V,*MYEE,S_H""7C=_0IIE2?1=RC!
M+L]V%%*3X6DY<5EZD2.,9!N4?3[C7HG(M-;?#'35?TS=^#\I@+^-'.^X<9^-
MNI_AJ:=]I#'+G:G_R4*S'-CP%HL0&<O+-(S4.0!AO_LSM:P/0#\M$?^%:W8H
MXCE$J]V5WK5D291#_[ZH/7T >C[>X0:EJ--C+-DLXS2*ZM=ED^WZ?XUCK-%>
MLKR/VC_\?^638F[V3CG#U?H+'V#@=<L:<C\U7NN5K-:%FP//.[JO=5^EXFDL
M 4MV-AM<I/ R%31468X.+]V GH[N]:54$>2MJ*" :U*R@Y_/?/UY*G+VV?$E
MXV.5RA]G2]K!*XLK4J*!D9BN[]6364&Z-C$"O-$5UVPZB2='*D>J1*=)<LIG
MQ>6:O^[&LL3J2;"MF\I0^L\)=@B4-V9J>K,#XPMG#.4+V_4M6!/LV5=.[#@
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M0HYEA=WP(=P?KC=37$\S\O:2/KPR"_@."&*&_K=Y@>FC_P:LPFMP-G=D!PY
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M_)DA"VH[XS2#:QJREUSAY.YJQ.R@.*WE?U&WZ F*7+A;,W($?P,@TF#"H,!
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MFP8],98"UAQ4EC<+>P*T_;VAJ[V!ZF8%?<X5VO7#*W/NIAXJO=G!R4NB/$_
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M92@AA)=^K[Z+Y[WX:JVZJ%5KU5IUSAY^_]IGGVI,N?*/\2GTE=XHEQ\-*[&
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MY5ZDK9_T+Z5M)*'5%^ZS.@[GY:8+17!6 +2S);##:]^NR./ ;6\GP"U>J!P
MDV_<NRYO4Q!-#]\569[H#>/F)AIZT JT6)%&FZ2 _BI!RV6M]R^WK=Y91L&7
MT@E*<. Z<4QQHV[G'2$8PD;RX,OC0+%0QK=MD^\;)Y (X<F91P"C;5L^FRDP
M9=P9,&IF5T31O^D6=J+#2[%EV(GII3T003@2D)>0'QA1=HDK 77K;U\*4$#O
MM#",8/6GT]7-#6XL=K^RUSQ:_/5K?M8WMT@[ZU6?\";2 ,E*5P0@L8Z:<8]
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M<DY7.*%Q*= T.^"3 4>ZJO1,SER& ,\O3XE(]V42:BEMZ;=X?X&Y?$MDRY#
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M@B[;<*P>)W9G+M6W>41X2N VJB,SV@Z7HY^:;*T!=T5NQ'WTS[]61\M@#R(
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M %X%P6_V7_:S-U08Q<RQ=8"LU?_!AT^6ZUE\\[IX):#[',L[<$+*Z]ACOYL
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MFG0R6&R9U]W3(53G_][\&H2WR\I,R0\YL12FXBKGMS3BW( JHPW2S4:$A>,
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MY1BW7Y;KAXT(7/)NY6BC7E*+X"@I(^)05T\[Z,Z!0QY\IS2<%T#UX#=ORMS
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M9)E+S9A5XZ>S6LVM0=QN7$F77QS,\7+5.-FE;Q0-6Z\W0O\\*:9(":^*#WB
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M*J;!523[P6MCG"(BWB1*UP[TDE) -A%G"/ $(<# :BSWUOR06392CH9*J0G
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M$83!^ GVKPH03.5W;)3=9"[ X$+[B2K+<SNMVTUK=K:0'^O@)]%$]1-D)"N
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M@*'YZ@%BBLAK/HF6/+^%'_ZO;(YX@!$$EW=*K!798#(FG2,X=$TLT7\BQG?
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M6(DZ6:!98-3O7^UY^\W7<0IB#K<>XIX<*E=SQL;0J=BXT#RUL[+<,T[P-M5
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MK!E? FU?9$(>7++04[@Z> >NY4Q1],&. W 65' !-!3Z@$ZG 8,!C$)TUQ&
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M5%ZE-4]DN5A&WNB9J"9[YNC3H1+Y7Q+94<Q4>!-YJO_?!#0RVZI+8TIB+_(
M'_*8:4=QOH2]."U^^@U1S!/LD/<H#$(10?F)W=^X<-EH*^@,7L>$NBG3(^$'
M!YI\(M:^XJQ:Z9C[C#6E**R[]B$;2=UTG1#LY$*_9%=>_Q'1J7$':'27\0C-
MAXM4QZ;W_"@F]G1>'NHM^XTV)MI?MSQ5I@:LL'[OH 0L9<UICZR35K6J5;_'
MXC48R0E[O,03BOJZFJ>V:UYAO!).H&J/,,8J"P)"*\/=PJ(&"PZY6*!\<I8]
M*?(3=>[E/L)@1P,5^^1SP0MV2\;W2S[:?>?OSB-KG1@O..<6&OT\I\Z]F.R2
MH.<*.;EG4\:&$$4'#0QZD)FZ*N+F9NKMC;. TZJ"\#).]P5X@F_.+<J$I?"#
M>NUTOI1"TQI@!IS.D]]>%LT93]#TY+%PE[:[*$U".@S.$13XU,.;#H]^0M_X
MP;QEH0$SF=^4D<=>0-_N>,@HTWS;I'&9ZYAE7V.1:SJ%2,[@7;J4JX^.^^.
M^3'C[8?/ZK<''J((:Z]6(&;)1EB[HU7T=)<[6WCDU(J3I&[' L-/_HM?/7.\
M*1EY).O#MB[UDZ5&!<>7\D--/:HEM@@MU\/E&:4!(I^+GR_^C-EA=R=TL%!M
MS^+5,Z_._@^JY_^M6K Y_7\ 4$L#!!0    ( &N!:5SJCID>ZX@  ->/   2
M    :6UG,3<P,S$P,#,R7S8N:G!GK+L)4%-9M.\=VX'9R#P)49%Y2"N38B0M
M-B @1.8Y::21(2(B(!%"TC*/TH) "P(JA!FB0$ Q))(PJ(C(% 04DB RRXD*
M'"&$EW[OUONJ;GUUZ]5][Z1V5:K.KI-:9Z_U7[__/B>['W;9D$/V-G8VD#V_
M[('\(?Q =J<@YR%[_B^/?R_R?WN-/;LO(=*BD*$]N+U[CD%^D=ZS5WK/;C<$
M!H'LV?^_)D#^X]CSR]Y]^P^(B(J)2P@G4 Y!?MFS=^\O^_;NW[]OG_!L@O \
M9)_T?IFC)\X=D'4.$#D6*7?R]MU'HAI63[OD78: X\:7;R2*B2LH*BFK:&II
MZ^CJF9B:F9\Z;7'^=VL;VPMV]JYN[AZ>7MX^@7\&70D."0V+BHZY&8N[%9>4
MG)*:EIZ1F9=_KZ"PZ)_[Q8\K*DE5U36U=<TMK92V]F?/.QC,[I[>OE>OWPR/
MC(ZQQC],3'*XLY_GOLPO+"[QOGW_L;ZQ"?[<^C>N/9"]_SOT_]^XI(5Q_;)O
MW]Y](O_&M>>7V'\G2._;?_3$ 9ESSB(!D;+'3MX6E;.Z^^AIEYB&L0L@?_G&
MD+C"<1..)N_?T/YG9/]G@27^MR+[WX']?W%-0B3W[A$NWEYI"!(B$.@\SH3H
M/*8CK]+#,-DJ?:OCO.4-VV&J/+"P2#Q(#R+NX4>!Q,9/RV@-?U2WI2YO)H?J
MS]YV-._9S+ABT J'?GC-B8J,C:@(Z9@FS?DI/QRMONOQZDV1:=@I7*]K(UII
M<3C997,7TO+M[;7P],S\,+T(D;^Z+2+#HT:S_RA^$?8@W(9RRU3%33,IQ[L=
M2(@_T347?7SXQ=S6-!*J_%K?2N;>=.;@#_%,O@A8L O9K[7SA" M&"B71V!Y
MLEWEXC^(JGS3G:?XH&TDL@^UA_".WIK;!YUX,\]!)2),U9^3\6B60!V4Z"O<
MA<C@C:M"RHYBZ:F$(V--ED>F%^(B<DP<K^D'C5:V%-EGK2_;@,MLN!CA'4$2
M7.>USZ*Z_$6ZS-%[ &@&U9/W?+T$DS*SEZS-([6E8*MP:;^/THZ"53MX8TZ$
M_'+'1@F6HPJ3P;4XCU8F!%X8UAR-D?*80^SHDL.M<)DWLA>M3OO]+/C$>1 4
M'94M.6G7@1X101N.=.N9%GBQJE5N1.M;1+G\P%JE7'@V]N"[19BA[^9]FR!7
MO=X>\R#7">XB9<!V\IQKJ?*[2QNC]W:V,GG0)$SKS,K4M@V18;<+D=S</L>'
M@FN[$-'8#21?<P:HHAG@H%PB_Q@=^'L7$D;\XW_.$[6A-Q$#=B'7B '+F ^[
MD$EBD&!$T#=FV3._"PG^]--RQF6/M=RE_[=#'B"O-FY'XEPW?H6)5?'"RYFO
M3,CI IU\IS&J,\]S-BV1M@]GRU17'HY!2OF %<XC,60EGR7X;(3*AU""1CCQ
M/!CUR(LDH),6T$<ZGK&BSSB>_CKIQU%VR28I=8P%V)3D.^>VUJRJA[YY7[V_
MH<Z]5L>%)/J&Y,UX$*3IG%P]^%K9D5'JTYSM>N^!SDB!SX,GGO?F7HO=&$DL
ML,]KU>UUO7=9L$3.6I_Y4,^<K%X5XZ5M% \)S/#1@&?W8#9Q3VOYQ-(61FP:
MKYEU 4 EMTIY^HV;&!)?7L?.B%)6G?I[BVV><L_Z7FH=H]K6X\H=0^<SKD7[
MIH>'/\YB(:^0)R6ZB!1%AIKL+(KYW.5[%T%C'!%5B2-ZM97Y#FATW[04XPVF
M\P_1=(%IDF%I4IA GG<&C%E?DUSBOOMD:BA[Z6G'!<8KL<W,F!"C>/=JG=$4
MA+N^G;ULM>0U">DB;D6XIIA'UV7>J=!./9O2N+M.1A=U66'&.:=[NL8>?RDR
MX.C](QES.$CUD[VQVPE03YY+2:Z[E%R<=X&_!CKO0O;]? :>?P@&,[>T5UNV
MK^$21Y@^'\<?@GV]Y7M-7SA&,89!'(C'FXXCS&$K/P/9KZFR(J4)3;ZT<DZC
M>:\S+LN%.J;8LTT;D&__I"X*8%()AW'&#"*4JEC9]0B'?"E0'4)H<L(51E^Q
MME!IU#-54Z$6EJ42%[]=Y$TL;A0"!OEVQX=%-_LU7KWMJWG<&J.M[=[>>.M2
MP94\IWJF2\%A9&NHMJF-O+Y%F&.-6_?E^N-UW*>R]<79GL<<["-KE?1?6'O4
M+;LU=Y)/4V[YEN3)U6K5.I-$\>?8L)]VL%7,+N3*N7^#W(6,?1<*B"FY?9D+
MA>Q"WEP0%L4N9/LD%-0>%)#+0=W&!/HEWYDYV.O]<LZ_)6;J_T7,1$-RN3GT
MKEB>Y3]T.2.J1!3/"":BC-IX :J/H-N!M]-'O[6M*B"GBG2K'\U\L3MYT5W\
MO(8AX\%2U VKJ,_)=:@\([\GN3VGO2V];%?M)HP:E=W)-FDM,?4N%:MAC!0X
MUL5DAQ36-+HP\@5;UFA3G')JVB5TXHS:CISGNZU=R&K\MA:(\AOCG^"63R9M
MQ +C&292-FL7QO%GR7PLB*W %ALU!IR9PBS&T?)KP.+)78CCZ-6FP+SIKV^^
M3:N6A,[BJC*.>S@WJ8ID]=I?8@1$*M5VZ3J="I/'OCEQ[8U+CL[K'K-AQ\JF
MU><5H=>&UT,)P4-R'C?OUB]:'AF.[HP_-V:R&G&>]6/9$&/-:LV:"G>P&_M1
M:C^I_^F,V_"ZJNZ5%OH(>>5+ZM<W&\.AX4V-I$R<9IZN]+N</T:R(O,B[_FZ
M9#F:C+0XGG5%V9359@M;S6]RSM:0_^Z0_ZDJ7,'K+,OC'_A&@&T:7Y6GNG%%
M* W\\S06?D\#F+51PZM^.7B0?QI US9A<!Z^R"PQ#B9G6HZU:JFUO LYB-<-
MGLW@&[.%7[%QFDQ<D?<012K"D:>5@8W"!FW-85)V(8 /7(360 Q&*BZ*/<:6
M&0+M?,,$<SO@#+'K; P,U!G/XMN2P *"NED+\2%?-W,--425KUR /EYLP<X<
MB@FW8N"N= [QSU2AX!NKJP4SZH83'-=<A&9VA<K?7^9R[,-1DZX/$DBZ]O(:
M<3>BZT:Z W[2VE,>1'K%&:R\K%IVK-6Q/W75;W&@RVTC)B"U7L]=3M.I\;1]
MJ;5RC0?)4\JYQ[7'M4P]YO(NQ'H7$I K,PE6;/P)$F.K\;^W@^2*4$\T'*A.
MHR8<H "8[I-8@2J0EDU9DP0)\:N8C5MBP)59ER3;X975"#9@X!PZF= -K48?
M'5LU%2&J@13A#58!4%WP;"3%EAF1CCE(=:@$HS;<=O)-A,VBO[O,(LMG".[;
MJZXZ2BF7"VFCJ0+TU$;)86:-GS_HLC4]_=V/9=*7]XT[+&;RRO S=FR9SB[>
MDL#%;IP!@RYOS2>;+FJ/XHEU#E'L\HFY74B0U#%&N"\7FD%1_J$Z.,'U/:-:
MGE*F :QLRH24Z0'KGUW\Z>D-,8;VW*\;#M]CS4OX?^Q"$B,G^#?!S6T7OA.8
MP[-YL\9I7[7;/K)(;];J! 9MP/B8*EP1TT*AJ '7XM_*:RKE'9OG*E0')#19
MU^(ZON(:M,"8\#]3F4YOFUS8'S?F)12>_I-;_]HI EKV?*#W@89!%.?CI/?%
M!YKB3B?QMCM%T;6,S*S:]6<-VFWM6N[KJ"#3].Q']LIE!^2.*KL]*/0_J/_2
M]:U<T*#K)S^3%L7]ISN&PAZ$^"K4_L:+SP4-TOYJ7/M*4"M/'H_@;?7WH(\.
M&0F4M',U!%V.(DQZ<_I.TS6J+S07E;3OVP<_G)9OA.B4MWE20(?EF8*5SR$_
M1'V[#;?N L:ST&1B"#()*2ZPP(E]G>DB*N+W<%#I-&659+L#%0=SN9\4!GV:
M*:-_W+&K2')NR01\9IB'A_OD/QK;Y+VJ4Z,;-A'9.65[GHT9"8[#LCQ?\[YM
M]ZAKL*X1M."W+PNZ+* 9R#_7=^XVX345;T.S)5\'AK,_A.,#PO$">.$"CJMK
M=-SS?;"%#"$==-BX!,IRUB;R7Q*;8>D$-1#%+7I9_@L>"<"8-50Q7B!379VW
M"TE#V%7P+;*LB0<_X>J9-(T1.!79&&:V1;M- N]>Z1B>/$,\-.F[5.CLZS?E
MBSAK:EF/CVWI;&3N0IS!M<&=^YF[$"\X\6?LSL,G1KF4S9WZ7CW82MCM=YV=
MS?U"I?,8V(503M^Z16C9:82MD(-C!_IW[J\BTT*VD8'KY1OTL%L1?Q'GCA,I
MQ)W[(GQ9(=YX#O+E6+09\MO!B7PVI@L^L;FQ"]DAXY4!1?8:@YYH"1W=A00.
M?I#HWBI*L93&GP6*F!%22^K'.\$Q85UH#),1YQ,>X8PO#$6_Z+RQYC 4G6 V
M[U'&<OBY8E)Z\IUO6OL3RAWXB,6<A2;]#3)/7.?Q[?W$,E@V/8(\F=LS0W$<
M7R55X<\]!6"]MUI'AW[4EXLMF+6KRP+S:9[,:J8CIU&;(3C]G'>GU"A-\UZ[
M9Y0W=F;J*&6J/R>Z8VG:_2-RX19F\.DN).DF,2B >XJ!_V/G$9*SST)RT?*?
MZ2-@Q"Y$#,/7Q$QZ#/NB>YIR4P)MU=54+KW(G+4C'E2SHYP/OZ7>UE9OF$1X
MSD'?>OGS>,O/R (Q]T*CPE]2?_E@\>Q9OR2-^OTB8M;)'O'LSE7QZ+IJI^;J
M?JU[_@)D%BY0K!OH#PV\3N&Y?:.ZM?C!QK[C^W5J4P> -\7]3R,;"P-_C0FR
MT,.EB;UQ/YM<6>VDYS2?_X'894=G/[84!=Y1N/!, 12(6)EG^\-<AEL;X3W$
M=MC*R+87!DSK]BQN1IMX+,[")HHX(DD$E==1T ]MG8WSMZG*MZ*.;__H=[01
M_2KH GUY^1O?=FKXWCQZ[RY$UI 80DY7\+F'UN"1<M.N$>3YE\!U3BYD$HSJ
MGA04U6#-,)*M=&6P"0H#S3E]V6MX0\[J+3PL;DN.M2&DD=5KT8X*CGOM1TQR
M?QB3YZ&S[7S5;P1C_C60R4N=VN@H80!X;[!TEIQAR/$MORT-WC51QD=Q2QUZ
MS%6LEOIF%;(42.KE,;5V$?N!H=9%S523V'9;(Q2%LPM1!;3<<]]&GJ;9'6Y9
MEM,=JGY]M4]D)4BG[D=(0$V0&R\::V?]_/());Y]9/TIYVH[?]2KP>:5;2U2
M<CWS'[_-]#I6@9^14<'%I5*?9U?/VIL>?YH1_/%\8<#92GU&LFZ_Y/2QXBA\
M?C8I'#6Q+!"?VK9:1HN"L9PN +81!E9SST;9 ]=*.42-#1"T!DIZB]].OLNM
M\ Z=5BCGT'LPZ;##!$-<6J_'Y/)T"*H.6P8?183.GOG<1F5131^"58)=B%42
M;W-6A*\0(1"WP_*P7+7&\A[#0/9.60%/M?>I%U]SS%(%?W24@DKUX&$[.N_!
M#@HMBC_H6+W<L;Z6&/[G+B3YYK?E'A6\!8GUB)3CX-S<-E:T"1M1KP!L-U)V
MR@BJH73Q(B9:4JCGMPFO.A1N<Z!B'_%0,)<#A^ B9JN3$!+L>DS:I$U.$,>.
M^'2%)H5/> H,E*?QSW/KH>*X>:%20/'8F+HI7)1C*WB;*^7H\9D@*AA7,>=+
MW_@^>Z6]*A0)15Y%IFV]F+&+:EBDM[S+!WJGNGS*TTU_:HY&F&S#]O,]>>Y]
MZ33U, &,M?85 :\7*A:C3"R)4;1U7*#4#*1F%CI3:=4B0QR\1^@_HR^O4P[/
M0K.+:ZTHAP\J9M2P%RYU,UI)=QA?\KH"3W90_&;32E5NN7C572<;F,%54]R#
M4-U<@?SL6QOW1 9 5^$^.95MIB_FXMSW)D4/X\D<2XE)3?%3.' Z53=JB&1_
MH^=*R\8_WBR2OUNMJ?F.):&[O-4S19CD$U-"9$E?%1CB)+AI/3H$2;[Z&,VL
MAP.3!L^XLO#F/&B/Y8&1M?5MHC(N@B%KH"XVMD:U#N5J6DB]*WA,:F25UWIY
M+[)>5PV$1WS&4&SY<KN0C="=NX+CH3/BA"-]LS,R.$:\VAFW<0/^_H>+%A1Z
M<O2J[\G0$5SJO#=/,6W4[Y//[1K;JD6'NC")ZM?[1UD\PT]YGPBW<#,;[D("
MP,L#L4P89?-ER5I:<2PS0H(/!]88N: N=*46SC^*E!'(^.)4;8=6$ ?I%)'D
M(A?>G4YV(XI9#/_K1PZLFRZM/48SX1\!2C<ZY7MSN+EI>6L\HP)P4RB[:J!V
MD^ =4=82YHMW ONY$7?0OX)I 0^7)HD]:E'=/LB,<$L=_,GOIA(2<!@:U['I
M^X*'2C:-U\FW!3ZKRX^W$M5PT:$^-Y8%2F!C?:BAT /#D^BGR8S6$_<IWG_\
MRU]/QR(I3]R>$/J6QHZ*O:F_(R&=5NJ#:-6U/UB%09]"#(HH#]_1V"ON,(4:
M?@M.J3*>8]JY#RQA8@X' 5S<_2\J[DMLDD^G/0['5+W=;1UX8VFL[HU3J;OG
MR7Z]D6IMR4FOCK^[R*O;7>HFP& W403GVR>0' M@\35GS^ZUYYFGF>)DO"I&
M3<+#WJCN6,Z_?G9'OR0V;Q+WMJW]5V8,UF@[_I_+9:<UT%4TDYTLFA9>992@
M!!+9P<Q7?&OVFAQ>#*#=%J:'+/\X>&_K++D'(^GUX8-/7P4N%TT9BE%SM6;]
MB%!9'/'"M?S.2TM>5W-@3++*R1\&0B.#(@TZ'(LF8G[N>,5;Y*=4YN7/S7OD
M)[%D;@Y]MQDX-6UXIJ=U!.E0X>Q.<GH<B1]R<CK(<VFG%JQO!D6/M.9[Y#F:
M",'\2MA_B^;!%N'JIG72J4.T SC]+K0JSP+OQI/?S*4@)?&.P.8J5\CB* K@
MF88X TOJR_IQ)C?S;]/5P1PCQ.6MML1PR\.Y!Y<O^9U_B,%5>9O, Z-1#MN.
MF$PZX V];;X+44&8 E9,Q_="QCQ[WG/<]!.1/9^"=]CV\L-#GP/E3(P"_@^6
M0/V##_X<4)U$,,7I=P_Q+_!8^8]P\=UFEE# /"G&7]&7A?"L7="O"2W3&W+Y
M[MC^N<<J1C.QVLG(I>R,E*C.,^N.EAMW5,I;:\48>=V72R5-ZAPF1K*QR' ,
M]-PH&47>;Q&]-%;J71?-2>Y]0[+3RW-;[!/S'JOCV-@W8H(<G<C-U2H4O6_Q
M%CB\HYTMU'4I%]2V[84GHT_ME%'%V.1]_54@ME<@.\)WA]X1*$T+WEL@5W5G
M.V7]AJBWFG#Q/>KZ/'A/O5H\>I1VS ?7WW-)V$[MP*3Z?BPR<V4]!.[RIB>Y
M(Z9H09X0NPOI0@@!AWY[%]*"8DJH1;Q$BE#WL#'I*E3+XT!1.O\69W ?_@!
MS+$\@K/]C=?;5G:H \Q KDQ4+I2+QY1&FDQA]6N13U8B*S\.Q@8BB^K:FL>1
MH7QG'BR;J@&L]5IJ@K%L+;!B=@!VCO9"J A/N?H84=M9N(Q!O D1^A%LWD:-
M-?!/!-9@$(=FP-1EA]&'0U=S>BLT4R9]56^=122$^:V?./RNLA'==O1]-9JD
M#8] 7_>R<-EX]KJ+DY!2Z^;:'1_K\<!M.*FH-(GD"AZNDYCJ<#O;:?]KN>&L
MB(%C-"?E!7D5PPK4&:H]/\'5UCD]8-OYF [%!PM3+0(L!9+8F]GX<"&<;D2
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M*<(--%/T%5J8.&\@$[R1\<W(-*9HRF8V<X0;TS^2Q)+ W8_CZHLR8O'Q 6&
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MA\9I*@PV'+Y,A'T/N^1423PP\NR7>]5#P$A/P=;!6+N438J:<T-+6W.8!MO
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MTX>EHL:0F'D5=TYV,O-M Q1^J2C,5!^.SG:>;/IP>U>DL^K/-ZWKBTF]GYJ
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M<#G$8<S5\XMSI<R'H-7/7%>;-P?2_O \KF4M4[!3ML1_S/\0#/\)H8[O1[Z
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ML2M2D UI&/:,9-!%^/=(_%#H^+:;T*^,8-DT/2QBD8UX!)"XX6L2=:T9MQ9
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MV:Q,) 8^,_TJ@B\!T(JYQ1MR2_##?$> P+F;R,%0'%\)C@'329M8G/(3*'[
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M.?*_XU6H:0)9?B"$(6%'!M#B=W=%>GJ H.3HD50"#*=6OERF [RZ/CT/;YE
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M@Y)H4_7,_G_^R?@_V.;T?P%02P,$%     @ :X%I7!PR6K1O2   \TP  !(
M  !I;6<Q-S S,3 P,S)?-RYJ<&>DNPDX6VO[-YI66RTE5912LEM5,QV$5E5V
M!Q0USV.JW4JDV(H*(FFKAAJ:O8V[E-1<0Z@AE"(EAEV*$D-%B40'8ZVTQ&HS
MG>SWG.M_ONO[WO=_?><[X7;QK/6LE?NY[_MW_W[+$^%[X0+D@+6%E05DQ\X=
MD.NB+XAP%G(9LN/_Y^N?B_S_O<8.X6N(S%[(R(Z#8CN.07;*[!"3V2'LA< @
MD!V[_^\3(/_/:\=.L5V[]XCOW2<A*3J!? "R<X>8V,Y=8KMW[]HE.AHO.@[9
M);/[X-%3%_?(.OJ+'PN7.WW_S^*]:I<:NN6=QH#C9V[<>;!/XI""XF$E]1,:
MFEK:AG CX[/G3"Y?,;>PO&IE[>SBZN;NX>EU\[> 6X%!J."(R*B[T9B8V(2'
MB4G)*8]2,[.R<W+S_GJ27U):5EY1^;RJNK&IF=S2^K*MO8?:V]<_\/>;P7':
MQ.34]/L9.I.U^/'3YR]+RROL;]\WMSC;X(^?__BU R+V7Z[_6[]D1'[MW+5+
M;)?X/W[MV!G]SPDRNW8?/;7GX$5'<?]PV6.G[^^5N_1G<4/W/K4S3H#\C3MC
M$H>.&S+5V?^X]B_/_O<<>_!_Y-E_.?;_^D6'[!?;(0J>F P$ 1$(-$M2(?^R
MBE=EP2-KSU-JOW[M=I6YJ/NV]U[ULX-OKT)V6O7A+H%$@41-)4H(.230P&J_
MZU(<T@DB-B/7DKEPWDGVB:::SLZ\##*%GG61#4WS9NG-)98WMQ[JV@<P$@V5
M"]'4*4=[U?+%JR4MPU^2U^$U<=S]GYQDLJ_/1F2_>)=^\[!5V^*I]]=:):5D
MK5W9[S_ ]YZ8_/#)D9ZC-*DUGO![C;.Y7>(1BV.UL^-R)_\*?O_6UBWG(_.R
M5'*-6ZC6C,5)]RJG;(V?/\RQ0]PCN/%\R_5XKB%6DU_2'+(3+S'+NSIF\+4>
M>R8<![=X!Y\3\YOLT&+9GM!S\!*Y0[^;Z_?+._+9V_ 3M#5505_(UX^-S3'Y
M\XB*FA*2UEB-4\:5'&OGG'-E$YG9QQ=UK/7ZK9?ICJ&GO2IHUQY^K;_UJJ*6
M-?7XM*_ZH?S,V(K\V&<EJ3JG$N4<?]W]?VAR<%\#NVG#3ILKDVL+$X:%-WJ^
MVTSJZCN_;>FBD25C] QN?Y7- 'QF;75/5U@LS27'\GK?418(^(:\!%-OMF0_
M0YIGS$(DMV\\-CN.%0,;2J'[_<#8"V>8R1GX0/.G&.WOS*_$YZ ?[^)-$OQK
M!195 5:'R5^NU2<]'Z@T2LF\U"*$5+FXQ)V-LW2US*UQ*5GI?NG2HMIQRD7/
M2<_6Y&QJ.,F\HM#DZ7@"P?1'U8A=0:G&L(5U;8#%W4(MBTZX=4> M?O#4J],
MEU4+Q^!RPV*X9ADA$VO,E<0-QEJNK0(#''>V>[=!,D)1(,E3YZI_><C38@^]
M%DB#]3>*3K2F^=@0COBBYG4!/B?)%/7\#8L@9Q]3MTRW*-2&'43?;9'Q6-[^
M[@E3Y3\P.XPU L^Q%002YX!%I@*5(<;3 6.8H[/X'B1 P$@R!QYNPL1 @XN"
M:2'D 4;P^B>'Q,]@ANWW0,6JYO&KZH+SBYJ>\Y/ZH2TK[1F<THC/\[X?;#66
M.K$7N9KX-S&B2?E"R,P&*"Z$^+8*(;M^D*I="KVR:IQ\)K7MG)_FV^1'A#K=
MM5*_.]MHI9=Y]:\ZCY<U,^:B/\?*[\Z&=*VWS*^WQ%/,L5I<O.!#EP(_07!@
M&2D3A=^+!(607C\=MBY.%HA^J+MU=5,Y;OT*:CN_G%-<BVY\'TR9R;=X$G +
M.]U"@RO/ULS62)X-<3K\M7XM0@A9*&*TYB4)(6'(Q"XU=DOAPBM&,DX3L$QA
M M-I//6(6HV4VH5<3L\%2ZO)YO@HP[E?&*CV,EAP^N6H"D^_]_/O_;R'Y#BL
M<<'VK,^9HHX'/@Z-/XGO'7OYCHO\<FESWV'GU@8.Q3.27^/2V5ZZ=J&)XT>C
MQY7%78W@F@6,HK^MMI)(<6CT/)T^P(AT-,>H_U>VR[\%IP1#UD!86M0%F]Y6
MO_VTYHW]J]/;@I,-!)O<[9Z[;K&N<WW3CVZSI@U)T>:9JY<>G(/;8+8RH)[C
M\V@7W\O6$R'[I[)PDH)>!N X*HT;(Y)/E )W%SDE_)K?FB9,?]NF[")A0Q:@
M,[*6 *.7N \3UDT_1*K#N+-4IA_B=GJ"I5>GM^;P-NQU08YQ,MQ>4I*PV^Q^
M645Y*4@7CW=?:L0I#)_IH)Q]"SBD]7S$1*4.C+@T9(67?=T03^JYH=6F>:G<
MLS\B(5')%6TWP=32_>1T,OO&=D%SE#>/_LVO;F!3Q5S.?23_?[^>'R;N_NO>
MLX-6OT @;XX70<0R[2'N(T5*_'I$ $,)560\90IC;S/M4YLWDE7UQ[!BBVB"
M-&;4?$H(>6$:PD*GH1&2H--G%:.5SZSXN#[WUMPI57F:;DG[*[91\>GW08XK
M"@7/)/.-,S^[/Y2WJJGI+R#92%=;Q?]ELK7DX'PWC>258_ACY9+>S,SY\^>J
M43,S$Y$KK@[V@<;6&<&I.O.1RRZ%;?XGNM+K4Q !T!\&", 9R;T@%#$.R*H(
M!A:(<(Y"(L^125'&1%QAXQ/(?.4^/SFV?EX@"8SN+5*=J!7%SF=L2_'@9ZK+
M>)3-OLI&RHN.UC]/M+23\SUN94R._7VNGH#_]Y=V2B_6NA0>GNV=7GI\47-0
M?^2TW; AS=8P/_BM(ZJOF6:G55%(LZW(1UOD3\+;EI%DR[4"((S3!P93)+O.
M+)L4?LY U7ICTBY-\A!5^)M@'M5KBT2>2X^M2WM.[OS4.,A1V&Z)/I2?DU1>
MX7OY=]N^]*:+:%W5,X"S8%\R]P#O(.#B)]D([@:^L[PE5S.LO_<QE'@*"Z.I
MJO")T+IC#W:J3_$N,EL)]@VIRD%N#,MWM9$92ONPW%Y:W];ZUN0H(]*]_G)*
MQ =])#\G:?C[$3.OF@[K[G?][J47W8-'2A+/]0_S['3F(K8_Q/!91W[Y]'91
M0<=K_<0:MEL(V6_.51!"QDIP;V'@]2XY(>2[A@^1@+]A,!,A.(!4PO>(<8_A
M!HE (;Y'@X4 +PDAS;@=6'7!J!#RL)6K^ET@,]H:,R_[K6N W\!!-/^@O/H6
MO?$C ADPYFQO-E(UD6B_[M./S4K_H7VSX4ZEF:?6G1&SF8A+;M:.[1V1[;#C
MB%S$'2%$#:P681Q2,(HD/Q#,3*GNFNY0XU[D&8"WP[9F"?1CHU3!+V G(':)
M*YWU#),GD.&&!'J#*!*X\\OZE.#$A)Y]PF;A&:=O99FL6^2F+.I-#QV^-YYZ
M#*LEA!0W<8@BD)OC-R-^"*9IF^X3X<DIY^KE/V=_U_X]U_)-0G%B$4RO_X:_
MQ/=RK4&/_/'TJHC)/%/4Q9=^A1*&6N=&9ZI,EQTR-%_R8EN>9K;;T?4VQP6D
MID]:E-_XQK:OFB8$*CP<OP:G%#Q5?WHH#CI D<<&-%->%(D_VIP=E11,I+&_
M=_L?BE9XL9);I-3,5NE8^F-V-1RU\+Z5I;'^IQ"RVXU?@O!'TIU[A9"F[8<=
MOF6X<1-D(HD'J\:\\@2W "[U)S1MT]>R-_;0$Y:5J1XS)&(!S3L!D 1_:B21
M?94$>NY>8$Q,U?+/^=+GWE9F-?ZH,#1L<PPI)AAC +;0&1BG"BPHX_F ;0N^
M3MO]N4;M=XDU?AA\[T]*TGJ'?P4*<:+ G_4JWBAH>*E)U%\N$AQ?9%V;*K#W
MCML7=4Y/M_8HN0[*,B5 \UV(1Q:JOSQQ>2&_? GATG.C8:R/:^U,'<&TCSR&
MCZ6K^3WUWW];+M!-JM+*3K?&+M2H9$(]:K(\)*RDO6L.QKAY']:J4E$,W((>
MQ(V+O WL#9/ ZH -P&.DXA+^0)=J(^\ZJ+X(VP$.=/M)3]0V(V4Q(^.CW?/'
M0 ,6], LR+&5< ,_+6PDPZ0CN84P[W9D:FL^/)W>BR<B 7LA!-1@))@=$(S=
MA37[I0'&G$PV\OYG]GYW1!,E-0J:PFBH3\7N8U)V@I1NNE%A-%M\0"F/ND'7
M\)PT=8TO#XX=R AI1H(7F^L/>B$2?WF'-0\)J :KOW.-KPA2F^/5; #!G^5+
M)JI$5-E2^XG"FV5!/UT?RLQZ+.?[%83(YQ(K9[ROU,AWEA>6'9CUOJA4&WY9
MR2)5_M?Z/^",>W['P*.D8"%$#O$;]S=:?RF&/M +FZGXXIEW#;1B'SEC2&^I
M 5:OM?_9;)" 5##H7WXV;7I!.FL!K[22OLS6L7A)Z4SK;Y?ZY.-J(YDP>OII
M4?:=LU\VBPZ13=Y_B/)IE;UH'5YNX:J>7NFMUSOR\)-%RVG2[="#'34NY6Y%
MR(3L+[;66:$'"[Y\G#0L*2O*PTN5U5=;F=?$5\07F\?D]1BD=>T%YQ8*#%1
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MS!]D!0KP)7TMC*<LE__S(K[:$_<4W6>17)LWT9^28#UALZJ>8_%'R<@-^I-
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MH-!C3T!("E1M]]P'WE 6"LSV@I;L+_9 7DJS9/P)]E:&&3XMUCB#=[G,)B1
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MG5*5G9W\65,_]&9]'E8P8_*A:*/YXY=/VS&D9VWPSY^V2>AOJZ'3Y+5_HM(
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M^X[ !IG&-X0ON?/]'V(\!_]7'_UU_G=02P,$%     @ :X%I7!1]'DV%70(
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MFHD;T3V6X3- (XJ:"G_*3@NY"!;[B\-KCP] %SE_@]7\J7(U$UM+L02#P<S
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M4E*R6+<5AWK90?R/D)$ $NO*)->?#'R:B;?;VTW%O)X-?OP6-U%C'ICV<'S
MK^3+ZZ G8?V=)H\!-[#)AK,5VPRG8.8NZMA6.3>5L_3MN>?H:36(;:VOZ9T5
M&WCF,5,9IIQ5$;FV(D#/,W)+<S2B=U/ ,&7]UB[:=9';V5?85^K^[*^"??1)
MOHI%S/4*W@Y5Y+015:2ZBNK!\6Q]A*EJ0**U)$(Q0WDF$)=FRRJGK6<5'T?H
MZ5@$^!1*J6<JZ,M9_LVO+\J9JUF/CD:Z-.VR39ZI,G]0?O.5X^1N6G>/XB]
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M?&&,TDSYBABY1,,CR/ZV!+[@C*V@2#T:-?26T6V]6,!]U*4=7"'<Q!H<)*]
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M9,6I]- 4.)]LA+_AS$]I[H!K1)#A]+_PS5*8YPU[WRL*LUR)V"8XG<@X[!D
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MDMQBNJ)M*C$GM>KE,-);'E8C62X3,8X-VP6T4@;%,;=(EO1@62T"!D&JNM)
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M<=G8D$,/]NGVD'Z'ZXDGB&D@3%.ZP'H"9V+ZY(6+XIJ$JLAKP]+,>X5(B7>
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MQ77F7_];T;/___C_#]R1('U >43]DUBS!?9KC>"(7:0._$;\_/%L5A*FSNZ
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MWJG>B;N%[N<6O_JBS6F^$&&2LGK)/&14?8+A"V>UM%^?Q>F3"&,SA0]I<L*
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M&<NR[K(RWL-RJ@@?%=1EY_M^MQX^F2\MY%<0-,99Z!(_*/8U6%T]-THPJ7W
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MX[.E1T)-(]HY6Z&"*N64#<OW^X*_HR<W3Z%;5'9KQ[\<?/JT3^!8TJ5B7"(
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MI1X7:['&0X;_SK*6]&"F=7A4RQ"R2J!9H OZ@"LZD>*:J,$)=;+?4H>4*U>
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MGD&ZZ$[C9G&$N=HTQ(*IXF6#M3G!_%1PN;<33%1)VHE6B('K2R8-7I_'+&<
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M9&\ TSMBO9[/2E*FDT#CX3=C>5 V;<7_V XU_=L454NT7SIDB2F5:."C&(V
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M6CAI3?3U5$LV@*S1[>?\)2+.W^93NEHW@";>7N5Y2<H1B3C,O8=6VWOG-=M
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M4OB<08;;G,$+H:@$[R"^X(O+315K<5==<2SA>IA3G:X,=P3#4J)Y#-F^A.T
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MF'-VE*#A!/L[+6T%66-^1?[Y0YB.1WY>]D-,/FD]09Q# H][$,)FX%WC3/"
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MWRP[]IR[ORIM 14:>,U4'V>'3LLO$&)NW(<O<+>^PA/4KVB&4 D/5 0\P\E
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M;UO-KZ7K\HJ'TV.NU?:>KOR";9]Y;:OP@+5D0S #+!,/YTH8IFXA#\_X10[
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MEMZU8/T8EG/DO=MM"X^ME_,HHX'K8Y[7WRX/S4J,_**CUG%Y$':%M)1PP03
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M/1<D/C)?,XQ*/-V4(GP:<\ O0$LK<NFK#'^D0+-SIRC>G>HE@P3QO?$E4)R
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M./O\U!&G0K^($B,(R/[V"7&]^V9L8JXE)<^Z.6W]TMGM&8@>;* D49(D*Y)
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M,"^3:B/["T1EA6?%L_7_@HL%IA% $$D3)DG2GCWMMR^8U29?%1;.=SE;=1+
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M:#+V[43 0T"0[!JEF%D=-KIMH&JJ+$,8YY\6,NBXHJ'G2IU9TX_8!L'E&50
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MSM?E!Q*T3MW:!H:DTHL1O:UJ YBA*>=9HYQT/2+^FMJ\GGX-=$H&C%45D*Y
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M7?4#?Z<&#7^7B4-4F7\*[R2HI0H'5PA .WS63U#L.="_7;P!C@%GIG$*3NI
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M2;J\?$AQZ<2C,.'T<)XZ8/WY59<#5WR2JCZM2-K>7>QK:*.(NKW"*Z5T:GQ
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M(1I%[C^%$MEE4C!GZJKZ@)?R ,>4'@#=4P?#1X#91<P&PJ:)W%_K7RNJ*+X
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M K^;K<F_FENC+[X*.]^KOH/R:E9[X5_)UGE:,L[!G^%SP,=F7D'I85.SV^>
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M89*O8TWKK"9TZ<HW>CK9'9!TM@C0\8GLHE;?G$/G&8>A!+4=\5,FH(PF4&M
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M'Z43"S38T8>F^-1U"O<X:E&80#/=CONQ2,J8R04=O.CGXGS@.H*OHVN!ZA3
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M/&DS>@W'@(P&. _-TDJAF_-EZ+/ M\RG4X*L_++)8DE'0$L=V7A%!NWM5S2
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M+:.K!JJ$!J19B97"8CO.AD^;G<,:^V%)]K,/61ZQG<L^+L*>G7QDMEF90$%
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M[,G,B?AO9L'='CBR[NH=I.!^>GWR)+^,%<P "<"FZ.3[+W^O.@'C[C$S3-X
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M;]_D8O\5>A\9ASH&@#5L5ZO:<T^=U7U21#.S6,EUO<2/.KWV+L7^-G%ODAS
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MU2V5? <?^5FW@)W-2RD-#$^)G3P_E5US6?IZ+'S_(:&1'&)]3EF?W4;5<@>
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M$(R(/"RH.6^#+R.I*1ZA=Y,'"DW>#+,0>)-<%Y8&0.#"4Y(TVQG0<=2Y5Z0
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M:B/NW1>M[J=$\!'1RQA:G2TER[EP=0M0GV]9+N2OZQ%DT3=X@(9=6N)&II4
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MZ)WF_)# K2"Q@[499*0B%X-8NZ!F7?0*C!,-T(_FBW[,X>9] +'8M(T_ZB-
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M_&XU/CI9)^I9*":DX'6LLEO8_;EA9,$@ZG/=P*7LE(!2HHXT'=H)>G!,T,:
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ME#=H[ZC8'!)EJ0X>K1(4(%M]GS_A!P*2KLI(W<_5?U8YO?^Q7)N44-E3]^F
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M[/IZ=K?Y6XR5F6/XDE^,_/4?/(\&9>.N(=;O%C9E8)6!4IK9G<P+-N6;KX5
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M@K_H]W5W_]TH%/$OPP!__ Z106H2P9VYD<<'300/-AB(?UQ:;G,;-+5JU)P
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M6B5Q%;IJ+51ZG98G#J^PP;5,@8+S>^J)'$>))U;_.E37,<<)J!%WX]6X\#;
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MIH=F3 "^U9098P.I[GF;E4K1#ZG9V\M82LS4"Z)-CSQ=0U"KH'SYF.5VW["
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M\J;0'"!.<2B.K>X<4\=R_2))UM2D?WAH F_]K(SS(,_<3,I2+GQ>H)[KR(0
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M.^NZ(L;*E@57B3XT69<W?XQS.>=6OF&I->0DF'?STPOZ24V^6GVNM&1$IO*
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MYT.E%>U=&(6"W:-+1B8N= 6'',_Y,3FG^G(A:NE*FW#4N><?*L_7RS6=^\W
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MN?E]"=L9GF&UHOK'R1U;_L6*>H9#6$KA5:-W!.JOJM\XQ@%H_] 1D68QLTJ
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MCB<G#UG0-^FP"V[_)2KL=$Y+H)"604GN2HYIB&X; &3BF-@L<FZ'^&94J!P
MY$#VWS&A<G3O3+_))MT0(5SBIB<&CI5*W<]+P1=>3S5[_NCYE]<[%V#X,1^]
MHX5E)^VZG'DT:1V\;RY(^-CI2[B7>$D\?<GC\S7O=NQ)_D\?CQ]YB>@@4%47
M<)QNA)I:ZM$%1'3NE^L=%:_![2A1=&,GXF0% 85*1AQ'-3F4813IX#!UF*2'
M#8P+PUM2'%TX1EW7B-'(5B$ZF\P2\I"7*V-?M[ONW1PJ2EHV'O8^]W#0S,E5
M_:[HM/JSJ<Y?K8O[:V%E?"O0YX<R5U6=K97I,LJ$Y&%D@+1RYLWZD3(F=P$
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MFAH82(DW)$8WU/DG8)W?W..D3Y$A$\6,+W3)VG"H!-!%EN^Z+D]>JE\PF_Q
M[!*V\R,=@**],MKHH3/8:OGX%GF=#+$[^1YRN9Q,A=R3;MIS,17E4A?@-T;5
M_Q:\7G!K6PK],5<90#4GFR4T'("BU%78F$_#&=*T8BKWW@W]^4T.-(*\$]]R
MI<MM]A+@3XM"1+.DAYO X(0_)@$6M,!Q)R"V>$6,:5?&<#P]7N$M9:QG.^9&
M^')(!'Z:32BT(?B97'M2K $6&*CR7^ F2 (!Y+'HPC4P_<B<"9[>9$XB+JZ,
MY5R,-AKQ#Y8=5_Q#]O#"5EDT9O3'1K;W74F%. S^SZ(/?FMZZ ,0E8V\R8VN
MFL_M /,"4Q2^$EI^F]UXN$8I^"33:!!C)A*VC>) ^I*^S*"33>GV6T2^EP%%
M\IODD<(TZ5IGGI\E9UY@SR'P/*&7Z0/4%7IR&_0"8$,I38XU7HBF%[<BHH)L
MU@>\**AHTDXBYL("!&3'O$Z_4TX_,=>6(<PZ\P6(G$=B;)T7"(*KLV>C> 5-
M:H0[9_N7AD2R]G0_:QWK_#ZC*]0\6%VK=>G6U/NP^;8</U75^TJGGGD;3'Q:
M/"59^@Y,\6B%\#2ID!$)CD*T\?4N.I;QY0 45H)^IB*R(DS"Q:L?.K$KXQ5@
MB)V?T?"/$=NT&H&J31^>_9!,LC,#"E:>1M7EZM$JPH.AQ3R\;E1YTG$4]<.H
MT12\Q.;6YUN%,J_ZSO&+)>)497K6$M0C4GX*RRR]D/^7UO\/YMX\JHEM>Q<-
M&Q$!(=(K75005)IL%43I8H^*$%M:(=N-"B%"= ,2)20J0NBCHJ"X(2*=2"=-
M0"$D0H"(B/0@(*2SH94JA5"2AAOO;XQ[WSCGO#'.O>^,=^\?-?B#8K+F6G-^
M\_M6U9KUM3-$3E/#2=TH]3([=8W>C@-U +=%6!A2&5(X)9"FD."KJ[UCTC9@
M:_Z(%3VJ.P]LP^P=^@_N4/V/Z["'@L4N6/K-=(Z30KL+N\Q:1^$[9E91?&82
MH40R(E2T[62J@^6L9Q,)HD%/&I \O?.Z'^;PK%)C6^[SC[ZNN- "CLU0UB?'
M;U2U-1?/!6#$IK+10"&773?(\.-1M;&D3;U(C\?/QZ HMN_[$G[VT3 ?BSZ;
MV=!OQ[9;11\<N/\^0 6NM?UWSOCUVO1"W,@%46KI!]^IZYY%H=;9,EKTZBB]
MNJO5N6G>0?%GSM^SW[=W-?S9)]56P.NF9!,PS<XPT0(\8HL(>';]G]M]L-<O
MU/N-'FQ,;M]PQC _RVO3YZQ]O8<_55?:+:U$./&.$HU3WN* JSOK= 8[@9>E
M]FNLOI](75V?K;*/J?VAU*+Z[((?J>N#^VG1\]*29N^0TU]CX\BX=<][3O<;
M1$ASOM='L>PO-,Z/C(Q%7(TZ,3XR.M92;1;U.V?[II;M?N]+-L:K66D]=].Y
M8>3TU];ZO^-A21(7$)V("D.FL&HH$IV5'!YWU@L//-XG?8"7(7PENZ"H8LGO
M "M)8B$P+$/S-;+!E3*X[E34R<F1)9^I^OQ>;W?KG"*=C*N]/WO.<VIDGX8^
M5[2B(//3W#4N2"(1RI03_$51"K2?SQW!,NR786H4/I7-@KST2 A0E1#>?'5<
M57.80#T%>.8*4]7$:+:H QMC?E?@>$3AFEEM\-E;+@K#M8(L]P;S;[W,Q ;+
MFIK&!XM5]BX'J^5I, .AF[FJLM\@L0#3Y!XVPN4P52&O4LG^(2OB!5Z,1A=Z
M4+81=X?@>9AD" 6U7)^E)<HV^&$-6I[.G7'?VNZ>>C]59_MXIV*8F-:$ $XB
M*28.8,4-IOYD@ IXGJPMP8KW$O=!\&@>EHLV8,51V/YZ*&TH6;"2;O"N#;6J
M+KZ\-#+49?*XLV L)@?%/2!@XJ#D9=B*7=(<(N::0 V^BN@!T8 *.28Z60/4
MYO$-$)F/@\.F1#]&B'K^MH2]-30]B-5<OY@BL0^US?)O'&3E3_B.I3THQ]C6
M90[>0V^X/E\Q_%AD/D1TEC/!WZ3YJ%"T"60SU,0:):T$7)NZXNIW@4XN&V.N
M(E9[QV3*-:)-C=C2S=J1'6 */J@:#1XZOE>G+LHWPL/F\\_ XS>@#IFJMMS2
M9H@K1DHBH!\HB1571;[$<S/2/*+V$%-/H@+";WX=C$2/U+F#[PNB<*#:<3IX
M.VK#? <2OG74Q]<U;_31O.6MH7H^85,B>MZ]$./Z'%M/*M Z?#=$;V=F3_ZS
MP >F#;=V]YP_]//NP'F%_N^EJYPM>?@10YD*R$>-N K\YY*=0D&R7&>I2TX@
M;@F@9,!\$*..(;J C "EQJQEV-$; =,&QLNP9"<$]EGG5JJV#X0\VSW+<#/2
MFRQQO;SQ&.G64ZN09TFZFF<T717.[%%]<A4&4Z;#''[1(];C.<@RJ)D,;=9O
M06H1GB(U@VE57BVT#P;=V*6%#(J '#<8X QU\LH\FM^9%Y5V%4%# FHS6>/L
MWG4X2MJ/?>#9ZWF^AT6QZ,=7O&1W<"!*5"8/-ML1T@"M)KY"O!_*%+V1/HEX
M:)/N;H* =CS'HM1=S"1ZP.GZR)K+:EVK"7"!:YR3:[XWYF,'8M2B4>\+O_SL
M2Z(23+%W&<9+E?.9*T+4L ZJF96 4'>*X1LK<L8W O-:$FM(H5CV?DF?$JGN
M8.P<B=;@$DZ=!%');8VE(P&VU5R(R3G+J!PTX#L]NOB[;2^I:N@]HFKQ=84.
MJ0NC8?C:9#/$$2!23[:6=$470+$M 6I0),]G/G7+;%GH+,,Y*(^X QB*JU$,
M/!\Z[AVVJ6_\YPB_UX^2NO'TDLL-U>^8U,7QC950H/ B($K$EKDA;Q-/&0O\
MIRC'_/Q./>'.O4R-R^9G=Y]/N,II6/M#86-CR+]Z3%E O44T\E8*Y&/@>L>C
ME +S?<\KWKRC<>CRCB'=_B'D/S=@_!]=FOYW+]TWA J.@7[LP4>#F=[G2!?T
MEF'#OBOIY4;-:UX^Q.K9%VH87[W69"\9W5$CK'ARX_H-$OWRY9,>^1=VX0C-
M(7_G9/F&Z6H-86YR0^UM\R</Y?M?#R\Y@LG2F7J^(R/5\O2#K6]W/GC<N-O?
MO*9QZ%.Y''>4?"!R@:Q_)WE%9A/3-+.)]!<4?0+TF_3-=UF?W%K]IF3%U7'=
M>SV16R(>)JYYUZ898U9Z/NE#RR-4X;@.N$B1!&WZZ+MU>F]I7I)/6@E_+.K
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M'@5>NSNLFW!2P6[R/NS$09W_E4OA,VJ-S!BBM=7YQK3=!,D<KOJ?U?'>135
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MP=6CUXQQ,C4%H*Z)6T5KG1MQ;&.IR$Q'"!0>JX6K330$T<VT5:/4!/VZ !3
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MI;$9-KQ9MZB9I826V.K9L2%*NN5//R4NEE,*TW _LQ*WWT6_>ZVJ-  @5!,
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M#!L8J4ORE*@@VM/;(B[O'\F]3&-9(RG4<]CU;^H\0J(.78Q+XA_[\''241F
M&$SP"A4R(&.-/U#I$&\>XBL#NQ<"53QR7CBP2H^B<,T1(7$-PPO9G2('4!+Z
M/Y(\X)*7"Z3$=J)\^X=/4\RW@P>C?-,>+9^>&BII6W1CHS12;1.0,,31HS88
MX%0N*9A70YVBGB5>WR09K;$*<?X.1N>=&/;;77,:7,V@2(EK9X5>]EMCO YG
M.&<\8%F >Y/2M:6>)^B$;RNN@=G *?QXJNI?6H!PFFSWD9AEH-^C>#. HF2#
MECH+Y',XDE+G!-*Y<DQ?B)>HE<2OHRMZQY9L<K;\$[HDUC@G5@U418R'I'S=
MR:\A_(V?':I=8<#.,Z]>/0IQI"XDP^]B6%?+W9%ET#[9T)7VC5(@$X/V<X!*
M9:Q^;&#/DI"?!A4I^])><S>XD]D7C+/JSM5;T)_:P!87TK+.+:2)?*8Z[K-Q
M+DT1%+> @;?3AA[OQR#F5&M1*535I]M9N@\ID]=TFC!BD4WRH>6G #N,;"T]
M\  ,YE,9P;*+Q$B8F2F=S,?+ V]53WL6*Q2Q%3,^Q7F[C*;'HR>?2.L_9>]'
MT9OGWT!CAN,$NSY'F9G1HO+.TC"Y@*7&6>8\D=RTFAC6%%5F$RQL*#+_FA!Y
M^V*DZNFK2D]AN&U6/6U;G:N =_X;U>W_+:UH_<1_ %!+ P04    " !K@6E<
M,6ZT*#IA!0 ;YCP $0   '-E<&XM,C R-3$R,S$N:'1M[+UY=]M(LB?Z__T4
M&/?T=-5Y2CF12  )N:KFJ&2YKKK+RTAR][WSSCLZN4IH@P0;(&6I/_V+2 !<
MM-B214J0"SUW7"*))9>(7RP9RT__^V)4!.>VJO-R_/-?PFWZE\".=6GR\>G/
M?]D]VCLX^,O__N4_?OH?A 2OWQR\"][9S\&NGN;G]G5>ZZ*L9Y4-?CAZ^V-P
M,"[RL0W^Z]?#WX/7I9Z-['@:D.!L.IWLO'SY^?/G;>/R<5T6LRF\J][6Y>AE
M0$C[\+W*2OP^>"VG-MAAE"6$1H1FQV&\ _]'PVT1LN3_H72'TJ7;RLEEE9^>
M38,?](\!W@7O'H]M4=C+X$T^EF.=RR(XZMZZ!</4V\%N402'>%L='-K:5N?6
M;#<//9O">L":C.N?7RP-_7.T75:G+\,LRUY>X#4OFHMV+E15F'Q^+7[T5S)*
MDY?-CRN73F^\-&XNG2Y?FJ\,8/GJZ"6LXQ2F9KOK8>4_?>%R_%G)>G[YQ;7K
M5^:'OW:7YA>W/3?$8>"6XXYWEX_+\3O8^2K7-]]FIM7+Z>7$OH0+R;BY<CZJ
M.K]I3#"#\.5_O?W]2)_9D217ISZKR:F4D_F=3M;*W]?^ />SN+L87D_P]?57
M1@?W<$)#$H7=G;J<C:?5Y>KNU59OGY;G+]L?5UZE+\TM%U^:E0OSBRF!WU9&
MU%V[6."7TTJ.:U=6(\\FN/XQH6)IA%8;4L_4S2]M?UQY<5U-KZ\:?+EZD9V,
MKPQM,K756'K^Q2M#MAC#;%K=2H;92_AUOA$VOWF@\,/JZM0E9V'Z)5YHKI@O
M U 5NXG)&'UI+Z9V7.>JL,1ZXO-K61.V39=6\=85O+IM-P_J2WO&&*&,A,F+
M7_XC^.G,2@/_#7Z:YM/"_A)2\K>?7C9_X[<C.Y4>/8G]URP___G%7CF&X4_)
M,5#HBT WGWY^,859O?20]!*?^K)][$^J-)=!/;TL[,\O)M(@HN^(R<6KD:Q.
M\_&.G$W+_Y&/)F4%[#1]]6]@+&,O=N@K\MFJ3_F4X'-)G?_;$FG^.:NG.R&E
M?WXU*>L<)[-3V4*B&'CUPH_6Y.?=RTQ>3PIYB5B O_Z47^S@F&S5_)D;8\?^
MSP58!#FL^IL3X3(K!4U)FG%->)JF)),\(9%,*(N8C+6!]1_+$;[%YCN[(&,,
MRIDWA3QME^1B>F@=+-8),QF75,-6IY82KE-'%$LE,3P,F<A"09EZ\8N316U_
M>KDRFEL&EQJM(P-/X3PBW-*,P&@5,88*0],X#IU='EPG ]^ G)3%!WA2:=[
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M\*NCE-$D!+REF(3%'<!OE!*I 'M9[)2625]WYM!.\\JO]@U*V)MR5OU?6Y7
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M+%8[ N>5/#J3^:>SXMF4O,>T&1<"T@F;.L*5I42FU!#)DT3$F0Y-U%O>>.H
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MXN74/)RLFBU^"&5E&R2LS2[U[KMW'W=_#P[W/[P_/ X^?#P\^KC[[C@X?A^
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M)YB *Z0D7*2PG(Y3$MHXXA&-F&,//K=K#;'+D"FOD7PC_=TYOPF(R[==V I
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M@3)Y?IJ+:)?7M3]77DX)7J0!AWS7/R9';WE3"0*D\[3UA%AXV.U3:RV'2PN
MT9QCOP;YC;VC@BAL[)0>P=Z6]S+F2VR/:DW5,3Z>W)7!!S""@H.#@WDN=+L=
MA_,3PS<@ (*0DK_A0LX/\:?-MAJP?2J;CU<@\IHY#9BYQ"./UHR*;3,LH6Y*
ML"OL [/&_+C6LR\W1$[A OU'$"P+EW_[)DP7.^R5*^P%:710(&#,Y)J-QJ],
M7D\*>;F#O_I7M>&"H.3GXU?_G-73W%UV;_57$2#95Z \^K" G887SS$A;/'^
MLWGP8;NR^;@ 6YO 7E=MEMGJ#_#(YNN)/+5-A"+QW+0CB\_ 6FTBU_+$5B+"
M_& 74[TVC^O#74H8F^_VQ:;+U'J"6<[EHZOY=[2WU.1[N>!VPNU=@AW^%S[;
MZL558HMOIH\U+VV([: VK JL<86/=W_]?3]X_R;8>__N&'6"[R7C,Z3;W](%
M2K!M\2T9G^DV_7I'K"\F?.*>*JD_G5;E;&Q(2R%-UY%-QD@W;7.7.^,EVP)3
M3[\6S3K*C0'1\RV->9?I*-QF2?KGE0'0M<G,_H4)-XNQP;4=ENZVI;MS"YHG
M;"._V38T'T"1N7>.QMJ0Z6Y(M&;6N(&,!U9Y5DLI@[,*W4-_JB<6_=@GXW)J
M3_!$J\(QGKBR^@Q_WLY(2*6W2DIC-=J/J!7Z&$[4_%M4N/L6'34C"][!R- >
M;T:&UB6.C/Q>EI_P\]$\)&:^FW*].WKG#)-K.[J HTWNJ7_[1M-.\@'?!GQ[
M5DLYQ[<JKS^=.(FG<2?U; 2W7CXEJ!W"<((W?CC!43.< ;8V!EOG VX]*K--
M9#4]R>_/7]>T[_4QW(?=P^/@8%,\]CSVYUG(E6<)5YM;S0&D-L@$:Y4R!V!^
M!.'VH&O]"99Q=!*>=.&63ZEG=54]!N5J4V0?#K#U'<#6[H!;'6[)DR5;\4G!
M:\E(' !L8PP010."?0<(]NN 8!V"J9/9N+* -N?6G-13Z=P)AJ^B;_PIX>SC
M?%#HK'?.Q]P-#OM-LD8F!FS[#K!M;\"V#MOTB;Y4MFJK6SRI#W]O>2 #A@T8
M]KP9;;,8Q@8(:R&,G4RJ<H+SL$^JCGV8CV+ KHUA5S9@U_/'KFC KA:[HI/"
MGLH"$4Q;W^3P22'L=QQ,\&$QF ')!B1[WORV623C Y*U2,9/8*'L22V=G5Z>
MF+S&RAFSZFE5LK=XTY$?4O!Z,:0!U?J :@.2?8?11L-2_K'19 C<>C9,<"6Z
MM(_AI0?;0X#I@%,#3OVA<6JS%EP\6'"M!1>?-(7],$?Q9%%SISYI2G4]J1W7
M5!S$XGN'UXL!-875@OU_S?+IY19<4?AZ.$O%BX*WV&FC+1MX@&7OJ^##K-)G
MLFZJD37W+A4S&DS$C<6W4CK@YO/'S63 S18W$P#+VE;G]DFSNO_?PW80_]\
M79N#KB$X_SN KG2 KA:ZTI-%N[':.^UGOF3CT^IZUQJ@O9X/S"MPNTN-6-[,
MFQ?ME6/3]#'$:P -9T73/>G]Q#:#&I2Z#2(C&Y#Q.T#&(6UI#HWRY%]8M#:?
M^N*+)P J^$71?GY*A/P_2^/R8/=_%N-:/N8,=E4YFW:-!S#Y:0# C0%@& \
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MUVNVXW8,AB+N9>O3:;YH@;/;5G\K <GW"C;!=W79:83CN7VER@ND(:0+55;
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M#5]9G8$PO]Q43Q9UN=19KW,_;G58O>CUYF7<2KLW["I1C;N]ZHH];:V6->P
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MJ^<(/-O(VPD*,Y8BY'6]C!%9;SL\\K;" &+H,QVK R.4TC>^;Q%#$A8N]F$
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MBR6A!(!,O@6$QYZ&FQW.Y!5K1UK$9!QV[\@ 7CEA@U(Q=.Y0AV<*R@=S;PC
M(]Y,R_6C)D1B/P(7KP$-PI"62C2>DL)%0D\+INT9X)<C(!YK^Z5W<$QUKX*^
MO>)/%$>[J!EAK9=4KLJWFP$V.#TV@BOEQSLY?01()RO.[EGS,6CG6=' C[NJ
M@D=S^L O5*?M<?AYS+BNHT:/1]_O7=-6B0-M@KVNK" >;%I?+,F)0JP)&PYY
MXA[>&=H]KD6>(A)!A&M3XW/0M1)]&HO0+<V:[Q$B0% 8@2O!A_7V>HQ!E\O+
M@A15 1#D_<(.U[+XT\N=;T!-$5ETHLL=^;M" T:#/&)7Z<I?E."H>;NLIV]!
M\^LT;W][D710W(1&/7*%D=B@)6<]<Q['2)Z1Q,?T1HJZKT_C+D<$!8T BZFC
MGF,O0)>+?O%X--N4H?>SR+Z61#9R>B[!A@V6K_:2HC70Z%R6]F*<27UJW6@S
MYG:G=V$GA!=.H ,/.]DS *R!7IP@"Q,L]5%33\#T1I%3*$GR5=%:X BDD,HT
M1&B-5BV5!H=T5B( M)*[-+%4COZY <YS[2"O2&2L@A)U/JR.M?E_+B*A'7T]
MERF;;4NGL92%JIII##X!TPZO03ZLE2OO1/3ER6$VP8R%+W][D9Z3Z.[IULC<
M/4Y^MDET9V0=/<3+4XVK!RW/X0),&[<A'C<%F4 ITK^;RS**VE+3E*C[1HU7
MYC1VHI,@P%I&TEA<[_U"[LA6^?JPMLJ0U?OMPY*?[PM+?MX3EGQRFD!C'IZ>
M#F')(2SY_M+FH/*;Z+CX769)Y8J)-> ]9DHT"[3'X@W1RAN5D=%SS&YYB3;V
MOKQAH$F3Q:%68T^MQFNE4H:5\-JZ@H16!V=P#Z>EURT-I1R]S5BR%A_PFA?E
MNA"9@0ZEVA^[VZR%O,0?I5G+\:VX?",U,HMP4M5RDJHY@RYTF^ /Q78K&OZ(
MC51B8$6^V6D>M*JDMT')@/#K  84(Z"5:]K^QCH;&(5YY#Y 4(N=#VRY0P\;
M7]UB=%Y<R5QKP6HDW/;=I0P969_Q:(!_^_U+N>E=-35_U]X.]&"Q]LY\%VT.
M40"AA.Z;:U;^\J6!]/4:=8KV-;HFUNLZ;A^OSY&/K%N4J,(QT'W,ZL9B2H(E
M]I6X [&A/ZNZ<%IXQCY?>].B6]0$-K3>.;!:YS+A]^#T%Y>^WHCD.)K(Y;,Q
MH&BS>H'(\/C6[C:_J 7 &/S_F@&H9Z$P+]D>^WJ/>O#POY^%X.'OW#N '0"Z
M#0 \=I--5'W)DT$8X RUCN5(^0'< /#N7RYA-:GC' 2V$,>CT8^U8K<U7U,J
M#QT?98D09<=V,BO+2\1^/*_C:,9*"IX.1T%JU7RFT5N4?V,JB S7.LQ[?YFO
MOSHY?OR.3Y,37R*QL*AXP+6/&)>EW4S^P85%K)5TXK%G"+D:Y'*O*VQ*PI:9
M[3-])UO "JK7!RO]!\S!'<0<G#P80 <#Z. CUM_]<0P0+>=N19@#M!RUCKMU
MY4V:(3(-,?ABXC^1_E&%)9WA@B:Z[>GOI7:@-V\;1M#@:"4@+\WN\83\_L'#
M< J76Z,\#C #&J2*O-/FXY%U#=VIJ6<S4G?Q_ON96WOR&><;(CZZ/:XR@PZ3
M6N06E5ECS/=QFFG_A,$'!5TOK;^5[*"UDC$>R6OJI@*Q+*B+:1_IE/KN<+^M
M8]:'AV+81:L!/:?%)=4*FPS&3BST S<+#^CEN&[K+U*,-G)&%2TRW<C@#\LA
M'- ".TV(S7Y62(QU5$3X"(8_-T#7(ZQV1(+3B"SWYB)ET[_QKCOAEX&M4KF\
MR$C9S8B+J5T6S8*46YGSD.Q>&W);D 3VGCX$>S*4Q)I/='^<]">YQXY T;.(
MU^1Q;!G;R8/1YN*OB^_YEY,'#_B#^ [A&N4ZZB((M'BP]08KZ&&"H+:^][PF
M@1'I4M*61&LK%/1OD-'MF3T(+!&M>! 6;,V6SSH%SXKMB*RD)U^=W#?37%:X
M+&9;6$EKN^2+^VE#Y.B\Y4T]L>8 %06=P+'(5G3O5ELK!1]F=Y1!D#C=#(*M
M%>E?1-;")&.SZG4YO;1^;:ARE=]86[?7TWI5,IXZ)1!$Y?%F+6[JOTK6X#3K
MHVO@F:KE>4,,"#%7: %*JG!Y1QR;#I??@9@:_^K -"3?J=5$6ZV-K4Z%W'PT
M)SEI,=^VE2',9O_8.(55LA*0EM=U5AQ*G!I<]C*Y"T@_69;_JB]E#WQ7K]XB
M]/:S$MA5;*GD9=Z193=+O\0]*AOT+__VQ>//OL+&A"3;$%"CZZ(;>'$ABFKL
MX)D2K'"6TH\Z@>>P:)/80.J7WHV<_^<'!P^)<K-OX6Y:.9I%6*:CN)7D]6(3
MBU6E+( &Z4B:8A:(2=EZWY4ENPLPC=_#2.A'-'RQ#]'PQ6V(AM-'CX8ZY=NW
MX\'E\5^DDMZL#^3F7V2"Q/XP^K%>&]GHLEZP%=[J"!*]]$@EX=*%J- TBCN:
MEV03CZ[DN8))H<49;@WV!3F_"^NM@D:L/S[]Z7_. B[4&YN(CU.]*]W)B3TL
M:%"B>^9*%:,_5@VCP(/!9-FT1O\.T45WP8^XZT[#+VVPX<[NL\@F/WJ)=O%8
M7G3"W'R$KAIW8PH_A'/6^IAJ6PM1_$1IDJD>P(%]R=XT^=!-_,9(!:HAY,PI
M>L#-! 02%@NQ'I!A$4'QVF(G# 9,0=Z'SJEV=01RDY.F.PY-T&"12>5:K;58
MQ).%D]'%O)X4\SQ'E6>O=C-69FBB^L!,4$]-XPLUR5XX"0L2S]N.8\INLV:S
MEIA5QGJT1 .?C,B+M:? 6\BB>ZVKH4^GW\.Z'#(\1QQ&RE9[38); TTG]?=&
M[).4] 11^)ZLM:._BI\@(T3^'6V=VNUR)J*W3-EL(W6M#20)3,4R(U!'UZ Y
MD#71/A$=\M^$$5W7V*FD5_7* ,!PDOX>5]E #G9Y1M^;]C#JAL"2'A,)'7!U
MI[H4?7+;X\WK[UYY@X#^O@J\ NR<6+%O&_%V6VL\,O*NU.QG]/S9D*B_B=[;
MCL.XM\E -LD[E-_YK,^265]?;INZ$A&U#;39(04N*^(Y\(P.'MGK\+[\P-HC
MCL2BDKEDE4<8!PT[S56R]FM&2N V-I#1#CB4C$S>!AKOB5$1XWE\,7 ^"3T)
MPU.,7SASN'\JDF>Q84OL%$/("!L!&449>_I"@8 U%G#$ZZ)!#8WV%K#^BIE$
MF*(9#B%3F/(7/SX[*I?%A#S(IFG^)&+BES86D8F_JL#MWMV?[R,5[K@(^(5S
MYC/S=3%]"S^$?<QG\F %=^)L#-B!NXX=.!FP P-VX-,2%MP)&?E><]QOV: +
MW3*D>1;H8HI6.<6<.0TY%-Y1*$D;,]9#+PH@XE, !>;,CW@S$G//?EXJX<V:
M0 :FW-2&\=;(FBQ#W@_]7<W JMH%G;C>\6IV QW=@-1#)+WM6"YJ/($Q@"RK
ML?6S67[,Q*DEIQPZR'5!A>9/B>6^-!'MCHMYH<^UESL?OO_]LFX6-1PXS=$;
M8&#GZ][DE_N4(O"_U8]KQ5DLT8BOK;.&T?V+:/7#P'D?@;J0L,>G]0*,"+??
M;=E5F:MWE?OA5=.(RG60J%BF"[8CO@16/>G#"\^:K:WF-9I7:TMAE$TW37E!
MKCVYHUE/2B 9V-IZ7I8K=BS<-!-@D8]'9W,Q:#?BB/>/#KUV;'ID=CBY%5.N
M"_BI4_W(8@'.A6OQHC4@M2IKE&IL1>]?$*F 0-5%.7KTX' "_X<@$\1F9&+;
ML9[CT;9<AX:2X]$5,[A'ZTNV@27=2)],,(=%37[-:64HF\</_F/_]G.IP4,O
M QIWC^*-9[EN)K -1^?5I*DGHB=(JC+5&OKRLK+6FN*TM6/M6C39YJ<S=%>V
M^GU['IJOH9.1MG$C/AJO:"M(#)\V-I$#S_-5F?F*LNF18Z^*BV7MJ>2D)Q-@
M$-8]>JW21,''US6:7"O.8A;1Q' X"Z2PTY;BZ/2ZYL/OX8+)9HYC?W\,KG Y
MN.U"[KRWJ%KN._=N?2H, 3&K5O"8B]&]R1R!2IY=#>#9TG]P/?,?NK[B+K69
M/C1)X]:%2>QP&MJ>8)<?)?+7:*LTT/> 4D>.U6:I&:N9VA\:%)$G/WD@TJMH
MS-((2FU=N79&S5_29FQ1KB]%0OT++J&UU%MM11G)H6N*:34?9XTA@:C0EVGS
M&YHMJK\S$V%!+B9T0 PMH9*:BHZAX+@@;5%+RJ-"&S168%LIK4M:,&N*:J&<
M2F@(L(W!G3*W:<9IP J FL463$FB"K?:['Y1:Q,!@GY$0;MLL%N.1R"9H37B
MTGF<M'S3N+ES4OEBB7?,XX'B1#A/B< +7:8[*X%1 J.IQ$S;51V-I*A-]&'%
M9!Y!B-F791'_L2<S=AI,PXZ([?XLIJ;H5: 9YPS!N;$T%GE*E-:6PAK5$+OQ
M.LW(*,.['-:HT%PIU,O!VN@3GYVS#VVJX!<<!Y]%AALK,T<UOAL/XV4Y7V%_
MPJ;+VF*2,:UO(;BC\[:PQ#?3X, >Y-Q8+ER?A=,EID\I7X :I@;GIM2\6.A4
MV*S1NY%%O")Z9%]SQU)YBP=5;1:$$,]9<H=^A;().78.8(8DUY:$GU5YKD.T
M8B(."QT^9)OS@7\%L="V]&,<A^ &RPQ<;;'OK#5-93'P#'3-QZ/OQ*RK&^TN
M,>YTCKPL5,A55U9MC$61KZ[FAE6,-A*Q:O),G%\>S4 1I8>EEE\N1P@PZ)-6
M2(@M'2)G%J68/T75*&7-TEF>=.86K(K]YZ9JDCZ5^ME!#MJQ\Z0GNV6(1['T
M"#F37 HOK5#F6AZ%;;4^.*#!W;&P#K(9N>=7AN!W-FE#)_+WZD2>6#5[.O%"
M1?6EZYSQ\L.S=?MSC")UM5.YD4&$AMVWI#+W-#/?UY64]X&^/W>T8R=OYOC@
M<L=NV_VP @SGQL])W/N?M.=UNZ/-S?T]?*'\)STN>S;0OK[INSU">7G:-BG;
M=[#9-VU&=ZK-M2W,L;:\\OF.!4<_I"U1 V"/VRK$L0V4MOD-JWJ^G8JWX4RG
M-IR8]A[L]51,8LK04[Q:+NNK0N60W'$$:XRXG]H=LZO$Y>IV"M=ZEUND;+4G
MX'\\^OLEZO$3GZ%\A\H;\QS&T? \KZ<; ZR&7(:9T]&+;>O =[A/F*H(#/W=
M97S779&7"S;OJDZ'P1,'Z4FI6B_ZT>SJS4 3?E5W!JMS_ J!?L[$+;%4"T#J
MX10+."0*4.MH%CZP*3?-PYA71*EO'D6@0+"8I9[^X&A%TFO9:W2K8L-HDF9X
M'L?]%TSE;@!(?(8:NG,[Q!]S4,,4FTR=XGV-W&DD^RH.0<C<[J.WJV("YHB*
MKJ?&BOY2SBTJO/[R;R=/'GU%U"NF2+X@>J+HYZY4Z-/+<J$%P.J9RM3?=)Y$
M4)C/4HA:NBS$*^[ ?M7Q]LMUJ!F!>1B$PZ_\U5$;4HM.W9J#E=481_C1O'K+
MHXID)"%>+Y:[W2J5\PF#&(^F9S^\3'K6>^[%.S\E6EQ$35LK6PC+"(J;Y9.V
MU8J*("MYX[<XV QS*NN48\XZ$3]<$/%HY3M_D%D':D'C;$!Z)U54+IT912Y&
M$['F,:$,AJH(^_;ETU>#39!W/5A:.#M3^9S:VWT;+:KWX(Y.>+X@OD&Z%J+&
MF*#EK0^/;!FN;W%^CJBN]2]3,B%RE^&/ZPKXZ]%LTX3]6T;#XIM-@U5&'MG#
MQAV'B"K/LH^QH1S*=4-%+Y,22GP9^LO-:F0L?']E@- B,3.*I1YQV"-B7A _
MGPJ&:AK8B.3]VJ6MX]&9Q(>\Z9^YPXUT#8B[NXBX.QT0=P/B;F@1]+Y)[SJU
MW]21RTL"BJ4)=E.#T<3;JPG+R+70U0.&Y,,K]AFAHWNO7QZ=/'P,S@BT\FEO
M<25##](D=")&9X'PIZ@TJL;4&_;'].!R1..&'SKMS[682YX*7)>\?F/]1;4C
MAL9;+[?%?-/4Z%]23*N90?#2)QB>SSY0:2G,6_7I[<[8R0.9K;7]J_N);0&W
M0.:<A;1FV$8[X&83]TZ4Y7]Q2.;!?0 CJ];06:-V<W%1 LZ5V8DH#,RV?'*<
MVK"E-=*@1(JAEW,:_,OMO'/Z4OM"4#'2,_1V^/C?>EMOAY,'^Z@0_"\9%\*C
MQY]'+H23SWN[.PQ<")D,."PN!)?>H55[GGGP?JA]N$^$)43I[4ARH#!4E(^F
MJ$&>ACC%;8C4Q=ED])^B19>U"PZ+=PQ!@8Z=DW0D*W=!;_"MZRPLF4)].I'B
M&QN8:62]F'?;7'0P]G=#_8H$.S0FHQ^J*2*;M+,896&,)W(QOI^QB&4^VLVP
M;9/U#(9N9_43OLN;3V<*AI9_-2792HRXL(NS?//($X-W96,<%E_2.)EBGULK
M_;@K$_KTP";4(<<&XK\CL_CLH&;Q>'1&""*98\OR+:E"S(#HP(\[C3;DV>,T
MRZ ZJBN++NMK,):(RK76K8:%B9)'N6Z3-IQ[)0^*PMQAK9:=4Z3;(5Y 2\?V
MQN!V_!YNQ\E>M^.DQ^UXS#YRWE3NY+/![7@/67)0?@<XV-YD%J;W >I8FOTP
ME7M?CT=/QZ-G]X/\22)_;90<!H-(S57%)'?T 5IVWF**)6Z) JR2?.S@NKQ_
MEQ=MCK(H\Y:NP7^)HMK8H$@CZS'86,S+VN ;RFP#-H>\8(F[%)K]5HH-X-Z
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ML\L&81;/.1<\":Y)\OG\R&+:R,GUBV--7,K<1:.$1DBXSDV0-MH@3U^VX<
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MV5A[GG=?Z3B6+ UO-XO4SL-W7Q9LK%R=5^4LWRJ>M\W?BJ>Q-J],3H"V"<-
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MY' ^+F?)_W#X/KQ]6O.O3;YTA'":O:'N9Q>ZA#Z\?_OK&^T3DL/3FG%?*>%
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M^9I1SB2FH,6#TC\HG(U,)H+B< UTY+P@SI.S*E"+2@*;2A\A1^WWRK]@'F5
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MG#S66_5Z?W=R\1%RBP_P5H>?'\Z^>_2$OR")D[[N%G.=XHNIF+@G!7$9_AI
MGS8P!M*E+55%OOT!:;Y$S[6 6,%\:^)E6>2GE?<P6/N0LRH(M@3^2V22*W=
M\UZ))@[4$?Z>9TU=249BZ3!#/8>N#"D,SB5*%\F]XK[J6?EXEH.,$08OEE;!
M(DG^&K@5ZZZ%M?*JFRQX[/4(7-:]^064AD(>Z5[A;TB*61.-8HX)X-T4%&/
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ME"NWQ#R>DVI;'/RS6'R<$Z<QL>%TU(7";J4_>6?%O*"#ANR$B+\_=-4I'33
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M$O-*/0N'/\:U;P4)\39.,D%&8;6BM@8ZNL](*>/7>PW-,RT+OEAVTB?USE&
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MP_(/H!-+(D6_CC8/A0M_[LP+B;Y.L2:I)A/*"L4+^7KNKS@9G<GHW&#QV);
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MN/$/0Z7F9B?=7PAP3LTP8N&R" REO:_A'U2+[<I3.TUUQ*7 ,\31I\IRW\8
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M@>(LBDWA K\=Z A6C21/O/&/ #I[$<4.:C.6@N)1X[2(P@3$SX0)X=YS)(X
MO0/8.]Z+UV+HA,W(0KTUXR27CM5Z2M^Y4IJ#'I==EH G$S#VY,-/1_]FCKY
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M@HK$;-'"O;+P)+0HT4B\T<R"RUM(7[+1KO=@JF6[R#=NN+S)?/4S*SJ73?T
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MM*=X/?*$U',))T#Z*6DL\QK0=$14W/%<6?@1SL5FR:!E(5-$22%9KBZ!V!;
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MVB,-Z/%IN&WPDO<^KEKUO"@VU!X"5S%NJ0X="VH>)1)^M9*@9/3S>$OQ N6
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MF4F'C637TGA)<Q_(\2*_0@Z;S#!@NB46M@/*-C+E4E)?#QQ-/)(B_^CO@+"
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MJ@LV2QE$A'DODH;D5/6A'0UW,\VPIG-0QS']_^R];9/;1K(F^E<0]\:Y84=
M/9;LL><<1]R(MJRQO3NR%)+FS.Y^ \EB$R,0H &B6YQ?O_E:E044V"U+M,=V
M;<2>D242! I96?GRY/,,0[>N:;A#9@4":H;1.*?P6[-;F\XU4872MV-YO(LD
MP(>1^#QH8*<-=50E%Y17P7-.-CZ,4_4#GK_4W(6'-DE[[^AU17.(SP+A!JV7
MC LMC M80HSSCQRFJ'@:B1XOS+J8.9B(2&8R+2?4)WY&T[,B"]W+MJH;'$ @
M<A;Z"8XWT#G97_/C4U6K [&>.:Q-3D =Z/$(XWV@+HOI@>/K2$Y+"22,-C-<
MH>ZGP[8\RB8SKJ7-8)71Q30N::1\"6XNDWHE3P@/B*A)(G^+0WV@:+J,"&3"
MD%Q@D!%N$UEIK*N;U;ZFF6^XCM8HDPO&ST[#I^MJA$<]=2,^=X-;'6R?YMVJ
MGM#R-#+/3((TK?+'F#1[T.'PJA[>#L6K0&G_+<XIPWL&W_'M!)OQ*KCG:P41
MPNJ^%$-XZC?D>Z[OKS=*]NL,\J'W<\3=)5LON=NH0(K\#DR&5=2!V8=FIN /
M>&[2B19#0^=;T\Q7I<:'_7P*%V49W?] 9/\9OC _HI:@"L./PU/5>[CP= (-
M-_V>(@6,2_H:V3"B@Y)&DNF4WQ WVM"5,5>5+A1>O6<&K5W5[]TF#SX:4WRS
M\^!V]:Y^!766#@X@>""<IAL/\4RC-9SR#+?# J_#0S:!(H_UJ.#S:UOWP[%X
MN</X]3'9GQ&1K''\VE4;:_NOG[U\]-5?OB3(VI//GOP9#G2*0"$@;.D?O_S\
M<1F#R? @QH1XPY1T/B+17XTM'>G+\%^OX?_] #?=8NB+A ?4-FZ+YW2NPF_
MKW^Y1$,W.W=U=)N6BH(,EX3-$4LN3XCVXPVO%SIP6!K(:PV+!I^ R* QKN#?
M8$V96ZYI=/U\#&!D(C8<L.I/:B?\1YY=?4KS$.^*EW P8,@'&=U77WQ=>LN@
M.G>'!E=S/3'UU,C8-C*IS.+0D/@9" _P._#0-U4K,/+2$[<128';6+_!M(IZ
M>8% 5C>UU>25K"$:F#TS.1+Q&:ZL(]UTX(L\6US2\G=U0SX;Z>*FO'SJ>L4F
MZ=X3;]S_/H71& 'AQ5HE[Y.+[-&]PKN1[0#OJ6->@^ZNZN%_!]<(UR1&V/#P
MX*8D%N="+B[Z'HUCW\$G1[C2RS??/WY55#==6P\QTX/9;7>>L^68'IUA:A&Y
MS3G)I)C<-)'1RU9Q!^8(WE:;)G[#,'$2[QKT,35RBM!FP*^$#4*4".E-%0_/
M$PY/Y"JF]_V(KAQ/0_\PRW+TK3#U'F? R7LG,,I\<:+7'Q@C:4F,M7O;]F]_
MNKQ#C?]4M:X;!UK7KG_K9S2$0'9^CO?^<WB<Z[4W]9;(JHZXID)BNE'AT]DH
MMR8%//%*V,@SP_,KE4Q=FMTJDZ.S4:J\Q/?I:@8!13/Y$V(.V6+P-9II'RND
MPG"29BCU"(899"!GQFSNU3F^*K[A2.[L,WL,J"DM1$,YB]?G]!@67!TADU,.
M1#U@S!\^>DSSOA*7"J2>G,I):KYUTNIT2"M4K>D@WXU@@6?$S#.5SR07T+(%
M,ZY$^J9P& O3E3TF9BP0;!56/X+ :^1'6KBI&)XF.R>1O7-EQO@2--IZ&$8=
M Z"H6WPF<D<DK51N:1(GWDLP8=KBF7LA]P@_+J%B%$.>/+DT<0OONKMTC5=8
MF!M,AKA^5],.K3 2'J@JWA'+%.U<S"[A#!*2)3CS47QM72#?L'P[(YBR?5\(
M#,V9&*6!\/?@1NEH5S.GW)4JIU,V=XDG9B3O"A'=IBG#((*LFZH70C+4[H8$
M0Y,/K-W6@R!!I']$9Q6?870M4WF?QA\"TD[<:K6".T#V00V5\W[*^^DBYP49
M_"-5>;4NW$1'U!-5K+66L!)FNSJ9=NA0C(.,=3%M5;23LI)LMO%?3G#.]G3#
MT*$+U&@XN9@D1[,?MW:;K35;ZR6L-1BB0 &LZ>+'$(,0V3!9++$OCX?)1.TR
MJS)/GV/WV'>:#6&@#J\W)Y&L<1L*E1(N?X+]R-LB;XO+8+BU"3J,*Z1&1_/^
MX<=OA[,0*S"L1BNT3 A-5^D\P(6#&5^)C/693 $6LPI? !I\D8='W^-=P01!
M6/,]L.:898_V#8A)2ZW#*^DE-WD/Y3WT"Q2':D)(4I9*S>8C1?\" _Q[2[U%
M!C)J[X^5#@0B6?7U=CL4GX01'_TK*J!2I6CE'-D_:W!PR9>I;5<DY=<- 6\9
M_Z+9UB,<>G"OGY9PPK2JM,%31#+'A-MJ[ZJ!=C26!O;8-OL3)#!(OV+%,A[X
MH^I  D-2]*#;L:>/->ZF'AH_"R(R("0.TC[TL7BU]![YN3[-'B![@ MX ",6
M-]D'"G;^.8AE^.NJW^CY.:R[@^/#%E%,/KY\ (-DGD_Y+<ZG?)7G4_)\RD/G
M4_(9EL^PCY4)NK;OFD9FR\^5IG,TE2WQ I:X X==;/KN\ @%QWJ.[U/1CK?/
M;(C9$"]3,U9N&:G:0O@M]*1&@=O /0@@VSJ1_M/! 9.>TG4PN _EL #)X\;V
M>P3VV<2SB7^LMHB9:0PL[%8F4[9 -.$@8&KL1S?ZX33B8VEK9+O.=GT!N[Z!
MYSWJ=$Z8F=[(>'3VL=D6?T%Z,-L[)@.D0;&]S,8+/KKT8_,$>K,#\OJ!4$>'
MRU'##&O<+<XKMS<.O>K;Y.1FX>!NNCV:.GIP5Z'FM<OFGLW]$NF;H)@CS!OA
M2@T"8TGU2R2>_32(:S>'KL:@82/;)[OL;,,7MV'#TV%GEJIBY5J''^WKX2W/
MG2$W2*3L'G/<O'_?)YMT-ND+F+3EY_G9YHEH@^$@R "FKKFMX68$4R<8ATF5
M;JBE0Q\'0O G/ ZP&#)BQU1P# K@CW5FG/F)C'+.V^87/PG$[E*H40S$.Z4&
M0F+_ &7#@@G-!9N]9.990F'P#GF6*/2!_ZI[?VWD@)C(!53%$9Z&$=2MZQD7
M=T0"AKP%\A:X7&>09KIW*'A!9KA@T9#%=DV]YJ'NFQ%R 'R4B+$:O3S!9&J/
MVPRS7.:R'1&%W>R0A0%9)XK9D!<S331<F)=]1L>3#L-X@1F"R=%8_AHNWW\-
M7\B;)6^6C[]9;JO^Q P71]<?D$E84-)\?A 1T(P(DS@H9(SK?')PE;+:/SP%
MPHNQCR>-O,!R@N@@)I9:8KN #YXG"RLV3+<SI_H<G-;G2B$8E#:)-CV4(6U"
MZQC3*@8*!X\N+/TX+EJ3)SM4ZA?R? OD&&?,X+?)2_@SB?->+LK)$^N5L98:
M6?,:U]X<=R>5;_!\)R2H5_*1,[9KUU/CC.(R?'TLWC >D>%S("*?!U+.GADL
MZNEWJ="[\3,7;E,F*:0\DXQ0[RX34&'PR<0QT07FFP0_6!W<B(P$YKYB7AH!
MH2]]U@2O<,S50PA=,Z6>,=+7?DYRXK^* Q97X09P90,3&OJEVZY!2M1[3186
M'?$U2,6G=LN&4"M='_U46[0C&$ W#L&7[>5%<_>WZCWQ,\^Y0<+2-5>>R#-B
M?,27#+%31::]KP?A@,)3D.G[#DB)Q\1:YHG1KC$!(RI:5ZUWEM46V\P#\B91
MU%@--+Z0"6!R6'>)+3DI:3V,_64X0__"9.G@FC_9$D5IA0%+.9]@XP!"-P%5
M".JC,FI2WO/6G5#U!S8B_H4V3#X9/OV4Z+2%11I<>ZA2"^\64<\TJ!G+@9/4
MLW,9(6^AR_945,<MG@M-<O31T">3AE% @U^D !PIZ4TL0X=2B3KBV$ 79E;X
M()U;%!T1P7?,N'&WZV1K8>&9B]7KWKG6R":7Q=# !F=0-$>&[31N"X*)A%L5
M>E,ZL6<?:+J!RA-;N%QW]V@\E')DTZ=A=2W+(=^3;X*6ME)"GXV*B>A)*,&L
MX-]/$E_AJ_H6@]OK,+1;?$+&\]G7/WY[37]Z_/6GG/'$.:B9\\4(%AL$G(<@
M^^4X#)1]"._A!\TZV?+0AXU,_31J_R#-#V2#;EJK3]B2!L)0/,*!8G@![^HU
M5XTD5O^4B:1;FBYTU+X86^_"@SN-.QP,V\CN-+O3"[C37YB2#LR+B&9I5VZW
M^E^9FRX;^J4ARE&KP+#.PD'Z*"$*8(_$7.?/5GD9JQ3?.A%F-;R'4ERK>Y&X
M,I1M\H_:F_)D!>BXE19WH0Q(C"DKQT!24Z+;)!L#>?#[MSCX_9<\^)T'O[,P
MX0,7^:_,&8/]-U84G&33D1Z'[PM.&R^L H ,6"2Y9O+>+:5ULRB#"/FI2=<$
MMMK5B926$K"YVXHX:4Q+$8'X1*K;+@3I7!QYQRH2_J/,;T/)YC\ARQPV3, S
M^X(4/5!< 2$/5'* %X$?GXGH!5[&F+9K_MAEQ$L75']2VGHBH$32(MQ9P*LW
MF#>(IAHW *K;JFX,-)QD-5 ,@[ND,H 9#T2(E$[ 8AVJ$_4H0ADA4 S)/Q::
MZ..//L>5J$3OE_^C-OH97N$%)X;P8U8I9M#6Q8R"2%[.(^S$XFLV-T&EA\DU
MM)CA.8NDC)6BA7+OZH"+E#;;7"K1DS4Q20R+C<!;'UDTA(9/<(W#-Z^*-[-E
ME**S!-+%."SP+DMQ)%*CCX-R;77V01K.WX9//ELU(K6<$C_'ZLL\;QB]?%TD
MOLD57ZT1\4,4%SRJ"A'/+E+_U5@#]6:IKF363Q[\SO6L.4.[I;O%[/9!]AB+
M]0Q,/*<[HM26E93@61=AD]I+=_I0_-(VBX*7TN']&#='+6"UN:VKCDKWM8;L
MOUICO0M,;SWM3@^EWU$;)+PT!<()(HR"VT1@*^$L%SN#P['+)% 9\Z9(D9%J
MJ;1^8SO!Q61)D/_G__\A").2:-]9X+2OQJ?<O>K3K"*M5XN,L8 ] U2=D%?A
MT3H,DL,;V1?>B!.O4;?HS"H#,C]X(;<>J>&.6H<F?1V\/Y5EM4)8@K_]A"JW
M ^,2JN,,QBO[G-P>?N%34<S][OE+_LGOGKX<O #/3-5&]8#%/=*CZ/J!Z[%O
M@C<: DLH *>5H4$2N4BY%#U0K!&DA4[%GF"17G$1]U9-4DS%V+YMN[M6!22D
M/!]F J/["SOX^AEM[[&UL[+479??WU)IO5V?KEBMK:;MJ;7_8=*)J ?QRJ)
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M'EQF<Z:50SL^>M5UWD=3\*('#WIA3%.9_YG*;RE&G2&\@1SBV1WS3=!MKMK
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MTA&!!SB"-L?Q_IS!%\K+\?GQKG'^AG$%GIK93+_!K:U/(<TW%\3!1^0R,[-
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M3OC>?YI6DU^6KW3.:SC\L$&I;U*N_3GR8\2ES.)]W-SW56F&3NZEI.RA"_+
ML(77(B-[E+<K5-2ET'#3&=94R4;0.4KJ&0G[WZ]>(]#R@'6OXBE\[>A)H?_'
M"*O]Y+,G7V"5DE:.8%;X@L>^M43AI-H JWB'8&]FR]X&&(.]Q1N>?-1M$HO)
M\Z[;K^J;$8$+M"OH:PTLX8BB JBF6V/7'QX,NU&M:%@0R,0J3A-NA?I:H5$%
MK](_FUGT,KQS5I=9BY7PRZ!NB>F3"=R;$[<;K)#MD*\<-W4I8-72DV'S9B=@
M2:4;5 SKS,+K+91^)P?CTQ544VFP.(AU.2KS4H_CIF*Q2"H^-N91C71=P[.
MQ0U2KA!>G&2[B5E5OH>]%@9F!-0EH::IE\[=PX&F3E2I98^=&AIRU24A\EBP
M/_R>Z(FQ6%K]%AS&KNLV7@"' BUZ:;! R>V!']&;XJU!+:N>,.58U?&Z=K"8
MX3V6^)[J06DXJ3L4*216:Q$YK&F%DW Y_-:J[ZH-\=H+&>> \'7XER .4VVJ
M V.!@IOWE$Q3!*E_%G5HF^Z@KA++O7$].KP.ZHZRQ992V)<;HM<CMZ+%_R6T
MC6!BFXXPLJ<8223*;-)/QL]13XE5W$3Y1OZ!@?2[VMTZ2?1X1J/OX. 5M'<&
M6]^#?X6UA*,\6DIVX.AU, (QXQPWG7!'BU(6&G^U9Z4CW&DC"0[(9/GZJ"(^
M00K0:TQQ/P6GND@4Q?L4\F+\EDMN^[+KXKFFX=BMWY)F*!L ;#1T/AG2;(?!
MJ,B,[P8#*D+%W9&T1KVO1-<Q:)S1WC==, Q><)\.N[VX0Z3(IA.1&+T1[![$
M,,KH? V-6SG\9Y93!D)A%%PZTC/V>%YSMZF 1X<;A:=C; "XA_ WHD##\ 8:
M<B,;D],[/H+)Y, 6=7XJYD(/CQ)AHU/(#0I((\RT>>(M24S"K::7G(1C?/"K
MNX,CA /OK? B2("*7TCTU'%@'C]'U2[PE/E\C?7+=,O%XVHJC0810M.D?IJQ
M[^AM!6_JI6O;$38T&D4%4?[^(*%,YCK/A8A+.#0:W?*YX[HZX"F'QP+\PUIZ
MU_*7V#&&T*IN>6PT\YMDT[P\K0,)1&Z-PB3-X@HNR6O_+DV-TC"\'3CBK[FJ
M1[??QO$7I@NW,O,9*XZ&_$6&8NE4Z-HM'#]>:]UK1(8C Z?[9?;-S%;G[9*W
MRX4\>6J4W]-+A %=KYL:]!YC#1G2 9N$/2DANFS*V91_!5,F'/SA&/68Y[/^
M/Z>PJVF)Y ZD'=AMDV:>)Y)^BQ-)?\X327DBZ:$32?DDRR?9!YYDW-M92Q4G
M]* 0GC(V)(P[C RH\D=2SA"R,?[*&0(R*"$'E%>;Q&IT4U,(Q=+L6^S#XW\2
M:E :ZU@$YPR<Q.RH6^5'.9905MG8L[%?B"U?F/JD)18SW,F4$-$FA('6A6Y:
M-MMLMK^@\N):IU^TWDE1*7G44LG?:&P3@P?J%'7KFCZ 5NV)-2;#-!76[9&O
M QQ[U3@ED?'P %__S,#7;-\7LF]OVV$BJ]ZOQGX@&\K(UH4I8V%1C+ %<3\9
M3B:$$YR*35_A:.I:&!:P\L6A&+7U!:E +0[NBZ\KI7X0E>YBY4Z=)4GJ&@)'
M)5O8-([LCD1),&W';QB4A<BRYAZTRC*3A6)6D-H3IX@52/-14"P9J<0F]BJT
MTN!>?.'? CA<U3=S_K:NO8?B3Y%DA/8EG" B\PCJX7\RS5F:<4<3'Z ,'^_]
MDA;? 0-P.-6#_VP(,3I]#<5S@K>C(VEKYP%J!Z0XA@<?R=4HB/[HUKL6H?2(
M)MJ,PJA!&$/,)1VZH@1O+ET5?Q[/M9L$?2T1&O#.I\.#JG6&QAKAF/CL\GW3
MUBT5TRAH560,%IX7A4$2! ?_#4(EQ/S#NZIZ?VL*EO*W2D^S<JZ%2U*:NSJE
M!N?+Z"UM:YJY$[XW9N*=/N4=+ ]/+MQ53 +#O !=;]AK#+F;YXY;,H?)#]BV
M=L3TX$EDKI_-*"#I3AG)5B-Z>-^!1Y;\?NFG>]5MYH-GY0)O<J6VIW+B ^-P
MX5*[$?8$LT,/+KJP_*:Q8X_+1;X+%CVQ,&1<ORI!34YO6EB%+=GXS.;_X?@U
M*\FQ(84EBG:RX82$I0*Q5\Z AT7#FJ&;$/\<D8)GTETE:J #S:,ED/^3EV+7
M)GK/1!%4D?PF.(XICAO# R9[B<'Y5-!IJ^9$E!I"SVBW/&T4,?N&#U\F=TXX
M?"%ZQGT.EQ\P^^AZ<'[O8:?\4^@/X5<(!X^3,1+$$%(Y!6IF?Y:\J<Q:$\&2
M)?"K6R26(5IOZG-2"(GH?^.?$:"J94$,&.<.23WPRAWOT"<BXS^.B$SQ W[P
M)DW=7VR8<-*C']EP(I]EL/>>4EYY0\$[8PQ[W+&=>:IYO9UU.+EP/3F)/AW\
M,:@\4(?N$.9'S _..#Q):R.2J MI-VX .YJ1TC((-^F;S@IV0MI^9.WG,V7Z
M-7%;.J^@[-;*#9<Z&A-O8HG(AQ[+@**(91[B9V6"FLTD,;QI&M9[.G8/Q=IW
MPY'E2M:&,<W^-,7SZZYG7E.E++7D[SPE5[=P#5E!^1$FYP?;57V+A@B9:-@J
M1_[GG,$_.$L2GE=<;#WR @84YZ<A0Q_QV&*8VX@!TGP/ZQ C#<HP:A3W6I=0
M"6&>(S/@Y^=^D&JP8ZD#&C1I'$M/&&I"^-=Z,$-.8>J(,'H<T>;\(7[-43P3
M-I$<]Q UDWOQ;UWJC!W&% RYIPMLN_4H0'4/I%2PNPZ&3M\TUB3%]X*1=>N^
MYA0!N;/VHZ0+/."Y;:J]$FNU;NS#O^TA7%GA=)2=;&'JX:L"PZ/7*/E!>J-/
M/GOR9[KC :('&@6H:.[JY9OO'[^*O)N_R;)X_>SEHR^^^D^?+B#E((\%$LR?
M;!^'6E?=(RF*-%C@>'W]+7WC.?POLU0^GHM'%M>8"8%A5*4GWS"Y%PK%Q,,'
MQM%:(C]9Q&W=#QB/-:BKBD_[Y57Q%/TF#?(>^IK03/^B2M'8/P3PBMLI[&QV
MGG"85L38V"/5AQS/^/-8LMP@:]O6T(FEV/W;S7R'W_D84N9?,2DEYT(]\ 9+
M/,373[?^(Z<+3UEJMG@):X)GZ__W_S[^ZHNOH^E+/Q0"_W[3A3%:NG;-) \4
M7JL:$Q//12,U4^?DT[F)O?&3<+;,C"JP,K0[U"&% S$LT57Q@E\&[2^LB77"
M;AE/IE)2B4N.2CKB3%7K)?*IM]R.M;^E\]5=;]VG$F+9Y^>[&=0:D9EH["EL
M(R?.%9E%R[EOQZ/1X-%,8T#6!C2%.]4.E5XXRY#;AP>41]+GT!C'C]#Y9$_4
M@MVDJF@,$J=TP#V[HSX^21"</;^L*D_=_C36PZZ@W\%[(L"3L 16Q\3A=]Q!
MW'JS,UU&\F+@L9 ?A\G-A*VO.U4-LG'V/<:77LR!*['P!S[HP&KO@J84%1SH
M8/2:;Q0F\_:D ) RHZ%KX@@N':"%QZ$1J 0;+D8&A@Z>WH]P%L8:=&;Y;WVR
M("'F0\\([W:E9(OD"QAVT%[HA*52:.GMPW7W28SP6-4( :7.>N$3R.BM"VHX
MDE?ZZ#DH4BU<^.'I;.:Q_\VC1K_,J-&,&GUO'ON<8_*BOV /"H&I(S+.LU$=
MAJ)A%A:"*W"CVE3PM<B*"N44>P7R"PP1 E>.%"@D?>08( HN=%X:6<#PW.53
M=$26##BT7"MTO'SUM^CQK9QE.'=MW9G&E/G '8Z&&6=V((?3DQNOL[I*="!*
MT=ND"R*Z9Z1(X3%4V2:*U.#?MY V=?9NLEY9FD*J>.M.RBNO,06QB3CL9[%]
M#!['^$![%FH=:MVAC>QJ%"*C^""29M@6W[U\^HI'%J/^53R+6$. )Z$EY#94
MI_5UQH%Y.4)K':^H:6/=(R.+R$?L&0! 1T(0LH5DJEMAS$?Q?DTRC!,+,NH-
ME(8^0D^)7I,[@,[^38?:9<,>)8+V$)7"OC%BP[*1-QL<ZV2Y,P0G/0+;)]-D
M+A)V +0P',WG6OZL+VP8%WRX38M+[YE3]FJH?=G7. U5H5THVK"EBSGC!H!G
M1SH#YD6@%,&ST]QQVXG"<6(V4@ZNB(@$_F_#E0EREZ%;3&W/YJ2)O_ZH$;8]
MQH_JD*!-:O':.:/B"'(XA21$GE"'N32//V*BSHF7/VRF#TLV><!<$ GXA(1#
M"FCSV@,^/A\E&V9@:D<J1A$7?N),04&0P1PHTY/D=&!(=6"AXA(\7< 2^, B
M="/)N&X8637)CY88P_Y*Q$PH>6C*>T3$=N-:E%AU_FDG#49=*RPT%8VK-M,Z
MVE=_^5)/UX:T9<C63 HGM&V8$?J#C@LH_J?I3GS[-<8U<'(&/XX_]N7GCP7Y
M0]4^\%IETO,\?_7=RU?_ZTGQX_5S+GYHP<,^4W1TU@=N?<![TAO!-QOUP461
MS=_:&@&6#?- 4T\GP%QBMBTX5EKDKG*L"\/-;V/N8'?NEJ1/9[\'OA6)N@))
M4[('OJ!]LYS.:O_=!![!MFQ3T)@D4J:%-BQ8! F SVYU2_6X/1-(''WY,]PA
M'F7',_>7O;[U^M^1\CHN(9V/8>&"0RUCG6=2]ULC)YCJ8U@&NH?/QS*5+BLT
M[D1=$C6JK6=6* &;'A?J#-1/I'=,,S_55ER6N/JZV'5W6"8NM2A=%0UJ;\="
MIP&QX7>B_Y5#==PA1.3<0IQA?M0.U5H"/@%D.WQ#P[CGEC#G@_245/2C;U"$
MP[HJ]EB\*I[-*E&T&]DWF1/N7-N6R$C?E\625BY&M^@KF^]2ZT<2/@3;</ 5
M))X3/TK.?WJFQ]I1)F,CO2@JN%=MH'&:J46K_DNIE(V6L6K"J4;H^5+JUPVC
MJH1Q\WW J);N< H@(P8=--L*R;<P/J(C42$"DV+E_5EI!:O@I $!M[BJ6[XY
MT[#P071VBU'^UH#Q80G^;-?+AK]X6E'<P5;(D+;J3 )M^UWGZ]EQZNZA8**V
M1.]763@XR5GOW)[1;I4R]F+3TN8^@A09A]EEE^/X!Y0&N-:O*G'2ZH^[902U
M8_4XLLQ'W-9PEOI641KDCVS)IK,"+G1V2%*-AT7#O)7,-$7ML^*?)'>'>Y2@
M/>*EZW[#W1N^'7:^RD%7C3?\1W($PLNI-W15?*\G1OJM&#Z4E.B];^UP!V'-
M9YX0EX:UR)O1;D9SHA&E:E2[DD1 U+6D^,#,EF<MM9RTGI+OBE,C_TZC IIT
M1+=6DLO\TB0K.J(BO2IJ[NC4ED8O@I_Q609L5#D"E!HY+@B045D:SM2!LEZZ
M)]7:Y/^B2W,9D] K)P'*,B4Y/X17HHZ6;HKEZCWT*P&*I!A<F$>E#XJCO0<"
M_DW:J^%WFI/W*-/N80*Z9P0*)_M*0ADJ:=&A.W*F(>UE##I(A%%215Z'NTE8
M8#,/7'8=93$X,.7-9Y >E:VP6<DXW\E02(:#G=NU+T.Y \R_.WCH'V&&Z_VD
M+SJ3M9/-YPDYT?6/1"8N^ER&QS-B41\$]"4P3/H9X>@.](3T?ON(M;L:X?RA
M?T"%05\--<A0P[4>C$H'U2-,*4%K6JDOY,KXO;2W$0<K1C;$.2V64D:E,](,
M9FN:=M8?.+K /@+?OB_859/J'*:=M>*,VT?!;O GRP"SE9(,(UIYKM:/9["_
MPXH[(W(FYB;FRC*V+,'@4\'>[1#I0=$DY2D"+:8'#@.\ C?V,!1\:EZ@GE!"
M6%1E^>"W+N: E>$]P297S=K+"\SNFN%<FM#XC!P+HGXM3"PD,3 =(S1JMZMX
MK4(42 <4GPWT:Q6JZS06BH/5-MHY<6V4JIGR[CG[\J],WT30MZ8DES @A-N.
MZ-]-*<WCR,5D2L:(>.2Y60K6HL9SNC<8I)]&V&?;$T=T<F&X"#%LAXB6WEQ
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MI\WKJ(ZATV)1_IGFLM'1N5F1=:5;AN"?9R'91R^@R&6SJ>97/'1]#,IUC('
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MR$"[WZ])JLANKUOFSIUOW2%7Q3AJJG)/LL1:F':I1Y&6[U>D4Q+>T7T[%/E
M+P/L K>C*3_,]YC9S6-0Y+_JRAV5S'ZQ]T"_P=^<)D\=W:QHZDZ8DXKH2 W0
M#+K,=++IKWSD66OBX;:ADG*<YBHU,V)L"_(F20A(7^U\>MAW?6=C']?G!V6[
M?)7\/,Q0E"V9E9^367F>^,8A* !)'72 /-XZ"049)F,?'[7JC^>Y/=_2(1!,
M7'J3=L3.L,HY1IHE@3PB"\([<1IY6TJ[*RI:>WXQ\% C)1;,(-F)T$K!=^V*
M9$C@AU)\L4B.:83S],='"D#2C*(5D16^A<IIR9VJ! $D;(6&\N3ZD:^A)9_"
M7#8Q#&*0F9];G\!&^7EP,[P?2-KEZFM2?/+?T3'XZ8 :L80NHO)#20H&JV57
M5)=F3$.JXMV$0?:=%" J#W]-/EP=VHE9P(X]ET1R6+T QZTDF"O)_PWT"7M+
MO$+V^U))I0%D^2?R#EH!3/R5#(9Y8QH#='(#V3\.2.E7-VR[Z9HW6RDM)D0]
M^0@<8^C7^?8W35-U6D?8QGN;CV9.SMTVB$<B$"3@"^#6]T#L1M[)_#5V+@KC
MK\UX(;%L7U;-L6=XN0*2Q.]*-<#,.;A+EKI!14M[L2P"&14@210B XJPG_ =
M_F;"^X)=!MKX*PV8Q8Y>T=V?H!OCHZ_^]N+J"O_Y[*NG>/7?D%-#O_S_R93Q
M%3]?W=&A(Q.^[M,H)O77N]4;R;NNOOSL6:&L1SN.0S:!W1\I%V)%>K>OO_OA
MS<OG/[U^R6NXU/NBV)U]$H]%-U$!9)BEKB'^ ;U^"6;MQ&3HGQ4+DL(?V@3)
MXY_B;2"A*ASA*%O[*F Q*@!R./+8BY.KQDX2FNCUR?.?)CB1P+UI]8?"MB/;
MX]7?A_^O7ET=CS\&J<KBWU^#_07<IDI2&('H_+FX'UB)#I9S.V0.TJXIQ>-M
M2^4A%&2/G):Y9[M<_7W+A)3]Y'W1>2)GBHQ+S;!2I./9L^TGKT]>6 +]>?I#
MUN[L]9X"AR>DQT=H=A8H/?L;.)M9JH&/8E"T!G,Q)=@?=+<4$%FNP"C'E5R^
M+]87WP:_@6=??#6JQ<'*Y^]/H1QM'.DZ^;[E.\0/X*G?$OTZ15N1^B$Q1VE2
MO 7U%8 ZB-)'N@#./9\LUP0W<T_PZ>,*7"0_LV"G^GB&N,X8A*AEA+B>(KIA
M*-&.PEDF+.LT!N?!+9 HYI^[9@R",QR!E8A:%]B0G+0461.^\G7H[_A51W/"
MWQ.#)O@TB6'IRML:%7RE96-5C#(H'V -^/&XN'R6#T(EE8.KB&1A=VP&ZNPG
MF;H6CB[JRN<OOO^AB\K2(_9VX;:44+NM5C%6-QKC$9;0$JQZ=O/,@^R6@B4I
MV$4.(O,2HC>C.\+)'I,IU,DE[S.*' P'@F=P:]>S[01$4LX::"17XQMYLQDA
M%$?OX:;NE-!1;)@Z89+VE9?*YA[N1_XD#1[WT$7;5YLWPY/2WEH2T/V"]"J%
MFM>L6ZY)J10^L,V]&#;[[):%G<N+ 6:M>P+%:UH8=^.H>N7L0%I/F.C^606>
MA7(2;.NYCE27TV+\PQ7SA#A,41U9WI"R&$*<N2*%L4L6YS42-J\3P]>?DQI^
M[;+$=)>_(GO_VJ5FH0D__NKO"4!T=B*NE1>>?_^#QKW0([5Z;*)4BJS7J&<U
MS%M( <"AOP<UD./J^3N/7 ;LF*ZB4,B.RR<ADZ3Q6\E?6R.)[D3;YZFA7.Q)
M5@[KIA.&D<?L/5;=@*68?"FC=!A<IU-\.#FX*T;SKO;DAC82/4SV8<SLELE/
MFU!8])K$?S2]:!RH<VD%$RMSPY;HTY,+DBD=#IORMI'RBG=A;)H[,E*34#&I
M_4G$8 S>10H 28.51TY;Q*]!V"SH4.N<* ;?9_"VV%R2"Y:/9"J+,[FE1S4
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MQ#+5D3?"KGE7=YB;/APR ZVO4/<V;4^>(;@2&F,YA."7->[S"+1!H,P:B7G
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MLJ(GIO.$FI3X9(--F;>ENUGU JUONF[$CHBJC15J AOX=4@7.+/XC,")?YC
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M]0O^;32A"R+I/P.1],F"2%H02>^-2/I/=<7_[OSOKUG(S2?\$;[3Z><F$Z[
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MA.&LK,ZI?K =0QXUM<S^PF^PB)OB9SND;4GH_'OV8:&N6H!BOR!0[-,%*+8
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MDU(42^XL/;4 JRIN$.G5GXYY)@D-D*EAJ)7+%?C86!,W>R&EYC 7'E.!U*!
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M/:+)31HE*9Y<N9#4[H^]3)'W)R7$66@.0SUJV1$<<:^<M+$D(Q)O-3=YP6N
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MR1T<35KZXK\$$6-,DR)G'@UUR],L&Z79$/#DB)/#.,0'TBV!%AK1"U>TWFC
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MWILG?6=PRBAR^/$B79^5;7U_BS"L"+U*5CG(V"%37WP&^J P62QD#FJ*E'+
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M0GRMHH\HYME7:9*V&U"@GSU7>B5^GF^,$>S-Y<H=P]<X>@:/6)J:O"NV;V!
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M8\XEUUH><Q=;WJI<_>'C@K:?!U->-)N+8[-^&SA7<X3TF$"O7C'KQ0L2WT-
M\W:;1M)E@VDQS<7+\QP%,8.=^"C)T2&5,[I-P3C-?=WW5G6&AG#"SQSMX:;A
MNE,8_?AKG!==KITR?A1K".(6X8MUNKU7JJ+J:"LD7T!:EEMR:GH^$KFR321%
M@ILS@*6;GXZ C3ZZAN*D?\;5V6%4X):\GHA<V91=#^T$.,LF<LX#C\.E=($X
M_86VEAN(T)#_R<?V D:48BB???M&EP&<H\:7"36(F:]:$=L$6X\:G).^Z%ZK
M*ZWT3:VWS(GEH(EI3A )(^.ICKQ^W=>643=AC_EK<;97W(ZT%?%5UD*)PFJ-
M]// 4)+=2<=0*MR$CG6\"S1\0I>FBC[?!S^U%",83K5X6-N4*2:[JKN@8*Z(
MAT1_>AF3EFRB@"K>\S#GXV[N]H#8L<6-WYFY,2<]^XCQ0[5W<XH#K]S.Z:9A
M*3^>?;U0,9[#QO%B&C>R@]\:\9H=*(;'DQP/XG8XEFO5;P!?/_)=R3*M \2M
M;PX)-,*0Q%IU) /=R:A3X7UY>VCN#HOQRFD+QR3C=]L S\:U37A7SV +QC(>
MR8YP7N2GW[RX&H&@(SU$FWAW1G3E6E/7"QFQM]H:Y9VRFRO+Q!1ATSU4)3B<
M"FV!&#FZ:;(J^6(,)3QQ^=[<2)-#>K(T^="\<F.NYNOF%7S1M< ^"Y1INN+"
MTS7:J;/>!ZXJ]VP3U$7#(^U*KI"HLX?X(%V5VW'M(V5+="'#(OKSHJ]<9")V
M3IVHF^R[08S 2P>!9K,=T4<C_&XV'2 H"%;)%R>73H.<W93SV8L7VAQC<&8(
M1UO?-#P760;^<),<Q1$ [VO#6CS"%6F^.Q[OS<$&SGEC0&A?>U/[%&MNT?*P
MSA; =QL=6O#$^' !9CFJ^=CV,0TSNM'#,!6;N$39U<GWT3G1?&&#S CXXIPU
M@RNF68ILCE%:S^0U=,;IBS,ZZ/VN TZ2#G0?5WP*-$&."SR%&'_#SW,;$EJ7
MSD=-"U(X]2/[T%;3!)$_GISX[:GC6,':HO+NJI,U,J<)085.-MQ91['^"^VZ
MTWC?B06H6^4(70^QP6=#]B58@Y/\:2)0Y^DG!7_FF7*GC7S3OE,_;<!W@,E/
M=YL+ETYBRL)](F;EY0P'DU_I.2O$MU3R*YD;+_V9@+J-&M)&@VK<1/$TA69!
M7<^BW7-6Q1E1?1A-*IX1USH$(K'G2*UM=FYJ&33-H4I12Y9*,FZFGP]7YD.Y
M=IABFV'<MNR'B6Z&T&RS)]]8X@TC4T /&0>!L02C9=:UU/HQ$?><[-P[&M.@
MI8,\=WKGK?"(K*Z(\3K"V3*UT-M-KDC\+_ZG7K^]YOYW?FM#'_*OS,QLFBB.
M&+OL0(^\WR.^)&,46JW3ZB2G5Z;S5J_,%KX96#\>A/)TI"^,4!;W@/@8A?)<
MSA*T(N1)(AELLV0S?U0]:<F6IA1S$I4TLBUSIA.;O(LC50-Z%H/SBE!1N[:I
M'K894='^I6:M#'Q HGB#NH#"\6'2Z_F!P?@_8&%.)_R5'FP!WL_HS:^#4#)H
MD,6E0/I2/HPG'1G--'4X?.#N?+<.QV06O44L-^@]O ;KA^O+ \DGB;40!DF_
M''?&:/28<@RI@+*VICDGTI& 7E-7DD\2H;*8E1>_!%[^=;],! B>%RK?^(F)
M@5&0SH.0AH'.S?%[R!T3Q0A&EMRK 48[]OC#IMZ0:>PD)J 7&\>_C0=%A=0V
MGG@5D   KY)=INX+E2//04+V9\C)%X5>8M3="KH"WJ098@.*1;C-E!864Z.Q
M,VXLU$J\O*TWO66;E9[#D^#:<3-.B.NAWE4YTU?;7 _*_B752NR^H_[R[R<F
M,W--C<^JFDF%PJ$?<87\4;C]Y^;,6KJF4QI+/LF*SF-9*O/F&!ERA9ASH)>Z
MH5> 7<F/J_A42[KD3)EK,QH6N)(RQ" T:Q@XF!^0R4"UE2%Y1VF!1&*;5YKX
M3)^DG_R,3Y%Q0+#C522O:X8%U<V]5'**PB:C575WT[1RK/(Y:4Q33 YB%T^7
M=#_5QTB'ZA(<FT&HY#)_6"NO1F,3,R2\0OE'S931*5MSSW#ER":KZD9F&F=#
M<5>)P4L:R=$(=M.&R.9JV9;T1TS[Z: 12]!7:25B,Z8_M\:TL5E6UF2[ X )
MZ.EV#?9GFG47%-AO$07VIP4%MJ# WAL%MJ0[1Z@P&4"N\U)22S @"GWY#AD"
M1X_P:&Z>==EM,>/I#$V/Z.B%1N%A!EW0.E5DT".]&5Z.IB9T (2DI'>-].7"
M)-/;T\1<JQ5R*0I*J*B(KNN3,C\:1V2J^V3S [3$"'3)22%&2MGX6@H2JS?2
M?QHM,E;Y8XORQVGU(K#;PN9Y-'*'O_H#.<)?US>KKP.IXIHY<+_F&,D/U?GV
M\O7EL_NP2BR"?QGH^3Z5Z0X:*U0C1C\5<?J-WT43]<O5\_0%_5NW>J)$+?I1
M/ YMZ-L&(7K&8/ST'-67,+-MZ9@K6:F.5]HW+&G-^NUH:^1-O=%$T+,O/K4H
MX7E38>P:WC$'/3P*A"&2)-=HS8<%2Q,O/I&)%\^*%--)F(+D$S*LE;*7219.
MD3IIBHY.1V6FGJ'G$>'I%<<"N@#M,?,<ON^>?<A_IA[VI$8.9]1'5!J7*[QO
M2V/K<@$O>:\G_O27>.(ZC6[A9RALZC<MY5B>0ANCX+ S%CR.1O9"!!<0AG/Z
M3VB.SF[3*(?YRVS ,SFR7&8,.=R*YY\8B"R0\I-,E#Y2'&:_D[ 53R9.>A3Y
M^%QIBW_&AAIC]^BQ3F0U!&2@- I\&.GF0WN0VTQ_I#0J3/TI:>;X+/'-<]$I
M/6L#D@T-BP[Q[:D"XY_8J_D 3WAF?YD>8R>%7KDZ-E@R WOEW1@.:6'T7\-!
M;*C269Y96WR")_736-FOVZ[/UO68 T4[\*2FB] BP4O3V%"B_JZYR"[&'%5-
MY:X9645^SIUQ/A1CK2]\S]&\J>4IAMWEY*(N1V'$"((ROE3/--3P/,XQND(9
M;9R7%*_Z\_@+[_>1/J2+]'O*"_4.0:9(&B:&%RP8VYX >)6@:_A\"L2+11%_
MDK?#-EQQ6@SZC6_6IA([F-FXM$X>&A>T)E_E3HAA)^.5&  @HXK$J'LJ<G^_
MG*_:(51R6CAD,X3D%8Z#^A1JB>1J"9\<45B9[&[CI )?KA(QDYM@)I8?8<#)
M2IT8)?"<3,"%'VAR.@3\H/1\'GLGC13-!KBEH05Y.9=H&V.I/<AH:%4:=>N&
M\?&U07\LW+">TZO>1T\,*THSAN9.;J-[RS?6WI&I6[8@9^Z=EEH%+N-&7(#Y
MU-=#=1.XXI"VO8N] *U^7*(/J6Y:J7*I@SM"R!<"8=XU8#T:P^>[[= SOBP2
MM=E<4B!75N4=1F=-T9$YI[KC7U.8@?76.T4M*(2HJU4]+PIYU(^26^GQ^P*^
M@]ZY'M%DMSTSUXZQ^>WDMTEHE+-8BFN[?.(=@\VO$CNH!)DI F4I>\&5,>Y4
M&$0@T;^NB]GL.'.,2PJ/F"V0"T7,.Z9#'VR"K(A+E&V]%#B9?%K\CL.F5DBK
M-XQI$B!*XA;-F\:D!#B!"4O!J>QZW=@J7),%#'6$Y,H6<>F/J9?Y')";;_N<
M8,;CNA473%(%8,T/UU^PQ\$LWW2Z;MJR,H@07;/9U^M51T>"/P/Y++9[+<O/
M'."K'8-:;C1O05I7N>V$X2SK<^,(H\00&Z='LB?D9IO8N["F@RDX-5DH+8^G
M+];F#>Z8C%6L;[_%^ AET<8'DN5H.),;VOVJ8RD#+Z4\O%[3@*J2SL@PX:"9
MUYK21II(_%8)O?98A&.T>/9^+88-)VYW^?B.7/ZM%*?/I!?BS4#&O6NN&?H3
M=96 9D8O,#J;O[M).;\CA9II,F_W9A3.G(8BW75J8CF=0BV(>R61SF'8!T"X
M9_11#_9W3?/) ?(U^L(,90:PCJ;<\H "BN,!,*Y,*12%W%H[DYS+2YK>9QAG
MJ&?O7,1A#&H=7 GS?0*UV>#K;*BVJ^DV%7/=OZ>W^.]+5_\;G,4?34>9K?.S
M@,ML%G!AJA43?_(QP?OR9,D;!Y])J=M-W6$R*;GY?H:%690H'ZG4?]]8AH>U
MT7]&.>)-?=#6<913S5F?'>1<'S3'*,RA0FH[3=7X,7S S<C 0'Z8<0O)-&N3
M9>O]??Q5M5R1"9U'#0BX>#R%.A* !P,=G?)TT+W(UCE++#;W5-BL*WVJGGV%
MU'G 27^9 61 D'U]8^<AH3J*6-UQ-YL?)UZD!EQW$DKV IUK=C=I1DKM;ZES
M+<U42ON>I[30V_JH22<_H0.8[LM=D9*)&4F)4)1RI<,:^VBQ79C[6@1"RMMB
MK4!:7UI)A^,V[*(<8*2UD7W#NV_N]+K1N,PTF)O Q#^DZ@U:J$''>NM\2AA9
M-]:YD?9/VLH"7Z3UID^M/=G <WO$QVF0RHBUF+^QY"0>Z*T;A5_Q.%K-PTCH
MPSO&.N$C[OUOI7NK;;AYH"-#K\<R[*]I@QIA:^]KNI<-9-"\';05?T+Z('#\
MBD2?S)^:@D!9%\UBFI#A2@._U5^I!=Z;DP"*["'M8@^E3CXR:MSBCL:9B$A+
M*<&D"+H@;0R<;<.168<1UC3E),L#9I0N<^?N:R(; 13G1-!$;R1(Q;S\%":B
M*I=.+-U[%#LR+VI7,P+K"E#'MMG6UW4V%S'.H6.E3^XY.N">O_YATCBC6;:F
M=8OYU8:2"]+O-XCT^^*C!>FW(/U^0:3?[\?>Q*&.<#YN4J\ZR?FV:2%Z4H?$
M(.\B3D\N%%B"_^P0#??RA59[\/&O<_W+:DOPY[T,NDW-\A*U(Q1",ZE-Q97"
M>BL+I"O5QUI;*207C5F!0E8AC?;< =>T\&40D,G]_5HDEBI]+P>L5<U,'$AT
MQG&J>?XIIHD;WP= ZF"#.1R,H&\ZX'00D=4 O<>LE@[$],,9L$H,8E<"!C:B
M#%T7HY_:N,X,9G7,#4T<H9>W''GH";^_$'LGNWZH;&WQCWUKN\!M++SUTF=[
M0(X>93>P4G6%C7[CQ!FGR)DFZ"8&P_Z19PA/HJMYS8U//,BL!N#"J("<J.AL
MT^ET:N-, 1#Q$)B3!+(,<309SYJ<JD:P/.^.$%V.CU3B0^PP1T(00=<N5#>I
M(2[=>*G;S<1,$.+[O-;<&Y7AQ8RR3+&2BZ7F'=(WUIB8$5_(C$YQ127UC$O(
MGX4&#@@#C76,,5*[=_WPDX&6AD1P.MNZ+ .[]EQ>U' ZKOQR]?_&H"?E.LKK
MYE8]:Y9S-\'6YQYCKS7FUN(DHA';M?SD33V]&QHN.\AZKZ;#@7:@0.&F?%%'
MA.OL)2EI\^M EWDBQ2K<<'):!P*U=')]>/<?DCIXE-"_KKNWW>IU&NG](W3N
M*_3^O_9\($M6_WXJHTC=IM:KB'E3#ZP3-DA\3,^SH[-E5F:FR=9L"(5@(!@Z
M%1FD$8?,<=UDW:93U@FAPO,]@:,5&$(T==#&KC^%ET4RDXCAS:G '-8(-T&V
M<KJ0)662B8Y6XSSK1GHS33MR?!XE ;Z9?HZ*C7^HK[8+X>W9>W>K$0;T54YA
MG*@RP3B%N]6-S']59*F6"_*K&K]5=*C0 $I&ZWH07>Z>TOPS@TVU35E!HSOA
MS?K5C8"'9\(+RED;IF5DL0(/1\+/^ZS?1VI ^BHFBY?O/C"CN4CS>O&?M='G
M_=SS%MZ%]= 'Q3O^'_;>;4ERX\@6_94T&YLQR0Q=6Z0H42,^M4B)XAY1;".I
MPW,>49G(*K S@1*0Z&+.UY_PY9?P" 2RLLDNBA1AMFVVV%6%2\##PR_+UR)\
MXAU3&_,J64C ISI87V:<,P0.$X),-#\VN=Z/$BRDI7BG<1[L2:27!9STL&0,
MO;8JA%H:4.TV4RZDIZ!K!G_9O*D7I7Q_H7XA&80A3MU@%=Q0)/EC\'OO3,)^
M\W&R&5[:6#$.E;_W;WKJ-RFY*_WWTE_@\K1[\4M,^HKA:S1AG %3AZ<'\@*\
M=\I4$\).H-/^SG-3*/(WWVU>B:;X?_W'>Q]^\!%,5\XTV^HS9]9$H),[5JA]
M/1YIRN'8'\*N 'U(0UU3.3"/X0%N*:-_H; X,?MQ<PO@5Q_;!2/SFH=_E(L1
M.(3W$&.=4B?3(REH61O+O8,?-C""Z*XG09ACW_4OPCM.]>$%?$'P<>&-7E 2
M!G\V?QW0L[J-RZD^=?:V \7+>UY8_V!?+S^S$5>#N8+(^>K=&Y;']"FTK9HQ
MD4-8E)=+7HT!=L5GKN]Z:A\KY.O3SUZAC/*@]0NS* 'AM2KD"0*M+6:1P,%Q
M1&6]H8[,\IB)3?3#O)$=/$S#.#%:+7)*%!>)/9N%5!O5@O=WL-4GCK=&<(A_
M"<<#'08A8\*KT,G2-"> U3PUW'3E1I,!#>+50LT&4RHJWWI*%SW=&<P&C)K%
MSM) MJZ4],,-@'#1(:+WJ4L^EV971-#A"42(]4G6 8VG([Q,;H';YDGPHD;!
M-!L)H;>4&6)SG2>>N"%/.?<=GZ%Z2!N53QIP[4!S<6ITAWIKSR@SGTPC/@][
MBUWWDZIL&D6,,]*ZPR'F0O/GU4$.OKC4#1-F'YDUD^#4^H&CZ40PCH##U^SV
MJWUZ^_PXC4IY#!IV5?S^7++J%:,<_KA_!%,**@D@BUDU=%=5LW=HH*DG@W?T
M(^UTE ^-@NYV#:5@/"AZND\%T3,O":P6/)$1'97J(JMHY&K5SV[5FO0CCFU^
M2)F/U4]UI)JNZ6=[$0 2H/C) ,"HPBUK*K7<^B'KN&E$6.6SEL7S78H9(>U
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MBR\?8840@$].;V#>Z>QV!+0]@8VW!T81Z("9*:\[I&999A!S*56BY4Y;91H
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M'U I;SO2*SLX+&0_E#PRGP(WFY>'<&NZA3H6?W3X_1B#%'JT%PJ#.\T]/?H
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M-3=:PNUJE8CU;F\. WDV_-._SU%^F8NL<NCZV7"PK'WED7N5#;]+JK\\Q5>
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MJVQE<#3PXY_N[4GHTS6'/0K#E%6?L(,B#X)T^<V=4UX8\IO8P EK=FCPBYS
M1UX]\]WI%%;(I DD@?D_U[!2B]B'O1!IYL.!TA(#Y6Y!I@H)P:"MSNZ\-,/8
MOXCC2$)MZ10+M-=6=\47-2;$?3@NA5S,[2DV1K09!;MSRJV?ZLO64N8S6PHY
MQ.# E.[R.3KON3DA)98=&NMSBH=6]-!A>S]M-6.MY[=+5]CE4;/'K7)4AYTW
M'@@2#J1#WYY2:$2KI%GN+714C1NJ1C*UI!^]YL@SK!]W;_=GAQ";*8J,$?*S
M[0<1.S&\B _\3'>-?9,1<$;J^/G5K3C"@+[L4RX,73LESX28;9UMOQ[2V4?]
MNGRN8(Z1@_(  T0JP77<'OKMZ[<LNI*SE=J?^-F[J::3HWD"%23D)OXNJL,:
MG#=QB*B *L6ZLPD*<N!7(_O7^#6SHO*G<N(%?!SK\#/-AS>.+C L*@B1=GD.
M*,Y')74+;,FYN$$*]A(VN=3/C.7K"+/HPZ'A3A:IVQ(A+L6F W"EC\ULIL>X
M$N1!B>J5]!Q A > 34%_"5.ERBX3]]$RI1YC0.W 3;"Z@R,I4@K7^2985HN6
MQI6'97$,;6M:)ZO*)SYKY7 K6/FH9DJ&A_J1/\]C""'"%3RX!_TLMQXQIHSM
M?R<9>-\2B\"9P;/EN]D)HY]]_@),Y%I8>>MPR_&5-$B$FX".M&/83K,3QYTR
MZB.-]^Z;9G8NVN+-_!FC*UA3R62/2R=BZ;@5'@RK")2;R*67AS-4G>[3O</?
MF:%A*7GQ4YTD6?O221XW_Y*4MS?KQR@.'F_[@S[+Y4 @.7)0SJK; \+Y/H8\
MW,J;!S0SRO8?\D"YS:QGBR\T=J0J]B#RRJ?[7*?+7+Y!T")EN]1!A*E'Z4+8
M*RA.0,I2] /)A4V\LM*,UY?IV%9KYC:A:S='ZD0;[0>R:F[D@@7C-?96E]4^
MAU,4 SCE]*/Z/,)N&E]%\E#=%5%E,Q_Y0)2#8,Z&%R16CEXV6Z_\W$RB.??'
MRQ)N\Y-BM>1<1N\0S&[<UGPJ+>!Y8K'YPAA.YC-8B1[B5N2H(->K^#U7N"C%
M^B3:E$)M+I!-//2G1L=-?,%Z&3\1::) *1NKS75D0^=(3USFOH3^N?!(4"M8
M-&NJ<#PA-PFMDD<:%A$NX+=^$CP"//G0-#MJ[?<""&FJDO[\S>9/%P:8OK<\
M>P*U1B1H>NVUD_<*#N'0U..IQ+L,\0GGBBH--!0D$BF< 5G*RF%Y9+R@U.XB
M Q^&/&GY_THQ]]65.5>6S!N0I0'(G5LQ'TE1%(ZAPQV*VSLY*)-S3R0@4&K?
MO/?[:O/^;][[;67IQ5QG6%5"J+3?OT["98&T]H,54S/!$0[(-!(GPMA'V?]F
MK'SP*NI)ABE0N#P2BFOP47IQT CQGUL5'O.9+Y:TG[DLS4D6[2B_5K92"XOD
M!C%T#O! X28FP8SAROIQ46.>_D6U//@G(96\LR#D)5'M;>O-9UB+D2NT_&5O
MD1U3=$]56@X1/#N>BL:K!K@#^Y,NE$_U.]55VJ$U2B;E:70OC6=BTB[C;_CJ
M'N4G!ZI^Y$&!Q(X,?5YE1N-DA6*#\QV>UBM8Z&</%GI_!0NM8*%WR8GT2^TN
MW>;SFU&1'J%G:R=CK'*FJ)."SSW=XVC:U-M_3JWP-HCLC3*IKWT@_T$T'Y'U
MO!OJHY(6N+9Q@E\06%&!;AARYCDMA2 "AOZ1YO8S]#Q31M I;UWC.1,F/N:
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MU.X4X6.#,-C:A;GOT?BD'2T//C[1Z)A%/UX=/38]M4^,DU@WPC1ZZ4):K23
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M5H( Y)2CJ/;<-J!KP%P7J]I4HEESHL] 30H#KS??M>,)I5?6I%[Z@L_U[61
MU*4#!^$3M<'N@V44\R!HR;1=V0X&DM1!,QDAQ\65U%QBJ?>NYNEPAZ*;A>3D
M"F5$_G!VI$Y>T,X)VN>)->LZ4FGR9O-),SZTI\8WP*M-;24^=/CC8PJQ\BEE
MPF74OENU*_U!9HD.%)C-QFG_7%OJ!HO8([T(3\0/1B_T9YUT--5SB4R%[NN
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MTAO]%TH8.V/W5B0DX43PJRO!\SH5]2ZGHOZP3D6M4U'OD.#YWR<BM!%P\+I
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M=2"&8 U?@].(F4BL7O1-"T08%% DESD;,EMQO&,D@<;>\QK1M$WW>W&0T5R
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M] &%4H*+5J O;<]RL7)SJ079:O_$VII@Y1'[E.N<LW0\UR#@%1STCE2!(!I
MVSBH78NA;7D7< ,)FK;\KN>%+]%9SE5G.NHD.PK_]7W#Q/_+H$W=$P]X:K<
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MKCQ[88&E+_ E6E6D) 2>A8:?IRX5K"+:D=CU2+[CIE<M!5:<Z0K(F944P+_
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MK1A=T-FG :?R9DS_#N0%GKA!%&A+;%SUG>B=0"$QBK&YXDL^P#SA?OH-U(?
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M-F/I>&E!;D!^&!"$3EP"?P@ OMLKR"VW(3$ #9-<X#K"&=^ >S%#FDD8\()
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MQ/@7K<"L0*X-T$F@[8@U("%Y:J(7?#&H4#&B41+PLU3'XM]_%-?+BQXAH.P
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MPJ@FE3DI[G@.(LU<S0B[WNR)VYR'$2$<^+ T')'8IR@C1:F,LQ:<M^V(1&[
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M=,Q2<,I8%SGK.5>5X.+H"Z;J-KY@=DP59JV'[*ZH*S5:MT*@UJTKC'E/<HA
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M,($_K%"'/64M,<7YF9^F:IGI3SU =1=VQ[CGD>V&W-@0@P,32K0CC!1@)/5
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MIP*X<J(D0I:"Y]*#4=Z&((P0^?;6ECWHC36H. ?LRJ@X]1FW0ICBAA$"=Y#
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M&-4C< <)7.37^HQ;(4R17Q&X"%QL4D:DXL))!PLGA">G*).0I;4@I$S@<TS
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M5BPG]'P%98[_-O45R!*4\YUWA @G8.7*&3_D=^/;SIOMQ6T@3.8.@+D#8.X
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MZ-Z@85<T-[L^M^A0Z'M652'@<(RB=?"+W8A&D@+MQD#<Q!J$U7I97PG!^EH
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MMX$?596Z8G]BN"W5!S=ZOHUJ+H +!547=^/M#MX'O+7*.+K7RF3E<743?G&
MG8$3R6'35UC5 4_5[+TLX97D^*DNRM5 J/!=R9IU4<B*,DPOJ>9\8RD+57&:
ME_JZ%NQ2O/V$O83O7A\@O,V^5)9R3)>;]P<#Y.=N?Z(!*G.P&TA;8%1:1""C
M< @8!I55>9$<I'BI_/<6-M_7NBL4U&["4S]PD'!M43Z@'C(2F[0'J@>IMXUU
M)7BCYED>VJB^20:B$GM\M.#0AVT'5=4HE^YVVXL.*J^6O\D:S5TB/HQ^E3&9
M*=\EG]Z(:G^A%M2=Q>_6>W=[3@6")?1HS_.AG>RAO:VK0Z$O!89]N+$*?K]#
M^2X:.\2YTIZ[4RWOT.DJME4VA(HZV'B@.SJ&-MI=CD[7[(?@RM)R4A* +))+
M_D6>'GP&B(I"E(A7/@:%(L.K5Q(/:[J'Y GB7W[N>:'/,Q:XJ6"^PWV6AF'
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M5<[[9QU[4\+TMX[7AJUV\G)UD9HABEX_O[AHQ(4\M$80P/KA\S;=D"1V73#
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MS!,]DN-_:')\^ZD"B2I^O(S3.E8?;%W]:5\0]1[/]!1-IK&BV6>@R.@4LFM
M.#+16L2343X0Z>2N/J7!<(M]5KJJC%#R*B%'E46!$T*U(1K3'7?B+D'66_6J
MW-*KXG.;F\]NKX;N _]4^?S)1BU-+YZI\/$ V#78[+,R&Y"AHNGL8[-/FY%=
M$\%"-@0,X3LSJ!5)BLHHD),F>\S,"F2$8,@PB96DEF9&/RJ[WNX#]X(U^LBN
MF:+5XCQ65]'.ZRIF  K5M]''"Q?G%2.CBF8[L&'J_ \^JN:QOHR9MN_CY.IL
M+Y+=#EM$'P>W/K0Y!3>;A'M3L;G5R_$B/X6_!UU?>S]?9E)^UX)8W5#PYTSH
M>?5F.9_G@ZH?QM:-)^/%.&XUX\E6T!Y*?@[QUV+>F5.KW<=.XF"SQ'HA"R@9
MC:P/"1%#K%<B,:7Y(4#I-W\>PW(2?T[=BV^\W-MB[KW-U__;9.;__:**6;@O
MB\63C[LM#?)9"TB>A@6T8I.XR2:SADU\QR:3:TJ6A:K']:*:I49FTVPRF7W(
M-ZF^'D_S-[-EG<^OOWEY3[D\(8-Z[64T3L8^UK++Q6SEEI5'+/?(+U4.1Q-[
M-5MVA[2W4]D=^VIU>.:2B;VLX\LZ7MJY7<05;5K/K3GMQ=ZLYOMQ/6Y6\>KE
MZB*WI2O;^TIY9@PK=_Y8B%8>LGOKO! ?7[WX\Z=.SG8;?>BI#SV/GFG-\/6?
M!U\(WOF6\SZ7,M?WSYCO%=1=57G7R,F!<['[0Q[Z0+KK.KIW$)/B;M;60V-2
M)T#9)XCKY\4K/S=^PTG3\G&Y]'5=#(Q-)P#8]I'8%G3ZX*7E>>CT(V5JUQJ=
M/HY&?V!)YNEQ<8GR/#TC#XC\1RU+.,+V$U GI\W/CZY.>*^8O6_D/ZY9":T#
M>E4KOXH"^]E%"0-OI;][4D_5UW4XG6K!OE)XZ)6 S[O*+UCF%/,8N13+T!_M
MD8LN(1(M3UZ(D/\ZT%;\HL)^LQ,['\>ZRW$>K+Y/XI[VY>NKU ZT=+VOY 28
M 9@!F+D=9E0P+C#*$?5*(VXT08ZG_#%R)9*F4N"=F2X/W&S^>###1Z2O6\?[
M*K7']EAA[OEQ/=9YK*.=^_.F;BG$]W$R:_9V@/<*9D4O*'RB=O!I6Q-)^<B$
M2"CHZ!!WG"*#)4,Z.>J9,8G*'6OB/DYK'2^G*U/BUTZ#O9Z&;Z_U5U>V>V@W
MEBBP+T!\ 6^ 80?&L*>--SA$FKBAB"8A$1<V(E<V15-J8\I>:.!I9R_4?;S7
M(^$-'6FM 6^&Y,]"!O:X_NR[.(US.VDW(X=\]+A>S&W9[08>+5@8O: P6!@#
MM# 2EDJ1Y)$S-GNTUKAL83"'$K:!8TXU#O)0'NW_M#JL[+'>TF"/8F,8(L#"
M /$%O &&'1;#GC;>..4-YD0@'3SM/%J=/RJKG LTA&C"H3S:)\4;A1G@S9 \
M6LC0'L>C_>[B<C*[BJ4%PLS_N[I<SOVYK6-U.<DW7/64N!J(L@;K M036!>]
ML2ZL=582P5 *)'NF+I#2$4PBXGS4UN.@\$ZKNR\H*EZILK]E0R,_WH&KOEA?
M1Z""R +& ,8 PSY/C%%*,J4(14$'@WA@#KF0,")>X$@D5RGN=*[[@HKB@V),
M&G^, ?T1Y[/"4IH2^@H@9DA.*Z1AC^.T_GQ;Y\.!J&2P(9[OC+R!6ADPJ/,S
MF=OHJ?5.(^<U1UR6#KI<)*2(<5SJI'34A_!U&]6WVSSWL+XNX3VM!P.Q[X_8
MPX0H8/MGR/: =L7K-MI26^:7T#(341F&M-(:*<4T3HY$CO$AO.XG03L%8-=7
MJ8?QSR<^_OE^@PUZ@@Y]%;M3-7B&-0YOZ!U*8"3FYYMER1"I3MF2"0KQ,@U3
M2T&13BS);-QX<9B)T(_NYM,1D6H(QL^P-,!).#TP#QI8'\ /P.\F^-%(O2)E
M8"G7!/% $K)21$22#E9PRH(Y9 NOQ_/Z1\H,PO$?E@)X'-=_/0RZ/ZCR^#.?
M]P^^ON7;\O],K<VQD'\TH8&/+^FK-(D?41C/8\/D9;3<\F+Z*HSKRXF]>EE^
MW6'#,Y'YJ3QK%VEIO^@&^:T>NSD5Q6EX=3FKQ\VUYW'2[.K8G%2VYN>/3Z,4
M-R,E>/6I$Y3[+O#G!FI^R0(_)B4Z$+H/*8XUW/)[U*=)MT1MR>!*KL[7H<>.
MB./I9#S-C[2P\VZDX_8/62K:KR_MN]A&(;/'E]?DI9U\L%=U-[-O4V"W<:7(
MV[4([XAB3R2N49J'%+A'U:B;6M)/;%V7Y<RGKV8IEK_SYSA_<5.)BCT$?V32
M]F]JZG\W6+-O@# +EBFF$TIE#R%GEB"C,$-$,<^$-TE3=H@!PK_&]W&ZC-_/
M9Q=O\L6*V?9_X\7YFTRJ67Z>MW'_^.#FSN-\8GB]N.OC_D[NMKY#G%9]I^7G
M9]6;,H0V*Y-VU$2)S:_Z$E6_Q?G[L8_5ZW?S&$MOHGHOM&VF*!YS6O,MPG(T
M3-L8EW[;M/11<\2;V45^WJO_JJMYR]O5N&XF?,S'=3ZKGDWBY*H,6K3SN9V^
M:TE=?<A,7_TT>S]K%N6?V;.('\^J.]R5WW;7#[9>W>SZ[MT Z8U;MW?N;GA/
M8^9XRWN$R>[-XFS+SUI40%(V:GFGU8_VJB)LCU!4C1&;^7 \761.WZ..?L@J
M:%IO:*$-R?BZ7*G4U5/\ZE.KT1Q"7GUS5OTC4[^5H$\=O_V(Y2E:09R7YD]^
MLJRS;=!(T?KLZ;LJ/_\D2]H\&X.;IS=E_^I575W.9UGF8K8FKZJ?VDY2Y9#L
M7U6_9'.CA#(R' OVJEPI>VY^EB\V6O52;IXBBVV&0#_.R_Q'K"Z6D\4XGU]=
MS@JE\[?5K+2LJB_L9%)=9$GWRTGS+'EIR]#X?(OJ(C] %I*Q1XV1DRF?;Q5M
M2<PZVRB$:>6S[&<;J:HOHQ^G<?ZRNUC6.?GQW\5%?=8G@[X":;LFQC\NR\BH
ME$HD(.O]6-<K'?\ICB_+_K_+S-/[D.M: LYMYMJ&"Z<^LT6:+;/3-"Z,:*=Q
MMJQO;P.>N?_=W%[4U=?1-C^OY/;7_]=>7+[ZMOJE/6 EJJ.J.>YR.:^71;KR
M*U>%?6?S>.,=WK8<67V=X2W$E&W[HDT^^\;?5"F;F&M!N\HGS&?+=^=;3^WS
M:XQ#%I.JCI,VMG)6_;9T_\K_+F*ZDI3)^"+#1_FY'G6Z8E(7<M59IS5N4CGZ
M8A8RHS1/MJ93LPN_T6CEZ]EE\Y#ERAV1J^(QEB^S8-\@57W6WNK#.(O[/(XO
M7";6ENYI))Y@_-6*!=)RDM<X'Y>EHADS5F?"V6P)%!(W]+#-M6Y9Q!)"?=]$
M:JME4:0+^^\XK=S5UCV7=U*Q9]7KXBI_CMJCRL4L>(7M6RJ-I^]CEK=WMJ/)
M-(M(F"_?96_<NDDY[/HA1QOT<0W-LVS4XQ)D+80IKYJ6\Z84Y=UDYO+5ME[V
MAL)M7Z"<V'+F?!:6?O.A[:(:+UH3JZ%L<X6N["5395)$L9 EGYE%MJK/"YYT
M*QZR,S,?N[PF+C_ AV(AQH_ESEDE=\N<OVJ8:M]K[#YGN[3U-:O> DD[3U(N
MN;PL9Q21Z\3VSHOZ2Y%7.UW?,2_QQ9T4T+;":98LW_O].,35(N;%7X-O%CC?
M5A/E^S0KWQU6H/-6P.R6+*N))E":B9V7K+WM'H5R5KW=>*)Y+()>-]1NJY<:
ML6X>H*SZIQ&]Z2)9SDQ[UZ&[X.=TYWYK''#N'CBWS6:9"V(^.:]-87:TR \S
MJO)=LVV4,L<W;+6\S'JQ+(*]:H$R57_:9_S<XR6?((=G1 S<.8:$]QIQ+4EI
M^Y20U%$DK8W2F-R,UD2:,"FE+B7]E\\A'AF* \)"LA24\BJ)K;9//\VFOZX)
M]?,TEO?\1TNN7UIJ_=H1^-:,GMS*Z(G/E;,8<89OS>CU@2NK?/ZD68;.GFJ-
MJ?P 6:Z+ YY9KD1N,\LUUDJ<SYOA*5U<8-KHDHQ$MD!_?1[C8EL-K4 @9I%L
M$& Q6W%QI[7M9587'S.]%L5%&0"K8BFLB(Z@V/3<ULDB;9A FGH3K):2Z)T>
M(BH9Y6S"R&##$.<TY,,=1E9C&KVQF%N]Q:H_CC/\+O+#=8Q9MYQ9&+>--&YH
MB[6R.!#7<J,'Q+4K%!IM0M H?_TN^W^+V?QJ= -9R\DM;5<ZLKZVDFZ8K&?5
MWZ=KBW9;%Q>+)SNQBTF6AP+JA=2-8YT/&S<A@OGLRDX:X[/$JM86Z\6X.>$\
MPW%5[-A)1"$+QV+#H>VLNY7)5N=%K,OW-K_&<KJ87R%7,I[-/YNWZXXL7Z].
MRA<;=U&Y8H%U5I6]^8:991;C2?-FQ;V>-Z"4C>02L,NRV]B\Y<?&8LR_I?$\
M6XH;U"P/MS;7FQ]73U \\N4N3=??=R\P*C;GN .^?*%K+_[2EO5>&2Z-VU.H
MV)Q\\R8K:G3QQMLN><T6:^-LO&C]C@>_ )@YFV;. P)6K=NYLF@VG,K6T.^<
MXSTN3^</E@+]R]B%M5H?H2Z,,)G5Q>3^NG%XX[)PPEKVV]/6(OK-CJ04_=!9
M[6OY:@-X+WYIW9#?FJ?[N7G:%]^,-IV7E9_=N!.C @:M"FGONN%]-PJF8=CW
MY846YVL+OR6-/Y_-5FY#YU\UO^]YA%'&X@W?\3_+\;Q53?.8]=S*RR]:);X?
MSY;UY.K:"=^RW^VD(^QE^Q9=L+!YMI5_E?]IRY5"+*_8Q##6X;V&L&OWOKEO
MX_=5E[/Y2B++.ZPS8&L!:V\[GC8;+<*&$]?ZUS'LKDBY6?/26[RR8H*\GN6I
M5JJWO>M-U[-[G)N7AI!A?W5,$YO(")7%>EZU'%ABPZ.U#W^G&.** >L.!+=!
MHX7$# >MDKAJK[M"BFRV9H9I/*X-N+CQRPH@&I/XDX\RWHI]^"9Y7 +OJW<K
M1S?QA;J-V649F2Q#(YD;1[BK(F5VOH%HK:O>?+=VWY=%P JUBM$]+R!>BD'\
M^1V>LS'FVYMGLET_9]8QQ1";=FJM%<LF2=<&M@IX3^VTT]:%92^F&9%]1VTW
MZ2)D$*COK=1MNG7YVX8%0L-C6VP\G;49KTX::I^AN8C3:]](0V'9WQ:9">P\
MU/EZX9H+--:CZHF6_X$IU VQR [LZ\W\=Y_XUM9;1D28Q79=6HS,IH$M8?5N
MA;+6F]59'S0&5^:[9D$:L[O^]UFS;/.B:"97-W(LQ;:J&PXH3OY&/CY?US9G
M-4&!QJYZ_=N;2F+9>6+7O--9.[XKG&D59IPWZJJ-AH^:$$*G:>(<U$-?U</K
MQ3H'M&OACPLU6@^L->?>-\.*LH'91"(*GVQ@P*;^^+07<0V#MP:CZ[8JJ/&?
MUP=U6>'1RM?H7,SS. D%1%O&ZPS"(A?+>G^.?)S??E),TV7KKA>+^:I-ATT;
MF^ .J:DV/E%8?NS'EQT@MB__K]FXO,$BMHYOH>]XD3]57W?)R/_][<UUK<#K
M(GH^7FX:,'=WPFXL4<KGS#XT#M7^17IYHPIO5;V8^>T"3<;U F6;O=RFX;G+
MC0+&S=I,>2:E^FJ[\/N&>.RM\&Z*7%\U@H#*'>N7)7A2REQW1.::88LTJJ]Z
M)4/\3$N"M5;:2$PU_6JS1<"_8[S,#SI9DZ<KY&VH] FRO/CKU^-O5LNS4<V[
M?9F^*([O2U(^L[9KO,C;5,).!5@GG272U]:%K$5M)?%[!:L].<O-=<RGW/]F
MJOJZQO1Z,P-P>>^X?$!L_J.=+E/6^LLVAKE"I17W=A&GCC]WV+&P,K#D(%AR
M0#SY^CH"<#/&?;'IF;4509O6T=D^9H2-8+ 1##:"/>)&, T;P6 CV%TW@JUV
M1G51;KM1PG#'S48/VJ-$7T LY+90:1?N6@46WI7P>%O5MXZ 77OP72PU0V%>
M@_S+.H.UX^A47;QO]X>->-[D:K.>=W_@HDFX3:Z:M,+U<YY5U>NF+KA)IHUN
M+988;;U<2>JZ&*?7KMVZ:GC/"V1'K?ADV\Y:M\>B+9*XQ3-<U2J-ZU5V[U-^
MY,/=R)VG>_*L?SFZORQ?ZF2:B'!3^7P>F[13(?![.R_9YB[25M^Q,O<ZH71M
MHK9!NNVHE2^5Q:$IMVER;]?%YZM?V@MO%>O.EL60C5OU.\M2GME% ]>9]K+P
M3;RR25A,BH.6?9U)6V90MAIV3+0A-^]FL]#R\XI_KC?!;;_)9L0M4^!]W'FS
MC11+]V1=B7'8J#&V[9: Y:IZ8+QH<WX?R@NTKUK42+,38E4_>FI1]/N8"/T6
MH^T2;C_+ZON/>+TE<B-:L*7M5DJW+;VXJ5UOT84K[K[8BDS<<G IOJJ:\IQE
MO<*'\?1RN2@[M,YG87.KVN;WHR['M.AJD9L"DF9GP>Q#DP+T307Z"O$NHBVY
MJ'!="]< 1GF&9L=I"UC-;H5UF4BIH2_5::L2_EFI8"F;+BX:6K5;&Q:;-^K$
M]I98XPI2-J71Q<DXKT&!M'JQ>LJZJ7[=>:,Z7Z9.:Q2]Y2YGU>OFT5#[IILT
M*\]WO>(-$[1N>%O44Y<5LUVRK6S3L?^.Z_=MJLJ;5VXWY917CI]XCK/J?Y?A
MW2IYNUDV%-_;R;+9)U+7RXM.>V\P8'.3]6W;VH%KJM^J,M-^9?BAJ2]>%Q-M
M+?_U5=>J;JT(\X.L-QUWE3^N&Q':ZL-64S9Z<*N"JM6H9S>S&/<O.7ZQO_^
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ML/Q7$ -0_:#Z@>=!]1\S/98$=R%B1)Q5B-O@D<;&(1RCI\X%PKUYK#D5X.>
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M/DXJTBN.[]L*@$XY"1J#3GE2G4)[Q?%]6P'0*2=!8] I3ZI36*\XOF\K<-Q
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MF#I#,=DM\WI(1W[P&IZSR (D 22=,G\#)('7T'<6AOT_)YY&@J[] ,?]IC#
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MS__]/JO(?Q8-^>VX]I-949T'<H0YX2,C]!!<X6&IB5X[!G=RAF_0&]QAX'N
M1X#'WYFRDGGLD'6$9:B3&-FD*"*68\Y$Q"S9F_#(M-+468YXLA)Q[!4R+(-K
M8!8K8YC$1O01'@DG(Z4,P..S@L>+<0B3" @)" D("0CY@-GL5F(=#44,R^Q%
MLH)VFG*D@J>!9H@D3.\@9 A**I^08Q1GA%08.1$-"MS&I 6FGJ<^(B15;$0
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M"4K6T\ZT)R_BQVV@<&HIR$=/RK^9S2]G<[N(D) _;>/D%*0!$O*],6!ZP]>
MR&!T]\?H-I8Y2G1$IC&Z2?#(>!L1=Y(3$BV7GC_E3+:G3\@S,9+&@/$-H@[P
M!#P+/-LK>*(A1F4I0RIYB;AQK#3;"0A[5^9;:VGM%\%3'_/Q/>VT W(-R0D
M(F#84P>B8Z7C*<LN&.8><99,V<:?/;$,5TACHP@-R;) >P!UATS']W2G8E\5
M!^3C ?*&26& O%Y#WBWY^,2\L4*C9$1&I8PHR 0=D(_.1,&B55+T(C1X\&WT
M8J0( VP:4CH>]L@?<8_\NUFFR/0B?U/9=W'J#[%9_CFL1&\,CU,@,.3:@:FA
M8\V@[6UH9O49BUR*X)@OAC6-B).HD"54H92\,HY)10)^RKEC3Y^LYR-*>VJ9
M@[9X2HL#VCT"SY\LSP-"/A0A12(Q"4.1"QB7&006:2H,4D83(EDDS.PD4;YX
M6O61ZP4 #I^1:K@8AS")@(B B,^*[0$1^UNXX)2. 0N&* FT[-LD2&.1D+2&
M:6I,OO%.B^4C8.[I]Q$8KNX9>F4#8"_P/V#O,\;>_<C(:/*<"8JDC!GE+ X9
M[SA'24CJL4U)VYUNIT>)UQZZ@J*$:7M:Q@Y*XL@=#S9WM3=WZLVN>W*F!3O2
MMON#:J.WLX6=0%.$$[213J%0XS0(#(49?<%P>D8+B(?9,EM O4?QA[JZ?^H)
M=Q^"]J=M]3L1:.(T($I*#VGB$]+9'$:,>QT<)S:HG3YFAQ@Y5FS]:\O_\4HP
ME!E)-8BLT[ TPT#A[I,DOW/T"UHO/'/N!UP\=5Q4RC&NB461ESG5DF-DG*:(
M&:\9\\+2$MEZ=%ST?GFQG-A%#'N*,OX6,_;%M_;C@<!2\D&$P8:E*IXU4(+W
M^)Q9'U#R=%#R6/4:@JJL:B1!05N+>* 661\X*LXI\\GPF';F/CPE#I="C4/C
M,.WIC*/GJ(OZ6;0!> PR 'C\G/%X/UK:X#$C)B&>U0'B95BMX=XAKPGG)!G*
M)7L,M-RNX;C^=*@HKL8CJGO:]G;(&N%QJC3RA\(;?8*9ZWM_ZG9?1(Z6-W]:
M7L3YV.?/8?R^_;:<-9XN;<>R[??E_YE>_YW_7CW]'TVEP,>7]%6:Q(\HC.>Q
M8?-\@<GR8OHJC.O+B;UZ67[=8<0SD3FJ/&U7%M-^\:]EO1BGJ]6#-Z>B. VO
M+F?UN+GV/&:K=OP^9C;^6*A4WGS-T1^?1D]NU4VL/G6B<M\EIH^XQ$_0$.(^
MI+@KGAR:][]'7^(+'OII*-F2PI5<G:_KQ#HBCJ>3\30_TL+.%R_M<C%[M?U#
MEHKVZTO[+K8E8QD'\YJ\M),/]JI^]>+/-P5V&UF*O%V+\(XH]D3B&K5Y2(%[
M5)VZJ27]Q-9U6<Y\>G=2\W?^'.<O;BI1L8?@^<T:Y7M#)Z]LIZBXT\$@[:3*
MMA,32&O#44HT!I:2(8;\SMIKW+) GZ+#BUOO*Y10G'+DG<SV5](6N9)N((IS
MPY+D$<O?R29;;%:5\3/!V%>?*"W[K$;<9A:9C]Y@EPY ^J)Z7M?5+%7?1A\O
M7)Q7C(PJBBD?58OSF$W(R63V(5^C:LR/JEY>Y'?+3U W/]M5C4&V?^M%9:>A
M^7JY#N54[\I&U^KKR:RN8_U-N5,Y(%_CW[&[XMJPK?)[UD5EA^K#>'$^GNX_
M;'3;U_DM4?XT;[I0Y2?QMCZOXG^6X_?9/)XN\E/D2R[.9\LZ_UI_\W)#*M96
M5G?5W=K#1HUU*J6L2B%K5@+E<)0-B-FR.Z2E,,'9'OUJ=7Q>V8F]K./+.E[:
M,KEJ6STTY[W86X_[?ER/W7@R7ER]7%WDMD+;]L:,G7'ZU:8:7(EUHP?__*ES
MR1E_Z)GBC,FGO^L#S]-GG..-/P^]SH//@S>&-S[\'?&9>=1;?F[3@+Y_6\:]
M(+?KC]XU!''@BMW]5J/N1;>Z#RW-W6P2[@'UU4.#.R= V:.&RY]\M]+I\>ZO
ML7@I^;#_=O,___5-_KY$+)=VTGSNMKA=-3;>5=G\_> DTQ$V 9^H/&2&*#__
MY05] ;+QF+*Q+O7N9*->](KY^[88IP<%H%Z>-T<_KGJYKLQI]$O3NZQ7[-^W
MY0 %<Q(T!@5S' 7S0Q,L[A7_]VT]0,.<!(U!PSR5A_3NW3R^LXO8*)COZL7X
MHA0>5Z7O3?-5T_RF5P+1MP5Z7'$X;DN:Y]!AXZ"EDF]F%Q=Q[L=V4EW:RSB'
MUB8#*-0^!0(_P9"?'V)=JAORU4E/BK1[7(#=&^8^V<%Z0]]AT&/F?8+= \81
M)[55R 5?=@\HBHQ*-O^/1JLC5BGM]()11'ME,4.,2(TX+O5S7'BD\Z6BI<$3
M(Q_: ?+_FLJJKF'R5HN8@\UTEB-,>KK;KJ\RWFMK8)"B#;@$N#18YGT"7(I&
M1)R<0]R676W">&2]9H@&9136GLNT,R?G/KBTMV?_G4#I$2?E2$ E0"6( YPL
MPP(D#0.2CM;XQ%##.8G(<R$1C]@@9Q)#1CC)#*$V?)DS=C#0.^"HFI[N\#XU
M%=*7GB9]I2N 7U\Y%\"O%_Y8]-IKQ9&(+B(>5$#:6IF=,J%*$Q$9R<YD[R>+
M$QYZ.DP;(^QI8\R^RO>Q4^V?W,D%J?9'TQ?_./OMK%ID4M?+^=7&AF?(" _
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M/TQG5].9G<>R"?V\H<DY2$-)C'<&OG2&KTOSF&ZJD=)7ZL%Y#*^\$TX@'A)
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MDOU\TI-=I7#?4X\O.ZTH4O1)"XQH)!IQXQ.RS#BD$L>$LA@TV>G#;RT1.M&
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M2RWG(U:2Q80\B1R<"P;.A5,4,1TT!L^"2+_3%9,&PRWV$445\^X"E9"CRJ+
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MC2KZ/5[-XZ4#705/35MUU.J=3[:N@,B@QT+F.W!@>J"&F,$L.<N0-@8\W.C
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M;/4[>#YPCS=?BMJNJIVS/,QF=M*68[>9T$]-55I3=1;BQH$@?HNK[%;\H?O
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M_Z9/T6A6SV]JAYI^*':C5]&M8&;N9;2.BU9IT29S,DOV!KYY+!FA+B)A<E^
MO-W/ =I'P05%DXP2\-MM1E3&D40T0SHJ\%U=Q,@J'! XOE(+XTE@Z>N^ZYIP
M/[=T^]Z"'_MV\N8J%T@#%QV)%7M39.3R^^=NVG9)@54B\ONIG35;ZW]<MP!N
M&J=/)W5L^Z'FHR[M_X ;.[]>?<[=27/_W8T\+-I,.=[%9F]E7K]LW=\M9OXB
MCTE;MU=:%;K7RS[FBZMEI_"T&"=XY\OEPZ]:&?M5<W#PB6+>%3Z"N]6YL^HG
M.+JZ6MT@-TV%2^?MW5N=SIIDPWJ'[HTC/YIL"NF=7F;95:0>5C\O9KD'_C:
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MB@J&%2/=0,*5>R;I.Q$4)<W+&[;($&6_X4^.7-D8H5$]*(!D^]??DU4 &F@
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M--Y#N8@L+@D2TEO#HJ?\@%7)3X\'U/XBY<SW?>/[GFFI)\(#C_0 ?34^GCU
M1WN1/V_72/5$>6:TEZ5^1GN=07LV&*]+JY%E:4HY%0X9ZDFJG&"NC-[A[6Z:
M)_?^+*7?37WN0_ >O6LL,?G* ,;,^7WC_.<,$[+_)R."+!<R(G@((@B64%*6
M%)4A.@2Z7B(EF4>^%%Q(2V-P6_&@D_M_CHP(<$8$9\3Y/=-3W?8 Y1R@$WN
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MFN\^[H^=:O"!I2A]3=/(@B$+AI[[3H[0T(-TJG:%#F4ISZ%VY?VT^C2JDQ(
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MU^BC>? B3-)"?H*]N+1A6E \*$A)>+-0^(5]B\_\T+Q0? 8&@&7 >Y@V54=
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MRI%V@J#4)A99R2,JF56:LF@QW<IP.:Z>(0-.]M=R9[9]LEYW)QVAQQ\[0>^
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M.:4'$S\(I(P)FGG+3-PJ;.@*N5&I!DQUO$GUNGNT=3$MBK0'/:"H$#"UABB
MDJE$-K7,5=8)A+4%H22"]7:[W$T)J6G$*)0X=2,H";**4T1*4@H>&)==%6#
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M-3BHK<JBAQC!=;B:O%S*M=]:L?;S0JJM0$?3Y?+')-'>K FT ^$/2@=,J Q
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M?;9K2@.67%L-!@\K(V*E(TBQ:%$92HE+*8EDXJ"6^/'TF2H'BN113R?69SD
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MAC"+*":]S0(*U_,]WJ6\.Z ,',&UNA&VK" *'<^/@J#KXT:.V"N[BK26B/Q
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MR(R[>%> 8'UGN<Y5$++FS@.6M&W<]C$$6TY%V=^9G@HUZ%C&4BAF:G9OH)*
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MZ7UL[#.1VQ !0IAM2$F_JLXU9)%N3?[$OJ06EH,K7'X#$G+S/<T)"8$?R/N
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MC7/X!INS:7R1:Y63XWAL%[J>0%VB<AGB "T?RE(67BZ1S?YE+4^].7/9J_1
M-ULUA*2R!L_04'Q..PLE.2*<,/E5_'=&A]<DC.8"Z@6WU_XZ"+=LPR?W U47
M\>/IV<#CZ*A99B'!&\_&'V@VQF%RIKB<4\Z*"0Y'Q(J)'$:&$,P2QCX)SZK!
M[[2"77):Y'92"]]=2'>6ZS!\)0WBER"'$0/3B5RZ)N[EY\Q(32U7Z9I[P8 ^
M*P^9+8>G)F/Y8 SE"1@<D)+E+RTPC\$=#?$2O@I")M)&9_M'&&&$:R1-B\8K
M0QE=!1DXRDQ \+B+*1#X'PXF #<+3F)BCXJ]=_YVOG_&;X1)//M[-_KMH^5;
M?(X/,9:\V>QA#7E1)-0R1UK!<L,1'(]D V+B+A_RB*U=-NJ,47ZE>(E1::YJ
MK(349H]F2G+5Q$EK+,NTR9\MAS2%;U^%/'@HIA2+CN_@5V@*XS+<8W 66.&8
M&.'&@YL&V4<\Z5S.@R@3$9(M?NYL+N17G,V\WS8;&(L\A-2.@S!:L=H>FY=X
M=-A:>74XDZ#%I*.1=+A9H]>J$"\O:&2'+L-J&<@QIWI$LOA=1A@4^HST@7%6
M'9;LL?R_%"N"0*OMI!((HH[^-PV#E4^_?W_R5\RB&A?>"_0($L2T,0(DR5\)
M2\V:!8=&&S<%J8IQ]4_D*DBY8J@>6T9]VD@U;4RI1PXH??W;-VQK)M?O9=[_
MX]B,WPQ!@&=M3V^:&#5U;^99\Q+.4X&&P8LJ &V&BF=L7-*"!W8F\,!(!1Y8
M/1S88P8'1I2)_NY6NG!O\95DF([$5E?<RB.P14J[G5AQAH/'+$NPXJZRXD$&
MP!;P%0^S"4][%2YJR?.&Y9M4':V$$PQG.I2C"R:.=B92X4S,AFX)V4(AW594
MG2]K?0I?I,9UFO93FV^A*K\CC>M$$M *X08#G='RR"YY]EP;2/!:=#.8QL1]
M@/;=V\"WQ]M6E3L&K?^'PH)7FCW2.R(9Q<E#6"N,^+Z3X2=DOL@T[S%+N1J?
M1K<54$CHQ\@03KXLII5C^KMA6O7D5#FNZI&Y5'P-)=_PBUJ=J@C_*L<E^^6V
M&LM$P0-RTHE,GD^/X!ZR2L.C]5DBA4J\)C1\)AZ:;5@0*[_">-@SM$Z-E -/
MDSHX2R[.@%)3P*AT B+.500[B=!K[)3.XLM<JUS,B^,(JS#78^#-QW3E76HL
M#GF!228>B)6: Q?J'FVPJ_53Q.'Q5L^QA=B^U_[E9] '0&]!7UAUA:!10@(.
M>QRLCQ/$#\:1B7*@7)]0,3SS@P5U%L@O:'6\PL(\(68V6Q@Y*B[+I;HL!7MS
M&GCW12Q+M?YZ&,=FL"% 0,8S-/CH  #P4XA[/N/E0-P?R$ZH5Z(D?FR)!8/3
M*TQ?&QSHF"7U3"^DEJS+-[+.GR;C.-(CC.!\%O+!/)2MY'-.O^WT1BW']_+S
MSN4XX75G^/(SEE*+Z!THO5->)%'7FT29<N-U(B=.V,Q_[SM1=9$0>9%0N50[
M)'T$&J!O4\^;SM:;Y69=N1X-SS&.)PAUI)8Q>D027/C\/0-3K[*.,H,G#_BY
M2-"LR,\?#P2ZI9_8GWK?C'FT^VLE ?H!R-.(G#7E@Q]E*=-V$,'U,$/&TGQK
MHY[<ZVZIX3*$ZO"9+_E<A%^4@P3QX0@?3QH#1&H7#,G__@6L0HMG11C_>;P<
M<?AJ\#0_&4OGPVJXDZY&&CR496R=^HY:.I*OT-"XJ(PLBR%7"8M#<6B<E<WF
M2NX>LQ&J23C_(C9[<FC=]9K:L?M*TRK$]_#,8,56WX:YL2.(-?A4!+6ACYD<
MBO"QF!T/1R/YX8[8'[(1$=,'I) 9PKWG6 SU&(Q?D9GR1&99&#5 F%EBF!2?
MJ.9BM'L^"POL],E\O(KY8W!JPZ<8TBHWPJA,$A$W$15* 42SU3>9A$7QM4O:
M:)46U,T4<='+9*5MT?Q.CC56"0T29VU(R^^NY*<S7;YJ;V;5*TV#U2N46T]B
ML0-\06T6A4N^.SE"T)P?IB\RAN;V>(\QNS%68I9UUT?G4&%Y@N,;>+?0:>AO
MF/+$/2/SU-)(@9)3G.0BCC%_Z:[]TRT"( UDLP*/&3,(B@#.BH,U*Z)T1/C0
MA[X4.>BQ$JSS$:A$,1$.'I JF!3&C.$B;%1."OXHEBBG6,U09P^S&U-(>-]A
M<9S"G\P1K\?'QLL<RA3U'K4.'F<L7>RGLX!@3\>NUY/3R=,W*C.H'E_<T$&T
MB'V:S 1K<.W O-RURZ$;&"HAS#'2FV[&AB9L;"63"I<G/SQ)QY\XQ:PY%UUS
MZ-;Y(D %9@C-FCD JQ:FOWSMCQ.U?RY?V8?$4X<:"P:**W11[T_C*^J ".FQ
MVCQQ$.YSC2>W"5DQ$1,@Z0R*G19E*-*\8.HM]O3MP[=D+5:# 5'@\D3ILF#V
M^^2Z3_(<P44*BWWYJL-+GI(CC-XLSG)1][YO L#3+O"O>=3]'0NZ7XF8^\'9
M_6H"0(/G"VTIN;().!,BID+X7,AJX@0 TXM6#+L]J.P)TXM71OH\J)6[W.Z\
M8$\I6Q1I=4.S@9;(4DE=<"GSVGA"].01@!,QZ!5XXQ>'),U3V">/_IR(M\)5
MT&W_)HNN;X$8R72^2W\#OYL.1D15\<18$^MP*NXZAL8'(7JL06H_V]_C54)!
MB!T+#I+2)^H :#9.AY@%$&127JL ]!L8G@7R%=/80+ODTJLPJ(Q3XAC9Y<^]
MPF/+34B"JE0_OA:$OYG)&ZN/LR*L\,',W.NR'6:T0%%$&40AD<<P/%6JNW9L
M5._5P7$Y.H:FS+N<>33FSZ'9YN04[JD;9HO.ASERP4MX_J;FX1J$^8A50.0[
M=>W#MPZ_&16-*&B(_3@4%CPY>TE.?DR2H!D;<#[YO/QW#A.LWRQ<R%*O:64.
M-'G.U:K!'CB? 7O@EHICC<C?IZ^6ZZ$'/J?TBTC ,RMR[9%XF5BW5[Z.##&>
MI$,6;4IBU"/"QIT1,7.F%5'W_!;D:WA1@O (4VM=>[*:V5S__1PC#JGW$_71
M< N'^-39NCZ"P5OXSDE?Y2@3AAB#;/@@[/.V<L.D%<(/DEFOP*>@SX*$\R.D
MOM^#Y+-HVNBQKY/#!\B$=,N[LUSGVC^W=BY(;".PA*K2W=&T".2/79_8?(##
MX\LKL824X2HF@G;NZIV</WFI7@4AUII5*E30Y_BC%8M_W0<>=-_\%[7"QT_!
MXTL8))N7*SABIULL9/!/#'>+8KR%!]?4@_%R:"'IU([707B,DSLB8D+[(R+J
M68A2* \P-X^F?V9YP2#7\$D3:PV'B6%TBHD3G#E!9B(6Z\0Y(,C"[V#!<U]6
MRCSF315B51W<$A6:Q!;(X@EBW:1;@3"A""Z!8L,:%Q;_,7T=Q 4LI**@'NY"
MWG.H$&8;'A]/)JAQ4_/RI^Y5S'JV$I</[L9GP55^G%6[9&H+')+196\RXD2I
MZRG)SPJ4/0VC.4" 9+O%=#C,%VUFW%CD\LW(< A)^(@YZ'A\7DI\OMB(R6!)
MHX?D^>\4ZV9D *6:M'<5G?2(1'P<O&4SI-+?[YK)^V)\0D8M8G&<(1:_K7\7
M&&-S^S"YIO@S?)9P'U\$6\L=6B)!T""_<BKFD5-ZX?[\% ;12'P$[C@0B-0"
M=9G!^DQ?^V4!:U$&WA2TU2K$ D7J=[$@^J[P!@@N-K/) ZO=R-IL0@P-8+%P
MHK;YF)($>9(H(<J"Z7.4**B-</KP_L/WX]4MI$*: KD.C3EIS&V*36-,SU)C
M90(&^P2HX2BF8M,J:[2-^0X'%VB;J?R)_4*=Q*.KM2S "Q>?O+A=&\O]\6*\
M;#JCM7,Q&EY':>5F&)#?S=+3QLK\\5'%,LQ:JW:>%2E(-G)A5E4+(];E5%D7
MOBRS6C/F69="=;Q=$J</6/ETH#=7N'&%4S==LTDOR,S \H!R%PJB3SN$EL0D
M\?=_'/_ G3X\L83SX_=_/#Q&I*\GLT*EQ FG3CCY>5ZS27@LO&?MO$Y;RD.%
M:(JBP';1KON+&[]<^P[=^FDN*\/^Q2SC4Q -.>;BF&.:PVU*QR6?8&"0H7,C
MDY -S=VUZ>!?RJ*((Y\#ZRJL1V%0<I^MQ^D7MQZ%S^-F[#F9W#Y3^::-0K2J
M$V_F JK2P9!7QPMGY2!XR M:3&+PF,0@@FE3A&@1^G003.5BMX EY&@V3M(:
M(^W%17@THAYAL'/)E</GV^O+\ISQJ?,M0U5=F4[E9"9_+NZHC^FB$J[E+HCB
MD,9NR"V? I<O YL8>Q#N4]I$$I]5]YN+W<H<U#+S\]2T'6G@7F5&^=MDB(K!
M\99 G0CC=JO_&=VX/KXK</5[<R!E+&1Y+GVG?7$NV7]!9OE]K,P$?I&5NIQ\
M5O/9F^ICWHJXJYI-E.583/7)S0]NU%(YSPK51!Y5"R1PL#Y:?P]"@L"%'-">
MV\"G#7G@TUJM6<$D#'$4&3(8;5Q?4$G/R<F6A)>2PN&SK"(6[]Q8<6K&(V1N
ML8IQ']FB\?I2MEPTELBZDXM66X9JXFK4)I:HYCM+$?SN,QCH\NEB$W'(P\Z:
M_J53S#KG VO>EI)=9=T^Q;2X?#8JS'_GT]:[S7)#.4BG1#&]]H4I&F]^"II2
M'\]E)42!I(=%X@3!@V*JF/PJ0$TE;4Q!25F\GXW%4^?O"4_"C3"*CC_2-)?Y
M]QBPBR8,7ET',36>(JP.F-XXIY@2SHVYXU(BE:F0QR 5:RA1<B5Q/OA'?M>(
M*9&S/<%)X1)FCUHVKQE3)I>PG/G4K6Q-6:"A7%-?&NO@MPR(E[UR<D%!:/HZ
MB5@5QF^4)\]*YS997F9Z%R+0*:UYUB2 _$5",;$$TTF&WI1LF*.B+'24"4-'
MN$+/E#UL1RQIB:4O'3K_^2BF[]Y/6Z/'^GP>4L>-SZTPW(-TP()[TR)JR,/0
MND18A8.1)BIMI? <V[)#XZY8;PBXM#F7MLHES;C$7*5I1= )V,Q%DE;S>*0P
M.7GT(]S04>S:Y_@(A^-2FB0M!A#S%U X(\>UN7X^4WJ3%F[4'1+@J5//^XIB
M1AZ-&I 81PH:<H0V;,_YQ(8)>2[C2YIBEMTB'T&B#UW+8[[]45^8I,0#&.8)
MX=$P^\+5GG+!P@VFO<$US%X]3?D-F"&QSZ;4B:["8(NF1>;IXZF[37;'X=E^
M;#2RAN$(L[ARGZ?(<&=%65HSYK^0-5&-(WH69J;8D[G6)_]12,LS+(65XSS"
MU3)2C.I)*=D& HGTE$HC!((Y)1[J&;A2=Z$;A#SM!-K>!9$[!C%/'9H)0W)P
MI?9-.CP_56P"LIHH=DGG\"6N4[6ZCI$SL& @+R+(WDX2!PV>I\J#4KICRS0/
MVD-F1H"OY99^4O+(P\"''VT>'S>B,E13Z.JTM:&X>A-:OOU"'S\%.J %!34"
MY.:13,9./Z>*99-?])R] UWKHG8__7*GGMI2S=R1JE1%%> 9U29][.1<715%
M?R>S=V;5Z1^VEN>=)9'KTW$YN:)$/:-'),&%S]\S,/4,QB:V8"!'!L3"0Y1L
M$_;,7L#S;[NCO(F2>I9.];4R !$CS 54/0&OJOBB,.9P<H?'D%>W;Q7;-GNA
M*_A!_DZXX7.Q7;XC1=;JX"\,'-!9&0M_3O\@)G24#_)"[3 3^6MCP>8 ?UO"
M:I8>FF,NZ-L*W7DB22ZCV-WB87Z*Z#KQL"9KM%K7XB?I#DU*AR<)&Y^P">!?
M6I"6#,4FS;I<]<%)M+ALGERV7;ILNW39J)S.3-%)LRY277A2ND)/-0<K?Z*F
MEXQ^H9[W5S_XY#]0*PK@3;F.HF0X-@.7D9#H\6](E4BRA--=>ESQ51"NJ<O\
M'1)V11\$32Y 6(RT?! :#4LB;UB-P=;*K#(DFB]Y*2OCSAK.USF&\7O>].=+
M-63C1X[CZJQWF+?JRQ'FKF,X.;?YRMLYEJLYY47*X>F0M?186/ <();3+$ Y
M!W676X:9*PBFW[R%R0,<Y2=T;2I34D?M;YX%M);;2I+MH; DKW6+9X(P@D>$
MD9P)8T04;C^'/[BVY3VBRQ<UG\&AUKF/D!>%MP5Q$C.'\J0?V21,>7E^)%W"
M"#/E=O)([$GX*B@B3?LE(^8GSWD=*R%<?J:A[4:9?,!>^&L?>/$CUV8%VA<@
M?:735%$ TUGR.O*_QZ4NR_[9HKPB0;PG(P6A,R)43&-R.2U+/<9(KFS%!, Y
M^Q)+"Z8)@IL9D\I'[PMCN>)#2S\@Y1N;,RE]%6XLW_VG, GZ4>"YCC0@PH49
MR>MSM;YR$5//Y07HA<-\G/]-'1L-K\KHS,JACH_?13H#DDUA1H<="V,?RS,G
M,N.LST6Y"(0H.D_@:MG2<'"%Y&*ZN$@&)U:,J4#,GTR^.SEB:%T'Q9C8'4F3
M@RI)JD?35[2>A"G5D]?*V4P^O F.HPKNH!S(OUA^@E;5F8XCSWFYX1EWD1VZ
M[/F^&5FX0:;XB,0>A?(L51O0#'P*]ZR#=^V0 N/Y>D&"$$%*BYVR-^=LHS!&
M@XF3V S^YX&&KZ <1Z,0[@4]7MR*$YP-[3XKY)N#3$A_+3R5PC5Y&HNT#'S/
MDS@(][E"P!.7.<9+0HQ/T@D4^[ :7\DL*<CF%D[]2I^^??B6K,6RQ-9G!!N,
M0261ZS-'R>1SSXJBU?H7"X7B>!6R&'T.F+):9Z'.YQ::K\_VHETD&HZ*/Y*F
M<@Q1G;B\B"%NI:B#HZ)4+>B1(.2Y$!*:1H$;8:GX;'C4_^4$TAZ3FY2+:']Z
M@.&JP"7-%2K6S&,1VY#EGD]N<ZT @\!737?@9@XAUG>(V4#.J9A5M_#F^O3L
M^N;Z\?KR@9S>7I"'Q]7Y7_]S=7-Q>?_P+^3R_W^Z?OPO\O7%Y=7U^?7C-]-'
M!9PZ#K2)$,/.\O[;W9T'SJA71\0%"++X'2)A I0)DCX,ACRCO,CC^!A:#I4@
M@V7(CU&%X"LP/DS<E9.P6(@%G1O+!"[ICM :8\P MQ(M0P!D5.)C'"ZK7L9E
M+Y"5P^6X^,X;V]SFFC?3%?0Q6\MG\CH^DSLDRS!1-;@M8[&BOI8C(&AX/7[?
MP?*;UR)S0'L1"\69WK2:%I8?GT8W9R'YT1/WRG.>_%ZH+(%U'V#@3%:::C1V
M>;GN%0[! 4/E(+/Z"RN!=+B)3"\*TER&-XT,-2$"$4%Y^BJ(=(V9/\S/XCXG
M^,+@0R7>F! ]WH@Z'OA6N%<;C=I#,2A1";+G^4@6& Q);N1\RWEV>MZ5*4#7
M9,Q2@4!J//PEZE5<]!>*IC[JG+["T[:A,CB&!?.-61M)EUB<<!KOPH,>EU.*
MU=QRB8^L2WQ6-+Q&:[H18LII#!</V)Q>+H-30:,XT[@UA&A*HK/"KFKBPRNP
MD!$\F@L7MP^.X^-+2&<%LF0#'OP*% KR_NOD8"AJBO$./@ON9X2?/2K"ON"]
M"V,1EE6;_38N+067]4\DGW&=38:7+5-F\<4M2H5E+I^@G4T"@S[$-'B9.V4B
M1\5TTZ-\=N!,,3VFEJ\<_C/-(F9E868J?F)V0;/POFF6<]Y",J;6TIMN"2<U
M==Z#K 'R7BR0.X7 ^) \_YW:,<*"2_/D8&@*25\8:F3$A1B"HZ=/'7LQ+:L%
M^Z["<CZT/Q(L,W!S.=BTV>Z3\:P*,OT87D*%GYN1<9H=8"-G"=C,D&4BD$CM
M%RPH3E^I%["+0U$491SN8P#Z'TQQBW58T)T:8:FA4?&'<FQ>9#P;7=53CT@:
MD QG04R!%_9ADSCB%8^F#ELL^?_%?W"G3G3&,X@?"#L"*W^^@(8Q#'EF>2DB
MWZ0ACDK C0X\((4<VD6"Z4&[=')4+O[C2.80?'/&"D!:N,JKBX^+8>[\!:^N
MM(8.PPYU?=L%&2[[50K]R9$_K[=;@3+-0Y*'.H'8T&BJ4U!&T]&/2 /VZ!')
MYD#X),BO<9A0LK:\B$Z??&1@U7*&]W3IK&R1=MG2*;^-TJ5+Q-*YV=)1-I/Y
M!)5J0[,JL6'V*;=01U&RY;^;!)&H9!96!N2!)OAJ"W/RZ2PN+K/K)*WQ2HG+
M!H-[3L<Y(NET<LLX?]7+*\L-60+SV3[]\3]=V&"0V_8W*+.- $-&BCS%FZ0T
MF3!X>_KSQ&C(=='4(P..RZ'B,\87Z^*E&"KV-9;0PF <EO"2@HL0*^;.2G8F
M03JW>5A%I 0V3UY!*Y4A](3Z9TD])D/\=3&5]W!)SJ:7@1[I=A? Y[SG<>TL
M8 *#%YE__%0Y-:!46D-<7GF$'[7@RRXM^!+-$9$T.:=UA6T*?![QX!&43U[G
M@,R8G.^*<NQR2)&X8<#</A/72I7U$L_SVL0G9]BKXU,.)4)^0'DI/#9\O%F#
M]F0I(&]_RL1\ZJS">X9*"9/:W[B_46__&!1;W<,IQ7=X5))Q17Q?-@Z1TV&)
M=NF$")\1+E:I+<EF17[%>4V/8I_L0)-BQFX/0]ROO.#3M8_6/"YUZX"T5X;@
M\>UK& 3DEG24R<61B;CT*AAD>0M(GR@#S%7@C&DK']Y_.!D>VUX(:#B9,4I?
MP^SECC"M[?"F7X1>SMB8-)> 31\/+OX_7O4@K&!@S,>T7)22QLQ#ETY]YS;P
M-81XX9!'_%J@V<A'U:6JTL+HJ(WZ@7]LSP!K-^/">.J:L)OD4EV3;-A<9K>R
M)K=?WIH4O@DMYV7RK!PA"#Z\4!K?!#9_989;9%*\K#R,EBS[1>001U("G<E,
MDP^L8V "J_531%F%@Z&H8L4@0D;V.%@? V%>_.&@V&K(*^)U-Y&U!/YAL;(0
M!\5;7N%OYVYZ%]9SG-T^Q7 !++!G>5A>#]$4Y,<SQF'WL>K2@=LI0)]$$B01
M2=(Q><5[64SOB# KZRQ6@3E6)77,=BB_F8TH8"W$F+.78&'.8ITE:6;U/H]C
MH\7OS"\C\DQAVR@[IB*TUP/59DH;1Z6*?Q98(>9U;-TXIG05/B3/MOS7/8UV
M@1^Y_$2OX$J*\-Z9('6/S8*DTT"U7IT(46;"0V'D7&;)\..)SI]AQHB=M5JO
M79N&&#_DAM2.@U" F3 /W[AT;CD&$8,P#!<YC,1OX0/-E-X])=?%9.^4^T!P
MC[*E([GG%?N(Q;F?5F.[1:#;=>([>+^N?/KH;NG3;AW"ZR.\F#SGA(XJ<0*$
MCV.@S.3G,!V/)'PDLA,.TU",=: LB\,- Y!L! R/(C@&$8.D[N'[P^:V<*AO
M\UL; -=LR^OV>'+]*85J#DYM^*)"6A_ZB2+'4*1%,0K:8L4XBZBL/BWS^4(5
M/(9W407#I^*_,I5ID2O @F@Q1S2D+Q0DBE?*_<0H+M<O1E8H^Y:"4@?RX1BA
M<'5^?=3E:P"IUW)]\C7.[9LC8JUCE BR6N+X/#+'_2RY3*96SIMDT;[4U2J&
MLBA:\@;7!1[A6;\[A/$]?W%I!I(O),EQ>"9(43'727%Y<IE8+S?Y@,Q*EJ;U
MJPRM Y)&QK'B$!*B9@S[F<T&7PLUL.I+7@%IA&;192WU9<X$? &IB*8D2F#A
M:DWF@"A:PO(5G7IL><J%=XF5+],3*>VD_,W42K*N/873ZIN/,+\(D>@PS7(X
M#H9"9EIH"BV3+NR>.OG=XB=?+E<4SS5_S&2Z$&N'N6#C7 N2$DLK6^J4O1GG
M6HI)I1%B:]P.\$\I,K\:C2JP.H#B3**[!E8*<06$U8M#4ZP(DH[G"+,=SX?7
MM!N3!Q="H]5:>1U'^*W/ P]^"M K^$IS<@++F5?^S301$K]8/LEWFL>1K4(P
M\6@%Y356;N%QEG,=RS%;1NTYQ01?[]IWZ.>_TE%PFB(#55 DC"0!FHMGPC,S
M?_;V/\$HD;OQT59U)\/*F0#*),CH-(E?@A!UYE'E0I11BM'KQ$J'.%!.O0HF
MTQ%D/5L^"#D]=&8+DFK3SAYQ[2)2=G@RU:'2H<N*3$=8+YU'R;K^9AD^7C$Q
M)C2D4UNXYS?-UBT'Y65('O@'>-GROU!:<AC!,KJR[268VG#YV6:YN%B>:%PV
M-,IEQ=!&HB".L+^A1[GX.[4]GRU)P:GE?$DZ82)GS$M'7<Z2 ;SL'2@6$G#E
MZKD^"Z@LAU4RN23,]@'_/GVL_G,$4X#A+U^%(C8*SB2C1QC!>9!))%@/0U)1
M0%3@?MF$UA:%S(^6GZQ!K$RP1+RL'#=*ODR16_Y?:[O[MQQVBQR7[6AN9%EC
M;J98C=G6I SBI*Z-HZS-3EV;;6YM(C&%R4&=YEF3',@36XB++B=C<NT+Y&O'
M]5A83>9F@@L/;C[J7(7!%@VWB:QD7$JH'H_VS6QCEC*-&9V]1K@7-X8ZMII3
M($<G:QB>*..CQ;FJ\-H\$.!J6+VH\9V5 !];VEF&SC/J1) G"OT9,0.80I"!
MN3E,;HA=$. OV*?)906N,8Q#>DNKE<#&)OXKO/4T_^0K[@7R-4@*7'.8K$;9
M'"L@)0/&DS(&NP+%*(0/D\)K\Y$.DNO*N)=LD&@I6R_>PG1>J_63F)4B,P_P
MP^G@_]!X+@J&.6;E$#D5:RYO['3,EB2^7CL\?:6F[<YR0YS@:GT3^)L;C*3D
M$?R/P1F%AV87P">_6@]U%Z3TD5T<X9@-(;(3! *[' ;:'"S#.0"5'-<><NTQ
MKN=)IU*.ZYT5KD*6J>>PH $IH&DHXR2,=CMKIHRA";CR<@R)2G# SRHDG+H(
M#)FMQJWP<SD<VW:4WMV X#=;Y?:F4#X9IG>'&-6!KP4 IY0^%#"7E:W.0+A=
MOS#6Q:9S%UUN6%E\7H9UHI$-+B4!6Q7R8*E9 5-RU7&>VT.@GFN*XZR2F $L
MPA$O5,:YIWB\X?<2$#BQO$<:;C]H*2HD00O348@R#+EQUUAU))O;VS+V*3;4
MM=:0,NN*,D/56X-SG]QP4HA0+N2Y<D1^W*HH!@;[!S'DRGM(:@3)'3QG:JWD
M+XHS<?P[A>#/RWE-^;K,OG0S&L.^IHB?8L.:%<2^.6TG^]>8[[+31L]316<J
M;M5O=;,)F16#7$:QNV5B<Q94?:@<=O]FIPVVS:/J,17EU'$8-('E727L 60O
MY<H_W>W" %2QL='$!8 ]H1=EHQ(QK BGQ_=;C'SP2R%V_?>\!!U11(F5+<9:
M+,:S7 QKXL50@Z*O7/\AWL:781B OA5BRCO,:@1^8AHJG64495!';!B2C3,7
M(B(N^744)54V=Q6:7-;7[!ZH56F(YMJSK*(4J+)V.L(!\UP9SH]#,5];(7^%
M)#M685<4+H6_YNL/S>U_FG1)R@[H+_T03*";RKDHI7 G]EZPC'3G#D8*;X/8
MM2DL%IO^8X!*KXL!EZ<@IM$15>?D*(0-0_@X1 Z$9J-T*)*.=<A\EUPW@O\=
MX]_G_#L*_W'*OR7'G#I&9](%R#OE!W _+=QCY@\8JZ7F' !S:*/:&"@"4<[I
M.ZP"UQRX 94@HH<P_QK@/55CG$71U\*+\KE7@@C.4%8UA(=>*?$U%,LW7P,9
MB8( AV\ZY2&%PB\D@%AG+/FECT75 O-ELNCEN5,(3EVKGEW/'UV/PD7J4PG]
MPW&MF*V)Q3^F*7"!/U:V2L<B*?Q3-AJYXO&.RG@S"5BS+$'A"<N68B>7(LR6
M@H5^VKFEF$G6FF4M<E?PX(68O'C4=N<%>TI%*'8-E(7G"0#HU1J6*MCXZ-7@
MVA"Z-D:7QZW4Q-1JL)?\.N01E.?6SHTYG(\,#)Y%TD-3E;BMKMS(MKS_HE9X
MZ3L7("B/,LV)BYT3)4@5"[X0I'L(O'CFV&"?\[4/+XGEW27/GFNOUFO*$AD4
M@\*X EJ,.-DQZ@C*27GFAFHX.BSVO#QGG#"1E/,E"0^+L\+[TVGO)M>MLL=E
M; :!0FF&7(%2K6AF.E^%=V'PZOKCP&(N"S6C&6E,>Y7$#X4ISS _N<BA(1A4
MW/UT[<-A8I].Q.+.'E\L7WR#MX$(;+Y-AH0PEBNZ<3II7=0H'_\S>W6WA:]<
M5A6N>=WFK1"WV$73YP(0[F)EJBIJ2NH@2.<+/[(9&W*CL @-[N2-F*"N.'Q'
MV_2X2, '+28NL8&/2#8TGE#5VSR?%7#6I2D[UR7S=H.KO5 OESLDW6HY95J+
MM2B]+JL]W--7ZB>C'O6T9$7(:1W"_*7NDA:"3YFX/QPFBIZ#E!EGIAU)D;4K
M &>45TI#_ I+JJK_O(+Y8K4U\UJ6D^J A,R*2Y.PG0DYG9B>5];1S+'7F=$#
M8RP?@G-7@P@UXQ=:D;(S$GZ]<S:.F2P<C0RK;K<\U]X,):A:HOAM>.X2!I_
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M4T01Y!51\U^LJ_]P7MXN5]E\%T9%FLV+@IF'N$-NXF!]JJ_N\N:1"(I$(TF
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ME1XYW'6$7J1AX ,*<UX 2WVDU5XYH@\+'XGPH<Z8Z[:V1\!]HG//^R"EG/L
M1W33 LD.W\9N2'+)K[N6W%6/%S-BY\@PK4[J>L?A1$\?89,FH62IS)MTT35W
M)*9J[A$_>,/O[F3O/:_XN$W8M89'2HYE@\]O02+\^H]4ME$+;Q,>%/\SA;PE
M&LZ_,^5@3;]"/A/$R%6<;$@$A1R(H%R(" HQ1%!D_8K&CBB#!(9D>(5H+ %^
MHXCT2ZZ(8(L@7QQ0KPS9_6,5^]Y*?)4,N3M!-1Z6:\]MQ6KB5855CVPU(VTU
M4US- E8S%:N9::L9)807WY$?<C4#L9IK7$TLH%_!:F(;>;N7X7DO9]5MH]1>
MKE)P7:(B^UGC W+TU;P@Q#_5; +4 $[M9"JH@1%9X?D<>*A]@F?-2Z41ZT2,
M:#T)2D@@3.4=QHW68: H"?/,:!'P?J+;0D2\/SF(>(_):VQ@4Z/)<Z'/AIO&
M-]6U>*Z@-5LJ0BT6PYX78ZUIZQ-A:3X5T+E^O6=V\=>478\0LJ)W ^&W.P$T
M 1":C\D=?N6P3F"V>?.T+%U2&F)5WTA-XV4(7U F*R@-[>@0?V[\U;O?O5<^
MJ]HE-/$$,P%<KNPHG8!/U75X'%\'/W,<>C:&>YL<]-[C>='9.F"W)V[P*]6?
M;&C 7*=*2K+NL-M'9JN>Y:VSIW5U*X"[5QC KBD[,G?5:B:=N'7\%-#85NSP
M83<Q#T%B8P=UF&E&]S.CEYO_-"S_6YUHNI_*5=WGR4Z)*YHOLPC]#X-@=##]
MN:=;Z*/!+30C83F3]R@MW1LZ+)_\RKZ@\'2XH^QJIM6^9-4B%_:U?4N3XNW4
MNPD'F-7[T\WJ!3VHZ>) 9\IO[=B7?-<ZT<WJA3W(]P8&M'L-V&-</R)X[T&-
M1>[3M<K9_'L0Q9!S=9-FH.)JB;;TM?@6%.)??XZ*MRA9)!2814 S< @$,;@#
M[HY!3C.V"BMI834714_0)LC^3@LHA0C95$BNY2LCX$FP+';L,MGP.3)S+V:K
M)'SDS,ZS7M#G7'0M+K5_".ZX0U4-#PU@(=M9Q](@, 52SH'P21 V"W[2XCR(
M)O<[B^!^DXJK=B:78@/\'S15RYW%=]JF%-L/+C:YG\@:Q;:K;E?K7D/3N2WM
MO;U0&O*K'4KL^4<Z]BVMAII!P< K97I*Q-03W$=LN#/G7C^'OGSZ\J_V$[3U
MW+<A7HI&9J 3Y-QA\X^-4W<W9XQEG9:^5+5Z-0YXQI+C5*516&JNAD@L=)%0
M7+\0ON%]#S^45P/TE3?5= ],M55#?V27P$>\.\O1]6L4%'.MX%N?@H.4VLG$
MU'9GHKCPSMR4XLJKXBK3,\A&FXKU2Q*T"$TB-:F)I.AT5],F9-$17#*0H?'Y
M"]H_^7S))+##OC$#=#34PO0*Q>;&4_G:;&IU?4R51+$[6.FVG[]P$QFHE9.T
MJK_Y)6*CZ?7-M!^YH2!D6U/:R+9;MD8%V7X@H)8'Q&OQ%ZLK*#X2.$:Y!CLX
M[ [[<SW+:IEN-JEJB/4AI$FZB9*@2+,_0'4MSN',)1#76)?93GP<J$@4(\GN
M:-I89\ZZKCO*H3[*I1=KGI;DR2[G$)1++*NC)*$%^1#KT+-,)Z_LF1D)W\4F
MT6V"'I*RSG;9P^<F&@6@@W?P 6*6\4G&F+GTJ)=ZQGQ9N)C\T0UBU$_)&O,S
M1,<61\UBM-%Y>HBSEC&N!>2L11!LWTM(O1E:VP<T7%D,EW@BHR4W4HB74[3;
M(F.TJ<?-.;O+(QB#@9KUY4SXBRQ:,VTO1@];^+0-EB-@]DBBW)G(M"H@>QYL
MQ!T<N'&1C,9*(Q]%L!1SEG*@;-U"?\CH-HA"D1HZ3T+>5&TL?&-!7@*D<&\$
MKSAQ"WIL@\]*M]#WRV=<95&F,3/:LB&>4S!H[%7Q$.S!KS & C?V-Q'T%"Z1
M([_]&+P8L(GT#AJ0Z0/DSX"5N&M%O$U+$NHRLT(7*\V\Y1& X&>TV6T&G2R*
M/,3?=5= PKTC[%=I_:Z4X>^B;YI/$I/FZ/ $KZJ\M>D)K55,<(IRKZ?=Z]^8
M2?><EK6*@Y0H50+6B#6)D=@AJ%7VNE&O;//>MYZ/Y$(&1:K59-K-!;/->]6
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MS2#Q>[QJ8T&9*-*N2XXMLEC1H 6?MPD[U#9."G2_TH1F0<S,A7FXB1+H:A!
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MFNNEL5731\Z)X*0(S(J(::FZBO<L0_$]_4-V)\BNCAVYE0)<5KK*IZUUV4J
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MG$L 5[RTI?QM-57BMUQ-VCQ)@^>Y<@ 9-I&\*J7.RN0(+3(,Q_9\%T9%F@W
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M.BPPA&R7]OK"C,M$Z:Y#8D25?KE:"Z%MU72L 9Y'M"9A7S7,2@?N1T@VS'X
MVCFJA]@C)<=&?3FT1,KE8;X0!>D(S3XTC54.2$(Y(H:,Q9#:C2W+X!U@[3L1
M1&R0@1IL1BYK0N"7FQR1X_.?OQ ,Z:[-#3'KM2,FRGD=HG0?P)6:0==EM(RN
M98MB)[&4D1AMP$=Q]+"E0_BH<3B)M=4B[C&P)%ZZ@&RN-,88"@FO@)JKC3_.
MB:6)^K&HXDB:WPULQE66@#(3U45?K=$8:.8\JRZ)UH_C*_I:E*U@YM^#*(;(
M_DV:0>:+*%=-=SF@* 8Q8*N CT/68-[1/ ?8B<]?OK$GWTY=.IB$UA9G1M0\
M/J[2["/,9$;*N9!R,KS+AIS.C,"$.+C$YR^$S^E]2[ 2#PVROU->_IUKPER6
M@MN5@N.P 5V"FY$2_772/!RI-T&5M*AI'J<LFK>TH#EH#-\ER*W;G!;;C#><
MJVW95W(LK)]7!?-NV9?.ICUH;-P!-0Z_RHVU)R7IL^.M"FE2LLAWK/3![L^.
M+_WC;.,*3S+(CK2\>-S;94[ZS&UTV7UJS_RT[7&UR:74]@5W;)2/)7HX'V>R
M]KE6&3<A3IJX=P8-?YML=T5^1[_3> 27+=(AG\]H]F(GEKK,C'"BH/0@,^X<
MG5K/H*'F3KU%D .#1[)Q3PMPK&*7]Y"&%_N7',#FQ Y/UG,HD!T2AP-8*W3=
MRB'(Q1ZP( "<F:AA2#G.^7*L.[* ;714;27;KWNR4NP&SMCE""BWB=YG/&*3
MV,:T_.D)6A\#6N++%DJA1:_O07E+."S@H 1ZZWDQ\DS_-9>#DQV./I.]Z-^1
M:.*Z5"H-UY54M%_5N.1%2$4,37XM,F;=K((XMU<SJ!6MWZ7+(3Y"6;@NR5C5
M!LQH_Q":''3?<++H9R\KI<OPK9.H[=BLU517C<5(L;B5+-I57L=FK1&6;ET_
MZW=-FJ35K"29!3(")!R/?W$(3,S!_O>S8T?J"!I=F3$FTUC<H?R]/'U-F5F>
MP%=QF69;48 .8;WYFK(CFN:E;_"TG5FU^E_^Z>F?2#DFP5'V#GJ*.^2X$MS^
M'? K=O3+D\ZH/A:>0G(TC7=GADL)<S!G!R$BS *>B)K(]4_(AZ4AM%""H-Z.
M7Q&+51WS=DP<6'TJNE#D9'@BIC8=>,F :SPE2NQ4XJP>*AH8X4-:P%T7Q/&>
M S[7A'N?%J(V@P-V7P;Q<A<K\0I,8^Q[SOO>R[/9.JZ8TM#%AT.K@9E!GZ:B
M26JA*G>N@S&YJG:,D*RY.U.[0V;#L%(.1A)M0Z> &<0!;V\3)FBTVNE54 27
MP[WCG"[1" /N6B"S=<^%I7A2;K1FKM@!4'8"O$UDSUE ,+[<Y04[MS(5WS@]
M+8$WBOP@Q_D#GIMB*-ZK1@XV*P-59\Z]L4><(U3;6I=>Z448A#]=-NEEMYPJ
M4%D*>/&+(,:$&2>0U+6N.KSE3X[Z@=;^YT%V_^$=ZE,-99.WRQG<?8>*[COE
M!#A246L'(NAL60$RX@V)WJ.P:IZ2\85FU[OB6FI&Q*<QA;;;LO]LZ0CFLO57
M2R!!1;W+0,(8WAZ,H:SB]$>U**T22[#O ++.<I^H49E74([GT$]TLV.&6['+
MH)3K)OH)_S7,(E$$T3<@23HS1\;CI])MO,+42M"U;UJUG&C\$.,P=R_L "F/
MGQ%:]+%M63^TTEV!<2VV2]\!SW&%73REU5 \:*T:]PG,1SRDRP&MWG#F]BS5
M'BSW:<).D=T2)R]\RP\TVP0)N]FO(K@^*-/Z\OD& G #4Q(Y51*69-\Y_]((
M[-W#IS*=LIBCE)TV)6;XXZ3>N0QK:F8IR[(;-T'?3E:395*1)96RW)KVX8P$
M.#GKN>A0C4PQK+>!GEF_":>G*IMB=PT[03;1;I/?)M"B$3-T!]1ZXV#D@S[<
M'[@74Q;18<,A,2;D#:E1SUP61H6[% F3@58W9A&JB8-N2I#8+%K2,CM[L8*<
M+9[47ND&L4ADM=RIA3L*-QA&)%I"^&+%D][YJ/66&(#4*8=^)Q*I@['^0S+&
M^UGA"Z-8MI4*@A6(9</%4NL@0O!;LBN6TCG++J#;$*(WJX@[INYW0S5RX:*%
M.[E*FG#:9\-4/"T_=HJ%^)P7*_EW+^NO9D*T/+HH)OH[DW.E78&2QL94KP7!
M@;8RK9S$NGPW3NK;E'(KVJL7>P!R'>1,US1]170F\&$M>]#A8 &_??SPEB9T
M^ &)M @2<W D#IUY['K2)5() J,\!!D[T;,@R<$!.3 D(V@2)$HTJM8WD5+2
M:^=*>>+ ^?,M*,2_'M.8O;[^"PVRYQ_I\UN6[M9O-\Q.4V4.-@]N,0_VA<WC
M&$)6 $'.[)HG-B5V],@_8P>O&1%S)<&J *0,MD/$? E,F  /3BM#IY-Q!=QG
MO<[05B+,U(HV*$/4^U39J':8A[ J]0I<<#/OV%>W43.>$?C^ *0/PA4KD*X+
MQ#[5GX-FWYDR:P9WN$_1J*0AMD_+$3!#_SM@#-RGQ5\H #FGZP3N*KV]U# \
MFTS1Y)Y1 ^:%]%G\+J4E8](]@$_XO&2_/CX>AY3'5*X]13AS,2?;7K,24"3-
M"NBG,!31'PE]!$K$(;C_\.E7B@21!^C]($I>K:)N2!YJE>92P^4.^449B!@8
MDVN4F9?:K_#]:V/-5/J@N\"<;3E4\V"2=!,E09%F,Q)R5JV'7VTS6,TDE:-]
ME#U.>%Q=#VV17<Y31Y>8V0J_)) M&F.VJ'!<EQZ4H"BRZ'7';]9:6/\MC4,F
M7VLR1(_3+Q"L^XE%N](--#S2R8GR4F#5QNP\V(@[.'!3UC0:*S7GIY$E:U$/
MK5QNL8T2-H.AR?&R;$Z0([\Z2&D?D8N*OEUEQ9=#DNE:T=+ME8A#>G@A#A)%
MZZWX"E2MWXE:\2Z /0Q//=(K<P5%ATNFY=U5E^LAX):O!)G4&I(.9%AO(S]K
M[. 9=I;G(:(2=;,<W:%LV*"!L-TQ@/K(4Y#O!J(O5,D"YX*P4R &,28O$VHF
M;_,R(M#MV(W&_E_X'/P\/D(L&V+P1@2@JCE*X[;)G>$<>GPW7,45ADCI33EG
MWHP9"^^+17-M'G<\N?KH(/1%:0O$EP0<O=I1\+/>,$(GMV*$86:D@4NGQIJ!
ML?<*3?>B<(9N9P+CG3O_-9R!?[-J*+7GZH^AHW=D=IX95_%!AIS84I:XJUFY
ME^UE$ZZ0<H=4>%9A?NV6<HXR[RG1?77 L4&QUCK:F*, *Y@9- /4O(> '<EC
M5#M+@@0IG@4#L7GNSHH]K,7 'K!5W$V:B9_@N5%:;"OW,V]&1U9I)G5$::^I
M;E:92"-@Z@9@<(J &3J?37''H RP60_2^"WXDZ.0K=''AW*UM(E9Q[-=K9AP
M51O7X8<,)U@VNST+!N+*W,NFMJX.F7M:E#WX5-)'I:A4A'M$D' ,W^,]NYDS
MM_$X9WR*!86J2*%S"$ 6-2@<>;HC3XP[11BV1,3!F5SL4>$8HB<*UV1=<7&%
M_7'--M::&9!?L_1'\0;G<9 , E$0F<N2+N&$B:!\)@S%4_)2:6?S6K]&M2OK
M8E\^(FXTO+E$MLXO_+9-L#LC]%U]3N$G+392BZ$\4E"6L;F3R@.#])$Q;ER=
M!?W:!>A8X\VL)P*Q3YTS@UYZR0X<"_#SK!J(:L2M%%M$XXL 8_]8P7XY $KT
M5!,]Z$HDP#/KBB[Q\B7__'F&F)K6 V,9#1:K.S:E4P-AC #,'$CX.]E*I%G,
M&'.O;$_Y.?AYF=$P*BZ9&;%G>BYLRL'I])!'S\D2G>[Q&?7S;%GA)LB6<CKL
M/P_,2#SQ?Z#0E&Z+CWQRXG6 GSC44*SY_5[4OU\.1W*;,*UDQUM?06012C4J
M7_9MPBV)VE?\E=$O(,M9I02KQ4L]G!SNAO\ST5()7^3F%5J"WC&3@+<A?J0Y
M96^_"8M48#[H8CSJQ4E9U$MMH=>R,+8O:$)749$+%#+3%NE^8U*F=*BV90DA
MBO!5EY"CD.TOT["R\7N^XL5:M8-5F-:I_6DOF!&H84]OE-9 RDS,M#_M!3/J
MV.+M3=@GK[4._\8NUQU;AT7R"&414 [+'KA/(=.?_Q/2B;B]I^(<)B&,/XH7
MPFN"\8F,HIQ=,#!=DRP.ON0%:WWK=R"*'B6+A$=6NR[H812]$ K@R(-R!MVH
MC0>7]G<O)CRLGE;6T2ZRNY0I49F)Y7%'\$)H7"&4/C03T]4G/%$<A!KS2+>
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M;#I<[3;&\4* 1[65C+X;=\NQ-*8_](QP]V6*/TRT<:3U>,>+%;UB^S$OHJ5
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MF)3E*[EKU7(S-LZ?@MM6B=@/LZ:P/G>E@IN8$Q@JWY)B)S0GL-*[)M6<W9P
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MIW)F#]X.__,Y\;"2M"%,1I@W3Z&CO<JQZY4PX='I[_9PSU_2P _P)5H#4L2
MN.V7%(OS3K$XL3Q#\TW]M_8.I4QW?F5Q=D#8!9C(WR/Z8[:NL#K/!W+9QZUH
M(HA!CZ!H2UGR:I0K.8DV;I"33$YJD) "I',GJR7ZT?C]QR?!)?I1WV'5*%@
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MAG20KV^ T)_<":0U7=$;0>$,-V\G,--V%6]4D.KCA.T$O$;]LQMQ>&K>S4Z
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MH!^@BBY>;Y)!VH"Q1(6NP:1&MP*P#M)9F!@PI'6(8S"!5Y.^EA]VD)@CA#R
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M<8JG?-:U&JM749HX\LK;!YD7!G\A4FEX[P7^\?&/6B35LQGT'A9>H%#G$"$
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M;T(C3X%XY8YXW+$K:T_QV!'/D =OARX^ EZR_$83>\YBY2RNXYT71)*IEHT
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M!S+( D2N\5LO2'[SPAQ]01YI5EA0-V_(ST,L*#'_O(JNO/3MYK]Y\.Z%I3C
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M;40T>_-U?C(ML?YY(?,!L6[(&/^<N8QAGZ><<_%_+>2M@[C\/;G$]9>%1??
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M_B24N643Y\I0JZ@6E7#II4&Z^./.Q1]W3NZ+\W%16QRD;-5>/KMAVM-FMH6
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M&-]BV6$=>E&&B?_FOWE 25^^)J51AN,&M<\W+^+'X/4M^VZU_>YKB@K<)<Q
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MS>RVIE\G_YOC:P7?.B0#Q3LB1QPW^HGO72KN8!;8-,EJH.*?3H#B'_YX)G?
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MJK2 F.>(>MCDFDF.]?ZS:Y;/.#GM0>V$E+XDG09A2Y>=V9*TISWZ.<8!KKV
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MD]&6I;F)G!G5DT?TG?U)+"YH38;P#*\PT?[(]MC>U(]O?;B]4-9*1RB*3*I
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MI3+G:[B>KP'LSE;TMMZ%G89^<TZ>LT</Y9DL\;<X>A,";O@C%X*L*2Z/ZIM
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M.+06/F7#+7/ )O:"A#QH&[3<+G/V%M^R%T[*$W77,$X\&J@'CO#>6#:$VL%
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M*CQ<&6$,%!O<@;MH+N&PBNENFW 7V1Q9Q@:ZNV[#781SI" []-UM&W 1KB]
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MQ[]\6AS+,N)',=%_8H=KURSZ4?#OK(]$-Q=_%*Q]7DMLIZ3_47#OK+5M8/F
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M!BA?:J;0?W%PC)!3/LKDRF!(OZ<*9)0KU-<&> %TB:'WVF#(88CB,8[4=/X
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MYVT^PU^Q5W4T:T[CX.A^>1KNC0X+  .RH_6^ _3=5IY=Q .W;\;Y( ?:R#=
M7P"QP;TWY0N7A$8S'6'ON@KH<^]JT^I-#1T_!(U&JA;/+E11F6>Z!.P8=O\:
M:*-]!MKA=K(8=#G]+@N#9A-*\N^X"#0*,,(&S:P-F@[DEOS>E"%=%C#?+/7;
M<=EF\170A"$Q+QH5&?(UH;$/@4F^"Y?@+P'ZS(<_FZ:_ HTNNMZ*SLN IH^V
M37F0Z%!;"MI):\*J.]O"FZ=OZ>[WVFFO#Q'V80^][O+0B+IMS>[\HE5G.Q?>
MWDHHR1\>:N0!V92O]40*&HIV\8R#KXS?.J3*V2B KXQ4-TV%'I?>.M1:MU'I
M\9^SY\F,:P_CXS;&WSWLNU-;BW^J,NCY].(>N-UN>KU3,O0H>C-WF]:$(,2]
MP)AJ$@V_K",8Z'&K3^:VVHTN&SBYB ']TZ]<BIX]K\'2.I,Z^4BI5T%YHM#^
ML-S^\)*@'!_.)(&HJ;Z)A>9#5BT#XU*_!@-40$NC+K>/<7071$24"[R0(<>9
M](6^AU\O_7-!X,HX?/F[L@-?5;V,_+(+Y05D*1A%$WT$\3MK_,?Z&GIATNXB
MZ4S8?=\+<^T=@C2O&<YOZT@)I'=D^;0I^CQ!6)"*7QL*9^/:1G/0AG"=]TM5
MMJ,ZQ3H@VF8"U5EIK0(!7 X/45%@/AC.YF4&#3V()"M  %/_5L&^3US5O ,\
MO/D00-33P/5(4;&*87=)7\VR[1GIN=)X\"AU1"D,JMF3G(-0M]-%OVB!L;'>
M5,XT4-V8 NI:#U>[M._^X$]!1IRF(M8767K+CTW[NGJ6QIW07 JRIY5H752F
MRJ7]%<*,<BG19FGN-M[2-H<;"E809BGRN1, >5W_QI1BY"_>R=/PAAZS_2O"
MRVVQ>[;;9)FE2>I%/GDX>"8+P1*MN0PSSCBIR,'EAT:/[]2\:1V3P]X701&[
M."2@) 5<;<34EG &\ $4P:Y]!4'+0Y%^YXBWQL"9KSR<!IO@P,2L2H^O($EQ
M\$HQ2'C#"\'<Z>=;#T=D;,+:_M6N"'BOSU!2>8G(\Y:RUX!@8T/G4!S#;K'<
M$^C&^]]U%6C@BKA[%V %:U@#M>?U;P#;=148X.H 8UK6Y+T4;3&2,\H:RHQP
M=RZB3:QL^'B$W+E]1J*AVJ)\\5?Z?Z]$#\Q__5]_)'OYJW<X!-$VIK\J?A%%
M<2YML]_17Z&0F<_^+?"+#:TP.GB!ST(BBSK-?_BWR-L3%'#_E&.'TD7P5T)M
M1#['1YK$L":__\._)=EKD@9I1K_Y%<?9H1Q:/(WLWP>$@]A?LX6"B+(T^LD@
M9-?_O_^08MJXRR,+86]#'K0M4>=0.??5"ZGGX[__X*/7,B^=#]@:[0\Q)KNC
M9O?T>!T3S..$:1[YOUF8/8&QK-Q,CJ'&>THT&%C(,-+\+*^VT!UK&V9AE*'M
MP2-*7N"%S&3W@.C[4R*"^Z<<-#_%/]!_)7_UX[T71",#QWZ6 %%FV:#@G2[P
MA%CWZ'4LM*OE ':>YM"YWNX/87Q$B%'D*L.;'>$>U#-5L=;E6- 9"84+J.&N
M7=%X'R1)C(^/<8J2EXARMQ4.(OJ:A*7QB'HH"9T3_ER337/<F%K-(<)A]EG_
M^>!M4)T=</X DAD\(_P>;-#B#2/VE]N/0Y"O2ON$E="H1E5/K-S5%!0O>^%X
M'B,^=%I#JR"RANJ34*0,0$R(=(>648/RVK\'27@% _B*(EHNAG($?Q]$5"[U
M:"91:>FO"UT=)[G#B%^(=D2X7VZ48"+$,A*^Q)J#'6*C3T'R>\(TDPUY0 AQ
MIL=5' :;XQI]I%=A1=[4&=FD][3\D^TKF\O(1!,FOR7D2L4&HB_]7+^_BD$@
M+_.OY"Q0[IXI9:(Z4)(!( $2*JWE#13\N7KG$F:7LDUS2_SF1<&_V$)G!U3K
M7BF'@;U4N36'L 3%O5*/ TF)]Q%A]%ZXREX)EUO2>AC4LE,S=N7P:0P$\R(H
M[1,"I3+)>;W@;>@X"2Q%<W5,2JB48!N/A<Y0D'3-#]:H!+%='<]#BA[&"RJ8
MWWD!IM&^>4/@ICW*^+)-Y!T*Y[MM(F'AID3-WB#D)ZRQ\TU>'B-Z>XE\A+]3
MRV_T1GDYS:NG,A.%BRCE5:8Q=!4P'$7#UN$E.RI;O1,ND4/RX.'?R8[)5\Z6
M<@%KZ3D9+(MYIFY9?%QNG] [BC)6J^$MHB$U+Q$^_9NJD@E9D'QMA:G^'_FW
M9+-[CXD^;")5N3;,#GA5663-?%4M_CSM1\$B_^3-NXLQ?;,>O)3(6OGU(VH[
M-2ZL=V0W;SO:IYW^F >74RSE<4^YJZW0B0VM!D59[NJ[8'SZ/DDRY-]D5.99
ML5WD7N%'])W]Z82MGI/AR?6]'[I2OR1?REBP.#/LKW=>E,N)3^A0R!'^X$>U
MT[< XIA)58660/@0^<^7NOPE&P%2['H(0J*SDNM='%/NT#D?M?COSO"'Q8;)
M*DS[\2*?)@J\''SR?%#?](]_KA^@YF"09\GC987J4TL'.?V.R;<R3J@SVR&1
M[QLB^A^JIRO4[?I4D(NC='=VV^C/:'D$V.]M\ZPE#M[(B85"SY1D $@J%X<1
MM(1TC9%@A<+;/<+D7-[(%[^G._K.>M&15=&GVL;SW@M#ZGXG5Y829NWO4J.(
M^77!HO#DCJ=J0U%)SWLC"CW5[7-]C?&P,GY^&95FLE-0SX 5.(8".MTV4BK&
M#*8@G2]+\_<U^2O%1?U5Z=[]]*^[(P4T>V4&$;C&HML/LLN@=;+FS$;"#P"E
M"][SO_!+K^)=5D;2(G\9+0X''+][H4QT4,]U2' HS:J$0S[&T0\U*VOA1V )
MJ'QCK.XLD,^M,FLQAU4YS!EU@5SXUR"BV7 ;&CQ #J_,*BNB7AJGK#\>Y/DV
MS465(&'TFC+C$?OI;T&Z"Z+"@-3!_-1_/6<HIF]Z>.OF=)H-!3UZEO:&P9QG
M+2_"=')NV0CT&;0$%$RIO9ST9> []KA_ LE0QN@E4;RG(ZP,1@A1$L<C2DO'
M7#6JOA(I*XZW7859THBP+9%J?%DP&-4-=^Z2G?!RH*WN.($5=9N#H24=0N5H
M+H%D2O]#(G1 P.8-I6I1)&$4?"^Y_=B$F5^&_;00UM13NLYV!S]W<8;_%^&8
MB)L___CE?]K/JV0 R$?V%+-6#>BJ@R0= A*H4F^JE.X@#\X;]O9Y@$64;<DZ
MS"W+5\4&+  2(33D)@G>(GHK*R_&RL-+S%IK^C7KXSD:M>.T$6*:3*1LB.O-
M\?,V],>W7#6VK6^G4)C*>>5!!T6Y'I^HTW<9C>2@(0B4[2VCBGQ!,W43192-
MR:7!VOPK0'X+(D;!R1_:)N[*WWJ8N<=VX^(]C8FJ&9%.J59GFZM\5!4L RE8
M9@*=RNW=H&2#@T-5".'_;?+# 1%G<Q_E84>- A=?R3?2&\*_3TZ&*0-R.FQJ
MA/?$R-E5&AJUF /_;^"8PQ,B)T:TL159%A,EG%SZFV+9=4QY0D"?_1:WZ#P-
M(OLPV[%-WZ:DOR90WY[0$/&$J)3+@KL#%O28"P8G.EC'UU0>"/^@BJC07ZAV
MHT!$]165.ZY# L#&"]>T:@,K&<BO\"$9YXRAN=3X^?Y*T#K1)+8?. ]PSUVY
M8YJA7AV:1:*54'&"\)R26/40#5O'F=N[W@78?R)<]U?R:QK;_VOP;=74 !I%
M +I, 7GO2S=ID?(AB&Y3C0*KMZ[(_65U-)CI51K!IS44+J"5*+I<*:#R HN2
MN@G> Q_Y5Y6J4>SW]U$NI9T0,&0)H"):Q?6_2))X$U S'8V1N(]\M(^"+1$Y
MF$)&63^KW5S>VI,&,V@)*,Q/IS3&.0^1/9:EOZR\$54SJ&*@.\]D(_UB&2FJ
M<^F/!X,##2>CMP^P1ZY\\/LN/#8")+A_ _V4Z;1?$$37269 N<EJDD9X&]/(
MC VZ+NO7-!PZTB$@S[:=?=F6/@GK/0F@#^3\B#S&N/"B^(HXD[//6N!,6,*2
M>1JE#, [9L_Y8RL<1^2?F_P\'N/T[RA=^/&!/,I2\6[("F"E/D%>+2/;I%$U
MA^G%O[)Z.K7HMS[3P3QNZA"%#$<!5<WN@H\\83ORB<!"9-=3)[1&R(+^!) W
MY3%^CZ]C.CO.%Q.HKNIQ(,$K@^KN<+Q7R6HZ0]VAY+/%*EENVY6Q.$5:NLP
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M)Z"JM\E/[BXW.1H].L--D!^T6RSE7VTQF)$_0G2FR1,%("=,(8++Y"F[3 9
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MO%ZXWC4N [F[;2AOMX_C(]G22+$. B$( &@>FNEP81)L0%''9]1A&5N.C'7
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M:EPB7;,K6$5S(6%79-D6:'*%S=!C$^FT"SW^L/U7^U2\(0 #ZF29S(?5HGZ
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M;B/KM1GEI?MUB-PE$X!2L4-R"6:'+16O--H6)WI68>BK))T D15%DDQ?/^?
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MC8">/A43.M4FPCJJXGM5CE\<5<T;6?X/4$L#!!0    ( &N!:5QS'9\T$0H
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M[,.;K?VFO;G?:K1V-B!=?Y &SP>D@PD5&4UMI0D6U"AB=H]70EZ^'/-#!/8
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MY;FME]6SQN5AT.*P<3T-/]6TX7K-KVS:_LIVW;;;W7M06_A/+UFF/&_MN0V
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M]^^<.T)28).MI$-C-3]#"^DS0CDX/[*/R]59<XDWN]D7Q9X"U@KU#3+& ,T
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M#:"E6V55E:7,<?W%)N*>T71G+,EP*#X,2'MC^R)SWIUOG> 9.$-QY$.T[CM
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MY4X8?7G'Y #Z.+Z\IP_G.M\\^\/3AZNV+)[]!U!+ 0(4 Q0    ( &N!:5R
M?A#TFA8! !(; 0 2              "  0    !I;6<Q-S S,3 P,S)?,"YJ
M<&=02P$"% ,4    " !K@6E<E@=!M!#;  "[X@  $@              @ '*
M%@$ :6UG,3<P,S$P,#,R7S$N:G!G4$L! A0#%     @ :X%I7)N3&H -NP
M/L8  !,              ( !"O(! &EM9S$W,#,Q,# S,E\Q,"YJ<&=02P$"
M% ,4    " !K@6E<%TMU+"@  @ L"@( $P              @ %(K0( :6UG
M,3<P,S$P,#,R7S$Q+FIP9U!+ 0(4 Q0    ( &N!:5S3WU+3:6 !  ^W 0 3
M              "  :&M! !I;6<Q-S S,3 P,S)?,3(N:G!G4$L! A0#%
M  @ :X%I7-/?4M-I8 $ #[<! !(              ( !.PX& &EM9S$W,#,Q
M,# S,E\R+FIP9U!+ 0(4 Q0    ( &N!:5SXNI'[X'<! .J' 0 2
M      "  =1N!P!I;6<Q-S S,3 P,S)?,RYJ<&=02P$"% ,4    " !K@6E<
M$[684O?<  !WY   $@              @ 'DY@@ :6UG,3<P,S$P,#,R7S0N
M:G!G4$L! A0#%     @ :X%I7&1\GYC0L   J[8  !(              ( !
M"\0) &EM9S$W,#,Q,# S,E\U+FIP9U!+ 0(4 Q0    ( &N!:5SJCID>ZX@
M ->/   2              "  0MU"@!I;6<Q-S S,3 P,S)?-BYJ<&=02P$"
M% ,4    " !K@6E<'#):M&](  #S3   $@              @ $F_@H :6UG
M,3<P,S$P,#,R7S<N:G!G4$L! A0#%     @ :X%I7!1]'DV%70( <I0" !(
M             ( !Q48+ &EM9S$W,#,Q,# S,E\X+FIP9U!+ 0(4 Q0    (
M &N!:5P3;[+:/@L! %X= 0 2              "  7JD#0!I;6<Q-S S,3 P
M,S)?.2YJ<&=02P$"% ,4    " !K@6E<,6ZT*#IA!0 ;YCP $0
M    @ 'HKPX <V5P;BTR,#(U,3(S,2YH=&U02P$"% ,4    " !K@6E<9(#>
M<4/( 0!!+QP $0              @ %1$10 <V5P;BTR,#(U,3(S,2YX<V10
M2P$"% ,4    " !K@6E<27-BV;,C  #D. $ $               @ '#V14
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M   /              "  4\9%@!S97!N+65X,S)?,2YH=&U02P$"% ,4
M" !K@6E<;]Y=O-(=  #[T0  #@              @ 'G(!8 <V5P;BUE>#1?
;,RYH=&U02P4&     !4 %0 O!0  Y3X6

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>sepn-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sepn="http://www.septerna.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sepn-20251231.xsd" xlink:type="simple"/>
    <context id="C_8115a838-2092-4741-a82f-c5a56ba848ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8213da3e-71aa-4154-b70b-40d696bee78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_82ed9a58-9067-49d5-bf77-47a022e4ad30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_84234d5b-13da-4f60-8e97-1e3d68e04f15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_84474bd9-0ca3-4043-a28f-246196964124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_855097d9-96a1-4e02-94d5-4334f3801f9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:OriginalLeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_87cdb1d5-fac7-4ece-beec-6c0efa23647c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_885615b0-7d7a-4feb-b3a7-220a271f5de4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_886793f1-e018-4e02-b853-202065e4572b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sepn:UnvestedRestrictedStockSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_88ac2057-9216-425c-b13e-16df574b3054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sepn:VertexResearchServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8a386e2d-47cd-42af-a8e3-db3089a6f1be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a5f118b-d06e-4890-a43e-997cc3e53337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sepn:InterimChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8a9deb64-57ac-4f0b-acec-1f6759eaac45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8c6cd37e-c9c8-4880-a575-854c05609cbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="C_909026b5-982c-4acc-89af-ef9bf4949a1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_925590ce-df4f-4dd8-8abe-e9865066e1a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2026-03-02</instant>
        </period>
    </context>
    <context id="C_93212ce3-a90a-4a57-a707-34c5cc5ff182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_93730b11-03a0-4363-ac76-9b4b4706269a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_975ebf25-328e-4bac-b245-59af615c9971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_976a0a52-eca0-4d4d-ae45-b70fef55d6e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9888954c-fbaf-4612-8b15-1d1088548ab8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_99f18d25-7a69-4282-995c-9eebff9e8b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9aa30191-c34b-4a93-8ee6-eeca325c6cba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:AdditionalLeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9bf04a86-29ff-485b-98ad-fd0cfacc548a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneAndTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_9c2248bf-d680-4e4c-9956-051672a0ad00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9c372061-ee03-484f-8e37-ab25c25fbca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sepn:FourZeroOne401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9cc53a78-1854-48cf-b102-67dba4fd3597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeAndNon-EmployeeStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9d256ca5-ca4e-416a-9cfc-3811d06616cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sepn:FourZeroOne401KPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9db2cf60-a723-488b-983c-bd979235ca35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9dd7f8d2-59e4-40bc-9f16-2e9328a32206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9e8af7b3-5a45-498e-98e0-2a164d3ce69b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="C_a022d47a-da08-4672-8253-3308b645d9aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a07cba62-15fb-408e-9eca-ccd2f26f2784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:MaterialRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a16a30b4-7855-443e-8e8c-93eee3c5898a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a219684e-e5f5-42fa-8a88-03671f64ca2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_a706c6c6-3f56-4dc2-a361-8d8d19beee7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a9403ba1-557a-40df-a781-80b2faef2036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="C_a9816031-a377-48f3-a65a-63d6a0198c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_aa158f2d-21a5-43a3-92f3-b104a9b70829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_aae82e13-ba71-4eff-a125-de3c3ef90394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ab94e00d-ea2a-4055-a162-0c519f4d3c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:ResearchDevelopmentProgramsAndManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b3d53d15-29ec-421d-989c-75e94a00a664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b5c224dc-4113-4169-a143-5596c3204f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:OriginalLeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bb23122e-3c2b-4030-8ff0-177914816c06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:LizBhattMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bec2c5bd-26fb-45e2-b7fd-c7e78e0c918b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c30be0fc-4d13-491e-b258-067754619704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:OriginalLeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:InitialTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_c3cf3248-6c46-426f-8551-507bf07f1e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_c800dc65-a3df-4be9-b13c-6170777fad6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:SamiraShaikhlyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c8ea85e2-1da3-448c-b148-4c967f416f46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ca4c5acf-d189-48eb-b452-a7a26d138b38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_cebc2669-0a16-4e56-bad3-816ef82b4bab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="C_d2961116-d112-4899-9e01-f6d82d75041d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sepn:VertexAssetPurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d3c78d76-dd2e-4cd2-a4ec-26c17d567446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d4bd1786-5f2f-4271-a5d8-e93f78bac79d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d5287ebc-ed11-4be9-a9a2-49a7065ae6fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d86b0a04-264c-4ec6-a98a-514c21b6fcd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da673621-a76d-4b43-ba2e-10ba33dfce9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_db2dcbd2-97a4-4ddf-ba1c-ede279cbcae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dc1996a6-5af5-4790-92b3-bf4653cfe783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e20810db-824c-4b6e-aef6-6aad0885a137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e2f01c6e-2c71-481c-920d-0563fd77c7f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="C_e34ee022-7881-4415-9223-49c1cc144b97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e5502035-9c62-4bfa-b75f-04b8934fb13b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5529578-cb7f-423b-ae3c-3d4cbfedbb24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:LizBhattMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e7f2b074-5874-4a74-ac56-9ee225b000cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <startDate>2024-10-18</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="C_e999414c-e45b-4680-8108-7315ee154945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ea277975-b2f2-4b8a-b194-b83995f01006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:InitialTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_edbd8258-cfdd-447f-8899-e8bf5ca401c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ef8945b7-cd7c-40a3-87d4-443fa84b4251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f01b0a9e-0bec-4e73-87b2-511f0f3402f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f4c23b37-5cfc-40da-a0d2-d57dcfb5120d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:RaCapitalManagementLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f57fea07-b224-42ba-828d-12e6d48e58e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneAndTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_f65b9339-0f3a-4b2a-8936-a9b7e8f4f353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f8051df8-6f74-4da2-9664-e548022686e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fab764e8-30d4-4a5a-8352-b6d7d8e5c87b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fb785e0f-2bdc-4e89-ac3b-e5d3f8322c6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_04565b03-4afb-406b-9060-3d79c752b374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_04ddd023-f899-4392-8195-43ee327ecc9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneAndTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_07465302-3c57-4c51-8649-8a24eb806c09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:CombinedLicenseAndResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0baed1d2-4492-4d81-b9ab-a87043b82d59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="C_0d155a10-3368-4e21-9ede-8d1675cae5c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0fbb9c90-762c-43f1-b17f-96b2e4b4c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_124207ea-9553-4036-b32d-b292d0dd4f7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_12930a8d-66c5-4c50-9202-0f635796fbca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_12bf748d-8c8f-43c8-986f-7e62abb1f3b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:SamsaraBiocapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_13a6815f-57a4-459f-b517-409e1abf0033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_14b12819-68bb-4fc2-a4a0-9759c3528569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_155d82b1-0c77-4ae4-bb15-deffd6d81ad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_15ee37b0-5f7b-4d77-b60f-a12687d07532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_188353cf-4494-4271-90fa-2b494b9ce37b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sepn:ResearchDevelopmentProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1966a14f-61e2-41d4-a6ff-47aa4fad01b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_1a5a03ec-3b78-4b4f-984f-9c02f37f3f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:SamsaraBiocapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1b93ff37-5094-4c86-95d8-dcd363b7feca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1c50a455-abd2-40af-bc2f-471cb232f201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20efa5c4-f0f4-4871-a51a-f97b96ba7528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_26b3acdc-a041-414e-a35d-958f1caf4710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_29cc3ec0-ed7a-4862-b908-992644953c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_2ca0b610-feb1-4fc4-9fb6-285c278593cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2f1fe350-b8c7-4223-a96e-9534890d1439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_31980d7f-00b5-4148-b37d-689b558648c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_319a9d87-f6e6-4839-a984-753a05d06533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_31b3e28f-bc58-4c85-9b5a-81f738157245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_322b3bab-f26e-4ef7-b671-7788690ea969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_322e150f-75d2-4c33-a81b-00ef3a3995d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_32ee6c26-363c-447f-b284-d18487b21d59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_36e0e89a-7c81-4296-9fff-19f854f1ce13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_38782ba4-4fa6-40c7-934f-d3a079936095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_388d86f8-b34d-4f0d-9ce6-8aae94db4af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_398ed5f7-f194-4e12-ab54-8894f63345b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39947422-5330-41f2-b716-f2d784c2e0cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3b25f05e-0de5-4de6-9e95-c302e515b95c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3cba6681-4177-41a6-98a7-0683daf19bf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3cfa7cb5-0ba6-432f-9236-d31d63d2d6b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3dd767cf-b320-4070-b5e9-d4aef8502c4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3f36de4b-8700-4f6c-bc71-ae1a9dc8ff7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4012e7ef-84ff-438a-9d21-608b4581ba16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeAndNon-EmployeeStockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_43471eb0-1ae4-4188-8890-d5649bb442c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_43f43b58-1c3c-4c77-a255-d8e27eb71c5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_451917b5-3692-415a-a8fc-e2773e3c5ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4586a8d6-90a1-4f22-a91e-ed46c95e215d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_45f515bf-1005-4082-bc32-9ade4315528d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_4856f235-0b67-45f9-87be-48a2c2e0e5a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4ce5aad8-c86e-421c-9386-a0a475a3e0cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4d8fbc94-ff88-4825-9417-f0e8f0e8e33a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:RaCapitalManagementLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4dd9f47b-1fb7-4754-a5f2-2c832537c007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4eecc548-826c-47a9-80f2-d64a0e8b8074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4fac1b78-8311-432d-aff9-c804f3132070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_50876280-ce05-4b2f-a74c-aab5ab966a93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_53a67097-47c1-490a-8b40-0541279b1af4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sepn:VertexResearchServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_55101ae3-0a3e-4d43-a901-c61588a76992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_572956ed-3133-4ecc-8cc8-1ffe3b8330b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_5bc6c479-79c8-4152-9bfc-76c56f1b6c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5e52f314-36a4-4891-b35b-86b9cc4844f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_60266656-e390-427d-9798-309361aca6dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_605171e8-8b01-43d7-a003-6089b7762a8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_61651a61-4b9e-4a51-a5f6-c5b66b40d36c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_62168868-0203-4750-a338-01cfd04ab7de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_62d33bbc-a9d1-4e0d-b374-febca2f135b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6336c77b-4ec0-4b5a-bb48-f2f824e6b90e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6351b22f-2be8-4ebf-a536-1da1776a2f78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sepn:ThirdRockVenturesViLPServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sepn:InterimChiefMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6646c47e-b885-4673-91f4-70ca9e64299e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_66e5c4ac-4b2d-4683-bb29-b0c9430f9075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchasePlan2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="C_6779c8bc-bf3a-4123-b629-4da74d3cadda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69798fd2-c3f2-4367-9df7-974806f034ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2024PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6babc3f6-8967-4f07-bbd1-1345bb333060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:Stock2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6c210c25-1bfe-4528-904c-2b7a7741e679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6d0ae500-5d31-4464-8a21-1873d26e4998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">sepn:AccountingStandardsUpdate202507Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6ec0577b-0a29-403d-97f4-adea4205df16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sepn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchase2024PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_718c5e70-92f5-4610-80c7-d02725f7db49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_718c7a03-3168-40d9-845c-81b6ea2dc196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_71f726e5-b69b-43a5-9553-9360762a27cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_76244c83-b690-42fd-93b3-51188d2e836f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7629b057-ea4b-4ebf-80e6-83afecdacd5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sepn:LeasedSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_76c0e442-ab86-41b5-ab70-7fb7e89c9db2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sepn:SamiraShaikhlyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_79b1f183-8e7f-4be0-a70d-a466859c1d3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sepn:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sepn:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_7ab5629f-2853-4b6b-ba19-5748e1822866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_7bbf537c-2701-4b45-969a-1f72cf64e583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sepn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sepn:EmployeeStockPurchase2024PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7f97baf0-9093-442d-82b0-a802ec9a04a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001984086</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sepn:NovoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Position">
        <measure>sepn:Position</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_8f9ea807-794c-4777-9a46-3a60232a5cd5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_87dcc3df-b443-4e09-9eab-dd08d07551fe">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_b85ac4cb-e129-4694-8025-6f87e7e2d8a2">0001984086</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      id="F_b8ad14a0-c1e3-48c5-855b-31addb820eb6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      id="F_b4a2dcb4-49e4-4ea1-b88c-386a51c040ce"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      id="F_1edf648f-796a-4d0b-aa2e-b021bcd9a7ee"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      id="F_1db7472e-771e-4c85-b753-944c6e60f5ad"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      id="F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_faecfa98-652d-4cca-94de-7a02c3297ab7">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_b8efe224-c188-42df-a41c-9d6bf32284b2">http://xbrl.sec.gov/country/2025#US</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_98796e35-84d1-4118-beeb-8699391f3ba9">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_88b5bbf2-a487-4712-b248-6ddb8819e78e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_fef408f8-6738-45f6-abc3-6341ac68949f">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_1c19b9eb-7b89-418a-b96e-7a8755fa1e1c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_cb143847-e506-43b9-9244-97520ed6bcdb">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_c8920cf7-5d20-4361-b6c7-bd8c55b8532b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_24bc474f-96a8-4576-a230-efa1079313cb">001-42382</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_d937af30-3e04-49e4-bc70-b7eb00f98fcb">Septerna, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_2db3c003-eb5a-4c67-bea5-ce85b4fe61c8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_928dca82-5da2-4805-936c-2dee784fca68">84-3891440</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_b8dbd03f-454c-4d82-9c22-f6fff6017efc">250 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_5b6b1859-1b90-4721-854e-cf943eebfb13">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_6d727ef5-7296-4282-bb4b-a233128593a5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_28bd6a5a-5262-4386-8ea3-8861a56e738a">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_fd874455-ab68-4a59-96ac-76ebb755f360">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_38174ef4-c12f-4f3f-a078-f383794608fd">338-3533</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_011b4661-b8aa-487d-bf40-1e5343032f25">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_7b3b0a3e-6916-4758-ad55-d0a873f00286">SEPN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_bc73c716-290f-46e7-9353-cad053852bc5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_8d7146a9-5f94-45f3-8755-51c573624fcf">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_6e9bdedd-173b-4b1c-91d5-8b95dcd20507">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_659789c5-cc28-4802-a8a3-007000bc7ec2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_7e90fb55-209b-4a6d-85ff-44ae9d7cd46a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_2beb7a86-a635-4ae0-92b3-0b5e16c50cac">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_c391a931-48c4-4147-b057-90c502760f47">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_ab0de347-68cf-4fc4-b364-7283bebe505d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_09bf6857-2192-42a5-ba20-1e855580c4e8">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_8b32b639-fd4a-4b2a-bbb6-1fef77dc659b">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_22fa8b98-66f3-49a1-bccd-615d4a775629">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_0f9bee74-0a81-4fcd-afaf-b20ef9b7ec46">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_a16a30b4-7855-443e-8e8c-93eee3c5898a"
      decimals="-5"
      id="F_bef0b64d-4c03-435d-8f70-ba73c24f8645"
      unitRef="U_USD">363300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_925590ce-df4f-4dd8-8abe-e9865066e1a9"
      decimals="INF"
      id="F_29661fb4-0b26-4041-b893-c122bf888c5e"
      unitRef="U_shares">44906374</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_e0a1ade7-c6fd-4109-a29f-3b32653ba419">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_059e3ba8-cf14-487e-8c88-78e40a1e95e6">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented a cybersecurity risk management program in accordance with our risk profile and business size that is informed by recognized industry standards, including elements of the National Institute of Standards and Technology Cybersecurity Framework and International Organization for Standardization 27001 Framework.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is comprised of a number of components, including but not limited to written information security policies, external cybersecurity risk assessments, and system monitoring. We also have an employee privacy and data security training awareness program that includes cybersecurity risk awareness trainings and phishing campaigns. We maintain an incident response plan to help guide our response to cybersecurity incidents.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We leverage the cybersecurity services of third-party vendors, including a third-party managed services provider and IT consultants, to support our cybersecurity risk management program and assist us in conducting external cybersecurity risk assessments. As part of our cybersecurity risk management program, we take a risk-based approach to the evaluation of third-party vendors. As part of our vendor diligence process we require vendors with access to our information technology systems and infrastructure to complete information security program questionnaires.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;However, like other companies in our industry, we and our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vendors have from time to time experienced threats relating to our and our third-party vendors&#x2019; information systems and infrastructure.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; For more information, please see &#x201c;Item 1A, Risk Factors.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance Related to Cybersecurity Risks&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#x2019;s general risk oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#x201c;IT&#x201d;), and is responsible for the strategic leadership of our cybersecurity risk management program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Head of IT relies on both internal and external cybersecurity resources to manage and remain appraised of overall cybersecurity risks to our business and our industry.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_7e39c6c2-d064-4334-88d1-d80aa6036ca9">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_dccd0c2e-f8f4-4ac3-a42d-b57cf5457f8e">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_87e1c4ae-8069-4aa8-b884-e8eaaa4d352c">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_ea59504a-cf36-43f9-b13e-2aed18356821">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance Related to Cybersecurity Risks&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#x2019;s general risk oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#x201c;IT&#x201d;), and is responsible for the strategic leadership of our cybersecurity risk management program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Head of IT relies on both internal and external cybersecurity resources to manage and remain appraised of overall cybersecurity risks to our business and our industry.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_45cd0564-8214-4fa1-96bb-5ae51c20129a">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#x2019;s general risk oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_4db0f61d-2099-482e-9620-145195999ea1">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors has delegated cybersecurity risk management to our Audit Committee as part of the Audit Committee&#x2019;s general risk oversight function.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_b9f44453-916c-4646-8449-3a6da8360567">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, through the oversight of the General Administrative Leadership team, is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_60ab5640-9dd8-49bd-9f84-3928625f043d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by our General Administrative Leadership team, which consists of our CEO, CFO, COO, CPO, CLO, Vice President of Finance and Business, Vice President of Technology and our Head of Information Technology (&#x201c;IT&#x201d;), and is responsible for the strategic leadership of our cybersecurity risk management program.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_3f96e871-6d2a-415b-8781-d7adbb0b5ca4">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Head of IT, who also serves as our Information Security Officer, is responsible for the day-to-day management of our cybersecurity risk management program. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The individual who is currently in this role has over thirty years of experience in information technology and cybersecurity risk management.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_a2f8b022-8114-415d-9ea9-3cdaa9dfd2e5">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_2ef30887-4bf6-4db8-a9b8-4853c1d76ca6">&lt;p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The General Administrative Leadership team provides regular briefings regarding cybersecurity risk and related matters to our Audit Committee.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Such briefings may include a discussion of cybersecurity risks and applicable risk assessments, key updates regarding our cyber strategy and related initiatives, and the emerging cybersecurity threats that may impact our business. We also provided the full board of directors with updates on matters relating to cybersecurity risk management, as necessary.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_c26337c2-6791-4f00-b070-ab1430a86c79">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_2b6aaa43-d18d-43b7-a9ab-515fd9a00197">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 Trading Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 20, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liz Bhatt&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, M.S., M.B.A., our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;President and Chief Operating Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Ms. Bhatt), which plan expires at the earlier of January 15, 2027, and the date upon which all authorized transactions thereunder are completed. Ms. Bhatt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Samira Shaikhly&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief People Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109,206&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Ms. Shaikhly), which plan expires at the earlier of October 30, 2026, and the date upon which all authorized transactions thereunder are completed.  Ms. Shaikhly&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended December 31, 2025, no other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) of the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;modified&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or a &#x201c;non-Rule 10b5-1 trading arrangement&#x201d; as each term is defined in Item 408 of Regulation S-K.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8"
      id="F_e6ca7103-79c4-4a0d-b893-8ab1ed9285d9">October 20, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8"
      id="F_9414c45b-5fb1-4044-bbb0-d1569fcca814">Liz Bhatt</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8"
      id="F_0be01cad-2ce6-4726-886d-de4af0b04d26">President and Chief Operating Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_be8d8b12-b30a-456a-a8dc-296c7e5519d8"
      id="F_d819fc81-922f-41fa-9f2f-d2e91f2e193b">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_e5529578-cb7f-423b-ae3c-3d4cbfedbb24"
      decimals="INF"
      id="F_0958cc2e-79c6-432c-a696-09e45d2ff5f6"
      unitRef="U_shares">41000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrAdoptionDate
      contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a"
      id="F_77334444-0a0b-4da4-aa8d-a1b5f4332db1">October 31, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a"
      id="F_5e6cf68d-6d7c-4927-b838-be61e9265ca5">Samira Shaikhly</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a"
      id="F_4ea7dd9a-c213-4a94-9d55-e78482520c25">Chief People Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_c800dc65-a3df-4be9-b13c-6170777fad6a"
      id="F_f1b9fdb6-22d3-4bc6-bfa2-5b5d2adcd519">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_76c0e442-ab86-41b5-ab70-7fb7e89c9db2"
      decimals="INF"
      id="F_6705a7b4-96a1-4b01-beed-597cc4cc7676"
      unitRef="U_shares">109206</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_3aa8bd89-dcbe-495e-a09f-fd03a16a1706">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_a8596a05-6da5-4a4d-bd37-2abb564f9e14">false</ecd:NonRule10b51ArrAdoptedFlag>
    <sepn:Rule10B51ArrModifiedFlag
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_d0874ef4-216c-4d37-a089-94e358695568">false</sepn:Rule10B51ArrModifiedFlag>
    <sepn:NonRule10B51ArrModifiedFlag
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_bc93741e-e7e0-4a68-b416-95c4f425fdf5">false</sepn:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_baa97e75-f638-4cca-a6c5-59059342872a">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_82ed9a58-9067-49d5-bf77-47a022e4ad30"
      id="F_bddcdd08-7f4e-491e-bfa3-513e5974df62">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_7946e69d-df28-4622-bc7b-199a5001c0d5">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_660bfb59-64ce-4d3d-9250-4527b2f8394b">42</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_f09b134c-3d81-4200-b54e-986498a72370">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of Septerna, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_b0f66161-0801-4bfa-a1d6-5716b9b7b915">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_6b0e0d24-d1ef-4c78-a6bf-7e2c72c0306f">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_acf4930c-ca83-4eca-9553-deddc08d7447"
      unitRef="U_USD">120722000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_5c33a08d-7ac7-4557-9143-52ff84da6bc6"
      unitRef="U_USD">238196000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_803383c6-132e-4d87-9d1e-2a29b13e409e"
      unitRef="U_USD">270367000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_ba95a5e9-e45f-4c21-8c09-99a739d8d292"
      unitRef="U_USD">112727000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_020b32e2-bdc3-483e-b100-4c6063d29320"
      unitRef="U_USD">10356000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_43c3154f-b0f5-4a15-a438-996fdc03fe92"
      unitRef="U_USD">171000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_970cc211-3caf-4987-9d35-3e1270cf0f35"
      unitRef="U_USD">9519000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_68e5f615-352c-441d-a280-0ed58fb3ad0f"
      unitRef="U_USD">5730000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_8fa3ad85-2174-468d-9d71-ce97a60c3791"
      unitRef="U_USD">410964000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_2d581683-3261-48db-bf21-3637b88221cf"
      unitRef="U_USD">356824000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_10b0b6c9-f777-4717-ab2e-eb7ab9ddc795"
      unitRef="U_USD">157569000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_73c85c6d-ca82-4087-8014-5b72f37e5098"
      unitRef="U_USD">69866000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_8b7e8a2b-c5d6-4f70-9caf-56a8644e656a"
      unitRef="U_USD">4434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_b115ceb9-b47b-4a71-9f3e-7ac8bbf66617"
      unitRef="U_USD">5090000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_f6475836-2ca9-4bf1-aad3-b5e018884b04"
      unitRef="U_USD">21499000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_aa8c6e7f-5f84-446d-9e7b-1b54aca36463"
      unitRef="U_USD">23602000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_44b41123-67c7-47db-8a3d-0f35136618ee"
      unitRef="U_USD">905000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_93bfb6d4-0811-40d3-822d-b1fb207866d2"
      unitRef="U_USD">905000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_ed568a99-ab9c-4438-8709-4c403abccf0d"
      unitRef="U_USD">816000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_a1b27dd2-02cf-4f2d-9258-93a2dbee11e3"
      unitRef="U_USD">267000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_94d7f6f9-612d-48a3-b159-52102bad45b7"
      unitRef="U_USD">596187000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_9b6b1de0-69b6-4a54-bf7c-54bbf29ba067"
      unitRef="U_USD">456554000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_8a09f0e0-b6ca-4763-b977-4638edc5494c"
      unitRef="U_USD">10283000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_a47b5f28-93ef-43f3-92d5-3c8354b4e83f"
      unitRef="U_USD">3200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_0003953d-4cc9-48dd-adb9-c2a736d74cf4"
      unitRef="U_USD">12167000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_2f902761-7206-4ece-8bf7-4aff6e505b84"
      unitRef="U_USD">7798000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_741c1dfd-7aad-4097-9f8d-0c48fc8506e9"
      unitRef="U_USD">62269000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_a56bd882-8043-43cf-a435-1beb427a365c"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_93861c93-92eb-42d4-a05e-9c3cd79e343f"
      unitRef="U_USD">2212000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_b9eaba3a-b43e-4ca9-904c-ffc00bfc79f0"
      unitRef="U_USD">1851000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_c1c3cd91-f131-4ad2-9ce9-c2611a14404b"
      unitRef="U_USD">86931000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_70ad7a51-7136-4775-83ed-384b55b1d7e4"
      unitRef="U_USD">12849000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_99f1eff6-b36e-4d2b-a860-0563ddae30c4"
      unitRef="U_USD">105917000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_4f8b2dee-01d2-4bd3-975d-69154b49b7b5"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_c4f15690-b52b-49a9-9d23-4f72cbd5b148"
      unitRef="U_USD">21413000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_47769dbf-fa49-4a58-a3a4-5b05d70fad8c"
      unitRef="U_USD">23625000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_e59bf442-9b10-4e44-804f-b47673321989"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_bfbd177b-a215-4a0f-b506-4b5e6aab3fc3"
      unitRef="U_USD">33000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_54fb2b0b-8aaf-48b6-8e2d-b3b7f329ac80"
      unitRef="U_USD">214261000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_3b405203-fe41-4cfd-a40a-22b8f3b16479"
      unitRef="U_USD">36507000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_6e847c6c-4fc9-458a-8f45-12139e20dcba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_2e56a17d-5c29-4bf9-8c27-d2944911b81e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_9a9bbb8c-ae80-41b0-b7e2-d2d2796fb8e7"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_a2502d80-7943-4c50-8e8f-412dda0d5df1"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="0"
      id="F_8629a021-7243-4a0f-aef9-0e87416da2a5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="0"
      id="F_c483f94a-dde5-46b7-8cd6-d92e8ab41274"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="0"
      id="F_6993f7c5-aa47-4e91-a559-5fcf200b944e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="0"
      id="F_8652078a-736b-47f3-8995-239194bf6c7c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_76af0a0e-66da-4521-89a5-9f14e18aa816"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_3a2fdb13-6c04-4a28-98f7-41b3505014d3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_1771f1d8-c878-4105-bc6d-1686dd281d48"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_02304057-5e80-4dcd-a943-b5cf1c15563b"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="0"
      id="F_735762cc-2505-4997-a0a5-a350b5c92cf6"
      unitRef="U_shares">44806272</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="0"
      id="F_123235ac-6527-475b-876f-3ae07e1abff4"
      unitRef="U_shares">44806272</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="0"
      id="F_57a4f1bb-d55c-4d97-ae21-cf440607a4bf"
      unitRef="U_shares">44422505</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="0"
      id="F_17cb09c7-1559-47bb-ac8f-5aca38940e9d"
      unitRef="U_shares">44422505</us-gaap:CommonStockSharesIssued>
    <sepn:RestrictedStockOptionsSubjectToRepurchase
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_baedc257-8ffd-48cd-9c36-401706a0c03b"
      unitRef="U_shares">131224</sepn:RestrictedStockOptionsSubjectToRepurchase>
    <sepn:RestrictedStockOptionsSubjectToRepurchase
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_e5654125-5499-4d59-98f5-c2db44db70be"
      unitRef="U_shares">576829</sepn:RestrictedStockOptionsSubjectToRepurchase>
    <us-gaap:CommonStockValue
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_3c889f7f-0a2d-4383-b0b8-97fe43683739"
      unitRef="U_USD">45000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_f6a8fee0-b52a-41ab-ad6e-9db04ff47e31"
      unitRef="U_USD">44000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_37fc9ef8-f656-497d-82d3-7efd09d2e665"
      unitRef="U_USD">548517000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_22c8996a-c057-4aa5-8d43-24371b8e4a82"
      unitRef="U_USD">538321000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_6d8a215e-c9ac-48a1-a147-0833fe6085b6"
      unitRef="U_USD">617000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_c1dbe982-0055-48b9-8c71-518458e0098f"
      unitRef="U_USD">56000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_b6a730cf-3943-42c4-9b38-84a9f7dfc6f5"
      unitRef="U_USD">-167253000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_00c0cb93-96d9-40a9-93e1-af62582a3c73"
      unitRef="U_USD">-118374000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_a739cdce-2cfa-4af3-bce2-6e8d6815253f"
      unitRef="U_USD">381926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_320e6421-5cc4-4965-b5c7-00df6e43c0d3"
      unitRef="U_USD">420047000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_1401aa07-7540-469e-9523-833550252cc1"
      unitRef="U_USD">596187000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_84e3e758-e7b7-4e53-9223-93a48d25562b"
      unitRef="U_USD">456554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_30789f73-4870-4e8c-a5ec-32eb8b630ca8"
      unitRef="U_USD">45951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_92583c8d-040d-47c1-9d9d-ec6e8732baa1"
      unitRef="U_USD">1075000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_16621812-e1a4-4b98-aaa3-da40b05aceb4"
      unitRef="U_USD">97584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_ada3a216-1f5e-4489-8273-2047dd78ec67"
      unitRef="U_USD">65337000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_e3e8ef15-85d2-4dde-92c1-00e7df543122"
      unitRef="U_USD">29164000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_22bb0fcd-1b90-40da-b751-04b01b55100e"
      unitRef="U_USD">16561000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_c8b50311-dab3-497c-a00d-ec284f7285ae"
      unitRef="U_USD">12500000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_5e352f7c-744a-40ad-bdae-5cd9ca20af61"
      unitRef="U_USD">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OperatingExpenses
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_9f85bca6-cda6-4cd2-b28a-37b573ca59dc"
      unitRef="U_USD">114248000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_2c6d2c16-a9b8-444c-b15a-0b0c179efee5"
      unitRef="U_USD">81898000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_bc4cbc55-efa3-47b8-863f-54e8877f3d69"
      unitRef="U_USD">-68297000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_7fafe3ae-2b35-4072-accb-17642d78ed21"
      unitRef="U_USD">-80823000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_b827d23c-1560-4d48-a0c2-fa0b8363a244"
      unitRef="U_USD">19530000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_27561eca-73dd-40f6-a08c-936d6dc12cf1"
      unitRef="U_USD">8617000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_d9a71ff3-51da-49c5-b67a-5cab83e6c1b0"
      unitRef="U_USD">-100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_9c29cb9a-79fc-474d-b1e7-1d37a121ccd2"
      unitRef="U_USD">-90000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_de8df4e2-fa67-4180-8b4d-59db7d7f97f8"
      unitRef="U_USD">19430000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_390fd8f9-82ab-4568-9777-987bd1a790b9"
      unitRef="U_USD">8527000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6336c77b-4ec0-4b5a-bb48-f2f824e6b90e"
      decimals="-3"
      id="F_ba35d45b-dbc1-446f-88ad-b5a205315855"
      unitRef="U_USD">-48867000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_0fa87c4f-d90e-4876-aa42-d6417dc3b50f"
      unitRef="U_USD">-72296000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_a4f098a3-c274-4d15-a38e-67bbf813c5d5"
      unitRef="U_USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_4d7be666-ee9f-4a2e-904c-9aa06a66bb10"
      unitRef="U_USD">-498000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_9389cdca-8c4c-4854-851b-1bbdac393278"
      unitRef="U_USD">-48879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_9796c77a-2ec6-4c90-8edc-be86ac89d654"
      unitRef="U_USD">-71798000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_72a960ca-292b-4634-9ad9-874290efd535"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_9f820c81-7b9d-43f4-b896-4c21b77312c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="2"
      id="F_a2d0f1d6-4baa-4081-ac71-519a46610a60"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="2"
      id="F_66f67dbb-fa03-4e76-b517-f37311a0a0d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="0"
      id="F_d4ead10c-abac-4a74-8172-c085009defd0"
      unitRef="U_shares">44258338</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="0"
      id="F_a1adea1b-f354-4e4d-9b51-528964dc3f39"
      unitRef="U_shares">44258338</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="0"
      id="F_697190e6-7e80-4358-9040-6167d0128b20"
      unitRef="U_shares">9891126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="0"
      id="F_823fe17c-8f0a-42df-b5eb-f10e7f82d83f"
      unitRef="U_shares">9891126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_49be5273-1aff-473f-a094-fa0dc96b2dca"
      unitRef="U_USD">-48879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_cdc702c1-f7f8-465f-b2e5-b1e27ecc1015"
      unitRef="U_USD">-71798000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_63a85641-24e1-4c05-b894-6a4a000a4d2f"
      unitRef="U_USD">561000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_7c6e4bcd-e938-4c3b-a706-1ffce953e367"
      unitRef="U_USD">56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_c69ba1ba-1425-43e6-ae0b-3a6c12918f45"
      unitRef="U_USD">561000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_d1a9c46c-9600-4bf7-80f0-7e25aaaaa2ee"
      unitRef="U_USD">56000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_9dc07d8f-5d9d-46e2-9682-65af4a3cd06e"
      unitRef="U_USD">-48318000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_24abbbf3-a407-493d-9329-51b266d8c40a"
      unitRef="U_USD">-71742000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_d4bd1786-5f2f-4271-a5d8-e93f78bac79d"
      decimals="INF"
      id="F_34afe894-fed7-4e50-9bf5-d42a078b8258"
      unitRef="U_shares">75000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_d4bd1786-5f2f-4271-a5d8-e93f78bac79d"
      decimals="-3"
      id="F_ba509a06-840f-452c-a438-05f4a592a573"
      unitRef="U_USD">74694000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_a706c6c6-3f56-4dc2-a361-8d8d19beee7f"
      decimals="INF"
      id="F_9d08cc37-035d-433c-8363-575bbbf071b3"
      unitRef="U_shares">60828720</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_a706c6c6-3f56-4dc2-a361-8d8d19beee7f"
      decimals="-3"
      id="F_60803c4b-0948-41d7-a7ff-9ca3522aeb73"
      unitRef="U_USD">74521000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6"
      decimals="0"
      id="F_02f3e3b9-983c-4741-861c-0811cbdc70e0"
      unitRef="U_shares">3168134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_09a2fcf3-45bb-4f80-935c-d22e76a4e4c6"
      decimals="-3"
      id="F_82412867-2ed1-4c61-9edc-a37fdba56162"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_718c5e70-92f5-4610-80c7-d02725f7db49"
      decimals="-3"
      id="F_a468f743-2b10-4394-ae24-167706eb2005"
      unitRef="U_USD">8199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e20810db-824c-4b6e-aef6-6aad0885a137"
      decimals="-3"
      id="F_17eb239c-bb88-4b5d-9f12-7c3f7c5577a6"
      unitRef="U_USD">-46576000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e5502035-9c62-4bfa-b75f-04b8934fb13b"
      decimals="-3"
      id="F_7c69a19b-941d-4505-ab2d-c086499a7260"
      unitRef="U_USD">-38374000</us-gaap:StockholdersEquity>
    <sepn:StockIssuanceCostsOfConvertibleSecurities
      contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f"
      decimals="-3"
      id="F_a4dcc26f-42e4-493c-94d9-48ba362d5ebb"
      unitRef="U_USD">58000</sepn:StockIssuanceCostsOfConvertibleSecurities>
    <sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f"
      decimals="INF"
      id="F_fe358f37-df2d-444d-b22d-076d8fb30dc2"
      unitRef="U_shares">60828732</sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f"
      decimals="-3"
      id="F_8be3da2b-3e92-49db-82d8-6970a4cf1d72"
      unitRef="U_USD">74942000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_bec2c5bd-26fb-45e2-b7fd-c7e78e0c918b"
      decimals="-3"
      id="F_a191bb0b-1d16-468a-8586-cbc031d8077e"
      unitRef="U_USD">28431000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"
      decimals="0"
      id="F_4c526744-e7fe-406a-ab92-8673b7184139"
      unitRef="U_shares">18400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"
      decimals="-3"
      id="F_a816e1c2-18e4-48eb-a0ff-131ad5059374"
      unitRef="U_USD">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6"
      decimals="-3"
      id="F_15dcfc19-f89e-430d-a280-3c5a21d39854"
      unitRef="U_USD">302749000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_cd022d9f-1b47-4c10-9acc-3fc50d368692"
      unitRef="U_USD">302767000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares
      contextRef="C_d5287ebc-ed11-4be9-a9a2-49a7065ae6fa"
      decimals="INF"
      id="F_eb456c17-2242-40b6-8ed2-e5741c05b9a3"
      unitRef="U_shares">75000000</sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares>
    <sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock
      contextRef="C_d5287ebc-ed11-4be9-a9a2-49a7065ae6fa"
      decimals="-3"
      id="F_373a4261-d1da-4f6a-9c49-7f320581c57e"
      unitRef="U_USD">74694000</sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock>
    <sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares
      contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f"
      decimals="INF"
      id="F_6282d11e-23a0-441b-9dca-17ee13b4248d"
      unitRef="U_shares">121657452</sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockShares>
    <sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock
      contextRef="C_8213da3e-71aa-4154-b70b-40d696bee78f"
      decimals="-3"
      id="F_5db28503-09ae-4ddb-a6d7-3cda96b0b877"
      unitRef="U_USD">149463000</sepn:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"
      decimals="INF"
      id="F_59a59132-c704-479c-a7b3-c0fdc84cfb6c"
      unitRef="U_shares">22839774</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"
      decimals="-3"
      id="F_f8fbaeb5-2715-46b6-9e4b-3015c1e3e4fe"
      unitRef="U_USD">23000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6"
      decimals="-3"
      id="F_b6fba5e3-d309-48bf-8c8f-e66250a88765"
      unitRef="U_USD">224134000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_2ada6e7f-f82a-429d-a4b6-ac7f3089cfc6"
      unitRef="U_USD">224157000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"
      decimals="0"
      id="F_a4164e9e-e534-411e-bca1-0e03eb702e3c"
      unitRef="U_shares">28896</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6"
      decimals="-3"
      id="F_deccab53-5119-44e7-8c37-cbcb59225dba"
      unitRef="U_USD">66000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_b01373dd-1a95-4a69-8043-d71150bd2d1a"
      unitRef="U_USD">66000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested
      contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6"
      decimals="-3"
      id="F_e5252e96-7f7a-4a65-a5de-f100bde373b3"
      unitRef="U_USD">21000</sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested>
    <sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_184ec5ac-a063-4c52-9356-b91292b93e8b"
      unitRef="U_USD">21000</sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_d3178c1c-683c-48d3-a2da-f4f9e728fd62"
      decimals="0"
      id="F_01a11ae5-e9c1-49e8-901d-c260c82b8c60"
      unitRef="U_shares">14299</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_234c0c66-34e9-4a32-b2ec-28499b69f1c6"
      decimals="-3"
      id="F_41d27d2e-4f9c-4a9e-8cff-5121aea8b38c"
      unitRef="U_USD">3152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_854ad16f-1b38-4bbc-8f51-c0bd54f29a64"
      unitRef="U_USD">3152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_3cfa7cb5-0ba6-432f-9236-d31d63d2d6b4"
      decimals="-3"
      id="F_5443f7ad-b997-4902-9d63-8d7c1a02e818"
      unitRef="U_USD">56000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_33915922-2f95-4dd7-b007-adfe6c6cbd09"
      unitRef="U_USD">56000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_04565b03-4afb-406b-9060-3d79c752b374"
      decimals="-3"
      id="F_f5dba921-bf71-4aed-b013-24e86d340e52"
      unitRef="U_USD">-71798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_08ce23ae-3d59-46f9-8445-b6c37f964fb4"
      unitRef="U_USD">-71798000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c"
      decimals="0"
      id="F_8ba27b92-da0c-4734-95d9-25985cf8e307"
      unitRef="U_shares">44422505</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c"
      decimals="-3"
      id="F_de992ec3-27eb-44a0-85ae-94e6ce4568cf"
      unitRef="U_USD">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_909026b5-982c-4acc-89af-ef9bf4949a1b"
      decimals="-3"
      id="F_5f0eb2a9-db44-45e1-b1ef-a6927d09b847"
      unitRef="U_USD">538321000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_451917b5-3692-415a-a8fc-e2773e3c5ae4"
      decimals="-3"
      id="F_b3584f71-d14e-490e-a9fd-bc25eca600a5"
      unitRef="U_USD">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4eecc548-826c-47a9-80f2-d64a0e8b8074"
      decimals="-3"
      id="F_a84c8abd-201e-40a5-a52a-36c205f585c8"
      unitRef="U_USD">-118374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_7201fd8d-0a67-4614-90e6-500cd41399bc"
      unitRef="U_USD">420047000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad"
      decimals="0"
      id="F_553b952d-aad7-43ec-8020-486c8041b922"
      unitRef="U_shares">268188</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad"
      decimals="-3"
      id="F_d6056667-97ab-4f05-89fa-831ba0f7201c"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4"
      decimals="-3"
      id="F_8e77ad29-8dd7-4e73-a26c-057eed7aba73"
      unitRef="U_USD">981000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_148da0e0-35bc-48e5-ac4d-0f7fb8d8d8ac"
      unitRef="U_USD">982000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad"
      decimals="0"
      id="F_1c9e8322-86fa-4faf-9362-2fbc30b701a9"
      unitRef="U_shares">118191</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4"
      decimals="-3"
      id="F_12b9e3ba-a195-48fc-b089-19991e1eab8e"
      unitRef="U_USD">717000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_03ea6125-f599-455e-bfde-388e0d37ecb5"
      unitRef="U_USD">717000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested
      contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4"
      decimals="-3"
      id="F_fd51cc63-b14d-4f2b-91da-77634a329fc6"
      unitRef="U_USD">23000</sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested>
    <sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_96291cdc-4a79-46e0-a80c-231cbac6ebc9"
      unitRef="U_USD">23000</sepn:StockIssuedDuringPeriodValuesRestrictedStockAwardVested>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_8115a838-2092-4741-a82f-c5a56ba848ad"
      decimals="0"
      id="F_71035690-5732-45fc-b162-62d0528ea670"
      unitRef="U_shares">2612</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4"
      decimals="-3"
      id="F_d5a91e74-3013-4160-95f9-86abac150f2b"
      unitRef="U_USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_3d10b529-bfbf-4fdb-bde9-c833a6841426"
      unitRef="U_USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5e52f314-36a4-4891-b35b-86b9cc4844f4"
      decimals="-3"
      id="F_68e5fe4d-4bcc-4c82-95a4-0163b30e5cd7"
      unitRef="U_USD">8476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_dba09ea2-6af9-4e52-826c-99743b7a1da3"
      unitRef="U_USD">8476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_155d82b1-0c77-4ae4-bb15-deffd6d81ad9"
      decimals="-3"
      id="F_5fd60ca5-2775-484a-a2f1-34e319d5138a"
      unitRef="U_USD">56000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_3e93dd72-4a9e-4250-9f45-18437126ca78"
      unitRef="U_USD">561000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_8a9deb64-57ac-4f0b-acec-1f6759eaac45"
      decimals="-3"
      id="F_bcab7922-280d-4b9d-8671-aadf9d0cf336"
      unitRef="U_USD">-48879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_657c3999-c36c-41a3-9b6f-ff494d65b1ec"
      unitRef="U_USD">-48879000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5"
      decimals="INF"
      id="F_2eb40e8e-3797-4549-b5cd-84900068ad92"
      unitRef="U_shares">44806272</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5"
      decimals="-3"
      id="F_dd7055ca-cd16-42ea-a8c4-86b67a8e50ec"
      unitRef="U_USD">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_124207ea-9553-4036-b32d-b292d0dd4f7d"
      decimals="-3"
      id="F_ae267966-6c6e-4a4e-aa4b-43c43534742c"
      unitRef="U_USD">548517000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_975ebf25-328e-4bac-b245-59af615c9971"
      decimals="-3"
      id="F_7171a0cf-d504-4da9-b829-f9673883392e"
      unitRef="U_USD">617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4856f235-0b67-45f9-87be-48a2c2e0e5a6"
      decimals="-3"
      id="F_9878c414-faed-432d-8a83-0188b517e649"
      unitRef="U_USD">-167253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_54e85172-e387-4553-81af-84e04a246747"
      unitRef="U_USD">381926000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_42d5dc6c-8dbc-4c99-91a6-84147298c0e8"
      unitRef="U_USD">-48879000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_ebf24dfb-325c-4ba9-9289-d749a4e99add"
      unitRef="U_USD">-71798000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_05eefdbc-5c5e-4551-95c8-01b0da2ba342"
      unitRef="U_USD">1604000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_4880d0ca-88e8-4bc9-8542-737ba83626a3"
      unitRef="U_USD">1401000</us-gaap:DepreciationAndAmortization>
    <sepn:GainOnSaleOfNonFinancialAsset
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_963e61a5-e778-4d01-9308-93f01348f3d7"
      unitRef="U_USD">12500000</sepn:GainOnSaleOfNonFinancialAsset>
    <sepn:GainOnSaleOfNonFinancialAsset
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_0d8e8910-c7e7-45ea-8466-b44289800052"
      unitRef="U_USD">0</sepn:GainOnSaleOfNonFinancialAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_5b33e889-9759-406b-a881-a2e88c4d2cf9"
      unitRef="U_USD">2103000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_7c02735e-f834-43ca-834a-7bc15ec673b4"
      unitRef="U_USD">1383000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_15b2ea4a-e855-4012-b243-f81c3411dd55"
      unitRef="U_USD">8476000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_2f00bc78-8390-4880-801b-551efead9257"
      unitRef="U_USD">3152000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_defa2793-aba5-4f43-b5ce-bcd5ff275372"
      unitRef="U_USD">3448000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_38af88fe-0825-4552-9e71-c29d44eb4086"
      unitRef="U_USD">1410000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_492a6149-3495-4042-9eaf-c0ba51a5c0fa"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_6437abb5-95b3-4fa9-8f06-a803774503f5"
      unitRef="U_USD">-491000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_b966fd9e-6d30-40c9-811e-0f0bc7a8eb2c"
      unitRef="U_USD">-56000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_d3b16ece-5759-42f7-9465-ec458b1ff7a5"
      unitRef="U_USD">-45000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_2c0721dd-d1f7-4742-b75e-653868ab1a7e"
      unitRef="U_USD">3781000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_85cf5d6a-3765-403b-a45e-4b0ce1ba23e1"
      unitRef="U_USD">4297000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_df322d3f-49a6-4570-957a-d31530bbb4e5"
      unitRef="U_USD">10185000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_f4d47af5-c30e-400b-8c7e-6aabb6db75d3"
      unitRef="U_USD">20000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_3a925f57-3713-4e3b-bc78-56f081d86e34"
      unitRef="U_USD">554000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_8b29a886-2468-455f-9ee8-f5eb63ed1ffc"
      unitRef="U_USD">170000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_6e21606d-b831-4f96-965d-1dfbb5f86b26"
      unitRef="U_USD">6603000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_6caf7157-8813-4c4c-a662-1ab278e59310"
      unitRef="U_USD">723000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_88fc072e-75bd-4772-8b7d-f640432f81cd"
      unitRef="U_USD">4359000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_6168eded-dfdd-48fc-857b-937748714007"
      unitRef="U_USD">3564000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_d2dd59cc-92c0-43d7-83b1-1d345cd6faeb"
      unitRef="U_USD">168186000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_7c0a26ef-97bd-46de-a0b5-63cf3da39299"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_6d93a574-42d3-4cf1-8e4a-b0125d32705e"
      unitRef="U_USD">-1851000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_f3875423-015d-4482-a37f-08bc8a5fca2b"
      unitRef="U_USD">448000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_62c2693e-bf20-4ff7-ab38-b8c8f696cd08"
      unitRef="U_USD">110189000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_37d7f642-e011-4ddf-afa2-5acdeca8a05f"
      unitRef="U_USD">-67470000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_155abb43-1e3e-43ec-b03b-d7924aa9880b"
      unitRef="U_USD">518000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_6d5a4c50-2f7f-4c73-8d6f-e7be35fc864d"
      unitRef="U_USD">2103000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <sepn:ProceedsFromSaleOfNonFinancialAsset
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_4ba28f75-599a-492e-a13a-7dda28430690"
      unitRef="U_USD">12500000</sepn:ProceedsFromSaleOfNonFinancialAsset>
    <sepn:ProceedsFromSaleOfNonFinancialAsset
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_33bbd77a-4cf8-4781-8cf1-2ac8bc318d95"
      unitRef="U_USD">22625000</sepn:ProceedsFromSaleOfNonFinancialAsset>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_c0f2d9e7-f0e5-45c9-ad4a-31ce571b4984"
      unitRef="U_USD">450950000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_cc891813-1560-492a-8d74-f92ea7a05b70"
      unitRef="U_USD">213390000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_528c3b15-5f9f-4cc7-ab7a-4050703d2975"
      unitRef="U_USD">209616000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_b0cda50d-6393-4588-b15c-fa74655f9e74"
      unitRef="U_USD">32270000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_f4fa0195-691e-48fc-9cd7-d4f2c0005fec"
      unitRef="U_USD">-229352000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_db308cc1-0cb1-4650-8cef-77e1996ed654"
      unitRef="U_USD">-160598000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_3a2fe528-e15d-4ffa-a656-05ce1dc172a9"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_8be8c213-1ff2-42bd-b663-271e5691930d"
      unitRef="U_USD">302788000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_69bddcf4-e25e-49eb-8dad-5b37b754db59"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_b4a4e822-7442-499f-b4c9-a3756f062ec4"
      unitRef="U_USD">74942000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:RepurchasesOfUnvestedRestrictedCommonStock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_a8c8784d-38c5-4b7d-b292-dc9694ced6ad"
      unitRef="U_USD">1000</sepn:RepurchasesOfUnvestedRestrictedCommonStock>
    <sepn:RepurchasesOfUnvestedRestrictedCommonStock
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_e2238336-65d9-4366-a009-3afb9c3def3b"
      unitRef="U_USD">1000</sepn:RepurchasesOfUnvestedRestrictedCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_712ec8f7-e46a-4954-98ca-864c970262a9"
      unitRef="U_USD">973000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_f72fa704-9f29-458a-aeab-08769de9ab38"
      unitRef="U_USD">52000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_89c119d0-6199-46e5-88c8-cc84784dc5d8"
      unitRef="U_USD">717000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_4df04974-d9db-4376-8253-288319cf9b77"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_fcc11a6e-6368-4554-badb-c0cee7188421"
      unitRef="U_USD">1689000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_33fcd8ce-427e-481a-9a39-b64cb003e8ac"
      unitRef="U_USD">377781000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_81f4f965-fc9a-463b-a29b-6e9b990de5ca"
      unitRef="U_USD">-117474000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_c4e90265-b111-45d4-b47c-809272260087"
      unitRef="U_USD">149713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_4d6429e0-d62b-416b-a12d-9cc12953fcbd"
      unitRef="U_USD">239101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e5502035-9c62-4bfa-b75f-04b8934fb13b"
      decimals="-3"
      id="F_32b632f9-f8a3-4133-8520-d92911952f87"
      unitRef="U_USD">89388000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_82e708b6-ae46-47bf-bd88-6494bad62de4"
      unitRef="U_USD">121627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_560bf814-1b04-4751-8314-90060d8ab6fc"
      unitRef="U_USD">239101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_37b0531d-60fd-4af2-8cbe-f0972a58c6b5"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_f6944952-9ffd-4ed2-bf5c-08ad9d7e29be"
      unitRef="U_USD">232000</us-gaap:IncomeTaxesPaidNet>
    <sepn:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_1d0ad69c-c185-4a02-b541-d4f810525693"
      unitRef="U_USD">517000</sepn:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities>
    <sepn:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_07bcdb4f-baf4-4a5c-a7bc-27e62467db98"
      unitRef="U_USD">37000</sepn:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_8ab6e6de-ec1f-4604-9e12-999d7316f0bb"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_21e3e429-28f0-4d83-b6f8-1288226b565a"
      unitRef="U_USD">12462000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sepn:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_5234c76c-2160-445b-a868-81465b94ff11"
      unitRef="U_USD">0</sepn:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <sepn:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_e0f00f11-be2e-4ef2-9d82-71a2bb68977e"
      unitRef="U_USD">224157000</sepn:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
    <sepn:UnpaidOfferingCostsIncludedInAccountsPayable
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_8d27a0b1-3917-4e75-adbd-910fe3a3f0d1"
      unitRef="U_USD">0</sepn:UnpaidOfferingCostsIncludedInAccountsPayable>
    <sepn:UnpaidOfferingCostsIncludedInAccountsPayable
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_0b03692b-c7e0-44ed-9331-65d1a2c6d256"
      unitRef="U_USD">21000</sepn:UnpaidOfferingCostsIncludedInAccountsPayable>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_aa1a5024-1fb5-4921-a4e7-a1fab7a55045"
      unitRef="U_USD">120722000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_dff037c1-a511-427e-b057-38e4d5370663"
      unitRef="U_USD">238196000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_1bf0967b-026a-4af1-9969-c935891b9512"
      unitRef="U_USD">905000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_424fed75-6151-4978-b594-94d4bb9e0ece"
      unitRef="U_USD">905000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_3e0be09a-09e9-4c4a-bc93-6ac1a3c4d64f"
      unitRef="U_USD">121627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_23f8d142-c508-4182-8c05-d02189a90bd7"
      unitRef="U_USD">239101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <sepn:OrganizationDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_26b7185e-1b57-4b7a-8109-564d97ff4c24">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of the Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Septerna, Inc. (&#x201c;Septerna&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company with a world-class team of G protein-coupled receptor (&#x201c;GPCR&#x201d;) experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The Company&#x2019;s proprietary Native Complex Platform&#xae; is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. The Company is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s proprietary Native Complex Platform&#xae; replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale. The Company&#x2019;s foundational technologies enable it to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. The Company then applies state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging its platform, the Company has transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable GPCR targets with novel oral small molecule medicines for patients. The Company&#x2019;s Native Complex Platform&#xae; is designed to enable it to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company was incorporated in Delaware in December 2019, under the name GPCR NewCo, Inc. In June 2021, the Company changed its name to Septerna, Inc. The Company is headquartered in South San Francisco, California.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 18, 2024, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1-for-8.6103&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reverse stock split of its issued and outstanding shares of common stock. Upon the effectiveness of the reverse stock split, (i) all shares of outstanding common stock were adjusted; (ii) the conversion ratio of the convertible preferred stock was adjusted; (iii) the number of shares of common stock for which each outstanding option to purchase common stock is exercisable were adjusted; and (iv) the exercise price of each outstanding option to purchase common stock was adjusted. All of the outstanding common stock (including shares of common stock subject to the Company&#x2019;s options and as converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. The number of authorized shares did not change.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company completed its initial public offering (&#x201c;IPO&#x201d;), pursuant to which it issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock at the IPO price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares that were issued to the underwriters pursuant to the full exercise of their option to purchase additional shares, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;302.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and other offering expenses payable by the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Immediately prior to the closing of the IPO, the Company&#x2019;s then outstanding convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,839,774&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the closing of the IPO, no shares of convertible preferred stock were authorized or outstanding. In connection with the completion of the IPO, on October 28, 2024, the Company&#x2019;s certificate of incorporation was amended and restated to (i) authorize &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which eliminates all references to the previously existing series of convertible preferred stock; and (ii) authorize &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of undesignated preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share,  that may be issued from time to time by the Company&#x2019;s board of directors in one or more series.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which assumes that the Company will realize its assets and satisfies its liabilities in the normal course of business. The Company is subject to risks inherent in operating an early-stage biotechnology business. These risks include, but are not limited to, dependence on the development of marketable products, the ability to attract, retain, and motivate qualified personnel, rapid technological changes and the rapidly evolving nature of the biotechnology industry.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred significant losses and cumulative negative cash flows from operations since its inception and expects to incur losses as a result of its continued research and development activities. To date, none of the Company&#x2019;s product candidates have been approved by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for commercial sale and, therefore, the Company has not generated any revenue from product sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company incurred net loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2025. The Company believes its cash, cash equivalents, and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;548.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of December 31, 2025 will be sufficient to fund its operations for, at least, 12 months from the date of issuance of the financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company historically financed its operations primarily through the issuance of convertible promissory notes, convertible preferred stock, the sale of its common stock in an IPO, and most recently, through a one-time, non-refundable upfront payment  upon commencement of its collaboration agreement with Novo Nordisk A/S (&#x201c;Novo&#x201d;) and achievement of a milestone event pursuant to its agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects to continue to generate operating losses for the foreseeable future. The Company will need additional financing to support its continuing operations and pursue its growth strategy. It expects to finance its operations through equity offerings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. Any failure to raise capital as and when needed would compromise the Company&#x2019;s ability to execute on its business plan and may cause the Company to significantly delay, scale back or discontinue the research and development of some of its programs or curtail any efforts to expand its product pipelines and will materially harm its business, financial position and results of operations.&lt;/span&gt;&lt;/p&gt;</sepn:OrganizationDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_e7f2b074-5874-4a74-ac56-9ee225b000cb"
      id="F_941c5c4e-0714-4e43-98f2-021e923d4785">1-for-8.6103</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="INF"
      id="F_1e5d713a-de47-4d97-a682-1286f41de02c"
      unitRef="U_shares">18400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"
      decimals="2"
      id="F_025e7a00-2e64-4cf3-a986-3120308918de"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_da673621-a76d-4b43-ba2e-10ba33dfce9a"
      decimals="-5"
      id="F_cead4b27-aa26-4181-b312-4b592c4a46ee"
      unitRef="U_shares">2400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="-5"
      id="F_352252f7-aa06-460f-af26-e08a05146855"
      unitRef="U_USD">302800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <sepn:UnderwritingDiscountsAndCommissions
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="-5"
      id="F_2d27f892-8199-4375-b620-442b34b2a7cf"
      unitRef="U_USD">23200000</sepn:UnderwritingDiscountsAndCommissions>
    <sepn:UnderwritingOtherOfferingExpenses
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="-5"
      id="F_786f60ce-3fe7-4a61-8a9e-87bbe0019792"
      unitRef="U_USD">5200000</sepn:UnderwritingOtherOfferingExpenses>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"
      decimals="INF"
      id="F_f00668ff-26f8-466d-a192-b5cd41200007"
      unitRef="U_shares">22839774</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036"
      decimals="INF"
      id="F_a16ce7ff-fb11-44bc-ba64-4bd26621f215"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036"
      decimals="INF"
      id="F_3d482291-ac9d-40ba-9fe4-c55f97efe42f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sepn:UndesignatedPreferredStockSharesAuthorized
      contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036"
      decimals="INF"
      id="F_f2e0b373-40f7-4b42-9120-0710ffa90948"
      unitRef="U_shares">10000000</sepn:UndesignatedPreferredStockSharesAuthorized>
    <sepn:UndesignatedCommonStockParOrStatedValuePerShare
      contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036"
      decimals="INF"
      id="F_1845d00f-068f-4dfd-b950-82471b101546"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</sepn:UndesignatedCommonStockParOrStatedValuePerShare>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_4a742416-5202-4731-9928-619dbf17a914"
      unitRef="U_USD">-48900000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-5"
      id="F_41786137-04dd-4c89-966e-f34fa8d9edac"
      unitRef="U_USD">-167300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <sepn:CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-5"
      id="F_317b09e0-41d6-4b43-9bce-08eb2ac4707c"
      unitRef="U_USD">548700000</sepn:CashCashEquivalentsMarketableSecuritiesCurrentAndNonCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_56367a61-8e12-4e22-abf2-5a22324efe3d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;), stated in U.S. dollars and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial statements as of December 31, 2025 and 2024, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASUs&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, of the Financial Accounting Standards Board &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FASB&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in determining the fair value of assets and liabilities, the useful lives of property and equipment, the rate used in determining the present value of lease payments, fair value of assets and liabilities, research and development accruals, the estimated fair value of common stock prior to the Company's IPO and assumptions used in stock-based compensation, the initial allocation and continued evaluation of a revenue contract&#x2019;s transaction price to each distinct performance obligation on a relative standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, tariffs, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company limits its credit risk by placing its cash, cash equivalents, and marketable securities with banks and institutions that are highly creditworthy. Such cash may be in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits, and the Company's cash equivalents and marketable securities are not insured by the FDIC. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities to the extent recorded in the balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The primary focus of the Company&#x2019;s investment strategy is to preserve capital and meet liquidity requirements. Management believes that the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash, cash equivalents and marketable securities since inception. The Company has no significant off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, efficacy of product candidates, intense competition, and dependence upon the availability of liquidity to sustain operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company holds marketable securities that consist of highly liquid, investment grade debt securities. The Company's cash and marketable securities are held or issued by financial institutions that management believes are of high credit quality. Marketable securities are classified and accounted for as available-for-sale. Marketable securities with original maturities of 90 days or less are classified as cash equivalents. Marketable securities with original maturities over 90 days and remaining maturities of less than 12 months are classified as current. Marketable securities with remaining maturities of more than 12 months for which the Company has the intent and ability to hold the security for more than 12 months are classified as non-current. The Company&#x2019;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported in stockholders&#x2019; equity as accumulated other comprehensive income. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. The Company does not generally intend to sell the investments and it is less likely that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, the Company recognizes a loss in its statement of operations and comprehensive loss, whereas if the decline in fair value is not due to credit-related factors, the Company records the loss in accumulated other comprehensive income on its balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of marketable securities for purposes of identifying and measuring an impairment. Accrued interest receivable on marketable securities is recorded within prepaid expenses and other current assets on the balance sheets. The Company&#x2019;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#x2019;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to its landlord. The collateral account is classified as restricted cash on the Company&#x2019;s balance sheets. As of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the remaining term of the leases is greater than one year and the related restricted cash is classified as non-current on the Company's balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue consists of amounts received prior to satisfying revenue recognition criteria (see Note 4).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of assets, or at the time services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses was recorded during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company&#x2019;s accounts receivable was entirely attributable to Novo. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s accounts receivable was entirely attributed to Vertex.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation and amortization. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:57.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:40.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation or amortization is removed from the balance sheet and the resulting gain or loss is recognized within other income, net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairments of the Company&#x2019;s long-lived assets for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its leases in accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 842&#x201d;). The Company adopted ASC 842 on January 1, 2021, prior to entering into the lease agreement for its office and research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments if the Company&#x2019;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Right-of-use assets represent the Company&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s right to use underlying assets for the lease term and operating lease liabilities represent the Company&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s obligation to make lease payments under the lease. Right-of-use assets also include any lease payments made prior to the commencement date and exclude lease incentives received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company elected to apply the practical expedient of combining lease and non-lease components for the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company elected the short-term lease practical expedient that allows the lessee to not record a lease liability and right-of-use asset for all leases with a term of 12 months or less. See Note 6 for additional information on the &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for revenue in accordance with ASC 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following four steps: (i) confirm it has a contract with a customer that creates enforceable rights and obligations; (ii) identify promised products or services to be transferred to a customer; (iii) determine the transaction price, or the amount it expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable and allocated to the performance obligations; and (iv) recognize revenue when or as performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price of each distinct performance obligation. In instances where standalone selling price is not directly observable, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract using a cost plus margin approach, which is an estimation method used when standalone selling price is not directly observable. Key assumptions used within this estimation method may include full-time equivalent personnel effort and estimated external costs associated with the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the Company's performance, (ii) the Company's  performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the Company does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s revenues are primarily derived through its license and research and development service arrangements. Payments to the Company under these arrangements typically include one or more of the following: one-time, non-refundable upfront payment, research and development service funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain collaboration, research and development and commercial milestones, as well as royalties based on net sales of approved drugs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Consideration received prior to revenue recognition is recorded as deferred revenue in the balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current. Contract assets represent research and development services which have been performed but have not yet been billed and are reduced when they are subsequently billed. Such contract assets include accounts receivable when the Company&#x2019;s right to consideration is unconditional. For its current contracts, the Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and, if over time, revenue recognized is based on the use of an input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms of the Company&#x2019;s collaborative arrangements include one or more of the following&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property, or IP - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the license to the Company&#x2019;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For a license that is determined not to be distinct, it is combined with other promises and the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost of each performance obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Customer options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - The Company evaluates the customer options for material rights or options to acquire additional goods or services at no incremental consideration or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised and performance obligations are satisfied. If an option is not exercised before the option right expires, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development services &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- The promises under the Company's collaboration agreement include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#x2019;s statements of operations and comprehensive loss. Expenses incurred as part of the Company&#x2019;s efforts to perform the research and development services are recognized in research and development expense in the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iv)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Manufacturing services &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- The promises under the Company's collaboration agreement include manufacturing services to be provided by the Company. Payments or reimbursements resulting from the Company's manufacturing services are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#x2019;s statements of operations and comprehensive loss. Expenses incurred to perform the manufacturing services are recognized in research and development expense in the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(v)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone payments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore, consideration included in the transaction price is constrained. The Company applied the variable consideration allocation exception under ASC 606 whereby variable milestone payments are not estimated and included in the transaction price at inception. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(vi)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commercial milestone payments and royalties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sale of Non-Financial Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sale of non-financial assets that are outside the scope of the &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary activities are accounted for under ASC 610-20, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Income - Gains and Losses from the Derecognition of Non-financial Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 610-20&#x201d;). Pursuant to ASC 610-20, the Company applies the guidance in ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 606&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to determine if a contract exists, identify the distinct non-financial assets, and determine when control transfers and, therefore, when to derecognize the non-financial asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation of the gain or loss for the non-financial asset.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies and clinical trials, contract manufacturing for the production of clinical and preclinical materials, information technology-related costs, allocated overhead costs including facility-related expenses, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into agreements with outsourced contract manufacturing and development and clinical research vendors. The Company estimates accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs to secure and maintain patents covering the Company&#x2019;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The carrying values of the Company&#x2019;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is recognized based on the grant-date fair value of the awards. The fair value of stock options and employee stock purchase plan ("ESPP") is determined using the Black-Scholes option pricing model on the date of grant. The fair value of restricted stock awards is determined using the estimated fair value of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the IPO, the Company utilized estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to the Company&#x2019;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For stock-based awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award of four years. For stock-based awards with vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based compensation expense on an accelerated basis over the vesting period when achievement of the performance criteria becomes probable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is recorded within research and development and general and administrative expenses in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company utilizes the asset and liability approach to account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. The Company&#x2019;s other comprehensive income (loss) is comprised solely of unrealized gains or losses on marketable securities. The Company has not recorded any reclassifications from other comprehensive gains or losses to net loss during the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of basic net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock, and ESPP shares. The dilutive effect of stock options, unvested restricted stock, and ESPP shares is computed using the treasury stock method. For all periods presented in a net loss position, diluted net loss per share is the same as basic net loss per share since the effect of including potential dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2025, the FASB issued ASU No. 2025-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expand the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. In addition, ASU 2025-07 is expected to reduce diversity in the accounting for share-based non-cash consideration from a customer for the transfer of goods or services, as well as provide investors with more comparable information and reduce accounting complexity and related reporting costs. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adoption of the amendment allows for either the prospective or modified retrospective application and is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company early &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this standard using the prospective method for the derivative scope refinement with the effective date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Prior to adoption, the Company did not have contracts that incl&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ude are subject to derivative accounting and the adoption of the ASU did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_faecfa98-652d-4cca-94de-7a02c3297ab7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU No. 2023-09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years beginning after December 15, 2024, on a prospective basis. Early adoption and retrospective reporting are permitted. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The company follows the provisions set forth in ASU No. 2023-09 on a prospective basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2025, the FASB issued ASU No. 2025-05, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which provides a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset in developing reasonable and supportable forecasts during the application of the current expected credit loss model for current accounts receivable and current contract assets arising from transactions under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-05.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires the Company to disclose more detailed information about the types of expenses (including employee compensation, depreciation, and amortization) included in each relevant income statement expense caption. The ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status and Smaller Reporting Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_40eef4f3-10d6-4427-8108-c157b04d055b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;), stated in U.S. dollars and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial statements as of December 31, 2025 and 2024, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASUs&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, of the Financial Accounting Standards Board &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FASB&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_11a997a5-7de8-41bb-b8be-8eecf0d19d3c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in determining the fair value of assets and liabilities, the useful lives of property and equipment, the rate used in determining the present value of lease payments, fair value of assets and liabilities, research and development accruals, the estimated fair value of common stock prior to the Company's IPO and assumptions used in stock-based compensation, the initial allocation and continued evaluation of a revenue contract&#x2019;s transaction price to each distinct performance obligation on a relative standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, tariffs, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_0fc264d0-6d4a-4fe0-bad6-1ffbade4a05d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <sepn:RisksAndUncertaintyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_84d19030-cff0-4ed6-9ea8-75b48f3b53e1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company limits its credit risk by placing its cash, cash equivalents, and marketable securities with banks and institutions that are highly creditworthy. Such cash may be in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits, and the Company's cash equivalents and marketable securities are not insured by the FDIC. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities to the extent recorded in the balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The primary focus of the Company&#x2019;s investment strategy is to preserve capital and meet liquidity requirements. Management believes that the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash, cash equivalents and marketable securities since inception. The Company has no significant off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, efficacy of product candidates, intense competition, and dependence upon the availability of liquidity to sustain operations.&lt;/span&gt;&lt;/p&gt;</sepn:RisksAndUncertaintyPolicyTextBlock>
    <sepn:CashEquivalentsAndMarketableSecuritiesPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_1f76725b-155a-40da-a3e7-2b2509575182">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company holds marketable securities that consist of highly liquid, investment grade debt securities. The Company's cash and marketable securities are held or issued by financial institutions that management believes are of high credit quality. Marketable securities are classified and accounted for as available-for-sale. Marketable securities with original maturities of 90 days or less are classified as cash equivalents. Marketable securities with original maturities over 90 days and remaining maturities of less than 12 months are classified as current. Marketable securities with remaining maturities of more than 12 months for which the Company has the intent and ability to hold the security for more than 12 months are classified as non-current. The Company&#x2019;s marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported in stockholders&#x2019; equity as accumulated other comprehensive income. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. The Company does not generally intend to sell the investments and it is less likely that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, the Company recognizes a loss in its statement of operations and comprehensive loss, whereas if the decline in fair value is not due to credit-related factors, the Company records the loss in accumulated other comprehensive income on its balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excludes the applicable accrued interest from both the fair value and amortized cost basis of marketable securities for purposes of identifying and measuring an impairment. Accrued interest receivable on marketable securities is recorded within prepaid expenses and other current assets on the balance sheets. The Company&#x2019;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected.&lt;/span&gt;&lt;/p&gt;</sepn:CashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_38e130e8-62e1-4b9e-97e9-d3276556b1d8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#x2019;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to its landlord. The collateral account is classified as restricted cash on the Company&#x2019;s balance sheets. As of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the remaining term of the leases is greater than one year and the related restricted cash is classified as non-current on the Company's balance sheet.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <sepn:DeferredRevenuePolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_8d3f14b0-a804-4a17-be0e-93a71e46cb4a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue consists of amounts received prior to satisfying revenue recognition criteria (see Note 4).&lt;/span&gt;&lt;/p&gt;</sepn:DeferredRevenuePolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_e7ca7e5f-2dfa-4a5a-9f24-5f89ca0bdad6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of assets, or at the time services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance for credit losses was recorded during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company&#x2019;s accounts receivable was entirely attributable to Novo. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s accounts receivable was entirely attributed to Vertex.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_533c5980-e98e-416e-8b6d-3b61f433a9c0"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_949707ce-c420-45d4-95f9-f88a2544dcde"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_f9586aee-b7c4-4fb6-b4f9-c956c9a55993">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation and amortization. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:57.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:40.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation or amortization is removed from the balance sheet and the resulting gain or loss is recognized within other income, net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <sepn:SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_a6241d8f-36f9-45c6-9b47-9dc7acc9ea03">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company depreciates property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:57.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:40.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_0bf355a7-e9ab-4a4e-8ae8-f3d38f5eae2b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</sepn:SummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0d155a10-3368-4e21-9ede-8d1675cae5c8"
      id="F_cb2dca2a-9e66-43f0-8aef-d5972d6691b4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_31980d7f-00b5-4148-b37d-689b558648c6"
      id="F_b981ec88-7fa3-405e-be6e-6d54b2677f0d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_db2dcbd2-97a4-4ddf-ba1c-ede279cbcae5"
      id="F_474f63fc-a746-4391-a726-2028fd05e384">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f65b9339-0f3a-4b2a-8936-a9b7e8f4f353"
      id="F_5d7a153b-6386-46fa-ad48-d1e7c631a372">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_ee621192-198d-4bc6-bd34-0934bf692952">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairments of the Company&#x2019;s long-lived assets for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="INF"
      id="F_be91ce25-4a89-4f3e-a27a-731e20cfb142"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="INF"
      id="F_c22542b7-a6b3-47b0-bdd0-5f3efacd0cd5"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_92e01aba-0dd8-4d72-ab66-2164baaf03a2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for its leases in accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 842&#x201d;). The Company adopted ASC 842 on January 1, 2021, prior to entering into the lease agreement for its office and research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments if the Company&#x2019;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Right-of-use assets represent the Company&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s right to use underlying assets for the lease term and operating lease liabilities represent the Company&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s obligation to make lease payments under the lease. Right-of-use assets also include any lease payments made prior to the commencement date and exclude lease incentives received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company elected to apply the practical expedient of combining lease and non-lease components for the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company elected the short-term lease practical expedient that allows the lessee to not record a lease liability and right-of-use asset for all leases with a term of 12 months or less. See Note 6 for additional information on the &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_3a8fa56e-8423-4c38-bf1f-5ab07e70b202">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for revenue in accordance with ASC 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when the customer obtains control of the promised goods or services at an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following four steps: (i) confirm it has a contract with a customer that creates enforceable rights and obligations; (ii) identify promised products or services to be transferred to a customer; (iii) determine the transaction price, or the amount it expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable and allocated to the performance obligations; and (iv) recognize revenue when or as performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. For arrangements that include multiple performance obligations, the Company allocates the transaction price to the identified performance obligations based on the standalone selling price of each distinct performance obligation. In instances where standalone selling price is not directly observable, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract using a cost plus margin approach, which is an estimation method used when standalone selling price is not directly observable. Key assumptions used within this estimation method may include full-time equivalent personnel effort and estimated external costs associated with the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the Company's performance, (ii) the Company's  performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the Company's performance does not create an asset with an alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. If the Company does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s revenues are primarily derived through its license and research and development service arrangements. Payments to the Company under these arrangements typically include one or more of the following: one-time, non-refundable upfront payment, research and development service funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain collaboration, research and development and commercial milestones, as well as royalties based on net sales of approved drugs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Consideration received prior to revenue recognition is recorded as deferred revenue in the balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current. Contract assets represent research and development services which have been performed but have not yet been billed and are reduced when they are subsequently billed. Such contract assets include accounts receivable when the Company&#x2019;s right to consideration is unconditional. For its current contracts, the Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and, if over time, revenue recognized is based on the use of an input method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When no remaining performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms of the Company&#x2019;s collaborative arrangements include one or more of the following&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of intellectual property, or IP - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the license to the Company&#x2019;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the licenses. For a license that is determined not to be distinct, it is combined with other promises and the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost of each performance obligation. The impact on revenue of changes in total estimated costs are recognized on a cumulative basis in the period that the change occurs. If estimates of the total cost change, or if contract amendments change the scope of the performance obligation, the required adjustments to revenue could be material.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Customer options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - The Company evaluates the customer options for material rights or options to acquire additional goods or services at no incremental consideration or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until the option is exercised and performance obligations are satisfied. If an option is not exercised before the option right expires, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and development services &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- The promises under the Company's collaboration agreement include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#x2019;s statements of operations and comprehensive loss. Expenses incurred as part of the Company&#x2019;s efforts to perform the research and development services are recognized in research and development expense in the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iv)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Manufacturing services &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- The promises under the Company's collaboration agreement include manufacturing services to be provided by the Company. Payments or reimbursements resulting from the Company's manufacturing services are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements are recognized in revenue in the Company&#x2019;s statements of operations and comprehensive loss. Expenses incurred to perform the manufacturing services are recognized in research and development expense in the Company&#x2019;s statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(v)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone payments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;- At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received, and therefore, consideration included in the transaction price is constrained. The Company applied the variable consideration allocation exception under ASC 606 whereby variable milestone payments are not estimated and included in the transaction price at inception. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(vi)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commercial milestone payments and royalties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <sepn:SaleOfNonFinancialAssetsPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_958e5903-d7e7-4c94-8727-8981db70c47d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sale of Non-Financial Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sale of non-financial assets that are outside the scope of the &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary activities are accounted for under ASC 610-20, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Income - Gains and Losses from the Derecognition of Non-financial Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;ASC 610-20&#x201d;). Pursuant to ASC 610-20, the Company applies the guidance in ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 606&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to determine if a contract exists, identify the distinct non-financial assets, and determine when control transfers and, therefore, when to derecognize the non-financial asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation of the gain or loss for the non-financial asset.&lt;/span&gt;&lt;/p&gt;</sepn:SaleOfNonFinancialAssetsPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_f1deb197-d9d9-4400-a4fa-d2d6e201c437">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies and clinical trials, contract manufacturing for the production of clinical and preclinical materials, information technology-related costs, allocated overhead costs including facility-related expenses, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into agreements with outsourced contract manufacturing and development and clinical research vendors. The Company estimates accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <sepn:PatentExpensesPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_9e92b6a4-0479-4275-b699-456032e02806">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs to secure and maintain patents covering the Company&#x2019;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</sepn:PatentExpensesPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_c6887664-429e-44d8-bb72-f5a71014b3bf">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_fb9a4ee1-0400-47b3-8408-58dba1922339">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The carrying values of the Company&#x2019;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_33ac6381-63ef-4091-8226-c3c881d81b44">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is recognized based on the grant-date fair value of the awards. The fair value of stock options and employee stock purchase plan ("ESPP") is determined using the Black-Scholes option pricing model on the date of grant. The fair value of restricted stock awards is determined using the estimated fair value of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the IPO, the Company utilized estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to the Company&#x2019;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For stock-based awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award of four years. For stock-based awards with vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based compensation expense on an accelerated basis over the vesting period when achievement of the performance criteria becomes probable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is recorded within research and development and general and administrative expenses in the accompanying statements of operations and comprehensive loss based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_4d3364ac-52be-41a4-b665-4667792daf5d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company utilizes the asset and liability approach to account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_aa326d61-c978-4da1-9773-ad914f28b61e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. The Company&#x2019;s other comprehensive income (loss) is comprised solely of unrealized gains or losses on marketable securities. The Company has not recorded any reclassifications from other comprehensive gains or losses to net loss during the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_a73542b2-0a9d-4d50-b255-e873483ef097">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of basic net loss per share. Diluted net loss per share is computed by dividing the net loss by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock, and ESPP shares. The dilutive effect of stock options, unvested restricted stock, and ESPP shares is computed using the treasury stock method. For all periods presented in a net loss position, diluted net loss per share is the same as basic net loss per share since the effect of including potential dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_9d127591-af58-4eaa-ba9c-c5a9b7ef6d3f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2025, the FASB issued ASU No. 2025-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expand the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. In addition, ASU 2025-07 is expected to reduce diversity in the accounting for share-based non-cash consideration from a customer for the transfer of goods or services, as well as provide investors with more comparable information and reduce accounting complexity and related reporting costs. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Adoption of the amendment allows for either the prospective or modified retrospective application and is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company early &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this standard using the prospective method for the derivative scope refinement with the effective date of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Prior to adoption, the Company did not have contracts that incl&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ude are subject to derivative accounting and the adoption of the ASU did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_faecfa98-652d-4cca-94de-7a02c3297ab7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU No. 2023-09&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years beginning after December 15, 2024, on a prospective basis. Early adoption and retrospective reporting are permitted. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The company follows the provisions set forth in ASU No. 2023-09 on a prospective basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_6d0ae500-5d31-4464-8a21-1873d26e4998"
      id="F_098c6036-dc51-49c4-b08c-51fe1a611401">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_6d0ae500-5d31-4464-8a21-1873d26e4998"
      id="F_51161d8f-8b45-451a-b7fd-afcc6507eac0">2025-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_6d0ae500-5d31-4464-8a21-1873d26e4998"
      id="F_093ad106-e1df-4ccb-be4b-5034b791030d">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <sepn:AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_7a044b4b-39e8-4452-8f1f-43894671186c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2025, the FASB issued ASU No. 2025-05, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which provides a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset in developing reasonable and supportable forecasts during the application of the current expected credit loss model for current accounts receivable and current contract assets arising from transactions under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2025-05.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires the Company to disclose more detailed information about the types of expenses (including employee compensation, depreciation, and amortization) included in each relevant income statement expense caption. The ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.&lt;/span&gt;&lt;/p&gt;</sepn:AccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <sepn:EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_4a013d9d-bee6-4a17-a210-2b776242b667">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status and Smaller Reporting Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.&lt;/span&gt;&lt;/p&gt;</sepn:EmergingGrowthCompanyStatusAndSmallerReportingCompanyStatusPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_54048a5a-3abc-4a7f-8e9d-34aecaca4d01">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture, fixtures, and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_8b432b3e-36b5-4f7b-97d6-1474e2402e7c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_e67e8d2d-6913-4179-b0e9-592926a06f5a"
      unitRef="U_USD">4622000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_d4c38d22-3318-4146-8437-e056a0ef2647"
      unitRef="U_USD">4278000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_32fdf685-044b-425a-a4e7-1a8c8abf4a39"
      unitRef="U_USD">3384000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_e6c94aac-d1aa-4450-a840-eaf424ff9f42"
      unitRef="U_USD">953000</us-gaap:InterestReceivableCurrent>
    <sepn:PrepaidBonusCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_44ee81b9-5052-48d8-b32d-b708e57bba50"
      unitRef="U_USD">361000</sepn:PrepaidBonusCurrent>
    <sepn:PrepaidBonusCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_4721d006-0ca5-4796-9933-97da9afe5d4f"
      unitRef="U_USD">260000</sepn:PrepaidBonusCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_9cfa22ee-8971-4bb5-89df-fddd2cf5fee8"
      unitRef="U_USD">1152000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_c8f8cbe3-5eeb-428c-9558-77fa8eeb5946"
      unitRef="U_USD">239000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_432580e9-0b83-4770-bc56-bdf6afe64f90"
      unitRef="U_USD">9519000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_4a436cfd-79af-4aa3-a6fb-8781b9a0f2a1"
      unitRef="U_USD">5730000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_4df8aa7f-5477-4ca2-aa35-4d490493a018">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture, fixtures, and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d155a10-3368-4e21-9ede-8d1675cae5c8"
      decimals="-3"
      id="F_1f54e573-c6cc-4cec-80c7-467cd8a8607a"
      unitRef="U_USD">6339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5bc6c479-79c8-4152-9bfc-76c56f1b6c0b"
      decimals="-3"
      id="F_96871689-9083-4ea2-bd16-9037e3fc5a92"
      unitRef="U_USD">5679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4586a8d6-90a1-4f22-a91e-ed46c95e215d"
      decimals="-3"
      id="F_aa3a2738-8de0-4170-8ff1-68decbe1e2ef"
      unitRef="U_USD">1222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0fbb9c90-762c-43f1-b17f-96b2e4b4c262"
      decimals="-3"
      id="F_ea87df9a-131c-485c-b248-dfd8a41effc7"
      unitRef="U_USD">1222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_62d33bbc-a9d1-4e0d-b374-febca2f135b7"
      decimals="-3"
      id="F_08a1c09d-9dbc-4ba7-a677-bcbb455485cc"
      unitRef="U_USD">717000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_398ed5f7-f194-4e12-ab54-8894f63345b1"
      decimals="-3"
      id="F_d24659c4-c1fe-4189-a7f3-45ab2b25fcfe"
      unitRef="U_USD">717000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f65b9339-0f3a-4b2a-8936-a9b7e8f4f353"
      decimals="-3"
      id="F_24796e13-63d7-4c31-bb70-8651b2fd001c"
      unitRef="U_USD">401000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d86b0a04-264c-4ec6-a98a-514c21b6fcd1"
      decimals="-3"
      id="F_4014319c-77dd-42b3-956c-201493433ebb"
      unitRef="U_USD">401000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9db2cf60-a723-488b-983c-bd979235ca35"
      decimals="-3"
      id="F_46ec1082-b9f8-420b-905d-ba05148362d9"
      unitRef="U_USD">107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_87cdb1d5-fac7-4ece-beec-6c0efa23647c"
      decimals="-3"
      id="F_7664446b-b1c6-4b7b-b57b-768d7dca1bfb"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_1e8b6e81-406a-4578-af52-baa8789dad62"
      unitRef="U_USD">8786000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_217f54cb-8431-4331-8496-7aca899ebc57"
      unitRef="U_USD">8019000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_ce1b600b-0485-43bc-a884-e278c51cbc71"
      unitRef="U_USD">4352000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_65f03d95-4fef-41dc-b06c-de32375ba82b"
      unitRef="U_USD">2929000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_122ca3ff-174b-41e7-89c6-8f0d8c18c6ec"
      unitRef="U_USD">4434000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_b4bae600-66a1-46c7-bc6e-e331bf08d025"
      unitRef="U_USD">5090000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_00728c62-98fd-4414-9eaa-4f97cd16b625"
      unitRef="U_USD">1600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-5"
      id="F_da24e3ad-925c-4eca-bb6e-8153dbc6914a"
      unitRef="U_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_7b60dae5-c56d-4498-acdf-191ac75f3784">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued general and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_da3b73c0-bfed-428c-bebf-1ea4fc55da4f"
      unitRef="U_USD">5606000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_7d9bd324-2c78-4981-b4f4-2e475f826509"
      unitRef="U_USD">4129000</us-gaap:AccruedSalariesCurrent>
    <sepn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_f7ce355f-d8eb-4b42-9063-8fb2c399f269"
      unitRef="U_USD">5179000</sepn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sepn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_0de2f492-2f56-45ae-b6a1-22aefa43d4fa"
      unitRef="U_USD">2888000</sepn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sepn:AccruedGeneralAndAdministrativeExpenseCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_f06771fc-b9ab-4a9b-b63b-f0ad404280d6"
      unitRef="U_USD">915000</sepn:AccruedGeneralAndAdministrativeExpenseCurrent>
    <sepn:AccruedGeneralAndAdministrativeExpenseCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_b7c90415-8dc2-45ae-b815-7a7bbd2dde9d"
      unitRef="U_USD">703000</sepn:AccruedGeneralAndAdministrativeExpenseCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_aaba6153-fd1e-4bd1-b696-1bce8ac0d705"
      unitRef="U_USD">319000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_77637712-d8d9-4d3b-bdf0-1c50e1647fe4"
      unitRef="U_USD">0</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_fec2acb8-bc84-4698-a45f-719b468f78e8"
      unitRef="U_USD">148000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_798a2afd-424b-4793-8788-77380fb1e400"
      unitRef="U_USD">78000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_da6de28f-c2d7-4c6e-8652-8f3f6245c5ec"
      unitRef="U_USD">12167000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_2e2c71aa-4481-4d1f-a65e-1f8da5423d99"
      unitRef="U_USD">7798000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_3da3738f-f5ae-43a1-9703-173c35c9f823">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Collaboration and Research Service Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2025, the Company's revenue is comprised solely of arrangements with Novo and Vertex. For the year ended December 31, 2024, the Company's revenue was solely comprised of the arrangement with Vertex.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Novo Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 13, 2025, the Company entered into a Collaboration and License Agreement with Novo (the &#x201c;Novo Collaboration Agreement&#x201d;). Under the Novo Collaboration Agreement, the Company and Novo are exclusively collaborating to leverage the Company&#x2019;s proprietary Native Complex Platform&#x99; to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon effectiveness of the Novo Collaboration Agreement on July 1, 2025, the Company and Novo have commenced four simultaneous research and development programs (each an &#x201c;R&amp;amp;D Program&#x201d;), each pursuing one or more Collaboration Targets (as defined in the Novo Collaboration Agreement) from discovery through development candidate selection. Subject to certain limitations, Novo also has a right to modify the research plan with the option to commence additional R&amp;amp;D Programs. Novo will reimburse the Company for 100% of the fully burdened costs arising from all research and development activities undertaken by the Company under the Novo Collaboration Agreement. After development candidate selection, beginning with investigational new drug-enabling activities, Novo will be responsible for all further global development and commercialization for each product candidate at its sole cost and expense unless the profit share option described below is exercised. Novo is also responsible for all commercialization costs subject to the Company&#x2019;s profit share option for up to one program under the Novo Collaboration Agreement. Pursuant to the terms of the Novo Collaboration Agreement, the Company will provide Novo with exclusive licenses to enable Novo to develop and commercialize products directed at the Collaboration Targets. The Company retains all other rights to its Native Complex Platform&#x99; and all of the Company&#x2019;s other research and development programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon effectiveness of the Novo Collaboration Agreement, the Company received a one-time, non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in July 2025, which was recorded as deferred revenue in its balance sheet. The Company is also eligible to receive up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;498.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in research, development, regulatory, and commercial milestone payments for each R&amp;amp;D Program. In addition, the Company is entitled to escalating, tiered royalties ranging from mid to high single-digits based on global product sales on a country-by-country and product-by-product basis with respect to a R&amp;amp;D Program until the later of ten years after the date of first commercial sale of the first product in such R&amp;amp;D Program in such country, expiration of specified patent rights covering such product in such country or the expiration of specified regulatory exclusivity for the first product in such R&amp;amp;D Program in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Novo Collaboration Agreement, the Company has a one-time option to share in the global development costs and operating profits or losses (in lieu of milestones and royalties) with respect to one licensed product (the "Profit Share Option"), subject to certain terms, conditions and limitations. In the event that the Company chooses to exercise the Profit Share Option, it will be required to repay Novo all previously reimbursed developmental costs pertaining to that program at a predetermined multiple and reimburse Novo for a portion of the continued R&amp;amp;D costs incurred under the selected licensed product and will share in the profits resulting from the commercialization of the licensed product.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unless earlier terminated, the term of the Novo Collaboration Agreement continues until expiration of the last royalty term for the applicable product in the applicable country. The Novo Collaboration Agreement is subject to customary termination provisions, including termination by a party for the other party&#x2019;s uncured, material breach. The Novo Collaboration Agreement also includes customary representations and warranties, covenants and indemnification obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded the Agreement is not within the scope of Accounting Standards Codification 808, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as the Company does not share equally in the exposure to significant risk. Accordingly, the Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Novo, is a customer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At commencement, the Company identified the several performance obligations within the Novo Collaboration Agreement, including research and development services on research targets, option rights held by Novo, license to use the Company&#x2019;s intellectual property to conduct research and development activities, and participation on the joint steering committee (&#x201c;JSC&#x201d;). At inception of the Novo Collaboration Agreement, the Company identified the following performance obligations:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Four combined performance obligations comprised of the license, related research services, and participation of the JSC for the four R&amp;amp;D Programs;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Manufacturing services related to one of the R&amp;amp;D Programs; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.86108878960282%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A material R&amp;amp;D Program modification right held by Novo.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company concluded that the license granted at contract inception is not distinct from the research services as the research services significantly modify the intellectual property underlying the license.  As a result, for each R&amp;amp;D Program, the license has been combined with the research services and JSC participation into a single performance obligation, which is the combined performance obligation comprised of the license, related research services, and JSC participation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In assessing whether the various options under the Novo Collaboration Agreement represent material rights, the Company considered the additional consideration the Company would be entitled to upon option exercise and the standalone selling price of the underlying goods and services. For the material right identified above, the Company concluded the option provided Novo with a discount that it otherwise would not have received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes revenue related to the combined license and research services performance obligation and the manufacturing performance obligation over time using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of actual cost incurred to date to the total estimated cost at completion of the performance obligations, which the Company believes best measures its progress towards satisfying the performance obligations. A cost-based input method of revenue recognition requires management to make estimates of cost to complete the performance obligation. Judgment is required to evaluate assumptions related to cost estimates. The estimated standalone selling price for the material right was determined based on the estimated discount provided to Novo and the probability that Novo would exercise the option.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents revenue recognized, unrecognized transaction price, and estimated revenue expected to be recognized in the future as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:73.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.759%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.855999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Transaction Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Combined license, research and manufacturing services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total transaction price&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized transaction price as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;_____________________&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprised of the allocation of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million one-time, non-refundable upfront payment, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the four R&amp;amp;D programs and manufacturing services and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the material right and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of variable consideration related to estimated research and manufacturing services for the four R&amp;amp;D Programs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recorded within revenue in the statement of operations and comprehensive loss for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recognized of the one-time, non-refundable upfront payment and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million variable considerations related to estimated research services for the four R&amp;amp;D Programs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the Novo Collaboration Agreement are recorded as accounts receivable in the Company&#x2019;s balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the changes in deferred revenue for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:73.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.759%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.855999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognized revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;_____________________&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deferred revenue, current and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deferred revenue, non-current, which is expected to be recognized over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all of the Company's performance obligations are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company periodically assesses the probability of receiving payments from achieving the research and development, collaboration target, and regulatory milestones and includes the payment in the transaction price when they are deemed probable. Royalties and commercial sale milestones will be recognized when the subsequent sales occur based on the sales or usage-based royalty exception.  The Company also periodically reassesses the probability of exercising Profit Share Option. As of December 31, 2025, none of the milestones were deemed probable and no royalty revenue has been recognized, and the Profit Share Option was deemed improbable with no amount recognized for repayment of reimbursements to Novo.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Vertex Asset Purchase and Research Service Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Vertex Asset Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the Company entered into an asset purchase agreement with Vertex, under which Vertex acquired an in-process research and development ("IPR&amp;amp;D") asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (the &#x201c;Vertex Asset Purchase Agreement&#x201d;). The Vertex Asset Purchase Agreement also provided for a potential milestone payment payable to the Company contingent upon the achievement of a milestone event.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2025, this milestone event was determined achieved and, as a result, the Company received a payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in August 2025, which was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;recorded as a gain on sale of non-financial asset within total operating expenses in the Company&#x2019;s statements of operations and comprehensive loss for the year ended December 31, 2025. The Company will not receive any other payments related to this IPR&amp;amp;D asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Vertex Research Service Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In conjunction with the Vertex Asset Purchase Agreement in September 2023, the Company entered into research service agreement with Vertex under which the Company agreed to perform certain exploratory research activities for Vertex (the "Vertex Research Service Agreement"). The Company recognized service revenue associated with the Vertex Research Service Agreement over the performance period of the research services as the services were provided in accordance with ASC 606. The Vertex Research Service Agreement expired in September 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to research activities performed in connection with the Vertex Research Service Agreement. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, the Company recorded revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related to research activities performed in connection with the Vertex Research Service Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <sepn:NonRefundableOneTimeUpfrontPaymentReceived
      contextRef="C_e2f01c6e-2c71-481c-920d-0563fd77c7f5"
      decimals="-5"
      id="F_95ed4bb3-5cc8-4861-b81f-68e5f8897801"
      unitRef="U_USD">195000000</sepn:NonRefundableOneTimeUpfrontPaymentReceived>
    <sepn:MilestonePaymentsReceivableFromCollaborationAgreement
      contextRef="C_7f97baf0-9093-442d-82b0-a802ec9a04a8"
      decimals="-5"
      id="F_065a5eb1-ef56-48fa-8935-82c9da866185"
      unitRef="U_USD">498000000</sepn:MilestonePaymentsReceivableFromCollaborationAgreement>
    <sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_aee86c79-307d-4e53-84e9-6922a2b1a969">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents revenue recognized, unrecognized transaction price, and estimated revenue expected to be recognized in the future as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:73.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.759%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.855999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Transaction Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Combined license, research and manufacturing services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;247,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total transaction price&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue recognized&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized transaction price as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;_____________________&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprised of the allocation of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million one-time, non-refundable upfront payment, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the four R&amp;amp;D programs and manufacturing services and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the material right and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of variable consideration related to estimated research and manufacturing services for the four R&amp;amp;D Programs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recorded within revenue in the statement of operations and comprehensive loss for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recognized of the one-time, non-refundable upfront payment and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million variable considerations related to estimated research services for the four R&amp;amp;D Programs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</sepn:SummaryOfRevenueRecognizedUnrecognizedTransactionPriceAndEstimatedRevenueExpectedToBeRecognizedTableTextBlock>
    <sepn:TransactionPrice
      contextRef="C_07465302-3c57-4c51-8649-8a24eb806c09"
      decimals="-3"
      id="F_d2d35a1b-cbcf-4e46-9b56-e460c20dcbb6"
      unitRef="U_USD">247846000</sepn:TransactionPrice>
    <sepn:TransactionPrice
      contextRef="C_a07cba62-15fb-408e-9eca-ccd2f26f2784"
      decimals="-3"
      id="F_ebc5b7d7-0805-4aef-932e-f214645a02f9"
      unitRef="U_USD">41190000</sepn:TransactionPrice>
    <sepn:TransactionPrice
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-3"
      id="F_7008d5d3-9bdd-490b-96e6-88078f8933a4"
      unitRef="U_USD">289036000</sepn:TransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-3"
      id="F_39fd5ca1-4334-4c7d-a6eb-c996d69d21c0"
      unitRef="U_USD">45377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sepn:UnrecognizedTransactionPrice
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-3"
      id="F_a37898f8-01ab-4e49-93da-d805cfbada43"
      unitRef="U_USD">243659000</sepn:UnrecognizedTransactionPrice>
    <sepn:NonRefundableOneTimeUpfrontPaymentReceived
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-5"
      id="F_534b6776-65ba-4792-886d-390937883e2c"
      unitRef="U_USD">195000000</sepn:NonRefundableOneTimeUpfrontPaymentReceived>
    <sepn:NonRefundableOneTimeUpfrontPaymentReceived
      contextRef="C_ab94e00d-ea2a-4055-a162-0c519f4d3c16"
      decimals="-5"
      id="F_e58275c8-400c-4fdb-8bda-097e15a9d5a9"
      unitRef="U_USD">153800000</sepn:NonRefundableOneTimeUpfrontPaymentReceived>
    <sepn:NonRefundableOneTimeUpfrontPaymentReceived
      contextRef="C_a07cba62-15fb-408e-9eca-ccd2f26f2784"
      decimals="-5"
      id="F_0b283a79-51b4-4a62-a6af-f73e156c5dec"
      unitRef="U_USD">41200000</sepn:NonRefundableOneTimeUpfrontPaymentReceived>
    <sepn:VariableConsideration
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-5"
      id="F_95603b85-e76d-40b6-acc1-2a65180f9cbf"
      unitRef="U_USD">94000000</sepn:VariableConsideration>
    <sepn:NonRefundableOneTimeUpfrontPaymentReceived
      contextRef="C_188353cf-4494-4271-90fa-2b494b9ce37b"
      decimals="-5"
      id="F_9aae6384-35b2-4cd6-9703-97d4d95e0e15"
      unitRef="U_USD">26800000</sepn:NonRefundableOneTimeUpfrontPaymentReceived>
    <sepn:VariableConsideration
      contextRef="C_188353cf-4494-4271-90fa-2b494b9ce37b"
      decimals="-5"
      id="F_6511bd0b-fc2a-4dec-a8cd-8c367e2d8f68"
      unitRef="U_USD">18600000</sepn:VariableConsideration>
    <sepn:SummaryOfChangesInDeferredRevenueTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_8e0a35c1-ffb9-46c1-9671-d4eec5cb8e9d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the changes in deferred revenue for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:73.385%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.759%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.855999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognized revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;_____________________&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deferred revenue, current and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of deferred revenue, non-current, which is expected to be recognized over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all of the Company's performance obligations are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</sepn:SummaryOfChangesInDeferredRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_9c2248bf-d680-4e4c-9956-051672a0ad00"
      decimals="-3"
      id="F_3e528a9f-e92e-43de-8138-e0be80e29a5f"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <sepn:ChangeInDeferredRevenue
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-3"
      id="F_f91d546d-e2f1-4f9f-80d7-158f408dbd8c"
      unitRef="U_USD">195000000</sepn:ChangeInDeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_6ea5876e-4f38-4f62-bb26-1a536fd2018e"
      decimals="-3"
      id="F_1a8182f3-8f47-49c6-9796-3c0df53ff2fc"
      unitRef="U_USD">-26814000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550"
      decimals="-3"
      id="F_ee90e8fb-797b-40bb-a12e-27c3b5986690"
      unitRef="U_USD">168186000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550"
      decimals="-5"
      id="F_9ea62926-c73d-48a5-b4f6-11e04cd97fbf"
      unitRef="U_USD">62300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_48dd3a22-72e9-47cf-8b0e-cc1774f6f550"
      decimals="-5"
      id="F_f844565e-1ada-4cdc-9142-1137924b9455"
      unitRef="U_USD">105900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_12930a8d-66c5-4c50-9202-0f635796fbca"
      id="F_24c11777-abf0-410f-bd5a-acbd3436d95b">P3Y6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <sepn:MilestonePaymentReceived
      contextRef="C_d2961116-d112-4899-9e01-f6d82d75041d"
      decimals="-5"
      id="F_92cdb64d-ad4d-42ca-9941-6a00d4fd4d46"
      unitRef="U_USD">12500000</sepn:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_88ac2057-9216-425c-b13e-16df574b3054"
      decimals="-5"
      id="F_7d5a5217-469a-46c6-a47d-0a4db8dbddd7"
      unitRef="U_USD">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_53a67097-47c1-490a-8b40-0541279b1af4"
      decimals="-5"
      id="F_540ef838-fc58-4d80-bb49-3b455dbd7d85"
      unitRef="U_USD">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sepn:MarketableSecuritiesAndFairValueMeasurementsTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_ae74b8d9-8b67-4235-8894-ff2ed3ff9191">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Marketable Securities and Fair Value Measurements&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records marketable securities and cash equivalents at their estimated fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.53%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;544,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.53%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;414,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company&#x2019;s marketable securities consist of debt securities, including U.S. treasury and agency securities, corporate debt securities and commercial paper. These marketable securities are carried at fair value and are included in the tables above. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these marketable securities and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met at December 31, 2025. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and the Company's expectation is that those payments will continue to be received timely. Based on this evaluation, as of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company determined that unrealized losses of its marketable securities were primarily attributable to changes in interest rates and non-credit related factors. As such, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowances for credit losses were recorded at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t hold marketable securities at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest receivable as of December 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and is recorded as a component of prepaid expenses and other current assets on the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, all marketable securities in an unrealized loss position had been in an unrealized loss position for less than 12 months. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; marketable securities had been in an unrealized loss position for a period of less than 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;322,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;322,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;479,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, the following table summarizes marketable securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:42.649%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.503%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Contractual Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</sepn:MarketableSecuritiesAndFairValueMeasurementsTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_974d35b5-0221-4b32-9702-40e93a0ca038">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.53%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;544,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.53%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;414,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9dd7f8d2-59e4-40bc-9f16-2e9328a32206"
      decimals="-3"
      id="F_866241fd-d267-4449-a95a-dcd13cba6547"
      unitRef="U_USD">63736000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_322e150f-75d2-4c33-a81b-00ef3a3995d8"
      decimals="-3"
      id="F_4cd14179-ff1f-4b13-8a15-bdaaf68e576f"
      unitRef="U_USD">63736000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_8106e33b-b35d-4b54-80a9-eda7570e154a"
      unitRef="U_USD">50163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_fab764e8-30d4-4a5a-8352-b6d7d8e5c87b"
      decimals="-3"
      id="F_e115698b-c129-4dc6-adb8-de21b50b46c6"
      unitRef="U_USD">50163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_d541711e-c5a8-4147-8cb1-279e6a6dacb0"
      unitRef="U_USD">2190000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48"
      decimals="-3"
      id="F_732d4d51-f611-4b40-87ad-03b96246557e"
      unitRef="U_USD">2190000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_d0c1262a-c534-4bf0-945b-6a5f21453c55"
      unitRef="U_USD">141984000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_c8ea85e2-1da3-448c-b148-4c967f416f46"
      decimals="-3"
      id="F_6f945a11-1c79-4f8e-be9d-5d7fd9c292e8"
      unitRef="U_USD">141984000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_907401fb-87da-40de-a02e-1157c2b3de35"
      unitRef="U_USD">67784000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_fab764e8-30d4-4a5a-8352-b6d7d8e5c87b"
      decimals="-3"
      id="F_0723cb20-9f29-4748-9af5-6fb038314ab5"
      unitRef="U_USD">67784000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_85556068-5818-4d8b-9fb6-47a7310fd5ba"
      unitRef="U_USD">32573000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48"
      decimals="-3"
      id="F_0b5aff61-4889-4168-911c-e1ed92536d24"
      unitRef="U_USD">32573000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_5d69701e-cd5e-4b2c-ab77-9883855a9663"
      unitRef="U_USD">28026000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_84474bd9-0ca3-4043-a28f-246196964124"
      decimals="-3"
      id="F_5ddcd1b1-34ea-48dc-b1b6-c541f6dc5c2f"
      unitRef="U_USD">28026000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_438fe1e7-abba-4743-a61e-1f6b9f3167a0"
      unitRef="U_USD">117632000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_c8ea85e2-1da3-448c-b148-4c967f416f46"
      decimals="-3"
      id="F_977d258b-bf02-4613-bcdd-9c29ee05c00f"
      unitRef="U_USD">117632000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_b52c5f7b-ae35-432d-adfe-5e203402d607"
      unitRef="U_USD">35713000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_ba78dae4-64f3-421f-bef6-f75df8ac8f48"
      decimals="-3"
      id="F_0560858c-21d6-41a7-9feb-38becea10448"
      unitRef="U_USD">35713000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_49ac7d26-9780-4fb1-afb7-ca59c3d5e50e"
      unitRef="U_USD">4224000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_84474bd9-0ca3-4043-a28f-246196964124"
      decimals="-3"
      id="F_0f54bde0-1ba7-4adc-809b-0eec2bbd14c9"
      unitRef="U_USD">4224000</us-gaap:MarketableSecuritiesNoncurrent>
    <sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_a491f840-eb5d-4193-9e35-84d10765e180"
      unitRef="U_USD">544025000</sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_93212ce3-a90a-4a57-a707-34c5cc5ff182"
      decimals="-3"
      id="F_88cbc855-3ea9-46d0-b3c1-e3f0293bd0d8"
      unitRef="U_USD">63736000</sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_3f36de4b-8700-4f6c-bc71-ae1a9dc8ff7d"
      decimals="-3"
      id="F_8c17a7c7-dd98-4e28-9e32-0d48cb1302c8"
      unitRef="U_USD">480289000</sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2f1fe350-b8c7-4223-a96e-9534890d1439"
      decimals="-3"
      id="F_df897add-a938-45f1-b6e9-1d5f9c86b14a"
      unitRef="U_USD">141779000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f01b0a9e-0bec-4e73-87b2-511f0f3402f1"
      decimals="-3"
      id="F_f6b15554-71b4-44c7-9c03-ca6fca933d89"
      unitRef="U_USD">141779000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196"
      decimals="-3"
      id="F_049d6095-3b58-4d68-949c-ba19119fda39"
      unitRef="U_USD">82527000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6779c8bc-bf3a-4123-b629-4da74d3cadda"
      decimals="-3"
      id="F_ce613127-fbbe-4cb2-9e5c-a1187db7d53f"
      unitRef="U_USD">82527000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_84da8f71-625a-4397-8a29-fbd16cb27f65"
      unitRef="U_USD">8059000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_99f18d25-7a69-4282-995c-9eebff9e8b6a"
      decimals="-3"
      id="F_a01d6536-c59f-452c-92d0-fe1576d72b78"
      unitRef="U_USD">8059000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_2fd6e4f9-a979-41a2-ad28-212623bf990d"
      unitRef="U_USD">73555000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_fb785e0f-2bdc-4e89-ac3b-e5d3f8322c6c"
      decimals="-3"
      id="F_e04d5794-670b-4abb-81f0-6e033c687fc9"
      unitRef="U_USD">73555000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196"
      decimals="-3"
      id="F_ce8373dd-d125-4c27-9725-78f9427e8ef8"
      unitRef="U_USD">23487000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_6779c8bc-bf3a-4123-b629-4da74d3cadda"
      decimals="-3"
      id="F_3e05b4d5-c0cf-414c-a26d-b0a02b92010d"
      unitRef="U_USD">23487000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_5dfee6fb-462e-4da9-b013-0f93e16e425a"
      unitRef="U_USD">14193000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_99f18d25-7a69-4282-995c-9eebff9e8b6a"
      decimals="-3"
      id="F_c4b4ae97-08a8-4a75-9bdf-91147c352103"
      unitRef="U_USD">14193000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_efb5d092-1f37-48c5-bc15-9dc37bbfb1ab"
      unitRef="U_USD">1492000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_62168868-0203-4750-a338-01cfd04ab7de"
      decimals="-3"
      id="F_ecbccfb2-d22e-4fd4-b96a-923a97b751be"
      unitRef="U_USD">1492000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_6a297b1f-e7af-4200-98f7-aa478477e469"
      unitRef="U_USD">65406000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_fb785e0f-2bdc-4e89-ac3b-e5d3f8322c6c"
      decimals="-3"
      id="F_34a36456-23d3-4a33-9a8d-57830927c882"
      unitRef="U_USD">65406000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_fada2b7f-d64f-4494-bdd6-beb8624609ff"
      unitRef="U_USD">2514000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_99f18d25-7a69-4282-995c-9eebff9e8b6a"
      decimals="-3"
      id="F_1dad3501-5bfc-4cd9-874d-94304201328f"
      unitRef="U_USD">2514000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_2a0e95bf-d040-4f25-bbf3-749a058e62dc"
      unitRef="U_USD">1946000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_62168868-0203-4750-a338-01cfd04ab7de"
      decimals="-3"
      id="F_1cc23fc7-7b58-4444-8a7e-21a10fae0ca4"
      unitRef="U_USD">1946000</us-gaap:MarketableSecuritiesNoncurrent>
    <sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_9a8e33a8-4e4f-42be-8be2-46822d883660"
      unitRef="U_USD">414958000</sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_38782ba4-4fa6-40c7-934f-d3a079936095"
      decimals="-3"
      id="F_37a63c0b-ab13-4960-af72-1a40435e03fa"
      unitRef="U_USD">141779000</sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
      contextRef="C_3dd767cf-b320-4070-b5e9-d4aef8502c4f"
      decimals="-3"
      id="F_ea608e92-3068-43c7-9824-7dc2d235e138"
      unitRef="U_USD">273179000</sepn:CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_2ecff618-3310-44da-a7ff-dc8ba1f727c8"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:MarketableSecurities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_aafdf896-77b5-434c-ae03-70ddba0ce5d9"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_b3d53d15-29ec-421d-989c-75e94a00a664"
      decimals="-5"
      id="F_41d005b7-1741-41f9-b8e6-d036a9ac2b16"
      unitRef="U_USD">3400000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_43f43b58-1c3c-4c77-a255-d8e27eb71c5c"
      decimals="-5"
      id="F_ddaf9b06-5160-421f-abf8-bced75dafb05"
      unitRef="U_USD">1000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_e887b2d3-5e3f-4853-a4fe-ed97879920aa"
      unitRef="U_Position">44</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_a5757424-cb6e-4f8a-b640-174493f64e06">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;322,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;322,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;479,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;480,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the following table summarizes the amortized cost and the unrealized gains (losses) of the marketable securities presented within marketable securities, marketable securities, non-current and cash equivalents (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_a10d9284-f7f4-4efb-8df6-25825daefa2f"
      unitRef="U_USD">117939000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_0f97c91b-b7af-4fcd-abf7-49c6e8b13e42"
      unitRef="U_USD">17000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_ad0ca3b8-7a04-466e-b041-781c846f1db7"
      unitRef="U_USD">9000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_7602c5fa-5591-4c85-a948-83336e9c416d"
      unitRef="U_USD">117947000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_2d976a60-367c-492c-b8aa-6b2176f8db14"
      unitRef="U_USD">141688000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_69cd85eb-1b8b-4574-add8-b50eb125e7bd"
      unitRef="U_USD">296000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_c6a8b47a-03ab-48cd-902c-19bbab818ec6"
      unitRef="U_USD">0</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_0b9d26e2-4130-448c-aa35-630d46ebd0cb"
      unitRef="U_USD">141984000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_f74abead-9de9-4996-85b8-0fb73810898a"
      unitRef="U_USD">34755000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_b09049e5-bb1d-490d-8722-79e43b29c1e2"
      unitRef="U_USD">14000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_e8ec1f0e-8652-40ee-ad69-7f7ae6d05ab8"
      unitRef="U_USD">6000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_b00889e5-8bb7-43e5-b139-6f053d0029bc"
      unitRef="U_USD">34763000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_96e8de3e-e674-4ba6-8d99-cc21027a6f2a"
      unitRef="U_USD">27992000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_8a0a5ee2-d75f-4065-ab03-02bb77b3a788"
      unitRef="U_USD">34000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_0f710121-cfda-4181-b86f-9af3d701b8e8"
      unitRef="U_USD">0</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_f29ca788-eb88-482e-8dc1-e57da88e412e"
      unitRef="U_USD">28026000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_019ba459-de37-4576-b56a-c08dec61083f"
      unitRef="U_USD">322374000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_ad1ecd1a-d702-480b-9f1c-5fdae6390b57"
      unitRef="U_USD">361000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_0ddc2cab-e242-4ade-93d0-069376ccef26"
      unitRef="U_USD">15000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_11e6800b-2a36-46c6-908b-2dd9429a7d91"
      unitRef="U_USD">322720000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_ca95d410-f606-4ce8-b258-3749c07276be"
      unitRef="U_USD">117376000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_687390da-46c5-4afe-ab9c-244b9ebaf186"
      unitRef="U_USD">257000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_7dfcbd08-1ecb-4efc-8f2d-7b6d3bffa3ad"
      unitRef="U_USD">1000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_da206d0b-355d-44b7-bd6b-324972a666e9"
      unitRef="U_USD">117632000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_9a3b218e-955d-41dc-9cae-4b6411ea46c4"
      unitRef="U_USD">35699000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_2dee7a23-7fc6-49b3-b56d-0cbe8ec86aa4"
      unitRef="U_USD">24000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_2395504c-43f9-4adc-963b-809712dfa3d2"
      unitRef="U_USD">10000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_df3c9a58-f95c-4d36-9d8d-ceb9e53ea765"
      unitRef="U_USD">35713000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_d65db3c4-4c2e-41e7-a127-ffc79b3671d0"
      unitRef="U_USD">4223000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_5f1ef592-bd00-480a-8259-7981163e1392"
      unitRef="U_USD">2000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_b78ed053-21d2-44b1-805f-6a9382990001"
      unitRef="U_USD">1000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_32fc4352-66e1-4a0d-8b44-f562c0aff8ae"
      unitRef="U_USD">4224000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_b5d2f42d-21c5-41cf-8224-34c8db41ad79"
      unitRef="U_USD">479672000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_77b3481a-e442-4640-9b82-39c833c5a28c"
      unitRef="U_USD">644000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_527fff61-d8aa-4d2a-acd4-8db43cf94efd"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_adc0319f-4ff0-4258-94cb-c81441f92463"
      unitRef="U_USD">480289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196"
      decimals="-3"
      id="F_9b1b68a7-bdc0-4272-97fa-972ea8e07ff9"
      unitRef="U_USD">106017000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196"
      decimals="-3"
      id="F_e95e0fbb-4af0-459c-ac83-2d79708c46f2"
      unitRef="U_USD">6000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196"
      decimals="-3"
      id="F_5929441e-c456-4e09-b9f3-95b63912adf9"
      unitRef="U_USD">9000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_718c7a03-3168-40d9-845c-81b6ea2dc196"
      decimals="-3"
      id="F_eec8c874-5ebe-4d7d-8aa6-ac57bb4e6e10"
      unitRef="U_USD">106014000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_d1b9a3b3-ecb7-45e1-a75c-b89c104f7b60"
      unitRef="U_USD">73511000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_0c743dfa-236c-488c-9805-f21c31c2d6ef"
      unitRef="U_USD">44000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_b5402750-0b2b-4146-8bd3-e175f7cf53dc"
      unitRef="U_USD">0</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_57bd5281-2e93-4008-8de0-9b3d30744629"
      unitRef="U_USD">73555000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_6837d6cc-73f5-4df6-8be3-5e98286a0945"
      unitRef="U_USD">22245000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_467baa86-5d8d-4c9a-8124-6bad64119672"
      unitRef="U_USD">10000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_032ebcdc-1b3e-4baf-bdb2-eb45730eaf29"
      unitRef="U_USD">3000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_fb31c94a-df71-4b19-baf2-1a345b386cd5"
      unitRef="U_USD">22252000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_f3dbb90d-cbec-4a58-a637-b88ff3b08fdc"
      unitRef="U_USD">1491000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_3c4cc00f-69d2-4cf7-888a-4b112ef69b13"
      unitRef="U_USD">1000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_2c2ba136-caf8-464c-8717-6dcbd53b41f9"
      unitRef="U_USD">0</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_f12b5de6-1254-458c-8e23-da468b3250d6"
      unitRef="U_USD">1492000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_38f8c8a6-06cb-4908-9952-21a9ac71e073"
      unitRef="U_USD">203264000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_b89e8bcc-003a-4c95-a01a-82b4769b9fe4"
      unitRef="U_USD">61000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGains>
    <sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_d6d1a0ed-e11a-4658-b223-43ae79cd1fb9"
      unitRef="U_USD">12000</sepn:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_8533fc9b-4085-4c38-af35-afd606a76ba5"
      unitRef="U_USD">203313000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_dc5e22a0-bf0d-4730-8198-5067f6adc222"
      unitRef="U_USD">65427000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_29f1f1da-ee46-497c-aa20-2213fddbf4e2"
      unitRef="U_USD">37000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_c39fa0ab-b088-4bac-900c-28fd56608ae0"
      unitRef="U_USD">58000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="C_14b12819-68bb-4fc2-a4a0-9759c3528569"
      decimals="-3"
      id="F_346382a5-8602-4c72-ace1-727b27847322"
      unitRef="U_USD">65406000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_57c338ca-c06e-4117-8c79-c4e933bbe884"
      unitRef="U_USD">2492000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_c550919d-e2f2-4726-82eb-521df1c64b75"
      unitRef="U_USD">22000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_15c53f9b-0fb8-45ef-9117-9e17da47ed4b"
      unitRef="U_USD">0</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="C_e999414c-e45b-4680-8108-7315ee154945"
      decimals="-3"
      id="F_30d50ae9-3152-4776-ba31-9b0436bd5828"
      unitRef="U_USD">2514000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_cc7cb5b5-4dfb-47e5-9e53-a063021318c9"
      unitRef="U_USD">1940000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_cf24e0ee-8bc5-46f1-aebb-32a52277d8ff"
      unitRef="U_USD">7000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedGains>
    <sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_7d7f2386-eb70-4913-bfe7-8598f7524fd9"
      unitRef="U_USD">1000</sepn:AvailableForSaleMaturesAfterOneYearThroughFiveYearsGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="C_dc1996a6-5af5-4790-92b3-bf4653cfe783"
      decimals="-3"
      id="F_a798d3a2-b13c-47d7-90b4-65bdb336e66b"
      unitRef="U_USD">1946000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_2103f87e-c2ca-4562-88eb-2df51544cc0a"
      unitRef="U_USD">273123000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_71572632-781f-4d07-8c13-d102d6ca0979"
      unitRef="U_USD">127000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_09090e3d-9c08-48fb-9fcf-c3187a3221ae"
      unitRef="U_USD">71000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_f3102b94-2bda-457c-ba9b-3bae7ba07c0d"
      unitRef="U_USD">273179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_3a16ffcd-d264-4fc3-83f5-ca3e617d53f3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, the following table summarizes marketable securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:42.649%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.503%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining Contractual Maturity (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 to 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_5fecf850-2e18-49cf-a39b-7f40123ed818"
      unitRef="U_USD">57503000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_aa158f2d-21a5-43a3-92f3-b104a9b70829"
      decimals="-3"
      id="F_9e1a2ee7-8192-4727-9cf0-2cf6346e4818"
      unitRef="U_USD">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_31c020cb-e1c6-440d-b425-cd01787cbbea"
      unitRef="U_USD">10064000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_dd3a0e12-a510-4ccc-9370-675f139312cf"
      unitRef="U_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_6fdaa94c-7272-405b-93b3-21ada17b6ab5"
      unitRef="U_USD">67567000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_f0c7044e-52aa-4535-9421-574e056ea03b"
      unitRef="U_USD">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_362c3b75-bf64-4edc-a4d0-0b511b882f29"
      unitRef="U_USD">17484000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_1b93ff37-5094-4c86-95d8-dcd363b7feca"
      decimals="-3"
      id="F_bb138e3f-b5ba-4f86-8eeb-7af9c9efa3b2"
      unitRef="U_USD">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_b592bd7b-3040-4c2e-8801-083c098b3878"
      unitRef="U_USD">4009000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_87f92cdf-0e6a-453e-ad0f-f51b24d05ef3"
      decimals="-3"
      id="F_e4b6c7c3-8ed2-49c5-9720-c552254e6961"
      unitRef="U_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_8d9a038d-ad3f-4101-b1b5-109c72397c0b"
      unitRef="U_USD">3389000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_605171e8-8b01-43d7-a003-6089b7762a8c"
      decimals="-3"
      id="F_e3fab707-5b0d-4170-a7b5-d6b42b069d1f"
      unitRef="U_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_fcee41e2-6a40-49a2-9e05-b93ccaa67018"
      unitRef="U_USD">92449000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_fad00663-bee7-4867-aa0a-9dc5f318c7e6"
      unitRef="U_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_ce0763ef-c1e4-4932-9b72-38d8070116c5">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leases&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases office and research and development space at the Company&#x2019;s headquarters in South San Francisco, California under an operating lease. In April 2021, the Company entered into a lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,560&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet, set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In September 2022, the lease was amended to add &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,348&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet, totaling &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,908&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet (the &#x201c;Original Leased Space&#x201d;), also expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In December 2022, the Company entered into another lease amendment to extend the term of the Original Leased Space and added &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,911&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet (the &#x201c;Additional Leased Space&#x201d;). The Company took control of the Additional Leased Space in November 2023, at which point the Company vacated the Original Leased Space to allow the landlord to renovate it.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Renovation of the Original Leased Space was completed in July 2024. Upon completion of the renovation of the Original Leased Space, the lease of the Original Leased Space commenced, resulting in the total leased premises increasing to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,819&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet (the &#x201c;Leased Space&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease term for the Leased Space expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease for eight additional years (the &#x201c;Extension Option&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, it was not probable that the Company would exercise the Extension Option, therefore, it was excluded from the right-of-use asset and lease liability calculations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, the Company recorded a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million operating lease right-of-use asset and operating lease liability upon completion of the renovations of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,908&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square foot office and research and development space (the "Original Leased Space") as the Company occupied the property. These amounts are disclosed in the supplemental information of noncash activities on the statements of cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to pay base rent plus its proportionate share of operating expenses, as defined in the applicable lease agreement on all of its leases. Variable lease payments related to operating expenses including utilities, maintenance costs and real estate taxes were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024,  respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease expenses, excluding variable lease payments, were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively. Short-term lease expense was not material for the periods presented.  As of December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the weighted average remaining lease term of the Leased Space was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively. The weighted average incremental borrowing rate used for the calculation of the present value of lease payments over the lease term was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for both the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, future minimum rental payments for operating leases were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Future&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did not have any finance leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_c3cf3248-6c46-426f-8551-507bf07f1e44"
      decimals="INF"
      id="F_da33746b-4912-4d6e-b4d8-14db164e6928"
      unitRef="U_sqft">12560</us-gaap:AreaOfLand>
    <sepn:LesseeOperatingLeaseExpirationYearAndMonth
      contextRef="C_29cc3ec0-ed7a-4862-b908-992644953c81"
      id="F_fca862ea-e7e8-449f-98a1-9479982b8041">2023-02</sepn:LesseeOperatingLeaseExpirationYearAndMonth>
    <us-gaap:AreaOfLand
      contextRef="C_322b3bab-f26e-4ef7-b671-7788690ea969"
      decimals="INF"
      id="F_3903fba3-899e-4eba-9239-49157002026d"
      unitRef="U_sqft">9348</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="C_855097d9-96a1-4e02-94d5-4334f3801f9b"
      decimals="INF"
      id="F_6b18de93-7b40-4ff7-8002-315c99fd963c"
      unitRef="U_sqft">21908</us-gaap:AreaOfLand>
    <sepn:LesseeOperatingLeaseExpirationYearAndMonth
      contextRef="C_b5c224dc-4113-4169-a143-5596c3204f77"
      id="F_fd27e090-9529-4da4-aefb-59bd02829ad6">2023-02</sepn:LesseeOperatingLeaseExpirationYearAndMonth>
    <us-gaap:AreaOfLand
      contextRef="C_9aa30191-c34b-4a93-8ee6-eeca325c6cba"
      decimals="INF"
      id="F_58883eed-8925-4768-9eae-89196f091e89"
      unitRef="U_sqft">22911</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="C_7629b057-ea4b-4ebf-80e6-83afecdacd5f"
      decimals="INF"
      id="F_2412be08-7816-4002-8f6f-c8e9479fb069"
      unitRef="U_sqft">44819</us-gaap:AreaOfLand>
    <sepn:LesseeOperatingLeaseExpirationYearAndMonth
      contextRef="C_cebc2669-0a16-4e56-bad3-816ef82b4bab"
      id="F_a5ae684b-e85c-4971-9f84-ea0b463e4af4">2032-07</sepn:LesseeOperatingLeaseExpirationYearAndMonth>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_cebc2669-0a16-4e56-bad3-816ef82b4bab"
      id="F_02bb35b3-fd78-45a7-8d83-6b3d5becc031">option to extend the lease for eight additional years (the &#x201c;Extension Option&#x201d;)</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_cebc2669-0a16-4e56-bad3-816ef82b4bab"
      id="F_9048f7c0-02a1-4a73-b5b0-0221a7cabb52">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c30be0fc-4d13-491e-b258-067754619704"
      decimals="-5"
      id="F_f9e9f198-e2c6-4a84-8717-8d8dcb0650df"
      unitRef="U_USD">12500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c30be0fc-4d13-491e-b258-067754619704"
      decimals="-5"
      id="F_5c38c817-7370-4424-9f02-83c9cc8d2d26"
      unitRef="U_USD">12500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:AreaOfLand
      contextRef="C_c30be0fc-4d13-491e-b258-067754619704"
      decimals="INF"
      id="F_346c39b6-4ce4-4edf-905b-faf06d5d7834"
      unitRef="U_sqft">21908</us-gaap:AreaOfLand>
    <us-gaap:LeaseCost
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_2b6bdd67-6069-4aeb-9506-8ba676d225e9"
      unitRef="U_USD">1100000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-5"
      id="F_d14ada56-9005-439b-992f-e84acccd02e4"
      unitRef="U_USD">700000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_7681ff8d-f14e-4c72-a30e-68c59d234df4"
      unitRef="U_USD">4700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-5"
      id="F_1bba6324-451d-43d7-b7ef-fc616410cb89"
      unitRef="U_USD">3500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4fac1b78-8311-432d-aff9-c804f3132070"
      id="F_9ac7a2df-e60c-4e4d-b866-93faeed05321">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_976a0a52-eca0-4d4d-ae45-b70fef55d6e0"
      id="F_1842b56d-41d8-4cf7-bf00-a0585ebefb8d">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4fac1b78-8311-432d-aff9-c804f3132070"
      decimals="4"
      id="F_366c9dfe-7c2f-461a-a9aa-0db45211d958"
      unitRef="U_pure">0.1134</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_976a0a52-eca0-4d4d-ae45-b70fef55d6e0"
      decimals="4"
      id="F_dd52d86b-f21c-4cda-81e4-0cb1d806708d"
      unitRef="U_pure">0.1134</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <sepn:SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_5b56e44d-789b-445d-a0f6-8944b92b8989">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</sepn:SummaryOfLeaseCostAndCashPaidForOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_13a6815f-57a4-459f-b517-409e1abf0033"
      decimals="-3"
      id="F_c21a148c-302c-4ce2-96b2-992f8b8a2139"
      unitRef="U_USD">4469000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_15ee37b0-5f7b-4d77-b60f-a12687d07532"
      decimals="-3"
      id="F_afd1a016-ddba-4016-a764-5cbd51872c40"
      unitRef="U_USD">1631000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="C_13a6815f-57a4-459f-b517-409e1abf0033"
      decimals="-3"
      id="F_562222a9-0de1-41d6-8d8f-735bcc603afe"
      unitRef="U_USD">4721000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_15ee37b0-5f7b-4d77-b60f-a12687d07532"
      decimals="-3"
      id="F_bf55776b-ca17-44b8-adaf-1044343df531"
      unitRef="U_USD">3462000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_13a6815f-57a4-459f-b517-409e1abf0033"
      decimals="-3"
      id="F_4be565eb-64e9-4b07-a323-2f59fc69422e"
      unitRef="U_USD">1035000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_15ee37b0-5f7b-4d77-b60f-a12687d07532"
      decimals="-3"
      id="F_9a41d067-7d5a-4557-990e-a570f283c6d2"
      unitRef="U_USD">644000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_3ef2694f-9679-4f28-9c24-9f10ed12c408">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, future minimum rental payments for operating leases were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Future&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_8cc48c19-0cce-4431-8108-7652a1eba29b"
      unitRef="U_USD">4612000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_cdb50233-33f5-4ba0-9c19-8b5662f64235"
      unitRef="U_USD">4760000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_e35c38a9-9649-4735-843d-49d1c919b115"
      unitRef="U_USD">4912000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_986e310e-745d-4de0-b260-286882f15e4f"
      unitRef="U_USD">5070000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_9fe1ee44-c4a1-4c0d-abe2-77e1c5131d0d"
      unitRef="U_USD">5234000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_7ab7f7b0-a902-46a8-83ba-01cacf4e7646"
      unitRef="U_USD">8616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_a1faf7b3-1932-4dff-bc4d-534743ee1d8f"
      unitRef="U_USD">33204000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_314e0a84-bd45-48f0-a055-c7b9c41455b6"
      unitRef="U_USD">9579000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_71bf2655-2c4a-4f32-9f80-1d268d5ef175"
      unitRef="U_USD">23625000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_b627b5d8-f335-4609-852e-4f986d546632"
      unitRef="U_USD">2212000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_ef01cb34-ed3b-4655-aad6-4813c404ff96"
      unitRef="U_USD">21413000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_d9028fe1-922a-44cb-bf8f-996cc6bebe23"
      unitRef="U_USD">23625000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_1c8988e2-9cf2-44ab-bf0f-16e9758b69d3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation, as the Company operates in an industry susceptible to patent or other legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company was not subject to any material legal proceedings as of December 31, 2025 and 2024, and the Company is not currently a party to any legal proceeding that, if determined adversely to the Company, in management&#x2019;s opinion, is currently expected to individually or in the aggregate have a material adverse effect on the Company&#x2019;s business, financial condition or results of operations taken as a whole.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;exposure &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and may enable it to recover a portion of any future amounts paid. The Company is not currently aware of any indemnification claims. In addition, the Company believes that the fair value of any potential indemnification obligations is minimal. Accordingly, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record any liabilities associated with these indemnification rights and agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_81b65ada-2118-4464-819d-ac43aa93e1fc"
      unitRef="U_USD">0</sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements>
    <sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_131e1feb-1c48-421e-a4a6-c1887e3a5a87"
      unitRef="U_USD">0</sepn:LiabilitiesAssociatedWithIndemnificationRightsAndAgreements>
    <sepn:ConvertiblePreferredStockTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_abe732cc-6df7-49c1-a5bd-868873051bed">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Immediately prior to the closing of the Company's IPO in October 2024, the Company&#x2019;s outstanding convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,839,774&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;shares of common stock. Converted preferred stock outstanding as of the date of the IPO consisted of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196,657,452&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. Each share of outstanding convertible preferred stock was converted into common stock at a ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6103&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; convertible preferred shares to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of convertible preferred stock were authorized, issued or outstanding at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2021, the Company executed a Series A Convertible Preferred Stock financing arrangement that would provide financing of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million over an initial tranche and subsequent callable tranches through the issuance of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Series A Convertible Preferred Stock at an issuance price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. In the initial tranche, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Series A Convertible Preferred Stock for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was received in cash, net of issuance costs, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. The Series A Convertible Preferred Stock financing arrangement represented an equity financing, per the terms of the outstanding convertible promissory notes, and as such the unpaid principal and accrued interest outstanding of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Series A Convertible Preferred Stock. Additionally, in November 2022, the Company executed the second tranche and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Series A Convertible Preferred Stock and received net cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2023, the Company entered into a Series B Convertible Preferred Stock financing arrangement in which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,657,452&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Series B Convertible Preferred Stock were authorized to be issued at an issuance price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.23297&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share over two tranches, for total proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In June 2023 and July 2023, the Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Series B Convertible Preferred Stock at an issuance price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.23297&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the first tranche, with a potential second tranche of additional funding for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based on approval of the Board of Directors and consent of the majority of the holders of the then-outstanding Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock Purchase Agreement provides that, upon the fulfillment of certain conditions, each investor will purchase its pro rata portion of the shares to be issued in additional Series B Convertible Preferred Stock closings. Further, the Company agreed to sell, and issue said shares of Series B Convertible Preferred Stock on the same terms as the first tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were not freestanding from the associated shares of convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of Series B Convertible Preferred Stock for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</sepn:ConvertiblePreferredStockTextBlock>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"
      decimals="INF"
      id="F_db009339-2c66-4d97-bc7e-7d0228e86025"
      unitRef="U_shares">22839774</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"
      decimals="INF"
      id="F_47fabfba-fe54-4596-87fa-74643a28ac5f"
      unitRef="U_shares">196657452</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"
      decimals="INF"
      id="F_74449b94-56a7-45e8-bcea-d40db0035886"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.6103</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_31b3e28f-bc58-4c85-9b5a-81f738157245"
      decimals="INF"
      id="F_17d758a1-cc1c-4968-afb9-355b0fcc2576"
      unitRef="U_shares">1</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_65734d6a-52c9-41da-9387-bae2b81b1aa9"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_f02b615c-1326-4311-b82f-f06b378da9d3"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_196d191a-8f5b-4e8e-844d-6c18ffa1ebc4"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_031d4f12-6157-47bd-93e8-546a5b82d756"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_2e36db69-bab1-44ec-8cf2-7554fbfdf9ef"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_9da6d97a-888a-4cd5-8f16-94c89da3b4a4"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <sepn:TemporaryEquityStockFinancingArrangementFinancingValue
      contextRef="C_ea277975-b2f2-4b8a-b194-b83995f01006"
      decimals="-5"
      id="F_88e58021-0748-4919-b60a-77a6e763faae"
      unitRef="U_USD">100000000</sepn:TemporaryEquityStockFinancingArrangementFinancingValue>
    <sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_45f515bf-1005-4082-bc32-9ade4315528d"
      decimals="INF"
      id="F_985233a9-f00a-46d6-b145-d64a1d3155c5"
      unitRef="U_shares">100000000</sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_1966a14f-61e2-41d4-a6ff-47aa4fad01b8"
      decimals="INF"
      id="F_0c9a2ee1-1a32-4530-8b26-0987a7581a7a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1</us-gaap:PreferredStockConvertibleConversionPrice>
    <sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102"
      decimals="INF"
      id="F_97593be6-d7e8-4f3d-b733-273ed2491542"
      unitRef="U_shares">45000000</sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102"
      decimals="-5"
      id="F_a229a4f2-d23a-4718-83e5-1ca4cef73a14"
      unitRef="U_USD">44700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:CashProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102"
      decimals="-5"
      id="F_665a08a3-aa98-4e43-b2bc-638168610639"
      unitRef="U_USD">30000000</sepn:CashProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest
      contextRef="C_c3bed3aa-2c40-46c7-a1c9-cc7028622102"
      decimals="-5"
      id="F_27a4065b-1769-49a9-a761-126883371239"
      unitRef="U_USD">14700000</sepn:NetProceedsConversionOfOutstandingConvertiblePromissoryNotesPlusAccruedInterest>
    <sepn:ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding
      contextRef="C_ca4c5acf-d189-48eb-b452-a7a26d138b38"
      decimals="-5"
      id="F_ae9d1864-6665-48a4-8f2d-b2db9453d634"
      unitRef="U_USD">14700000</sepn:ConvertiblePromissoryNotesUnpaidPrincipalAndAccruedInterestOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_ca4c5acf-d189-48eb-b452-a7a26d138b38"
      decimals="INF"
      id="F_fac38477-c548-41db-b9ec-95d36bd318c8"
      unitRef="U_shares">14700000</us-gaap:ConversionOfStockSharesIssued1>
    <sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_60266656-e390-427d-9798-309361aca6dd"
      decimals="INF"
      id="F_8fc4926f-96a1-4e7e-bc93-40867e263467"
      unitRef="U_shares">30000000</sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_60266656-e390-427d-9798-309361aca6dd"
      decimals="-5"
      id="F_9c95b481-2f7c-4006-a53c-6e0b44ea222c"
      unitRef="U_USD">30000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares
      contextRef="C_9bf04a86-29ff-485b-98ad-fd0cfacc548a"
      decimals="INF"
      id="F_036cbecd-94dd-4a46-af85-7e1878db3912"
      unitRef="U_shares">121657452</sepn:TemporaryEquityStockAuthorisedToBeIssuedDuringPeriodShares>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_04ddd023-f899-4392-8195-43ee327ecc9a"
      decimals="INF"
      id="F_18e9246f-732a-402c-a0c3-06e1442ee714"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.23297</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_f57fea07-b224-42ba-828d-12e6d48e58e5"
      decimals="-5"
      id="F_4dcf7394-a3d0-4b65-a2b1-675fd93dce0f"
      unitRef="U_USD">150000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_61651a61-4b9e-4a51-a5f6-c5b66b40d36c"
      decimals="INF"
      id="F_0fc85858-bbb7-4fad-8d04-82ec5850d552"
      unitRef="U_shares">60800000</sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_572956ed-3133-4ecc-8cc8-1ffe3b8330b1"
      decimals="INF"
      id="F_1964966e-74e9-4174-a503-e0afc59f23c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.23297</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_61651a61-4b9e-4a51-a5f6-c5b66b40d36c"
      decimals="-5"
      id="F_333086c1-1c7d-4d8c-85c9-eda168f291e1"
      unitRef="U_USD">74500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:TemporaryEquityStockAdditionalFundingBasedOnApproval
      contextRef="C_79b1f183-8e7f-4be0-a70d-a466859c1d3f"
      decimals="-5"
      id="F_c06312be-5966-4b5a-b7ec-dbd72f6e6ce0"
      unitRef="U_USD">75000000</sepn:TemporaryEquityStockAdditionalFundingBasedOnApproval>
    <sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0baed1d2-4492-4d81-b9ab-a87043b82d59"
      decimals="INF"
      id="F_51001d22-3a9c-43fc-8e9f-049bf57b1773"
      unitRef="U_shares">60800000</sepn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0baed1d2-4492-4d81-b9ab-a87043b82d59"
      decimals="-5"
      id="F_f6707a7e-bed2-4e74-84ae-459319132daa"
      unitRef="U_USD">74900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sepn:CommonStockTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_0a0eeb76-ec24-4e18-916f-f2b68c069e8f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company was authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company amended and restated its certificate of incorporation, which was filed immediately prior to the closing of its IPO and among other things, increased the number of shares of common stock authorized for issuance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company completed its IPO of its common stock. In connection with the Company's IPO, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock, which included an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock that were issued to the underwriters pursuant to the full exercise of their option to purchase additional shares of common stock, at the public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. As a result, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;302.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net proceeds, after deducting underwriting discounts and commissions and other offering costs payable by the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holders of common stock are entitled to dividends when and if declared by the board of directors. The board of directors has not declared any dividends and the Company has not paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reserved the following shares of common stock, on an as-converted basis, for future issuance:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,378,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,938,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future grants under 2024 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,257,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,743,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for 2024 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,887,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,052,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</sepn:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5"
      decimals="-5"
      id="F_17a50f98-5761-4268-8039-275cdb3ea55d"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c"
      decimals="-5"
      id="F_6a03237d-51a6-4575-ba3a-0dcf1f6b281c"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_55584b29-8759-4aa6-8eef-4c5377a2f3a5"
      decimals="INF"
      id="F_d4ceab65-931f-47c8-b9fc-036891c956a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7e89301a-aa7a-40e3-9dd3-73b25264a67c"
      decimals="INF"
      id="F_71fd5c02-0f2d-4405-aeea-a365c3018031"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a9403ba1-557a-40df-a781-80b2faef2036"
      decimals="INF"
      id="F_8f799e56-6196-4258-9cbb-b9897993282d"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="-5"
      id="F_cc7e368a-b615-420a-85ca-e4bde02bcd8e"
      unitRef="U_shares">18400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_da673621-a76d-4b43-ba2e-10ba33dfce9a"
      decimals="-5"
      id="F_64523752-98a4-4bd6-bfa1-2cda8fd027c9"
      unitRef="U_shares">2400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a219684e-e5f5-42fa-8a88-03671f64ca2e"
      decimals="2"
      id="F_b1917de6-ce62-4b63-b3b1-76acadce2965"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="-5"
      id="F_0010126f-546e-4583-9a9e-88eba16d37fc"
      unitRef="U_USD">302800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <sepn:UnderwritingDiscountsCommissionsAndOtherOfferingCosts
      contextRef="C_7ab5629f-2853-4b6b-ba19-5748e1822866"
      decimals="-5"
      id="F_c10b5a72-ddcc-4457-87d3-bb5dea95f53e"
      unitRef="U_USD">28400000</sepn:UnderwritingDiscountsCommissionsAndOtherOfferingCosts>
    <sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_e815310a-3b45-48cc-ab0b-1cacc03af9c7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reserved the following shares of common stock, on an as-converted basis, for future issuance:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,378,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,938,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for future grants under 2024 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,257,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,743,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for 2024 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,887,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,052,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</sepn:SummaryOfCommonStockSharesReservedForFutureIssuanceOnConvertibleBasisTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_20efa5c4-f0f4-4871-a51a-f97b96ba7528"
      decimals="INF"
      id="F_f085ea9e-f4bb-4d37-8bab-a8e53c3980f9"
      unitRef="U_shares">4378484</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_319a9d87-f6e6-4839-a984-753a05d06533"
      decimals="INF"
      id="F_908c2689-f8f3-4fe5-995c-c031ea9f65cb"
      unitRef="U_shares">2938982</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_69798fd2-c3f2-4367-9df7-974806f034ff"
      decimals="INF"
      id="F_cd0e7627-7dbd-4be2-be9c-731256b0d599"
      unitRef="U_shares">4257640</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_93730b11-03a0-4363-ac76-9b4b4706269a"
      decimals="INF"
      id="F_80266da5-6b33-4fbe-bfcf-37f94004e998"
      unitRef="U_shares">3743915</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7bbf537c-2701-4b45-969a-1f72cf64e583"
      decimals="INF"
      id="F_a58ce5d1-1f8e-470e-9878-25ae5cc80577"
      unitRef="U_shares">251211</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6ec0577b-0a29-403d-97f4-adea4205df16"
      decimals="INF"
      id="F_d4b35ff8-4f28-4053-b910-6709d02e828a"
      unitRef="U_shares">369402</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_069adc29-bdf3-45d5-9aa2-8bb64e5e8e7a"
      unitRef="U_shares">8887335</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_b1ba1c00-2848-4739-b1bf-bd72edc51b9c"
      unitRef="U_shares">7052299</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_222b5ae5-c413-4482-8567-cc97393aec15">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company's board of directors adopted, and its stockholders approved, the 2024 Stock Option and Incentive Plan (the &#x201c;2024 Plan&#x201d;) which became effective on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 25, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The 2024 Plan allows for the issuance of equity-based incentive awards to the Company's officers, employees, directors and consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034 by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding number of shares of the Company's common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company's compensation committee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2024 Plan replaced the Septerna, Inc. 2021 Stock Option and Grant Plan (the &#x201c;2021 Plan&#x201d;) as the Company&#x2019;s board of directors determined not to make additional awards under the 2021 Plan following the completion of the IPO. However, the 2021 Plan will continue to govern outstanding equity awards granted thereunder. The shares of common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added to the shares of the Company's common stock available for issuance under the 2024 Plan. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares remained available for future issuance under the 2024 Plan as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options are governed by stock option agreements between the Company and recipients of stock options. Incentive stock options and nonqualified stock options may be granted under the 2024 Plan at an exercise price of not less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the board of directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of the stock options may not exceed ten years from the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Stock Option and Grant Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2021, the Company adopted the 2021 Plan, which authorizes the Company to grant incentive stock options, non-qualified stock options, restricted stock awards, unrestricted stock awards and restricted stock units, to officers, employees, directors, consultants, or other key persons of the Company. The terms of the stock option and restricted stock agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2021 Plan. Stock option awards expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the grant date, or as otherwise determined by the Board of Directors, or in the case of incentive stock options granted to 10% stockholders, the term is no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the grant date. Additionally, the Company granted and issued restricted stock awards and allowed the recipients to purchase the unvested restricted stock awards at par value per share. The shares issued for unvested restricted stock awards under the 2021 Plan are subject to repurchase by the Company at the original issuance price in the event of the holder&#x2019;s termination of its relationship with the Company. Consideration received for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#x2019; equity as the related awards vest over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares re&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;mained available for future issuance under the 2021 Plan as of December 31, 2025 and 2024 as the 2021 Plan was replaced by the 2024 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company granted restricted stock awards from the 2021 Plan and from outside of its stock plans, under the terms of restricted stock purchase agreements and subscription agreements. Unvested shares are subject to repurchase by the Company upon the holder&#x2019;s termination of its relationship with the Company at the original purchase price. Consideration received for shares associated with the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#x2019; equity as the related awards vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes restricted stock award activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;576,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock awards vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;442,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock awards repurchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The restricted stock awards generally include a service condition for vesting and vest over four years with a one-year cliff vesting and pro-rata monthly vesting thereafter, but some awards vest over different time periods. In addition, some restricted stock awards include vesting criteria subject to the achievement of performance-based conditions in addition to service conditions (&#x201c;performance RSAs&#x201d;). As of December 31, 2025, none of the outstanding and unvested performance RSAs were subject to achievement of performance-based criteria for vesting. The aggregate grant date fair value of shares vested during the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The remaining liability related to restricted stock awards as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 was not material and was recorded in accrued expenses and other current liabilities on the balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes stock option activity under the 2024 Plan:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,938,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,914,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;268,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,378,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.79&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,096,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options include a service condition for vesting and generally vest over four years. The aggregate intrinsic values of options outstanding and exercisable were calculated as the difference between the exercise price of the options and the closing market price of the Company&#x2019;s common stock as of December 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate grant date fair value of options that vested for the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The options granted in the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; had a weighted-average per share grant-date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and a total grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The total intrinsic value of stock options exercised during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company's board of directors adopted, and its stockholders approved, the 2024 ESPP. The 2024 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2026 and each January 1 thereafter through January 1, 2034, by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the outstanding number of shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the administrator of the 2024 ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2024 ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The offering periods begin on May 1 and November 1, will be twenty-four (24) months in duration and include four (4) purchase periods, each purchase period lasting six (6) months.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The purchase price will be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value per share of the Company's common stock on either the offering date, which is the first trading day of the offering period, or the purchase date, which is the last trading day of the purchase period, whichever is less.  If the fair market value of a share of the Company's common stock on any purchase date within a particular offering period is less than the fair market value on the start date of that offering period, then the offering period will automatically terminate and the employees in that offering period will automatically be transferred and enrolled in a new offering period which will begin on the next day following such purchase date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,191&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares at a weighted average share price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares available for issuance under the 2024 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option and ESPP Valuation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining the fair value of the stock options and ESPP granted, the Company uses the Black-Scholes option pricing model and assumptions discussed below. This model utilizes inputs that are subjective.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Term &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expected term represents the period that the Company&#x2019;s stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The Company will continue to apply this process until a sufficient amount of historical information regarding employee exercise patterns and post-vesting employment termination behavior becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Volatility &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the Company&#x2019;s limited operating history and lack of company-specific historical volatility as a public company, due to the Company's IPO in October 2024, or implied volatility as a private company, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free Interest Rate &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected Dividend &#x2014; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the near future. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average assumptions used to value employee and non-employee stock option awards granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="9" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average assumptions used to value employee stock purchase plan shares granted during the year ended December 31, 2025, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:64.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.562%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:4.688%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.22&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense for restricted stock awards, stock options, and ESPP recognized in the Company&#x2019;s statements of operations and comprehensive loss is presented as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total unrecognized stock-based compensation expense related to unvested restricted stock awards, stock options, and ESPP was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="C_84234d5b-13da-4f60-8e97-1e3d68e04f15"
      id="F_275fba1b-0062-4ecf-90eb-0be32e137197">2024-10-25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_9e8af7b3-5a45-498e-98e0-2a164d3ce69b"
      decimals="INF"
      id="F_03e5ab04-124a-4f49-900d-9bcb896f3ec5"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="-5"
      id="F_b325c16d-9d73-4277-9b84-6c195aea5adc"
      unitRef="U_shares">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9"
      decimals="-5"
      id="F_03f4626f-b3a2-4de6-8769-601ac345fbd6"
      unitRef="U_shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="2"
      id="F_3324023a-518e-43e4-adb6-4d233a3ee325"
      unitRef="U_pure">1</sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueExercisePricePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_3b25f05e-0de5-4de6-9e95-c302e515b95c"
      id="F_dc98810d-7993-43e5-96a0-52996fbd0ec5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_ef8945b7-cd7c-40a3-87d4-443fa84b4251"
      id="F_6c9194c6-206f-455b-affc-f5ae69825b61">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_6babc3f6-8967-4f07-bbd1-1345bb333060"
      decimals="INF"
      id="F_4742bb25-c80f-43c2-a257-f4a4823db67a"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_aae82e13-ba71-4eff-a125-de3c3ef90394"
      decimals="INF"
      id="F_2b1ab7fd-59e9-4f73-bec6-1161a4e2f696"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_f73a2776-6459-4fb0-a9bc-4204d876730b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes restricted stock award activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;576,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock awards vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;442,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock awards repurchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_885615b0-7d7a-4feb-b3a7-220a271f5de4"
      decimals="INF"
      id="F_a877dcf1-62f0-41a0-961c-d0105b464b40"
      unitRef="U_shares">576829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_885615b0-7d7a-4feb-b3a7-220a271f5de4"
      decimals="2"
      id="F_4cb02752-2306-47f7-a873-6435ca59e001"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679"
      decimals="0"
      id="F_bd1b0f3f-7b9e-4639-af0b-07941c713905"
      unitRef="U_shares">442993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679"
      decimals="2"
      id="F_0720e725-3f28-4602-bceb-141b6d29e684"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased
      contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679"
      decimals="INF"
      id="F_6279aac7-9bea-448e-9452-59ffa456f53f"
      unitRef="U_shares">2612</sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchased>
    <sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679"
      decimals="2"
      id="F_d74723fc-bf87-4187-9c7f-6ba336b25d09"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.3</sepn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionRepurchasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6646c47e-b885-4673-91f4-70ca9e64299e"
      decimals="INF"
      id="F_9e2498d3-011e-4c35-9e31-8a3cecc50526"
      unitRef="U_shares">131224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6646c47e-b885-4673-91f4-70ca9e64299e"
      decimals="2"
      id="F_5c693ab7-ff10-438a-b10e-0fcf24c209d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_6c210c25-1bfe-4528-904c-2b7a7741e679"
      decimals="-5"
      id="F_e17014c4-e993-4f13-8648-0fff1c77bf3c"
      unitRef="U_USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      id="F_70d154be-d27c-4919-8c42-a02ce0a58981">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following summarizes stock option activity under the 2024 Plan:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.11%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.662%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,938,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,914,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;268,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,378,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.79&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,096,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9"
      decimals="INF"
      id="F_495cd3eb-f09f-47fd-bf1a-ee90e8c150b5"
      unitRef="U_shares">2938982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9"
      decimals="2"
      id="F_111a53ac-5577-4322-9fe1-22f2514226ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_36e0e89a-7c81-4296-9fff-19f854f1ce13"
      id="F_1f99cf87-715c-4869-9b1d-234ed0784e88">P9Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a8105ecc-3402-4d93-af5f-2dce7689dfe9"
      decimals="-3"
      id="F_d1a6d772-d351-47a3-9c2a-92db708bf4f5"
      unitRef="U_USD">53706000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="INF"
      id="F_5bece00b-5390-4eb4-8fb2-05560499bbac"
      unitRef="U_shares">1914914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="2"
      id="F_6f45813f-3087-4aff-a6f8-48453f58f6ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="INF"
      id="F_b2b2572b-63a6-4f99-9e50-077051bfb8e7"
      unitRef="U_shares">268188</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="2"
      id="F_e13f2fff-5988-4d75-9002-61460ccd4ba6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="INF"
      id="F_9c9f603c-7462-4d53-a854-2c1fb79513d6"
      unitRef="U_shares">207224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      decimals="2"
      id="F_4b7d5433-8382-4f12-8354-e9c9fa211663"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="INF"
      id="F_0e9bb596-edec-4220-ba06-9cb5bd1615fc"
      unitRef="U_shares">4378484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="2"
      id="F_8132464e-48eb-4455-ad20-b4041799938b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      id="F_df8f3904-f3a5-4f99-925b-343432c5b6e6">P8Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="-3"
      id="F_61627bc3-f9aa-479d-a6d6-022beb3ba001"
      unitRef="U_USD">87194000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="INF"
      id="F_93206a6d-99f6-4d27-952b-09820a4bcb27"
      unitRef="U_shares">1096087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="2"
      id="F_bb658692-95f1-43cb-a735-63c01fcbfe4a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_f2a41fc6-d7ed-4d30-adf3-e0455a40f962"
      id="F_5451532e-fdad-4045-833b-003b6a9dcfb2">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_a022d47a-da08-4672-8253-3308b645d9aa"
      decimals="-3"
      id="F_409cc626-54f5-463e-8a95-69cfe363a0b4"
      unitRef="U_USD">25516000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_0a10672b-6d6a-4f27-9a2c-239b09cdd2d9"
      unitRef="U_USD">4900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_c6dd91c1-f91d-4646-8d00-ec28d3c497a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="2"
      id="F_08af04ef-cb74-4098-a723-cc5ffc73a453"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_f586d490-8495-4fd6-a31d-47938d745b50"
      unitRef="U_USD">18300000</sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue>
    <sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-5"
      id="F_37413059-43ed-4ecb-bd42-d510347f674e"
      unitRef="U_USD">13100000</sepn:ShareBasedCompensationEquityAwardsOptionsGrantsFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_a5a28169-4954-41e3-a955-c80d527375b9"
      unitRef="U_USD">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_8c6cd37e-c9c8-4880-a575-854c05609cbb"
      decimals="INF"
      id="F_6a222287-f1d7-489a-bf56-d2832a5515dc"
      unitRef="U_shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_66e5c4ac-4b2d-4683-bb29-b0c9430f9075"
      decimals="2"
      id="F_5db1c626-6566-472c-8579-a9f99c27f4da"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f"
      id="F_9d018352-3b91-4581-a5a1-809e83ff21b5">The offering periods begin on May 1 and November 1, will be twenty-four (24) months in duration and include four (4) purchase periods, each purchase period lasting six (6) months.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <sepn:PurchasePricePercentageOfFairMarketValuePerShareOnOffering
      contextRef="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f"
      decimals="2"
      id="F_dec4f4b1-cc1c-4696-b112-fa9078b9ba13"
      unitRef="U_pure">0.85</sepn:PurchasePricePercentageOfFairMarketValuePerShareOnOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_15932d5e-6ece-4aa4-b2b4-039fe8d9184f"
      decimals="INF"
      id="F_d2546b6a-3504-4163-93db-3b27ff5974fa"
      unitRef="U_shares">118191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e34ee022-7881-4415-9223-49c1cc144b97"
      decimals="2"
      id="F_5f799150-1616-407e-91cb-86ce4be05321"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_e34ee022-7881-4415-9223-49c1cc144b97"
      decimals="-5"
      id="F_70a34857-9fb8-4a28-b82f-21b39da1dd4b"
      unitRef="U_shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_75b23b9e-d296-43b2-848e-151aa1919a39">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average assumptions used to value employee and non-employee stock option awards granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="9" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average assumptions used to value employee stock purchase plan shares granted during the year ended December 31, 2025, using the Black-Scholes option pricing model, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:64.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.562%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:4.688%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.22&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16"
      decimals="4"
      id="F_d2422f48-57fd-4ef2-8775-d155fe8f8d7c"
      unitRef="U_pure">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597"
      decimals="4"
      id="F_7f1c34b4-9c4c-4903-af8f-a6dacbe92556"
      unitRef="U_pure">0.0383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16"
      decimals="3"
      id="F_bead90b9-b46a-436c-a3d2-d294c0fdc113"
      unitRef="U_pure">0.921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597"
      decimals="3"
      id="F_eb232003-0efc-4017-874d-d06567b3fecc"
      unitRef="U_pure">0.911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16"
      id="F_206530c4-f315-4dd8-b101-24d188cf12b0">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597"
      id="F_8ddf9f42-7b4e-4fc0-bc8c-d44f6dfc1d25">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4012e7ef-84ff-438a-9d21-608b4581ba16"
      decimals="2"
      id="F_6017a525-b52d-429a-9e3a-9168b19414d8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9cc53a78-1854-48cf-b102-67dba4fd3597"
      decimals="2"
      id="F_234d0c84-082a-45bb-885c-ef9e507a6542"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8"
      decimals="4"
      id="F_e2a5a917-515e-44ac-8141-5c9aea0489b3"
      unitRef="U_pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8"
      decimals="4"
      id="F_d63f224b-38fa-430c-9064-70fab294143d"
      unitRef="U_pure">0.8653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8"
      id="F_850bd51b-334c-481e-b2d6-4dd45be63b4e">P1Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9888954c-fbaf-4612-8b15-1d1088548ab8"
      decimals="2"
      id="F_da472cfb-b42f-4849-ab64-fdcd72025f06"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_29eeaf90-b2ab-4526-8d3b-ab4faf818608">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense for restricted stock awards, stock options, and ESPP recognized in the Company&#x2019;s statements of operations and comprehensive loss is presented as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3cba6681-4177-41a6-98a7-0683daf19bf3"
      decimals="-3"
      id="F_4a261a29-6fb0-4fb0-8cd4-a39b2f94d93a"
      unitRef="U_USD">4087000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4dd9f47b-1fb7-4754-a5f2-2c832537c007"
      decimals="-3"
      id="F_24e60093-c685-4e81-a4cf-94d1396d472f"
      unitRef="U_USD">1619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bb23122e-3c2b-4030-8ff0-177914816c06"
      decimals="-3"
      id="F_3c50a772-0fa1-4a1b-8613-170cb4c479aa"
      unitRef="U_USD">4389000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_39947422-5330-41f2-b716-f2d784c2e0cc"
      decimals="-3"
      id="F_985a2a9a-5103-4d28-b6ff-997b02482e00"
      unitRef="U_USD">1533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_29f53b4a-88c9-4916-83b4-ad7bee94b62c"
      unitRef="U_USD">8476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_8ef76a8e-2ae7-4f92-8861-0ad2a8a781ea"
      unitRef="U_USD">3152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-5"
      id="F_70c57a5a-499a-46c5-9a01-06a404633062"
      unitRef="U_USD">24500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_2b456bcd-0d2b-416a-945c-d51c53edbb74">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_003ccfd2-5240-48c9-8615-e31fc337ae09">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the provision (benefit) for income taxes were as follows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As discussed in Note 2, we adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. For the year ended December 31, 2025, the tax provision expense was not material. For the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded income tax benefit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s effective tax rate to the statutory U.S. federal rate is as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.807%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.278%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.073%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.434%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percentage&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8efe224-c188-42df-a41c-9d6bf32284b2;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;federal taxes at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:74.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal taxes at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The types of temporary differences that give rise to significant portions of the Company&#x2019;s deferred income tax assets and liabilities are set out below (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 174 capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has established a valuation allowance for the amount of deferred tax assets that are not more likely than not to be realized. Management considered all available evidence, both positive and negative, including but not limited to the Company&#x2019;s historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in the total valuation allowance for the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was an increase of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal net operating loss carryforwards and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of state net operating loss carryforwards, available to reduce future taxable income. The federal net operating loss carryforwards will carryforward indefinitely. The state net operating loss carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, if not utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal research and development tax credits carryforward of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and state research and development tax credits carryforward of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, available to reduce future income taxes. The federal research and development tax credits will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if not utilized. The state research and development tax credits have no expiration date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Internal Revenue Code section 382 (&#x201c;IRC Section 382&#x201d;) places a limitation (the &#x201c;Section 382 Limitation&#x201d;) on the amount of taxable income that can be offset by net operating loss (&#x201c;NOL&#x201d;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules. When an ownership change occurs, IRC Section 382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax attributes in one year but the identified ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. The Company performed a Section 382 analysis through the year ended December 31, 2024 and determined there were ownership changes in 2021 and 2023. The ownership changes did not result in a reduction of its net operating loss or in its research and development credit carryforwards expiring unused.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment based on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reversal of the uncertain tax benefits would not impact the Company&#x2019;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. During the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize accrued interest and penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income taxes in the U.S. federal jurisdiction, the state of California and various other U.S. states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All income tax returns will remain open for examination by the federal, state and foreign authorities for three or four years, from the date of utilization of any NOLs or credits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_71c5ab32-345f-460b-a5eb-bef439869b4f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the provision (benefit) for income taxes were as follows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_cbafc55b-dfc3-4ff3-8c76-d7d052d3fd19"
      unitRef="U_USD">12000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_94a5af08-ce0d-4c27-9709-d04011f0d487"
      unitRef="U_USD">-7000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_eb47ed6c-a9cf-4c08-b1dd-67035a9d5a9d"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_34735712-9eb0-471d-88e7-f6e194b9ac30"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_4ed8eb1e-d28e-4374-815a-0fd1bddfa0f4"
      unitRef="U_USD">12000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_3b5d8827-6b2f-4772-94bf-ba308b56e913"
      unitRef="U_USD">-7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_85efae01-538f-48fe-848f-0bc5deced04e"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_b606fd47-2129-4b87-a302-1935fd08457e"
      unitRef="U_USD">-491000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_0bdbda1c-8e52-4b1d-8a8a-e823c0828bc4"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_58a60ec7-51ea-4b4c-9c24-8708c95b6d42"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_4203683a-da93-4dc1-93e7-c6fa60fab12c"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_f74448b7-8826-4ad6-877e-a75e85b4e3ac"
      unitRef="U_USD">-491000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_0fa1680e-8e27-4656-8c36-2ea27b0542ac"
      unitRef="U_USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_4bfacaa6-b3ad-49e0-956e-89d4c3a75b5e"
      unitRef="U_USD">-498000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-5"
      id="F_7916679f-305a-4d2c-8d53-63f1e94fd17e"
      unitRef="U_USD">-500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_eea6df1a-1d03-4e5a-a47b-400e37c670b0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company&#x2019;s effective tax rate to the statutory U.S. federal rate is as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.807%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.278%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.073%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.434%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Percentage&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8efe224-c188-42df-a41c-9d6bf32284b2;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;federal taxes at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:74.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal taxes at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_1090205a-a771-478f-8473-9d0bdc357945"
      unitRef="U_USD">-10262000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="3"
      id="F_450134bb-3eb6-4e68-a504-4a0e9e9b7100"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_acb829bd-62a3-49ca-bfa9-a0b5d5de8766"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_741577d5-7c6d-4594-b866-ce6cb3f3be87"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_3f995fd7-8ff1-4e71-9aaa-5d9e7b3fd58a"
      unitRef="U_USD">1195000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="3"
      id="F_267ec387-6225-4f82-84ab-8b304cea4195"
      unitRef="U_pure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_8b4b3ef5-84e9-4663-a15a-26927ea61a30"
      unitRef="U_USD">9972000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="3"
      id="F_f3d3e8de-a290-43e0-b509-df74d6890d8a"
      unitRef="U_pure">-0.204</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_a9e97ba6-a000-4483-83b1-4ecaac43cbdb"
      unitRef="U_USD">1081000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="3"
      id="F_50ea7269-df6c-488a-8776-79dc76ba4c44"
      unitRef="U_pure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sepn:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_1922472e-d2ba-46e4-8b39-12b74d6b0e85"
      unitRef="U_USD">56000</sepn:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesAmount>
    <sepn:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="3"
      id="F_16b15f43-236c-4f89-8246-86f13cae191c"
      unitRef="U_pure">-0.001</sepn:EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferencesPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_435c1c5f-8b94-4ee4-9fbe-ca4b01fb8961"
      unitRef="U_USD">-2000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_8f67e271-e5b8-4bfd-8534-e11bf91da47a"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_2c450d89-17ee-4be3-ac26-86f63f91abef"
      unitRef="U_USD">359000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="3"
      id="F_1adc672b-c75c-4168-87ee-9e12424eb196"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_5fb96a9c-956c-4a6c-b9d6-8f2f6726d661"
      unitRef="U_USD">3000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_bbdbb1ba-9601-4501-bbbd-b42a5714d6b1"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_b4bac637-4c31-4815-a5b9-4acd24f12215"
      unitRef="U_USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="2"
      id="F_eb97566f-6e64-43a7-b8cf-78ef1a9e2adb"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="INF"
      id="F_247b49bb-e370-472b-8828-3f4057e3a102"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="3"
      id="F_2b1024ba-8ed8-4c59-8c66-1565c0a9a1b7"
      unitRef="U_pure">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="3"
      id="F_c4d4ffbb-efef-4daa-82a0-1104e1efee0d"
      unitRef="U_pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="3"
      id="F_b852214c-6e32-451b-bc73-8f48d62aa211"
      unitRef="U_pure">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="3"
      id="F_0a517eff-706c-491a-ac46-bde7e81065e9"
      unitRef="U_pure">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="3"
      id="F_e03bbd02-c76b-4802-b71c-479d392e3711"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="3"
      id="F_c0b0925f-2806-4d1c-9c69-671fa80a0d58"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_3af38355-6a33-4c24-b210-2c2a76b00411">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The types of temporary differences that give rise to significant portions of the Company&#x2019;s deferred income tax assets and liabilities are set out below (in thousands):&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 174 capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_90e57dfd-7c9f-49fb-829d-3fa169afd2b3"
      unitRef="U_USD">14149000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_bd34e9a9-6f3b-4062-a112-e576f6275819"
      unitRef="U_USD">7122000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_e0800c25-7a1c-4c38-bd74-3dbeb6f564e0"
      unitRef="U_USD">5318000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_76aa8bfb-0ff9-4c4c-a5b9-c08425ecdf03"
      unitRef="U_USD">4102000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sepn:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_3845c132-5ba7-4482-a3fa-05b1e43fddf0"
      unitRef="U_USD">5620000</sepn:DeferredTaxAssetsOperatingLeaseLiabilities>
    <sepn:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_742fe482-2bc2-4029-aa83-3b6e8a73d1d4"
      unitRef="U_USD">7129000</sepn:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_4c43a3e0-a694-43fe-9f11-afc37d36dc81"
      unitRef="U_USD">474000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_699f16fa-634d-4a75-92d6-f2e3eab0374e"
      unitRef="U_USD">61000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_539f12d0-cb76-4ece-a0a3-491ff881bf63"
      unitRef="U_USD">1319000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_d07df18b-f43a-43cd-be2e-1acf9bb02b47"
      unitRef="U_USD">1163000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <sepn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_9e6dc719-76e2-48a1-851a-878e0cd3f302"
      unitRef="U_USD">22932000</sepn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <sepn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_6e9f3402-c267-4166-917c-c971250ca2fb"
      unitRef="U_USD">20855000</sepn:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_6d2b1aec-0696-45cc-8c52-8bc69d5697cf"
      unitRef="U_USD">49812000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_ee8701f8-93ea-4970-b4e4-50dec22133f1"
      unitRef="U_USD">40432000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_fe94b3ef-3a4d-4b95-8280-1e4dedd43d83"
      unitRef="U_USD">44015000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_fd5f235f-d9ed-4fcc-b1ff-1985daffb8d9"
      unitRef="U_USD">33061000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_1d67f089-b052-458d-8643-c0a5523852c3"
      unitRef="U_USD">5797000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_8e30e30d-3835-470d-90a6-35d91fbf5435"
      unitRef="U_USD">7371000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_cfe9f8df-de93-475d-ba1e-3a6546299f51"
      unitRef="U_USD">683000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_1abd7d52-4366-405b-b4f2-e1828862744c"
      unitRef="U_USD">766000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <sepn:DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_480e70ff-c43b-4f23-b319-a423a5b8cb31"
      unitRef="U_USD">5114000</sepn:DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets>
    <sepn:DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_a293dbb1-0f11-4efe-99ad-86adffcbdd28"
      unitRef="U_USD">6605000</sepn:DeferredTaxLiabilitiesOperatingLeaseRight-Of-UseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_5855f46d-9c86-412f-a943-b1794cdc8a51"
      unitRef="U_USD">5797000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_8dc74dc2-177a-4e49-98f1-8cf837c39bda"
      unitRef="U_USD">7371000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_8b66c429-94b6-48ac-8961-8997f4bfab04"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_9daddc26-68d6-4647-afbb-095554e3b2a4"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-5"
      id="F_43acd0d0-f218-4b13-aab9-ea3d936f9c66"
      unitRef="U_USD">11000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-5"
      id="F_a905d0d6-c4cf-4b15-9766-1e7b043d826b"
      unitRef="U_USD">20900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_32ee6c26-363c-447f-b284-d18487b21d59"
      decimals="-5"
      id="F_4d80a6bd-3208-4cee-b2d2-5afafb66b3cf"
      unitRef="U_USD">45800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_edbd8258-cfdd-447f-8899-e8bf5ca401c7"
      decimals="-5"
      id="F_2869cc8f-8dd3-49cf-a841-092585823ae1"
      unitRef="U_USD">77900000</us-gaap:OperatingLossCarryforwards>
    <sepn:OperatingLossCarryforwardsExpirationYear
      contextRef="C_76244c83-b690-42fd-93b3-51188d2e836f"
      id="F_2a66cca3-7fe3-4955-b201-77b13dce445f">2041</sepn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_55101ae3-0a3e-4d43-a901-c61588a76992"
      decimals="-5"
      id="F_443f0503-ae26-4e09-a044-0940456210dc"
      unitRef="U_USD">5200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_26b3acdc-a041-414e-a35d-958f1caf4710"
      decimals="-5"
      id="F_1ed1a552-4c35-462e-8af0-029dad1fd69c"
      unitRef="U_USD">3700000</us-gaap:TaxCreditCarryforwardAmount>
    <sepn:TaxCreditCarryforwardExpirationYear
      contextRef="C_43471eb0-1ae4-4188-8890-d5649bb442c2"
      id="F_68f1d6d1-09fc-4e1d-8c6b-3fa5675c5ab5">2040</sepn:TaxCreditCarryforwardExpirationYear>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_79945723-a476-428f-908d-e16d8313efc1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment based on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_7e04d017-dd8c-4f8f-943c-0bea8a90186a"
      unitRef="U_USD">3567000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e5502035-9c62-4bfa-b75f-04b8934fb13b"
      decimals="-3"
      id="F_9d4cc549-e633-4ad5-82b1-e59e3fc1d2ed"
      unitRef="U_USD">2529000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_f166d3e7-ab50-42b7-86f4-cb26646b0f4a"
      unitRef="U_USD">620000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_3c35427c-05e8-412b-86ba-eec965f21830"
      unitRef="U_USD">998000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_6ebf5435-cf6b-4bae-b0e6-6251371915a4"
      unitRef="U_USD">42000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_6784753c-3c33-4984-944d-14d6b4de33f2"
      unitRef="U_USD">40000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="-3"
      id="F_d917316a-e572-444a-a040-22bcd8fc21dc"
      unitRef="U_USD">4145000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="-3"
      id="F_d4a67bba-707d-4dfa-a03c-38d30455b9e1"
      unitRef="U_USD">3567000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_b2b552f6-bb4e-448e-af6c-24ebbf7e157b"
      decimals="INF"
      id="F_0daaddc5-7697-4ed7-83cf-a833afedc2d4"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_c9ed796e-c245-49e4-a05c-5a3905d6aa43"
      decimals="INF"
      id="F_2228e0cf-94cb-416f-b7e4-a7829bb69920"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_4af4c4d0-275a-4f4f-9698-a235b7429a22">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Third Rock Ventures&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its Series B Convertible Preferred Stock to Third Rock Ventures VI, L.P., a holder of more than 5% of the Company&#x2019;s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2021, the Company entered into a service agreement with Third Rock Ventures, LLC (&#x201c;TRV&#x201d;), a holder of more than 5% of the Company&#x2019;s outstanding capital stock, (the &#x201c;TRV service agreement&#x201d;) under which TRV provides consulting services to the Company. For the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for such services as general and administrative expenses in the Company&#x2019;s statements of operations and comprehensive loss. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of expense related to TRV was recorded in accrued expenses and other current liabilities. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; expense recorded in accrued expenses and other current liabilities and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; outstanding accounts payable to TRV at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's former interim Chief Medical Officer, and also a current member of the Company's board of directors, was designated to the Company's board of directors by TRV and is affiliated with TRV. He did not receive any cash compensation from the Company for his service as its interim Chief Medical Officer as his services were provided to the Company through the TRV service agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Of the total fees the Company incurred under the TRV service agreement for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,  $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was attributed to consulting services provided by the board member. Additionally, as compensation for his services as the Company's interim Chief Medical Officer, the Company granted him options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,227&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares during the year ended December 31, 2024 at the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The board member ceased serving as interim Chief Medical Officer in September 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company entered into a separate consulting agreement with the board member, under which he may provide up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of consulting services per month, which are also provided to the Company through the TRV service agreement. For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for such consulting services. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, there was a minimal expense recorded in accrued expenses and other current liabilities and a minimal outstanding accounts payable to the board member.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;RA Capital&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its Series B Convertible Preferred Stock to entities affiliated with RA Capital Management, L.P. (collectively, &#x201c;RA Capital&#x201d;), which held more than 5% of the Company&#x2019;s outstanding capital stock, during the second tranche closing in May 2024, for total cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These shares were&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;converted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to shares of the Company's common stock upon the consummation of its IPO in October 2024. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Samsara BioCapital&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its Series B Convertible Preferred Stock to Samsara BioCapital, L.P. (&#x201c;Samsara BioCapital&#x201d;), a holder of more than 5% of the Company&#x2019;s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_2ca0b610-feb1-4fc4-9fb6-285c278593cf"
      decimals="-5"
      id="F_48e4f2dc-8cfe-4aac-94a5-8ae053164eae"
      unitRef="U_shares">12400000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_2ca0b610-feb1-4fc4-9fb6-285c278593cf"
      decimals="-5"
      id="F_49702887-f5fe-4928-8e2c-e645e4c23348"
      unitRef="U_USD">15300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_4ce5aad8-c86e-421c-9386-a0a475a3e0cf"
      decimals="-6"
      id="F_18489e8e-0662-41c8-a00a-94053e993601"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_d3c78d76-dd2e-4cd2-a4ec-26c17d567446"
      decimals="-5"
      id="F_91f7db92-11e1-4a79-8578-96dceeb173cc"
      unitRef="U_USD">300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <sepn:AccruedExpenseAndOtherCurrentLiabilities
      contextRef="C_a9816031-a377-48f3-a65a-63d6a0198c1e"
      decimals="-2"
      id="F_bb36c901-5c4b-47f7-8b98-e8629b0c6c09"
      unitRef="U_USD">100</sepn:AccruedExpenseAndOtherCurrentLiabilities>
    <sepn:AccruedExpenseAndOtherCurrentLiabilities
      contextRef="C_1c50a455-abd2-40af-bc2f-471cb232f201"
      decimals="INF"
      id="F_76eb8565-5951-4084-92e8-1c24ebf5fc86"
      unitRef="U_USD">0</sepn:AccruedExpenseAndOtherCurrentLiabilities>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="C_1c50a455-abd2-40af-bc2f-471cb232f201"
      decimals="INF"
      id="F_99fff109-9eb1-473b-9743-45ab09a66a82"
      unitRef="U_USD">0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_6351b22f-2be8-4ebf-a536-1da1776a2f78"
      decimals="-5"
      id="F_5afbd66d-31bc-4f40-959b-1472452bacca"
      unitRef="U_USD">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_8a5f118b-d06e-4890-a43e-997cc3e53337"
      decimals="INF"
      id="F_91a12df6-09a9-4fc9-97f0-3583d216b11c"
      unitRef="U_shares">23227</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8a5f118b-d06e-4890-a43e-997cc3e53337"
      decimals="2"
      id="F_4d8c152d-ba77-4737-aec4-4f5935cdf895"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProfessionalFees
      contextRef="C_8a386e2d-47cd-42af-a8e3-db3089a6f1be"
      decimals="0"
      id="F_a4ef091a-3cda-4097-9abd-c12c76d67d01"
      unitRef="U_USD">9500</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_50876280-ce05-4b2f-a74c-aab5ab966a93"
      decimals="-5"
      id="F_f415dcb9-a712-451c-9e19-a2d8452a2acd"
      unitRef="U_USD">100000</us-gaap:ProfessionalFees>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_f4c23b37-5cfc-40da-a0d2-d57dcfb5120d"
      decimals="-5"
      id="F_e5811967-fcab-4f58-a999-dba874737465"
      unitRef="U_shares">12200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_f4c23b37-5cfc-40da-a0d2-d57dcfb5120d"
      decimals="-5"
      id="F_c73e15a4-cdd2-4dd5-bf46-d69b2e35c6d7"
      unitRef="U_USD">15000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_4d8fbc94-ff88-4825-9417-f0e8f0e8e33a"
      decimals="-6"
      id="F_c258376f-5878-4369-8cc4-4476aaacd5c9"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_12bf748d-8c8f-43c8-986f-7e62abb1f3b2"
      decimals="-5"
      id="F_43f87130-4ba3-4613-b4ac-551529382eec"
      unitRef="U_shares">4300000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_12bf748d-8c8f-43c8-986f-7e62abb1f3b2"
      decimals="-5"
      id="F_a2ac5ae7-9c5e-434f-ac21-415509c5fedb"
      unitRef="U_USD">5200000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_1a5a03ec-3b78-4b4f-984f-9c02f37f3f79"
      decimals="-6"
      id="F_05987e37-3815-47e5-83f0-b4d1ee9401ae"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_32f93eca-88f4-47ea-8404-15a47fd8b951">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,554,420&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of potentially dilutive securities, comprised of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,378,484&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; outstanding stock options, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,224&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unvested restricted stock awards subject to repurchase, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,712&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable under the ESPP, not included in the calculation of diluted net loss per share for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025  because to do so would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="INF"
      id="F_89fc8877-ee06-4468-9d06-35cefd18ca6e"
      unitRef="U_shares">4554420</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_388d86f8-b34d-4f0d-9ce6-8aae94db4af3"
      decimals="INF"
      id="F_8bb08eb9-6131-4fa4-a885-81ccd5216459"
      unitRef="U_shares">4378484</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_886793f1-e018-4e02-b853-202065e4572b"
      decimals="INF"
      id="F_ee13ba28-af77-41c8-8bc6-19bb276ebdb1"
      unitRef="U_shares">131224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f8051df8-6f74-4da2-9664-e548022686e5"
      decimals="INF"
      id="F_a31113a0-258f-4fcf-8f4f-4cb768d5cd16"
      unitRef="U_shares">44712</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_a49f3a35-c126-4e69-ba0d-150484379159">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Employee Retirement Benefit Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains a 401(k) retirement savings plan (the &#x201c;401(k) Plan&#x201d;) for its employees. The 401(k) Plan allows eligible employees to make contributions up to the maximum allowable by the Internal Revenue Service (&#x201c;IRS&#x201d;). For the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company made matching contributions of and recorded contribution expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_9d256ca5-ca4e-416a-9cfc-3811d06616cf"
      decimals="-5"
      id="F_4e9fa86a-664e-4d3f-8762-30777e34d14d"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_9c372061-ee03-484f-8e37-ab25c25fbca6"
      decimals="-5"
      id="F_744eed61-3851-4bfb-82c2-3c5c3b29f343"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_d1f41741-4cc8-456b-9eb9-dfe62d99b6c8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM assesses performance for the Company&#x2019;s operating segment and decides how to allocate resources based on the Company&#x2019;s available cash resources. Total operating expenses and net loss of the Company&#x2019;s operating segment are used to monitor budget versus actual results. The measure of segment assets is reported as total assets on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM is regularly provided with the following significant segment expenses:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee-related expenses, excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gain on sale of non-financial asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(*) Other segment expenses include facility related and office costs, information technology costs, general laboratory costs, and other operating expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, all of the Company&#x2019;s property and equipment was maintained in the U.S. For each of the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s revenue was generated from providing research services and was earned in the U.S.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_86a46e5c-76ee-48cc-b1d7-b5a79a6d4b9b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM is regularly provided with the following significant segment expenses:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee-related expenses, excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gain on sale of non-financial asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(*) Other segment expenses include facility related and office costs, information technology costs, general laboratory costs, and other operating expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_d5c7d069-c49e-49f4-bc89-9a648f6bdd1a"
      unitRef="U_USD">45951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_28377e25-2202-4d9e-b1bd-594d350cc814"
      unitRef="U_USD">1075000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_1cdcfd57-b101-499f-9655-2c87f23a1e8d"
      unitRef="U_USD">33468000</sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation>
    <sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_ae206dbb-d0db-43c3-9662-5227f311070e"
      unitRef="U_USD">22233000</sepn:EmployeeRelatedExpensesExcludingStockBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_85527a3c-bc12-43ba-bcac-47bee3c80282"
      unitRef="U_USD">8476000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_ed6b2395-81ce-461c-a393-732a29a3b9e5"
      unitRef="U_USD">3152000</us-gaap:ShareBasedCompensation>
    <sepn:ExternalResearchAndDevelopmentExpenses
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_d2d0ae6d-9ea5-4332-ab17-745a60a896a7"
      unitRef="U_USD">53519000</sepn:ExternalResearchAndDevelopmentExpenses>
    <sepn:ExternalResearchAndDevelopmentExpenses
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_5f7c048d-3064-4039-8e6b-bc0b94cf1c81"
      unitRef="U_USD">32786000</sepn:ExternalResearchAndDevelopmentExpenses>
    <sepn:ExternalGeneralAndAdministrativeExpenses
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_100ee1c6-642f-4d44-8bd3-61d470768cef"
      unitRef="U_USD">8856000</sepn:ExternalGeneralAndAdministrativeExpenses>
    <sepn:ExternalGeneralAndAdministrativeExpenses
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_c3ff6dd6-046c-431c-bd25-4c5de461443c"
      unitRef="U_USD">6511000</sepn:ExternalGeneralAndAdministrativeExpenses>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_b15dbf73-7935-462c-9911-b16eb668a629"
      unitRef="U_USD">12500000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_66d43db9-5794-47ab-80b6-c5dc0877930f"
      unitRef="U_USD">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_97e771ac-d2d0-4c5b-94fc-844d48538fa8"
      unitRef="U_USD">22429000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_4aca3999-5999-4461-8f21-16793f35440f"
      unitRef="U_USD">17216000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingExpenses
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_b1c15270-4116-48fd-87ab-6a544cb6579b"
      unitRef="U_USD">114248000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_aff99c5c-5061-45bc-aa15-59c512ce4c05"
      unitRef="U_USD">81898000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_e0a1a4ee-d6f9-433e-955c-c2c412cc3510"
      unitRef="U_USD">-68297000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_81759b9d-b40f-40c2-84fb-0e0710772746"
      unitRef="U_USD">-80823000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_e1fb3497-e99b-4ba5-988a-342e45d56f87"
      unitRef="U_USD">19430000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_0d8bbde8-ddf5-42a4-afbe-f73a4a9229f3"
      unitRef="U_USD">8527000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_3ab61134-98e4-4d6d-8135-3289e0ccc5e5"
      unitRef="U_USD">-48867000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_ba6a9d87-ab31-4410-a351-51cee11c30a9"
      unitRef="U_USD">-72296000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_c5a1259f-05ee-481d-842e-f5bda2526c67"
      unitRef="U_USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_acef9cfb-5979-4efb-b8a7-12460b85235f"
      unitRef="U_USD">-498000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      decimals="-3"
      id="F_8b4280da-52ab-4283-817f-985a5dda9489"
      unitRef="U_USD">-48879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71f726e5-b69b-43a5-9553-9360762a27cd"
      decimals="-3"
      id="F_dc673cca-1a43-4a35-9203-6aee313dfe9a"
      unitRef="U_USD">-71798000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_dc2353db-b260-4ea2-b9e8-697135966b5e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 8, 2026, the Company appointed Mark A. Wilson as Chief Legal Officer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:AuditorName
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_e920429a-9797-4ed3-91e2-2293fa07ba84">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_2d94a0ce-e7e0-4c7f-b27a-d4112891802b"
      id="F_c9eae183-1cc1-4c27-990a-db5da3ce3579">San Mateo, California</dei:AuditorLocation>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_7008d5d3-9bdd-490b-96e6-88078f8933a4"
          xlink:label="F_7008d5d3-9bdd-490b-96e6-88078f8933a4"
          xlink:type="locator"/>
        <link:footnote id="FNT_f1953c39-e551-4940-8c04-a300b368e702" xlink:label="FNT_f1953c39-e551-4940-8c04-a300b368e702" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprised of the allocation of the $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195.0</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million one-time, non-refundable upfront payment, of which $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153.8</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the four R&amp;D programs and manufacturing services and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.2</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the material right and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94.0</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of variable consideration related to estimated research and manufacturing services for the four R&amp;D Programs.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7008d5d3-9bdd-490b-96e6-88078f8933a4"
          xlink:to="FNT_f1953c39-e551-4940-8c04-a300b368e702"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_39fd5ca1-4334-4c7d-a6eb-c996d69d21c0"
          xlink:label="F_39fd5ca1-4334-4c7d-a6eb-c996d69d21c0"
          xlink:type="locator"/>
        <link:footnote id="FNT_9ae89f8a-23fd-4c50-a308-c16f6583e5df" xlink:label="FNT_9ae89f8a-23fd-4c50-a308-c16f6583e5df" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recorded within revenue in the statement of operations and comprehensive loss for the year ended </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, comprised of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.8</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recognized of the one-time, non-refundable upfront payment and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.6</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million variable considerations related to estimated research services for the four R&amp;D Programs.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_39fd5ca1-4334-4c7d-a6eb-c996d69d21c0"
          xlink:to="FNT_9ae89f8a-23fd-4c50-a308-c16f6583e5df"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
